<SEC-DOCUMENT>0001628280-26-012346.txt : 20260226
<SEC-HEADER>0001628280-26-012346.hdr.sgml : 20260226
<ACCEPTANCE-DATETIME>20260226163457
ACCESSION NUMBER:		0001628280-26-012346
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		145
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260226
DATE AS OF CHANGE:		20260226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ginkgo Bioworks Holdings, Inc.
		CENTRAL INDEX KEY:			0001830214
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				872652913
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40097
		FILM NUMBER:		26689507

	BUSINESS ADDRESS:	
		STREET 1:		27 DRYDOCK AVENUE
		STREET 2:		8TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		(877) 442-5362

	MAIL ADDRESS:	
		STREET 1:		27 DRYDOCK AVENUE
		STREET 2:		8TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Soaring Eagle Acquisition Corp.
		DATE OF NAME CHANGE:	20210210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Spinning Eagle Acquisition Corp.
		DATE OF NAME CHANGE:	20201027
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dna-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:52002c9c-7569-4bc2-a5b5-c24c0eeac02a,g:42911b52-7f60-440e-93d3-9584b5edbad8,d:d8596373948b4ae4958ccd7c02fd70c1-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dna="http://www.ginkgobioworks.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dna-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-35">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-36">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-37">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-38">0001830214</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-76" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-556">0.025</ix:nonFraction><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-562">http://fasb.org/us-gaap/2025#RestructuringCostsAndAssetImpairmentCharges</ix:nonNumeric><ix:nonNumeric contextRef="c-200" name="dna:EquitySecuritiesFVNIMeasurementInputTerm" id="f-801">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-204" decimals="INF" name="dna:ClassOfWarrantOrRightStockSplitConversionRatio" scale="0" id="f-805">0.025</ix:nonFraction><ix:nonNumeric contextRef="c-7" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1005">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1006">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1079">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="c-8" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1080">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="c-379" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-1401">1</ix:nonNumeric><ix:nonNumeric contextRef="c-380" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-1402">2</ix:nonNumeric><ix:nonNumeric contextRef="c-381" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-1403">3</ix:nonNumeric><ix:nonNumeric contextRef="c-382" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-1404">4</ix:nonNumeric><ix:nonNumeric contextRef="c-383" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-1405">5</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dna-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>dna:segment</xbrli:measure></xbrli:unit><xbrli:unit id="offering"><xbrli:measure>dna:offering</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="materialright"><xbrli:measure>dna:materialRight</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>dna:employee</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="extensionoption"><xbrli:measure>dna:extensionOption</xbrli:measure></xbrli:unit><xbrli:unit id="facility"><xbrli:measure>dna:facility</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>dna:vote</xbrli:measure></xbrli:unit><xbrli:unit id="stockoption"><xbrli:measure>dna:stockOption</xbrli:measure></xbrli:unit><xbrli:unit id="installment"><xbrli:measure>dna:installment</xbrli:measure></xbrli:unit><xbrli:unit id="founder"><xbrli:measure>dna:founder</xbrli:measure></xbrli:unit><xbrli:unit id="hurdle"><xbrli:measure>dna:hurdle</xbrli:measure></xbrli:unit><xbrli:unit id="condition"><xbrli:measure>dna:condition</xbrli:measure></xbrli:unit><xbrli:unit id="asset"><xbrli:measure>dna:asset</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:EquityMethodInvestmentFundingOfAdditionalLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:EquityMethodInvestmentFundingOfAdditionalLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:EquityMethodInvestmentFundingOfAdditionalLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-19</xbrli:startDate><xbrli:endDate>2024-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:AgBiomeInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-10</xbrli:startDate><xbrli:endDate>2024-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:AgBiomeInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-10</xbrli:startDate><xbrli:endDate>2024-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:AgBiomeInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:OtherAssetAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:OtherAssetAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-05</xbrli:startDate><xbrli:endDate>2023-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-05</xbrli:startDate><xbrli:endDate>2023-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:ZymergenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-03</xbrli:startDate><xbrli:endDate>2023-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenBankruptcyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-03</xbrli:startDate><xbrli:endDate>2023-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenBankruptcyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dna:ZymergenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dna:ZymergenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-18</xbrli:startDate><xbrli:endDate>2024-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dna:AltarSasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">dna:SeniorSecuredNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">dna:SeniorSecuredNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">dna:SeniorSecuredNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">dna:ConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:CircularisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:CircularisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:OneInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:GenomaticaIncPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:GenomaticaIncPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SafeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:GenomaticaIncPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:BiomeditLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:BiomeditLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:BiomeditLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:OtherEquityInvestessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:OtherEquityInvestessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:OtherEquityInvestessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dna:EquipmentLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dna:EquipmentLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-29</xbrli:startDate><xbrli:endDate>2023-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:StrategicCloudAndAIPartnershipWithGoogleCloudMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:StrategicCloudAndAIPartnershipWithGoogleCloudMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2027-04-01</xbrli:startDate><xbrli:endDate>2027-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:SuretyBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dna:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dna:SalesAgreementWithAllenCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:NewGinkgoPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dna:WarrantsToPurchaseClassACommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-16</xbrli:startDate><xbrli:endDate>2021-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-16</xbrli:startDate><xbrli:endDate>2021-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">dna:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">dna:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderPSUAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">dna:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-16</xbrli:startDate><xbrli:endDate>2021-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-16</xbrli:startDate><xbrli:endDate>2021-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:PharmaceuticalAndBiotechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:PharmaceuticalAndBiotechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:PharmaceuticalAndBiotechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:AgricultureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:AgricultureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:AgricultureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:GovernmentAndDefenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:GovernmentAndDefenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:GovernmentAndDefenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:IndustrialAndEnvironmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:IndustrialAndEnvironmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:IndustrialAndEnvironmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CustomerAndTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CustomerAndTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CustomerAndTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:FoodAndNutritionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:FoodAndNutritionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:FoodAndNutritionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year1Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year12Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year13Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year14Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year15Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year1Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year12Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year13Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year14Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year15Member</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringAndBiosecuritySegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringAndBiosecuritySegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringAndBiosecuritySegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LeaseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:MotifMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:MotifFoodworksIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:OtherEquityInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dna:AgreementAxis">dna:TwoThousandAndEighteenTechnicalDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dna:AgreementAxis">dna:TwoThousandAndEighteenTechnicalDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:GenomaticaIncPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:MotifMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:MotifMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:MotifMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AyanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AyanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AyanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:VerbBioticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:VerbBioticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:VerbBioticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:OtherEquityInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:OtherEquityInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:OtherEquityInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:BeginToExpireInTwoThousandAndTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:CarriedForwardIndefinitelyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:BeginToExpireInTwoThousandAndThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:CarriedForwardIndefinitelyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:BeginToExpireIn2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:CarriedForwardIndefinitelyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EarnOutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EscrowSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EscrowSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EscrowSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001830214</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-26</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-130 f-131 f-132" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/></ix:resources></ix:header></div><div id="id8596373948b4ae4958ccd7c02fd70c1_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:2.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">OR </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:2.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                  TO </span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-40097</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">GINKGO BIOWORKS HOLDINGS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">87-2652913</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">27 Drydock Avenue</ix:nonNumeric></span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">8th Floor</ix:nonNumeric></span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">02210</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">877</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">422-5362</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:38.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Class A common stock, par value $0.0001 per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">DNA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" id="f-19">NYSE</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">   No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">   No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:3pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">   No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by our non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-6" name="dei:EntityPublicFloat" scale="6" id="f-30">553</ix:nonFraction> million based upon the closing price reported for such date on the New York Stock Exchange.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">As of February&#160;16, 2026, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">49,941,878</ix:nonFraction> shares of Class A common stock, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-32">8,982,474</ix:nonFraction> shares of Class B common stock, and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-33">3,000,000</ix:nonFraction> shares of non-voting Class C common stock outstanding.  </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-34" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">The information required by Part III of this report is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to its annual meeting of stockholders to be held in 2026, which definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</span></div></ix:nonNumeric><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Item 1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_653">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_653">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Item 1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_609">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_609">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_22">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_25">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_25">Cybersecurity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_25">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_28">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_28">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_31">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_31">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_34">62</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_37">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_40">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_40">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_43">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_43">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_46">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_76">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_76">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_79">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_79">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_79">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_82">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_82">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_82">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_85">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_85">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_88">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_88">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_88">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_91">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_91">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_91">81</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_94">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_97">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_97">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_97">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_100">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_100">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_100">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_103">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_103">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_103">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_106">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_106">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_106">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_109">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_109">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_109">82</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_112">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_115">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_115">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_115">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_118">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_118">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_118">87</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward Looking Statements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This annual report on Form 10-K and our annual report to shareholders (the &#8220;Annual Report&#8221;) include forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of Ginkgo Bioworks Holdings, Inc. (&#8220;Ginkgo&#8221;). These statements are based on the beliefs and assumptions of the management of Ginkgo. Although Ginkgo believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, Ginkgo cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;expects&#8221;, &#8220;projects&#8221;, &#8220;forecasts&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;seeks&#8221;, &#8220;plans&#8221;, &#8220;scheduled&#8221;, &#8220;anticipates&#8221; or &#8220;intends&#8221; or similar expressions. Forward-looking statements contained in the Annual Report include, but are not limited to, statements about:</span></div><div style="margin-top:1pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Ginkgo&#8217;s ability to raise additional capital in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">factors relating to the business, operations and financial performance of Ginkgo, including:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Ginkgo&#8217;s ability to develop and expand its offerings</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the performance and output of Ginkgo&#8217;s cell engineering and biosecurity offerings;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Ginkgo&#8217;s ability to effectively manage its organizational changes, including its restructuring actions commenced in 2024, and related impacts on Ginkgo&#8217;s financial performance;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Ginkgo&#8217;s expectations regarding research and development (&#8220;R&amp;D&#8221;), general and administrative (&#8220;G&amp;A&#8221;) and restructuring expenses;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Ginkgo&#8217;s exposure to the volatility and liquidity risks inherent in holding equity interests in certain of its customers;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the scope and timing of Ginkgo&#8217;s partnerships around the world; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the acquisition and integration of companies, assets or intellectual property that advance Ginkgo&#8217;s objectives and the costs required to maintain, expand and protect Ginkgo&#8217;s intellectual property.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">intense competition and competitive pressures from other companies worldwide in the industries in which Ginkgo operates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">litigation, including securities or shareholder litigation, and the ability to adequately protect Ginkgo&#8217;s intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">rapidly changing technology and extensive competition in the synthetic biology industry that could make the products and processes Ginkgo is developing obsolete or non-competitive unless it is able to successfully collaborate on the development of new and improved products and processes and pursue new market opportunities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Ginkgo&#8217;s ability to convert potential customers from &#8220;on prem&#8221; research and development (&#8220;R&amp;D&#8221;) to outsourced services, Ginkgo&#8217;s reliance on its customers to develop, produce and manufacture products using the engineered </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">cells and/or biomanufacturing processes that Ginkgo develops and Ginkgo&#8217;s ability to accurately predict customer demand, including with respect to the data we access and hold;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Ginkgo&#8217;s ability to comply with laws and regulations applicable to its business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">market conditions and global and economic factors beyond Ginkgo&#8217;s control, including initiatives undertaken by the U.S. government in the biotechnology sector, adverse effects from the U.S. government shutdown, the frequency and scale of biological risks and threats, and the future potential and commercial applications of artificial intelligence (&#8220;AI&#8221;) and the biotechnology sector;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the success of Ginkgo&#8217;s programs, including the growing efficiency and cost-advantage of cell engineering services, and their potential to contribute revenue, and the relative contribution of Ginkgo&#8217;s programs to its future revenue, including the potential for future revenue related to downstream value share in the form of potential future milestone payments, royalties, and/or equity consideration; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">other factors detailed under the section entitled &#8220;Risk Factors.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">These and other factors that could cause actual results to differ from those implied by the forward-looking statements in this Annual Report are more fully described under the heading &#8220;Risk Factors&#8221; and elsewhere in this report. The risks described under the heading &#8220;Risk Factors&#8221; are not exhaustive. Other sections of this Annual Report describe additional factors that could adversely affect the business, financial condition or results of Ginkgo. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can Ginkgo assess the impact of all such risk factors on the business of Ginkgo, or the extent to which any factor or combination of factors may cause actual results to differ materially </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to Ginkgo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Ginkgo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors Summary</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our securities involves risks. You should carefully consider the risks described in &#8220;Risk Factors&#8221; beginning on page </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_609">20</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> before making a decision to invest in our Class A common stock. If any of these risks actually occur, our business, financial condition and results of operations would likely be materially adversely affected. Some of the risks related to Ginkgo&#8217;s business and industry are summarized below. References in the summary below to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;the Company&#8221; generally refer to Ginkgo.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses. We expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Only our employees and directors are entitled to hold shares of Class B common stock (including shares of Class B common stock issued in the future), which have ten votes per share. This limits or precludes other stockholders&#8217; ability to influence the outcome of matters submitted to stockholders for approval, including the election of directors, the approval of certain employee compensation plans, the adoption of certain amendments to our organizational documents and the approval of any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transactions requiring stockholder approval. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need substantial additional capital in the future in order to fund our business. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have experienced periods of significant organizational change, and if we fail to effectively manage these changes, then our business, results of operations, and financial condition could be adversely affected. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our limited operating history and evolving business makes it difficult to evaluate our current business and future prospects. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have in the past, and in the future may continue to pursue strategic acquisitions and investments that are dilutive to our stockholders and that could have an adverse impact on our business if they are unsuccessful. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must continue to secure and maintain sufficient and stable supplies of laboratory reagents, consumables, equipment, and laboratory services. We depend on a limited number of suppliers, some of which are single-source suppliers, and contract manufacturers for critical supplies, equipment, and services for research, development, and manufacturing of our products and processes. Our reliance on these third parties exposes us to risks relating to costs, contractual terms, supply, and logistics, and the loss of any one or more of these suppliers or contract manufacturers or their failure to supply us with the necessary supplies, equipment, or services on a timely basis, could cause delays in our research, development, or production capacity and adversely affect our business. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use biological, hazardous, flammable and/or regulated materials that require considerable training, expertise and expense for handling, storage and disposal and may result in claims against us. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may use our engineered cells, materials, and organisms and accompanying production processes in ways that could damage our reputation. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investments in and use of AI may result in reputational harm, liabilities, or other adverse consequences to our business operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our recent restructuring actions in connection with our plans to reduce operational expenditures may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our customers discontinue their development, production and manufacturing efforts using our engineered cells and/or biomanufacturing processes, our future financial position may be adversely impacted. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Further, because our revenue is concentrated in a limited number of customers, some of which are related parties, our revenue, results of operations, cash flows and reputation in the marketplace may suffer upon the loss of a significant customer.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We are or could become involved in securities or shareholder litigation and other related matters, which could be expensive and time-consuming. Such litigation and related matters could harm our business.</span></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In certain cases, our business partners may have discretion in determining when and whether to make announcements about the status of our collaborations, including about developments and timelines for advancing programs, and the price of our common stock may decline as a result of announcements of unexpected results or developments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Uncertainty regarding the demand for passive monitoring programs and biosecurity services could materially adversely affect our business. </span></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Rapidly changing technology and emerging competition in the synthetic biology industry could make the platform, programs, services, tools and products we and our customers are developing obsolete or non-competitive unless we continue to develop our platform and pursue new market opportunities. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ethical, legal and social concerns about genetically modified organisms (&#8220;GMOs&#8221;) and genetically modified plant or animal cells and genetically modified proteins and biomaterials (collectively, &#8220;Genetically Modified Materials&#8221;) and their resulting products could limit or prevent the use of products or processes using our technologies, limit public acceptance of such products or processes and limit our revenues. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain, maintain and defend patents protecting our intellectual property, our competitive position will be harmed. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position will be harmed. We may become involved in lawsuits or other enforcement proceedings to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and potentially unsuccessful. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on our customers, joint venturers, equity investees and other third parties to deliver timely and accurate information in order to accurately report our financial results in the time frame and manner required by law.</span></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We had in the past identified a material weakness in our internal controls over financial reporting, and we may identify additional material weaknesses in the future. A failure to maintain an effective system of internal control over financial reporting may result in a failure to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Failure to comply with federal, state, local and international laws and regulations could expose us to significant liabilities or penalties and adversely affect our business, our financial condition and results of operations and we may incur significant costs complying with such laws and regulations</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our laboratory partners are subject to a variety of laboratory testing standards, compliance with which is an expensive and time-consuming process, and any failure to comply could result in substantial penalties and disruptions to our business. </span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant disruptions to our and our service providers&#8217; information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">iii</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_653"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Item 1.&#160;&#160;&#160;&#160;Business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Unless the context otherwise requires, all references in this section to the &#8220;Company,&#8221; &#8220;Ginkgo,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; refer to the business of Ginkgo Bioworks Holdings, Inc. and our subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Overview: Our Mission is to Make Biology Easier to Engineer</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Our mission is to make biology easier to engineer. That has never changed. Every choice we&#8217;ve made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Why? Because:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:10.5pt">Biology is programmable. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">All living things run on the same DNA code.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:10.5pt">Biology matters. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The ability to engineer biology has had and will have a profound impact on how we develop new medicines and vaccines, grow our food, and manufacture many of the things we use every day.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">3.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:10.5pt">Biology is hard. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Today, it is still too difficult and too costly to engineer biology, preventing critical innovations from reaching the market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo sells services to government and commercial customers in two business segments: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">cell engineering</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">, where we provide tools and biological R&amp;D services across a range of industries, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">biosecurity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">, where we provide services to customers who are working to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. An overview of these two business segments is provided below.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Cell engineering</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Our cell engineering customers work with biology to discover and manufacture new products that have transformative potential across industries:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">in medicine, developing innovative new therapeutics and vaccines;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">in agriculture, advancing the sustainability and security of our food systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">in industrial biotechnology, advancing the way we manufacture a wide range of products for better performance and lower environmental impact; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">in government, advancing new R&amp;D priorities of strategic importance to the United States and its allies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Because engineering biology is difficult and unpredictable, biotech R&amp;D is traditionally performed by in-house labs filled with highly trained scientists running lab experiments by hand over several years in the hope of ultimately developing a working product. Many cell engineering projects fail in development due to scientific challenges, and many are terminated because they are taking too long or are over budget.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Ginkgo does not make end products; instead, we offer biological R&amp;D services on our platform to enable our customers to bring </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">their</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> products to market. Historically, Ginkgo&#8217;s primary service offering has been cell engineering R&amp;D services (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">solutions</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">) where Ginkgo performs technical activities. In 2024, Ginkgo expanded its service offering to include services that provide our customers cell engineering </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">tools</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> for biological R&amp;D, where Ginkgo enables its customers to conduct certain in-house R&amp;D activities themselves. Our services are designed to offer customers better results on the dimensions of probability of success, speed, or cost &#8211; and ideally on all three. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The fundamental advantage of our cell engineering platform over traditional cell engineering done by hand at our customers&#8217; labs is that our platform improves with scale while in-house cell engineering in our customers' labs largely does not. Compounding and mutually reinforcing improvements of our laboratory automation and software infrastructure&#8212;our Autonomous Lab&#8212;and our reusable data assets enable us to improve our services with each successive project.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Our Autonomous Lab is a flexible wet lab built from our Reconfigurable Automation Cart (&#8220;RAC&#8221;) systems capable of large scale data generation; it powers generative AI and machine learning (&#8220;ML&#8221;) tools that enable more successful biological R&amp;D. We now offer services providing such data generation, AI and automation tools directly to Ginkgo customers. Our data assets comprise best practices for cell engineering, along with sequences and host cells that have been honed through dozens of programs and can be directly reusable for our cell engineering solutions.  We now offer licenses to our host cells and other IP assets, such as our broad metagenomic library. </span></div><div><span><br/></span></div><div style="text-align:center"><img src="dna-20251231_g1.jpg" alt="image_1.jpg" style="height:302px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-1"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Cell engineering service offerings, depicted on a spectrum of customization and technical risk borne by Ginkgo on the vertical axis, and the mix of up-front service fees and downstream value we charge on the horizontal axis. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Biosecurity</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">In every technological revolution, reaping the benefits to the economy and society requires grappling with the corresponding risks. A critical part of making biology easier to engineer is creating robust biosecurity infrastructure to help manage the many accelerating and diversifying sources of biological risk, whether natural or engineered, accidental or malicious.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">In the digital world, we&#8217;ve learned that we need to build comprehensive infrastructure to protect our digital systems &#8212;from financial markets to power grids&#8212;from harmful code. The modern cybersecurity industry offers tools to constantly identify, monitor, prevent, and mitigate cyber risk in near real-time. This is happening constantly, all around us. Our physical world demands the same type of widespread biosecurity infrastructure to detect, characterize, respond to, attribute, and prevent biological threats.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Building widespread biosecurity infrastructure is not easy, but the COVID-19 pandemic and subsequent biothreats (e.g., H5N1 and mpox) illustrate the growing risk and urgent need for a solution. During the COVID-19 pandemic, our healthcare infrastructure, the biomedical technology industry, and communities across the world mobilized in valiant and unprecedented ways, but millions of lives and trillions of dollars were still lost. Our current systems are overly reactive and remain insufficient to protect us from future biothreats, whether they come from Mother Nature, bioerror, or bioterror.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We need a fundamentally different approach to securing biology&#8212;one that starts with data. The genomic information that underlies the biological world is what allows us to program it like computers, and it&#8217;s what allows us to understand biology at a molecular level and learn to predict how it&#8217;s going to behave in the world. Our biosecurity platform is built on the premise that genetic information is a critical data asset that will form the foundation for next-generation biosecurity. By building services to help our customers monitor and analyze this data, we believe we are contributing to a step change in humanity's ability to rapidly and reliably identify, monitor, prevent, and mitigate biological threats.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Because biosecurity is a matter of national and global security, our primary biosecurity customers are governments. Our biosecurity offering has evolved over the past several years. We currently provide biosecurity services via two core offerings:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">Canopy</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">, which helps our customers generate high value genomic data from strategically-positioned nodes (like airports and border checkpoints) via end-to-end biomonitoring programs; and</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">Horizon</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">, our digital surveillance, analytics and insights platform that detects and monitors biothreats worldwide.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Like our cell engineering platform, our biosecurity platform gets better with scale. As we deploy more detection nodes, we can achieve earlier detection and develop deeper insights about biothreats as they originate and travel across the globe. We invest in our platform to build out our operational (e.g., new node types), lab (e.g., new target detection), and digital (e.g., better prediction) capabilities. Increasing scale substantially strengthens the efficacy of our platform, as global data from multiple sources provides insights beyond what any single country&#8217;s data could yield alone.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Cell Engineering: enabling the discovery, functional optimization and efficient manufacturing of biotechnology products</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Biology runs on a digital code. It&#8217;s just A&#8217;s, T&#8217;s, C&#8217;s, and G&#8217;s rather than 0&#8217;s and 1&#8217;s. There are sequences that code for programming logic&#8212;turning genes on when certain conditions are met&#8212;and there are sequences that encode functions and behaviors&#8212;the physical structures of proteins and enzymes that create biological structures and materials or catalyze chemical reactions. Synthetic biologists build cell programs by writing new sequences combining regulatory and functional elements into a synthesized strand of DNA and booting them up in cells to perform useful tasks, usually producing a particular bioproduct such as RNA, protein, enzyme, or chemical. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Biological code programs the world of atoms, not bits. This is what makes the potential impact of cell engineering so great, and inspires us to work to make biology easier to engineer and secure. But it also poses incredible challenges that make cell programming so hard today. Our code is a physical object with chemical properties. It folds and binds and interacts in many complex ways. It produces proteins that catalyze chemical reactions that interact in a complex web of connections. Even the simplest cell programs encounter incredible complexity, emerging from all of the interactions of chemicals, DNA, RNA, and proteins inside of a cell.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Because all organisms run on the same DNA code, general-purpose cell programming can be applied across many different markets to enable the design of new innovative products as well as improve manufacturing cost and sustainability of existing ones. Given the breadth of application areas and the potential of biology, we believe that the end markets for bioengineered products will be enormous. As we develop a greater ability to program biology and direct it towards novel and more challenging applications, the spectrum of possibilities will undoubtedly grow.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Today, our services span markets and modalities to enable a wide range of biotech products, including, but not limited to, systems for the discovery, optimization, and manufacturing of:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">DNA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> sequences delivered as vaccines and gene therapies,</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">RNA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> sequences for vaccines and therapeutics including mRNA, circular RNA, and other approaches,</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">Proteins</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> used in biologic medicines and antibodies, adeno-associated virus (&#8220;AAV&#8221;) capsids and other delivery methods for gene therapies, vaccines, plant traits for crop protection, and food and alternative meat and dairy,</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">Enzymes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> used in biocatalysis, diagnostics, therapeutics, and RNA vaccine production,</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">Small molecules</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> and natural products that can be produced via pathways of multiple enzymes in engineered cells for pharmaceutical ingredients and adjuvants, agricultural biochemicals, cosmetics and food ingredients, and specialty or commodity chemicals,</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">Microbial</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">cells</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> that can provide crop nutrition or crop protection in agriculture, impact soil carbon sequestration to help address climate change, and microbiome therapeutics, and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">Mammalian</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">cells</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> for manufacturing of biologics, genomic medicines, and cell therapies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Ginkgo provides these services using its platform for cell engineering. This platform brings together technology, data, biological assets and subject matter experts:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">proprietary automation technologies that enable flexibility and scale,</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">in-house software, machine learning, and generative AI models for cell programming,</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">massive databases of DNA sequences and labeled data on functional performance of engineered cells,</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">reusable assets that enable faster and more predictable cell programming, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">expert scientists that leverage platform tools and data to enable partners to achieve their desired results</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Enabling customer success across markets</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We sell engineering solutions and cell engineering tools offerings to customers across markets. Our customers bring incredible depth and expertise in their unique technical domains and market areas. Whether it&#8217;s their understanding of underlying disease biology or plant physiology, their experience with the performance of regulatory trials in animal studies, in the clinic, or in the field, or their knowledge of product formulation and functional testing, they have specialized deeply to be able to develop, manufacture, distribute, and market a product. Our role is to enable the customer's success: we provide R&amp;D tools and solutions that help them access more biological design space in order to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">discover and optimize functionality</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">develop efficient manufacturing methods</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> for their products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Government</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Ginkgo is a trusted partner to government agencies worldwide as they work to protect people, supply chains, and critical resources, all by leveraging the power of biology. We regularly serve as a prime contractor on major research awards, bringing together partners and integrating their diverse biological capabilities. We also often support projects and research consortia as an R&amp;D subcontractor.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Pharmaceutical and Biotechnology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">There is an urgent and critical need for new, better, and more accessible therapeutics and vaccines worldwide. There is also widespread realization across the pharmaceutical industry that research productivity must be enhanced in order to meet this need. Yet, even with hundreds of billions of dollars spent annually on pharmaceutical R&amp;D, the cost to bring a new drug to market is only increasing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The pharmaceutical industry today relies heavily on outsourced R&amp;D, both to specialized, innovative small biotech, as well as to contract research organizations (&#8220;CROs&#8221;) that can perform specific common workflows at different stages of the R&amp;D process for enhanced efficiency. These approaches enable access to both innovation and efficiency, but incur high switching costs both organizationally and technically. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">At the same time, there is great promise in how AI tools may help uncover new disease biology and targets for therapeutics, as well as enable the programming of new medicines, in particular biologics and genomic medicines that are directly encoded in DNA and RNA sequences. Pharmaceutical R&amp;D teams are looking for ways to generate and federate data to train better AI models, design and test more technical approaches, drive candidates at the preclinical stage to &#8220;fail fast&#8221; before costly clinical trials, and develop better leads by simultaneously optimizing along multiple dimensions important for therapeutic index as well as manufacturability and cost.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Our pharmaceutical and biotechnology customers use our services to develop new manufacturing methods for gene therapies, biologics, vaccines, and small molecule therapeutics and active pharmaceutical ingredients (&#8220;APIs&#8221;), and to discover new RNA therapeutics, natural products, and much more. They use our tools to generate high-quality data for training and validating AI models of cell and disease biology for use in target identification, target validation and drug discovery as well as for antibody developability.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Agriculture</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Agriculture likewise faces an urgent need for innovation to address growing pressure on growers and food systems. Worldwide, agricultural innovation struggles due to long timelines, complex regulatory paths, and siloed data and capabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Innovators in agricultural technology tap into biological diversity to develop new crop protection strategies, to combat resistance, and to provide safer, low residue options for growers that meet consumer expectations and regulatory guidelines. These product developers need to understand mode of action and improve the performance and stability of innovative biologicals for crop nutrition and crop protection. And increasingly, they are also innovating in soil carbon sequestration and climate strategies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Our customers in agriculture use our services to improve the performance and manufacturability of existing agricultural biologics, develop revolutionary new products for crop nutrition in nitrogen fixation, phosphate solubilization, or carbon sequestration, and design new insect control proteins and other crop protection products to protect food security. We also offer 3,000 liters of pilot plant capacity for efficacy trial material generation, as well as a network of growth chambers and an approximately 12,000 square foot greenhouse facility for screening engineered microbes and wild-type microbes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">in planta.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Industrial Biotechnology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">There is an enormous breadth of products&#8212;chemicals, enzymes, and proteins&#8212;already produced via biotechnology today or being actively developed by companies across many markets, including food and nutritional ingredients, wellness, cosmetics, and personal care, industrial processes and chemicals, and materials innovation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Our customers in industrial biotech use our services to achieve a variety of objectives, such as improve the manufacturing efficiency and cost of goods sold for their new and existing biotechnological products, innovate materials with enhanced performance, develop enzymes for breaking down harmful pollutants or cells and proteins optimized for capturing rare earth elements, or valorize waste streams into feedstocks for more valuable products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Cell Engineering Tools</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A selection of our cell engineering </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">tools</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> offerings are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">Reconfigurable Automation Cart (&#8220;RAC&#8221;) Systems</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo Automation&#8217;s capabilities build on years of internal expertise honed at Ginkgo and Zymergen, encompassing hardware design, software integration, and applications development, epitomized in our offering of RACs: our Reconfigurable Automation Cart systems. The modularity and flexibility of the RACs enables high walkway time, high uptime, reduced cycle times, and high throughput experimentation for high-mix biological workflows like the kinds performed in Ginkgo&#8217;s Autonomous Lab and in our partners&#8217; labs. In addition to providing advanced automation hardware and software, Ginkgo Automation&#8217;s deployments to third party customers include access to our top-tier Apex Support, a fully remote, active error resolution and troubleshooting support service. Apex Support&#8217;s proactive monitoring is expected to enable Ginkgo&#8217;s support engineers to identify and resolve approximately 80-90% of system errors remotely, without the need for our customers to initiate tickets. We are actively developing, both internally and in collaboration with external partners, enhanced autonomous capabilities for our automation platform. These efforts are focused on enabling increasingly AI-driven, closed-loop experimentation, which has the potential to materially improve experimental efficiency, throughput, and decision-making for customers ranging from pharmaceutical companies to academic and government research institutions. We expect that, as these technologies mature, RAC systems deployed in customer environments could be upgraded through software updates to support higher levels of autonomous operation. We believe this software-upgradable architecture positions the RAC platform to incorporate future advances in autonomous science without requiring wholesale replacement of deployed systems.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Datapoints </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Recent advances in ML, molecular simulation, and other computational techniques hold great promise to improve our ability to program cells. We believe our Autonomous Lab is well-positioned to build the kind of large, well-structured datasets that such computational approaches need to succeed. In time, we believe computational approaches will reduce the need for certain kinds of experiments (for example, we already use ML to make protein and enzyme design projects more efficient). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">To this end, we have introduced three new data generation services to provide high-quality data at the scale, price, and speed that AI-powered drug development demands:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">a.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.07pt">Our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Functional Genomics</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"> Datapoints services generate large, high fidelity transcriptomic and phenotypic datasets in the disease context of our customers&#8217; choice to power AI models of cell and disease biology for use in target identification, target validation, and drug discovery.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">b.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:10.5pt">Our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Antibody Developability</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"> Datapoints services generate biophysical antibody characterization developability datasets for our customers to use in AI model training and validation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">c.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.07pt">Our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Small Molecule Developability </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Datapoints service generates high-quality small-molecule characterization data spanning absorption, distribution, metabolism, and excretion (&#8220;ADME&#8221;). These datasets support human dose prediction and power AI-driven predictive medicinal chemistry campaigns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">AI models</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">As Ginkgo drives scalability through our models, we have heavily invested in the use and creation of AI foundational and fine-tuned models, which we believe can provide significant benefits to our customers. Because of our access to large amounts of data, which is critical to efficiently leverage AI, Ginkgo is well-positioned to build superior foundational models and from there, build fine-tuned models designed to cater to our customer needs, all powered by our partnership with Google Cloud. We have released a selection of  these models on our Model API. </span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Cell Engineering Solutions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">A selection of our end-to-end cell engineering </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">solutions </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">offerings are described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Protein engineering and production for biopharmaceutical applications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We provide a suite of microservices for product developers across industries that support bioengineers with protein engineering an enzyme variant library design service, access to our proprietary low-viscosity </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Aspergillus niger </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">strains, the performance of proof-of-concept protein production studies to evaluate and optimize protein production in high-performance chassis, as well as access to our EncapS platform - a cutting-edge, ultra-high throughput screening service designed to rapidly identify strains with enhanced protein titers. These on-demand services balance flexibility and cost-effectiveness with access to powerful technologies that enhance R&amp;D efficiency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Genetic medicines </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We provide comprehensive R&amp;D services spanning the major genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. Our capabilities include developing precision delivery systems through viral and non-viral approaches, engineering payloads for targeted expression, and optimizing manufacturing processes at scale. For gene therapy, we provide AAV capsid design and optimization, payload engineering, and high-titer production solutions. In cell therapy and gene editing, we support CAR-T development, gene editor discovery, and immune cell engineering with our high-throughput screening platforms. For RNA therapeutics, our services are intended to help customers optimize mRNA and circular RNA sequences for improved stability and expression, alongside lipid nanoparticle delivery system development. These services are complemented by our suite of licensable assets including capsids, promoters, untranslated regions (&#8220;UTRs&#8221;), internal ribosome entry sites (&#8220;IRESs&#8221;), and chimeric antigen receptor (&#8220;CAR&#8221;) components, validated through extensive in vitro and in vivo testing. Our integrated approach combines domain expertise in protein engineering, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">high-throughput experimentation, and advanced analytics to address key challenges in immunogenicity, off-target effects, and regulatory compliance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Packaged solutions for biopharmaceutical applications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We provide standardized, ready-to-use solutions for accelerating biopharmaceutical R&amp;D. We provide curated panels of enzymes for active pharmaceutical ingredient (API) manufacturing, including 192 Imine Reductase (IRED) enzymes and 384 2-Oxoglutarate Dependent Dioxygenases (2ODD) enzymes. Our EncapS platform for API production leverages ultra-high throughput screening technology to improve production strain productivity by 10-30%, screening libraries of over 1 million variants through nanoliter co-encapsulation. For genetic medicines, we provide licensable assets including promoters that surpass industry standards, optimized UTRs for enhanced RNA stability and protein expression, engineered AAV capsids with reduced antigenicity and improved tissue targeting, and synthetic immune receptors for cell therapies. These offerings are supported by easy-to-access fee-for-service programs, including our collaboration with Virica Biotech for AAV manufacturing optimization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Small molecules &amp; biologics for biopharmaceutical applications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We provide comprehensive R&amp;D services spanning both small molecule therapeutics and biologics. For small molecules, we enable the discovery and production of diverse compounds including APIs, natural products, antibiotics, antifungals, antivirals, and antibody-drug conjugate (ADC) payloads through our strain engineering expertise and biosynthetic pathway discovery capabilities. Our biologics services support the development and optimization of therapeutic proteins, peptides, enzymes, and other biological products using AI-driven protein engineering and our proprietary production platforms, including high-output methanol-free Pichia pastoris strains. These complementary capabilities are supported by our integrated approach to strain design, high-throughput screening, fermentation optimization, and downstream processing, all focused on achieving economical and high-quality production outcomes for both chemical and biological therapeutics.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Crop nutrition </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We provide comprehensive R&amp;D services focused on advancing biological solutions for crop nutrition and plant health. Our services span three key areas: nutrient use efficiency, where we help develop products that optimize nutrient bioavailability; carbon fixation, where we work on biologicals that enhance soil health; and abiotic stress management, where we develop solutions to improve crop resilience against environmental stressors. These capabilities are supported by our extensive strain collection of over 315,000 agriculturally-relevant microorganisms, validated </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">in planta</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> screening assays, and expertise in scaling up both whole-cell and biochemical active products. We offer both fee-for-service testing using our validated assay cascade from 384-well plates to greenhouse studies, as well as collaborative R&amp;D partnerships spanning strain engineering through process development and formulation optimization. A flagship example of our capabilities is our partnership with Bayer Crop Sciences, where we are developing biological solutions for nitrogen fixation in non-legume crops to reduce reliance on industrial fertilizers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Crop protection </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We provide comprehensive R&amp;D services to help partners develop and optimize biological crop protection products. Our capabilities include validated </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">in planta</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> screening assays that enable confident selection of lead candidates, extensive expertise in scaling up active ingredients including both Cry proteins and novel bioactives, and access to our proprietary collection of over 315,000 strains isolated from agriculturally relevant environments. We work with partners through both fee-for-service arrangements focused on generating rigorous data packages to inform decision-making, as well as collaborative R&amp;D projects aimed at developing market-ready products. Our services span the full product development cycle from strain selection and screening through process optimization, formulation development, and field trial support. Partners can access our platform to expand their product portfolios with novel biocontrols, optimize the performance of existing products, reduce manufacturing costs, or generate reliable data to support their development programs. Throughout the development process, we focus on optimizing manufacturing costs and process efficiency to ensure products can be produced at commercially viable price points that meet market requirements for growers and product developers that market to them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Plant traits </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We provide comprehensive R&amp;D services for discovering and optimizing plant traits, leveraging our proprietary metagenomic library of over 2.7 billion genes (with less than 5% overlap with public databases). Our capabilities in this space combine machine learning-based protein engineering, informed by over 15 years of experimental data collection, with expertise in optimizing multi-gene-of-interest trait expression in complex eukaryotic systems. We provide services spanning the full development cycle, from early trait discovery using patented enrichment and amplification techniques, through lead optimization using iterative high-throughput screening approaches, to gene construct design with optimized codons and promoters for more reliable expression. Our pilot plant site allows us to leverage proprietary host strains optimized for protein and enzyme production to test out material generation capabilities through large-scale efficacy trials. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Protein engineering and production for industrial biotechnology </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We provide R&amp;D services that help our partners optimize production hosts for nutritional and functional protein manufacturing, and to develop effective enzymes and biocatalysts for industrial applications. Our industrial partners can access our enzyme discovery, enzyme optimization, assay development &amp; high-throughput screening, and protein production expertise, taking advantage of our range of well-characterized and high-performance bacterial, fungal, and mammalian chassis strains, as well as our very wide range of experience designing and running scientific campaigns to engineer and improve these hosts. Our partners in the nutritional and functional protein space work with us to build research campaigns that leverage the above capabilities, as well as our investment into an in-house suite of host strains designed for glycoprotein, iron-bound, and structural protein production. Whether they are developing sweeteners, alternative dairy, alternative egg, thickeners, preservatives, or other exciting protein-based innovations, we can offer our partners in this space a mix of host evaluation and proof-of-concept studies, production host design and optimization campaigns, enzyme discovery and optimization research, and process development &amp; scale-up (described further below) capabilities to help de-risk and accelerate their R&amp;D and go-to-market timelines.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Small molecules for industrial biotechnology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We work with partners in the sustainable ingredients and chemical spaces, as well as across the flavors, fragrance, and colorant industries to support their R&amp;D and manufacturing optimization efforts. Our particular expertise includes experience with microbial bio-production of many classes of natural products, including of terpenoids, esters, aromatics, organic acids, pigments, and bioactive alkaloids. We offer a range of custom R&amp;D solutions that support our customers with molecule prototyping and pathway discovery, strain design and optimization for bioproduction, non-genetically modified strain improvement technologies, and our bioprocess development and scale-up capabilities (described below). In the flavors, fragrances, and colorants industries, customers also often access our proprietary database of microbial chassis and specialized tailoring enzymes (like terpene synthases, glycosyl transferases (UGTs), O-methyltransferases, and cytochrome P450s) which supports their efforts to improve pathway optimization, byproduct reduction, and enhanced product safety. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Fermentation and scale-up</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Our wet lab includes a fleet of Sartorius Ambr&#174; 250 bioreactors, as well as a suite of colocated analytical instruments that our customers can leverage to deeply and widely explore strain performance across multiple fermentation and media conditions. We can pair this service with customized ML-enabled analysis to obtain and provide to our customers deep physiological, genetic, and chemical insight into strain performance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">On the larger scale, we also offer in-house pilot fermentation capacities at 5, 10, 30, and all the way up to 3,000 liters of pilot plant capacity for bioprocess development and scale-up. We can support our partners in proving out production processes with iterative and statistical approaches to develop robust fermentation process conditions, informed by automated sampling and standard analyses of secreted metabolites.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Biosecurity: scaling biological intelligence for securing lives and livelihoods</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">Addressing biosecurity starts with being clear-eyed about biological risks and threats. We hold at our core the tremendous positive potential of biology, and we know that we&#8217;re facing a biological landscape with more frequent, more severe, and more varied threats through time.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our world is increasingly interconnected through travel and trade, giving pathogens and biological agents new opportunities to spread across the globe, impacting people&#8217;s health along with the complex global supply chains that our societies depend on to function. Climate change and habitat disruption are creating conditions for pathogens to emerge and spill over between animal populations and into humans more often and with more severe consequences. A global boom in investments into bio-laboratory capacity, designed to improve our tools to combat such pathogens, also comes with heightened risk of lab accidents&#8212;in spite of substantial efforts to improve biosafety. And unfortunately, there are those who seek to use biology for nefarious purposes, misusing its incredible potential to cause harm.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">These trends are intertwined with geopolitical competition and destabilization, eroding buy-in and trust in institutions, and emerging technologies in both biotechnology and AI/ML, presenting a core security challenge for nations and the world. Our biosecurity platform is designed to help national and global leaders answer questions about and potentially protect from biological threats.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Governments around the world are currently our primary customers as they seek to protect their citizens, economies, and critical infrastructures from biothreats. We have worked extensively with the U.S. government across the federal, state, and regional levels, and maintain the lab, logistical, and local relationships necessary to work closely with partners across the country in the event of any large-scale biothreat response. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">The biosecurity services that we sell</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We serve these customers through two core offerings:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">Canopy</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> helps our customers generate high value genomic data from strategically positioned nodes (e.g., airports and borders) via end-to-end biomonitoring programs including: </span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',serif;font-size:10pt;font-weight:400;line-height:133%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12pt">Program services such as program design, lab enablement, procurement, collection, and lab support;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',serif;font-size:10pt;font-weight:400;line-height:133%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12pt">Data services such as bioinformatics and epidemiological tools, data delivery and data visualization;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',serif;font-size:10pt;font-weight:400;line-height:133%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12pt">Insights such as specialized reports and technical briefings specific to customers&#8217; programs; and</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',serif;font-size:10pt;font-weight:400;line-height:133%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12pt">Products such as standard of procedures (SOPs) and specialized lab assays. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:14.5pt">Horizon</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> is our data, analytics and insights platform that detects and monitors biothreats worldwide. It seeks to answer questions like: </span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',serif;font-size:10pt;font-weight:400;line-height:133%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;padding-left:12pt">What biothreats are occurring? </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Where in the world do we see emerging biothreats?</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',serif;font-size:10pt;font-weight:400;line-height:133%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;padding-left:12pt">What is this new biothreat and how bad is it?</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> How might it spread and evolve? Who (or what infrastructure) will be affected? How likely is the biothreat to result in a major outbreak?</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',serif;font-size:10pt;font-weight:400;line-height:133%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;padding-left:12pt">Where did a biothreat emerge and how?</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> Is there evidence of misuse and if so, what can we learn about the perpetrators? </span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',serif;font-size:10pt;font-weight:400;line-height:133%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;padding-left:12pt">What can I do about a biothreat?</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"> How effective will existing countermeasures be? Should we develop new countermeasures, and if so, what should they look like? What are my ideal response options given resource constraints and mitigation goals? </span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Ginkgo Biosecurity&#8217;s tailored Canopy product is a persistent, pervasive, locally-operated collection of environmental samples from strategic high-risk nodes&#8212;designed to detect and identify biothreats across a growing array of collection and sample types. The samples are analyzed through genomic sequencing of non-human DNA to turn the environment into data. Today, we are looking for a large and growing set of known threats, and we are developing methods that are threat agnostic and able to pick up on entirely novel genetic signatures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><img src="dna-20251231_g2.jpg" alt="image_2.jpg" style="height:295px;margin-bottom:5pt;vertical-align:text-bottom;width:666px" id="i-2"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Our Canopy technologies are expanding, and our goal is to be able to sample from a wide variety of nodes where pathogens emerge or spread, such as those pictured below. Our network scales to be more efficient as we add greater volume and diversity of nodes. Our Canopy product scales primarily by driving efficiency through increased volume by better physical and lab operations including program learnings, lower overhead requirements, and purchasing power.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="text-align:center"><img src="dna-20251231_g3.jpg" alt="Biosecurity-Nodes.jpg" style="height:446px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-3"/></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">(Note: nodes are illustrative and not necessarily indicative of current or past programs.)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Horizon is our data, analytics and insights platform that provides reporting of biothreat events worldwide, using three distinct data feeds: Early Detection, Genomic Surveillance, and Digital Biothreat Intelligence. The Canopy data from given programs or jurisdictions are integrated with other global data sources&#8212;from our monitoring network, open-source intelligence capability, and other sources&#8212;and analyzed using a suite of computational tools to help customers gain a more comprehensive picture of the biothreats they&#8217;re facing. Our Horizon business also scales as volume and node diversity increases as we have more information (e.g., via volumes) and more diverse data (e.g., via nodes), our insights across the system are further enhanced. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our operations are anchored by Ginkgo&#8217;s headquarters in Boston which serves as a hub for managing our programs and analyzing data from our global network. Our network is increasingly bolstered by our operational and laboratory partners throughout the world. We will continue to enhance this network in the future through new partnerships. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">How we make money</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Cell engineering revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">Cell engineering tools offerings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We charge customers fees for the services we provide in our cell engineering tools offerings. Fees for our automation solutions (RAC systems) are typically earned over a period that covers design, build, and deployment and range from six to twelve months. In addition, we offer support services for our RAC systems with fixed fees covering the support periods. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Fees for our Datapoints services are typically earned over a shorter period of time (weeks to months) than for cell engineering solutions, which may be multi-year programs. A typical deliverable for a Datapoints program is a data package. Fees for cell engineering solutions programs are typically structured as a fixed fee for a fixed scope of work.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">Cell engineering solutions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our cell engineering solutions are typically scoped and delivered as a program ranging in duration from several months to several years. A typical deliverable for the program would comprise an enzyme sequence, or an engineered strain or cell line and its associated bioprocess. For each of these programs, we generate economic value in two primary ways. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">First, we charge service fees for Autonomous Lab services, in much the same way that cloud computing companies charge usage fees for utilization of computing capacity or CROs charge for services. R&amp;D is inherently risky and our customers recognize that this is a cost they will incur regardless of success and whether they are working on the program in-house or with a partner. Typically, service fees for a program include a fixed fee for a fixed scope of work and may also include payments contingent upon hitting certain technical milestones. If we are able to deliver program results with less work through the use of Codebase assets and/or generative AI tools, then we can achieve the same revenue with lower cost or in a shorter duration. Service fees provide a strong foundation of revenue that is independent of any commercialization efforts by our partners. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Second, as the key enabling technology for our customers&#8217; products, we have historically negotiated a value share with our customers (in the form of royalties, milestones, and/or equity interests) in order to align our economics with the success of the programs enabled by our platform. Because we typically do not incur material downstream costs (e.g., manufacturing or product development, which our customers manage), these value share payments flow through with approximately 100% contribution margin. We have structured a variety of value sharing mechanisms, including royalties, lump-sum milestones, and equity payments. As Ginkgo has matured, we have shifted our downstream value towards milestone payments and commercial royalties rather than equity. In addition, commencing in the second quarter of 2024, we announced changes in prospective commercial terms, including the removal of downstream value share from certain program types.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">This flexible business model allows for more predictable near-term revenue in up-front research fees and technical milestones without sacrificing our ability to create long-term value with asymmetric upside through downstream value share (typically in the form of a royalty stream, milestone, and/or equity share). As we add more programs to the platform over time, we expect downstream value share to contribute income, which could in turn grow our overall margins and cash flow profile for our cell engineering solutions. The realization of potential revenue related to downstream value in the form of potential future milestone payments and royalties and/or equity consideration is dependent upon a number of factors, including our ability to successfully develop engineered cells, bioprocesses, data packages, or other deliverables, and the product development and commercialization success of our customers.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Biosecurity revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Since the end of the COVID-19 public health emergency in May 2023, Ginkgo has transitioned its Biosecurity business to focus on building out scalable biosecurity infrastructure through our two offerings, Canopy and Horizon. Through our partnerships, Ginkgo operates Canopy programs for collections, testing, sequencing, and insights delivery on pathogen samples in different countries. Ginkgo is also investing in building our Horizon product, in consultation with our existing network and additional public and private partners, as we think it has the potential to significantly drive revenue in the future. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Our commitment to caring about how our platform is developed and used</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Biotechnologies already touch nearly every part of society, and they will only grow in importance to our collective security and livelihoods in the future. Because of their far-reaching impacts on the world and because we are biological beings who are both dependent on and vulnerable to the capabilities we enable, we must take great care in the ways these technologies are developed and used.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We are cognizant that making biology easier to engineer won&#8217;t make the world better by default, but we believe these capabilities are essential to creating a better future where we can contend with both existing and emerging threats. To succeed in our long-term mission, we must avoid multiple failure modes. We must avoid creating capabilities that cause harm in ways that aren&#8217;t or can&#8217;t be mitigated. We must avoid reinforcing inequities in the uses of technologies and to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">whom their benefits accrue&#8212;thereby claiming to change the world but changing not much at all. We must avoid a loss in trust in biotechnologies and the motivations of their developers that limits our ability to bring solutions to global challenges from protecting against pandemics to feeding the planet. And so, we must chase, every day, the development of capabilities and partnerships that can lead to value generation undergirded by sustained attention to the values they reflect.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">As our platform grows, so too does our power to enable and shape many impacts we care about. While we are proud of our direct impacts on making biology easier to engineer, most of the world cares about the impacts on the world that we indirectly enable through helping our customers with the products they deliver. We grow as a platform precisely because we help create more value for our customers and the world than we capture. Our position serving customers across many industries provides strategic insights into what issues need collective attention to ensure future products can deliver meaningful solutions. But as a platform we cannot anticipate and control all future uses of our technologies by our customers and those they work with.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Far from abdicating responsibility, we realize our power is to inspire and help enable others to carefully steward technologies with attention to their impacts over time. This is directly in line with our long-term value proposition, as we need our customers and the ecosystem to succeed in avoiding the failure models outlined above and build the collective biotechnology-enabled future we all can wish for. We believe that stewardship starts with our platform and the people within it. Just as we must build and inspire trust in our partners to steward our technologies with care, we build and inspire trust in all of our bioworker-owners to build our platform with care.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We must also pay special attention to the governance of leading capabilities for we have outsized ability to shape.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">At a macroscopic level, building biosecurity capabilities is an example of where we assessed the need for complementary efforts that could safeguard future biotechnologies&#8211;including those developed on our platform. But this same philosophy applies across our platform including as we work to harness powerful new capabilities in AI. We believe that our platform design is a foundation for architecting security and access that can both enable positive uses while better understanding and protecting against scenarios of misuse.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We see caring about how our platform is developed and used not as a net cost but as an enabler at multiple scales of impact aligned with long-term value. It builds trust and credibility not only in our capabilities but those of our customers. It motivates and enables our employee-owners to drive the platform towards the many diverse uses they co-envision with our platform. It also advances a framework to go beyond a reactive historical frame that has often positioned genetic engineering as a risk to the environment rather than a value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We recognize that platforms across other industries have lessons&#8212;many negative&#8212;on how to steward their development and use. Our high-level commitment to care also comes with the expectation of needing to regularly revisit the approaches to realizing that commitment.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Our People &amp; Culture</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">A company is made of people. We have sought to bring together a talented and multidisciplinary group of people who share our mission to make biology easier to engineer. Today, our extensive cross-functional team is collaborating to build our ecosystem, from organism designers to automation engineers, software developers to the people team, business development to facilities management, finance to molecular biology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">A culture built on care</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We&#8217;ve strived to grow a culture based on care. As engineers, it is easy to fall into the trap of thinking of ourselves simply as tool builders. Tools can be used in many different ways, both good and bad, and engineers often discuss their tools as value neutral. But tools reflect the social beliefs and biases of the people who make them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We are keenly aware of the need to care about how our platform is used. More significant than the impacts we have seen from digital platforms on our social world, biology is our health, our bodies, our food, and our environment. As we build </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">the tools for programming biology, we must also care how those tools are used, and ensure that the risks and benefits are transparently and equitably shared.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">A talented, world-class team</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">As of December 31, 2025 we had 485 employees. In addition to our employees, our success would not be possible without the collaboration and support of the network of partners, contractors, contingent workers and temporary staff who make up the Ginkgo team.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Technologies reflect the values of the people who build them. We believe that it is essential to have a talented team where people from different backgrounds are included and empowered to speak up and shape the growth of this technology. We are committed to having a team reflecting a broad range of viewpoints, backgrounds and skills and continuing to foster a culture with strong employee ownership and engagement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Laying the groundwork for strong employee engagement in the future</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">As a founder-led company we have been able to infuse the organization with long-term strategic thinking from the start. We have continued to execute on programs, achieve milestones, and launch new products while navigating uncertainty. We have emerged from a restructuring with a strengthened focus on the long-term performance and sustainability of our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">The individuals who work at Ginkgo and build our platform care deeply about how that platform is used and the impact our company will have in the world. We hope to strengthen the long-term mentality we have benefited from as a founder-led public company. We believe a workforce with strong equity ownership will make the wise decisions needed to build long-term value for our company and build a company whose long-term impacts make them proud. That is why we have implemented a multi-class stock structure that permits all employees (current and future), not just founders, to hold high-vote (10 votes per share) common stock, that we hope will help strengthen this long-term mentality and encourage long-term equity ownership by our employees. For more information, see </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">&#8220;Risk Factors&#8212;Risks Related to Ginkgo&#8217;s Business&#8212;Risks Related to Our Organizational Structure and Governance&#8212;Only our employees and directors are entitled to hold shares of Class B common stock (including shares of Class B common stock granted or otherwise issued to our employees and directors in the future), which shares have ten votes per share. This limits or precludes other stockholders&#8217; ability to influence the outcome of matters submitted to stockholders for approval, including the election of directors, the approval of certain employee compensation plans, the adoption of certain amendments to our organizational documents and the approval of any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transaction requiring stockholder approval.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Competition</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">To our knowledge, there are currently no other cell engineering companies that serve the same breadth of industries that we do. The services and products offered by potential competitors vary in size, breadth, and scope, and given our broad set of application areas, we could face competition in many different forms. We face competition from customers&#8217; internal R&amp;D departments and other research solution providers that largely conduct genetic engineering by-hand. We also compete against companies that seek to utilize synthetic biology technologies to develop specific products or target certain end markets. Additionally, with our expansion into tools offerings in 2024, we compete against life science tools companies and CROs as well as newer AI entrants in the emerging TechBio area. Finally, competing platforms may emerge from various sources, including from joint ventures and partnerships between well-capitalized technology and life sciences companies. We identify the following three groups as our principal set of competitors:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Cell Engineering competition</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">The Status Quo: &#8220;on prem&#8221; cell programming efforts</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The main source of competition we encounter for our cell engineering solutions offerings is from potential customers choosing to build or maintain in-house cell engineering teams and capabilities. This status quo includes building out laboratory space and then hiring a team of highly trained scientists to conduct research, largely &#8220;by-hand&#8221; and with limited scale efficiencies. Some internal R&amp;D operations maintain a full suite of capabilities and can design, build and test relatively complex pathways while others may have certain internal capabilities and need to outsource other elements to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">CROs. We believe this is far less efficient for the customer and likely to yield worse outcomes as customers get fewer shots on goal for a given program budget.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">That said, it can still be very difficult for companies to choose to trust Ginkgo with their R&amp;D efforts versus building more traditional &#8220;on prem&#8221; labs. Smaller companies may feel like they&#8217;re &#8220;betting the farm&#8221; on Ginkgo, while larger companies may be sensitive to displacing existing R&amp;D teams. As such, a key focus area for us is reducing the barriers to adoption for the platform by decreasing the upfront investment for earlier-stage companies and by helping larger companies integrate their scientists closely into our workflows and empower their scientists to manage requests directly so we feel more like a resource and partner than a fully outsourced provider. Our Datapoints products in Functional Genomics, Antibody Developability, and more recently launched offerings in Small Molecule Developability, are key examples of new services designed with our customers&#8217; scientists in mind.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The vast majority of therapeutics companies that are leveraging genetic engineering have in-house capabilities, including Biogen, Novo Nordisk, Vertex, Regeneron, Bayer, and many others. These companies may be viewed as competitors to Ginkgo because they are creating products, using cell programming, that may compete with the products Ginkgo is enabling for our customers. However, as a platform company, we view these companies not as competitors but as potential customers and focus not on &#8220;beating&#8221; them but rather on demonstrating our value proposition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">Verticalized cell engineering platforms</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Within certain end markets, Ginkgo may compete against vertically-focused biotechnology companies providing cell engineering R&amp;D capabilities to customers within a narrow set of end markets. While we believe the siloed nature of these companies limits their long-term potential, in the near-term, we may have a harder time penetrating those end markets given the incumbent vertical specialists in that space. The vast majority of these companies exist within therapeutic end markets given the history of cell engineering in that market segment. In theory, the expertise and learnings they develop from work in one field could be leveraged into neighboring end markets if these companies decided to adopt (and invest in) a more horizontal strategy. Examples of these vertically-focused platforms include AbCellera (antibody discovery), Codexis (enzymes), Senti Bio (cell therapy for oncology applications) and WuXi biologics (therapeutics).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">Contract research organizations (CROs) and life science tools companies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">With our expansion into cell engineering tools offerings, we now offer data generation services and RAC laboratory automation to our customers. These offerings appeal to customers who want to retain either scientific control and/or experimental execution of their biological R&amp;D. As such, we now more directly compete with CROs that offer research services, though usually such services are not purpose-built for generating high quality, large datasets to train and validate AI/ML models. Examples of these CROs include Evotec, WuXi Biologics, and Charles River Laboratories. Similarly, we compete with integrated automation companies like HighRes Biosolutions, Automata, and Thermo Fisher Scientific with our RAC laboratory automation products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">Other possible entrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We may also face competition from new entrants in the market, including well-capitalized technology companies with possible strategic interests in synthetic biology and its capabilities. Such companies may emerge as competitors given their access to capital, capacity to create multi-disciplinary teams across biology, chemistry, computer science and engineering, and flexibility to enter strategic ventures with life sciences companies.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Biosecurity competition</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We&#8217;re unique in the global biosecurity market because our approach is global and comprehensively covers end-to-end biosecurity needs. We face competition from a small number of companies who operate in focused biosecurity verticals, such as wastewater monitoring (e.g., Verily and Biobot, both primarily in the U.S.) and digital biosurveillance and modeling (e.g., BlueDot, Airfinity, and the Public Health Company), as well as internationally from BGI, China&#8217;s national champion for sequencing and diagnostics. As we partner with national governments, we also face competition from homegrown public solutions to particular challenges, especially among high-income countries and large multilaterals with little history of engagement with the private sector. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">We have several important attributes that contribute to our competitive advantage: </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">A comprehensive offering that allows customers to come to a single platform for multimodal physical and digital surveillance and integrated global insights, rather than fragmented approaches;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">A suite of technical capabilities across epidemiological, bioinformatics, and scientific R&amp;D;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">Unique technological tools, like our ENDAR platform for engineering detection;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">Our prominent role as a thought-leader and talent-attractor in this market;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">A foundation of partnerships with countries across the globe and key multilaterals such as Africa CDC, African Risk Capacity, and the International Livestock Research Institute; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">Our global leadership in the airport-based pathogen monitoring space.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Intellectual Property </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Patents </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our general policy has been to seek patent protection for those inventions likely to be incorporated into our offerings and for which patent protection will provide value or competitive advantages to Ginkgo.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our worldwide patent portfolio includes patents acquired in transactions over time. We may decide that it is in our interest to abandon, sell, or otherwise dispose of certain patents or patent applications that we determine are no longer relevant to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Patents generally have a term of twenty years from the date they are filed. As our patent portfolio has been built over time, the remaining terms of the individual patents across our patent portfolio vary. No single patent or patent family is essential to Ginkgo as a whole or to any of Ginkgo&#8217;s subsidiaries. In addition to developing our patent portfolio, we license patents from third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We intend to pursue additional patent protection to the extent that we believe that it would be beneficial and cost-effective. We cannot provide any assurance that any of our current or future patent applications will result in the issuance of patents. We also cannot assure the scope of any of our future issued patents or warrant that any of our patents will prevent others from commercializing infringing products or technology. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Trade secrets </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo&#8217;s technology-related intellectual property that is not patent-protected is maintained as trade secrets. We employ a variety of safeguards to protect our information and trade secrets, including contractual arrangements with our employees, consultants, contractors and other advisors that impose obligations of confidentiality, assignment of inventions, and security; digital security measures; and physical security precautions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We require confidentiality and material transfer agreements from third parties that receive our confidential data or materials, and we also incorporate confidentiality and material transfer precautions into our collaboration agreements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Trademarks and domain names </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Although our business is directed at sophisticated corporate customers rather than end consumers, we have trademark rights and registrations in our name, logo, and other brand indicia in the United States and other jurisdictions around the world. We also have registered domain names for websites that we use in our business, such as www.ginkgobioworks.com. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Suppliers </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo&#8217;s suppliers for cell engineering operations comprise primarily manufacturers and distributors of life science tools, consumables and equipment as well as certain specific providers of contract research, development and manufacturing services. We will sometimes enter into long-term, strategic partnerships with innovative suppliers. Because of the scale of our operations, we believe we are often an early adopter and the largest customer at scale of certain new life science tools and technologies. We will also occasionally acquire technology or IP assets for strategic reasons, including integration into our platform.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We utilize various third party software and information technology service providers for data storage and processing. We also routinely engage a variety of third parties for professional services, contract employment services and consulting services. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Government Contracts </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have entered into agreements with governmental entities and contractors in the past to serve as a U.S. government contractor or subcontractor and may do so again in the future. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">Risk Factors&#8212;Risks Related to Governmental Regulation and Litigation&#8212;We have pursued in the past and may pursue additional U.S. Government contracting and subcontracting opportunities in the future and as a U.S. Government prime contractor and subcontractor, we are subject to a number of procurement rules and regulations.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#8221; </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Government Regulations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our business, or the business of our customers, may be regulated by the FDA and other federal authorities in the United States, including the U.S. Federal Trade Commission (&#8220;FTC&#8221;), U.S. Department of Agriculture (&#8220;USDA&#8221;), U.S. Drug Enforcement Administration (&#8220;DEA&#8221;) and U.S. Environmental Protection Agency (&#8220;EPA&#8221;), as well as comparable authorities in foreign jurisdictions and various state and local authorities in the United States. Failure to comply with applicable regulations may result in enforcement actions, civil or criminal sanctions, and adverse publicity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">FDA regulation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We provide cell engineering and product discovery services to customers engaged in the manufacture of pharmaceutical, food, and cosmetic products. The FDA regulates the research, development, testing, quality control, import, export, safety, effectiveness, storage, recordkeeping, premarket review, approval or licensure, processing, formulation, manufacturing, packaging, labeling, advertising, promotion, marketing, distribution, sale, post-market monitoring and reporting of our customers&#8217; pharmaceutical, food and cosmetic products, and the FTC also regulates the advertising and promotion of these products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have acted as a systems integrator and authorized distributor of certain COVID-19 over-the counter diagnostic tests manufactured by independent third parties. We worked with laboratory partners that provide surveillance testing services as part of the COVID-19 and other pathogen surveillance testing services we offer, and these tests and test kits may be subject to regulation by the FDA. In particular, the tests and test kits used in our testing services may be subject to regulation by the FDA as medical devices, and may be required to comply with the requirement that such products have obtained clearance, approval, or other marketing authorizations, before they can be commercialized, as well as post-market requirements such as adverse event reporting and restrictions on labeling, marketing, and distribution.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Laboratories must seek FDA marketing authorization and otherwise comply with FDA device regulations when marketing COVID-19 Laboratory Developed Tests (&#8220;LDTs&#8221;). An LDT is an </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"> diagnostic test that is intended for clinical use and is designed, manufactured, and used within a single laboratory. LDTs are classified as medical devices, but the FDA has historically exercised enforcement discretion and has generally not enforced FDA requirements, including premarket review, with respect to laboratories that offer LDTs. However, FDA intends to phase out its enforcement discretion for LDTs. While HHS and FDA have announced their intention to require premarket review of COVID-19 LDTs, either agency may change its position in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Medical products, including COVID-19 tests, that are granted a clearance, Emergency Use Authorization (&#8220;EUA&#8221;), or other marketing authorization must comply fully with the terms and conditions provided in the clearance, EUA, or other marketing authorization. For example, EUAs for COVID-19 tests may include conditions of authorization applicable to the EUA holder, authorized distributors and authorized laboratories. Noncompliance with applicable requirements could result in negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters or untitled letters from the FDA, mandated corrective promotional materials, advertising or communications with doctors, and civil or criminal penalties, among others. The FDA can also withdraw marketing authorization for the applicable product, and in the case of a product subject to an EUA, the FDA may require EUA holders to transition to permanent marketing authorization which could impact some of the tests in our supply chain.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">DEA regulation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We are engaged in the research, development, and export of certain products that may be regulated as controlled substances. The Controlled Substances Act of 1970, as amended from time to time, establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements administered by the DEA. The DEA is concerned with the control of handlers of controlled substances, and with the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. Schedule I substances are considered to present the highest risk of abuse, and Schedule V substances the lowest relative risk of abuse among controlled substances. Marijuana is classified as a Schedule I controlled substance. However, the term does not include &#8220;hemp,&#8221; which means the cannabis plant and any part of that plant, including the seeds and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 THC concentration of not more than 0.3% on a dry weight basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, business activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which controlled substance schedule is authorized for that activity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The DEA typically inspects a facility to review its security measures prior to issuing a registration. The DEA requires &#8220;effective controls and procedures&#8221; to guard against theft and diversion of controlled substances. Security requirements vary by controlled substance schedule (with the most stringent requirements applying to Schedule I and Schedule II substances), type of business activity conducted, quantity of substances handled, and a variety of other factors. Required security measures include background checks on employees and physical control of inventory. While the specific means by which effective controls and procedures are achieved may vary, security practices may include use of cages, surveillance cameras and inventory reconciliations. Records must be maintained for the handling of all controlled substances, and, in certain scenarios, periodic reports made to the DEA. Reports must also be made for thefts or losses of any controlled substance, and disposal of controlled substances must adhere to various methods authorized by the regulations. In addition, special authorization and notification requirements apply to imports and exports.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Failure by registered establishments to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could eventuate in criminal proceedings. Individual states also regulate controlled substances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Laboratory Licensing and Certification Requirements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The clinical laboratories we partnered with for our COVID-19 testing program are subject to federal oversight under the Clinical Laboratory Improvement Amendment of 1988 (&#8220;CLIA&#8221;), which requires all clinical laboratories to meet certain quality assurance, quality control and personnel standards. Laboratories also must undergo proficiency testing and are subject to inspections. Standards for testing under CLIA are based on the complexity of the tests performed by the laboratory, with tests classified as &#8220;high complexity,&#8221; &#8220;moderate complexity,&#8221; or &#8220;waived.&#8221; Laboratories performing high complexity testing are required to meet more stringent requirements than moderate complexity laboratories. Certain of our partner laboratories must undergo on-site surveys at least every two years, which may be conducted by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) under the CLIA program or by a private CMS-approved accrediting agency. The sanction for failure to comply with CLIA requirements may be suspension, revocation or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct business, as well as significant fines and criminal penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The operations of our partner laboratories holding CLIA Certificates of Waiver are also subject to state and local laboratory regulation. CLIA provides that a state may adopt laboratory regulations different from or more stringent than those under federal law, and a number of states have implemented their own laboratory regulatory requirements. State laws may require that laboratory personnel meet certain qualifications, specify certain quality controls, or require maintenance of certain records. No assurances can be given that our partner laboratories will pass all future licensure or certification inspections.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our facilities and laboratories hold local, state and federal permits, licenses and registrations necessary for compliance in specific work and operations, including from the Massachusetts Water Resource Authority, Boston Fire Department, Massachusetts Department of Environmental Protection, Boston Public Health Commission, Cambridge Biosafety Committee, Massachusetts Department of Public Health, USDA and DEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Federal Select Agent Regulations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our research facilities that synthesize DNA sequences or perform other activities could become subject to the FSAP, which involves rules administered by the CDC and the USDA Animal and Plant Health Inspection Service (&#8220;APHIS&#8221;). The FSAP regulates the possession, use, and transfer of biological select agents and toxins that have the potential to pose a severe threat to public health, animal or plant health, or animal or plant products. FSAP regulatory requirements include: (i) registration with the CDC and/or APHIS for research facilities that deal with the select agents and toxins; (ii) submission to periodic biosafety and security inspections; and (iii) reporting of theft, loss or release of select agents. Federal agency enforcement actions for violations of FSAP regulations can include the initiation of corrective actions, complete or partial suspension or revocation of select agent registrations or civil or criminal liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Genetically Modified Materials Regulations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our technologies and the technologies of our customers involve the use of genetically modified cells, organisms and biomaterials, including, without limitation, GMOs and genetically modified microorganisms (&#8220;GMMs&#8221;), and their respective products. In the United States, the FDA, the USDA through its APHIS, and the EPA are the primary agencies that regulate the use of GMOs, GMMs and potential products derived from GMOs or GMMs or Genetically Modified Materials, pursuant to the Coordinated Framework for the Regulation of Biotechnology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The FDA reviews the safety of food consumed by humans and of feed consumed by animals under the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;). Under the FDCA, food and feed manufacturers are responsible for ensuring that the products they market, including those developed through genetic engineering, are safe and properly labeled. In addition, the FDA must approve the use of any food additives, including GMOs, before marketing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">USDA's APHIS examines whether a plant itself presents a &#8220;plant pest&#8221; risk under the Plant Protection Act (&#8220;PPA&#8221;). Specifically, APHIS is responsible for regulating the introduction (i.e., importation, interstate movement or release into the environment) of certain GMOs and plants under the plant pest provisions in the PPA to ensure that they do not pose a plant pest risk. APHIS finalized changes to the PPA&#8217;s implementing regulations with respect to certain GMOs in May 2020. A person or organization may request a regulatory status review from APHIS to determine whether a GMO is unlikely to pose a plant pest risk and, therefore, is not regulated under the plant pest provisions of the PPA or the regulations codified at 7 C.F.R. Part 340; requesting a regulatory status review tends to assume the GMO at issue does not otherwise fall within a regulatory exemption. If the GMO does not qualify for an exemption or if the APHIS regulatory status review process finds that the plant poses a plausible plant pest risk, then the GMO may require an APHIS permit, i.e., be a regulated article under Part 340. A regulated article may be subject to APHIS for the environmental release, importation, or interstate movement of the GMO or its progeny.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">EPA regulates, under the Federal Insecticide, Fungicide and Rodenticide Act (&#8220;FIFRA&#8221;), the pesticides (including plant incorporated protectants) that are used with crops, including GMO herbicide-tolerant crops. FIFRA generally requires all pesticides to be registered before distribution or sale, unless they are exempted. Under FIFRA, a pesticide registrant must demonstrate that the pesticide at issue, when used pursuant to its specifications, &#8220;will not generally cause unreasonable adverse effects on the environment&#8221; to secure a registration. EPA must approve each distinct pesticide product, each distinct use pattern, and each distinct use site. In addition to EPA&#8217;s FIFRA authority, EPA also regulates potential human health impacts from pesticides under the FDCA. EPA does so by establishing &#8220;tolerance levels&#8221; (i.e., &#8220;the amount of pesticide that may remain on food products&#8221;) under the FDCA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Certain genetically modified microorganisms that are not otherwise regulated under FIFRA and FDCA may be subject to EPA regulation under the Toxic Substances Control Act (&#8220;TSCA&#8221;). New microorganisms that are formed by combining genetic material from organisms in different genera (known as intergeneric microorganisms) may be subject to reporting requirements prior to production or distribution in commerce (Microbial Activity Commercial Activity Notice), or use in research and development (TSCA Experimental Release Application), unless the entity can meet all required criteria to obtain an exemption under TSCA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Federal and state data privacy and security regulations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. HIPAA, and its respective implementing regulations, imposes obligations on &#8220;covered entities,&#8221; including certain health care providers, health plans, and health care clearinghouses, and their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, as well as their covered subcontractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information. Violations of the HIPAA privacy and security regulations may result in civil and criminal penalties. HHS is required to conduct periodic compliance audits of covered entities and their business associates. HIPAA also authorizes state attorneys general to bring civil actions seeking either an injunction or damages in response to violations of HIPAA privacy and security regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, certain state laws, such as the California Confidentiality of Medical Information Act, govern the privacy and security of health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. States including California, Virginia, Colorado, Connecticut and Utah have also enacted comprehensive privacy laws that are currently in effect, and similar laws have been passed or are being considered in several other states, as well as at the federal and local levels. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other (thus complicating compliance efforts), and can result in investigations, proceedings, or actions that lead to significant civil or criminal penalties and restrictions on data processing.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Ginkgo Corporate Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo&#8217;s principal executive office is located at 27 Drydock Avenue, Boston, Massachusetts 02210, and Ginkgo&#8217;s telephone number is (877) 422-5362. Ginkgo&#8217;s corporate website address is www.ginkgobioworks.com. We make available on the Investor Relations section of our website, free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and Forms 3, 4 and 5, and amendments to those reports as soon as reasonably practicable after filing such documents with, or furnishing such documents to, the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). The SEC maintains a website (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The information contained on, or accessible through, our corporate website is not incorporated into this Annual Report and should not be considered part of this Annual Report. The inclusion of the corporate website address is an inactive textual reference only.</span></div><div><span><br/></span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_609"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our securities involves a high degree of risk. You should carefully consider the following risk factors, together with all of the other information included in this Annual Report, before making an investment decision. Our business, prospects, financial condition or operating results could decline due to any of these risks and, as a result, you may lose all or part of your investment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this section to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to the business of Ginkgo and its subsidiaries</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Risks Related to Ginkgo&#8217;s Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We have a history of net losses. We expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have incurred significant operating losses since our inception. As of December 31, 2025, we had an accumulated deficit of approximately $6.2 billion. We may incur losses and negative cash flow from operating activities for the foreseeable future as we continue to invest significant additional funds toward further developing our platform and customer offerings, the cell engineering programs we perform on behalf of our customers and otherwise growing our business, including our Biosecurity and Automation business units. We have derived a significant portion of our revenues from fees and milestone payments from technical development services provided to customers to advance programs, as well as a significant portion of our revenues from Biosecurity. Historically, these fees have not been sufficient to cover the full cost of our operations. Additionally, if our customers terminate their agreements or development plans with us, our near-term revenues could be adversely affected. In addition, certain of our customer agreements provide for milestone payments, future royalties and other forms of contingent consideration, the payment of which are uncertain, as they are dependent on our ability to successfully develop engineered cells, bioprocesses, or other deliverables and our customers&#8217; ability and willingness to successfully develop and commercialize products and processes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our expenses may continue to exceed revenues in the foreseeable future and we may not achieve profitability. If we fail to achieve profitability, or if the time required to achieve profitability is longer than we anticipate, we may not be able to expand or continue our business, and the value of our common stock could be negatively impacted. Our ability to achieve or sustain profitability is based on numerous factors, many of which are beyond our control, including the development of our platform, the initiation of new programs with new and existing customers, the commercial terms of our programs, the realization of any potential downstream value from our programs, our ability to advance cell engineering programs in a timely and cost-effective manner, our ability to extend new offerings to customers, our customers&#8217; ability to scale up bioprocesses, the ability of our customers to produce and sell products, the impact of market acceptance of our customers&#8217; products, and our customers&#8217; market penetration and margins. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We may need substantial additional capital in the future in order to fund our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have consumed considerable amounts of capital to date, and we expect to incur continued net losses for the foreseeable future as we continue to develop our business, advance our programs, expand and enhance our platform and customer offerings, perform on behalf of our customers, and make the capital investments necessary to scale up our business. We have used, and may continue to use, additional capital for Biosecurity, strategic investments and acquisitions. We believe that our cash and cash equivalents, short-term investments, and interest earnings will be sufficient to meet our projected operating requirements until we reach profitability. However, these assumptions may prove to be incorrect and we could exhaust our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with our programs, including risks and uncertainties that could impact the rate of progress of our programs, we are unable to estimate with certainty the amounts of capital outlays and operating expenditures associated with these activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We do not currently have any commitments for future funding. We may receive fees, milestones, and royalty payments under our customer agreements, but these are not guaranteed. We have received non-cash consideration in the past and we may receive additional non-cash consideration in the future where we may not be able to realize the eventual cash proceeds expected or at all such that the amount of cash proceeds eventually realized may be less than the revenue recognized and the costs incurred to perform those services. Additionally, we may wish to sell our equity interests in certain subsidiaries or collaborations but most of these equity stakes are in private companies and we may not be able to find a buyer due to contractual restrictions or otherwise, or may incur significant impairment if we sell these positions for liquidity. We may not receive any further funds or future non-cash consideration under those agreements, the funds or non-cash consideration we receive may be lower than projected and/or disclosed as potential downstream value, or our program costs may be higher than projected. In addition, we may not be able to sign new customer agreements or enter into new development plans with existing customers with adequate funds to cover program development expenses. As a result of these and other factors, we do not know whether additional financing will be available when needed, or, if available, whether such financing would be on terms favorable to our stockholders or us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">If additional future financings, including pursuant to our at-the-market program, involve the issuance of equity securities, our existing stockholders would suffer dilution. See &#8220;Management&#8217;s Discussion and Analysis &#8211; At-The-Market Program&#8221; for more information. If we raise debt financing in the future, we may be subject to restrictive covenants that limit our ability to conduct our business. Our ability to raise funds may be adversely impacted by current or future economic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">conditions. If we fail to raise sufficient funds and continue to incur losses, our ability to fund our operations, take advantage of strategic opportunities, or otherwise respond to competitive pressures could be significantly limited. If adequate funds are not available, we may not be able to successfully execute our business plan or continue our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We have experienced periods of significant organizational change and if we fail to effectively manage these changes, then our business, results of operations, and financial condition could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have experienced both rapid growth and recent periods of decline in our business since inception, which has placed and may continue to place significant demands on our company culture, operational infrastructure, and management. We believe that our culture has been a critical component of our success. We have invested substantial time and resources in our team and have continued to nurture a culture of empowerment of, and active engagement by, our employees. In addition, in order to manage through these periods of organizational change, we will need to continue to adapt our operational, financial, and management controls and processes, as well as our reporting systems and procedures. As we manage our business and mature as a public company, we may find it difficult to maintain our culture and adapt effectively. Any failure to manage our organizational changes in a manner that preserves the key aspects of our culture and allows us to effectively adapt could be detrimental to future success in pursuing our objectives, including our ability to recruit and retain personnel, maintain reliable service levels and offerings for our customers, and achieve the necessary level of capacity, quality and efficiency in performing services and other development activities, or the necessary level of efficiency in our organizational structures. This, in turn, could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our limited operating history and evolving business makes it difficult to evaluate our current business and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have a portfolio of cell engineering programs which vary in start date, duration, complexity, and revenue potential. Additionally, our downstream economics in the form of royalties, milestones, and/or equity interests add an additional level of uncertainty to our possible future performance. Consequently, predictions about our future success or viability are highly uncertain and may not be as accurate as they could be if we had a longer company history of successfully developing, commercializing and generating revenue from our programs and/or downstream economic participation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our long-term objective is to generate free cash flow from the commercialization of programs for customers across a variety of industries, as well as from our biosecurity-focused offerings. Our estimated costs and timelines for the completion of programs are based on our experiences to date and our expectations for each stage of the program in development. Given the variety of types of programs we support and the continued growth of our platform, there is variability in timelines and costs for launching and executing programs, and completion dates can change over the course of a customer engagement. Our costs and timelines may be greater or subject to variability where regulatory requirements lead to longer timelines, such as in agriculture, food, and therapeutics. In addition, we have equity interests in certain companies and there is and will continue to be variability in the financial performance of these other companies or future companies in which we may have equity interests.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have encountered in the past, and will encounter in the future, risks and uncertainties frequently experienced by growing companies with limited operating histories in emerging and rapidly changing industries. If our assumptions regarding these risks and uncertainties, which we use to plan and operate our business, are incorrect or change, or if we do not address these risks successfully, our results of operations could differ materially from our expectations, and our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Uncertainty regarding the demand for biosecurity services could materially adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our Biosecurity offering consists of pathogen testing, sequencing, and insights delivery which are subject to inherent risks of commercial viability, such as demand for services and price or market share erosion due to competition. Our Biosecurity business is focused on global surveillance programs and analytic services. However, creating the commercial and technical infrastructure to provide Biosecurity services globally is expensive. We may also be limited in our ability to scale up based on expense or unavailability of the required materials, equipment, personnel and infrastructure necessary to deliver biosecurity on a large, international scale. We may not be able to recover our investment expenses with sufficient revenue generated by our Biosecurity efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our ability to commercialize our Biosecurity offerings is also subject to available government, private, and multilateral funding. If governments decide that the Biosecurity offerings are not necessary or that they do not have the funds to support them, we may experience difficulty in expanding and growing the biosecurity business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We are or could become involved in securities or shareholder litigation and other related matters, which could be expensive and time-consuming. Such litigation and related matters could harm our business.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have been and may in the future be a target for securities and shareholder lawsuits. The outcome of such pending and potential litigation is uncertain. Such disputes, including any related governmental or regulatory investigations and the cost of defending such, could result in an adverse effect on our business, results of operations, financial condition, reputation and cash flows, and could adversely impact the market price of our common stock. Although the results of lawsuits and claims cannot be predicted with certainty, defending against such claims could be costly and could impose a significant burden on management and employees. Any litigation to which we become a party may result in an onerous or unfavorable judgment, or may be resolved with a monetary payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">If we cannot attract new customers, retain existing customers,  and expand our relationships across both our cell engineering solutions and tools businesses, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We generate revenue from our cell engineering solutions and cell engineering tools businesses. In our cell engineering solutions business, which has been our core business since inception and continues to be the primary driver of our revenues, we receive fees for performing R&amp;D activities and, for some of our legacy arrangements, downstream value in the form of royalties, milestone payments and/or equity. In our more recently launched cell engineering tools business, we receive fees from performing data generation services and from the sale of our automation hardware, software and ongoing customer support services. Our ability to achieve our growth objectives depends in significant part on our success in attracting new customers to each of these businesses, retaining and expanding our relationships with existing customers, and driving broader adoption and utilization of both our solutions and tools offerings over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our ability to win new business and expand existing relationships in both businesses depends on many factors, including our reputation in the market, the quality, reliability and performance of our service and product offerings, our pricing and commercial terms, the features and interoperability of our tools, the perceived and demonstrated return on investment for our customers, our technical and operational capabilities, the effectiveness of our sales, marketing and customer success organizations, and broader conditions in our customers&#8217; industries. If we fail to maintain a position of strength in any of these areas, or if our offerings do not meet evolving customer expectations, we may be unable to acquire new customers, retain existing customers or increase the scope of work or level of spend with existing customers, which could adversely affect our business and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">As a relatively new entrant in the cell engineering tools market, we face additional risks in establishing and expanding our customer base in this business. We compete with incumbent providers that have established brands, larger installed bases and longer operating histories, and whose hardware and software are often already deeply integrated into customers&#8217; laboratories and IT environments. These factors can create significant barriers to adoption of our tools, as customers may be reluctant to incur the time, expense and operational disruption associated with evaluating, validating, integrating and maintaining new systems. In order to justify replacing or augmenting existing systems, customers must perceive our offerings as providing meaningful and durable advantages in functionality, performance, scalability, data quality, ease of use, support and total cost of ownership. Our sales cycles for tools can be long and resource-intensive, often involving proof-of-concept projects, technical integration work and customer-specific validation. If we are unable to effectively demonstrate the benefits of our tools, if initial deployments do not meet customer expectations, or if we are unable to provide high-quality implementation, training, maintenance and support, customers may decide not to adopt our tools, may limit their use to smaller-scale projects or may discontinue or fail to renew support, software or service contracts. Any of these outcomes could limit the growth of our tools business and could also negatively affect our reputation in the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In our cell engineering solutions business, we typically generate valuable know-how in the course of performing customer programs, such as onboarding of new high-throughput assays or the development of optimized proteins and chassis strains. This know-how not only advances our technical and operational capabilities, but also serves as an important product development engine for expanding and refining our tools offerings. As a result, the loss of one or more significant customer relationships, the failure to renew, extend or expand existing programs, delays in starting new programs, or our inability to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">attract new solutions customers or programs would not only reduce our revenues and potential downstream value, but could also slow our accumulation of know-how and data assets, thereby hindering our ability to advance our technological differentiation and improve our tools and services offerings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We engage in conversations with prospective and existing customers regarding potential solutions and tools relationships on an ongoing basis. We may devote substantial time and resources to business development discussions, technical evaluations, feasibility assessments, pilot projects, proof-of-concept studies and legal and regulatory diligence that may not result in a commercial agreement or that may result in only limited scope relationships. Even where a commercial agreement is reached, the resulting relationship may not be successful for various reasons. For example, in the case of cell engineering solutions, our customers may be unsuccessful in developing or commercializing products or processes based on our work, may change their strategic priorities or budgets, or may experience internal or external challenges that limit the size or duration of their programs with us, which has in the past and may in the future materially reduce both our near-term revenues and our downstream value opportunity from such collaborations. Similarly, in the case of cell engineering tools, customers may fail to deploy our tools at the scale initially contemplated, may not expand to additional sites, use cases or workflows, or may discontinue use of our offerings if they do not meet expectations. Any such outcomes could adversely affect our revenues, our ability to scale our platform, and our prospects for long-term growth.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We have exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We currently own equity interests in several of our customers, and we may receive non-cash consideration for our services, which involves estimations of fair market value. The initial fair market value of the non-cash consideration we receive has decreased in the past with respect to certain of our holdings, and in the future may decrease after contract inception and the amount of cash proceeds eventually realized may be less than the revenue recognized, or may even be zero. In the future, we may also own equity interests in other companies. The process and timing by which we receive equity interests and the factors we consider in deciding whether to accept, hold or dispose of these equity positions may differ significantly from those that an independent investor would evaluate when considering equity interests in a company. Owning equity interests increases our exposure to the risks of the other company and, in the case of customers, beyond the products of our collaborations. Our equity ownership positions expose us to market volatility and the potential for negative returns. We may have restrictions on resale or limited markets to sell our equity ownership. In many cases, our equity position is a minority position which exposes us to further risk, as we are not able to exert control over the companies in which we hold securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In connection with future collaborations or joint ventures, we may, from time to time, receive warrants or options, all of which involve additional risks involving, for example, pricing differences between the market value of underlying securities and our exercise price for the warrants or options, a possible lack of liquidity, and the related inability to close a warrant or option position, all of which could ultimately have an adverse effect on our financial position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We leverage our own resources and partner with strategic and financial investors in order to help early stage companies and innovators secure funding and benefit from our platform, which exposes us to a number of risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Since our founding, alongside strategic and financial investors, we have leveraged our own resources to help secure funding for early stage and small companies. Going forward, we may continue to leverage our own balance sheet and partner with investors to enable companies at all stages to benefit from our platform.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Partnering with and investing in early stage and small companies has exposed and may continue to expose us to losses on our invested capital and the loss of revenue from the inability to recover fees for our services from these companies. Such  companies are exposed to a number of risks that could impair an early stage or small company&#8217;s financial condition, results of operation, or cash flow or result in other adverse events, such as bankruptcy.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We may be unable to complete future strategic acquisitions or successfully integrate strategic acquisitions which could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our inability to complete any future strategic acquisitions or to successfully integrate any new strategic acquisitions could have a material adverse effect on our business. Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services. We may continue to seek attractive opportunities to acquire technologies or businesses, enter into joint ventures and make other investments that are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">complementary to our existing strengths. There are no assurances, however, that any strategic acquisition opportunities will arise or, if they do, that they will be consummated. Certain acquisitions may be difficult to complete for a number of reasons, including the need to satisfy customary closing conditions, the need for antitrust and/or other regulatory approvals, as well as disputes or litigation. In addition, any strategic acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets in the acquisition and thus our realization of this value relies on successful integration and continued operations. We may not be able to successfully integrate acquired technologies, assets, products, operations or businesses , make acquired businesses profitable, retain key employees</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">(or integrate employees) or realize anticipated revenues, cost savings, or synergies, if any, from these acquisitions, or do so in an effective, timely and non-disruptive manner, which could adversely affect our business and financial condition. Further, our ongoing business may be disrupted, and our management's attention may be diverted, by acquisitions, investments, transition and/or integration activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We have in the past, and in the future may continue to pursue strategic acquisitions and investments that are dilutive to our stockholders, and such strategic acquisitions or investments could have an adverse impact on our business if they are unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have made acquisitions in the past and, as appropriate opportunities become available, we may acquire additional businesses, assets, technologies, or products to enhance our business or engage in other strategic transactions in the future, but our ability to do so successfully cannot be ensured. We have also made investments in companies that we view as synergistic with our business. Although we conduct due diligence on these acquisitions and investments, such processes may underestimate or fail to reveal significant liabilities and we could incur losses resulting from liabilities of the acquired business that are not covered by indemnification we may obtain from the seller. Even if we identify suitable opportunities, including pending transactions, we may not be able to complete such acquisitions on favorable terms or at all, which could damage our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Additionally, pursuing acquisitions or other strategic transactions, whether successful or unsuccessful, could result in civil litigation and regulatory penalties. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt or spend cash in connection with a strategic acquisition, which may cause us to face liquidity concerns or be subject to restrictive covenants in the future. We have issued, and in the future may issue, common stock or other equity securities to the stockholders of the acquired company, which, if such issuances were unregistered, we may be contractually required to register on Form S-3 and may be subject to piggyback registration rights. Such issuances could constitute a material portion of our then-outstanding shares of common stock and may reduce the percentage ownership of our existing stockholders.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Acquisitions or other strategic transactions may also increase our expenses and reduce our cash available for operations and other uses. In addition, we may not be able to fully recover the costs of such acquisitions or be successful in leveraging any such strategic transactions into increased business, revenue, or profitability. We also cannot predict the number, timing, or size of any future acquisitions or the effect that any such transactions might have on our operating results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Accordingly, although there can be no assurance that we will undertake or successfully complete any future acquisitions, any transaction that we have completed, or in the future do complete, may not yield the anticipated benefits and may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations, and prospects. Conversely, any failure to pursue or delay in completing any acquisition or other strategic transaction that would be beneficial to us, including those caused by competing parties, could impact our ability to sign new programs, delay the development of our platform, or slow the advancement of our programs and, thus, potential commercialization of our customer&#8217;s products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our programs may not achieve milestones, earn royalties or complete other anticipated key events on the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common stock to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We may adopt various technical, manufacturing, regulatory, commercial, and other objectives for our programs. These milestones may include our or our customers&#8217; expectations regarding the commencement or completion of technical development, the achievement of manufacturing targets, the submission of regulatory filings, or the realization of other development, regulatory, or commercialization objectives by us or our customers. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, including </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">assumptions regarding capital resources, constraints, and priorities, progress of and results from R&amp;D activities, and other factors, any of which may cause the timing of achievement of the milestones to vary considerably. If we, our collaborators, or our customers fail to achieve milestones in the expected timeframes, the commercialization of our programs may be delayed, our credibility may be undermined, our expectations with respect to potential future downstream value may be inaccurate, our ability to earn royalties may be impacted, our business and results of operations may be harmed, and the trading price of our common stock may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We must continue to secure and maintain sufficient and stable supplies of laboratory reagents, consumables, equipment, and laboratory services. We depend on a limited number of suppliers, some of which are single-source suppliers, and contract manufacturers for critical supplies, equipment, and services for research, development, and manufacturing of our products and processes. Our reliance on these third parties exposes us to risks relating to costs, contractual terms, supply, and logistics, and the loss of any one or more of these suppliers or contract manufacturers or their failure to supply us with the necessary supplies, equipment, or services on a timely basis, could cause delays in our research, development, or production capacity and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Widespread inflationary pressures and other adverse macroeconomic pressures, such as tariffs, increased duties and taxes, international trade disputes, political instability, supply or raw material shortages, and labor disruptions, exist across global economies, resulting in disruptions or higher costs for disposable lab equipment, raw materials and synthetic biology materials and services, and significant increases in the future could adversely affect our results of operations. We have experienced shortages in some of our key equipment and supplies, including those required in our labs, as well as disruptions in services provided by third parties, and may do so in the future as a result of supply chain issues tied to global pandemics, conflicts, or otherwise. We may also experience price increases, quality issues and longer lead times due to unexpected material shortages, service disruptions, and other unanticipated events, which may adversely affect our supply of lab equipment, lab supplies, chemicals, reagents, supplies, and lab services. For some suppliers, we do not enter into long-term agreements and instead secure our materials and services on a purchase order basis. Our suppliers may reduce or cease their supply of materials or services to us at any time in the future. If the supply of materials or services is interrupted, our programs may be delayed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We depend on a limited number of suppliers for critical items, including lab consumables and equipment, for the development of our programs. Some of these suppliers are single-source suppliers. We do not currently have the infrastructure or capability internally to manufacture these items at the necessary scale or at all. Although we have a reserve of supplies and although alternative suppliers exist for some of these critical products, services, and equipment, our existing processes used in our Autonomous Lab have been designed based on the functions, limitations, features, and specifications of the products, services, and equipment that we currently utilize. While we work with a variety of domestic and international suppliers, our suppliers may not be obligated to supply products or services or our arrangements may be terminated with relatively short notice periods. Additionally, we do not have any control over the process or timing of the acquisition or manufacture of materials by our manufacturers and cannot ensure that they will deliver to us the items we order on time, or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In particular, we rely on Twist for custom DNA synthesis and Thermo Fisher Scientific Inc. and others for certain instruments and consumables. The price and availability of DNA, chemicals, reagents, equipment, consumables, and instruments have a material impact on our ability to provide Cell Engineering services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The loss of the products, services, and equipment provided by one or more of our suppliers could require us to change the design of our research, development, and manufacturing processes based on the functions, limitations, features, and specifications of the replacement items or seek out a new supplier to provide these items. Additionally, as we grow, our existing suppliers may not be able to meet our increasing demand, and we may need to find additional suppliers. We may not be able to secure suppliers who provide lab supplies at, or equipment and services to, the specification, quantity, and quality levels that we demand (or at all) or be able to negotiate acceptable fees and terms of services with any such suppliers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">As described above, some lab equipment, lab consumables, and other services and materials that we purchase are purchased from single-source or preferred suppliers, which limits our negotiating leverage and our ability to rely on additional or alternative suppliers for these items. Our dependence on these single-source and preferred suppliers exposes us to certain risks, including the following:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">our suppliers may cease or reduce production or deliveries, raise prices, or renegotiate terms; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">we may be unable to locate a suitable replacement on acceptable terms or on a timely basis, if at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">if there is a disruption to our single-source or preferred suppliers&#8217; operations, and if we are unable to enter into arrangements with alternative suppliers, we will have no other means of continuing the relevant research, development, or manufacturing operations until they restore the affected facilities or we or they procure alternative sources of supply;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">delays caused by supply issues may harm our reputation, frustrate our customers, and cause them to turn to our competitors for future programs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">our ability to progress the development of existing programs and the expansion of our capacity to begin future programs could be materially and adversely impacted if the single-source or preferred suppliers upon which we rely were to experience a significant business challenge, disruption, or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory, or reputational issues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Moreover, to meet anticipated market demand, our suppliers may need to increase manufacturing capacity, which could involve significant challenges. This may require us and our suppliers to invest substantial additional funds and hire and retain the technical personnel who have the necessary experience. Neither we nor our suppliers may successfully complete any required increase to existing research, development, or manufacturing capacity in a timely manner, or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">For the year ended December 31, 2025, our cost of lab equipment, lab supplies, and lab services accounted for a significant portion of our total R&amp;D expenses. In the event of price increases by suppliers, whether as a result of inflationary pressures, tariffs or otherwise, we may attempt to pass the increased costs to our customers. However, we may not be able to raise the prices of our Cell Engineering services sufficiently to cover increased costs resulting from increases in the cost of our materials and services, or the interruption of a sufficient supply of materials or services. As a result, materials and services costs, including any price increase for our materials and services, may negatively impact our business, financial condition, and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Some of our suppliers and contract manufacturers are foreign entities. We may face disruptions due to the inability to obtain customs clearances in a timely manner or restrictions on shipping or international travel. As a result of ongoing global supply chain challenges resulting in very long lead times for certain products and equipment, we may order in larger volumes in order to secure the supplies we require for our future operations, which may negatively impact our financial conditions, especially if we are unable to use the supplies ordered.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We use biological, hazardous, flammable and/or regulated materials that require considerable training, expertise and expense for handling, storage and disposal and may result in claims against us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We work with biological and chemical materials that could be hazardous to human, animal, or plant health and safety or the environment. Our operations produce hazardous and biological waste products, and we largely contract with third parties for the disposal of these products. Federal, state, and local laws and regulations govern the use, generation, manufacture, storage, handling, and disposal of these materials and wastes. Compliance with applicable laws and regulations is expensive, and current or future laws and regulations may restrict our operations. If we do not comply with applicable laws and regulations, we may be subject to fines and penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, we cannot eliminate the risk of (a) accidental or intentional injury or (b) release, or contamination from these materials or wastes, which could expose us to liability. Furthermore, laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Accordingly, in the event of release, contamination, or injury, we could be liable for the resulting harm or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected. These liabilities could also include regulatory actions, litigation, investigations, remediation obligations, damage to our reputation and brand, supplemental disclosure obligations, loss of customer, consumer, and partner confidence in the safety of our laboratory operations, impairment to our business, and corresponding fees, costs, expenses, loss of revenues, and other potential liabilities, as well as increased costs or loss of revenue or other harm to our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">The release of GMOs or Genetically Modified Materials, whether inadvertent or purposeful, into uncontrolled environments could have unintended consequences, which may result in increased regulatory scrutiny and otherwise harm our business and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The genetically engineered organisms and materials that we develop may have significantly altered characteristics compared to those found in the wild, and the full effects of deployment or release of our genetically engineered organisms and materials into uncontrolled environments may be unknown. In particular, such deployment or release, including an unauthorized release, could impact the environment or community generally or the health and safety of our employees, our customers&#8217; employees, and the consumers of our customers&#8217; products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, if a high profile biosecurity breach or unauthorized release of a biological agent occurs within our industry, our customers and potential customers may lose trust in the security of the laboratory environments in which we produce GMOs, Genetically Modified Microorganisms (&#8220;GMMs&#8221;) and Genetically Modified Materials, even if we are not directly affected. Any adverse effect resulting from such a release, by us or others, could have a material adverse effect on the public acceptance of products from engineered cells and our business and financial condition. Such a release could result in increased regulatory scrutiny of our facilities, platform, and programs, and could require us to implement additional costly measures to maintain our regulatory permits, licenses, authorizations and approvals. To the extent such regulatory scrutiny or changes impact our ability to execute on existing or new programs for our customers, or make doing so more costly or difficult, our business, financial condition, or results of operations may be adversely affected. In addition, we could have exposure to liability for any resulting harm, as well as to regulatory actions, litigation, investigations, remediation obligations, damage to our reputation and brand, supplemental disclosure obligations, loss of customer, consumer, and partner confidence in the safety of engineered cells materials and organisms, impairment to our business, and corresponding fees, costs, expenses, loss of revenues, and other potential liabilities, as well as increased costs or loss of revenue or other harm to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We could synthesize DNA sequences or engage in other activity that inadvertently contravenes biosecurity requirements, or regulatory authorities could promulgate more far-reaching biosecurity requirements that our standard business practices cannot accommodate, which could give rise to substantial legal liability, impede our business, and damage our reputation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The Federal Select Agent Program (&#8220;FSAP&#8221;) involves rules administered by the Centers for Disease Control and Prevention and the USDA's APHIS that regulate possession, use, and transfer of biological select agents and toxins that have the potential to pose a severe threat to public, animal, or plant health or to animal or plant products. In accordance with the International Gene Synthesis Consortium&#8217;s (&#8220;IGSC&#8221;) Harmonized Screening Protocol for screening of synthetic DNA sequence orders, we follow biosafety and biosecurity industry practices and avoid DNA synthesis activities that implicate FSAP rules by screening synthetic DNA sequence orders against the IGSC&#8217;s Regulated Pathogen Database; however, we could err in our observance of compliance program requirements in a manner that leaves us in noncompliance with FSAP or other biosecurity rules. In addition, authorities could promulgate new biosecurity requirements that restrict our operations. One or more resulting legal penalties, restraints on our business or reputational damage could have material adverse effects on our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Third parties may use our engineered cells, materials, and organisms and accompanying production processes in ways that could damage our reputation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">After our customers have received our engineered cells, materials, and organisms and accompanying production processes, we do not have any control over their use and our customers may use them in ways that are harmful to our reputation. In addition, while we have established biosecurity offerings designed to comply with biosafety and biosecurity requirements and export control requirements in an effort to ensure that third parties do not obtain our engineered cells or other biomaterials for malevolent purposes, we cannot guarantee that these preventative measures will eliminate or reduce the risk of the domestic and global opportunities for the misuse or negligent use of our engineered cells materials, organisms and production processes. Accordingly, in the event of such misuse or negligent use, our reputation, future revenue, and operating results may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We currently market our services and deliver our programs, materials, and processes outside of the United States and may market future offerings outside of the United States. We, and our suppliers, collaborators, and customers, currently conduct business outside of the United States. From time to time, our services may include the hiring or secondment of our employees outside the United States at third party facilities or require the hiring or secondment of foreign persons within our facilities, including as a result of foreign acquisitions. Accordingly, we are subject to a variety of risks inherent in doing business internationally, and our exposure to these risks will increase as we continue to expand our operations and customer base. These risks include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">political, social and economic instability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">higher levels of credit risk, corruption, and payment fraud; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">enhanced difficulties of integrating any foreign acquisitions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">increased expenses and diversion of our management&#8217;s attention from advancing programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">regulations that might add difficulties in repatriating cash earned outside the United States and otherwise prevent us from freely moving cash;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">import and export controls and restrictions and changes in trade regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">compliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and similar laws in other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">multiple, conflicting and changing laws and regulations such as privacy, security and data use regulations, tax laws, tariffs, including tariffs announced by the Trump administration in 2025, trade regulations, economic sanctions and embargoes, employment laws, anti-corruption laws, regulatory requirements, reimbursement or payor regimes and other governmental approvals, permits and licenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">failure by us, our collaborators or our customers to obtain regulatory clearance, authorization or approval for the use of our services in various countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">additional potentially relevant third-party patent rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">difficulties in staffing and managing foreign operations, including difficulties related to the increased operations, travel, infrastructure and legal compliance costs associated with international locations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">logistics and regulations associated with shipping chemicals, biomaterials and product samples, including infrastructure conditions and transportation delays;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, widespread inflationary pressure, the impact of local and regional financial crises, on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, the outbreak of disease, or public health epidemics/pandemics, which could have an adverse impact on our employees, contractors, customers, partners, travel and the global economy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">breakdowns in infrastructure, utilities and other services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">boycotts, curtailment of trade and other business restrictions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the other risks and uncertainties described in this Annual Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Additionally, as part of our growth strategy, we will continue to evaluate potential opportunities for international expansion. Operating in international markets requires significant resources and management attention and will subject us to regulatory, economic and political risks in addition to those we face in the United States. However, our international expansion efforts may not be successful, which could limit the size of our market or the ability to provide services or programs internationally.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, due to potential costs from any international expansion efforts and potentially higher supplier costs outside of the United States, our international operations may operate with a lower margin profile. As a result, our margins may fluctuate as we expand our operations and customer base internationally.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our investments in and use of AI may result in reputational harm, liabilities, or other adverse consequences to our business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In August 2023, we entered into a strategic partnership with Google Cloud to develop and deploy AI tools for biology and biosecurity, which included certain minimum annual commitment obligations that we must pay. Under the strategic partnership, Ginkgo has developed and will continue to develop new, state-of-the-art large language models (&#8220;LLMs&#8221;) running on Google Cloud's Vertex AI platform across genomics, protein function, and synthetic biology, helping Ginkgo's customers accelerate innovation and discovery in fields as diverse as drug discovery, agriculture, industrial manufacturing, and biosecurity. Effective October 3, 2025, we entered into an amendment to the partnership to reduce our annual commitment amounts, which required a one-time payment of $14 million to be released from the obligations of the original agreement. If we are not able to meet our minimum annual commitment obligations again in the future, additional shortfall liabilities may be incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In September 2024, we launched our first model API, a tool aimed at making biological AI models accessible to researchers, developers, and machine learning scientists. However, our development and use of AI technology in our products and operations remains in the early phases. While we aim to develop and use AI responsibly and attempt to mitigate ethical and legal issues presented by its use, we may ultimately be unsuccessful in identifying or resolving issues before they arise. There is no guarantee that Ginkgo will be successful in developing or successfully deploying the use of commercially available AI tools and as with many innovations, the use of AI presents many risks and challenges, including misuse, intellectual property infringement or trade secret misappropriation, flawed algorithms, inadequate data provenance for datasets used to train models, and insufficient, flawed, and/or biased datasets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Additionally, AI technologies, including current tools available for business use in the marketplace, are complex and rapidly evolving. Uncertainty around new and emerging AI technologies may require additional investment to remain commercially relevant and/or to develop appropriate protections and safeguards. These investments may be costly and could increase our expenses as we contemplate expanding the use of AI in our platform and services. In addition, perceived or actual technical, legal, compliance, privacy, security, ethical or other issues relating to the use of AI may cause public confidence in AI to be undermined, which could slow our customers&#8217; adoption of our products and services that use AI. We may also face significant potential disruption as a result of rapidly evolving domestic and international laws and regulations, which could impose significant costs and obligations on the company. For example, in 2023, an executive order on safe, secure and trustworthy AI was issued; and a White House memorandum released in 2024 as a result of this executive order made specific recommendations for enhanced biosecurity screening and software for biofoundries using AI. The EU has similarly introduced the AI Act to establish rules for providers and users. Emerging regulations may pertain to data privacy, data protection, and the ethical use of AI, as well as clarifying intellectual property considerations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Challenges inherent to the use of AI generally or specific to Google's AI systems could adversely impact the reliability of our data and subject us to delays and competitive harm, result in new or enhanced governmental or regulatory scrutiny, pose confidentiality or security risks, ethical concerns, or legal liability, as well as brand or reputational harm, and our business and results of operations may suffer. Our use of AI could result in cybersecurity incidents that implicate the personal data or confidential information of the Company or our customers, which could adversely affect our reputation and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our recent restructuring actions in connection with our plans to reduce operational expenditures may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In connection with our plans to reduce operational expenditures, we implemented a restructuring plan, including a reduction in workforce and a planned consolidation and subleasing of certain facilities. Initial workforce reductions commenced in June 2024 and continued throughout 2025. Our reductions in force were substantially completed in 2025, although certain reductions will continue into 2026, subject to compliance with applicable laws. Our restructuring actions </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">may result in other disruptions to our business, including customer program delivery issues, loss of historical customer or technical knowledge, our ability to comply with applicable laws and regulations, and our ability to retain key employees. Our efforts to reduce the size of our patent portfolio may result in inadequate protection of our intellectual property assets. The Company has consolidated certain facilities through various actions, including combining office and laboratory operations into fewer locations, subleasing unused or underutilized facilities, and has taken or plans to take other related measures. While the Company completed the majority of its facility consolidation actions in 2025, we continue to look for opportunities for subleasing unused or underutilized facilities, which will extend beyond 2026 or may not occur prior to termination of such leases, depending on market conditions. Additionally, restructuring expenses related to potential asset impairments, contract amendments or terminations for any facilities no longer in use or underutilized could be material. For the years ended December 31, 2025 and 2024, the costs associated with our reductions in force was $11.4 million and $19.3 million, respectively, consisting of cash severance and related costs.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Risks Related to Our Customers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We are dependent on our customers&#8217; willingness and ability to successfully develop, produce and commercialize products using the cell engineering solutions we deliver and to a lesser extent, on the successful adoption and use of our cell engineering tools.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We sell cell engineering solutions and cell engineering tools. Our solutions offering involves performing R&amp;D services to engineer cells, biological assets and biomanufacturing processes for our customers which are intended to be scaled-up and deployed for commercialization. We rely on our customers to advance, manufacture, and commercialize products enabled by our work. A portion of the value from some of these customer collaborations has historically been earned through downstream value sharing in the form of royalty streams, milestone payments, and/or equity interests. If they are not successful in development, regulatory approval, manufacturing or commercialization, or if they choose to delay, deprioritize or discontinue such programs, the downstream value we expect to receive will be reduced or may not be realized at all. Because we do not control our customers&#8217; development, regulatory, manufacturing or commercial activities, we have limited ability to influence these outcomes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our ability to secure new solutions business and expand existing programs also depends on our customers&#8217; R&amp;D budgets, strategic priorities and willingness to outsource cell engineering work. If customers reduce R&amp;D spending, shift focus away from synthetic biology or biomanufacturing, decide to bring work in-house, or experience business, financial or operational difficulties, they may not initiate, renew or expand collaborations with us, which could reduce both our near-term services revenues and longer-term downstream value opportunity (in the collaborations where downstream value applies).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our cell engineering tools business is generally less directly tied to customers&#8217; product-level commercial outcomes because we earn revenue primarily from sales of hardware, software and related services. However, if customers do not achieve expected benefits from our tools, or if their internal R&amp;D or manufacturing efforts are unsuccessful, they may reduce or discontinue use of our tools or limit further deployments, which could adversely affect the growth of our tools business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Because many of the products pursued by our customers are at early stages of development and the markets and regulatory frameworks for bioengineered products and processes continue to evolve, we have limited historical information to accurately estimate the probability, timing and scale of commercial success. If we overestimate the probability or scale of commercial success, our actual future revenues and cash flows from customer collaborations may be lower than expected, which could adversely affect the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our revenue is concentrated in a limited number of customers, some of which are related parties, and our revenue, results of operations, cash flows and reputation may suffer upon the loss of a significant customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have derived, and may continue to derive, a significant portion of our revenue from a limited number of large customers. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">For the year ended December&#160;31, 2025, one customer in the Cell Engineering segment accounted for 15% of the Company&#8217;s total revenue, while one customer in the Biosecurity segment accounted for 12% of the Company&#8217;s total revenue</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">. Due to the significant time required to acquire new customers, to plan and develop new programs for customers, and to satisfactorily execute on existing programs, the loss of any of these customers, or the loss of any other significant customer or a significant reduction in the amount of demand from a significant customer would adversely affect our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">revenue, results of operations, cash flows and reputation in the marketplace. There is always a risk that existing customers will not elect to do business with us in the future or will experience financial difficulties. If our customers experience financial difficulties or business reversals which reduce or eliminate the need for our services, they may be unable or unwilling to fulfill their contracts with us. There is also the risk that our customers will attempt to impose new or additional requirements on us that reduce the profitability of the services performed by us. Our customer concentration also increases the concentration of our accounts receivable and our exposure to payment defaults by key customers, which could expose us to substantial and potentially unrecoverable costs if we do not receive payment from key customers. Additionally, the loss of any significant customer could pose reputational harm to us and make it more challenging to acquire new customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, while our customer collaborations are typically multi-year, we generally do not require our customers to generate a minimum amount of annual demand and without such contracts, our customers are not obligated to use our services beyond the amounts they choose to incur. Our customers may choose to use fewer of our services depending on program progress, their own technological capabilities, market demand for their products and/or their own internal budget cycles. As a result, we cannot accurately predict our customers&#8217; decisions to reduce or cease utilizing our services. Even where we enter into long-term contracts with our customers, there is no guarantee that such agreements will be negotiated on terms that are commercially favorable to us in the long-term. In addition, existing customers may choose to perform some or all of the services they expect from us internally, with another third-party partner or by using capabilities from acquisitions of assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">In certain cases, our business partners may have discretion in determining when and whether to make announcements about the status of our collaborations, including about developments and timelines for advancing programs, and the price of our common stock may decline as a result of announcements of unexpected results or developments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Generally, we and our customers must mutually agree on determining when and whether to make announcements about the status of our collaborations, including developments in our programs and timelines for commercialization of or improvements to products using engineered cells developed using our platform. However, in some cases our customers may report or otherwise may be obligated to disclose certain matters without our consent. Our partners may also wish to report such information more or less frequently than we intend to or may not wish to report such information at all. We or our partners may announce a collaboration or partnership even if there is no guarantee that we will recognize program fees. The price of our common stock may decline as a result of a public announcement of unexpected results or developments in our partnerships, or as a result of our partners not consenting to an announcement or withholding information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Risks Related to the Synthetic Biology Industry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Rapidly changing technology and emerging competition in the synthetic biology industry could make the platform, programs, services, tools, and products we and our customers are developing obsolete or non-competitive unless we continue to develop our platform and pursue new market opportunities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The synthetic biology industry is still emerging and is characterized by rapid and significant technological changes, frequent new product introductions and enhancements, and evolving industry demands and standards. We participate in this industry through both our R&amp;D services (cell engineering solutions) and our cell engineering tools (including automation hardware, software and data-generation offerings). Our future success will depend on our ability to sign and initiate new programs and deploy tools that address the evolving needs of our customers on a timely and cost-effective basis, to advance existing programs, and to pursue new market opportunities that develop as a result of technological and scientific advances. Additionally, our customers may face significant competition or other risks in their own markets which may impact demand for our services and tools thereby adversely impacting our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">There are a number of companies in the broader synthetic biology industry, and our future success will depend on our ability to maintain a competitive position with respect to technological advances in both cell engineering solutions and tools. Technological developments, including emerging AI and machine learning technologies, may result in our platform, our service offerings or our hardware and software tools becoming less differentiated, obsolete or non-competitive. For example, competitors or customers could develop alternative cell engineering platforms,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%"> in silico</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"> design capabilities, or automation and analytics tools that reduce the need for, or attractiveness of, our R&amp;D services or tools. Our ability to compete successfully will depend on our ability to develop and maintain proprietary technologies, such as our Autonomous Lab, that enable our customers to develop products using our platform in a manner that is less expensive, faster, superior or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">otherwise differentiated from what a competitor&#8217;s technologies and products might enable and to integrate our tools into customers&#8217; existing laboratory and data environments. If we are unable to continue to successfully advance our platform or the services it provides at scale, or to keep our tools offerings current, effective, interoperable and cost-competitive, or if our customers are unable to commercialize the products or processes made or improved upon by using our R&amp;D services and tools, our business and results of operations will be adversely impacted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Due to the significant lead time involved in launching a new program or developing a new product or process using our platform, our customers are required to make a number of assumptions and estimates regarding the commercial feasibility of a new product, including assumptions and estimates regarding the size of an emerging product category and demand for those end-products and processes which will use our technology, the ability to scale-up manufacturing processes to produce a product on a commercial scale, the ability to penetrate that emerging product category, customer adoption of a downstream product, the existence or non-existence of products being simultaneously developed by competitors, potential market penetration and obsolescence, planned or unplanned. As a result, it is possible that we may commence a new program with a customer who wishes to develop a product or process that has been displaced by the time of launch, addresses a market that no longer exists or is smaller than previously thought, that end-consumers do not like or otherwise is not competitive at the time of launch, in each case, after the incurrence of significant opportunity costs on our part to develop such product. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The ultimate success of the products developed by our customers using our services and tools may be dependent on the success of other markets in which we or our customers do not operate in or have knowledge or expertise or which, in each case, may not reach the size anticipated by us or our customers or may be replaced by another emerging product category or eliminated entirely.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">The market, including customers and potential investors, may be skeptical of our ability to deliver on programs because they are based on a relatively novel and complex technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The market, including customers and potential investors, may be skeptical of the viability and benefits of bioengineered products as well as our enabling abilities, including our platform and programs, because they are based on a relatively novel approach and the adoption of complex technology and because we are still demonstrating to the market the value of our platform. There can be no assurance that our platform and programs will be understood, approved, or accepted by customers, regulators and potential investors or that we will be able to sell our services profitably at competitive prices and with features sufficient to establish demand.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, in order for novel products from our programs to be successfully commercialized, support from the entire relevant supply chain is needed. Relationships with all parts of the supply chain are important in order to gain visibility into market trends and feature and specification requirements and in order to ensure customers are able to successfully manufacture their products, obtain regulatory approval and gain access to key distribution channels. If we are unable to convince these potential customers, their suppliers, or the consumers who purchase products containing or made or developed using engineered cells and/or biomanufacturing processes, of the utility and value of such products or that such products are superior to the products they currently use, we will not be successful in entering these markets and our business and results of operations will be adversely affected. If potential investors are skeptical of the success of our platform or cell programs, our ability to raise capital and the value of our common stock may be adversely affected. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Ethical, legal and social concerns about GMOs and Genetically Modified Materials and their resulting products could limit or prevent the use of products or processes using our technologies, limit public acceptance of such products or processes and limit our revenues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our technologies and the technologies of our customers involve the use of genetically modified cells, organisms and biomaterials, including, without limitation, GMOs, GMMs, Genetically Modified Materials and their respective products. The use, production and marketing of Genetically Modified Materials are subject to laws and regulations in many countries, some of which are new and some of which are still evolving. In the United States, the FDA, the EPA and the USDA are the primary agencies that regulate the use of GMOs, GMMs and potential products derived from GMOs or GMMs. If regulatory approval of the Genetically Modified Materials or resulting products is not secured, our business operations, financial condition and our ability to grow as a business could be adversely affected. We expect to encounter regulations regarding Genetically Modified Materials in most, if not all, of the countries in which our customers may seek to establish production capabilities or sell their products and the scope and nature of these regulations will likely be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">different from country to country. Governmental authorities could, for safety, social or other purposes, impose limits on, or implement regulation of, the use, production or marketing of Genetically Modified Materials. If our customers cannot meet the applicable requirements in other countries in which they intend to produce or sell their products, or if it takes longer than anticipated to obtain such approvals, our business could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, public perception regarding the safety and environmental hazards of, and ethical concerns over, Genetically Modified Materials or the processes used to create them, including gene editing or gene regulating technologies, could influence public acceptance of our and our customers&#8217; technologies, products, and processes. For instance, certain advocacy groups engage in efforts that include regulatory legal challenges and labeling campaigns for genetically modified products, as well as application of pressure to consumer retail outlets seeking a commitment not to carry genetically modified foods. These groups in the past have pressured retail food outlets and grocery store chains to publicly state that they will not carry genetically modified foods and have pressured food brands to publicly state that they will not use ingredients produced by genetically modified microbes. In addition, certain labeling-related initiatives have heightened consumer awareness of GMOs, which may make consumers less likely to purchase products containing GMO ingredients, and could have a negative impact on the commercial success of our customers&#8217; products and programs. These concerns could result in increased expenses, regulatory scrutiny, delays or other impediments to our programs. The subject of Genetically Modified Materials has received negative publicity, which has aroused public debate. This adverse publicity has led to, and could continue to lead to, greater regulation and trade restrictions on imports of Genetically Modified Materials or their resulting products. In addition, we have expanded into the European Union market, which has increased government regulation and scrutiny over genetically modified products. There is a risk that products produced using our technologies could cause adverse health effects or other adverse events, which could also lead to negative publicity, regulatory action or private litigation. If we are unable to overcome the ethical, legal and social concerns relating to genetic engineering, our programs could face increased expenses, regulatory scrutiny, delays or other impediments to deliver our programs or the commercialization of resulting products and processes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">If we are unable to obtain, maintain and defend patents protecting our intellectual property, our competitive position could be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our success depends in part on our ability to obtain and maintain intellectual property protection for our proprietary technologies. We protect our proprietary technologies through patents and trade secrets, both of which entail risk. If we are unable to obtain, maintain or protect intellectual property rights related to our technology, or if our intellectual property rights are inadequate, our competitive position, business, financial conditions, results of operations and prospects may be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Because of the volume and nature of our inventions, patent protection may not be practicable, available, or appropriate for some aspects of our proprietary technologies. While we own patents and pending patent applications in the United States and in foreign jurisdictions, these applications do not ensure the protection of our intellectual property. There may be prior art of which we are not aware. Additionally, obtaining, maintaining, defending and enforcing patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain and enforce any patents that may issue from such patent applications at a reasonable cost or in a timely manner. As a result of our restructuring and cost-reduction efforts, we have determined to reduce the size of our patent portfolio and, therefore, some of our intellectual property assets may be inadequate protected. It is also possible that we will fail to identify patentable aspects of our technologies before it is too late to obtain patent protection. Although we enter into confidentiality agreements with parties who have access to confidential or patentable aspects of our R&amp;D output, such as our employees, collaborators, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Further, pending applications may not be issued or may be issued with claims significantly narrower than we currently seek. Patents for which claims have been allowed may be successfully challenged and invalidated. Unless and until our pending applications issue, their protective scope is impossible to determine and, even after issuance, their protective scope may be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Changes in patent law may make patents covering life science inventions more difficult to obtain and enforce. Further legislative changes or changes in the interpretation of existing patent law could increase the uncertainty and cost </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">surrounding the prosecution of our owned patent applications and the maintenance, enforcement or defense of our owned patents. In some cases, we develop inventions with the assistance of machine learning and other computational tools that may be considered to be AI, and we expect to use such tools, and to use generative AI, in future development. Because the law is in flux with respect to AI-assisted inventions, there is uncertainty and risk associated with patenting such inventions.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a further material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. It is also possible that disclosure requirements with respect to use of AI tools may be imposed by the patent office, which could increase the cost of patent prosecution and cause uncertainty and delay in the enforcement of patent rights.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In some cases, we use genetic sequence information from naturally occurring organisms. U.S. Supreme Court rulings have narrowed the scope of patent protection for naturally occurring sequences and for inventions based on the observation and exploitation of natural phenomena. These decisions have weakened the rights of patent owners in certain situations. The Federal Circuit and the Supreme Court have also issued a series of rulings that create obstacles to the patenting of groups of genetic sequences that share functional characteristics, making it more difficult to obtain claims to certain genetic constructs, particularly antibodies. These changes in the law have created uncertainty with respect to the validity and enforceability of patents covering natural and engineered sequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Further, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such challenge could result in loss of exclusivity, or patent claims being narrowed, invalidated or held unenforceable, in whole or in part. Any of these results could limit our ability to stop others from using or commercializing similar or identical technology to compete directly with us. In addition, if the breadth or strength of protection provided by our patents or patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The laws of some countries do not protect intellectual property rights to the same extent as do the laws of the United States or may apply different rules concerning the assignment of intellectual property rights. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain jurisdictions. We may encounter similar difficulties, particularly as we expand to work with foreign employees and contractors and expand our collaboration activities into foreign markets. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents by foreign holders and, in some cases, do not favor the enforcement of patents at all, particularly patents in the life sciences. This could make it difficult for us to stop the infringement of our patents. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business and could be unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Reductions in the scope or enforceability of our patent protection may adversely affect our customers&#8217; ability to commercialize their products and may thus reduce our downstream value from royalties, commercial milestone payments and/or equity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Because patent protection may not be available or appropriate for significant aspects of the technology we are developing, our success may depend in large part on our proprietary information, including genetic and other chemical and biological data, processes, know-how, and other trade secrets developed over years of R&amp;D, some of which are embodied in proprietary software. We rely heavily on trade secret protections, especially in cases where we believe patents or other forms of registered intellectual property protection may not be appropriate or obtainable. However, trade secrets are difficult to protect. The secrecy of the Company&#8217;s trade secrets must be maintained for them to retain their status and protection as trade secrets. While we strive to protect the secrecy of our trade secrets and other proprietary information, including by requiring our employees, customers, consultants, and contractors to enter into confidentiality agreements and instituting multilayered protections covering our digital environment and biomaterials, we may not be able to adequately protect our trade secrets or other proprietary information. We cannot guarantee that we have entered into such agreements with every party that may have or has had access to our trade secrets, biomaterials or proprietary technology and processes. Further, despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We seek to preserve the integrity and confidentiality of our information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. We also rely on systems provided by third parties, which may suffer security breaches or incidents. Such security breaches may be inadvertent or may come about due to intentional misconduct or other malfeasance or by human error or technical malfunctions, including those caused by hackers, employees, contractors, or vendors. It may be difficult or impossible to recover trade secrets or other confidential information once it is hacked, and hackers may operate from jurisdictions that will not cooperate with such efforts. Enforcing any claim that a third party unlawfully obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts in some jurisdictions are less willing or unwilling to protect trade secrets even when a hacker or thief can be identified. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our competitors may lawfully obtain or independently develop knowledge that is equivalent to one or more of our trade secrets. Were they to do so, we would be unable to prevent them from using that independently developed knowledge. Such a competitor could claim that we had learned the trade secret from them and bring an action against us on that basis. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position could be materially and adversely harmed. Moreover, a competitor could file for patent protection covering intellectual property that we have chosen to protect as a trade secret. In such a case, we might be restricted or excluded from using that intellectual property even if we had developed it before our competitor did.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our facilities hold large collections of microbial strains, cell lines and other biomaterials. Failure to implement adequate controls and protections, failure to implement adequate disposal procedures, unauthorized visitors in the labs, or customers&#8217; failure to adequately protect biological materials can put us and our customers at risk of losing valuable assets through negligence or theft and enabling the use of those lost materials by our competitors. While we believe that we take reasonable measures to protect the security of biomaterials owned by us or our customers, it is possible that our security controls and practices may not prevent unauthorized or other improper access to such genetic material. Any unauthorized access, acquisition, use, destruction, or release of the GMOs we engineer could result in our having exposure to significant liability under our contracts, as well as to regulatory actions, litigation, investigations, remediation obligations, damage to our reputation and brand, supplemental disclosure obligations, loss of customer, consumer, or partner confidence in the security of our platform, impairment to our business, and corresponding fees, costs, expenses, loss of revenues, and other potential liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our customers sometimes provide organisms, genetic material and/or data to us in connection with our collaborations. In the event that we fail to protect customer materials or data or inadvertently use such materials or data for unauthorized purposes, we could be liable to our customers under trade secret laws or contractual provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We may be subject to claims challenging the inventorship or ownership of our patents, biomaterials and other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Certain of our employees, consultants and contractors were previously employed at universities or other software or biotechnology companies, including our competitors or potential competitors. Additionally, some of our consultants or contractors may have ongoing relationships with universities. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property of others in their work for us, we may be subject to claims that these individuals or other contractors have used or disclosed intellectual property, including trade secrets or other proprietary information, of another. Litigation may result from these claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">While it is our policy to require that our employees, consultants and contractors who may be involved in the development of intellectual property for us execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">If we are unsuccessful in litigating any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to use or commercialize our technology or products, which license might not be available on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">commercially reasonable terms, or at all. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The life science academic and research community has abided by norms of free exchange of biomaterials, but norms have begun to change so that parties may assert ownership and control over biomaterials that they permitted to be freely disseminated in the past. Thus, despite our best efforts to confirm our right to use biomaterials in our possession, we may use organisms that we believe to be free of encumbrance that are, in fact, subject to claims of title by others. In such a situation, litigation may be required to clear title, if it can be cleared at all. Similarly, we may be subject to claims that we have used biomaterials obtained from licensors or repositories for unauthorized purposes, or purposes not consistent with the licensing terms of the providing organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We may become involved in lawsuits or other enforcement proceedings to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and potentially unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Competitors and other third parties may infringe or otherwise violate our issued patents or other intellectual property. In addition, our patents may become involved in inventorship, ownership, or priority disputes. We may also become subject to claims by collaboration partners that intellectual property or biomaterials that we believe to be owned by us are actually owned by them. Any litigation concerning any of these issues would be expensive, time consuming and uncertain. There can be no assurances that we would prevail in any suit brought by us or against us by third parties, or successfully settle or otherwise resolve those claims. Significant litigation would have substantial costs, even if the eventual outcome were favorable to us, and would divert management&#8217;s attention from our business objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Under certain circumstances, we may share or lose rights to intellectual property developed under U.S. federally funded research grants and contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Some of our inventions, data, or other intellectual property have been or may be developed during the course of research funded by the U.S. government. The U.S. government may have the right to take title to government-funded inventions if we fail to disclose the inventions to the government in a timely manner or fail to file a patent for the intellectual property within specified time limits. Further, in consequence of our receiving government funding, the U.S. government may have certain rights to intellectual property that we use in our platform or programs pursuant to the Bayh-Dole Act of 1980, as amended (the &#8220;Bayh-Dole Act&#8221;). Under the Bayh-Dole Act, U.S. government rights in certain &#8220;subject inventions&#8221; developed under a government-funded program may include a non-exclusive, irrevocable worldwide license to use inventions for any governmental purpose. In some circumstances, the U.S. government may acquire unlimited rights in data we generate. In addition, the U.S. government has the right to require us, or an assignee or exclusive licensee to U.S. Government-funded inventions, to grant licenses to any of these inventions to the government or a third party if the government determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; (iii) government action is necessary to meet requirements for public use under federal regulations; or (iv) the right to use or sell such inventions is exclusively licensed to an entity within the United States and substantially manufactured outside the United States without the U.S. government&#8217;s prior approval. Additionally, we may be restricted from granting exclusive licenses for the right to use or sell such inventions unless the licensee agrees to comply with relevant Bayh-Dole Act restrictions (e.g., manufacturing substantially all of the invention in the United States) and reporting requirements. In addition, the U.S. government may acquire title in any country in which a patent application is not filed. Certain technology and inventions are also subject to transfer restrictions during the term of these agreements with the U.S. government and for a period thereafter. These restrictions may limit sales of products or components, transfers to foreign subsidiaries for the purpose of the relevant agreements, and transfers to certain foreign third parties. If any of our intellectual property becomes subject to any of the rights or remedies available to the U.S. government or third parties pursuant to the Bayh-Dole Act, this could impair the value of our intellectual property and could adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">The use of digital genetic sequence information may be subject to the Nagoya Protocol or other treaties or local legislation concerning biodiversity, which could increase our costs and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The Nagoya Protocol is a supplemental agreement to the Convention on Biological Diversity (&#8220;CBD&#8221;) that is designed to provide for equitable sharing of benefits arising from the utilization of genetic resources and traditional knowledge. There are other international treaties, as well as local legislation in many countries, with similar objectives. Under the Nagoya Protocol and many other treaties and laws, countries possessing genetic resources (&#8220;source countries&#8221;) are tasked with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">setting up procedures and institutional infrastructure for researchers to obtain prior informed consent, both from the source country and from any relevant indigenous or traditional communities, for biological research. Many have been slow to adopt workable institutions permitting the rational negotiation of benefit-sharing agreements. Many source countries are now asserting that the use of digital genetic sequence information is subject to the constraints of the Nagoya Protocol or similar national- or local-level benefit-sharing requirements. It is unclear whether this position will ultimately be adopted or what the implications of such adoption might be. It is unclear what a source country might assert if we used genetic sequences (i) extracted by a third party from a natural resource that was removed from its source country before that source country ratified the CBD or signed the Nagoya Protocol (ii) extracted by a third party and uploaded to public sequence databases after the source country ratified the CBD; (iii) in a heterologous host organism; or (iv) as a base for further engineering, so that the sequence we use no longer conforms to the natural sequence on which it was based.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We make extensive use of public and proprietary sequence databases to support our work. While we undertake efforts to identify and comply with laws and international protocols relating to the use of genetic resources, the uncertainty surrounding the use of digital sequence information and the lack of workable institutions in many source countries for the efficient negotiation of benefit-sharing agreements may limit our use or cause uncertainty in our use of certain sequences that we obtain from public access databases or natural sources. New financial obligations may arise regarding our use of sequence information. Customers that must certify their compliance with Nagoya Protocol obligations may be reluctant to do business with us unless we engage in expensive and time-consuming benefit-sharing negotiations with source countries of publicly available genetic sequences. Moreover, the World Intellectual Property Organization is considering requiring disclosures in patents of the origin of genetic resources, which may further increase uncertainty and the cost of patent prosecution. These changes could increase our R&amp;D costs and adversely affect our business, financial condition, and results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Third party patents may limit our freedom to operate in certain areas, which may adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">There may be patents that affect our freedom to operate in certain areas, and we may as a result choose to design around or license such patents from third parties. If we must spend significant time and money designing around or licensing patents held by others, our business and financial prospects may be harmed. We may be restricted from carrying out certain operations, or we may be limited in our ability to design new products for our customers. We may become subject to claims by third parties alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">If we are sued for infringing, misappropriating, or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from using our platform and technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Litigation arising from disputes relating to the intellectual property of third parties is expensive, time-consuming, and uncertain. There can be no assurance that we will prevail in such disputes. Parties making claims against us might be able to obtain injunctive or other relief, which could block our or our customers&#8217; ability to develop, commercialize and sell products or use our technologies, and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs and expenses if we were found to have willfully infringed. In the event of a successful claim against us, we or our customers might be required to pay damages and ongoing royalties, and obtain licenses from third parties, or be prohibited from selling certain products or using certain technologies. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all. In addition, we or our customers could encounter delays in product or service introductions while we attempt to develop alternative designs or redesign existing products or technologies to avoid or resolve these claims. Our loss in any lawsuit or failure to obtain a license could prevent us from using our platform and technologies. Such a loss or failure could materially affect our business and reputation. Any litigation pertaining to these issues would have substantial costs, even if the eventual outcome were favorable to us, and would divert management&#8217;s attention from our business objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, dilution or tarnishment claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Any claims or lawsuits relating to infringement of, misappropriating, or otherwise violating intellectual property rights brought by or against us will be costly and time consuming and may adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Any of the risks identified above could result in significant litigation. In addition to the specific litigation-related risks identified above, litigation of any kind carries certain inherent risks. Because of the substantial amount of discovery required in connection with litigation in U.S. courts, there is a risk that some of our confidential information could be compromised in the discovery process. There could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our share price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Further, our agreements with some of our customers, suppliers or other entities require us to defend or indemnify these parties if they become involved in infringement claims that target our products, services or technologies, or in certain other situations. If we must defend or indemnify third parties, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Intellectual property rights do not necessarily address all potential threats to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">we may choose not to file a patent in order to maintain certain intellectual property as trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the patents of others may harm our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">we might not have been the first to file patent applications covering certain of our inventions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">issued patents that we hold rights to may fail to provide us with any competitive advantage, or may be held invalid or unenforceable, including as a result of legal challenges by our competitors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Should any of these events occur, they could harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Intellectual property disputes of third parties and customers could have a material adverse effect on our business, financial condition, and results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We rely, and expect to continue to rely on, certain capital equipment, machinery, consumables, reagents, software, services and intellectual property that we purchase or license from third parties for use in our operations, platform, products, services and offerings. We cannot be certain that our vendors, suppliers, and licensors are not infringing upon the intellectual property rights of others or that they have sufficient rights to the third-party technology used in our business in all jurisdictions in which we may operate. Disputes with any of these third parties over uses or terms could result in the payment of additional royalties or penalties by us, cancellation or non-renewal of the underlying license, termination of supplies or rights to use, or litigation. In the event that we cannot resolve issues of this kind, we may be required to discontinue or limit our use of the operations, platform, products, services or offerings that include or incorporate the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">licensed intellectual property. Any such discontinuation or limitation could have a material and adverse impact on our business, financial condition and results of operation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our customers may become involved in intellectual property disputes with third parties that are related or unrelated to any products or services we have supplied or rendered to them. Such disputes could result in a customer being unable to market its products, thus depriving us of license, milestone, or other revenues. Such deprivation could have a material adverse impact on our financial condition and results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our use of &#8220;open-source&#8221; software could negatively affect our ability to market or provide our services and could subject us to possible litigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have used &#8220;open-source&#8221; software in connection with the development and deployment of our software platform, and we expect to continue to use open-source software in the future. Open-source software is licensed by its authors or other third parties under open-source licenses, which in some instances may subject us to certain unfavorable conditions, including requirements that we offer our products that incorporate the open-source software for no cost, that we make publicly available all or part of the source code for any modifications or derivative works we create based upon, incorporating or using the open-source software, or that we license such modifications or derivative works under the terms of the particular open-source license.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Companies that incorporate open-source software into their products have, from time to time, faced claims challenging the use of open-source software and compliance with open-source license terms. We could be subject to similar suits by parties claiming ownership of what we believe to be open-source software or claiming noncompliance with open-source licensing terms. While we monitor our use of open-source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open-source agreement, we cannot guarantee that we will be successful, that all open-source software is reviewed prior to use in our platform, that our developers have not incorporated open- source software into our products that we are unaware of or that they will not do so in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Furthermore, there are an increasing number of open-source software license types, almost none of which have been interpreted by U.S. or foreign courts, resulting in a dearth of guidance regarding the proper legal interpretation of such licenses. As a result, there is a risk that open-source software licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to market or provide our products and services. If we are held to have breached or failed to fully comply with all the terms and conditions of an open-source software license, we could face infringement claims or other liability, or be required to seek costly licenses from third parties to continue providing our offerings on terms that are not economically feasible, if at all, to re-engineer all or a portion of our platform, to discontinue or delay the provision of our offerings if re-engineering could not be accomplished on a timely basis or to make generally available, in source code form, our proprietary code. Further, in addition to risks related to license requirements, use of certain open-source software carries greater technical and legal risks than does the use of third-party commercial software. For example, open-source software is generally provided without any support or warranties or other contractual protections regarding infringement or the quality of the code, including the existence of security vulnerabilities. To the extent that our platform depends upon the successful operation of open-source software, any undetected errors or defects in open-source software that we use could prevent the deployment or impair the functionality of our systems and injure our reputation. In addition, the public availability of such software may make it easier for others to compromise our platform. Any of the foregoing risks could materially and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Risks Related to Personnel, IT and Physical Infrastructure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Loss of key personnel, including our founders and senior executives, and/or failure to attract, train and retain additional key personnel , or unintended consequences caused by our workforce reduction, could delay our cell engineering programs, harm our platform development efforts, limit our biosecurity and public health offerings, and harm our ability to meet our business objectives, particularly given the substantial investment required to recruit, hire and train our employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our business involves complex, global operations across a variety of markets and requires a management team and employee workforce that is knowledgeable in the many areas in which we operate. Our future success depends upon our ability to attract, train, retain and motivate highly qualified management, scientific, engineering, information technology, operations, business development and marketing personnel, among others. In addition, the market for qualified personnel is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">competitive because of (a) the limited number of people available who have the necessary technical skills and understanding of our technology and products and (b) the nature of our industry which requires certain of our technical personnel to be on-site in our facilities. We compete for qualified technical personnel with other life sciences and information technology companies, as well as academic institutions and research institutions in the markets in which we operate, including: Massachusetts, USA; California, USA; The Netherlands; and Switzerland. Our senior leadership team is critical to our vision, strategic direction, platform development, operations and commercial efforts. Our employees, including members of our leadership team, could leave our company with little or no prior notice and would be free to work for a competitor. We also do not maintain &#8220;key person&#8221; life insurance on any of our employees. The departure of one or more of our founders, senior leadership team members or other key employees could be disruptive to our business until we are able to hire qualified successors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, we implemented a workforce reduction of more than 50% of our employees, which was substantially completed in 2025. While we believe this workforce reduction was necessary to help realign the Company&#8217;s cost structure, this reduction may yield unintended consequences, such as the loss of certain institutional knowledge and technical expertise, as well as attrition beyond our intended reduction in workforce and reduced employee morale, which may cause our employees who were not affected by the reduction in workforce to seek alternate employment. Additional attrition could impede our ability to meet our operational goals, which could have a material adverse effect on our financial performance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our continued platform development, growth and commercial success depends, in part, on recruiting and retaining highly-trained personnel across our various target industries and markets with the necessary background and ability to develop and use our platform and to effectively identify and sell to current and new customers. New hires and employees onboarded as a result of any of our recent acquisitions may require significant training and, in most cases, take significant time before they achieve full productivity. Our failure to successfully hire and integrate these key personnel into our business could adversely affect our business. To attract top talent, we believe we will need to offer competitive compensation and benefits packages, including equity incentive programs, which may require significant investment. If we are unable to offer competitive compensation this may make it more difficult for us to attract and retain key employees. To the extent our compensation programs and workplace culture are not viewed as competitive, or changes in our workforce and related restructuring, reduction-in-force, or other initiatives are not viewed favorably, our ability to attract, retain and motivate employees can be weakened, which could harm our results of operations. Moreover, if the perceived value of our equity awards declines, it may adversely affect our ability to attract and retain key employees. If we do not maintain the necessary personnel to accomplish our business objectives, we may experience staffing constraints that adversely affect our ability to support our programs and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, some of our personnel are qualified foreign nationals whose ability to live and work in the U.S. is contingent upon the continued availability of appropriate visas and whose ability to work on some of our technologies may require the procurement of appropriate export licenses. Due to the competition for qualified personnel in the key markets in which we operate, we expect to continue to utilize foreign nationals to fill part of our recruiting needs. As a result, changes to United States immigration policies have restrained, and could further restrain, the flow of technical and professional talent into the United States and adversely affect our ability to hire and retain qualified personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our business and results of operations are dependent on adequate access to laboratory and office space and suitable physical infrastructure to conduct our operations. If we are unable to access enough space or we experience failures of our physical infrastructure, including due to natural disasters affecting us or our suppliers, our business and results of operations could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our business depends on providing customers with R&amp;D services and tools. In order to properly conduct our business, we need access to sufficient laboratory space and equipment to perform the activities necessary to advance and complete our programs. Additionally, we need to ensure that our laboratories and corporate offices remain operational at all times, which includes maintaining suitable physical infrastructure, including electrical, waste management, plumbing and HVAC, logistics and transportation systems and network infrastructure. We own certain properties in California and lease most of our laboratories and office spaces. We rely on the landlords, as applicable, for basic maintenance of our leased laboratories and office buildings. If one of our landlords has not maintained a leased property sufficiently, we may be forced to stop working on a particular program or even exit early from the facility, which could be disruptive to our business. Furthermore, we may continue to acquire laboratories not built by us in order to sufficiently scale and expand our output </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">capacity. If we discover that these buildings and their infrastructure assets are not in the condition we expected when they were acquired, we may be required to incur substantial additional costs to repair or upgrade the laboratories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Problems in and around one or more of our laboratories or corporate offices, whether or not within our control, could result in service interruptions or significant infrastructure or equipment damage. These could result from numerous factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">human error;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">equipment failure;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">physical, electronic and cybersecurity breaches;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">fire, earthquake, hurricane, flood, tornado and other natural disasters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">extreme temperatures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">flood and/or water damage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">fiber cuts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">power loss;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">terrorist acts, including acts of bioterrorism;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">sabotage, vandalism and cyberattacks; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">local epidemics or global pandemics.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Certain of our facilities are located in an active floor, earthquake and/or tsunami zone, and certain of our suppliers conduct their operations in the same region or in other locations that are susceptible to natural disasters. The occurrence of a natural or other disaster, such as an earthquake, tsunami, hurricane, drought, flood, fire, wildfire or any potential effects of climate change or localized extended outages of critical utilities or transportation systems, or any critical resource shortages affecting us or our suppliers or manufacturers could cause a significant interruption in our business, damage or destroy our facilities, production equipment or inventory or those of our suppliers and cause us to incur significant costs or result in limitations on the availability of our raw materials, any of which could harm our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have timeline obligations to certain customers with respect to their programs. As a result, service interruptions or significant equipment damage in our laboratories could result in difficulty maintaining program timelines for these customers and potential claims related to such failures. Because the services we provide in our laboratories are critical to many of our customers&#8217; businesses, service interruptions or significant equipment damage in our laboratories could also result in lost revenue or other indirect or consequential damages to our customers. We cannot guarantee that a court would enforce any contractual limitations on our liability in the event that one of our customers brings a lawsuit against us result of a problem at one of our laboratories and we may decide to reach settlements with affected customers irrespective of any such contractual limitations. In addition, any loss of service, equipment damage or inability to meet our service obligations could reduce the confidence of our customers and could consequently impair our ability to obtain and retain customers, which would adversely affect both our ability to generate revenues and our operating results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Furthermore, we are dependent upon internet service providers, telecommunications carriers and other website operators, some of which have experienced significant system failures and electrical outages in the past.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our customers may, in the future, experience difficulties due to system failures unrelated to our systems and offerings. If, for any reason, these providers fail to provide the required services, our business, financial condition and results of operations could be materially and adversely impacted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Risks Related to Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We use estimates in determining the fair value of certain assets and liabilities. If our estimates prove to be incorrect, we may be required to write down the value of these assets or write up the value of these liabilities, which could adversely affect our financial position.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our ability to measure and report our financial position and operating results is influenced by the need to estimate the fair value of an asset or liability. Fair value is estimated based on a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. We estimate the impact or outcome of future events on the basis of information available at the time of the financial statements. An accounting estimate is considered critical if it requires that management make assumptions about matters that were highly uncertain at the time the accounting estimate was made. If actual results differ from management&#8217;s judgments and assumptions, then they may have an adverse impact on our results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have incurred net losses since our inception and we may never achieve or sustain profitability. Generally, for U.S. federal income tax purposes, net operating losses incurred will carry forward. However, net operating loss carryforwards generated prior to January 1, 2018 are subject to expiration for U.S. federal income tax purposes. As of December&#160;31, 2025, the Company had federal net operating loss carryforwards of approximately $1.8 billion, of which $139.2 million will begin to expire in 2029 and $1.6 billion can be carried forward indefinitely. As of December&#160;31, 2025, the Company had state net operating loss carryforwards of approximately $1.5 billion, of which $1.2 billion will begin to expire in 2030 and $257.5 million can be carried forward indefinitely. The Company also had $3.9&#160;million of foreign net operating losses as of December&#160;31, 2025, of which $1.5&#160;million will begin to expire in 2034 and $2.4&#160;million can be carried forward indefinitely.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change by value in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-ownership change net operating loss carryforwards and other pre-ownership change tax attributes, such as research tax credits, to offset its post-ownership change income or taxes may be limited. Similar provisions of state tax law may also apply to limit the use of our state net operating loss carryforwards and other state tax attributes. We have not performed an analysis to determine whether our past issuances of stock and other changes in our stock ownership may have resulted in one or more ownership changes. If it is determined that we have in the past experienced an ownership change, or if we undergo one or more ownership changes as a result of future transactions in our stock, which may be outside our control, then our ability to utilize our net operating loss carryforwards and other tax attributes may be materially limited. As a result, even if we earn taxable income, we may be unable to use a material portion of our net operating loss carryforwards and other tax attributes, which could adversely affect our future cash flows. There is also a risk that regulatory changes, such as suspensions on the use of net operating losses or other unforeseen reasons, may result in our existing net operating loss carryforwards expiring or otherwise becoming unavailable to offset future taxable income. For these reasons, we may not be able to utilize a material portion of our net operating loss carryforwards and other tax attributes even if we attain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We had in the past identified a material weakness in our internal controls over financial reporting, and we may identify additional material weaknesses in the future. A failure to maintain an effective system of internal control over financial reporting, may result in failure to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">SEC and New York Stock Exchange (&#8220;NYSE&#8221;) rules and regulations require, among other things, that we establish and periodically evaluate procedures with respect to our internal control over financial reporting. In addition, we are required to document and test our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 so that our management can certify as to the effectiveness of our internal control over financial reporting. Likewise, our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">As previously disclosed in Part II-Item 9A, &#8220;Controls and Procedures&#8221;, of our Annual Report on Form 10-K for the year ended December 31, 2023, in connection with the audit of our financial statements for the year ended December 31, 2023, we concluded that there was a material weakness in our internal controls over financial reporting. The material weakness identified did not result in any material misstatement of our financial statements. The material weakness identified for the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">year ended December 31, 2023 was remediated as of December 31, 2024. However, we may in the future discover other areas of our internal controls that require remediation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We cannot provide assurances that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, or results of operations. Any material weaknesses or significant deficiencies in our internal control over financial reporting could cause investors to lose confidence in the accuracy and completeness of our financial reports, the market price of shares of our common stock to decline, and result in sanctions or investigations by NYSE, the SEC or other regulatory authorities. Failure to remedy material weaknesses in our internal control over financial reporting or to implement or maintain other effective control systems could also restrict our future access to the capital markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Adverse developments affecting the financial services industry could adversely affect our business operations, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Actual or rumored events involving reduced or limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, have in the past and may in the future lead to market-wide liquidity problems. Future adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies to access working capital needs, and create additional market and economic uncertainty.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation insurance limit. Any failure of a depository institution to return our deposits, or if a depository institution is subject to other adverse conditions in the financial or credit markets, could further impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, widespread investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, or result in breaches of our financial and/or contractual obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Risks Related to Governmental Regulation and Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Failure to comply with federal, state, local and international laws and regulations could adversely affect our business and our financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">A variety of federal, state, local and international laws and regulations govern certain aspects of our business. For example, we maintain a registration from the DEA for the research of certain controlled substances and permits from the Boston Public Health Commission to conduct work with recombinant DNA. Some of our programs or products made or developed using our engineered cells and/or biomanufacturing processes are subject to regulations, including those promulgated by the FDA, DEA, EPA or USDA. In addition, we are subject to laws relating to, among other things, anti-bribery, insider trading, sourcing of biological materials and data privacy. The legal and regulatory requirements that apply to our business may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with other rules or our practices. As a result, our practices may not comply, or may not comply in the future with all such laws, regulations, requirements and obligations. Any failure, or perceived failure, by us to comply with any federal, state, local or international laws, regulations, industry self-regulatory principles, industry standards or codes of conduct, regulatory guidance, orders to which we may be subject or other legal obligations could adversely affect our reputation, brand and business, and may result in claims, proceedings or actions against us by governmental entities or others or other liabilities or require us to change our operations. We may also be contractually required to indemnify and hold harmless third parties from the costs or consequences of non-compliance with any laws, regulations or other legal obligations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We may also become subject to increasing regulation in the future as we expand our business. As we continue to expand our operations and offerings domestically and globally, we will have to expend significant management and financial resources to maintain compliant practices in those locations. Non-compliance could lead to litigation, which would require substantial management and financial resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We may incur significant costs complying with environmental, health and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We use hazardous chemical and biological materials in our business and are subject to a variety of federal, state, local and international laws and regulations governing, among other matters, the use, generation, manufacture, transportation, storage, handling, disposal of, and human exposure to these materials, including regulation by governmental regulatory agencies, such as the Occupational Safety and Health Administration and the EPA. We have incurred, and will continue to incur, capital and operating expenditures and other costs in the ordinary course of our business in complying with these laws and regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Although we have implemented safety procedures for storing, handling and disposing of these materials and waste products in an effort to comply with these laws and regulations, we cannot be sure that our safety measures will be compliant or capable of eliminating the risk of injury or contamination from the generation, manufacturing, use, storage, transportation, handling, disposal of and human exposure to hazardous materials and/or flammable chemicals. Failure to comply with environmental, health and safety laws could subject us to liability and resulting damages. There can be no assurance that violations of environmental, health and safety laws will not occur as a result of human error, accident, equipment failure, contamination, intentional misconduct or other causes. Compliance with applicable environmental laws and regulations may be expensive, and the failure to comply with past, present or future laws could result in the imposition of fines, regulatory oversight costs, third party property damage, product liability and personal injury claims, investigation and remediation costs, the suspension of production or a cessation of operations, and our liability may exceed our total assets. Liability under environmental laws can be imposed for the full amount of damages without regard to comparative fault for the investigation and cleanup of contamination and impacts to human health and for damages to natural resources. Contamination at properties we may own and operate and at properties to which we send hazardous materials, may result in liability for us under environmental laws and regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our business and operations may be affected by other new environmental, health and safety laws and regulations, which may require us to change our operations, or result in greater compliance costs and increasing risks and penalties associated with violations, which could impair our research, development or production efforts and harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">If we fail to comply with healthcare and other governmental regulations, we could face substantial penalties and our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our business activities may be subject to regulation and enforcement by the FDA, U.S. Department of Justice, HHS, Office of Inspector General, and other federal and state governmental authorities. Although our offerings are not currently billed to any third-party payor, including any commercial payor or government healthcare program, we may, in the future, submit claims for our services to third-party payors, including government healthcare programs. If we submit claims to third-party payors, such activity will expand the scope of federal and state healthcare laws applicable to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Federal and state healthcare laws and regulations that may affect our ability to conduct business include, without limitation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits a physician, in the absence of an applicable exception, from making a referral for certain designated health services covered by the Medicare or Medicaid program, including clinical laboratory services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Stark Law also prohibits the entity furnishing the designated health services from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the federal civil false claims laws, including without limitation the federal False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government), and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute or Stark Law constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the EKRA, which created a new federal crime for knowingly and willfully: (1) soliciting or receiving any remuneration in return for referring a patient to a recovery home, clinical treatment facility, or laboratory; or (2) paying or offering any remuneration to induce such a referral or in exchange for an individual using the services of a recovery home, clinical treatment facility, or laboratory. Unlike the Anti-Kickback Statute, EKRA is not limited to services reimbursable under a government health care program, but instead extends to all services reimbursed by &#8220;health care benefit programs&#8221;;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the healthcare fraud statutes under HIPAA, which impose criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) enacted as part of the American Recovery and Reinvestment Act of 2009, and its implementing regulations, and as amended again by the Modifications to the HIPAA Privacy, Security, Enforcement and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to the HIPAA Rules, commonly referred to as the Final HIPAA Omnibus Rule, published in January 2013, which imposes certain obligations, including mandatory contractual terms, on covered entities subject to HIPAA (i.e., health plans, healthcare clearinghouses and certain healthcare providers), as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information, to safeguard the privacy, security and transmission of individually identifiable health information from any unauthorized use or disclosure;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the U.S. Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) which imposes civil and criminal liability for engaging in any of a number of Prohibited acts, including distributing drugs, devices and foods that are adulterated or misbranded. To charge a criminal misdemeanor violation of the FDCA, no intent need be shown;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">federal consumer protection and unfair competition laws, which broadly regulate platform activities and activities that potentially harm consumers; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">state law equivalents of each of the above federal laws, such as anti-kickback, self-referral, and fee-splitting, and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers and self-pay patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, exceptions, and safe harbors, it is possible that some of our activities could be subject to challenge under one or more of such laws. We may face claims and proceedings by private parties, and claims, investigations and other proceedings by governmental authorities, relating to allegations that our business practices do not comply with current or future laws or regulations involving applicable fraud and abuse or other healthcare laws and regulations, and it is possible that courts or governmental authorities may conclude that we or any of our partners have not complied with them, or that we may find it necessary or appropriate to settle any such claims or other proceedings. Any action brought against us for violation of these or other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any federal or state laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to claims and proceedings by private parties, investigations and other proceedings by governmental authorities, as well as penalties, including significant criminal, civil and administrative penalties, damages and fines, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws or regulations, imprisonment for individuals and exclusion from participation in government programs, such as Medicare and Medicaid, as well as contractual damages and reputational harm. We could also be required to curtail or cease our operations. In addition, if any customers, healthcare professionals we engage, laboratory partners or other entities with whom we do business are found not to be in compliance with applicable laws, they may be subject to the same criminal, civil or administrative sanctions, including exclusion from government-funded healthcare programs. Any of the foregoing could seriously harm our business and financial results. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We and our laboratory partners are subject to a variety of laboratory testing standards, compliance with which is an expensive and time-consuming process, and any failure to comply could result in substantial penalties and disruptions to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We and the third-party laboratories that we partner with are subject to the CLIA. CLIA is a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA requires certain clinical laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements depending on the level of complexity for which the laboratory is certified. CLIA certification is also a prerequisite to be eligible to bill state and federal healthcare programs, as well as many private third-party payors, for laboratory testing services. Our partner laboratories hold CLIA certifications for high complexity testing, which mandate compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements depending on the level of complexity for which the laboratory is certified. Sanctions for failure to comply with CLIA requirements may include suspension, revocation, or limitation of a laboratory&#8217;s CLIA certificate, as well as the imposition of significant fines or criminal penalties. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our partner laboratories&#8217; failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, our partner laboratories are subject to state laws and regulations governing laboratory licensure. Some states have enacted state licensure laws that are more stringent than CLIA. In certain markets such as California, New York, and Pennsylvania, we or our partner laboratories may also need to obtain and maintain additional licensure from such states. It is uncertain that our partner laboratories will be granted such licensure and, in such cases, we cannot offer testing to patients located in those states, which could limit our ability to offer testing on a wide scale.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">It is possible that additional states may enact laboratory licensure requirements in the future, which could further limit our ability to expand our services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We rely on third-party laboratories in the conduct of our biosecurity and public health business offerings. If any of our partners cease working with us, or face supply chain disruptions or other difficulties, our business could be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">The testing industry is subject to complex and costly regulation and if government regulations are interpreted or enforced in a manner adverse to us, we may be subject to enforcement actions, penalties, exclusion, and other material limitations on our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In connection with our previous offering of COVID-19 testing services, we partnered with third-party laboratories, diagnostic test manufacturers and manufacturers of collection kits, which are subject to extensive and frequently changing federal, state and local laws and regulations governing various aspects of our business, including significant governmental certification and licensing regulations. Additionally, new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, may limit potential revenues, and we may need to revise our R&amp;D or commercialization programs. The costs of defending claims associated with violations, as well as any sanctions imposed, could significantly adversely affect our financial performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our testing does not identify nor sequence any individual human DNA or RNA nor can results be tied to any individual. As a result, we do not collect informed consents from any individual participating in our programs. However, our approach could be challenged in the future based on the claims or privacy considerations and searches governed by the 4th Amendment of the U.S. Constitution. Any legal challenges could consume our management and financial resources. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Current regulations governing the testing services we offer are shifting and in some cases unclear. In addition, our laboratory partners may be unsuccessful in validating, or obtaining or maintaining authorizations for, the tests we relied on to provide our prior COVID-19 testing services. If any third-party manufacturers or laboratories offering tests that we use in our testing services are deemed by the FDA or other regulatory authorities to have violated applicable law or if the tests or test components are marketed, processed or distributed in violation of applicable law, we may be subject to enforcement action or litigation, or we may be required to find alternative tests to support our testing services, which could increase our costs.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, we are required to comply with applicable FDA regulations with respect to distribution of certain COVID-19 diagnostic test kits and collection kits, including, for certain kits, compliance with applicable terms and conditions of an EUA. Such conditions may include requirements related to collection of information on the performance of the product, reporting of adverse events, recordkeeping requirements, and labeling and promotional activities. To the extent that we marketed or promoted third-party tests or test kits outside of the uses authorized for these products or in a false or misleading manner, the tests or collection kits could be considered misbranded or adulterated and distributing them in interstate commerce could violate the FDCA. Violations of applicable FDA requirements could result in enforcement actions, such as warning or &#8220;untitled&#8221; letters, revocation of EUAs, seizures, injunctions, civil penalties and criminal prosecutions and fines, and violation of the FTC Act could result in injunctions and other associated remedies, all of which could have a material adverse effect on our business. Most states also have similar regulatory and enforcement authority for laboratory testing and distribution of related collection kits. For example, many state laws require us to hold a specific form of license to distribute COVID-19 diagnostic test kits and collection kits into such states. These requirements vary from one state to another and frequently change. Complying with state laws and regulations may subject us to similar risks and delays as those we could experience under federal regulation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our surveillance testing efforts do not collect identifying individual data and do not return a diagnostic result, but some surveillance methods, such as double collection, require samples from individuals. Regulatory authorities could take issue with our characterization of such testing as surveillance and/or impose additional requirements or restrictions. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Advertising for any of the tests or collection kits we distribute or the testing services we offer is also subject to regulation by the Federal Trade Commission (&#8220;FTC&#8221;), under the Federal Trade Commission Act (&#8220;FTC Act&#8221;). The FTC may take enforcement action for advertising claims that are not adequately substantiated or that are false or misleading. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We are subject to federal and state laws and regulations governing the protection, use, and disclosure of health information and other types of personal information, and our failure to comply with those laws and regulations or to adequately secure the information we hold could result in significant liability or reputational harm.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Numerous state and federal laws, regulations, standards and other legal obligations, including consumer protection laws and regulations, which govern the collection, dissemination, use, access to, confidentiality, security and processing of personal information, including health-related information, could apply to our operations or the operations of our partners. For example, HIPAA imposes privacy, security and breach notification obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities, and their covered subcontractors. HIPAA requires covered entities and business associates to develop and maintain policies with respect to the protection of, use and disclosure of protected health information (&#8220;PHI&#8221;), including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a breach of unsecured PHI. If in the future we engage in certain types of standard electronic transactions involving payors, including billing the Medicare or Medicaid programs or commercial health plans, we will be subject to HIPAA as a &#8220;covered entity.&#8221; We are currently subject to HIPAA as a &#8220;business associate&#8221; because we performed certain services involving the use or disclosure of PHI on behalf of covered entity customers with respect to our prior COVID-19 testing service offerings. Implementation of the infrastructure necessary to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">meet HIPAA standards requires substantial investment. Being subject to HIPAA as a covered entity or business associate exposes us to significant fines and penalties, including criminal fines and penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Entities that are found to be in violation of HIPAA as the result of a breach of unsecured PHI, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Even when HIPAA or a state law does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair and/or deceptive acts or practices in violation of Section 5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Several states have enacted privacy laws governing the use and disclosure of health information, such as the California Confidentiality of Medical Information Act; these laws are not preempted by HIPAA to the extent they are more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our partners. Further, in recent years, there have been a number of well-publicized data breaches involving the improper dissemination of personal information of individuals both within and outside of the healthcare industry. Laws in all 50 states require businesses to provide notice to individuals whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. States are also constantly amending existing laws, and creating new data privacy and security laws, requiring attention to frequently changing regulatory requirements. For example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) went into effect on January 1, 2020. The CCPA creates new transparency requirements and grants California residents several new rights with respect to their personal information. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or potential statutory or actual damages. On November 3, 2020, California voters passed a ballot initiative for the California Privacy Rights Act (&#8220;CPRA&#8221;), which significantly expands the CCPA. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data, such as the right to opt out of the sale of personal information or the sharing of personal information for purposes of cross-context behavioral advertising. The CPRA also provides for a private right of action for certain data breaches. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required to remain compliant with similar laws that have been proposed or passed in other states. For example, comprehensive privacy laws akin to the CPRA have recently gone into effect in twelve other states, and several other states have passed similar laws that will go into effect in the next two years. It is possible that other states, federal agencies or local governments will follow suit. The data privacy laws under consideration by federal and state legislators also include sector-specific laws. The My Health My Data Act, which recently became effective in Washington, contains new notice and consent requirements for the processing of &#8220;consumer health data&#8221; with the potential for large penalties enforceable through private lawsuits. The FTC and other authorities are likewise imposing standards for the collection, use, dissemination and security of personal information under consumer protection laws. Additionally, in the United States, laws in all 50 states require businesses to provide notice to individuals whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. In addition, laws, regulations, and standards covering marketing and advertising activities conducted by telephone, email, mobile devices and the internet are applicable to our business, including the Telephone Consumer Protection Act (the &#8220;TCPA&#8221;) and the Controlling the Assault of Non&#8209;Solicited Pornography and Marketing Act (&#8220;CAN-SPAM Act&#8221;). The TCPA places certain restrictions on making certain outbound calls, faxes, and text messages to consumers. The CAN-SPAM Act imposes penalties for the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">transmission of commercial emails that do not comply with certain requirements, such as providing an opt-out mechanism for stopping future emails from the sender. Further, state and federal auto-renewal laws continue to evolve, which may require us to make changes to our processes in order to comply with such laws. The evolving patchwork of differing state and federal privacy and data security laws increases the cost and complexity of operating our business and increases our exposure to liability, including from third-party litigation and regulatory investigations, enforcement, fines, and penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Through our wholly owned subsidiaries with established offices in the European Union, parts of our business are subject to the European Union General Data Protection Regulation (&#8220;GDPR&#8221;), which went into effect in May 2018, and imposes strict requirements for processing the personal data of individuals within the European Economic Area. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States. Further, from January 1, 2021, companies that process the personal information of UK residents have to comply with the United Kingdom GDPR (the &#8220;UK GDPR&#8221;), which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. Enforcement uncertainty and the costs associated with ensuring compliance may be onerous and adversely affect our business, operating results, prospects and financial condition. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Although we work to comply with applicable laws, regulations and standards, contractual obligations and other legal obligations relating to data privacy, protection and security, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which Ginkgo must comply. Monitoring, preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). And as our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. There is also increased public awareness of privacy issues in the wake of revelations about the data-collection activities of various government agencies and in the number of private privacy-related lawsuits filed against companies. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in fines, legal claims, or proceedings, including regulatory investigations and actions, or liability for failure to comply with privacy and information security laws, which could disrupt our operations, damage our reputation, and expose us to claims from impacted individuals, any of which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our employees, agents, contractors, research partners, consultants or vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We are exposed to the risk that our employees, agents, contractors, research partners, consultants or vendors may engage in fraudulent or other illegal activity or misconduct. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that causes us to breach our contracts and/or violates applicable laws and regulations, including but not limited to laws:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">applicable to the provision of health care services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">governing the storage and handling of controlled substances;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">requiring the reporting of true, complete and accurate information to the FDA, USDA, and other government agencies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">specifying vendor qualification standards and recordkeeping requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">international, federal and state fraud and abuse laws and regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">protecting the privacy and security of personally identifiable information and requiring breach notification; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">relating to anti-corruption, anti-bribery, and anti-money laundering; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">requiring the true, complete and accurate reporting of services, financial information, or data.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Specifically, the health care industry and government contractors are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, and other business arrangements. Additionally, activities that involve the improper use or misrepresentation of information obtained in the course of research or creating fraudulent data could result in breach of contract, regulatory sanctions, and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this kind of activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations, other actions, or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal health care programs, debarment under 21 U.S.C. &#167; 335a or a comparable foreign law, contractual damages, reputational harm, diminished potential profits and future earnings, and curtailment of our operations, any of which could adversely affect our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Distribution and use of screening and/or diagnostic tests marketed under an EUA from the FDA are subject to certain limitations, and the continued availability of such authorizations is subject to government discretion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Screening and/or diagnostic tests used in the testing programs and services of our Biosecurity business are subject to EUAs granted by the FDA to the manufacturers or laboratories marketing such tests. Each EUA requires compliance with certain conditions, including specific workflow requirements, and imposes other limitations on the test&#8217;s marketing, distribution, and use. The FDA has signaled that, while there will be a grace period for EUA holders to transition their devices, not all of the EUA products we distribute may apply for or be approved by the FDA and may need to withdraw from the market. Sourcing and finding products that transition from EUA to FDA cleared status may increase our costs of sourcing these products and may impact our profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We have pursued in the past and may pursue additional U.S. government contracting and subcontracting opportunities in the future and as a U.S. government prime contractor and subcontractor, we are subject to a number of procurement rules and regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have entered into agreements with governmental entities and contractors in the past to serve as a U.S. government prime contractor or subcontractor and may do so again in the future. U.S. government procurement contractors and subcontractors must comply with specific procurement regulations and other requirements. These requirements, although customary in U.S. government contracts, could impact our performance and compliance costs, including by limiting or delaying our ability to share information with business partners, customers and investors. The U.S. government has in the past and may in the future demand contract terms that are less favorable than standard arrangements with private sector customers, including certain financial requirements obligating the Company to hold surety bonds which restrict our cash, and may have statutory, contractual, or other legal rights to terminate contracts with us for convenience or for other reasons. Generally, U.S. government contracts contain provisions permitting unilateral termination or modification, in whole or in part, at the government&#8217;s convenience. Under general principles of government contracting law, if the government terminates a contract for convenience, the government contractor may recover only its incurred or committed costs, settlement expenses and profit on work completed prior to the termination. If the government terminates a contract for default, the government contractor is entitled to recover costs incurred and associated profits on accepted items only and may be liable for excess costs incurred by the government in procuring undelivered items from another source. Any termination for default may also adversely affect our ability to contract with other government customers and agencies, as well as our reputation, business, financial condition and results of operations. In addition, changes in U.S. government administration and budgetary priorities, including with respect to funding allocated to government agencies, could affect the availability of U.S. government contracting, subcontracting, or funding opportunities, which could lead to modification, reduction, or termination of our U.S. government contracts or subcontracts. If and to the extent such changes occur, they could impact our results and potential growth opportunities, and there can be no assurance that we will be able to derive further revenue from the public sector or our government contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Furthermore, our U.S. government contracts grant the government the right to use technologies developed by us under the government contract or the right to share data related to our technologies, for or on behalf of the government. Under our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">government contracts, we may not be able to limit third parties, including our competitors, from accessing certain of these technology or data rights, including intellectual property, in providing products and services to the government.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In addition, failure by us, our employees, representatives, contractors, partners, agents, intermediaries, other customers or other third parties to comply with these regulations and requirements could result in reductions of the value of contracts, contract modifications or termination, claims for damages, refund obligations, the assessment of civil or criminal penalties and fines, loss of rights in our intellectual property and temporary suspension or permanent debarment from government contracting, all of which could negatively impact our results of operations and financial condition. Any such damages, penalties, disruptions or limitations in our ability to do business with the public sector could result in reduced sales of our products, reputational damage, penalties and other sanctions, any of which could harm our business, reputation and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We are engaged in certain research activities involving controlled substances which may be subject to significant regulation by the DEA, FDA, and other regulatory agencies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We are engaged in certain research activities involving the development of microbes designed to generate precursors and other chemical intermediaries which may be regulated as controlled substances in the United States. Controlled substances are subject to state, federal, and foreign laws and regulations regarding their manufacture, use, sale, importation, exportation, and distribution. Among other laws, controlled substances are regulated under the federal Controlled Substances Act of 1970 and implementing regulations of the DEA. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use and may generally not be marketed or sold in the United States. Schedule I substances are subject to the most stringent controls and Schedule V the least controls of the five schedules, based on their relative risk of abuse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Regulations associated with controlled substances govern manufacturing, labeling, packaging, testing, dispensing, production and procurement quotas, recordkeeping, reporting, handling, shipment and disposal. These regulations include required security measures, such as background checks on employees and physical control of inventory and increase the personnel needs and the expense associated with development and commercialization of products or product candidates including controlled substances. Regulators conduct periodic inspections of entities involved in handling, manufacturing, or otherwise distributing controlled substances, and have broad enforcement authorities. If we are found to be non-compliant with applicable controlled substance registrations and related requirements, we may need to modify its business activities and/or stop handling or producing the products regulated as controlled substances, and could be subject to enforcement action, significant fines or penalties, and/or adverse publicity, among other consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Various states also independently regulate controlled substances. Though state-controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule substances, as well. The failure to comply with applicable regulatory requirements could lead to enforcement actions and sanctions from the states in addition to those from the DEA or otherwise arising under federal law.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Changes in government regulations may materially and adversely affect our sales and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The markets where we provide our services are heavily influenced by foreign, federal, state and local government regulations and policies. The U.S. or foreign governments may take administrative, legislative, or regulatory action that could materially interfere with our customer&#8217;s ability to sell products derived from engineered cells in certain countries and/or to certain customers. The uncertainty regarding future standards and policies may also affect our ability to develop our programs or to license engineered cells to customers and to initiate new programs with our customers, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Changes in U.S. trade policy more generally could trigger retaliatory actions by affected countries, which could impose restrictions on our ability to do business in or with affected countries or prohibit, reduce or discourage purchases of our services by foreign customers, leading to increased program costs, increased costs of developing or manufacturing our customers&#8217; products and higher prices for their products in foreign markets. Changes in, and responses to, U.S. trade policy could reduce the competitiveness of our services or our customers&#8217; products, cause our services to be less in demand and our sales to decline and adversely impact our ability to compete, which could materially and adversely impact our business, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We are subject to certain U.S. and foreign anti-corruption, anti-bribery and anti-money laundering laws and regulations. We can face serious consequences for violations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;FCPA&#8221;), the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the U.K. Bribery Act and possibly other anti-corruption, anti-bribery and anti-money laundering laws and regulations in the jurisdictions in which we do business, both domestic and abroad. Anti-corruption and anti-bribery laws have been enforced aggressively in recent years. The FCPA and other anti-corruption laws generally prohibit companies, their employees, agents, representatives, business partners and third-party intermediaries from corruptly promising, authorizing, offering, or providing, directly or indirectly, anything of value to government officials, political parties, or candidates for public office for the purpose of obtaining or retaining business or securing an improper business advantage. The UK Bribery Act and other anti-corruption laws also prohibit commercial bribery not involving government officials, and requesting or accepting bribes; and anti-money laundering laws prohibit engaging in certain transactions involving criminally-derived property or the proceeds of criminal activity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We and our third-party business partners, representatives and agents may have direct or indirect interactions with officials and employees of government agencies or state-owned or -affiliated universities or other entities (for example, to obtain necessary permits, licenses, patent registrations and other regulatory approvals), which increases our risks under the FCPA and other anti-corruption laws. We also engage contractors, consultants and other third parties from time to time to conduct business development activities abroad. We may be held liable for the corrupt or other illegal activities of our employees or third parties even if we do not explicitly authorize such activities. We have increased and, in the future, expect our non-U.S. activities to increase over time, which may also increase our exposure under these laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The FCPA also requires that we keep accurate books and records and maintain a system of adequate internal controls. While we have controls to address compliance with such laws and will continue to review and enhance our compliance program, we cannot assure you that our employees, agents, representatives, business partners or third-party intermediaries will always comply with our policies and applicable law, for which we may be ultimately held responsible.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Any allegations or violation of the FCPA or other applicable anti-bribery, anti-corruption laws and anti-money laundering laws may result in whistleblower complaints, sanctions, settlements, investigations, prosecution, enforcement actions, substantial criminal fines and civil penalties, disgorgement of profits, imprisonment, debarment, tax reassessments, breach of contract and fraud litigation, loss of export privileges, suspension or debarment from U.S. government contracts, adverse media coverage, reputational harm and other consequences, all of which may have an adverse effect on our reputation, business, financial condition, results of operations and prospects. Responding to an investigation or action can also result in a materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional fees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Significant disruptions to our and our service providers&#8217; information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We are increasingly dependent on information technology systems and infrastructure, including services licensed, leased or purchased from third parties such as cloud computing infrastructure and operating systems, to operate our business. In the ordinary course of business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may have access to our networks or our confidential information. While we take measures to safeguard and protect this information, threats to network and data security are constantly evolving and growing in frequency and sophistication. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. We are required to expend significant resources in an effort to protect against security incidents, and may be required or choose to spend additional resources or modify our business activities, particularly where required by applicable data privacy and security laws or regulations or industry standards. Security incidents result from the actions of a wide variety of actors with a wide range of motives and expertise, such as traditional hackers, personnel or the personnel of third parties, sophisticated nation-states and nation-state-supported actors. While we have developed systems and processes designed to protect the integrity, confidentiality and security of the confidential and personal information under our control, we cannot guarantee that any security measures that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">we or our third-party service providers implement will be effective in preventing security breaches and incidents, cyberattacks or similar events such as viruses and worms, phishing attacks and other forms of social engineering, denial-of-service attacks, ransomware attacks, physical or electronic break-ins, third-party or employee theft or misuse, and other negligent actions, errors or malfeasance by employees or other third parties, and similar disruptions from unauthorized tampering with our servers and computer systems or those of third parties that we use in our operations. These incidents could lead to interruptions, delays, loss or corruption of critical data, and unauthorized access to or acquisition of health-related and other personal information. In addition, we may be the target of email scams and other social engineering attacks that attempt to acquire personal information or company assets or access to our systems. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Despite our efforts to create security barriers to such threats, we may not be able to entirely mitigate these risks. Our third-party service providers face similar risks. Any cyberattack that attempts to obtain our data or assets, including data that we maintain on behalf of our customers, disrupt our service, or otherwise access our systems, or those of third parties we use, or any other security breach or incident, could adversely affect our business, financial condition and operating results, be expensive to remedy, and damage our reputation. We and our third-party service providers may be unable to anticipate or detect attempted security incidents or face difficulties or delays in identifying or otherwise responding to any attacks or actual or potential security breaches or security incidents. We may incur significant costs and operational consequences of investigating, remediating, eliminating and putting in place additional tools and devices designed to prevent actual or perceived security breaches and other security incidents, including in response to any actual or perceived incident we may suffer, and substantial costs to comply with any notification or other legal obligations resulting from any security breaches or other security incidents. In addition, any such breaches or incidents, or the perception that they have occurred, may result in substantial remediation costs and expose us to litigation (including class claims), regulatory enforcement action (for example, investigations, fines, penalties, audits, and inspections), liability under laws that protect the privacy of personal information, additional reporting requirements and/or oversight, indemnification obligations, negative publicity, reputational harm, and interruptions in our operations (including availability of data), any of which could have a material adverse effect on our business, financial condition, and operating results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Although we maintain insurance coverage that may cover certain liabilities in connection with security breaches and other security incidents, we cannot be certain our insurance coverage will be adequate for liabilities actually incurred, that insurance will continue to be available to us on commercially reasonable terms (if at all) or that any insurer will not deny coverage as to any future claim.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Governmental trade controls, including export and import controls, sanctions, customs requirements and related regimes, could subject us to liability or loss of contracting privileges or limit our ability to compete in certain markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our programs and technologies are subject to U.S. and non-U.S. export controls. Export authorizations may be required for biotechnology products, technologies, or services to be exported outside of the United States, to a foreign person, or outside of a foreign jurisdiction. Our current or future programs or technologies are, and may in the future, be subject to the Export Administration Regulations (&#8220;EAR&#8221;). If a program, technology, or service meets certain criteria for control under the EAR, then that engineered cell, production process, resulting product, technology, or service would be exportable outside the United States or to a foreign person or from one foreign jurisdiction to another foreign jurisdiction only if we obtain the applicable export license or other applicable authorization including qualifying for a license exception, if required. Compliance with the U.S. and foreign export laws and regulations and other applicable regulatory requirements regarding the sales, shipment and use of our engineering cells, bioprocesses and other technology may affect our ability to work with foreign partners, affect the speed at which we can introduce new products into non-U.S. markets, or limit our ability to sell programs or services or license technologies into some countries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Additionally, certain materials that we use in our programs are subject to U.S. import controls. We currently have, and may in the course of business need to procure, certain import authorizations, for example, related to plant pests, chemicals, biological agents and other controlled materials, including from the USDA, EPA and CDC. Compliance with applicable regulatory requirements regarding the import of such materials may limit our access to materials critical to our development activities or affect the speed at which we can advance new programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our activities are also subject to the economic sanctions, laws and regulations of the United States and other jurisdictions. Such controls prohibit certain transactions, potentially including financial transactions and the transfer of products, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">technologies and services, to sanctioned countries, governments and persons, without a license or other appropriate authorization. U.S. sanctions policy changes could affect our or our customers&#8217; ability to interact, directly and indirectly, with targeted companies or companies in sanctioned countries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">While we take precautions to comply with U.S. and non-U.S. export control, import control and economic sanctions laws and regulations, we cannot guarantee that such precautions will prevent violations of such laws, including transfers to unauthorized persons or destinations, and including inadvertent violations as a result of a misclassification of a product, technology or service under export control laws. Violations could result in our business being subject to government investigations, denial of export or import privileges, significant fines or penalties, denial of government contracts and reputational harm. Any limitation on our ability to export our engineered cells, production processes, resulting products, technology, or services, or import materials critical to our programs would likely adversely affect our business and financial condition. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Changes in U.S. and foreign tax laws could have a material adverse effect on our business, cash flow, results of operations or financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We are subject to income and non-income based taxes in the U.S. and foreign jurisdictions. Changes in tax laws, regulations and policies, or their interpretation and application, in the jurisdictions where we are subject to tax, could have a material adverse effect on our business, cash flow, results of operations or financial condition. The U.S. Congress frequently debates changes to U.S. corporate income tax laws and the Group of Twenty (G20), the Organization for Economic Co-operation and Development (OECD), the European Commission (EC) and individual taxing jurisdictions have published proposals covering various international tax-related issues, including country-by-country reporting, permanent establishment rules, transfer pricing and tax treaties. It is possible that any future tax legislation which may be enacted could materially impact our effective tax rate and cash tax liability as well as tax credits and incentives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We may become subject to lawsuits or indemnity claims in the ordinary course of business, which could materially and adversely affect our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">From time to time, we may in the ordinary course of business be named as a defendant in lawsuits, indemnity claims and other legal proceedings. These actions may seek, among other things, compensation for alleged product liability, personal injury, employment discrimination, breach of contract, property damage and other losses or injunctive or declaratory relief.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The marketing, sale and use of our services, engineered cells, production processes and resulting products could lead to the filing of product liability claims were someone to allege that our services, engineered cells, production processes or resulting products failed to perform as designed or intended or caused injury or other harms. A product liability claim could result in substantial damages and be costly and time-consuming for us to defend.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">decreased demand for programs and resulting products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">substantial monetary payments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">significant time and costs to defend related litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the inability to commercialize any products from our programs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">injury to our reputation and significant negative media attention.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In the event that such actions, claims or proceedings are ultimately resolved unfavorably to us at amounts exceeding our accrued liability, or at material amounts, the outcome could materially and adversely affect our business and results of operations. In addition, payments of significant amounts, even if reserved, could adversely affect our liquidity position. We maintain product liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability claims. Any product liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause current collaborators to terminate existing agreements or potential collaborators to seek other companies, any of which could impact our business and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:132%">Risks Related to our Common Stock, Organizational Structure and Governance</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Only our employees and directors are entitled to hold shares of Class B common stock (including shares of Class B common stock granted or otherwise issued to our employees and directors in the future), which shares have ten votes per share. This limits or precludes other stockholders&#8217; ability to influence the outcome of matters submitted to stockholders for approval, including the election of directors, the approval of certain employee compensation plans, the adoption of certain amendments to our organizational documents and the approval of any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transaction requiring stockholder approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Shares of our Class B common stock have ten votes per share, whereas shares of our Class A common stock have one vote per share and shares of our Class C common stock have no voting rights (except as otherwise expressly provided in our amended and restated certificate of incorporation (the &#8220;Charter&#8221;) or required by applicable law). As of December 31, 2025, our directors and executive officers hold in the aggregate almost half of the total voting power of our outstanding capital stock, and our directors, founders and executive officers hold in the aggregate more than half of the total voting power of our outstanding capital stock. Accordingly, holders of shares of Class B common stock are able to significantly influence the outcome of matters submitted to our stockholders for approval, including the election of directors, the approval of certain employee compensation plans, the adoption of amendments to our organizational documents and the approval of any merger, consolidation, sale of all or substantially all of our assets or other major corporate transaction requiring stockholder approval. This concentrated voting power limits or precludes other stockholders&#8217; ability to influence the outcome of these matters. Holders of Class B common stock may have interests that differ from holders of Class A common stock and may vote in a way with which holders of Class A common stock disagree and which may be adverse to the interests of holders of Class A common stock. This concentrated voting power is likely to have the effect of limiting the likelihood of an unsolicited merger proposal, unsolicited tender offer or proxy contest for the removal of directors. As a result, our governance structure and Charter may have the effect of depriving our stockholders of an opportunity to sell their shares at a premium over prevailing market prices and make it more difficult to replace our directors and management. Furthermore, this concentrated voting power could discourage a potential investor from acquiring Class A common stock due to the limited voting power of such stock relative to Class B common stock, which could also adversely affect the trading price of Class A common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Our multi-class stock structure is intended to preserve our existing founder-led governance structure, to promote employee retention and engagement, to facilitate continued innovation and the risk-taking that it requires, to permit us to continue to prioritize our long-term goals rather than short-term results, to enhance the likelihood of continued stability in the composition of our board of directors and its policies, and to discourage certain types of transactions that may involve an actual or threatened acquisition of the company, all of which we believe are essential to the long-term success of our company and to long-term stockholder value. We expect to maintain this concentrated voting power among our founders and employees for the foreseeable future, including by issuing additional shares of Class B common stock to our employees pursuant to our equity compensation plans and allowing our employees and directors to exchange shares of Class A common stock for shares of Class B common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Future transfers of shares of Class B common stock to persons other than Ginkgo directors and employees, or trusts or legal entities through which the right to vote the shares of Class B common stock held thereby is exercised exclusively by one or more of Ginkgo&#8217;s directors or employees (any such director, employee, trust or legal entity, an &#8220;Eligible Holder&#8221;), or the holder of shares of Class B common stock ceasing to be an Eligible Holder, will generally result in those shares converting to shares of Class A common stock on a one-to-one basis, subject to certain exceptions and unless a majority of the independent directors of our board of directors determine that such transfer or event will not result in such automatic conversion. Each share of Class B common stock is also convertible at any time at the option of the holder into one share of Class A common stock. The conversion of Class B common stock to Class A common stock over time will have the effect of increasing the relative voting power of those holders of Class B common stock who retain their shares of Class B common stock in the long term. As a result, the relative voting power of holders of Class A common stock is expected to remain limited for a significant period of time, and it is possible that one or more of the persons or entities holding Class B common stock could gain significant voting control as other holders of Class B common stock sell or otherwise convert their shares into Class A common stock. In addition, the conversion of Class B common stock to Class A common stock would dilute holders of Class A common stock in terms of voting power within the Class A common stock. Because holders of Class C common stock have no voting rights (except as otherwise expressly provided in the Charter or required </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">by applicable law), the holders of Class B common stock may be able to significantly influence the outcome of matters submitted to our stockholders for approval for a longer period of time than would be the case if we issued Class A common stock rather than Class C common stock in such transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our share price may change significantly over time, and you may not be able to resell our common stock at or above the price you paid or at all, and you could lose all or part of your investment as a result.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The trading price of our Class A common stock has been in the past and is likely to continue to be volatile. Such volatility may be, in part, attributable to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">future sales of our common stock or other securities by us or our existing stockholders, or the perception of such future sales;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">results of operations of the company or our competitors that vary from the expectations of securities analysts and investors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">changes in expectations as to our future financial performance and growth, including assessments of our business, prospects, financial estimates and investment recommendations by securities analysts, investors and short sellers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">additions or departures of key management personnel or members of our board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">announcements by us or our competitors of significant contracts, new products, acquisitions, joint marketing relationships, joint ventures, other strategic relationships or capital commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">announcements relating to actual or potential civil and non-civil litigation, as well as governmental or regulatory investigations or inquiries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">guidance that we provide to the public, any changes in this guidance or our failure to meet this guidance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">changes in the perception of our offerings or the synthetic biology industry more general including changes in regulatory conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">the development and sustainability of an active trading market for our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">changes in accounting principles;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">changes in general economic or market conditions or trends in our industry or markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">&#9679;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;padding-left:11.96pt">other events or factors, including those resulting from natural disasters, pandemics, epidemics, war, acts of terrorism or responses to these events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">These factors among others may materially adversely affect the market price of our Class A common stock, regardless of our actual operating performance. In addition, price volatility may be greater if the public float and trading volume of our common stock are low.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In the past, following periods of market volatility, stockholders have instituted securities class action litigation. If we were involved in securities litigation, it could have a substantial cost and divert resources and the attention of executive management from our business regardless of the outcome of such litigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Future sales, or the perception of future sales, by us or our stockholders in the public market could cause the market price for our securities to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The sale of our securities in the public market, including by entities to which we have issued shares in connection with transactions, or the perception that such sales could occur, could harm the prevailing market price of our securities. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">There are up to approximately 5 million shares of common stock that may be earned if the trading price is greater than or equal to certain earnout price thresholds ranging from $500 to $800 for any point in a trading day during 20 trading days in a 30 consecutive trading day period, of which approximately 1.3 million shares were earned as of December 31, 2025. The vast majority of the shares that are part of the earnout will not be subject to lock-up once the earnout conditions are met.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In connection with the SRNG Business Combination, in September 2021, Jason Kelly, Reshma Shetty, Austin Che and Bartholomew Canton were granted restricted stock units, which vested, along with certain related earnout shares that achieved the $500 price threshold, on October 1, 2022. Certain of such shares have been sold into the market, and any future sales could harm the prevailing market price of our securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We have also issued shares of our common stock in connection with certain of our acquisitions, which issuances dilute our existing shareholders. In addition, the shares of our common stock reserved for future issuance under our equity incentive plans will become eligible for sale in the public market once those shares are issued, subject to provisions relating to various vesting agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144, as applicable. Our compensation committee of our board of directors may determine the exact number of shares to be reserved for future issuance under our equity incentive plans at its discretion. We have filed, and expect to file in the future, one or more registration statements on Form S-8 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) to register shares of Class A common stock or securities convertible into or exchangeable for shares of Class A common stock issued pursuant to our equity incentive plans. Any such Form S-8 registration statements automatically become effective upon filing. Accordingly, shares registered under such registration statements will be available for sale in the open market. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Short sellers may engage in manipulative activity intended to drive down the market price of our Class A common stock, which could also result in related regulatory and governmental scrutiny, among other effects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Short selling is the practice of selling securities that the seller does not own but rather has borrowed or intends to borrow from a third party with the intention of later buying lower priced identical securities to return to the lender. Accordingly, it is in the interest of a short seller of our Class A common stock for the price to decline. At any time, short sellers may publish, or arrange for the publication of, opinions or characterizations that are intended to create negative market momentum. Issuers, like us, whose securities have historically had limited trading history or volumes and/or have been susceptible to relatively high volatility levels can be vulnerable to such short seller attacks. Short selling reports can cause increased volatility in an issuer&#8217;s stock price, and result in regulatory and governmental inquiries. On October 6, 2021, such a report was published about us. Shortly after, we received a preliminary and informal inquiry from the U.S. Department of Justice related to this report. Any related inquiry or formal investigation from a governmental organization or other regulatory body, including any inquiry from the SEC, is not within the control of the Company. Although we have received confirmation from the SEC that it concluded its inquiry into Ginkgo Bioworks Holdings, Inc. begun in October 2021 or soon after with no recommendation of enforcement action, any inquiry or formal investigation by any governmental organization or regulatory body could result in a material diversion of our management&#8217;s time and could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our Charter authorizes a large number of shares of Class B common stock for issuance in the future. The future issuance of shares of Class B common stock may have the effect of further concentrating voting power with our employees and other Class B stockholders, and could have an adverse effect on the trading price of Class A common stock.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Under our Charter, we are authorized to issue 4,500.0 million shares of Class B common stock, which are entitled to ten votes per share. We currently intend to issue additional shares of Class B common stock in the future to existing and newly hired employees pursuant to our equity compensation plans. Our authorized but unissued shares of Class B common stock are available for issuance to Eligible Holders with the approval of our board of directors without stockholder approval, except as may be required by the Listing Rules of the NYSE. In addition, our authorized but unissued shares of Class B common stock are available for issuance to persons other than Eligible Holders only with the approval of a majority of our directors elected by the holders of Class B common stock, voting separately as a class. If we issue additional shares of Class B common stock in the future, holders of shares of Class A common stock, which are entitled to one vote per share, will experience disproportionate voting power dilution relative to economic dilution, and the holders of Class B common stock may be able to significantly influence the outcome of matters submitted to our stockholders for approval for a longer period of time than would be the case if we issued shares of Class A common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">See </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">&#8220;Risk Factors-Risks Related to Our Common Stock Organizational Structure and Governance-Only our employees and directors are entitled to hold shares of Class B common stock (including shares of Class B common stock granted or otherwise issued to our employees and directors in the future), which shares have ten votes per share. This limits or precludes other stockholders&#8217; ability to influence the outcome of matters submitted to stockholders for approval, including the election of directors, the approval of certain employee compensation plans, the adoption of amendments to our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">organizational documents and the approval of any merger, consolidation, sale of all or substantially all of our assets or other major corporate transaction requiring stockholder approval.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Under our Charter, we are authorized to issue 800.0 million shares of Class C common stock, which have no voting rights (except as otherwise expressly provided in the Charter or required by applicable law). Outstanding Class C common stock may have the effect of extending voting power in Class B common stock, and may discourage potential acquisitions of our business and could have an adverse effect on the trading price of Class A common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Under our Charter, we are authorized to issue</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"> 800.0 million shar</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">es of Class C common stock, which have no voting rights (except as required by law). Class C common stock may be used for a variety of corporate purposes, including financings, acquisitions and investments. Our authorized but unissued shares of Class C common stock are available for issuance with the approval of our board of directors without stockholder approval, except as may be required by the Listing Rules of the NYSE. Because the Class C common stock carries no voting rights (except as otherwise expressly provided in the Charter or required by applicable law), is not convertible into any other capital stock, and is not listed for trading on an exchange or registered for sale with the SEC, shares of Class C common stock may be less liquid and less attractive to any future recipients of these shares than shares of Class A common stock, although we may seek to list the Class C common stock for trading and register shares of Class C common stock for sale in the future. In addition, because our Class C common stock has no voting rights (except as otherwise expressly provided in the Charter or required by applicable law), the holders of Class B common stock may be able to significantly influence the outcome of matters submitted to our stockholders for approval for a longer period of time than would be the case if we issued Class A common stock rather than Class C common stock in such transactions. In addition, further issuances of Class C common stock would have a dilutive effect on the economic interests of Class A common stock and Class B common stock. Any such issuance could also cause the trading price of Class A common stock to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">We cannot predict the effect the multi-class structure of our common stock may have on the trading price of our Class A common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The holding of low-voting stock, such as Class A common stock, may not be permitted by the investment policies of certain institutional investors or may be less attractive to the portfolio managers of certain institutional investors. In addition, certain index providers have announced restrictions on including companies with multiple-class share structures in certain of their indices. Because of our multi-class stock structure, our Class A common stock will likely continue to be excluded from certain indices, and we cannot assure you that other stock indices will not take similar actions. Given the sustained flow of investment funds into passive strategies that seek to track certain indices, exclusion from stock indices would likely preclude investment by many of these funds in our Class A common stock and could make shares of our Class A common stock less attractive to other investors. As a result, the trading price of shares of our Class A common stock could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:132%">Our focus on the long-term best interests of our company and our consideration of all of our stakeholders, including our stockholders, workforce, customers, suppliers, academic researchers, governments, communities and other stakeholders that we may identify from time to time, may conflict with short-term or medium-term financial interests and business performance, which may adversely impact the value of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We believe that focusing on the long-term best interests of our company and our consideration of all of our stakeholders, including our stockholders, workforce, customers, suppliers, academic researchers, governments, communities and other stakeholders we may identify from time to time, is essential to the long-term success of our company and to long-term stockholder value. Therefore, we have made decisions, and may in the future make decisions, that we believe are in the long-term best interests of our company and our stockholders, even if such decisions may negatively impact the short- or medium-term performance of our business, results of operations, and financial condition or the short- or medium-term performance of our Class A common stock. Our commitment to pursuing long-term value for the company and its stockholders, potentially at the expense of short- or medium-term performance, may materially adversely affect the trading price of our Class A common stock, including by making owning our Class A common stock less appealing to investors who are focused on returns over a shorter time horizon. Our decisions and actions in pursuit of long-term success and long-term stockholder value, which may include our multi-class stock structure, making investments in R&amp;D and our employees, and investing in and introducing new products and services, may not result in the long-term benefits that we expect, in which case our business, results of operations and financial condition, as well as the trading price of our Class A common stock, could be materially adversely affected. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">60</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_22"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_25"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity risk management and strategy</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-40" continuedAt="f-40-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-41" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-39">Ginkgo integrates risk management into its overall cybersecurity strategy, and has implemented processes designed to identify, assess, prioritize and manage risks to protect Ginkgo&#8217;s data, intellectual property and information assets.</ix:nonNumeric> As part of our risk governance and management, Ginkgo has developed processes designed to: identify and assess risks, evaluate those risks against pre-defined criteria, develop and implement strategies to address identified risks, monitor and review those risks and communicate risks to relevant stakeholders.</ix:nonNumeric> Identifying Ginkgo&#8217;s cybersecurity risks involves a multifaceted approach that encompasses both internal assessments and external information sources. For example, we use security audits conducted by internal and external auditors to assess compliance with security policies and industry frameworks; vulnerability assessments to discover vulnerabilities in networks, systems and applications; and risk assessment processes to evaluate IT infrastructure, including using a risk register to identify risks, likelihood of their occurrence, potential impact, and remediation. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-42">We also oversee <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-43">third-party service providers</ix:nonNumeric> by conducting vendor diligence upon onboarding and additional monitoring. Vendors are assessed for risk based on the nature of their services, access to data and systems and supply chain risk.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Cybersecurity risk management is overseen by Ginkgo&#8217;s Chief Information Security Officer (&#8220;CISO&#8221;), who is supported by full-time information security staff. The CISO advises the executive team on the development and implementation of the information security program.</span></div></ix:nonNumeric><div><span><br/></span></div><div><ix:continuation id="f-40-1"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-44" continuedAt="f-44-1">Ginkgo incorporates learning from its cybersecurity risk management process into its overall cybersecurity program. To date, Ginkgo has not experienced a cybersecurity incident that resulted in a material effect on our business strategy, results of operations, or financial condition. Despite our efforts, we cannot provide assurance that we will not be materially affected in the future by cybersecurity risks or any future material incidents. For more information, see Item 1A. Risk Factors, </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%"><ix:continuation id="f-44-1">&#8220;Significant disruptions to our and our service providers&#8217; information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us</ix:continuation>.&#8221;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">Cybersecurity governance</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-45" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-46" escape="true">The Board provides regular oversight of the Company&#8217;s cybersecurity risk management program. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-47" escape="true">The CISO presents to the Board and the audit committee of our Board (the &#8220;<ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-48">Audit Committee</ix:nonNumeric>&#8221;) at least annually and quarterly updates via business review dashboards. The Board provides guidance to the CISO, including with respect to any changes to business priorities, risk tolerance, or security initiatives. These briefings are also augmented by ongoing and continuous interactions between the Board and the CISO, as needed.</ix:nonNumeric></ix:nonNumeric> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-51" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-50" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-49" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo's <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-52">CISO</ix:nonNumeric> has primary responsibility for assessing and managing Ginkgo&#8217;s risks from cybersecurity threats. The CISO has public and private-sector experience in information technology and has served as Ginkgo&#8217;s CISO since 2025. Executive leadership provides oversight and governance through monthly business reviews of the cybersecurity program.</span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-53" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo also has a Disclosure Committee, which is composed of representatives from executive leadership from various departments across Ginkgo (e.g., legal, finance, accounting). Their role is to determine materiality of a cyber incident and provide guidance with respect to any disclosure obligations resulting from a cyber incident.</span></div></ix:nonNumeric></ix:nonNumeric><div id="id8596373948b4ae4958ccd7c02fd70c1_28"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo&#8217;s headquarters are located in the Seaport district of Boston, Massachusetts and comprise a set of non-cancellable operating leases within a facility totaling over 320,000 square feet of office and laboratory space. These lease agreements expire on dates ranging from 2030 to 2036 and each contain one option to extend the lease for a five-year period at then-market rates. Of this 320,000 square feet of leased space, none is currently subleased, with an additional 196,000 available for sublease in connection with our restructuring. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We also lease approximately 164,000 square feet of office and lab space in Cambridge, Massachusetts; Emeryville, California; and Zeist, Netherlands. This includes 32,000 square feet subleased in Emeryville through 2030, and 63,000 square feet in Cambridge with leases ending in February 2026. We have exited the Cambridge spaces in connection with our restructuring.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">In April 2021, we entered into a lease, as amended, consisting of approximately 260,000 rentable square feet of new office and laboratory space being developed in Boston, Massachusetts near our headquarters. The lease commenced on April 11, 2024, with rent payments beginning in June 2024, and it will expire on the fifteenth anniversary of the rent commencement date. The lease includes an option to extend for an additional ten years at then-market rates, as well as an expansion option if the owner constructs an additional building on the property. We believe our footprint prior to this new facility is now sufficient to meet our needs, therefore, this facility is available for sublease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We also own approximately 193,000 square feet of real property in West Sacramento, California, of which 16,000 is subleased and an additional 31,000 is available for sublease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">We intend to continue to evaluate our space needs and offer any excess space for subleasing.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">From time to time, the Company may in the ordinary course of business be named as a defendant in lawsuits, indemnity claims and other legal proceedings. The Company does not believe any pending litigation to be material, or that the outcome of any such pending litigation, in management&#8217;s judgment based on information currently available, would have a material adverse effect on the Company&#8217;s results of operations, cash flows or financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">See Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_172">12</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">, Commitments and Contingencies, to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K. </span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">62</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Class A common stock began trading on the NYSE under the symbol &#8220;DNA&#8221; on September 17, 2021. Prior to that date, there was no public trading market for our Class A common stock.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there were approximately 421 stockholders of record of our Class A common stock, 104 stockholders of record of our Class B common stock and 1 stockholder of record of our Class C common stock, which does not include persons whose stock is held in nominee or &#8220;street name&#8221; accounts through brokers, banks and intermediaries.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Number of securities to be issued upon exercise of outstanding options and vesting of outstanding restricted stock units (#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Weighted-average exercise price of outstanding options ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in the first column) (#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Equity compensation plans approved by security holders (1)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,002,588&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">151.78&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,336,606&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Equity compensation plans not approved by security holders (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">34,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">292,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,036,707&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">151.78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,628,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes the Ginkgo Bioworks Holdings, Inc. 2021 Equity Incentive Plan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes 366,567 shares of common stock issuable upon the exercise of outstanding stock options and 5,636,021 shares of common stock issuable upon settlement of outstanding restricted stock units.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Plan provides that the number of shares of common stock reserved and available for issuance under the Plan shall be cumulatively increased on January 1 of each year. The number of shares of common stock increased each year will be equal to the lesser of: (i) 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31 or (ii) such lesser amount as determined by our board of directors.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes the Ginkgo Bioworks Holdings, Inc. 2022 Inducement Plan.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total stockholder return on our Class A common stock relative to the cumulative total returns of the S&amp;P 500 Index and the S&amp;P Biotechnology Select Industry Index between September 17, 2021 (the date our common stock began trading on the NYSE after the SRNG Business Combination) through December&#160;31, 2025. All values assume a $100 initial investment at market close on September 17, 2021 and data for the S&amp;P 500 and the S&amp;P Biotechnology Select indices assume reinvestment of all dividends.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><img src="dna-20251231_g4.jpg" alt="Performance Graph.jpg" style="height:580px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-4"/></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On May 9, 2025, in a private placement transaction exempt from the registration requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities Act, we issued a total of 102,922 shares of our Class A common stock to StrideBio, Inc., valued at approximately $0.8 million, in settlement of the purchase price holdback amount payable in connection with Ginkgo&#8217;s acquisition of certain assets from StrideBio in 2023.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_43"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_46"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K. Further, this section of this Form 10-K generally discusses 2025 and 2024 items and year-to-year comparisons between 2025 and 2024. For discussion related to 2023 items and year-to-year comparisons between 2024 and 2023 that are not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">included in this Form 10-K, please refer to Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our 2024 Form 10-K, filed with the United States Securities and Exchange Commission on February 25, 2025. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs that involve risks and uncertainties. Actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed in Item 1A. &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; elsewhere in this Annual Report on Form 10-K. </span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_49"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to make biology easier to engineer. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo sells services to government and commercial customers in two business segments: cell engineering, where we provide tools and biological R&amp;D services across a range of industries, and biosecurity, where we provide services to customers who are working to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. An overview of these two business segments is provided below. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cell Engineering</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo does not make end products; instead, we offer biological R&amp;D services on our platform to enable our customers to bring their products to market. Historically, Ginkgo&#8217;s primary service offering has been cell engineering R&amp;D services (solutions) where Ginkgo performs technical activities. In 2024, Ginkgo expanded its service offering to include services that provide our customers cell engineering tools for biological R&amp;D, where Ginkgo enables its customers to conduct certain in-house R&amp;D activities themselves. Our services are designed to offer customers better results on the dimensions of probability of success, speed, or cost &#8211; and ideally on all three. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The fundamental advantage of our cell engineering platform over traditional cell engineering done by hand at our customers&#8217; labs is that our platform improves with scale while in-house cell engineering in our customers' labs largely does not. Compounding and mutually reinforcing improvements of our laboratory automation and software infrastructure&#8212;our Autonomous Lab&#8212;and our reusable data assets enable us to improve our services with each successive project.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our Autonomous Lab is a flexible wet lab built from our Reconfigurable Automation Cart (&#8220;RAC&#8221;) systems capable of large scale data generation; it powers generative AI and machine learning (&#8220;ML&#8221;) tools that enable more successful biological R&amp;D. We now offer services providing such data generation, AI and automation tools directly to Ginkgo customers. Our data assets comprise best practices for cell engineering, along with sequences and host cells that have been honed through dozens of programs and can be directly reusable for our cell engineering solutions.  We now offer licenses to our host cells and other IP assets, such as our broad metagenomic library.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cell engineering tools offerings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We charge customers fees for the services we provide in our cell engineering tools offerings. Fees for our automation solutions (RAC systems) are typically earned over a period that covers design, build, and deployment and range from six to twelve months. In addition, we offer support services for our RAC systems with fixed fees covering the support periods. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Fees for our Datapoints services are typically earned over a shorter period of time (weeks to months) than for cell engineering solutions, which may be multi-year programs. A typical deliverable for a Datapoints program is a data package. Fees for cell engineering solutions programs are typically structured as a fixed fee for a fixed scope of work.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cell engineering solutions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Our cell engineering solutions are typically scoped and delivered as a program ranging in duration from several months to several years. A typical deliverable for the program would comprise an enzyme sequence, or an engineered strain or cell line and its associated bioprocess. For each of these programs, we generate economic value in two primary ways. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">First, we charge service fees for Autonomous Lab services, in much the same way that cloud computing companies charge usage fees for utilization of computing capacity or CROs charge for services. R&amp;D is inherently risky and our customers recognize that this is a cost they will incur regardless of success and whether they are working on the program in-house or with a partner. Typically, service fees for a program include a fixed fee for a fixed scope of work and may also include payments contingent upon hitting certain technical milestones. If we are able to deliver program results with less work through the use of Codebase assets and/or generative AI tools, then we can achieve the same revenue with lower cost or in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">a shorter duration. Service fees provide a strong foundation of revenue that is independent of any commercialization efforts by our partners. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Second, as the key enabling technology for our customers&#8217; products, we have historically negotiated a value share with our customers (in the form of royalties, milestones, and/or equity interests) in order to align our economics with the success of the programs enabled by our platform. Because we typically do not incur material downstream costs (e.g., manufacturing or product development, which our customers manage), these value share payments flow through with approximately 100% contribution margin. We have structured a variety of value sharing mechanisms, including royalties, lump-sum milestones, and equity payments. As Ginkgo has matured, we have shifted our downstream value towards milestone payments and commercial royalties rather than equity. In addition, commencing in the second quarter of 2024, we announced changes in prospective commercial terms, including the removal of downstream value share from certain program types.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">This flexible business model allows for more predictable near-term revenue in up-front research fees and technical milestones without sacrificing our ability to create long-term value with asymmetric upside through downstream value share (typically in the form of a royalty stream, milestone, and/or equity share). As we add more programs to the platform over time, we expect downstream value share to contribute income, which could in turn grow our overall margins and cash flow profile for our cell engineering solutions. The realization of potential revenue related to downstream value in the form of potential future milestone payments and royalties and/or equity consideration is dependent upon a number of factors, including our ability to successfully develop engineered cells, bioprocesses, data packages, or other deliverables, and the product development and commercialization success of our customers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Biosecurity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With a mission to make biology easier to engineer, we have always recognized the need to invest in biosecurity as a key component of our platform. We are building the future bioeconomy with our customers and partners, and we envision the future of biosecurity as a global immune system equipped with the capabilities to rapidly and reliably identify, monitor, prevent, and mitigate biological threats. The first, critical step in realizing this future is to build a robust early warning system for biological threats&#8212;this is the primary focus of Ginkgo&#8217;s Biosecurity business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our primary biosecurity customers are governments. We currently provide biosecurity services via two core offerings as introduced in early 2024:  </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Canopy, which helps our customers generate high value genomic data from strategically positioned nodes (like airports and border checkpoints) via end-to-end biomonitoring programs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Horizon, our digital surveillance, analytics and insights platform that detects and monitors biothreats worldwide.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our recent strategic business and asset acquisitions are described in detail in Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_148">4</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. </span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_52"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Business Metrics</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In the past, we reported New Programs, Current Active Programs and Cumulative Programs as our key business metrics. We have undertaken a strategic review of these metrics, including in light of our new service offerings and our restructuring plan announced and commenced in the second quarter of 2024, and, beginning with the three months ending December 31, 2024, we no longer rely on New Programs, Current Active Programs and Cumulative Programs as key business metrics. We may in the future report on key business metrics, which metrics may change or be substituted for additional or different metrics as our business develops.</span></div><div><span><br/></span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_58"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Engineering Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We generate Cell Engineering revenue primarily through service and license agreements for our tools and solutions offerings. Under our automation solutions agreements we typically provide services related to the design, build, and deployment of our RAC systems as well as ongoing support services. Datapoints agreements typically include fixed fees for services related to producing a data package for our customers and are earned over a shorter time period than legacy </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">cell engineering solutions projects.  Under our solutions agreements, we typically provide R&amp;D services for cell programming with the goal of producing an engineered cell that meets a mutually agreed specification. Our customers obtain license rights to the output of our services, which are primarily the optimized strains or cell lines, in order to manufacture and commercialize products derived from that licensed strain or cell line. Generally, the terms of these agreements provide that we receive some combination of: (1) service fees in the form of (i) upfront payments upon consummation of the agreement or other fixed payments, (ii) reimbursement for costs incurred for R&amp;D services and (iii) milestone payments upon the achievement of specified technical criteria, plus (2) downstream value share payments in the form of (i) milestone payments upon the achievement of specified commercial criteria, (ii) royalties on sales of products from or comprising engineered organisms arising from the collaboration or licensing agreement and/or (iii) royalties related to cost of goods sold reductions realized by our customers. Royalties did not comprise a material amount of our revenue during any of the periods presented. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cell Engineering revenue has historically included transactions with Platform Ventures and Legacy Structured Partnerships where we received non-cash consideration in the form of equity interests and financial instruments that are convertible into equity upon a triggering event.  We view the upfront non-cash consideration as prepayments for licenses which will be granted in the future as we complete mutually agreed upon technical development plans. In these instances, we also receive cash consideration for the R&amp;D services performed by us on a fixed fee or cost-plus basis. We are not compensated through additional milestone or royalty payments under these arrangements. As we perform R&amp;D services under the mutually agreed upon development plans, we recognize a reduction in the prefunded obligation on a cost-plus basis. In some cases we issued the customer a prepaid Cell Engineering services credit in exchange for the upfront non-cash consideration, which can and has been drawn down as payment for R&amp;D services performed under mutually agreed upon development plans. These arrangements are further described in Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_154">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_157">8</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_190">17</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K..</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Downstream value share in the form of equity interest appreciation is not recognized as revenue but is expected to contribute to future cash flows upon liquidation, the amount and timing of which is inherently unpredictable. The initial fair market value of the equity interests received may also decrease after contract inception and the amount of cash proceeds eventually realized may be less than the revenue recognized. Equity investments are accounted for under the equity method, cost method or are carried at fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As Ginkgo has matured, we have shifted our downstream value towards milestone payments and commercial royalties rather than equity. In addition, commencing in the second quarter of 2024, we announced changes in prospective commercial terms, including the removal of downstream value share from certain program types.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosecurity Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We offer biosecurity services through our two core offerings: Canopy and Horizon. We are currently offering biomonitoring and bioinformatics support services domestically through our partnerships with the CDC and XpresCheck, and internationally. We are also engaged in a series of smaller partnerships that generate revenues through biosecurity services and R&amp;D.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We generate service revenue through the sale of our end-to-end biomonitoring and bioinformatics support services. These service offerings generally consist of goods and services including, but not limited to, sample collection, sample storage and transportation, outsourced laboratory analysis, access to results reported through a web-based portal, analytical reporting of results, and overall program management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In general, these agreements stipulate that we are entitled to compensation for service revenue as services are performed, and for product revenue. The timing of revenue recognition depends on the identified performance obligations but is generally recognized over time or as results are reported to the customer.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs and Operating Expenses </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Biosecurity Service Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The cost of Biosecurity service revenue consists of costs related to our biomonitoring and bioinformatics support services. This includes costs incurred for sample collection equipment and materials, outsourced laboratory analysis, access to results reported through our proprietary web-based portal, and reporting of results to government and non-government customers. Additionally, the cost of Biosecurity service revenue includes direct labor cost associated with bioinformatics, lab network management, delivery logistics, and customer support.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Other Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of other revenue consists of costs related to our Cell Engineering tools offerings, including Datapoints and lab automation solutions. Such costs primarily include hardware, software, materials and labor.  </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The nature of our business, and primary focus of our activities, generates a significant amount of R&amp;D expenses. R&amp;D expenses represent costs incurred by us for the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development, operation, expansion and enhancement of our Foundry and Codebase; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred to deliver our end-to-end cell engineering solutions offering to customers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The activities above incur the following expenses: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel compensation and benefits; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rent, facilities, depreciation, software, professional fees and other direct and allocated overhead expenses; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory supplies, consumables and related services provided under agreements with third parties and in-licensing arrangements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expense R&amp;D expenses as incurred. We experienced lower R&amp;D costs in 2025 compared to 2024 primarily due to our restructuring plan announced and commenced in the second quarter of 2024 as we rationalize our current development programs and prioritize our investments in our tools offerings. We expect that our R&amp;D expenses will either remain consistent or decline in 2026 as compared to 2025, reflecting the stabilization of our operational overhead and the impact of our restructuring actions. However, our R&amp;D expenses could increase in 2026 due to continued investment in our tools offerings. The nature, timing, and estimated costs required to support our growth will be dependent on advances in technology, our ability to attract new customers, and the rate of market penetration within our existing customer industries.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative (&#8220;G&amp;A&#8221;) expenses consist primarily of costs for personnel in executive, business development, finance, human resources, legal and other corporate administrative functions. G&amp;A expenses also include professional legal services fees and costs incurred relating to litigation, corporate, intellectual property and patent matters, professional fees incurred for accounting, auditing, tax and administrative consulting services, insurance costs, facility-related costs not otherwise included in R&amp;D expenses, and asset impairments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We experienced lower G&amp;A costs in 2025 compared to 2024 primarily due to our restructuring plan announced and commenced in the second quarter of 2024, as we began reducing our operational overhead. We expect that our G&amp;A expenses will either remain consistent or decline in 2026 as compared to 2025, reflecting the stabilization of our operational overhead and the impact of our restructuring actions. Conversely, we intend to maintain a strategic and opportunistic approach regarding inorganic G&amp;A expenses arising from mergers, acquisitions, and other inorganic growth initiatives.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Lease Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of lease assets relates to impairment losses recognized on a right-of-use asset and the related leasehold improvements associated with exited leased facilities.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we fully impaired the goodwill attributable to our Cell Engineering reporting unit.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charges</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Restructuring charges are related to our restructuring plan, which was announced and commenced in the second quarter of 2024. These charges primarily include severance and other employee termination costs from a reduction in force that commenced in 2024, as well as the impairment of a right-of-use asset due to the subleasing of a facility as part of real estate consolidation. Reductions in force were substantially completed in 2025. While the company completed the majority of our facility consolidation actions in 2025, we continue to look for opportunities for  subleasing unused or underutilized facilities, which will extend beyond 2026 or may not occur prior to termination of such lease, depending on market </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">conditions. Additionally, restructuring expenses related to potential asset impairments or contract amendments or terminations for any facilities no longer in use or underutilized could be material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additional details are included in Note </span><span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_575">3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, Restructuring, of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of interest earned on our cash, cash equivalents, and marketable debt securities. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Investments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on investments includes the change in fair value of our marketable equity securities in publicly traded companies and impairment losses recognized on non-marketable equity securities in privately held companies.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Deconsolidation of Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on deconsolidation of subsidiaries pertains to the deconsolidation of our former foreign subsidiary Altar SAS (&#8220;Altar&#8221;) in 2024 as a result of a sale and the deconsolidation of our former subsidiary Zymergen Inc. (&#8220;Zymergen&#8221;) in 2023. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Warrant Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of warrant liabilities reflects adjustments to the fair value of private placement warrants (&#8220;Private Placement Warrants&#8221;) and warrants formerly publicly traded on the NYSE (&#8220;Public Warrants&#8221;). These warrants, classified as liabilities, were assumed as part of our merger with Soaring Eagle Acquisition Corp. (&#8220;SRNG&#8221;) on September 16, 2021, and were initially issued in connection with SRNG&#8217;s initial public offering. Warrant liabilities are remeasured at fair value at each balance sheet date and have substantially no value as of December 31, 2025. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net primarily consists of sublease rent income and changes in fair value of notes receivable that we elected to account for under the fair value option.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with ASC 740</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our audited consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all the deferred tax assets will not be realized. For all periods presented, we have recorded a valuation allowance against the deferred tax assets that are not expected to be realized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors, including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had federal net operating loss carryforwards of approximately $1.8 billion, of which $139.2 million will begin to expire in 2029 and $1.6 billion can be carried forward indefinitely. As of December&#160;31, 2025, we had state net operating loss carryforwards of approximately $1.5 billion, of which $1.2 billion will begin to expire in 2030 and $257.5 million can be carried forward indefinitely. As of December&#160;31, 2025, we had federal research and development tax credit carryforwards of approximately $38.8 million, which will begin to expire in 2029. As of December&#160;31, 2025, we also had state research and development and investment tax credit carryforwards of approximately $31.4 million, which will begin to expire in 2030. The Company also had $3.9&#160;million of foreign net operating losses as of December&#160;31, 2025, of which $1.5&#160;million will begin to expire in 2034 and $2.4&#160;million can be carried forward indefinitely.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, R&amp;D tax credits and other permanent differences. Our income tax provision may be affected by changes to our estimates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">69</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2025 and 2024</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our result of operations for the periods indicated:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"/><td style="width:57.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Change</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cell Engineering revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">132,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">173,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(41,226)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Biosecurity revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">37,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(15,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">170,155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">227,043&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(56,888)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of Biosecurity service revenue </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">31,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of other revenue </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">243,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">424,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(180,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">183,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">246,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(62,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">47,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(47,858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restructuring charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(12,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">485,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">786,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(301,367)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(315,278)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(559,757)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">244,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">22,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(15,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(16,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(28,827)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss on deconsolidation of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(4,527)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(8,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(10,571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(313,600)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(547,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">233,908&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(837)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(312,763)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(547,029)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">234,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.2pt">The following table presents the allocation of stock-based compensation expense, inclusive of employer payroll taxes.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.393%"><tr><td style="width:1.0%"/><td style="width:56.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">34,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">57,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">57,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of Biosecurity revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">82,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">115,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell Engineering Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cell Engineering revenue was $132.7 million in 2025, compared to $174.0 million in 2024, a decrease of $41.2 million. The decrease was primarily due to the recognition of $45.4 million in non-cash revenue from the release of a deferred revenue balance associated with the terminated Motif FoodWorks, Inc. (&#8220;Motif&#8221;) contract in 2024, the recognition of $4.5 million in non-cash revenue from the release of a deferred revenue balance associated with the termination of contract with a related party in 2024, and decreases in revenue for certain programs with customers in the industrial biotechnology </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">industry. These decreases were partially offset by the recognition of $7.5 million in non-cash revenue from the release of a deferred revenue balance associated with the terminated BiomEdit, Inc. (&#8220;BiomEdit&#8221;) contract in 2025 (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_190">17</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for further details) and an increase in revenue related to programs with large enterprise customers primarily in the pharmaceutical and biotechnology industries and with the U.S. government (healthcare and defense sectors).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above in Components of Results of Operations, Cell Engineering revenue comprises both cash and non-cash consideration. Cell Engineering revenue recognized relating to non-cash consideration decreased from $61.4 million in 2024 to $11.6 million in 2025. The decrease was primarily due to the recognition of $45.4 million in non-cash revenue from the release of the deferred revenue balance associated with the terminated Motif contract in 2024, partially offset by lower non-cash revenue from other customers.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosecurity Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Biosecurity revenue was $37.4 million in 2025, compared to $53.1 million in 2024, a decrease of $15.7 million. This decrease was primarily due to lower revenue related to programs with the U.S. government and a foreign government.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Biosecurity Service Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Biosecurity service revenue was $31.5 million in 2025, compared to $38.5 million in 2024, a decrease of $7.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">million. This decrease was primarily due to cost reductions implemented during 2025 as well as a reduction in activities supporting a program with the U.S. government.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Other Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of other revenue was $15.5&#160;million in 2025 and $6.0&#160;million in 2024. This increase was primarily due to an increase in activity to support Datapoints contracts. These costs relate to our cell engineering customer offerings, Datapoints and lab automation solutions, which commenced in the second quarter of 2024. Costs associated with our end-to-end cell engineering solutions offering are included in research and development expenses.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses principally relate to the development of new offerings and the operation, expansion and enhancement of our existing service offerings utilizing our proprietary platform, which includes our Foundry and Codebase assets, to our cell engineering customers. Research personnel costs, including stock-based compensation, is our largest expense, aggregating to $97.6&#160;million and $184.9 million for the years ended December 31, 2025 and 2024, respectively. We also acquired and expensed in-process research and development primarily through the issuance of our equity, aggregating to zero and $19.8 million for the years ended December 31, 2025 and 2024, respectively. Our remaining research and development costs are comprised primarily of rent and related facilities costs, information technology costs, depreciation pertaining to facilities and equipment, laboratory consumables, contract services and routine costs and fees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $243.8 million in 2025, compared to $424.1 million in 2024, a decrease of $180.3 million. This decrease was primarily driven by reductions of $64.5 million in personnel-related compensation and benefits expenses (net of $2.6 million tax credit), $39.6 million in rent and facilities expenses, $22.9 million in stock-based compensation expense (inclusive of employer payroll taxes), $19.8 million in acquired in-process research and development expense, $16.7 million in laboratory supplies, $7.9 million in allocated overhead expenses (reclassified from R&amp;D to G&amp;A and cost of sales), $9.3 million in depreciation and amortization, $5.4 million in temporary labor and contractors, and $1.8 million increase in other operating expenses. These decreases were partially offset by an increase of $7.6 million in information technology expenses primarily due to a shortfall in contractually committed spending related to our strategic cloud and AI partnership with Google Cloud (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_172">12</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for further details).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $183.3 million in 2025, compared to $246.2 million in 2024, a decrease of $62.9 million. This decrease was primarily driven by reductions of $28.8 million in personnel-related compensation and benefits expenses (net of $0.9 million tax credit), $23.0 million in professional fees, $14.6 million in stock-based compensation expense (inclusive of employer payroll taxes), $8.1 million in allocated overhead expenses (reclassified from R&amp;D to G&amp;A), $7.4 million in earnout remeasurement expenses, $5.8 million reduction in impairment of construction in progress assets, $4.7 million in temporary labor and contractors, $4.0 million in travel, and $1.2 million in other operating expenses. These decreases were partially offset by an increase of $34.7 million in rent and facilities expenses primarily due to a new lease that commenced in the second quarter of 2024 and remains unoccupied.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we recorded goodwill impairment expense of $47.9 million related to our Cell Engineering reporting unit, further discussed within &#8220;Critical Accounting Estimates&#8221; below.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charges</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges were $11.4 million in 2025, compared to $24.2 million in 2024, a decrease of $12.8&#160;million. The change was primarily driven by lower employee termination costs. See Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_575">3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for further details.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $22.6 million in 2025, compared to $38.6 million in 2024, a decrease of $16.0 million. This decrease was primarily due to lower average cash and investment balances.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Investments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on investments was $16.4 million in 2025, compared to $28.8 million in 2024, a decrease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of $12.4 million. The change was primarily driven by lower impairment losses on our non-marketable equity investments in privately held companies, partially offset by fluctuations in the stock prices of marketable equity securities, compared to 2024. We assess our non-marketable equity investments quarterly for potential impairment and remeasure them to fair value when events or changes in circumstances indicate that their carrying value may not be recoverable.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Deconsolidation of Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we recorded a $7.0 million loss on the deconsolidation of our former foreign subsidiary Altar as a result of a sale of this business.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There was substantially no value related to these warrant liabilities as of December 31, 2025 and 2024. The change in fair value of warrant liabilities was a gain of $5.7 million in 2024. The change in fair value of warrant liabilities is primarily driven by reductions in the value of our common stock. Increases or decreases in the value of our common stock result in a loss or gain, respectively, in the fair value of warrant liabilities. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net was $(4.5) million in 2025, compared to $3.9 million in 2024, a decrease of $8.4 million. This decrease was primarily due to losses on the change in fair value of a note receivable accounted for under the fair value option recorded in 2025.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_64"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Information </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our results determined in accordance with GAAP, we use earnings before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;) and Adjusted EBITDA internally to evaluate our performance and make financial and operational decisions. We believe these non-GAAP measures, when viewed with our GAAP results, may be helpful to investors in assessing our operating performance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We define EBITDA as net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders before the impact of interest income, interest expense, provision for income taxes and depreciation and amortization. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We define Adjusted EBITDA as EBITDA adjusted for stock-based compensation expense, gain or loss on equity method investments, gain or loss on investments, change in fair value of warrant liabilities, gain or loss on deconsolidation of subsidiaries, transaction and integration costs associated with planned, completed or terminated mergers and acquisitions, including related litigation costs, restructuring and impairment charges (inclusive of impairments of goodwill and long-lived assets), costs associated with the bankruptcy filing of our former subsidiary, Zymergen (the &#8220;Zymergen Bankruptcy&#8221;), and certain other income and expenses. We believe that the use of EBITDA and Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends because it eliminates the effect of financing activities, investing activities, and certain non-cash charges and other items that are not related to our core operating performance or affect comparability period over period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for GAAP performance measures. These measures exclude significant expenses and income required by GAAP, which impacts their alignment with consolidated financial statements. They also rely on management's judgment to determine which items are included or excluded, making them inherently subjective. Additionally, non-GAAP measures lack uniform definitions and may differ from those used by other companies, limiting comparability. A reconciliation of EBITDA and Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure, is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(312,763)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(547,029)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(22,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(38,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">63,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">EBITDA</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(277,226)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(523,006)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">82,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">115,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment expense </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Merger and acquisition related expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on deconsolidation of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(167,026)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(293,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All periods include non-cash revenue when earned. For the year ended December&#160;31, 2025 this included $7.5 million in non-cash revenue from the release of a deferred revenue balance associated with the terminated BiomEdit, Inc. (&#8220;BiomEdit&#8221;) contract. For the year ended December 31, 2024 this included $45.4 million recognized pursuant to the termination of revenue contracts with Motif and $4.5 million in non-cash revenue from the release of a deferred revenue balance associated with the termination of contract with a related party.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For the years ended December&#160;31, 2025 and 2024, includes $1.2 million and $3.0 million, respectively, in related employer payroll taxes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For 2024, includes $47.9&#160;million related to goodwill impairment and $5.8 million related to lab equipment.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Restructuring charges consist of employee termination costs from the reduction in force commenced in June 2024, as well as the impairment of a right-of-use asset relating to facilities consolidation. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery. Not included in this adjustment are acquired in-process research and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">development expenses, which totaled zero and $19.8 million for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_67"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2024, with the approval of our board of directors and shareholders, we effected a one-for-forty (1:40) reverse stock split for our common stock. Accordingly, all common shares presented herein have been retrospectively adjusted to reflect the reverse stock split.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sources of Liquidity </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had cash and cash equivalents of $167.2 million and marketable securities of $255.4 million, which we believe will be sufficient to enable us to fund our projected operations through at least the next 12 months from the date of filing of this Annual Report on Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">At-The-Market Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2025, we filed a universal shelf registration statement on Form S-3, which was declared effective by the SEC on August 14, 2025, on which we registered for sale up to $500 million of any combination of our Class A common stock, preferred stock, warrants, and/or units from time to time and at prices and on terms that we may determine. On September 4, 2025, the Company entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;) with Allen &amp; Company LLC, who is acting as the sales agent (the &#8220;Agent&#8221;), pursuant to which the Company may sell shares of its Class A common stock from time to time at prices and on terms determined by market conditions at the time of offering, up to an aggregate offering price of $100.0 million through or directly to the Agent in one or more at-the-market (&#8220;ATM&#8221;) offerings. Since inception of the Sales Agreement through December 31, 2025, the Company has issued 1.9 million shares of Class A common stock under the Sales Agreement for net proceeds of $18.1 million. We currently intend to use the net proceeds from this offering for general corporate purposes, which may include, but are not limited to, financing our operations, technology development, working capital and capital expenditures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenditures will exceed our revenue through at least the next 12 months from the date of filing of this Annual Report on Form 10-K, as we: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our R&amp;D activities under existing and new programs and further invest in and expand our tools offerings;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upgrade, expand or adapt our operational, financial and management systems and support our operations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially acquire and integrate companies, assets or intellectual property that advance our company objectives; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand, and protect our intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have various noncancelable operating leases for office and laboratory space, with significant leases expiring between 2030 and 2039. As of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, we have fixed minimum rental commitments under noncancellable operating leases of</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> $56.3 million in 2026 and $606.5 million thereafter, plus additional variable rents. See Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_163">10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K for more information. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into a five-year strategic cloud and AI partnership with Google Cloud, which included minimum annual commitments to purchase cloud hosting services. The partnership previously included minimum annual commitments over the contract years ending August 27, 2027 to purchase cloud hosting services in exchange for various discounts on such services. The aggregate $289 million future purchase commitment included minimum annual commitments were as follows: year 1, $8.0 million; year 2, $28.0 million; year 3, $54.0 million; year 4, $86.0 million; and year 5, $113.0 million. Effective October 3, 2025, the Company entered into amendment that revised the total aggregate future purchase commitment to $110 million and reset the annual commitments as follows (each annual year is defined as October 3 to October 2): year 1 (starting on October 3, 2025), $6.0 million; year 2, $8.0 million; year 3, $12.0 million; year 4, $18.0 million; year 5, $28.0 million; year 6, $38.0 million. The Company recognized a contractual liability of $20.9 million during year ended December 31, 2025 as a result of shortfall in purchasing relative to its commitments under the original agreement. The Company is required to make a one-time payment of $14.0 million to be released from its </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">minimum annual commitment obligations under the original agreement in January 2026. If the Company does not meet its minimum annual commitment obligations in the future, additional shortfall liabilities may be incurred and future contractual losses may be material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 1, 2025, the Company entered into an amendment to its four-year supply agreement with Twist for the purchase of diverse products including synthetic DNA. The original agreement was effective as of April 1, 2022 and obligated the Company to spend a minimum of $58.0 million over the four-year term with the following minimum annual commitments (each annual year is defined as April 1 to March 31): year 1, $10.0 million; year 2, $13.0 million; year 3, $16.0 million; and year 4, $19.0 million. The amendment converts the remaining minimum annual commitments into non-refundable payments creditable against future purchases by the Company, with no expiration. The Company paid $4.0 million in April 2025 and is obligated to non-refundable payments of $5.0 million on April 1, 2026 and $6.0 million on April 1, 2027, respectively. A contractual loss of $8.7 million was recorded in the year ended December 31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Surety Bond</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2026, the Company will be required to fund a surety bond in the amount of $47.0 million to fulfill its obligations under a contract with a U.S. Government National Laboratory related to the sale of RAC automation equipment. The $47.0 million will be restricted until the Company completes all of its obligations under the contract. Currently the Company expects the cash to be restricted until 2029.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for each period presented: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(171,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(319,585)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(240,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(62,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">17,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,739)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effect of exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(393,372)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(383,841)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2025 consisted of a net loss of $312.8 million, adjusted for a net decrease in cash due to changes in operating assets and liabilities of $44.1 million and non-cash charges of $185.8 million. The net change in operating assets and liabilities was primarily driven by a $32.4 million decrease in deferred revenue primarily from one-time releases of deferred revenue balances associated with terminated customer contracts and the recognition of previously deferred revenue, a $27.9 million decrease in operating lease liabilities from rent payments, and a $5.2 million increase in prepaid expenses and other current assets; partially offset by a $10.4 million increase in accrued expenses and other current liabilities and an $11.5 million increase in other non-current liabilities due to shortfalls in contractually committed spending related to our contracts with Twist and Google Cloud (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_172">12</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for further details), and a $3.8 million decrease in operating lease right-of-use assets from lease incentives received. Non-cash adjustments primarily consisted of $59.0 million in depreciation and amortization, $81.5 million in stock-based compensation expense, $16.4 million loss on investments, and $30.1 million non-cash lease expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December 31, 2024 consisted of a net loss of $547.0 million, adjusted for a net decrease in cash due to changes in operating assets and liabilities of $89.7 million and non-cash charges of $317.1 million. The net change in operating assets and liabilities was primarily driven by a $40.4 million decrease in accrued expenses and other current liabilities primarily due to the payment or release of restructuring-related accruals and litigation costs, a $68.6 million decrease in deferred revenue primarily from a one-time release of a deferred revenue balance associated with a terminated customer contract, and a $14.9 million decrease in operating lease liabilities from rent payments, partially offset by a $23.5 million decrease in operating lease right-of-use assets from lease incentives received and a $10.1 million decrease in prepaid expenses and other current assets, primarily driven by the derecognition of an insurance receivable and a reduction in contract renewals resulting from our restructuring actions. Non-cash adjustments primarily consisted of $63.0 million in depreciation and amortization, $112.3 million in stock-based compensation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">expense, $28.8 million loss on investments, $28.1 million non-cash lease expense, $19.8 million in acquired in-process research and development expense, and $58.5 million in various asset impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December&#160;31, 2025 primarily consisted of purchases of marketable debt securities of $418.6 million, maturities of marketable debt securities of $159.5 million, and sales of marketable debt securities of $25.9 million, and $7.7 million in purchases of property and equipment related to the build-out of new office and laboratory space near our headquarters.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December 31, 2024 primarily consisted of $62.5 million in purchases of property and equipment related to a build out of new office and laboratory space being developed near our headquarters, $5.4 million paid for the acquisition of certain Zymergen assets, offset by $4.5 million in proceeds from the sale of marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the year ended December&#160;31, 2025 primarily consisted of $18.1 million in net proceeds from the ATM offering and $0.4 million of principal payments on finance leases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the year ended December 31, 2024 primarily consisted of principal payments on finance leases and payments of contingent consideration related to business acquisitions.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_70"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, are reflected in our consolidated financial statements prospectively from the date of change in estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_145">2</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and estimates. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Engineering Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For certain Cell Engineering revenue contracts, we recognize revenue over the period of performance using a measure of progress based on costs incurred to date relative to total expected costs (i.e., cost-to-cost method). A significant level of judgment is involved in estimating the total expected costs. When estimating total expected costs, we make assumptions and estimates regarding the contracted scope of work, tasks required to complete each project, technical and schedule risks associated with the science, the expected duration of each project, and the total amount of internal and external resources required. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration and licensing agreements often include multiple promises, such as (i) licenses and assignments of intellectual property and materials and (ii) research and development services. We assess whether each promise constitutes a distinct performance obligation based on the specific terms of each agreement. Determining whether the promises within a customer contract should be accounted for separately as distinct performance obligations requires significant judgment. Therefore, we review customer contracts to identify all individual promises to transfer goods and services that qualify as performance obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Options to acquire additional goods and services are evaluated to determine whether they provide a material right to the customer that would not otherwise be available without entering into the contract. Judgment is required to assess whether a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">customer option constitutes a material right. If a material right is identified, the option is treated as a separate performance obligation, and the revenue allocated to the option is deferred until the option is either exercised or expires.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also evaluate contract modifications and amendments to determine whether any changes should be accounted for as a separate contract, prospectively or on a cumulative catch-up basis.   </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer contracts include payment in the form of equity securities or other financial instruments that convert into equity upon a triggering event. Any non-cash consideration is measured at its estimated fair value at contract inception. For equity securities and financial instruments that are not actively traded, we generally determine the estimated fair value by referencing a recent financing round or utilizing a scenario-based valuation model. Significant unobservable inputs are used in these valuations, including expectations regarding future financings of the customer, scenario dates and probabilities, expected volatility, discount rates, and recovery rates. Changes in these assumptions can materially affect the fair value of the non-cash consideration and, consequently, the total revenue recognized for the contract.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We review our long-lived assets and asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the carrying value of the long-lived assets to the future undiscounted cash flows expected to be generated by the assets. In determining the expected future cash flows, we use assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. We recognize an impairment loss when and to the extent that the estimated fair value of the long-lived assets is less than their carrying value.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, due to a sustained decrease in the market price of our Class A common stock and market capitalization, we identified that a possible indicator of impairment was present as of June 30, 2024. As such, we completed a quantitative impairment test related to our Cell Engineering reporting unit. To conduct the impairment test of goodwill, the estimated fair value of the reporting unit was compared to its carrying value. The estimated fair value of the Cell Engineering reporting unit was determined using a weighted approach that considered a discounted cash flow (&#8220;DCF&#8221;) model under the income approach and the guideline public company (&#8220;GPC&#8221;) method under the market approach. Inputs used in the DCF model included the projected future operating results of the reporting unit and the applicable discount rate, while inputs used in the GPC method consisted of a revenue multiple. The projected future operating results were based on historical experience and internal annual operating plans reviewed by management, extrapolated over the forecast period. The discount rate was determined using a weighted average cost of capital adjusted for risk factors specific to the reporting unit. The revenue multiple was based on the GPC method using comparable publicly traded company multiples of revenue for a group of benchmark companies. The DCF method was weighted 75% and the GPC 25%. We reconciled the resulting fair value of the reporting unit to our market capitalization to corroborate the fair value estimate used in the impairment test. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The interim impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. As a result, we fully impaired goodwill and recorded an impairment loss of $47.9 million in the second quarter of 2024 and for the year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Non-Marketable Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We account for our non-marketable equity securities using the measurement alternative, where the carrying value is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Determining whether an observed transaction is similar to the security owned by us requires judgment based on the rights and obligations of the investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We evaluate non-marketable equity investments for impairment on a quarterly basis, considering both qualitative and quantitative factors that may have a significant effect on the investment&#8217;s fair value. Qualitative factors considered include the companies&#8217; financial and liquidity position, access to capital resources, adverse changes in the economic environment of the investee, and adverse changes in the business prospects of the investee, among others. When indicators of impairment exist, we prepare quantitative assessments of the fair value of our non-marketable equity securities using market and income approaches that require judgment and the use of estimates, including discount rates, assumptions around the investees' expected time to exit event, investee revenues and expenses, and comparable market data of guideline public companies, among others. When our assessment indicates that an impairment exists, we write down the investment to its fair value.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">77</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_145">2</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Summary of Significant Accounting Policies,&#8221; of our consolidated financial statements contained in Part II, Item 8 of this Annual Report on Form 10-K for a discussion of recently issued accounting pronouncements.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_76"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk on our cash equivalents and marketable debt securities. As of December&#160;31, 2025, we had cash equivalents and marketable debt securities of $382.9 million, consisting of highly liquid investments in money market funds, U.S. Treasury securities, corporate bonds, and commercial paper. We do not enter into investments for trading or speculative purposes. Our investments are exposed to market risk due to fluctuations in interest rates, which may affect our interest income and the fair market value of our investments. However, due to the short-term nature and quality of investments in our portfolio, an immediate change in market interest rates of 100 basis points would not have a material impact on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to foreign currency exchange rate risk from the translation of the financial statements of our foreign subsidiaries, whose financial condition and results of operations are reported in their local currencies and then translated into U.S. dollars at the applicable currency exchange rate for inclusion in our consolidated financial statements. Foreign currency translation (loss) gain was $3.5 million and $(4.8) million for the years ended December&#160;31, 2025 and 2024, respectively. Foreign currency translation adjustments are accounted for as a component of accumulated other comprehensive income (loss) within stockholders&#8217; equity. Additionally, we have contracted with and may continue to contract with foreign customers, suppliers, and contractors. We do not believe that an immediate 10% increase or decrease in the relative value of the U.S. dollar to other currencies would have a material effect on operating results or financial condition. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor, laboratory supplies, consumables and equipment. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the years ended December&#160;31, 2025 and 2024.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_79"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements, together with the report of our independent registered public accounting firm, appear beginning on page</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_115">F-1 in Part IV, Item 15, &#8220;Exhibits, Financial Statement Schedules&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and are incorporated herein by reference.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_82"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_85"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of December 31, 2025, which is the end of the period covered by this Annual Report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective as of December 31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such terms are defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is a framework designed under the supervision and with the participation of our management, including our Chief Executive </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Officer and Chief Financial Officer, and effected by our board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of management and our directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (2013). Based on this evaluation, we concluded that the Company's system of internal control over financial repor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ting was effective as of December&#160;31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December 31, 2025 has been audited by our independent registered public accounting firm, Deloitte &amp; Touche LLP, as stated in their report which is included herein.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">79</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_1228"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">To the stockholders and the Board of Directors of Ginkgo Bioworks Holdings, Inc.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the internal control over financial reporting of Ginkgo Bioworks Holdings, Inc. (the &#8220;Company&#8221;) as of December 31, 2025, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> issued by COSO.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2025, of the Company and our report dated February 26, 2026, expressed an unqualified opinion on those financial statements.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Deloitte &amp; Touche LLP</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">Boston, Massachusetts</span><span style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:127%"><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">February&#160;26, 2026</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">80</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_88"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-54"><ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-55"><ix:nonNumeric contextRef="c-6" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-56"><ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-57">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_91"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">81</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_97"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the relevant information from our definitive Proxy Statement for our 2026 Annual Meeting of Shareholders, which will be filed not later than 120 days after December&#160;31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Insider Trading Compliance Policy</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has adopted an <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-58">Insider Trading Compliance Policy</ix:nonNumeric> governing the purchase, sale and/or other disposition of its securities by directors, officers and employees, or the Company itself, that it believes is reasonably designed to promote compliance with insider trading laws, rules and regulations and applicable NYSE listing standards. A copy of the Company&#8217;s Insider Trading Compliance Policy is filed with this Annual Report on Form 10-K as Exhibit 19.1.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_100"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the relevant information from our definitive Proxy Statement for our 2026 Annual Meeting of Shareholders, which will be filed not later than 120 days after December&#160;31, 2025.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_103"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the relevant information from our definitive Proxy Statement for our 2026 Annual Meeting of Shareholders, which will be filed not later than 120 days after December&#160;31, 2025.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_106"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the relevant information from our definitive Proxy Statement for our 2026 Annual Meeting of Shareholders, which will be filed not later than 120 days after December&#160;31, 2025.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_109"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the relevant information from our definitive Proxy Statement for our 2026 Annual Meeting of Shareholders, which will be filed not later than 120 days after December&#160;31, 2025. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">82</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_112"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_115"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As part of this Annual Report on Form 10-K, the consolidated financial statements are listed in the accompanying index to financial statements on page </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_2748779070649">F-1</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521156844/d66969dex21.htm">Merger Agreement, dated as of May 11, 2021, by and among Soaring Eagle Acquisition Corp., SEAC Merger Sub Inc. and Ginkgo Bioworks, Inc. (incorporated by reference to Exhibit 2.1 of SRNG&#8217;s Current Report on Form 8-K filed with the SEC on May 11, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521171095/d560468dex21.htm">Amendment to the Agreement and Plan of Merger, dated as of May 14, 2021, by and among Soaring Eagle Acquisition Corp., SEAC Merger Sub Inc. and Ginkgo Bioworks, Inc. (incorporated by reference to Exhibit 2.1 to SRNG&#8217;s Quarterly Report on Form 10-Q (File No. 001-40097) for the quarter ended March 31, 2021, filed with the SEC on May 24, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001830214/000162828024037685/dna-20240819.htm">Amended and Restated Certificate of Incorporation of Ginkgo Bioworks Holdings, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 19, 2024)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312523265256/d563263dex31.htm">Amended and Restated Bylaws of Ginkgo Bioworks Holdings, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 27, 2023)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521235409/d177007dex45.htm">Specimen Class A Common Stock Certificate of Ginkgo Bioworks Holdings, Inc. (incorporated by reference to Exhibit 4.5 to Amendment No. 3 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on August 4, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex42.htm">Description of Securities of the Registrant</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521060375/d115307dex41.htm">Warrant Agreement, dated as of February 23, 2021, by and among Soaring Eagle Acquisition Corp. and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 of SRNG&#8217;s Current Report on Form 8-K (File No. 001-40097), filed with the SEC on February 26, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000095017022004821/dna-ex4_4.htm">Assignment and Assumption Agreement, dated as of September 16, 2021, by and among Ginkgo Bioworks Holdings, Inc., Continental Stock Transfer &amp; Trust Company and Computershare Trust Company, N.A. (incorporated by reference to Exhibit 4.4 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 29, 2022)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.1+*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex101.htm">Form of Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.2+*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex102.htm">Form of Ginkgo Bioworks Holdings, Inc. 2021 Employee Stock Purchase Plan</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.3+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521277420/d186750dex104.htm">Registration Rights Agreement, dated as of September 16, 2021, by and among Ginkgo Bioworks Holdings, Inc., Eagle Equity Partners III, LLC and the other Holders signatory thereto. (incorporated by reference to Exhibit 10.4 of Ginkgo&#8217;s Current Report on Form 8-K filed with the SEC on September 20, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.4+*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex104.htm">Ginkgo Bioworks, Inc. 2008 Stock Incentive Plan, as amended as of June 18, 2014</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.5+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex109.htm">Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.9 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.6+*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex106.htm">Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, effective May 1, 2019</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.7+*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex107.htm">Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, effective September 9, 2019</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.8+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1012.htm">Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, effective November 14, 2019 (incorporated by reference to Exhibit 10.12 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.9+*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex109.htm">Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, effective April 8, 2020</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.10+*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex1010.htm">Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, effective March 15, 2021</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.11+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1015.htm">Form of Incentive Stock Option Agreement, granted under the Ginkgo Bioworks, Inc. 2008 Stock Incentive Plan (incorporated by reference to Exhibit 10.15 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.12+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1016.htm">Form of Restricted Stock Unit Agreement, granted under the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.16 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.13+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1017.htm">Form of Restricted Stock Agreement, granted under the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.17 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.14+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000162828025022761/dna-20250331xex101.htm">Form of Restricted Stock Unit Agreement, granted under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.15+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000095017022017412/dna-ex10_1.htm">Form of Stock Option Agreement, granted under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 15, 2022)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.16+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000095017022017412/dna-ex10_2.htm">Form of Global Restricted Stock Unit Agreement, granted under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 15, 2022)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.17+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000162828025022761/dna-20250331xex102.htm">Form of Performance-Based Restricted Stock Unit Agreement, granted under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.18&#8224;&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1018.htm">Lease Agreement, dated December 22, 2011, between Zoom Group LLC and Ginkgo Bioworks, Inc. (incorporated by reference to Exhibit 10.18 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.19&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1019.htm">First Amendment to Lease Agreement, dated April 1, 2012 (incorporated by reference to Exhibit 10.19 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.20&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1020.htm">Second Amendment to Lease, dated August 1, 2014 (incorporated by reference to Exhibit 10.20 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1021.htm">Third Amendment to Lease, dated August 15, 2014 (incorporated by reference to Exhibit 10.21 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.22&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1022.htm">Fourth Amendment to Lease, dated May 1, 2016 (incorporated by reference to Exhibit 10.22 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.23&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1023.htm">Fifth Amendment to Lease, dated May 31, 2016 (incorporated by reference to Exhibit 10.23 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1024.htm">Sixth Amendment to Lease, dated August 5, 2016 (incorporated by reference to Exhibit 10.24 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.25&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1025.htm">Seventh Amendment to Lease, dated July 31, 2017 (incorporated by reference to Exhibit 10.25 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.26&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1026.htm">Eighth Amendment to Lease, dated March 23, 2018 (incorporated by reference to Exhibit 10.26 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.27&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1027.htm">Ninth Amendment to Lease, dated September 6, 2018 (incorporated by reference to Exhibit 10.27 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.28&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1028.htm">Tenth Amendment to Lease, dated July 29, 2020 (incorporated by reference to Exhibit 10.28 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.29&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1029.htm">Eleventh Amendment to Lease, dated August 14, 2020 (incorporated by reference to Exhibit 10.29 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.30&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1030.htm">Twelfth Amendment to Lease, dated January 13, 2021 (incorporated by reference to Exhibit 10.30 to Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.31&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521273556/d172577dex1031.htm">Thirteenth Amendment to Lease, dated September 6, 2021 (incorporated by reference to Exhibit 10.31 to the Registration Statement on Form S-1 (File No. 333-258712), filed with the SEC on September 15, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000095017022017412/dna-ex10_3.htm">Fourteenth Amendment to Lease Agreement, dated June 1, 2022, by and between BCP-CG 27 Property LLC and Ginkgo Bioworks, Inc. (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 15, 2022)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000162828024008052/dna-20231231xex1031.htm">Fifteenth Amendment to Lease Agreement, dated August 9, 2023, by and between BCP-CG 27 Property LLC and Ginkgo Bioworks, Inc. (incorporated by reference to Exhibit 10.31 of the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on February 29, 2024) </a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1031.htm">Lease Agreement, dated March 18, 2016, by and between Jamestown 21-23-25 Drydock, L.P. and Ginkgo Bioworks, Inc. (incorporated by reference to Exhibit 10.31 to Amendment No. 1 to the Registration Statement (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.35&#8224;&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1032.htm">First Amendment to Lease Agreement, dated August 13, 2018 (incorporated by reference to Exhibit 10.32 to Amendment No. 1 to the Registration Statement (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.36&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001830214/000095017022017412/dna-ex10_4.htm">Second Amendment to Lease Agreement, dated August 10, 2022, by and between IDB 21-25 Drydock Limited Partnership and Ginkgo Bioworks, Inc. (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 15, 2022)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1033.htm">Sublease, dated December 10, 2019, by and between Stanley Convergent Security Solutions, Inc., and Ginkgo Bioworks, Inc. (incorporated by reference to Exhibit 10.33 to Amendment No. 1 to the Registration Statement (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.38&#8224;&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1035.htm">License Agreement, dated September 11, 2020, by and between Jamestown 21-23-25 Drydock, L.P. and Ginkgo Bioworks, Inc. (incorporated by reference to Exhibit 10.35 to Amendment No. 1 to the Registration Statement (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.39&#8224;+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521202062/d177007dex1038.htm">Offer Letter, dated October 7, 2020, between Ginkgo Bioworks, Inc. and Mark Dmytruk (incorporated by reference to Exhibit 10.38 to Amendment No. 1 to the Registration Statement (File No. 333-256121), filed with the SEC on June 28, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.40+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000162828025038982/dna-20250630xex102.htm">Ginkgo Bioworks Holdings, Inc. Amended and Restated Non-Employee Director Compensation Program (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.41+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521235409/d177007dex1040.htm">Form of Founder Equity Grant Agreement (incorporated by reference to Exhibit 10.40 of SRNG&#8217;s Form S-4/A (File No. 333-256121), filed with the SEC on August 4, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.42</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521235409/d177007dex1041.htm">Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 10.41 of SRNG&#8217;s Form S-4/A (File No. 333-256121), filed with the SEC on August 4, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.43</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312521156844/d66969dex104.htm">Sponsor Support Agreement, dated as of May 11, 2021, by and among Eagle Equity Partners III, LLC, Ginkgo Bioworks, Inc., Soaring Eagle Acquisition Corp. and certain of its shareholders (incorporated by reference to Exhibit 10.4 of SRNG&#8217;s Current Report on Form 8-K (File No. 001-40097), filed with the SEC on May 11, 2021)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.44+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000119312522200433/d368627dex101.htm">Form of Stock Option Agreement for 2024 Founder Award Program, granted under the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.45+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000162828025038982/dna-20250630xex101.htm">Compensation Adjustment Letter dated May 30, 2025, between Ginkgo Bioworks, Inc. and Steven Coen (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10.46</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000183021425000009/ex11.htm">Sales Agreement, dated September 4, 2025, by and among the Ginkgo Bioworks Holdings, Inc. and Allen &amp; Company LLC (incorporated by reference to Exhibit 1.1 of the Company&#8217;s Current Report on Form 8-K, filed with the SEC on Sept 4, 2025)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex191.htm">Insider Trading Compliance Policy</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex211.htm">Subsidiaries of the Registrant</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex231.htm">Consent of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex231.htm">Deloitte &amp; Touche</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex231.htm"> LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex232.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dna-20251231xex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">97</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1830214/000162828024008052/dna-20231231xex97.htm">Policy for Recoupment of Incentive Compensation (incorporated by reference to Exhibit 97 of the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on February 29, 2024)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Filed herewith.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8225;&#160;&#160;&#160;&#160;Certain confidential information contained in this Exhibit has been omitted because it is (i) not material and (ii) of the type that the registrant treats as private or confidential.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">86</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_118"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">87</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_121"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">GINKGO BIOWORKS HOLDINGS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date: February&#160;26, 2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Jason Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Jason Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:31.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Jason Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;26, 2026</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Jason Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Steven Coen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;26, 2026</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Steven Coen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Shyam Sankar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Director, Chair of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;26, 2026</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Shyam Sankar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Ross Fubini</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;26, 2026</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Ross Fubini</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Christian Henry</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;26, 2026</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Christian Henry</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Sri Kosuri</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;26, 2026</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Sri Kosuri</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Reshma Shetty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">President and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;26, 2026</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Reshma Shetty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Harry E. Sloan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;26, 2026</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Harry E. Sloan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">88</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_2748779070649"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GINKGO BIOWORKS HOLDINGS, INC. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements as of December&#160;31, 2025 and 2024 and for the Years Ended December&#160;31, 2025, 2024 and 2023</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Page</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">  </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_1251">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-59">34</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_124">)</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_1251">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_124">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42</span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_124">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_124">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_127">Consolidated Balance Sheets</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_127"> </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_127">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_130">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_130">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_133">Consolidated Statements of Stockholders&#8217; Equity</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_133"> </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_133">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_136">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_136">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_139">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_139">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_142">1. Organization and Basis of Presentation </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_142">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_145">2. Summary of Significant Accounting Policies </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_142">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_575">3. Restructuring</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_575">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_148">4. Acquisitions and Divestitures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_148">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_151">5. Fair Value Measurements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_151">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_21990232556947">6. Marketable Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_21990232556947">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_154">7. Investments and Equity Method Investments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_154">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_157">8. Variable Interest Entities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_157">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_160">9. Goodwill and Intangible Assets, net</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_160">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_163">10. Leases </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_163">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_169">11. Supplemental Financial Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_169">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_172">12. Commitments and Contingencies</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_172">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_175">13. Stockholders' Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_175">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_178">14. Stock-Based Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_178">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_184">15. Revenue Recognition</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_184">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_187">16. Segment Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_187">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_190">17. Significant Collaboration Agreements and Transactions with Related Parties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_190">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_193">18. Employee Benefit Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_193">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_196">19. Income Taxes</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_193">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_199">20. Net Loss per Share</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_199">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_205">21. Subsequent Events</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#id8596373948b4ae4958ccd7c02fd70c1_205">54</a></span></div></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> F-1</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_1251"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">To the stockholders and the Board of Directors of Ginkgo Bioworks Holdings, Inc.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Ginkgo Bioworks Holdings, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2025, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 26, 2026, expressed an unqualified opinion on the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matter </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cell Engineering Revenue Recognition &#8212; Refer to Notes 2 and 15 to the financial statements</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Critical Audit Matter Description</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company generates Cell Engineering revenue primarily through service and license agreements for its tools and solutions offerings. Cell Engineering revenue was $133 million for the year ended December 31, 2025. The Company generally recognizes Cell Engineering revenue over time based on the cost incurred to date relative to total expected costs or for cost-plus contracts, as costs are incurred. The Company evaluates its measure of progress to recognize revenue at each reporting period and, as necessary, adjusts the measure of progress and related revenue recognition. The Company&#8217;s measure of progress and revenue recognition involves significant judgment and assumptions, including, but not limited to, evaluating contract terms and estimating the cost to complete the performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the Cell Engineering revenue was challenging due to the extent of audit effort required to evaluate the volume and complexity of customer contracts, including estimates of the measure of progress.  </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to Cell Engineering revenue included the following, among others:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We selected a sample of Cell Engineering contracts and performed the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.75pt">Evaluated whether the contracts were properly included in management&#8217;s calculation of Cell Engineering revenue based on the terms and conditions of each contract, including whether continuous transfer of control to the customer occurred as progress was made toward fulfilling the performance obligation(s).</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.75pt">Compared the transaction price to the consideration expected to be received based on current rights and obligations under the contracts and any modifications that were agreed upon with the customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.75pt">Tested management&#8217;s identification of distinct performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.75pt">To the extent a contract did not represent a single distinct performance obligation, we tested the allocation of the transaction price to each distinct performance obligation by comparing the relative standalone selling prices to the selling prices of similar goods or services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.75pt">Tested the accuracy and completeness of the costs incurred to date for each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.75pt">Evaluated the estimates of total cost incurred and total estimated cost, when applicable, for the performance obligation by: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.75pt">Testing the costs incurred to date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.75pt">Evaluating management&#8217;s estimates of total cost by performing corroborating inquiries with those that are responsible for managing the contract execution, and comparing the estimates to management&#8217;s work plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.75pt">Tested the mathematical accuracy of management&#8217;s calculation of revenue for the performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We evaluated management&#8217;s ability to estimate total costs accurately by comparing actual costs to management&#8217;s historical estimates for performance obligations that have been fulfilled.</span></div><div style="margin-bottom:10pt;margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-60">Deloitte &amp; Touche LLP</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:127%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-61">Boston, Massachusetts</ix:nonNumeric><br/>February 26, 2026</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> F-3</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_124"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:150%">To the Stockholders and the Board of Directors of Ginkgo Bioworks Holdings, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows of Ginkgo Bioworks Holdings, Inc. (the Company) for the year ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We served as the Company&#8217;s auditor from 2018 to 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">February 29, 2024, except for note 16 and the effects of the reverse stock split described in note 2, as to which the date is February 25, 2025</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> F-4</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_127"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share data)  </span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-62">167,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-63">561,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">255,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">24,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">21,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable - related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="f-68">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="f-69">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">24,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">18,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">471,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">602,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-74">167,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-75">203,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-76">360,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-77">394,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="3" id="f-78">15,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="3" id="f-79">48,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-80">56,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-81">72,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">47,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">55,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-84">1,119,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-85">1,377,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">10,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">14,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue (includes $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-88">98</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-89">795</ix:nonFraction> from related parties)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">18,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">27,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-92">66,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-93">65,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-94">95,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">107,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue, net of current portion (includes $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">64,787</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">72,260</ix:nonFraction> from related parties)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-98">75,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-99">98,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-100">417,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">438,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-102">22,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-103">16,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-104">611,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-105">661,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-106"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-8" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-107"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-108"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-109">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-111">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-112"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-113">none</ix:nonFraction></ix:nonFraction> issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-116"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-117">0.0001</ix:nonFraction></ix:nonFraction> par value (Note 13)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-118">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-119">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-120">6,657,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-121">6,555,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-122">6,150,320</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-123">5,837,557</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-124">1,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-125">1,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-126">508,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-127">716,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-128">1,119,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-129">1,377,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-5</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_130"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share data)  </span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cell Engineering revenue </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-130">132,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-131">173,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-132">143,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Biosecurity revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Service</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-133">37,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-134">53,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-135">78,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-138">28,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total revenue</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-139">170,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-140">227,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-141">251,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of Biosecurity service revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-142">31,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-143">38,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-144">46,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of Biosecurity product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-147">7,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of other revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-148">15,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-149">5,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-151">243,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-152">424,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">580,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">183,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">246,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">385,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impairment of lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-159">96,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-161">47,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-163">11,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-164">24,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-166">485,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-167">786,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-168">1,115,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">315,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">559,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-171">864,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense):</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-172">22,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-173">38,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-174">57,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:fixed-zero" scale="3" id="f-175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-176">94</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-177">93</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss on equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-180">2,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss on investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-181">16,411</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-182">28,827</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-183">54,827</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss on deconsolidation of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="3" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="3" id="f-185">7,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="3" id="f-186">42,502</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-188">5,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-189">5,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-190">4,527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-191">3,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-192">9,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-193">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-194">12,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-195">28,534</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-196">313,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-197">547,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-198">892,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-199">837</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-200">479</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-201">71</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-202">312,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">547,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-204">892,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-205"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-206">5.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-207"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-208">10.54</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-209"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-210">18.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-211"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-212">55,457,676</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-213"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-214">51,894,639</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-215"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-216">48,610,507</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">312,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-218">547,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-219">892,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-220">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-221">4,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-222">4,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:fixed-zero" scale="3" id="f-223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-224">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-226">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-229">3,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-230">3,290</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-231">4,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-232">309,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-233">550,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-234">888,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(1)</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:7.52pt">Includes related party revenue of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-235">8,784</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-236">53,041</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-237">22,222</ix:nonFraction> for the years ended December 31, 2025, 2024, and 2023, respectively.</span></ix:footnote></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-6</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_133"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands except share data) </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.333%"><tr><td style="width:1.0%"/><td style="width:34.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.830%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Shares</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Capital </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Deficit </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(Loss) Income </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Equity </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-238">47,299,399</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-239">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-240">6,136,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-241">4,397,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">2,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">1,736,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock upon exercise or vesting of equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-244">2,469,178</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" id="f-245">555</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" id="f-246">555</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Tax withholdings related to net share settlement of equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="f-247">360</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-248">23</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-249">23</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Settlement of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="dna:SettlementOfContingentConsiderationSharesRestrictedStock" format="ixt:num-dot-decimal" scale="0" id="f-250">96,198</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="dna:SettlementOfContingentConsiderationValueRestrictedStock" format="ixt:num-dot-decimal" scale="3" id="f-251">8,896</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:SettlementOfContingentConsiderationValueRestrictedStock" format="ixt:num-dot-decimal" scale="3" id="f-252">8,896</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock for asset acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-253">119,278</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-254">6,820</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-255">6,820</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock in exchange for services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-256">50,587</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-257">2,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-258">2,500</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Forfeiture of restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" name="us-gaap:RestrictedStockAwardForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-259">1,407</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation expense and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-260">230,880</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-261">230,880</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-262">4,116</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-263">4,116</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-264">892,869</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">892,869</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-266">50,032,873</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-267">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-268">6,386,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-269">5,290,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-270">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">1,097,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock upon exercise or vesting of equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-272">1,783,763</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" id="f-273">543</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" id="f-274">543</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Payment for fractional shares after reverse stock split</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-275">4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-276">4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Settlement of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="dna:SettlementOfContingentConsiderationSharesRestrictedStock" format="ixt:num-dot-decimal" scale="0" id="f-277">1,385,532</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="dna:SettlementOfContingentConsiderationValueRestrictedStock" format="ixt:num-dot-decimal" scale="3" id="f-278">14,742</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:SettlementOfContingentConsiderationValueRestrictedStock" format="ixt:num-dot-decimal" scale="3" id="f-279">14,742</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock for asset acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-280">802,038</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-281">36,801</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-282">36,801</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock in exchange for services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-283">361,579</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-284">4,799</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-285">4,799</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-286">1,492</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-287">1,492</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-288">112,344</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-289">112,344</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-290">4,782</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-291">4,782</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-292">547,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-293">547,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-294">54,365,785</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-295">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-296">6,555,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-297">5,837,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-298">1,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-299">716,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock upon exercise or vesting of equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-300">1,798,041</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock in ATM offering, net of $(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="dna:StockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-301">1,393</ix:nonFraction>) issuance costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-302">1,940,550</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-303">18,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-304">18,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Release of <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="dna:SharesReleaseFromEscrowDuringPeriod" format="ixt:num-dot-decimal" scale="0" id="f-305">24,913</ix:nonFraction> common shares from escrow related to acquisition</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="dna:SettlementOfContingentConsiderationValueRestrictedStock" format="ixt:num-dot-decimal" scale="3" id="f-306">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:SettlementOfContingentConsiderationValueRestrictedStock" format="ixt:num-dot-decimal" scale="3" id="f-307">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock in settlement of purchase price holdback</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-308">102,922</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-309">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-310">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-311">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands except share data) </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.333%"><tr><td style="width:1.0%"/><td style="width:34.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.830%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Shares</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Capital </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Deficit </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(Loss) Income </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Equity </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-312">81,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-313">81,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-314">3,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-315">3,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-316">312,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-317">312,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-318">58,207,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-319">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-320">6,657,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-321">6,150,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-322">1,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-323">508,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-8</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_136"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-324">312,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-325">547,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-326">892,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-327">58,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-328">63,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-329">70,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-330">81,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-331">112,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-332">229,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-334">47,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Restructuring related impairment charges</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCosts" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="3" id="f-337">4,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:RestructuringCosts" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash customer consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:NoncashCustomerConsideration" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="dna:NoncashCustomerConsideration" format="ixt:num-dot-decimal" scale="3" id="f-340">1,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="dna:NoncashCustomerConsideration" format="ixt:num-dot-decimal" scale="3" id="f-341">1,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Loss on equity method investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-344">2,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-345">16,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-346">28,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-347">54,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Change in fair value of notes receivable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:ChangesInFairValueOfLoansReceivable" format="ixt:num-dot-decimal" scale="3" id="f-348">5,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:ChangesInFairValueOfLoansReceivable" format="ixt:num-dot-decimal" scale="3" id="f-349">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:ChangesInFairValueOfLoansReceivable" format="ixt:num-dot-decimal" scale="3" id="f-350">2,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-352">5,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-353">5,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Change in fair value of contingent consideration liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-354">4,232</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-355">3,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-356">9,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Loss on deconsolidation of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="3" id="f-358">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="3" id="f-359">42,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-361">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-362">121,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deferred income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-363">1,364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-364">936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-365">801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Loss on disposal of equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="f-367">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="f-368">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-369">30,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-370">28,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-371">28,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash in-process research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:NoncashInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:NoncashInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-373">19,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:NoncashInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-374">9,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accretion of discount on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:AccretionOfDiscountOnMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-375">3,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:AccretionOfDiscountOnMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:AccretionOfDiscountOnMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other non-cash activity</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-378">2,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-379">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-380">3,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable ($<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-381">357</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-382">156</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-383">816</ix:nonFraction> from related parties)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-384">1,473</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-385">4,725</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-386">50,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-387">5,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-388">10,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-389">10,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="dna:IncreaseDecreaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-390">3,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="dna:IncreaseDecreaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-391">23,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="dna:IncreaseDecreaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-392">9,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-393">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-394">1,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-395">2,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-396">2,992</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-397">4,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-398">1,183</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-399">10,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-400">40,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-401">16,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue, current and non-current ($(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-402">8,147</ix:nonFraction>), $(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-403">51,422</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-404">17,018</ix:nonFraction>) from related parties)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-405">32,393</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-406">68,645</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-407">35,917</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities, current and non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-408">27,932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-409">14,881</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-410">22,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-411">11,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-412">2,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-413">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-414">171,059</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-415">319,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-416">295,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of marketable debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-417">418,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Maturities of marketable debt securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-420">159,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="f-422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from sale of marketable debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-423">25,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-426">7,665</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-427">62,541</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-428">40,801</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deconsolidation of subsidiaries - cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="f-429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-431">42,980</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Business acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-433">5,400</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="3" id="f-437">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from sales of marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-439">4,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-441">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-442">648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-443">4,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="f-444">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="f-445">538</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="f-446">990</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-447">240,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-448">62,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-449">80,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from ATM offering</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-450">19,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Payment of issuance costs related to ATM offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-453">1,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-457">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-458">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-461">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Principal payments on finance leases</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-462">354</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-463">897</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-464">1,295</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Contingent consideration payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="f-466">922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-467">1,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Payment of equity issuance costs and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-469">4</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-470">580</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-471">17,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-472">1,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-473">3,216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-474">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-475">281</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-476">588</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-477">393,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-478">383,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-479">379,997</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-480">561,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-481">944,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-482">1,315,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash, beginning of year</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-483">44,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-484">45,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-485">53,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-486">605,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-487">989,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-488">1,369,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents, end of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-489">167,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-490">561,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-491">944,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash, end of year</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-492">45,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-493">44,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-494">45,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-495">212,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-496">605,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-497">989,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-10</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_139"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:6pt"><span><br/></span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_142"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="f-498" continuedAt="f-498-1" escape="true">Organization and Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="f-498-1"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.'s (&#8220;Ginkgo&#8221; or the &#8220;Company&#8221;) mission is to make biology easier to engineer. Ginkgo sells services to government and commercial customers in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-499">two</ix:nonFraction> business segments: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cell engineering</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, where we provide tools and biological R&amp;D services across a range of industries, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">biosecurity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, where we provide services to customers who are working to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Engineering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo does not make end products; instead, Ginkgo offers biological R&amp;D services on our platform to enable our customers to bring their products to market. Historically, Ginkgo&#8217;s primary service offering has been cell engineering R&amp;D services (solutions) where Ginkgo performs technical activities. In 2024, Ginkgo expanded its service offering to include services that provide our customers cell engineering tools for biological R&amp;D, where Ginkgo enables its customers to conduct certain in-house R&amp;D activities themselves. Ginkgo's services are designed to offer customers better results on the dimensions of probability of success, speed, or cost &#8211; and ideally on all three. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Autonomous Lab is a flexible wet lab built from our Reconfigurable Automation Cart (&#8220;RAC&#8221;) systems capable of large scale data generation; it powers generative AI and machine learning (&#8220;ML&#8221;) tools that enable more successful biological R&amp;D.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosecurity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo's primary biosecurity customers are governments. Ginkgo currently provides biosecurity services via <ix:nonFraction unitRef="offering" contextRef="c-7" decimals="INF" name="dna:NumberOfCoreOfferings" format="ixt-sec:numwordsen" scale="0" id="f-500">two</ix:nonFraction> core offerings as introduced in early 2024:  </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Canopy, which helps our customers generate high value genomic data from strategically positioned nodes (like airports and border checkpoints) via end-to-end biomonitoring programs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Horizon, our digital surveillance, analytics and insights platform that detects and monitors biothreats worldwide.</span></div></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_145"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-501" continuedAt="f-501-1" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="f-501-1" continuedAt="f-501-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-502" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-503" continuedAt="f-503-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-503-1">The accompanying consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, majority owned subsidiaries and variable interest entities if the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-504" continuedAt="f-504-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2024 (the &#8220;Effective Date&#8221;), with the approval of the Company's board of directors and shareholders, the Company effected a one-for-forty (1:40) reverse stock split (the &#8220;Reverse Stock Split&#8221;) for the Company&#8217;s common stock (inclusive of Class A common stock, Class B common stock and Class C common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-505">0.0001</ix:nonFraction> per share). Accordingly, all common shares, common stock equity awards and common stock per share amounts presented herein have been retrospectively adjusted to reflect the Reverse Stock Split.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On the Effective Date, every forty shares of common stock issued and outstanding immediately prior to the Effective Date were automatically combined into one share of such class of common stock without any change to the par value per share. The number of shares reserved under the Company&#8217;s equity plans and the number of shares underlying awards outstanding under the Company&#8217;s equity plans was reduced proportionately. No fractional shares were issued in connection with the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-501-2" continuedAt="f-501-3"><ix:continuation id="f-504-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reverse Stock Split. Shareholders entitled to receive a fractional share as a result of the Reverse Stock Split received a cash payment in lieu of such fractional shares. The number of authorized shares of common stock was not reduced.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-506" continuedAt="f-506-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-506-1">The Company evaluates its variable interests in variable interest entities (&#8220;VIE&#8221;) and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of each VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#8217;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion. As of December&#160;31, 2025 and 2024, the maximum risk of loss related to the Company&#8217;s VIEs was limited to the carrying value of its investment in such entities.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-507" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the consolidated financial statements. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Reported amounts and disclosures reflect the overall economic conditions that management believes are most likely to occur, and the anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-508" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, trade accounts receivable, marketable securities and notes receivable. The Company&#8217;s cash and cash equivalents and restricted cash are maintained in bank deposit accounts and money market funds that regularly exceed federally insured limits. The Company is exposed to credit risk on its cash, cash equivalents and restricted cash in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company believes that it is not exposed to significant credit risk as its deposits are generally held in financial institutions that management believes to be of high credit quality. To date, the Company has not experienced any material write-offs related to its trade accounts receivable. A portion of the Company&#8217;s Biosecurity revenue is derived from sales of services to foreign government agencies in certain developing countries. The Company is exposed to credit risk on its marketable securities. The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s policy is for no one issuer or group of issuers from the same holding company is to exceed 10% of the marketable securities portfolio at the time of purchase, with the exception of U.S. government securities or agencies, U.S. Treasuries, bank sweep and deposit programs and money market funds.  The Company&#8217;s maximum credit risk exposure with respect to notes receivable is equivalent to the carrying value of the notes as of the balance sheet date.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, one customer in the Cell Engineering segment accounted for <ix:nonFraction unitRef="number" contextRef="c-58" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-509">15</ix:nonFraction>% of the Company&#8217;s total revenue, while one customer in the Biosecurity segment accounted for <ix:nonFraction unitRef="number" contextRef="c-59" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-510">12</ix:nonFraction>% of the Company&#8217;s total revenue. For the year ended December&#160;31, 2024, two customers in the Cell Engineering segment accounted for <ix:nonFraction unitRef="number" contextRef="c-60" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-511">13</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-61" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-512">20</ix:nonFraction>% of the Company&#8217;s total revenue, while one customer in the Biosecurity segment accounted for <ix:nonFraction unitRef="number" contextRef="c-62" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-513">16</ix:nonFraction>% of the Company&#8217;s total revenue. For the year ended December&#160;31, 2023, one customer in the Cell Engineering segment and one customer in the Biosecurity segment accounted for <ix:nonFraction unitRef="number" contextRef="c-63" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-514">12</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-515">11</ix:nonFraction>%, respectively, of the Company's total revenue.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="f-516" continuedAt="f-516-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-516-1">The Company&#8217;s cash is comprised of bank deposits, overnight sweep accounts and money market funds. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying value of the Company&#8217;s cash and cash equivalents approximate fair value due to their short-term maturities.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-517" continuedAt="f-517-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily includes cash balances collateralizing letters of credit associated with the Company&#8217;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-501-3" continuedAt="f-501-4"><ix:continuation id="f-517-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreement. Restricted cash is included in prepaid expenses and other current assets and other non-current assets on the consolidated balance sheet.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="f-518" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses to provide for the estimated amounts of receivables that will not be collected over the estimated life of the assets. The allowance is calculated by considering previous loss history, delinquency of receivables balances, current economic conditions and anticipated future economic conditions in the geographies and industries in which the Company&#8217;s customers operate. To the extent an individual customer&#8217;s credit quality deteriorates, the Company measures an allowance based on the risk characteristics of the individual customer. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. The allowance is calculated at each reporting period with changes recorded to general and administrative expense in the consolidated statements of operations and comprehensive loss. Accounts receivable are net of an allowance for credit losses of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="f-519">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="f-520">1.9</ix:nonFraction> million at December&#160;31, 2025 and 2024, respectively. There were no material changes in the allowance for credit losses for the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, the Company began investing its excess cash in marketable debt securities. All debt securities are classified as available-for-sale at the time of purchase. Available-for-sale debt securities, including those with maturities extending beyond one year, are classified as current assets on the balance sheet due to their highly liquid nature and because they are considered available for use in current operations. Debt securities that are highly liquid and have original maturities of three months or less at the time of acquisition are classified as cash equivalents on the consolidated balance sheet. The Company considers securities to be highly liquid if they can be readily converted to cash with an insignificant risk of changes in value, typically due to active markets and high credit quality.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses on available-for-sale marketable debt securities that are not related to credit losses are included in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. Amortization of premium or accretion of discount, along with interest income earned on debt securities, is included in interest income, net. Realized gains and losses, if any, are included in other income (expense), net, and the cost of securities sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the balance sheet date, the Company evaluates its debt securities in an unrealized loss position to determine the extent of the loss, if any, that is attributable to expected credit losses. Expected credit losses on debt securities are recorded as an allowance on the balance sheet, with an offsetting amount recognized in other income (expense), net, in the consolidated statements of operations and comprehensive loss. To date, the Company has not recorded any credit losses on its marketable debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities also includes equity securities of publicly-traded companies that are considered to be available for use in current operations. Equity securities of publicly-traded companies that are not considered to be available for use in current operations are presented within investments on the consolidated balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-521" continuedAt="f-521-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, net </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost less accumulated depreciation. Land is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets or the remaining lease term for leasehold improvements. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-522" continuedAt="f-522-1" escape="true">Estimated lives of property, plant and equipment are as follows: </ix:nonNumeric></span></div><ix:continuation id="f-522-1" continuedAt="f-522-2"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"><tr><td style="width:1.0%"/><td style="width:46.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.222%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-65" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-523">2</ix:nonNumeric> to <ix:nonNumeric contextRef="c-66" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-524">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-67" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-525">7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-68" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-526">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-69" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-527">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Buildings and facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-70" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-528">15</ix:nonNumeric> to <ix:nonNumeric contextRef="c-71" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-529">30</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vehicles</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-72" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-530">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shorter of useful life or remaining lease term</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the related cost and accumulated depreciation is removed from the balance sheet and any resulting gain or loss is recorded in </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-501-4" continuedAt="f-501-5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-521-1">the consolidated statements of operations and comprehensive loss. Construction in progress relates to assets which have not been placed in service as of the period end.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-531" continuedAt="f-531-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the equity method to account for its investments in common stock, or in-substance common stock, when it possesses the ability to exercise significant influence, but not control, over the operating and financial policies of the investee. The Company uses judgment when determining the level of influence over the operating and financial policies of the investee considering key factors including, among others, the Company&#8217;s ownership interest, representation on the board of directors, participation in policy-making decisions and material contractual arrangements and obligations. Income and losses are allocated based upon relative ownership interest unless there is a substantive profit-sharing agreement in place. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For investments with a substantive profit-sharing agreement, the Company utilizes the hypothetical liquidation at book value (&#8220;HLBV&#8221;) method to allocate income and losses from the equity method investment. Under the HLBV method, the Company utilizes the capital account at the end of the period assuming the book value of the entity was liquidated or sold minus the same calculation at the beginning of the period. The difference is the share of earnings or losses attributable to the equity method investment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity method, if there is a commitment for the Company to fund the losses of its equity method investees, the Company would continue to record its share of losses resulting in a negative equity method investment, which would be presented as a liability on the consolidated balance sheet. Commitments may be explicit and may include formal guarantees, legal obligations, or arrangements by contract. Implicit commitments may arise from reputational expectations, intercompany relationships, statements by the Company of its intention to provide support, a history of providing financial support or other facts and circumstances. When the Company has no commitment to fund the losses of its equity method investees, the carrying value of its equity method investments will not be reduced below zero. The Company had <ix:nonFraction unitRef="usd" contextRef="c-73" decimals="INF" name="us-gaap:OtherCommitment" format="ixt:fixed-zero" scale="0" id="f-532"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="INF" name="us-gaap:OtherCommitment" format="ixt:fixed-zero" scale="0" id="f-533"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="INF" name="us-gaap:OtherCommitment" format="ixt:fixed-zero" scale="0" id="f-534">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> commitment to fund additional losses of its equity method investments during the years ended December&#160;31, 2025, 2024 and 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its equity method investments for impairment whenever events or circumstances indicate that the carrying value of the investment may not be recoverable. The Company considers the investee&#8217;s financial position, forecasts and economic outlook, and the estimated duration and extent of losses to determine whether a recovery is anticipated. An impairment that is other-than-temporary is recognized in the period identified. The Company has <ix:nonFraction unitRef="usd" contextRef="c-21" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-535"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-536"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-537">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognized an impairment loss related to its equity method investments for the years ended December&#160;31, 2025, 2024 and 2023.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-531-1">The Company may elect the fair value option for its equity method investments on an investment-by-investment basis. For all equity method investments accounted for under the fair value option, the Company carries the equity method investment at fair value and records all subsequent changes in fair value as a component of loss on equity method investments in the consolidated statements of operations and comprehensive loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-538" continuedAt="f-538-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments include marketable equity securities in publicly-traded companies, non-marketable equity securities in privately-held companies, Simple Agreement for Future Equity (&#8220;SAFE&#8221;) and warrants, in each case, in which the Company does not possess the ability to exercise significant influence over the investee. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable equity securities or warrants of publicly-traded companies are measured at fair value with subsequent changes in fair value recorded in loss on investments in the consolidated statements of operations and comprehensive loss. Marketable equity securities are classified as non-current on the balance sheet if they are not currently available for sale.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in non-marketable equity securities of privately-held companies and SAFEs, which do not have readily determinable fair values, are carried at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Each period the Company assesses relevant transactions to identify observable price changes, and the Company regularly monitors these investments to evaluate whether there is an indication of impairment. An equity security without a readily determinable fair value is written down to its fair value if a qualitative assessment indicates that the investment is impaired and the fair value of the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-501-5" continuedAt="f-501-6"><div style="margin-top:12pt"><ix:continuation id="f-538-1" continuedAt="f-538-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">investment is less than its carrying value. For periods in which there is no estimate of fair value, the Company evaluates whether an event or change in circumstances has occurred that may have a significant adverse effect on the value of the investment. See Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_151">5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_154">7</a></span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-538-2"> for additional information on Investments.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-539" continuedAt="f-539-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value and requires disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1- Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2- Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3- Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are either less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-539-1">The Company valued its money market fund holdings, notes receivable  marketable debt securities, marketable equity securities, warrant liabilities and contingent consideration liabilities at fair value on a recurring basis. The carrying amounts of the Company&#8217;s other financial instruments, which include accounts receivable, certain prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-540" continuedAt="f-540-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div></ix:nonNumeric><div style="margin-top:6pt"><ix:continuation id="f-540-1" continuedAt="f-540-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its long-lived assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the carrying value of the long-lived assets to the future undiscounted cash flows expected to be generated by the assets. In determining the expected future cash flows, the Company uses assumptions believed to be reasonable, but which inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of long-lived asset is less than the carrying value. See Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_575">3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_163">10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_169">11</a></span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-540-2"> for a description of impairment losses recorded on long-lived assets.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-541" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognizes any excess of the total consideration paid over the fair value of the identifiable net assets as goodwill. Any purchase price that is considered contingent consideration is measured at its estimated fair value at the acquisition date and remeasured at each reporting period, with changes in estimated fair value recorded in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Acquisition transaction costs are expensed when incurred. The operating results of an acquisition are included in the Company&#8217;s consolidated financial statements as of the acquisition date.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-501-6" continuedAt="f-501-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-542" continuedAt="f-542-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, net </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-542-1">Intangible assets, net consist of certain definite-lived assets including patents, processes and know-how related to technology acquired through business combinations and asset acquisitions. The Company amortizes such intangible assets on a straight-line basis over their estimated useful life.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-543" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represented the excess of the acquisition cost over the fair market value of the net assets acquired. All goodwill was allocated to the Cell Engineering reporting unit and segment identified in Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_187">16</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company considers various qualitative factors that could indicate impairment of goodwill such as macroeconomic conditions, industry and market environment, overall financial performance of the Company, cash flow from operating activities and market capitalization. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment to compare the fair value of the reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds the fair value, an impairment loss is recognized limited to the total amount of goodwill allocated to that reporting unit. A combination of the income approach and the market approach may be used to determine fair value of the reporting unit. The Company recorded a full goodwill impairment during the year ended December 31, 2024 (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_160">9</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). No impairment losses were recognized during the years ended December 31, 2025, and 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-544" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determines if an arrangement is or contains a lease at contract inception based on the terms and conditions in the contract. A contract contains a lease if there is an identified asset and the Company has the right to control the asset. For leases with terms greater than 12 months, the Company recognizes a right-of-use asset (&#8220;ROU asset&#8221;) and a lease liability as of the lease commencement date on the balance sheet. ROU assets represent the Company&#8217;s right to use an underlying asset over the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are measured based on the present value of fixed lease payments that are unpaid as of the lease commencement date. The Company&#8217;s ROU assets balance is increased by any initial direct costs and reduced by lease incentives received or expected to be received. Some of the Company's leases include options to extend or terminate the lease; these options are included in the lease term for calculations of its ROU assets and liabilities when it is reasonably certain that the Company will exercise those options. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s leases are classified as either operating or finance, as determined at inception, with the classification affecting the pattern of expense recognition in the statement of operations. A lease is classified as a finance lease if risks and rewards are conveyed without the transfer of control. For operating leases, expense is generally recognized on a straight-line basis over the lease term. For finance leases, interest on the lease liability is recognized using the effective interest method, while the ROU asset is amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term. Leases with an initial term of 12 months or less which meet the definition of a short-term lease are not recorded on the balance sheet and the lease expense for these leases is recognized on a straight-line basis over the lease term. In limited instances, the Company acts as a lessor, primarily with certain real estate subleases. Finance leases, short-term leases and subleases are not a significant component of the Company's financial condition or results of operations. The current portion of the Company&#8217;s operating lease liabilities is included in accrued expenses and other current liabilities on the balance sheet. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements with both lease and non-lease components (such as real estate taxes, insurance and common area maintenance charges) and has elected the practical expedient to combine these lease and non-lease components for its real estate leases and non-lab equipment leases. The Company has not elected this practical expedient for lab equipment leases and the lease and non-lease components are accounted for separately for these leases. Non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses an incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments and uses the implicit rate when it is readily determinable. The Company&#8217;s incremental borrowing rate is based on management&#8217;s estimate of the rate of interest the Company would have to pay to borrow on a fully collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-545" continuedAt="f-545-1" escape="true"><ix:continuation id="f-501-7" continuedAt="f-501-8"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Engineering Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates Cell Engineering service revenue by providing end-to-end cell engineering solutions and tools to customers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We generate Cell Engineering revenue primarily through service and license agreements for our tools and solutions offerings. Under our automation solutions agreements we typically provide services related to the design, build, and deployment of our RAC systems as well as ongoing support services. These agreements typically include a fee for the sale and installation of RAC hardware and a fee for follow on support services and control software. Datapoints agreements typically include fixed fees for services related to producing a data package for our customers and are earned over a shorter time period than legacy cell engineering solutions projects.  Under our solutions agreements, we typically provide R&amp;D services for cell programming with the goal of producing an engineered cell that meets a mutually agreed specification. Our customers obtain license rights to the output of our services, which are primarily the optimized strains or cell lines, in order to manufacture and commercialize products derived from that licensed strain or cell line. Generally, the terms of these agreements provide that we receive some combination of: (1) service fees in the form of (i) upfront payments upon consummation of the agreement or other fixed payments, (ii) reimbursement for costs incurred for R&amp;D services and (iii) milestone payments upon the achievement of specified technical criteria, plus (2) downstream value share payments in the form of (i) milestone payments upon the achievement of specified commercial criteria, (ii) royalties on sales of products from or comprising engineered organisms arising from the collaboration or licensing agreement and/or (iii) royalties related to cost of goods sold reductions realized by our customers. Royalties did not comprise a material amount of our revenue during any of the periods presented. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cell Engineering revenue has historically included transactions with Platform Ventures and Legacy Structured Partnerships where we received non-cash consideration in the form of equity interests and financial instruments that are convertible into equity upon a triggering event.  We view the upfront non-cash consideration as prepayments for licenses which will be granted in the future as we complete mutually agreed upon technical development plans. In these instances, we also receive cash consideration for the R&amp;D services performed by us on a fixed fee or cost-plus basis. We are not compensated through additional milestone or royalty payments under these arrangements. As we perform R&amp;D services under the mutually agreed upon development plans, we recognize a reduction in the prefunded obligation on a cost-plus basis. In some cases we issued the customer a prepaid Cell Engineering services credit in exchange for the upfront non-cash consideration, which can and has been drawn down as payment for R&amp;D services performed under mutually agreed upon development plans. These arrangements are further described in Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_154">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_157">8</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_190">1</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_190">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Options to acquire additional distinct goods and services are evaluated to determine if such options provide a material right to the customer that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which is accounted for as a separate contract upon the customer&#8217;s election of the option. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. Any upfront cash payment received upon consummation of the contract is fixed and generally nonrefundable. Variable consideration is subject to a constraint, and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. This is attained when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursement for costs incurred for the Company&#8217;s research and development efforts, milestone payments upon the achievement of certain technical and/or commercial criteria, and royalties on sales of products from or comprising engineered organisms arising from the contract. With respect to the research and development reimbursements and milestone payments, the Company uses the most likely amount method to estimate variable consideration. Milestone payments are generally not included in the transaction price until the milestone is achieved.</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-545-1" continuedAt="f-545-2"><ix:continuation id="f-501-8" continuedAt="f-501-9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain agreements include payment in the form of equity securities or other financial instruments that convert into equity upon a triggering event. Any non-cash consideration is measured at its estimated fair value at contract inception. For equity securities and financial instruments that are not actively traded, the estimated fair value is generally determined by referencing a recent financing round or utilizing a scenario-based valuation model. Significant unobservable inputs are used in these valuations, including expectations regarding future financings of the customer, scenario dates and probabilities, expected volatility, discount rates, and recovery rates. Changes in these assumptions can materially affect the fair value of the non-cash consideration and, consequently, the total revenue recognized for the contract. The Company did not have material non-cash consideration included in contracts entered into during  the years ended December&#160;31, 2025 and 2024, but does continue to recognize non-cash revenue from contracts originating in prior periods. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For agreements with promises that are combined into a single performance obligation, the entire transaction price is allocated to the single performance obligation. For agreements with multiple performance obligations, the transaction price is allocated to the performance obligations using the relative standalone selling price methodology. For agreements featuring variable consideration, the Company allocates variable consideration to one or more, but not all, performance obligations if certain conditions are met. Specifically, the Company assesses whether the variable consideration relates solely to its efforts to satisfy the performance obligation and whether allocating such variable consideration entirely to the performance obligation is consistent with the overall allocation objective. If these conditions are not met, the Company allocates the variable consideration based on the relative standalone selling price methodology. The key assumptions utilized in determining the standalone selling price for each performance obligation include development timelines, estimated research and development costs, commercial markets, likelihood of exercise (in the case of options considered to be material rights), and probabilities of success. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For agreements where licenses or assignments are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time when the license is effectively granted, as the licenses or assignments represent functional intellectual property. For agreements where licenses and research and development services are combined into a single performance obligation, the Company recognizes revenue over the performance period using the cost-to-cost method. This method measures progress based on the ratio of costs incurred to date to total estimated costs, as it best reflects the transfer of control to the customer for obligations satisfied over time. For automation sales the Company typically recognizes revenue at a point in time at which the hardware has been installed and passed acceptance testing at the customer site. The ongoing support services are recognized over time on a straight line basis over the related support period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its measure of progress to recognize revenue at each reporting period and, as necessary, adjusts the measure of progress and related revenue recognition. The Company&#8217;s measure of progress and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs to complete its performance obligations. The Company evaluates contract modifications and amendments to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis. The Company utilizes the right to invoice practical expedient when it has a right to consideration in an amount that corresponds directly with the value of the Company&#8217;s performance to date. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties are recognized as revenue when (or as) the later of the sales occurrence or the satisfaction (or partial satisfaction) of the related performance obligation. The Company has determined that applying this exception is appropriate when the license granted in the contract is the predominant item to which the royalties relate. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As the Company receives upfront payments for technical services under certain of its arrangements, the Company evaluates whether any significant financing components exist given the term over which the fees will be earned may exceed one year. Based on the nature of the Company&#8217;s agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing, but rather to secure technical services, exclusivity rights, and Foundry capacity, or the timing of transfer of those goods or services is at the discretion of the customer. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue represents consideration received by the Company in excess of revenue recognized and primarily results from transactions where the Company receives upfront cash payments or non-cash equity consideration. In instances where the Company has received consideration in advance for an undefined number of technical development plans (&#8220;TDPs&#8221;) under its customer agreements, the Company records the advance payments as deferred revenue, net of current portion on the consolidated balance sheet. Upon the execution of a specific TDP, the Company reclassifies the estimated consideration to be earned under that TDP within the next twelve months as current deferred revenue. The Company also classifies unexercised material rights related to future TDPs as deferred revenue, net of current portion on the consolidated balance </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-501-9" continuedAt="f-501-10"><ix:continuation id="f-545-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sheet. When a TDP is executed, and the material right is exercised, the amount allocated to the material right, which will be earned within the next twelve months, is reclassified to current deferred revenue. All other deferred revenue is classified as current or non-current based on the timing of when the Company expects to earn the underlying revenue based upon the projected progress of activities under the TDP. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2025 any costs to obtain contracts with customers were immaterial.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosecurity Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates Biosecurity revenue through its biomonitoring and bioinformatics services provided to both government and non-government customers through the Company's two core offerings: Canopy and Horizon.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2024, product revenue consisted of sales of lateral flow assay (&#8220;LFA&#8221;) diagnostic test kits, polymerase chain reaction (&#8220;PCR&#8221;) sample collection kits, and pooled test kits, which the Company sold to customers on a standalone basis. Product revenue was billed and recognized when the test kits were shipped, and risk of loss was transferred to the carrier. The Company&#8217;s test kits were generally not subject to a customer right of return except for product recalls under the rules and regulations of the U.S. Food and Drug Administration (&#8220;FDA&#8221;). The Company included shipping and handling fees billed to customers as a component of Biosecurity revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Biosecurity service revenue generally consists of various biomonitoring and bioinformatics services including, but not limited to, sample collection, sample storage and transportation, outsourced laboratory analysis, access to results reported through a web-based portal, analytical reporting of results, and overall program management. The various services are generally combined into one performance obligation as they are either not distinct or have substantially the same pattern of transfer to the customer. Service revenue is generally recognized over time using the time elapsed method as the related services are performed, which best depicts the pattern of transfer to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts with customers are generally three years or less in length and contain a fixed amount of consideration. Under typical payment terms for testing services, amounts are billed monthly in arrears for services performed or in advance based on contractual billing terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Options to acquire additional services are evaluated to determine whether they provide the customer with a material right that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer, and upon the customer's election of the option, it is accounted for as a separate contract.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-546" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Biosecurity Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The cost of Biosecurity service revenue consists of costs related to the Company's biomonitoring and bioinformatics services. This includes costs incurred for sample collection equipment, services and materials, outsourced laboratory analysis, access to results reported through a proprietary web-based portal, and reporting of results to public authorities. Additionally, the cost of Biosecurity service revenue includes direct labor cost associated with bioinformatics, lab network management, delivery logistics, and customer support. Prior to 2024, cost of Biosecurity product revenue consisted of costs associated with the sale of diagnostic and sample collection test kits, which included costs incurred to purchase test kits from third parties.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Other Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of other revenue consists of costs related to the Company's Cell Engineering tools offerings, including Datapoints and lab automation solutions. Such costs primarily include hardware, software, materials and labor. Costs related to the Company&#8217;s end-to-end cell engineering solutions offering in which the Company retains rights to intellectual property are included in research and development expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-547" continuedAt="f-547-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-547-1">Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects and initiatives, acquired intellectual property deemed to be in-process research and development, as well as fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-501-10" continuedAt="f-501-11"><ix:nonNumeric contextRef="c-1" name="dna:PatentCostsPolicyTextBlock" id="f-548" continuedAt="f-548-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-548-1">The Company expenses all costs as incurred in connection with the filing, prosecution, maintenance, defense, and enforcement of patent applications, including direct application fees and related legal and consulting expenses. Patent costs are included in general and administrative expenses within the consolidated statements of operations and comprehensive loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-549" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based awards based on estimated grant-date fair values recognized over the requisite service period. For awards that vest solely based on a service condition, the Company recognizes compensation expense on a straight-line basis over the requisite service period. For awards that vest based on multiple conditions, the Company recognizes compensation expense using the accelerated attribution method on a tranche-by-tranche basis over the requisite service period such that the amount of compensation expense recognized at each reporting period is at least equal to the vested tranches at that date. For awards with a performance-based vesting condition, the Company recognizes stock-based compensation when achievement of the performance condition is deemed probable. Upon achieving a performance condition that was not previously considered as probable, the Company records a cumulative catch-up adjustment to reflect the portion of the grantee&#8217;s requisite service that has been provided to date. For awards with market conditions, the compensation expense recognized over the requisite service period is not reversed if the market condition is not satisfied. The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model, inclusive of assumptions for expected term, expected volatility, risk-free interest rate and expected dividend yield. The expected term is determined using the &#8220;simplified&#8221; method, which estimates the expected term as the average of the vesting term plus the contractual term. The Company uses the &#8220;simplified&#8221; method as it does not have sufficient historical data regarding employee exercise behavior. Expected volatility is based on the historical volatility of the Company's Class A common stock. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the stock options. The Company has not paid, and does not expect to pay, dividends in the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For awards with market conditions, the Company recognizes stock-based compensation based on the estimated grant-date fair value of the awards, determined using a Monte Carlo simulation model. This model incorporates assumptions for expected stock price volatility, risk-free interest rates, expected term, and expected dividend yield. Volatility is estimated using either the historical volatility of the Company&#8217;s Class A common stock or a weighted average of its own historical volatility and the historical volatility of selected comparable publicly traded companies, particularly for awards granted when there was limited trading history for the Company&#8217;s Class A common stock. The risk-free interest rate is derived from the yield on U.S. Treasury zero-coupon securities with a duration similar to the expected term of the awards. The expected term equals the contractual term, and a dividend yield of zero is assumed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-550" continuedAt="f-550-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies. </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-550-1">The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an annual basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</ix:continuation> As of December&#160;31, 2025 and 2024, the Company did <ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-551"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-552">no</ix:nonFraction></ix:nonFraction>t have any uncertain tax positions.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-501-11"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, a budget and reconciliation package known as the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law in the United States. Among other provisions, the OBBBA amends U.S. tax law including the permanent extension of certain expiring provisions of the 2017 Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The OBBBA did not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-553" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gains on available-for-sale securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-554" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share by dividing the net loss attributable to Ginkgo Bioworks Holdings, Inc. common stockholders by the weighted average number of common shares outstanding during the period. For the purposes of the net loss per share calculation, the Company has combined Class A common stock, Class B common stock, and Class C common stock, as all classes of common stock are legally entitled to equal per-share distributions, whether through dividends or liquidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is computed using the weighted average number of common shares outstanding during the period, increased to include the effect of dilutive potential common shares, such as outstanding stock options, unvested restricted stock awards, unvested restricted stock units, warrants, and contingently issued shares. Dilutive securities are excluded from the calculation of diluted weighted average common shares outstanding if their effect would be anti-dilutive under the treasury stock method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-555" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which focuses on improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this ASU require that public business entities on an annual basis (1) disclose specific categories in the tabular rate reconciliation, using both percentages and reporting currency amounts, and (2) provide additional information for reconciling items that meet a quantitative threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company adopted this standard on January 1, 2025 using the prospective method. The adoption did not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This ASU requires public business entities to disaggregate, on both an interim and annual basis, each relevant expense caption presented on the face of the income statement into specific expense categories. Additionally, entities are required to provide a qualitative description of amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, as well as disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this ASU will have on its disclosures in the consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_575"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-557" continuedAt="f-557-1" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="f-557-1" continuedAt="f-557-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, in connection with the Company&#8217;s plans to reduce operational expenditures, management, with the approval of the Board of Directors, approved and commenced a restructuring plan. This plan includes a reduction in labor expenses, primarily through a workforce reduction of more than <ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="dna:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" scale="-2" id="f-558">50</ix:nonFraction>%, and the consolidation and subleasing of certain facilities. Initial workforce reductions commenced in June 2024 and continued throughout 2025. All reductions were substantially complete in 2025. The Company has consolidated certain facilities through various actions, including </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-557-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">combining office and laboratory operations into fewer locations, subleasing unused or underutilized facilities, and has taken or plans to take other related measures, such as the sale of its subsidiary, Altar, in the third quarter of 2024 (see Note </span><span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_148">4</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). While the Company completed the majority of its facility consolidation actions in 2025 we continue to look for opportunities for subleasing unused or underutilized facilities, which will extend beyond 2026 or may not occur prior to termination of such lease, depending on market conditions. Additionally, restructuring expenses related to potential asset impairments or contract amendments or terminations for any facilities no longer in use or underutilized could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The costs for the reduction in force are expected to range from $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="f-559">31.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="f-560">32.0</ix:nonFraction>&#160;million primarily in the Cell Engineering segment and consist of cash severance and related costs. The employee termination costs are recognized as of the communication date to employees, given (i) the Company instituted a one-time employee termination benefit related to its restructuring, and (ii) the employees will not be retained to render service beyond a minimum retention period. The Company is currently unable to estimate the costs associated with consolidating its facilities. These costs may include, but are not limited to, losses on subleases, contract terminations, asset impairments, sale or disposal of equipment or other long-lived assets, and related costs and fees pertaining to the consolidation, closure, or disposition of facilities. Additional charges may be incurred as the Company progresses its restructuring plan and such charges could be material.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-561" continuedAt="f-561-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents restructuring costs incurred during the years ended December&#160;31, 2025 and 2024, which are recorded as &#8220;Restructuring charges&#8221; in the consolidated statements of operations and comprehensive loss (in thousands):&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.333%"><tr><td style="width:1.0%"/><td style="width:53.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-562">Employee termination costs and other</span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-563">11,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-564">19,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impairment of right-of-use asset (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-566">4,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total restructuring</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-567">11,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-568">24,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">1) Relates to the sublease of a facility in connection with the restructuring and reflects the excess of the right-of-use asset's carrying value over its fair value, which was determined based on estimates of future discounted cash flows and is classified as Level 3 in the fair value hierarchy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-569">7.0</ix:nonFraction> million loss on the sale and deconsolidation of Altar as a component of other income (expense) in the consolidated statements of operations and comprehensive loss for year ended December 31, 2024.</span></div><ix:continuation id="f-561-1"><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the change in the accrued liability balance related to the restructuring activities, which is included in &#8220;Accounts payable&#8221; and &#8220;Accrued expenses and other current liabilities&#8221; in the accompanying consolidated balance sheet as of December&#160;31, 2025 (in thousands):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.333%"><tr><td style="width:1.0%"/><td style="width:63.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Employee Termination Costs and Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Liability balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-570">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expenses incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-571">11,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-572">11,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Liability balance at December 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-573">2,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_148"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-574" continuedAt="f-574-1" escape="true">Acquisitions and Divestitures</ix:nonNumeric></span></div><ix:continuation id="f-574-1" continuedAt="f-574-2"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024 AgBiome Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2024, the Company acquired certain platform assets, including fully sequenced and isolated strains, unique gene sequences, relevant functional data and metadata, and a development pipeline from AgBiome, Inc. (&#8220;AgBiome&#8221;), a biotechnology company in the agriculture industry. These assets expanded the Company&#8217;s proprietary unified metagenomics database. The fair value of the consideration transferred totaled $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="f-575">18.2</ix:nonFraction>&#160;million and was paid with the issuance of <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-576">407,240</ix:nonFraction> shares of Ginkgo's Class A common stock. The Company accounted for the transaction as an asset </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-574-2" continuedAt="f-574-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">acquisition since substantially all of the value received was concentrated in the acquired developed technology, which is being amortized over a useful life of <ix:nonNumeric contextRef="c-85" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-577">three years</ix:nonNumeric>.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024 Other Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed <ix:nonFraction unitRef="materialright" contextRef="c-8" decimals="INF" name="dna:AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" format="ixt-sec:numwordsen" id="f-578">three</ix:nonFraction> other asset acquisitions during the year ended December 31, 2024. The aggregate purchase price for the <ix:nonFraction unitRef="materialright" contextRef="c-8" decimals="INF" name="dna:AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" format="ixt-sec:numwordsen" id="f-579">three</ix:nonFraction> acquisitions was $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="f-580">19.8</ix:nonFraction>&#160;million and was paid with the issuance of <ix:nonFraction unitRef="shares" contextRef="c-87" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-581">394,799</ix:nonFraction> shares of Ginkgo&#8217;s Class A common stock. Each transaction was accounted for as an asset acquisition as the acquired assets, consisting primarily of intellectual property rights, did not meet the definition of a business. The assets acquired represent in-process research and development with no alternative future use. Accordingly, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-582">19.8</ix:nonFraction>&#160;million as acquired in-process research and development expense in the accompanying consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2023 StrideBio Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, the Company entered into an Asset Purchase Agreement (&#8220;APA&#8221;) with StrideBio, Inc. (&#8220;StrideBio&#8221;) to acquire StrideBio&#8217;s adeno-associated virus capsid discovery and engineering platform assets, with a secondary closing contingent upon the transfer of certain additional in-license agreements to Ginkgo. The secondary closing was finalized in October 2023. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identifiable asset. The fair value of the consideration transferred totaled $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="f-583">7.6</ix:nonFraction>&#160;million and consisted of <ix:nonFraction unitRef="shares" contextRef="c-89" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-584">119,278</ix:nonFraction> shares of Ginkgo&#8217;s Class A common stock valued at $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="f-585">6.8</ix:nonFraction>&#160;million and a $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-586">0.8</ix:nonFraction>&#160;million contingent holdback, all of which was expensed as in-process research and development during the year ended December 31, 2023. On May 9, 2025, we issued a total of <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-587">102,922</ix:nonFraction> shares of our Class A common stock to StrideBio, Inc., in settlement of the $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-588">0.8</ix:nonFraction>&#160;million contingent holdback amount. The APA, as amended, also provides for royalty payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:PaymentsForRoyalties" scale="6" id="f-589">21.3</ix:nonFraction>&#160;million as described in Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_172">12</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2023 Zymergen Bankruptcy and Deconsolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2023, the Company&#8217;s former subsidiary, Zymergen, Inc. (&#8220;Zymergen&#8221;), and certain of its subsidiaries filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code (the &#8220;Zymergen Bankruptcy&#8221;) in the U.S. Bankruptcy Court for the District of Delaware (&#8220;Bankruptcy Court&#8221;). Neither the Company nor any of its other subsidiaries filed for bankruptcy protection. Zymergen had been operated as a distinct legal entity, separate and apart from the Company, since it was acquired in October 2022. Shortly after its acquisition, the Company entered into a non-exclusive license with Zymergen with respect to Zymergen&#8217;s intellectual property, including its databases, automation, and software capabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Zymergen Bankruptcy, also on October 3, 2023, the Company entered into an asset purchase agreement with Zymergen (the &#8220;Zymergen APA&#8221;) as the stalking horse bidder under Section 363 of the U.S. Bankruptcy Code to acquire exclusive rights to substantially all of Zymergen&#8217;s intellectual property assets and certain other assets. The Company&#8217;s bid included a $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:AssetAcquisitionPriceOfAcquisitionExpected" scale="6" id="f-590">6.2</ix:nonFraction>&#160;million cash component, assumption of a facility lease (previously included in the Company's consolidated financial statements prior to Zymergen's deconsolidation discussed below), and acquiring Zymergen's workforce. On December 14, 2023, Zymergen concluded its auction. On December 21, 2023, the Bankruptcy Court approved the sale of substantially all of Zymergen&#8217;s assets to the Company through certain of the Company's affiliates as contemplated by the Zymergen APA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While as of December 31, 2023, Zymergen remained a wholly-owned subsidiary of the Company, as a result of the bankruptcy proceedings, the Company no longer had a controlling financial interest over Zymergen as defined under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and therefore deconsolidated Zymergen&#8217;s financial position as of October 2, 2023. The deconsolidation included the derecognition of the carrying amounts of Zymergen&#8217;s consolidated assets and liabilities that were previously included in the Company&#8217;s consolidated financial statements. Upon deconsolidation, the Company recorded a loss of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" sign="-" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="f-591">42.5</ix:nonFraction>&#160;million, representing the remaining net book value of the Company&#8217;s investment that was reduced to a fair value of <ix:nonFraction unitRef="usd" contextRef="c-94" decimals="INF" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:fixed-zero" scale="0" id="f-592">zero</ix:nonFraction>. Subsequent to the deconsolidation, the Company accounted for its investment in Zymergen using the cost method of accounting, which was recorded at <ix:nonFraction unitRef="usd" contextRef="c-95" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-593">zero</ix:nonFraction> in the Company&#8217;s consolidated balance sheet as of December 31, 2023. Zymergen&#8217;s results of operations were removed from the Company&#8217;s consolidated statements of operations and comprehensive loss beginning October 3, 2023. The historical financial results for Zymergen have not been classified as a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-574-3" continuedAt="f-574-4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">discontinued operation because it does not represent a strategic shift with a major effect on the Company's operations and financial results.</span></div><ix:nonNumeric contextRef="c-1" name="dna:DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock" id="f-594" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents Zymergen&#8217;s consolidated assets and liabilities which have been deconsolidated from the Company's consolidated balance sheet as of October 2, 2023. The amounts presented are before the elimination of intercompany balances.</span></div><div><span><br/></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.636%"><tr><td style="width:1.0%"/><td style="width:73.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">October 2, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-595">34,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-596">11,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-597">11,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-598">56,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-599">8,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="dna:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-600">135,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-601">16,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" format="ixt:num-dot-decimal" scale="3" id="f-602">10,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-603">19,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-604">248,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" scale="3" id="f-605">730</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-606">20,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-607">21,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="dna:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-608">184,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="3" id="f-609">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-610">205,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Net assets deconsolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="dna:DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-611">42,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents Zymergen&#8217;s results of operations for the periods presented, included in the Company's consolidated statements of operations and comprehensive loss prior to the elimination of intercompany balances.</span></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"/><td style="width:53.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Period from January 1, 2023 - October 2, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-612">8,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-613">200,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-614">192,605</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-615">23,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-616">168,985</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="f-617">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-618">168,999</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transactions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the deconsolidation, the Company had an existing employee leasing arrangement with Zymergen. The employee leasing charges were considered intercompany transactions and were eliminated in the Company's consolidated financial statements. As of the deconsolidation date, the employee leasing charges were considered related party transactions and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-574-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have been recognized in the Company's consolidated financial statements. Employee lease expense totaled $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dna:EmployeeLeaseExpense" scale="6" id="f-619">4.9</ix:nonFraction>&#160;million for the period from October 3, 2023 to December 31, 2023, and was immaterial during fiscal 2024. The Company had $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="f-620">1.7</ix:nonFraction>&#160;million due to Zymergen as of December 31, 2023, included in accrued expenses and other current liabilities on the balance sheet. This amount was subsequently paid in fiscal 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024 Zymergen Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2024, the Company, through certain of its affiliates, completed its acquisition of substantially all of Zymergen&#8217;s assets under the Zymergen APA, including offering employment to <ix:nonFraction unitRef="employee" contextRef="c-99" decimals="INF" name="dna:NumberOfEmployeesAcquired" scale="0" id="f-621">91</ix:nonFraction> of Zymergen&#8217;s employees. On February 5, 2024, Zymergen&#8217;s plan of liquidation was confirmed by the Bankruptcy Court. All of the Company&#8217;s interests in the Zymergen entities were extinguished and terminated as of February 23, 2024. The acquisition under the Zymergen APA was accounted for as a business combination in accordance with ASC 805,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and was not material to the Company's consolidated financial statements. The total cash purchase price was $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="f-622">6.2</ix:nonFraction>&#160;million, with $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="f-623">5.4</ix:nonFraction>&#160;million paid at closing and $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" scale="6" id="f-624">0.8</ix:nonFraction>&#160;million released from escrow. The allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date primarily includes $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="dna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="6" id="f-625">19.9</ix:nonFraction>&#160;million of operating lease right-of-use assets, $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="f-626">6.0</ix:nonFraction>&#160;million of property and equipment, and $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="f-627">19.9</ix:nonFraction>&#160;million of operating lease liabilities. No goodwill or intangible assets were recognized. Transaction costs associated with the Zymergen APA were <ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="0" id="f-628">not</ix:nonFraction> material for the year ended December 31, 2024. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024 Altar Divestiture</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2024, the Company sold the equity interests of Altar for a nominal amount. As a result of the sale, the Company deconsolidated all of Altar's assets and liabilities from its consolidated financial statements effective September 30, 2024, and recognized a loss on deconsolidation of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-629">7.0</ix:nonFraction>&#160;million in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. The loss on deconsolidation includes a $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="6" id="f-630">1.5</ix:nonFraction>&#160;million reclassification of accumulated currency translation adjustments to earnings. The sale did not meet the criteria to be reported as a discontinued operation.</span></div></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_151"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-631" continuedAt="f-631-1" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-632" continuedAt="f-632-1" escape="true"><ix:continuation id="f-631-1" continuedAt="f-631-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands): </span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-631-2" continuedAt="f-631-3"><ix:continuation id="f-632-1" continuedAt="f-632-2"><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"><tr><td style="width:1.0%"/><td style="width:42.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-633">146,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-634">146,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-637">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-639">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-641">118,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-642">118,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-645">114,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-647">114,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-649">18,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-650">18,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Synlogic, Inc. warrants </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="f-653">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="f-655">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-657">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-658">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-661">7,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:ReceivablesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-662">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:ReceivablesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:ReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-664">7,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-665">410,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-666">284,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-667">118,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-668">7,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-669">5,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-672">5,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="f-673">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="f-676">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-677">5,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-680">5,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"><tr><td style="width:1.0%"/><td style="width:42.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-681">521,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-682">521,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Synlogic, Inc. warrants </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="f-685">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="f-687">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-689">17,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-690">17,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-693">14,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:ReceivablesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-694">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:ReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-695">12,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:ReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-696">1,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-697">553,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-698">539,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-699">12,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-700">1,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-701">5,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-702">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-704">5,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-705">4,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-708">4,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-709">9,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-712">9,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><ix:continuation id="f-632-2" continuedAt="f-632-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"><ix:continuation id="f-632-3">The fair value of Synlogic, Inc. warrants is calculated as the quoted price of the underlying common stock, less the unpaid exercise price of the warrants.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. In 2025 and 2024, transfers from Level 2 to Level 1 occurred due to lapse of regulatory </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-631-3" continuedAt="f-631-4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales restrictions on marketable equity securities. During 2025, transfers into Level 3 consisted of a note receivable that was transferred from Level 2 to Level 3 upon a change in valuation technique. Additionally, in 2024, a portion of the Private Placement Warrants' estimated fair value was transferred from Level 3 to Level 2 as a result of the Private Placement Warrants having substantially the same terms as the Public Warrants when transferred to anyone other than the initial purchasers or their permitted transferees, leading the Company to determine their fair value to be equivalent to that of the Public Warrants. There were no other transfers between Levels 1, 2, or 3 during 2025 or 2024. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-713" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a reconciliation of the beginning and ending balances for assets and liabilities measured at fair value using Level 3 significant unobservable inputs for the years ended December 31 (in thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"/><td style="width:43.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.516%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.516%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Notes Receivable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Private Placement Warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-714">1,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-716">9,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="3" id="f-717">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="f-720">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-722">4,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="3" id="f-723">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="f-724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="f-725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:num-dot-decimal" scale="3" id="f-726">6,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" format="ixt:fixed-zero" scale="3" id="f-727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" format="ixt:fixed-zero" scale="3" id="f-728">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Conversion to preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" sign="-" name="dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" format="ixt:num-dot-decimal" scale="3" id="f-729">1,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" format="ixt:fixed-zero" scale="3" id="f-730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" format="ixt:fixed-zero" scale="3" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-732">7,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-734">5,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-735">14,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-736">1,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-737">24,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="f-738">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-740">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="0" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="f-741">3,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="0" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-742">1,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-743">3,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="3" id="f-744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="f-745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="0" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-746">17,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transfers to Level 2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="3" id="f-747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" scale="3" id="f-748">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" format="ixt:fixed-zero" scale="3" id="f-749">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Conversion to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" sign="-" name="dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" format="ixt:num-dot-decimal" scale="3" id="f-750">10,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" format="ixt:fixed-zero" scale="3" id="f-751">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" format="ixt:fixed-zero" scale="3" id="f-752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-753">1,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-755">9,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notes Receivable</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For all of its notes receivable, the Company has elected the fair value option, for which changes in fair value are recorded in other (expense) income, net in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025 and 2024, the Company's notes receivable includes a senior secured note in the original principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:FinancingReceivableSignificantPurchases" scale="6" id="f-756"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:FinancingReceivableSignificantPurchases" scale="6" id="f-757">11.8</ix:nonFraction></ix:nonFraction>&#160;million, issued by Bolt Threads, Inc. (&#8220;Bolt Threads&#8221;), which bears interest at <ix:nonFraction unitRef="number" contextRef="c-166" decimals="2" name="dna:FinancingReceivableInterestRateStatedPercentage" scale="-2" id="f-758">12</ix:nonFraction>% per annum, is due December 31, 2027, and is included in other non-current assets at its estimated fair value. The Company used a discounted cash flow model to estimate the fair value of the senior secured note, incorporating significant unobservable inputs such as the recovery rate, a risk-adjusted discount rate, and a potential settlement scenario. These inputs reflect the Company&#8217;s own assumptions and was reclassified as a Level 3 measurement within the fair value hierarchy during the year ended December 31, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also holds a series of convertible debt instruments issued by customers as payment for Cell Engineering services. The Company used a scenario-based method to value the convertible debt instruments issued by customers and by Bolt Threads prior to conversion. Under this method, future cash flows are evaluated under various payoff scenarios, probability-weighted, and discounted to present value. The significant unobservable (Level 3) inputs used in the fair value measurement as of December&#160;31, 2025 included scenario probabilities ranging from <ix:nonFraction unitRef="number" contextRef="c-167" decimals="2" name="dna:FinancingReceivableMeasurementInput" scale="-2" id="f-759">5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-168" decimals="2" name="dna:FinancingReceivableMeasurementInput" scale="-2" id="f-760">45</ix:nonFraction>%, a discount rate of <ix:nonFraction unitRef="number" contextRef="c-169" decimals="3" name="dna:FinancingReceivableMeasurementInput" scale="-2" id="f-761">15.5</ix:nonFraction>% and estimated time to event date of up to <ix:nonNumeric contextRef="c-170" name="dna:FinancingReceivableMeasurementInputPeriod" format="ixt-sec:durmonth" id="f-762">5</ix:nonNumeric> months. The significant unobservable (Level 3) inputs used in the fair value measurement as of December&#160;31, 2024 included scenario probabilities ranging from <ix:nonFraction unitRef="number" contextRef="c-171" decimals="2" name="dna:FinancingReceivableMeasurementInput" scale="-2" id="f-763">5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-172" decimals="2" name="dna:FinancingReceivableMeasurementInput" scale="-2" id="f-764">45</ix:nonFraction>%, a discount rate of <ix:nonFraction unitRef="number" contextRef="c-173" decimals="3" name="dna:FinancingReceivableMeasurementInput" scale="-2" id="f-765">15.5</ix:nonFraction>% and estimated time to event date of up to <ix:nonNumeric contextRef="c-174" name="dna:FinancingReceivableMeasurementInputPeriod" format="ixt-sec:durwordsen" id="f-766">two years</ix:nonNumeric>. Significant changes in these inputs could have resulted in a significantly lower or higher fair value measurement. As of December&#160;31, 2025, the convertible debt instruments had an unpaid principal balance of $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-767">9.7</ix:nonFraction> million and a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-768">0.5</ix:nonFraction>&#160;million. As of December&#160;31, 2024, the convertible debt instruments had an unpaid principal balance of $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-769">13.2</ix:nonFraction> million and a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-770">1.8</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-631-4" continuedAt="f-631-5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="f-771">1.5</ix:nonFraction>&#160;million in principal related to a convertible note issued by a customer was converted into <ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-772">10,564</ix:nonFraction> shares of the entity's preferred stock, which, as a new private company investment, has been classified as an investment on the balance sheet as of December&#160;31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company's merger with Soaring Eagle Acquisition Corp. (&#8220;SRNG&#8221;) on September 16, 2021 (&#8220;SRNG Business Combination&#8221;), the Company assumed <ix:nonFraction unitRef="shares" contextRef="c-178" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="f-773">34.5</ix:nonFraction>&#160;million warrants (formerly traded on the New York Stock Exchange (the &#8220;NYSE,&#8221; and such warrants, the &#8220;Public Warrants&#8221;) and <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="f-774">17.3</ix:nonFraction>&#160;million private placement warrants (the &#8220;Private Placement Warrants&#8221;, and together with the Public Warrants, the &#8220;Warrants&#8221;), which were initially issued in connection with SRNG&#8217;s initial public offering. The number of outstanding Warrants did not change as a result of the Reverse Stock Split. However, each Warrant equals one-fortieth (1/40) of one share of Class A common stock (a minimum of <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="dna:ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum" scale="0" id="f-775">40</ix:nonFraction> Warrants must be exercised for <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt-sec:numwordsen" id="f-776">one</ix:nonFraction> share of Class A common stock) following the Reverse Stock Split.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Public Warrants was based on their observable quoted price on the NYSE. However, the Public Warrants were delisted by the NYSE on September 4, 2024, due to abnormally low selling price levels, and subsequently began trading on the over-the-counter markets. As of December&#160;31, 2025  and 2024, the Company determined that the Public Warrants had no value.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement Warrants are identical to the Public Warrants, except that they are exercisable on a cashless basis and are non-redeemable as long as they are held by the initial purchasers or their permitted transferees. As of December&#160;31, 2025, the Company concluded that the difference between the fair values of the Public Warrants and Private Placement Warrants was de minimis. Therefore, the Private Placement Warrants were measured by reference to the value of the Public Warrants and had no value. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various business acquisitions, the Company is required to make contingent earnout payments payable upon the achievement of certain technical, commercial and/or performance milestones. The Company also issued restricted stock in connection with acquisitions, which is subject to vesting conditions and is classified as contingent consideration liability.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company can settle a majority of its contingent consideration liabilities in cash or shares of Class A common stock at the Company&#8217;s election with the remainder payable in cash. During the year ended December&#160;31, 2025, no contingent consideration liabilities were settled. During the year ended December&#160;31, 2024, the Company settled $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-777">17.6</ix:nonFraction> million in contingent consideration liabilities through payment of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="f-778">2.8</ix:nonFraction> million in cash and vesting of <ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-779">1,413,909</ix:nonFraction> shares of restricted stock valued at $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="dna:BusinessCombinationContingentConsiderationVestedValue" scale="6" id="f-780">14.7</ix:nonFraction> million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration related to earnout payments from acquisitions was estimated using unobservable (Level 3) inputs as illustrated in the table below. The fair value of contingent consideration related to restricted stock was estimated using the quoted price of Ginkgo's Class A common stock, an estimate of the number of shares expected to vest, probability of vesting, and a discount rate. Material increases or decreases in these inputs could result in a higher or lower fair value measurement. Changes in the fair value of contingent consideration are recorded in general and administrative expense in the consolidated statements of operations and comprehensive loss.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-781" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides quantitative information regarding Level 3 inputs used in the fair value measurements of contingent consideration liabilities as of the periods presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2025<br/>Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024<br/>Range</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Earnout payments (FGen and Dutch DNA acquisitions)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Probability-weighted present value</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Probability of payment</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate" scale="-2" id="f-782">5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-184" decimals="2" name="us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate" scale="-2" id="f-783">10</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-185" decimals="2" name="us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate" scale="-2" id="f-784">5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-186" decimals="2" name="us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate" scale="-2" id="f-785">50</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-187" decimals="3" name="us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate" scale="-2" id="f-786">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-188" decimals="3" name="us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate" scale="-2" id="f-787">9.3</ix:nonFraction>% </span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Earnout payments (Dutch DNA acquisition) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Projected years of payments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2028-2031</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-189" decimals="3" name="us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate" scale="-2" id="f-788">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1) During the year ended December&#160;31, 2025, all Dutch DNA milestones valued using the discounted cash flow method were reduced to zero due to the termination of a customer agreement to which those milestones were tied.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-631-5"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of certain assets, including investments in privately held companies without readily determinable fair values, on a nonrecurring basis when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, or when observable price changes occur for identical or similar securities from the same issuer.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of non-marketable equity securities is classified as Level 3 within the fair value hierarchy when the Company estimates fair value using unobservable inputs to measure an impairment loss. It is classified as Level 2 when fair value is estimated using the observable transaction price paid by third-party investors for an identical or similar security of the same issuer.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Impairments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" scale="6" id="f-789">2.7</ix:nonFraction>&#160;million downward adjustment from an observable price change related to one of its investments in non-marketable equity securities. Additionally, during the year ended December&#160;31, 2025, the Company recorded an impairment of $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" scale="6" id="f-790">1.8</ix:nonFraction>&#160;million due to a significant deterioration in the liquidity of one of its investments in non-marketable equity securities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024, and 2023, the Company recorded impairment losses of $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" scale="6" id="f-791">11.9</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" scale="6" id="f-792">33.0</ix:nonFraction>&#160;million, respectively, related to its investment in Genomatica preferred stock. The fair value estimates used to determine the impairment charges in 2023 were derived using the guideline public company method under the market approach. Significant unobservable (Level 3) inputs included estimated annual net cash flows (including revenue and expense growth rates and capitalization rates), the weighted-average cost of capital used to discount future cash flows, and the selection of guideline public company multiples for revenue and EBITDA. Material increases or decreases in these inputs could result in higher or lower fair value measurements. As of December 31, 2024, the Company determined that the investment had substantially no value. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024 and 2023, the Company recorded impairment losses of $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" scale="6" id="f-793">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" scale="6" id="f-794">8.3</ix:nonFraction>&#160;million, respectively, related to an investment in the preferred stock of a privately held company. The fair value as of December 31, 2023 was determined by deriving the investee&#8217;s equity value from a 2021 financing transaction involving its own securities and applying an <ix:nonFraction unitRef="number" contextRef="c-193" decimals="2" name="dna:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage" scale="-2" id="f-795">87</ix:nonFraction>% downward market adjustment to the implied equity value. The equity value was then allocated to the different classes of the securities of the investee using the option-pricing model (&#8220;OPM&#8221;). The OPM involves making assumptions around the investees&#8217; expected time to liquidity and volatility derived from selected guideline public companies. These assumptions are considered Level 3 inputs. As of December 31, 2024, the Company determined that the investment had substantially no value.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SAFEs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company received a total purchase amount of $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-796">11.0</ix:nonFraction>&#160;million in SAFEs from customers as prepayment for Cell Engineering services. The Company used a scenario-based method to value the SAFEs as of each contract inception date, which resulted in total fair value of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations" scale="6" id="f-797">4.5</ix:nonFraction>&#160;million for SAFEs received during the year ended December 31, 2023. Under the scenario-based method, future cash flows were evaluated under qualified financing and dissolution scenarios with partial recovery and no recovery in dissolution. The cash flows under each scenario were probability-weighted and discounted to present value. The significant unobservable (Level 3) inputs used in the fair value measurement at contract inception during 2023 were scenario probabilities in the range of <ix:nonFraction unitRef="number" contextRef="c-197" decimals="2" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="f-798">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-198" decimals="2" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="f-799">60</ix:nonFraction>%, a discount rate of <ix:nonFraction unitRef="number" contextRef="c-199" decimals="2" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="f-800">14</ix:nonFraction>% and estimated time to event date of <span style="-sec-ix-hidden:f-801">one</span> to <ix:nonNumeric contextRef="c-201" name="dna:EquitySecuritiesFVNIMeasurementInputTerm" format="ixt-sec:durwordsen" id="f-802">two years</ix:nonNumeric>. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2025 and 2024, the Company recorded impairment losses of $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" scale="6" id="f-803">14.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" scale="6" id="f-804">7.2</ix:nonFraction> million, respectively, related to SAFEs. The fair values were generally estimated using the scenario-based method, where various payout scenarios were probability-weighted and discounted to present value.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the years ended December 31, 2024, the Company recorded an impairments of lab equipment, construction in progress assets, and assets related to an operating lease. Refer to Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_169">11</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional detail.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-29</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_21990232556947"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-806" continuedAt="f-806-1" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="f-806-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-807" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities, including those classified in cash and cash equivalents, are summarized as follows (in thousands):</span></div><div style="margin-top:6pt;padding-right:-13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-808">117,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="f-809">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="f-810">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-811">118,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-812">114,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="f-813">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="f-814">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-815">114,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-816">4,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="f-817">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="f-818">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-819">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="0" id="f-820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" format="ixt:fixed-zero" scale="0" id="f-821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="0" id="f-822">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-823">18,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-824">236,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="f-825">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="f-826">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-827">255,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-828" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable debt securities are summarized below by contractual maturity dates (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.333%"><tr><td style="width:1.0%"/><td style="width:41.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-829">205,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-830">205,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-831">31,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-832">31,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_154"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="f-833" continuedAt="f-833-1" escape="true">Investments and Equity Method Investments </ix:nonNumeric></span></div><ix:continuation id="f-833-1" continuedAt="f-833-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has partnered with other investors to form business ventures, including Motif FoodWorks, Inc. (&#8220;Motif&#8221;), Allonnia, LLC (&#8220;Allonnia&#8221;), Arcaea, LLC (&#8220;Arcaea&#8221;), Verb Biotics, LLC (&#8220;Verb Biotics&#8221;), BiomEdit, LLC (&#8220;BiomEdit&#8221;) and Ayana Bio, LLC (&#8220;Ayana Bio&#8221;) (collectively &#8220;Platform Ventures&#8221;). The Company has also partnered with existing entities, including Genomatica, Inc. (&#8220;Genomatica&#8221;) and Synlogic, Inc. (&#8220;Synlogic&#8221;) (collectively, &#8220;Legacy Structured Partnerships&#8221;) with complementary assets for synthetic biology applications. The Company holds equity interests in these Platform Ventures and Legacy Structured Partnerships. The Company also holds equity interests in other public and private companies as a result of entering into collaboration and license revenue arrangements with these entities. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its investments in Platform Ventures under the equity method. The Company's marketable equity securities consist of Synlogic common stock, Synlogic warrants and the shares of common stock of other publicly traded companies. Marketable equity securities are measured at fair value with changes in fair value recorded in other income (expense) in the consolidated statements of operations and comprehensive loss. The Company&#8217;s non-marketable equity securities consist of preferred stock of Genomatica and preferred and common stock of other privately held companies without readily determinable fair values. Non-marketable equity securities are initially recorded using the measurement alternative at cost and subsequently adjusted for any impairment and observable price changes in orderly transactions for the identical or a similar security of the same issuer. Impairment losses and adjustments from observable price changes are recorded in loss on investments in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also holds investments in early-stage synthetic biology product companies via SAFEs. The Company entered into SAFE agreements in conjunction with a revenue contract with a customer under which the Company grants the customer a prepaid Cell Engineering services credit equal to the principal amount of the SAFE (the &#8220;Purchase Amount&#8221;), which may be used and drawn down as payment for the Company&#8217;s research and development services. The SAFEs will automatically convert into shares of preferred stock equal to the Purchase Amount divided by the discount price, which is calculated as the price per share sold in a qualified equity financing multiplied by a discount rate. The SAFEs also provide the Company with the right to future equity of the entity in a liquidation scenario or the cash-out amount in liquidation and dissolution scenarios or at the election of the SAFE issuer prior to an agreed outside date. The Company initially records SAFEs at fair value (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_151">5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) and adjusts the carrying amount of the instrument at each reporting period for any impairments.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-833-2" continuedAt="f-833-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsTextBlock" id="f-834" continuedAt="f-834-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"/><td style="width:68.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Investments:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">SAFEs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-835">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-836">16,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-837">11,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-838">14,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-839">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-840">17,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Synlogic warrants</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="f-841">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="f-842">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-843">15,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-844">48,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable equity securities of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-845">18.7</ix:nonFraction> million are not restricted for sale and are included in marketable securities in the consolidated balance sheet as of December&#160;31, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on investments and equity method investments consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.727%"><tr><td style="width:1.0%"/><td style="width:56.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.721%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(Loss) gain on investments:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Genomatica preferred stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="f-846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-847">11,885</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-848">33,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-849">4,557</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-850">1,735</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-851">9,928</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-852">2,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-853">7,583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-854">7,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">SAFEs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-855">14,501</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-856">7,208</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-857">2,742</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Synlogic warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="f-858">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" scale="3" id="f-859">416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-860">1,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total loss on investments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-861">16,411</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-862">28,827</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-863">54,827</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Loss on equity method investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BiomEdit</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-864">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-866">1,461</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-869">1,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total loss on equity method investments</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-872">2,635</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GainLossOnInvestmentsTextBlock" id="f-873" continuedAt="f-873-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss on investments for each period were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-874">16,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-875">20,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-876">44,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized gains (losses) recognized on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-877">2,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-878">7,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-879">9,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Downward adjustments from observable price changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-880">2,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:fixed-zero" scale="3" id="f-881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-882">1,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total loss on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-883">16,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-884">28,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-885">54,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-833-3"><ix:continuation id="f-873-1"><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total realized and unrealized losses associated with equity investments accounted for at fair value or the fair value measurement alternative consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss recognized on equity investments sold </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-887">5,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses recognized on equity investments held as of the end of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-889">16,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-890">22,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-891">54,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total loss on investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-892">16,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-893">28,827</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-894">54,827</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1) Reflects the difference between the sale proceeds and the carrying value of the equity investments at the beginning of the period or the acquisition date, if later.</span></div></ix:continuation><ix:continuation id="f-834-1"><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of non-marketable equity securities accounted for using the fair value measurement alternative and still held as of December&#160;31, 2025, including cumulative unrealized losses, were as follows (in thousands):</span></div><div style="margin-top:10pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"/><td style="width:75.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total initial cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="f-895">109,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" format="ixt:num-dot-decimal" scale="3" id="f-896">91,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Downward adjustments from observable price changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="3" id="f-897">4,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-898">13,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_157"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-899" continuedAt="f-899-1" escape="true">Variable Interest Entities </ix:nonNumeric></span></div><ix:continuation id="f-899-1" continuedAt="f-899-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Company&#8217;s investments in Motif, Allonnia, Genomatica, Arcaea, BiomEdit, Verb Biotics, and Ayana Bio, the Company has concluded these entities represent VIEs. While the Company has board representation on certain of these entities and is involved in the ongoing development activities of these entities via its participation on such entities' JSC, the Company has concluded that it is not the primary beneficiary of these entities because: (i) the Company does not control the board of directors of any of the VIEs, and no voting or consent agreements exist between the Company and other members of each respective board of directors or other investors, (ii) the holders of preferred security interests in the VIEs hold certain rights that require their consent prior to taking certain actions, which include certain significant operating and financing decisions, and (iii) the Company&#8217;s representation on the JSC of each respective entity does not give it control over the development activities of any of the VIEs, as all JSC decisions are made by consensus and there are no agreements in place that would require any of the entities to vote in alignment with the Company. As the Company&#8217;s involvement in the VIEs does not give it the power to control the decisions with respect to their development or other activities, which are their most significant activities, the Company has concluded that it is not the primary beneficiary of the VIEs.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company holds equity interests in certain other privately-held companies that are not consolidated as the Company is not the primary beneficiary. As of December&#160;31, 2025 and 2024, the maximum risk of loss related to the Company&#8217;s unconsolidated VIEs was limited to the carrying value of its investments in such entities. </span></div></ix:continuation><div style="margin-top:10pt"><ix:continuation id="f-899-2" continuedAt="f-899-3"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_154">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_190">17</a></span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-899-3"> for additional details on the Company&#8217;s investments and equity method investments.</ix:continuation> </span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_160"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-900" continuedAt="f-900-1" escape="true">Goodwill and Intangible Assets, net </ix:nonNumeric></span></div><ix:continuation id="f-900-1" continuedAt="f-900-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, due to a sustained decrease in the market price of the Company's Class A common stock and market capitalization, the Company identified that an indicator of impairment was present during the second quarter of 2024. As such, the Company completed a quantitative impairment test related to its Cell Engineering reporting unit. To conduct the impairment test of goodwill, the estimated fair value of the reporting unit was compared to its carrying value. The estimated fair value of the reporting unit was determined using a weighted approach that considered a discounted cash flow (&#8220;DCF&#8221;) model under the income approach and the guideline public company (&#8220;GPC&#8221;) method under the market approach. Significant inputs used in the DCF model included the projected future operating results of the reporting unit and the applicable discount rate, while inputs used in the GPC method consisted of a revenue multiple. The projected future operating results were based on historical experience and internal annual operating plans reviewed by management, extrapolated over the forecast period. The discount rate was determined using a weighted average cost of capital adjusted for risk factors specific to the reporting unit. The revenue multiple was based on the GPC method using comparable publicly traded company multiples of revenue for a group of benchmark companies. The DCF method was </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-900-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">weighted <ix:nonFraction unitRef="number" contextRef="c-7" decimals="2" name="dna:GoodwillImpairmentDCFWeight" scale="-2" id="f-901">75</ix:nonFraction>% and the GPC <ix:nonFraction unitRef="number" contextRef="c-7" decimals="2" name="dna:GoodwillImpairmentGPCWeight" scale="-2" id="f-902">25</ix:nonFraction>%. The fair value measurement of the reporting unit is classified as Level 3 in the fair value hierarchy because it involves significant unobservable inputs. The Company reconciled the resulting fair value of its reporting unit to the market capitalization of the Company to corroborate the fair value estimate used in the impairment test.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The result of the interim impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. As a result, the Company fully impaired goodwill and recorded an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-903">47.9</ix:nonFraction>&#160;million in the second quarter of 2024 and for the year ended December 31, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-904" continuedAt="f-904-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of goodwill consisted of the following year ended December 31, 2024 (in thousands): </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:center"><ix:continuation id="f-904-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.727%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 31, 2023</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-905">49,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill impairment (accumulated impairment loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-906">47,858</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impact of foreign currency translation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-907">1,380</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-909" continuedAt="f-909-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.545%"><tr><td style="width:1.0%"/><td style="width:35.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.142%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Amortization </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(in Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">December 31, 2025:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-910">111,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-911">54,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-912">56,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-237" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-913">6.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">December 31, 2024:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-914">111,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-915">38,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-916">72,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-239" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-917">6.6</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><ix:continuation id="f-909-1" continuedAt="f-909-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"><ix:continuation id="f-909-2">Gross carrying value and accumulated amortization include the impact of cumulative foreign currency translation adjustments.</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-918">18.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-919">18.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-920">15.7</ix:nonFraction> million for the years ended December&#160;31, 2025, 2024 and 2023, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="f-921" continuedAt="f-921-1" escape="true">The estimated future amortization expense for intangible assets remaining as of December&#160;31, 2025 is as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-921-1"><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.212%"><tr><td style="width:1.0%"/><td style="width:77.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.464%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-922">18,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-923">11,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-924">2,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-925">2,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-926">2,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-927">17,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-928">56,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_163"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-930" continuedAt="f-930-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-929" continuedAt="f-929-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-930-1" continuedAt="f-930-2"><ix:continuation id="f-929-1" continuedAt="f-929-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases real estate for office and lab space as well as equipment used in research and development activities under operating and finance leases.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s real estate leases have initial lease terms ranging from <ix:nonNumeric contextRef="c-78" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-931">1.4</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-79" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-932">15.3</ix:nonNumeric> years and are all classified as operating. Real estate leases may contain periods of free rent, tenant improvement incentives, expansion options, rent escalation clauses at pre-determined rates or at the prevailing market rates at the time of the increase, and options to extend or terminate the lease without cause at the option of either party during the lease term. The Company is not reasonably certain to exercise these options at the commencement of the lease. Equipment leases have initial lease terms ranging from <ix:nonNumeric contextRef="c-240" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-933">2.2</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-241" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-934">5</ix:nonNumeric> years and are classified as operating or finance if the lease contains bargain purchase options which the Company is reasonably certain to exercise. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-930-2" continuedAt="f-930-3"><ix:continuation id="f-929-2" continuedAt="f-929-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost for real estate leases primarily consists of certain non-lease components such as real estate taxes, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">insurance and common area maintenance charges. These non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise. None of the Company's lease agreements contain material restrictive covenants or residual value guarantees. </span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's headquarters are located in the Seaport district of Boston, Massachusetts and comprise a set of non-cancellable operating leases within a facility totaling over <ix:nonFraction unitRef="sqft" contextRef="c-1" decimals="0" name="dna:LesseeOperatingLeaseAreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-935">320,000</ix:nonFraction> square feet of office and laboratory space. These leases expire on dates ranging from 2030 to 2036 and each contain <ix:nonFraction unitRef="extensionoption" contextRef="c-7" decimals="INF" name="dna:LesseeOperatingLeaseNumberOfExtensionOptions" format="ixt-sec:numwordsen" scale="0" id="f-936">one</ix:nonFraction> option to extend the lease for a <ix:nonNumeric contextRef="c-7" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-937">five-year</ix:nonNumeric> period at then-market rates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company entered into a lease, as amended, consisting of approximately <ix:nonFraction unitRef="sqft" contextRef="c-242" decimals="INF" name="dna:LesseeOperatingLeaseAreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-938">260,000</ix:nonFraction> rentable square feet of new office and laboratory space being developed in Boston, Massachusetts near the Company's headquarters. The lease commenced on April 11, 2024, with rent payments beginning in June 2024, and it will expire on the fifteenth anniversary of the rent commencement date. The lease includes an option to extend for an additional <ix:nonNumeric contextRef="c-243" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-939">ten years</ix:nonNumeric> at then-market rates, as well as an expansion option if the owner constructs an additional building on the property. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has a substantial amount of excess space and is seeking to sublease excess space consistent with its restructuring plan. The leased facilities continue to be included in the Cell Engineering asset group as they have not been abandoned and do not have separately identifiable cash flows. If the Company enters into subleases at rates that are below the existing lease minimum payments, terminates or amends existing leases, or abandons the leased facilities, the right-of-use lease assets and any associated leasehold improvements would be evaluated for potential impairment and impairment charges could be material.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company&#8217;s former subsidiary, Zymergen, ceased the use of and exited a leased facility consisting of approximately <ix:nonFraction unitRef="sqft" contextRef="c-244" decimals="INF" name="dna:LesseeOperatingLeaseAreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-940">300,000</ix:nonFraction> square feet of office and laboratory space in Emeryville, California. The facility was used pursuant to an operating lease with a minimum term expiring in August 2033. Zymergen&#8217;s exit resulted in an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="f-941">96.2</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="f-942">36.6</ix:nonFraction>&#160;million for the right-of-use asset and $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="f-943">59.6</ix:nonFraction>&#160;million for the related leasehold improvements. The impairment loss represents the amount by which the carrying value of the assets exceed their estimated fair values, as determined using a discounted cash flow model under the income approach. The fair value measurements are based on significant inputs not observable in the market and therefore represent Level 3 fair value measurements. The key inputs used in the valuation were estimated sublease rental income and a discount rate of <ix:nonFraction unitRef="number" contextRef="c-247" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-944">8.5</ix:nonFraction>%. The impairments are presented as impairment of lease assets in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-930-3" continuedAt="f-930-4"><ix:continuation id="f-929-3" continuedAt="f-929-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-945" continuedAt="f-945-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of total lease cost (in thousands): </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:center"><ix:continuation id="f-945-1" continuedAt="f-945-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.545%"><tr><td style="width:1.0%"/><td style="width:46.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-946">63,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-947">57,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-948">59,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-949">708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-950">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-951">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-952">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-953">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-954">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:FinanceLeaseCost" scale="3" id="f-955">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:FinanceLeaseCost" scale="3" id="f-956">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:FinanceLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-957">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-958">19,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-959">19,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-960">15,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-961">7,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-962">5,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-963">11,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-964">76,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-965">72,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-966">65,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="f-967" continuedAt="f-967-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases were as follows (in thousands):  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"/><td style="width:59.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-968">61,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-969">45,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-970">44,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-971">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-972">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-973">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-974">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-975">897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-976">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:continuation id="f-945-2" continuedAt="f-945-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:  </span></div></ix:continuation><div style="margin-top:10pt;text-align:center"><ix:continuation id="f-945-3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"/><td style="width:71.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-977">11.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-978">11.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-7" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-979">0.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-8" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-980">0.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-981">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-982">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate - finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-983">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-984">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-986" continuedAt="f-986-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-985" continuedAt="f-985-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of the Company&#8217;s lease liabilities (in thousands): </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:10pt;text-align:center"><ix:continuation id="f-986-1"><ix:continuation id="f-985-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.848%"><tr><td style="width:1.0%"/><td style="width:59.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Finance Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-987">56,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-988">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-989">56,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:fixed-zero" scale="3" id="f-990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-991">58,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="3" id="f-992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-993">60,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="f-994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-995">59,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="f-996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-997">371,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-998">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total undiscounted payments</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-999">662,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-1000">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1001">222,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1003">439,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-1004">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">L<span style="-sec-ix-hidden:f-1005"><span style="-sec-ix-hidden:f-1006">ess: current portion of lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1007">22,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1008">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities, non-current</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1009">417,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously subleased a portion of its office and lab space to certain of its equity method investees, which are considered related parties. These lease agreements ended in 2025. Related party sublease income for the years ended December&#160;31, 2025, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="f-1010">2.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="f-1011">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="f-1012">2.1</ix:nonFraction> million, respectively, included within </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-930-4"><ix:continuation id="f-929-4"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operating expenses in 2025 and within other income, net in the consolidated statements of operations and comprehensive loss in prior years.</span></div></ix:continuation></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_169"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="f-1013" continuedAt="f-1013-1" escape="true">Supplemental Financial Information </ix:nonNumeric></span></div><ix:continuation id="f-1013-1" continuedAt="f-1013-2"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-1015" continuedAt="f-1015-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-1014" continuedAt="f-1014-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet to the totals shown within the consolidated statements of cash flows is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1016">167,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1017">561,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1018">944,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash included in prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1019">7,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1020">5,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1021">4,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Restricted cash included in other non-current assets </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1022">38,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1023">38,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1024">40,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1025">212,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1026">605,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1027">989,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><ix:continuation id="f-1015-1" continuedAt="f-1015-2"><ix:continuation id="f-1014-1" continuedAt="f-1014-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"><ix:continuation id="f-1015-2"><ix:continuation id="f-1014-2">Includes cash balances collateralizing letters of credit associated with the Company&#8217;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer agreement.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment, net </span></div><ix:continuation id="f-522-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"/><td style="width:68.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1028">146,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1029">150,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1030">140,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1031">135,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Buildings and facilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1032">49,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1033">48,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1034">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1035">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1036">9,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1037">14,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1038">6,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1039">6,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1040">6,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1041">6,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1042">358,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1043">364,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1044">190,597</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1045">160,872</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1046">167,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1047">203,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2025, 2024 and 2023 totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1048">40.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1049">45.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1050">54.8</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company determined that $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="f-1051">5.8</ix:nonFraction>&#160;million of construction in progress assets were impaired and this loss is included in general and administrative expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company identified excess lab equipment at <ix:nonFraction unitRef="facility" contextRef="c-20" decimals="INF" name="dna:TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment" format="ixt-sec:numwordsen" scale="0" id="f-1052">two</ix:nonFraction> of its facilities whereby the assets were sold, classified as held for sale or otherwise impaired, resulting in aggregate impairment losses of $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="f-1053">25.2</ix:nonFraction> million, included in general and administrative expense in the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1013-2"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities </span></div><ix:nonNumeric contextRef="c-1" name="dna:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="f-1054" continuedAt="f-1054-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands): </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:center"><ix:continuation id="f-1054-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"/><td style="width:68.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1055">22,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1056">28,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contractual shortfall liabilities (Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:ContractualShortfallLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1057">15,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:ContractualShortfallLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-1058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1059">5,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1060">5,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Biosecurity costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:AccruedBiosecurityServiceRevenueAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1061">5,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:AccruedBiosecurityServiceRevenueAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1062">4,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1063">4,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1064">9,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and securities litigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1065">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1066">2,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">External research and development expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:AccruedExternalResearchAndDevelopmentExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1067">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:AccruedExternalResearchAndDevelopmentExpensesCurrent" scale="3" id="f-1068">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1069">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1070">2,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee termination costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:AccruedEmployeeTerminationCosts" scale="3" id="f-1071">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:AccruedEmployeeTerminationCosts" format="ixt:num-dot-decimal" scale="3" id="f-1072">2,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1073">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1074">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:AccruedPropertyAndEquipmentCurrent" format="ixt:fixed-zero" scale="3" id="f-1075">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:AccruedPropertyAndEquipmentCurrent" scale="3" id="f-1076">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1077">5,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1078">8,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1079"><span style="-sec-ix-hidden:f-1080">Accrued expenses and other current liabilities</span></span></span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1081">66,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1082">65,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental cash flow information</span></div><ix:continuation id="f-967-1" continuedAt="f-967-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information for each reporting period (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.068%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for interest</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-1083">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-1084">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-1085">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-1086">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-1087">894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-1088">670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-1089">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1090">223,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1091">27,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-1092">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-1093">2,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-1094">2,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Convertible financial instruments received for Cell Engineering services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:ConvertibleFinancialInstrumentsReceivedForFoundryServices" format="ixt:fixed-zero" scale="3" id="f-1095">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:ConvertibleFinancialInstrumentsReceivedForFoundryServices" format="ixt:fixed-zero" scale="3" id="f-1096">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:ConvertibleFinancialInstrumentsReceivedForFoundryServices" format="ixt:num-dot-decimal" scale="3" id="f-1097">4,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Equity securities and warrants received for Cell Engineering services</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:PurchaseOfNonCashMarketableEquitySecurities" format="ixt:fixed-zero" scale="3" id="f-1098">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:PurchaseOfNonCashMarketableEquitySecurities" scale="3" id="f-1099">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:PurchaseOfNonCashMarketableEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-1100">17,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment" scale="3" id="f-1101">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment" format="ixt:num-dot-decimal" scale="3" id="f-1102">18,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment" format="ixt:num-dot-decimal" scale="3" id="f-1103">6,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued as settlement of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:SettlementOfContingentConsideration" format="ixt:fixed-zero" scale="3" id="f-1104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:SettlementOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-1105">14,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:SettlementOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-1106">8,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for retention payments related to business and asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:IssuanceOfCommonStockForAcquisitionRetentionPayments" format="ixt:fixed-zero" scale="3" id="f-1107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:IssuanceOfCommonStockForAcquisitionRetentionPayments" format="ixt:num-dot-decimal" scale="3" id="f-1108">5,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:IssuanceOfCommonStockForAcquisitionRetentionPayments" format="ixt:fixed-zero" scale="3" id="f-1109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Return of investment in equity securities for reduction in deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="f-1110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1111">6,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="f-1112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Conversion of notes receivable for common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="f-1113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="f-1114">10,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="f-1115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance costs related to ATM offering included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" scale="3" id="f-1116">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="dna:SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" format="ixt:fixed-zero" scale="3" id="f-1117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dna:SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" format="ixt:fixed-zero" scale="3" id="f-1118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_172"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1119" continuedAt="f-1119-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-1119-1" continuedAt="f-1119-2"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Obligations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into a <ix:nonNumeric contextRef="c-263" name="us-gaap:UnrecordedUnconditionalPurchaseObligationTerm" format="ixt-sec:durwordsen" id="f-1120">five-year</ix:nonNumeric> strategic cloud and AI partnership with Google Cloud, which included minimum annual commitments to purchase cloud hosting services. The partnership previously included minimum annual commitments over the contract years ending August 27, 2027 to purchase cloud hosting services in exchange for various discounts on such services. The aggregate $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" scale="6" id="f-1121">289</ix:nonFraction>&#160;million future purchase commitment included minimum annual commitments were as follows: year 1, $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" scale="6" id="f-1122">8.0</ix:nonFraction>&#160;million; year 2, $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" scale="6" id="f-1123">28.0</ix:nonFraction>&#160;million; year 3, $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" scale="6" id="f-1124">54.0</ix:nonFraction>&#160;million; year 4, $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" scale="6" id="f-1125">86.0</ix:nonFraction>&#160;million; and year 5, $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" scale="6" id="f-1126">113.0</ix:nonFraction>&#160;million. Effective October 3, 2025, the Company entered into amendment that revised the total aggregate future purchase commitment to $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" scale="6" id="f-1127">110</ix:nonFraction>&#160;million and reset the annual commitments as follows (each annual year is defined as October 3 to October 2): year 1 (starting on October 3, 2025), $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" scale="6" id="f-1128">6.0</ix:nonFraction>&#160;million; year 2, $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" scale="6" id="f-1129">8.0</ix:nonFraction>&#160;million; year 3, $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" scale="6" id="f-1130">12.0</ix:nonFraction>&#160;million; year </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1119-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4, $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" scale="6" id="f-1131">18.0</ix:nonFraction>&#160;million; year 5, $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" scale="6" id="f-1132">28.0</ix:nonFraction>&#160;million; year 6, $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="dna:UnrecordedUnconditionalPurchaseObligationToBePaidYearSix" scale="6" id="f-1133">38.0</ix:nonFraction>&#160;million. The Company recognized a contractual liability of $<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="dna:ContractualShortfallLiability" scale="6" id="f-1134">20.9</ix:nonFraction>&#160;million during year ended December 31, 2025 as a result of shortfall in purchasing relative to its commitments under the original agreement. The Company is required to make a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="dna:ContractualShortfallLiabilityRequiredPayment" scale="6" id="f-1135">14.0</ix:nonFraction>&#160;million to be released from its minimum annual commitment obligations under the original agreement in January 2026. If the Company does not meet its minimum annual commitment obligations in the future, additional shortfall liabilities may be incurred and future contractual losses may be material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 1, 2025, the Company entered into an amendment to its <ix:nonNumeric contextRef="c-268" name="us-gaap:UnrecordedUnconditionalPurchaseObligationTerm" format="ixt-sec:durwordsen" id="f-1136">four-year</ix:nonNumeric> supply agreement with Twist for the purchase of diverse products including synthetic DNA. The original agreement was effective as of April 1, 2022 and obligated the Company to spend a minimum of $<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" scale="6" id="f-1137">58.0</ix:nonFraction>&#160;million over the <ix:nonNumeric contextRef="c-268" name="us-gaap:UnrecordedUnconditionalPurchaseObligationTerm" format="ixt-sec:durwordsen" id="f-1138">four-year</ix:nonNumeric> term with the following minimum annual commitments (each annual year is defined as April 1 to March 31): year 1, $<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" scale="6" id="f-1139">10.0</ix:nonFraction>&#160;million; year 2, $<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" scale="6" id="f-1140">13.0</ix:nonFraction>&#160;million; year 3, $<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" scale="6" id="f-1141">16.0</ix:nonFraction>&#160;million; and year 4, $<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" scale="6" id="f-1142">19.0</ix:nonFraction>&#160;million. The amendment converts the remaining minimum annual commitments into non-refundable payments creditable against future purchases by the Company, with no expiration. The Company paid $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases" scale="6" id="f-1143">4.0</ix:nonFraction>&#160;million in April 2025 and is obligated to non-refundable payments of $<ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases" scale="6" id="f-1144">5.0</ix:nonFraction>&#160;million on April 1, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases" scale="6" id="f-1145">6.0</ix:nonFraction>&#160;million on April 1, 2027, respectively. A contractual loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LossOnContracts" scale="6" id="f-1146">8.7</ix:nonFraction>&#160;million was recorded in the year ended December 31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Surety Bond</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2026, the Company will be required to fund a surety bond in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="dna:LossContingencyAmountRequiredToFund" scale="6" id="f-1147">47.0</ix:nonFraction>&#160;million to fulfill its obligations under a contract with a U.S. Government National Laboratory related to the sale of RAC automation equipment. The $<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="dna:LossContingencyAmountRequiredToFund" scale="6" id="f-1148">47.0</ix:nonFraction>&#160;million will be restricted until the Company completes all of its obligations under the contract. Currently the Company expects the cash to be restricted until 2029.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Related to Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the StrideBio acquisition (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_148">4</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">), the Company is obligated to make royalty payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:PaymentsForRoyalties" scale="6" id="f-1149">21.3</ix:nonFraction>&#160;million payable in cash or shares of Class A common stock at the Company's election until the earlier of the tenth anniversary date of the initial closing and the date on which the aggregate amount of the royalty payments equals the amount cap. The royalties are calculated based on <ix:nonFraction unitRef="number" contextRef="c-275" decimals="INF" name="dna:RoyaltyReceivedFromLicensingRevenue" scale="-2" id="f-1150">10</ix:nonFraction>% of the net licensing revenue and <ix:nonFraction unitRef="number" contextRef="c-275" decimals="INF" name="dna:RoyaltyReceivedFromLicenseOrSaleOfAProduct" scale="-2" id="f-1151">40</ix:nonFraction>% of all consideration received for a license or sale of a product incorporating the acquired platform assets. <ix:nonFraction unitRef="usd" contextRef="c-90" decimals="INF" name="us-gaap:PaymentsForRoyalties" format="ixt:fixed-zero" scale="0" id="f-1152">No</ix:nonFraction> amounts for the royalty payments have been recorded during the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company routinely acquires rights to intellectual property that may provide for payment of future contingent consideration, including royalties, should revenue be generated from the use of such.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may in the ordinary course of business be named as a defendant in lawsuits, indemnity claims and other legal proceedings. The Company accrues for a loss contingency when it concludes that the likelihood of a loss is probable and the amount of loss can be reasonably estimated. The Company adjusts its accruals from time to time as it receives additional information. The Company does not believe any pending litigation to be material, or that the outcome of any such pending litigation, in management&#8217;s judgment based on information currently available, would have a material adverse effect on the Company&#8217;s results of operations, cash flows or financial condition.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into standard indemnification agreements and has agreements with indemnification clauses in the ordinary course of business. Under such arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, who are generally the Company&#8217;s business partners. The terms of these indemnification arrangements are generally perpetual and effective any time after contract execution. The maximum potential liability resulting from these indemnification arrangements may be unlimited. The Company has never incurred costs to defend lawsuits or settle claims as a result of such indemnifications and the Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations as of December&#160;31, 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-38</span></div></div></div><div id="id8596373948b4ae4958ccd7c02fd70c1_175"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1153" continuedAt="f-1153-1" escape="true">Stockholders' Equity </ix:nonNumeric></span><ix:continuation id="f-1153-1" continuedAt="f-1153-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation></div><ix:continuation id="f-1153-2" continuedAt="f-1153-3"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalization</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCapitalizationTextBlock" id="f-1154" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s authorized, issued, and outstanding common stock as of the dates indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock as of December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1155">10,500,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1156">49,694,610</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1157">46,791,082</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class B</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1158">4,500,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1159">8,985,839</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1160">8,416,216</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class C</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1161">800,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1162">3,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1163">3,000,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1164">15,800,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1165">61,680,449</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1166">58,207,298</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock as of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class A</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1167">10,500,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1168">45,575,423</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1169">42,696,585</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1170">4,500,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1171">9,239,682</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1172">8,669,200</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class C</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1173">800,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1174">3,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1175">3,000,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1176">15,800,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1177">57,815,105</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1178">54,365,785</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-The-Market Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2025, the Company filed a universal shelf registration statement on Form S-3, which was declared effective by the SEC on August 14, 2024, on which the Company registered for sale up to $<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="dna:SaleOfStockAuthorizedAmount" scale="6" id="f-1179">500.0</ix:nonFraction>&#160;million of any combination of the Company's Class A common stock, preferred stock, warrants, and/or units from time to time and at prices and on terms that the Company may determine. On September 4, 2025, the Company entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;) with Allen &amp; Company LLC, who is acting as the sales agent (the &#8220;Agent&#8221;), pursuant to which the Company may sell shares of its Class A common stock from time to time at prices and on terms determined by market conditions at the time of offering, up to an aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="dna:SaleOfStockAuthorizedAmount" scale="6" id="f-1180">100.0</ix:nonFraction>&#160;million through or directly to the Agent in one or more at-the-market (&#8220;ATM&#8221;) offerings. Since inception of the Sales Agreement through December&#160;31, 2025, the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-1181">1.9</ix:nonFraction> million shares of Class A common stock under the Sales Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-1182">18.1</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-284" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-1183">200</ix:nonFraction>&#160;million shares of preferred stock with a par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-284" decimals="4" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1184">0.0001</ix:nonFraction> per share. The Company&#8217;s board of directors are authorized, without stockholder approval, to issue such shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, voting, and other rights, preferences and privileges of the shares. There were <ix:nonFraction unitRef="shares" contextRef="c-284" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1185"><ix:nonFraction unitRef="shares" contextRef="c-284" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1186">no</ix:nonFraction></ix:nonFraction> issued and outstanding shares of preferred stock as of December&#160;31, 2025. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1187">15,800</ix:nonFraction>&#160;million shares of common stock, including <ix:nonFraction unitRef="shares" contextRef="c-276" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1188">10,500</ix:nonFraction>&#160;million shares of Class A common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-276" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1189">0.0001</ix:nonFraction> per share, <ix:nonFraction unitRef="shares" contextRef="c-277" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1190">4,500</ix:nonFraction>&#160;million shares of Class B common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-277" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1191">0.0001</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="c-278" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-1192">800</ix:nonFraction>&#160;million shares of Class C common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-278" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1193">0.0001</ix:nonFraction> per share. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Class A common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-285" decimals="INF" name="dna:CommonStockVotingRight" format="ixt-sec:numwordsen" scale="0" id="f-1194">one</ix:nonFraction> vote per share and holders of Class B common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-286" decimals="INF" name="dna:CommonStockVotingRight" format="ixt-sec:numwordsen" scale="0" id="f-1195">ten</ix:nonFraction> votes per share. Holders of Class C common stock are not entitled to vote except as otherwise expressly provided in the certificate of incorporation or required by applicable law. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to receive dividends, as may be declared by the board of directors. Different classes of common stock are legally entitled to equal per share distributions whether through dividends or liquidation. <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:Dividends" format="ixt:fixed-zero" scale="3" id="f-1196">No</ix:nonFraction> dividends have been declared to date. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1153-3"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Class B common stock is convertible at any time at the option of the holder into <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="dna:CommonStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-1197">one</ix:nonFraction> share of Class A common stock. Generally, shares of Class B common stock will convert automatically into Class A common stock upon the holder ceasing to be an Eligible Holder (i.e., director, employee, trust or legal entity of Ginkgo), unless otherwise determined by affirmative vote of a majority of independent directors of Ginkgo. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuances </span></div><ix:nonNumeric contextRef="c-1" name="dna:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock" id="f-1198" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following common stock reserved for future issuance as of the date indicated:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.272%"><tr><td style="width:1.0%"/><td style="width:77.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for grant under the 2021 Plan</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-287" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1199">3,336,606</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restricted stock units outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-288" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1200">1,262,853</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Performance stock units outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-289" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1201">4,407,287</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Warrants to purchase Class A common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-290" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1202">1,295,622</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for grant under the ESPP</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-291" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1203">2,500,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for grant under the 2022 Inducement Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-292" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1204">292,172</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-293" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1205">366,567</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Total common stock reserved for future issuances </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1206">13,461,107</ix:nonFraction></span></td></tr></table></div><div style="margin-top:10pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Excludes unvested earnout shares, which are restricted shares issued to equity holders of legacy Ginkgo prior to the closing of the SRNG Business Combination and to SRNG. These earnout shares are recorded in equity as shares outstanding upon satisfying the vesting conditions.</span></div></ix:nonNumeric></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_178"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1207" continuedAt="f-1207-1" escape="true">Stock-Based Compensation </ix:nonNumeric></span><ix:continuation id="f-1207-1" continuedAt="f-1207-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation></div><ix:continuation id="f-1207-2" continuedAt="f-1207-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1208" continuedAt="f-1208-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense by financial statement line item in the Company&#8217;s consolidated statements of operations and comprehensive loss for the periods presented (in thousands): </span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:center"><ix:continuation id="f-1208-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.121%"><tr><td style="width:1.0%"/><td style="width:58.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1209">34,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1210">56,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1211">145,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1212">42,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1213">56,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1214">84,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of Biosecurity revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1215">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1218">2,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1221">81,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1222">112,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1223">229,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Inducement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2022, the Company's Board of Directors adopted the Ginkgo Bioworks Holdings, Inc. 2022 Inducement Plan (the &#8220;2022 Inducement Plan&#8221;), which is a non-shareholder approved equity incentive plan adopted pursuant to the &#8220;inducement exception&#8221; provided under NYSE Listed Company Manual Section 303A.08. Pursuant to the terms of the 2022 Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock and other stock-based awards as an inducement material to individuals being hired or rehired following a bona fide period of interruption of employment, as an employee of the Company or any of its subsidiaries, including in connection with a merger or acquisition. The terms of the 2022 Inducement Plan are substantially similar to the terms of the Company&#8217;s 2021 Incentive Award Plan. The Company has reserved <ix:nonFraction unitRef="shares" contextRef="c-306" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1224">625,000</ix:nonFraction> shares of the Company&#8217;s common stock (which may be shares of Class A common stock or Class B common stock) for issuance under the 2022 Inducement Plan. As of December&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-307" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1225">292,172</ix:nonFraction> shares are available for future issuance under the 2022 Inducement Plan.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Inc</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">entive Award Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;16, 2021, the 2021 Incentive Award Plan (the &#8220;2021 Plan&#8221;) became effective. The 2021 Plan provides for the grant of stock options, including incentive stock options (&#8220;ISOs&#8221;) and nonqualified stock options, stock appreciation </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1207-3" continuedAt="f-1207-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rights, restricted stock, dividend equivalents, RSUs and other stock or cash-based awards to employees, consultants and directors of Ginkgo and its subsidiaries. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate number of shares of common stock available for issuance under the 2021 Plan, which may be issued as Class A common stock and/or Class B common stock, was initially <ix:nonFraction unitRef="shares" contextRef="c-308" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1226">5,011,024</ix:nonFraction> shares. As of December&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-287" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1227">3,336,606</ix:nonFraction> shares are available for future issuance under the 2021 Plan. The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase for <ix:nonNumeric contextRef="c-7" name="dna:ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm" format="ixt-sec:durwordsen" id="f-1228">ten years</ix:nonNumeric> on January 1 of each year in an amount equal to the lesser of (a) <ix:nonFraction unitRef="number" contextRef="c-308" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-1229">4</ix:nonFraction>% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by the Board. The maximum number of shares of common stock that may be issued pursuant to the exercise of incentive stock options granted under the 2021 Plan is <ix:nonFraction unitRef="shares" contextRef="c-309" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1230">5,000,000</ix:nonFraction> shares. Shares issued under the 2021 Plan may consist of authorized but unissued shares, shares purchased on the open market or treasury shares.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2021, the 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) became effective. The ESPP authorizes (i) the grant of options that are intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code of 1986 (the &#8220;Section 423 Component&#8221;) and (ii) the grant of options that are not intended to be tax-qualified (the &#8220;Non-Section 423 Component&#8221;). All of the Company&#8217;s employees are expected to be eligible to participate in the ESPP. However, with respect to the Section 423 Component, an employee may not be granted rights to purchase stock under the ESPP if the employee, immediately after the grant, would own (directly or through attribution) stock possessing <ix:nonFraction unitRef="number" contextRef="c-310" decimals="2" name="dna:PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate" scale="-2" id="f-1231">5</ix:nonFraction>% or more of the total combined voting power or value of all classes of the Company&#8217;s common stock. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP initially permits the Company to deliver up to <ix:nonFraction unitRef="shares" contextRef="c-311" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1232">500,000</ix:nonFraction> shares of common stock pursuant to awards issued under the ESPP, which may be Class A common stock and/or Class B common stock. The number of shares of common stock reserved for issuance under the ESPP will automatically increase each January 1 by an amount equal to the lesser of (a) <ix:nonFraction unitRef="number" contextRef="c-310" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-1233">1</ix:nonFraction>% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by the Board, provided that no more than <ix:nonFraction unitRef="shares" contextRef="c-311" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1234">2,500,000</ix:nonFraction> shares may be issued under the Section 423 Component. Prior to or in connection with issuing any shares of common stock under the ESPP, the ESPP administrator may convert awards covering shares of Class B common stock to Class A common stock. As of December&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-312" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt-sec:numwordsen" id="f-1235">no</ix:nonFraction> awards have been granted under the ESPP, and <ix:nonFraction unitRef="shares" contextRef="c-291" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1236">2,500,000</ix:nonFraction> shares remain available for future issuance. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2014 Stock Incentive Plan (the &#8220;2014 Plan&#8221;) provided for the Company to grant options, stock appreciation rights, restricted stock, restricted stock units (&#8220;RSUs&#8221;) and other stock-based awards. From and after the effective date of the 2021 Incentive Award Plan, the Company ceased granting awards under the 2014 Plan. However, the 2014 Plan continues to govern the terms and conditions of the outstanding awards previously granted thereunder. Shares of common stock underlying any awards that are forfeited, cancelled, repurchased, or otherwise terminated by the Company under the 2014 Plan will be added back to the shares available for issuance under the 2021 Incentive Award Plan.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-based Stock Options </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All time-based options outstanding consist of awards granted to non-employee directors and are of <ix:nonFraction unitRef="stockoption" contextRef="c-7" decimals="INF" name="dna:TypesOfTimeBasedStockOptions" format="ixt-sec:numwordsen" scale="0" id="f-1237">two</ix:nonFraction> types: (i) initial awards granted to newly elected or appointed directors, which vest in <ix:nonFraction unitRef="installment" contextRef="c-1" decimals="INF" name="dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" format="ixt-sec:numwordsen" scale="0" id="f-1238">three</ix:nonFraction> equal annual installments, and (ii) subsequent awards, which vest on the earlier of the first anniversary of the grant date or the day prior to the next annual shareholder meeting. These options expire no later than <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-1239">ten years</ix:nonNumeric> from the grant date. The exercise price of each option is equal to the closing price of the Company&#8217;s common stock on the date of grant. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1207-4" continuedAt="f-1207-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1240" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of time-based stock options activity for the year ended December&#160;31, 2025 is presented below: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.757%"><tr><td style="width:1.0%"/><td style="width:43.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Exercise Price per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Remaining Contractual Term (in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:115%">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of  December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1241">267,520</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1242">25.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1243">171,875</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1244">9.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-1245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1247">72,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1248">36.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1249">366,567</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1250">15.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1251">8.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-1252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1253">136,014</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1254">24.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1255">8.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="f-1256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:6.7pt">The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the year and the exercise prices, multiplied by the number of in-the-money stock options.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1257">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1258">9.1</ix:nonFraction> million, respectively. There were <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt-sec:numwordsen" id="f-1259">no</ix:nonFraction> stock option exercises during the year ended December 31, 2025. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1260" continuedAt="f-1260-1" escape="true">The weighted-average fair value of options granted during the years ended December&#160;31, 2025, 2024, and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1261">7.48</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1262">11.35</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1263">57.20</ix:nonFraction> per share, respectively, and was calculated using the following key assumptions in the Black-Scholes option-pricing model:</ix:nonNumeric></span></div><ix:continuation id="f-1260-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.030%"><tr><td style="width:1.0%"/><td style="width:50.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.438%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1264">4.06</ix:nonFraction></span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1265">4.27</ix:nonFraction></span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1266">3.94</ix:nonFraction></span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1267">100</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1268">97</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1269">93</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1270">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-20" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1271">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-21" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1272">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1273">&#8212;</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1274">&#8212;</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1275">&#8212;</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-1276">1.5</ix:nonFraction> million of unrecognized compensation expense related to options recognizable over a weighted-average period of <ix:nonNumeric contextRef="c-313" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1277">2.3</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company granted to each of the Company's <ix:nonFraction unitRef="founder" contextRef="c-314" decimals="0" name="dna:NumberOfCompanyFounders" format="ixt-sec:numwordsen" id="f-1278">four</ix:nonFraction> founders an option to purchase in aggregate <ix:nonFraction unitRef="shares" contextRef="c-315" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1279">125,000</ix:nonFraction> shares of Ginkgo's Class A common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-315" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" id="f-1280">100</ix:nonFraction> per share, subject both to time-based and market-based vesting criteria (the &#8220;Founder Options&#8221;). The market-based vesting is tied to the achievement of <ix:nonFraction unitRef="hurdle" contextRef="c-316" decimals="INF" name="dna:NumberOfStockPriceHurdles" format="ixt-sec:numwordsen" scale="0" id="f-1281">four</ix:nonFraction> specified stock price hurdles within a <ix:nonNumeric contextRef="c-317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1282">five-year</ix:nonNumeric> period, with <ix:nonFraction unitRef="number" contextRef="c-318" decimals="2" name="dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="f-1283">10</ix:nonFraction>% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-319" decimals="0" name="us-gaap:SharePrice" scale="0" id="f-1284">200</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="c-320" decimals="2" name="dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="f-1285">10</ix:nonFraction>% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-321" decimals="0" name="us-gaap:SharePrice" scale="0" id="f-1286">300</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="c-322" decimals="2" name="dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="f-1287">20</ix:nonFraction>% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-323" decimals="0" name="us-gaap:SharePrice" scale="0" id="f-1288">400</ix:nonFraction> and the remaining <ix:nonFraction unitRef="number" contextRef="c-324" decimals="2" name="dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="f-1289">60</ix:nonFraction>% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-325" decimals="0" name="us-gaap:SharePrice" scale="0" id="f-1290">500</ix:nonFraction>. If the market-based criteria are achieved during the <ix:nonNumeric contextRef="c-317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1291">five-year</ix:nonNumeric> period, the awards will vest on the <ix:nonNumeric contextRef="c-317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1292">five-year</ix:nonNumeric> anniversary of the grant date. The weighted-average grant-date fair value of the options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-317" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" id="f-1293">7.80</ix:nonFraction> per share and was calculated using a Monte Carlo simulation model using a risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="c-317" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1294">4.65</ix:nonFraction>%, expected volatility of <ix:nonFraction unitRef="number" contextRef="c-317" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1295">72</ix:nonFraction>%, suboptimal exercise multiple of <ix:nonFraction unitRef="number" contextRef="c-317" decimals="1" name="dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple" scale="0" id="f-1296">2.8</ix:nonFraction>, and a dividend yield of <ix:nonFraction unitRef="number" contextRef="c-317" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1297">zero</ix:nonFraction> percent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, the compensation committee of the Company&#8217;s Board of Directors canceled the Founder Options and granted replacement performance-based restricted stock unit (&#8220;PSU&#8221;) awards (the &#8220;Founder PSU Awards&#8221;). The cancellation and concurrent grant of replacement awards were accounted for as a modification, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1298">10.5</ix:nonFraction>&#160;million of incremental compensation expense. The performance period for these awards was through December&#160;31, 2025 and the aggregate compensation expense for the cancelled award and the new award will be recognized over the remaining requisite service period of the PSUs, which is the grant date through March 31, 2026. The PSU awards are subject to substantially similar performance metrics, vesting terms and employment terms as described in the section &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1207-5" continuedAt="f-1207-6"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted under the 2014 Plan are subject to <ix:nonFraction unitRef="condition" contextRef="c-7" decimals="INF" name="dna:NumberOfVestingConditions" format="ixt-sec:numwordsen" scale="0" id="f-1299">two</ix:nonFraction> vesting conditions: (i) a service-based vesting condition, generally satisfied over <ix:nonNumeric contextRef="c-327" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1300">four years</ix:nonNumeric> with <ix:nonFraction unitRef="number" contextRef="c-327" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1301">25</ix:nonFraction>% of the shares vesting on the first anniversary of the grant date and monthly vesting thereafter, and (ii) a performance-based vesting condition, which was met in 2021 in connection with the Company's merger with SRNG. RSUs granted under the 2021 Plan are subject only to the service-based vesting condition. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-1302" continuedAt="f-1302-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the year ended December&#160;31, 2025 is presented below: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:center"><ix:continuation id="f-1302-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.212%"><tr><td style="width:1.0%"/><td style="width:50.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.801%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of  December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-328" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1303">3,327,398</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-328" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1304">69.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-329" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1305">1,176,419</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-329" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1306">8.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-329" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1307">1,797,720</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-329" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1308">48.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-329" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1309">1,443,244</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-329" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1310">56.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of  December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-288" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1311">1,262,853</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-288" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1312">55.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of RSUs granted during the years ended December&#160;31, 2025, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-329" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1313">8.02</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-330" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1314">43.81</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1315">55.60</ix:nonFraction>, respectively. The total fair value of the RSUs that vested during the years ended December&#160;31, 2025, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-1316">87.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-1317">232.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-1318">365.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-1319">58.3</ix:nonFraction> million of unrecognized compensation expense related to RSUs recognizable over a weighted-average period of <ix:nonNumeric contextRef="c-329" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1320">1.8</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the compensation committee of the Company's Board of Directors approved a grant of PSU awards under the 2021 Plan to substantially all employees. The PSUs are eligible to vest based on the achievement of specific performance metrics tied to the Company&#8217;s 2025 cash flow and bookings targets. Recipients must remain employed through the date the applicable vested shares are distributed, which is expected to occur in March 2026. PSU achievement percentages may range from <ix:nonFraction unitRef="number" contextRef="c-332" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="f-1321">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-333" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1322">100</ix:nonFraction>% of the award. The grant-date fair value of the PSUs was determined based on the closing price of the Company&#8217;s Class A common stock on the grant date. Additionally, as summarized above, the Founder PSU Awards were granted in June 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="f-1323" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of PSU activity for the year ended December&#160;31, 2025 is presented below:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"><tr><td style="width:1.0%"/><td style="width:60.620%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.611%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Performance Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1324">5,599,647</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-334" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1325">8.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-1326">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-334" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="f-1327"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1328">1,192,360</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-334" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1329">7.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-289" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1330">4,407,287</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-289" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1331">8.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-1332">7.3</ix:nonFraction>&#160;million of unrecognized compensation expense related to unvested PSUs outstanding, which is expected to be recognized over a service period of approximately <ix:nonNumeric contextRef="c-334" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1333">0.3</ix:nonNumeric> years. Actual expense recognized may vary based on the final achievement rate.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnouts</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Earnout shares represent equity awards, primarily in the form of restricted stock, granted to existing employees of the Company as of the closing date of the Company's merger with SRNG on September 16, 2021 (the &#8220;Closing Date&#8221;). These earnout shares are subject to the same time-based vesting and performance conditions (change in control or an initial public offering) as the underlying awards, including provisions related to vesting and termination. Additionally, the earnout shares are subject to a market condition, which is satisfied when the trading price of the Company's common stock is greater than </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1207-6" continuedAt="f-1207-7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-335" decimals="0" name="us-gaap:SharePrice" scale="0" id="f-1334">500</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-336" decimals="0" name="us-gaap:SharePrice" scale="0" id="f-1335">600</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-337" decimals="0" name="us-gaap:SharePrice" scale="0" id="f-1336">700</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-338" decimals="0" name="us-gaap:SharePrice" scale="0" id="f-1337">800</ix:nonFraction> per share for any <ix:nonNumeric contextRef="c-339" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durday" id="f-1338">20</ix:nonNumeric> trading days within a <ix:nonNumeric contextRef="c-340" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durday" id="f-1339">30</ix:nonNumeric> consecutive trading day period, on or before the fifth anniversary of the Closing Date (collectively, the &#8220;Earnout Targets&#8221;). The first Earnout Target of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-341" decimals="0" name="us-gaap:SharePrice" scale="0" id="f-1340">500</ix:nonFraction> per share was achieved on November&#160;15, 2021. </span></div><ix:nonNumeric contextRef="c-1" name="dna:SummaryOfActivityForEarnoutRSATableTextBlock" id="f-1341" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity during the year ended December&#160;31, 2025 for the earnout shares is presented below: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"/><td style="width:61.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-342" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1342">552,457</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-342" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1343">510.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-343" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="f-1344">321</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-343" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1345">533.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-343" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="f-1346">859</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-343" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1347">512.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-344" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1348">551,277</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-344" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1349">510.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of the earnout shares that vested during the years ended December&#160;31, 2025, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-1350">0.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-1351">4.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-1352">7.6</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1207-7">As of December&#160;31, 2025</ix:continuation>, there was <ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:fixed-zero" scale="0" id="f-1353">zero</ix:nonFraction> unrecognized compensation expense related to earnout shares.</span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_184"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-1354" continuedAt="f-1354-1" escape="true">Revenue Recognition </ix:nonNumeric></span></div><ix:continuation id="f-1354-1" continuedAt="f-1354-2"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-1355" continuedAt="f-1355-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the percentage of Cell Engineering revenues by industry based on total Cell Engineering revenue: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:center"><ix:continuation id="f-1355-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"><tr><td style="width:1.0%"/><td style="width:56.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.669%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.669%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pharmaceutical and biotechnology</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-347" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1356">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-348" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1357">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-349" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1358">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Agriculture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-350" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1359">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-351" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1360">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-352" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1361">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Government and defense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-353" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1362">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-354" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1363">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-355" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1364">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Industrial and environment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-356" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1365">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-357" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1366">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-358" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1367">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Consumer and technology</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-359" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1368">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-360" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1369">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-361" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1370">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Food and nutrition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-362" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1371">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-363" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1372">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-364" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1373">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total Cell Engineering revenue</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-365" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1374">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-366" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1375">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-367" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1376">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cell Engineering revenue includes both cash and non-cash consideration. The non-cash consideration primarily consists of equity received from customers as partial or full payment in certain contracts, which is recognized as revenue as services are provided or upon contract termination. The Company did not receive equity as consideration for any customer contracts entered into during the years ended December&#160;31, 2025 or 2024, but continues to recognize revenue from prior contracts. Cell Engineering revenue recognized relating to non-cash consideration was $<ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="dna:RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" scale="6" id="f-1377">11.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="dna:RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" scale="6" id="f-1378">61.4</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-5" name="dna:RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" scale="6" id="f-1379">48.5</ix:nonFraction>&#160;million for the years ended December&#160;31, 2025, 2024, and 2023, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s total revenue is derived from customers located primarily in the United States. For the years ended December&#160;31, 2025, 2024, and 2023, the Company&#8217;s revenue from customers within the United States comprised <ix:nonFraction unitRef="number" contextRef="c-371" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1380">76</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-372" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1381">81</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-373" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1382">82</ix:nonFraction>%, respectively, of total revenue.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as accounts receivable. The Company had <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="f-1383"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="f-1384">no</ix:nonFraction></ix:nonFraction> contract asset balances as of December&#160;31, 2025 and 2024. The Company&#8217;s accounts receivable consists of both billed and unbilled amounts. Unbilled receivables arise when revenue is recognized in excess of invoiced amounts and represent the Company&#8217;s unconditional right to consideration for goods or services already transferred to the customer. The balance </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1354-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of unbilled accounts receivable, included in accounts receivable, net in the accompanying consolidated balance sheets, was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="f-1385">14.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="f-1386">11.3</ix:nonFraction> million as of December&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities, or deferred revenue, primarily consist of payments received in advance of performance under the contract or when the Company has an unconditional right to consideration under the terms of the contract before it transfers goods or services to the customer. The Company&#8217;s collaborative arrangements with its investees and related parties typically include upfront payments consisting of cash or non-cash consideration for future research and development services and non-cash consideration in the form of convertible financial instruments and equity securities for licenses that will be transferred in the future. The Company records the upfront cash payments and fair value of the convertible financial instruments and equity securities as deferred revenue. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invoices customers based on contractual billing schedules, which results in the recording of deferred revenue to the extent payment is received prior to the Company&#8217;s performance of the related services. Contract liabilities are recognized as revenue as (or when) the Company performs under the contract. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-1387">48.7</ix:nonFraction> million of revenue that was included in the contract liabilities balance of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1388">126.5</ix:nonFraction> million as of December&#160;31, 2024. During the year ended December&#160;31, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-1389">88.1</ix:nonFraction> million of revenue that was included in the contract liabilities balance of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1390">202.5</ix:nonFraction> million as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price that was allocated to performance obligations that have not yet been satisfied or are partially satisfied as of December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-1391">158.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-1392">85.8</ix:nonFraction> million, respectively. The Company has elected the practical expedient not to provide the remaining performance obligation disclosures related to contracts for which the Company recognizes revenue on a cost-plus basis in the amount to which it has the right to invoice.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, approximately $<ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="f-1393">23.0</ix:nonFraction>&#160;million of the unsatisfied or partially satisfied performance obligations is expected to be recognized as revenue in 2026, based on the projected customer program end date; $<ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="f-1394">40.9</ix:nonFraction>&#160;million between 2026 and 2027; $<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="f-1395">86.9</ix:nonFraction>&#160;million between 2026 and 2028; $<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="f-1396">3.4</ix:nonFraction>&#160;million between 2026 and 2029; and $<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="f-1397">4.4</ix:nonFraction>&#160;million between 2026 and 2030.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When a milestone subject to the variable consideration constraint is achieved, the Company updates its estimate of the transaction price to include the milestone payment and records a cumulative catch-up in revenue. For the years ended December&#160;31, 2025, 2024 and 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="f-1398">2.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="f-1399">7.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="f-1400">2.3</ix:nonFraction> million, respectively, as cumulative catch-up in revenue, primarily due to the recognition of previously constrained variable consideration related to milestones or a contract modification.</span></div></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_187"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1406" continuedAt="f-1406-1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="f-1406-1" continuedAt="f-1406-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1407"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1408">two</ix:nonFraction></ix:nonFraction> operating and reportable segments: Cell Engineering and Biosecurity. This structure reflects the Company's internal management framework and the approach its CODM uses to evaluate operating results and allocate resources. The Company&#8217;s reportable segments are described as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cell Engineering consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological R&amp;D. The Company&#8217;s cell engineering platform includes R&amp;D services (solutions) where Ginkgo performs technical activities.  Our Autonomous Lab is a flexible wet lab built from our Reconfigurable Automation Cart (&#8220;RAC&#8221;) systems capable of large scale data generation; it powers generative AI and machine learning (&#8220;ML&#8221;) tools that enable more successful biological R&amp;D. We now offer services providing such data generation, AI and automation tools directly to Ginkgo customers. Cell Engineering revenue is generated primarily through R&amp;D service fees for our solutions and Datapoints services; and design, build, installation and ongoing support fees for our automation solutions (RAC) systems. Historically our solutions deals also included downstream value share in the form of milestone payments, royalties or equity interests. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biosecurity consists of the Company&#8217;s biomonitoring and bioinformatics support services, offered to both government and non-government customers through the Company's <ix:nonFraction unitRef="asset" contextRef="c-1" decimals="INF" name="dna:NumberOfCoreAssets" format="ixt-sec:numwordsen" id="f-1409">two</ix:nonFraction> core offerings: Canopy and Horizon. Biosecurity revenue is generated from fees for data, analytics, and services. Prior to 2024, Biosecurity revenue also included sales of COVID-19 diagnostic and sample collection test kits.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1406-2" continuedAt="f-1406-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reportable segments are those for which discrete financial information is available and whose results are regularly provided to the Company&#8217;s CODM, consisting of the Chief Executive Officer and the Chief Operating Officer, for the purpose of allocating resources and assessing financial performance. The CODM evaluates the financial performance of the Company&#8217;s segments based on segment operating income (loss). The CODM is primarily provided with the segment operating income (loss) on a quarterly basis, as well as during the annual budgeting and forecasting process, and uses this information to monitor the Company&#8217;s performance, including budget-to-actual results, and to make decisions about the allocation of operating and capital resources to each segment. For management reporting purposes, the Company&#8217;s measure of segment operating income (loss) excludes the impact of stock-based compensation expense, depreciation and amortization, asset impairment charges, restructuring charges, costs associated with excess space, transaction and integration costs associated with planned, completed or terminated mergers and acquisitions, and acquired in-process research and development expenses. The Company has determined its significant segment expenses are cost of revenue for Biosecurity, research and development expenses for Cell Engineering, and general and administrative expenses for both segments, which are regularly provided to the CODM. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The CODM is not provided with asset information by segment; therefore, such information is not presented. The accounting policies used to prepare the reportable segments financial information are the same as those used to prepare the Company&#8217;s consolidated financial statements. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1410" continuedAt="f-1410-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary results of the Company&#8217;s reportable segments and a reconciliation of total segment operating loss to consolidated loss before income taxes (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cell Engineering</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1411">132,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1412">173,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1413">143,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1414">13,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1415">5,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-1416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1417">158,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1418">271,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1419">335,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1420">56,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1421">115,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1422">171,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cell Engineering operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1423">95,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1424">218,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1425">363,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Biosecurity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1426">37,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1427">53,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1428">78,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-1429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1431">28,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Costs and operating expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Cost of Biosecurity service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1432">28,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1433">38,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1434">46,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Cost of Biosecurity product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="0" id="f-1435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-1436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1437">7,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-1438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1439">771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1440">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1441">27,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1442">44,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1443">55,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Biosecurity operating (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1444">18,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1445">30,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1446">3,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1447">114,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1448">249,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1449">366,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Reconciling items to reconcile total segment operating loss to loss before income taxes:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1450">82,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1451">115,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1452">234,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impairment expense </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-1453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-1454">53,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-1455">121,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1456">58,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1457">63,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1458">70,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restructuring charges </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-1459">11,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-1460">24,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-1461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Carrying cost of excess space (net of sublease income) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1462">53,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1463">25,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:LeaseCost" format="ixt:fixed-zero" scale="3" id="f-1464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Merger and acquisition related expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" sign="-" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-1465">5,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-1466">4,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-1467">61,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="dna:AcquiredInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-1468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="dna:AcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1469">19,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="dna:AcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1470">9,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1471">1,678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1472">8,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1473">28,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1474">313,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1475">547,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1476">892,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1410-1"><ix:continuation id="f-1406-3"><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dna:EmployerPayrollTaxes" scale="6" id="f-1477">1.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="dna:EmployerPayrollTaxes" scale="6" id="f-1478">3.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="dna:EmployerPayrollTaxes" scale="6" id="f-1479">5.0</ix:nonFraction> million in related employer payroll taxes for the years ended December&#160;31, 2025, 2024, and 2023, respectively. </span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">For 2024, includes $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-1480">47.9</ix:nonFraction>&#160;million related to goodwill impairment and $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="f-1481">5.8</ix:nonFraction>&#160;million related to lab equipment. For 2023, includes a $<ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-1482">25.2</ix:nonFraction>&#160;million impairment loss on lab equipment and a $<ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-1483">96.2</ix:nonFraction>&#160;million impairment loss on lease assets associated with an exited Zymergen leased facility.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">See Note </span><span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_575">3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">, Restructuring, for composition of costs. </span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">Includes interest income, interest expense, loss on investments, losses/gains on deconsolidation of subsidiaries, changes in fair value of certain assets and liabilities, and other gains or losses.</span></div></ix:continuation></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_190"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-1484" continuedAt="f-1484-1" escape="true">Significant Collaboration Agreements and Transactions with Related Parties</ix:nonNumeric></span></div><ix:continuation id="f-1484-1" continuedAt="f-1484-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant transactions with its related parties are primarily comprised of revenue generating activities under collaboration and license agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Platform Ventures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has partnered with other investors, including investors who were also Company investors at the time, to form business ventures, including Motif FoodWorks, Inc. in 2018 (&#8220;Motif&#8221;), Allonnia, LLC in 2019 (&#8220;Allonnia&#8221;), Arcaea, LLC in 2021 (&#8220;Arcaea&#8221;), Verb Biotics, LLC in 2021 (&#8220;Verb&#8221;), Ayana Bio, LLC in 2021 (&#8220;Ayana&#8221;) and BiomEdit, LLC in 2022 (&#8220;BiomEdit&#8221;) (collectively &#8220;Platform Ventures&#8221;). Each of these entities is privately held with the Company holding common equity interests in each.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially consolidated Ayana and Verb at formation as variable interests where the Company was initially the primary beneficiary, subsequently deconsolidating both in 2022 when it was concluded that was no longer the case. With respect to the investments in Motif, Allonnia, Arcaea, and BiomEdit, the Company concluded these entities represent variable interest entities, however the Company has never been the primary beneficiary of these entities. The Company accounts for its investments in Platform Ventures under the equity method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the launch of each of the Platform Ventures, the Company received common equity and, with respect to Arcaea, subsequently received additional common equity. The Company generally granted each Platform Venture licenses to certain of the Company&#8217;s intellectual property and executed Technical Development Agreements (&#8220;TDAs&#8221;) that established terms under which the Company would provide technical research and development services to those entities, generally in return for fees on a fixed fee or cost-plus basis for services provided.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The common equity investments in each of the Platform Ventures were initially recorded at the then fair values determined at inception of the investments. The Company is recognizing earnings and losses on these equity method investments using the HLBV method. Accordingly, the carrying values of each of the Platform Ventures investments were reduced to zero immediately following the Company&#8217;s investments. There is no commitment for the Company to provide further financial support to these Platform Ventures, and therefore the carrying value of the equity method investments will not be reduced below zero.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The relationship with the Platform Ventures is as vendor-customer relationships and is within the scope of ASC 606, as the provision of services and corresponding license rights are considered a part of the Company&#8217;s ordinary activities. The common equity issued to the Company represent non-cash consideration under revenue contracts. While TDAs executed by the parties provides payment terms for future services, the TDAs do not provide for any transfer of goods or services between the parties as the Company contemplated provided licenses and services upon execution of future contemplated TDPs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of Ayana and Verb, the Company&#8217;s performance obligations under the initial arrangements consisted of a number of estimated materials rights provided to the Platform Ventures (BiomEdit having <ix:nonFraction unitRef="materialright" contextRef="c-404" decimals="INF" name="dna:NumberOFEstimatedMaterialRights" format="ixt-sec:numwordsen" scale="0" id="f-1485">four</ix:nonFraction> and Arcaea, Allonia and Motif having <ix:nonFraction unitRef="materialright" contextRef="c-405" decimals="INF" name="dna:NumberOFEstimatedMaterialRights" format="ixt-sec:numwordsen" scale="0" id="f-1486"><ix:nonFraction unitRef="materialright" contextRef="c-406" decimals="INF" name="dna:NumberOFEstimatedMaterialRights" format="ixt-sec:numwordsen" scale="0" id="f-1487"><ix:nonFraction unitRef="materialright" contextRef="c-407" decimals="INF" name="dna:NumberOFEstimatedMaterialRights" format="ixt-sec:numwordsen" scale="0" id="f-1488">ten</ix:nonFraction></ix:nonFraction></ix:nonFraction>) to future technical research and development services and commercial licenses under individual TDPs that the Company expected to execute. These material rights equated in aggregate to the fair values of the common equity issued by each of the Platform Ventures to the Company and represented advanced payment for the license rights, which would be granted upon the execution of future applicable TDPs. As there would be no additional payment for these license </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1484-2" continuedAt="f-1484-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rights when future TDPs are executed, the Company determined that there are material rights associated with each of the contemplated TDPs under each of the TDAs. The value of the material rights are included in deferred revenue until recognized as revenue. The material rights are recorded as non-current deferred revenue until such time as the parties execute an applicable TDP inclusive of the material rights. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For each TDP underlying a material right, the transaction price consists of (i) either a fixed fee or, if a cost-plus arrangement, variable consideration for the most likely amount of estimated consideration to be received and (ii) non-cash consideration allocated to the material right. As the services performed by the Company under a TDP inclusive of a material right, the Company creates or enhances an asset that the Platform Ventures controls, the Company satisfies the performance obligation and recognizes revenue over time using an input method that compares total costs incurred relative to total estimated cost to complete to estimate progress under the contract. Any revisions to the estimated total budgeted costs to complete, and the resulting impact on revenue recognition, are reflected in the period of the change through a cumulative catch-up adjustment.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company and Motif mutually terminated its services agreements with no adjustment to the original consideration. As a result, the Company has no further obligation to perform services for Motif and, accordingly, the then remaining $<ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1489">45.4</ix:nonFraction> million in material rights deferred revenue has been recognized in full as revenue during the year ended December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company and BiomEdit mutually terminated its services agreements with no adjustment to the original consideration. As a result, the Company has no further obligation to perform services for BiomEdit, and accordingly, the then remaining $<ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1490">7.5</ix:nonFraction>&#160;million in material rights deferred revenue has been recognized in full as revenue during the year ended December 31, 2025. BiomEdit is no longer considered a significant related party due to a reduction of the Company&#8217;s equity ownership interest that occurred during the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genomatica, Inc. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also partnered with Genomatica, Inc. (&#8220;Genomatica&#8221;), a previously established business that is privately held. Genomatica is deemed a variable interest entity, however the Company has never been the primary beneficiary of this entity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company purchased Series A preferred stock of Genomatica, Inc. for $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-1491">15.0</ix:nonFraction>&#160;million and entered into a collaboration agreement, which was subsequently terminated in September 2018, whereby the Company received $<ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" scale="6" id="f-1492">40.0</ix:nonFraction>&#160;million of Series B preferred stock in Genomatica in exchange for providing Genomatica with up to $<ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-5" name="dna:UpfrontAmountReceived" scale="6" id="f-1493">40.0</ix:nonFraction>&#160;million in services at no charge to Genomatica. The agreements between the Company and Genomatica were determined to be within the scope of ASC 606 directly or by analogy. The Company recognized the revenue for the combined performance obligations using an over-time input method. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded the preferred stock investments were not in-substance common stock and therefore did not qualify for accounting as an equity method investment and should be accounted for as equity security under the measurement alternative for equity investments that do not have a readily determinable fair value. As of December 31, 2024, the Company determined that the investment had substantially no value. During the years ended December 31, 2024, and 2023, the Company recorded impairment losses of $<ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-5" name="dna:PreferredStockInvestmentImpairmentLoss" scale="6" id="f-1494">11.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" name="dna:PreferredStockInvestmentImpairmentLoss" scale="6" id="f-1495">33.0</ix:nonFraction> million, respectively, related to its investment in Genomatica preferred stock.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1484-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="f-1496" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant related party transactions included in the consolidated balance sheet, excluding the Company&#8217;s investments and equity method investments, are summarized below (in thousands):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"><tr><td style="width:1.0%"/><td style="width:63.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Deferred revenue, current and non-current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Allonnia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1497">36,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1498">36,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Arcaea</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1499">28,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1500">28,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BiomEdit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-1501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1502">7,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Genomatica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-1503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="f-1504">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1505">64,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1506">73,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant related party transactions included in the consolidated statements of operations and comprehensive loss, excluding the losses on the Company&#8217;s investments and equity method investments, are summarized below (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"><tr><td style="width:1.0%"/><td style="width:56.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.669%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.669%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cell Engineering revenue:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Motif FoodWorks</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1508">45,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1509">6,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Arcaea</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1511">4,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1512">6,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Genomatica</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1513">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1514">1,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1515">4,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Ayana Bio</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1516">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1517">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1518">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BiomEdit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1519">7,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1520">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1521">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Verb Biotics</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1524">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Allonnia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1526">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1527">523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other equity investees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1529">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1530">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1531">8,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1532">53,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1533">22,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_154">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on the Company&#8217;s investments and equity method investments held in its related parties.</span></div></ix:continuation><div id="id8596373948b4ae4958ccd7c02fd70c1_193"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="c-1" name="us-gaap:DefinedContributionPlanTextBlock" id="f-1534" continuedAt="f-1534-1" escape="true">Employee Benefit Plan </ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1534-1">The Company maintains a 401(k) retirement savings plan for its employees who satisfy certain eligibility requirements. Under this plan, the Company makes a <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1535">5</ix:nonFraction>% non-elective contribution to all eligible employees equal to up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1536">5</ix:nonFraction>% of eligible compensation, which fully vests once such eligible participant has completed <ix:nonNumeric contextRef="c-1" name="dna:DefinedContributionPlanVestingPeriod" format="ixt-sec:durwordsen" id="f-1537">two years</ix:nonNumeric> of continuous service. Effective January 1, 2024, the <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1538">5</ix:nonFraction>% non-elective contribution is capped for employees earning $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="dna:DefinedContributionPlanEmployeeAnnualEarningAmount" format="ixt:num-dot-decimal" scale="0" id="f-1539">100,000</ix:nonFraction> or more in annual salary, resulting in a maximum employer contribution of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="dna:DefinedContributionPlanMaximumEmployerContributionsAmount" format="ixt:num-dot-decimal" scale="0" id="f-1540">5,000</ix:nonFraction>. For the years ended December&#160;31, 2025, 2024 and 2023, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="f-1541">3.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="f-1542">5.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="f-1543">8.2</ix:nonFraction> million, respectively, to the plan.</ix:continuation> </span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_196"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1544" continuedAt="f-1544-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-1544-1" continuedAt="f-1544-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1545" continuedAt="f-1545-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the loss before income taxes consisted of the following (in thousands):  </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:center"><ix:continuation id="f-1545-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.090%"><tr><td style="width:1.0%"/><td style="width:54.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Domestic</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1546">308,990</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1547">514,354</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1548">890,986</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1549">4,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1550">33,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1551">1,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1552">313,600</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1553">547,508</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1554">892,940</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1544-2" continuedAt="f-1544-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1555" continuedAt="f-1555-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the Company recorded the following income tax expense (benefit) (in thousands):  </span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:center"><ix:continuation id="f-1555-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.515%"><tr><td style="width:1.0%"/><td style="width:49.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1556">873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1557">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1558">690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1559">346</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1560">109</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1561">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1562">527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1563">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1564">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1571">1,364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-1572">936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-1573">884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-1574">1,364</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-1575">936</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-1576">884</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1577">837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1578">479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1579">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1580" continuedAt="f-1580-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of income tax benefit computed by applying the 21% statutory U.S. Federal income tax rate to income before income taxes after the adoption of ASU 2023-09 for year ended December&#160;31, 2025 is as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.272%"><tr><td style="width:1.0%"/><td style="width:50.238%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.230%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Tax at U.S. Statutory Rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1581">65,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1582">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">State and Local Income Taxes (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-1583">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1584">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Foreign Tax Effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1585">743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1586">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Nontaxable or Nondeductible Items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1587">14,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1588">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Limitation on executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount" format="ixt:num-dot-decimal" scale="3" id="f-1589">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" scale="-2" id="f-1590">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Gain/Loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-1591">3,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent" scale="-2" id="f-1592">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-1593">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-1594">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Tax Credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Research &amp; Development Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1595">1,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1596">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Changes in Valuation Allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1597">45,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1598">14.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other Items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1599">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1600">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1601">837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1602">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The states and local jurisdictions that contribute to the majority (greater than 50%) of the tax effect in this category include Massachusetts and New York state and city. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax benefit computed at the statutory corporate income tax rate to the effective income tax rate for the years ended December 31, 2024 and 2023 is as follows:</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1544-3" continuedAt="f-1544-4"><ix:continuation id="f-1580-1"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.212%"><tr><td style="width:1.0%"/><td style="width:52.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal income tax at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1603">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1604">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1605">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1606">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1607">10.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1608">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1609">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1610">14.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" scale="-2" id="f-1611">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" scale="-2" id="f-1612">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1613">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1614">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Investments in subsidiaries and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="f-1615">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="f-1616">29.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1617">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1618">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1619">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-1620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:continuation id="f-967-2"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended December&#160;31, 2025, the amount of cash income taxes paid by the Company was as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.545%"><tr><td style="width:1.0%"/><td style="width:68.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxPaidFederalAfterRefundReceived" format="ixt:fixed-zero" scale="3" id="f-1621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State and local:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">California</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-1622">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">South Carolina</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-1623">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">All other state and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="3" id="f-1624">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxPaidForeignAfterRefundReceived" format="ixt:fixed-zero" scale="3" id="f-1625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash income taxes, net of refunds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-1626">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1544-4" continuedAt="f-1544-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1627" continuedAt="f-1627-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s deferred tax assets and liabilities consist of the following (in thousands):  </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:center"><ix:continuation id="f-1627-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.303%"><tr><td style="width:1.0%"/><td style="width:65.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1628">459,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1629">332,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1630">63,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1631">61,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1632">155,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1633">214,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="f-1634">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="f-1635">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:DeferredTaxAssetsDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1636">21,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:DeferredTaxAssetsDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1637">28,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1638">48,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1639">52,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortizable intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:DeferredTaxAssetsAmortizableIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-1640">11,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:DeferredTaxAssetsAmortizableIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-1641">10,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1642">112,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1643">116,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Investments in subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:DeferredTaxAssetsInvestmentsInSubsidiaries" format="ixt:num-dot-decimal" scale="3" id="f-1644">59,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:DeferredTaxAssetsInvestmentsInSubsidiaries" format="ixt:num-dot-decimal" scale="3" id="f-1645">57,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1646">2,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-1647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1648">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1649">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1650">936,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1651">875,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1652">840,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1653">771,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1654">96,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1655">103,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortizable intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dna:DeferredTaxLiabilitiesAmortizableIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-1656">10,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="dna:DeferredTaxLiabilitiesAmortizableIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-1657">11,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-1658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-1659">545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1660">92,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1661">98,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1662">102,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1663">110,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred taxes</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1664">6,094</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1665">6,552</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-1666" continuedAt="f-1666-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Activity in the deferred tax assets valuation allowance is summarized as follows (in thousands):  </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:center"><ix:continuation id="f-1666-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:60.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Beginning of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Additions<br/>(Subtractions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets valuation allowance:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Year ended December 31, 2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1667">771,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-1668">68,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1669">840,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Year ended December 31, 2024</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1670">711,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-1671">60,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1672">771,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. The Company considered its history of cumulative net losses incurred since inception and has concluded that it is more-likely-than-not that it will not realize the benefits of the deferred tax assets. Accordingly, a valuation allowance has been established against the deferred tax assets as of December&#160;31, 2025 and 2024 that are not expected to be realized. The Company reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased on a net basis by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-1673">68.2</ix:nonFraction> million during the year ended December&#160;31, 2025 primarily due to increases in the deferred tax assets related to net operating loss carryforwards partially offset by the continued amortization of capitalized research and development costs as allowed by certain provisions of the One Big Beautiful Bill Act of 2025.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2025, the Company had federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="9" id="f-1674">1.8</ix:nonFraction> billion, of which $<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1675">139.2</ix:nonFraction> million will begin to expire in 2029 and $<ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="9" id="f-1676">1.6</ix:nonFraction> billion can be carried forward indefinitely. As of December&#160;31, 2025, the Company had state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="9" id="f-1677">1.5</ix:nonFraction> billion, of which $<ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="9" id="f-1678">1.2</ix:nonFraction> billion will begin to expire in 2030 and $<ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1679">257.5</ix:nonFraction> million can be carried forward indefinitely. The Company also had $<ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1680">3.9</ix:nonFraction>&#160;million of foreign net operating losses as of December&#160;31, 2025, of which $<ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1681">1.5</ix:nonFraction>&#160;million will begin to expire in 2034 and $<ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1682">2.4</ix:nonFraction>&#160;million can be carried forward indefinitely.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-1544-5" continuedAt="f-1544-6"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had federal research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1683">38.8</ix:nonFraction> million, which will begin to expire in 2029. As of December&#160;31, 2025, the Company also had state research and development and investment tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1684">31.4</ix:nonFraction> million, which will begin to expire in 2030. </span></div><div style="margin-bottom:9pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the U.S. Internal Revenue Code, if a corporation undergoes an ownership change, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income and taxes may be limited. The Company may have experienced an ownership change in the past and may experience ownership changes in the future as a result of future transactions in its share capital, some of which may be outside of the Company&#8217;s control. As a result, if the Company earns net taxable income, the Company's ability to use its pre-change net operating loss carryforwards, or other pre-change tax attributes, to offset U.S. federal and state taxable income and taxes may be subject to significant limitations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it operates to assess their potential effect on its business and assumptions regarding future taxable income. The Company cannot predict whether specific proposals will be enacted, the terms of such proposals, or their potential impact on its business if enacted. In 2025, no major tax legislation was enacted in the jurisdictions where the Company operates that materially impacted its consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which the Company operates. In the normal course of business, the Company is subject to examination by U.S. federal, state, local, and foreign taxing authorities, where applicable. There are currently no tax examinations in progress. As of December&#160;31, 2025, with few exceptions, the Company is no longer subject to U.S. federal, state, local, or foreign examinations by tax authorities for tax years before 2016. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state taxing authorities to the extent utilized in a future period.</span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1544-6">The Company accounts for uncertain tax positions using a more likely than not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an annual basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2025 and 2024, the Company had <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt-sec:numwordsen" id="f-1685">no</ix:nonFraction> recorded liabilities for uncertain tax positions and had <ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt-sec:numwordsen" id="f-1686">no</ix:nonFraction> accrued interest or penalties related to uncertain tax positions.</ix:continuation> </span></div><div id="id8596373948b4ae4958ccd7c02fd70c1_199"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1687" continuedAt="f-1687-1" escape="true">Net Loss per Share </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1688" escape="true"><ix:continuation id="f-1687-1" continuedAt="f-1687-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of earnings per common share is as follows (in thousands, except share data): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1689">312,763</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1690">547,029</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1691">892,869</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1692">55,457,676</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1693">51,894,639</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1694">48,610,507</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1695">5.64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1696">10.54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1697">18.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id8596373948b4ae4958ccd7c02fd70c1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1698" escape="true"><ix:continuation id="f-1687-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:60.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested PSUs</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-456" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1699">4,407,287</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-457" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-458" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1701">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Warrants to purchase Class A common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-459" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1702">1,295,622</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-460" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1703">1,295,622</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-461" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1704">1,295,622</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested RSUs</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-462" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1705">1,262,853</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-463" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1706">3,327,398</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-464" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1707">3,804,189</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Earnout shares </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-465" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1708">3,793,063</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-466" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1709">3,794,243</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-467" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1710">3,803,049</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-468" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1711">366,567</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-469" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1712">767,520</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-470" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1713">192,208</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Escrow shares </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-471" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-472" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1715">20,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-473" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1717">11,125,392</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1718">9,205,115</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1719">9,095,068</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Represents employee and non-employee earnout shares for which the service-based and/or market-based vesting conditions have not been satisfied. </span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Represents restricted common stock issued in connection with asset acquisitions, held in escrow for indemnification purposes, and subject to forfeiture.</span></div></ix:continuation></ix:nonNumeric><div id="id8596373948b4ae4958ccd7c02fd70c1_205"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1720" continuedAt="f-1720-1" escape="true">Subsequent Events </ix:nonNumeric></span></div><ix:continuation id="f-1720-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2026, the Company entered into a definitive Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) to sell substantially all of the operations comprising its Biosecurity segment (the &#8220;Biosecurity Business&#8221;) to a newly formed entity (&#8220;Tower Biosecurity Holdings, Inc.&#8221;). Under the terms of the agreement, the Company will contribute the Biosecurity Business to Tower Biosecurity Holdings, Inc. in exchange for approximately <ix:nonFraction unitRef="number" contextRef="c-474" decimals="2" name="dna:StockPurchaseAgreementPercentOfEquityInterestToBeReceived" scale="-2" id="f-1721">20</ix:nonFraction>% equity interest of the total issued and outstanding equity of Tower Biosecurity Holdings, Inc. as of closing. The transaction is expected to close in the first half of 2026, subject to customary closing conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Upon closing, the Company expects to present the Biosecurity Business as discontinued operations in its consolidated financial statements and to recast prior period amounts to conform to this presentation. The transaction was approved by the Company's Board of Directors in February 2026, and, accordingly, the assets and liabilities of the Biosecurity Business are not reflected as held for sale as of December 31, 2025 and the accompanying consolidated financial statements do not reflect the effects of this transaction.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-54</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>dna-20251231xex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i04df4daac30141d3a8be1477060e9846_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The following summary of the material terms of the capital stock of Ginkgo Bioworks Holdings, Inc. (&#8220;Ginkgo,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our certificate of incorporation (as amended, the &#8220;Charter&#8221;), our amended and restated bylaws (the &#8220;Bylaws&#8221;) and the warrant-related documents described herein, which are filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). We urge you to read each of our Charter, our Bylaws and the warrant-related documents described herein in their entirety for a complete description of the rights and preferences of our securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Authorized Capital Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ginkgo&#8217;s Charter authorizes the issuance of 16,000,000,000 shares of all classes of Ginkgo&#8217;s capital stock, consisting of&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">200,000,000 shares of undesignated preferred stock, par value $0.0001 per share&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">10,500,000,000 shares of Class A common stock, par value $0.0001 per share (&#8220;Class A common stock&#8221;)&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">4,500,000,000 shares of Class B common stock, par value $0.0001 per share (&#8220;Class B common stock&#8221;)&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">800,000,000 shares of Class C common stock, par value $0.0001 per share (&#8220;Class C common stock&#8221;).</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Common Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ginkgo has three classes of authorized common stock&#58; Class A common stock, Class B common stock, and Class C common stock (collectively, the &#8220;Common Stock&#8221;). Generally, Class B common stock can only be issued to, transferred to, and held by Ginkgo&#8217;s directors and employees, or trusts or legal entities through which the right to vote the shares of Class B common stock held thereby is exercised exclusively by one or more of Ginkgo&#8217;s directors or employees (any such director, employee, trust or legal entity, an &#8220;Eligible Holder&#8221;), unless otherwise determined by a majority of the Class B Directors (defined below) then serving.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Class A Common Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Holders of Class A common stock are entitled to one (1) vote for each share of Class A common stock held of record by such holder on all matters voted upon by Ginkgo stockholders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Class B Common Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Holders of Class B common stock are entitled to ten (10) votes for each share of Class B common stock held of record by such holder on all matters voted upon by Ginkgo stockholders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Class C Common Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Except as expressly provided in Ginkgo&#8217;s Charter or required by applicable law, holders of Class C common stock generally are not entitled to vote on matters voted upon by Ginkgo stockholders. Solely to the extent that a holder of Class C common stock is expressly entitled to vote on any matter pursuant to Ginkgo&#8217;s Charter or by applicable law, the holder will be entitled to one (1) vote for each share of Class C common stock held of record by such holder.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Stockholder Votes</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Holders of Common Stock generally vote together as a single class on all matters submitted to a vote of Ginkgo stockholders (including the election and removal of directors), unless otherwise provided in Ginkgo&#8217;s Charter or required by applicable law. Any action or matter submitted to a vote of the Ginkgo stockholders will be approved if the number of votes cast in favor of the action or matter exceeds the number of votes cast in opposition to the action or matter, except that Ginkgo&#8217;s directors will be elected by a plurality of the votes cast. Holders of Class A common stock are not entitled to cumulate their votes in the election of Ginkgo&#8217;s directors.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Delaware law could require holders of a class of Ginkgo&#8217;s capital stock to vote separately as a class on any proposed amendment of Ginkgo&#8217;s Charter if the amendment would increase or decrease the par value of the shares of that class or would alter or change the powers, preferences or special rights of the shares of that class in a manner that affects them adversely.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Holders of Common Stock are not entitled to vote on any amendment to Ginkgo&#8217;s Charter that relates solely to the terms of one or more series of Ginkgo&#8217;s preferred stock and on which the holders of such affected series are entitled to vote, either separately as a class or together with the holders of one or more other series of Ginkgo&#8217;s preferred stock, pursuant to Ginkgo&#8217;s Charter or by applicable law.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Stockholder Action by Written Consent</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides that Ginkgo&#8217;s stockholders may act by written consent only if (a) the action to be taken or effected has been approved by the affirmative vote of all of the directors of Ginkgo then serving or (b) the holders of Class B common stock collectively beneficially own shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo. In all other circumstances, any action required or permitted to be taken by Ginkgo&#8217;s stockholders must be effected at a duly called annual or special meeting of stockholders and may not be taken or effected by written consent.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Special Meetings of Stockholders</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides that, except as otherwise required by applicable law, special meetings of Ginkgo&#8217;s stockholders may be called only by the Ginkgo Board of Directors (the &#8220;Ginkgo Board&#8221;), the chairman of the Ginkgo Board, Ginkgo&#8217;s chief executive officer or president, or, at any time that the holders of Class B common stock collectively beneficially own shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo, the holders of shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Economic Rights</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Except as otherwise expressly provided in Ginkgo&#8217;s Charter or required by applicable law, shares of each class of Common Stock have the same rights, powers and preferences and rank equally, share ratably and be identical in all respects as to all matters, including the following&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Dividends and Distributions&#59; Rights upon Liquidation</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the rights of holders of any outstanding series of Ginkgo preferred stock, the holders of shares of each class of Common Stock are entitled to receive ratably, on a per share basis, any dividend or distribution (including upon the liquidation, dissolution or winding up of Ginkgo) paid by Ginkgo, unless otherwise approved by the affirmative vote of the holders of a majority of each of the outstanding shares of Class A common stock, the outstanding shares of Class B common stock, and the outstanding shares of Class C common stock, each voting separately as a class, except that, if a dividend or distribution is paid in the form of shares (or options, warrants or other rights to acquire shares) of Common Stock, then holders of Class A common stock will receive shares (or options, warrants or other rights to acquire shares) of Class A common stock, holders of Class B common stock will receive shares (or options, warrants or other rights to acquire shares) of Class B common stock, and holders of shares of Class C common stock will receive shares (or options, warrants or other rights to acquire shares) of Class C common stock.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Subdivisions, Combinations and Reclassifications</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If Ginkgo subdivides or combines any class of Common Stock with any other class of Common Stock, then each class of Common Stock must be subdivided or combined in the same proportion and manner, unless different treatment of the shares of each such class of Common Stock otherwise is approved by the affirmative votes cast for such different treatment exceeding votes cast against such different treatment of Class A Common Stock, the affirmative votes cast for such different treatment exceeding votes cast against such different treatment of Class B Common Stock and the affirmative votes cast for such different treatment exceeding votes cast against such different treatment of Class C Common Stock, each voting separately as a class.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Mergers and Other Extraordinary Transactions</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides that, in the event of certain extraordinary transactions affecting Ginkgo (including certain transactions resulting in a change of control of Ginkgo, the acquisition by a third party of assets of Ginkgo generating at least 50% of Ginkgo&#8217;s revenues on a consolidated </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">basis, or any merger or consolidation of Ginkgo), shares of each class of Common Stock will be entitled to receive ratably, on a per share basis, any consideration paid or otherwise distributed to, or rights received by, Ginkgo stockholders, or into which such shares are converted or for which such shares are exchanged, in connection with such extraordinary transaction (including with respect to the form, amount and timing thereof), unless different treatment of the shares of each such class is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A common stock, the holders of a majority of the outstanding shares of Class B common stock and the holders of a majority of the outstanding shares of Class C common stock, each voting separately as a class, except that, to the extent that such consideration is paid in the form of securities or other equity interests, holders of Class B common stock may receive a class, series or other form of such securities or other equity interests each having voting power that is ten (10) times greater than the voting power of any security or other equity interest received by holders of Class A common stock and holders of Class C common stock may receive a class, series or other form of such securities or other equity interests having no voting power.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Additionally, the Charter prohibits Ginkgo from entering into any agreement with respect to a tender or exchange offer by a third party unless such agreement provides for consideration to be paid or distributed to, or rights to be received by, Ginkgo stockholders in the manner provided in the paragraph immediately above.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Equal Value upon Disposition</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides that, in the case of any disposition of Class B common stock for value, the value paid in respect of such share of Class B common stock must be equal to the prevailing price per share of Class A common stock at the time of such disposition for value. Ginkgo may (and expects to) from time to time establish restrictions, policies and procedures relating to transfers and dispositions of shares of Class B common stock as it deems necessary or advisable.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Earn-outs Applicable to Certain Equity Holders of Old Ginkgo</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In connection with the Merger, equity holders of Ginkgo Bioworks, Inc. (&#8220;Old Ginkgo&#8221;) received approximately 4.7 million shares of Common Stock (as adjusted for the one-for-forty (1&#58;40) reverse stock split of the Company&#8217;s Class A common stock, Class B common stock and Class C common stock effected on August 19, 2024) (the &#8220;Earnout Consideration&#8221;), which are subject to forfeiture to the extent that the vesting conditions described below are not satisfied on or before the fifth anniversary of September 16, 2021 (the &#8220;Closing Date&#8221; and such period, the &#8220;Earnout Period&#8221;). If at any point during the trading hours of a trading day, for any 20 trading days within any period of 30 consecutive trading days during the Earnout Period, the trading price per share of the Company&#8217;s Class A common stock is greater than or equal to&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">$500.00, then 25% of the Earnout Consideration will immediately vest&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">$600.00, then an additional 25% of the Earnout Consideration will immediately vest&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">$700.00, then an additional 25% of the Earnout Consideration will immediately vest&#59; and</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">$800.00, then the remaining 25% of the Earnout Consideration will immediately vest.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The first earnout target of $500.00 was met on November 15, 2021 and, as a result, approximately 1 million earnout shares (as adjusted for the one-for-forty (1&#58;40) reverse stock split of the Company&#8217;s Class A common stock, Class B common stock and Class C common stock effected on August 19, 2024) became vested and outstanding.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Conversion</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Optional Conversion</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Holders of Class B common stock have the right to convert shares of their Class B common stock into fully paid and non assessable shares of Class A common stock, on a one-to-one basis, at the option of the holder at any time upon written notice to Ginkgo&#8217;s transfer agent.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Automatic Conversion</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Generally, shares of Class B common stock will convert automatically into Class A common stock upon the holder of such shares ceasing to be an Eligible Holder (whether as a result of the holder&#8217;s termination, resignation or removal as a director or employee of Ginkgo, the transfer of such shares to an individual, trust or entity that is not an Eligible Holder, a person other than a director or employee of Ginkgo gaining any direct or indirect right to vote such shares, or otherwise), unless otherwise determined by the affirmative vote of a majority of the directors of Ginkgo then serving who qualify as &#8220;independent&#8221; in accordance with the requirements of the securities exchange on which equity securities of Ginkgo are then listed for trading. A determination by the secretary of the Ginkgo that an event has occurred that triggers the automatic conversion of Class B common stock into Class A common stock will be conclusive and binding&#59; however, a holder of Class B common stock (or Class A common stock into which Class B common stock has converted) who believes in good faith that such determination is in error may appeal such determination to the Ginkgo Board, in which case, the determination of the Ginkgo Board (including as to whether or not to review such determination) will be conclusive and binding.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Conversion Policies and Procedures</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ginkgo may (and expects to) establish from time to time certain restrictions, policies and procedures relating to the general administration of its multi-class stock structure and the conversion of Class B common stock to Class A common stock. Adoption or amendment of any such policy or procedure must be approved by the affirmative vote of a majority of Ginkgo&#8217;s directors and, if any Class B Director is then serving, at least one Class B Director (defined below).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Registration Rights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Certain Ginkgo stockholders are party to agreements, which grant certain Ginkgo stockholders the right to require, subject to certain conditions and limitations, that Ginkgo register for resale </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">securities held by such stockholders and certain &#8220;piggyback&#8221; registration rights with respect to. certain registrations initiated by Ginkgo. The registration of shares of Class A common stock pursuant to the exercise of any of these registration rights would enable the applicable Ginkgo stockholders to resell such shares without restriction under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) when the applicable registration statement is declared effective. Ginkgo will bear the expenses incurred in connection with the filing of any registration statements pursuant to these agreements.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Rights</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter and Bylaws do not provide for any preemptive or subscription rights with respect to the Common Stock, and there are no redemption or sinking fund provisions applicable to the Common Stock. All the outstanding shares of Common Stock are validly issued, fully paid and non-assessable.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter authorizes the Ginkgo Board, to the fullest extent permitted by applicable law, to issue up to an aggregate of 200,000,000 shares of Ginkgo preferred stock in one or more series from time to time by resolution, without further action by Ginkgo&#8217;s stockholders, and to fix the powers (which may include full, limited or no voting power), designations, preferences and relative, participating, optional or other special rights, if any, of the shares of each such series (which rights may be greater than the rights of any or all of the classes of Common Stock) and any qualifications, limitations or restrictions thereof. The issuance of Ginkgo preferred stock could adversely affect the voting power of holders of Common Stock and the likelihood that such holders will receive dividend payments or payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deterring or preventing a change of control or other corporate action. No shares of preferred stock are currently outstanding, and there is no present plan to issue any shares of preferred stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Other Constituencies</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In acknowledgment of our goal of serving all of our stakeholders over the long term, the Charter provides that, in addition to any other considerations which the Ginkgo Board, any committee thereof, or any individual director lawfully may take into account in determining whether to take or refrain from taking corporate action on any matter, including making or declining to make any recommendation to our stockholders, our board of directors, any committee thereof, or any individual director may, in his, her, or its discretion, consider the long-term as well as the short-term interests of Ginkgo, taking into account and considering, as deemed appropriate, the effects of such action on our (a) stockholders and (b) other stakeholders, including our workforce, customers, suppliers, academic researchers, governments and communities, in the case of (b), as may be identified or revised by the Ginkgo Board from time to time. The Charter also provides that nothing in the Charter or any other governing document, policy, or guideline adopted by us will (i) create any duty owed by any director to any person or entity to consider, or afford any particular weight to, any of the foregoing matters or to limit his or her consideration thereof or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii) other than as vested in our stockholders to the extent provided under applicable law, be construed as creating any rights against any director or us. These constituency provisions grant discretionary authority only to the extent consistent with and permitted by law, and do not confer third-party beneficiary status on any person or entity.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Election, Appointment and Removal of Directors</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Until the time at which the outstanding shares of Class B common stock cease to represent at least 2% of all of the outstanding shares of Common Stock, the holders of Class B common stock, voting separately as a class, will be entitled to nominate and elect a number of directors equal to 25% (rounded up to the nearest whole number) of the total number of directors constituting the Ginkgo Board (each such director, a &#8220;Class B Director&#8221;). All other directors of Ginkgo will be elected by the holders of all classes of Common Stock, voting together as a single class.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The total number of directors constituting the Ginkgo Board will be fixed from time to time by Ginkgo&#8217;s Board, but will be subject to adjustment to ensure that the total number of directors that the holders of Class B common stock are entitled to nominate and elect is at least 25% of the total number of directors constituting the Ginkgo Board.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides that any Class B Director may be removed from office (a) with cause, only by the affirmative vote of the holders of shares representing a majority of the voting power of all of the outstanding shares of Class B common stock and (b) without cause, by the affirmative vote of the holders of shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo, voting together as a single class. Any director of Ginkgo other than a Class B Director may be removed from office, with or without cause, by the affirmative vote of the holders of shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo, voting together as a single class.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides that vacant directorships, including vacancies resulting from any increase in the total number of directors constituting the Ginkgo Board, may be filled only by the Ginkgo Board. Vacancies with respect to any Class B Director may be filled only by the remaining Class B Directors.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Committees of the Board of Directors</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Ginkgo Board has established, and will maintain, an audit committee, a nominating and corporate governance committee and a compensation committee, and may establish such other committees as it determines from time to time. For so long as any of Jason Kelly, Reshma Shetty, Austin Che, Bartholomew Canton or Thomas F. Knight, Jr. (each, a &#8220;Founder&#8221;) serves as a director of Ginkgo and holds shares of Class B common stock, such director will not be permitted to serve as a member of the compensation committee of the Ginkgo Board. Subject to applicable requirements of the securities exchange on which equity securities of Ginkgo are then listed for trading, at any time that any Class B Director is serving as a director of Ginkgo, each committee (other than the compensation committee) of the Ginkgo Board must include at least </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">one Class B Director unless a majority of the Class B Directors then serving approve the formation and composition of such committee.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Action by the Ginkgo Board of Directors to Terminate a Founder</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ginkgo may not terminate the employment of any Founder for cause, or materially and adversely reduce the responsibilities, title or position of such Founder for cause, without the prior written consent of such Founder, or make any determination that an event has occurred with respect to such Founder that constitutes &#8220;cause&#8221; (as that term or any similar concept may be defined or used in any agreement relating to the employment of such Founder by Ginkgo or any of its subsidiaries or any policy of Ginkgo or any of its subsidiaries applicable to the employment of such Founder), unless such termination, reduction or determination has been approved by at least 75% of the directors of Ginkgo then in office.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ginkgo may not terminate the employment of any Founder other than for cause, or materially and adversely reduce the responsibilities, title or position of such Founder other than for cause, without the prior written consent of such Founder, unless such termination or reduction has been approved by at least 75% of the directors of Ginkgo then in office and, if any Founder who is not the subject of the action requiring such approval is then serving as a director of Ginkgo, at least one director of Ginkgo who is a Founder.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Takeover Effects of the Charter and the Bylaws</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter and Bylaws contain certain provisions that may delay, discourage or impede efforts by another person or entity to acquire control of Ginkgo. We believe that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons or entities seeking to acquire control of us to first negotiate with the Ginkgo Board, which we believe may result in improvement of the terms of any such acquisition in favor of Ginkgo&#8217;s stockholders. However, these provisions also give the Ginkgo Board the power to discourage acquisitions that some stockholders may favor.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Authorized but Unissued Capital Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The authorized but unissued shares of our common stock and our preferred stock will be available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of the securities exchange on which Ginkgo&#8217;s equity securities are then listed for trading. These additional shares of capital stock may be used for a variety of corporate purposes, including growth acquisitions, corporate finance transactions, and issuances under our Equity Incentive Plan and our Employee Stock Purchase Plan. The existence of authorized but unissued and unreserved capital stock could discourage or impede an attempt to obtain control of Ginkgo by means of a proxy contest, tender offer, merger, or otherwise.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment of Certificate of Incorporation or Bylaws</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Delaware General Corporation Law, as amended (&#8220;DGCL&#8221;) generally provides that the affirmative vote of a majority of the outstanding shares entitled to vote on amendments to a corporation&#8217;s certificate of incorporation or bylaws is required to approve such amendment, unless a corporation&#8217;s certificate of incorporation or bylaws, as applicable, imposes a higher voting standard.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides that certain provisions thereof may be adopted, amended, altered or repealed only upon the affirmative vote of the holders of at least two-thirds of the voting power of all of the outstanding shares of capital stock of Ginkgo. Such provisions include those relating to (i) stockholder action by written consent, (ii) special meetings of stockholders, (iii) the Ginkgo Board (including the election, appointment and removal of directors), (iv) termination of the employment of any Founder, material and adverse reduction of the responsibilities, title or position of any Founder without the prior written consent of such Founder, or determination that an event has occurred with respect to any Founder that constitutes &#8220;cause&#8221;, (v) limitation of the personal liability of Ginkgo&#8217;s directors, and (vi) Ginkgo&#8217;s waiver of the corporate opportunity doctrine.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides that Ginkgo&#8217;s Bylaws may be adopted, amended, altered or repealed by the Ginkgo Board or by the affirmative vote of the holders of at least two-thirds of the voting power of all of the outstanding shares of capital stock of Ginkgo (or, if the Ginkgo Board has recommended that stockholders approve such modification to Ginkgo&#8217;s Bylaws, the affirmative vote of a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo).</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">These provisions may have the effect of deterring hostile takeovers or delaying or preventing changes of control of Ginkgo or its management such as a merger, reorganization or tender offer. These provisions are intended to enhance the likelihood of continued stability in the composition of the Ginkgo Board and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of Ginkgo and to reduce Ginkgo&#8217;s vulnerability to an unsolicited acquisition proposal. These provisions are also intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for Ginkgo&#8217;s shares and, as a consequence, may inhibit fluctuations in the market price of Ginkgo&#8217;s shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in management.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Multi-Class Structure</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">As described above, the Charter provides for a multi-class stock structure, which gives Ginkgo&#8217;s directors and employees (including the Founders) and certain of their affiliated entities and trusts, for so long as they continue to collectively beneficially own shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo, significant influence over all matters requiring stockholder approval, including the election of Ginkgo&#8217;s directors and significant corporate transactions, such as a merger or other sale of Ginkgo or all or substantially all of its assets.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">No Cumulative Voting for Directors</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The DGCL provides that stockholders are not entitled to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. The Charter does not provide for cumulative voting. As a result, the holders of shares of Common Stock representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo will be able to elect all of the directors (other than the Class B Directors) then standing for election.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Vacancies on the Ginkgo Board</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter authorizes only the Ginkgo Board to fill vacant directorships, including vacancies resulting from any increase in the total number of directors constituting the Ginkgo Board. In addition, the total number of directors constituting the Ginkgo Board is permitted to be changed only by the Ginkgo Board, subject to the requirement that at least 25% of the total number of Ginkgo&#8217;s directors be Class B Directors (for so long as the outstanding shares of Class B common stock continue to represent at least 2% of all the outstanding shares of Common Stock). These provisions could prevent a stockholder from increasing the total number of Ginkgo&#8217;s directors and then gaining control of the Ginkgo Board.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Special Meetings of Stockholders, Action by Written Consent, and Advance Notice Requirements for Stockholder Proposals</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Special Meetings of Stockholders</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter permits special meetings of Ginkgo&#8217;s stockholders to be called only by the Ginkgo Board, the chairman of the Ginkgo Board, Ginkgo&#8217;s chief executive officer or president, or, at any time that the holders of Class B common stock collectively beneficially own shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo, the holders of shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo. These provisions might delay the ability of Ginkgo&#8217;s stockholders to force consideration of a proposal or to take any action, including with respect to the removal of any of Ginkgo&#8217;s directors from office.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Stockholder Action by Written Consent</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides that Ginkgo&#8217;s stockholders may act by written consent only if (a) the action to be taken or effected has been approved by the affirmative vote of all of the directors of Ginkgo then serving or (b) the holders of Class B common stock collectively beneficially own shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo. As a result, if the holders of Class B common stock were to cease to collectively beneficially own shares representing a majority of the voting power of all of the outstanding shares of capital stock of Ginkgo, Ginkgo&#8217;s stockholders would not be able to take action by written consent on any matter and would only be able to take action at an annual or special </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">meeting of stockholders, unless the Ginkgo Board had unanimously approved the action to be taken or effected.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Advance Notice Requirement for Stockholder Proposals and Director Nominations</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to the Ginkgo Board. In order for any matter to be &#8220;properly brought&#8221; before a meeting (and thereby considered or acted upon at such meeting), a stockholder will have to comply with certain advance notice requirements and provide Ginkgo with certain information. Stockholders at an annual meeting will only be permitted to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Ginkgo Board or by a stockholder of record both on the record date and at the time of the meeting who is entitled to vote at the meeting and has delivered a timely notice, in the form and manner specified in the Bylaws, of such stockholder&#8217;s intention to bring such business before the meeting. These provisions might preclude Ginkgo&#8217;s stockholders from bringing matters before our annual meeting of stockholders or from nominating candidates for election to the Ginkgo Board, or might discourage or impede an attempt by a potential acquirer of Ginkgo to conduct a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise obtain control of Ginkgo.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Business Combinations</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ginkgo has elected not to be subject to Section 203 of the DGCL. Under Section 203 of the DGCL, a corporation will not be permitted to engage in a business combination with any interested stockholder for a period of three years following the time that such interested stockholder became an interested stockholder, unless&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(1) prior to such time, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(2) upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(3) at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an &#8220;interested stockholder&#8221; is a person who, together with that person&#8217;s affiliates and associates, owns, or within the previous three years owned, 15% or more of Ginkgo&#8217;s outstanding voting stock. For purposes of this section only, &#8220;voting stock&#8221; has the meaning given to it in Section 203 of the DGCL.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Because Ginkgo has opted out of Section 203 of the DGCL in the Charter, Section 203 of the DGCL will not apply to Ginkgo.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Warrants</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there are outstanding an aggregate of 51,824,895 warrants to acquire Class A common stock (the &#8220;Warrants&#8221;).</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">At the effective time of the domestication pursuant to which Soaring Eagle Acquisition Corp.&#8217;s (&#8220;SRNG&#8221;) jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware, each warrant to purchase SRNG ordinary shares (each, a &#8220;SRNG Warrant&#8221;) that was issued and outstanding, and not terminated pursuant to its terms, was converted into a warrant to purchase shares of Common Stock on the same terms and conditions as were in effect with respect to such SRNG Warrant immediately prior to the effective time.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">At the effective time of the Merger Agreement (the &#8220;Merger Agreement&#8221;) dated May 11, 2021, by and among Old Ginkgo, SRNG and SEAC Merger Sub Inc., each warrant to purchase shares of Old Ginkgo capital stock (each, an &#8220;Old Ginkgo Warrant&#8221;) that was outstanding and unexercised, other than such Old Ginkgo Warrants that were automatically exercised in full by virtue of the occurrence of the Merger, were assumed by Ginkgo and converted into a warrant to purchase shares of Class A common stock on the same terms and conditions as were in effect with respect to such Old Ginkgo Warrant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">immediately prior to the effective time, with appropriate adjustments.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Public Warrants</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ginkgo&#8217;s warrants, which were previously issued in connection with SNRG&#8217;s initial public offering and listed on the New York Stock Exchange (&#8220;NYSE&#8221;) until the NYSE delisted such warrants on September 4, 2024 (the &#8220;Public Warrants&#8221;), entitle the holder to acquire Class A common stock. Each whole Public Warrant entitles the registered holder to purchase one-fortieth (1&#47;40) of one share of Class A common stock at a price of $460.00 per share, subject to adjustment as discussed below, beginning 30 days after the Closing Date, provided that Ginkgo has an effective registration statement under the Securities Act covering the Class A common stock issuable upon exercise of the Public Warrants and a current prospectus relating to such Class A common stock is available (or Ginkgo permits holder to exercise their respective warrants on a cashless basis under the circumstances specified in the warrant agreement) and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the warrant agreement, a holder may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">exercise its Public Warrants only for a whole number of shares of Class A common stock. No fractional shares of Class A common stock will be issued upon exercise of the Public Warrants&#59; therefore, a minimum of 40 Warrants must be exercised to receive any entitlement. The Public Warrants will expire five years after the Closing Date, at 5&#58;00 p.m., New York City time, or earlier upon redemption or liquidation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Redemption of Warrants for Cash</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Once the Warrants become exercisable, Ginkgo may call the Warrants for redemption for cash&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">in whole and not in part&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">at a price of $0.01 per Warrant&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">upon not less than 30 days&#8217; prior written notice of redemption (the &#8220;30-day redemption period&#8221;) to each warrant holder&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">if, and only if, the reported closing price of the Class A common stock equals or exceeds $720.00 per share (as adjusted for stock sub-divisions, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before Ginkgo sends the notice of redemption to the warrant holders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If and when the Warrants become redeemable by Ginkgo, Ginkgo may exercise its redemption right even if Ginkgo is unable to register or qualify the underlying securities for sale under all applicable state securities laws.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ginkgo has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and Ginkgo issues a notice of redemption of the Warrants, each warrant holder will be entitled to exercise his, her or its Warrant prior to the scheduled redemption date. However, the price of the Class A common stock may fall below the $720.00 redemption trigger price (as adjusted for stock sub-divisions, stock capitalizations, reorganizations, recapitalizations and the like) as well as the $460.00 warrant exercise price after the redemption notice is issued.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Redemption Procedures and Cashless Exercise</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If Ginkgo calls the Warrants for redemption as described above, Ginkgo&#8217;s management will have the option to require any holder that wishes to exercise his, her or its Warrant to do so on a &#8220;cashless basis.&#8221; In determining whether to require all holders to exercise their Warrants on a &#8220;cashless basis,&#8221; Ginkgo&#8217;s management will consider, among other factors, Ginkgo&#8217;s cash position, the number of Warrants that are outstanding and the dilutive effect on Ginkgo&#8217;s stockholders of issuing the maximum number of shares of Class A common stock issuable upon the exercise of its Warrants. If Ginkgo management takes advantage of this option, all holders of Warrants would pay the exercise price by surrendering their Warrants for that number of shares of Class A common stock equal to the quotient obtained by dividing (x) the product of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">number of Class A common stock underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; of the Class A common stock over the exercise price of the warrants by (y) the fair market value. The &#8220;fair market value&#8221; will mean the average reported closing price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. If the Ginkgo management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of shares of Class A common stock to be received upon exercise of the warrants, including the &#8220;fair market value&#8221; in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption.</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Ginkgo believes this feature is an attractive option to Ginkgo if Ginkgo does not need the cash from the exercise of the Warrants. If Ginkgo calls the Warrants for redemption and Ginkgo&#8217;s management does not take advantage of this option, the holders of private placement warrants (the &#8220;Private Placement Warrants&#8221;) and their permitted transferees would still be entitled to exercise their Private Placement Warrants or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their Warrants on a cashless basis, as described in more detail below.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A holder of a Warrant may notify Ginkgo in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of the Class A common stock outstanding immediately after giving effect to such exercise.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the number of outstanding shares of Class A common stock is increased by a share capitalization payable in shares of Class A common stock, or by a split-up of common stock or other similar event, then, on the effective date of such share capitalization, split-up or similar event, the number of shares of Class A common stock issuable on exercise of each Warrant will be increased in proportion to such increase in the outstanding shares of Common Stock. A rights offering to holders of common stock entitling holders to purchase Class A common stock at a price less than the fair market value will be deemed a share capitalization of a number of shares of Class A common stock equal to the product of (i) the number of shares of Class A common stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A common stock) and (ii) the quotient of (x) the price per share of Class A common stock paid in such rights offering and (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into or exercisable for shares of Class A common stock, in determining the price payable for Class A common stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the volume weighted average price of shares of Class A common stock as reported during the 10 trading day period ending on the trading day prior to the first date on which the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Class A common stock trades on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In addition, if Ginkgo, at any time while the Warrants are outstanding and unexpired, pays a dividend or make a distribution in cash, securities or other assets to the holders of Class A common stock on account of such Class A common stock (or other securities into which the warrants are convertible), other than (a) as described above or (b) certain ordinary cash dividends, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and&#47;or the fair market value of any securities or other assets paid on each share of Class A common stock in respect of such event.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the number of outstanding shares of Class A common stock is decreased by a consolidation, combination or reclassification of Class A common stock or other similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of shares of Class A common stock issuable on exercise of each Warrant will be decreased in proportion to such decrease in outstanding share of Class A common stock.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Whenever the number of shares of Class A common stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the Warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Class A common stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which will be the number of shares of Class A common stock so purchasable immediately thereafter.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In case of any reclassification or reorganization of the outstanding Class A common stock (other than those described above or that solely affects the par value of such Class A common stock), or in the case of any merger or consolidation of Ginkgo with or into another corporation (other than a consolidation or merger in which Ginkgo is the continuing corporation and that does not result in any reclassification or reorganization of the issued and outstanding Class A common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of Ginkgo as an entirety or substantially as an entirety in connection with which Ginkgo is dissolved, the holders of the Warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the Class A common stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of Class A common stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised their Warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Class A common stock in such a transaction is payable in the form of Class A common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the Warrant properly exercises the Warrant within thirty days following public disclosure of such transaction, the Warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes Warrant Value (as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">defined in the warrant agreement) of the Warrant. The purpose of such exercise price reduction is to provide additional value to holders of the Warrants when an extraordinary transaction occurs during the exercise period of the Warrants pursuant to which the holders of the Warrants otherwise do not receive the full potential value of the Warrants.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Warrants were issued in registered form under a warrant agreement between Continental Stock Transfer &#38; Trust Company, as warrant agent, and Ginkgo. In connection with the Merger, Continental Stock Transfer &#38; Trust Company assigned the warrant agreement to Computershare Trust Company, N.A. The warrant agreement provides that the terms of the Warrants may be amended without the consent of any holder for the purpose of (i) curing any ambiguity or correct any defective provision, or mistake, including to conform the provisions of the warrant agreement to the description of the terms of the Warrants and the warrant agreement set forth herein, (ii) adjusting the provisions relating to cash dividends on Class A common stock as contemplated by and in accordance with the warrant agreement or (iii) adding or changing any provisions with respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the Warrants, provided that the approval by the holders of at least 50% of the then outstanding Public Warrants is required to make any change that adversely affects the interests of the registered holders of Public Warrants, and, solely with respect to any amendment to the terms of the Private Placement Warrants, a majority of the then outstanding Private Placement Warrants. You should review a copy of the warrant agreement, which is filed with the SEC, for a complete description of the terms and conditions applicable to the Warrants.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to Ginkgo, for the number of Warrants being exercised. The Warrant holders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their Warrants and receive Class A common stock. After the issuance of Class A common stock upon exercise of the Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Warrants</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Private Placement Warrants (including the Class A common stock issuable upon exercise of the Private Placement Warrants) will not be redeemable by Ginkgo for cash so long as they are held by the Sponsor, members of the Sponsor or their permitted transferees.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The initial purchasers of the Private Placement Warrants, or their permitted transferees, have the option to exercise the Private Placement Warrants on a cashless basis. Except as described in this section, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants sold in the IPO, including that they may be redeemed for shares of Class A common stock. If the Private Placement Warrants are held by holders other than the Sponsor or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">their permitted transferees, the Private Placement Warrants will be redeemable by Ginkgo and exercisable by the holders on the same basis as the Public Warrants included in the units that were sold in the IPO.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exclusive Forum</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Bylaws provide that, unless Ginkgo otherwise consents in writing, the Court of Chancery (the &#8220;Chancery Court&#8221;) of the State of Delaware (or, in the event that the Chancery Court does not have subject matter jurisdiction, another state or federal court located within the State of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for resolution of (a) any derivative action or proceeding brought on behalf of Ginkgo, (b) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, employee, agent or stockholder of Ginkgo to Ginkgo or any of Ginkgo&#8217;s stockholders, or any claim for aiding and abetting such an alleged breach, (c) any action governed by the &#8220;internal affairs doctrine&#8221; or arising pursuant to any provision of Ginkgo&#8217;s Charter or Bylaws, or to interpret, apply, enforce or determine the validity of Ginkgo&#8217;s Charter or Bylaws, or (d) any action asserting a claim against Ginkgo or any current or former director, officer, employee, agent or stockholder of Ginkgo (i) arising pursuant to any provision of the DGCL or (ii) as to which the DGCL confers jurisdiction on the Chancery Court. The foregoing will not apply, however, to any action, claim or proceeding as to which the Chancery Court (or, if applicable, another state or federal court located within the State of Delaware) determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within ten (10) days following such determination).</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, unless Ginkgo otherwise consents in writing, the federal district courts of the United States will be the exclusive forum for the resolution of any action, claim or proceeding arising under the Securities Act.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Limitations on Liability and Indemnification of Officers and Directors</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The DGCL authorizes corporations to limit or eliminate the personal liability of directors, officers and stockholders of corporations for monetary damages for breaches of directors&#8217; fiduciary duties, subject to certain exceptions. The Charter includes a provision that eliminates, to the fullest extent permitted by the DGCL (as currently in effect or as it may in the future be amended), the personal liability of Ginkgo&#8217;s directors or officers for damages for any breach of fiduciary duty as a director or officer.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Bylaws provide that, to the fullest extent permitted by the DGCL (as currently in effect or as it may in the future be amended), Ginkgo must indemnify and hold harmless and advance expenses to any of its directors and officers who is involved in any action, suit or proceeding by reason of the fact that he or she is or was a director or officer of Ginkgo or, while serving as a director or officer of Ginkgo, is or was serving at the request of Ginkgo as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity. Ginkgo also is expressly authorized to carry directors&#8217; and officers&#8217; liability </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">insurance providing indemnification for Ginkgo&#8217;s directors, officers, and certain employees for some liabilities. Ginkgo believes that these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The limitation of liability, advancement and indemnification provisions in the Charter and the Bylaws may discourage stockholders from bringing lawsuits against Ginkgo&#8217;s directors or officers for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against Ginkgo&#8217;s directors and officers, even though such an action, if successful, might otherwise benefit Ginkgo and its stockholders. In addition, your investment in Ginkgo may be adversely affected to the extent that Ginkgo pays the costs of settlement and damage awards against directors and officer pursuant to these indemnification provisions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">There is currently no pending material litigation or proceeding involving any of Ginkgo&#8217;s directors, officers, or employees for which indemnification is sought.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Corporate Opportunities</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Charter provides for the renouncement by Ginkgo of any interest or expectancy of Ginkgo in, or being offered an opportunity to participate, in any matter, transaction, or interest that is presented to, or acquired, created, or developed by, or which otherwise comes into the possession of, any director of Ginkgo who is not an employee of Ginkgo or any of its subsidiaries, unless such matter, transaction, or interest is presented to, or acquired, created, or developed by, or otherwise comes into the possession of, that director first in that director&#8217;s capacity as a director of Ginkgo.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Dissenters&#8217; Rights of Appraisal and Payment</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Under the DGCL, with certain exceptions, Ginkgo&#8217;s stockholders will have appraisal rights in connection with a merger or consolidation of Ginkgo. Pursuant to the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Stockholders&#8217; Derivative Actions</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Under the DGCL, any of Ginkgo&#8217;s stockholders may bring an action in Ginkgo&#8217;s name to procure a judgment in Ginkgo&#8217;s favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of Ginkgo&#8217;s shares at the time of the transaction to which the action relates or such stockholder&#8217;s stock thereafter devolved by operation of law.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Agent and Warrant Agent</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Fidelity Stock Transfer is the transfer agent for Class A common stock and Computershare Trust Company, N.A. is the warrant agent for the Warrants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Listing of Class A common stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Class A common stock is listed on the NYSE under the symbol &#8220;DNA.&#8221;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>dna-20251231xex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ie0b44bcc22014eecb9be3c5a4f6db97c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GINKGO BIOWORKS HOLDINGS, INC. </font></div><div style="padding-left:3.52pt;padding-right:3.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2021 INCENTIVE AWARD PLAN </font></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE I. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PURPOSE </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Plan&#8217;s purpose is to enhance the Company&#8217;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article&#160;XI. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE II. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ELIGIBILITY </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE III. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ADMINISTRATION AND DELEGATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements, to impose a mandatory holding period pursuant to which some or all Participants may not dispose of or transfer Shares issued under the Plan for a period of time determined by the Administrator in its discretion, and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any Award as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator&#8217;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Appointment of Committees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent Applicable Laws permit, the Board may delegate any or all of its powers under the Plan to one or more Committees or officers of the Company or any of its Subsidiaries. The Board may abolish any Committee or re-vest in itself any previously delegated authority at any time. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IV. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">STOCK AVAILABLE FOR AWARDS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to adjustment under Article&#160;VIII and the terms of this Article&#160;IV, Awards may be made under the Plan covering up to the Overall Share Limit. As of the Plan&#8217;s effective date, the Company will cease granting awards under any Prior Plan&#59; however, Prior Plan Awards will remain subject to the terms of the applicable Prior Plan. Shares issued under the Plan (i)&#160;may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares and (ii)&#160;may be issued as Class&#160;A Common Stock or Class&#160;B Common Stock, as determined by the Administrator in its sole discretion. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Recycling</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If all or any part of an Award or Prior Plan Award expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award or Prior Plan Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or purchase price of an Award or Prior Plan Award and&#47;or to satisfy any applicable tax withholding obligation (including Shares retained by the Company from the Award or Prior Plan Award being exercised or purchased and&#47;or creating the tax obligation) will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards or Prior Plan Awards shall not count against the Overall Share Limit. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incentive Stock Option Limitations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary herein, no more than 5,000,000 Shares (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of the Company&#8217;s Common Stock effected on August 19, 2024) may be issued pursuant to the exercise of Incentive Stock Options (any or all of which may be granted with respect to Class&#160;A Common Stock and&#47;or Class&#160;B Common Stock). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Substitute Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In connection with an entity&#8217;s merger or consolidation with the Company or the Company&#8217;s acquisition of an entity&#8217;s property or stock, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted before such merger or consolidation by such entity or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Overall Share Limit (nor shall Shares subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a pre-existing plan approved by stockholders, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not be added to the Shares available for Awards under the Plan as provided above)&#59; provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, and shall only be made to individuals who were not Employees or Directors prior to such acquisition or combination. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Employee Director Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any provision to the contrary in the Plan, the Administrator may establish compensation for Non-Employee Directors from time to time, subject to the limitations in the Plan. The Administrator will from time to time determine the terms, conditions and amounts of all such Non-Employee Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a Non-Employee Director as compensation for services as a Non-Employee Director during any fiscal year of the Company may not exceed $1,000,000, increased to $1,250,000 in the fiscal year in which the Plan&#8217;s effective date occurs or in the fiscal year of a Non-Employee Director&#8217;s initial service as a Non-Employee Director (in either case, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NED Limit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). For the avoidance of doubt, the value of any cash or equity-based compensation granted prior to the Plan&#8217;s effective date shall not count against the NED Limit. The Administrator may make exceptions to a NED Limit for individual Non-Employee Directors in extraordinary circumstances, as the Administrator may determine in its discretion, provided that the Non-Employee Director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving Non-Employee Directors. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE V. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">STOCK OPTIONS AND STOCK APPRECIATION RIGHTS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to the limitations in the Plan, including any limitations in the Plan that apply to Incentive Stock Options. The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">exercise price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator will establish each Option&#8217;s and Stock Appreciation Right&#8217;s exercise price and specify the exercise price in the Award Agreement. Unless otherwise determined by the Administrator, the exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Duration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that, unless otherwise determined by the Administrator, the term of an Option or Stock Appreciation Right will not exceed ten years. Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right (i)&#160;violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries or (ii)&#160;commits a material violation or breach of a Company policy that relates to discrimination, harassment, retaliation or that is otherwise customarily punishable by termination of employment, the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation or breach, unless the Company otherwise determines. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i)&#160;as specified in Section&#160;5.5 for the number of Shares for which the Award is exercised and (ii)&#160;as specified in Section&#160;9.5 for any applicable taxes. Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Upon Exercise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Section&#160;10.8, any Company insider trading policy (including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A)&#160;delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B)&#160;the Participant&#8217;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price&#59; provided that such amount is paid to the Company at such time as may be required by the Administrator&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) to the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their fair market value&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#8217;s exercise valued at their fair market value on the exercise date&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(e) to the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is good and valuable consideration&#59; or </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(f) to the extent permitted by the Company, any combination of the above payment forms approved by the Administrator. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VI. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RESTRICTED STOCK&#59; RESTRICTED STOCK UNITS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject to the Company&#8217;s right to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant Restricted Stock Units to Service Providers, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement. The Administrator will determine and set forth in the Award Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(g) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(h) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Certificates</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Units.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#8217;s election, in a manner intended to comply with Section&#160;409A. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(j) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(k) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VII. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OTHER STOCK OR CASH BASED AWARDS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or long- term cash bonus awards </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal (which may be based on the Performance Criteria), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VIII. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ADJUSTMENTS FOR CHANGES IN COMMON STOCK </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AND CERTAIN OTHER EVENTS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Restructuring</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article&#160;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and&#47;or the Award&#8217;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments provided under this Section&#160;8.1 will be nondiscretionary and final and binding on the affected Participant and the Company&#59; provided that the Administrator will determine whether an adjustment is equitable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Transactions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such change) and either automatically or upon the Participant&#8217;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x)&#160;prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y)&#160;to facilitate such transaction or event or (z)&#160;give effect to such changes in Applicable Laws or accounting principles&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(m) To provide for the cancellation of any such Award in exchange for either an amount of cash (except with respect to Non-Employee Directors) or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights under the vested portion of such Award, as applicable&#59; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights, in any case, is equal to or less than zero, then the Award may be terminated without payment&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(n) To provide that such Award shall vest and, to the extent applicable, be exercisable as to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(o) To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and&#47;or applicable exercise or purchase price, in all cases, as determined by the Administrator&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(p) To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Awards and&#47;or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&#160;IV hereof on the maximum number and kind of shares which may be issued) and&#47;or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(q) To replace such Award with other rights or property selected by the Administrator&#59; and&#47;or </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(r) To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding Section&#160;8.2 above, if a Change in Control occurs and Awards are not continued, converted, assumed, or replaced with a comparable award (as determined by the Administrator) by (i)&#160;the Company or (ii)&#160;a successor entity or its parent or subsidiary (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assumption</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and provided that the Participant has not had a Termination of Service, then immediately prior to the Change in Control such Awards (other than any Award that is regularly scheduled to vest based on the attainment of performance-based vesting conditions) will become fully vested, exercisable and&#47;or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards will lapse, in which case, such Awards will be canceled upon the consummation of the Change in Control in exchange for the right to receive the Change in Control consideration payable to other holders of Common Stock, which may be on such terms and conditions as apply generally to holders of Common Stock under the Change in Control documents (including, without limitation, any escrow, earn-out or other deferred consideration provisions) or such other terms and conditions as the Administrator may provide, and determined by reference to the number of Shares subject to such Awards and net of any applicable exercise price&#59; provided that to the extent that any Awards constitute &#8220;nonqualified deferred compensation&#8221; that may not be paid upon the Change in Control under Section&#160;409A without the imposition of taxes thereon under Section&#160;409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to any deferred consideration provisions applicable under the Change in Control documents)&#59; and provided, further, that if the amount to which a Participant would be entitled upon the settlement or exercise of such Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated without payment. An Award will be considered replaced with a comparable award if the Award is exchanged for an amount of cash or other property with a value equal to the amount that could have been obtained upon the settlement of such Award in such Change in Control (as determined by the Administrator), even if such cash or other property payable with respect to the unvested portion of such Award remains subject to similar vesting provisions following such Change in Control. Notwithstanding the foregoing, the Administrator will have full and final authority to determine whether an Assumption of an Award has occurred in connection with a Change in Control. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Stand Still</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty days before or after such transaction. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Except as expressly provided in the Plan or the Administrator&#8217;s action under the Plan, no Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as expressly provided with respect to an Equity Restructuring under Section&#160;8.1 above or the Administrator&#8217;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#8217;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way the Company&#8217;s right or power to make or authorize (i)&#160;any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, (ii)&#160;any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii)&#160;any sale or issuance of securities, including securities with rights superior to those of the Shares or securities </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">convertible into or exchangeable for Shares. The Administrator may treat Participants and Awards (or portions thereof) differently under this Article&#160;VIII. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IX. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL PROVISIONS APPLICABLE TO AWARDS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Except as the Administrator may determine or provide in an Award Agreement or otherwise for Awards other than Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution, or, subject to the Administrator&#8217;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, will include references to a Participant&#8217;s authorized transferee that the Administrator specifically approves. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Documentation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Discretion</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. Notwithstanding anything in the Plan to the contrary, the Administrator may, without the approval of the stockholders of the Company, grant one or more Awards to any Employee, Director or Consultant (including any Employee, Director or Consultant </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">who is a substantial security holder (i.e., those controlling 5% or more of the Company&#8217;s shares or voting power)) that represent, directly or indirectly, one percent or more of the Common Stock or one percent or more of the voting power of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Status</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator will determine how the disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant&#8217;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Each Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#8217;s Awards by the date of the event creating the tax liability. The Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of any kind otherwise due to a Participant. Subject to Section&#160;10.8 and any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i)&#160;in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted, (ii)&#160;to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares retained from the Award creating the tax obligation, valued at their fair market value, (iii)&#160;if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A)&#160;delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B)&#160;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding&#59; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv)&#160;to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator. If any tax withholding obligation will be satisfied under clause (ii)&#160;of the immediately preceding sentence by the Company&#8217;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#8217;s behalf some or all of the Shares retained and to remit the proceeds of the sale to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the Company or its designee, and each Participant&#8217;s acceptance of an Award under the Plan will constitute the Participant&#8217;s authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.6 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Award&#59; Repricing</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a Non-Qualified Stock Option. The Participant&#8217;s consent to such action will be required unless (i)&#160;the action, taking into account any related action, does not materially and adversely affect the Participant&#8217;s rights under the Award, or (ii)&#160;the change is permitted under Article&#160;VIII or pursuant to Section&#160;10.6. Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may, without the approval of the stockholders of the Company, reduce the exercise price or base price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights that have an exercise price or base price in excess of Fair Market Value in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price or base price per share that is less than the exercise price or base price per share of the original Options or Stock Appreciation Rights. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.7 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions on Delivery of Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i)&#160;all Award conditions have been met or removed to the Company&#8217;s satisfaction, (ii)&#160;as determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii)&#160;the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#8217;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.8 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acceleration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> . The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.9 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Terms of Incentive Stock Options</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> . The Administrator may grant Incentive Stock Options only to employees of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections&#160;424(e) or (f)&#160;of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not be less than 110% of the Fair Market Value on the Option&#8217;s grant date, and the term of the Option will not exceed five years. All Incentive Stock Options will be subject to and construed consistently with Section&#160;422 of the Code. By accepting an Incentive Stock Option, the Participant agrees to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i)&#160;two years from the grant date of the Option or (ii)&#160;one year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or other consideration, in such disposition or other transfer. Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code. Any Incentive Stock Option or portion thereof that fails to qualify as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code for any reason, including becoming exercisable with respect to Shares having a fair market value exceeding the $100,000 limitation under Treasury Regulation Section&#160;1.422-4, will be a Non-Qualified Stock Option. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE X. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MISCELLANEOUS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Right to Employment or Other Status</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Rights as Stockholder&#59; Certificates</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date and Term of Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan will become effective upon the consummation of the Initial Business Combination. However, the effectiveness of the Plan shall be subject to approval of the Plan by the Company&#8217;s stockholders. If the Plan is not approved by the Company&#8217;s stockholders, the Plan will not become effective and no Awards will be granted under the Plan. The Plan shall remain in effect until terminated by the Administrator under Section&#160;10.4&#59; provided, that, any provision of the Plan that constitutes a &#8220;formula&#8221; under the New York Stock Exchange Listed Company Manual (or such successor manual of the New York Stock Exchange) shall only remain in effect until the tenth anniversary of the date the Company&#8217;s stockholders last approved the Plan, and Incentive Stock Options may not be granted under the Plan after the tenth anniversary of the earlier of (i)&#160;the date the Board adopted the Plan or (ii)&#160;the date the Company&#8217;s stockholders approved the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may amend, suspend or terminate the Plan at any time&#59; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#8217;s consent. No Awards may be granted under the Plan during any suspension period or after Plan termination. Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provisions for Foreign Participants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.6 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(s) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company intends that all Awards be structured to comply with, or be exempt from, Section&#160;409A, such that no adverse tax consequences, interest, or penalties under Section&#160;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#8217;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to (A)&#160;exempt this Plan or any Award from Section&#160;409A, or (B)&#160;comply with Section&#160;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#8217;s grant date. The Company makes no representations or warranties as to an Award&#8217;s tax treatment under Section&#160;409A or otherwise. The Company will have no obligation under this Section&#160;10.6 or otherwise to avoid the taxes, penalties or interest under Section&#160;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#8220;nonqualified deferred compensation&#8221; subject to taxes, penalties or interest under Section&#160;409A. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(t) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If an Award constitutes &#8220;nonqualified deferred compensation&#8221; under Section&#160;409A, any payment or settlement of such Award upon a termination of a Participant&#8217;s Service Provider relationship will, to the extent necessary to avoid taxes under Section&#160;409A, be made only upon the Participant&#8217;s &#8220;separation from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">service&#8221; (within the meaning of Section&#160;409A), whether such &#8220;separation from service&#8221; occurs upon or after the termination of the Participant&#8217;s Service Provider relationship. For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms means a &#8220;separation from service.&#8221; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(u) </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payments to Specified Employees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of &#8220;nonqualified deferred compensation&#8221; required to be made under an Award to a &#8220;specified employee&#8221; (as defined under Section&#160;409A and as the Administrator determines) due to his or her &#8220;separation from service&#8221; will, to the extent necessary to avoid taxes under Section&#160;409A(a)(2)(B)(i) of the Code, be delayed for the six-month period immediately following such &#8220;separation from service&#8221; (or, if earlier, until the specified employee&#8217;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such six-month period or as soon as administratively practicable thereafter (without interest). Any payments of &#8220;nonqualified deferred compensation&#8221; under such Award payable more than six months following the Participant&#8217;s &#8220;separation from service&#8221; will be paid at the time or times the payments are otherwise scheduled to be made. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.7 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations on Liability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other employee or agent of the Company or any Subsidiary. The Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#8217;s administration or interpretation, against any cost or expense (including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#8217;s approval) arising from any act or omission concerning this Plan unless arising from such person&#8217;s own fraud or bad faith. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.8 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lock-Up Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company may, at the request of any underwriter representative or the Company, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any Shares or other Company securities during a period of up to one hundred eighty days following the effective date of a Company registration statement filed under the Securities Act, or such shorter or longer period as determined by the underwriter or the Company (including as set forth in the Charter), and subject to such exceptions as may be determined by the underwriter or the Company (including as set forth in the Charter). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.9 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion of Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Awards granted and Shares issuable and issued pursuant to this Plan are subject to the provisions of the Charter regarding the conversion of shares of Class&#160;B Common Stock to Class&#160;A Common Stock. In addition, prior to or in connection with issuing any Shares subject to Awards under the Plan, the Administrator may convert Awards previously granted covering shares of Class&#160;B Common Stock to Class&#160;A Common Stock or convert Awards previously granted covering shares of Class&#160;A Common Stock to Class&#160;B Common Stock. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.10 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#8217;s participation in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#8217;s name, address and telephone number&#59; birthdate&#59; social security, insurance number or other identification number&#59; salary&#59; nationality&#59; job title(s)&#59; any Shares held in the Company or its Subsidiaries and affiliates&#59; and Award details, to implement, manage and administer the Plan and Awards (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#8217;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. These recipients may be located in the Participant&#8217;s country, or elsewhere, and the Participant&#8217;s country may have different data privacy laws and protections than the recipients&#8217; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">electronic or other form, to implement, administer and manage the Participant&#8217;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section&#160;10.10 in writing, without cost, by contacting the local human resources representative. The Company may cancel Participant&#8217;s ability to participate in the Plan and, in the Administrator&#8217;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the consents in this Section&#160;10.10. For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.11 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.12 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Documents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.13 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#8217;s choice-of-law principles requiring the application of a jurisdiction&#8217;s laws other than the State of Delaware. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.14 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Claw-back Provisions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. All Awards (including any proceeds, gains or other economic benefit the Participant actually or constructively receives upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will be subject to any Company claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.15 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Titles and Headings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#8217;s text, rather than such titles or headings, will control. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.16 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.17 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Relationship to Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement thereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.18 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Broker-Assisted Sales</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&#160;9.5&#58; (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable&#59; (b)&#160;such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price&#59; (c)&#160;the applicable Participant will be responsible for all broker&#8217;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale&#59; (d)&#160;to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable&#59; (e)&#160;the Company and its designees are under no obligation to arrange for such sale at any particular price&#59; and (f)&#160;in the event the proceeds of such sale are insufficient to satisfy the Participant&#8217;s applicable obligation, the Participant may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#8217;s obligation. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE XI. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DEFINITIONS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As used in the Plan, the following words and phrases will have the following meanings&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.1 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Board or a Committee to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.2 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.3 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.4 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.5 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.6 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means and includes each of the following&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i)&#160;and (ii) of subsection&#160;(c) below) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections&#160;13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition&#59; or </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&#160;a merger, consolidation, reorganization, or business combination or (y)&#160;a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related transactions or (z)&#160;the acquisition of assets or stock of another entity, in each case other than a transaction&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i) which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successor Entity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ii) after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, that no person or group shall be treated for purposes of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">this clause (ii)&#160;as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in no event shall the Initial Business Combination or the transactions occurring in connection therewith constitute a Change in Control and, if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section&#160;409A, to the extent required to avoid the imposition of additional taxes under Section&#160;409A, the transaction or event described in subsection&#160;(a) or (b)&#160;with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#8220;change in control event,&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto&#59; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5) shall be consistent with such regulation. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.7 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Charter</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Certificate of Incorporation of Soaring Eagle Acquisition Corp, as amended from time to time. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.8 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class&#160;A Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Class&#160;A common stock of the Company, par value of $0.0001 per share, which entitle the holder thereof to one vote per share on all Company voting matters. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.9 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class&#160;B Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Class&#160;B common stock of the Company, par value of $0.0001 per share, which entitle the holder thereof to ten votes per share on all Company voting matters. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.10 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.11 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means one or more committees or subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule 16b-3, it is intended that each member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule 16b-3, a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3&#59; however, a Committee member&#8217;s failure to qualify as a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3 will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.12 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means either the Class&#160;A Common Stock or Class&#160;B Common Stock of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.13 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Ginkgo Bioworks Holdings, Inc., a Delaware corporation, or any successor. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.14 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consultant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant or adviser&#58; (i)&#160;renders bona fide services to the Company&#59; (ii)&#160;renders services not in connection with the offer or sale of securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&#8217;s securities&#59; and (iii)&#160;is a natural person. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.15 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Designated Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#8217;s rights if the Participant dies or becomes incapacitated. Without a Participant&#8217;s effective designation, &#8220;Designated Beneficiary&#8221; will mean the Participant&#8217;s estate. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.16 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a Board member. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.17 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a permanent and total disability under Section&#160;22(e)(3) of the Code, as amended. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.18 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.19 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earn-out Share</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Merger Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.20 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any employee of the Company or its Subsidiaries. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.21 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Restructuring</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.22 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.23 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date, the value of Common Stock determined as follows&#58; (i)&#160;if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for the last market trading day prior to such date, as reported in The Wall Street Journal or another source the Administrator deems reliable&#59; (ii)&#160;if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable&#59; or (iii)&#160;in any case, the Administrator may determine the Fair Market Value in its discretion. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.24 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Greater Than 10% Stockholder</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an individual then owning (within the meaning of Section&#160;424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary corporation, as defined in Section&#160;424(e) and (f)&#160;of the Code, respectively. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.25 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Stock Option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Option intended to qualify as an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.26 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Business Combination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the transactions contemplated by the Merger Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.27 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Agreement and Plan of Merger, dated as of May&#160;11, 2021, by and among Soaring Eagle Acquisition Corp., SEAC Merger Sub Inc., and Ginkgo Bioworks, Inc. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.28 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a Director who is not an Employee. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.29 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Qualified Stock Option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Option not intended or not qualifying as an Incentive Stock Option. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.30 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an option to purchase Shares. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.31 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Stock or Cash Based Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.32 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overall Share Limit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the sum of (i) 5,000,000 Shares (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of the Company&#8217;s Common Stock effected on August 19, 2024)&#59; (ii)&#160;any shares of Common Stock which remain available for future grants under any Prior Plan as of immediately prior to approval of the Plan by the Company&#8217;s stockholders&#59; (iii)&#160;any shares of Common Stock which are subject to Prior Plan Awards which become available for issuance under the Plan pursuant to Article IV&#59; (iv)&#160;any Remaining Earn-out Shares&#59; and (v)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2022 and ending on and including January&#160;1, 2031, equal to the lesser of (A) 4% of the aggregate number of shares of common stock of the Company outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of Shares as is determined by the Board. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.33 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a Service Provider who has been granted an Award. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.34 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Criteria</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; mean the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals for a performance period, which may include the following&#58; net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense)&#59; gross or net sales or revenue or sales or revenue growth&#59; net income (either before or after taxes) or adjusted net income&#59; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin&#59; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus)&#59; cash flow (including operating cash flow and free cash flow or cash flow return on capital)&#59; return on assets&#59; return on capital or invested capital&#59; cost of capital&#59; return on stockholders&#8217; equity&#59; total stockholder return&#59; return on sales&#59; costs, reductions in costs and cost control measures&#59; expenses&#59; working capital&#59; earnings or loss per share&#59; adjusted earnings or loss per share&#59; price per share or dividends per share (or appreciation in or maintenance of such price or dividends)&#59; regulatory achievements or compliance&#59; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments&#59; market share&#59; economic value or economic value added models&#59; division, group or corporate financial goals&#59; customer satisfaction&#47;growth&#59; customer service&#59; employee satisfaction&#59; recruitment and maintenance of personnel&#59; human resources management&#59; supervision of litigation and other legal matters&#59; strategic partnerships and transactions&#59; financial ratios (including those measuring liquidity, activity, profitability or leverage)&#59; debt levels or reductions&#59; sales-related goals&#59; financing and other capital raising transactions&#59; cash on hand&#59; acquisition activity&#59; investment sourcing activity&#59; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the Company&#8217;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. The Committee may provide for exclusion of the impact of an event or occurrence which the Committee determines should appropriately be excluded, including (a)&#160;restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or non-recurring charges or events, (b)&#160;asset write-downs, (c)&#160;litigation or claim judgments or settlements, (d)&#160;acquisitions or divestitures, (e)&#160;reorganization or change in the corporate structure or capital structure of the Company, (f)&#160;an event either not directly related to the operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management, (g)&#160;foreign exchange gains and losses, (h)&#160;a change in the fiscal year of the Company, (i)&#160;the refinancing or repurchase of bank loans or debt securities, (j)&#160;unbudgeted capital expenditures, (k)&#160;the issuance or repurchase of equity securities and other changes in the number of outstanding shares, (l)&#160;conversion of some or all of convertible securities to Common Stock, (m)&#160;any business interruption event (n)&#160;the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles, or (o)&#160;the effect of changes in other laws or regulatory rules affecting reported results. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.35 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means this 2021 Incentive Award Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.36 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prior Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Ginkgo Bioworks, Inc. 2008 Stock Incentive Plan and&#47;or the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.37 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prior Plan Award</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an award outstanding under any Prior Plan as of immediately prior to approval of the Plan by the Company&#8217;s stockholders. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.38 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Earn-out Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Merger Agreement, which Remaining Earn-out Shares shall be subject to the vesting and forfeiture conditions set forth in the Merger Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.39 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Shares awarded to a Participant under Article&#160;VI subject to certain vesting conditions and other restrictions. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.40 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.41 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 16b-3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Rule 16b-3 promulgated under the Exchange Act. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.42 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Section&#160;409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.43 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities Act of 1933, as amended. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.44 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Provider</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an Employee, Consultant or Director. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.45 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means shares of Common Stock. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.46 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Appreciation Right</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a stock appreciation right granted under Article&#160;V. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.47 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.48 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Substitute Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.49 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the date the Participant ceases to be a Service Provider. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150645998_2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>dna-20251231xex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i431e4fe543a54bfeb58fe08144209bd3_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GINKGO BIOWORKS HOLDINGS, INC. </font></div><div style="padding-left:3.52pt;padding-right:3.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2021 EMPLOYEE STOCK PURCHASE PLAN </font></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE I. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PURPOSE </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Plan consists of two components&#58; (i)&#160;the Section&#160;423 Component and (ii)&#160;the Non-Section 423 Component. The Section&#160;423 Component is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and shall be administered, interpreted and construed in a manner consistent with the requirements of Section&#160;423 of the Code. The Non-Section 423 Component authorizes the grant of rights which need not qualify as rights granted pursuant to an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code. Rights granted under the Non-Section 423 Component shall be granted pursuant to separate Offerings containing such sub-plans, appendices, rules or procedures as may be adopted by the Administrator and designed to achieve tax, securities laws or other objectives for Eligible Employees and Designated Subsidiaries but shall not be intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code. Except as otherwise determined by the Administrator or provided herein, the Non-Section 423 Component will operate and be administered in the same manner as the Section&#160;423 Component. Offerings intended to be made under the Non-Section 423 Component will be designated as such by the Administrator at or prior to the time of such Offering. Notwithstanding the foregoing, to the extent a limitation or requirement set forth in the Plan is specifically mandated under Section&#160;423 of the Code, such limitation or requirement need not apply to the Non-Section 423 Component and the Administrator may eliminate application of such limitation or requirement to the Non-Section 423 Component in its discretion, subject to stockholder approval only to the extent required by Applicable Law. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Plan, the Administrator may designate separate Offerings under the Plan in which Eligible Employees will participate. The terms of these Offerings need not be identical, even if the dates of the applicable Offering Period(s) in each such Offering are identical, provided that the terms of participation are the same within each separate Offering under the Section&#160;423 Component (as determined under Section&#160;423 of the Code). Solely by way of example and without limiting the foregoing, the Company could, but shall not be required to, provide for simultaneous Offerings under the Section&#160;423 Component and the Non-Section 423 Component of the Plan. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE II. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DEFINITIONS AND CONSTRUCTION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.1 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the entity that conducts the general administration of the Plan as provided in Article&#160;XI. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the brokerage firm, bank or other financial institution, entity or person(s), if any, engaged, retained, appointed or authorized to act as the agent of the Company or an Employee with regard to the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which Shares are listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where rights under this Plan are granted. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.4 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of the Company. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.5 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class&#160;A Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Class&#160;A common stock of the Company, par value of $0.0001 per share, which entitle the holder thereof to one vote per share on all Company voting matters. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.6 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class&#160;B Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Class&#160;B common stock of the Company, par value of $0.0001 per share, which entitle the holder thereof to ten votes per share on all Company voting matters. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.7 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.8 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means either the Class&#160;A Common Stock or Class&#160;B Common Stock of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Ginkgo Bioworks Holdings, Inc., a Delaware corporation, or any successor. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.10 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of an Eligible Employee means, unless otherwise determined by the Administrator, the gross base compensation or wages received by such Eligible Employee as compensation for services to the Company or any Designated Subsidiary, excluding overtime payments, sales commissions, incentive compensation, bonuses, expense reimbursements, income received in connection with any stock options, stock appreciation rights, restricted stock, restricted stock units or other compensatory equity awards, fringe benefits and other special payments. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.11 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Designated Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Subsidiary designated by the Administrator in accordance with Section&#160;11.2(b), such designation to specify whether such participation is in the Section&#160;423 Component or Non-Section 423 Component. A Designated Subsidiary may participate in either or both the Section&#160;423 Component or Non-Section 423 Component, unless otherwise prohibited by Applicable Law&#59; provided that a Subsidiary that, for U.S. tax purposes, is disregarded from the Company or any Subsidiary that participates in the Section&#160;423 Component shall automatically constitute a Designated Subsidiary that participates in the Section&#160;423 Component. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.12 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) With respect to the Section&#160;423 Component, an Employee who does not, immediately after any rights under this Plan are granted, own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of shares and other securities of the Company, a Parent or a Subsidiary (as determined under Section&#160;423(b)(3) of the Code). For purposes of the foregoing, the rules of Section&#160;424(d) of the Code with regard to the attribution of stock ownership shall apply in determining the stock ownership of an individual, and stock that an Employee may purchase under outstanding options shall be treated as stock owned by the Employee. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) Notwithstanding the foregoing, the Administrator may provide in an Offering Document that an Employee shall not be eligible to participate in an Offering Period under the Section&#160;423 Component if&#58; (i)&#160;such Employee is a highly compensated employee within the meaning of Section&#160;423(b)(4)(D) of the Code&#59; (ii)&#160;such Employee has not met a service requirement designated by the Administrator pursuant to Section&#160;423(b)(4)(A) of the Code (which service requirement may not exceed two years)&#59; (iii) such Employee&#8217;s customary employment is for twenty hours per week or less&#59; (iv)&#160;such Employee&#8217;s customary employment is for less than five months in any calendar year&#59; and&#47;or (v)&#160;such Employee is a citizen or resident of a foreign jurisdiction and the grant of a right to purchase Shares under the Plan to such Employee would be prohibited under the laws of such foreign jurisdiction or the grant of a right to purchase Shares under the Plan to such Employee in compliance with the laws of such foreign jurisdiction would cause the Plan to violate the requirements of Section&#160;423 of the Code, as determined by the Administrator in its sole discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> further</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, that any exclusion in clauses (i), (ii), (iii), (iv) or (v)&#160;shall be applied in an identical manner under each Offering Period to all Employees in the Section&#160;423 Component, in accordance with Treasury Regulation Section&#160;1.423-2(e).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) With respect to the Non-Section 423 Component, an Employee&#59; provided that the Administrator may limit eligibility within the Company or a Designated Subsidiary so as to only designate some Employees of the Company or a Designated Subsidiary as Eligible Employees. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.13 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any individual who renders services to the Company or any Designated Subsidiary in the status of an employee, and, with respect to the Section&#160;423 Component, a person who is an employee within the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">meaning of Section&#160;3401(c) of the Code. For purposes of an individual&#8217;s participation in, or other rights under the Plan, all determinations by the Company shall be final, binding and conclusive, notwithstanding that any court of law or governmental agency subsequently makes a contrary determination. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company or Designated Subsidiary and, with respect to the Section&#160;423 Component, meeting the requirements of Treasury Regulation Section&#160;1.421-1(h)(2). With respect to participation in the Section&#160;423 Component, where the period of leave exceeds three (3)&#160;months and the individual&#8217;s right to reemployment is not guaranteed either by statute or by contract, the employment relationship shall be deemed to have terminated on the first day immediately following such three (3)-month period. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.14 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enrollment Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the first Trading Day of each Offering Period. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.15 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date, the value of Shares determined as follows&#58; (i)&#160;if the Shares are listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Shares as quoted on such exchange for the last market Trading Day prior to such date, as reported in The Wall Street Journal or another source the Administrator deems reliable&#59; (ii)&#160;if the Shares are not traded on a stock exchange but are quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable&#59; or (iii)&#160;in any case, the Administrator may determine the Fair Market Value in its discretion. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.16 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Business Combination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May&#160;11, 2021, by and among Soaring Eagle Acquisition Corp., SEAC Merger Sub Inc., and Ginkgo Bioworks, Inc. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.17 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Section 423 Component</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means those Offerings under the Plan, together with the sub-plans, appendices, rules or procedures, if any, adopted by the Administrator as a part of this Plan, in each case, pursuant to which rights to purchase Shares during an Offering Period may be granted to Eligible Employees that need not satisfy the requirements for rights to purchase Shares granted pursuant to an &#8220;employee stock purchase plan&#8221; that are set forth under Section&#160;423 of the Code. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.18 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an offer under the Plan of a right to purchase Shares that may be exercised during an Offering Period as further described in Article IV hereof. Unless otherwise specified by the Administrator, each Offering to the Eligible Employees of the Company or a Designated Subsidiary shall be deemed a separate Offering, even if the dates and other terms of the applicable Offering Periods of each such Offering are identical, and the provisions of the Plan will separately apply to each Offering. To the extent permitted by Treas. Reg. &#167; 1.423-2(a)(1), the terms of each separate Offering under the Section&#160;423 Component need not be identical, provided that the terms of the Section&#160;423 Component and an Offering thereunder together satisfy Treas. Reg. &#167; 1.423-2(a)(2) and (a)(3). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.19 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering Document</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning given to such term in Section&#160;4.1. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.20 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning given to such term in Section&#160;4.1. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.21 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any corporation, other than the Company, in an unbroken chain of corporations ending with the Company if, at the time of the determination, each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.22 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Eligible Employee who has executed a subscription agreement and been granted rights to purchase Shares pursuant to the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.23 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payday</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the regular and recurring established day for payment of Compensation to an Employee of the Company or any Designated Subsidiary. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.24 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means this 2021 Employee Stock Purchase Plan, including both the Section&#160;423 Component and Non-Section 423 Component and any other sub-plans or appendices hereto, as amended from time to time. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.25 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the last Trading Day of each Offering Period, or such other date as determined by the Administrator and set forth in the Offering Document. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.26 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the purchase price designated by the Administrator in the applicable Offering Document (which purchase price, for purposes of the Section&#160;423 Component, shall not be less than 85% of the Fair Market Value of a Share on the Enrollment Date or on the Purchase Date, whichever is lower)&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, that, in the event no purchase price is designated by the Administrator in the applicable Offering Document, the purchase price for the Offering Periods covered by such Offering Document shall be 85% of the Fair Market Value of a Share on the Enrollment Date or on the Purchase Date, whichever is lower&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, that the Purchase Price may be adjusted by the Administrator pursuant to Article&#160;VIII and shall not be less than the par value of a Share. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.27 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section&#160;423 Component</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means those Offerings under the Plan, together with the sub-plans, appendices, rules or procedures, if any, adopted by the Administrator as a part of this Plan, in each case, pursuant to which rights to purchase Shares during an Offering Period may be granted to Eligible Employees that are intended to satisfy the requirements for rights to purchase Shares granted pursuant to an &#8220;employee stock purchase plan&#8221; that are set forth under Section&#160;423 of the Code. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.28 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities Act of 1933, as amended. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.29 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a share of Common Stock. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.30 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any corporation, other than the Company, in an unbroken chain of corporations beginning with the Company if, at the time of the determination, each of the corporations other than the last corporation in an unbroken chain owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, however, that a limited liability company or partnership may be treated as a Subsidiary to the extent either (a)&#160;such entity is treated as a disregarded entity under Treasury Regulation Section&#160;301.7701-3(a) by reason of the Company or any other Subsidiary that is a corporation being the sole owner of such entity, or (b)&#160;such entity elects to be classified as a corporation under Treasury Regulation Section&#160;301.7701-3(a) and such entity would otherwise qualify as a Subsidiary. In addition, with respect to the Non-Section 423 Component, Subsidiary shall include any corporate or non-corporate entity in which the Company has a direct or indirect equity interest or significant business relationship and that constitutes a &#8220;subsidiary&#8221; of the Company for purposes of Form&#160;S-8. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.31 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a day on which national stock exchanges in the United States are open for trading. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.32 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treas. Reg.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means U.S. Department of the Treasury regulations. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE III. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SHARES SUBJECT TO THE PLAN </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Article&#160;VIII, the aggregate number of Shares that may be issued pursuant to rights granted under the Plan shall be 500,000 Shares (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of the Company&#8217;s Common Stock effected on August 19, 2024). In addition to the foregoing, subject to Article VIII, on the first day of each calendar year beginning on January&#160;1, 2022 and ending on and including January&#160;1, 2031, the number of Shares available for issuance under the Plan shall be increased by that number of Shares equal to the lesser of (a) 1% of the aggregate number of shares of common stock of the Company outstanding on the final day of the immediately preceding calendar year and (b)&#160;such smaller number of Shares as determined by the Board. If any right granted under the Plan shall for any reason terminate without having been exercised, the Shares not purchased under such right shall again become available for issuance under the Plan. Notwithstanding anything in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Section&#160;3.1 to the contrary, the number of Shares that may be issued or transferred pursuant to the rights granted under the Section&#160;423 Component of the Plan shall not exceed an aggregate of 2,500,000 Shares (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of the Company&#8217;s Common Stock effected on August 19, 2024), subject to Article&#160;VIII. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Shares Distributed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Any Shares distributed pursuant to the Plan (i)&#160;may consist, in whole or in part, of authorized and unissued Shares, treasury shares or Shares purchased on the open market and (ii)&#160;may be issued as Class&#160;A Common Stock or Class&#160;B Common Stock, as determined by the Administrator in its sole discretion. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IV. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OFFERING PERIODS&#59; OFFERING DOCUMENTS&#59; PURCHASE DATES </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Offering Periods</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may from time to time grant or provide for the grant of rights to purchase Shares under the Plan to Eligible Employees during one or more periods (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) selected by the Administrator. The terms and conditions applicable to each Offering Period shall be set forth in an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering Document</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; adopted by the Administrator, which Offering Document shall be in such form and shall contain such terms and conditions as the Administrator shall deem appropriate and shall be incorporated by reference into and made part of the Plan and shall be attached hereto as part of the Plan. The provisions of separate Offerings or Offering Periods under the Plan need not be identical. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Offering Documents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Each Offering Document with respect to an Offering Period shall specify (through incorporation of the provisions of this Plan by reference or otherwise)&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) the length of the Offering Period, which period shall not exceed twenty-seven months&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) the maximum number of Shares that may be purchased by any Eligible Employee during such Offering Period, which, in the absence of a contrary designation by the Administrator, shall be 625 Shares (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of the Company&#8217;s Common Stock effected on August 19, 2024)&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) such other provisions as the Administrator determines are appropriate, subject to the Plan. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE V. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ELIGIBILITY AND PARTICIPATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Any Eligible Employee who shall be employed by the Company or a Designated Subsidiary on a given Enrollment Date for an Offering Period shall be eligible to participate in the Plan during such Offering Period, subject to the requirements of this Article&#160;V and, for the Section&#160;423 Component, the limitations imposed by Section&#160;423(b) of the Code. </font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enrollment in Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) Except as otherwise set forth in an Offering Document or determined by the Administrator, an Eligible Employee may become a Participant in the Plan for an Offering Period by delivering a subscription agreement to the Company by such time prior to the Enrollment Date for such Offering Period (or such other date specified in the Offering Document) designated by the Administrator and in such form as the Company provides. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) Each subscription agreement shall designate a whole percentage of such Eligible Employee&#8217;s Compensation to be withheld by the Company or the Designated Subsidiary employing such Eligible Employee on each Payday during the Offering Period as payroll deductions under the Plan. The percentage of Compensation designated by an Eligible Employee may not be less than 1% and may not be more than the maximum percentage specified by the Administrator in the applicable Offering Document (which percentage shall be 25% in the absence of any such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">designation) as payroll deductions. The payroll deductions made for each Participant shall be credited to an account for such Participant under the Plan and shall be deposited with the general funds of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) A Participant may increase or decrease the percentage of Compensation designated in his or her subscription agreement, subject to the limits of this Section&#160;5.2, or may suspend his or her payroll deductions, at any time during an Offering Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, that the Administrator may limit the number of changes a Participant may make to his or her payroll deduction elections during each Offering Period in the applicable Offering Document (and in the absence of any specific designation by the Administrator, a Participant shall be allowed one change to his or her payroll deduction elections during each Offering Period). Any such change or suspension of payroll deductions shall be effective with the first full payroll period that is at least five business days after the Company&#8217;s receipt of the new subscription agreement (or such shorter or longer period as may be specified by the Administrator in the applicable Offering Document). In the event a Participant suspends his or her payroll deductions, such Participant&#8217;s cumulative payroll deductions prior to the suspension shall remain in his or her account and shall be applied to the purchase of Shares on the next occurring Purchase Date and shall not be paid to such Participant unless he or she withdraws from participation in the Plan pursuant to Article&#160;VII. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) Except as otherwise set forth in an Offering Document or determined by the Administrator, a Participant may participate in the Plan only by means of payroll deduction and may not make contributions by lump sum payment for any Offering Period. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payroll Deductions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Except as otherwise provided in the applicable Offering Document, payroll deductions for a Participant shall commence on the first Payday following the Enrollment Date and shall end on the last Payday in the Offering Period to which the Participant&#8217;s authorization is applicable, unless sooner terminated by the Participant as provided in Article&#160;VII or suspended by the Participant or the Administrator as provided in Section&#160;5.2 and Section&#160;5.6, respectively. Notwithstanding any other provisions of the Plan to the contrary, in non-U.S. jurisdictions where participation in the Plan through payroll deductions is prohibited, the Administrator may provide that an Eligible Employee may elect to participate through contributions to the Participant&#8217;s account under the Plan in a form acceptable to the Administrator in lieu of or in addition to payroll deductions&#59; provided, however, that, for any Offering under the Section&#160;423 Component, the Administrator shall take into consideration any limitations under Section&#160;423 of the Code when applying an alternative method of contribution. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effect of Enrollment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. A Participant&#8217;s completion of a subscription agreement will enroll such Participant in the Plan for each subsequent Offering Period on the terms contained therein until the Participant either submits a new subscription agreement, withdraws from participation under the Plan as provided in Article&#160;VII or otherwise becomes ineligible to participate in the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Purchase of Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. An Eligible Employee may be granted rights under the Section&#160;423 Component only if such rights, together with any other rights granted to such Eligible Employee under &#8220;employee stock purchase plans&#8221; of the Company, any Parent or any Subsidiary, as specified by Section&#160;423(b)(8) of the Code, do not permit such employee&#8217;s rights to purchase stock of the Company or any Parent or Subsidiary to accrue at a rate that exceeds $25,000 of the fair market value of such stock (determined as of the first day of the Offering Period during which such rights are granted) for each calendar year in which such rights are outstanding at any time. This limitation shall be applied in accordance with Section&#160;423(b)(8) of the Code. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.6 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Suspension of Payroll Deductions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, to the extent necessary to comply with Section&#160;423(b)(8) of the Code and Section&#160;5.5 (with respect to the Section&#160;423 Component) or the other limitations set forth in this Plan, a Participant&#8217;s payroll deductions may be suspended by the Administrator at any time during an Offering Period. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares by reason of Section&#160;423(b)(8) of the Code, Section&#160;5.5 or the other limitations set forth in this Plan shall be paid to such Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.7 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Employees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In order to facilitate participation in the Plan, the Administrator may provide for such special terms applicable to Participants who are citizens or residents of a foreign jurisdiction, or who are employed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">by a Designated Subsidiary outside of the United States, as the Administrator may consider necessary or appropriate to accommodate differences in local law, tax policy or custom. Except as permitted by Section&#160;423 of the Code, with respect to the Section&#160;423 Component, such special terms may not be more favorable than the terms of rights granted under the Section&#160;423 Component to Eligible Employees who are residents of the United States. Such special terms may be set forth in an addendum to the Plan in the form of an appendix or sub-plan (which appendix or sub-plan may be designed to govern Offerings under the Section&#160;423 Component or the Non-Section 423 Component, as determined by the Administrator). To the extent that the terms and conditions set forth in an appendix or sub-plan conflict with any provisions of the Plan, the provisions of the appendix or sub-plan shall govern. The adoption of any such appendix or sub-plan shall be pursuant to Section&#160;11.2(g). Without limiting the foregoing, the Administrator is specifically authorized to adopt rules and procedures, with respect to Participants who are foreign nationals or employed in non-U.S. jurisdictions, regarding the exclusion of particular Subsidiaries from participation in the Plan, eligibility to participate, the definition of Compensation, handling of payroll deductions or other contributions by Participants, payment of interest, conversion of local currency, data privacy security, payroll tax, withholding procedures, establishment of bank or trust accounts to hold payroll deductions or contributions. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.8 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leave of Absence</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. During leaves of absence approved by the Company and, with respect to the Section&#160;423 Component, meeting the requirements of Treasury Regulation Section&#160;1.421-1(h)(2) under the Code, a Participant may continue participation in the Plan by making cash payments to the Company on his or her normal Payday equal to the Participant&#8217;s authorized payroll deduction. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VI. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GRANT AND EXERCISE OF RIGHTS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grant of Rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. On the Enrollment Date of each Offering Period, each Eligible Employee participating in such Offering Period shall be granted a right to purchase the maximum number of Shares specified under Section&#160;4.2, subject to the limits in Section&#160;5.5, and shall have the right to buy, on each Purchase Date during such Offering Period (at the applicable Purchase Price), such number of whole Shares as is determined by dividing (a)&#160;such Participant&#8217;s payroll deductions accumulated prior to such Purchase Date and retained in the Participant&#8217;s account as of the Purchase Date, by (b)&#160;the applicable Purchase Price (rounded down to the nearest Share). The right shall expire on the earliest of&#58; (x)&#160;the last day of the Offering Period, and (y)&#160;the date on which the Participant withdraws in accordance with the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise of Rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. On each Purchase Date, each Participant&#8217;s accumulated payroll deductions and any other additional payments specifically provided for in the applicable Offering Document will be applied to the purchase of whole Shares, up to the maximum number of Shares permitted pursuant to the terms of the Plan and the applicable Offering Document, at the Purchase Price. No fractional Shares shall be issued upon the exercise of rights granted under the Plan, unless the Offering Document specifically provides otherwise. Any cash in lieu of fractional Shares remaining after the purchase of whole Shares upon exercise of a purchase right will be credited to a Participant&#8217;s account and carried forward and applied toward the purchase of whole Shares for the next following Offering Period. Shares issued pursuant to the Plan may be evidenced in such manner as the Administrator may determine and may be issued in certificated form or issued pursuant to book-entry procedures. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pro Rata Allocation of Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If the Administrator determines that, on a given Purchase Date, the number of Shares with respect to which rights are to be exercised may exceed (a)&#160;the number of Shares that were available for issuance under the Plan on the Enrollment Date of the applicable Offering Period, or (b)&#160;the number of Shares available for issuance under the Plan on such Purchase Date, the Administrator may in its sole discretion provide that the Company shall make a pro rata allocation of the Shares available for purchase on such Enrollment Date or Purchase Date, as applicable, in as uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all Participants for whom rights to purchase Shares are to be exercised pursuant to this Article&#160;VI on such Purchase Date, and shall either (i)&#160;continue all Offering Periods then in effect, or (ii)&#160;terminate any or all Offering Periods then in effect pursuant to Article&#160;IX. The Company may make pro rata allocation of the Shares available on the Enrollment Date of any applicable Offering Period pursuant to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">preceding sentence, notwithstanding any authorization of additional Shares for issuance under the Plan by the Company&#8217;s stockholders subsequent to such Enrollment Date. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares shall be paid to such Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date or such earlier date as determined by the Administrator. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. At the time a Participant&#8217;s rights under the Plan are exercised, in whole or in part, or at the time some or all of the Shares issued under the Plan is disposed of, the Participant must make adequate provision for the Company&#8217;s federal, state, or other tax withholding obligations, if any, that arise upon the exercise of the right or the disposition of the Shares. At any time, the Company may, but shall not be obligated to, withhold from the Participant&#8217;s compensation or Shares received pursuant to the Plan the amount necessary for the Company to meet applicable withholding obligations, including any withholding required to make available to the Company any tax deductions or benefits attributable to sale or early disposition of Shares by the Participant.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions to Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company shall not be required to issue or deliver any certificate or certificates for, or make any book entries evidencing, Shares purchased upon the exercise of rights under the Plan prior to fulfillment of all of the following conditions&#58; (a)&#160;the admission of such Shares to listing on all stock exchanges, if any, on which the Shares are then listed&#59; (b)&#160;the completion of any registration or other qualification of such Shares under any state or federal law or under the rulings or regulations of the Securities and Exchange Commission or any other governmental regulatory body, that the Administrator shall, in its absolute discretion, deem necessary or advisable&#59; (c)&#160;the obtaining of any approval or other clearance from any state or federal governmental agency that the Administrator shall, in its absolute discretion, determine to be necessary or advisable&#59; (d)&#160;the payment to the Company of all amounts that it is required to withhold under federal, state or local law upon exercise of the rights, if any&#59; and (e)&#160;the lapse of such reasonable period of time following the exercise of the rights as the Administrator may from time to time establish for reasons of administrative convenience. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VII. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WITHDRAWAL&#59; CESSATION OF ELIGIBILITY </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. A Participant may withdraw all but not less than all of the payroll deductions credited to his or her account and not yet used to exercise his or her rights under the Plan at any time by giving written notice to the Company in a form acceptable to the Company no later than one week prior to the end of the Offering Period (or such shorter or longer period as may be specified by the Administrator in the applicable Offering Document). All of the Participant&#8217;s payroll deductions credited to his or her account during an Offering Period shall be paid to such Participant as soon as reasonably practicable after receipt of notice of withdrawal and such Participant&#8217;s rights for the Offering Period shall be automatically terminated, and no further payroll deductions for the purchase of Shares shall be made for such Offering Period. If a Participant withdraws from an Offering Period, payroll deductions shall not resume at the beginning of the next Offering Period unless the Participant timely delivers to the Company a new subscription agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Future Participation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. A Participant&#8217;s withdrawal from an Offering Period shall not have any effect upon his or her eligibility to participate in any similar plan that may hereafter be adopted by the Company or a Designated Subsidiary or in subsequent Offering Periods that commence after the termination of the Offering Period from which the Participant withdraws. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cessation of Eligibility</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Upon a Participant&#8217;s ceasing to be an Eligible Employee for any reason, he or she shall be deemed to have elected to withdraw from the Plan pursuant to this Article&#160;VII and the payroll deductions credited to such Participant&#8217;s account during the Offering Period shall be paid to such Participant or, in the case of his or her death, to the person or persons entitled thereto under Section&#160;12.4, as soon as reasonably practicable, and such Participant&#8217;s rights for the Offering Period shall be automatically terminated. If a Participant transfers employment from the Company or any Designated Subsidiary participating in the Section&#160;423 Component to any Designated Subsidiary participating in the Non-Section 423 Component, such transfer shall not be treated as a termination of employment, but the Participant shall immediately cease to participate in the Section&#160;423 Component&#59; however, any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">contributions made for the Offering Period in which such transfer occurs shall be transferred to the Non-Section 423 Component, and such Participant shall immediately join the then-current Offering under the Non-Section 423 Component upon the same terms and conditions in effect for the Participant&#8217;s participation in the Section&#160;423 Component, except for such modifications otherwise applicable for Participants in such Offering. A Participant who transfers employment from any Designated Subsidiary participating in the Non-Section 423 Component to the Company or any Designated Subsidiary participating in the Section&#160;423 Component shall not be treated as terminating the Participant&#8217;s employment and shall remain a Participant in the Non-Section 423 Component until the earlier of (i)&#160;the end of the current Offering Period under the Non-Section 423 Component or (ii)&#160;the Enrollment Date of the first Offering Period in which the Participant is eligible to participate following such transfer. Notwithstanding the foregoing, the Administrator may establish different rules to govern transfers of employment between entities participating in the Section&#160;423 Component and the Non-Section 423 Component, and general transfers between participation in the Section&#160;423 Component and the Non-Section 423 Company, consistent with the requirements of Section&#160;423 of the Code, to the extent applicable. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VIII. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ADJUSTMENTS UPON CHANGES IN SHARES </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Capitalization</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Section&#160;8.3, in the event that the Administrator determines that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), change in control, reorganization, merger, amalgamation, consolidation, combination, repurchase, redemption, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Shares or other securities of the Company, issuance of warrants or other rights to purchase Shares or other securities of the Company, or other similar corporate transaction or event, as determined by the Administrator, affects the Shares such that an adjustment is determined by the Administrator to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any outstanding purchase rights under the Plan, the Administrator shall make equitable adjustments, if any, to reflect such change with respect to (a)&#160;the aggregate number and type of Shares (or other securities or property) that may be issued under the Plan (including, but not limited to, adjustments of the limitations in Section&#160;3.1 and the limitations established in each Offering Document pursuant to Section&#160;4.2 on the maximum number of Shares that may be purchased)&#59; (b) the class(es) and number of Shares and price per Share subject to outstanding rights&#59; and (c)&#160;the Purchase Price with respect to any outstanding rights. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Adjustments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Section&#160;8.3, in the event of any transaction or event described in Section&#160;8.1 or any unusual or nonrecurring transactions or events affecting the Company, any affiliate of the Company, or the financial statements of the Company or any affiliate, or of changes in Applicable Law or accounting principles, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right under the Plan, to facilitate such transactions or events or to give effect to such changes in laws, regulations or principles&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) To provide for either (i)&#160;termination of any outstanding right in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such right had such right been currently exercisable or (ii)&#160;the replacement of such outstanding right with other rights or property selected by the Administrator in its sole discretion&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) To provide that the outstanding rights under the Plan shall be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar rights covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) To make adjustments in the number and type of Shares (or other securities or property) subject to outstanding rights under the Plan and&#47;or in the terms and conditions of outstanding rights and rights that may be granted in the future&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) To provide that Participants&#8217; accumulated payroll deductions may be used to purchase Shares prior to the next occurring Purchase Date on such date as the Administrator determines in its sole discretion and the Participants&#8217; rights under the ongoing Offering Period(s) shall be terminated&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(e) To provide that all outstanding rights shall terminate without being exercised. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Adjustment Under Certain Circumstances</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Unless determined otherwise by the Administrator, no adjustment or action described in this Article&#160;VIII or in any other provision of the Plan shall be authorized to the extent that such adjustment or action would cause the Section&#160;423 Component of the Plan to fail to satisfy the requirements of Section&#160;423 of the Code. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Other Rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Except as expressly provided in the Plan, no Participant shall have any rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of shares of stock of any class or any dissolution, liquidation, merger, or consolidation of the Company or any other corporation. Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares subject to outstanding rights under the Plan or the Purchase Price with respect to any outstanding rights. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IX. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT, MODIFICATION AND TERMINATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment, Modification and Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may amend, suspend or terminate the Plan at any time and from time to time&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, that approval of the Company&#8217;s stockholders shall be required to amend the Plan to the extent required by Applicable Law, including to&#58; (a)&#160;increase the aggregate number, or change the type, of shares that may be sold pursuant to rights under the Plan under Section&#160;3.1 (other than an adjustment as provided by Article&#160;VIII) or (b)&#160;change the corporations or classes of corporations whose employees may be granted rights under the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Changes to Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Without stockholder consent and without regard to whether any Participant rights may be considered to have been adversely affected (and, with respect to the Section&#160;423 Component of the Plan, after taking into account Section&#160;423 of the Code), the Administrator shall be entitled to change or terminate the Offering Periods, limit the frequency and&#47;or number of changes in the amount withheld from Compensation during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the Company&#8217;s processing of withholding elections, establish reasonable waiting and adjustment periods and&#47;or accounting and crediting procedures to ensure that amounts applied toward the purchase of Shares for each Participant properly correspond with amounts withheld from the Participant&#8217;s Compensation, and establish such other limitations or procedures as the Administrator determines in its sole discretion to be advisable that are consistent with the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Actions In the Event of Unfavorable Financial Accounting Consequences</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion and, to the extent necessary or desirable, modify or amend the Plan to reduce or eliminate such accounting consequence including, but not limited to&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) altering the Purchase Price for any Offering Period including an Offering Period underway at the time of the change in Purchase Price&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) shortening any Offering Period so that the Offering Period ends on a new Purchase Date, including an Offering Period underway at the time of the Administrator action&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) allocating Shares. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Such modifications or amendments shall not require stockholder approval or the consent of any Participant. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payments Upon Termination of Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Upon termination of the Plan, the balance in each Participant&#8217;s Plan account shall be refunded as soon as practicable after such termination, without any interest thereon, or the Offering Period may be shortened so that the purchase of Shares occurs prior to the termination of the Plan. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE X. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TERM OF PLAN </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Plan shall become effective upon the consummation of the Initial Business Combination. The effectiveness of the Plan shall be subject to approval of the Plan by the Company&#8217;s stockholders within twelve months following the date the Plan is first approved by the Board. No right may be granted under the Plan prior to such stockholder approval. The Plan shall remain in effect until terminated under Section&#160;9.1. No rights may be granted under the Plan during any period of suspension of the Plan or after termination of the Plan. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE XI. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ADMINISTRATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administrator</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Unless otherwise determined by the Board, the Administrator of the Plan shall be the Compensation Committee of the Board (or another committee or a subcommittee of the Board to which the Board delegates administration of the Plan). The Board may at any time vest in the Board any authority or duties for administration of the Plan. The Administrator may delegate administrative tasks under the Plan to the services of an Agent or Employees to assist in the administration of the Plan, including establishing and maintaining an individual securities account under the Plan for each Participant. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authority of Administrator</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator shall have the power, subject to, and within the limitations of, the express provisions of the Plan&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) To determine when and how rights to purchase Shares shall be granted and the provisions of each offering of such rights (which need not be identical). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) To designate from time to time which Subsidiaries of the Company shall be Designated Subsidiaries, which designation may be made without the approval of the stockholders of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) To impose a mandatory holding period pursuant to which Employees may not dispose of or transfer Shares purchased under the Plan for a period of time determined by the Administrator in its discretion. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) To construe and interpret the Plan and rights granted under it, and to establish, amend and revoke rules and regulations for its administration. The Administrator, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(e) To amend, suspend or terminate the Plan as provided in Article&#160;IX. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(f) Generally, to exercise such powers and to perform such acts as the Administrator deems necessary or expedient to promote the best interests of the Company and its Subsidiaries and to carry out the intent that the Plan be treated </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Code for the Section&#160;423 Component. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(g) The Administrator may adopt sub-plans applicable to particular Designated Subsidiaries or locations, which sub-plans may be designed to be outside the scope of Section&#160;423 of the Code. The rules of such sub-plans may take precedence over other provisions of this Plan, with the exception of Section&#160;3.1 hereof, but unless otherwise superseded by the terms of such sub-plan, the provisions of this Plan shall govern the operation of such sub-plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Decisions Binding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator&#8217;s interpretation of the Plan, any rights granted pursuant to the Plan, any subscription agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding, and conclusive on all parties. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE XII. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MISCELLANEOUS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restriction upon Assignment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A right granted under the Plan shall not be transferable other than by will or the applicable laws of descent and distribution, and is exercisable during the Participant&#8217;s lifetime only by the Participant. Except as provided in Section&#160;12.4 hereof, a right under the Plan may not be exercised to any extent except by the Participant. The Company shall not recognize and shall be under no duty to recognize any assignment or alienation of the Participant&#8217;s interest in the Plan, the Participant&#8217;s rights under the Plan or any rights thereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to Shares subject to a right granted under the Plan, a Participant shall not be deemed to be a stockholder of the Company, and the Participant shall not have any of the rights or privileges of a stockholder, until such Shares have been issued to the Participant or his or her nominee following exercise of the Participant&#8217;s rights under the Plan. No adjustments shall be made for dividends (ordinary or extraordinary, whether in cash securities, or other property) or distribution or other rights for which the record date occurs prior to the date of such issuance, except as otherwise expressly provided herein or as determined by the Administrator. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. No interest shall accrue on the payroll deductions or contributions of a Participant under the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Designation of Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) A Participant may, in the manner determined by the Administrator, file a written designation of a beneficiary who is to receive any Shares and&#47;or cash, if any, from the Participant&#8217;s account under the Plan in the event of such Participant&#8217;s death subsequent to a Purchase Date on which the Participant&#8217;s rights are exercised but prior to delivery to such Participant of such Shares and cash. In addition, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant&#8217;s account under the Plan in the event of such Participant&#8217;s death prior to exercise of the Participant&#8217;s rights under the Plan. If the Participant is married and resides in a community property state, a designation of a person other than the Participant&#8217;s spouse as his or her beneficiary shall not be effective without the prior written consent of the Participant&#8217;s spouse. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) Such designation of beneficiary may be changed by the Participant at any time by written notice to the Company. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant&#8217;s death, the Company shall deliver such Shares and&#47;or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such Shares and&#47;or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. All notices or other communications by a Participant to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.6 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equal Rights and Privileges</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Section&#160;5.7, all Eligible Employees will have equal rights and privileges under the Section&#160;423 Component so that the Section&#160;423 Component of this Plan qualifies as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Code. Subject to Section&#160;5.7, any provision of the Section&#160;423 Component that is inconsistent with Section&#160;423 of the Code will, without further act or amendment by the Company, the Board or the Administrator, be reformed to comply with the equal rights and privileges requirement of Section&#160;423 of the Code. Eligible Employees participating in the Non-Section 423 Component need not have the same rights and privileges as other Eligible Employees participating in the Non-Section 423 Component or as Eligible Employees participating in the Section&#160;423 Component. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.7 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Funds</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. All payroll deductions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.8 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Statements of account shall be given to Participants at least annually, which statements shall set forth the amounts of payroll deductions, the Purchase Price, the number of Shares purchased and the remaining cash balance, if any. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.9 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Employment Rights</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Nothing in the Plan shall be construed to give any person (including any Eligible Employee or Participant) the right to remain in the employ of the Company or any Parent or Subsidiary or affect the right of the Company or any Parent or Subsidiary to terminate the employment of any person (including any Eligible Employee or Participant) at any time, with or without cause. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.10 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Disposition of Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Each Participant shall give prompt notice to the Company of any disposition or other transfer of any Shares purchased upon exercise of a right under the Section&#160;423 Component of the Plan if such disposition or transfer is made&#58; (a)&#160;within two years from the Enrollment Date of the Offering Period in which the Shares were purchased or (b)&#160;within one year after the Purchase Date on which such Shares were purchased. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.11 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan and any agreements hereunder shall be administered, interpreted and enforced in accordance with the laws of the State of Delaware, disregarding any state&#8217;s choice of law principles requiring the application of a jurisdiction&#8217;s laws other than the State of Delaware. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.12 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion of Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Shares purchased under the Plan are subject to the Company&#8217;s certificate of incorporation regarding the conversion of shares of Class&#160;B Common Stock to Class&#160;A Common Stock. In addition, prior to or in connection with issuing any Shares under the Plan, the Administrator may convert shares of Class&#160;B Common Stock to Class&#160;A Common Stock or convert shares of Class&#160;A Common Stock to Class&#160;B Common Stock. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.13 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Electronic Forms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent permitted by Applicable Law and in the discretion of the Administrator, an Eligible Employee may submit any form or notice as set forth herein by means of an electronic form approved by the Administrator. Before the commencement of an Offering Period, the Administrator shall prescribe the time limits within which any such electronic form shall be submitted to the Administrator with respect to such Offering Period in order to be a valid election. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">150646002_2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>dna-20251231xex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ic83992c917184b7a9d76f9a20b97d9eb_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GINKGO BIOWORKS, INC. </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2008 STOCK INCENTIVE PLAN </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS AMENDED AS OF JUNE 18, 2014 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Purpose. </font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of this plan (the &#8220;Plan&#8221;) is to secure for Ginkgo BioWorks, Inc., a Delaware corporation (the &#8220;Company&#8221;), and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary corporations who are expected to contribute to the Company&#8217;s future growth and success. Under the Plan recipients may be awarded both (i) Options (as defined in Section 2.1) to purchase the Company&#8217;s common stock, $.01 par value (&#8220;Common Stock&#8221;) and (ii) shares of the Company&#8217;s Common Stock (&#8220;Restricted Stock Awards&#8221;). Except where the context otherwise requires, the term &#8220;Company&#8221; shall include any parent and all present and future subsidiaries of the Company as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or replaced from time to time (the &#8220;Code&#8221;). Those provisions of the Plan which make express reference to Section 422 of the Code shall apply only to Incentive Stock Options (as that term is defined below). </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Types of Awards and Administration. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Options.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Options granted pursuant to the Plan (&#8220;Options&#8221;) shall be authorized by action of the Board of Directors of the Company (the &#8220;Board&#8221; or &#8220;Board of Directors&#8221;) and may be either incentive stock options (&#8220;Incentive Stock Options&#8221;) meeting the requirements of Section 422 of the Code or non-statutory Options which are not intended to meet the requirements of Section 422 of the Code. The vesting of Options may be conditioned upon the completion of a specified period of employment with the Company and&#47;or such other conditions or events as the Board may determine. The Board may also provide that Options are immediately exercisable subject to certain repurchase rights in the Company dependent upon the continued employment of the optionee and&#47;or such other conditions or events as the Board may determine. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Incentive Stock Options.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> All Options when granted are intended to be non-statutory Options, unless the applicable Option Agreement (as defined in Section 5.1) explicitly states that the Option is intended to be an Incentive Stock Option. Incentive Stock Options may only be granted to employees of the Company and shall be subject to and construed consistently with the requirements of Section 422 of the Code. For so long as the Code shall so provide, Options granted to any employee under the Plan (and any other incentive stock option plans of the Company) which are intended to constitute Incentive Stock Options shall not constitute Incentive Stock Options to the extent that such Options, in the aggregate, become exercisable for the first time in any one </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">calendar year for shares of Common Stock with an aggregate fair market value (determined as of the respective date or dates of grant) of more than $100,000. If an Option is intended to be an Incentive Stock Option, and if for any reason such Option (or any portion thereof) shall not qualify as an Incentive Stock Option, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a non-statutory Option appropriately granted under the Plan provided that such Option (or portion thereof) otherwise meets the Plan&#8217;s requirements relating to non-statutory Options. The Company shall have no liability to any optionee, or to any other party, if an Option (or portion thereof) which is intended to be an Incentive Stock Option shall not qualify as an Incentive Stock Option. </font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Board in its discretion may grant Restricted Stock Awards, entitling the recipient to acquire, for a purchase price determined by the Board, shares of Common Stock subject to such restrictions and conditions as the Board may determine at the time of grant (&#8220;Restricted Stock&#8221;), including continued employment and&#47;or achievement of pre-established performance goals and objectives.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Administration. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Plan shall be administered by the Board, whose construction and interpretation of the terms and provisions of the Plan shall be final and conclusive. The Board may in its sole discretion issue Restricted Stock and grant Options and issue shares upon exercise of such Options as provided in the Plan. The Board shall have authority, subject to the express provisions of the Plan, to construe Restricted Stock Agreements, Option Agreements and the Plan, to prescribe, amend and rescind rules and regulations relating to the Plan, to determine the terms and provisions of Restricted Stock Agreements and Option Agreements, and to make all other determinations in the judgment of the Board necessary or desirable for the administration of the Plan. The Board may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any Restricted Stock Agreement or Option Agreement in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency. No director or person acting pursuant to authority delegated by the Board shall be liable for any action or determination under the Plan made in good faith. The Board may, to the full extent permitted by or consistent with applicable laws or regulations, delegate any or all of its powers under the Plan to a committee (the &#8220;Committee&#8221;) appointed by the Board, and if the Committee is so appointed all references to the Board in the Plan shall mean and relate to such Committee, other than references to the Board in this sentence and in Sections 19 (as to amendment of the Plan) and 22. No director or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under the Plan made in good faith. </font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-2- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Eligibility. </font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Options may be granted, and Restricted Stock may be issued, to persons who are, at the time of such grant or issuance, employees, officers or directors of, or consultants or advisors to, the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> that the class of persons to whom Incentive Stock Options may be granted shall be limited to employees of the Company. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10% Shareholder. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For so long as the Code shall so provide, if any employee to whom an Incentive Stock Option is to be granted is, at the time of the grant of such Option, the owner of stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (after taking into account the attribution of stock ownership rules of Section 424(d) of the Code) (&#8220;10% Shareholder&#8221;), any Incentive Stock Option granted to such individual must&#58; (i) have an exercise price per share of not less than 110% of the fair market value of one share of Common Stock at the time of grant&#59; and (ii) expire by its terms not more than five years from the date of grant. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Stock Subject to Plan. </font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to adjustment as provided in Section 14.2 below, as of June 18, 2014, the maximum number of shares of Common Stock which may be issued under the Plan is Forty-Three Thousand Four Hundred and Fifty (43,450) shares (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of Ginkgo Bioworks Holdings, Inc.&#8217;s Common Stock effected on August 19, 2024), and the maximum number of Incentive Stock Options which may be granted under the Plan is Forty-Three Thousand Four Hundred and Fifty (43,450) Incentive Stock Options (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of Ginkgo Bioworks Holdings, Inc.&#8217;s Common Stock effected on August 19, 2024). If an Option shall expire or terminate for any reason without having been exercised in full, the unpurchased shares subject to such Option shall again be available for subsequent Option grants or Restricted Stock Awards under the Plan. If shares of Restricted Stock shall be forfeited to, or otherwise repurchased by, the Company pursuant to a Restricted Stock Agreement, such purchased shares shall again be available for subsequent Option </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">grants or Restricted Stock Awards under the Plan. If shares issued upon exercise of an Option are tendered to the Company in payment of the exercise price of an Option, such tendered shares shall again be available for subsequent Option grants or Restricted Stock Awards under the Plan. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Forms of Restricted Stock Agreements and Option Agreements. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Option Agreement. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a condition to the grant of an Option, each recipient of an Option shall execute an option agreement (&#8220;Option Agreement&#8221;) in such form not inconsistent with the Plan as may be approved by the Board of Directors. Such Option Agreements may differ among recipients. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> As a condition to the issuance of Restricted Stock, each recipient thereof shall execute a restricted stock agreement (&#8220;Restricted Stock Agreement&#8221;) in such form not inconsistent with the Plan as may be approved by the Board of Directors. Such Restricted Stock Agreements may differ among recipients. </font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-3- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Lock-Up&#8221; Agreement.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Unless the Board specifies otherwise, each Restricted Stock Agreement and Option Agreement shall provide that upon the request of the Company or the managing underwriter(s), the holder of any Option or the purchaser of any Restricted Stock shall, in connection with any registration of securities of the Company under the Securities Act of 1933, as amended from time to time (the &#8220;Act&#8221;), agree in writing that for a period of time (not to exceed 180 days) from the effective date of the registration statement under the Act for such offering, the holder or purchaser will not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares of the Common Stock, no par value, of the Company owned or controlled by him or her. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">6.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Purchase Price. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">General.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The purchase price per share of Restricted Stock and the per share exercise price of an Option shall be determined by the Board at the time of issuance in the case of Restricted Stock and at the time of grant in the case of Options. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Payment of Purchase Price.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Option Agreements may provide for the payment of the exercise price by (i) delivery of a personal, certified or bank check or postal money order payable to the order of the Company in an amount equal to the exercise price of such Option, (ii) with the consent of the Board, delivery to the Company of shares of Common Stock of the Company already owned by the optionee for a period of six months and having a fair market value equal in amount to the exercise price of the Options being exercised, (iii) with the consent of the Board, a personal recourse note issued by the optionee to the Company in a principal amount equal to such aggregate exercise price and with such other terms, including interest rate and maturity, as the Company may determine in its discretion&#59; provided, however, that the interest rate borne by such note shall not be less than the lowest applicable federal rate, as defined in Section 1274(d) of the Code, (iv) in the event there is a public market for the Common Stock at such time, subject to rules as may be established by the Board, through delivery of irrevocable instructions to a broker to sell such shares and deliver promptly to the Company an amount equal to the aggregate exercise price, (v) any other means which the Board of Directors determines are consistent with the purpose of the Plan and with applicable laws and regulations or (vi) any combination of such methods of payment. The fair market value of any shares of Common Stock or other non-cash consideration which may be delivered upon exercise of an Option shall be determined by the Board. Restricted Stock Agreements may provide for the payment of any purchase price in any manner approved by the Board at the time of authorizing the issuance thereof. </font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">7.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Option Period. </font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable Option Agreement. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-4- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">8.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exercise of Options. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">General.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Each Option shall be exercisable either in full or in installments at such time or times and during such period as shall be set forth in the agreement evidencing such Option, subject to the provisions of the Plan. To the extent not exercised, installments shall accumulate and be exercisable, in whole or in part, at any time after becoming exercisable, but not later than the date the Option expires. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notice of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> An Option may be exercised by the optionee by delivering to the Company on any business day a written notice specifying the number of shares of Common Stock the optionee then desires to purchase and specifying the address to which the certificates for such shares are to be mailed (the &#8220;Notice&#8221;), accompanied by payment for such shares. In addition, the Company may require any individual to whom an Option is granted, as a condition of exercising such Option, to give written assurances in a substance and form satisfactory to the Company to the effect that such individual is acquiring the Common Stock subject to the Option for his or her own account for investment and not with a view to the resale or distribution thereof, and to such other effects as the Company deems necessary or advisable in order to comply with any securities law(s). In addition, the Company may require any individual to whom an Option is granted, as a condition of exercising such Option, to become a party to a stockholders&#8217; agreement or similar agreement, as may be amended from time to time, between the Company and its stockholders. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Delivery. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As promptly as practicable after receipt of such written notification and payment, the Company shall deliver or cause to be delivered to the optionee certificates for the number of shares with respect to which such Option has been so exercised, issued in the optionee&#8217;s name&#59; provided, however, that such delivery shall be deemed effected for all purposes when the Company or a stock transfer agent shall have deposited such certificates in the United States mail, addressed to the optionee, at the address specified in the Notice.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">9.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nontransferability of Options. </font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Except as the Board may otherwise permit or provide in an applicable Option Agreement, no Option shall be assignable or transferable by the person to whom it is granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution. During the life of an optionee, an Option shall be exercisable only by the optionee. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">10.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Termination of Employment&#59; Disability&#59; Death.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Except as may be otherwise expressly provided in the terms and conditions of the Option Agreement, Options shall terminate on the earliest to occur of&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the date of expiration thereof&#59; </font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-5- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">immediately upon the effective date of termination of the optionee&#8217;s employment with, or provision of services to, the Company by the Company for Cause (as hereinafter defined)&#59; </font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">90</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">days after the date of voluntary termination of the optionee&#8217;s employment with, or provision of services to, the Company by the optionee (other than for death or permanent disability as defined below)&#59; or </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">90 days</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">after the date of termination of the optionee&#8217;s employment with, or provision of services to, the Company by the Company without Cause (other than for death or permanent disability as defined below). </font></div></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until the date on which the Option so expires, the optionee may exercise that portion of his or her Option which is exercisable at the time of termination of the employment or service relationship. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An employment or service relationship between the Company and the optionee shall be deemed to exist during any period during which the optionee is employed by or providing services to the Company, either on a full-time or a part-time basis. Whether an authorized leave of absence or an absence due to military or government service shall constitute termination of the employment relationship between the Company and the optionee shall be determined by the Board at the time thereof. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Section 10, the term &#8220;Cause&#8221; shall mean (a) a good faith finding by the Board that the optionee willfully failed to perform his or her assigned duties for the Company, (b) any material breach by the optionee of any agreement to which the optionee and the Company are both parties, (c) any act (other than retirement) or omission to act by the optionee which may have a material and adverse effect on the Company&#8217;s business or on the optionee&#8217;s ability to perform services for the Company, including, without limitation, the commission of any crime (other than minor traffic violations), or (d) any material misconduct or material neglect of duties by the optionee in connection with the business or affairs of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the event of the permanent and total disability or death of an optionee while in an employment or other relationship with the Company and before the date of expiration of such option, such option shall terminate on the earlier of such date of expiration or one year following the date of such disability or death. After disability or death, the optionee (or in the case of death, his or her executor, administrator or any person or persons to whom this option may be transferred by will or by laws of descent and distribution) shall have the right, at any time prior to such termination, to exercise the option to the extent the optionee was entitled to exercise such option as of the date of his or her disability or death. An optionee is permanently and totally disabled if he or she is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to last for a continuous period of not less than 12 months&#59; permanent and total disability shall be determined in accordance with Section 22(e)(3) of the Code and the regulations issued thereunder. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-6- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">11.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Rights as a Shareholder. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The holder of an Option shall have no rights as a shareholder with respect to any shares covered by the Option (including, without limitation, any rights to receive dividends or non-cash distributions with respect to such shares) until the date of issue of a stock certificate to him or her for such shares. No adjustment shall be made for dividends or other rights for which the record date occurs prior to the date such stock certificate is issued.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">12.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Additional Provisions. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors may, in its sole discretion, include additional provisions in Restricted Stock Agreements and Option Agreements, including, without limitation, restrictions on transfer, rights of the Company to repurchase shares of Restricted Stock or shares of Common Stock acquired upon exercise of Options, commitments to pay cash bonuses, to make, arrange for or guaranty loans or to transfer other property to optionees upon exercise of Options, or such other provisions as shall be determined by the Board of Directors&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> such additional provisions shall not be inconsistent with any other term or condition of the Plan and such additional provisions shall not be such as to cause any Incentive Stock Option to fail to qualify as an Incentive Stock Option within the meaning of Section 422 of the Code.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">13.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Acceleration, Extension, Etc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Board of Directors may, in its sole discretion, (i) accelerate the date or dates on which all or any particular Option or Options may be exercised or (ii) extend the period or periods of time during which all, or any particular, Option or Options may be exercised.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">14.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Adjustment Upon Changes in Capitalization </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">No Effect of Options upon Certain Corporate Transactions.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The existence of outstanding Options shall not affect in any way the right or power of the Company to make or authorize any or all adjustments, recapitalizations, reorganizations or other changes in the Company&#8217;s capital structure or its business, or any merger or consolidation, or any issue of Common Stock, or any issue of bonds, debentures, preferred or prior preference stock ahead of or affecting the Common Stock or the rights thereof, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Adjustment Provisions. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If, through or as a result of any merger, consolidation, sale of all or substantially all of the assets of the Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar transaction, (i) the outstanding shares of Common Stock are increased, decreased or exchanged for a different number or kind of shares or other securities of the Company, or (ii) additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Common Stock or other securities, an appropriate and proportionate adjustment shall be made in (x) the maximum number and kind of shares reserved for issuance under the Plan, (y) the number and kind of shares or other securities subject to any then outstanding Options, and (z) the price for </font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-7- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">each share subject to any then outstanding Options, without changing the aggregate purchase price as to which such Options remain exercisable. Notwithstanding the foregoing, no adjustment shall be made pursuant to this Section 14 if such adjustment would cause the Plan to fail to comply with Section 422 of the Code. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">No Adjustment in Certain Cases.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Except as expressly provided for herein, the issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, for cash or property or for labor or services, either upon direct sale or upon the exercise of rights or warrants to subscribe therefor, or upon conversion of shares or obligations of the Company convertible into such shares or other securities, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock then subject to outstanding options. </font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Board Authority to Make Adjustments. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any adjustments under this Section 14 will be made by the Board of Directors, whose determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued under the Plan on account of any such adjustments.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">15.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Certain Transactions </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">General.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In the event of a consolidation or merger or sale of all or substantially all of the assets of the Company in which outstanding shares of capital stock are exchanged for securities, cash or other property of any other corporation or business entity, the Board, or the board of directors of any corporation assuming the obligations of the Company, may, in its discretion, take any one or more of the following actions, as to some or all outstanding Options (and need not take the same action as to each such Option)&#58; (i) provide that such Options shall be assumed, or equivalent Options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> any such Options substituted for Incentive Stock Options shall meet the requirements of Section 424(a) of the Code, (ii) upon written notice to the optionees, provide that all unexercised Options will terminate immediately following the consummation of such transaction unless exercised by the optionee to the extent otherwise then exercisable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">within a specified period following the date of such notice,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> provided that </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the vesting of any such Options so terminated shall have been accelerated as of immediately prior to the consummation of such transaction so that such Options may be exercised in full concurrently with the consummation of such transaction, (iii) in the event of a merger under the terms of which holders of the Common Stock of the Company will receive upon consummation thereof a cash payment for each share surrendered in the merger (the &#8220;Merger Price&#8221;), make or provide for a cash payment to the optionees equal to the difference between (A) the Merger Price times the number of shares of Common Stock subject to such outstanding Options (to the extent then exercisable at prices not in excess of the Merger Price) and (B) the aggregate exercise price of all such outstanding </font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-8- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options, in exchange for the termination of such Options, and (iv) provide that all or any outstanding Options shall become exercisable in part or in full immediately prior to such event. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Substitute Options.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company may grant Options in substitution for options held by employees of another corporation who become employees of the Company, as the result of a merger or consolidation of the employing corporation with the Company or as a result of the acquisition by the Company, of property or stock of the employing corporation. The Company may direct that substitute Options be granted on such terms and conditions as the Board considers appropriate in the circumstances. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In the event of a business combination or other transaction of the type detailed in Section 15.1, any securities, cash or other property received in exchange for shares of Restricted Stock shall continue to be governed by the provisions of any Restricted Stock Agreement pursuant to which they were issued, including any provision regarding vesting, and such securities, cash, or other property may be held in escrow on such terms as the Board of Directors may direct, to insure compliance with the terms of any such Restricted Stock Agreement. </font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">16.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">No Special Rights to an Employment or Other Business Relationship. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nothing contained in the Plan or in any Option or Restricted Stock Agreement shall confer upon any optionee or holder of Restricted Stock any right with respect to the continuation of his or her employment by the Company or any other business relationship with the Company or interfere in any way with the right of the Company at any time to terminate such employment or other business relationship or to increase or decrease the compensation of such person.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">17.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other Employee Benefits. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amount of any compensation deemed to be received by an employee as a result of the issuance of shares of Restricted Stock or the grant or exercise of an Option or the sale of shares received upon such award or exercise will not constitute compensation with respect to which any other employee benefits of such employee are determined, including, without limitation, benefits under any bonus, pension, profit-sharing, life insurance or salary continuation plan, except as otherwise specifically determined by the Board of Directors. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">18.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Special Provisions Relating to Section 409A of the Code and Regulations Promulgated Thereunder. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intention to Price Options at Not Lower than Fair Market Value.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> It is the intention of the Company to issue all Options under the Plan with exercise prices at least equal to the fair market value of the Common Stock as of the date of grant. However, this Section 18 is included herein to ensure compliance with Section 409A of the Code in the event that any Option is issued with an exercise price lower than the fair market value of the Common Stock as of the date of grant. </font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-9- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Earliest Distribution Date.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Notwithstanding anything contained in the Plan or any Option Agreement issued pursuant to the Plan, to the extent that any Option or Common Stock issuable upon exercise of an Option constitutes &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code (&#8220;Section 409A&#8221;), such Option or Stock may not be distributed to the recipient earlier than&#58; </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the date of the recipient&#8217;s &#8220;separation from service&#8221; as determined in accordance with Section 409A (except as otherwise provided in Section 18.3(a), </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the date the recipient becomes disabled (within the meaning of Section 18.4), </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the date of the recipient&#8217;s death, </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">to the extent provided under Section 409A and regulations promulgated thereunder, a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the assets of the Company, or </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">the occurrence of an unforeseeable emergency. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Special rules. </font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Specified employees. In the case of any specified employee, the requirement of Section 18.2(a) is met only if distributions may not be made before the date which is 6 months after the date of separation from service (or, if earlier, the date of death of the recipient). For purposes of the preceding sentence, a specified employee is a key employee (as defined in section 416(i) of the Code without regard to paragraph (5) thereof) of a Company any stock in which is publicly traded on an established securities market or otherwise. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unforeseeable emergency. For purposes of Section 18.2(e)&#58; </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">In general. The term &#8220;unforeseeable emergency&#8221; means a severe financial hardship to the recipient resulting from an illness or accident of the recipient, the recipient&#8217;s spouse, or a dependent (as defined in section 152(a) of the Code) of the recipient, loss of the recipient&#8217;s property due to casualty, or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the recipient. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Limitation on distributions. The requirement of Section 18.2(e) is met only if, as determined under regulations promulgated pursuant to the Code, the amounts distributed with respect to an emergency do not exceed the amounts </font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-10- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">necessary to satisfy such emergency, including amounts necessary to pay taxes reasonably anticipated as a result of the distribution, after taking into account the extent to which such hardship is or may be relieved through reimbursement or compensation by insurance or otherwise or by liquidation of the participant&#8217;s assets (to the extent the liquidation of such assets would not itself cause severe financial hardship). </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Disabled.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> For purposes of Section 18.2(b), a recipient shall be considered disabled if the recipient&#58; </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">is, by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than 3 months under an accident and health plan covering employees of the Company. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">No Acceleration.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> No acceleration of the time or schedule of any payment governed by this Section 18 shall occur except as provided in regulations promulgated pursuant to Section 409A. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Compliance with Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> This Section 18 is intended to comply with Section 409A and the regulations promulgated thereunder, and to the extent it conflicts with Section 409A and such regulations at any time, it shall be construed in accordance with Section 409A and such regulations as they may be in effect at such time. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">19.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amendments. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The Board may at any time, and from time to time, modify, amend or suspend the Plan in any respect. </font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">The termination or any modification or amendment of the Plan shall not, without the consent of an optionee or the holder of Restricted Stock, adversely affect his or her rights under an Option or Restricted Stock Award previously granted to him or her. With the consent of the recipient of Restricted Stock or optionee affected, the Board may amend outstanding Restricted Stock Agreements or Option Agreements in a manner not inconsistent with the Plan. The Board shall have the right to amend or modify the terms and provisions of the Plan and of any outstanding Incentive Stock Options to the extent necessary to qualify any or all such Options for such favorable federal income tax treatment (including deferral of taxation upon exercise) as may be afforded incentive stock options under Section 422 of the Code. </font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-11- </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">20.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Withholding. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall have the right to deduct from payments of any kind otherwise due to the optionee or recipient of Restricted Stock, any federal, state or local taxes of any kind required by law to be withheld with respect to issuance of any shares of Restricted Stock or shares issued upon exercise of Options. Subject to the prior approval of the Company, which may be withheld by the Company in its sole discretion, the obligor may elect to satisfy such minimum withholding obligations, in whole or in part, (i) by causing the Company to withhold shares of Common Stock otherwise issuable or (ii) by delivering to the Company shares of Common Stock of the Company already owned by the obligor for a period of at least six months. The shares so withheld shall have a fair market value equal to such withholding obligation. The fair market value of the shares used to satisfy such withholding obligation shall be determined by the Company as of the date that the amount of tax to be withheld is to be determined. A person who has made an election pursuant to this Section 20 may only satisfy his or her withholding obligation with shares of Common Stock which are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">21.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date and Duration of the Plan. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Effective Date.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Plan shall become effective when adopted by the Board of Directors. If shareholder approval is not obtained within twelve months after the date of the Board&#8217;s adoption of the Plan, no Options previously granted under the Plan shall be deemed to be Incentive Stock Options and no Incentive Stock Options shall be granted thereafter. Amendments to the Plan not requiring shareholder approval shall become effective when adopted by the Board. Amendments requiring shareholder approval shall become effective when adopted by the Board, but if shareholder approval is not obtained within twelve months of the Board&#8217;s adoption of such amendment, unless otherwise permitted under the Code, any Incentive Stock Options granted pursuant to such amendment shall be deemed to be non-statutory Options provided that such Options are authorized by the Plan. Subject to this limitation, Options may be granted under the Plan at any time after the effective date and before the date fixed for termination of the Plan. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Termination.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Unless sooner terminated by action of the Board of Directors, the Plan shall terminate upon the close of business on the day next preceding the tenth anniversary of the date of its adoption by the Board of Directors. </font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">22.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Requirements of Law.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company shall not be required to sell or issue any shares under any Option or Restricted Stock Agreement if the issuance of such shares shall constitute a violation by the optionee, the Restricted Stock Award recipient, or by the Company of any provisions of any law or regulation of any governmental authority. In addition, in connection with the Act, the Company shall not be required to issue any shares upon exercise of any Option unless the Company has received evidence satisfactory to it to the effect that the holder of such Option will not transfer such shares except pursuant to a registration statement in effect under the Act or unless an opinion of </font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-12- </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">counsel satisfactory to the Company has been received by the Company to the effect that such registration is not required in connection with any such transfer. Any determination in this connection by the Board shall be final, binding and conclusive. In the event the shares issuable on exercise of an Option are not registered under the Act or under the securities laws of each relevant state or other jurisdiction, the Company may imprint on the certificate(s) appropriate legends that counsel for the Company considers necessary or advisable to comply with the Act or any such state or other securities law. The Company may register, but in no event shall be obligated to register, any securities covered by the Plan pursuant to the Act&#59; and in the event any shares are so registered the Company may remove any legend on certificates representing such shares. The Company shall not be obligated to take any affirmative action in order to cause the exercise of an Option or the issuance of shares pursuant thereto to comply with any law or regulation of any governmental authority. </font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">23.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Plan and each Option or Restricted Stock Agreement shall be governed by the laws of the State of Delaware, without regard to its principles of conflicts of law. </font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-13- </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>6
<FILENAME>dna-20251231xex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i418466e3d5c54b32b26dd5e4dcf3e321_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT TO THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GINKGO BIOWORKS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2014 STOCK INCENTIVE PLAN </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 1, 2019 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is effective as of the date first set forth above, such amendment having been approved by the Board of Directors of Ginkgo Bioworks, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), on April 8, 2019 and approved by the holders of a majority of the Company&#8217;s outstanding shares of voting capital stock on April 15, 2019, in each case in accordance with Section 11(d) of the Plan. Capitalized but undefined terms shall have the meanings provided in the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of result of the foregoing approvals, the Plan is hereby amended as follows&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. Section 4(a) of the Plan is hereby amended and restated in its entirety to read as follows&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;(a) Number of Shares. Subject to adjustment under Section 9, Awards may be made under the Plan (any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)) for up to such number of shares of common stock, $0.01 par value per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as is equal to the sum of&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1) 12,612 (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of Ginkgo Bioworks Holdings, Inc.&#8217;s Common Stock effected on August 19, 2024)&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2) the number of shares of Common Stock subject to awards granted under the Existing Plan which awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company pursuant to a contractual repurchase right (subject, however, in the case of Incentive Stock Options to any limitations of the Code)&#59; and. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If any Award expires or is terminated, surrendered or canceled without having been fully exercised, is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right), or results in any Common Stock not being issued, the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options, the two immediately preceding sentences shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.&#8221; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, being the duly elected and acting Secretary of the Company, hereby certifies that the foregoing amendment was duly approved and adopted by the Board of Directors and the Stockholders of the Company effective as of the date first referenced above. </font></div><div style="padding-left:280.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.544%"><tr><td style="width:1.0%"></td><td style="width:6.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.414%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bartholomew Canton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Bartholomew Canton, Secretary</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>7
<FILENAME>dna-20251231xex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i61b8228ce4cc4da2aab0421134454501_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Plan Amendment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT TO THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GINKGO BIOWORKS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2014 STOCK INCENTIVE PLAN </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 9, 2019 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is effective as of the date first set forth above, such amendment having been approved by the Board of Directors of Ginkgo Bioworks, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), on September 9, 2019 and approved by the holders of a majority of the Company&#8217;s outstanding shares of voting capital stock on September 9, 2019, in each case in accordance with Section 11(d) of the Plan. Capitalized but undefined terms shall have the meanings provided in the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of result of the foregoing approvals, the Plan is hereby amended as follows&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. Section 4(a) of the Plan is hereby amended and restated in its entirety to read as follows&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;(a) Number of Shares. Subject to adjustment under Section 9, Awards may be made under the Plan (any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)) for up to such number of shares of common stock, $0.01 par value per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as is equal to the sum of&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1) 43,810 (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of Ginkgo Bioworks Holdings, Inc.&#8217;s Common Stock effected on August 19, 2024)&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2) the number of shares of Common Stock subject to awards granted under the Existing Plan which awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company pursuant to a contractual repurchase right (subject, however, in the case of Incentive Stock Options to any limitations of the Code)&#59; and. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If any Award expires or is terminated, surrendered or canceled without having been fully exercised, is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right), or results in any Common Stock not being issued, the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options, the two immediately preceding sentences shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, being the duly elected and acting Secretary of the Company, hereby certifies that the foregoing amendment was duly approved and adopted by the Board of Directors and the Stockholders of the Company effective as of the date first referenced above. </font></div><div style="padding-left:280.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.544%"><tr><td style="width:1.0%"></td><td style="width:6.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.414%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bartholomew Canton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Bartholomew Canton, Secretary</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>8
<FILENAME>dna-20251231xex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i0098fd07591c41139fb1d2dc1cd161dc_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan Amendment </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT TO THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GINKGO BIOWORKS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2014 STOCK INCENTIVE PLAN </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 8, 2020 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is effective as of the date first set forth above, such amendment having been approved by the Board of Directors of Ginkgo Bioworks, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), on April 8, 2020 and approved by the holders of a majority of the Company&#8217;s outstanding shares of voting capital stock on April 27, 2020, in each case in accordance with Section 11(d) of the Plan. Capitalized but undefined terms shall have the meanings provided in the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of result of the foregoing approvals, the Plan is hereby amended as follows&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. Section 4(a) of the Plan is hereby amended and restated in its entirety to read as follows&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;(a) Number of Shares. Subject to adjustment under Section 9, Awards may be made under the Plan (any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)) for up to such number of shares of common stock, $0.01 par value per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as is equal to the sum of&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1) 66,604 (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of Ginkgo Bioworks Holdings, Inc.&#8217;s Common Stock effected on August 19, 2024)&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2) the number of shares of Common Stock subject to awards granted under the Company&#8217;s 2008 Stock Incentive Plan which awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company pursuant to a contractual repurchase right (subject, however, in the case of Incentive Stock Options to any limitations of the Code)&#59; and. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If any Award expires or is terminated, surrendered or canceled without having been fully exercised, is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right), or results in any Common Stock not being issued, the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options, the two immediately preceding sentences shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, being the duly elected and acting Secretary of the Company, hereby certifies that the foregoing amendment was duly approved and adopted by the Board of Directors and the Stockholders of the Company effective as of the date first referenced above. </font></div><div style="padding-left:280.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.544%"><tr><td style="width:1.0%"></td><td style="width:6.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.414%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bartholomew Canton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Bartholomew Canton, Secretary</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>9
<FILENAME>dna-20251231xex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i952698b8ce90400e89be0d003ce49cd2_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT TO THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GINKGO BIOWORKS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2014 STOCK INCENTIVE PLAN </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective March 15, 2021 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Amendment to the Ginkgo Bioworks, Inc. 2014 Stock Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is effective as of the date first set forth above, such amendment having been approved by the Board of Directors of Ginkgo Bioworks, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), on March 15, 2021 and approved by the holders of a majority of the Company&#8217;s outstanding shares of voting capital stock on March 15, 2021, in each case in accordance with Section 11(d) of the Plan. Capitalized but undefined terms shall have the meanings provided in the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of result of the foregoing approvals, the Plan is hereby amended as follows&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. Section 4(a) of the Plan is hereby amended and restated in its entirety to read as follows&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;(a) Number of Shares. Subject to adjustment under Section 9, Awards may be made under the Plan (any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)) for up to such number of shares of common stock, $0.01 par value per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as is equal to the sum of&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1) 86,959 (adjusted to reflect a one-for-forty (1&#58;40) reverse stock split of Ginkgo Bioworks Holdings, Inc.&#8217;s Common Stock effected on August 19, 2024)&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2) the number of shares of Common Stock subject to awards granted under the Company&#8217;s 2008 Stock Incentive Plan which awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company pursuant to a contractual repurchase right (subject, however, in the case of Incentive Stock Options to any limitations of the Code)&#59; and. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If any Award expires or is terminated, surrendered or canceled without having been fully exercised, is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right), or results in any Common Stock not being issued, the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options, the two immediately preceding sentences shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.&#8221; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, being the duly elected and acting Secretary of the Company, hereby certifies that the foregoing amendment was duly approved and adopted by the Board of Directors and the Stockholders of the Company effective as of the date first referenced above. </font></div><div><font><br></font></div><div style="padding-left:280.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.544%"><tr><td style="width:1.0%"></td><td style="width:6.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.414%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bartholomew Canton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Bartholomew Canton, Secretary</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>10
<FILENAME>dna-20251231xex191.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i389f03a7761d4c7ea77c55c08c27e535_1"></div><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">GINKGO BIOWORKS HOLDINGS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">INSIDER TRADING COMPLIANCE POLICY </font></div><div style="margin-top:11.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(As of August 2, 2024) </font></div><div style="margin-top:7.75pt;padding-left:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This Insider Trading Compliance Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) consists of six sections&#58; </font></div><div style="margin-top:7.75pt;padding-left:36.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Section 1 provides an overview&#59; </font></div><div style="padding-left:36.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Section 2 sets forth Ginkgo&#8217;s policies prohibiting insider trading&#59; </font></div><div style="padding-left:36.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Section 3 explains insider trading terms&#59; </font></div><div style="padding-left:36.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Section 4 consists of procedures that have been put in place by Ginkgo to prevent insider trading&#59; </font></div><div style="padding-left:36.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Section 5 sets forth special and prohibited transactions that are prohibited by this Policy&#59; and </font></div><div style="padding-left:36.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Section 6 explains Rule 10b5-1 trading plans. </font></div><div style="margin-top:7.1pt;padding-left:0.25pt;padding-right:2.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:110%">In addition, Exhibit A contains a more detailed description of insider trading generally, Exhibit B provides information about Section 16 and Exhibit C provides a Certification of Compliance form. </font></div><div style="margin-top:7.95pt;padding-left:0.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">1. SUMMARY </font></div><div style="margin-top:7.1pt;padding-left:36.05pt;padding-right:1.45pt;text-align:justify;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:110%">Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of Ginkgo Bioworks Holdings, Inc. (together with its subsidiaries, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:110%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) as well as that of all persons affiliated with the Company. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:110%">Insider trading</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; occurs when any person purchases or sells a security while in possession of material non-public information relating to the security. Insider trading is a crime. The penalties for violating insider trading laws include imprisonment, disgorgement of profits, civil fines, and criminal fines. Insider trading is also prohibited by this Policy, and violation of this Policy may result in Company-imposed sanctions, including removal or termination for cause. </font></div><div style="margin-top:7.95pt;padding-left:36pt;padding-right:0.85pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:110%">This Policy applies to directors, employees, and certain contingent workers of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:110%">Team Members</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;). This policy also applies to members of a Team Member&#8217;s household, any family members who do not live in the household but whose securities transactions are directed by the Team Member or who are subject to such Team Member&#8217;s influence or control, any entities controlled by individuals subject to the Policy, including any corporations, partnerships or trusts (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:110%">Controlled Entities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), and any person to whom an individual subject to this Policy has disclosed material, nonpublic information. Transactions by Controlled Entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&#8217;s own account, unless the individual subject to the Policy has certified on a Certification of Compliance in the form attached hereto as Exhibit C (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:110%">Certification of Compliance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) that such Controlled Entity has established insider trading controls and procedures in compliance with applicable securities laws, and any such Controlled Entity engages in the investment of securities in the ordinary course of its business (e.g., an investment fund). This Policy extends to all activities within and outside an individual&#8217;s Company duties. Every Team Member must review this Policy and comply with requests from the Company to attend trainings and&#47;or certify compliance with the Policy. </font></div><div style="margin-top:7.95pt;padding-left:36pt;padding-right:0.85pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:110%">Questions regarding this Policy should be directed to the General Counsel at ethics&#64;ginkgobioworks.com. </font></div><div style="margin-top:12.3pt;padding-left:0.3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">2. STATEMENT OF POLICIES PROHIBITING INSIDER TRADING </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.75pt;padding-left:36.35pt;padding-right:1.35pt;text-align:justify;text-indent:-0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">No Team Member or other person subject to this Policy may purchase or sell any type of security while in possession of material nonpublic information relating to the security, whether the issuer of such security is the Company or any other company, including, without limitation, any of our customers, when that information was obtained as a result of the insider&#8217;s employment or relationship with the Company. </font></div><div style="margin-top:12.3pt;padding-left:36pt;padding-right:0.85pt;text-align:justify;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Additionally, no person subject to this policy may directly or indirectly communicate (or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">tip</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;) material, nonpublic information to anyone outside of the Company (except in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of Company information, including the Company&#8217;s Guidelines for Corporate Disclosure) or to anyone within the Company other than on a need-to-know basis. This practice, known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">tipping</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;, also includes recommending the purchase or sale of any securities when you are aware of material nonpublic information. Tipping violates the securities laws and can result in the same civil and criminal penalties that apply to insider trading. </font></div><div style="margin-top:12.3pt;padding-left:36.05pt;padding-right:1.4pt;text-align:justify;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Persons subject to this Policy are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">individually responsible </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">for complying with this Policy, and for making sure that any family member, household member, or entity whose transactions are also subject to this Policy, as discussed below, also comply with this Policy. </font></div><div style="margin-top:12.3pt;padding-left:36.05pt;padding-right:1.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Additionally, it is the Company&#8217;s policy to comply with all applicable securities laws when transacting in its own securities. </font></div><div style="margin-top:12.3pt;padding-left:0.2pt;padding-right:7.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:207%">Please see Section 4 for an outline of Company procedures to prevent insider trading. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:207%">3. EXPLANATION OF INSIDER TRADING TERMS </font></div><div style="margin-top:2.3pt;padding-left:36pt;padding-right:1.1pt;text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:111%">Insider trading</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">refers to the purchase or sale of a security while in possession of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">material,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">nonpublic</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; information relating to the security. It is generally understood that insider trading includes the following&#58; </font></div><div style="margin-top:12.35pt;padding-left:79.8pt;padding-right:1.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">trading by insiders while in possession of material nonpublic information&#59;</font></div><div style="padding-left:79.8pt;padding-right:1.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">trading by persons other than insiders while in possession of material nonpublic information, if the information either was given in breach of an insider&#8217;s fiduciary duty to keep it confidential or was misappropriated&#59; and</font></div><div style="padding-left:79.8pt;padding-right:1.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">communicating or tipping material nonpublic information to others, including recommending the purchase or sale of a security while in possession of such information. </font></div><div style="margin-top:12.3pt;padding-left:36.4pt;padding-right:1.85pt;text-indent:1.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:111%">Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">includes stocks, bonds, notes, debentures, options, warrants, and other convertible securities, as well as derivative instruments. </font></div><div style="margin-top:12.3pt;padding-left:36.35pt;padding-right:1pt;text-indent:1.95pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:111%">Purchase</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:111%">sale</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">are defined broadly under federal securities law. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:111%">Purchase</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:111%">Sale</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">includes not only the actual sale of a security, but any contract to sell or otherwise dispose of a security. These definitions extend to a broad range of transactions, including conventional cash-for-stock transactions, conversions, the exercise of stock options, and acquisitions and exercises of warrants or puts, calls, or other derivative securities. </font></div><div style="margin-top:12.3pt;padding-left:36.1pt;padding-right:2.2pt;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:111%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; refers to a day on which national stock exchanges are open for trading. </font></div><div style="margin-top:12.3pt;padding-right:6.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Open Trading Window</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; refers to a time period when no blackout period is in effect. </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.75pt;padding-left:34.55pt;padding-right:1.3pt;text-align:justify;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:111%">Blackout period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; refers to any time period in which no Team Member or other person subject to this Policy may purchase or sell any security of the Company and includes regularly-scheduled quarterly blackout periods and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:111%">event-specific blackout periods</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; </font></div><div style="margin-top:12.3pt;padding-left:36.05pt;padding-right:2pt;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Please see Exhibit A for a further explanation of terms relevant to insider trading, as well as a detailed discussion of insider trading and its consequences. </font></div><div style="margin-top:12.3pt;padding-left:0.3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">4. STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.5pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The following procedures have been established, and will be maintained and enforced, by the Company to prevent insider trading. Every Team Member and other person subject to this Policy is required to follow these procedures. </font></div><div style="margin-top:12.3pt;padding-left:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Open Trading Windows, Blackout Periods, and Permitted Transactions </font></div><div style="margin-top:11.75pt;padding-left:36.05pt;padding-right:0.35pt;text-align:justify;text-indent:0.65pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">Open Trading Windows</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">. Team Members and other persons subject to this Policy may only purchase or sell any security of the Company during Open Trading Windows. Unless a blackout period is in effect, the following periods during any fiscal quarter constitute Open Trading Windows&#58; the period </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">beginning one full trading day after the public release of earnings data for a fiscal quarter </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">ending at 11&#58;59 pm Eastern Time on the 15th day of the last month of the next fiscal quarter</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">. </font></div><div style="margin-top:12.3pt;padding-left:36.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Open Trading Windows </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unless a blackout period is in effect) </font></div><div style="padding-left:35.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.290%"><tr><td style="width:1.0%"></td><td style="width:40.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 8.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:133%">Fiscal Quarter </font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 2.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:133%">Beginning&#58; </font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.37pt;padding-right:2.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Ending at 11&#58;59pm </font></div><div style="padding-left:2.37pt;padding-right:2.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Eastern Time on&#58;</font></div></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 8.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Q1 &#61; January through March</font></td><td colspan="3" rowspan="4" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">One full trading day after the </font></div><div style="padding-left:2.37pt;padding-right:2.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">public release of earnings data for the fiscal quarter</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 2.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">June 15</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 8.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Q2 &#61; April through June </font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 2.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">September 15</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 8.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Q3 &#61; July through September </font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 2.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">December 15</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 2.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Q4 &#61; October through December </font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 2.18pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">March 15</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Examples of Open Trading Windows for reference&#58; </font></div><div style="margin-top:11.8pt;padding-left:79.85pt;padding-right:1.1pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">If the Company publicly releases Q1 earnings data on Thursday, May 8 at 5&#58;00pm Eastern Time, the open trading window would begin when markets open on Monday, May 12 at 9&#58;30am. This is because you must wait ONE FULL TRADING DAY (e.g., must wait all day Friday before you can start trading). The trading window would close on June 15 at 11&#58;59pm. </font></div><div style="padding-left:79.85pt;padding-right:1.1pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">If the Company publicly releases Q3 earnings data on Wednesday, November 7 at 8&#58;00am Eastern Time, the open trading window would begin when markets open on Thursday, November 8 at 9&#58;30am. In this example, the ONE FULL TRADING DAY is Wednesday. The trading window would close on December 15 at 11&#58;59pm. </font></div><div style="margin-top:12.3pt;padding-left:36.4pt;padding-right:1.2pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">For the avoidance of doubt, even in an Open Trading Window, trading in Company securities is prohibited for any individual in possession of material nonpublic information relating to the Company. </font></div><div style="margin-top:12.3pt;padding-left:36pt;padding-right:1.25pt;text-align:justify;text-indent:-0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">Event-Specific Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">. From time to time, the Company may impose a blackout period in connection with non-routine events outside of the financial reporting cycle. </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.3pt;padding-left:36pt;padding-right:0.3pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">These events may include consideration of major strategic transactions (e.g., negotiation of mergers, acquisitions, dispositions, collaborations), significant program milestones, interim earnings releases, significant legal proceedings and other circumstances that potentially implicate material nonpublic information. Individuals affected by an event-specific blackout period will be notified by the Company that they are subject to the blackout. Except for purchases and sales made pursuant to the permitted transactions described below, all those affected, which may include all Team Members depending on the circumstances, may not trade in Company securities while the blackout period is in effect, and may not disclose to others that the Company has imposed a blackout period. </font></div><div style="margin-top:12.3pt;padding-left:36.45pt;padding-right:2.05pt;text-indent:0.4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">Transactions Permitted During Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">. The prohibitions above do not apply to&#58; </font></div><div style="margin-top:12.35pt;padding-left:79.85pt;padding-right:1.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">purchases of the Company&#8217;s securities from the Company or sales of the Company&#8217;s securities to the Company&#59; </font></div><div style="padding-left:79.85pt;padding-right:1.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">exercises of stock options or other equity awards or the surrender of shares to or withholding of shares by the Company in payment of the exercise price or in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement, or vesting or settlement of equity-based awards, that in each case do not involve a market sale of the Company&#8217;s securities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">cashless exercise</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; of a Company stock option does involve a market sale of the Company&#8217;s securities, and therefore would not qualify under this exception)&#59; </font></div><div style="padding-left:79.85pt;padding-right:1.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">if required by the Board of Directors of the Company or the Compensation Committee thereof (without an election or decision on the part of the Team Member or other person subject to this Policy), a market sale of the Company&#8217;s securities solely in satisfaction of any tax withholding obligations in connection with an exercise or settlement of equity-based awards&#59; </font></div><div style="padding-left:79.85pt;padding-right:1.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">transferring shares to an entity that does not involve a change in the beneficial ownership of the shares (for example, to an </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">inter vivos </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">trust of which Team Members are the sole beneficiary during their lifetimes)&#59; </font></div><div style="padding-left:79.85pt;padding-right:1.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%;padding-left:13.8pt">bona fide </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">gifts of the Company&#8217;s securities, unless the person making the gift has reason to believe that the recipient intends to sell the Company&#8217;s securities while such donee is aware of material nonpublic information, or is subject to the trading restrictions specified below under Section 4.2&#59; </font></div><div style="padding-left:79.85pt;padding-right:1.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%;padding-left:13.8pt">bona fide </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">estate planning transfers of the Company&#8217;s securities for no consideration&#59; </font></div><div style="padding-left:79.85pt;padding-right:1.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">the purchase of stock through the Company&#8217;s employee stock purchase plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">ESPP</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;) or withdrawal from participation in the ESPP&#59; however, the sale of any such stock and changing instructions regarding the level of withholding contributions which are used to purchase stock are subject to this Policy&#59; or</font></div><div style="padding-left:79.85pt;padding-right:1.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">purchases or sales of the Company&#8217;s securities made pursuant to any binding contract, specific instruction, or written plan entered into while the purchaser or seller was not in possession of MNPI, as applicable, was unaware of any material nonpublic information and which contract, instruction, or plan (i) meets all of the requirements of the affirmative defense provided by Rule 10b5-1 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Rule 10b5-1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;) promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;), (ii) was precleared in advance pursuant to this Policy, and (iii) has not been amended or modified in any respect after such initial preclearance without such amendment or modification being precleared in advance pursuant to this Policy. For more information about Rule 10b5-1 trading plans, see Section 6 below. </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.3pt;padding-left:36.05pt;padding-right:1.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Any exceptions to the Company&#8217;s blackout period policies may be approved only by the General Counsel or their designee, or (i) in the case of an exception for the General Counsel, or persons or entities subject to this Policy as a result of their relationship with the General Counsel, the Chief Executive Officer, the Chief Financial Officer or the Chief Operating Officer (each, along with the General Counsel, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Authorizing Officer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;) or such Authorizing Officer&#8217;s designee, and (ii) in the case of an exception for a director, the Board of Directors or Audit Committee of the Board of Directors. </font></div><div style="margin-top:12.3pt;padding-left:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Preclearance and Rule 10b5-1 Requirements for Listed Insiders </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.4pt;text-align:justify;text-indent:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Certain Team Members or other persons subject to this Policy may be more likely to possess material nonpublic information about the Company and are therefore subject to additional requirements concerning transactions in the Company&#8217;s securities. In an effort to reduce the risk that an insider trading violation will occur and to avoid the appearance of impropriety in connection with the purchase and sale of the Company&#8217;s securities&#58; </font></div><div style="margin-top:12.35pt;padding-left:79.8pt;padding-right:1.1pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%;padding-left:13.8pt">10b5-1 Plans Required for Certain Listed Insiders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">. All transactions in Company securities by the individuals listed on Schedule I hereto (as amended from time to time by the Company, including by its officers) must occur exclusively under one or more trading plans established in accordance with Rule 10b5-1 and this Policy. Any exceptions to this requirement must be precleared in advance by an Authorizing Officer. </font></div><div style="padding-left:79.8pt;padding-right:1.1pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%;padding-left:13.8pt">Preclearance Procedures Required for All Other Listed Insiders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">. All transactions in Company securities by the individuals listed on Schedule II hereto (as amended from time to time by the Company, including by its officers) must be precleared in advance by an Authorizing Officer. As part of the preclearance process, the individual requesting preclearance must confirm that they are not in possession of material nonpublic information. Preclearance does not relieve anyone of their responsibility under SEC rules. In addition, if a preclearance request is denied, the requestor must keep the fact of such denial and the reasons therefore confidential. </font></div><div style="margin-top:12.3pt;padding-left:36pt;padding-right:1.05pt;text-align:justify;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">A request for preclearance may be oral or in writing (including by e-mail), should be made at least two business days in advance of the proposed transaction, and should include the identity of the preclearance person, the type of proposed transaction (for example, an open market purchase, a privately negotiated sale, an option exercise, etc.), the proposed date of the transaction, and the number of shares or other securities to be involved. In addition, unless otherwise determined by the General Counsel or the General Counsel&#8217;s designee, the preclearance person must execute a certification (in the form approved by the General Counsel or the General Counsel&#8217;s designee) that such person is not aware of material nonpublic information about the Company. The General Counsel or the General Counsel&#8217;s designee has sole discretion to decide whether to clear any contemplated transaction. All trades that are precleared must be effected within five business days of receipt of the preclearance unless a specific exception has been granted by the General Counsel or the General Counsel&#8217;s designee. A precleared trade (or any portion of a precleared trade) that has not been effected during the five business day period must be precleared again prior to execution. Notwithstanding receipt of preclearance, if the preclearance person becomes aware of material nonpublic information or becomes subject to a blackout period before the transaction is effected, the transaction may not be completed. </font></div><div style="margin-top:12.3pt;padding-left:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Post-Termination Transactions </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.75pt;padding-left:36.1pt;padding-right:1.2pt;text-align:justify;text-indent:0.15pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Except for the preclearance and Rule 10b5-1 requirements for Listed Insiders noted above, this Policy continues to apply to transactions in the Company&#8217;s securities even after termination of service to the Company. If an individual is in possession of material nonpublic information when their service terminates, that individual may not trade in the Company&#8217;s securities until that information has become public or is no longer material. While not mandated, the Company encourages employees who leave the Company in a blackout period to consider not making any trades until an Open Trading Window begins. </font></div><div style="margin-top:12.3pt;padding-left:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Information Relating to the Company </font></div><div style="margin-top:11.75pt;padding-left:36.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(a) Access to Information </font></div><div style="margin-top:11.75pt;padding-left:72pt;padding-right:1.35pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The Company may in its discretion restrict access by Team Members to material nonpublic information about the Company, including the Company&#8217;s business, earnings, or prospects. Team Members should use their best efforts to avoid access to any such information that is not relevant to their role relative to the Company. In addition, such information should not be communicated to anyone outside the Company under any circumstances (except in accordance with the Company&#8217;s confidentiality trainings and policies and the Company&#8217;s Guidelines for Corporate Disclosure). </font></div><div style="margin-top:12.3pt;padding-left:72pt;padding-right:1.35pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">In communicating material nonpublic information to employees of the Company, all Team Members must take care to emphasize the need for confidential treatment of such information and adherence to the Company&#8217;s policies with regard to confidential information. </font></div><div style="padding-left:72pt;padding-right:1.35pt;text-align:justify;text-indent:0.3pt"><font><br></font></div><div style="padding-left:36.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(b) Inquiries from Third Parties </font></div><div style="margin-top:11.75pt;padding-left:72.1pt;padding-right:1.5pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Inquiries from third parties, such as industry analysts or members of the media, about the Company should be directed to the Head of Investor Relations or the Head of Creative and Marketing, as applicable. </font></div><div style="margin-top:12.3pt;padding-left:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Brokerage Procedures </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.15pt;text-align:justify;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">A knowledgeable, alert broker can act as a gatekeeper for a Team Member, helping ensure compliance with this Policy and preventing inadvertent violations. Fidelity Stock Plan Services, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Fidelity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;) currently administers the Company&#8217;s equity incentive plans. Persons subject to this Policy are encouraged, and may in some cases be required (e.g., for Rule 10b5-1 trading plans and shares granted under the Company&#8217;s equity incentive plans), to utilize Fidelity as their broker for any transactions in the Company&#8217;s securities. </font></div><div style="margin-top:12.3pt;padding-left:36.15pt;padding-right:1.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Whether you choose to utilize Fidelity or your own broker, persons subject to this Policy are individually responsible for complying with this Policy, and for making sure that any family member, household member, or entity whose transactions are also subject to this Policy, also comply with this Policy. Persons subject to this Policy should use particular caution if they choose to utilize electronic trading platforms such as Robinhood, Stash, or E-Trade, which make trading easy but also increase the risk of inadvertent violations of this Policy. </font></div><div style="margin-top:12.3pt;padding-left:0.4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">5. SPECIAL AND PROHIBITED TRANSACTIONS </font></div><div style="margin-top:11.75pt;padding-left:36.1pt;padding-right:1.15pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The Company has determined that there is a heightened legal risk and&#47;or the appearance of improper or inappropriate conduct if the persons subject to this Policy </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.75pt;padding-left:36.1pt;padding-right:1.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">engage in certain types of transactions. Therefore, Team Members and other persons subject to this Policy must comply with the following policies with respect to certain transactions in the Company&#8217;s securities&#58; </font></div><div style="margin-top:12.3pt;padding-left:0.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Short Sales </font></div><div style="margin-top:11.75pt;padding-left:36.1pt;padding-right:1.2pt;text-align:justify;text-indent:0.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Short sales of the Company&#8217;s securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce the seller&#8217;s incentive to improve the Company&#8217;s performance. For these reasons, short sales of the Company&#8217;s securities are prohibited by this Policy. In addition, as noted below, Section 16(c) of the 1934 Act absolutely prohibits Section 16 reporting persons from making short sales of the Company&#8217;s equity securities, i.e., sales of shares that the insider does not own at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days after the sale. </font></div><div style="margin-top:12.3pt;padding-left:0.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Publicly Traded Options </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:0.2pt;text-align:justify;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">A transaction in options is, in effect, a bet on the short-term movement of the Company&#8217;s stock and therefore creates the appearance that a Team Member is trading based on inside information. Transactions in options also may focus a Team Member&#8217;s attention on short-term performance at the expense of the Company&#8217;s long-term objectives. Accordingly, transactions in warrants, puts, calls, or other derivative securities involving the Company&#8217;s equity securities, on an exchange, on any other organized market, or on an over-the-counter market, are prohibited by this Policy. </font></div><div style="margin-top:12.3pt;padding-left:0.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.3 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Hedging Transactions </font></div><div style="margin-top:11.75pt;padding-left:36.05pt;padding-right:1.35pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Certain forms of hedging or monetization transactions, including purchasing financial instruments, such as prepaid variable forward contracts, equity swaps, collars, and exchange funds, or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company&#8217;s equity securities, allow a Team Member to continue to own the covered securities, but without the full risks and rewards of ownership. When that occurs, the Team Member may no longer have the same objectives as the Company&#8217;s other stockholders. Therefore, all such transactions involving the Company&#8217;s equity securities, whether such securities were granted as compensation or are otherwise held, directly or indirectly, are prohibited by this Policy. </font></div><div style="margin-top:12.3pt;padding-left:36.6pt;padding-right:29.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">5.4 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Purchases of the Company&#8217;s Securities on Margin&#59; Pledging the Company&#8217;s Securities to Secure Margin or Other Loans </font></div><div style="margin-top:12.3pt;padding-left:36pt;padding-right:1.4pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Purchasing on margin means borrowing from a brokerage firm, bank, or other entity in order to purchase the Company&#8217;s securities (other than in connection with a cashless exercise of stock options under the Company&#8217;s equity plans). Margin purchases of the Company&#8217;s securities are prohibited by this Policy. Pledging the Company&#8217;s securities as collateral to secure loans is prohibited. This prohibition means, among other things, that you cannot hold the Company&#8217;s securities in a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">margin account</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; (which would allow you to borrow against your holdings to buy securities). </font></div><div style="margin-top:12.3pt;padding-left:0.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.5 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Director and Executive Officer Cashless Exercises </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.45pt;text-align:justify;text-indent:0.15pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Directors and executive officers of the Company may use the cashless exercise feature of their equity awards through their independent broker. Cashless exercise is subject to </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">the trading restrictions included in this Policy. Any sale of the underlying stock or a &#8220;cashless exercise&#8221; of an option through a broker will entail selling a portion of the underlying stock to cover the costs of exercise. Therefore, because such &#8220;cashless exercise&#8221; includes a sale of securities, the transaction is subject to the restrictions set forth in this Policy. Questions about cashless exercises should be directed to the General Counsel. </font></div><div style="margin-top:12.3pt;padding-left:0.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.6 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Partnership Distributions </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.7pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">It is the responsibility of each affected director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances and applicable securities laws. </font></div><div style="margin-top:12.3pt;padding-left:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">6. RULE 10B5-1 TRADING PLANS </font></div><div style="margin-top:11.75pt;padding-left:0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6.1 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Overview </font></div><div style="padding-left:36pt;padding-right:1.1pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Rule 10b5-1 is intended to protect persons subject to this Policy from insider trading liability under Rule 10b5-1 for transactions under a previously established contract, plan, or instruction to trade in the Company&#8217;s stock (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Trading Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;) entered into in good faith and in accordance with the terms of Rule 10b5-1 and all applicable state laws. The initiation or termination of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company&#8217;s securities, and such initiation, termination or modification is subject to all limitations and prohibitions relating to transactions in the Company&#8217;s securities. Each such Trading Plan, and any modification or termination thereof, must be submitted to and pre-approved by an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Authorizing Officer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; who may impose such conditions on the implementation and operation of the Trading Plan as such Authorizing Officer deems necessary or advisable. For example, an Authorizing Officer may prescribe certain forms of Trading Plans to which employees&#8217; Trading Plans must conform and&#47;or may require that Trading Plans be arranged with a specified broker. Currently, all Trading Plans must be arranged through the Company&#8217;s selected vendor, Fidelity unless an exception is permitted by an Authorizing Officer. However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not the Company or an Authorizing Officer. </font></div><div style="margin-top:12.3pt;padding-left:36pt;text-align:justify;text-indent:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Trading Plans do not exempt individuals from complying with Section 16 short-swing profit rules or liability thereunder. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without the restrictions of complying with Open Trading Windows and blackout periods, even when there is undisclosed material information. A Trading Plan may also help reduce negative publicity that may result when key executives sell the Company&#8217;s stock. Trading Plans only provide an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">affirmative defense,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; however, in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit in the first instance. </font></div><div style="margin-top:12.3pt;padding-left:36.1pt;padding-right:1.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">A Team Member or other person subject to this Policy may enter into or modify a Trading Plan only when they are not in possession of material nonpublic information, and only during an Open Trading Window. Although transactions effected under a Trading Plan will not require further preclearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company&#8217;s filing coordinator to assist in the preparation and </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.3pt;padding-left:36.1pt;padding-right:1.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">filing of a required Form 4. However, the ultimate responsibility and liability for timely filing remains with the Section 16 reporting person. </font></div><div style="margin-top:12.3pt;padding-left:36pt;padding-right:1.5pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The Company reserves the right from time to time to suspend, discontinue, or otherwise prohibit any transaction in the Company&#8217;s securities, even pursuant to a previously approved Trading Plan, if an Authorizing Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation, or other prohibition is in the best interests of the Company. Any Trading Plan submitted for approval hereunder should explicitly acknowledge the Company&#8217;s right to prohibit transactions in the Company&#8217;s securities. Failure to discontinue purchases and sales as directed constitutes a violation of the terms of this Section 6 and result in a loss of the exemption set forth herein. </font></div><div style="padding-left:36.25pt;padding-right:1.35pt"><font><br></font></div><div style="padding-left:36.25pt;padding-right:1.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Pursuant to Rule 10b5-1, an individual&#8217;s purchase or sale of securities will not be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">on the basis of</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; material nonpublic information if&#58; </font></div><div style="margin-top:12.35pt;padding-left:79.85pt;padding-right:1.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities, or adopts a written plan for trading the securities (i.e., the Trading Plan). </font></div><div style="padding-left:79.85pt;padding-right:1.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">Second, the Trading Plan must either&#58; </font></div><div style="padding-left:115.85pt;padding-right:1.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:12pt;font-weight:400;line-height:111%">o</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:10.8pt">specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold, and the date on which the securities are to be purchased or sold&#59; </font></div><div style="padding-left:115.85pt;padding-right:1.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:12pt;font-weight:400;line-height:111%">o</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:10.8pt">include a written formula or computer program for determining the amount, price, and date of the transactions&#59; or </font></div><div style="padding-left:115.85pt;padding-right:1.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',serif;font-size:12pt;font-weight:400;line-height:111%">o</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:10.8pt">prohibit the individual from exercising any subsequent influence over the purchase or sale of the Company&#8217;s stock under the Trading Plan in question.</font></div><div style="padding-left:79.85pt;padding-right:1.2pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">Third, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan. </font></div><div style="margin-top:12.25pt;padding-left:0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6.2 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Company Requirements </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.4pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The Company may from time to time provide additional guidance and rules regarding the use of Trading Plans, including requiring a certain form of Trading Plan, pre-approval of a Trading Plan, and&#47;or restrictions as to when a Trading Plan may be entered into, amended, or terminated. </font></div><div style="margin-top:11.75pt;padding-left:18.7pt;padding-right:18.7pt;text-align:center;text-indent:0.35pt"><font><br></font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE I and SCHEDULE II</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">*****</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A </font></div><div style="margin-top:11.75pt;padding-left:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">A. What Facts are Material&#63; </font></div><div style="margin-top:11.75pt;padding-left:36.05pt;padding-right:1.05pt;text-align:justify;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The materiality of a fact depends upon the circumstances. A fact is considered &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">material</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; if there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision (i.e., a decision to buy, sell, or hold a security), if it would significantly alter the total mix of information available to investors, or if the fact is likely to have a significant effect on the market price of the security. Material information can be positive or negative and can relate to virtually any aspect of a company&#8217;s business or to any type of security, debt or equity. </font></div><div style="margin-top:12.3pt;padding-left:36.45pt;padding-right:1.25pt;text-indent:-0.15pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Examples of material information may include (but are not limited to) information about&#58; </font></div><div style="margin-top:12.35pt;padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">dividend information&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">financial information, including corporate earnings results or earnings forecasts, estimates, and guidance, and changes in previously released earnings results, forecasts, estimates, or guidance&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">possible mergers, acquisitions, tender offers, joint ventures, or changes in assets&#59;</font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant new programs or program milestones&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">important business developments, such as developments regarding strategic collaborations or the Company&#8217;s relationship with licensors, collaborators, customers, or suppliers (such as the acquisition or loss of a contract)&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">incidents involving cybersecurity, data protection, or breach resulting in loss of personally identifiable information&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">developments regarding the Company&#8217;s intellectual property portfolio&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">new service offerings or significant news related to service offerings&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in control or in management&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">restructurings or layoffs&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant litigation or regulatory action&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant financing developments including pending public sales or offerings of debt or equity securities&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the outside auditor or notification by the auditor that the Company may no longer rely on an auditor&#8217;s report&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">events regarding the Company&#8217;s securities, for example, defaults on senior securities, calls of securities for redemption, repurchase plans, stock splits or changes in dividends, changes to the rights of security holders, and public or private sales of additional securities&#59; and </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">borrowings, bankruptcies, or receiverships. </font></div><div style="margin-top:11.75pt;padding-left:36.15pt;padding-right:1.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Moreover, material information does not have to be related to a company&#8217;s business. For example, the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material. A good general rule of thumb&#58; When in doubt, do not trade. </font></div><div style="margin-top:12.3pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">B. What is Nonpublic&#63; </font></div><div style="margin-top:11.75pt;padding-left:36.1pt;padding-right:1.65pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Information is &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">nonpublic</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; if it is not available to the general public. In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors through such media as Dow Jones, Business </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.75pt;padding-left:36.1pt;padding-right:1.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Wire, Reuters, The Wall Street Journal, Associated Press, or United Press International, a broadcast on widely available radio or television programs, publication in a widely available newspaper, magazine or news website, a Regulation FD-compliant conference call, or public disclosure documents filed or furnished with the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">SEC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;) that are available on the SEC&#8217;s web site. </font></div><div style="margin-top:12.3pt;padding-left:36pt;padding-right:1.45pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination. In addition, even after a public announcement, a reasonable period of time must lapse in order for the market to react to the information. Generally, one should allow </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:111%">one full trading day </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">following publication as a reasonable waiting period before such information is deemed to be public. If you have any questions as to whether information is publicly available, please direct an inquiry to the General Counsel at ethics&#64;ginkgobioworks.com. </font></div><div style="margin-top:12.35pt;padding-left:77.55pt;padding-right:0.05pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">Example 1&#58; The Company makes an announcement on Monday prior to 9&#58;30am Eastern Time. The information would be deemed public after the close of trading on Monday. </font></div><div style="padding-left:77.55pt;padding-right:0.05pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">Example 2&#58; The Company makes an announcement Monday after 9&#58;30am Eastern Time. The information would be deemed public after the close of trading on Tuesday. </font></div><div style="margin-top:12.3pt;padding-left:0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">C. Who is an Insider&#63; </font></div><div style="margin-top:11.75pt;padding-left:36.05pt;padding-right:0.2pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Insiders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; include directors, employees, certain contingent workers of a company, and anyone else who has material nonpublic information about a company. Insiders owe independent fiduciary duties to their company and its stockholders not to trade on material nonpublic information relating to the company&#8217;s securities. Team Members of the Company should consider themselves insiders with respect to material nonpublic information about the Company&#8217;s business, activities, and securities. Team Members may not trade in the Company&#8217;s securities while in possession of material nonpublic information relating to the Company, nor may they tip such information to anyone outside the Company (except in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis. </font></div><div style="margin-top:12.3pt;padding-left:36.05pt;padding-right:1.05pt;text-align:justify;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Team Members are also responsible for ensuring that other persons subject to this Policy, such as members of the Team Member&#8217;s household, any family members who do not live in the household but whose securities transactions are directed by the Team Member or who are subject to their influence or control, any Controlled Entities and any person to whom an individual subject to this Policy has disclosed material, nonpublic information, also comply with this Policy. Transactions by Controlled Entities should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&#8217;s own account, unless the individual subject to the Policy has certified on a Certification of Compliance that such Controlled Entity has established insider trading controls and procedures in compliance with applicable securities laws. </font></div><div style="margin-top:12.3pt;padding-left:0.15pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">D. Trading by Persons Other than Insiders </font></div><div style="padding-left:36.1pt;padding-right:1.1pt;text-align:justify;text-indent:0.15pt"><font><br></font></div><div style="padding-left:36.1pt;padding-right:1.1pt;text-align:justify;text-indent:0.15pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Insiders may be liable for communicating or tipping material nonpublic information to a third party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">tippee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;), and insider trading violations are not limited to trading or tipping by insiders. </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.3pt;padding-left:36.05pt;padding-right:1.85pt;text-align:justify;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Persons other than insiders also can be liable for insider trading, including tippees who trade on material nonpublic information tipped to them or individuals who trade on material nonpublic information that has been misappropriated. </font></div><div style="margin-top:12.3pt;padding-left:36.05pt;padding-right:1.35pt;text-align:justify;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Tippees inherit an insider&#8217;s duties and are liable for trading on material nonpublic information illegally tipped to them by an insider. Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade. In other words, a tippee&#8217;s liability for insider trading is no different from that of an insider. Tippees can obtain material nonpublic information by receiving overt tips from others or through, among other things, conversations at social, business, or other gatherings. </font></div><div style="margin-top:12.3pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">E. Penalties for Engaging in Insider Trading </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.05pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Penalties for trading on or tipping material nonpublic information can extend significantly beyond any profits made or losses avoided, both for individuals engaging in such unlawful conduct and their employers. The SEC and Department of Justice have made the civil and criminal prosecution of insider trading violations a top priority. Enforcement remedies available to the government or private plaintiffs under the federal securities laws include&#58; </font></div><div style="margin-top:12.35pt;padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">SEC administrative sanctions&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">securities industry self-regulatory organization sanctions&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">civil injunctions&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">damage awards to private plaintiffs&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">disgorgement of all profits&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">civil fines for the violator of up to three times the amount of profit gained or loss avoided&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">civil fines for the employer or other controlling person of a violator (i.e., where the violator is an employee or other controlled person)&#59; </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">criminal fines for individual violators&#59; and </font></div><div style="padding-left:77.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">jail sentences of up to 20 years. </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.7pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">In addition, insider trading could result in serious sanctions by the Company, including termination. Insider trading violations are not limited to violations of the federal securities laws. Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and the Racketeer Influenced and Corrupt Organizations Act (RICO), also may be violated in connection with insider trading. </font></div><div style="margin-top:12.3pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">F. Size of Transaction and Reason for Transaction Do Not Matter </font></div><div style="margin-top:11.75pt;padding-left:36.05pt;padding-right:1.4pt;text-align:justify;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The size of the transaction or the amount of profit received does not have to be significant to result in prosecution. The SEC has the ability to monitor even the smallest trades, and the SEC performs routine market surveillance. Brokers and dealers are required by law to inform the SEC of any possible violations by people who may have material nonpublic information. The SEC aggressively investigates even small insider trading violations. </font></div><div style="padding-left:36.05pt;padding-right:1.4pt;text-align:justify;text-indent:0.25pt"><font><br></font></div><div style="padding-left:0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">G. Examples of Insider Trading </font></div><div style="margin-top:11.75pt;padding-left:36.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Examples of insider trading cases include&#58; </font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.8pt;padding-left:77.55pt;padding-right:1.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">actions brought against corporate officers, directors, and employees who traded in a company&#8217;s securities after learning of significant confidential corporate developments&#59; </font></div><div style="padding-left:77.55pt;padding-right:1.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">friends, business associates, family members, and other tippees of such officers, directors, and employees who traded in the securities after receiving such information&#59; </font></div><div style="padding-left:77.55pt;padding-right:1.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">government employees who learned of such information in the course of their employment&#59; and </font></div><div style="padding-left:77.55pt;padding-right:1.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%;padding-left:13.8pt">other persons who misappropriated, and took advantage of, confidential information from their employers. </font></div><div style="margin-top:12.3pt;padding-left:36pt;padding-right:1.95pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The following are illustrations of insider trading violations. These illustrations are hypothetical and, consequently, not intended to reflect on the actual activities or business of the Company or any other entity. </font></div><div style="margin-top:12.3pt;padding-left:36.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Trading by Insider </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.95pt;text-align:justify;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">An officer of X Corporation learns that earnings to be reported by X Corporation will increase dramatically. Prior to the public announcement of such earnings, the officer purchases X Corporation&#8217;s stock. The officer, an insider, is liable for all profits as well as penalties of up to three times the amount of all profits. The officer also is subject to, among other things, criminal prosecution, including up to $5,000,000 in additional fines, and 20 years in jail. Depending upon the circumstances, X Corporation and the individual to whom the officer reports also could be liable as controlling persons. </font></div><div style="margin-top:12.3pt;padding-left:36.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Trading by Tippee </font></div><div style="margin-top:11.75pt;padding-left:36.05pt;padding-right:1.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">An officer of X Corporation tells a friend that X Corporation is about to publicly announce that it has signed an agreement for a major acquisition. This tip causes the friend to purchase X Corporation&#8217;s stock in advance of the announcement. The officer is jointly liable with the officer&#8217;s friend for all of the friend&#8217;s profits, and each is liable for all civil penalties of up to three times the amount of the friend&#8217;s profits. The officer and the officer&#8217;s friend are also subject to criminal prosecution and other remedies and sanctions, as described above. </font></div><div style="margin-top:12.3pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">H. Prohibition of Records Falsification and False Statements </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:1.2pt;text-align:justify;text-indent:0.75pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Section 13(b)(2) of the 1934 Act requires companies subject to the Act to maintain proper internal books and records and to devise and maintain an adequate system of internal accounting controls. The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading, or incomplete statement to any accountant in connection with any audit or filing with the SEC. These provisions reflect the SEC&#8217;s intent to discourage officers, directors, and other persons with access to the Company&#8217;s books and records from taking action that might result in the communication of materially misleading financial information to the investing public. </font></div><div style="margin-top:26.2pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="padding-right:176.8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT B </font></div><div style="margin-top:11.75pt;padding-right:143.2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 16 MATTERS </font></div><div style="margin-top:11.75pt;padding-left:1.4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Reporting Obligations Under Section 16(a)&#58; SEC Forms 3, 4, and 5 </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:0.35pt;text-align:justify;text-indent:0.75pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Section 16(a) of the 1934 Act generally requires all officers, directors, and 10% stockholders (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Section 16 Insiders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221;), within 10 days after the Section 16 Insider becomes an officer, director, or 10% stockholder, to file with the SEC an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">Initial Statement of Beneficial Ownership of Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; on Form 3 listing the amount of the Company&#8217;s securities (including stock, options, restricted stock units, warrants, and other derivative securities) which the Section 16 Insider beneficially owns. Following the initial filing on Form 3, changes in beneficial ownership of the Company&#8217;s securities must be reported on Form 4, generally within two business days after the date on which such change occurs. A Form 4 must be filed even if, as a result of balancing transactions, there has been no net change in holdings. Similarly, certain purchases or sales of Company stock made within six months after an officer or director ceases to be a Section 16 Insider must be reported on Form 4. The filing requirement extends to Company securities held by certain family members of Section 16 Insiders sharing a Section 16 Insider&#8217;s household and transactions in which a Section 16 Insider has an indirect interest (such as transactions by trusts, corporations, or partnerships in which the Section 16 Insider has or shares control). </font></div><div style="margin-top:12.3pt;padding-left:36pt;padding-right:1.1pt;text-align:justify;text-indent:0.75pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Section 16 Insiders are personally liable for the failure to file required reports on a timely basis. To assist the Company&#8217;s officers and directors in meeting required filing deadlines, the Company will prepare and file required Section 16 reports if requested. In order for the Company to prepare and file Section 16 reports, the officer or director must sign a power of attorney to give Company representatives the authority to prepare and file the required forms and must timely provide to the Company the required information to prepare the filing. </font></div><div style="margin-top:12.3pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Recovery of Profits Under Section 16(b) </font></div><div style="margin-top:11.75pt;padding-left:36pt;padding-right:0.15pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">For the purpose of preventing the unfair use of information which may have been obtained by a Section 16 Insider, any profits realized by any officer, director, or 10% stockholder from any &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">purchase</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">sale</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; of Company stock during a six-month period, so called &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:111%">short-swing profits,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">&#8221; may be recovered by the Company. When such a purchase and sale occurs, good faith is no defense. The Section 16 Insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and without the use of any inside information. There are several exemptive rules &#8211; including one that applies to some compensatory awards &#8211; that may apply to exempt a particular purchase or sale from the &#8220;short-swing profit&#8221; rules, however the application of those rules is complex and they should not be relied on (including with respect to compensatory awards) absent discussion with the General Counsel. </font></div><div style="margin-top:12.3pt;padding-left:36.4pt;padding-right:1.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">The liability of a Section 16 Insider under Section 16(b) of the 1934 Act is only to the Company itself. The Company, however, cannot waive its right to short swing profits, and any Company stockholder can bring suit in the name of the Company. Reports of ownership filed with the SEC on Form 3, Form 4, or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully monitor these reports for potential Section 16(b) violations. Failure to report transactions and late filing of reports require separate disclosure in the Company&#8217;s proxy statement.</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.3pt;padding-left:36.4pt;padding-right:1.25pt;text-align:justify"><font><br></font></div><div style="margin-top:12.3pt;padding-left:0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Short Sales Prohibited Under Section 16(c) </font></div><div style="margin-top:11.75pt;padding-left:36.1pt;padding-right:1.1pt;text-align:justify;text-indent:0.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">Section 16(c) of the 1934 Act prohibits Section 16 Insiders from making short sales of the Company&#8217;s equity securities. Short sales include sales of stock which the Section 16 Insider does not own at the time of sale, or sales of stock against which the Section 16 Insider does not deliver the shares within 20 days after the sale. Under certain circumstances, the purchase or sale of put or call options, or the writing of such options, can result in a violation of Section 16(c). Section 16 Insiders violating Section 16(c) face criminal liability. </font></div><div style="margin-top:11.75pt;padding-left:36.1pt;padding-right:1.1pt;text-align:justify;text-indent:0.6pt"><font><br></font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT C </font></div><div style="margin-top:11.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">GINKGO BIOWORKS HOLDINGS, INC. </font></div><div style="margin-top:11.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">INSIDER TRADING COMPLIANCE POLICY </font></div><div style="margin-top:11.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF COMPLIANCE </font></div><div style="margin-top:37.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">RETURN BY &#91;_____________&#93; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;insert return deadline&#93; </font></div><div style="margin-top:37.55pt;padding-left:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">TO&#58; </font></div><div style="margin-top:11.75pt;padding-left:0.2pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">FROM&#58; </font></div><div style="margin-top:11.75pt;padding-left:0.6pt;padding-right:1.35pt;text-indent:-0.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">I hereby designate the following entities for which the Insider Trading Compliance Policy shall not apply&#58; </font></div><div style="margin-top:12.3pt;padding-right:1.15pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:111%">I hereby represent to Ginkgo Bioworks Holdings, Inc. that each such entity&#58; (a) engages in the investment of securities in the ordinary course of its business&#59; (b) has established insider trading controls and procedures in compliance with applicable securities laws&#59; and (c) is aware that such securities laws prohibit any person or entity who has material nonpublic information concerning Ginkgo Bioworks Holdings, Inc. from purchasing or selling securities of Ginkgo Bioworks Holdings, Inc. or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell securities. </font></div><div style="margin-top:63.85pt;padding-left:9.75pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">SIGNATURE DATE </font></div><div style="margin-top:63.35pt;padding-left:9.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">TITLE</font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>11
<FILENAME>dna-20251231xex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ied091f2368db4e3893ef8929fc828d9c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 21.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Subsidiaries of the Registrant</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Legal Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation or Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ginkgo Bioworks, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ginkgo Bioworks Securities Corporation</font></td><td colspan="3" style="padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ginkgo Biosecurity, LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ginkgo International Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 3.32pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>dna-20251231xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i6da753c8584a45e4a9426d706980abd0_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Exhibit 23.1</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:125%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:107%">We consent to the incorporation by reference in Registration Statement No. 333-289390 on Form S-3 and Registration Statement Nos. 333-285235, 333-277558, 333-270506, 333-267952, and 333-261205 on Form S-8 of our reports dated February 26, 2026, relating to the financial statements of Ginkgo Bioworks Holdings, Inc. (the &#8220;Company&#8221;) and the effectiveness of the Company&#8217;s internal control over financial reporting appearing in this Annual Report on Form 10-K of Ginkgo Bioworks Holdings, Inc. for the year ended December 31, 2025.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><br>&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 26, 2026</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>13
<FILENAME>dna-20251231xex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ia0064dbf228347ffb4dac84748bb1a64_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58; &#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Registration Statement (Form S-8 No. 333-</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">277558</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">) pertaining to the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%">2.</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9pt">Registration Statement (Form S-3 Nos. 333-279280, 333-274171, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%">333-269443, 333-267743, 333-267315, 333-258712, 333-261318, 333-264129 and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%">333-289390</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%">) of Ginkgo Bioworks Holdings, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Registration Statement (Form S-8 No. 333-270506) pertaining to the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Registration Statement (Form S-8 No. 333-261205) pertaining to the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan, 2021 Employee Stock Purchase Plan, 2014 Stock Incentive Plan and 2008 Stock Incentive Plan, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Registration Statement (Form S-8 No. 333-267952) pertaining to the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan and 2022 Inducement Plan, and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#333333;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.</font><font style="color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.66pt">Registration Statement (Form S-8 No. 333-285235) pertaining to the Ginkgo Bioworks Holdings, Inc. 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">of our report dated February 29, 2024 (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">except for note 16 and the effects of the reverse stock split described in note 2, as to which the date is February 25, 2025</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">), with respect to the consolidated financial statements of Ginkgo Bioworks Holdings, Inc. included in this Annual Report (Form 10-K) of Ginkgo Bioworks Holdings, Inc. for the year ended December 31, 2025.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Boston, Massachusetts</font></div><div><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">February 26, 2026</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>14
<FILENAME>dna-20251231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i1f0a65f65cd34f28a0858bd1dcbd7edd_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">I, Jason Kelly, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:67.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60pt">I have reviewed this Annual Report on Form 10-K of Ginkgo Bioworks Holdings, Inc.&#59;</font></div><div style="margin-top:18pt;padding-left:67.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:18pt;padding-left:67.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:18pt;padding-left:67.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:139%"> </font></div><div style="margin-top:18pt;padding-left:135pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:56.41pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:18pt;padding-left:135pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:55.84pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:18pt;padding-left:135pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:56.41pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:18pt;padding-left:135pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:55.84pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:139%"> </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-left:67.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:18pt;padding-left:135pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:56.41pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:18pt;margin-top:18pt;padding-left:135pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:55.84pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"></td><td style="width:52.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:3.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Date&#58; February&#160;26, 2026</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jason Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Jason Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.2pt;margin-top:3.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Chief Executive Officer</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>15
<FILENAME>dna-20251231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i5f379cb34e0e439e9d784f5ce55a0ba7_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">I, Steven Coen, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:64.5pt">I have reviewed this Annual Report on Form 10-K of Ginkgo Bioworks Holdings, Inc.&#59;</font></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:64.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:64.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:64.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:18pt;padding-left:144pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:18pt;padding-left:144pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:18pt;padding-left:144pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:18pt;padding-left:144pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:64.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:139%"> </font></div><div style="margin-top:18pt;padding-left:144pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:18pt;margin-top:18pt;padding-left:144pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:60.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:139%"> </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"></td><td style="width:52.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:3.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Date&#58; February&#160;26, 2026</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Steven Coen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Steven Coen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.2pt;margin-top:3.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Chief Financial Officer</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>16
<FILENAME>dna-20251231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i44abf0c7f20345979aa7a5e38dd9bbd0_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Annual Report on Form 10-K of Ginkgo Bioworks Holdings, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:18pt;padding-left:139.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:55.84pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:18pt;margin-top:18pt;padding-left:139.5pt;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:55.84pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:139%"> </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"></td><td style="width:52.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:3.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Date&#58; February&#160;26, 2026</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jason Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Jason Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.2pt;margin-top:3.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Chief Executive Officer</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>17
<FILENAME>dna-20251231xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i54dc31ba7ad148b4a6214668374374f1_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Annual Report on Form 10-K of Ginkgo Bioworks Holdings, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:18pt;padding-left:135pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:55.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:18pt;margin-top:18pt;padding-left:135pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:55.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"></td><td style="width:52.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:3.25pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Date&#58; February&#160;26, 2026</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Steven Coen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Steven Coen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.2pt;margin-top:3.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Chief Financial Officer</font></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt;padding-left:135pt;text-indent:-63pt"><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>dna-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:52002c9c-7569-4bc2-a5b5-c24c0eeac02a,g:42911b52-7f60-440e-93d3-9584b5edbad8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dna="http://www.ginkgobioworks.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ginkgobioworks.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dna-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dna-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dna-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dna-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ginkgobioworks.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.ginkgobioworks.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical">
        <link:definition>9952154 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952155 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>9952156 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952157 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>9952158 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentation">
        <link:definition>9952159 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952160 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.ginkgobioworks.com/role/Restructuring">
        <link:definition>9952161 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestitures">
        <link:definition>9952162 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurements">
        <link:definition>9952163 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.ginkgobioworks.com/role/MarketableSecurities">
        <link:definition>9952164 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandEquityMethodInvestments" roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestments">
        <link:definition>9952165 - Disclosure - Investments and Equity Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://www.ginkgobioworks.com/role/VariableInterestEntities">
        <link:definition>9952166 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsnet" roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnet">
        <link:definition>9952167 - Disclosure - Goodwill and Intangible Assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ginkgobioworks.com/role/Leases">
        <link:definition>9952168 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformation" roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformation">
        <link:definition>9952169 - Disclosure - Supplemental Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.ginkgobioworks.com/role/CommitmentsandContingencies">
        <link:definition>9952170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ginkgobioworks.com/role/StockholdersEquity">
        <link:definition>9952171 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensation">
        <link:definition>9952172 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.ginkgobioworks.com/role/RevenueRecognition">
        <link:definition>9952173 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.ginkgobioworks.com/role/SegmentInformation">
        <link:definition>9952174 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCollaborationTransactionswithRelatedParties" roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedParties">
        <link:definition>9952175 - Disclosure - Significant Collaboration Transactions with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.ginkgobioworks.com/role/EmployeeBenefitPlan">
        <link:definition>9952176 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.ginkgobioworks.com/role/IncomeTaxes">
        <link:definition>9952177 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.ginkgobioworks.com/role/NetLossperShare">
        <link:definition>9952178 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.ginkgobioworks.com/role/SubsequentEvents">
        <link:definition>9952179 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.ginkgobioworks.com/role/RestructuringTables">
        <link:definition>9955513 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresTables" roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresTables">
        <link:definition>9955514 - Disclosure - Acquisitions and Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsTables">
        <link:definition>9955515 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.ginkgobioworks.com/role/MarketableSecuritiesTables">
        <link:definition>9955516 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandEquityMethodInvestmentsTables" roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsTables">
        <link:definition>9955517 - Disclosure - Investments and Equity Method Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsnetTables" roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetTables">
        <link:definition>9955518 - Disclosure - Goodwill and Intangible Assets, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ginkgobioworks.com/role/LeasesTables">
        <link:definition>9955519 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationTables" roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables">
        <link:definition>9955520 - Disclosure - Supplemental Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityTables">
        <link:definition>9955521 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationTables">
        <link:definition>9955522 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionTables">
        <link:definition>9955523 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.ginkgobioworks.com/role/SegmentInformationTables">
        <link:definition>9955524 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsTables" roleURI="http://www.ginkgobioworks.com/role/OrganizationConsolidationandPresentationofFinancialStatementsTables">
        <link:definition>9955525 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesTables">
        <link:definition>9955526 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.ginkgobioworks.com/role/NetLossperShareTables">
        <link:definition>9955527 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>9955528 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9955529 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails" roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails">
        <link:definition>9955530 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails">
        <link:definition>9955531 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringSummaryofRestructuringChargesDetails" roleURI="http://www.ginkgobioworks.com/role/RestructuringSummaryofRestructuringChargesDetails">
        <link:definition>9955532 - Disclosure - Restructuring - Summary of Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails" roleURI="http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails">
        <link:definition>9955533 - Disclosure - Restructuring - Summary of Changes in Accrued Liability Balance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>9955534 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails" roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails">
        <link:definition>9955535 - Disclosure - Acquisitions and Divestitures - Deconsolidated Assets and Liabilities (Zymergen) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails" roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails">
        <link:definition>9955536 - Disclosure - Acquisitions and Divestitures - Results of Operations Deconsolidation (Zymergen) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>9955537 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails">
        <link:definition>9955538 - Disclosure - Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails" roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails">
        <link:definition>9955539 - Disclosure - Fair Value Measurements - Quantitative Information Regarding Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9955540 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails">
        <link:definition>9955541 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails" roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails">
        <link:definition>9955542 - Disclosure - Investments and Equity Method Investments - Schedule of Investments and Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails" roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails">
        <link:definition>9955543 - Disclosure - Investments and Equity Method Investments - Summary of Gains (Losses) on Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails" roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails">
        <link:definition>9955544 - Disclosure - Investments and Equity Method Investments - Schedule of Realized and Unrealized Gains and Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails" roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails">
        <link:definition>9955545 - Disclosure - Investments and Equity Method Investments - Carrying Values of Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsnetNarrativeDetails" roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails">
        <link:definition>9955546 - Disclosure - Goodwill and Intangible Assets, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails" roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails">
        <link:definition>9955547 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails" roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails">
        <link:definition>9955548 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails">
        <link:definition>9955549 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9955550 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofTotalLeaseCostDetails" roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails">
        <link:definition>9955551 - Disclosure - Leases - Schedule of Components of Total Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails" roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails">
        <link:definition>9955552 - Disclosure - Leases - Schedule of Operating Leases Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalBalanceSheetInformationDetails" roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails">
        <link:definition>9955553 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails" roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails">
        <link:definition>9955554 - Disclosure - Leases - Schedule of Maturity of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9955555 - Disclosure - Supplemental Financial Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail" roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail">
        <link:definition>9955556 - Disclosure - Supplemental Financial Information - Summary of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationAdditionalInformationDetail" roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail">
        <link:definition>9955557 - Disclosure - Supplemental Financial Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail">
        <link:definition>9955558 - Disclosure - Supplemental Financial Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails" roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails">
        <link:definition>9955559 - Disclosure - Supplemental Financial Information - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>9955560 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofCapitalizationDetails" roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails">
        <link:definition>9955561 - Disclosure - Stockholders' Equity - Schedule of Capitalization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>9955562 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail" roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail">
        <link:definition>9955563 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuances (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationDetails" roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails">
        <link:definition>9955564 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>9955565 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>9955566 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails">
        <link:definition>9955567 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails" roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails">
        <link:definition>9955568 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Founder Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails" roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails">
        <link:definition>9955569 - Disclosure - Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofActivityForEarnoutRSADetails" roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails">
        <link:definition>9955570 - Disclosure - Stock-Based Compensation - Summary of Activity For Earnout RSA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>9955571 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionAdditionalInformationDetails" roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails">
        <link:definition>9955572 - Disclosure - Revenue Recognition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionAdditionalInformationDetails_1" roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails_1">
        <link:definition>9955572 - Disclosure - Revenue Recognition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalInformationDetails" roleURI="http://www.ginkgobioworks.com/role/SegmentInformationAdditionalInformationDetails">
        <link:definition>9955573 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>9955574 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails" roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails">
        <link:definition>9955575 - Disclosure - Significant Collaboration Transactions with Related Parties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails" roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails">
        <link:definition>9955576 - Disclosure - Significant Collaboration Transactions with Related Parties - Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails" roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails">
        <link:definition>9955577 - Disclosure - Significant Collaboration Transactions with Related Parties - statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanAdditionalInformationDetail" roleURI="http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail">
        <link:definition>9955578 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails" roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails">
        <link:definition>9955579 - Disclosure - Income Taxes - Summary of Loss Before Provision for Incomes Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails" roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails">
        <link:definition>9955580 - Disclosure - Income Taxes - Summary of Income Taxes Expenses (Benefit) Incurred During the Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails" roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails">
        <link:definition>9955581 - Disclosure - Income Taxes - Summary of Reconciliation of the Statutory Corporate Income Tax Rate to the Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails" roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails">
        <link:definition>9955582 - Disclosure - Income Taxes - Summary of Deferred Taxes Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails" roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails">
        <link:definition>9955583 - Disclosure - Income Taxes - Summary of Deferred Tax Assets Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9955584 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxPaidDetails" roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails">
        <link:definition>9955585 - Disclosure - Income Taxes - Tax Paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>9955586 - Disclosure - Net Loss per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareSummaryofAntiDilutiveSharesDetails" roleURI="http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails">
        <link:definition>9955587 - Disclosure - Net Loss per Share - Summary of Anti-Dilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetails" roleURI="http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails">
        <link:definition>9955588 - Disclosure - Subsequent Events (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dna_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dna_CellEngineeringRevenueMember" abstract="true" name="CellEngineeringRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_SettlementOfContingentConsiderationSharesRestrictedStock" abstract="false" name="SettlementOfContingentConsiderationSharesRestrictedStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dna_SettlementOfContingentConsiderationValueRestrictedStock" abstract="false" name="SettlementOfContingentConsiderationValueRestrictedStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_StockIssuanceCosts" abstract="false" name="StockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_SharesReleaseFromEscrowDuringPeriod" abstract="false" name="SharesReleaseFromEscrowDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dna_NoncashCustomerConsideration" abstract="false" name="NoncashCustomerConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_ChangesInFairValueOfLoansReceivable" abstract="false" name="ChangesInFairValueOfLoansReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_NoncashInProcessResearchAndDevelopment" abstract="false" name="NoncashInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_AccretionOfDiscountOnMarketableSecurities" abstract="false" name="AccretionOfDiscountOnMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_IncreaseDecreaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_SupplementalBalanceSheetInformationAbstract" abstract="true" name="SupplementalBalanceSheetInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dna_PatentCostsPolicyTextBlock" abstract="false" name="PatentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock" abstract="false" name="DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dna_SummaryOfActivityForEarnoutRSATableTextBlock" abstract="false" name="SummaryOfActivityForEarnoutRSATableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dna_NumberOfCoreOfferings" abstract="false" name="NumberOfCoreOfferings" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_OneCustomerMember" abstract="true" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_CellEngineeringSegmentMember" abstract="true" name="CellEngineeringSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_BiosecuritySegmentMember" abstract="true" name="BiosecuritySegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_EquityMethodInvestmentFundingOfAdditionalLossesMember" abstract="true" name="EquityMethodInvestmentFundingOfAdditionalLossesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" abstract="false" name="RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dna_AgBiomeInc.Member" abstract="true" name="AgBiomeInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_ZymergenBankruptcyMember" abstract="true" name="ZymergenBankruptcyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_ZymergenMember" abstract="true" name="ZymergenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_OtherAssetAcquisitionsMember" abstract="true" name="OtherAssetAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_StridebioMember" abstract="true" name="StridebioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_AltarSasMember" abstract="true" name="AltarSasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" abstract="false" name="AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_EmployeeLeaseExpense" abstract="false" name="EmployeeLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_NumberOfEmployeesAcquired" abstract="false" name="NumberOfEmployeesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_SynlogicIncWarrantsMember" abstract="true" name="SynlogicIncWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_MarketableEquitySecuritiesMember" abstract="true" name="MarketableEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_PrivatePlacementWarrantsMember" abstract="true" name="PrivatePlacementWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_ProbabilityWeightedPresentValueMember" abstract="true" name="ProbabilityWeightedPresentValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_SeniorSecuredNoteMember" abstract="true" name="SeniorSecuredNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_ConvertiblePromissoryNotesMember" abstract="true" name="ConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_MeasurementInputScenarioProbabilitiesMember" abstract="true" name="MeasurementInputScenarioProbabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_PublicWarrantsMember" abstract="true" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_CircularisMember" abstract="true" name="CircularisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_GenomaticaIncPreferredStockMember" abstract="true" name="GenomaticaIncPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_SafesMember" abstract="true" name="SafesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_NonMarketableEquitySecuritiesMember" abstract="true" name="NonMarketableEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_OneInvestmentMember" abstract="true" name="OneInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_SafeMember" abstract="true" name="SafeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_FinancingReceivableInterestRateStatedPercentage" abstract="false" name="FinancingReceivableInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dna_FinancingReceivableMeasurementInput" abstract="false" name="FinancingReceivableMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="dna_FinancingReceivableMeasurementInputPeriod" abstract="false" name="FinancingReceivableMeasurementInputPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum" abstract="false" name="ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dna_ClassOfWarrantOrRightStockSplitConversionRatio" abstract="false" name="ClassOfWarrantOrRightStockSplitConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dna_BusinessCombinationContingentConsiderationVestedValue" abstract="false" name="BusinessCombinationContingentConsiderationVestedValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dna_EquitySecuritiesFVNIMeasurementInputTerm" abstract="false" name="EquitySecuritiesFVNIMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dna_SynlogicIncWarrantMember" abstract="true" name="SynlogicIncWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_BiomeditLlcMember" abstract="true" name="BiomeditLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_OtherEquityInvestessMember" abstract="true" name="OtherEquityInvestessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_GoodwillImpairmentDCFWeight" abstract="false" name="GoodwillImpairmentDCFWeight" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dna_GoodwillImpairmentGPCWeight" abstract="false" name="GoodwillImpairmentGPCWeight" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dna_EquipmentLeasesMember" abstract="true" name="EquipmentLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_LesseeOperatingLeaseAreaOfRealEstateProperty" abstract="false" name="LesseeOperatingLeaseAreaOfRealEstateProperty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="dna_LesseeOperatingLeaseNumberOfExtensionOptions" abstract="false" name="LesseeOperatingLeaseNumberOfExtensionOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment" abstract="false" name="FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment" abstract="false" name="TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_ContractualShortfallLiabilityCurrent" abstract="false" name="ContractualShortfallLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_AccruedBiosecurityServiceRevenueAccrualsCurrent" abstract="false" name="AccruedBiosecurityServiceRevenueAccrualsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_AccruedEmployeeTerminationCosts" abstract="false" name="AccruedEmployeeTerminationCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_AccruedExternalResearchAndDevelopmentExpensesCurrent" abstract="false" name="AccruedExternalResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_AccruedPropertyAndEquipmentCurrent" abstract="false" name="AccruedPropertyAndEquipmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_SupplementalFinancialStatementInformationAbstract" abstract="true" name="SupplementalFinancialStatementInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices" abstract="false" name="ConvertibleFinancialInstrumentsReceivedForFoundryServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_PurchaseOfNonCashMarketableEquitySecurities" abstract="false" name="PurchaseOfNonCashMarketableEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_SettlementOfContingentConsideration" abstract="false" name="SettlementOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_IssuanceOfCommonStockForAcquisitionRetentionPayments" abstract="false" name="IssuanceOfCommonStockForAcquisitionRetentionPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" abstract="false" name="ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" abstract="false" name="SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember" abstract="true" name="StrategicCloudAndAIPartnershipWithGoogleCloudMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix" abstract="false" name="UnrecordedUnconditionalPurchaseObligationToBePaidYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_ContractualShortfallLiability" abstract="false" name="ContractualShortfallLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_ContractualShortfallLiabilityRequiredPayment" abstract="false" name="ContractualShortfallLiabilityRequiredPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_RoyaltyReceivedFromLicensingRevenue" abstract="false" name="RoyaltyReceivedFromLicensingRevenue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct" abstract="false" name="RoyaltyReceivedFromLicenseOrSaleOfAProduct" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dna_LossContingencyAmountRequiredToFund" abstract="false" name="LossContingencyAmountRequiredToFund" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_NewGinkgoPreferredStockMember" abstract="true" name="NewGinkgoPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_ATMProgramMember" abstract="true" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_SalesAgreementWithAllenCompanyLLCMember" abstract="true" name="SalesAgreementWithAllenCompanyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_CommonStockVotingRight" abstract="false" name="CommonStockVotingRight" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_SaleOfStockAuthorizedAmount" abstract="false" name="SaleOfStockAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_CommonStockConversionRatio" abstract="false" name="CommonStockConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember" abstract="true" name="TwoThousandAndTwentyOneIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_InducementPlanMember" abstract="true" name="InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_WarrantsToPurchaseClassACommonStockMember" abstract="true" name="WarrantsToPurchaseClassACommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_OtherRevenueMember" abstract="true" name="OtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_TwoThousandTwentyTwoInducementPlanMember" abstract="true" name="TwoThousandTwentyTwoInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_EarnoutRestrictedStockUnitsMember" abstract="true" name="EarnoutRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_FounderOptionsMember" abstract="true" name="FounderOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_FounderPSUAwardsMember" abstract="true" name="FounderPSUAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_EarnOutSharesMember" abstract="true" name="EarnOutSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_ShareBasedCompensationAwardTrancheFourMember" abstract="true" name="ShareBasedCompensationAwardTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm" abstract="false" name="ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate" abstract="false" name="PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dna_TypesOfTimeBasedStockOptions" abstract="false" name="TypesOfTimeBasedStockOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="dna_NumberOfCompanyFounders" abstract="false" name="NumberOfCompanyFounders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_NumberOfStockPriceHurdles" abstract="false" name="NumberOfStockPriceHurdles" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dna_NumberOfVestingConditions" abstract="false" name="NumberOfVestingConditions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dna_PharmaceuticalAndBiotechnologyMember" abstract="true" name="PharmaceuticalAndBiotechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_AgricultureMember" abstract="true" name="AgricultureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_GovernmentAndDefenseMember" abstract="true" name="GovernmentAndDefenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_IndustrialAndEnvironmentMember" abstract="true" name="IndustrialAndEnvironmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_CustomerAndTechnologyMember" abstract="true" name="CustomerAndTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_FoodAndNutritionMember" abstract="true" name="FoodAndNutritionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_CellEngineeringMember" abstract="true" name="CellEngineeringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_RevenuePerformanceObligationAxis" abstract="true" name="RevenuePerformanceObligationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="dna_RevenuePerformanceObligationDomain" abstract="true" name="RevenuePerformanceObligationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_Year1Member" abstract="true" name="Year1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_Year12Member" abstract="true" name="Year12Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_Year13Member" abstract="true" name="Year13Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_Year14Member" abstract="true" name="Year14Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_Year15Member" abstract="true" name="Year15Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" abstract="false" name="RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_NumberOfCoreAssets" abstract="false" name="NumberOfCoreAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_CellEngineeringAndBiosecuritySegmentsMember" abstract="true" name="CellEngineeringAndBiosecuritySegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_LeaseAssetsMember" abstract="true" name="LeaseAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_OperatingExpensesNotAllocatedToSegmentsAbstract" abstract="true" name="OperatingExpensesNotAllocatedToSegmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dna_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_EmployerPayrollTaxes" abstract="false" name="EmployerPayrollTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_MotifFoodworksIncMember" abstract="true" name="MotifFoodworksIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_OtherEquityInvesteeMember" abstract="true" name="OtherEquityInvesteeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_GenomaticaMember" abstract="true" name="GenomaticaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_BiomeditMember" abstract="true" name="BiomeditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_ArcaeaMember" abstract="true" name="ArcaeaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_AlloniaMember" abstract="true" name="AlloniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_MotifMember" abstract="true" name="MotifMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_AgreementAxis" abstract="true" name="AgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="dna_AgreementDomain" abstract="true" name="AgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember" abstract="true" name="TwoThousandAndEighteenTechnicalDevelopmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_NumberOFEstimatedMaterialRights" abstract="false" name="NumberOFEstimatedMaterialRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dna_UpfrontAmountReceived" abstract="false" name="UpfrontAmountReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_PreferredStockInvestmentImpairmentLoss" abstract="false" name="PreferredStockInvestmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_AyanaMember" abstract="true" name="AyanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_VerbBioticsMember" abstract="true" name="VerbBioticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_OtherEquityInvesteesMember" abstract="true" name="OtherEquityInvesteesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_DefinedContributionPlanVestingPeriod" abstract="false" name="DefinedContributionPlanVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dna_DefinedContributionPlanEmployeeAnnualEarningAmount" abstract="false" name="DefinedContributionPlanEmployeeAnnualEarningAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_DefinedContributionPlanMaximumEmployerContributionsAmount" abstract="false" name="DefinedContributionPlanMaximumEmployerContributionsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dna_DeferredTaxAssetsDeferredRevenue" abstract="false" name="DeferredTaxAssetsDeferredRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_DeferredTaxAssetsAmortizableIntangibles" abstract="false" name="DeferredTaxAssetsAmortizableIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_DeferredTaxAssetsInvestmentsInSubsidiaries" abstract="false" name="DeferredTaxAssetsInvestmentsInSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_DeferredTaxLiabilitiesAmortizableIntangibles" abstract="false" name="DeferredTaxLiabilitiesAmortizableIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dna_DeferredTaxAssetsValuationAllowanceRollForward" abstract="true" name="DeferredTaxAssetsValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dna_IncomeTaxDisclosureTable" abstract="true" name="IncomeTaxDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dna_CarryForwardsExpirationPeriodAxis" abstract="true" name="CarryForwardsExpirationPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="dna_CarryForwardsExpirationPeriodDomain" abstract="true" name="CarryForwardsExpirationPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_BeginToExpireInTwoThousandAndTwentyNineMember" abstract="true" name="BeginToExpireInTwoThousandAndTwentyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_CarriedForwardIndefinitelyMember" abstract="true" name="CarriedForwardIndefinitelyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_BeginToExpireInTwoThousandAndThirtyMember" abstract="true" name="BeginToExpireInTwoThousandAndThirtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_BeginToExpireIn2034Member" abstract="true" name="BeginToExpireIn2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_IncomeTaxDisclosureLineItems" abstract="true" name="IncomeTaxDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dna_EscrowSharesMember" abstract="true" name="EscrowSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived" abstract="false" name="StockPurchaseAgreementPercentOfEquityInterestToBeReceived" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>dna-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:52002c9c-7569-4bc2-a5b5-c24c0eeac02a,g:42911b52-7f60-440e-93d3-9584b5edbad8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6af25cc2-8fa5-4a20-9711-3c5e84837cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15d8cba9-b21f-4a5d-bd05-aef2cb34628e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6af25cc2-8fa5-4a20-9711-3c5e84837cc0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_15d8cba9-b21f-4a5d-bd05-aef2cb34628e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_8e5b6ec5-cc39-4532-bb04-3b1103195595" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6af25cc2-8fa5-4a20-9711-3c5e84837cc0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_8e5b6ec5-cc39-4532-bb04-3b1103195595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_02e49a2a-57f2-42e1-9cde-16216e428725" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6af25cc2-8fa5-4a20-9711-3c5e84837cc0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_02e49a2a-57f2-42e1-9cde-16216e428725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_198b4910-b9e2-4893-a1bb-567d55544e51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6af25cc2-8fa5-4a20-9711-3c5e84837cc0" xlink:to="loc_us-gaap_AccountsReceivableNet_198b4910-b9e2-4893-a1bb-567d55544e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019c4ef9-3635-7467-a80f-40f0e6f96dea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6af25cc2-8fa5-4a20-9711-3c5e84837cc0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019c4ef9-3635-7467-a80f-40f0e6f96dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a50882c1-4665-45e7-ab5c-bf564eecf133" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d4e9e8b0-2685-4020-a815-f7d895d85cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a50882c1-4665-45e7-ab5c-bf564eecf133" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d4e9e8b0-2685-4020-a815-f7d895d85cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_88e17bcb-db84-45d4-9ff4-309b08854883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a50882c1-4665-45e7-ab5c-bf564eecf133" xlink:to="loc_us-gaap_LiabilitiesCurrent_88e17bcb-db84-45d4-9ff4-309b08854883" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_26079490-0ac4-486c-9592-0e6bbbb7ef92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a50882c1-4665-45e7-ab5c-bf564eecf133" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_26079490-0ac4-486c-9592-0e6bbbb7ef92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_03925e44-f4e4-49c1-b4f4-949b8c7dc469" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a50882c1-4665-45e7-ab5c-bf564eecf133" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_03925e44-f4e4-49c1-b4f4-949b8c7dc469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_747de52f-d3a8-45e6-8ab2-61c1bed1c9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b896503-5f16-4a04-96eb-a162f7ebff00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_747de52f-d3a8-45e6-8ab2-61c1bed1c9b2" xlink:to="loc_us-gaap_Liabilities_6b896503-5f16-4a04-96eb-a162f7ebff00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ed4279c4-d893-4681-844f-ea876450936a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_747de52f-d3a8-45e6-8ab2-61c1bed1c9b2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ed4279c4-d893-4681-844f-ea876450936a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a08ad46b-a222-4c13-82dc-6d0149560417" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_747de52f-d3a8-45e6-8ab2-61c1bed1c9b2" xlink:to="loc_us-gaap_StockholdersEquity_a08ad46b-a222-4c13-82dc-6d0149560417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cfe06548-4940-4af0-ac4f-12d13c5af347" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d27b93db-62e4-4804-b023-c5c478a21294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cfe06548-4940-4af0-ac4f-12d13c5af347" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d27b93db-62e4-4804-b023-c5c478a21294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6699e59c-9049-474f-8c93-b3fe42bc0dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cfe06548-4940-4af0-ac4f-12d13c5af347" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6699e59c-9049-474f-8c93-b3fe42bc0dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_56c16bc9-58d5-49f9-96bf-077779273b39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cfe06548-4940-4af0-ac4f-12d13c5af347" xlink:to="loc_us-gaap_PreferredStockValue_56c16bc9-58d5-49f9-96bf-077779273b39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_08eb49fe-9496-463f-9ccb-d09e1ba33285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cfe06548-4940-4af0-ac4f-12d13c5af347" xlink:to="loc_us-gaap_AdditionalPaidInCapital_08eb49fe-9496-463f-9ccb-d09e1ba33285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4eb3c30e-3147-4a73-9fcb-182ea78ec2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cfe06548-4940-4af0-ac4f-12d13c5af347" xlink:to="loc_us-gaap_CommonStockValue_4eb3c30e-3147-4a73-9fcb-182ea78ec2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e80cddc4-2e99-45bb-b3f3-3efb5e9ba49b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4a511128-344f-4363-a7cd-f5db7e9f283b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e80cddc4-2e99-45bb-b3f3-3efb5e9ba49b" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4a511128-344f-4363-a7cd-f5db7e9f283b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e942f12c-a068-40f1-8882-e74e26d76014" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e80cddc4-2e99-45bb-b3f3-3efb5e9ba49b" xlink:to="loc_us-gaap_AccountsPayableCurrent_e942f12c-a068-40f1-8882-e74e26d76014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_528250b1-1c8b-4a71-be8d-af2e135a3b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e80cddc4-2e99-45bb-b3f3-3efb5e9ba49b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_528250b1-1c8b-4a71-be8d-af2e135a3b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_09b93c96-28da-4d2f-ab50-275ab3b5e044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_c7084aca-9b9d-421f-b356-5d4dc6d2226a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09b93c96-28da-4d2f-ab50-275ab3b5e044" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_c7084aca-9b9d-421f-b356-5d4dc6d2226a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c339c65a-51be-405c-8f37-69488afe05e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09b93c96-28da-4d2f-ab50-275ab3b5e044" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c339c65a-51be-405c-8f37-69488afe05e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_655f1192-7fa4-4192-b839-711e6305d1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09b93c96-28da-4d2f-ab50-275ab3b5e044" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_655f1192-7fa4-4192-b839-711e6305d1b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b7c74120-556b-49f6-b8d7-7ab12c681d25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09b93c96-28da-4d2f-ab50-275ab3b5e044" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b7c74120-556b-49f6-b8d7-7ab12c681d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bd5e6400-c1d2-493e-8a05-3602442804e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09b93c96-28da-4d2f-ab50-275ab3b5e044" xlink:to="loc_us-gaap_AssetsCurrent_bd5e6400-c1d2-493e-8a05-3602442804e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_76aec14f-74a4-4833-bd81-4d5266955f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_09b93c96-28da-4d2f-ab50-275ab3b5e044" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_76aec14f-74a4-4833-bd81-4d5266955f5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4b2a1ef0-c5eb-481d-9a1a-174da17dbb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e245f58f-912d-4035-9152-9605546cfbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4b2a1ef0-c5eb-481d-9a1a-174da17dbb3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e245f58f-912d-4035-9152-9605546cfbf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_be12baa8-04ae-4d46-9481-be54327afd78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4b2a1ef0-c5eb-481d-9a1a-174da17dbb3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_be12baa8-04ae-4d46-9481-be54327afd78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019c4eff-4dbc-7838-b32d-b19845574690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4b2a1ef0-c5eb-481d-9a1a-174da17dbb3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019c4eff-4dbc-7838-b32d-b19845574690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_25d8a515-e033-43b1-acd7-1a190c47bf62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1ceec2b6-292e-4c32-960f-1ca87fdf57a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_25d8a515-e033-43b1-acd7-1a190c47bf62" xlink:to="loc_us-gaap_OperatingExpenses_1ceec2b6-292e-4c32-960f-1ca87fdf57a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_91b92760-48bc-490b-b345-21ac0b7fb22b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_25d8a515-e033-43b1-acd7-1a190c47bf62" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_91b92760-48bc-490b-b345-21ac0b7fb22b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_38294a73-1097-42bc-8e0a-91eefef7dd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b9017c8b-ff69-4c23-9b10-d654e2b3ca92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_38294a73-1097-42bc-8e0a-91eefef7dd3e" xlink:to="loc_us-gaap_NetIncomeLoss_b9017c8b-ff69-4c23-9b10-d654e2b3ca92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fae0e1f7-2fdd-4ab4-914a-2e00bbd5515f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_38294a73-1097-42bc-8e0a-91eefef7dd3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fae0e1f7-2fdd-4ab4-914a-2e00bbd5515f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d98c7913-3cee-4f89-980e-229221110d24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f829caef-308e-4f9e-89be-d5da2fcd9277" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d98c7913-3cee-4f89-980e-229221110d24" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f829caef-308e-4f9e-89be-d5da2fcd9277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_1617d192-ba73-4282-8aea-cd95fcfac657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d98c7913-3cee-4f89-980e-229221110d24" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_1617d192-ba73-4282-8aea-cd95fcfac657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9cef8806-364a-470e-8f57-b27411a6a520" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d98c7913-3cee-4f89-980e-229221110d24" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9cef8806-364a-470e-8f57-b27411a6a520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9a68fe10-3633-4aa4-860e-954383a7dc00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d98c7913-3cee-4f89-980e-229221110d24" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9a68fe10-3633-4aa4-860e-954383a7dc00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c0617368-5db1-48ce-8328-b65217a86f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d98c7913-3cee-4f89-980e-229221110d24" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c0617368-5db1-48ce-8328-b65217a86f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_f016f760-b647-48af-99b9-ab5fd9fab274" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d98c7913-3cee-4f89-980e-229221110d24" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_f016f760-b647-48af-99b9-ab5fd9fab274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90c749ea-7844-4d84-9a7a-403ab3f44e61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_97751b5b-d145-4c44-95a7-2884eaa7bdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90c749ea-7844-4d84-9a7a-403ab3f44e61" xlink:to="loc_us-gaap_OperatingIncomeLoss_97751b5b-d145-4c44-95a7-2884eaa7bdc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5c3e7220-7083-4697-b5b8-b0493e07cc26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90c749ea-7844-4d84-9a7a-403ab3f44e61" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5c3e7220-7083-4697-b5b8-b0493e07cc26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8cf28e9b-8809-4ee4-99d2-258daca668d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_e35aafab-b87b-42a4-98c5-e52e0ef8b0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_8cf28e9b-8809-4ee4-99d2-258daca668d2" xlink:to="loc_us-gaap_InterestExpenseNonoperating_e35aafab-b87b-42a4-98c5-e52e0ef8b0a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_222deeca-d5f4-4979-9590-403fb33da106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_8cf28e9b-8809-4ee4-99d2-258daca668d2" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_222deeca-d5f4-4979-9590-403fb33da106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_090e8378-9c94-4dd4-ba43-61c0ce998b73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_8cf28e9b-8809-4ee4-99d2-258daca668d2" xlink:to="loc_us-gaap_InterestIncomeOther_090e8378-9c94-4dd4-ba43-61c0ce998b73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_26ac8f57-fe22-4d2d-b117-c06667172db1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_8cf28e9b-8809-4ee4-99d2-258daca668d2" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_26ac8f57-fe22-4d2d-b117-c06667172db1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_9729bb60-020d-488f-bd24-d5bc4812d268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_8cf28e9b-8809-4ee4-99d2-258daca668d2" xlink:to="loc_us-gaap_GainLossOnInvestments_9729bb60-020d-488f-bd24-d5bc4812d268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_7e1095c6-2cdc-4acb-a706-dec32e56cd68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_8cf28e9b-8809-4ee4-99d2-258daca668d2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_7e1095c6-2cdc-4acb-a706-dec32e56cd68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b2d84a1f-7950-4d28-88ec-9b9bdadc15d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_8cf28e9b-8809-4ee4-99d2-258daca668d2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b2d84a1f-7950-4d28-88ec-9b9bdadc15d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d9a4f7e3-5aea-4412-b74f-4fa23bf12a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e30b6655-199e-4349-a267-5a006a4b8519" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d9a4f7e3-5aea-4412-b74f-4fa23bf12a9e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e30b6655-199e-4349-a267-5a006a4b8519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6708fec7-751d-42bf-a8a1-5017e8984fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d9a4f7e3-5aea-4412-b74f-4fa23bf12a9e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6708fec7-751d-42bf-a8a1-5017e8984fdc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6cb08497-7d60-434f-8029-15c583130a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_986db23c-cff8-4187-a13a-9d8383adf6da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6cb08497-7d60-434f-8029-15c583130a64" xlink:to="loc_us-gaap_RestrictedCash_986db23c-cff8-4187-a13a-9d8383adf6da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4827ec98-ed04-4c73-be23-8357626cf9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6cb08497-7d60-434f-8029-15c583130a64" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4827ec98-ed04-4c73-be23-8357626cf9b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02256fa3-6950-4acc-8675-6d3ee1233c57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_90780176-f774-4691-b016-5acaf164f143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02256fa3-6950-4acc-8675-6d3ee1233c57" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_90780176-f774-4691-b016-5acaf164f143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7e5244e-da28-402e-ab45-1dc25b8ac388" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02256fa3-6950-4acc-8675-6d3ee1233c57" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7e5244e-da28-402e-ab45-1dc25b8ac388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_308df625-a6bf-4ea9-a145-b4932131e237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02256fa3-6950-4acc-8675-6d3ee1233c57" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_308df625-a6bf-4ea9-a145-b4932131e237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0ee9f5be-1830-450f-9edf-5d5490865916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02256fa3-6950-4acc-8675-6d3ee1233c57" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0ee9f5be-1830-450f-9edf-5d5490865916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_542c9fb3-34d6-43a1-a23e-3d011862b6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02256fa3-6950-4acc-8675-6d3ee1233c57" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_542c9fb3-34d6-43a1-a23e-3d011862b6ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0cc1e041-4cc9-4fe1-90b8-b3911b9acf03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02256fa3-6950-4acc-8675-6d3ee1233c57" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0cc1e041-4cc9-4fe1-90b8-b3911b9acf03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_019c5c6b-da69-70b1-9c89-6df1c2e0861f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02256fa3-6950-4acc-8675-6d3ee1233c57" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_019c5c6b-da69-70b1-9c89-6df1c2e0861f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6258458a-90ca-4248-82e9-0878dcd9d272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6258458a-90ca-4248-82e9-0878dcd9d272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_37ddecb5-43e6-424b-b755-6bfd844323af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_37ddecb5-43e6-424b-b755-6bfd844323af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a7a27c76-bf6f-49d2-b8f0-4cfd243261b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a7a27c76-bf6f-49d2-b8f0-4cfd243261b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e25a094a-b9b0-4a80-a10e-0187259fb509" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e25a094a-b9b0-4a80-a10e-0187259fb509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_6b98afdc-4a4d-484b-a9c7-ea9e6faf162b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_6b98afdc-4a4d-484b-a9c7-ea9e6faf162b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ce03498e-41c7-4549-a090-e73ea19d1281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ce03498e-41c7-4549-a090-e73ea19d1281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_fe03fd34-585e-46db-8def-ea6f10f53e52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_fe03fd34-585e-46db-8def-ea6f10f53e52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8170f207-b487-47a7-b361-ed9f01a83ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8170f207-b487-47a7-b361-ed9f01a83ac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6a964fa5-8324-41d1-a527-6ff4c0f3dddb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6a964fa5-8324-41d1-a527-6ff4c0f3dddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_302d794d-38a1-4fd2-88d2-4a1f6d88a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4bc5ffa-683d-47ff-975a-a8bd332e6f3b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_302d794d-38a1-4fd2-88d2-4a1f6d88a1af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ChangesInFairValueOfLoansReceivable_32f8ff3b-4c6f-4e64-8dc5-1d5b71b393a1" xlink:href="dna-20251231.xsd#dna_ChangesInFairValueOfLoansReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_dna_ChangesInFairValueOfLoansReceivable_32f8ff3b-4c6f-4e64-8dc5-1d5b71b393a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_667582c7-1b2d-4eda-b67d-5007f98127be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_667582c7-1b2d-4eda-b67d-5007f98127be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1a6bd0a8-9609-4188-b0f8-1a05e021e6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_ProfitLoss_1a6bd0a8-9609-4188-b0f8-1a05e021e6bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NoncashInProcessResearchAndDevelopment_c82f530a-8265-42a0-bcc2-ecdd0758d265" xlink:href="dna-20251231.xsd#dna_NoncashInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_dna_NoncashInProcessResearchAndDevelopment_c82f530a-8265-42a0-bcc2-ecdd0758d265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NoncashCustomerConsideration_9e310224-8360-4442-b32d-62dfefc6bd1d" xlink:href="dna-20251231.xsd#dna_NoncashCustomerConsideration"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_dna_NoncashCustomerConsideration_9e310224-8360-4442-b32d-62dfefc6bd1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_85bace3d-352b-4063-95dc-22069295a03b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_85bace3d-352b-4063-95dc-22069295a03b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_26c48089-0507-4848-89dd-fd6442f54871" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_26c48089-0507-4848-89dd-fd6442f54871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2f7782af-f45b-4a10-ba65-7029ebb4aafd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2f7782af-f45b-4a10-ba65-7029ebb4aafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_d1b18323-62f6-42a9-a456-3e20cd794346" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_d1b18323-62f6-42a9-a456-3e20cd794346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_edb98ac2-742d-45a5-915a-bfe05ea0c1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_edb98ac2-742d-45a5-915a-bfe05ea0c1a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_c75c3127-9ed9-4be5-a2f8-c7798a79994b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_c75c3127-9ed9-4be5-a2f8-c7798a79994b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3db47a03-9631-44d7-ada7-30a69ee33e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3db47a03-9631-44d7-ada7-30a69ee33e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_542a22be-4aac-4822-a8d0-d140550bc0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_542a22be-4aac-4822-a8d0-d140550bc0e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_569303c5-518b-42e2-8b5a-9b52da7afbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_569303c5-518b-42e2-8b5a-9b52da7afbf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6a53c652-9efe-4860-98ff-d8195a5cd3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6a53c652-9efe-4860-98ff-d8195a5cd3ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_46dccb56-54de-4666-9873-9b88b3d09f26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_46dccb56-54de-4666-9873-9b88b3d09f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e227f3c5-2045-4750-888f-73e701a037a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_DepreciationAndAmortization_e227f3c5-2045-4750-888f-73e701a037a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_14ab26da-8465-471d-96fa-7276fb4e6a45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_14ab26da-8465-471d-96fa-7276fb4e6a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9f93a07e-1f3f-47ff-bed5-8156ba1528ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9f93a07e-1f3f-47ff-bed5-8156ba1528ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_39eefbe3-74ce-46e8-9bad-99e6957802a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_GainLossOnInvestments_39eefbe3-74ce-46e8-9bad-99e6957802a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5fcd8a57-3365-45a2-b142-4184522c2d25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5fcd8a57-3365-45a2-b142-4184522c2d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4f389fc6-4ad4-48f3-84f8-8b9a6d9e062f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_ShareBasedCompensation_4f389fc6-4ad4-48f3-84f8-8b9a6d9e062f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c1ba9a87-ee96-4a63-9dd1-07423b9e59b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c1ba9a87-ee96-4a63-9dd1-07423b9e59b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1a34f4cf-ec4c-478d-9a32-6b6666237ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_1a34f4cf-ec4c-478d-9a32-6b6666237ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_e5d16f4b-48f5-4303-9948-ff857b05cc27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCosts"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_RestructuringCosts_e5d16f4b-48f5-4303-9948-ff857b05cc27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_b6401b5a-63fe-403d-8860-cbbf5b8c10f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="26" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_b6401b5a-63fe-403d-8860-cbbf5b8c10f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncreaseDecreaseRightOfUseAssets_7e0b1439-82d6-4d23-a3f4-3e94ccf402c9" xlink:href="dna-20251231.xsd#dna_IncreaseDecreaseRightOfUseAssets"/>
    <link:calculationArc order="27" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_dna_IncreaseDecreaseRightOfUseAssets_7e0b1439-82d6-4d23-a3f4-3e94ccf402c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccretionOfDiscountOnMarketableSecurities_019c5c68-edcd-70a7-b56e-f827f3de5602" xlink:href="dna-20251231.xsd#dna_AccretionOfDiscountOnMarketableSecurities"/>
    <link:calculationArc order="28" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02447230-ecb0-4092-b367-3d78f0caa6fe" xlink:to="loc_dna_AccretionOfDiscountOnMarketableSecurities_019c5c68-edcd-70a7-b56e-f827f3de5602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_734c9d25-b916-4baf-80fa-e870a40dc9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24798a95-1d36-43f0-aad3-ebef7fb22c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_734c9d25-b916-4baf-80fa-e870a40dc9ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24798a95-1d36-43f0-aad3-ebef7fb22c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ff703207-24be-4423-96cb-365b20ec44df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_734c9d25-b916-4baf-80fa-e870a40dc9ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ff703207-24be-4423-96cb-365b20ec44df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_418103fe-2517-40e0-82de-5acce029d4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_734c9d25-b916-4baf-80fa-e870a40dc9ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_418103fe-2517-40e0-82de-5acce029d4f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b3a0627-5abf-4b54-9cb2-6d11bb5c65ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_734c9d25-b916-4baf-80fa-e870a40dc9ca" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b3a0627-5abf-4b54-9cb2-6d11bb5c65ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-77eb-b125-9d547d8de4da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019c5c83-8732-7b7e-b6e9-26ad758ac634" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-77eb-b125-9d547d8de4da" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019c5c83-8732-7b7e-b6e9-26ad758ac634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_019c5c83-8732-762a-949e-4451ba306edb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-77eb-b125-9d547d8de4da" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_019c5c83-8732-762a-949e-4451ba306edb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-70fc-ba3e-ca18994a2844" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_019c5c83-8732-7957-b5a1-965fe3aa7aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-70fc-ba3e-ca18994a2844" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_019c5c83-8732-7957-b5a1-965fe3aa7aa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019c5c83-8732-782b-a694-330af7fab064" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-70fc-ba3e-ca18994a2844" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019c5c83-8732-782b-a694-330af7fab064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_019c5c83-8732-7f50-9ea2-fa4f437a6c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-70fc-ba3e-ca18994a2844" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_019c5c83-8732-7f50-9ea2-fa4f437a6c6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7af8-9b27-52b172abf42f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-715f-82cf-56d534b61c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7af8-9b27-52b172abf42f" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-715f-82cf-56d534b61c5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_019c5c83-8732-78b8-ac4b-a5495544fe6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7af8-9b27-52b172abf42f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_019c5c83-8732-78b8-ac4b-a5495544fe6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_019c5c83-8732-79ba-aead-9cfdb1e37bca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7af8-9b27-52b172abf42f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_019c5c83-8732-79ba-aead-9cfdb1e37bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_019c5c83-8732-79ea-9b46-f4b1c42387eb" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7af8-9b27-52b172abf42f" xlink:to="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_019c5c83-8732-79ea-9b46-f4b1c42387eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_019c5c83-8732-7221-b6da-a4ff34a1936e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7af8-9b27-52b172abf42f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_019c5c83-8732-7221-b6da-a4ff34a1936e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_019c5c83-8732-745a-b2bf-beb9baa280fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7af8-9b27-52b172abf42f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_019c5c83-8732-745a-b2bf-beb9baa280fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7db1-864c-412f86a0bbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_019c5c83-8732-764f-bb71-fed00a2bd6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7db1-864c-412f86a0bbcd" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_019c5c83-8732-764f-bb71-fed00a2bd6ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_019c5c83-8732-707c-9eeb-b725d8c0f1a3" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7db1-864c-412f86a0bbcd" xlink:to="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_019c5c83-8732-707c-9eeb-b725d8c0f1a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-794f-bbff-c494d8a9caa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7db1-864c-412f86a0bbcd" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-794f-bbff-c494d8a9caa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_019c5c83-8732-70e7-9da4-c8019130387c" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-725d-b0b5-fa34d5638922" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_019c5c83-8732-70e7-9da4-c8019130387c" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-725d-b0b5-fa34d5638922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7115-8f88-4693c808ab9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_019c5c83-8732-70e7-9da4-c8019130387c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7115-8f88-4693c808ab9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_019c5c83-a645-7ead-b2d4-01198ea4bd27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_019c5c83-a645-7793-aeca-9a7687b6ba55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_019c5c83-a645-7ead-b2d4-01198ea4bd27" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_019c5c83-a645-7793-aeca-9a7687b6ba55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_019c5c83-a645-7aa8-955a-174b4edd0583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_019c5c83-a645-7ead-b2d4-01198ea4bd27" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_019c5c83-a645-7aa8-955a-174b4edd0583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_019c5c83-a645-7842-9420-bec08a3e76c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_019c5c83-a645-72e2-b528-d90b47e0daac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_019c5c83-a645-7842-9420-bec08a3e76c1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_019c5c83-a645-72e2-b528-d90b47e0daac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_019c5c83-a645-7e4e-aafc-48c8089dcb48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_019c5c83-a645-7842-9420-bec08a3e76c1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_019c5c83-a645-7e4e-aafc-48c8089dcb48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_019c5c83-a645-74b4-9d69-5f3c224f59e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_019c5c83-a645-773d-a7c5-59b53d271a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_019c5c83-a645-74b4-9d69-5f3c224f59e8" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_019c5c83-a645-773d-a7c5-59b53d271a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_019c5c83-a645-7b48-bf84-9d03ad77bfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_019c5c83-a645-74b4-9d69-5f3c224f59e8" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_019c5c83-a645-7b48-bf84-9d03ad77bfc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_670c602c-2906-4aa9-9344-ff8771dddffd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4fc47f29-5c10-459d-b6b9-a765093165f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_670c602c-2906-4aa9-9344-ff8771dddffd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4fc47f29-5c10-459d-b6b9-a765093165f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2a31a2ae-8bd7-4290-b68b-9d39735841d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_670c602c-2906-4aa9-9344-ff8771dddffd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2a31a2ae-8bd7-4290-b68b-9d39735841d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bdbd19f3-f602-4f6f-b4a1-e520a2e13841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure_67b6929e-e292-4506-b1d5-d750f834a21e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_bdbd19f3-f602-4f6f-b4a1-e520a2e13841" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosure_67b6929e-e292-4506-b1d5-d750f834a21e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_f588a80c-6a3b-43c1-878b-656353a15ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_bdbd19f3-f602-4f6f-b4a1-e520a2e13841" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_f588a80c-6a3b-43c1-878b-656353a15ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e101d6c8-fbe7-40df-9a09-4c75fd9d5399" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_bdbd19f3-f602-4f6f-b4a1-e520a2e13841" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e101d6c8-fbe7-40df-9a09-4c75fd9d5399" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_c4e91ef6-6cec-4ecc-a753-84c5f45ee60c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7c296dad-e44b-4533-b36c-b679ebbd061f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_c4e91ef6-6cec-4ecc-a753-84c5f45ee60c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7c296dad-e44b-4533-b36c-b679ebbd061f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_bcf665d2-3c18-4429-b39c-fe4acec2299c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_c4e91ef6-6cec-4ecc-a753-84c5f45ee60c" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_bcf665d2-3c18-4429-b39c-fe4acec2299c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_93e9bc11-7c35-4053-ac16-0b46406ef721" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_89c798a2-7f62-437d-b3b1-fec1012e79ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_93e9bc11-7c35-4053-ac16-0b46406ef721" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_89c798a2-7f62-437d-b3b1-fec1012e79ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_e994c3de-ed55-4a8e-88b8-927d475be1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_93e9bc11-7c35-4053-ac16-0b46406ef721" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_e994c3de-ed55-4a8e-88b8-927d475be1c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_11075e73-baee-4a79-954b-e2652450c539" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_93e9bc11-7c35-4053-ac16-0b46406ef721" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_11075e73-baee-4a79-954b-e2652450c539" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_edfaf8e3-bda9-4f57-8c53-8fda7738935f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7030f699-f3ef-4792-b638-ad538af409dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_edfaf8e3-bda9-4f57-8c53-8fda7738935f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7030f699-f3ef-4792-b638-ad538af409dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4bcfaf26-e868-4c5c-8064-3b7860931df8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_edfaf8e3-bda9-4f57-8c53-8fda7738935f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4bcfaf26-e868-4c5c-8064-3b7860931df8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_557d46a9-63d9-4bdf-8401-2edd8b155ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_7b70e0d7-0bb5-4e2d-a36a-12ceabc187ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_557d46a9-63d9-4bdf-8401-2edd8b155ef0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_7b70e0d7-0bb5-4e2d-a36a-12ceabc187ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_3c508b3d-e59e-470a-be06-b10afae5c170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_557d46a9-63d9-4bdf-8401-2edd8b155ef0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_3c508b3d-e59e-470a-be06-b10afae5c170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_7999d64a-340c-406c-8a18-60ac867c60c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_557d46a9-63d9-4bdf-8401-2edd8b155ef0" xlink:to="loc_us-gaap_Investments_7999d64a-340c-406c-8a18-60ac867c60c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93a611cf-9bfa-4881-994a-6f54561c9e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_070b4173-8a21-4a91-ad2d-ed12ee03c0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93a611cf-9bfa-4881-994a-6f54561c9e9d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_070b4173-8a21-4a91-ad2d-ed12ee03c0e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bb2d6868-ee23-40bd-8117-04252837b24f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93a611cf-9bfa-4881-994a-6f54561c9e9d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bb2d6868-ee23-40bd-8117-04252837b24f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c69c9593-23e4-4fd6-8092-28fbbead6afc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6db3817e-decc-4020-a00e-2d815c413d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c69c9593-23e4-4fd6-8092-28fbbead6afc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6db3817e-decc-4020-a00e-2d815c413d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_82827827-1e8f-4665-9726-64589471cacb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c69c9593-23e4-4fd6-8092-28fbbead6afc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_82827827-1e8f-4665-9726-64589471cacb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c7fcc72-974b-4743-afc1-dc354377470d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c69c9593-23e4-4fd6-8092-28fbbead6afc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c7fcc72-974b-4743-afc1-dc354377470d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_97de93f1-dfea-48b6-9df4-92a525b41532" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c69c9593-23e4-4fd6-8092-28fbbead6afc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_97de93f1-dfea-48b6-9df4-92a525b41532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_48cf3d12-18b5-41f3-b003-c89b81298cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c69c9593-23e4-4fd6-8092-28fbbead6afc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_48cf3d12-18b5-41f3-b003-c89b81298cd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_77b5cfec-eaa6-4724-96b4-40beb207630e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c69c9593-23e4-4fd6-8092-28fbbead6afc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_77b5cfec-eaa6-4724-96b4-40beb207630e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#LeasesScheduleofComponentsofTotalLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinanceLeaseCost_81079c70-585a-47ec-be79-064ae7fb2c25" xlink:href="dna-20251231.xsd#dna_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_780a63db-d1d5-411d-8de7-59eaac34cbef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dna_FinanceLeaseCost_81079c70-585a-47ec-be79-064ae7fb2c25" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_780a63db-d1d5-411d-8de7-59eaac34cbef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3007fdb1-a549-4345-ad5c-10851036cf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dna_FinanceLeaseCost_81079c70-585a-47ec-be79-064ae7fb2c25" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3007fdb1-a549-4345-ad5c-10851036cf1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c3a31601-aa4f-4cc9-a510-9f76d6e41eee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5654cfd5-d268-46b8-b48a-8686d625cee4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c3a31601-aa4f-4cc9-a510-9f76d6e41eee" xlink:to="loc_us-gaap_OperatingLeaseCost_5654cfd5-d268-46b8-b48a-8686d625cee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinanceLeaseCost_7294c97f-3281-4a4f-892f-7e355c8edb84" xlink:href="dna-20251231.xsd#dna_FinanceLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c3a31601-aa4f-4cc9-a510-9f76d6e41eee" xlink:to="loc_dna_FinanceLeaseCost_7294c97f-3281-4a4f-892f-7e355c8edb84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_d7bd6c4e-ce1d-4db8-9aa2-1da620a3a117" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c3a31601-aa4f-4cc9-a510-9f76d6e41eee" xlink:to="loc_us-gaap_VariableLeaseCost_d7bd6c4e-ce1d-4db8-9aa2-1da620a3a117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_6def95a8-fc1f-43c5-bcc1-92967540c21a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c3a31601-aa4f-4cc9-a510-9f76d6e41eee" xlink:to="loc_us-gaap_SubleaseIncome_6def95a8-fc1f-43c5-bcc1-92967540c21a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8a04278f-886e-4bd3-b833-0cd8639a7af8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_911cba68-05a9-4605-b567-573aaf73f6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8a04278f-886e-4bd3-b833-0cd8639a7af8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_911cba68-05a9-4605-b567-573aaf73f6ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_69aa7727-b892-41de-8993-c9108b0ab295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8a04278f-886e-4bd3-b833-0cd8639a7af8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_69aa7727-b892-41de-8993-c9108b0ab295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_13b7cd40-0780-4fcb-9483-1d4ae923083f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8a04278f-886e-4bd3-b833-0cd8639a7af8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_13b7cd40-0780-4fcb-9483-1d4ae923083f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_0c342c4e-7ea0-4598-8424-4e0a5915b161" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8a04278f-886e-4bd3-b833-0cd8639a7af8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_0c342c4e-7ea0-4598-8424-4e0a5915b161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_59a2dcdc-5ec0-4fe9-8e6c-daa037e68ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8a04278f-886e-4bd3-b833-0cd8639a7af8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_59a2dcdc-5ec0-4fe9-8e6c-daa037e68ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_076820bb-6a71-4397-b096-ea779d6727d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8a04278f-886e-4bd3-b833-0cd8639a7af8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_076820bb-6a71-4397-b096-ea779d6727d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_73126696-4582-48fa-bc7e-7432b49e4e03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_af8d81b2-c50a-4e28-a210-0de7194097bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_73126696-4582-48fa-bc7e-7432b49e4e03" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_af8d81b2-c50a-4e28-a210-0de7194097bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d0f876ae-f3f4-4dc0-b48a-4194e557d66a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_102cd48c-2765-4f84-b0b5-0ffa468b20b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d0f876ae-f3f4-4dc0-b48a-4194e557d66a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_102cd48c-2765-4f84-b0b5-0ffa468b20b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a21eada5-6fa9-4880-99c6-95df8f6b6305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d0f876ae-f3f4-4dc0-b48a-4194e557d66a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a21eada5-6fa9-4880-99c6-95df8f6b6305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73560a61-39c3-4142-90c3-dc5a89db36d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1bf35d45-1ef5-4e1e-a93a-f0a3f7315012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73560a61-39c3-4142-90c3-dc5a89db36d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1bf35d45-1ef5-4e1e-a93a-f0a3f7315012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b5dfc70b-e532-4391-852a-e1b9c1b5cecc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73560a61-39c3-4142-90c3-dc5a89db36d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b5dfc70b-e532-4391-852a-e1b9c1b5cecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c3db4749-e7e9-4382-9d6b-7d4d6f8f7b49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73560a61-39c3-4142-90c3-dc5a89db36d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c3db4749-e7e9-4382-9d6b-7d4d6f8f7b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c8b9c2e1-b539-4da5-8e47-4e3f6655af55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73560a61-39c3-4142-90c3-dc5a89db36d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c8b9c2e1-b539-4da5-8e47-4e3f6655af55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9483d2ce-16ba-495a-830f-b4e88409348a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73560a61-39c3-4142-90c3-dc5a89db36d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9483d2ce-16ba-495a-830f-b4e88409348a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d81ffa0c-e658-4655-9611-42ce2c5f22d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73560a61-39c3-4142-90c3-dc5a89db36d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d81ffa0c-e658-4655-9611-42ce2c5f22d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_580a493c-ec47-428f-ba9d-792c48a24d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_e9d2da21-e5d3-41d5-b58b-8705f480d009" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_580a493c-ec47-428f-ba9d-792c48a24d3f" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_e9d2da21-e5d3-41d5-b58b-8705f480d009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_db8d858d-85a7-44f7-bd6d-a52e83ed49ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_580a493c-ec47-428f-ba9d-792c48a24d3f" xlink:to="loc_us-gaap_RestrictedCashCurrent_db8d858d-85a7-44f7-bd6d-a52e83ed49ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_175156f3-74e9-4861-ae39-c3da2d74f060" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_580a493c-ec47-428f-ba9d-792c48a24d3f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_175156f3-74e9-4861-ae39-c3da2d74f060" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3ffc3c4d-7598-4177-9d3b-c55b42a76cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_96343657-6f47-4848-adae-70bb87b50bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3ffc3c4d-7598-4177-9d3b-c55b42a76cb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_96343657-6f47-4848-adae-70bb87b50bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eb116d2b-6d4c-4b98-aa11-9d1581d00522" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3ffc3c4d-7598-4177-9d3b-c55b42a76cb6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eb116d2b-6d4c-4b98-aa11-9d1581d00522" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1227e173-c8b0-4d77-a05f-545dac59b780" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1227e173-c8b0-4d77-a05f-545dac59b780" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContractualShortfallLiabilityCurrent_356e1dd1-1266-48a0-9c7d-6ce41ebf7534" xlink:href="dna-20251231.xsd#dna_ContractualShortfallLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_dna_ContractualShortfallLiabilityCurrent_356e1dd1-1266-48a0-9c7d-6ce41ebf7534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5bff0886-ac2e-4137-a752-9ee4ad6805d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5bff0886-ac2e-4137-a752-9ee4ad6805d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent_bfbe4e86-5e41-4e60-be5c-711d790d09e5" xlink:href="dna-20251231.xsd#dna_AccruedBiosecurityServiceRevenueAccrualsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent_bfbe4e86-5e41-4e60-be5c-711d790d09e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_02ff86d3-942a-478a-9f0d-d3cd1ebc5aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_02ff86d3-942a-478a-9f0d-d3cd1ebc5aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_b55f731e-9b44-41f2-8fed-ab3db609a0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_b55f731e-9b44-41f2-8fed-ab3db609a0f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent_142639bc-13c3-49be-97d9-cfb38673d644" xlink:href="dna-20251231.xsd#dna_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent_142639bc-13c3-49be-97d9-cfb38673d644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_37738ae5-4084-46c1-8105-89210294fe9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_us-gaap_DeferredIncome_37738ae5-4084-46c1-8105-89210294fe9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedEmployeeTerminationCosts_2eb926aa-beb0-4227-be6c-6afce23d924d" xlink:href="dna-20251231.xsd#dna_AccruedEmployeeTerminationCosts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_dna_AccruedEmployeeTerminationCosts_2eb926aa-beb0-4227-be6c-6afce23d924d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f6b81c2a-92e5-4ec8-a6cf-6652cb0f5f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f6b81c2a-92e5-4ec8-a6cf-6652cb0f5f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedPropertyAndEquipmentCurrent_0f0f3d48-75c5-44c4-b16d-04ca1b48b0e2" xlink:href="dna-20251231.xsd#dna_AccruedPropertyAndEquipmentCurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_dna_AccruedPropertyAndEquipmentCurrent_0f0f3d48-75c5-44c4-b16d-04ca1b48b0e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019c9017-4575-714e-a0d5-c561ec112731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1ecd200b-6648-49e1-811f-3d492b659bd5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019c9017-4575-714e-a0d5-c561ec112731" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b0138861-6a11-4630-940a-3617f1ef935d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e7a55723-a9e7-415e-b621-6bc557a84bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b0138861-6a11-4630-940a-3617f1ef935d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e7a55723-a9e7-415e-b621-6bc557a84bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0423ce8d-d66d-4526-ae83-f26ce8bc8154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b0138861-6a11-4630-940a-3617f1ef935d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0423ce8d-d66d-4526-ae83-f26ce8bc8154" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1bb401c2-f4c1-411e-b6b5-0de3cc7f08da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b45194b7-7a78-46c4-9b57-02cf21a3846c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1bb401c2-f4c1-411e-b6b5-0de3cc7f08da" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b45194b7-7a78-46c4-9b57-02cf21a3846c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_868740cb-2913-4979-9542-2a4521e5f85d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1bb401c2-f4c1-411e-b6b5-0de3cc7f08da" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_868740cb-2913-4979-9542-2a4521e5f85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7619f547-52a1-44f3-9ed4-d7d17741ba89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_92148e4a-9219-4445-9375-d390e2291e26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7619f547-52a1-44f3-9ed4-d7d17741ba89" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_92148e4a-9219-4445-9375-d390e2291e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b0f71246-8449-4545-bc62-8b39b2f8e0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7619f547-52a1-44f3-9ed4-d7d17741ba89" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b0f71246-8449-4545-bc62-8b39b2f8e0d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fa826cb3-b1cf-45fa-9e65-89f0b35a23a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fa826cb3-b1cf-45fa-9e65-89f0b35a23a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3c9cd1e8-71bc-4f2a-9742-8c6bc3095e81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3c9cd1e8-71bc-4f2a-9742-8c6bc3095e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ca1d4a44-e47b-478c-8508-aa867551c2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ca1d4a44-e47b-478c-8508-aa867551c2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5b947f65-1369-4c21-9706-afee56629dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5b947f65-1369-4c21-9706-afee56629dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent_5577ca3c-addc-4033-8dfb-075d96465fc3" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent_5577ca3c-addc-4033-8dfb-075d96465fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent_930c2f02-4728-453e-b5cc-bf6c3f8b04ed" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent_930c2f02-4728-453e-b5cc-bf6c3f8b04ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_e7fdbe94-a961-4363-9090-8bee36bc7b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_e7fdbe94-a961-4363-9090-8bee36bc7b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_7d961b1e-efbf-4d33-8c03-728dd5694a18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_7d961b1e-efbf-4d33-8c03-728dd5694a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c5cc9-cfbf-7218-8b1b-cbd30472c4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c5cc9-cfbf-7218-8b1b-cbd30472c4c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c5cc9-cfbf-7d31-a2cc-484bcddd0e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c5cc9-cfbf-7d31-a2cc-484bcddd0e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_019c5ccf-0e17-7eeb-8405-7c6da1d8fa44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e93e5ba8-305c-4ca4-9f61-d49b78a7a183" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_019c5ccf-0e17-7eeb-8405-7c6da1d8fa44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c5ccc-43ba-7172-91b6-f9f1fe9b7ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c5ccc-43ba-7172-91b6-f9f1fe9b7ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c5ccc-43ba-7532-9a10-93ce12e6a388" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c5ccc-43ba-7532-9a10-93ce12e6a388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c5ccc-43ba-710d-af98-8b2ac1fc2a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c5ccc-43ba-710d-af98-8b2ac1fc2a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c5ccc-43ba-7df2-afb2-3460c30f829e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c5ccc-43ba-7df2-afb2-3460c30f829e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount_019c5ccc-43ba-7f67-aba1-b2c9fd6ca235" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount_019c5ccc-43ba-7f67-aba1-b2c9fd6ca235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount_019c5ccc-43ba-7ca9-b77a-df178e3628ba" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount_019c5ccc-43ba-7ca9-b77a-df178e3628ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c5ccc-43ba-7f26-8650-0471c4c46ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c5ccc-43ba-7f26-8650-0471c4c46ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c5ccc-43ba-7a31-9484-69d8daad9cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c5ccc-43ba-7a31-9484-69d8daad9cc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c5ccc-43ba-7c27-b00a-3b5a70050f20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c5ccc-43ba-7c27-b00a-3b5a70050f20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c5ccc-43ba-7e0b-8ca4-6c7af39af74b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-43ba-7160-87d0-8e417d521c08" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c5ccc-43ba-7e0b-8ca4-6c7af39af74b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_46729028-9348-41de-a7eb-ac2cb633964f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_292aa9ab-1ffb-48d7-b392-e56f4cfb070e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_46729028-9348-41de-a7eb-ac2cb633964f" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_292aa9ab-1ffb-48d7-b392-e56f4cfb070e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1f1f6b8e-2eaa-4e20-addd-c43b6abedb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_46729028-9348-41de-a7eb-ac2cb633964f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1f1f6b8e-2eaa-4e20-addd-c43b6abedb5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0fe21305-205c-4992-a0c3-50127f159872" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxLiabilitiesAmortizableIntangibles_c53d97a7-9407-4bcd-bbad-0708e327506f" xlink:href="dna-20251231.xsd#dna_DeferredTaxLiabilitiesAmortizableIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0fe21305-205c-4992-a0c3-50127f159872" xlink:to="loc_dna_DeferredTaxLiabilitiesAmortizableIntangibles_c53d97a7-9407-4bcd-bbad-0708e327506f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_042d8ed1-7884-4ffc-8b3a-e90c3c6d6efd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0fe21305-205c-4992-a0c3-50127f159872" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_042d8ed1-7884-4ffc-8b3a-e90c3c6d6efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_497ac97e-ce57-46d5-89b7-c6385d53f469" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0fe21305-205c-4992-a0c3-50127f159872" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_497ac97e-ce57-46d5-89b7-c6385d53f469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0eca5b6a-4898-42f7-a92d-3b6bc99f413f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_41da673b-d44e-4315-b669-67766f33c106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_0eca5b6a-4898-42f7-a92d-3b6bc99f413f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_41da673b-d44e-4315-b669-67766f33c106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_044a3d20-fa6b-4196-b04c-8cd70880b2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_0eca5b6a-4898-42f7-a92d-3b6bc99f413f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_044a3d20-fa6b-4196-b04c-8cd70880b2a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3ece00c2-43a6-4614-8a54-6958e8795f68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3ece00c2-43a6-4614-8a54-6958e8795f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4865fe3a-32a0-4e98-ba5a-52d554a87fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4865fe3a-32a0-4e98-ba5a-52d554a87fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_24002e83-81a7-412f-893c-e19e7e2f6fde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_24002e83-81a7-412f-893c-e19e7e2f6fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_7fa4f043-3ce6-4727-a574-9129a866277f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_7fa4f043-3ce6-4727-a574-9129a866277f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsDeferredRevenue_e8b99b26-bad4-4db0-a4a6-2f7af33e3a3f" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsDeferredRevenue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_dna_DeferredTaxAssetsDeferredRevenue_e8b99b26-bad4-4db0-a4a6-2f7af33e3a3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_77d8de05-6228-40e4-8622-7a41b420bf90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_77d8de05-6228-40e4-8622-7a41b420bf90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsAmortizableIntangibles_d271a054-5e16-4806-b879-f4731a73dab1" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsAmortizableIntangibles"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_dna_DeferredTaxAssetsAmortizableIntangibles_d271a054-5e16-4806-b879-f4731a73dab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsLeaseLiabilities_a7b5a267-3579-401d-a01b-33e3e3019cf0" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_dna_DeferredTaxAssetsLeaseLiabilities_a7b5a267-3579-401d-a01b-33e3e3019cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsInvestmentsInSubsidiaries_305e704c-5599-42a5-90eb-19b851985ce1" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsInvestmentsInSubsidiaries"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_dna_DeferredTaxAssetsInvestmentsInSubsidiaries_305e704c-5599-42a5-90eb-19b851985ce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1e64361a-4126-4669-997a-5848f2e1f5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1e64361a-4126-4669-997a-5848f2e1f5d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_019c902c-a34d-7d53-9adc-ffb7bd024ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2024bdf3-6180-4ff5-a05a-d9eb8c97f7ea" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_019c902c-a34d-7d53-9adc-ffb7bd024ef8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesTaxPaidDetails"/>
  <link:calculationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c5cd0-7f6d-76a0-afb5-53040f9e758f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c5cd0-7f6d-7b25-bca0-8ae76f65037d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_019c5cd0-7f6d-76a0-afb5-53040f9e758f" xlink:to="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c5cd0-7f6d-7b25-bca0-8ae76f65037d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c5cd0-7f6d-7b2a-b6d8-255b6b34e20b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_019c5cd0-7f6d-76a0-afb5-53040f9e758f" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c5cd0-7f6d-7b2a-b6d8-255b6b34e20b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019c5cd0-7f6d-7595-9673-c28cca22570f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_019c5cd0-7f6d-76a0-afb5-53040f9e758f" xlink:to="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019c5cd0-7f6d-7595-9673-c28cca22570f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>dna-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:52002c9c-7569-4bc2-a5b5-c24c0eeac02a,g:42911b52-7f60-440e-93d3-9584b5edbad8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/Cover" xlink:type="simple" xlink:href="dna-20251231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_7a8684e8-3685-4d09-b453-bafff921d43c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentInformationTable_7a8684e8-3685-4d09-b453-bafff921d43c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cef99515-8855-4fc5-a234-c2df86b73eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_7a8684e8-3685-4d09-b453-bafff921d43c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cef99515-8855-4fc5-a234-c2df86b73eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cef99515-8855-4fc5-a234-c2df86b73eb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cef99515-8855-4fc5-a234-c2df86b73eb4" xlink:to="loc_us-gaap_ClassOfStockDomain_cef99515-8855-4fc5-a234-c2df86b73eb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cef99515-8855-4fc5-a234-c2df86b73eb4" xlink:to="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3a4b70b2-0f59-4ebe-9c6e-1a8ca709f73a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:to="loc_us-gaap_CommonClassAMember_3a4b70b2-0f59-4ebe-9c6e-1a8ca709f73a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_6f1dd95a-a2df-4b1e-944e-31d96d55e62a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:to="loc_us-gaap_CommonClassBMember_6f1dd95a-a2df-4b1e-944e-31d96d55e62a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvotingCommonStockMember_2476eb81-d734-4c57-8fad-ad2a4a12c2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:to="loc_us-gaap_NonvotingCommonStockMember_2476eb81-d734-4c57-8fad-ad2a4a12c2c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_042b89eb-9fcc-4a31-82a5-6004fab5c6cf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentType_042b89eb-9fcc-4a31-82a5-6004fab5c6cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_af3d6dad-3e43-446f-ae07-be22f7cba2ae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentAnnualReport_af3d6dad-3e43-446f-ae07-be22f7cba2ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_85bf9cb7-0e94-4cc9-9673-a7861906a888" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentPeriodEndDate_85bf9cb7-0e94-4cc9-9673-a7861906a888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_977ade8b-64a6-45ec-ae5e-6df1def095db" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_CurrentFiscalYearEndDate_977ade8b-64a6-45ec-ae5e-6df1def095db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_981a6a81-b05b-4d35-98dd-ec9f5d840609" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentTransitionReport_981a6a81-b05b-4d35-98dd-ec9f5d840609" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0f4626d5-3d5b-4fc9-9a1f-dcd098518d6c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityFileNumber_0f4626d5-3d5b-4fc9-9a1f-dcd098518d6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5158f889-1e20-4239-a1ab-f6722d242c02" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityRegistrantName_5158f889-1e20-4239-a1ab-f6722d242c02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f3cafa1a-8ba4-4f56-88cb-5fe53bc992e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f3cafa1a-8ba4-4f56-88cb-5fe53bc992e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_51d7dbf3-4576-4ec6-b75a-0a563da91294" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityTaxIdentificationNumber_51d7dbf3-4576-4ec6-b75a-0a563da91294" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f85eefb2-cd34-4a44-a97b-861bea1f60be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressAddressLine1_f85eefb2-cd34-4a44-a97b-861bea1f60be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_db3dc2ea-608f-463f-95fe-772e1c87c5c6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressAddressLine2_db3dc2ea-608f-463f-95fe-772e1c87c5c6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f728e6cf-015f-4207-8009-6bca8009914d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressCityOrTown_f728e6cf-015f-4207-8009-6bca8009914d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_03887e3a-dcba-4f45-a015-cddbeef915fd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressStateOrProvince_03887e3a-dcba-4f45-a015-cddbeef915fd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bc003bdc-0c0a-4ff9-a337-e3411eb5b768" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressPostalZipCode_bc003bdc-0c0a-4ff9-a337-e3411eb5b768" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_56c76648-2410-4b3f-b4db-24c72e8273ad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_CityAreaCode_56c76648-2410-4b3f-b4db-24c72e8273ad" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4fc5bbe6-d62d-456d-af94-0e71bda28dbf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_LocalPhoneNumber_4fc5bbe6-d62d-456d-af94-0e71bda28dbf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a02a832-ea50-4f0d-b09d-f9d682c7bc0c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_Security12bTitle_4a02a832-ea50-4f0d-b09d-f9d682c7bc0c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ffdc0466-d73b-48db-8c28-6f9fb57bf4aa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_TradingSymbol_ffdc0466-d73b-48db-8c28-6f9fb57bf4aa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6d55b202-aba3-4c4a-ac4f-fb7985890d5f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_SecurityExchangeName_6d55b202-aba3-4c4a-ac4f-fb7985890d5f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7bc7e58e-9da4-48c6-8495-77b887358952" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7bc7e58e-9da4-48c6-8495-77b887358952" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d854d89e-f45e-46f5-a877-49cbecec1625" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityVoluntaryFilers_d854d89e-f45e-46f5-a877-49cbecec1625" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8583a3b6-f7a2-40c8-9ffb-fbd0f9a97dbd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityCurrentReportingStatus_8583a3b6-f7a2-40c8-9ffb-fbd0f9a97dbd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fe70b27f-cee5-4d52-8aae-86ac9d291c96" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityInteractiveDataCurrent_fe70b27f-cee5-4d52-8aae-86ac9d291c96" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_07daf951-0ca5-4a94-8ad6-c0aa2efa44e0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityFilerCategory_07daf951-0ca5-4a94-8ad6-c0aa2efa44e0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dff4ab27-ec4f-4c05-81fc-ee1712535355" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntitySmallBusiness_dff4ab27-ec4f-4c05-81fc-ee1712535355" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_332494ae-e32f-4de7-91a4-6112a49086d3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityEmergingGrowthCompany_332494ae-e32f-4de7-91a4-6112a49086d3" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_f11c7dae-0228-4c7e-838a-9ff2bfd795e4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_f11c7dae-0228-4c7e-838a-9ff2bfd795e4" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_0dca4b85-a832-4144-969c-c1651c14166e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_0dca4b85-a832-4144-969c-c1651c14166e" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6ee8df24-a9fc-42c2-8b2a-d119d7614325" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityShellCompany_6ee8df24-a9fc-42c2-8b2a-d119d7614325" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_88f05479-72eb-409a-a549-eb4f9ccb323c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityPublicFloat_88f05479-72eb-409a-a549-eb4f9ccb323c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d17b3948-7533-4cac-bc52-79208dc0b78a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d17b3948-7533-4cac-bc52-79208dc0b78a" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_87701677-fad8-43c5-b9b8-5a21ee4d90a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_87701677-fad8-43c5-b9b8-5a21ee4d90a4" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ba4cad89-06bf-4e6a-84bf-1531fccc1d5f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_AmendmentFlag_ba4cad89-06bf-4e6a-84bf-1531fccc1d5f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7dd79db6-849c-4dca-b7d0-1caf7d92a3a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentFiscalYearFocus_7dd79db6-849c-4dca-b7d0-1caf7d92a3a4" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_dc96d48c-2766-454b-9080-29e927db378e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_dc96d48c-2766-454b-9080-29e927db378e" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6dcb9f85-f23b-4170-aa5f-5376203bf1df" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityCentralIndexKey_6dcb9f85-f23b-4170-aa5f-5376203bf1df" xlink:type="arc" order="35"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d2df620b-2f40-475e-b9d3-e73a8bf8e619" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_StatementTable_d2df620b-2f40-475e-b9d3-e73a8bf8e619" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfc19669-15a1-4884-82e3-1af61367807c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d2df620b-2f40-475e-b9d3-e73a8bf8e619" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfc19669-15a1-4884-82e3-1af61367807c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cfc19669-15a1-4884-82e3-1af61367807c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfc19669-15a1-4884-82e3-1af61367807c" xlink:to="loc_us-gaap_RelatedPartyDomain_cfc19669-15a1-4884-82e3-1af61367807c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_62b179d8-6acb-4595-a720-157f4481db6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfc19669-15a1-4884-82e3-1af61367807c" xlink:to="loc_us-gaap_RelatedPartyDomain_62b179d8-6acb-4595-a720-157f4481db6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_96929a93-8163-4b09-a39d-fe25942f0d34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_62b179d8-6acb-4595-a720-157f4481db6a" xlink:to="loc_us-gaap_RelatedPartyMember_96929a93-8163-4b09-a39d-fe25942f0d34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a3c23d95-af92-40f1-ac14-be8a3efb6608" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a3c23d95-af92-40f1-ac14-be8a3efb6608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7df3324f-83a3-4674-af89-8109e8f6af79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7df3324f-83a3-4674-af89-8109e8f6af79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_54f44cf5-1b0a-45fc-8b92-aefcac258e65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_54f44cf5-1b0a-45fc-8b92-aefcac258e65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e5b6ba09-4424-4522-ada4-e92b56e38fec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e5b6ba09-4424-4522-ada4-e92b56e38fec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_476cf4af-63bd-43a0-b81f-573d156035c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_476cf4af-63bd-43a0-b81f-573d156035c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eb522fec-f709-4b45-b66b-71f27be9c564" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eb522fec-f709-4b45-b66b-71f27be9c564" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_423753ab-013e-4f22-831f-c9b5e8e066b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_StatementTable_423753ab-013e-4f22-831f-c9b5e8e066b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c3905eb5-204d-415a-a7f6-40d7df20f6b9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_423753ab-013e-4f22-831f-c9b5e8e066b2" xlink:to="loc_srt_ProductOrServiceAxis_c3905eb5-204d-415a-a7f6-40d7df20f6b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3905eb5-204d-415a-a7f6-40d7df20f6b9_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c3905eb5-204d-415a-a7f6-40d7df20f6b9" xlink:to="loc_srt_ProductsAndServicesDomain_c3905eb5-204d-415a-a7f6-40d7df20f6b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c3905eb5-204d-415a-a7f6-40d7df20f6b9" xlink:to="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringRevenueMember_104a1aae-98f3-4db2-ab4a-d37c3992bbc1" xlink:href="dna-20251231.xsd#dna_CellEngineeringRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:to="loc_dna_CellEngineeringRevenueMember_104a1aae-98f3-4db2-ab4a-d37c3992bbc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_8952d83a-9095-4662-abd0-56548af4d3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:to="loc_us-gaap_ServiceMember_8952d83a-9095-4662-abd0-56548af4d3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2cb6a374-c384-4eed-8f29-793127eb5a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:to="loc_us-gaap_ProductMember_2cb6a374-c384-4eed-8f29-793127eb5a2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ee70d815-90b0-4e44-9d33-c1541e71b7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ee70d815-90b0-4e44-9d33-c1541e71b7d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8668557-1ed8-419e-b871-147a79ea9451" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8668557-1ed8-419e-b871-147a79ea9451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5920d920-2a09-41dc-85b5-8c354c623c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5920d920-2a09-41dc-85b5-8c354c623c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_489d15c1-15ff-4e35-bbd4-fb60f366ec92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_489d15c1-15ff-4e35-bbd4-fb60f366ec92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c00ad635-8c3b-436a-b117-d34ae7c033eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c00ad635-8c3b-436a-b117-d34ae7c033eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_e41b74e2-3ec9-4999-ab2f-d9edf1d9f7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_e41b74e2-3ec9-4999-ab2f-d9edf1d9f7ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0f50657a-d99d-4e80-b0dc-ea34feeed10d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0f50657a-d99d-4e80-b0dc-ea34feeed10d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_1b556974-8f74-4df9-86cc-e099cba361ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_1b556974-8f74-4df9-86cc-e099cba361ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8b8160e0-84a1-4b49-921a-6f4d4ca974e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_OperatingExpenses_8b8160e0-84a1-4b49-921a-6f4d4ca974e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3c5b6472-6738-48eb-b027-7ca70006abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_OperatingIncomeLoss_3c5b6472-6738-48eb-b027-7ca70006abbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_17bb52e5-0850-4333-9767-e86e137dd0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_InterestIncomeOther_17bb52e5-0850-4333-9767-e86e137dd0a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_b98bf6f2-98b3-4432-a013-3db823fa3151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_InterestExpenseNonoperating_b98bf6f2-98b3-4432-a013-3db823fa3151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_937f67b7-53ce-4067-8ad6-0a6e9f8c3d07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_937f67b7-53ce-4067-8ad6-0a6e9f8c3d07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_8bbc9e5f-d5ea-4ecb-9b83-eaa743a42569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_GainLossOnInvestments_8bbc9e5f-d5ea-4ecb-9b83-eaa743a42569" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_141d8348-9660-438d-a2e8-9cbd44d9a566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_141d8348-9660-438d-a2e8-9cbd44d9a566" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_6f49eddf-90af-40a3-9c4d-3d0a269b8358" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_6f49eddf-90af-40a3-9c4d-3d0a269b8358" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_5e5f9cf1-69f4-414a-b639-a90536634c32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_5e5f9cf1-69f4-414a-b639-a90536634c32" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2ef9c493-b129-42ce-872e-f2a0b3ae66cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2ef9c493-b129-42ce-872e-f2a0b3ae66cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4338c8d6-a5f9-4972-b47b-bfe97faa6859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4338c8d6-a5f9-4972-b47b-bfe97faa6859" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_61d6e4cf-1342-4fb6-9128-4242b0084e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_61d6e4cf-1342-4fb6-9128-4242b0084e8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c4efa-94ed-7c4c-ac50-59af7a5aaa86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_NetIncomeLoss_019c4efa-94ed-7c4c-ac50-59af7a5aaa86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a2f8f1e1-fb75-4fbe-ad85-8350b2372b89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a2f8f1e1-fb75-4fbe-ad85-8350b2372b89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6e59624f-02b3-4085-9995-201a217890ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2f8f1e1-fb75-4fbe-ad85-8350b2372b89" xlink:to="loc_us-gaap_EarningsPerShareBasic_6e59624f-02b3-4085-9995-201a217890ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a7353990-0b01-4f26-9d45-9a7e32ef8071" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2f8f1e1-fb75-4fbe-ad85-8350b2372b89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a7353990-0b01-4f26-9d45-9a7e32ef8071" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_efe32c16-9080-4d3a-99db-31524eb5e0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_efe32c16-9080-4d3a-99db-31524eb5e0fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e8f5344b-b453-467a-bad3-9e7fbc7667cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_efe32c16-9080-4d3a-99db-31524eb5e0fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e8f5344b-b453-467a-bad3-9e7fbc7667cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c68cd-a8d3-72e5-bb83-064d6b98acfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_efe32c16-9080-4d3a-99db-31524eb5e0fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c68cd-a8d3-72e5-bb83-064d6b98acfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_952df6cb-4bfb-4804-8acc-1eadd301e336" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_952df6cb-4bfb-4804-8acc-1eadd301e336" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c4efa-1c84-795b-a7bb-8b0d63f02989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_952df6cb-4bfb-4804-8acc-1eadd301e336" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-f535-7c3c-a1dd-5b83f403ee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-f535-7c3c-a1dd-5b83f403ee2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_85571dff-d458-4433-992a-dd3dd473d547" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_85571dff-d458-4433-992a-dd3dd473d547" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-8084-7902-85dd-c532a4bc719e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-8084-7902-85dd-c532a4bc719e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7b067bda-e44b-4cb2-82d4-eadc2b711579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7b067bda-e44b-4cb2-82d4-eadc2b711579" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e339b8d-41cd-4d56-b47c-f06e8f39174c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_952df6cb-4bfb-4804-8acc-1eadd301e336" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e339b8d-41cd-4d56-b47c-f06e8f39174c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_342478a4-a4c1-4405-99c0-341c1036edf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e6170364-da8b-408a-9e3d-f4ab5b8b28e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_342478a4-a4c1-4405-99c0-341c1036edf0" xlink:to="loc_us-gaap_StatementTable_e6170364-da8b-408a-9e3d-f4ab5b8b28e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b703d51-6965-4253-8d64-dcd964376401" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e6170364-da8b-408a-9e3d-f4ab5b8b28e3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b703d51-6965-4253-8d64-dcd964376401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1b703d51-6965-4253-8d64-dcd964376401_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b703d51-6965-4253-8d64-dcd964376401" xlink:to="loc_us-gaap_RelatedPartyDomain_1b703d51-6965-4253-8d64-dcd964376401_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6efa734d-ebbc-4e72-9b65-9fb774ea4a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b703d51-6965-4253-8d64-dcd964376401" xlink:to="loc_us-gaap_RelatedPartyDomain_6efa734d-ebbc-4e72-9b65-9fb774ea4a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_c054769a-3d37-43c9-88c2-12593c412074" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6efa734d-ebbc-4e72-9b65-9fb774ea4a57" xlink:to="loc_us-gaap_RelatedPartyMember_c054769a-3d37-43c9-88c2-12593c412074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb889d43-d854-4104-874f-15076a013224" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_342478a4-a4c1-4405-99c0-341c1036edf0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb889d43-d854-4104-874f-15076a013224" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_766e4fd3-86d5-400e-92fc-f61ceafd4cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f4c0d99c-7fac-4a5a-9681-dbd3fc8f5950" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_766e4fd3-86d5-400e-92fc-f61ceafd4cfd" xlink:to="loc_us-gaap_StatementTable_f4c0d99c-7fac-4a5a-9681-dbd3fc8f5950" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ed08ea5-27c6-4189-ad86-99219cfe1e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f4c0d99c-7fac-4a5a-9681-dbd3fc8f5950" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ed08ea5-27c6-4189-ad86-99219cfe1e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ed08ea5-27c6-4189-ad86-99219cfe1e3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ed08ea5-27c6-4189-ad86-99219cfe1e3f" xlink:to="loc_us-gaap_EquityComponentDomain_5ed08ea5-27c6-4189-ad86-99219cfe1e3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ed08ea5-27c6-4189-ad86-99219cfe1e3f" xlink:to="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fa5a9141-9e45-4e33-a420-4e79d5cc573d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:to="loc_us-gaap_CommonStockMember_fa5a9141-9e45-4e33-a420-4e79d5cc573d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_632080cf-a46a-46a2-8f58-e9b08858e43b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_632080cf-a46a-46a2-8f58-e9b08858e43b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_90f758f9-ae85-4545-9d35-1821544791e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:to="loc_us-gaap_RetainedEarningsMember_90f758f9-ae85-4545-9d35-1821544791e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d75059cf-2ef2-4501-a9bb-d0557ca913ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d75059cf-2ef2-4501-a9bb-d0557ca913ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_766e4fd3-86d5-400e-92fc-f61ceafd4cfd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5fe79e9e-b066-47ae-92f2-8546208abb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5fe79e9e-b066-47ae-92f2-8546208abb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c4f00-3516-7d1e-a3d3-7da777632bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockholdersEquity_019c4f00-3516-7d1e-a3d3-7da777632bfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_14b18154-c802-43b9-a943-9f93998480a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_14b18154-c802-43b9-a943-9f93998480a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_7c1946e2-86d4-4959-ad48-c3609c92e72f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_7c1946e2-86d4-4959-ad48-c3609c92e72f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e128deca-1137-470e-a1e1-7bcf1f7d6b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e128deca-1137-470e-a1e1-7bcf1f7d6b2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockAwardForfeitures_019c68f8-d001-762e-84b2-2f0fdf29c11a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockAwardForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_RestrictedStockAwardForfeitures_019c68f8-d001-762e-84b2-2f0fdf29c11a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_97455451-80e2-4f26-a973-466ff7090959" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_97455451-80e2-4f26-a973-466ff7090959" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SettlementOfContingentConsiderationSharesRestrictedStock_e44f2a3b-6e61-463e-947f-99573b64668a" xlink:href="dna-20251231.xsd#dna_SettlementOfContingentConsiderationSharesRestrictedStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_dna_SettlementOfContingentConsiderationSharesRestrictedStock_e44f2a3b-6e61-463e-947f-99573b64668a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SettlementOfContingentConsiderationValueRestrictedStock_3a632f4e-c34e-4e20-a1ae-ff3f98723f9d" xlink:href="dna-20251231.xsd#dna_SettlementOfContingentConsiderationValueRestrictedStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_dna_SettlementOfContingentConsiderationValueRestrictedStock_3a632f4e-c34e-4e20-a1ae-ff3f98723f9d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_036194e7-1cc5-4837-ad04-ba25740bcb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_036194e7-1cc5-4837-ad04-ba25740bcb2a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f0c4d094-9e7c-4e8c-8726-3aa1f2b8d9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f0c4d094-9e7c-4e8c-8726-3aa1f2b8d9ef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ded538f8-8d0d-4898-8d08-9459644f3b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ded538f8-8d0d-4898-8d08-9459644f3b8d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0ddb11d-abcc-4ee4-bbf8-026bbd0679b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0ddb11d-abcc-4ee4-bbf8-026bbd0679b5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23ea668a-7e27-427f-a6bb-fd2fb717a4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23ea668a-7e27-427f-a6bb-fd2fb717a4c9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_02556bf0-3678-4b8c-9166-f88809c8233c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_02556bf0-3678-4b8c-9166-f88809c8233c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_08340fa8-676d-428d-8f26-5cae47bf05ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_08340fa8-676d-428d-8f26-5cae47bf05ad" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019c4f03-27a2-7ec4-bfac-b70db48c8eea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019c4f03-27a2-7ec4-bfac-b70db48c8eea" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c4f03-6644-7416-84b3-217c5dae7907" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_NetIncomeLoss_019c4f03-6644-7416-84b3-217c5dae7907" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_addafa99-9635-4efd-ae18-38ddb9c59e48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_addafa99-9635-4efd-ae18-38ddb9c59e48" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c4f02-77f6-76e5-b086-4b293747e00d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c4f02-77f6-76e5-b086-4b293747e00d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f87fdce8-9cbf-4cec-bebe-48a3f8bac989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c4f00-afe9-75ad-aea7-57da868f1899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8060487d-062a-43d2-b46b-65a7f9e141b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:to="loc_us-gaap_StatementTable_8060487d-062a-43d2-b46b-65a7f9e141b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56d0120a-b5ef-4f6e-9982-54b3645a561a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8060487d-062a-43d2-b46b-65a7f9e141b7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56d0120a-b5ef-4f6e-9982-54b3645a561a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_56d0120a-b5ef-4f6e-9982-54b3645a561a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56d0120a-b5ef-4f6e-9982-54b3645a561a" xlink:to="loc_us-gaap_RelatedPartyDomain_56d0120a-b5ef-4f6e-9982-54b3645a561a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5f47fd04-4021-4b1b-be73-5b5180b3508e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56d0120a-b5ef-4f6e-9982-54b3645a561a" xlink:to="loc_us-gaap_RelatedPartyDomain_5f47fd04-4021-4b1b-be73-5b5180b3508e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_6176dad4-2c43-426e-9697-4b04c6b96321" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5f47fd04-4021-4b1b-be73-5b5180b3508e" xlink:to="loc_us-gaap_RelatedPartyMember_6176dad4-2c43-426e-9697-4b04c6b96321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_814d7f6a-bb4e-47ff-8ce9-ffc6eda47a78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_814d7f6a-bb4e-47ff-8ce9-ffc6eda47a78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3d3bb898-1d2c-4c3a-adc1-58531a5caaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3d3bb898-1d2c-4c3a-adc1-58531a5caaf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_cc7d823c-9ac1-41f3-803b-86bd4667b062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_cc7d823c-9ac1-41f3-803b-86bd4667b062" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a3311607-6c3e-42b6-9ecd-8c31a5f80170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a3311607-6c3e-42b6-9ecd-8c31a5f80170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a3311607-6c3e-42b6-9ecd-8c31a5f80170_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a3311607-6c3e-42b6-9ecd-8c31a5f80170" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a3311607-6c3e-42b6-9ecd-8c31a5f80170_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7c5d7099-26e1-4e9c-8539-60d9f2deb4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a3311607-6c3e-42b6-9ecd-8c31a5f80170" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7c5d7099-26e1-4e9c-8539-60d9f2deb4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a8fdd1d6-58f8-401a-aceb-df99a393e481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7c5d7099-26e1-4e9c-8539-60d9f2deb4d4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a8fdd1d6-58f8-401a-aceb-df99a393e481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8f0bb111-259b-4ebe-b140-2cc03deb94ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8f0bb111-259b-4ebe-b140-2cc03deb94ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8f0bb111-259b-4ebe-b140-2cc03deb94ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8f0bb111-259b-4ebe-b140-2cc03deb94ca" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8f0bb111-259b-4ebe-b140-2cc03deb94ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_639e367e-21c9-4df2-80a3-d3c9d63391e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8f0bb111-259b-4ebe-b140-2cc03deb94ca" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_639e367e-21c9-4df2-80a3-d3c9d63391e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_94dfcc94-5590-4341-bf46-8e608b2e2a24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_639e367e-21c9-4df2-80a3-d3c9d63391e7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_94dfcc94-5590-4341-bf46-8e608b2e2a24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5e7cf198-2a31-4b73-a6fe-9538540fc592" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_srt_MajorCustomersAxis_5e7cf198-2a31-4b73-a6fe-9538540fc592" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5e7cf198-2a31-4b73-a6fe-9538540fc592_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_5e7cf198-2a31-4b73-a6fe-9538540fc592" xlink:to="loc_srt_NameOfMajorCustomerDomain_5e7cf198-2a31-4b73-a6fe-9538540fc592_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_5e7cf198-2a31-4b73-a6fe-9538540fc592" xlink:to="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OneCustomerMember_13a84a86-1d49-45b4-918e-64740fc48933" xlink:href="dna-20251231.xsd#dna_OneCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:to="loc_dna_OneCustomerMember_13a84a86-1d49-45b4-918e-64740fc48933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CustomerOneMember_019c5c70-ceb7-7ebf-837b-2e1f57d14068" xlink:href="dna-20251231.xsd#dna_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:to="loc_dna_CustomerOneMember_019c5c70-ceb7-7ebf-837b-2e1f57d14068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CustomerTwoMember_019c5c71-00fb-72e4-8852-88e7cf0cf710" xlink:href="dna-20251231.xsd#dna_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:to="loc_dna_CustomerTwoMember_019c5c71-00fb-72e4-8852-88e7cf0cf710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ade1b62d-959c-41f8-8ed7-be5f3ccf1074" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ade1b62d-959c-41f8-8ed7-be5f3ccf1074" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ade1b62d-959c-41f8-8ed7-be5f3ccf1074_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ade1b62d-959c-41f8-8ed7-be5f3ccf1074" xlink:to="loc_us-gaap_SegmentDomain_ade1b62d-959c-41f8-8ed7-be5f3ccf1074_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3561b37a-b2c9-4a9f-b237-69969bd4bc07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ade1b62d-959c-41f8-8ed7-be5f3ccf1074" xlink:to="loc_us-gaap_SegmentDomain_3561b37a-b2c9-4a9f-b237-69969bd4bc07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringSegmentMember_b0390925-dde0-466f-b276-17e145bd1bec" xlink:href="dna-20251231.xsd#dna_CellEngineeringSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3561b37a-b2c9-4a9f-b237-69969bd4bc07" xlink:to="loc_dna_CellEngineeringSegmentMember_b0390925-dde0-466f-b276-17e145bd1bec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiosecuritySegmentMember_76ef96a8-9bc7-42d2-97cd-6189a099eced" xlink:href="dna-20251231.xsd#dna_BiosecuritySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3561b37a-b2c9-4a9f-b237-69969bd4bc07" xlink:to="loc_dna_BiosecuritySegmentMember_76ef96a8-9bc7-42d2-97cd-6189a099eced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_c02717f1-b9ec-4617-b62a-497a37c424a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_OtherCommitmentsAxis_c02717f1-b9ec-4617-b62a-497a37c424a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_c02717f1-b9ec-4617-b62a-497a37c424a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_c02717f1-b9ec-4617-b62a-497a37c424a7" xlink:to="loc_us-gaap_OtherCommitmentsDomain_c02717f1-b9ec-4617-b62a-497a37c424a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_ae0e52c8-e2ef-4c06-9c7f-c2cc9104c41f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_c02717f1-b9ec-4617-b62a-497a37c424a7" xlink:to="loc_us-gaap_OtherCommitmentsDomain_ae0e52c8-e2ef-4c06-9c7f-c2cc9104c41f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember_17a186f7-2455-4218-b4c7-2d7bc28ad6d8" xlink:href="dna-20251231.xsd#dna_EquityMethodInvestmentFundingOfAdditionalLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_ae0e52c8-e2ef-4c06-9c7f-c2cc9104c41f" xlink:to="loc_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember_17a186f7-2455-4218-b4c7-2d7bc28ad6d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_01fe66b5-51d4-4082-bc21-05f5cc92940f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_StatementClassOfStockAxis_01fe66b5-51d4-4082-bc21-05f5cc92940f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_01fe66b5-51d4-4082-bc21-05f5cc92940f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_01fe66b5-51d4-4082-bc21-05f5cc92940f" xlink:to="loc_us-gaap_ClassOfStockDomain_01fe66b5-51d4-4082-bc21-05f5cc92940f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_01fe66b5-51d4-4082-bc21-05f5cc92940f" xlink:to="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_21f6547f-663b-4cf5-8d36-565cf195d195" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:to="loc_us-gaap_CommonClassAMember_21f6547f-663b-4cf5-8d36-565cf195d195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_d6528cc0-1ae7-43aa-80b6-a31dc7f3c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:to="loc_us-gaap_CommonClassBMember_d6528cc0-1ae7-43aa-80b6-a31dc7f3c9a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_3e54c314-e540-4d3e-ba25-d8b5584a1d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:to="loc_us-gaap_CommonClassCMember_3e54c314-e540-4d3e-ba25-d8b5584a1d0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_52f43860-7fd9-4d2e-8976-857cd206e8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_52f43860-7fd9-4d2e-8976-857cd206e8ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_531391e9-b081-4fb3-80ba-7588be8a4395" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_531391e9-b081-4fb3-80ba-7588be8a4395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2321b47c-4392-4117-a238-5103d96d1b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2321b47c-4392-4117-a238-5103d96d1b04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_b46da138-ee82-4c03-87b9-6576cd3dc625" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_OtherCommitment_b46da138-ee82-4c03-87b9-6576cd3dc625" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_a205fa6b-d979-4aab-aaf3-88a7540b830e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_a205fa6b-d979-4aab-aaf3-88a7540b830e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cd4177b9-1f87-494f-9001-586af0d8cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cd4177b9-1f87-494f-9001-586af0d8cdd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e87a2b38-eb1b-4914-b6e1-07190b198385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e87a2b38-eb1b-4914-b6e1-07190b198385" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_019c900e-47fc-79d1-a095-f028cedb16ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_019c900e-47fc-79d1-a095-f028cedb16ab" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2bfde11d-7b79-4e64-99d8-525c479b0a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dd0dc67-0617-461f-9a82-146a8b878eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2bfde11d-7b79-4e64-99d8-525c479b0a9b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dd0dc67-0617-461f-9a82-146a8b878eb8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90736a23-05bc-4273-ad5c-549045ba526a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dd0dc67-0617-461f-9a82-146a8b878eb8" xlink:to="loc_srt_RangeAxis_90736a23-05bc-4273-ad5c-549045ba526a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90736a23-05bc-4273-ad5c-549045ba526a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_90736a23-05bc-4273-ad5c-549045ba526a" xlink:to="loc_srt_RangeMember_90736a23-05bc-4273-ad5c-549045ba526a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7791d560-2271-49ca-95a0-4103a1cad3e9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_90736a23-05bc-4273-ad5c-549045ba526a" xlink:to="loc_srt_RangeMember_7791d560-2271-49ca-95a0-4103a1cad3e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7767576-6493-46a2-912e-816c23233025" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7791d560-2271-49ca-95a0-4103a1cad3e9" xlink:to="loc_srt_MinimumMember_f7767576-6493-46a2-912e-816c23233025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1209569f-703b-439c-a148-89bde98463a0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7791d560-2271-49ca-95a0-4103a1cad3e9" xlink:to="loc_srt_MaximumMember_1209569f-703b-439c-a148-89bde98463a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ca4d6809-e678-4721-a6b5-ff69c7939c47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dd0dc67-0617-461f-9a82-146a8b878eb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ca4d6809-e678-4721-a6b5-ff69c7939c47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4d6809-e678-4721-a6b5-ff69c7939c47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ca4d6809-e678-4721-a6b5-ff69c7939c47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4d6809-e678-4721-a6b5-ff69c7939c47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ca4d6809-e678-4721-a6b5-ff69c7939c47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ComputerEquipmentAndSoftwareMember_348fe881-a07a-4714-be91-ef4fbdc6c366" xlink:href="dna-20251231.xsd#dna_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_dna_ComputerEquipmentAndSoftwareMember_348fe881-a07a-4714-be91-ef4fbdc6c366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3efbc79a-0201-47d0-a784-c543c78857d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3efbc79a-0201-47d0-a784-c543c78857d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LabEquipmentMember_964e9f70-fb53-49b3-93b4-d33f0d558966" xlink:href="dna-20251231.xsd#dna_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_dna_LabEquipmentMember_964e9f70-fb53-49b3-93b4-d33f0d558966" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_7504ab05-d33b-4cc6-8910-1f1903389a47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_us-gaap_ManufacturingFacilityMember_7504ab05-d33b-4cc6-8910-1f1903389a47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_e594d93a-3f45-4e8a-b2cf-30bef7f094d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_us-gaap_VehiclesMember_e594d93a-3f45-4e8a-b2cf-30bef7f094d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9aec20cd-adc5-4501-856d-ce7d515df03b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2bfde11d-7b79-4e64-99d8-525c479b0a9b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9aec20cd-adc5-4501-856d-ce7d515df03b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4cd65d81-036d-4c85-96f3-273e306a6d16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4cd65d81-036d-4c85-96f3-273e306a6d16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55ad3263-227d-4129-8dfe-b6e4a1b6884c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4cd65d81-036d-4c85-96f3-273e306a6d16" xlink:to="loc_srt_RangeAxis_55ad3263-227d-4129-8dfe-b6e4a1b6884c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_55ad3263-227d-4129-8dfe-b6e4a1b6884c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_55ad3263-227d-4129-8dfe-b6e4a1b6884c" xlink:to="loc_srt_RangeMember_55ad3263-227d-4129-8dfe-b6e4a1b6884c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c533875a-5a9e-456e-b992-1e7ad13bd3c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_55ad3263-227d-4129-8dfe-b6e4a1b6884c" xlink:to="loc_srt_RangeMember_c533875a-5a9e-456e-b992-1e7ad13bd3c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51e92514-b37c-46e3-b8a9-f54d24b555b8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c533875a-5a9e-456e-b992-1e7ad13bd3c8" xlink:to="loc_srt_MinimumMember_51e92514-b37c-46e3-b8a9-f54d24b555b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73481a27-ed94-48b1-8bdf-3b19fa501293" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c533875a-5a9e-456e-b992-1e7ad13bd3c8" xlink:to="loc_srt_MaximumMember_73481a27-ed94-48b1-8bdf-3b19fa501293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent_077296b6-f3e4-4545-bae6-da2eaea619c3" xlink:href="dna-20251231.xsd#dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:to="loc_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent_077296b6-f3e4-4545-bae6-da2eaea619c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_faefbb84-71ed-4ae7-82e2-9d2a01e1cefb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_faefbb84-71ed-4ae7-82e2-9d2a01e1cefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_1b921af6-9359-4790-add4-27e877c211cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_1b921af6-9359-4790-add4-27e877c211cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_019c5c76-5a11-7234-8e78-aeb28ec29b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_019c5c76-5a11-7234-8e78-aeb28ec29b2b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ce5e71f5-bc60-4911-ae41-9c6036bdd9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ce5e71f5-bc60-4911-ae41-9c6036bdd9d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6efec795-2385-487e-90a1-13388f57269a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ce5e71f5-bc60-4911-ae41-9c6036bdd9d5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6efec795-2385-487e-90a1-13388f57269a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6efec795-2385-487e-90a1-13388f57269a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6efec795-2385-487e-90a1-13388f57269a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6efec795-2385-487e-90a1-13388f57269a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b1aa0749-76b8-4245-8a13-b6bb8a5b5d96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6efec795-2385-487e-90a1-13388f57269a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b1aa0749-76b8-4245-8a13-b6bb8a5b5d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_aed4bb03-2dc9-468e-8801-845a2f98b5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b1aa0749-76b8-4245-8a13-b6bb8a5b5d96" xlink:to="loc_us-gaap_EmployeeSeveranceMember_aed4bb03-2dc9-468e-8801-845a2f98b5f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d5f945a1-c395-4ef7-8df6-86817aa27745" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:to="loc_us-gaap_RestructuringCharges_d5f945a1-c395-4ef7-8df6-86817aa27745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_ba15ae8a-25ac-4cb5-9748-657b316d41b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:to="loc_us-gaap_PaymentsForRestructuring_ba15ae8a-25ac-4cb5-9748-657b316d41b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_41d2c247-2b11-4a68-822a-b76a42d8952c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:to="loc_us-gaap_RestructuringReserve_41d2c247-2b11-4a68-822a-b76a42d8952c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019c5c81-2aa1-7dc2-803c-f1a877f29222" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019c5c81-2aa1-7dc2-803c-f1a877f29222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-7dc2-803c-f1a877f29222_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019c5c81-2aa1-7dc2-803c-f1a877f29222" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-7dc2-803c-f1a877f29222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019c5c81-2aa1-7dc2-803c-f1a877f29222" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgBiomeInc.Member_019c5c81-2aa1-7727-9677-d888a7f5541a" xlink:href="dna-20251231.xsd#dna_AgBiomeInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:to="loc_dna_AgBiomeInc.Member_019c5c81-2aa1-7727-9677-d888a7f5541a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenBankruptcyMember_019c5c81-58aa-7ecc-870d-c0c644dd273b" xlink:href="dna-20251231.xsd#dna_ZymergenBankruptcyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:to="loc_dna_ZymergenBankruptcyMember_019c5c81-58aa-7ecc-870d-c0c644dd273b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_019c5c81-a248-738f-85f5-6ffd086266fa" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:to="loc_dna_ZymergenMember_019c5c81-a248-738f-85f5-6ffd086266fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c5c81-2aa1-728f-bcdb-5867d0aaff2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c5c81-2aa1-728f-bcdb-5867d0aaff2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c5c81-2aa1-728f-bcdb-5867d0aaff2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c5c81-2aa1-728f-bcdb-5867d0aaff2e" xlink:to="loc_us-gaap_ClassOfStockDomain_019c5c81-2aa1-728f-bcdb-5867d0aaff2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c5c81-2aa1-79d2-b853-4cc8b0b2e014" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c5c81-2aa1-728f-bcdb-5867d0aaff2e" xlink:to="loc_us-gaap_ClassOfStockDomain_019c5c81-2aa1-79d2-b853-4cc8b0b2e014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019c5c81-2aa1-7c65-a2b2-076582e9ec80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019c5c81-2aa1-79d2-b853-4cc8b0b2e014" xlink:to="loc_us-gaap_CommonClassAMember_019c5c81-2aa1-7c65-a2b2-076582e9ec80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019c5c81-2aa1-7dd4-8b46-4463d2d5d9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019c5c81-2aa1-7dd4-8b46-4463d2d5d9ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019c5c81-2aa1-7dd4-8b46-4463d2d5d9ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019c5c81-2aa1-7dd4-8b46-4463d2d5d9ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019c5c81-2aa1-7dd4-8b46-4463d2d5d9ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019c5c81-2aa1-7bcf-be80-c640bfe75132" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019c5c81-2aa1-7dd4-8b46-4463d2d5d9ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019c5c81-2aa1-7bcf-be80-c640bfe75132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019c5c81-2aa1-7fd1-b9e4-d0b243a0d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019c5c81-2aa1-7bcf-be80-c640bfe75132" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019c5c81-2aa1-7fd1-b9e4-d0b243a0d0e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_019c5c81-2aa1-7d3a-ac63-4141b8b00407" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_AssetAcquisitionAxis_019c5c81-2aa1-7d3a-ac63-4141b8b00407" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7d3a-ac63-4141b8b00407_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019c5c81-2aa1-7d3a-ac63-4141b8b00407" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7d3a-ac63-4141b8b00407_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019c5c81-2aa1-7d3a-ac63-4141b8b00407" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherAssetAcquisitionsMember_019c5c81-2aa1-7d37-9ffe-14bb4dcc8522" xlink:href="dna-20251231.xsd#dna_OtherAssetAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:to="loc_dna_OtherAssetAcquisitionsMember_019c5c81-2aa1-7d37-9ffe-14bb4dcc8522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StridebioMember_019c5c81-58aa-7c26-add6-53dfb222a1fc" xlink:href="dna-20251231.xsd#dna_StridebioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:to="loc_dna_StridebioMember_019c5c81-58aa-7c26-add6-53dfb222a1fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_019c5c81-58aa-7d0b-9382-cffac02fb20c" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:to="loc_dna_ZymergenMember_019c5c81-58aa-7d0b-9382-cffac02fb20c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5c81-8264-72a3-92a2-5ad126d71128" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5c81-8264-72a3-92a2-5ad126d71128" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5c81-8264-72a3-92a2-5ad126d71128_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5c81-8264-72a3-92a2-5ad126d71128" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5c81-8264-72a3-92a2-5ad126d71128_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5c81-8264-77fd-8811-aa8c2d3f1639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5c81-8264-72a3-92a2-5ad126d71128" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5c81-8264-77fd-8811-aa8c2d3f1639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019c5c81-8264-796c-9e82-a435b06df36c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019c5c81-8264-77fd-8811-aa8c2d3f1639" xlink:to="loc_us-gaap_RelatedPartyMember_019c5c81-8264-796c-9e82-a435b06df36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c5c81-a248-798a-bf08-3777d9e1714d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c5c81-a248-798a-bf08-3777d9e1714d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c5c81-a248-798a-bf08-3777d9e1714d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c5c81-a248-798a-bf08-3777d9e1714d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c5c81-a248-798a-bf08-3777d9e1714d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c5c81-a248-7b2b-85be-9cfd187ad7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c5c81-a248-798a-bf08-3777d9e1714d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c5c81-a248-7b2b-85be-9cfd187ad7f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019c5c81-a248-7997-9311-fb78a595542c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c5c81-a248-7b2b-85be-9cfd187ad7f3" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019c5c81-a248-7997-9311-fb78a595542c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c81-a248-78bd-858d-1099887a3f90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c81-a248-78bd-858d-1099887a3f90" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c81-a248-78bd-858d-1099887a3f90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c81-a248-78bd-858d-1099887a3f90" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c81-a248-78bd-858d-1099887a3f90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c81-a248-7c74-add5-78f9e2ea349a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c81-a248-78bd-858d-1099887a3f90" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c81-a248-7c74-add5-78f9e2ea349a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AltarSasMember_019c5c81-a248-74bc-a9e7-85a30c1ca430" xlink:href="dna-20251231.xsd#dna_AltarSasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c81-a248-7c74-add5-78f9e2ea349a" xlink:to="loc_dna_AltarSasMember_019c5c81-a248-74bc-a9e7-85a30c1ca430" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_019c5c81-2aa1-7a94-a0b7-ce1fec21a2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_019c5c81-2aa1-7a94-a0b7-ce1fec21a2c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_019c5c81-2aa1-7510-a52b-f05f0dd8fbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_019c5c81-2aa1-7510-a52b-f05f0dd8fbe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019c5c81-2aa1-79d8-b552-967e1ed7f87c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019c5c81-2aa1-79d8-b552-967e1ed7f87c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod_019c5c81-2aa1-723c-8b08-82c4f518fdbf" xlink:href="dna-20251231.xsd#dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod_019c5c81-2aa1-723c-8b08-82c4f518fdbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_019c5c81-2aa1-7d24-8733-f091fa50ac6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_019c5c81-2aa1-7d24-8733-f091fa50ac6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019c5c81-2aa1-7f03-965f-1051d37a2cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019c5c81-2aa1-7f03-965f-1051d37a2cc2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_019c5c81-58aa-7a83-97fc-14047755a7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_PaymentsForRoyalties_019c5c81-58aa-7a83-97fc-14047755a7a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_019c5c81-58aa-743c-bd43-5f7ab8ad8961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_019c5c81-58aa-743c-bd43-5f7ab8ad8961" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_019c5c81-58aa-7e86-9764-6b36c1144273" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_019c5c81-58aa-7e86-9764-6b36c1144273" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_019c5c81-58aa-7312-9572-ea2cdf6877c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_019c5c81-58aa-7312-9572-ea2cdf6877c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_019c5c81-58aa-7b7d-9c8e-0a29157ba75f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_EquityMethodInvestments_019c5c81-58aa-7b7d-9c8e-0a29157ba75f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EmployeeLeaseExpense_019c5c81-8264-76c1-8650-11467223cb81" xlink:href="dna-20251231.xsd#dna_EmployeeLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_dna_EmployeeLeaseExpense_019c5c81-8264-76c1-8650-11467223cb81" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019c5c81-a248-726a-b592-9cc4f776a824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019c5c81-a248-726a-b592-9cc4f776a824" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfEmployeesAcquired_019c5c81-a248-7c4c-b624-1d8528d9075d" xlink:href="dna-20251231.xsd#dna_NumberOfEmployeesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_dna_NumberOfEmployeesAcquired_019c5c81-a248-7c4c-b624-1d8528d9075d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_019c5c81-a248-7cf5-aa12-fbc89619ad27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_019c5c81-a248-7cf5-aa12-fbc89619ad27" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_019c5c81-a248-7dea-98a9-52f3abc4ac1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_019c5c81-a248-7dea-98a9-52f3abc4ac1e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_019c5c81-a248-71a7-8b59-d21bacd44a74" xlink:href="dna-20251231.xsd#dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_019c5c81-a248-71a7-8b59-d21bacd44a74" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_019c5c81-a248-7579-bbc0-0eb66c20d650" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_019c5c81-a248-7579-bbc0-0eb66c20d650" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_019c5c81-a248-7ae3-89cf-9c8e55fdbe40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_019c5c81-a248-7ae3-89cf-9c8e55fdbe40" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019c5c81-a248-72fc-bcdf-319699960cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019c5c81-a248-72fc-bcdf-319699960cc1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_019c5c81-a248-7266-a11c-9521f44e3898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_019c5c81-a248-7266-a11c-9521f44e3898" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_019c5c81-a248-7e24-a5b9-612827f435b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_019c5c81-a248-7e24-a5b9-612827f435b7" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-8732-7dbc-8228-60f894863cff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-8732-7dbc-8228-60f894863cff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-8732-7c98-abca-9d9f274ce548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-8732-7dbc-8228-60f894863cff" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-8732-7c98-abca-9d9f274ce548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-8732-7c98-abca-9d9f274ce548_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-8732-7c98-abca-9d9f274ce548" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-8732-7c98-abca-9d9f274ce548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-8732-78f8-a075-4c16575130f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-8732-7c98-abca-9d9f274ce548" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-8732-78f8-a075-4c16575130f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_019c5c83-8732-7c67-a0cb-b90414dad063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-8732-78f8-a075-4c16575130f2" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_019c5c83-8732-7c67-a0cb-b90414dad063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-8732-78bf-9db6-724d6c8d6995" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-8732-7dbc-8228-60f894863cff" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-8732-78bf-9db6-724d6c8d6995" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-8732-78bf-9db6-724d6c8d6995_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-8732-78bf-9db6-724d6c8d6995" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-8732-78bf-9db6-724d6c8d6995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-8732-7cc4-9d0d-44affa586147" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-8732-78bf-9db6-724d6c8d6995" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-8732-7cc4-9d0d-44affa586147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_019c5c83-8732-7884-9b42-249ef279aa89" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-8732-7cc4-9d0d-44affa586147" xlink:to="loc_dna_ZymergenMember_019c5c83-8732-7884-9b42-249ef279aa89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_019c5c83-8732-7b2c-8e51-61eabad6e301" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_019c5c83-8732-7b2c-8e51-61eabad6e301" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019c5c83-8732-7209-aadf-d8647eb62237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019c5c83-8732-7209-aadf-d8647eb62237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_019c5c83-8732-76bc-b01e-72b3e33d83f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_019c5c83-8732-76bc-b01e-72b3e33d83f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-7c73-93dc-36e0f630e846" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-7c73-93dc-36e0f630e846" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_019c5c83-8732-7a65-bd29-50ef16fa39b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_019c5c83-8732-7a65-bd29-50ef16fa39b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_019c5c83-8732-7de3-88d8-b2337d39d74b" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_019c5c83-8732-7de3-88d8-b2337d39d74b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_019c5c83-8732-77b2-860e-27b422988741" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_019c5c83-8732-77b2-860e-27b422988741" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_019c5c83-8732-7525-b24e-efcc3ac28f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_019c5c83-8732-7525-b24e-efcc3ac28f3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_019c5c83-8732-7f96-8b93-bd9abfce58bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_019c5c83-8732-7f96-8b93-bd9abfce58bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-74f4-87f6-217b54c38692" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-74f4-87f6-217b54c38692" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_019c5c83-8732-7d0f-b159-704aae04fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_019c5c83-8732-7d0f-b159-704aae04fcb8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019c5c83-8732-7dcf-bdc9-5eb5276da1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019c5c83-8732-7dcf-bdc9-5eb5276da1e2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-79cc-9dc1-54002c98e04c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-79cc-9dc1-54002c98e04c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_019c5c83-8732-713a-9d89-39062ec1766d" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_019c5c83-8732-713a-9d89-39062ec1766d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_019c5c83-8732-7bfb-8b6d-2cd4396649f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_019c5c83-8732-7bfb-8b6d-2cd4396649f4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7aba-a5fc-d2aca3bdf9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7aba-a5fc-d2aca3bdf9e5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_019c5c83-8732-7f26-b5d3-4a99b5e69a3d" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_019c5c83-8732-7f26-b5d3-4a99b5e69a3d" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-a645-7fc0-9c9b-ce3544ae5937" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-a645-7fc0-9c9b-ce3544ae5937" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-a645-79a9-be83-1354dbc4a685" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-a645-7fc0-9c9b-ce3544ae5937" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-a645-79a9-be83-1354dbc4a685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-a645-79a9-be83-1354dbc4a685_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-a645-79a9-be83-1354dbc4a685" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-a645-79a9-be83-1354dbc4a685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-a645-7268-9dcd-720784f4a7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-a645-79a9-be83-1354dbc4a685" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-a645-7268-9dcd-720784f4a7ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_019c5c83-a645-79c5-9cb1-67460f15c615" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-a645-7268-9dcd-720784f4a7ec" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_019c5c83-a645-79c5-9cb1-67460f15c615" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-a645-7b9e-b537-553285448b27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-a645-7fc0-9c9b-ce3544ae5937" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-a645-7b9e-b537-553285448b27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-a645-7b9e-b537-553285448b27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-a645-7b9e-b537-553285448b27" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-a645-7b9e-b537-553285448b27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-a645-76a4-8d32-086426f49848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-a645-7b9e-b537-553285448b27" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-a645-76a4-8d32-086426f49848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_019c5c83-a645-7883-93cc-179a1060e01e" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-a645-76a4-8d32-086426f49848" xlink:to="loc_dna_ZymergenMember_019c5c83-a645-7883-93cc-179a1060e01e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_019c5c83-a645-7ec8-84b3-40ad3c076cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_019c5c83-a645-7ec8-84b3-40ad3c076cf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_019c5c83-a645-73a0-b274-af8240b89cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_019c5c83-a645-73a0-b274-af8240b89cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_019c5c83-a645-7094-99bd-3950d6fed4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_019c5c83-a645-7094-99bd-3950d6fed4e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_019c5c83-a645-7933-995d-7ca9088b46f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_019c5c83-a645-7933-995d-7ca9088b46f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_019c5c83-a645-7f86-a1a4-013ab21ea6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_019c5c83-a645-7f86-a1a4-013ab21ea6cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_019c5c83-a645-71a7-99a3-7febc5f4ed46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_019c5c83-a645-71a7-99a3-7febc5f4ed46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_019c5c83-a645-7d88-97d9-f99231a9c94e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_019c5c83-a645-7d88-97d9-f99231a9c94e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_904e7b0c-1503-4d3e-b400-30993b38d0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_904e7b0c-1503-4d3e-b400-30993b38d0bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_904e7b0c-1503-4d3e-b400-30993b38d0bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_904e7b0c-1503-4d3e-b400-30993b38d0bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_904e7b0c-1503-4d3e-b400-30993b38d0bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_904e7b0c-1503-4d3e-b400-30993b38d0bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_10bf2f7c-487e-462e-a724-a40605baf48c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_10bf2f7c-487e-462e-a724-a40605baf48c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5ebbe79a-2c90-479c-aa73-48b198ad71a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5ebbe79a-2c90-479c-aa73-48b198ad71a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d1928747-edd3-4463-9d01-78eb72f2c6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d1928747-edd3-4463-9d01-78eb72f2c6f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_c6082c92-ac05-4202-bcad-9cccfce67def" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_c6082c92-ac05-4202-bcad-9cccfce67def" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c6082c92-ac05-4202-bcad-9cccfce67def_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c6082c92-ac05-4202-bcad-9cccfce67def" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c6082c92-ac05-4202-bcad-9cccfce67def_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9250dab-9c99-4e5e-a707-457729e6e871" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c6082c92-ac05-4202-bcad-9cccfce67def" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9250dab-9c99-4e5e-a707-457729e6e871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_201e1154-c214-4fd0-b7ff-6ca9b36f0128" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9250dab-9c99-4e5e-a707-457729e6e871" xlink:to="loc_us-gaap_MoneyMarketFundsMember_201e1154-c214-4fd0-b7ff-6ca9b36f0128" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_442453a9-5684-4ba0-9ce6-6f21ca90ae00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:to="loc_us-gaap_InvestmentTypeAxis_442453a9-5684-4ba0-9ce6-6f21ca90ae00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_442453a9-5684-4ba0-9ce6-6f21ca90ae00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_442453a9-5684-4ba0-9ce6-6f21ca90ae00" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_442453a9-5684-4ba0-9ce6-6f21ca90ae00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_846e0f25-7a19-4e70-b947-a9595993fd71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_442453a9-5684-4ba0-9ce6-6f21ca90ae00" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_846e0f25-7a19-4e70-b947-a9595993fd71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SynlogicIncWarrantsMember_7348075f-b574-4811-a1a7-4aa8d87c5903" xlink:href="dna-20251231.xsd#dna_SynlogicIncWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_846e0f25-7a19-4e70-b947-a9595993fd71" xlink:to="loc_dna_SynlogicIncWarrantsMember_7348075f-b574-4811-a1a7-4aa8d87c5903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MarketableEquitySecuritiesMember_ef95a119-0345-4402-b15d-177b7aa0d0ec" xlink:href="dna-20251231.xsd#dna_MarketableEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_846e0f25-7a19-4e70-b947-a9595993fd71" xlink:to="loc_dna_MarketableEquitySecuritiesMember_ef95a119-0345-4402-b15d-177b7aa0d0ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c5c86-3427-784a-a89a-acd22ee062c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c5c86-3427-784a-a89a-acd22ee062c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-784a-a89a-acd22ee062c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c5c86-3427-784a-a89a-acd22ee062c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-784a-a89a-acd22ee062c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c5c86-3427-784a-a89a-acd22ee062c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019c5c86-3427-711b-b3a7-5ef7223e97cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019c5c86-3427-711b-b3a7-5ef7223e97cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019c5c86-3427-7d96-82fa-3e155c8b625c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019c5c86-3427-7d96-82fa-3e155c8b625c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019c5c86-3427-7e52-be67-08531eae3c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019c5c86-3427-7e52-be67-08531eae3c91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MarketableEquitySecuritiesMember_019c5c86-3427-7be3-8720-1bcc66577294" xlink:href="dna-20251231.xsd#dna_MarketableEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:to="loc_dna_MarketableEquitySecuritiesMember_019c5c86-3427-7be3-8720-1bcc66577294" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f4b0cbea-3fee-4bff-8411-eb0494447e73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f4b0cbea-3fee-4bff-8411-eb0494447e73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_77b0ccd7-a0dc-49b9-a2e8-10e8d177dd83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_77b0ccd7-a0dc-49b9-a2e8-10e8d177dd83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure_1ced911f-c4a3-4415-94d3-f60c16ded3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosure_1ced911f-c4a3-4415-94d3-f60c16ded3dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e34bd374-0b56-4850-bcbc-efdf63e2dbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e34bd374-0b56-4850-bcbc-efdf63e2dbfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e2140ebd-a231-4480-8fc2-8656f786a08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e2140ebd-a231-4480-8fc2-8656f786a08e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_646c9a6c-643a-45dd-a7e0-01b3444de11b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_646c9a6c-643a-45dd-a7e0-01b3444de11b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_72f07125-caaa-44c6-a17b-278998c0b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_72f07125-caaa-44c6-a17b-278998c0b53c" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29a85826-daf6-4eda-a31b-91787aeb0f56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29a85826-daf6-4eda-a31b-91787aeb0f56" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b555e43d-dfc9-4771-9aa8-8b528eec3c15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b555e43d-dfc9-4771-9aa8-8b528eec3c15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b555e43d-dfc9-4771-9aa8-8b528eec3c15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b555e43d-dfc9-4771-9aa8-8b528eec3c15" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b555e43d-dfc9-4771-9aa8-8b528eec3c15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4adc5bba-f5ed-47a2-a9c3-10f3d0cb47c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b555e43d-dfc9-4771-9aa8-8b528eec3c15" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4adc5bba-f5ed-47a2-a9c3-10f3d0cb47c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_138182bf-f4e3-4cec-ad99-6fbc004d0aff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4adc5bba-f5ed-47a2-a9c3-10f3d0cb47c6" xlink:to="loc_us-gaap_NotesReceivableMember_138182bf-f4e3-4cec-ad99-6fbc004d0aff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_cae2f1e2-c7fe-44ea-b7c2-893acc8017d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_cae2f1e2-c7fe-44ea-b7c2-893acc8017d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_cae2f1e2-c7fe-44ea-b7c2-893acc8017d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cae2f1e2-c7fe-44ea-b7c2-893acc8017d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_cae2f1e2-c7fe-44ea-b7c2-893acc8017d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_07b45b90-00db-4e64-8332-2f5a0b592c48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cae2f1e2-c7fe-44ea-b7c2-893acc8017d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_07b45b90-00db-4e64-8332-2f5a0b592c48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PrivatePlacementWarrantsMember_44cad4cb-9013-4f3b-9075-ffc4730c4e05" xlink:href="dna-20251231.xsd#dna_PrivatePlacementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_07b45b90-00db-4e64-8332-2f5a0b592c48" xlink:to="loc_dna_PrivatePlacementWarrantsMember_44cad4cb-9013-4f3b-9075-ffc4730c4e05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_eaaf0f40-2730-4e76-a472-42fd02e2fd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_eaaf0f40-2730-4e76-a472-42fd02e2fd1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eaaf0f40-2730-4e76-a472-42fd02e2fd1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_eaaf0f40-2730-4e76-a472-42fd02e2fd1b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_eaaf0f40-2730-4e76-a472-42fd02e2fd1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14905bc4-7075-4713-a033-9f886a77091c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_eaaf0f40-2730-4e76-a472-42fd02e2fd1b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14905bc4-7075-4713-a033-9f886a77091c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_WarrantLiabilityMember_019c68e2-2603-77ab-aba1-a60043f79693" xlink:href="dna-20251231.xsd#dna_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14905bc4-7075-4713-a033-9f886a77091c" xlink:to="loc_dna_WarrantLiabilityMember_019c68e2-2603-77ab-aba1-a60043f79693" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContingentConsiderationMember_8a3a76a0-704b-4432-a5ae-d9a53820c152" xlink:href="dna-20251231.xsd#dna_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14905bc4-7075-4713-a033-9f886a77091c" xlink:to="loc_dna_ContingentConsiderationMember_8a3a76a0-704b-4432-a5ae-d9a53820c152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_34d691da-5690-46a6-b823-925f8dec9756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29a85826-daf6-4eda-a31b-91787aeb0f56" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_34d691da-5690-46a6-b823-925f8dec9756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_34d691da-5690-46a6-b823-925f8dec9756" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_785f50c4-8fdf-4969-950a-d183f42a4e50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_785f50c4-8fdf-4969-950a-d183f42a4e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_40be9958-57a1-41cf-afb0-d791d6fc12b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_40be9958-57a1-41cf-afb0-d791d6fc12b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_2b75f0c7-e97e-4883-b528-778003a545e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_2b75f0c7-e97e-4883-b528-778003a545e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c68e4-14dc-7dfa-b6d4-dce9a777ef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c68e4-14dc-7dfa-b6d4-dce9a777ef1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_dda35aa4-04a9-4f42-b438-a9d7e8cd5ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_dda35aa4-04a9-4f42-b438-a9d7e8cd5ff9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions_378359de-e330-4172-9967-c521e2dffe0d" xlink:href="dna-20251231.xsd#dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions_378359de-e330-4172-9967-c521e2dffe0d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019c68e1-2220-7412-a52a-60131fcfa8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019c68e1-2220-7412-a52a-60131fcfa8b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_6b2c221e-7cee-4ef5-8808-a70dc8a2b101" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_34d691da-5690-46a6-b823-925f8dec9756" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eac483e2-5664-40e3-a9ae-5acbfa4eb5af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eac483e2-5664-40e3-a9ae-5acbfa4eb5af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f253632c-d258-4e89-806a-3be9340c5cde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f253632c-d258-4e89-806a-3be9340c5cde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_019c68e5-397f-70e2-8e26-d3feab93b4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_019c68e5-397f-70e2-8e26-d3feab93b4c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019c68e0-ffda-7968-8365-a371d55e223e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019c68e0-ffda-7968-8365-a371d55e223e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_03c0c9a5-f4d9-4887-b825-807de3eaf0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_03c0c9a5-f4d9-4887-b825-807de3eaf0ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_7dc6cca9-ead9-4076-8fb3-1b6e33debf56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_7dc6cca9-ead9-4076-8fb3-1b6e33debf56" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e9be4194-4c2b-434e-8d96-06676db4c649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_eb253483-dcb3-413c-824d-8168ab5084d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_eb253483-dcb3-413c-824d-8168ab5084d1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b323f0f2-70a6-479c-8aed-a99f9fce5342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b323f0f2-70a6-479c-8aed-a99f9fce5342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b323f0f2-70a6-479c-8aed-a99f9fce5342_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b323f0f2-70a6-479c-8aed-a99f9fce5342" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b323f0f2-70a6-479c-8aed-a99f9fce5342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17601b-a404-4a82-a208-0fe03a224b18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b323f0f2-70a6-479c-8aed-a99f9fce5342" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17601b-a404-4a82-a208-0fe03a224b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6437ea51-7d99-494b-9273-9b162c42f2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17601b-a404-4a82-a208-0fe03a224b18" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6437ea51-7d99-494b-9273-9b162c42f2bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_148790db-8c5e-4c32-9032-a1d752bc04dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:to="loc_us-gaap_ValuationTechniqueAxis_148790db-8c5e-4c32-9032-a1d752bc04dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_148790db-8c5e-4c32-9032-a1d752bc04dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_148790db-8c5e-4c32-9032-a1d752bc04dd" xlink:to="loc_us-gaap_ValuationTechniqueDomain_148790db-8c5e-4c32-9032-a1d752bc04dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_2964a2b0-aa86-40dc-8bc7-370be6120a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_148790db-8c5e-4c32-9032-a1d752bc04dd" xlink:to="loc_us-gaap_ValuationTechniqueDomain_2964a2b0-aa86-40dc-8bc7-370be6120a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ProbabilityWeightedPresentValueMember_46f68266-4e5b-42b6-8a94-ec89f08c7456" xlink:href="dna-20251231.xsd#dna_ProbabilityWeightedPresentValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_2964a2b0-aa86-40dc-8bc7-370be6120a3f" xlink:to="loc_dna_ProbabilityWeightedPresentValueMember_46f68266-4e5b-42b6-8a94-ec89f08c7456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_80009179-d6a0-4595-adfc-65e6b76d27af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_2964a2b0-aa86-40dc-8bc7-370be6120a3f" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_80009179-d6a0-4595-adfc-65e6b76d27af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d2ddd93-da80-48e1-aca0-0844ad562f4d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:to="loc_srt_RangeAxis_1d2ddd93-da80-48e1-aca0-0844ad562f4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d2ddd93-da80-48e1-aca0-0844ad562f4d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1d2ddd93-da80-48e1-aca0-0844ad562f4d" xlink:to="loc_srt_RangeMember_1d2ddd93-da80-48e1-aca0-0844ad562f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_884d0b28-e88a-4e8b-bfb0-26f0863d5dc7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1d2ddd93-da80-48e1-aca0-0844ad562f4d" xlink:to="loc_srt_RangeMember_884d0b28-e88a-4e8b-bfb0-26f0863d5dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d1314107-e3a8-4321-8fe9-f63c159a65e8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_884d0b28-e88a-4e8b-bfb0-26f0863d5dc7" xlink:to="loc_srt_MinimumMember_d1314107-e3a8-4321-8fe9-f63c159a65e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d2d310c-4123-4c06-ba4f-e7ed9142532e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_884d0b28-e88a-4e8b-bfb0-26f0863d5dc7" xlink:to="loc_srt_MaximumMember_2d2d310c-4123-4c06-ba4f-e7ed9142532e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate_ddb100c5-ede0-4a5a-a7bc-56b9fd056f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_eb253483-dcb3-413c-824d-8168ab5084d1" xlink:to="loc_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate_ddb100c5-ede0-4a5a-a7bc-56b9fd056f4f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c5c8e-5780-715f-82d2-a65babbb8394" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c5c8e-5780-715f-82d2-a65babbb8394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-715f-82d2-a65babbb8394_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c5c8e-5780-715f-82d2-a65babbb8394" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-715f-82d2-a65babbb8394_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-7ab6-8171-8f5ff1506207" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c5c8e-5780-715f-82d2-a65babbb8394" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-7ab6-8171-8f5ff1506207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SeniorSecuredNoteMember_019c5c8e-5780-78c1-98e8-1ea894503224" xlink:href="dna-20251231.xsd#dna_SeniorSecuredNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-7ab6-8171-8f5ff1506207" xlink:to="loc_dna_SeniorSecuredNoteMember_019c5c8e-5780-78c1-98e8-1ea894503224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ConvertiblePromissoryNotesMember_019c5c8e-5780-7aca-a492-74f24dc7c5b4" xlink:href="dna-20251231.xsd#dna_ConvertiblePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-7ab6-8171-8f5ff1506207" xlink:to="loc_dna_ConvertiblePromissoryNotesMember_019c5c8e-5780-7aca-a492-74f24dc7c5b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c5c8e-5780-7753-a7b0-fa1bfa8c0d1b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_srt_RangeAxis_019c5c8e-5780-7753-a7b0-fa1bfa8c0d1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c5c8e-5780-7753-a7b0-fa1bfa8c0d1b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019c5c8e-5780-7753-a7b0-fa1bfa8c0d1b" xlink:to="loc_srt_RangeMember_019c5c8e-5780-7753-a7b0-fa1bfa8c0d1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c5c8e-5780-7203-87a2-3e5239d59ae7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019c5c8e-5780-7753-a7b0-fa1bfa8c0d1b" xlink:to="loc_srt_RangeMember_019c5c8e-5780-7203-87a2-3e5239d59ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c5c8e-5780-778e-aeee-18132d5b27de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c5c8e-5780-7203-87a2-3e5239d59ae7" xlink:to="loc_srt_MinimumMember_019c5c8e-5780-778e-aeee-18132d5b27de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c5c8e-5780-78eb-8f79-0728b1f188e5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c5c8e-5780-7203-87a2-3e5239d59ae7" xlink:to="loc_srt_MaximumMember_019c5c8e-5780-78eb-8f79-0728b1f188e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019c5c8e-5780-7fd8-a0ed-7137b62da485" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019c5c8e-5780-7fd8-a0ed-7137b62da485" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7fd8-a0ed-7137b62da485_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019c5c8e-5780-7fd8-a0ed-7137b62da485" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7fd8-a0ed-7137b62da485_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019c5c8e-5780-7fd8-a0ed-7137b62da485" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MeasurementInputScenarioProbabilitiesMember_019c5c8e-5780-706b-ab55-28e07cbcb0ce" xlink:href="dna-20251231.xsd#dna_MeasurementInputScenarioProbabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:to="loc_dna_MeasurementInputScenarioProbabilitiesMember_019c5c8e-5780-706b-ab55-28e07cbcb0ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019c5c8e-5780-764a-b033-3565c65ba140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019c5c8e-5780-764a-b033-3565c65ba140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_019c5c8e-5780-7358-a48a-b2fb97041d15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_019c5c8e-5780-7358-a48a-b2fb97041d15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c5c8e-5780-70e0-87b0-d215f31af4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c5c8e-5780-70e0-87b0-d215f31af4fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c5c8e-5780-70e0-87b0-d215f31af4fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c5c8e-5780-70e0-87b0-d215f31af4fc" xlink:to="loc_us-gaap_SegmentDomain_019c5c8e-5780-70e0-87b0-d215f31af4fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c5c8e-5780-7a94-8223-4f7ad01c7117" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c5c8e-5780-70e0-87b0-d215f31af4fc" xlink:to="loc_us-gaap_SegmentDomain_019c5c8e-5780-7a94-8223-4f7ad01c7117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringSegmentMember_019c5c8e-5780-7e33-a335-c3399c5f3c48" xlink:href="dna-20251231.xsd#dna_CellEngineeringSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c5c8e-5780-7a94-8223-4f7ad01c7117" xlink:to="loc_dna_CellEngineeringSegmentMember_019c5c8e-5780-7e33-a335-c3399c5f3c48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c5c8e-5780-7a8d-8c2b-a9f07e7d37f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c5c8e-5780-7a8d-8c2b-a9f07e7d37f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c5c8e-5780-7a8d-8c2b-a9f07e7d37f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c5c8e-5780-7a8d-8c2b-a9f07e7d37f1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c5c8e-5780-7a8d-8c2b-a9f07e7d37f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c5c8e-5780-7b2e-9876-349dca37ceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c5c8e-5780-7a8d-8c2b-a9f07e7d37f1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c5c8e-5780-7b2e-9876-349dca37ceb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c5c8e-5780-727f-ae76-e082f1418c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c5c8e-5780-7b2e-9876-349dca37ceb8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c5c8e-5780-727f-ae76-e082f1418c5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019c5c8e-5780-7a26-875b-2fa682cb8a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019c5c8e-5780-7a26-875b-2fa682cb8a5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-7a26-875b-2fa682cb8a5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019c5c8e-5780-7a26-875b-2fa682cb8a5f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-7a26-875b-2fa682cb8a5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-76dd-bb1c-ede813328307" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019c5c8e-5780-7a26-875b-2fa682cb8a5f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-76dd-bb1c-ede813328307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PublicWarrantsMember_019c5c8e-5780-70bc-8ded-8fdc1cf3ed3b" xlink:href="dna-20251231.xsd#dna_PublicWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-76dd-bb1c-ede813328307" xlink:to="loc_dna_PublicWarrantsMember_019c5c8e-5780-70bc-8ded-8fdc1cf3ed3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PrivatePlacementWarrantsMember_019c5c8e-5780-7d7f-bdaf-34ecd8969f2c" xlink:href="dna-20251231.xsd#dna_PrivatePlacementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-76dd-bb1c-ede813328307" xlink:to="loc_dna_PrivatePlacementWarrantsMember_019c5c8e-5780-7d7f-bdaf-34ecd8969f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c5c8e-5780-7b7e-8629-8b97eb65a78d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c5c8e-5780-7b7e-8629-8b97eb65a78d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c5c8e-5780-7b7e-8629-8b97eb65a78d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c5c8e-5780-7b7e-8629-8b97eb65a78d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c5c8e-5780-7b7e-8629-8b97eb65a78d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c5c8e-5780-7528-b0cb-fbe5df93304a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c5c8e-5780-7b7e-8629-8b97eb65a78d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c5c8e-5780-7528-b0cb-fbe5df93304a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c5c8e-828f-78c1-9812-4857d9cb97f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c5c8e-828f-78c1-9812-4857d9cb97f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c5c8e-828f-78c1-9812-4857d9cb97f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c5c8e-828f-78c1-9812-4857d9cb97f4" xlink:to="loc_us-gaap_ClassOfStockDomain_019c5c8e-828f-78c1-9812-4857d9cb97f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c5c8e-828f-768c-91ee-4a247bd977b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c5c8e-828f-78c1-9812-4857d9cb97f4" xlink:to="loc_us-gaap_ClassOfStockDomain_019c5c8e-828f-768c-91ee-4a247bd977b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019c5c8e-828f-7902-b0b4-16959f7ceec0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019c5c8e-828f-768c-91ee-4a247bd977b8" xlink:to="loc_us-gaap_CommonClassAMember_019c5c8e-828f-7902-b0b4-16959f7ceec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c5c8e-828f-717d-9e5a-2a3ea7bdef4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_AwardTypeAxis_019c5c8e-828f-717d-9e5a-2a3ea7bdef4b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c5c8e-828f-717d-9e5a-2a3ea7bdef4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019c5c8e-828f-717d-9e5a-2a3ea7bdef4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c5c8e-828f-717d-9e5a-2a3ea7bdef4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c5c8e-828f-74af-b506-0fbc3de9e848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019c5c8e-828f-717d-9e5a-2a3ea7bdef4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c5c8e-828f-74af-b506-0fbc3de9e848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_019c5c8e-828f-7e6b-bb0d-78bbf0b9f9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c5c8e-828f-74af-b506-0fbc3de9e848" xlink:to="loc_us-gaap_RestrictedStockMember_019c5c8e-828f-7e6b-bb0d-78bbf0b9f9c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019c5c8e-828f-7a42-981d-ae11b06c3c37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019c5c8e-828f-7a42-981d-ae11b06c3c37" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c8e-828f-7a42-981d-ae11b06c3c37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019c5c8e-828f-7a42-981d-ae11b06c3c37" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c8e-828f-7a42-981d-ae11b06c3c37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c8e-828f-77a1-bd20-3f2b522a8628" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019c5c8e-828f-7a42-981d-ae11b06c3c37" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c8e-828f-77a1-bd20-3f2b522a8628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CircularisMember_019c5c8e-828f-78fe-8757-8d12437e0e38" xlink:href="dna-20251231.xsd#dna_CircularisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c8e-828f-77a1-bd20-3f2b522a8628" xlink:to="loc_dna_CircularisMember_019c5c8e-828f-78fe-8757-8d12437e0e38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5c8e-c0e2-7c9d-b5bd-b6e23891150f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5c8e-c0e2-7c9d-b5bd-b6e23891150f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-7c9d-b5bd-b6e23891150f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5c8e-c0e2-7c9d-b5bd-b6e23891150f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-7c9d-b5bd-b6e23891150f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5c8e-c0e2-7c9d-b5bd-b6e23891150f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaIncPreferredStockMember_019c5c8e-c0e2-7a29-bfee-ab59307a90dc" xlink:href="dna-20251231.xsd#dna_GenomaticaIncPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:to="loc_dna_GenomaticaIncPreferredStockMember_019c5c8e-c0e2-7a29-bfee-ab59307a90dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafesMember_019c5c8e-c0e2-7f0e-9efa-f8a45ba42eb4" xlink:href="dna-20251231.xsd#dna_SafesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:to="loc_dna_SafesMember_019c5c8e-c0e2-7f0e-9efa-f8a45ba42eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NonMarketableEquitySecuritiesMember_019c5c8e-c0e2-7ceb-98f9-33bc3d4c10d5" xlink:href="dna-20251231.xsd#dna_NonMarketableEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:to="loc_dna_NonMarketableEquitySecuritiesMember_019c5c8e-c0e2-7ceb-98f9-33bc3d4c10d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OneInvestmentMember_019c94b0-503f-73be-adf0-3cb8f8f1e630" xlink:href="dna-20251231.xsd#dna_OneInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:to="loc_dna_OneInvestmentMember_019c94b0-503f-73be-adf0-3cb8f8f1e630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c5c8e-c0e2-7901-a0af-2c841c109fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c5c8e-c0e2-7901-a0af-2c841c109fa2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c5c8e-c0e2-7901-a0af-2c841c109fa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c5c8e-c0e2-7901-a0af-2c841c109fa2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c5c8e-c0e2-7901-a0af-2c841c109fa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c5c8e-c0e2-7a92-a01f-04398600b77d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c5c8e-c0e2-7901-a0af-2c841c109fa2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c5c8e-c0e2-7a92-a01f-04398600b77d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafeMember_019c5c8e-c0e2-7189-a623-6608f538f118" xlink:href="dna-20251231.xsd#dna_SafeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c5c8e-c0e2-7a92-a01f-04398600b77d" xlink:to="loc_dna_SafeMember_019c5c8e-c0e2-7189-a623-6608f538f118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableSignificantPurchases_019c5c8e-5780-7779-8961-7cae7530ca4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableSignificantPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_FinancingReceivableSignificantPurchases_019c5c8e-5780-7779-8961-7cae7530ca4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinancingReceivableInterestRateStatedPercentage_019c5c8e-5780-7a83-b503-313032e04c6b" xlink:href="dna-20251231.xsd#dna_FinancingReceivableInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_FinancingReceivableInterestRateStatedPercentage_019c5c8e-5780-7a83-b503-313032e04c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinancingReceivableMeasurementInput_019c5c8e-5780-7a9c-9722-82e5fe95765b" xlink:href="dna-20251231.xsd#dna_FinancingReceivableMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_FinancingReceivableMeasurementInput_019c5c8e-5780-7a9c-9722-82e5fe95765b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinancingReceivableMeasurementInputPeriod_019c5c8e-5780-7712-9cea-402328aacdf7" xlink:href="dna-20251231.xsd#dna_FinancingReceivableMeasurementInputPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_FinancingReceivableMeasurementInputPeriod_019c5c8e-5780-7712-9cea-402328aacdf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_019c5c8e-5780-74b0-aaa1-176a287faca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_019c5c8e-5780-74b0-aaa1-176a287faca9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019c5c8e-5780-7713-bde5-49acb34b0720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019c5c8e-5780-7713-bde5-49acb34b0720" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_019c5c8e-5780-7592-a9a9-b13e7cd39e64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_019c5c8e-5780-7592-a9a9-b13e7cd39e64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_019c5c8e-5780-7fc8-a677-ec54e27e8b90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_019c5c8e-5780-7fc8-a677-ec54e27e8b90" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019c5c8e-5780-7115-9007-e2bc02e50c88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019c5c8e-5780-7115-9007-e2bc02e50c88" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum_019c5c8e-828f-7fc8-a33f-23c09a939048" xlink:href="dna-20251231.xsd#dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum_019c5c8e-828f-7fc8-a33f-23c09a939048" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019c5c8e-828f-7da1-911d-44926e1c9d07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019c5c8e-828f-7da1-911d-44926e1c9d07" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_019c5c8e-828f-7e63-9e65-d714fb04bf6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_019c5c8e-828f-7e63-9e65-d714fb04bf6a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_019c5c8e-828f-7669-9997-d3d2cc53dcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_019c5c8e-828f-7669-9997-d3d2cc53dcc0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ClassOfWarrantOrRightStockSplitConversionRatio_019c9010-d36e-72a0-8af9-a6cc6856b4fd" xlink:href="dna-20251231.xsd#dna_ClassOfWarrantOrRightStockSplitConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_ClassOfWarrantOrRightStockSplitConversionRatio_019c9010-d36e-72a0-8af9-a6cc6856b4fd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BusinessCombinationContingentConsiderationVestedValue_019c5c8e-828f-7b49-8017-145382020450" xlink:href="dna-20251231.xsd#dna_BusinessCombinationContingentConsiderationVestedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_BusinessCombinationContingentConsiderationVestedValue_019c5c8e-828f-7b49-8017-145382020450" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_019c5c8e-c0e2-7cda-a9ae-32c22975f536" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_GainLossOnInvestments_019c5c8e-c0e2-7cda-a9ae-32c22975f536" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_019c5c8f-4a3f-7d59-8c2b-64c1b14782fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_019c5c8f-4a3f-7d59-8c2b-64c1b14782fd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_019c5c8e-c0e2-70c3-9268-4ed2e7852c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_019c5c8e-c0e2-70c3-9268-4ed2e7852c0c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage_019c5c8e-c0e2-7119-a616-dfc89d6245b8" xlink:href="dna-20251231.xsd#dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage_019c5c8e-c0e2-7119-a616-dfc89d6245b8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c5c8e-c0e2-730e-afd2-bc50b1281904" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c5c8e-c0e2-730e-afd2-bc50b1281904" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_019c5c8e-c0e2-74ab-8211-39ad6dbec90b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_019c5c8e-c0e2-74ab-8211-39ad6dbec90b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_019c5c8e-c0e2-73b2-9fd9-3db1f939c414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_019c5c8e-c0e2-73b2-9fd9-3db1f939c414" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquitySecuritiesFVNIMeasurementInputTerm_019c5c8e-c0e2-780c-b8fe-881fb66f2e00" xlink:href="dna-20251231.xsd#dna_EquitySecuritiesFVNIMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_EquitySecuritiesFVNIMeasurementInputTerm_019c5c8e-c0e2-780c-b8fe-881fb66f2e00" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_019c5c90-8cc0-732b-81ce-b1c92b324b49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_MarketableSecuritiesTable_019c5c90-8cc0-732b-81ce-b1c92b324b49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c5cea-d6e9-7511-b373-edab03fcce70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_019c5c90-8cc0-732b-81ce-b1c92b324b49" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c5cea-d6e9-7511-b373-edab03fcce70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7511-b373-edab03fcce70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c5cea-d6e9-7511-b373-edab03fcce70" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7511-b373-edab03fcce70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c5cea-d6e9-7511-b373-edab03fcce70" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019c5c90-8cc0-7829-b961-d00b15b6d79f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019c5c90-8cc0-7829-b961-d00b15b6d79f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019c5c90-8cc0-7588-a321-11c8e016df3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019c5c90-8cc0-7588-a321-11c8e016df3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019c5c90-8cc0-79a9-9093-e9fc33b06640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:to="loc_us-gaap_CommercialPaperMember_019c5c90-8cc0-79a9-9093-e9fc33b06640" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019c5c90-8cc0-747d-bdc5-8845ff1ae76c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:to="loc_us-gaap_EquitySecuritiesMember_019c5c90-8cc0-747d-bdc5-8845ff1ae76c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c5c90-8cc0-7b3a-8dfd-66d3a34f2f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c5c90-8cc0-7b3a-8dfd-66d3a34f2f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_019c5ce8-6113-70e3-96cb-0951e40c5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_019c5ce8-6113-70e3-96cb-0951e40c5ed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_019c5ce8-7e33-7f90-b657-5d76ca3d31ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_019c5ce8-7e33-7f90-b657-5d76ca3d31ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c5ce9-349e-7113-a634-c289f4382f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c5ce9-349e-7113-a634-c289f4382f41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c5ceb-8090-79bf-9bb2-41b43fa31e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c5ceb-8090-79bf-9bb2-41b43fa31e6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c5cea-0247-7c7b-b51a-17c676309f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c5ceb-8090-79bf-9bb2-41b43fa31e6d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c5cea-0247-7c7b-b51a-17c676309f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c5cea-14b8-7264-89a7-5ebf17d20d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c5ceb-8090-79bf-9bb2-41b43fa31e6d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c5cea-14b8-7264-89a7-5ebf17d20d1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c5ceb-5b74-711f-bcda-75c212266034" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c5ceb-5b74-711f-bcda-75c212266034" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c5cea-6ba3-7adf-b089-e72f1ffca020" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c5ceb-5b74-711f-bcda-75c212266034" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c5cea-6ba3-7adf-b089-e72f1ffca020" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c5cea-7d19-7875-846c-676b30cdb046" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c5ceb-5b74-711f-bcda-75c212266034" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c5cea-7d19-7875-846c-676b30cdb046" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5a3d26fc-fde6-4e4e-9491-fe04f56a0ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5a3d26fc-fde6-4e4e-9491-fe04f56a0ce4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_837a7420-ae12-4881-9c98-28b38f273c51" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5a3d26fc-fde6-4e4e-9491-fe04f56a0ce4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_837a7420-ae12-4881-9c98-28b38f273c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_837a7420-ae12-4881-9c98-28b38f273c51_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_837a7420-ae12-4881-9c98-28b38f273c51" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_837a7420-ae12-4881-9c98-28b38f273c51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_837a7420-ae12-4881-9c98-28b38f273c51" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafesMember_7c9645ef-b95d-469f-a32f-451abed709f9" xlink:href="dna-20251231.xsd#dna_SafesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_SafesMember_7c9645ef-b95d-469f-a32f-451abed709f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NonMarketableEquitySecuritiesMember_e9ac50ed-07e9-4c3c-8a8e-3fa86243ac1b" xlink:href="dna-20251231.xsd#dna_NonMarketableEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_NonMarketableEquitySecuritiesMember_e9ac50ed-07e9-4c3c-8a8e-3fa86243ac1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MarketableEquitySecuritiesMember_0f379e71-18b9-4034-9a41-d8e92788500b" xlink:href="dna-20251231.xsd#dna_MarketableEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_MarketableEquitySecuritiesMember_0f379e71-18b9-4034-9a41-d8e92788500b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaIncPreferredStockMember_7c920c19-df2c-41fa-bbea-996a6609dd54" xlink:href="dna-20251231.xsd#dna_GenomaticaIncPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_GenomaticaIncPreferredStockMember_7c920c19-df2c-41fa-bbea-996a6609dd54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SynlogicIncWarrantMember_36980883-5ab5-4e23-a2e6-ff4001edffe2" xlink:href="dna-20251231.xsd#dna_SynlogicIncWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_SynlogicIncWarrantMember_36980883-5ab5-4e23-a2e6-ff4001edffe2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditLlcMember_898e22f3-aceb-4e3b-95f9-38c6e3cc76fb" xlink:href="dna-20251231.xsd#dna_BiomeditLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_BiomeditLlcMember_898e22f3-aceb-4e3b-95f9-38c6e3cc76fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherEquityInvestessMember_969cb049-c46a-49d7-8d25-0acd5b72b0da" xlink:href="dna-20251231.xsd#dna_OtherEquityInvestessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_OtherEquityInvestessMember_969cb049-c46a-49d7-8d25-0acd5b72b0da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8118f3b7-1829-4606-b3f0-2dd133914260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8118f3b7-1829-4606-b3f0-2dd133914260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_817fa631-0e29-4be6-a23e-80d8075f91bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_817fa631-0e29-4be6-a23e-80d8075f91bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_d50e727b-2846-449a-833f-74a589ac431b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_Investments_d50e727b-2846-449a-833f-74a589ac431b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_50da5a01-2ab1-4d76-a566-a7a968f3a95c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_GainLossOnInvestments_50da5a01-2ab1-4d76-a566-a7a968f3a95c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f90cee1c-6807-4e97-bdf6-94eb80bae9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f90cee1c-6807-4e97-bdf6-94eb80bae9e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_254469df-a12e-44e7-8401-4bd0e61aab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_EquityMethodInvestments_254469df-a12e-44e7-8401-4bd0e61aab7f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49927493-6a09-4eb3-bb35-f26ddaa05e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49927493-6a09-4eb3-bb35-f26ddaa05e5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f8b65fc3-9bb3-4723-8617-948ca97885c0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49927493-6a09-4eb3-bb35-f26ddaa05e5d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f8b65fc3-9bb3-4723-8617-948ca97885c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f8b65fc3-9bb3-4723-8617-948ca97885c0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f8b65fc3-9bb3-4723-8617-948ca97885c0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f8b65fc3-9bb3-4723-8617-948ca97885c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e8a83b6a-bf5f-42ac-9d83-25b12bacf406" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f8b65fc3-9bb3-4723-8617-948ca97885c0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e8a83b6a-bf5f-42ac-9d83-25b12bacf406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NonMarketableEquitySecuritiesMember_0c781b10-f4ab-4e1d-a743-3b30c014082f" xlink:href="dna-20251231.xsd#dna_NonMarketableEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e8a83b6a-bf5f-42ac-9d83-25b12bacf406" xlink:to="loc_dna_NonMarketableEquitySecuritiesMember_0c781b10-f4ab-4e1d-a743-3b30c014082f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_117e52cb-60df-4d78-8279-6f4cc9cfeb65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_117e52cb-60df-4d78-8279-6f4cc9cfeb65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_37f80c48-6c71-48c5-be1d-af296e51af72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_37f80c48-6c71-48c5-be1d-af296e51af72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_9360e803-3a87-4cb1-a88a-e38499de0fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_9360e803-3a87-4cb1-a88a-e38499de0fa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_ee2c77ae-f65c-478c-9bb2-4b0f5abeb7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:to="loc_us-gaap_Investments_ee2c77ae-f65c-478c-9bb2-4b0f5abeb7f0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b961f137-09a0-4ba3-aeac-da6962cbbbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b961f137-09a0-4ba3-aeac-da6962cbbbb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b961f137-09a0-4ba3-aeac-da6962cbbbb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b961f137-09a0-4ba3-aeac-da6962cbbbb4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b961f137-09a0-4ba3-aeac-da6962cbbbb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f17c9421-51bd-433c-8885-334ae6d7bd82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b961f137-09a0-4ba3-aeac-da6962cbbbb4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f17c9421-51bd-433c-8885-334ae6d7bd82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgBiomeInc.Member_5403ff2f-6a1b-45fa-a4af-072f36dd0c30" xlink:href="dna-20251231.xsd#dna_AgBiomeInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f17c9421-51bd-433c-8885-334ae6d7bd82" xlink:to="loc_dna_AgBiomeInc.Member_5403ff2f-6a1b-45fa-a4af-072f36dd0c30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7ee53d9d-1118-4f43-85b0-fd50ace755f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7ee53d9d-1118-4f43-85b0-fd50ace755f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7ee53d9d-1118-4f43-85b0-fd50ace755f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7ee53d9d-1118-4f43-85b0-fd50ace755f8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7ee53d9d-1118-4f43-85b0-fd50ace755f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_12187ce7-fac1-48d9-a349-9af413000342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7ee53d9d-1118-4f43-85b0-fd50ace755f8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_12187ce7-fac1-48d9-a349-9af413000342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_dad7c7cb-f656-49b3-add8-dd562d8557e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_12187ce7-fac1-48d9-a349-9af413000342" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_dad7c7cb-f656-49b3-add8-dd562d8557e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a5bcabf-ed8d-4231-ab87-aaef03ba66b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a5bcabf-ed8d-4231-ab87-aaef03ba66b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5a5bcabf-ed8d-4231-ab87-aaef03ba66b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a5bcabf-ed8d-4231-ab87-aaef03ba66b6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5a5bcabf-ed8d-4231-ab87-aaef03ba66b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_730111a7-e747-48ea-8e83-b17006578eba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a5bcabf-ed8d-4231-ab87-aaef03ba66b6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_730111a7-e747-48ea-8e83-b17006578eba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AltarSasMember_cc49d179-71d7-4206-8190-40d11ceb18ed" xlink:href="dna-20251231.xsd#dna_AltarSasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_730111a7-e747-48ea-8e83-b17006578eba" xlink:to="loc_dna_AltarSasMember_cc49d179-71d7-4206-8190-40d11ceb18ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_f0e15f30-3a36-4fa8-927e-74e2d8de65d0" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_730111a7-e747-48ea-8e83-b17006578eba" xlink:to="loc_dna_ZymergenMember_f0e15f30-3a36-4fa8-927e-74e2d8de65d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GoodwillImpairmentDCFWeight_019c9013-2acc-745d-9ad3-d84def4ebeb1" xlink:href="dna-20251231.xsd#dna_GoodwillImpairmentDCFWeight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_dna_GoodwillImpairmentDCFWeight_019c9013-2acc-745d-9ad3-d84def4ebeb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GoodwillImpairmentGPCWeight_019c9013-989e-7e63-97b4-3a301b534c5c" xlink:href="dna-20251231.xsd#dna_GoodwillImpairmentGPCWeight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_dna_GoodwillImpairmentGPCWeight_019c9013-989e-7e63-97b4-3a301b534c5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a1dbaeb4-c81e-4068-8546-c6872557337e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a1dbaeb4-c81e-4068-8546-c6872557337e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fba86350-3dcb-4253-b90b-499b1326c4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fba86350-3dcb-4253-b90b-499b1326c4a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_73e90646-e16a-4e7e-a9e7-0610a2a8b6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_73e90646-e16a-4e7e-a9e7-0610a2a8b6ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6ef62589-b2f5-43d4-947c-eb9b2b6f3a17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6ef62589-b2f5-43d4-947c-eb9b2b6f3a17" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3867579d-39bd-4723-b0f6-86cabb3ea7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3867579d-39bd-4723-b0f6-86cabb3ea7d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ac75a7d5-0e08-4854-aca8-017fc50e959c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3867579d-39bd-4723-b0f6-86cabb3ea7d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ac75a7d5-0e08-4854-aca8-017fc50e959c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac75a7d5-0e08-4854-aca8-017fc50e959c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ac75a7d5-0e08-4854-aca8-017fc50e959c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac75a7d5-0e08-4854-aca8-017fc50e959c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60ab09eb-cdc5-43d6-9940-4d1b32b04f26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ac75a7d5-0e08-4854-aca8-017fc50e959c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60ab09eb-cdc5-43d6-9940-4d1b32b04f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_dcb5d254-cbda-4019-a053-9f4da5b87ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60ab09eb-cdc5-43d6-9940-4d1b32b04f26" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_dcb5d254-cbda-4019-a053-9f4da5b87ceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3673a207-311e-48a9-ba08-c1c8efbad224" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3673a207-311e-48a9-ba08-c1c8efbad224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca73e384-b141-4a02-9b97-639d8750fa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca73e384-b141-4a02-9b97-639d8750fa4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_31f76285-db86-4536-8db7-23d25cf5ffb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_31f76285-db86-4536-8db7-23d25cf5ffb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1fc7a878-04c2-43fd-ba6c-61b663fa8f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1fc7a878-04c2-43fd-ba6c-61b663fa8f8d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c39b1c9-41c4-4143-9c77-6cd7e00c4eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c39b1c9-41c4-4143-9c77-6cd7e00c4eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c39b1c9-41c4-4143-9c77-6cd7e00c4eab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c39b1c9-41c4-4143-9c77-6cd7e00c4eab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c39b1c9-41c4-4143-9c77-6cd7e00c4eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26125a98-cf34-4ed8-be09-bf8eeb0faee0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c39b1c9-41c4-4143-9c77-6cd7e00c4eab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26125a98-cf34-4ed8-be09-bf8eeb0faee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquipmentLeasesMember_37f58242-29ee-4c65-b8bc-144b2e15a774" xlink:href="dna-20251231.xsd#dna_EquipmentLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26125a98-cf34-4ed8-be09-bf8eeb0faee0" xlink:to="loc_dna_EquipmentLeasesMember_37f58242-29ee-4c65-b8bc-144b2e15a774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a957ab17-22f1-4086-bef2-0296f98e57a2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:to="loc_srt_RangeAxis_a957ab17-22f1-4086-bef2-0296f98e57a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a957ab17-22f1-4086-bef2-0296f98e57a2_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a957ab17-22f1-4086-bef2-0296f98e57a2" xlink:to="loc_srt_RangeMember_a957ab17-22f1-4086-bef2-0296f98e57a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4cc8f96a-7e4a-42b4-aa99-fa52f7d7c3b7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a957ab17-22f1-4086-bef2-0296f98e57a2" xlink:to="loc_srt_RangeMember_4cc8f96a-7e4a-42b4-aa99-fa52f7d7c3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_78235d61-057e-4ab2-a4c3-feebca9122c6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4cc8f96a-7e4a-42b4-aa99-fa52f7d7c3b7" xlink:to="loc_srt_MinimumMember_78235d61-057e-4ab2-a4c3-feebca9122c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b34a251-9662-4d37-a94b-c8bad6a0d6b6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4cc8f96a-7e4a-42b4-aa99-fa52f7d7c3b7" xlink:to="loc_srt_MaximumMember_7b34a251-9662-4d37-a94b-c8bad6a0d6b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfb04779-0365-4adc-903a-9ef450966159" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfb04779-0365-4adc-903a-9ef450966159" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cfb04779-0365-4adc-903a-9ef450966159_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfb04779-0365-4adc-903a-9ef450966159" xlink:to="loc_us-gaap_RelatedPartyDomain_cfb04779-0365-4adc-903a-9ef450966159_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_14a44f4a-7949-484f-9d9b-d0aa2d649b12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfb04779-0365-4adc-903a-9ef450966159" xlink:to="loc_us-gaap_RelatedPartyDomain_14a44f4a-7949-484f-9d9b-d0aa2d649b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f1b93534-3f7d-49f4-a22c-604298a6cd54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_14a44f4a-7949-484f-9d9b-d0aa2d649b12" xlink:to="loc_us-gaap_RelatedPartyMember_f1b93534-3f7d-49f4-a22c-604298a6cd54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_13e5e448-9eb4-43ec-a32e-c637c606e46e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_13e5e448-9eb4-43ec-a32e-c637c606e46e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_13e5e448-9eb4-43ec-a32e-c637c606e46e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_13e5e448-9eb4-43ec-a32e-c637c606e46e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_13e5e448-9eb4-43ec-a32e-c637c606e46e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d3bde41-8c76-4af7-b4e7-f1f2a32f8ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_13e5e448-9eb4-43ec-a32e-c637c606e46e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d3bde41-8c76-4af7-b4e7-f1f2a32f8ed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_8253b814-bfdf-45bd-9135-c733c2b6c30f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d3bde41-8c76-4af7-b4e7-f1f2a32f8ed9" xlink:to="loc_us-gaap_BuildingMember_8253b814-bfdf-45bd-9135-c733c2b6c30f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c78198a7-ee34-4e33-9012-43e51e14e7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d3bde41-8c76-4af7-b4e7-f1f2a32f8ed9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c78198a7-ee34-4e33-9012-43e51e14e7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dc39f553-a16b-4d12-b56c-5e300247b2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dc39f553-a16b-4d12-b56c-5e300247b2b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LesseeOperatingLeaseAreaOfRealEstateProperty_a43f2c28-99ce-48bd-93de-29e05d989b53" xlink:href="dna-20251231.xsd#dna_LesseeOperatingLeaseAreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_dna_LesseeOperatingLeaseAreaOfRealEstateProperty_a43f2c28-99ce-48bd-93de-29e05d989b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LesseeOperatingLeaseNumberOfExtensionOptions_019c9014-ff70-7adb-a09b-120e1ac40ccd" xlink:href="dna-20251231.xsd#dna_LesseeOperatingLeaseNumberOfExtensionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_dna_LesseeOperatingLeaseNumberOfExtensionOptions_019c9014-ff70-7adb-a09b-120e1ac40ccd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_cab64411-560a-4eed-86da-1e335b402edb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_cab64411-560a-4eed-86da-1e335b402edb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_c9b7d941-f3b3-4093-a8ce-2ed10ff5db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_c9b7d941-f3b3-4093-a8ce-2ed10ff5db2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_7bf4c169-b684-48d2-855f-23bfb4d12548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_7bf4c169-b684-48d2-855f-23bfb4d12548" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_462fa007-d118-4ecd-b5b5-b0931f1eae46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_SubleaseIncome_462fa007-d118-4ecd-b5b5-b0931f1eae46" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3a5e3950-e3e8-458a-938c-e5d385cf4e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3a5e3950-e3e8-458a-938c-e5d385cf4e78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23c16c9e-ee09-4736-a2a3-65c0946de749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3a5e3950-e3e8-458a-938c-e5d385cf4e78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23c16c9e-ee09-4736-a2a3-65c0946de749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_23c16c9e-ee09-4736-a2a3-65c0946de749_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23c16c9e-ee09-4736-a2a3-65c0946de749" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_23c16c9e-ee09-4736-a2a3-65c0946de749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23c16c9e-ee09-4736-a2a3-65c0946de749" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LabEquipmentMember_0c60213e-66f8-471a-8f51-5760a2b59762" xlink:href="dna-20251231.xsd#dna_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_dna_LabEquipmentMember_0c60213e-66f8-471a-8f51-5760a2b59762" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_04c491e5-880a-4923-9536-2b7c2874ec37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_04c491e5-880a-4923-9536-2b7c2874ec37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_9a53a4b8-dc7c-4043-8b91-5994b9430f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_ManufacturingFacilityMember_9a53a4b8-dc7c-4043-8b91-5994b9430f6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_3620dd61-6ded-490c-979b-9f71da2661d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_ConstructionInProgressMember_3620dd61-6ded-490c-979b-9f71da2661d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ComputerEquipmentAndSoftwareMember_049e7db8-975f-4054-a3b7-b657ad6d8afd" xlink:href="dna-20251231.xsd#dna_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_dna_ComputerEquipmentAndSoftwareMember_049e7db8-975f-4054-a3b7-b657ad6d8afd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_239d0331-c605-4c68-b962-9d9dac29e746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_239d0331-c605-4c68-b962-9d9dac29e746" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_8296992c-8bf9-441b-a7c9-a8885c787860" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_LandMember_8296992c-8bf9-441b-a7c9-a8885c787860" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6df45faa-fb68-4c40-8509-5f6c9f5eeec4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6df45faa-fb68-4c40-8509-5f6c9f5eeec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8ace023c-680c-46a9-87d3-f8c337ffeb03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8ace023c-680c-46a9-87d3-f8c337ffeb03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d03a8be9-279b-4952-bb79-7c2758af9865" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d03a8be9-279b-4952-bb79-7c2758af9865" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_10ba66a1-82ef-4fa3-ab4d-220c41669ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_10ba66a1-82ef-4fa3-ab4d-220c41669ee5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_88e81d69-f432-48d2-9fa3-ba14701c60c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_10ba66a1-82ef-4fa3-ab4d-220c41669ee5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_88e81d69-f432-48d2-9fa3-ba14701c60c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88e81d69-f432-48d2-9fa3-ba14701c60c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_88e81d69-f432-48d2-9fa3-ba14701c60c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_88e81d69-f432-48d2-9fa3-ba14701c60c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff0adce1-93e6-4ce5-a8d1-641333aac044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_88e81d69-f432-48d2-9fa3-ba14701c60c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff0adce1-93e6-4ce5-a8d1-641333aac044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_7c199ab6-fb0f-4ade-b589-3e6a3a64a486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff0adce1-93e6-4ce5-a8d1-641333aac044" xlink:to="loc_us-gaap_ConstructionInProgressMember_7c199ab6-fb0f-4ade-b589-3e6a3a64a486" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LabEquipmentMember_d46112a2-5a98-4479-ab00-91a42469db46" xlink:href="dna-20251231.xsd#dna_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff0adce1-93e6-4ce5-a8d1-641333aac044" xlink:to="loc_dna_LabEquipmentMember_d46112a2-5a98-4479-ab00-91a42469db46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7698fa96-4f10-4bbe-b72f-ec4a35aa7e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:to="loc_us-gaap_Depreciation_7698fa96-4f10-4bbe-b72f-ec4a35aa7e5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_16519ebb-15db-463d-a953-ddc92005d00c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_16519ebb-15db-463d-a953-ddc92005d00c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment_9b489878-7848-439c-84c5-e06b64dbc701" xlink:href="dna-20251231.xsd#dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:to="loc_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment_9b489878-7848-439c-84c5-e06b64dbc701" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_d4e44a39-c163-4805-be00-1854ea37dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_AssetAcquisitionAxis_d4e44a39-c163-4805-be00-1854ea37dca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d4e44a39-c163-4805-be00-1854ea37dca8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d4e44a39-c163-4805-be00-1854ea37dca8" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d4e44a39-c163-4805-be00-1854ea37dca8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_7b6a2645-0532-4fba-a99d-fe01875699cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d4e44a39-c163-4805-be00-1854ea37dca8" xlink:to="loc_us-gaap_AssetAcquisitionDomain_7b6a2645-0532-4fba-a99d-fe01875699cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StridebioMember_8bcdcb2e-9d19-4f70-aba0-53930df0a000" xlink:href="dna-20251231.xsd#dna_StridebioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7b6a2645-0532-4fba-a99d-fe01875699cf" xlink:to="loc_dna_StridebioMember_8bcdcb2e-9d19-4f70-aba0-53930df0a000" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f6713d2d-ac37-4bac-9bb4-a731789251e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f6713d2d-ac37-4bac-9bb4-a731789251e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f6713d2d-ac37-4bac-9bb4-a731789251e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f6713d2d-ac37-4bac-9bb4-a731789251e3" xlink:to="loc_us-gaap_ClassOfStockDomain_f6713d2d-ac37-4bac-9bb4-a731789251e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_64d224ec-cd49-4643-ba3c-e8e846de2e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f6713d2d-ac37-4bac-9bb4-a731789251e3" xlink:to="loc_us-gaap_ClassOfStockDomain_64d224ec-cd49-4643-ba3c-e8e846de2e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_235fed98-f95d-4fc8-aada-856eb98e8935" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64d224ec-cd49-4643-ba3c-e8e846de2e2f" xlink:to="loc_us-gaap_CommonClassAMember_235fed98-f95d-4fc8-aada-856eb98e8935" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_019c5ca4-7248-7b8e-94de-421e128ac012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_OtherCommitmentsAxis_019c5ca4-7248-7b8e-94de-421e128ac012" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_019c5ca4-7248-7b8e-94de-421e128ac012_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_019c5ca4-7248-7b8e-94de-421e128ac012" xlink:to="loc_us-gaap_OtherCommitmentsDomain_019c5ca4-7248-7b8e-94de-421e128ac012_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_019c5ca4-7248-762b-81e5-b86bf892d4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_019c5ca4-7248-7b8e-94de-421e128ac012" xlink:to="loc_us-gaap_OtherCommitmentsDomain_019c5ca4-7248-762b-81e5-b86bf892d4ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember_019c5ca4-7248-79de-aece-af6ab6ef45fd" xlink:href="dna-20251231.xsd#dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019c5ca4-7248-762b-81e5-b86bf892d4ad" xlink:to="loc_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember_019c5ca4-7248-79de-aece-af6ab6ef45fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019c5ca4-7248-77d6-9afb-22cc21b34137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019c5ca4-7248-77d6-9afb-22cc21b34137" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019c5ca4-7248-77d6-9afb-22cc21b34137_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019c5ca4-7248-77d6-9afb-22cc21b34137" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019c5ca4-7248-77d6-9afb-22cc21b34137_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019c5ca4-7248-752e-9721-eebd35811c36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019c5ca4-7248-77d6-9afb-22cc21b34137" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019c5ca4-7248-752e-9721-eebd35811c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019c5ca4-7248-7781-9dc3-dd4d21687831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019c5ca4-7248-752e-9721-eebd35811c36" xlink:to="loc_us-gaap_SubsequentEventMember_019c5ca4-7248-7781-9dc3-dd4d21687831" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019c5ca4-7248-7cc2-8eff-4fd5ef989507" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_srt_StatementScenarioAxis_019c5ca4-7248-7cc2-8eff-4fd5ef989507" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019c5ca4-7248-7cc2-8eff-4fd5ef989507_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_019c5ca4-7248-7cc2-8eff-4fd5ef989507" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019c5ca4-7248-7cc2-8eff-4fd5ef989507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019c5ca4-7248-79da-8b34-163f44303b6f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_019c5ca4-7248-7cc2-8eff-4fd5ef989507" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019c5ca4-7248-79da-8b34-163f44303b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019c5ca4-7248-7b3e-a15f-1e74ec1fbd34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019c5ca4-7248-79da-8b34-163f44303b6f" xlink:to="loc_srt_ScenarioForecastMember_019c5ca4-7248-7b3e-a15f-1e74ec1fbd34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9666-2021-7efd-a4d1-7e9160913f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9666-2021-7efd-a4d1-7e9160913f81" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c9666-2021-7efd-a4d1-7e9160913f81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9666-2021-7efd-a4d1-7e9160913f81" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c9666-2021-7efd-a4d1-7e9160913f81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c9666-2021-7c23-b94c-a19c00d8c682" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9666-2021-7efd-a4d1-7e9160913f81" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c9666-2021-7c23-b94c-a19c00d8c682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuretyBondMember_019c9666-2021-7d3e-9ade-f83b73bf7174" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuretyBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c9666-2021-7c23-b94c-a19c00d8c682" xlink:to="loc_us-gaap_SuretyBondMember_019c9666-2021-7d3e-9ade-f83b73bf7174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm_2cede8da-7ddb-4f35-a07c-b0549c3aedbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm_2cede8da-7ddb-4f35-a07c-b0549c3aedbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_3d60a6ff-2936-4f85-8d6f-504689f49c20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_3d60a6ff-2936-4f85-8d6f-504689f49c20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_e04e3983-5f0e-4f05-a7de-c15b6a9b5448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_e04e3983-5f0e-4f05-a7de-c15b6a9b5448" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_05139c4a-8fc4-4f48-94a3-0951246c15aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_05139c4a-8fc4-4f48-94a3-0951246c15aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_d08526fa-df4e-47d3-85b3-bf758bea510e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_d08526fa-df4e-47d3-85b3-bf758bea510e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_e1d1499d-937c-42fe-b3b5-600aabb8282b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_e1d1499d-937c-42fe-b3b5-600aabb8282b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix_019c5ca4-7248-7b49-bed1-840dd2c3cac9" xlink:href="dna-20251231.xsd#dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix_019c5ca4-7248-7b49-bed1-840dd2c3cac9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases_29fce391-06ef-46ea-8a18-0c214b46ddb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases_29fce391-06ef-46ea-8a18-0c214b46ddb7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContractualShortfallLiability_019c9017-ce5d-7554-8fb2-6b2e3253066a" xlink:href="dna-20251231.xsd#dna_ContractualShortfallLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_ContractualShortfallLiability_019c9017-ce5d-7554-8fb2-6b2e3253066a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContractualShortfallLiabilityRequiredPayment_019c9018-b952-7b2f-9bac-f378f11cbe8a" xlink:href="dna-20251231.xsd#dna_ContractualShortfallLiabilityRequiredPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_ContractualShortfallLiabilityRequiredPayment_019c9018-b952-7b2f-9bac-f378f11cbe8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_274a9e2e-a587-49bd-bf42-f24ce0543f18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_274a9e2e-a587-49bd-bf42-f24ce0543f18" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_e9fea904-437f-4c32-bd6a-a52262f4c95b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_PaymentsForRoyalties_e9fea904-437f-4c32-bd6a-a52262f4c95b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RoyaltyReceivedFromLicensingRevenue_17edbb33-6721-45ab-8029-7a4d57cd712a" xlink:href="dna-20251231.xsd#dna_RoyaltyReceivedFromLicensingRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_RoyaltyReceivedFromLicensingRevenue_17edbb33-6721-45ab-8029-7a4d57cd712a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct_e89eee17-88ac-4e01-ac9a-f42bb1c11538" xlink:href="dna-20251231.xsd#dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct_e89eee17-88ac-4e01-ac9a-f42bb1c11538" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_019c5ca4-7248-700a-b5fc-3357ba1cff7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_OtherCommitment_019c5ca4-7248-700a-b5fc-3357ba1cff7f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContracts_019c5ca4-7248-75c5-a66d-e1636f207519" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossOnContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_LossOnContracts_019c5ca4-7248-75c5-a66d-e1636f207519" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LossContingencyAmountRequiredToFund_019c9666-2021-77b9-9196-15ee1ae7d43b" xlink:href="dna-20251231.xsd#dna_LossContingencyAmountRequiredToFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_LossContingencyAmountRequiredToFund_019c9666-2021-77b9-9196-15ee1ae7d43b" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockholdersEquityScheduleofCapitalizationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_69b514a3-e679-4cf4-b92a-cdef55b376df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_69b514a3-e679-4cf4-b92a-cdef55b376df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6186b902-9b6a-4cbc-a8d4-49c7c1cfa839" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_69b514a3-e679-4cf4-b92a-cdef55b376df" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6186b902-9b6a-4cbc-a8d4-49c7c1cfa839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6186b902-9b6a-4cbc-a8d4-49c7c1cfa839_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6186b902-9b6a-4cbc-a8d4-49c7c1cfa839" xlink:to="loc_us-gaap_ClassOfStockDomain_6186b902-9b6a-4cbc-a8d4-49c7c1cfa839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6186b902-9b6a-4cbc-a8d4-49c7c1cfa839" xlink:to="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_be3ccf3b-8331-4570-b4c3-756716287ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:to="loc_us-gaap_CommonClassAMember_be3ccf3b-8331-4570-b4c3-756716287ea5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ca965ffe-6ce7-40c2-b8aa-f0ab64af348a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:to="loc_us-gaap_CommonClassBMember_ca965ffe-6ce7-40c2-b8aa-f0ab64af348a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_53f07766-df9a-4aef-93b2-37f83450c515" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:to="loc_us-gaap_CommonClassCMember_53f07766-df9a-4aef-93b2-37f83450c515" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4912c138-704a-4c62-904c-0c95830fc94d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4912c138-704a-4c62-904c-0c95830fc94d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f14ce1b7-2b21-4278-b3dd-b313984dae30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:to="loc_us-gaap_CommonStockSharesIssued_f14ce1b7-2b21-4278-b3dd-b313984dae30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cdade0f6-9191-4c79-92e0-9e5f0a257918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cdade0f6-9191-4c79-92e0-9e5f0a257918" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d46cf508-aedc-4dae-a7b9-40fd71bad897" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d46cf508-aedc-4dae-a7b9-40fd71bad897" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_55233545-1f60-41f0-bab6-8cbfa3ad9be4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d46cf508-aedc-4dae-a7b9-40fd71bad897" xlink:to="loc_us-gaap_StatementClassOfStockAxis_55233545-1f60-41f0-bab6-8cbfa3ad9be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_55233545-1f60-41f0-bab6-8cbfa3ad9be4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_55233545-1f60-41f0-bab6-8cbfa3ad9be4" xlink:to="loc_us-gaap_ClassOfStockDomain_55233545-1f60-41f0-bab6-8cbfa3ad9be4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_55233545-1f60-41f0-bab6-8cbfa3ad9be4" xlink:to="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NewGinkgoPreferredStockMember_ab9cae2f-a84b-4971-8b6f-6644a160bfdf" xlink:href="dna-20251231.xsd#dna_NewGinkgoPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:to="loc_dna_NewGinkgoPreferredStockMember_ab9cae2f-a84b-4971-8b6f-6644a160bfdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ac3fbfc3-39c2-421b-a756-aca5f6bc8442" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:to="loc_us-gaap_CommonClassAMember_ac3fbfc3-39c2-421b-a756-aca5f6bc8442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_4923cce0-2cc5-4a7a-b386-9911497dded2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:to="loc_us-gaap_CommonClassBMember_4923cce0-2cc5-4a7a-b386-9911497dded2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_4f85f550-42b1-4aea-b757-ffc606327243" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:to="loc_us-gaap_CommonClassCMember_4f85f550-42b1-4aea-b757-ffc606327243" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019c5ca7-12fd-7ee6-a206-0989fee39125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d46cf508-aedc-4dae-a7b9-40fd71bad897" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019c5ca7-12fd-7ee6-a206-0989fee39125" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7ee6-a206-0989fee39125_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019c5ca7-12fd-7ee6-a206-0989fee39125" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7ee6-a206-0989fee39125_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7493-a437-5fba24e29065" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019c5ca7-12fd-7ee6-a206-0989fee39125" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7493-a437-5fba24e29065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ATMProgramMember_019c5ca7-376d-70c0-b05d-e12fcbca9479" xlink:href="dna-20251231.xsd#dna_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7493-a437-5fba24e29065" xlink:to="loc_dna_ATMProgramMember_019c5ca7-376d-70c0-b05d-e12fcbca9479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SalesAgreementWithAllenCompanyLLCMember_019c5ca7-8f0e-7227-9df8-d44aac9cd74c" xlink:href="dna-20251231.xsd#dna_SalesAgreementWithAllenCompanyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7493-a437-5fba24e29065" xlink:to="loc_dna_SalesAgreementWithAllenCompanyLLCMember_019c5ca7-8f0e-7227-9df8-d44aac9cd74c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_44b94447-808b-40e8-ae99-50e502828d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_44b94447-808b-40e8-ae99-50e502828d1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a63d47a2-abf0-4b5e-ac46-9d6e55cab976" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a63d47a2-abf0-4b5e-ac46-9d6e55cab976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3c17487b-2e9d-4d8f-a77e-215dde5d65aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3c17487b-2e9d-4d8f-a77e-215dde5d65aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0fd5e42d-1d81-4c92-b5ad-435442aaf9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0fd5e42d-1d81-4c92-b5ad-435442aaf9f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f00796fc-88e5-436a-9080-145c129056b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f00796fc-88e5-436a-9080-145c129056b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2a25a142-0ac8-4a4e-a24d-dc73376e1edb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2a25a142-0ac8-4a4e-a24d-dc73376e1edb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c9c75bc0-e281-4dd9-8538-334fcef394d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c9c75bc0-e281-4dd9-8538-334fcef394d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CommonStockVotingRight_11522957-d07a-4fee-93d7-ac440c28fbf4" xlink:href="dna-20251231.xsd#dna_CommonStockVotingRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_dna_CommonStockVotingRight_11522957-d07a-4fee-93d7-ac440c28fbf4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_8d54ddb0-6896-4244-94a0-05103d346944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_Dividends_8d54ddb0-6896-4244-94a0-05103d346944" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SaleOfStockAuthorizedAmount_019c5ca6-87bc-7c2c-932b-42b8f4dc2cd3" xlink:href="dna-20251231.xsd#dna_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_dna_SaleOfStockAuthorizedAmount_019c5ca6-87bc-7c2c-932b-42b8f4dc2cd3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CommonStockConversionRatio_019c9121-0d47-765c-93fd-c71c72d548bf" xlink:href="dna-20251231.xsd#dna_CommonStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_dna_CommonStockConversionRatio_019c9121-0d47-765c-93fd-c71c72d548bf" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6b173b27-7230-4d81-b413-64aa38dc4d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b173b27-7230-4d81-b413-64aa38dc4d8c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5bf4d1e2-54c9-47b7-8d83-bdf323529f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:to="loc_us-gaap_AwardTypeAxis_5bf4d1e2-54c9-47b7-8d83-bdf323529f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5bf4d1e2-54c9-47b7-8d83-bdf323529f3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5bf4d1e2-54c9-47b7-8d83-bdf323529f3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5bf4d1e2-54c9-47b7-8d83-bdf323529f3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5bf4d1e2-54c9-47b7-8d83-bdf323529f3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_70effe29-13ce-42d7-8560-c973679291cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:to="loc_us-gaap_EmployeeStockOptionMember_70effe29-13ce-42d7-8560-c973679291cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c5ca8-54a0-7344-8401-2b0b68e30dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c5ca8-54a0-7344-8401-2b0b68e30dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019c5ca8-9fb9-781d-aedd-2cc28807a525" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:to="loc_us-gaap_PerformanceSharesMember_019c5ca8-9fb9-781d-aedd-2cc28807a525" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_38ee17b6-a3e3-42ea-b698-144f3d5d83e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:to="loc_us-gaap_PlanNameAxis_38ee17b6-a3e3-42ea-b698-144f3d5d83e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_38ee17b6-a3e3-42ea-b698-144f3d5d83e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_38ee17b6-a3e3-42ea-b698-144f3d5d83e4" xlink:to="loc_us-gaap_PlanNameDomain_38ee17b6-a3e3-42ea-b698-144f3d5d83e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_38ee17b6-a3e3-42ea-b698-144f3d5d83e4" xlink:to="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_fddc1983-9647-478b-ab80-f862fdf9b011" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:to="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_fddc1983-9647-478b-ab80-f862fdf9b011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_2bfc517e-06ef-4fe0-97d2-dde96995e0d3" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:to="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_2bfc517e-06ef-4fe0-97d2-dde96995e0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_InducementPlanMember_e27ffa12-19d4-4c63-9cb7-2d679cb863e1" xlink:href="dna-20251231.xsd#dna_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:to="loc_dna_InducementPlanMember_e27ffa12-19d4-4c63-9cb7-2d679cb863e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6dbedfbf-fdd9-45d3-9021-e88ad2adf080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6dbedfbf-fdd9-45d3-9021-e88ad2adf080" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6dbedfbf-fdd9-45d3-9021-e88ad2adf080_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6dbedfbf-fdd9-45d3-9021-e88ad2adf080" xlink:to="loc_us-gaap_EquityComponentDomain_6dbedfbf-fdd9-45d3-9021-e88ad2adf080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aecf8e2d-bcd9-4712-a262-782428f0e743" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6dbedfbf-fdd9-45d3-9021-e88ad2adf080" xlink:to="loc_us-gaap_EquityComponentDomain_aecf8e2d-bcd9-4712-a262-782428f0e743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_WarrantsToPurchaseClassACommonStockMember_2fa94e4f-15cd-4e15-8564-740a58339515" xlink:href="dna-20251231.xsd#dna_WarrantsToPurchaseClassACommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aecf8e2d-bcd9-4712-a262-782428f0e743" xlink:to="loc_dna_WarrantsToPurchaseClassACommonStockMember_2fa94e4f-15cd-4e15-8564-740a58339515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_97664f4f-3ab5-4506-8da7-ad165c2851d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b173b27-7230-4d81-b413-64aa38dc4d8c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_97664f4f-3ab5-4506-8da7-ad165c2851d1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationSummaryofStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_363333cf-de50-4ffa-b350-d727334552e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_363333cf-de50-4ffa-b350-d727334552e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a0e69cf6-31f8-4878-b6b5-4563cf14a3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a0e69cf6-31f8-4878-b6b5-4563cf14a3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a0e69cf6-31f8-4878-b6b5-4563cf14a3ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a0e69cf6-31f8-4878-b6b5-4563cf14a3ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a0e69cf6-31f8-4878-b6b5-4563cf14a3ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a0e69cf6-31f8-4878-b6b5-4563cf14a3ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60f502af-fa96-407f-b5a2-0a255bc487de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60f502af-fa96-407f-b5a2-0a255bc487de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e6b15207-f52f-4a93-beb7-da21a42d0f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e6b15207-f52f-4a93-beb7-da21a42d0f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_019c5ca9-522b-7069-9a96-80bea606e6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:to="loc_us-gaap_CostOfSalesMember_019c5ca9-522b-7069-9a96-80bea606e6ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c5ca9-7870-7e43-898d-91e8093bdc29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c5ca9-7870-7e43-898d-91e8093bdc29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c5ca9-7870-7e43-898d-91e8093bdc29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c5ca9-7870-7e43-898d-91e8093bdc29" xlink:to="loc_us-gaap_SegmentDomain_019c5ca9-7870-7e43-898d-91e8093bdc29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c5ca9-7870-7392-a702-df2cb3f9d24a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c5ca9-7870-7e43-898d-91e8093bdc29" xlink:to="loc_us-gaap_SegmentDomain_019c5ca9-7870-7392-a702-df2cb3f9d24a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiosecuritySegmentMember_019c5ca9-94b3-7ad4-a908-c023da44f690" xlink:href="dna-20251231.xsd#dna_BiosecuritySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019c5ca9-7870-7392-a702-df2cb3f9d24a" xlink:to="loc_dna_BiosecuritySegmentMember_019c5ca9-94b3-7ad4-a908-c023da44f690" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c5caa-1b36-74d9-a37c-315506832181" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:to="loc_srt_ProductOrServiceAxis_019c5caa-1b36-74d9-a37c-315506832181" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c5caa-1b36-74d9-a37c-315506832181_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c5caa-1b36-74d9-a37c-315506832181" xlink:to="loc_srt_ProductsAndServicesDomain_019c5caa-1b36-74d9-a37c-315506832181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c5caa-1b36-7151-9989-1cda26d976d6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c5caa-1b36-74d9-a37c-315506832181" xlink:to="loc_srt_ProductsAndServicesDomain_019c5caa-1b36-7151-9989-1cda26d976d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherRevenueMember_019c5ca9-ec70-7d02-8a34-c36ee7a10aea" xlink:href="dna-20251231.xsd#dna_OtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c5caa-1b36-7151-9989-1cda26d976d6" xlink:to="loc_dna_OtherRevenueMember_019c5ca9-ec70-7d02-8a34-c36ee7a10aea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_80276c9c-2517-406e-867f-b1765dea28bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_363333cf-de50-4ffa-b350-d727334552e6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_80276c9c-2517-406e-867f-b1765dea28bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_96e9a0da-3edb-4a3c-a547-22e4f8b2db66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_PlanNameAxis_96e9a0da-3edb-4a3c-a547-22e4f8b2db66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_96e9a0da-3edb-4a3c-a547-22e4f8b2db66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_96e9a0da-3edb-4a3c-a547-22e4f8b2db66" xlink:to="loc_us-gaap_PlanNameDomain_96e9a0da-3edb-4a3c-a547-22e4f8b2db66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_96e9a0da-3edb-4a3c-a547-22e4f8b2db66" xlink:to="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandTwentyTwoInducementPlanMember_de0c53fb-1ee8-4d0c-8a65-c021fbf9adcf" xlink:href="dna-20251231.xsd#dna_TwoThousandTwentyTwoInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:to="loc_dna_TwoThousandTwentyTwoInducementPlanMember_de0c53fb-1ee8-4d0c-8a65-c021fbf9adcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_0f2cfb79-f665-41c8-932c-83b31ebcaadc" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:to="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_0f2cfb79-f665-41c8-932c-83b31ebcaadc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_00d5c583-83dc-4a5d-9170-6b1b882f0c04" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:to="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_00d5c583-83dc-4a5d-9170-6b1b882f0c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b2a74660-7ffd-4b8f-b9f2-26a3bd6403d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b2a74660-7ffd-4b8f-b9f2-26a3bd6403d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b2a74660-7ffd-4b8f-b9f2-26a3bd6403d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2a74660-7ffd-4b8f-b9f2-26a3bd6403d3" xlink:to="loc_us-gaap_EquityComponentDomain_b2a74660-7ffd-4b8f-b9f2-26a3bd6403d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aef04fe6-86eb-4682-9deb-fb23d7ef5b67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2a74660-7ffd-4b8f-b9f2-26a3bd6403d3" xlink:to="loc_us-gaap_EquityComponentDomain_aef04fe6-86eb-4682-9deb-fb23d7ef5b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_61f9ee09-7d41-48a1-ae4a-d79f7f84733e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aef04fe6-86eb-4682-9deb-fb23d7ef5b67" xlink:to="loc_us-gaap_CommonStockMember_61f9ee09-7d41-48a1-ae4a-d79f7f84733e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_94981200-d0c5-4589-af26-c8821d78b294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_AwardTypeAxis_94981200-d0c5-4589-af26-c8821d78b294" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94981200-d0c5-4589-af26-c8821d78b294_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_94981200-d0c5-4589-af26-c8821d78b294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94981200-d0c5-4589-af26-c8821d78b294_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_94981200-d0c5-4589-af26-c8821d78b294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a1a75580-1547-49ce-8ce3-d39258eff170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a1a75580-1547-49ce-8ce3-d39258eff170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_452a14ce-fecd-4964-bc7a-65355fbcd687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_us-gaap_RestrictedStockMember_452a14ce-fecd-4964-bc7a-65355fbcd687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5815eda0-f195-4283-bcb0-c941cd50a24f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5815eda0-f195-4283-bcb0-c941cd50a24f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnoutRestrictedStockUnitsMember_71faa61e-395a-49b2-b924-138eb0a91727" xlink:href="dna-20251231.xsd#dna_EarnoutRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_dna_EarnoutRestrictedStockUnitsMember_71faa61e-395a-49b2-b924-138eb0a91727" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FounderOptionsMember_1cbd6fa6-8d0c-4ec7-bc1e-0e67d0ed6a2e" xlink:href="dna-20251231.xsd#dna_FounderOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_dna_FounderOptionsMember_1cbd6fa6-8d0c-4ec7-bc1e-0e67d0ed6a2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019c5cb3-e587-7305-9286-1f3a8a1b29aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_us-gaap_PerformanceSharesMember_019c5cb3-e587-7305-9286-1f3a8a1b29aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FounderPSUAwardsMember_019c5cb4-e5da-7eae-92f4-d25f2cb090be" xlink:href="dna-20251231.xsd#dna_FounderPSUAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_dna_FounderPSUAwardsMember_019c5cb4-e5da-7eae-92f4-d25f2cb090be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b56663ee-448b-4a4d-8f38-94f2245dd2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b56663ee-448b-4a4d-8f38-94f2245dd2b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b56663ee-448b-4a4d-8f38-94f2245dd2b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b56663ee-448b-4a4d-8f38-94f2245dd2b3" xlink:to="loc_us-gaap_ClassOfStockDomain_b56663ee-448b-4a4d-8f38-94f2245dd2b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cde8a729-ddde-44e0-92df-22911c45fb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b56663ee-448b-4a4d-8f38-94f2245dd2b3" xlink:to="loc_us-gaap_ClassOfStockDomain_cde8a729-ddde-44e0-92df-22911c45fb4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnOutSharesMember_98126c81-0da5-41b5-acf4-874901d3cc7c" xlink:href="dna-20251231.xsd#dna_EarnOutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cde8a729-ddde-44e0-92df-22911c45fb4f" xlink:to="loc_dna_EarnOutSharesMember_98126c81-0da5-41b5-acf4-874901d3cc7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5223761f-4cf0-4137-ba0b-4e87a83c4216" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_VestingAxis_5223761f-4cf0-4137-ba0b-4e87a83c4216" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5223761f-4cf0-4137-ba0b-4e87a83c4216_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_5223761f-4cf0-4137-ba0b-4e87a83c4216" xlink:to="loc_us-gaap_VestingDomain_5223761f-4cf0-4137-ba0b-4e87a83c4216_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_5223761f-4cf0-4137-ba0b-4e87a83c4216" xlink:to="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e0033465-845d-487c-9cf0-1454a1a9a165" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e0033465-845d-487c-9cf0-1454a1a9a165" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d10edc4f-2314-46e3-b8fb-23f523a610da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d10edc4f-2314-46e3-b8fb-23f523a610da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_047f9024-a68c-403d-85d8-cd3d9f59a300" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_047f9024-a68c-403d-85d8-cd3d9f59a300" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationAwardTrancheFourMember_821fc866-f995-4e7f-abd3-859511836c67" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationAwardTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:to="loc_dna_ShareBasedCompensationAwardTrancheFourMember_821fc866-f995-4e7f-abd3-859511836c67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_01545eae-3a4f-4292-acdd-4638f2b78776" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_srt_RangeAxis_01545eae-3a4f-4292-acdd-4638f2b78776" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01545eae-3a4f-4292-acdd-4638f2b78776_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_01545eae-3a4f-4292-acdd-4638f2b78776" xlink:to="loc_srt_RangeMember_01545eae-3a4f-4292-acdd-4638f2b78776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ed97e9e-2a01-4b6c-9b1d-6b04c67373c7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_01545eae-3a4f-4292-acdd-4638f2b78776" xlink:to="loc_srt_RangeMember_2ed97e9e-2a01-4b6c-9b1d-6b04c67373c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2d277455-c4cd-46c9-a090-892901efd496" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2ed97e9e-2a01-4b6c-9b1d-6b04c67373c7" xlink:to="loc_srt_MinimumMember_2d277455-c4cd-46c9-a090-892901efd496" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3ff32171-0cc7-43e1-9945-fd5601ddd34d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2ed97e9e-2a01-4b6c-9b1d-6b04c67373c7" xlink:to="loc_srt_MaximumMember_3ff32171-0cc7-43e1-9945-fd5601ddd34d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f7514f7-d573-49a3-93ec-1ccaffb36132" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f7514f7-d573-49a3-93ec-1ccaffb36132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_06677c55-9c55-4449-9e8b-9939c6b4f5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_06677c55-9c55-4449-9e8b-9939c6b4f5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm_298a5249-10a9-4753-9426-fccf0e82c973" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm_298a5249-10a9-4753-9426-fccf0e82c973" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_e1a18ee0-681d-4bbd-b19c-37e92afe5c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_e1a18ee0-681d-4bbd-b19c-37e92afe5c4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b45e0254-2011-4ced-a281-eab7e1437a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b45e0254-2011-4ced-a281-eab7e1437a15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate_51f1e29e-5013-4736-a2aa-660769cf4fe8" xlink:href="dna-20251231.xsd#dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate_51f1e29e-5013-4736-a2aa-660769cf4fe8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d8beda6e-7436-41ef-991f-9f0ec71b5278" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d8beda6e-7436-41ef-991f-9f0ec71b5278" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TypesOfTimeBasedStockOptions_019c901a-b4f8-7188-8199-fb8179d47ab8" xlink:href="dna-20251231.xsd#dna_TypesOfTimeBasedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_TypesOfTimeBasedStockOptions_019c901a-b4f8-7188-8199-fb8179d47ab8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_c2ed765f-6033-4025-b25e-4767b0a0cf08" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_c2ed765f-6033-4025-b25e-4767b0a0cf08" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cb393f33-0a49-4a3b-8660-f67fa9167b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cb393f33-0a49-4a3b-8660-f67fa9167b5f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0812b5f9-5a0d-4e93-b0c1-2d2076a77579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0812b5f9-5a0d-4e93-b0c1-2d2076a77579" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dd8918df-d126-48dc-a28b-4df4e8deeac8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dd8918df-d126-48dc-a28b-4df4e8deeac8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eb8ab907-4064-4971-b010-ea030287d65a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eb8ab907-4064-4971-b010-ea030287d65a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfCompanyFounders_b27216c1-35af-4dd4-9a15-93eae0e5e21a" xlink:href="dna-20251231.xsd#dna_NumberOfCompanyFounders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_NumberOfCompanyFounders_b27216c1-35af-4dd4-9a15-93eae0e5e21a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be33fb9e-8a45-4ee7-a6da-cbfa8c2067d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be33fb9e-8a45-4ee7-a6da-cbfa8c2067d2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1509e0d8-1f30-4899-bae8-073c0afe9f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1509e0d8-1f30-4899-bae8-073c0afe9f0d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfStockPriceHurdles_019c901d-8297-75e3-bca3-609a60e2f3b8" xlink:href="dna-20251231.xsd#dna_NumberOfStockPriceHurdles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_NumberOfStockPriceHurdles_019c901d-8297-75e3-bca3-609a60e2f3b8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_34223fcb-8e86-45ac-b8d9-6e28e6c5a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_34223fcb-8e86-45ac-b8d9-6e28e6c5a0c0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_45e9c996-b0bd-4b2c-9952-92b5a98439b7" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_45e9c996-b0bd-4b2c-9952-92b5a98439b7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_600335d9-772d-4db4-9c37-88f005d71daa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_SharePrice_600335d9-772d-4db4-9c37-88f005d71daa" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfVestingConditions_019c901f-0aae-76db-92de-f765386b7f73" xlink:href="dna-20251231.xsd#dna_NumberOfVestingConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_NumberOfVestingConditions_019c901f-0aae-76db-92de-f765386b7f73" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_48571889-3212-493d-aa6b-a90b1af1d4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_48571889-3212-493d-aa6b-a90b1af1d4ca" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5f4033fe-f9c1-4d1c-8980-873076fa2a83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5f4033fe-f9c1-4d1c-8980-873076fa2a83" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_eed8f737-f3cb-4da5-babc-765cb7597c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_eed8f737-f3cb-4da5-babc-765cb7597c5c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c5cb4-c588-7b21-9004-31566306b0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c5cb4-c588-7b21-9004-31566306b0e2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019c5cb4-e5da-74c5-beed-dddc57102aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019c5cb4-e5da-74c5-beed-dddc57102aaa" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019c5cb4-e5da-79bb-943f-d3db77f3d176" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019c5cb4-e5da-79bb-943f-d3db77f3d176" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_019c5cb4-e5da-74f5-bf11-6c9ed358682d" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_019c5cb4-e5da-74f5-bf11-6c9ed358682d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019c5cb4-e5da-71c9-b559-61701f284864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019c5cb4-e5da-71c9-b559-61701f284864" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c5cb4-e5da-7eae-8ab2-730b72e4b84b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c5cb4-e5da-7eae-8ab2-730b72e4b84b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019c901c-13c4-7779-af4b-bca994b8c4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019c901c-13c4-7779-af4b-bca994b8c4fb" xlink:type="arc" order="30"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22dc240b-f0af-4224-91c7-50d505ecb983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22dc240b-f0af-4224-91c7-50d505ecb983" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ed2edf2f-c1db-4bd5-83bc-4880b9cbd7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22dc240b-f0af-4224-91c7-50d505ecb983" xlink:to="loc_us-gaap_AwardTypeAxis_ed2edf2f-c1db-4bd5-83bc-4880b9cbd7f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed2edf2f-c1db-4bd5-83bc-4880b9cbd7f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ed2edf2f-c1db-4bd5-83bc-4880b9cbd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed2edf2f-c1db-4bd5-83bc-4880b9cbd7f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06a496ad-d58f-4adc-8713-5af27d12b89a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ed2edf2f-c1db-4bd5-83bc-4880b9cbd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06a496ad-d58f-4adc-8713-5af27d12b89a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FounderOptionsMember_3041699a-840a-49b2-b4a0-c807a62e9b52" xlink:href="dna-20251231.xsd#dna_FounderOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06a496ad-d58f-4adc-8713-5af27d12b89a" xlink:to="loc_dna_FounderOptionsMember_3041699a-840a-49b2-b4a0-c807a62e9b52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_87195932-b0e4-4207-954a-a817a0e6280a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_87195932-b0e4-4207-954a-a817a0e6280a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e802a6c-d177-4e20-9bff-2428c63df366" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e802a6c-d177-4e20-9bff-2428c63df366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30988e1a-cc64-424b-a103-ffa60fadf650" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30988e1a-cc64-424b-a103-ffa60fadf650" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_d6f4e613-ac31-4326-b06b-4464d1aa17ff" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_d6f4e613-ac31-4326-b06b-4464d1aa17ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bcc3b450-5a77-450e-bf8b-1b9d87c74054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bcc3b450-5a77-450e-bf8b-1b9d87c74054" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6313f9ad-cdab-45b8-bfbd-96fdbf22e0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d36faa4-3715-4f8d-8270-c00cd47b85f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6313f9ad-cdab-45b8-bfbd-96fdbf22e0c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d36faa4-3715-4f8d-8270-c00cd47b85f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c6bcbced-712f-4a4d-9c1c-aa3bff0e012c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d36faa4-3715-4f8d-8270-c00cd47b85f1" xlink:to="loc_us-gaap_AwardTypeAxis_c6bcbced-712f-4a4d-9c1c-aa3bff0e012c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6bcbced-712f-4a4d-9c1c-aa3bff0e012c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c6bcbced-712f-4a4d-9c1c-aa3bff0e012c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6bcbced-712f-4a4d-9c1c-aa3bff0e012c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c6bcbced-712f-4a4d-9c1c-aa3bff0e012c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4d840836-dedd-400b-9dd6-73f58d674aed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4d840836-dedd-400b-9dd6-73f58d674aed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_362f2f4d-c78d-4600-b91d-0df5a9efe547" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:to="loc_us-gaap_RestrictedStockMember_362f2f4d-c78d-4600-b91d-0df5a9efe547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019c5cb3-5b0a-7541-a802-04170eccbfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:to="loc_us-gaap_PerformanceSharesMember_019c5cb3-5b0a-7541-a802-04170eccbfe6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6313f9ad-cdab-45b8-bfbd-96fdbf22e0c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7dd78b5c-cacb-43d0-9680-338bb88a9f37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7dd78b5c-cacb-43d0-9680-338bb88a9f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a90b57fa-a423-4dc6-a297-cfa75efee0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a90b57fa-a423-4dc6-a297-cfa75efee0ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d3d4357f-e582-4bd0-ae51-3b6f274235fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d3d4357f-e582-4bd0-ae51-3b6f274235fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_323a76cf-6338-4b29-b555-3336c7c82124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_323a76cf-6338-4b29-b555-3336c7c82124" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06c4ff16-415d-48de-941b-71c5375ac99c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6313f9ad-cdab-45b8-bfbd-96fdbf22e0c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_235816be-2f9e-43bf-ae77-d89e7d7400de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_235816be-2f9e-43bf-ae77-d89e7d7400de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50031f51-37b4-4ead-b7c9-13c8d4ea22f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50031f51-37b4-4ead-b7c9-13c8d4ea22f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7447b790-0af4-49c1-8af7-ce858a753e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7447b790-0af4-49c1-8af7-ce858a753e5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_68596f07-c0cd-40c9-96e9-d316837d5af5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_68596f07-c0cd-40c9-96e9-d316837d5af5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_752af2e1-33b1-466d-9812-42dc33a39b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationSummaryofActivityForEarnoutRSADetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43827e4f-dcf8-44e6-821f-98c8e8586c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c35d61-7646-4ecd-9398-0914e4449716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43827e4f-dcf8-44e6-821f-98c8e8586c5a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c35d61-7646-4ecd-9398-0914e4449716" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6eac5d8b-e078-488d-9c0f-fb684ec37360" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c35d61-7646-4ecd-9398-0914e4449716" xlink:to="loc_us-gaap_AwardTypeAxis_6eac5d8b-e078-488d-9c0f-fb684ec37360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eac5d8b-e078-488d-9c0f-fb684ec37360_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6eac5d8b-e078-488d-9c0f-fb684ec37360" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6eac5d8b-e078-488d-9c0f-fb684ec37360_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11c3e779-f1e9-4103-a04c-a5ab61aaa1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6eac5d8b-e078-488d-9c0f-fb684ec37360" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11c3e779-f1e9-4103-a04c-a5ab61aaa1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnoutRestrictedStockUnitsMember_89a02baa-c459-4790-b59c-2a841fe60b1a" xlink:href="dna-20251231.xsd#dna_EarnoutRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11c3e779-f1e9-4103-a04c-a5ab61aaa1d3" xlink:to="loc_dna_EarnoutRestrictedStockUnitsMember_89a02baa-c459-4790-b59c-2a841fe60b1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43827e4f-dcf8-44e6-821f-98c8e8586c5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a464f5e0-3630-4b0f-ac55-c560ef41a0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a464f5e0-3630-4b0f-ac55-c560ef41a0bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7f1327bd-d607-4d41-b02a-263a10e69165" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7f1327bd-d607-4d41-b02a-263a10e69165" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_794ed8ae-241e-4a94-bab6-4931a3dddbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_794ed8ae-241e-4a94-bab6-4931a3dddbb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b699b8a2-8ba9-44bd-8f63-d20fe2417f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43827e4f-dcf8-44e6-821f-98c8e8586c5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48356f86-f00b-40bb-8fbd-97c421d17709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48356f86-f00b-40bb-8fbd-97c421d17709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3324ec81-cd65-46c6-83cc-66d8c3514739" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3324ec81-cd65-46c6-83cc-66d8c3514739" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_866ff2cb-1c5b-4360-9bf6-af3523096a84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_866ff2cb-1c5b-4360-9bf6-af3523096a84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_89ac379d-469b-4baf-a78e-cf9a7adc4e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_28f3f16f-c992-439a-9601-1a47229bf414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_28f3f16f-c992-439a-9601-1a47229bf414" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d306ae4-6e19-41e2-8bc0-ba9a8b754e27" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:to="loc_srt_ProductOrServiceAxis_5d306ae4-6e19-41e2-8bc0-ba9a8b754e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d306ae4-6e19-41e2-8bc0-ba9a8b754e27_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5d306ae4-6e19-41e2-8bc0-ba9a8b754e27" xlink:to="loc_srt_ProductsAndServicesDomain_5d306ae4-6e19-41e2-8bc0-ba9a8b754e27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5d306ae4-6e19-41e2-8bc0-ba9a8b754e27" xlink:to="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PharmaceuticalAndBiotechnologyMember_aeb16895-b3ff-447f-86b8-26841318d355" xlink:href="dna-20251231.xsd#dna_PharmaceuticalAndBiotechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_PharmaceuticalAndBiotechnologyMember_aeb16895-b3ff-447f-86b8-26841318d355" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgricultureMember_06789455-a771-49eb-8552-54a47bf421ca" xlink:href="dna-20251231.xsd#dna_AgricultureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_AgricultureMember_06789455-a771-49eb-8552-54a47bf421ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GovernmentAndDefenseMember_dbed9795-013b-451e-806c-fa921071d1b0" xlink:href="dna-20251231.xsd#dna_GovernmentAndDefenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_GovernmentAndDefenseMember_dbed9795-013b-451e-806c-fa921071d1b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IndustrialAndEnvironmentMember_35256bfb-6fce-4c61-948f-c34080befd02" xlink:href="dna-20251231.xsd#dna_IndustrialAndEnvironmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_IndustrialAndEnvironmentMember_35256bfb-6fce-4c61-948f-c34080befd02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CustomerAndTechnologyMember_1d6217f6-0ecd-41e0-9073-d16267396343" xlink:href="dna-20251231.xsd#dna_CustomerAndTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_CustomerAndTechnologyMember_1d6217f6-0ecd-41e0-9073-d16267396343" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FoodAndNutritionMember_4920ff5b-5038-4ccc-b62c-19d135bd98db" xlink:href="dna-20251231.xsd#dna_FoodAndNutritionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_FoodAndNutritionMember_4920ff5b-5038-4ccc-b62c-19d135bd98db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringRevenueMember_306ed298-9b29-4d5f-b3e3-cd8efbb30df8" xlink:href="dna-20251231.xsd#dna_CellEngineeringRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_CellEngineeringRevenueMember_306ed298-9b29-4d5f-b3e3-cd8efbb30df8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b4a258e4-7552-4773-9f3c-5715cd05b541" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b4a258e4-7552-4773-9f3c-5715cd05b541" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b4a258e4-7552-4773-9f3c-5715cd05b541_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b4a258e4-7552-4773-9f3c-5715cd05b541" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b4a258e4-7552-4773-9f3c-5715cd05b541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b3c0ed8e-375f-4ea2-9564-131a9519b2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b4a258e4-7552-4773-9f3c-5715cd05b541" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b3c0ed8e-375f-4ea2-9564-131a9519b2d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_1c746aea-0aeb-45e2-8416-a3233c91e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b3c0ed8e-375f-4ea2-9564-131a9519b2d4" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_1c746aea-0aeb-45e2-8416-a3233c91e8a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d7cc5c5-26b8-49f1-a850-909f580ac84b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d7cc5c5-26b8-49f1-a850-909f580ac84b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d7cc5c5-26b8-49f1-a850-909f580ac84b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d7cc5c5-26b8-49f1-a850-909f580ac84b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d7cc5c5-26b8-49f1-a850-909f580ac84b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05be5fdd-28c9-40df-9e74-50f54b23563e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d7cc5c5-26b8-49f1-a850-909f580ac84b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05be5fdd-28c9-40df-9e74-50f54b23563e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_277457fe-e4bf-4ea5-9a82-7ff21a8953fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05be5fdd-28c9-40df-9e74-50f54b23563e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_277457fe-e4bf-4ea5-9a82-7ff21a8953fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d55929a0-e133-4380-a405-556f11e626eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_28f3f16f-c992-439a-9601-1a47229bf414" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d55929a0-e133-4380-a405-556f11e626eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#RevenueRecognitionAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:to="loc_srt_ProductsAndServicesDomain_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:to="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringRevenueMember_a9aeee8f-eaa8-4ae9-8ad4-a8826d43f5f1" xlink:href="dna-20251231.xsd#dna_CellEngineeringRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:to="loc_dna_CellEngineeringRevenueMember_a9aeee8f-eaa8-4ae9-8ad4-a8826d43f5f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringMember_019c5cb5-5c57-79b9-a392-25bb314c8de3" xlink:href="dna-20251231.xsd#dna_CellEngineeringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:to="loc_dna_CellEngineeringMember_019c5cb5-5c57-79b9-a392-25bb314c8de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:to="loc_srt_SegmentGeographicalDomain_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_df196c00-44df-468e-b212-cc2e164d5afe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:to="loc_srt_SegmentGeographicalDomain_df196c00-44df-468e-b212-cc2e164d5afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_014f59d4-9401-4744-9f0c-65cbe0aebf8f" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_df196c00-44df-468e-b212-cc2e164d5afe" xlink:to="loc_country_US_014f59d4-9401-4744-9f0c-65cbe0aebf8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c65e6271-0068-4e99-b8c4-50c82fae4e86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c65e6271-0068-4e99-b8c4-50c82fae4e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_06254400-998a-4ca0-9fb2-25cef5d6dfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c65e6271-0068-4e99-b8c4-50c82fae4e86" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_06254400-998a-4ca0-9fb2-25cef5d6dfe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cc1c78-2d6e-45b2-9018-99c381085cb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cc1c78-2d6e-45b2-9018-99c381085cb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dffcb9f9-c691-4d49-bdc1-561f9dcc8051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dffcb9f9-c691-4d49-bdc1-561f9dcc8051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_be310249-bc4a-4477-ab2f-6a45df597155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dffcb9f9-c691-4d49-bdc1-561f9dcc8051" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_be310249-bc4a-4477-ab2f-6a45df597155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-74b8-87a7-997e6e913424_default" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:to="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-74b8-87a7-997e6e913424_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:to="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year1Member_019c5cb8-7115-788c-be9d-c57e400809e3" xlink:href="dna-20251231.xsd#dna_Year1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year1Member_019c5cb8-7115-788c-be9d-c57e400809e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year12Member_019c5cb8-7115-7d0c-9844-f93d78044e5b" xlink:href="dna-20251231.xsd#dna_Year12Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year12Member_019c5cb8-7115-7d0c-9844-f93d78044e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year13Member_019c5cb8-7115-7361-b7b3-1e98acabc218" xlink:href="dna-20251231.xsd#dna_Year13Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year13Member_019c5cb8-7115-7361-b7b3-1e98acabc218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year14Member_019c5cb9-7139-77d4-b14b-ee4e1e45dca9" xlink:href="dna-20251231.xsd#dna_Year14Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year14Member_019c5cb9-7139-77d4-b14b-ee4e1e45dca9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year15Member_019c5cb9-713a-710c-8f26-653f2cafd205" xlink:href="dna-20251231.xsd#dna_Year15Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year15Member_019c5cb9-713a-710c-8f26-653f2cafd205" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_019c5cb8-7115-7555-b702-4094f12ffb47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_019c5cb8-7115-7555-b702-4094f12ffb47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash_0282014e-9a03-4d1d-b865-370867934464" xlink:href="dna-20251231.xsd#dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash_0282014e-9a03-4d1d-b865-370867934464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_24ff3fe4-df94-400c-a457-4b4e6862cbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_24ff3fe4-df94-400c-a457-4b4e6862cbe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b3628e3f-27b5-479a-b0bc-ed9f6629fec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b3628e3f-27b5-479a-b0bc-ed9f6629fec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_dfd0afd2-3871-4a20-ab0c-0013fee6cd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_UnbilledContractsReceivable_dfd0afd2-3871-4a20-ab0c-0013fee6cd5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5c18182d-4e2f-44fe-9e36-7350c487436c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5c18182d-4e2f-44fe-9e36-7350c487436c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_112e6cde-7f91-4c11-9d43-204bd77c95d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiability_112e6cde-7f91-4c11-9d43-204bd77c95d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4d37722a-d69c-419a-aada-4d0bd7033378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4d37722a-d69c-419a-aada-4d0bd7033378" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_df600c6e-cdef-49e2-82be-203793c8ed65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_df600c6e-cdef-49e2-82be-203793c8ed65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d507d9f8-70a9-46e6-9979-1542bc339163" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d507d9f8-70a9-46e6-9979-1542bc339163" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_019c5cba-fb84-72d4-8d09-45198ef2c5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_019c5cba-fb84-72d4-8d09-45198ef2c5d9" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails_1" xlink:type="simple" xlink:href="dna-20251231.xsd#RevenueRecognitionAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:to="loc_srt_ProductsAndServicesDomain_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:to="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringRevenueMember_a9aeee8f-eaa8-4ae9-8ad4-a8826d43f5f1" xlink:href="dna-20251231.xsd#dna_CellEngineeringRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:to="loc_dna_CellEngineeringRevenueMember_a9aeee8f-eaa8-4ae9-8ad4-a8826d43f5f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringMember_019c5cb5-5c57-79b9-a392-25bb314c8de3" xlink:href="dna-20251231.xsd#dna_CellEngineeringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:to="loc_dna_CellEngineeringMember_019c5cb5-5c57-79b9-a392-25bb314c8de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:to="loc_srt_SegmentGeographicalDomain_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_df196c00-44df-468e-b212-cc2e164d5afe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:to="loc_srt_SegmentGeographicalDomain_df196c00-44df-468e-b212-cc2e164d5afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_014f59d4-9401-4744-9f0c-65cbe0aebf8f" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_df196c00-44df-468e-b212-cc2e164d5afe" xlink:to="loc_country_US_014f59d4-9401-4744-9f0c-65cbe0aebf8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c65e6271-0068-4e99-b8c4-50c82fae4e86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c65e6271-0068-4e99-b8c4-50c82fae4e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_06254400-998a-4ca0-9fb2-25cef5d6dfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c65e6271-0068-4e99-b8c4-50c82fae4e86" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_06254400-998a-4ca0-9fb2-25cef5d6dfe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cc1c78-2d6e-45b2-9018-99c381085cb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cc1c78-2d6e-45b2-9018-99c381085cb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dffcb9f9-c691-4d49-bdc1-561f9dcc8051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dffcb9f9-c691-4d49-bdc1-561f9dcc8051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_be310249-bc4a-4477-ab2f-6a45df597155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dffcb9f9-c691-4d49-bdc1-561f9dcc8051" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_be310249-bc4a-4477-ab2f-6a45df597155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-74b8-87a7-997e6e913424_default" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:to="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-74b8-87a7-997e6e913424_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:to="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year1Member_019c5cb8-7115-788c-be9d-c57e400809e3" xlink:href="dna-20251231.xsd#dna_Year1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year1Member_019c5cb8-7115-788c-be9d-c57e400809e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year12Member_019c5cb8-7115-7d0c-9844-f93d78044e5b" xlink:href="dna-20251231.xsd#dna_Year12Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year12Member_019c5cb8-7115-7d0c-9844-f93d78044e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year13Member_019c5cb8-7115-7361-b7b3-1e98acabc218" xlink:href="dna-20251231.xsd#dna_Year13Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year13Member_019c5cb8-7115-7361-b7b3-1e98acabc218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year14Member_019c5cb9-7139-77d4-b14b-ee4e1e45dca9" xlink:href="dna-20251231.xsd#dna_Year14Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year14Member_019c5cb9-7139-77d4-b14b-ee4e1e45dca9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year15Member_019c5cb9-713a-710c-8f26-653f2cafd205" xlink:href="dna-20251231.xsd#dna_Year15Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year15Member_019c5cb9-713a-710c-8f26-653f2cafd205" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash_0282014e-9a03-4d1d-b865-370867934464" xlink:href="dna-20251231.xsd#dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash_0282014e-9a03-4d1d-b865-370867934464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_24ff3fe4-df94-400c-a457-4b4e6862cbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_24ff3fe4-df94-400c-a457-4b4e6862cbe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b3628e3f-27b5-479a-b0bc-ed9f6629fec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b3628e3f-27b5-479a-b0bc-ed9f6629fec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_dfd0afd2-3871-4a20-ab0c-0013fee6cd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_UnbilledContractsReceivable_dfd0afd2-3871-4a20-ab0c-0013fee6cd5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5c18182d-4e2f-44fe-9e36-7350c487436c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5c18182d-4e2f-44fe-9e36-7350c487436c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_112e6cde-7f91-4c11-9d43-204bd77c95d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiability_112e6cde-7f91-4c11-9d43-204bd77c95d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4d37722a-d69c-419a-aada-4d0bd7033378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4d37722a-d69c-419a-aada-4d0bd7033378" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_df600c6e-cdef-49e2-82be-203793c8ed65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_df600c6e-cdef-49e2-82be-203793c8ed65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d507d9f8-70a9-46e6-9979-1542bc339163" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d507d9f8-70a9-46e6-9979-1542bc339163" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_019c5cba-fb84-72d4-8d09-45198ef2c5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_019c5cba-fb84-72d4-8d09-45198ef2c5d9" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_95782e32-d1e2-4c49-9b0e-45e24de03ced" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_95782e32-d1e2-4c49-9b0e-45e24de03ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_95782e32-d1e2-4c49-9b0e-45e24de03ced_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_95782e32-d1e2-4c49-9b0e-45e24de03ced" xlink:to="loc_us-gaap_SegmentDomain_95782e32-d1e2-4c49-9b0e-45e24de03ced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30a6c006-619e-48fd-91f7-b0e6d6842d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_95782e32-d1e2-4c49-9b0e-45e24de03ced" xlink:to="loc_us-gaap_SegmentDomain_30a6c006-619e-48fd-91f7-b0e6d6842d0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringAndBiosecuritySegmentsMember_c88aa77b-2136-4b71-a048-468b59025632" xlink:href="dna-20251231.xsd#dna_CellEngineeringAndBiosecuritySegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30a6c006-619e-48fd-91f7-b0e6d6842d0b" xlink:to="loc_dna_CellEngineeringAndBiosecuritySegmentsMember_c88aa77b-2136-4b71-a048-468b59025632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringSegmentMember_4cff99fa-0df7-4aa6-bbf2-23c093723cc6" xlink:href="dna-20251231.xsd#dna_CellEngineeringSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_CellEngineeringAndBiosecuritySegmentsMember_c88aa77b-2136-4b71-a048-468b59025632" xlink:to="loc_dna_CellEngineeringSegmentMember_4cff99fa-0df7-4aa6-bbf2-23c093723cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiosecuritySegmentMember_2d69a0fb-6366-4faa-8da8-204bc41e4881" xlink:href="dna-20251231.xsd#dna_BiosecuritySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_CellEngineeringAndBiosecuritySegmentsMember_c88aa77b-2136-4b71-a048-468b59025632" xlink:to="loc_dna_BiosecuritySegmentMember_2d69a0fb-6366-4faa-8da8-204bc41e4881" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a3b031cf-b57b-419d-b42e-ba5df7ed4e5c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:to="loc_srt_ConsolidationItemsAxis_a3b031cf-b57b-419d-b42e-ba5df7ed4e5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a3b031cf-b57b-419d-b42e-ba5df7ed4e5c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a3b031cf-b57b-419d-b42e-ba5df7ed4e5c" xlink:to="loc_srt_ConsolidationItemsDomain_a3b031cf-b57b-419d-b42e-ba5df7ed4e5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d0d2af1d-0dcf-42d2-a7e3-b82fd0981ba9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a3b031cf-b57b-419d-b42e-ba5df7ed4e5c" xlink:to="loc_srt_ConsolidationItemsDomain_d0d2af1d-0dcf-42d2-a7e3-b82fd0981ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2cbe9e3b-37c4-4671-b454-be2fe93e657f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d0d2af1d-0dcf-42d2-a7e3-b82fd0981ba9" xlink:to="loc_us-gaap_OperatingSegmentsMember_2cbe9e3b-37c4-4671-b454-be2fe93e657f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e99989ae-7c27-4eca-beae-a00dee988d09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d0d2af1d-0dcf-42d2-a7e3-b82fd0981ba9" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e99989ae-7c27-4eca-beae-a00dee988d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7c03ba33-55e9-49ab-9692-3f81ba83c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7c03ba33-55e9-49ab-9692-3f81ba83c21c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7c03ba33-55e9-49ab-9692-3f81ba83c21c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7c03ba33-55e9-49ab-9692-3f81ba83c21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7c03ba33-55e9-49ab-9692-3f81ba83c21c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f99534f4-a909-49b2-a4d8-b5b413bcab5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7c03ba33-55e9-49ab-9692-3f81ba83c21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f99534f4-a909-49b2-a4d8-b5b413bcab5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LabEquipmentMember_33040a95-dfa3-4542-b8d8-5e7be8b01d43" xlink:href="dna-20251231.xsd#dna_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f99534f4-a909-49b2-a4d8-b5b413bcab5a" xlink:to="loc_dna_LabEquipmentMember_33040a95-dfa3-4542-b8d8-5e7be8b01d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LeaseAssetsMember_183cee1d-a4bf-4c5f-b2b7-5950f725fd6b" xlink:href="dna-20251231.xsd#dna_LeaseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f99534f4-a909-49b2-a4d8-b5b413bcab5a" xlink:to="loc_dna_LeaseAssetsMember_183cee1d-a4bf-4c5f-b2b7-5950f725fd6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_30f5ed42-b918-4ca0-8188-bb8fef47d242" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:to="loc_srt_ProductOrServiceAxis_30f5ed42-b918-4ca0-8188-bb8fef47d242" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_30f5ed42-b918-4ca0-8188-bb8fef47d242_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_30f5ed42-b918-4ca0-8188-bb8fef47d242" xlink:to="loc_srt_ProductsAndServicesDomain_30f5ed42-b918-4ca0-8188-bb8fef47d242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4e0f62b3-c48f-42ad-827b-a0358cf30409" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_30f5ed42-b918-4ca0-8188-bb8fef47d242" xlink:to="loc_srt_ProductsAndServicesDomain_4e0f62b3-c48f-42ad-827b-a0358cf30409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_b497651a-871e-4a94-9cc1-63ffe4faf1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4e0f62b3-c48f-42ad-827b-a0358cf30409" xlink:to="loc_us-gaap_ServiceMember_b497651a-871e-4a94-9cc1-63ffe4faf1f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_06c83e25-c3c3-4c99-a3cc-9377ec65ca46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4e0f62b3-c48f-42ad-827b-a0358cf30409" xlink:to="loc_us-gaap_ProductMember_06c83e25-c3c3-4c99-a3cc-9377ec65ca46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_5a4a162a-70e7-4136-96b9-233b1fe90380" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_5a4a162a-70e7-4136-96b9-233b1fe90380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7090d8ed-219e-43aa-9e36-09a9246f452b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_5a4a162a-70e7-4136-96b9-233b1fe90380" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7090d8ed-219e-43aa-9e36-09a9246f452b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_fe4187da-46ca-4331-b95d-e557ff652c95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_CostOfRevenueAbstract_fe4187da-46ca-4331-b95d-e557ff652c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b250c41b-588c-4617-8c7c-09a89c54011d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_fe4187da-46ca-4331-b95d-e557ff652c95" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b250c41b-588c-4617-8c7c-09a89c54011d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_537302a6-53ca-442b-b39c-1e627a545820" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_537302a6-53ca-442b-b39c-1e627a545820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_87665109-f4fe-4c87-9f6e-2e4776cdbdba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_537302a6-53ca-442b-b39c-1e627a545820" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_87665109-f4fe-4c87-9f6e-2e4776cdbdba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_c89f6223-2e48-48d0-be8f-c2ec59f92fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_c89f6223-2e48-48d0-be8f-c2ec59f92fb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d3555b52-af07-4a4c-977f-14f97e2c92f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_c89f6223-2e48-48d0-be8f-c2ec59f92fb6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d3555b52-af07-4a4c-977f-14f97e2c92f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_3b020912-aca8-4269-ac4b-30a568e887ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_3b020912-aca8-4269-ac4b-30a568e887ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0f3fbd1f-438f-4ce7-bcda-97f8f4be1cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_3b020912-aca8-4269-ac4b-30a568e887ea" xlink:to="loc_us-gaap_OperatingIncomeLoss_0f3fbd1f-438f-4ce7-bcda-97f8f4be1cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:href="dna-20251231.xsd#dna_OperatingExpensesNotAllocatedToSegmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ab5a855-85b9-4a81-9a15-1ea447c378c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_ShareBasedCompensation_7ab5a855-85b9-4a81-9a15-1ea447c378c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_eb1c5a95-f90b-4751-898c-4658c7ca1f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_AssetImpairmentCharges_eb1c5a95-f90b-4751-898c-4658c7ca1f8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_fd5a7fa5-bb36-4e32-83cb-228c19349eed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_DepreciationAndAmortization_fd5a7fa5-bb36-4e32-83cb-228c19349eed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_d4a68662-aab3-4d04-b825-7c7b7ead2c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_d4a68662-aab3-4d04-b825-7c7b7ead2c4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_6a03a49a-b5ee-4748-ae8b-8de1a9292537" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_LeaseCost_6a03a49a-b5ee-4748-ae8b-8de1a9292537" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_91a23564-8038-4776-8107-5d8cbd5b65ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_91a23564-8038-4776-8107-5d8cbd5b65ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AcquiredInProcessResearchAndDevelopment_19e43d20-0411-4081-8adb-fe4b7278e642" xlink:href="dna-20251231.xsd#dna_AcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_dna_AcquiredInProcessResearchAndDevelopment_19e43d20-0411-4081-8adb-fe4b7278e642" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9cefd801-b8b6-4075-8740-a8ecea41d567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9cefd801-b8b6-4075-8740-a8ecea41d567" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bb39e0c7-e455-491e-8047-9176f47e634b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bb39e0c7-e455-491e-8047-9176f47e634b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EmployerPayrollTaxes_1212b410-466a-48a2-a048-f1d4e2664cc3" xlink:href="dna-20251231.xsd#dna_EmployerPayrollTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_dna_EmployerPayrollTaxes_1212b410-466a-48a2-a048-f1d4e2664cc3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9aada09c-8095-43b8-9137-38a20639a473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9aada09c-8095-43b8-9137-38a20639a473" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019c5cbf-c095-72b2-9710-6445f1c2ec5b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_srt_MajorCustomersAxis_019c5cbf-c095-72b2-9710-6445f1c2ec5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c5cbf-c095-72b2-9710-6445f1c2ec5b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_019c5cbf-c095-72b2-9710-6445f1c2ec5b" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c5cbf-c095-72b2-9710-6445f1c2ec5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c5cbf-c095-7e1f-8b3f-210905f3dfb3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_019c5cbf-c095-72b2-9710-6445f1c2ec5b" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c5cbf-c095-7e1f-8b3f-210905f3dfb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MotifFoodworksIncMember_019c5cbf-c095-7676-a79b-4ac427573764" xlink:href="dna-20251231.xsd#dna_MotifFoodworksIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c5cbf-c095-7e1f-8b3f-210905f3dfb3" xlink:to="loc_dna_MotifFoodworksIncMember_019c5cbf-c095-7676-a79b-4ac427573764" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c5cbf-c095-7f93-a522-ddadda9d076f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_srt_CounterpartyNameAxis_019c5cbf-c095-7f93-a522-ddadda9d076f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7f93-a522-ddadda9d076f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019c5cbf-c095-7f93-a522-ddadda9d076f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7f93-a522-ddadda9d076f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019c5cbf-c095-7f93-a522-ddadda9d076f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherEquityInvesteeMember_019c5cc1-e3a6-7a0f-88ea-eac28ef84da7" xlink:href="dna-20251231.xsd#dna_OtherEquityInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_OtherEquityInvesteeMember_019c5cc1-e3a6-7a0f-88ea-eac28ef84da7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaMember_019c9025-d053-72ce-b17b-f5e3a47d774d" xlink:href="dna-20251231.xsd#dna_GenomaticaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_GenomaticaMember_019c9025-d053-72ce-b17b-f5e3a47d774d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditMember_019c9028-2871-7cb1-b9af-9e67aad8b363" xlink:href="dna-20251231.xsd#dna_BiomeditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_BiomeditMember_019c9028-2871-7cb1-b9af-9e67aad8b363" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ArcaeaMember_019c9033-dbe3-7a0e-9a43-4437949b5d84" xlink:href="dna-20251231.xsd#dna_ArcaeaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_ArcaeaMember_019c9033-dbe3-7a0e-9a43-4437949b5d84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AlloniaMember_019c9033-dbe3-7a1f-82b6-4b1e58bdef2f" xlink:href="dna-20251231.xsd#dna_AlloniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_AlloniaMember_019c9033-dbe3-7a1f-82b6-4b1e58bdef2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MotifMember_019c9033-dbe3-7a01-8302-0242ef4fbe3b" xlink:href="dna-20251231.xsd#dna_MotifMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_MotifMember_019c9033-dbe3-7a01-8302-0242ef4fbe3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc1-e3a6-7941-88f2-1b57caabab70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc1-e3a6-7941-88f2-1b57caabab70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5cc1-e3a6-7941-88f2-1b57caabab70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc1-e3a6-7941-88f2-1b57caabab70" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5cc1-e3a6-7941-88f2-1b57caabab70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5cc1-e3a6-71db-82e5-6f049be7ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc1-e3a6-7941-88f2-1b57caabab70" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5cc1-e3a6-71db-82e5-6f049be7ff1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019c5cc1-e3a6-761d-9e15-701d8b0c9ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019c5cc1-e3a6-71db-82e5-6f049be7ff1e" xlink:to="loc_us-gaap_RelatedPartyMember_019c5cc1-e3a6-761d-9e15-701d8b0c9ff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgreementAxis_019c5cc1-e3a6-75f3-adbc-1809fbb21e67" xlink:href="dna-20251231.xsd#dna_AgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_dna_AgreementAxis_019c5cc1-e3a6-75f3-adbc-1809fbb21e67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgreementDomain_019c5cc1-e3a6-75f3-adbc-1809fbb21e67_default" xlink:href="dna-20251231.xsd#dna_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dna_AgreementAxis_019c5cc1-e3a6-75f3-adbc-1809fbb21e67" xlink:to="loc_dna_AgreementDomain_019c5cc1-e3a6-75f3-adbc-1809fbb21e67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgreementDomain_019c5cc1-e3a6-7409-9503-e84ad9c840cf" xlink:href="dna-20251231.xsd#dna_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dna_AgreementAxis_019c5cc1-e3a6-75f3-adbc-1809fbb21e67" xlink:to="loc_dna_AgreementDomain_019c5cc1-e3a6-7409-9503-e84ad9c840cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember_019c5cc1-e3a6-75df-931e-3d27f9138648" xlink:href="dna-20251231.xsd#dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_AgreementDomain_019c5cc1-e3a6-7409-9503-e84ad9c840cf" xlink:to="loc_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember_019c5cc1-e3a6-75df-931e-3d27f9138648" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_019c5cc1-e3a6-75ad-80d9-dfe4fc648538" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_019c5cc1-e3a6-75ad-80d9-dfe4fc648538" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_019c5cc1-e3a6-75ad-80d9-dfe4fc648538_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_019c5cc1-e3a6-75ad-80d9-dfe4fc648538" xlink:to="loc_srt_ConsolidatedEntitiesDomain_019c5cc1-e3a6-75ad-80d9-dfe4fc648538_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_019c5cc1-e3a6-75a6-b8f3-d46534f7657c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_019c5cc1-e3a6-75ad-80d9-dfe4fc648538" xlink:to="loc_srt_ConsolidatedEntitiesDomain_019c5cc1-e3a6-75a6-b8f3-d46534f7657c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_019c5cc1-e3a6-72bf-b50b-a9db58463dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_019c5cc1-e3a6-75a6-b8f3-d46534f7657c" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_019c5cc1-e3a6-72bf-b50b-a9db58463dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5cc1-e3a6-78bb-af70-19ef463319a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5cc1-e3a6-78bb-af70-19ef463319a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-78bb-af70-19ef463319a5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5cc1-e3a6-78bb-af70-19ef463319a5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-78bb-af70-19ef463319a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5cc1-e3a6-78bb-af70-19ef463319a5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaMember_019c5cc1-e3a6-71a2-9d69-eedee8456215" xlink:href="dna-20251231.xsd#dna_GenomaticaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:to="loc_dna_GenomaticaMember_019c5cc1-e3a6-71a2-9d69-eedee8456215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaIncPreferredStockMember_019c5cc1-e3a6-790d-9b9d-9ddd7217e8c1" xlink:href="dna-20251231.xsd#dna_GenomaticaIncPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:to="loc_dna_GenomaticaIncPreferredStockMember_019c5cc1-e3a6-790d-9b9d-9ddd7217e8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafesMember_019c5cc1-e3a6-76e5-800f-76e9bd04e29a" xlink:href="dna-20251231.xsd#dna_SafesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:to="loc_dna_SafesMember_019c5cc1-e3a6-76e5-800f-76e9bd04e29a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOFEstimatedMaterialRights_019c9029-3c79-7a85-a3f4-c097b86fd64e" xlink:href="dna-20251231.xsd#dna_NumberOFEstimatedMaterialRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_dna_NumberOFEstimatedMaterialRights_019c9029-3c79-7a85-a3f4-c097b86fd64e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019c5cbf-c095-7ffe-b356-750b81528f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019c5cbf-c095-7ffe-b356-750b81528f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_019c5cc1-e3a6-7f00-9ef9-c864ff5ca3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_019c5cc1-e3a6-7f00-9ef9-c864ff5ca3e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_019c5cc1-e3a6-72c0-b06b-8635c24d6ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_019c5cc1-e3a6-72c0-b06b-8635c24d6ed2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_UpfrontAmountReceived_019c5cc1-e3a6-76fd-84bb-a2c1b7af1239" xlink:href="dna-20251231.xsd#dna_UpfrontAmountReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_dna_UpfrontAmountReceived_019c5cc1-e3a6-76fd-84bb-a2c1b7af1239" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_019c5cc1-e3a6-7f77-bf93-6bcfd1ab9a82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_us-gaap_GainLossOnInvestments_019c5cc1-e3a6-7f77-bf93-6bcfd1ab9a82" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PreferredStockInvestmentImpairmentLoss_019c9025-30fb-7574-9f8d-104e7f068da9" xlink:href="dna-20251231.xsd#dna_PreferredStockInvestmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_dna_PreferredStockInvestmentImpairmentLoss_019c9025-30fb-7574-9f8d-104e7f068da9" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-719d-70b4-86a7-6bc12f17303c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-719d-7dd8-9d05-c8f0734e111e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-719d-70b4-86a7-6bc12f17303c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-719d-7dd8-9d05-c8f0734e111e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c5cc2-719d-74bc-89e6-9300520a0011" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-719d-7dd8-9d05-c8f0734e111e" xlink:to="loc_srt_CounterpartyNameAxis_019c5cc2-719d-74bc-89e6-9300520a0011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-74bc-89e6-9300520a0011_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019c5cc2-719d-74bc-89e6-9300520a0011" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-74bc-89e6-9300520a0011_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019c5cc2-719d-74bc-89e6-9300520a0011" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AlloniaMember_019c5cc2-719d-7186-bc8c-de3c74bd2d08" xlink:href="dna-20251231.xsd#dna_AlloniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:to="loc_dna_AlloniaMember_019c5cc2-719d-7186-bc8c-de3c74bd2d08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ArcaeaMember_019c5cc2-719d-708f-a572-28ec099dc856" xlink:href="dna-20251231.xsd#dna_ArcaeaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:to="loc_dna_ArcaeaMember_019c5cc2-719d-708f-a572-28ec099dc856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditMember_019c5cc2-719d-7aa2-9a23-50bfece2472a" xlink:href="dna-20251231.xsd#dna_BiomeditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:to="loc_dna_BiomeditMember_019c5cc2-719d-7aa2-9a23-50bfece2472a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaMember_019c5cc2-719d-78f3-9e00-e6a9b549457a" xlink:href="dna-20251231.xsd#dna_GenomaticaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:to="loc_dna_GenomaticaMember_019c5cc2-719d-78f3-9e00-e6a9b549457a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cf2-42f9-7da6-b67c-c75359ece604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-719d-7dd8-9d05-c8f0734e111e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cf2-42f9-7da6-b67c-c75359ece604" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5cf2-42f9-7da6-b67c-c75359ece604_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cf2-42f9-7da6-b67c-c75359ece604" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5cf2-42f9-7da6-b67c-c75359ece604_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5cf2-42f9-7891-a1fc-5ba69a1dfcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cf2-42f9-7da6-b67c-c75359ece604" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5cf2-42f9-7891-a1fc-5ba69a1dfcc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019c5cf2-42f9-7b09-a99f-7c33ef223349" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019c5cf2-42f9-7891-a1fc-5ba69a1dfcc4" xlink:to="loc_us-gaap_RelatedPartyMember_019c5cf2-42f9-7b09-a99f-7c33ef223349" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019c5cc2-719d-728d-b127-cb3f5789168a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-719d-70b4-86a7-6bc12f17303c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019c5cc2-719d-728d-b127-cb3f5789168a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-dfd1-765b-8552-cffed0092245" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-dfd1-7eae-859c-1373d34520cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-dfd1-765b-8552-cffed0092245" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-dfd1-7eae-859c-1373d34520cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c5cc2-dfd1-7018-8edc-5977bc672552" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-dfd1-7eae-859c-1373d34520cf" xlink:to="loc_srt_CounterpartyNameAxis_019c5cc2-dfd1-7018-8edc-5977bc672552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7018-8edc-5977bc672552_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019c5cc2-dfd1-7018-8edc-5977bc672552" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7018-8edc-5977bc672552_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019c5cc2-dfd1-7018-8edc-5977bc672552" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MotifMember_019c5cc2-dfd1-706f-9f2b-81437e55d004" xlink:href="dna-20251231.xsd#dna_MotifMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_MotifMember_019c5cc2-dfd1-706f-9f2b-81437e55d004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ArcaeaMember_019c5cc2-dfd1-775e-8bb2-a95accf2486c" xlink:href="dna-20251231.xsd#dna_ArcaeaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_ArcaeaMember_019c5cc2-dfd1-775e-8bb2-a95accf2486c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaMember_019c5cc2-dfd1-713c-b85e-7251d1868169" xlink:href="dna-20251231.xsd#dna_GenomaticaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_GenomaticaMember_019c5cc2-dfd1-713c-b85e-7251d1868169" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AyanaMember_019c5cc2-dfd1-7cfe-b896-8357c9bd2445" xlink:href="dna-20251231.xsd#dna_AyanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_AyanaMember_019c5cc2-dfd1-7cfe-b896-8357c9bd2445" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditMember_019c5cc2-dfd1-772a-84a5-48a767834a5d" xlink:href="dna-20251231.xsd#dna_BiomeditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_BiomeditMember_019c5cc2-dfd1-772a-84a5-48a767834a5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_VerbBioticsMember_019c5cc2-dfd1-71d8-9782-860a8f03216c" xlink:href="dna-20251231.xsd#dna_VerbBioticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_VerbBioticsMember_019c5cc2-dfd1-71d8-9782-860a8f03216c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AlloniaMember_019c5cc2-dfd1-7627-b314-4593b1329df7" xlink:href="dna-20251231.xsd#dna_AlloniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_AlloniaMember_019c5cc2-dfd1-7627-b314-4593b1329df7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherEquityInvesteesMember_019c5cc2-dfd1-78b5-8ba4-8c2bb8af4ec3" xlink:href="dna-20251231.xsd#dna_OtherEquityInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_OtherEquityInvesteesMember_019c5cc2-dfd1-78b5-8ba4-8c2bb8af4ec3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc2-dfd1-7851-910a-f87878f6f9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-dfd1-7eae-859c-1373d34520cf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc2-dfd1-7851-910a-f87878f6f9fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5cc2-dfd1-7851-910a-f87878f6f9fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc2-dfd1-7851-910a-f87878f6f9fa" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5cc2-dfd1-7851-910a-f87878f6f9fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5cc2-dfd1-7daf-8a86-ba89ba75c7db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc2-dfd1-7851-910a-f87878f6f9fa" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5cc2-dfd1-7daf-8a86-ba89ba75c7db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019c5cc2-dfd1-72c0-84ad-d927f934583e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019c5cc2-dfd1-7daf-8a86-ba89ba75c7db" xlink:to="loc_us-gaap_RelatedPartyMember_019c5cc2-dfd1-72c0-84ad-d927f934583e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c5cc2-dfd1-7e64-b745-268c89ac8c33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-dfd1-765b-8552-cffed0092245" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c5cc2-dfd1-7e64-b745-268c89ac8c33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_75272990-9371-4a65-9a77-33cd6b4bc7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_75272990-9371-4a65-9a77-33cd6b4bc7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_75272990-9371-4a65-9a77-33cd6b4bc7b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_75272990-9371-4a65-9a77-33cd6b4bc7b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_75272990-9371-4a65-9a77-33cd6b4bc7b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_75272990-9371-4a65-9a77-33cd6b4bc7b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6bb71d06-7564-42b6-9672-de0ed2170b01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:to="loc_us-gaap_DomesticCountryMember_6bb71d06-7564-42b6-9672-de0ed2170b01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ff835b3d-d737-440b-95d8-1efe74da4ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ff835b3d-d737-440b-95d8-1efe74da4ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019c5cd2-1d5f-7276-a034-9d6a56c17063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:to="loc_us-gaap_ForeignCountryMember_019c5cd2-1d5f-7276-a034-9d6a56c17063" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarryForwardsExpirationPeriodAxis_0004649b-8b7a-4226-b22b-5e6b8fc18d4d" xlink:href="dna-20251231.xsd#dna_CarryForwardsExpirationPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:to="loc_dna_CarryForwardsExpirationPeriodAxis_0004649b-8b7a-4226-b22b-5e6b8fc18d4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarryForwardsExpirationPeriodDomain_0004649b-8b7a-4226-b22b-5e6b8fc18d4d_default" xlink:href="dna-20251231.xsd#dna_CarryForwardsExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dna_CarryForwardsExpirationPeriodAxis_0004649b-8b7a-4226-b22b-5e6b8fc18d4d" xlink:to="loc_dna_CarryForwardsExpirationPeriodDomain_0004649b-8b7a-4226-b22b-5e6b8fc18d4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:href="dna-20251231.xsd#dna_CarryForwardsExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dna_CarryForwardsExpirationPeriodAxis_0004649b-8b7a-4226-b22b-5e6b8fc18d4d" xlink:to="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BeginToExpireInTwoThousandAndTwentyNineMember_6edd2a3c-eb20-4645-9b51-7199473de6d6" xlink:href="dna-20251231.xsd#dna_BeginToExpireInTwoThousandAndTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:to="loc_dna_BeginToExpireInTwoThousandAndTwentyNineMember_6edd2a3c-eb20-4645-9b51-7199473de6d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarriedForwardIndefinitelyMember_b2a67163-2e8e-48ea-a4cb-a243868b7be7" xlink:href="dna-20251231.xsd#dna_CarriedForwardIndefinitelyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:to="loc_dna_CarriedForwardIndefinitelyMember_b2a67163-2e8e-48ea-a4cb-a243868b7be7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BeginToExpireInTwoThousandAndThirtyMember_bdce925a-3e65-49b6-a435-17735264df02" xlink:href="dna-20251231.xsd#dna_BeginToExpireInTwoThousandAndThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:to="loc_dna_BeginToExpireInTwoThousandAndThirtyMember_bdce925a-3e65-49b6-a435-17735264df02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BeginToExpireIn2034Member_019c5cd2-9d34-78e5-a50b-25a1300d03fd" xlink:href="dna-20251231.xsd#dna_BeginToExpireIn2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:to="loc_dna_BeginToExpireIn2034Member_019c5cd2-9d34-78e5-a50b-25a1300d03fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_853ff554-459a-414c-9b3c-9d4989247770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_853ff554-459a-414c-9b3c-9d4989247770" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_853ff554-459a-414c-9b3c-9d4989247770_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_853ff554-459a-414c-9b3c-9d4989247770" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_853ff554-459a-414c-9b3c-9d4989247770_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d02070ee-cd2c-486f-976f-b9c105de75a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_853ff554-459a-414c-9b3c-9d4989247770" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d02070ee-cd2c-486f-976f-b9c105de75a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_a35191cc-f813-40be-89f4-bcb0d8d89060" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d02070ee-cd2c-486f-976f-b9c105de75a2" xlink:to="loc_us-gaap_ResearchMember_a35191cc-f813-40be-89f4-bcb0d8d89060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_27403c4e-7af4-4f01-8f1b-2209f6340d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_27403c4e-7af4-4f01-8f1b-2209f6340d0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_27797211-5b1c-4209-acb3-fec9328d1041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_OperatingLossCarryforwards_27797211-5b1c-4209-acb3-fec9328d1041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_7e23414f-ebb5-45d9-a10d-533995fe124f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_7e23414f-ebb5-45d9-a10d-533995fe124f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2b71f4b2-beb3-4226-9f40-e61f13e28a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2b71f4b2-beb3-4226-9f40-e61f13e28a2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2564cadb-d8d5-424c-9227-edd178bc6bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2564cadb-d8d5-424c-9227-edd178bc6bd1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesTaxPaidDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureTable_019c5ccf-edbf-7b92-b159-a60abd56b594" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:to="loc_dna_IncomeTaxDisclosureTable_019c5ccf-edbf-7b92-b159-a60abd56b594" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c5cd0-b3ea-7d8c-99de-7886a5b108ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dna_IncomeTaxDisclosureTable_019c5ccf-edbf-7b92-b159-a60abd56b594" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c5cd0-b3ea-7d8c-99de-7886a5b108ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7d8c-99de-7886a5b108ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c5cd0-b3ea-7d8c-99de-7886a5b108ae" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7d8c-99de-7886a5b108ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c5cd0-b3ea-7d8c-99de-7886a5b108ae" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_019c5cd0-cb6e-7009-bbb9-564e92732e09" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:to="loc_stpr_CA_019c5cd0-cb6e-7009-bbb9-564e92732e09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_019c5cd0-e5c9-7dac-ac78-06f2dbd78866" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:to="loc_stpr_SC_019c5cd0-e5c9-7dac-ac78-06f2dbd78866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019c5cd1-03bd-767d-b98e-27f45f0d9124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:to="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019c5cd1-03bd-767d-b98e-27f45f0d9124" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c5ccf-edbf-714c-bb80-c41915992d90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:to="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c5ccf-edbf-714c-bb80-c41915992d90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c5cd0-1f0f-71f0-a733-79862d66aa44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c5cd0-1f0f-71f0-a733-79862d66aa44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019c5cd0-48ce-7a79-be9a-d629f2c583a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:to="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019c5cd0-48ce-7a79-be9a-d629f2c583a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c5cd0-6dfa-7647-ad35-e84b6a8f3c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019c5cd0-6dfa-7647-ad35-e84b6a8f3c55" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#NetLossperShareSummaryofAntiDilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d5715358-24f9-43fd-9516-ab9afbf9d737" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69949e01-48c9-4037-b40b-5c23eaa4cd91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d5715358-24f9-43fd-9516-ab9afbf9d737" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69949e01-48c9-4037-b40b-5c23eaa4cd91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ad0924-bce7-4174-8710-676156ce37dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69949e01-48c9-4037-b40b-5c23eaa4cd91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ad0924-bce7-4174-8710-676156ce37dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_01ad0924-bce7-4174-8710-676156ce37dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ad0924-bce7-4174-8710-676156ce37dc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_01ad0924-bce7-4174-8710-676156ce37dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ad0924-bce7-4174-8710-676156ce37dc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_7e4a9098-dbe9-42b9-b4ff-f5e5fe326d60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_us-gaap_WarrantMember_7e4a9098-dbe9-42b9-b4ff-f5e5fe326d60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cb998be0-1db3-420e-9022-5fa1eed435d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cb998be0-1db3-420e-9022-5fa1eed435d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnOutSharesMember_e9103bfc-f1d3-4651-ac35-4a459040120e" xlink:href="dna-20251231.xsd#dna_EarnOutSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_dna_EarnOutSharesMember_e9103bfc-f1d3-4651-ac35-4a459040120e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_54a8fb47-4ded-4e9e-a8f7-b9423e0edb86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_us-gaap_EmployeeStockOptionMember_54a8fb47-4ded-4e9e-a8f7-b9423e0edb86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EscrowSharesMember_1c52694a-97f4-4efc-891e-7fbf334fdf90" xlink:href="dna-20251231.xsd#dna_EscrowSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_dna_EscrowSharesMember_1c52694a-97f4-4efc-891e-7fbf334fdf90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019c5cd4-2bb9-794c-89b2-987eaf9e7b81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_us-gaap_PerformanceSharesMember_019c5cd4-2bb9-794c-89b2-987eaf9e7b81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b7398f5a-d6c5-4e05-9385-022a6fb46c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d5715358-24f9-43fd-9516-ab9afbf9d737" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b7398f5a-d6c5-4e05-9385-022a6fb46c0b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_67096e91-c916-4d92-9d93-e34f03daff1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c692615d-c8a6-4c58-a20a-ee1f0824cf35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_67096e91-c916-4d92-9d93-e34f03daff1f" xlink:to="loc_us-gaap_SubsequentEventTable_c692615d-c8a6-4c58-a20a-ee1f0824cf35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cc30e656-3119-407f-b793-e07053615d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c692615d-c8a6-4c58-a20a-ee1f0824cf35" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cc30e656-3119-407f-b793-e07053615d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cc30e656-3119-407f-b793-e07053615d0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cc30e656-3119-407f-b793-e07053615d0e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cc30e656-3119-407f-b793-e07053615d0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_eefb48ac-612b-46a0-bded-c7ba179b3f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cc30e656-3119-407f-b793-e07053615d0e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_eefb48ac-612b-46a0-bded-c7ba179b3f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4a98d0c2-66d5-468a-a913-d340edf4cc70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_eefb48ac-612b-46a0-bded-c7ba179b3f0d" xlink:to="loc_us-gaap_SubsequentEventMember_4a98d0c2-66d5-468a-a913-d340edf4cc70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived_019c9665-29ce-76eb-8ce8-b5755e6f6a47" xlink:href="dna-20251231.xsd#dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_67096e91-c916-4d92-9d93-e34f03daff1f" xlink:to="loc_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived_019c9665-29ce-76eb-8ce8-b5755e6f6a47" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:type="arc" order="691"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="41"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>dna-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:52002c9c-7569-4bc2-a5b5-c24c0eeac02a,g:42911b52-7f60-440e-93d3-9584b5edbad8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3acbecb6-319d-4983-8e1f-f2329adbfc35_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_e395d52f-e678-4840-84b2-1d697f089b00_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019c5c90-8cc0-77ec-9d43-c5652b3e7df6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_081323a0-739a-44ff-ac78-a5f6c4d45159_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded unconditional purchase obligation, year five</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum_68358322-f1a0-40b1-915d-d8ee24eaaf34_terseLabel_en-US" xlink:label="lab_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, outstanding (in shares)</link:label>
    <link:label id="lab_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum_label_en-US" xlink:label="lab_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant of Right, Number Of Warrants To Be Exercised, Minimum</link:label>
    <link:label id="lab_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum_documentation_en-US" xlink:label="lab_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant of Right, Number Of Warrants To Be Exercised, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum" xlink:href="dna-20251231.xsd#dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum" xlink:to="lab_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_00bf635d-314b-42b8-b306-8a446a56336f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b1c21813-8257-46ab-81e9-fdbe364c7ff1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_b5fe926a-9f9a-41a1-971f-d6fef06a2234_terseLabel_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, options vested, percentage</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_label_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Vested, Percentage</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_documentation_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Vested, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:to="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_BeginToExpireInTwoThousandAndThirtyMember_9e1baf7f-8291-4f20-80d2-062e99f6fcb8_terseLabel_en-US" xlink:label="lab_dna_BeginToExpireInTwoThousandAndThirtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Begin To Expire In 2030</link:label>
    <link:label id="lab_dna_BeginToExpireInTwoThousandAndThirtyMember_label_en-US" xlink:label="lab_dna_BeginToExpireInTwoThousandAndThirtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Begin To Expire In Two Thousand And Thirty [Member]</link:label>
    <link:label id="lab_dna_BeginToExpireInTwoThousandAndThirtyMember_documentation_en-US" xlink:label="lab_dna_BeginToExpireInTwoThousandAndThirtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Begin To Expire In Two Thousand And Thirty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BeginToExpireInTwoThousandAndThirtyMember" xlink:href="dna-20251231.xsd#dna_BeginToExpireInTwoThousandAndThirtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_BeginToExpireInTwoThousandAndThirtyMember" xlink:to="lab_dna_BeginToExpireInTwoThousandAndThirtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_c3303b48-0b1d-42d9-a68a-421aadc9b5b8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DeferredTaxAssetsLeaseLiabilities_40252644-be41-4a6a-b996-0ca35fc99437_terseLabel_en-US" xlink:label="lab_dna_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_dna_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_dna_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsLeaseLiabilities" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_dna_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_061e36ef-a6a3-48cd-96de-2a5279fc0b3b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_BusinessCombinationContingentConsiderationVestedValue_43aac47c-5348-4586-971d-5dceb91e1441_terseLabel_en-US" xlink:label="lab_dna_BusinessCombinationContingentConsiderationVestedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, contingent consideration, vested value</link:label>
    <link:label id="lab_dna_BusinessCombinationContingentConsiderationVestedValue_label_en-US" xlink:label="lab_dna_BusinessCombinationContingentConsiderationVestedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Vested Value</link:label>
    <link:label id="lab_dna_BusinessCombinationContingentConsiderationVestedValue_documentation_en-US" xlink:label="lab_dna_BusinessCombinationContingentConsiderationVestedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Vested Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BusinessCombinationContingentConsiderationVestedValue" xlink:href="dna-20251231.xsd#dna_BusinessCombinationContingentConsiderationVestedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_BusinessCombinationContingentConsiderationVestedValue" xlink:to="lab_dna_BusinessCombinationContingentConsiderationVestedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_4298c3d5-0dac-44f3-8f08-a38e619fe10a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_fc81e321-e1fa-4d60-a93d-89d6a593e241_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, consideration transferred</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c5ccc-2e76-728f-8cba-b8be2c616bfa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research &amp; Development Credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_1bc6ef54-f3b8-4d22-92af-fbd5c15532fd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f314c69d-455f-49d3-ae88-1babf367f495_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_faaf0e4c-e5af-40fd-8b7e-08ad600aa888_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_6159331e-1be6-4ca8-b2dc-f41efd0ed15f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in other non-current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash Equivalent, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1d79dd46-693c-404d-81ae-b16189b9e9ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_ba959995-7cda-46ed-b763-0443a666d6f7_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_18783baa-9733-4872-b1b6-3aaf71ecc655_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_82600bdd-ebf2-444a-a60c-cff775addf7a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_daae7304-d29f-41d7-8f5d-728df915a72c_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from customers within the United States</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_eadf4a9d-8ee3-4ea5-9d3d-3826c08e9b7d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6f81b6c6-19e8-4019-ba53-052083fe5c9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_3811e5b5-00f6-4eda-87f1-cba21012bed1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d664daa6-1a1c-4076-af74-b6234cc07020_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_14c590b1-bfe6-4416-a686-fd5cdf1232db_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d37e0adc-eee7-47a2-8ed1-bc4c2afeb6d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_f6101a4c-b053-4573-99e7-2c375e6aa118_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7ea1-a2f8-60ea0bd2e65d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c2ea906b-b5e7-4a41-b24d-e5f7ce9f0076_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_09d55843-36b4-4ef9-b165-e3d06e2502c5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_c2888807-68ee-4d7f-af0f-9aa26d9d4228_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment expense</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fa3b3ea0-0854-42e8-aacd-38fdb9c66ba2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c1505f87-b688-4b16-9ef0-6c1b9a1a0fe4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_19e47545-47e2-4c6b-8d22-c6c02e711cc2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_bf498712-dab8-46a8-b79a-cbdba61ef4e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f543a9ea-689e-4983-bf9a-3373f4de4f41_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9ff7e09b-ec86-4f7f-8c32-1ff4ec7c770c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_5e3e416f-2072-4777-8659-fbe48ba373ad_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information, Revenue for Reportable Segment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuretyBondMember_019c5cd5-cfe4-7bf0-85b5-9837d91ff4ff_terseLabel_en-US" xlink:label="lab_us-gaap_SuretyBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Surety Bond</link:label>
    <link:label id="lab_us-gaap_SuretyBondMember_label_en-US" xlink:label="lab_us-gaap_SuretyBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surety Bond [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuretyBondMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuretyBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuretyBondMember" xlink:to="lab_us-gaap_SuretyBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_FinancingReceivableMeasurementInputPeriod_a1db1572-7f97-4c2a-8e86-bfe7f475e585_terseLabel_en-US" xlink:label="lab_dna_FinancingReceivableMeasurementInputPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing receivable, measurement input, period</link:label>
    <link:label id="lab_dna_FinancingReceivableMeasurementInputPeriod_label_en-US" xlink:label="lab_dna_FinancingReceivableMeasurementInputPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Measurement Input, Period</link:label>
    <link:label id="lab_dna_FinancingReceivableMeasurementInputPeriod_documentation_en-US" xlink:label="lab_dna_FinancingReceivableMeasurementInputPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Receivable, Measurement Input, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinancingReceivableMeasurementInputPeriod" xlink:href="dna-20251231.xsd#dna_FinancingReceivableMeasurementInputPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_FinancingReceivableMeasurementInputPeriod" xlink:to="lab_dna_FinancingReceivableMeasurementInputPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SafeMember_0b2f982b-3583-48e6-bad0-6ebeb6cd19ec_terseLabel_en-US" xlink:label="lab_dna_SafeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SAFE</link:label>
    <link:label id="lab_dna_SafeMember_label_en-US" xlink:label="lab_dna_SafeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SAFE [Member]</link:label>
    <link:label id="lab_dna_SafeMember_documentation_en-US" xlink:label="lab_dna_SafeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SAFE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafeMember" xlink:href="dna-20251231.xsd#dna_SafeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SafeMember" xlink:to="lab_dna_SafeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9af0b11e-2ff5-484d-8520-ceee36e69d0f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_80bc301b-2747-445c-ba5b-b0ef05f98258_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_934dec0b-13ac-4f0b-92df-3a6f63acab9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a90d4cd-1109-4e28-b9f7-59b3183a6b41_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_a48920f9-fea9-48e1-a0c3-def2f8777897_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2092f07d-8594-4a82-9921-beadf3cfeebc_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_aee23eb6-8250-4b3d-afa6-80846f9a738f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4ecd3f8d-30d0-459a-9740-e16253f76a30_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_98385d28-c011-4d2c-a87d-5d09d9beea74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c90790c1-bb20-4a4c-b439-e733c673fe38_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e8d30ab0-81c1-4083-ad6d-906eb75a25ba_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_8252976e-648c-4bbf-9be1-951e7973babb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Escrow Shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_64a3ad58-2c92-474e-b2a2-6a79b963fd6b_netLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_695bc384-998e-46bb-a3a2-b779cb82a7b2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment operating (loss) income:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information, Operating Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CustomerOneMember_019c5c70-ceb7-7928-8005-623be9fac6ff_terseLabel_en-US" xlink:label="lab_dna_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_dna_CustomerOneMember_label_en-US" xlink:label="lab_dna_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_dna_CustomerOneMember_documentation_en-US" xlink:label="lab_dna_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CustomerOneMember" xlink:href="dna-20251231.xsd#dna_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CustomerOneMember" xlink:to="lab_dna_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_670ed54a-f63c-4c1c-bca4-23b964b27679_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_fee1022e-b382-472d-baf7-7928d4802f93_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AgricultureMember_b12b07e0-4c04-4d55-8fc9-9c4f0897baf5_terseLabel_en-US" xlink:label="lab_dna_AgricultureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agriculture</link:label>
    <link:label id="lab_dna_AgricultureMember_label_en-US" xlink:label="lab_dna_AgricultureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agriculture [Member]</link:label>
    <link:label id="lab_dna_AgricultureMember_documentation_en-US" xlink:label="lab_dna_AgricultureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agriculture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgricultureMember" xlink:href="dna-20251231.xsd#dna_AgricultureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AgricultureMember" xlink:to="lab_dna_AgricultureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d9f2a5b-8829-4a0a-a53e-e545c03a5b1b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_622f04c1-39e8-4ee6-bdf5-c9d0fdea3a1d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d65c9326-d195-44bc-988d-2903303e8d26_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm_79ba639c-64a1-47e6-b0e6-7099b92176e6_terseLabel_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement, common stock reserved for issuance, automatic increase term</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm_label_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement, Common Stock Reserved For Issuance, Increase, Term</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm_documentation_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement, Common Stock Reserved For Issuance, Increase, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm" xlink:to="lab_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_FinancingReceivableMeasurementInput_d0f6a51e-a944-405c-80e8-0633af15d5be_terseLabel_en-US" xlink:label="lab_dna_FinancingReceivableMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing receivable, measurement input</link:label>
    <link:label id="lab_dna_FinancingReceivableMeasurementInput_label_en-US" xlink:label="lab_dna_FinancingReceivableMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Measurement Input</link:label>
    <link:label id="lab_dna_FinancingReceivableMeasurementInput_documentation_en-US" xlink:label="lab_dna_FinancingReceivableMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Receivable, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinancingReceivableMeasurementInput" xlink:href="dna-20251231.xsd#dna_FinancingReceivableMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_FinancingReceivableMeasurementInput" xlink:to="lab_dna_FinancingReceivableMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9ff65eb8-b06d-4c01-b20a-338c4f915cfb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c5cd6-0193-7af5-887e-277e1b36ec85_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9a6d3ade-9221-406f-b7bb-d797edd39a36_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_4ebfa3b6-d189-43f2-bf26-32adc7c8d9aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_ca951e7f-7159-4af2-8385-344686d99f8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leases Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_OtherEquityInvestessMember_14cc05a3-f3d5-4437-b4cb-cc6aa2e712b5_terseLabel_en-US" xlink:label="lab_dna_OtherEquityInvestessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dna_OtherEquityInvestessMember_label_en-US" xlink:label="lab_dna_OtherEquityInvestessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Investess [Member]</link:label>
    <link:label id="lab_dna_OtherEquityInvestessMember_documentation_en-US" xlink:label="lab_dna_OtherEquityInvestessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Investess [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherEquityInvestessMember" xlink:href="dna-20251231.xsd#dna_OtherEquityInvestessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_OtherEquityInvestessMember" xlink:to="lab_dna_OtherEquityInvestessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_GoodwillImpairmentDCFWeight_019c9013-2acc-700b-8e14-9459b998ab79_terseLabel_en-US" xlink:label="lab_dna_GoodwillImpairmentDCFWeight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment, DCF weight</link:label>
    <link:label id="lab_dna_GoodwillImpairmentDCFWeight_label_en-US" xlink:label="lab_dna_GoodwillImpairmentDCFWeight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, DCF Weight</link:label>
    <link:label id="lab_dna_GoodwillImpairmentDCFWeight_documentation_en-US" xlink:label="lab_dna_GoodwillImpairmentDCFWeight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, DCF Weight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GoodwillImpairmentDCFWeight" xlink:href="dna-20251231.xsd#dna_GoodwillImpairmentDCFWeight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_GoodwillImpairmentDCFWeight" xlink:to="lab_dna_GoodwillImpairmentDCFWeight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_104ca7b2-9488-4edb-843e-f81320619c18_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability balance at December 31, 2025</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ab9b94b7-2e5c-4cdd-8274-b79a28e0975c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_12773a5a-3585-43dc-a6aa-c06ff8abfd87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9f43381b-1b90-4ef8-9c18-3cfb3690e279_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ff985020-e614-443c-9f0b-c13ffd625d90_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AuditInformationAbstract_label_en-US" xlink:label="lab_dna_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_dna_AuditInformationAbstract_documentation_en-US" xlink:label="lab_dna_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AuditInformationAbstract" xlink:href="dna-20251231.xsd#dna_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AuditInformationAbstract" xlink:to="lab_dna_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_7118f812-deff-4ddc-8913-bb0285581fcd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_c11ba565-7592-4e39-a587-d54b15371d80_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1f3c0519-823c-44b7-88dd-5829ac0bba4f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_b2845b0a-f41f-49d9-ac9b-0c61a0e6ea1e_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_84ac0b01-dad5-4e6a-970c-b9540a6a588b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_634b4ce7-7b07-4764-9ef3-c54d6de8a6c1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion (includes $64,787 and $72,260 from related parties)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_451ed87e-7c60-4f7d-8805-24b2e653808c_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion, from related parties</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DefinedContributionPlanVestingPeriod_019c902b-50c8-7134-bbdf-c0b0b50d3bcb_terseLabel_en-US" xlink:label="lab_dna_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, vesting period</link:label>
    <link:label id="lab_dna_DefinedContributionPlanVestingPeriod_label_en-US" xlink:label="lab_dna_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Vesting Period</link:label>
    <link:label id="lab_dna_DefinedContributionPlanVestingPeriod_documentation_en-US" xlink:label="lab_dna_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DefinedContributionPlanVestingPeriod" xlink:href="dna-20251231.xsd#dna_DefinedContributionPlanVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DefinedContributionPlanVestingPeriod" xlink:to="lab_dna_DefinedContributionPlanVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices_f9864a8b-2160-45fc-9f95-133ddef58492_terseLabel_en-US" xlink:label="lab_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible financial instruments received for Cell Engineering services</link:label>
    <link:label id="lab_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices_label_en-US" xlink:label="lab_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Financial Instruments Received For Foundry Services</link:label>
    <link:label id="lab_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices_documentation_en-US" xlink:label="lab_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible financial instruments received for Foundry services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices" xlink:href="dna-20251231.xsd#dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices" xlink:to="lab_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d5174f1a-acd1-430a-93c8-ab28df158c2b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_de26427c-14b8-420b-bea5-1312308d4458_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5fb10fa3-dc04-4c53-b661-2a9b30b34b80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_80f4e546-1322-466b-a0d5-37c24959aa73_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a90f6a1b-0798-491a-9412-99b77017f817_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_be32243d-5381-414b-b541-7d6485beab7f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8e2adb48-73ce-43b2-ba23-ca47df4481e0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_9f54d481-9be6-4ee9-b8b0-a34f2b8f9de5_terseLabel_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, number of annual installments</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_label_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_documentation_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:to="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_30e99a9c-0df8-45c2-9a5d-067aa8a18224_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7badd298-ce2f-4547-aea1-38d3878e478f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise or vesting of equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_211f4733-2cbd-4f34-9f40-abf2dc7997b9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_c3b56ed4-04c4-456b-bb1e-3424f2f469ff_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1eacbc89-2701-4d32-b464-6a56dae06fdf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f22e7487-9be9-4118-8df5-91b3c4909491_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate - finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7aec-bf7d-f5a1136ede9e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_a9d14251-8131-477d-83bf-47a42c4c3be3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Financing Receivable [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Financing Receivable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f2607f2-224e-4c70-b7dc-81d4c0a38166_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_00d2fa44-15f2-4091-a26a-9e0f9e11e9b0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_fd62de4a-bded-45ab-81a9-7ce94a6dc253_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_27a917c7-4a74-4797-8103-608c3a2e6bca_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_a76064dc-5cd4-4bee-bec1-9a135aadb04d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_bd7e0c8c-2259-4430-904c-ee9fa4271b9e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_cc233469-b2fc-49c9-970a-a3dcdc26d0e0_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_019c5cd0-e5c9-7850-ad6e-3351b785a3fb_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">South Carolina</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_0a79f03f-c471-48d1-bfa0-7e5a29437924_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_95f47e79-925a-4429-83e2-e74bbf297e54_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Other-than-Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4fd997f0-2c11-4c3a-b735-eb12deab1a43_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b34ba225-8bc6-4f1a-b0d3-15ebd473d438_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term - finance leases (in years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c60aa3e9-da9a-43f4-a901-ce11ffc2d7f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5821b8b1-4c53-4227-95e2-74b909f48e6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8c8eaaeb-98e8-40fc-9a2e-2cf634e7b8a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassCMember_5f240ee4-f6f1-4996-b874-46458798896a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class C</link:label>
    <link:label id="lab_us-gaap_CommonClassCMember_8a0a5fc9-7cae-4146-a776-76fca766fda4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class C</link:label>
    <link:label id="lab_us-gaap_CommonClassCMember_label_en-US" xlink:label="lab_us-gaap_CommonClassCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassCMember" xlink:to="lab_us-gaap_CommonClassCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a75a194f-588e-4fd8-9010-63e58222fa7c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_83f2fba9-f98e-4d2a-ace0-3734ee45a09f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e2329938-633c-4527-8f5e-39a70f592dba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_019c5c90-8cc0-77f2-a674-47c77751979b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_aed34313-22db-4721-b93d-d6b61f31935d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation Of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_132092aa-4133-4449-8c0d-32eeefec64cf_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Financing Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Financing Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3162ff83-69d3-4124-b06a-b07a3d43b67d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_73078478-d540-4ae4-a825-37be4c5c2e9c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions (Subtractions)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d3422431-ae06-4b5d-8259-2cff0c6d9e28_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance, deferred tax asset, increase (decrease), amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_b254182b-9e33-4c4c-aae5-2246f84c8043_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_RoyaltyReceivedFromLicensingRevenue_f1239985-38ba-44d1-a318-2693bbc6c523_terseLabel_en-US" xlink:label="lab_dna_RoyaltyReceivedFromLicensingRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty received from licensing revenue</link:label>
    <link:label id="lab_dna_RoyaltyReceivedFromLicensingRevenue_label_en-US" xlink:label="lab_dna_RoyaltyReceivedFromLicensingRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Received From Licensing Revenue</link:label>
    <link:label id="lab_dna_RoyaltyReceivedFromLicensingRevenue_documentation_en-US" xlink:label="lab_dna_RoyaltyReceivedFromLicensingRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Received From Licensing Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RoyaltyReceivedFromLicensingRevenue" xlink:href="dna-20251231.xsd#dna_RoyaltyReceivedFromLicensingRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_RoyaltyReceivedFromLicensingRevenue" xlink:to="lab_dna_RoyaltyReceivedFromLicensingRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_UpfrontAmountReceived_17c3414f-3322-47df-bedd-093e4a74b156_terseLabel_en-US" xlink:label="lab_dna_UpfrontAmountReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront amount received</link:label>
    <link:label id="lab_dna_UpfrontAmountReceived_label_en-US" xlink:label="lab_dna_UpfrontAmountReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Amount Received</link:label>
    <link:label id="lab_dna_UpfrontAmountReceived_documentation_en-US" xlink:label="lab_dna_UpfrontAmountReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront amount received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_UpfrontAmountReceived" xlink:href="dna-20251231.xsd#dna_UpfrontAmountReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_UpfrontAmountReceived" xlink:to="lab_dna_UpfrontAmountReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_PublicWarrantsMember_25549bf9-4c89-49e3-9425-aa700c179db0_terseLabel_en-US" xlink:label="lab_dna_PublicWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Warrants</link:label>
    <link:label id="lab_dna_PublicWarrantsMember_label_en-US" xlink:label="lab_dna_PublicWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Warrants [Member]</link:label>
    <link:label id="lab_dna_PublicWarrantsMember_documentation_en-US" xlink:label="lab_dna_PublicWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PublicWarrantsMember" xlink:href="dna-20251231.xsd#dna_PublicWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_PublicWarrantsMember" xlink:to="lab_dna_PublicWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_Year1Member_019c5cb8-7115-7aeb-8ac3-7f421872f8bd_terseLabel_en-US" xlink:label="lab_dna_Year1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 1</link:label>
    <link:label id="lab_dna_Year1Member_label_en-US" xlink:label="lab_dna_Year1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year 1 [Member]</link:label>
    <link:label id="lab_dna_Year1Member_documentation_en-US" xlink:label="lab_dna_Year1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year1Member" xlink:href="dna-20251231.xsd#dna_Year1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_Year1Member" xlink:to="lab_dna_Year1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_6c705373-ab6d-4458-8c42-93b468d032b7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Fair Value, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Fair Value, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c619b8ad-d66a-40f9-af87-c809dfb890dd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7cdb554d-ea5d-4f58-b491-e84d45a1cc76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0790d1cb-4760-48ce-a2c0-abb236e48d9f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_IncomeTaxDisclosureTable_cd8bab8e-4941-44fe-9a94-9aed446c098d_terseLabel_en-US" xlink:label="lab_dna_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_dna_IncomeTaxDisclosureTable_label_en-US" xlink:label="lab_dna_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_dna_IncomeTaxDisclosureTable_documentation_en-US" xlink:label="lab_dna_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureTable" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_IncomeTaxDisclosureTable" xlink:to="lab_dna_IncomeTaxDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_44c7d7c2-107c-44e1-a5ea-98f07890836d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1793bf61-756a-4fdf-975d-176d10ac4928_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_79e43f5e-dda5-4e38-a687-84f1bf52617a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_2d6291b9-9055-40f3-bac2-f8002556b15b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_16a166d0-d2d1-47ee-8939-14aa1cad8473_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_b07226da-84a6-4681-8c9e-84276353a993_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_46c40212-5a3e-4410-ad93-60d318fa552a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_20c09a8a-134d-4df7-bb5d-9e9bdaf27e74_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_08523a70-74d5-415d-ad8b-7e7dc506816d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AccruedPropertyAndEquipmentCurrent_40c52b75-ec06-421f-a714-b1ce92d5f2bd_terseLabel_en-US" xlink:label="lab_dna_AccruedPropertyAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_dna_AccruedPropertyAndEquipmentCurrent_label_en-US" xlink:label="lab_dna_AccruedPropertyAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Property And Equipment Current</link:label>
    <link:label id="lab_dna_AccruedPropertyAndEquipmentCurrent_documentation_en-US" xlink:label="lab_dna_AccruedPropertyAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued property and equipment current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedPropertyAndEquipmentCurrent" xlink:href="dna-20251231.xsd#dna_AccruedPropertyAndEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AccruedPropertyAndEquipmentCurrent" xlink:to="lab_dna_AccruedPropertyAndEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_91147fea-b3f2-4741-b197-455f8abd319d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4854a413-bcc8-41df-9753-881516fe2812_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ContractualShortfallLiabilityCurrent_019c9017-1da2-791d-999c-a5259fc05693_terseLabel_en-US" xlink:label="lab_dna_ContractualShortfallLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual shortfall liabilities (Note 12)</link:label>
    <link:label id="lab_dna_ContractualShortfallLiabilityCurrent_label_en-US" xlink:label="lab_dna_ContractualShortfallLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Shortfall Liability, Current</link:label>
    <link:label id="lab_dna_ContractualShortfallLiabilityCurrent_documentation_en-US" xlink:label="lab_dna_ContractualShortfallLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Shortfall Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContractualShortfallLiabilityCurrent" xlink:href="dna-20251231.xsd#dna_ContractualShortfallLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ContractualShortfallLiabilityCurrent" xlink:to="lab_dna_ContractualShortfallLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_a08ca06c-1d43-4f18-9d82-a6a6c235abac_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contribution by company, amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_a3ec4d33-2ef6-464a-a84c-9a7e1beb6e86_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse Stock Split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ea09c63d-b47b-4923-b84a-e33145408ff6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_edb9e084-5903-48a2-adb7-ff979b22f2ae_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d309a1dc-4a18-4b9f-a535-eeedc3d953eb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_34f7bd2c-95bc-4dca-a551-9b150c1e547b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c5ccf-edbf-7847-a3ad-ac07c85eb48d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, Federal, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:to="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c5ccc-0977-7517-b986-308a5e5e30b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_432d6f7c-5e30-4e0d-980d-fe24b1c07183_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested beginning period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6b675550-43a1-42d6-b829-6ae0ce1e8778_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e4d8df3a-77db-44ed-b45f-22e162823af1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_PharmaceuticalAndBiotechnologyMember_78a5a263-3b7e-4a06-a3f0-51d4bf2b4e57_terseLabel_en-US" xlink:label="lab_dna_PharmaceuticalAndBiotechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmaceutical and biotechnology</link:label>
    <link:label id="lab_dna_PharmaceuticalAndBiotechnologyMember_label_en-US" xlink:label="lab_dna_PharmaceuticalAndBiotechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmaceutical And Biotechnology [Member]</link:label>
    <link:label id="lab_dna_PharmaceuticalAndBiotechnologyMember_documentation_en-US" xlink:label="lab_dna_PharmaceuticalAndBiotechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmaceutical And Biotechnology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PharmaceuticalAndBiotechnologyMember" xlink:href="dna-20251231.xsd#dna_PharmaceuticalAndBiotechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_PharmaceuticalAndBiotechnologyMember" xlink:to="lab_dna_PharmaceuticalAndBiotechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e5c4277-1722-4980-ae79-b9f377c598b1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-7d36-a002-548429896d48_terseLabel_en-US" xlink:label="lab_dna_RevenuePerformanceObligationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Performance Obligation [Axis]</link:label>
    <link:label id="lab_dna_RevenuePerformanceObligationAxis_label_en-US" xlink:label="lab_dna_RevenuePerformanceObligationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Performance Obligation [Axis]</link:label>
    <link:label id="lab_dna_RevenuePerformanceObligationAxis_documentation_en-US" xlink:label="lab_dna_RevenuePerformanceObligationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Performance Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationAxis" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_RevenuePerformanceObligationAxis" xlink:to="lab_dna_RevenuePerformanceObligationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e8e6bbb6-249a-4ad4-9f5c-eb5bbec5da78_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_019c5c69-f8a1-7e7e-a19d-e497e567e506_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_201e468a-f9c1-4e54-9206-fa84c39d9c73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_05009eed-9c97-4dc3-819f-01c95bdb88c9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_2695799b-e807-4382-8654-1632cb1ff7fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1482cacd-896c-47e4-b937-0e41e77cdeee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_94a0080f-de7b-4b60-844a-fcb8ac9d43e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_81693c21-f98e-4cb2-a1a3-158f0974ff91_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ee4a9785-12cc-4ec9-93ad-9199cd9c771e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_5d12a995-fc1f-44fd-8c27-7ba7f0b828a8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_956c06de-e5c9-4272-9537-a356b1ce390a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2bba5e64-d036-4db8-8385-4f6fd08e534a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8686e3c8-ea30-4d3f-8d3c-45d7b52f650d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_b548b66f-3b8b-4eac-a080-299674ad2110_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_115bded1-427f-4e81-9c76-d940f139f3e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_16ffe598-4d2b-4bc0-93b3-aa41c3268e5b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment_bdcdbc36-0d99-46b6-a2f1-afa4b1467179_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for acquisitions</link:label>
    <link:label id="lab_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment_label_en-US" xlink:label="lab_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Securities, US Treasury and Other US Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment" xlink:to="lab_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_50472034-d1f3-495a-8688-b94b88303382_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_17e738ab-8d08-445d-ac37-bca82dcb6ab2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent_019c5cc6-ff86-705e-8846-47cabd090868_terseLabel_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on investments</link:label>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent_label_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Percent</link:label>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent_documentation_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent" xlink:to="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_d2c048ef-81b9-4984-a87a-dab50689ba4b_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_9de19835-0881-4d44-9312-7dab23843a18_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9fefe661-bca1-4cec-a021-b846304f068f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_34d798fb-d4fe-4631-9f81-b199bca6a220_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_048b022f-1d24-4e61-953c-14e29f71f173_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_31ce5575-0584-4ffa-a55c-daa29082110e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_77d0d333-15e5-4f17-8e1e-3c9f8de8c0ac_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e45c702f-b853-4661-9b7b-bb60803e5ca6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cc8d249f-2253-4f1d-95ec-8ba3a5e64483_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CarriedForwardIndefinitelyMember_fb20eded-815d-4ccd-a54a-d58777f63ace_terseLabel_en-US" xlink:label="lab_dna_CarriedForwardIndefinitelyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carried Forward Indefinitely</link:label>
    <link:label id="lab_dna_CarriedForwardIndefinitelyMember_label_en-US" xlink:label="lab_dna_CarriedForwardIndefinitelyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carried Forward Indefinitely [Member]</link:label>
    <link:label id="lab_dna_CarriedForwardIndefinitelyMember_documentation_en-US" xlink:label="lab_dna_CarriedForwardIndefinitelyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carried Forward Indefinitely [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarriedForwardIndefinitelyMember" xlink:href="dna-20251231.xsd#dna_CarriedForwardIndefinitelyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CarriedForwardIndefinitelyMember" xlink:to="lab_dna_CarriedForwardIndefinitelyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_0e6c6e93-ead8-46a0-93d3-25cbac42ae3e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_6afa742a-59bf-4980-87a2-1842de29a0dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SeniorSecuredNoteMember_bb4920ea-7ad3-4462-8117-37aaf9049b2d_terseLabel_en-US" xlink:label="lab_dna_SeniorSecuredNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Note</link:label>
    <link:label id="lab_dna_SeniorSecuredNoteMember_label_en-US" xlink:label="lab_dna_SeniorSecuredNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Note [Member]</link:label>
    <link:label id="lab_dna_SeniorSecuredNoteMember_documentation_en-US" xlink:label="lab_dna_SeniorSecuredNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Secured Note Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SeniorSecuredNoteMember" xlink:href="dna-20251231.xsd#dna_SeniorSecuredNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SeniorSecuredNoteMember" xlink:to="lab_dna_SeniorSecuredNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_7c0d40fb-833d-450a-94e3-bd50942cb05b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_62287b33-19ac-40e9-94ed-25b54f4d8170_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NumberOfVestingConditions_019c901f-0aae-7f85-9bd3-e335adfec151_terseLabel_en-US" xlink:label="lab_dna_NumberOfVestingConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of vesting conditions</link:label>
    <link:label id="lab_dna_NumberOfVestingConditions_label_en-US" xlink:label="lab_dna_NumberOfVestingConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Vesting Conditions</link:label>
    <link:label id="lab_dna_NumberOfVestingConditions_documentation_en-US" xlink:label="lab_dna_NumberOfVestingConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Vesting Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfVestingConditions" xlink:href="dna-20251231.xsd#dna_NumberOfVestingConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NumberOfVestingConditions" xlink:to="lab_dna_NumberOfVestingConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_c67a85f0-d20f-4f3e-8e3a-4e819d28370d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Downward adjustments from observable price changes</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AlloniaMember_d248811a-9d95-410e-936f-bea71ba99d6e_terseLabel_en-US" xlink:label="lab_dna_AlloniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allonnia</link:label>
    <link:label id="lab_dna_AlloniaMember_label_en-US" xlink:label="lab_dna_AlloniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allonia [Member]</link:label>
    <link:label id="lab_dna_AlloniaMember_documentation_en-US" xlink:label="lab_dna_AlloniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allonnia [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AlloniaMember" xlink:href="dna-20251231.xsd#dna_AlloniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AlloniaMember" xlink:to="lab_dna_AlloniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ShareBasedCompensationAwardTrancheFourMember_587db4f7-cb69-4faf-930f-91d4fbec5d3d_verboseLabel_en-US" xlink:label="lab_dna_ShareBasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">800 Then 25%</link:label>
    <link:label id="lab_dna_ShareBasedCompensationAwardTrancheFourMember_label_en-US" xlink:label="lab_dna_ShareBasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Award Tranche Four Member</link:label>
    <link:label id="lab_dna_ShareBasedCompensationAwardTrancheFourMember_documentation_en-US" xlink:label="lab_dna_ShareBasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation award tranche four member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationAwardTrancheFourMember" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationAwardTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ShareBasedCompensationAwardTrancheFourMember" xlink:to="lab_dna_ShareBasedCompensationAwardTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a342a8ae-d141-4cc6-9942-1accb8e43c63_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7c002ef0-963b-4679-af26-b10bde57fe0f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_019c5cd6-0193-7949-97dd-a734630b4848_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_08ca9759-b5c0-48bb-a2ee-ffed00c49150_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c5ccb-0d50-750f-8099-f0c4e7521066_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_ec759602-8a4d-4a4e-a4af-07786e677617_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment owned, at cost</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions_574d8356-e012-4e95-aef9-aa4fcd2b7b3c_terseLabel_en-US" xlink:label="lab_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion to preferred stock</link:label>
    <link:label id="lab_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions_label_en-US" xlink:label="lab_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Conversions</link:label>
    <link:label id="lab_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions_documentation_en-US" xlink:label="lab_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Conversions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" xlink:href="dna-20251231.xsd#dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" xlink:to="lab_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5f495d68-34f5-408c-a7d3-59766f4dfe3f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation Of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e3d20077-ee1d-4bfa-8449-ec35e4d311f6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cd4a71c3-a8f4-4fe2-96af-98e2ce365e29_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_8bbac367-d179-45b1-b74e-02f1c21964d8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_dba6bebc-e862-481a-bc99-e00fe5f28d66_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_OtherAssetAcquisitionsMember_75443f7b-8c2d-4cd8-bf56-24e3fca0c707_terseLabel_en-US" xlink:label="lab_dna_OtherAssetAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Acquisitions</link:label>
    <link:label id="lab_dna_OtherAssetAcquisitionsMember_label_en-US" xlink:label="lab_dna_OtherAssetAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Asset Acquisitions [Member]</link:label>
    <link:label id="lab_dna_OtherAssetAcquisitionsMember_documentation_en-US" xlink:label="lab_dna_OtherAssetAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherAssetAcquisitionsMember" xlink:href="dna-20251231.xsd#dna_OtherAssetAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_OtherAssetAcquisitionsMember" xlink:to="lab_dna_OtherAssetAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c2ddebca-cb44-49b7-ae93-8511e0cc7e45_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_fd79da07-7e12-4fff-ad5b-2d306566a9c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_590bfb87-22fb-48e0-8a2d-f52b35737606_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_12d470c7-19a8-4465-aee3-b11bdd73e263_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosureAbstract_bd67a5be-8fcd-4859-ae4f-168ef5334a1c_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_ReceivablesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract_5926e7ad-a1e1-421e-b3f7-fc532867ce93_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_BiomeditLlcMember_49ac33c0-70c5-496f-97cd-88a8c720189e_terseLabel_en-US" xlink:label="lab_dna_BiomeditLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BiomEdit</link:label>
    <link:label id="lab_dna_BiomeditLlcMember_label_en-US" xlink:label="lab_dna_BiomeditLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BiomEdit LLC [Member]</link:label>
    <link:label id="lab_dna_BiomeditLlcMember_documentation_en-US" xlink:label="lab_dna_BiomeditLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BiomEdit LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditLlcMember" xlink:href="dna-20251231.xsd#dna_BiomeditLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_BiomeditLlcMember" xlink:to="lab_dna_BiomeditLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_7d994e9f-644c-43d3-97f7-f94d7be0289f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation of subsidiaries - cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0809343f-b8c1-4a0c-9646-173005d90035_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5aec0e4f-0d70-4e77-9de7-06638b11e60b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6f5a789c-156b-4030-8df9-0bd6848516de_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3c403650-c0b8-4de1-8426-d9f90b99cd47_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_26323816-42f5-43d2-b36f-ae0846dc6636_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_dd183f34-ac98-4f16-a412-19a5c5705098_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">500 Then 25%</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_85633eea-d0d9-4954-a648-af289a651e12_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue (includes $98 and $795 from related parties)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c288c613-f39a-482c-800d-05102879569f_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f8edcfc7-244a-4f68-a363-bfb3921c52e3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_2fa71964-4fed-4ce4-8576-a44efdb5e548_terseLabel_en-US" xlink:label="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_label_en-US" xlink:label="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Liabilities, Noncurrent</link:label>
    <link:label id="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:to="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b9a665ad-6e95-42c2-826b-1d24dbf9862d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_34906678-e69e-4258-9da8-9dbfd4f34db7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_79d22503-99d9-4f48-b4c9-ec03a327f770_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax at U.S. Statutory Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_LossContingencyAmountRequiredToFund_019c5cd5-43bd-776e-87d3-530481d8094c_terseLabel_en-US" xlink:label="lab_dna_LossContingencyAmountRequiredToFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount required to fund</link:label>
    <link:label id="lab_dna_LossContingencyAmountRequiredToFund_label_en-US" xlink:label="lab_dna_LossContingencyAmountRequiredToFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Amount Required To Fund</link:label>
    <link:label id="lab_dna_LossContingencyAmountRequiredToFund_documentation_en-US" xlink:label="lab_dna_LossContingencyAmountRequiredToFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Amount Required To Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LossContingencyAmountRequiredToFund" xlink:href="dna-20251231.xsd#dna_LossContingencyAmountRequiredToFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_LossContingencyAmountRequiredToFund" xlink:to="lab_dna_LossContingencyAmountRequiredToFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_9f44ed8c-a29d-4410-8aba-abcd6a8d54bf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c9648cec-b0b5-48b1-86f9-b367c0457780_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f2c0756d-6a6b-4d7a-a3c0-c2050c40dd50_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_e02d4659-4c5d-4153-b0bc-9f15589ef669_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a445985d-05d7-4b32-afa0-9c2da87c3599_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_OneInvestmentMember_019c94b0-503f-7f8e-b85e-39f8a9f5f646_terseLabel_en-US" xlink:label="lab_dna_OneInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One Investment</link:label>
    <link:label id="lab_dna_OneInvestmentMember_label_en-US" xlink:label="lab_dna_OneInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Investment [Member]</link:label>
    <link:label id="lab_dna_OneInvestmentMember_documentation_en-US" xlink:label="lab_dna_OneInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OneInvestmentMember" xlink:href="dna-20251231.xsd#dna_OneInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_OneInvestmentMember" xlink:to="lab_dna_OneInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_380e86f4-4402-4f52-9da3-9344faa70c32_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_8a2856b7-282c-49b8-be1b-dee12fb72452_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2565689b-10a3-4f6a-851b-9239a84eec1d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_2ca904f8-8892-4f9f-8dfc-58a4b62f6c88_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SummaryOfActivityForEarnoutRSATableTextBlock_27e4e173-66be-42f2-bd47-aa3c90b80805_terseLabel_en-US" xlink:label="lab_dna_SummaryOfActivityForEarnoutRSATableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity For Earnout RSA</link:label>
    <link:label id="lab_dna_SummaryOfActivityForEarnoutRSATableTextBlock_label_en-US" xlink:label="lab_dna_SummaryOfActivityForEarnoutRSATableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity For Earnout RSA [Table Text Block]</link:label>
    <link:label id="lab_dna_SummaryOfActivityForEarnoutRSATableTextBlock_documentation_en-US" xlink:label="lab_dna_SummaryOfActivityForEarnoutRSATableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Earnout RSUs Table Text Block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SummaryOfActivityForEarnoutRSATableTextBlock" xlink:href="dna-20251231.xsd#dna_SummaryOfActivityForEarnoutRSATableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SummaryOfActivityForEarnoutRSATableTextBlock" xlink:to="lab_dna_SummaryOfActivityForEarnoutRSATableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cbb404c5-1af5-4b9f-b7e9-d46703d2b842_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c131b8e3-9a0d-452c-a717-bc7bb7c367c4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5c3a8e7c-33c2-45af-86f7-90470b84a1c7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_19c54109-f1a4-4516-964f-2546cd67fb79_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5c128849-ee6d-4a8a-82e4-9b740d0d67c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_f88154c2-07db-4908-aadb-cc4efd81390f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c9d935db-6157-4ca7-b6ad-7173687a7ac6_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d6eaf7e9-57d1-4e67-9fdb-b8f3939562a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax withholdings related to net share settlement of equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ba62b817-3a6b-4407-aa85-2ac75f661783_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_0a2617fd-a2a9-4f53-9fca-8d968b7755bc_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total initial cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_e1cbc3a8-ff6f-4ec3-8fdb-707089c06a51_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EscrowSharesMember_4f0ccc38-9a68-4cf5-ba82-55deccd5eda3_terseLabel_en-US" xlink:label="lab_dna_EscrowSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Escrow Shares</link:label>
    <link:label id="lab_dna_EscrowSharesMember_label_en-US" xlink:label="lab_dna_EscrowSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Escrow Shares [Member]</link:label>
    <link:label id="lab_dna_EscrowSharesMember_documentation_en-US" xlink:label="lab_dna_EscrowSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Escrow Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EscrowSharesMember" xlink:href="dna-20251231.xsd#dna_EscrowSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EscrowSharesMember" xlink:to="lab_dna_EscrowSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b7f7363-ce2a-4dea-b369-cd3988139813_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NumberOfCoreAssets_356a7a18-7721-4a5f-b7a8-aa33b9362391_terseLabel_en-US" xlink:label="lab_dna_NumberOfCoreAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of core assets</link:label>
    <link:label id="lab_dna_NumberOfCoreAssets_label_en-US" xlink:label="lab_dna_NumberOfCoreAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Core Assets</link:label>
    <link:label id="lab_dna_NumberOfCoreAssets_documentation_en-US" xlink:label="lab_dna_NumberOfCoreAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfCoreAssets" xlink:href="dna-20251231.xsd#dna_NumberOfCoreAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NumberOfCoreAssets" xlink:to="lab_dna_NumberOfCoreAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d07e7d76-9e6b-4364-af7a-3ed44b651d28_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1a0c125a-19b8-45ca-a114-922df2c7eaa2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_d1356106-0150-4d94-9f2e-9c21b4b15fb5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CarryForwardsExpirationPeriodAxis_662b20bb-b495-47ec-a348-ea6c758ffe32_terseLabel_en-US" xlink:label="lab_dna_CarryForwardsExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carry Forwards Expiration Period</link:label>
    <link:label id="lab_dna_CarryForwardsExpirationPeriodAxis_label_en-US" xlink:label="lab_dna_CarryForwardsExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carry Forwards Expiration Period [Axis]</link:label>
    <link:label id="lab_dna_CarryForwardsExpirationPeriodAxis_documentation_en-US" xlink:label="lab_dna_CarryForwardsExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carry Forwards Expiration Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarryForwardsExpirationPeriodAxis" xlink:href="dna-20251231.xsd#dna_CarryForwardsExpirationPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CarryForwardsExpirationPeriodAxis" xlink:to="lab_dna_CarryForwardsExpirationPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_86df2ea4-2b61-4529-8404-c189d0c5474b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Measurements Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_bdd32f79-8254-4b52-ab88-0999ab7b2eca_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cec5a622-0c12-44f0-9a6a-0f493013592d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6e98a722-f4e8-4fab-a3b8-7a5a7ba9fb7c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_289df50c-1040-4c73-bdde-070e4d4a1612_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_d9fd382a-c49b-4411-a84c-a36df4c730d3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_81a1b60a-bf66-4ab4-92e9-3293c7d6a38e_totalLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_Investments_d530ec29-b9d5-48b3-adc4-be64ef6e9c66_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_9820a967-378a-4913-9d34-6187b4512f7f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative catch-up adjustment to revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_b18d8db5-f9ec-4228-8d3c-7340ed48880a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_19d45176-28cf-4c2e-a9d1-00415773ba80_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_StockIssuanceCosts_019c5ce6-c2f0-7de3-8844-6239d781c593_terseLabel_en-US" xlink:label="lab_dna_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_dna_StockIssuanceCosts_label_en-US" xlink:label="lab_dna_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:label id="lab_dna_StockIssuanceCosts_documentation_en-US" xlink:label="lab_dna_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StockIssuanceCosts" xlink:href="dna-20251231.xsd#dna_StockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_StockIssuanceCosts" xlink:to="lab_dna_StockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49b2ab5c-0283-4e13-836f-4ada75ef3935_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SettlementOfContingentConsiderationSharesRestrictedStock_836a2cec-0ce8-407c-9e94-849eafad5af7_terseLabel_en-US" xlink:label="lab_dna_SettlementOfContingentConsiderationSharesRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of contingent consideration (in shares)</link:label>
    <link:label id="lab_dna_SettlementOfContingentConsiderationSharesRestrictedStock_label_en-US" xlink:label="lab_dna_SettlementOfContingentConsiderationSharesRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Of Contingent Consideration, Shares, Restricted Stock</link:label>
    <link:label id="lab_dna_SettlementOfContingentConsiderationSharesRestrictedStock_documentation_en-US" xlink:label="lab_dna_SettlementOfContingentConsiderationSharesRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement Of Contingent Consideration, Shares, Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SettlementOfContingentConsiderationSharesRestrictedStock" xlink:href="dna-20251231.xsd#dna_SettlementOfContingentConsiderationSharesRestrictedStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SettlementOfContingentConsiderationSharesRestrictedStock" xlink:to="lab_dna_SettlementOfContingentConsiderationSharesRestrictedStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ce19aa8c-0bf0-4119-bd20-049782cef73f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_899309d5-b72a-4637-bddd-f5a60df55c3d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquire consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Tangible and Intangible Assets, Excluding Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_1e38d513-ea59-47ad-b80b-5856a8b6d5a1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_LesseeOperatingLeaseNumberOfExtensionOptions_019c9014-ff70-7486-b3e5-be46b04032d7_terseLabel_en-US" xlink:label="lab_dna_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of extension options</link:label>
    <link:label id="lab_dna_LesseeOperatingLeaseNumberOfExtensionOptions_label_en-US" xlink:label="lab_dna_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Options</link:label>
    <link:label id="lab_dna_LesseeOperatingLeaseNumberOfExtensionOptions_documentation_en-US" xlink:label="lab_dna_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:href="dna-20251231.xsd#dna_LesseeOperatingLeaseNumberOfExtensionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:to="lab_dna_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e91c5ec1-f8c0-429f-8b5f-cedb9da1ad58_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_ab643ce4-d47d-4b92-8923-4eb5178d9b80_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c73be91d-c7d6-4713-9f82-fae7676ad465_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0781a41a-c7fe-42f6-a1c3-6718e7eace97_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ArcaeaMember_a6978bb3-cb28-44ff-b233-8fc13598e44b_terseLabel_en-US" xlink:label="lab_dna_ArcaeaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arcaea</link:label>
    <link:label id="lab_dna_ArcaeaMember_label_en-US" xlink:label="lab_dna_ArcaeaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arcaea [Member]</link:label>
    <link:label id="lab_dna_ArcaeaMember_documentation_en-US" xlink:label="lab_dna_ArcaeaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arcaea [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ArcaeaMember" xlink:href="dna-20251231.xsd#dna_ArcaeaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ArcaeaMember" xlink:to="lab_dna_ArcaeaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityMeasureOfActivityAbstract_4dd2b16a-6ac2-496a-b30a-e7f71a912af0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityMeasureOfActivityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Measure of Activity [Abstract]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityMeasureOfActivityAbstract_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityMeasureOfActivityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Measure of Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityMeasureOfActivityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityMeasureOfActivityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityMeasureOfActivityAbstract" xlink:to="lab_us-gaap_VariableInterestEntityMeasureOfActivityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_51bb0da8-db34-4613-8b6e-d09497a6bfae_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e4c43030-eaa4-487f-95b1-9d839315b789_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-cash activity</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_7ebfda89-a7b9-4977-9438-730b19d0cffc_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on deconsolidation of subsidiaries</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_9678755e-7a9b-4aa7-8b76-6c0f3f42c037_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on deconsolidation of subsidiaries</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_39a43a76-f41b-4f86-9f40-15ea734594e1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss on deconsolidation of subsidiaries</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0506c37c-d5e5-4b2c-afc8-1fcb7eaed05f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_62b9cfd2-d90e-451a-a037-2bdef5e8e770_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5cf82141-767d-466b-98fc-40030c60b7d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e371eb05-c056-41fc-abdd-591ac229049d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c5cea-14b8-7bca-bc28-b62821b19b5f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c5cc5-ca7a-7ff2-8d36-4650e1337821_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other foreign jurisdictions</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SupplementalFinancialStatementInformationAbstract_label_en-US" xlink:label="lab_dna_SupplementalFinancialStatementInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Financial Statement Information [Abstract]</link:label>
    <link:label id="lab_dna_SupplementalFinancialStatementInformationAbstract_documentation_en-US" xlink:label="lab_dna_SupplementalFinancialStatementInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Financial Statement Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SupplementalFinancialStatementInformationAbstract" xlink:href="dna-20251231.xsd#dna_SupplementalFinancialStatementInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract" xlink:to="lab_dna_SupplementalFinancialStatementInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableSignificantPurchases_7ad486b8-bf57-48c2-95a8-4daac163428b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableSignificantPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing receivable</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableSignificantPurchases_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableSignificantPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableSignificantPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableSignificantPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableSignificantPurchases" xlink:to="lab_us-gaap_FinancingReceivableSignificantPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_60f28de7-60e7-4d53-b845-e69efd0dccfc_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13a2528c-3d1c-4235-8517-16fba777989f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7f15-81f4-f3ca86b32893_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_3693a487-218c-4621-9eb3-39109bb5a8cf_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_d64f0a77-77ef-43cc-a65f-f23d9c6815d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_b2d9c35e-021e-4645-886c-0e2cb3c3c617_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c5ccb-a918-7c1d-9f81-a76696cf02d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_fd07492b-97e5-4047-bfd0-660c6446e729_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash_8e74f940-44a1-4a9c-a756-baacce02c758_terseLabel_en-US" xlink:label="lab_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized as non cash consideration</link:label>
    <link:label id="lab_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash_label_en-US" xlink:label="lab_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Noncash</link:label>
    <link:label id="lab_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash_documentation_en-US" xlink:label="lab_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" xlink:href="dna-20251231.xsd#dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" xlink:to="lab_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_86a6fdd2-b861-49f4-bdc1-4e7eaf34db15_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Technology Rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1822ede0-273d-49ed-9809-0d13f02e1c5b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1aeb1036-c2d0-45e9-b169-135d4b196f30_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ContingentConsiderationMember_e92c8cd8-2801-4f45-b2d6-653afd0e737b_terseLabel_en-US" xlink:label="lab_dna_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_dna_ContingentConsiderationMember_label_en-US" xlink:label="lab_dna_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_dna_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_dna_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContingentConsiderationMember" xlink:href="dna-20251231.xsd#dna_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ContingentConsiderationMember" xlink:to="lab_dna_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_aad626b2-a668-4cc6-8fd6-9a7f4fd0a766_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Biosecurity Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f39631bb-eb96-4382-b0aa-91a43fcbb788_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_8cf9e7f1-a1cf-4e6b-ae86-1b6758be469e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0911734b-3c68-48d0-afc5-5748b77bceb3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_0806574a-65bc-4791-8f4a-e5c3292bd29c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise or vesting of equity awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_82cc770c-00a6-45bd-9064-0756daa98820_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_e020f40b-b26a-493b-9936-ec01ba654b2b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_7aded931-706d-42cb-b509-95aa2d666d6f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_658e1850-a10c-4a79-aadd-4b68097bb067_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_decfc591-1817-4ad4-a1b1-63a6139e5022_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">600 Then 25%</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_aea181fa-b267-439a-8c70-04f74467606e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e820fce4-00d6-4ea7-87e2-7cd8a3b306f5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a8810f5a-98d4-4a9e-bd66-b904d4cdc40c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of vested stock options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember_a0215099-ba8c-4234-b3fb-c5609d96c21d_terseLabel_en-US" xlink:label="lab_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Funding Of Additional Losses</link:label>
    <link:label id="lab_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember_label_en-US" xlink:label="lab_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Funding Of Additional Losses [Member]</link:label>
    <link:label id="lab_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember_documentation_en-US" xlink:label="lab_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Funding Of Additional Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember" xlink:href="dna-20251231.xsd#dna_EquityMethodInvestmentFundingOfAdditionalLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember" xlink:to="lab_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NewGinkgoPreferredStockMember_afc33dfc-8f9d-4f6d-aca5-77a76b6ad92b_terseLabel_en-US" xlink:label="lab_dna_NewGinkgoPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Ginkgo Preferred Stock</link:label>
    <link:label id="lab_dna_NewGinkgoPreferredStockMember_label_en-US" xlink:label="lab_dna_NewGinkgoPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Ginkgo Preferred Stock [Member]</link:label>
    <link:label id="lab_dna_NewGinkgoPreferredStockMember_documentation_en-US" xlink:label="lab_dna_NewGinkgoPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Ginkgo Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NewGinkgoPreferredStockMember" xlink:href="dna-20251231.xsd#dna_NewGinkgoPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NewGinkgoPreferredStockMember" xlink:to="lab_dna_NewGinkgoPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_09be8c28-4094-4049-9e54-b3f164f8126e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_019c5c6b-551f-771b-b975-ae4758470ecf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of issuance costs related to ATM offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_bef8e081-63f7-4282-851c-d1c9b057728f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_PreferredStockInvestmentImpairmentLoss_019c9025-30fb-779d-82f7-f7c5be4d1756_terseLabel_en-US" xlink:label="lab_dna_PreferredStockInvestmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock investment, impairment loss</link:label>
    <link:label id="lab_dna_PreferredStockInvestmentImpairmentLoss_label_en-US" xlink:label="lab_dna_PreferredStockInvestmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Investment, Impairment Loss</link:label>
    <link:label id="lab_dna_PreferredStockInvestmentImpairmentLoss_documentation_en-US" xlink:label="lab_dna_PreferredStockInvestmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Investment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PreferredStockInvestmentImpairmentLoss" xlink:href="dna-20251231.xsd#dna_PreferredStockInvestmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_PreferredStockInvestmentImpairmentLoss" xlink:to="lab_dna_PreferredStockInvestmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f9d1e572-7446-40b6-9249-4d3f0d665996_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CustomerTwoMember_019c5c71-00fb-77b8-bfc4-8f75a67f7851_terseLabel_en-US" xlink:label="lab_dna_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer two</link:label>
    <link:label id="lab_dna_CustomerTwoMember_label_en-US" xlink:label="lab_dna_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer two [Member]</link:label>
    <link:label id="lab_dna_CustomerTwoMember_documentation_en-US" xlink:label="lab_dna_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CustomerTwoMember" xlink:href="dna-20251231.xsd#dna_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CustomerTwoMember" xlink:to="lab_dna_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_15a380cb-84ac-41f8-913f-ec3587c17056_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f87c7985-d71a-4673-9fda-b5b1053d4397_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c5cea-7d19-7ca4-8a76-52a4f0c4837e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ConvertiblePromissoryNotesMember_a3cf124c-8fbe-4d2f-8ca7-d43d593d2312_terseLabel_en-US" xlink:label="lab_dna_ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes</link:label>
    <link:label id="lab_dna_ConvertiblePromissoryNotesMember_label_en-US" xlink:label="lab_dna_ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
    <link:label id="lab_dna_ConvertiblePromissoryNotesMember_documentation_en-US" xlink:label="lab_dna_ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ConvertiblePromissoryNotesMember" xlink:href="dna-20251231.xsd#dna_ConvertiblePromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ConvertiblePromissoryNotesMember" xlink:to="lab_dna_ConvertiblePromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_f1cab105-ec4d-4863-9460-a14a10a094cd_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract_63c61ae0-89a8-4781-835c-310a597a7df9_terseLabel_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract_label_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosure [Abstract]</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract_documentation_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract" xlink:to="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fce88578-bdb5-4e66-90e6-6d41c000e715_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4efb039f-bf42-4088-a3af-8b356e291334_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_07a1931a-9395-4f3d-8d60-7eb05a9eaff1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_36e507fc-e810-4500-98f2-62efa31b994c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_944d3915-fad0-4029-bc51-08342b9a6e47_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_d08ca7e9-42d7-4df2-8b79-96c2255c8bac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_14f84a4a-77e4-4c47-b055-ef8ebfa993c6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b1504725-b01e-457e-a1ae-ff99aefa1fda_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payment</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_4944e1fe-9778-45ef-9e77-3df3953b09aa_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payment</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4ba8d6c1-f85c-421b-b7a5-234476bd7196_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a0b29787-f247-4b60-9e84-303b68c61c43_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current and non-current</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_019c5c89-598d-78bc-a825-590f2235df09_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt, fair value</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_55d1f548-932f-40e8-a6a2-a6f71040ff63_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AccretionOfDiscountOnMarketableSecurities_019c5c68-b0c6-7359-8e4c-dc5476a4db6c_negatedTerseLabel_en-US" xlink:label="lab_dna_AccretionOfDiscountOnMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount on marketable securities</link:label>
    <link:label id="lab_dna_AccretionOfDiscountOnMarketableSecurities_label_en-US" xlink:label="lab_dna_AccretionOfDiscountOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion Of Discount On Marketable Securities</link:label>
    <link:label id="lab_dna_AccretionOfDiscountOnMarketableSecurities_documentation_en-US" xlink:label="lab_dna_AccretionOfDiscountOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accretion Of Discount On Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccretionOfDiscountOnMarketableSecurities" xlink:href="dna-20251231.xsd#dna_AccretionOfDiscountOnMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AccretionOfDiscountOnMarketableSecurities" xlink:to="lab_dna_AccretionOfDiscountOnMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1ddd17c3-8cce-4f9f-9723-89bd53bfad7d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_49702335-f340-4b04-9487-7f9f4625c349_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4900f315-574b-4402-8e17-6ba2086fca86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_870ab37d-45ca-44e3-b5e0-eec3a6b53ba5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_019c5c90-8cc0-7eea-a846-9d45e831c35e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d0a048c3-d8f1-4c5b-9122-daecec7c50f2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_e78b079a-2a18-41e2-9a2a-cb82a534e665_terseLabel_en-US" xlink:label="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:to="lab_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ebe6d1bd-b815-4365-a92f-a5d76148a458_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_73e651aa-4b25-4949-ae63-5cd9de34bf5c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_1bad03c6-525e-4dc8-bdd6-88e63f415675_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f65abb6b-1a2b-46dc-8b07-068e3b600825_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9907b758-669c-4619-bc38-b27fbcb598bb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03ea6112-8b5e-451a-8d6c-ea2bf87773f8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_e6d72209-30d5-42f0-964e-9d7b1cbc6375_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_742e19c6-0c36-4e92-b7dc-cab20430d64c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Investment Income Reported Amounts By Category [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3d3a6a45-ab8e-48a9-8075-ce6b11c06c4a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_58aa416b-3542-4ceb-b01e-76fc788ad82e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_MeasurementInputScenarioProbabilitiesMember_5ae28400-1338-4928-a666-6dd1fecb9945_terseLabel_en-US" xlink:label="lab_dna_MeasurementInputScenarioProbabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Scenario Probabilities</link:label>
    <link:label id="lab_dna_MeasurementInputScenarioProbabilitiesMember_label_en-US" xlink:label="lab_dna_MeasurementInputScenarioProbabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Scenario Probabilities [Member]</link:label>
    <link:label id="lab_dna_MeasurementInputScenarioProbabilitiesMember_documentation_en-US" xlink:label="lab_dna_MeasurementInputScenarioProbabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Scenario Probabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MeasurementInputScenarioProbabilitiesMember" xlink:href="dna-20251231.xsd#dna_MeasurementInputScenarioProbabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_MeasurementInputScenarioProbabilitiesMember" xlink:to="lab_dna_MeasurementInputScenarioProbabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_5f5bf5aa-01a1-40a6-8b59-d81bb0aa7450_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of notes receivable</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_cc2f1e70-23b5-4d37-afe4-1f94c7c18c1f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of notes receivable</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_25f6c39f-1a93-4eb5-92d3-9ef5148c4220_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments_d213f95a-de13-4a22-b847-d15445fa91a5_terseLabel_en-US" xlink:label="lab_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for retention payments related to business and asset acquisitions</link:label>
    <link:label id="lab_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments_label_en-US" xlink:label="lab_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock For Acquisition Retention Payments</link:label>
    <link:label id="lab_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments_documentation_en-US" xlink:label="lab_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock For Acquisition Retention Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments" xlink:href="dna-20251231.xsd#dna_IssuanceOfCommonStockForAcquisitionRetentionPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments" xlink:to="lab_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_e4005ebb-17b8-4bee-93b6-1724b72ee4df_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_90cfd59a-d0a4-49d4-90cb-07c878568bc2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4dc76c71-028e-4a7f-b6e4-a747252b76f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fda59914-1697-4b51-9073-31e40f7c3c1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e4eeb517-b433-4127-9d33-272e08756d7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019c5ce7-99fc-7939-999e-5bd9fbcefe88_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_019c4ef9-0cda-771d-aab9-93752850256b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019c4ef9-eedc-7082-a1ab-11f87a383bca_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019c4f03-27a3-7c64-9953-534d6177c5f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9d50e418-b309-4fdb-95b8-cf7643006448_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c8dd15dc-9b69-42c5-be76-5a8bdde6b2f3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d5af6863-54b7-494e-9cb4-39a5fb4468c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_bc560d6c-d37a-47e1-9a57-109ab58e381d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_51d721d8-9ee1-4595-a3e6-64ee0b545dab_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_30f2f37f-8cc9-4573-b848-513beeab0ddc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_FounderOptionsMember_0193d629-1a93-4eb4-936a-ba1a78d7b995_terseLabel_en-US" xlink:label="lab_dna_FounderOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Founder Options</link:label>
    <link:label id="lab_dna_FounderOptionsMember_label_en-US" xlink:label="lab_dna_FounderOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Founder Options [Member]</link:label>
    <link:label id="lab_dna_FounderOptionsMember_documentation_en-US" xlink:label="lab_dna_FounderOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Founder Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FounderOptionsMember" xlink:href="dna-20251231.xsd#dna_FounderOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_FounderOptionsMember" xlink:to="lab_dna_FounderOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_04de19bc-decb-4772-a974-a3f953fc34af_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7cb4ceb1-5843-4863-b8eb-0f042549abb8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_StridebioMember_e0d4eb05-4a62-4989-8be9-90f500dd6c99_terseLabel_en-US" xlink:label="lab_dna_StridebioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">StrideBio</link:label>
    <link:label id="lab_dna_StridebioMember_label_en-US" xlink:label="lab_dna_StridebioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">StrideBio [Member]</link:label>
    <link:label id="lab_dna_StridebioMember_documentation_en-US" xlink:label="lab_dna_StridebioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">StrideBio (Member)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StridebioMember" xlink:href="dna-20251231.xsd#dna_StridebioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_StridebioMember" xlink:to="lab_dna_StridebioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DeferredTaxLiabilitiesAmortizableIntangibles_e3af1063-9f68-438b-8e0e-44a7db7e9851_negatedLabel_en-US" xlink:label="lab_dna_DeferredTaxLiabilitiesAmortizableIntangibles" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortizable intangibles</link:label>
    <link:label id="lab_dna_DeferredTaxLiabilitiesAmortizableIntangibles_label_en-US" xlink:label="lab_dna_DeferredTaxLiabilitiesAmortizableIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Amortizable Intangibles</link:label>
    <link:label id="lab_dna_DeferredTaxLiabilitiesAmortizableIntangibles_documentation_en-US" xlink:label="lab_dna_DeferredTaxLiabilitiesAmortizableIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Amortizable Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxLiabilitiesAmortizableIntangibles" xlink:href="dna-20251231.xsd#dna_DeferredTaxLiabilitiesAmortizableIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DeferredTaxLiabilitiesAmortizableIntangibles" xlink:to="lab_dna_DeferredTaxLiabilitiesAmortizableIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_8ce0d5ff-968c-464e-8463-fd72569c4b89_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c5cd0-1f0f-7690-903a-821766e697b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local:</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, State and Local, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:to="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_e5a1ebcf-093a-4017-9c6f-8009acb583a2_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e082eb08-cdb0-4188-a361-2b8ca8f90d50_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock_40bc7ad4-a3e9-48b9-b135-5fa505ef095b_terseLabel_en-US" xlink:label="lab_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved For Future Issuances</link:label>
    <link:label id="lab_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock_label_en-US" xlink:label="lab_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuances [Table Text Block]</link:label>
    <link:label id="lab_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock_documentation_en-US" xlink:label="lab_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of common stock reserved for future issuances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:href="dna-20251231.xsd#dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:to="lab_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_659003e6-5563-45ec-96da-80a4377f59e0_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_81ae25b4-89d3-41af-a1a2-3e705e736699_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_0ad2998a-9b2e-4e6e-bad7-ccc402935c98_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_625490ec-591b-472b-b9df-f53ad19897e2_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_2f8b37b9-2008-490b-bed1-1fec3c6e7901_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_87a487d6-da37-4d31-98a4-f22c0fbb8224_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SynlogicIncWarrantMember_f5823004-ab25-44a1-8179-80cde5467dbf_terseLabel_en-US" xlink:label="lab_dna_SynlogicIncWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Synlogic warrants</link:label>
    <link:label id="lab_dna_SynlogicIncWarrantMember_label_en-US" xlink:label="lab_dna_SynlogicIncWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Synlogic, Inc. Warrant [Member]</link:label>
    <link:label id="lab_dna_SynlogicIncWarrantMember_documentation_en-US" xlink:label="lab_dna_SynlogicIncWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Synlogic, Inc. warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SynlogicIncWarrantMember" xlink:href="dna-20251231.xsd#dna_SynlogicIncWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SynlogicIncWarrantMember" xlink:to="lab_dna_SynlogicIncWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_abf2f305-e434-4a40-b93c-6e57d2e6d02c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_206d1744-f024-4508-b1ee-3fc90fce9b07_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash income taxes, net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c5cc9-24c1-7c1b-be4e-748dc079d9b7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_019c5c90-8cc0-7a3b-9a0b-517ea0394bbd_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d939f468-ed71-4056-b696-a593e7cb24bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f5fdba83-eb35-41d2-aabd-9519905de0f3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NumberOfCoreOfferings_019c900c-bcab-75d8-b961-b35b2f00d36f_terseLabel_en-US" xlink:label="lab_dna_NumberOfCoreOfferings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of core offerings</link:label>
    <link:label id="lab_dna_NumberOfCoreOfferings_label_en-US" xlink:label="lab_dna_NumberOfCoreOfferings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Core Offerings</link:label>
    <link:label id="lab_dna_NumberOfCoreOfferings_documentation_en-US" xlink:label="lab_dna_NumberOfCoreOfferings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Core Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfCoreOfferings" xlink:href="dna-20251231.xsd#dna_NumberOfCoreOfferings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NumberOfCoreOfferings" xlink:to="lab_dna_NumberOfCoreOfferings" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock_17a42b2b-6c66-488c-aab9-b101233aa55b_terseLabel_en-US" xlink:label="lab_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deconsolidated Assets and Liabilities</link:label>
    <link:label id="lab_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock_label_en-US" xlink:label="lab_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Including Discontinued Operations [Table Text Block]</link:label>
    <link:label id="lab_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock_documentation_en-US" xlink:label="lab_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock" xlink:href="dna-20251231.xsd#dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock" xlink:to="lab_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_66c87b0d-ec8d-4566-a073-0acb4da8343c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5b7bf8fa-a0b5-49d8-bf8a-34cc80ed2438_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SafesMember_c5feac7e-423f-4abc-a84c-256ea79a9af6_terseLabel_en-US" xlink:label="lab_dna_SafesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SAFEs</link:label>
    <link:label id="lab_dna_SafesMember_label_en-US" xlink:label="lab_dna_SafesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SAFEs [Member]</link:label>
    <link:label id="lab_dna_SafesMember_documentation_en-US" xlink:label="lab_dna_SafesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SAFEs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafesMember" xlink:href="dna-20251231.xsd#dna_SafesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SafesMember" xlink:to="lab_dna_SafesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_a59ecffd-3f26-417b-99b5-25d9ab36e88e_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Receivable</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_2123e08a-faa7-4d34-80bd-d03e1919722c_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7e62c290-37db-40cc-a96b-2ec8c2294272_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b69079d6-51bb-4afc-9f85-7e83ce0a552c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_a4ed8290-a51c-4988-8574-ae638e384ee4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5fbd89c8-895c-4b83-bb56-08b7ff3f0850_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4a24fb40-4ab7-4c96-96a9-05948403dcab_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized and unrealized gains (losses) recognized on marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_8a21a258-1156-49de-a082-0f1e681b42e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments and Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-8084-76f1-8051-246fb5e1e01c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_95117bca-d8e2-42d3-88ac-573a724b5834_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f79f7fc3-adf2-4077-80aa-7558302acf88_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_38e011b1-75cf-44f0-b595-8ee1d0116c36_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_70b8bfef-d6eb-4f14-a530-97b5c467736a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expenses incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_a63a8187-8790-4b37-b979-8de0fd13e637_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_885483d9-1b35-44a0-a085-ab90f11c8c4a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded unconditional purchase obligation, year one</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a15a0baa-bec8-4b92-85bd-e66ea756ede3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable ($357, $156 and $816 from related parties)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f1b86084-b32e-4e27-b283-16e42d3cc8d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, from related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bc08700a-5b95-4e2a-9363-2dac6ea63da1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0ed0ead8-2f4b-4c07-98e2-e41157984494_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_fc9d2bdc-5055-479e-b9d2-7ffefebfb74a_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c5cea-0247-723e-ae39-d6e8d99954bc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c5cca-c999-7104-ad1b-4b157be9de47_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax at U.S. Statutory Rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_019c5c86-3427-7f79-ab26-6d37534ede2a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a9eb053b-4f58-4b96-81d0-4d5d413e3938_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c5cc6-0ccd-7baa-9e02-6e1494650918_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f7f12d2f-615f-4e0d-9027-797593c31997_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Income Taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_b08b4e6f-f19a-4709-ab77-9e5ba0eef1ca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_b0fb33be-02fb-4e17-a4d1-4e4d63940c50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_97fa2806-4b31-4aa6-ab1d-34f170f2800e_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_163d2607-11fd-47ff-84d7-229c271cd4c4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2d61235-7389-4ab6-884f-2c7c7625ccd3_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_85c805c3-f4e6-4e66-8969-823cc15804f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of notes receivable for common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fbeaa268-c25e-414b-876f-ba5798adcbb9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a07b0a3c-97d3-422b-b715-fa865ba77c2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7fab144e-b175-49da-8cd0-40bc2844dd1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares to be issued pursuant to awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_BeginToExpireInTwoThousandAndTwentyNineMember_a58beb7e-d254-4ca0-8bea-668cdb618f99_terseLabel_en-US" xlink:label="lab_dna_BeginToExpireInTwoThousandAndTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Begin To Expire In 2029</link:label>
    <link:label id="lab_dna_BeginToExpireInTwoThousandAndTwentyNineMember_label_en-US" xlink:label="lab_dna_BeginToExpireInTwoThousandAndTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Begin To Expire In Two Thousand And Twenty Nine [Member]</link:label>
    <link:label id="lab_dna_BeginToExpireInTwoThousandAndTwentyNineMember_documentation_en-US" xlink:label="lab_dna_BeginToExpireInTwoThousandAndTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Begin To Expire In 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BeginToExpireInTwoThousandAndTwentyNineMember" xlink:href="dna-20251231.xsd#dna_BeginToExpireInTwoThousandAndTwentyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_BeginToExpireInTwoThousandAndTwentyNineMember" xlink:to="lab_dna_BeginToExpireInTwoThousandAndTwentyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_daf29188-7254-408c-92ce-fb7d0c093353_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Collaboration Transactions with Related Parties</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b3d9554-8259-4f11-a617-4357719af6cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ClassOfWarrantOrRightStockSplitConversionRatio_019c9010-d36e-783b-b9b3-94c3c24e1387_terseLabel_en-US" xlink:label="lab_dna_ClassOfWarrantOrRightStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant, stock split, conversion ratio</link:label>
    <link:label id="lab_dna_ClassOfWarrantOrRightStockSplitConversionRatio_label_en-US" xlink:label="lab_dna_ClassOfWarrantOrRightStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Stock Split, Conversion Ratio</link:label>
    <link:label id="lab_dna_ClassOfWarrantOrRightStockSplitConversionRatio_documentation_en-US" xlink:label="lab_dna_ClassOfWarrantOrRightStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ClassOfWarrantOrRightStockSplitConversionRatio" xlink:href="dna-20251231.xsd#dna_ClassOfWarrantOrRightStockSplitConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ClassOfWarrantOrRightStockSplitConversionRatio" xlink:to="lab_dna_ClassOfWarrantOrRightStockSplitConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_56cae381-e45b-4939-a8ac-24fa2648bbc6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent_019c5cc6-95ab-7f02-b10c-2e9b10890ffb_terseLabel_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limitation on executive compensation</link:label>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent_label_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Percent</link:label>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent_documentation_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" xlink:to="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_332563d5-0515-47da-a47a-605ce836ed22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Assets and Liabilities That Are Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4aabb07b-28c5-4d0d-9f7e-d64641e4b574_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of marketable equity securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_d18a9832-06e7-4261-a563-d06e2220d51c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for asset acquisitions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ZymergenMember_48e5e81f-d502-48c9-9304-389c0f74d988_terseLabel_en-US" xlink:label="lab_dna_ZymergenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zymergen</link:label>
    <link:label id="lab_dna_ZymergenMember_label_en-US" xlink:label="lab_dna_ZymergenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zymergen [Member]</link:label>
    <link:label id="lab_dna_ZymergenMember_documentation_en-US" xlink:label="lab_dna_ZymergenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zymergen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ZymergenMember" xlink:to="lab_dna_ZymergenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_445670f0-5268-44c3-8e94-0a48e039d3ad_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_73e5cb4c-648d-4ebf-a48f-691645701bf5_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares excluded from the computation of diluted loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5a9a0dc0-ec01-4c44-832c-7189739c00dc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod_019c5c81-2aa1-71a8-9ff1-54bda0dc8a1c_terseLabel_en-US" xlink:label="lab_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Number Of Additional Acquisitions during Period</link:label>
    <link:label id="lab_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod_label_en-US" xlink:label="lab_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Number Of Additional Acquisitions during Period</link:label>
    <link:label id="lab_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod_documentation_en-US" xlink:label="lab_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Number Of Additional Acquisitions during Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" xlink:href="dna-20251231.xsd#dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" xlink:to="lab_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_8328f813-9df0-497f-b87b-1b1cebbd86e2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded unconditional purchase obligation</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_05dcfa9d-03b5-4045-80c1-a482dc66c800_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_33f2c1a0-c7dc-41c0-8e43-e23c17e76e46_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd779c5e-ad34-42d8-ab66-93055282f4e0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_20fd96af-da2f-42eb-8a06-3ef7fe3cf96a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_1ab78502-3f78-4e9b-856a-bbaeb21ea9e3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_b70f6df0-297e-4b9e-9e5a-a0b2af1f5d9e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded unconditional purchase obligation, year two</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e2cd1bf-1a55-46c4-9f1f-6e43f94e52f2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a4b7e477-73a4-44eb-ad15-2e539b4036ab_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c451cf2a-8fd1-4685-b666-009ad77f5ae2_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total segment cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_b18a697f-bd46-484d-949d-bb6c513353c8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_9742137d-de43-4a01-a864-ea2e7ce00398_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d96bd948-9d69-4cda-9106-ff8f8b2beb5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3dc1ea07-e20a-4c36-8054-e4ca5e10707d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_9b40f96b-f993-403a-a30b-3b3847725e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_9c01b1f1-0b26-43a5-94d5-bf58a94cb1e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_49504d37-544a-44a4-a6f0-d33379aa51af_terseLabel_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Suboptimal exercise multiple</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_label_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Suboptimal Exercise Multiple</link:label>
    <link:label id="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_documentation_en-US" xlink:label="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Suboptimal Exercise Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple" xlink:to="lab_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_FinanceLeaseCost_c3ac7f18-d994-4e7b-895b-ad0ed4944e2a_totalLabel_en-US" xlink:label="lab_dna_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Finance lease cost</link:label>
    <link:label id="lab_dna_FinanceLeaseCost_label_en-US" xlink:label="lab_dna_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:label id="lab_dna_FinanceLeaseCost_documentation_en-US" xlink:label="lab_dna_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinanceLeaseCost" xlink:href="dna-20251231.xsd#dna_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_FinanceLeaseCost" xlink:to="lab_dna_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1b3934d2-f771-46ea-802e-b1721732785f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c0076bf-6ad8-4cd4-9134-669116f506ca_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_019c5ce8-83c7-7877-ab82-a336c2d6f2a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c85cf74e-025b-4987-896c-98b4ed5c2596_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d80c732d-d028-487d-9001-3ac17fba4ebf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term - operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_e5e61940-bbb6-4ad4-8163-7c839e7b8f74_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_be71cf48-88d6-4d3e-8ad3-452e6a652ddd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AyanaMember_8ffd9719-14ea-4717-b122-dd54da9008be_terseLabel_en-US" xlink:label="lab_dna_AyanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ayana Bio</link:label>
    <link:label id="lab_dna_AyanaMember_label_en-US" xlink:label="lab_dna_AyanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ayana [Member]</link:label>
    <link:label id="lab_dna_AyanaMember_documentation_en-US" xlink:label="lab_dna_AyanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ayana member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AyanaMember" xlink:href="dna-20251231.xsd#dna_AyanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AyanaMember" xlink:to="lab_dna_AyanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_0daec10b-f76f-412e-9b34-5b43bf4649de_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_aee4e1cd-c5c8-4a5a-a840-dca5d23b9b33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_561d54fd-9398-4e74-88fc-7fc8f4f5eca9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f0ad4835-111a-4390-b98d-1ca96f8c9105_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_WarrantsToPurchaseClassACommonStockMember_b23e507b-e43f-44c6-b782-35540fc6e01f_terseLabel_en-US" xlink:label="lab_dna_WarrantsToPurchaseClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_dna_WarrantsToPurchaseClassACommonStockMember_label_en-US" xlink:label="lab_dna_WarrantsToPurchaseClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants To Purchase Class A Common Stock [Member]</link:label>
    <link:label id="lab_dna_WarrantsToPurchaseClassACommonStockMember_documentation_en-US" xlink:label="lab_dna_WarrantsToPurchaseClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants To Purchase Class A Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_WarrantsToPurchaseClassACommonStockMember" xlink:href="dna-20251231.xsd#dna_WarrantsToPurchaseClassACommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_WarrantsToPurchaseClassACommonStockMember" xlink:to="lab_dna_WarrantsToPurchaseClassACommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_8c64b2eb-a350-488f-9ce5-3d30fac71fbd_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_68ec7600-a016-43af-9398-e63a0414c0db_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_b7094c5f-5287-4557-b15a-646a163afd5c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ea0520e4-f821-423c-9d38-4cafd948db90_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019c5cd0-48ce-7ada-8dc9-e7960b8d2dde_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, Foreign, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:to="lab_us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_305eb837-956a-40ac-8a7d-2f72e767e1ff_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, price of acquisition, expected</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Price of Acquisition, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:to="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b8068fc4-994f-4e20-ab10-bdad604c7fa9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c7c39b13-4a4f-47fc-8ab8-ecf6c75c54aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_214c7768-b336-4870-ae24-6c02a4bbe30e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_2ab1f2d2-f34d-4295-b571-10ccb171039a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, equity interest in acquiree, fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_12789132-e1b8-4569-9979-983a5d868ad0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_3507fd1c-e0d5-4e52-81b6-e4288ab79207_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_dbf5f557-d330-49d2-ba15-3fb44b80c47e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69c3a0fb-f9ba-43bb-9650-84798a5c0d12_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_67d564d6-22f9-420b-85da-54c38acadfba_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bdb42db6-1eb2-46ba-87f5-4251120f7af3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_fcec186b-c03e-40fc-8145-3cf8e06089c7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_944559e8-9c94-4e92-b875-db431d07299f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8aabea83-f0e1-4fff-aa13-fe892f9112fc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3e252ff2-c258-4305-9b06-e66d7649ced4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_7bbcd56a-256f-474a-9605-ddefc7e68ae7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_6c25c016-2073-48ad-b7e0-79c31e0636ac_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_IncreaseDecreaseRightOfUseAssets_0a4ecd6a-fe62-4ac5-b024-64bee157ae83_negatedTerseLabel_en-US" xlink:label="lab_dna_IncreaseDecreaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_dna_IncreaseDecreaseRightOfUseAssets_label_en-US" xlink:label="lab_dna_IncreaseDecreaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Right of Use Assets</link:label>
    <link:label id="lab_dna_IncreaseDecreaseRightOfUseAssets_documentation_en-US" xlink:label="lab_dna_IncreaseDecreaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Right of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncreaseDecreaseRightOfUseAssets" xlink:href="dna-20251231.xsd#dna_IncreaseDecreaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_IncreaseDecreaseRightOfUseAssets" xlink:to="lab_dna_IncreaseDecreaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3297b567-7059-4e00-b799-df79e8186b9c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount_019c5ccb-92da-7f46-a933-07faad71a3ca_terseLabel_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on investments</link:label>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount_label_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Amount</link:label>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount_documentation_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount" xlink:to="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3dfcd843-e623-47ef-be8a-4d17ee89ef03_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees and securities litigation costs</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_WarrantLiabilityMember_019c68e2-2603-72fc-b795-ddc90b5a82a5_terseLabel_en-US" xlink:label="lab_dna_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_dna_WarrantLiabilityMember_label_en-US" xlink:label="lab_dna_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_dna_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_dna_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_WarrantLiabilityMember" xlink:href="dna-20251231.xsd#dna_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_WarrantLiabilityMember" xlink:to="lab_dna_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_72397f21-a47b-46b8-b409-a95a1cda8b8a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_LesseeOperatingLeaseAreaOfRealEstateProperty_9373d50e-690e-4a25-9a7e-f7e54f104c69_terseLabel_en-US" xlink:label="lab_dna_LesseeOperatingLeaseAreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leased facility, square feet</link:label>
    <link:label id="lab_dna_LesseeOperatingLeaseAreaOfRealEstateProperty_label_en-US" xlink:label="lab_dna_LesseeOperatingLeaseAreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area Of Real Estate Property</link:label>
    <link:label id="lab_dna_LesseeOperatingLeaseAreaOfRealEstateProperty_documentation_en-US" xlink:label="lab_dna_LesseeOperatingLeaseAreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area Of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LesseeOperatingLeaseAreaOfRealEstateProperty" xlink:href="dna-20251231.xsd#dna_LesseeOperatingLeaseAreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_LesseeOperatingLeaseAreaOfRealEstateProperty" xlink:to="lab_dna_LesseeOperatingLeaseAreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_31aef60a-7e70-4864-9715-5515bc621be4_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9b9a2036-87c3-494a-b93b-d91db77328ba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_c67f69e5-3e52-462d-a75f-a0d1af12be80_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_acd6a8a2-b13e-418e-b276-1bf391c738c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_96d386d1-281f-4cf2-a155-ab76a159c940_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockAwardForfeitures_019c68f8-d4b4-7b97-9956-8ba091ab5b46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeiture of restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockAwardForfeitures_label_en-US" xlink:label="lab_us-gaap_RestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Award, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockAwardForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_RestrictedStockAwardForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_762cb925-5923-4de7-bbc3-d6c8305863a3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_019c5cb1-4376-7b1f-80c2-9a586dc28541_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_OneCustomerMember_4d3a92e4-bfc6-40fe-88c1-dc4e4fd62bab_terseLabel_en-US" xlink:label="lab_dna_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One Customer</link:label>
    <link:label id="lab_dna_OneCustomerMember_label_en-US" xlink:label="lab_dna_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Customer [Member]</link:label>
    <link:label id="lab_dna_OneCustomerMember_documentation_en-US" xlink:label="lab_dna_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OneCustomerMember" xlink:href="dna-20251231.xsd#dna_OneCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_OneCustomerMember" xlink:to="lab_dna_OneCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b2c387ed-9c77-4b0e-80b7-4098973d21d2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7813-bcd8-7086f6a8a24d_terseLabel_en-US" xlink:label="lab_dna_RevenuePerformanceObligationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Performance Obligation [Domain]</link:label>
    <link:label id="lab_dna_RevenuePerformanceObligationDomain_label_en-US" xlink:label="lab_dna_RevenuePerformanceObligationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Performance Obligation [Domain]</link:label>
    <link:label id="lab_dna_RevenuePerformanceObligationDomain_documentation_en-US" xlink:label="lab_dna_RevenuePerformanceObligationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Performance Obligation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationDomain" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_RevenuePerformanceObligationDomain" xlink:to="lab_dna_RevenuePerformanceObligationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_0301b5a0-f38f-45f7-aab6-dacae6a27a7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_BeginToExpireIn2034Member_019c5cd2-9d34-7846-b024-9176d22b73db_terseLabel_en-US" xlink:label="lab_dna_BeginToExpireIn2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Begin To Expire In 2034</link:label>
    <link:label id="lab_dna_BeginToExpireIn2034Member_label_en-US" xlink:label="lab_dna_BeginToExpireIn2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Begin To Expire In 2034 [Member]</link:label>
    <link:label id="lab_dna_BeginToExpireIn2034Member_documentation_en-US" xlink:label="lab_dna_BeginToExpireIn2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Begin To Expire In 2034</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BeginToExpireIn2034Member" xlink:href="dna-20251231.xsd#dna_BeginToExpireIn2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_BeginToExpireIn2034Member" xlink:to="lab_dna_BeginToExpireIn2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_64fd593d-390f-47cb-b6d1-c0a7844c64f1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_019c68e7-834d-7f17-bc5d-0085e3f18ebe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of equity issuance costs and other</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5dc149e7-36f8-4f86-bd68-3c06271b86bb_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent_8aeb7d71-112a-4859-80eb-7f9aab29044a_terseLabel_en-US" xlink:label="lab_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External research and development expenses</link:label>
    <link:label id="lab_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued External Research And Development Expenses Current</link:label>
    <link:label id="lab_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued external research and development expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:href="dna-20251231.xsd#dna_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:to="lab_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_66718356-db35-4e0e-a79e-a110d9633089_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_efd8ece6-51df-4e24-b979-0f3e36d52aaf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_77381ddb-c81c-4583-83a1-effe20a5c4ac_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_b04ef2df-fcef-43ec-af8a-5155e3a9a70b_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled contracts receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_7f036f6a-2ad7-4a6d-a383-9cc5bdcfc8fc_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Acquired, Finite-Lived [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_PrivatePlacementWarrantsMember_85784178-5ca1-42d3-8663-031494af495a_terseLabel_en-US" xlink:label="lab_dna_PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Warrants</link:label>
    <link:label id="lab_dna_PrivatePlacementWarrantsMember_label_en-US" xlink:label="lab_dna_PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Warrants [Member]</link:label>
    <link:label id="lab_dna_PrivatePlacementWarrantsMember_documentation_en-US" xlink:label="lab_dna_PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PrivatePlacementWarrantsMember" xlink:href="dna-20251231.xsd#dna_PrivatePlacementWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_PrivatePlacementWarrantsMember" xlink:to="lab_dna_PrivatePlacementWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_066bf0d6-ea6a-4eae-a139-e788db79bf9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_ed39a44d-1f6d-4423-b365-bdbf78d7220f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7d7e9653-dc3c-4c64-a210-a4b59c5c3e2d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax withholdings related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_f3704c51-f70a-4df7-ba23-f0e67b5d1b6b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3f9be11c-0608-4510-8330-b95185d4c781_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosure_cc1b719c-84ad-4f0e-945b-420942e40c10_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosure" xlink:to="lab_us-gaap_ReceivablesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_019c5c90-8cc0-7044-9ebf-5ea9d23e4915_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b054422c-76d9-4ef1-ad3b-c0a895358a67_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total common stock reserved for future issuances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_65aca878-6ad5-4309-8717-2a936a443857_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligation satisfied, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_d318d58e-5806-4f4e-9fe5-c762405ca696_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_f29ab9df-e8f2-4f85-9184-709db6d8363c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_74bf36c7-244e-466b-80b1-4661e70ec563_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_BiomeditMember_54843597-97d9-41a6-98a2-392f8e88b9f5_terseLabel_en-US" xlink:label="lab_dna_BiomeditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BiomEdit</link:label>
    <link:label id="lab_dna_BiomeditMember_label_en-US" xlink:label="lab_dna_BiomeditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BiomEdit [Member]</link:label>
    <link:label id="lab_dna_BiomeditMember_documentation_en-US" xlink:label="lab_dna_BiomeditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BiomEdit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditMember" xlink:href="dna-20251231.xsd#dna_BiomeditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_BiomeditMember" xlink:to="lab_dna_BiomeditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_TypesOfTimeBasedStockOptions_019c901a-b4f8-7028-9a13-1a61c143c551_terseLabel_en-US" xlink:label="lab_dna_TypesOfTimeBasedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of time-based stock options</link:label>
    <link:label id="lab_dna_TypesOfTimeBasedStockOptions_label_en-US" xlink:label="lab_dna_TypesOfTimeBasedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types Of Time-Based Stock Options</link:label>
    <link:label id="lab_dna_TypesOfTimeBasedStockOptions_documentation_en-US" xlink:label="lab_dna_TypesOfTimeBasedStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Types Of Time-Based Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TypesOfTimeBasedStockOptions" xlink:href="dna-20251231.xsd#dna_TypesOfTimeBasedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_TypesOfTimeBasedStockOptions" xlink:to="lab_dna_TypesOfTimeBasedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_d077ce4a-d2f7-4f34-89a7-9883e637fd23_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue remaining performance obligation amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_cb5e41e9-6307-43da-9b42-c4542323f020_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SettlementOfContingentConsiderationValueRestrictedStock_9f876541-b313-4bad-8264-0dd7e51ccb2b_terseLabel_en-US" xlink:label="lab_dna_SettlementOfContingentConsiderationValueRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of contingent consideration</link:label>
    <link:label id="lab_dna_SettlementOfContingentConsiderationValueRestrictedStock_label_en-US" xlink:label="lab_dna_SettlementOfContingentConsiderationValueRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Of Contingent Consideration, Value, Restricted Stock</link:label>
    <link:label id="lab_dna_SettlementOfContingentConsiderationValueRestrictedStock_documentation_en-US" xlink:label="lab_dna_SettlementOfContingentConsiderationValueRestrictedStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement Of Contingent Consideration, Value, Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SettlementOfContingentConsiderationValueRestrictedStock" xlink:href="dna-20251231.xsd#dna_SettlementOfContingentConsiderationValueRestrictedStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SettlementOfContingentConsiderationValueRestrictedStock" xlink:to="lab_dna_SettlementOfContingentConsiderationValueRestrictedStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_313e4aaa-ecf3-4937-adf5-4b6d91ddc404_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ab834181-ed90-42cb-b99b-6828a2ac3bd9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EmployeeLeaseExpense_d9c91db7-6a66-464e-a80e-26e41ef9e96f_terseLabel_en-US" xlink:label="lab_dna_EmployeeLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee lease expense</link:label>
    <link:label id="lab_dna_EmployeeLeaseExpense_label_en-US" xlink:label="lab_dna_EmployeeLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Lease Expense</link:label>
    <link:label id="lab_dna_EmployeeLeaseExpense_documentation_en-US" xlink:label="lab_dna_EmployeeLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EmployeeLeaseExpense" xlink:href="dna-20251231.xsd#dna_EmployeeLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EmployeeLeaseExpense" xlink:to="lab_dna_EmployeeLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_02851bd5-65f6-478d-8290-ea1ad8e5b0b5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ChangesInFairValueOfLoansReceivable_c0f8139a-f50a-4df5-8b2c-209ed96fc618_terseLabel_en-US" xlink:label="lab_dna_ChangesInFairValueOfLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of notes receivable</link:label>
    <link:label id="lab_dna_ChangesInFairValueOfLoansReceivable_label_en-US" xlink:label="lab_dna_ChangesInFairValueOfLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in Fair Value of Loans Receivable</link:label>
    <link:label id="lab_dna_ChangesInFairValueOfLoansReceivable_documentation_en-US" xlink:label="lab_dna_ChangesInFairValueOfLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes in fair value of loans receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ChangesInFairValueOfLoansReceivable" xlink:href="dna-20251231.xsd#dna_ChangesInFairValueOfLoansReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ChangesInFairValueOfLoansReceivable" xlink:to="lab_dna_ChangesInFairValueOfLoansReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d4ec1ad5-94b4-42bf-a375-15b6a0a6e723_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ca79db6e-5e24-4566-80e6-cb8a0e08eed2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7ad08bb7-4e75-4787-8262-a66f6c31b30b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e64baca4-8e21-41bd-b77c-d41d68453a00_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e3ca6b5f-7d44-4837-83c4-b0cf5307e0b7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for business and asset acquisitions, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_34eba80e-1d33-48a8-92d5-635ffba3f7b1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for a business and asset acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0999d30a-96c7-444a-b1f1-af98faf70a9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1aad44f9-ab29-4784-a3df-e897a7a4b920_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_c2ecd85b-ef50-48c0-8a42-7e46859edd13_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f0794279-d937-4668-bfb3-479786b908eb_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e05e7d58-407c-4813-9abe-92f072852bd6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember_f862831c-02ce-4c65-8b4b-1f7daedf8835_terseLabel_en-US" xlink:label="lab_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Thousand And Eighteen Technical Development Agreement</link:label>
    <link:label id="lab_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember_label_en-US" xlink:label="lab_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Eighteen Technical Development Agreement [Member]</link:label>
    <link:label id="lab_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember_documentation_en-US" xlink:label="lab_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Eighteen Technical Development Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember" xlink:href="dna-20251231.xsd#dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember" xlink:to="lab_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_72b87630-699d-4577-88e9-44274f245e3e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_af71585f-300b-47a6-b609-ac363f94d06a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_3258e2f1-be48-46c7-8b8d-d1d3f23894ac_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_021042d9-37b1-419b-9e3c-cce3cc9c1e45_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e1329084-b8f5-4b7b-afa1-7c3c3936f159_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_6765e07b-b6e4-4507-8b6b-18717d6eea49_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Downward adjustments from observable price changes</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_4f3556db-edf9-4485-846e-d836cba50435_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Downward adjustments from observable price changes</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-f535-7405-9301-73f232bc844d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_de0f0ce1-cd9d-4aaa-98f1-4cb03aa6cd99_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in exchange for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_VerbBioticsMember_3133a1b9-a008-4c67-9510-f15c2e25d105_terseLabel_en-US" xlink:label="lab_dna_VerbBioticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Verb Biotics</link:label>
    <link:label id="lab_dna_VerbBioticsMember_label_en-US" xlink:label="lab_dna_VerbBioticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Verb Biotics [Member]</link:label>
    <link:label id="lab_dna_VerbBioticsMember_documentation_en-US" xlink:label="lab_dna_VerbBioticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Verb Biotics member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_VerbBioticsMember" xlink:href="dna-20251231.xsd#dna_VerbBioticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_VerbBioticsMember" xlink:to="lab_dna_VerbBioticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_6d3e7a7c-86ac-4e0e-a63c-c98c799afcef_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Deferred Tax Assets Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_4021fc23-9cc8-4ab0-9a93-8698069bf1c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NoncashCustomerConsideration_0768f302-5823-4e94-ac6e-c97791c3ff32_terseLabel_en-US" xlink:label="lab_dna_NoncashCustomerConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash customer consideration</link:label>
    <link:label id="lab_dna_NoncashCustomerConsideration_label_en-US" xlink:label="lab_dna_NoncashCustomerConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Customer Consideration</link:label>
    <link:label id="lab_dna_NoncashCustomerConsideration_documentation_en-US" xlink:label="lab_dna_NoncashCustomerConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Customer Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NoncashCustomerConsideration" xlink:href="dna-20251231.xsd#dna_NoncashCustomerConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NoncashCustomerConsideration" xlink:to="lab_dna_NoncashCustomerConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_61ea2938-d585-49d2-ac41-8b94cc1248ef_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b02fbccf-7525-49dd-89d1-eb5167491458_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_221734c6-95f8-4da0-87f2-1680f3866ac9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6063013c-6472-4da2-89f8-4518d6835796_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_703c8685-562d-42e4-b223-5fe223089c39_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_41cb5ca6-c528-4e88-9ebb-b8985047ebe4_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_d2bf46e5-a33d-4ab7-a0d1-976e532fdaf5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EquipmentLeasesMember_e3f99cde-3f49-426e-b0bf-8a5d1090fa73_terseLabel_en-US" xlink:label="lab_dna_EquipmentLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment leases</link:label>
    <link:label id="lab_dna_EquipmentLeasesMember_label_en-US" xlink:label="lab_dna_EquipmentLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment leases [Member]</link:label>
    <link:label id="lab_dna_EquipmentLeasesMember_documentation_en-US" xlink:label="lab_dna_EquipmentLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquipmentLeasesMember" xlink:href="dna-20251231.xsd#dna_EquipmentLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EquipmentLeasesMember" xlink:to="lab_dna_EquipmentLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_bd4b7a7c-389f-4859-bede-4b484281d501_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f85876b9-85b2-41be-84ce-d9cb72585383_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5122e611-417c-4d62-8b55-bb4c4de69cf8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ef865e7b-94d8-41b8-af50-d64f500b3a91_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_144b9459-8a80-47f9-b29b-36be6b5f84ee_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_a95d2abc-ef68-4e3c-991a-43ed9fbc8676_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_02780b9a-7872-40f5-997c-85189ea765ee_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CustomerAndTechnologyMember_1e73503f-2064-49e8-9e50-88c39a88c900_terseLabel_en-US" xlink:label="lab_dna_CustomerAndTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer and technology</link:label>
    <link:label id="lab_dna_CustomerAndTechnologyMember_label_en-US" xlink:label="lab_dna_CustomerAndTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer And Technology [Member]</link:label>
    <link:label id="lab_dna_CustomerAndTechnologyMember_documentation_en-US" xlink:label="lab_dna_CustomerAndTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer And Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CustomerAndTechnologyMember" xlink:href="dna-20251231.xsd#dna_CustomerAndTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CustomerAndTechnologyMember" xlink:to="lab_dna_CustomerAndTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d31e8b3e-5cfe-470a-850d-b38313ff6661_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Loss Before Provision for Incomes Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c5cea-6ba3-79b1-8e4b-41255c8cc811_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DeferredTaxAssetsDeferredRevenue_11fa558f-b486-4f4b-bdd7-9625256dde97_terseLabel_en-US" xlink:label="lab_dna_DeferredTaxAssetsDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsDeferredRevenue_label_en-US" xlink:label="lab_dna_DeferredTaxAssetsDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Deferred Revenue</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsDeferredRevenue_documentation_en-US" xlink:label="lab_dna_DeferredTaxAssetsDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsDeferredRevenue" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DeferredTaxAssetsDeferredRevenue" xlink:to="lab_dna_DeferredTaxAssetsDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e7efba1a-b25a-4d2a-9fea-a0a323da626d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019c5c69-c343-7fee-9147-81a11f5cbc14_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_77d013ee-d3c0-4968-b327-2887f4d77e21_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CircularisMember_fe108309-9307-4b25-ab68-df8514c3415f_terseLabel_en-US" xlink:label="lab_dna_CircularisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Circularis</link:label>
    <link:label id="lab_dna_CircularisMember_label_en-US" xlink:label="lab_dna_CircularisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Circularis [Member]</link:label>
    <link:label id="lab_dna_CircularisMember_documentation_en-US" xlink:label="lab_dna_CircularisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Circularis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CircularisMember" xlink:href="dna-20251231.xsd#dna_CircularisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CircularisMember" xlink:to="lab_dna_CircularisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e2a87369-6690-4b5f-831b-493a7fa628db_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0e2ef18d-b5ec-4ebb-90d7-6042a3c20ce3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_BiosecuritySegmentMember_8a3916a3-045c-4fa8-8ebe-829b44905f83_terseLabel_en-US" xlink:label="lab_dna_BiosecuritySegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosecurity</link:label>
    <link:label id="lab_dna_BiosecuritySegmentMember_label_en-US" xlink:label="lab_dna_BiosecuritySegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosecurity Segment [Member]</link:label>
    <link:label id="lab_dna_BiosecuritySegmentMember_documentation_en-US" xlink:label="lab_dna_BiosecuritySegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosecurity Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiosecuritySegmentMember" xlink:href="dna-20251231.xsd#dna_BiosecuritySegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_BiosecuritySegmentMember" xlink:to="lab_dna_BiosecuritySegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7ff4c758-cc3f-42c5-8fe8-524b48ea51f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_70cad7d7-06ab-4f85-bc0a-ca84ac510f32_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_5841974b-015f-4078-bf74-9551562e3308_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6319da0d-7f5d-4604-b27b-8d05ffe88ea9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a5f18ab9-d69f-4aeb-921a-f432e5d7542c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c5cc9-54f3-7b65-8ff0-0571253e8a56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research &amp; Development Credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_PurchaseOfNonCashMarketableEquitySecurities_04f2edf8-56f5-40ce-ab6b-445ef4df9f99_terseLabel_en-US" xlink:label="lab_dna_PurchaseOfNonCashMarketableEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities and warrants received for Cell Engineering services</link:label>
    <link:label id="lab_dna_PurchaseOfNonCashMarketableEquitySecurities_label_en-US" xlink:label="lab_dna_PurchaseOfNonCashMarketableEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Of Non Cash Marketable Equity Securities</link:label>
    <link:label id="lab_dna_PurchaseOfNonCashMarketableEquitySecurities_documentation_en-US" xlink:label="lab_dna_PurchaseOfNonCashMarketableEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Of Non Cash Marketable Equity Securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PurchaseOfNonCashMarketableEquitySecurities" xlink:href="dna-20251231.xsd#dna_PurchaseOfNonCashMarketableEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_PurchaseOfNonCashMarketableEquitySecurities" xlink:to="lab_dna_PurchaseOfNonCashMarketableEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_119fbfed-648f-4024-bd7d-e4757410e70e_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Amortization Period (in Years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_ab67d3d3-5424-4c15-bbe8-86923b8779a4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_IndustrialAndEnvironmentMember_43284c1a-7cb9-4ae9-8d9c-c1416019383b_terseLabel_en-US" xlink:label="lab_dna_IndustrialAndEnvironmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industrial and environment</link:label>
    <link:label id="lab_dna_IndustrialAndEnvironmentMember_label_en-US" xlink:label="lab_dna_IndustrialAndEnvironmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industrial And Environment [Member]</link:label>
    <link:label id="lab_dna_IndustrialAndEnvironmentMember_documentation_en-US" xlink:label="lab_dna_IndustrialAndEnvironmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Industrial And Environment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IndustrialAndEnvironmentMember" xlink:href="dna-20251231.xsd#dna_IndustrialAndEnvironmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_IndustrialAndEnvironmentMember" xlink:to="lab_dna_IndustrialAndEnvironmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NumberOFEstimatedMaterialRights_019c9029-3c79-7ef8-a44d-b710d5d8aa86_terseLabel_en-US" xlink:label="lab_dna_NumberOFEstimatedMaterialRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of estimated material rights</link:label>
    <link:label id="lab_dna_NumberOFEstimatedMaterialRights_label_en-US" xlink:label="lab_dna_NumberOFEstimatedMaterialRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number OF Estimated Material Rights</link:label>
    <link:label id="lab_dna_NumberOFEstimatedMaterialRights_documentation_en-US" xlink:label="lab_dna_NumberOFEstimatedMaterialRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number OF Estimated Material Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOFEstimatedMaterialRights" xlink:href="dna-20251231.xsd#dna_NumberOFEstimatedMaterialRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NumberOFEstimatedMaterialRights" xlink:to="lab_dna_NumberOFEstimatedMaterialRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses_590811e0-0e76-425b-95a9-366b4ca2cbd0_terseLabel_en-US" xlink:label="lab_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs related to ATM offering included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses_label_en-US" xlink:label="lab_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E convertible preferred stock issuance costs included in accrued expenses</link:label>
    <link:label id="lab_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses_documentation_en-US" xlink:label="lab_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E convertible preferred stock issuance costs included in accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:href="dna-20251231.xsd#dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:to="lab_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_83adc22c-882e-459f-b1ce-1b67b7232faf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_33a2c455-cb13-4fd3-9a83-0c6c11a609e8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring related impairment charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_c6ee099d-d05e-4a8a-ba84-6d01066c7c99_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase Class A common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2f147bb4-2982-4842-acac-563f7233fe5f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_0612df87-2dba-4757-9ee0-e65cb06871a8_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ec267161-7d3d-45ac-9421-acb56bdd4fb5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2a5b7252-2eb6-4eba-9932-720f3b0a8c21_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ROU Asset obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment_3f46430c-7b84-405d-818e-ee91592d36b4_terseLabel_en-US" xlink:label="lab_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of facilities</link:label>
    <link:label id="lab_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment_label_en-US" xlink:label="lab_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment, Number Of Facilities With Impaired Equipment</link:label>
    <link:label id="lab_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment_documentation_en-US" xlink:label="lab_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment, Number Of Facilities With Impaired Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment" xlink:href="dna-20251231.xsd#dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment" xlink:to="lab_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5eebdc69-c9fd-4478-addf-90ceeb40d5bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_40780717-ab20-41ef-b924-c01f11045e7b_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c5cca-e100-7833-91b2-d7417211e5af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_87dc0ef4-f7c3-4b3f-a331-661ce7403c5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants in period, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_3e122077-dd28-4d89-95dd-46f754c37a83_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options, grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_b78be5f4-262c-4388-a2a0-b4017982c549_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_6c7b04c9-3c93-466b-8bcd-e1a68f895514_netLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d5b7d435-1391-4847-8992-cda675cf5239_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_45ff3ebc-3619-409d-b24b-8212fae1bfd6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_fb2b2034-936b-48a9-8bab-d9b633db95b7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_37739795-dde5-4dac-9bd8-5f8c5ca1aea1_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3a7ef21e-6b56-4baf-9c58-3858cbf8d44a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_039d35d4-1402-4666-babe-17478f1a661d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Income Taxes Expenses (Benefit) Incurred During the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9fc15631-4cb3-4d18-9c3b-972d5da50668_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fb4f2005-6e6f-4112-8272-aca9f7cc2859_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_20caadf4-a9f9-4431-9915-3a084ba75196_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AltarSasMember_8f9b7fb6-f635-43b5-bd14-7ddee9f1cbc6_terseLabel_en-US" xlink:label="lab_dna_AltarSasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Altar</link:label>
    <link:label id="lab_dna_AltarSasMember_label_en-US" xlink:label="lab_dna_AltarSasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Altar SAS [Member]</link:label>
    <link:label id="lab_dna_AltarSasMember_documentation_en-US" xlink:label="lab_dna_AltarSasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Altar SAS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AltarSasMember" xlink:href="dna-20251231.xsd#dna_AltarSasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AltarSasMember" xlink:to="lab_dna_AltarSasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c68e4-14dc-7b02-a64f-689e842ee64e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers into Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_5de86f26-1d6d-4878-874d-334e6ddc4f58_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Termination Costs and Other</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ATMProgramMember_019c5ca7-376d-7461-a0cb-fd0c63ffce27_terseLabel_en-US" xlink:label="lab_dna_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_dna_ATMProgramMember_label_en-US" xlink:label="lab_dna_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label id="lab_dna_ATMProgramMember_documentation_en-US" xlink:label="lab_dna_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ATMProgramMember" xlink:href="dna-20251231.xsd#dna_ATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ATMProgramMember" xlink:to="lab_dna_ATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3661c6b0-bdf4-4e7d-b252-093375bff806_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_c319ffdf-ad07-4b08-a95c-148152044cc0_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a100c981-548b-4597-b88b-55328dc0a8a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c5ccb-f3b3-7680-8a90-8d6269b2f1be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3fcac47c-7890-4817-8855-d58d1d362e51_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1ac9593b-3688-484d-831f-a3acf61c4887_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2102da04-2792-47fe-9149-d62a46bf624d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_fe74a87c-de25-4bca-b3b7-5a7320482c9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dad689d-c27a-4b3a-8961-f8112a746906_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bbd83ccc-680d-4799-9db0-c69ed20d703e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e8ca783-fa3d-4790-8182-aa3b76998388_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bffa708d-7ba1-4473-b14d-6f33c66d116b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7ee3ecd1-8853-4458-a56a-fb7f1ce83eb5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_196094ce-b913-4843-86a8-62c4e18cd120_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_9cb83f88-dea7-482f-bb63-ea2b53c812f6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3aa64566-338e-4c8e-a71a-8072563c5047_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SharesReleaseFromEscrowDuringPeriod_019c4f07-2dbb-7798-b270-dafc4fdeee87_terseLabel_en-US" xlink:label="lab_dna_SharesReleaseFromEscrowDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares release from escrow during period</link:label>
    <link:label id="lab_dna_SharesReleaseFromEscrowDuringPeriod_label_en-US" xlink:label="lab_dna_SharesReleaseFromEscrowDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Release From Escrow During Period</link:label>
    <link:label id="lab_dna_SharesReleaseFromEscrowDuringPeriod_documentation_en-US" xlink:label="lab_dna_SharesReleaseFromEscrowDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Release From Escrow During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SharesReleaseFromEscrowDuringPeriod" xlink:href="dna-20251231.xsd#dna_SharesReleaseFromEscrowDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SharesReleaseFromEscrowDuringPeriod" xlink:to="lab_dna_SharesReleaseFromEscrowDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_fa3cdb73-fd51-4ba4-b60a-64fc0557e743_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5697d09e-54ed-430e-b5a6-24b099f8cd25_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_fa38c260-775f-454f-ac1c-b0578e4a715c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers to Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_8afaee12-02f8-43ce-8bf8-ec3e1ea11955_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_8dd470a1-61e8-4b31-8de7-0fe7f0a1ba64_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, measurement input</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_79081699-92f2-4421-a825-9fba2553c2df_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98854541-6e9e-4698-937b-e03054849877_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent_bc246924-4b87-4a5a-be60-b854b8c22f56_terseLabel_en-US" xlink:label="lab_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected number of positions eliminated, percent (more than)</link:label>
    <link:label id="lab_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent_label_en-US" xlink:label="lab_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent</link:label>
    <link:label id="lab_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent_documentation_en-US" xlink:label="lab_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" xlink:href="dna-20251231.xsd#dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" xlink:to="lab_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NoncashInProcessResearchAndDevelopment_6f73d88f-8b73-4be2-a20b-e9014b3f8342_terseLabel_en-US" xlink:label="lab_dna_NoncashInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash in-process research and development</link:label>
    <link:label id="lab_dna_NoncashInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_dna_NoncashInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash In Process Research And Development</link:label>
    <link:label id="lab_dna_NoncashInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_dna_NoncashInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash In Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NoncashInProcessResearchAndDevelopment" xlink:href="dna-20251231.xsd#dna_NoncashInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NoncashInProcessResearchAndDevelopment" xlink:to="lab_dna_NoncashInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0355d057-0fbf-475c-bd03-e1a03c1cda42_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_747a5744-ee6e-4282-a635-9a041f3659a5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_147b5d34-2060-43e1-a79e-90150e2e194a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlements and payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AgBiomeInc.Member_2b82044f-9ea1-44d1-aeaf-ff72f23a46ca_terseLabel_en-US" xlink:label="lab_dna_AgBiomeInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AgBiome, Inc.</link:label>
    <link:label id="lab_dna_AgBiomeInc.Member_label_en-US" xlink:label="lab_dna_AgBiomeInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AgBiome, Inc. [Member]</link:label>
    <link:label id="lab_dna_AgBiomeInc.Member_documentation_en-US" xlink:label="lab_dna_AgBiomeInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AgBiome, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgBiomeInc.Member" xlink:href="dna-20251231.xsd#dna_AgBiomeInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AgBiomeInc.Member" xlink:to="lab_dna_AgBiomeInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_e5c3411d-e254-4b0d-bc15-003ccaa65619_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5d45cccd-10f5-4506-8e7d-e0b487e95b2b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_55f7f44b-70a7-433e-a7bc-18ba913daed6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CarryForwardsExpirationPeriodDomain_64c4a51c-3519-46da-92c6-229eb353b082_terseLabel_en-US" xlink:label="lab_dna_CarryForwardsExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carry Forwards Expiration Period</link:label>
    <link:label id="lab_dna_CarryForwardsExpirationPeriodDomain_label_en-US" xlink:label="lab_dna_CarryForwardsExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carry Forwards Expiration Period [Domain]</link:label>
    <link:label id="lab_dna_CarryForwardsExpirationPeriodDomain_documentation_en-US" xlink:label="lab_dna_CarryForwardsExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carry Forwards Expiration Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarryForwardsExpirationPeriodDomain" xlink:href="dna-20251231.xsd#dna_CarryForwardsExpirationPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CarryForwardsExpirationPeriodDomain" xlink:to="lab_dna_CarryForwardsExpirationPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019c5c81-a248-79e7-b61a-51f3cc445cf3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_f000061a-b2be-466b-b52c-f23082e720fe_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_2d426f7e-7ff5-4b48-8754-809cba95e868_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying cost of excess space (net of sublease income)</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_019c5ca9-522b-7625-bdc4-7dd2885ac97e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f4a27d98-933e-4ce2-875b-a9ec78f3bf1f_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2023</link:label>
    <link:label id="lab_us-gaap_Goodwill_682e86cf-fcbf-481b-8b14-f9ea0eaf992b_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2024</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_ab5a4ba6-cdb2-4a16-b7de-add70a95badf_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c7fc0a23-9666-4d78-bd58-976268d17191_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_92350d34-c9ab-4d71-8a63-1aa8f7570cee_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss on investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_c15c1ddf-7508-471e-bc7a-b25eed90de8b_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_235f3167-7385-4906-8615-9ed8e7137567_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss) gain on investments:</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_5e334eaf-c680-4164-ae1a-b57ae9175701_totalLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total loss on investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_8e9779d7-1188-4bff-b541-c96daca18e72_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fdb961f3-dad6-4391-961f-76abc4d38693_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_aa480d8f-0ce7-4a47-9a7e-cd566c36506e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers to Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_ec34e848-de81-44de-b666-1641e9b0ae94_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_OtherEquityInvesteeMember_019c5c90-8cc0-7c5a-83c7-fd1b98a63350_terseLabel_en-US" xlink:label="lab_dna_OtherEquityInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Equity Investee [Member]</link:label>
    <link:label id="lab_dna_OtherEquityInvesteeMember_label_en-US" xlink:label="lab_dna_OtherEquityInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Investee [Member]</link:label>
    <link:label id="lab_dna_OtherEquityInvesteeMember_documentation_en-US" xlink:label="lab_dna_OtherEquityInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Investee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherEquityInvesteeMember" xlink:href="dna-20251231.xsd#dna_OtherEquityInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_OtherEquityInvesteeMember" xlink:to="lab_dna_OtherEquityInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_234a652f-657d-497f-a0ee-8eef97239442_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeiture of restricted stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7468cf63-8607-46f7-9c60-f861ff7edceb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c5ce8-bcdf-7062-a142-43ab72cc24ea_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_1019753e-10b9-4f8d-b5cd-caa726b74cbd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aff70153-b1d2-4c93-b57d-f560acf17017_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_019c5c90-8cc0-74e8-90a8-cb79403d94c9_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Treasury and Government</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_06dc5f2f-3473-4228-ade2-05ac9a6e150e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent_8b0ca84c-fa06-414b-93c1-20aab530b6e8_terseLabel_en-US" xlink:label="lab_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosecurity costs</link:label>
    <link:label id="lab_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent_label_en-US" xlink:label="lab_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Biosecurity Service Revenue Accruals Current</link:label>
    <link:label id="lab_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent_documentation_en-US" xlink:label="lab_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued biosecurity service revenue accruals current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent" xlink:href="dna-20251231.xsd#dna_AccruedBiosecurityServiceRevenueAccrualsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent" xlink:to="lab_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d60b69ee-413e-461f-9486-d77d9e1cf3a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_8a2d47a9-b71a-4378-9bc5-6d3088f84f5f_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0be87641-5b78-4a33-932a-0b3210eb7e8f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-73a2-b65e-9c64c2c58226_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_TwoThousandTwentyTwoInducementPlanMember_eb29f9dd-38a0-4755-9926-d7b6acc31c5e_terseLabel_en-US" xlink:label="lab_dna_TwoThousandTwentyTwoInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan Member</link:label>
    <link:label id="lab_dna_TwoThousandTwentyTwoInducementPlanMember_label_en-US" xlink:label="lab_dna_TwoThousandTwentyTwoInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Two Inducement Plan [Member]</link:label>
    <link:label id="lab_dna_TwoThousandTwentyTwoInducementPlanMember_documentation_en-US" xlink:label="lab_dna_TwoThousandTwentyTwoInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Two Inducement Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandTwentyTwoInducementPlanMember" xlink:href="dna-20251231.xsd#dna_TwoThousandTwentyTwoInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_TwoThousandTwentyTwoInducementPlanMember" xlink:to="lab_dna_TwoThousandTwentyTwoInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_70ad77b9-c458-4b53-b2b7-50bf55241569_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized losses recognized on equity investments held as of the end of the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_ba6f7f7c-dbfb-4d96-8f0d-aec10f9f9cc9_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_321140bf-f0ca-454d-baf5-c5e72d9db1be_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_d66f8ece-d4fc-48f0-b6ab-6804814b8fbf_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_e81f273a-e088-4e0f-bd03-ed864a69fe4b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_54aeecf3-bd09-45f9-901a-9e9c981a4b06_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9d142441-f5f7-4b74-b016-75f3a3f489c7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_019c6900-f22c-7292-8b78-cb33fb79b66e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries and other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_019c5c76-6210-76e4-bbed-d3ad3a3de045_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ad4b1d5d-9e8f-4a91-831b-780d16146c3a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fb9f88a5-1644-4ecf-8792-6ff1622ae3be_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3fda9be2-03c2-4326-b28f-208da9909832_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fdf283bc-6f15-4dfb-a292-544fc44c2301_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e257ad70-ec47-40fb-ba95-d7f65c1009c3_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4f3a919d-8247-4dff-8e4c-ef37fb9077a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0e2fce5c-761f-48e5-a155-5ee1d8336abe_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_268d6ffe-d43a-4953-bc20-7bd8bd25d7a1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger and acquisition related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition-Related Cost, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_664f3def-1e8e-4d5b-9730-99c4a2ef0bd1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock-based compensation recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5d0e544b-d2ca-4c27-9880-37df37043e65_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ad1783c8-1ded-44a2-81e9-191c674ecede_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d3e58f5f-110c-4dd9-b26a-356e4af6b1a9_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_cf67ef11-f05c-48e2-9d6d-889ef4f463a3_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of Period</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_613c6e2e-681a-4708-853d-e6ea561760a6_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of Period</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AcquiredInProcessResearchAndDevelopment_845d1c4d-f4b8-4252-8dae-3ddf03965a00_terseLabel_en-US" xlink:label="lab_dna_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_dna_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_dna_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:label id="lab_dna_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_dna_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AcquiredInProcessResearchAndDevelopment" xlink:href="dna-20251231.xsd#dna_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_dna_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CellEngineeringAndBiosecuritySegmentsMember_d6b997ed-8819-434c-84d5-4826a2f8beb1_terseLabel_en-US" xlink:label="lab_dna_CellEngineeringAndBiosecuritySegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cell Engineering and Biosecurity</link:label>
    <link:label id="lab_dna_CellEngineeringAndBiosecuritySegmentsMember_label_en-US" xlink:label="lab_dna_CellEngineeringAndBiosecuritySegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cell Engineering and Biosecurity Segments [Member]</link:label>
    <link:label id="lab_dna_CellEngineeringAndBiosecuritySegmentsMember_documentation_en-US" xlink:label="lab_dna_CellEngineeringAndBiosecuritySegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cell Engineering and Biosecurity Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringAndBiosecuritySegmentsMember" xlink:href="dna-20251231.xsd#dna_CellEngineeringAndBiosecuritySegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CellEngineeringAndBiosecuritySegmentsMember" xlink:to="lab_dna_CellEngineeringAndBiosecuritySegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_1e1a9823-1c1e-458c-a235-bb44212ab48c_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ProbabilityWeightedPresentValueMember_3305a8b0-11aa-4eac-8ee3-7fce83e23206_terseLabel_en-US" xlink:label="lab_dna_ProbabilityWeightedPresentValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability-weighted present value</link:label>
    <link:label id="lab_dna_ProbabilityWeightedPresentValueMember_label_en-US" xlink:label="lab_dna_ProbabilityWeightedPresentValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probability-weighted present value [Member]</link:label>
    <link:label id="lab_dna_ProbabilityWeightedPresentValueMember_documentation_en-US" xlink:label="lab_dna_ProbabilityWeightedPresentValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probability-weighted present value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ProbabilityWeightedPresentValueMember" xlink:href="dna-20251231.xsd#dna_ProbabilityWeightedPresentValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ProbabilityWeightedPresentValueMember" xlink:to="lab_dna_ProbabilityWeightedPresentValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6dbbd27c-9118-43cf-b42d-cb53caf3f728_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_a3763581-4779-4a94-a781-6a780910aaef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ContractualShortfallLiabilityRequiredPayment_019c9018-b952-7758-891a-9f59b8e8a049_terseLabel_en-US" xlink:label="lab_dna_ContractualShortfallLiabilityRequiredPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual shortfall liability, required payment</link:label>
    <link:label id="lab_dna_ContractualShortfallLiabilityRequiredPayment_label_en-US" xlink:label="lab_dna_ContractualShortfallLiabilityRequiredPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Shortfall Liability, Required Payment</link:label>
    <link:label id="lab_dna_ContractualShortfallLiabilityRequiredPayment_documentation_en-US" xlink:label="lab_dna_ContractualShortfallLiabilityRequiredPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Shortfall Liability, Required Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContractualShortfallLiabilityRequiredPayment" xlink:href="dna-20251231.xsd#dna_ContractualShortfallLiabilityRequiredPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ContractualShortfallLiabilityRequiredPayment" xlink:to="lab_dna_ContractualShortfallLiabilityRequiredPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_ebbd0538-bd30-4376-92d8-66194a493f6e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded unconditional purchase obligation, year three</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66764007-8e92-481e-93fb-c937378ddbf3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_019c5c86-3427-77d2-a879-943937840654_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_38f5995d-7ebc-4b6b-8867-1af3354cd187_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_309f1e3b-e0f7-46e3-a44c-860888222e95_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77b91c91-7de5-4bbd-87a3-52d36af87b6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_019c68e5-397f-769e-8d1d-3309e26f1c87_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers into Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CommonStockConversionRatio_019c9121-0d47-7fad-b7fa-d8887d3c87d9_terseLabel_en-US" xlink:label="lab_dna_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, conversion ratio (in shares)</link:label>
    <link:label id="lab_dna_CommonStockConversionRatio_label_en-US" xlink:label="lab_dna_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Conversion Ratio</link:label>
    <link:label id="lab_dna_CommonStockConversionRatio_documentation_en-US" xlink:label="lab_dna_CommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CommonStockConversionRatio" xlink:href="dna-20251231.xsd#dna_CommonStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CommonStockConversionRatio" xlink:to="lab_dna_CommonStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e1330751-3805-44dd-b045-4878722a0101_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, included in other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b3105a4-adaa-446f-bdbf-2df9c1b133df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f7beaf3f-5bb8-4391-a089-fc3859e88a0e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_f11afe1b-9764-4364-8d88-0a2e293233eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NumberOfEmployeesAcquired_86470a3b-97fa-43eb-bdfa-12e8c221d4de_terseLabel_en-US" xlink:label="lab_dna_NumberOfEmployeesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees acquired</link:label>
    <link:label id="lab_dna_NumberOfEmployeesAcquired_label_en-US" xlink:label="lab_dna_NumberOfEmployeesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Employees Acquired</link:label>
    <link:label id="lab_dna_NumberOfEmployeesAcquired_documentation_en-US" xlink:label="lab_dna_NumberOfEmployeesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Employees Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfEmployeesAcquired" xlink:href="dna-20251231.xsd#dna_NumberOfEmployeesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NumberOfEmployeesAcquired" xlink:to="lab_dna_NumberOfEmployeesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_c8dabe14-1e6f-41bd-93c6-cd2be0fb816f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember_019c5ca4-7248-79bc-b41e-de0af45f5e07_terseLabel_en-US" xlink:label="lab_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Cloud and AI Partnership with Google Cloud</link:label>
    <link:label id="lab_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember_label_en-US" xlink:label="lab_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Cloud and AI Partnership with Google Cloud [Member]</link:label>
    <link:label id="lab_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember_documentation_en-US" xlink:label="lab_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic Cloud and AI Partnership with Google Cloud</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember" xlink:href="dna-20251231.xsd#dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember" xlink:to="lab_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c5cca-f392-7056-9cf9-6148f4ae8f8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other foreign jurisdictions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_235d1053-2231-482b-993d-dd79e2ec8016_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_GoodwillImpairmentGPCWeight_019c9013-989e-7df2-a371-ccd02fed72f8_terseLabel_en-US" xlink:label="lab_dna_GoodwillImpairmentGPCWeight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment, GPC weight</link:label>
    <link:label id="lab_dna_GoodwillImpairmentGPCWeight_label_en-US" xlink:label="lab_dna_GoodwillImpairmentGPCWeight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, GPC Weight</link:label>
    <link:label id="lab_dna_GoodwillImpairmentGPCWeight_documentation_en-US" xlink:label="lab_dna_GoodwillImpairmentGPCWeight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, GPC Weight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GoodwillImpairmentGPCWeight" xlink:href="dna-20251231.xsd#dna_GoodwillImpairmentGPCWeight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_GoodwillImpairmentGPCWeight" xlink:to="lab_dna_GoodwillImpairmentGPCWeight" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_38aa51d7-5ec1-4fac-acdd-301cdf64d5ba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate_63952e85-2ef3-4103-9fb6-63f9873fc30a_terseLabel_en-US" xlink:label="lab_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of non-participation of combined voting power or value of all classes of stock</link:label>
    <link:label id="lab_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate_label_en-US" xlink:label="lab_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Combined Voting Power or Value of All Classes of Stock Not Eligible to Participate</link:label>
    <link:label id="lab_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate_documentation_en-US" xlink:label="lab_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of combined voting power or value of all classes of stock not eligible to participate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate" xlink:href="dna-20251231.xsd#dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate" xlink:to="lab_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_17492a22-ba22-4be3-8f4c-096bffc260d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9b388afa-4c42-4fcd-81d0-643cbcf1c989_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DefinedContributionPlanEmployeeAnnualEarningAmount_9454cecd-783a-40ee-8e60-6c276f16e03d_terseLabel_en-US" xlink:label="lab_dna_DefinedContributionPlanEmployeeAnnualEarningAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee annual earning</link:label>
    <link:label id="lab_dna_DefinedContributionPlanEmployeeAnnualEarningAmount_label_en-US" xlink:label="lab_dna_DefinedContributionPlanEmployeeAnnualEarningAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employee Annual Earning, Amount</link:label>
    <link:label id="lab_dna_DefinedContributionPlanEmployeeAnnualEarningAmount_documentation_en-US" xlink:label="lab_dna_DefinedContributionPlanEmployeeAnnualEarningAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employee Annual Earning, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DefinedContributionPlanEmployeeAnnualEarningAmount" xlink:href="dna-20251231.xsd#dna_DefinedContributionPlanEmployeeAnnualEarningAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DefinedContributionPlanEmployeeAnnualEarningAmount" xlink:to="lab_dna_DefinedContributionPlanEmployeeAnnualEarningAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_11472654-edf2-493f-9280-0ecb775aa67b_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_68b979d0-7060-4110-b629-824f35893377_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for (Proceeds from) Other Investing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_GenomaticaIncPreferredStockMember_1b0c574c-f249-4f58-a80c-bec95378bc47_terseLabel_en-US" xlink:label="lab_dna_GenomaticaIncPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genomatica, Inc. Preferred Stock</link:label>
    <link:label id="lab_dna_GenomaticaIncPreferredStockMember_label_en-US" xlink:label="lab_dna_GenomaticaIncPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genomatica, Inc. Preferred Stock [Member]</link:label>
    <link:label id="lab_dna_GenomaticaIncPreferredStockMember_documentation_en-US" xlink:label="lab_dna_GenomaticaIncPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genomatica, Inc. Preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaIncPreferredStockMember" xlink:href="dna-20251231.xsd#dna_GenomaticaIncPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_GenomaticaIncPreferredStockMember" xlink:to="lab_dna_GenomaticaIncPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1b6718a8-86c3-4069-9f13-158f5d915362_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DeferredTaxAssetsInvestmentsInSubsidiaries_881c5562-b7b4-4620-8dac-fc4855d27221_terseLabel_en-US" xlink:label="lab_dna_DeferredTaxAssetsInvestmentsInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsInvestmentsInSubsidiaries_label_en-US" xlink:label="lab_dna_DeferredTaxAssetsInvestmentsInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, investments In Subsidiaries</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsInvestmentsInSubsidiaries_documentation_en-US" xlink:label="lab_dna_DeferredTaxAssetsInvestmentsInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, investments In Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsInvestmentsInSubsidiaries" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsInvestmentsInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DeferredTaxAssetsInvestmentsInSubsidiaries" xlink:to="lab_dna_DeferredTaxAssetsInvestmentsInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_ce188027-ea48-4786-b089-6cad9e8c4bd8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2fd0df02-f797-47c7-ba77-8624e1921271_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_491d1602-f8bd-48db-bcf8-6881cbac11d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_02ee140b-d105-41e8-b77c-e88eadaec080_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6f5b9ec9-b7f9-454e-9f34-edc3f5abf5cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_832816e3-8293-4260-aa9d-c52c56cb23a2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_053dc372-646f-4133-9183-4bc796bdbae9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_708faf5d-7333-426b-8bd9-fbe46662dcb7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage_09a44429-1587-4eba-86d0-d65a52e069bd_terseLabel_en-US" xlink:label="lab_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, downward price adjustment percentage</link:label>
    <link:label id="lab_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage_label_en-US" xlink:label="lab_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Percentage</link:label>
    <link:label id="lab_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage_documentation_en-US" xlink:label="lab_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage" xlink:href="dna-20251231.xsd#dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage" xlink:to="lab_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1fee8db5-12d7-490b-84fa-35e34183da7b_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_d61ed728-c6fb-496b-a7c7-60a08d97ed15_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Range of Outcomes, Liability, Maximum, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b6fd7466-29d6-488c-a1fb-e1f652f499f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_112bbce9-130a-472b-a5af-80b936a82376_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_b236a599-9288-49fe-abdf-93f4e78b778e_terseLabel_en-US" xlink:label="lab_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="dna-20251231.xsd#dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EmployerPayrollTaxes_a1e508e2-f2e7-4f07-9b64-0adac6ab3d83_terseLabel_en-US" xlink:label="lab_dna_EmployerPayrollTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer payroll taxes</link:label>
    <link:label id="lab_dna_EmployerPayrollTaxes_label_en-US" xlink:label="lab_dna_EmployerPayrollTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employer Payroll Taxes</link:label>
    <link:label id="lab_dna_EmployerPayrollTaxes_documentation_en-US" xlink:label="lab_dna_EmployerPayrollTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employer payroll taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EmployerPayrollTaxes" xlink:href="dna-20251231.xsd#dna_EmployerPayrollTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EmployerPayrollTaxes" xlink:to="lab_dna_EmployerPayrollTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_28d256fa-f6e2-45cd-aa8c-e9b1fcc8bd2a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable - related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1b9d8153-fb14-445f-8307-744812ea39ef_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2215d686-d0a5-4837-b1ed-09df82571cd3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_7c55129a-c1fe-48e0-8b51-ee2df887efe8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_LeaseAssetsMember_e8cb44d0-b36f-483e-af87-bb1cca6baa0d_terseLabel_en-US" xlink:label="lab_dna_LeaseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Assets</link:label>
    <link:label id="lab_dna_LeaseAssetsMember_label_en-US" xlink:label="lab_dna_LeaseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Assets [Member]</link:label>
    <link:label id="lab_dna_LeaseAssetsMember_documentation_en-US" xlink:label="lab_dna_LeaseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LeaseAssetsMember" xlink:href="dna-20251231.xsd#dna_LeaseAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_LeaseAssetsMember" xlink:to="lab_dna_LeaseAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1b419153-bb84-433b-80dc-92e07a1e6786_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SupplementalBalanceSheetInformationAbstract_e3ac1ce1-e1af-436a-8531-0d06f531f2e3_terseLabel_en-US" xlink:label="lab_dna_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_dna_SupplementalBalanceSheetInformationAbstract_label_en-US" xlink:label="lab_dna_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_dna_SupplementalBalanceSheetInformationAbstract_documentation_en-US" xlink:label="lab_dna_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SupplementalBalanceSheetInformationAbstract" xlink:href="dna-20251231.xsd#dna_SupplementalBalanceSheetInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract" xlink:to="lab_dna_SupplementalBalanceSheetInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CellEngineeringSegmentMember_74aa11bb-6b98-4607-b699-453fb6301540_terseLabel_en-US" xlink:label="lab_dna_CellEngineeringSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cell Engineering</link:label>
    <link:label id="lab_dna_CellEngineeringSegmentMember_label_en-US" xlink:label="lab_dna_CellEngineeringSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cell Engineering Segment [Member]</link:label>
    <link:label id="lab_dna_CellEngineeringSegmentMember_documentation_en-US" xlink:label="lab_dna_CellEngineeringSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cell Engineering Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringSegmentMember" xlink:href="dna-20251231.xsd#dna_CellEngineeringSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CellEngineeringSegmentMember" xlink:to="lab_dna_CellEngineeringSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019c5cd1-03bd-7de8-a455-a86beaff7a9a_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other state and local</link:label>
    <link:label id="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Tax Jurisdiction, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:to="lab_us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e5091400-2d08-4330-91f3-85d32434ab65_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_20c27372-8e00-41e0-a57d-839ac82cddb7_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SAFEs</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2870927c-aabf-42d1-8916-adfca7d04bae_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ComputerEquipmentAndSoftwareMember_af3b6784-ac65-4b90-b95b-95222528f150_terseLabel_en-US" xlink:label="lab_dna_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_dna_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_dna_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_dna_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_dna_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ComputerEquipmentAndSoftwareMember" xlink:href="dna-20251231.xsd#dna_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ComputerEquipmentAndSoftwareMember" xlink:to="lab_dna_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DefinedContributionPlanMaximumEmployerContributionsAmount_dfe49d4f-52e4-4b3b-a183-e10c6e555c43_terseLabel_en-US" xlink:label="lab_dna_DefinedContributionPlanMaximumEmployerContributionsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum employer contributions</link:label>
    <link:label id="lab_dna_DefinedContributionPlanMaximumEmployerContributionsAmount_label_en-US" xlink:label="lab_dna_DefinedContributionPlanMaximumEmployerContributionsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Employer Contributions, Amount</link:label>
    <link:label id="lab_dna_DefinedContributionPlanMaximumEmployerContributionsAmount_documentation_en-US" xlink:label="lab_dna_DefinedContributionPlanMaximumEmployerContributionsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Employer Contributions, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DefinedContributionPlanMaximumEmployerContributionsAmount" xlink:href="dna-20251231.xsd#dna_DefinedContributionPlanMaximumEmployerContributionsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DefinedContributionPlanMaximumEmployerContributionsAmount" xlink:to="lab_dna_DefinedContributionPlanMaximumEmployerContributionsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2169726d-f9ac-42ba-811d-439bb8f82c46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a105eede-73f8-4fa5-8672-70ff5da94c2d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_53f6cd45-8c5b-4718-b231-0bc4ecdac63a_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_32c9d447-1f8a-4c75-9add-155a6ba47e24_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EarnoutRestrictedStockUnitsMember_829afdc6-18a1-42dd-82c6-1bb6fdd2154e_terseLabel_en-US" xlink:label="lab_dna_EarnoutRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnout RSUs</link:label>
    <link:label id="lab_dna_EarnoutRestrictedStockUnitsMember_label_en-US" xlink:label="lab_dna_EarnoutRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnout Restricted Stock Units [Member]</link:label>
    <link:label id="lab_dna_EarnoutRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_dna_EarnoutRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnout restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnoutRestrictedStockUnitsMember" xlink:href="dna-20251231.xsd#dna_EarnoutRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EarnoutRestrictedStockUnitsMember" xlink:to="lab_dna_EarnoutRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncome_e938b789-649b-4cf4-9510-33319de5574f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred other income</link:label>
    <link:label id="lab_us-gaap_DeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncome" xlink:to="lab_us-gaap_DeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_019c902c-80aa-70b0-86bf-ba10eae7f45b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EquitySecuritiesFVNIMeasurementInputTerm_04e8df51-445f-49cb-99c6-dbd686928937_terseLabel_en-US" xlink:label="lab_dna_EquitySecuritiesFVNIMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, measurement input, term</link:label>
    <link:label id="lab_dna_EquitySecuritiesFVNIMeasurementInputTerm_label_en-US" xlink:label="lab_dna_EquitySecuritiesFVNIMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input, Term</link:label>
    <link:label id="lab_dna_EquitySecuritiesFVNIMeasurementInputTerm_documentation_en-US" xlink:label="lab_dna_EquitySecuritiesFVNIMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquitySecuritiesFVNIMeasurementInputTerm" xlink:href="dna-20251231.xsd#dna_EquitySecuritiesFVNIMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EquitySecuritiesFVNIMeasurementInputTerm" xlink:to="lab_dna_EquitySecuritiesFVNIMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_3eb44889-7c06-4092-b4fc-e5a71a6bccd2_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NumberOfCompanyFounders_857e1dc1-b56c-4dc2-ace9-b3a1fa9b09cd_terseLabel_en-US" xlink:label="lab_dna_NumberOfCompanyFounders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of company founders</link:label>
    <link:label id="lab_dna_NumberOfCompanyFounders_label_en-US" xlink:label="lab_dna_NumberOfCompanyFounders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Company Founders</link:label>
    <link:label id="lab_dna_NumberOfCompanyFounders_documentation_en-US" xlink:label="lab_dna_NumberOfCompanyFounders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Company Founders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfCompanyFounders" xlink:href="dna-20251231.xsd#dna_NumberOfCompanyFounders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NumberOfCompanyFounders" xlink:to="lab_dna_NumberOfCompanyFounders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6e772454-c2b0-4cb4-8692-02fdba9bd05d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0838a599-824f-4507-9bd9-b302c4dc1866_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_6801e8b9-d375-44f4-8bac-ebef1c33c488_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_36e3c019-eba2-44e2-9d95-83c0380aa15e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_aa73c336-26af-4394-bf40-e433e85c17cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment to fund additional losses on equity method investments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_0b816228-8f0a-43b8-9713-4cb06c7df6fe_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_0989cac0-983b-4c83-b411-ce18137fe455_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contribution by company, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ab215d99-5caf-4db7-bedc-8366316147e9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_8aafc8bb-f8ed-4a30-a038-7559efb2ff3e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_3793ba05-d974-433d-b164-5669418d2598_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_6d6446ce-f431-4332-b401-6cd892d9a220_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Capital Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CommonStockVotingRight_c1bf89e1-747a-468e-a065-43511210be6b_terseLabel_en-US" xlink:label="lab_dna_CommonStockVotingRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, voting rights</link:label>
    <link:label id="lab_dna_CommonStockVotingRight_label_en-US" xlink:label="lab_dna_CommonStockVotingRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Right</link:label>
    <link:label id="lab_dna_CommonStockVotingRight_documentation_en-US" xlink:label="lab_dna_CommonStockVotingRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CommonStockVotingRight" xlink:href="dna-20251231.xsd#dna_CommonStockVotingRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CommonStockVotingRight" xlink:to="lab_dna_CommonStockVotingRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_68da5fa9-9ff7-4f4b-bbe2-c9445946aa8e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_def9df64-7ec1-4f04-90a1-f9a14ae61e69_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_1bd6b3f3-bc28-48e6-a6c7-b3e38d087547_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SalesAgreementWithAllenCompanyLLCMember_019c5ca7-8f0e-74a0-ab91-621a8b65b6b0_terseLabel_en-US" xlink:label="lab_dna_SalesAgreementWithAllenCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Agreement with Allen &amp; Company LLC</link:label>
    <link:label id="lab_dna_SalesAgreementWithAllenCompanyLLCMember_label_en-US" xlink:label="lab_dna_SalesAgreementWithAllenCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Agreement with Allen &amp; Company LLC [Member]</link:label>
    <link:label id="lab_dna_SalesAgreementWithAllenCompanyLLCMember_documentation_en-US" xlink:label="lab_dna_SalesAgreementWithAllenCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Agreement with Allen &amp; Company LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SalesAgreementWithAllenCompanyLLCMember" xlink:href="dna-20251231.xsd#dna_SalesAgreementWithAllenCompanyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SalesAgreementWithAllenCompanyLLCMember" xlink:to="lab_dna_SalesAgreementWithAllenCompanyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_4094ff79-23bd-407e-9930-7115e7f88127_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_81d7179e-5e83-404c-88c4-1d232ed22279_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_46105e7e-0cb0-41b0-b372-9dbf725fdc86_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d82e7968-e1f1-42aa-964b-ece486a9a7f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019c5c86-3427-7419-a7d6-9666eac83921_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived_019c9665-29ce-75b0-a0ff-d46ce1e9458a_terseLabel_en-US" xlink:label="lab_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock purchase agreement, percent of equity interest to be received</link:label>
    <link:label id="lab_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived_label_en-US" xlink:label="lab_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Percent Of Equity Interest To Be Received</link:label>
    <link:label id="lab_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived_documentation_en-US" xlink:label="lab_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Percent Of Equity Interest To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived" xlink:href="dna-20251231.xsd#dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived" xlink:to="lab_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b9c5a411-9a6e-44b2-9e80-3a213c565a1e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, number of securities called by rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_de597b5f-ceec-4a68-a765-d7e71a7c621f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cb76ea9c-07e5-4855-bead-74f4eef89efd_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_40b7042c-dabb-4ce0-98c6-188c606ef04a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NumberOfStockPriceHurdles_019c901d-8297-7db1-a702-b0afebd0cc61_terseLabel_en-US" xlink:label="lab_dna_NumberOfStockPriceHurdles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of stock price hurdles</link:label>
    <link:label id="lab_dna_NumberOfStockPriceHurdles_label_en-US" xlink:label="lab_dna_NumberOfStockPriceHurdles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Stock Price Hurdles</link:label>
    <link:label id="lab_dna_NumberOfStockPriceHurdles_documentation_en-US" xlink:label="lab_dna_NumberOfStockPriceHurdles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Stock Price Hurdles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfStockPriceHurdles" xlink:href="dna-20251231.xsd#dna_NumberOfStockPriceHurdles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NumberOfStockPriceHurdles" xlink:to="lab_dna_NumberOfStockPriceHurdles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_65bd405f-0960-4b5d-a4a2-afb6d362e0b4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment general and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_76e3131d-91d2-459f-962b-b7853de33ce4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019c5c69-8fb4-7841-b227-fdea6f774ac2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_GovernmentAndDefenseMember_03ccc2b8-f70d-400d-ab28-e9e1384c47f9_terseLabel_en-US" xlink:label="lab_dna_GovernmentAndDefenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government and defense</link:label>
    <link:label id="lab_dna_GovernmentAndDefenseMember_label_en-US" xlink:label="lab_dna_GovernmentAndDefenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government and Defense [Member]</link:label>
    <link:label id="lab_dna_GovernmentAndDefenseMember_documentation_en-US" xlink:label="lab_dna_GovernmentAndDefenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government and Defense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GovernmentAndDefenseMember" xlink:href="dna-20251231.xsd#dna_GovernmentAndDefenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_GovernmentAndDefenseMember" xlink:to="lab_dna_GovernmentAndDefenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_e863d5be-8854-4811-91a4-d7a7c755f0ae_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_29047671-d866-43fc-8445-49f3a0dbf5f8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c5ceb-5b74-7c3e-853a-cfa550cea9e2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_FounderPSUAwardsMember_019c5cb4-e5da-701e-bd5b-9208df87c979_terseLabel_en-US" xlink:label="lab_dna_FounderPSUAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Founder PSU Awards</link:label>
    <link:label id="lab_dna_FounderPSUAwardsMember_label_en-US" xlink:label="lab_dna_FounderPSUAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Founder PSU Awards [Member]</link:label>
    <link:label id="lab_dna_FounderPSUAwardsMember_documentation_en-US" xlink:label="lab_dna_FounderPSUAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Founder PSU Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FounderPSUAwardsMember" xlink:href="dna-20251231.xsd#dna_FounderPSUAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_FounderPSUAwardsMember" xlink:to="lab_dna_FounderPSUAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_11981f2a-d3c1-40ca-8e49-c067eb314f50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Liability Assumed, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2cd58545-dee2-4a92-8418-3b60ef58f7b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Deferred Taxes Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7f573b60-f788-4a79-8e33-61dc72e9d016_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_35cde085-38eb-42f7-ba40-14a6f2f321b8_terseLabel_en-US" xlink:label="lab_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="dna-20251231.xsd#dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate_8e9f1468-1435-4ae8-9591-a6f0f36600ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Input</link:label>
    <link:label id="lab_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate_label_en-US" xlink:label="lab_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Duration Contract, Discounted Liability, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate" xlink:to="lab_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4b1d09fe-928b-4445-b525-313de5bffd74_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_00c70a0e-3fdf-4464-a5ea-0af4d86609af_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d9f1a90b-37b7-46fe-9681-3ede54159feb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e319440f-ab4e-4c7d-89eb-6fe783ebe829_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_7d33553b-118a-4bc5-9877-7262d1ab42b1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_284e6a74-17ee-45ff-a360-42ff77cfb272_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_019c5c90-8cc0-742a-9104-43ee7bf48100_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Marketable Security [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_55dea6d2-73b4-461c-804f-e71c3b76af86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_800558dc-576c-42e7-8362-384bd1570ece_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_6b224b56-0db7-44e5-aeb4-182bf913be40_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a4fe42d8-d27a-42ac-8fd4-7b5fbf8b240d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_019c5ca4-7248-775b-b431-762af5d959d2_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_466eed01-4fe4-4df7-888d-fc8417fa0d82_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_PatentCostsPolicyTextBlock_1db1c446-82d1-403f-8ad7-37efa39a9265_terseLabel_en-US" xlink:label="lab_dna_PatentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_dna_PatentCostsPolicyTextBlock_label_en-US" xlink:label="lab_dna_PatentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
    <link:label id="lab_dna_PatentCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_dna_PatentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patent costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PatentCostsPolicyTextBlock" xlink:href="dna-20251231.xsd#dna_PatentCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_PatentCostsPolicyTextBlock" xlink:to="lab_dna_PatentCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_32d080ae-8810-4922-a2f2-65c56d5f4fb5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_019c5cd0-cb6e-78cf-88bd-e7367c0fb985_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_019c5c6b-3339-7736-bab8-b109c8b875ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from ATM offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_NonMarketableEquitySecuritiesMember_52c9127a-28ff-40f1-a5e5-dc3163490fdf_terseLabel_en-US" xlink:label="lab_dna_NonMarketableEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-marketable equity securities</link:label>
    <link:label id="lab_dna_NonMarketableEquitySecuritiesMember_label_en-US" xlink:label="lab_dna_NonMarketableEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Marketable Equity Securities [Member]</link:label>
    <link:label id="lab_dna_NonMarketableEquitySecuritiesMember_documentation_en-US" xlink:label="lab_dna_NonMarketableEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-marketable equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NonMarketableEquitySecuritiesMember" xlink:href="dna-20251231.xsd#dna_NonMarketableEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_NonMarketableEquitySecuritiesMember" xlink:to="lab_dna_NonMarketableEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1ea19d91-ef4e-4957-9cb6-5a6c8a0cdfde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_50546e1e-481c-4267-9bc5-5b251f9fdefb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3710c8ad-9ade-45b4-a26e-744134b85d7f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_a002e09e-eb3c-4890-97ae-80102a235220_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded unconditional purchase obligation, year four</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DeferredTaxAssetsAmortizableIntangibles_618fa8e9-b226-4ad5-bae0-b0110f5353ac_terseLabel_en-US" xlink:label="lab_dna_DeferredTaxAssetsAmortizableIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortizable intangibles</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsAmortizableIntangibles_label_en-US" xlink:label="lab_dna_DeferredTaxAssetsAmortizableIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Amortizable Intangibles</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsAmortizableIntangibles_documentation_en-US" xlink:label="lab_dna_DeferredTaxAssetsAmortizableIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets amortizable intangibles.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsAmortizableIntangibles" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsAmortizableIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DeferredTaxAssetsAmortizableIntangibles" xlink:to="lab_dna_DeferredTaxAssetsAmortizableIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SynlogicIncWarrantsMember_40066037-a266-4bd5-b093-e4f37cb54ef7_terseLabel_en-US" xlink:label="lab_dna_SynlogicIncWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Synlogic, Inc. warrants</link:label>
    <link:label id="lab_dna_SynlogicIncWarrantsMember_label_en-US" xlink:label="lab_dna_SynlogicIncWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Synlogic, Inc. Warrants [Member]</link:label>
    <link:label id="lab_dna_SynlogicIncWarrantsMember_documentation_en-US" xlink:label="lab_dna_SynlogicIncWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Synlogic, Inc. Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SynlogicIncWarrantsMember" xlink:href="dna-20251231.xsd#dna_SynlogicIncWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SynlogicIncWarrantsMember" xlink:to="lab_dna_SynlogicIncWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_1c5af87f-2866-4614-b660-13b357416e19_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_FinancingReceivableInterestRateStatedPercentage_3b01f760-f083-492b-9e2e-5d3118c14b22_terseLabel_en-US" xlink:label="lab_dna_FinancingReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing receivable, interest rate</link:label>
    <link:label id="lab_dna_FinancingReceivableInterestRateStatedPercentage_label_en-US" xlink:label="lab_dna_FinancingReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_dna_FinancingReceivableInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_dna_FinancingReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Receivable, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinancingReceivableInterestRateStatedPercentage" xlink:href="dna-20251231.xsd#dna_FinancingReceivableInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_FinancingReceivableInterestRateStatedPercentage" xlink:to="lab_dna_FinancingReceivableInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_956ff280-2e47-41e0-b51d-c1841f36b4d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment award, percentage of outstanding stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm_0c777cc9-fa2b-4207-8a54-127c04a3caf7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded unconditional purchase obligation, term (in years)</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fb05014c-7618-4d30-803c-f7d5b613caae_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impact of foreign currency translation</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Foreign Currency Translation, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c5ceb-8090-758c-9d22-96a73768d67c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_OtherRevenueMember_019c5ca9-ec70-754c-a5c0-0965d27bbde6_terseLabel_en-US" xlink:label="lab_dna_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Revenue</link:label>
    <link:label id="lab_dna_OtherRevenueMember_label_en-US" xlink:label="lab_dna_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:label id="lab_dna_OtherRevenueMember_documentation_en-US" xlink:label="lab_dna_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherRevenueMember" xlink:href="dna-20251231.xsd#dna_OtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_OtherRevenueMember" xlink:to="lab_dna_OtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_26ccd807-3e95-4854-b34e-c91798bc664a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue_9dd4a0d8-0ace-486b-9eec-4207feb51f84_terseLabel_en-US" xlink:label="lab_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return of investment in equity securities for reduction in deferred revenue</link:label>
    <link:label id="lab_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue_label_en-US" xlink:label="lab_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Return Of Investment In Equity Securities For Reduction In Deferred Revenue</link:label>
    <link:label id="lab_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue_documentation_en-US" xlink:label="lab_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Return Of Investment In Equity Securities For Reduction In Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" xlink:href="dna-20251231.xsd#dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" xlink:to="lab_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_ea7c28a1-e9b8-4232-a4f1-a1128f192b95_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_22130901-a616-4889-8cc8-611c56534d78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8bc1c458-3cae-4b82-9186-20a8dd7c80a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, converted instrument, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_4a9f28f8-8bc4-4a23-92e6-2dbf5dc6d541_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligations, fair value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligations, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_019c5ca4-7248-7144-a7e4-a559dbce719e_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_dd32572b-b94f-4633-976f-72cb4060c985_totalLabel_en-US" xlink:label="lab_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets deconsolidated</link:label>
    <link:label id="lab_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Assets and Liabilities, Net</link:label>
    <link:label id="lab_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet" xlink:to="lab_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_9f0771dd-4b22-4c19-a01f-63cddf8144c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a9b2f7ae-cff1-43ef-84c8-72a6c01d620c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_21496f80-3b19-4f30-8c1e-f99f32578e27_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_1982003a-f901-4fbb-84f5-cdb02846066a_terseLabel_en-US" xlink:label="lab_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Incentive Award Plan</link:label>
    <link:label id="lab_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_label_en-US" xlink:label="lab_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand and Twenty One Incentive Award Plan [Member]</link:label>
    <link:label id="lab_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and twenty one incentive award plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember" xlink:to="lab_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a47f4e5f-58cd-4914-9b81-57409681a3b6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_356c6b85-57b1-4eb6-b4d4-d11dd170226c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvotingCommonStockMember_84551167-9874-407f-bff8-86f76b1da195_terseLabel_en-US" xlink:label="lab_us-gaap_NonvotingCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonvoting Common Stock</link:label>
    <link:label id="lab_us-gaap_NonvotingCommonStockMember_label_en-US" xlink:label="lab_us-gaap_NonvotingCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvoting Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvotingCommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvotingCommonStockMember" xlink:to="lab_us-gaap_NonvotingCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_019c5ce8-6113-7f1d-97ce-b2739e8ffd73_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_MotifMember_0375f89f-b7b9-4f3b-8c6b-1c97a398641a_terseLabel_en-US" xlink:label="lab_dna_MotifMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Motif FoodWorks</link:label>
    <link:label id="lab_dna_MotifMember_label_en-US" xlink:label="lab_dna_MotifMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Motif [Member]</link:label>
    <link:label id="lab_dna_MotifMember_documentation_en-US" xlink:label="lab_dna_MotifMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Motif [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MotifMember" xlink:href="dna-20251231.xsd#dna_MotifMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_MotifMember" xlink:to="lab_dna_MotifMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EarnOutSharesMember_2ddefe4c-423b-41a0-a413-c7696d19760a_terseLabel_en-US" xlink:label="lab_dna_EarnOutSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnout Shares</link:label>
    <link:label id="lab_dna_EarnOutSharesMember_label_en-US" xlink:label="lab_dna_EarnOutSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earn-Out Shares [Member]</link:label>
    <link:label id="lab_dna_EarnOutSharesMember_documentation_en-US" xlink:label="lab_dna_EarnOutSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earn-Out Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnOutSharesMember" xlink:href="dna-20251231.xsd#dna_EarnOutSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EarnOutSharesMember" xlink:to="lab_dna_EarnOutSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_46932ad9-12d0-48b9-8a43-a1f0895c1c75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Anti-Dilutive Shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_80192900-58e1-4958-9c87-bdc3f2fab130_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_DeferredTaxAssetsValuationAllowanceRollForward_7c16fbe6-9300-4922-91cc-03f5c08f4720_terseLabel_en-US" xlink:label="lab_dna_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets valuation allowance:</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsValuationAllowanceRollForward_label_en-US" xlink:label="lab_dna_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_dna_DeferredTaxAssetsValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_dna_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsValuationAllowanceRollForward" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_DeferredTaxAssetsValuationAllowanceRollForward" xlink:to="lab_dna_DeferredTaxAssetsValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d58494ca-feb2-4ecb-90b3-8c5883f09a9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current and non-current ($(8,147), $(51,422) and $(17,018) from related parties)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_65fde394-e958-4daa-a8c4-30d26f1ebc58_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current and non-current, from related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4c87e34b-f3b2-4f36-9180-8712ca829019_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_ef4372e9-bbcc-4c1b-856c-d18dc39a9a3b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a3b25c92-c44c-4c55-af28-53c526c0e46c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_GenomaticaMember_58024e9f-4630-40e9-aa3c-a2c876a7b9ae_terseLabel_en-US" xlink:label="lab_dna_GenomaticaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genomatica</link:label>
    <link:label id="lab_dna_GenomaticaMember_label_en-US" xlink:label="lab_dna_GenomaticaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genomatica [Member]</link:label>
    <link:label id="lab_dna_GenomaticaMember_documentation_en-US" xlink:label="lab_dna_GenomaticaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genomatica [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaMember" xlink:href="dna-20251231.xsd#dna_GenomaticaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_GenomaticaMember" xlink:to="lab_dna_GenomaticaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_6821b03b-b108-49fa-9882-fd8821b163c6_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Losses and Gains on Investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6002ae63-60d6-4935-ab1f-a9a733f5c8aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_LabEquipmentMember_f5964403-f6fa-4ab6-a4d7-b34f2c5e7211_terseLabel_en-US" xlink:label="lab_dna_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_dna_LabEquipmentMember_label_en-US" xlink:label="lab_dna_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_dna_LabEquipmentMember_documentation_en-US" xlink:label="lab_dna_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lab equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LabEquipmentMember" xlink:href="dna-20251231.xsd#dna_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_LabEquipmentMember" xlink:to="lab_dna_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_4c7bbd4e-3ab9-430f-9ba1-5d8e95b65515_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, option to extend (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e4529fcb-8e10-484f-8749-e46159772154_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_42776e9c-bd49-4a9f-b084-c5e45d76080f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_ca17aa35-4975-4a9b-9d7e-e6440226b400_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_ccdfd339-6902-4636-8bec-a7ebcd3eddb5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing receivable, excluding accrued interest, after allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationTextBlock_38530d97-df51-4743-9e21-e530f6a2d1b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCapitalizationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationTextBlock" xlink:to="lab_us-gaap_ScheduleOfCapitalizationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_bb33b22e-9ece-47ee-8779-61799e8bb238_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bd9dadf5-73b5-4506-b9cc-74f596efca23_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_b6c03265-0e06-4813-8aad-39df96ae2d92_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_a4d3e006-a1c0-4faf-b1c3-5e437f405c6f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_941680e6-7a69-4a1e-b0d2-f71002a833ed_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_3c999e09-9a4e-49a9-a27e-82344da59ac5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4a24cf53-3bee-402f-a8f8-216087190aa8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Reconciliation of the Statutory Corporate Income Tax Rate to the Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_65064f70-c73a-44ea-a5a6-9c410fd669c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c6900-f22c-7d4e-9c52-414c0e4e81e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_cf9556a7-3788-46dd-a073-7326ca3a7265_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2cda2fc2-a819-4529-8898-2917591d3de6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_8df3d236-e8ac-41dd-a3bc-ca8fa5bc8d6a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_30ad4998-307d-42c6-b640-727fbcf4c544_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_023e04bc-5335-4ad0-a24d-59906a9a4def_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b7f89a06-334b-4869-bb90-7e292043a871_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_090f6b18-c322-4a58-99e7-3b057d3f8ef6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1c3c08d6-f884-4bec-9c29-2e7061fdc930_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total segment operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_29281148-01fa-4845-af89-41dc6e7e9e1e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ZymergenBankruptcyMember_2462493c-6916-4264-b187-f39480738163_terseLabel_en-US" xlink:label="lab_dna_ZymergenBankruptcyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zymergen Bankruptcy</link:label>
    <link:label id="lab_dna_ZymergenBankruptcyMember_label_en-US" xlink:label="lab_dna_ZymergenBankruptcyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zymergen Bankruptcy [Member]</link:label>
    <link:label id="lab_dna_ZymergenBankruptcyMember_documentation_en-US" xlink:label="lab_dna_ZymergenBankruptcyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zymergen Bankruptcy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenBankruptcyMember" xlink:href="dna-20251231.xsd#dna_ZymergenBankruptcyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ZymergenBankruptcyMember" xlink:to="lab_dna_ZymergenBankruptcyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_bde4bd21-2b9e-4f30-aa01-b7548b980e9d_terseLabel_en-US" xlink:label="lab_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand and Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and twenty one employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:to="lab_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d5546b56-330b-4de4-8ed9-310eb64c41c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e90df3cc-d8c8-4bf7-a8fc-19a865496f5d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6d26a9be-e9b5-41a9-a2bc-c73d5eb14814_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6b71dcc2-3987-47b0-a5bb-a920efbe7007_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e941df4a-1a36-4fab-8689-c1edbe801820_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e60036d2-c6a0-4a66-afbd-f25cda0f1344_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c69caf98-007a-401a-8a86-366880cd7465_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c54a71c1-2d85-4121-8acf-d956c5a9bd2d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71177614-f5f4-410d-b727-716b4c6d7e37_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CellEngineeringRevenueMember_0f40187b-6b0c-4210-9a51-2e9edf330dbe_terseLabel_en-US" xlink:label="lab_dna_CellEngineeringRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cell Engineering</link:label>
    <link:label id="lab_dna_CellEngineeringRevenueMember_8ee37fb9-0483-4f50-9aad-dc15a5cf0980_verboseLabel_en-US" xlink:label="lab_dna_CellEngineeringRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Cell Engineering revenue</link:label>
    <link:label id="lab_dna_CellEngineeringRevenueMember_label_en-US" xlink:label="lab_dna_CellEngineeringRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cell Engineering Revenue [Member]</link:label>
    <link:label id="lab_dna_CellEngineeringRevenueMember_documentation_en-US" xlink:label="lab_dna_CellEngineeringRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cell Engineering Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringRevenueMember" xlink:href="dna-20251231.xsd#dna_CellEngineeringRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CellEngineeringRevenueMember" xlink:to="lab_dna_CellEngineeringRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_de461346-6864-4687-b169-d599296f8bac_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_36b1b75a-0b6d-4e23-bb68-d1bb26414a90_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AccruedEmployeeTerminationCosts_f436084d-9497-4ec5-ae99-bf82de41d0d6_terseLabel_en-US" xlink:label="lab_dna_AccruedEmployeeTerminationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee termination costs</link:label>
    <link:label id="lab_dna_AccruedEmployeeTerminationCosts_label_en-US" xlink:label="lab_dna_AccruedEmployeeTerminationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Termination Costs</link:label>
    <link:label id="lab_dna_AccruedEmployeeTerminationCosts_documentation_en-US" xlink:label="lab_dna_AccruedEmployeeTerminationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Employee Termination Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedEmployeeTerminationCosts" xlink:href="dna-20251231.xsd#dna_AccruedEmployeeTerminationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AccruedEmployeeTerminationCosts" xlink:to="lab_dna_AccruedEmployeeTerminationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment_9fdbb9fa-4a27-46fb-966e-b3a86483f885_terseLabel_en-US" xlink:label="lab_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment_label_en-US" xlink:label="lab_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount, Including Adjustment</link:label>
    <link:label id="lab_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment_documentation_en-US" xlink:label="lab_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount, Including Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment" xlink:href="dna-20251231.xsd#dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment" xlink:to="lab_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c6cd14a7-fee3-43be-9f2a-6d04b482581c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_Year15Member_019c5cb9-713a-769d-af55-f78e426523f8_terseLabel_en-US" xlink:label="lab_dna_Year15Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 1 - 5</link:label>
    <link:label id="lab_dna_Year15Member_label_en-US" xlink:label="lab_dna_Year15Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year 1 - 5 [Member]</link:label>
    <link:label id="lab_dna_Year15Member_documentation_en-US" xlink:label="lab_dna_Year15Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year 1 - 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year15Member" xlink:href="dna-20251231.xsd#dna_Year15Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_Year15Member" xlink:to="lab_dna_Year15Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_be2c96fa-db96-478e-990e-09e00755d153_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_dc6c265d-a56c-4975-963a-79600fbf063e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3e3fd017-cbd6-4d45-b499-d28c68ae072e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">700 Then 25%</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases_e9d38540-754f-4a81-a6c2-3b2abadd77da_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded unconditional purchase obligation, purchases</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1f799119-78ee-4b70-b4eb-b1789431424a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d0d0034b-7a65-449f-81ba-19253cffdaaa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_Year12Member_019c5cb8-7115-70c8-8f94-dffaa43496ff_terseLabel_en-US" xlink:label="lab_dna_Year12Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 1 - 2</link:label>
    <link:label id="lab_dna_Year12Member_label_en-US" xlink:label="lab_dna_Year12Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year 1 - 2 [Member]</link:label>
    <link:label id="lab_dna_Year12Member_documentation_en-US" xlink:label="lab_dna_Year12Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year 1 - 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year12Member" xlink:href="dna-20251231.xsd#dna_Year12Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_Year12Member" xlink:to="lab_dna_Year12Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_458cded2-4766-4d8a-a8b4-10747e18e3c4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, Income tax penalties and interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd3ccb92-700e-4e00-bd0c-166a6d137c6a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d613024d-4d51-4aaf-9080-47ed359ae9bc_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f380b072-f802-40b7-a205-5d6d559f14d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_InducementPlanMember_66277b60-1bca-40dd-8f56-bd0341ad7f71_terseLabel_en-US" xlink:label="lab_dna_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:label id="lab_dna_InducementPlanMember_label_en-US" xlink:label="lab_dna_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan [Member]</link:label>
    <link:label id="lab_dna_InducementPlanMember_documentation_en-US" xlink:label="lab_dna_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_InducementPlanMember" xlink:href="dna-20251231.xsd#dna_InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_InducementPlanMember" xlink:to="lab_dna_InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05ae7d4b-43ce-4f78-9552-4c512dbf1a31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_f10ecdab-87a4-4478-b087-b243fa49d0fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_bca55bcc-bd15-427e-96ac-4dd5920a1ae7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_e43d381a-bede-47ae-a55c-94b63f5264cb_terseLabel_en-US" xlink:label="lab_dna_OperatingExpensesNotAllocatedToSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciling items to reconcile total segment operating loss to loss before income taxes:</link:label>
    <link:label id="lab_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_label_en-US" xlink:label="lab_dna_OperatingExpensesNotAllocatedToSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses not allocated to segments abstract</link:label>
    <link:label id="lab_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_documentation_en-US" xlink:label="lab_dna_OperatingExpensesNotAllocatedToSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating expenses not allocated to segments abstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract" xlink:href="dna-20251231.xsd#dna_OperatingExpensesNotAllocatedToSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract" xlink:to="lab_dna_OperatingExpensesNotAllocatedToSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_56e87c42-182a-4f52-acae-39290178e289_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_019c5ca4-7248-7c32-8a45-ddeb158aff73_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_FoodAndNutritionMember_c8152777-a376-43ca-8e92-c9893b8f545c_terseLabel_en-US" xlink:label="lab_dna_FoodAndNutritionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Food and nutrition</link:label>
    <link:label id="lab_dna_FoodAndNutritionMember_label_en-US" xlink:label="lab_dna_FoodAndNutritionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Food And Nutrition [Member]</link:label>
    <link:label id="lab_dna_FoodAndNutritionMember_documentation_en-US" xlink:label="lab_dna_FoodAndNutritionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Food And Nutrition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FoodAndNutritionMember" xlink:href="dna-20251231.xsd#dna_FoodAndNutritionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_FoodAndNutritionMember" xlink:to="lab_dna_FoodAndNutritionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_MarketableEquitySecuritiesMember_b7059729-05bc-4d5f-b89c-57ab74b209d6_terseLabel_en-US" xlink:label="lab_dna_MarketableEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_dna_MarketableEquitySecuritiesMember_label_en-US" xlink:label="lab_dna_MarketableEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Equity Securities [Member]</link:label>
    <link:label id="lab_dna_MarketableEquitySecuritiesMember_documentation_en-US" xlink:label="lab_dna_MarketableEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MarketableEquitySecuritiesMember" xlink:href="dna-20251231.xsd#dna_MarketableEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_MarketableEquitySecuritiesMember" xlink:to="lab_dna_MarketableEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d96bd94e-c4c1-4a4f-a354-142c0dcd5d97_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_068ebd78-ad23-4b1a-bc3a-ef2f22d58a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7b4fb66f-c787-449f-aa66-52a318e040c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f2347d32-2f63-4081-b4a6-bb233417a115_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net realized gains (losses) recognized on equity investments sold</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0f70e894-923f-4d5f-bdbf-afa3d9838ec3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_51ffc77a-d2ce-4604-8e27-d1dc3b682981_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_61730cfa-7459-46ce-a5f2-7e77fa4e636e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_IncomeTaxDisclosureLineItems_d8910848-b5ad-4e1b-9582-bfc88a734708_terseLabel_en-US" xlink:label="lab_dna_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_dna_IncomeTaxDisclosureLineItems_label_en-US" xlink:label="lab_dna_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_dna_IncomeTaxDisclosureLineItems_documentation_en-US" xlink:label="lab_dna_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureLineItems" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_IncomeTaxDisclosureLineItems" xlink:to="lab_dna_IncomeTaxDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_42ca19ea-e182-413b-87d9-9849573c8bdf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_4e7b79cb-5042-4681-aa76-491a61e34073_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlements and payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_73169bc4-bc44-410e-99cc-368175f6445d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount_019c5ccb-53f6-7563-9042-c69f9b5e58f6_terseLabel_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limitation on executive compensation</link:label>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount_label_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Amount</link:label>
    <link:label id="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount_documentation_en-US" xlink:label="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount" xlink:to="lab_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_Year14Member_019c5cb9-713a-76b5-a874-69c3d5693612_terseLabel_en-US" xlink:label="lab_dna_Year14Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 1 - 4</link:label>
    <link:label id="lab_dna_Year14Member_label_en-US" xlink:label="lab_dna_Year14Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year 1 - 4 [Member]</link:label>
    <link:label id="lab_dna_Year14Member_documentation_en-US" xlink:label="lab_dna_Year14Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year 1 - 4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year14Member" xlink:href="dna-20251231.xsd#dna_Year14Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_Year14Member" xlink:to="lab_dna_Year14Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_55472943-4251-4f4e-8d45-cbbf6fb4f412_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ad87bf85-312e-44e2-8bd6-e36056653f97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_CellEngineeringMember_019c5cb5-5c57-74d3-ad89-beaa66160bbe_terseLabel_en-US" xlink:label="lab_dna_CellEngineeringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cell Engineering</link:label>
    <link:label id="lab_dna_CellEngineeringMember_label_en-US" xlink:label="lab_dna_CellEngineeringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cell Engineering [Member]</link:label>
    <link:label id="lab_dna_CellEngineeringMember_documentation_en-US" xlink:label="lab_dna_CellEngineeringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cell Engineering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringMember" xlink:href="dna-20251231.xsd#dna_CellEngineeringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_CellEngineeringMember" xlink:to="lab_dna_CellEngineeringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct_bffdd0e8-05c4-466f-b4e7-ec659eefceef_terseLabel_en-US" xlink:label="lab_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty received from license or sale of a product</link:label>
    <link:label id="lab_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct_label_en-US" xlink:label="lab_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Received From License Or Sale Of a Product</link:label>
    <link:label id="lab_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct_documentation_en-US" xlink:label="lab_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Received From License Or Sale Of a Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct" xlink:href="dna-20251231.xsd#dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct" xlink:to="lab_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_019c5c90-8cc0-7114-acd5-3e87f9f16279_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SettlementOfContingentConsideration_256b00ec-68a1-460b-acc1-fabe130c90f0_terseLabel_en-US" xlink:label="lab_dna_SettlementOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued as settlement of contingent consideration liabilities</link:label>
    <link:label id="lab_dna_SettlementOfContingentConsideration_label_en-US" xlink:label="lab_dna_SettlementOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Of Contingent Consideration</link:label>
    <link:label id="lab_dna_SettlementOfContingentConsideration_documentation_en-US" xlink:label="lab_dna_SettlementOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement Of Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SettlementOfContingentConsideration" xlink:href="dna-20251231.xsd#dna_SettlementOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SettlementOfContingentConsideration" xlink:to="lab_dna_SettlementOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_d9dd8984-aa73-4321-a3fa-fc6f910f3820_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContracts_019c5ca4-7248-7bf4-aeec-cfa976b94fc0_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on contracts</link:label>
    <link:label id="lab_us-gaap_LossOnContracts_label_en-US" xlink:label="lab_us-gaap_LossOnContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContracts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossOnContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContracts" xlink:to="lab_us-gaap_LossOnContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a9ea80c4-836f-4127-a3bf-7c43f802d829_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_38ca02d9-a213-4e58-8f8f-2855526a5122_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_d238e9ca-6ec9-408e-882e-4d6800c08ed9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_MotifFoodworksIncMember_3d05fdf9-751a-4ffd-be4b-b71d149fb2c7_terseLabel_en-US" xlink:label="lab_dna_MotifFoodworksIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Motif FoodWorks, Inc.</link:label>
    <link:label id="lab_dna_MotifFoodworksIncMember_label_en-US" xlink:label="lab_dna_MotifFoodworksIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Motif FoodWorks, Inc. [Member]</link:label>
    <link:label id="lab_dna_MotifFoodworksIncMember_documentation_en-US" xlink:label="lab_dna_MotifFoodworksIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Motif FoodWorks, Inc.member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MotifFoodworksIncMember" xlink:href="dna-20251231.xsd#dna_MotifFoodworksIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_MotifFoodworksIncMember" xlink:to="lab_dna_MotifFoodworksIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_ece730d8-b70a-47be-b3b0-8d23ac1aa3df_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_25cbb65b-3231-4f37-9c0b-542bd01df4c4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_Year13Member_019c5cb8-7115-767e-8c10-91da30a91738_terseLabel_en-US" xlink:label="lab_dna_Year13Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 1 - 3</link:label>
    <link:label id="lab_dna_Year13Member_label_en-US" xlink:label="lab_dna_Year13Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year 1 - 3 [Member]</link:label>
    <link:label id="lab_dna_Year13Member_documentation_en-US" xlink:label="lab_dna_Year13Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year 1 - 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year13Member" xlink:href="dna-20251231.xsd#dna_Year13Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_Year13Member" xlink:to="lab_dna_Year13Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AgreementDomain_cf488e59-fa29-4310-b5c1-3d34ea76c78b_terseLabel_en-US" xlink:label="lab_dna_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_dna_AgreementDomain_label_en-US" xlink:label="lab_dna_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_dna_AgreementDomain_documentation_en-US" xlink:label="lab_dna_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgreementDomain" xlink:href="dna-20251231.xsd#dna_AgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AgreementDomain" xlink:to="lab_dna_AgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_d80ac6f1-aaeb-4cc5-aaed-70b88ed1ea25_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings and facilities</link:label>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_label_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturingFacilityMember" xlink:to="lab_us-gaap_ManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_cb50b989-1b11-4ad9-84f5-2dc00176a7d2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in exchange for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_OtherEquityInvesteesMember_2152d7a8-3669-4016-b56a-ce64b08bfd69_terseLabel_en-US" xlink:label="lab_dna_OtherEquityInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other equity investees</link:label>
    <link:label id="lab_dna_OtherEquityInvesteesMember_label_en-US" xlink:label="lab_dna_OtherEquityInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Investees [Member]</link:label>
    <link:label id="lab_dna_OtherEquityInvesteesMember_documentation_en-US" xlink:label="lab_dna_OtherEquityInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherEquityInvesteesMember" xlink:href="dna-20251231.xsd#dna_OtherEquityInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_OtherEquityInvesteesMember" xlink:to="lab_dna_OtherEquityInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_ContractualShortfallLiability_019c9017-ce5d-71e2-acf1-2925a8351ab0_terseLabel_en-US" xlink:label="lab_dna_ContractualShortfallLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual shortfall liability</link:label>
    <link:label id="lab_dna_ContractualShortfallLiability_label_en-US" xlink:label="lab_dna_ContractualShortfallLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Shortfall Liability</link:label>
    <link:label id="lab_dna_ContractualShortfallLiability_documentation_en-US" xlink:label="lab_dna_ContractualShortfallLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Shortfall Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContractualShortfallLiability" xlink:href="dna-20251231.xsd#dna_ContractualShortfallLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_ContractualShortfallLiability" xlink:to="lab_dna_ContractualShortfallLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_ee5547f2-60da-4825-8bc5-2ab15eb473eb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a390c561-91b9-4746-85e2-f1e36acd3189_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_14b2afa9-a8db-4a90-a929-9c4faf4fde7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of RSU and RSA Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3a95b401-3edd-4dc6-9f68-4caf9a66953d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix_019c5ca4-7248-7821-a363-5acdad004b05_terseLabel_en-US" xlink:label="lab_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded unconditional purchase obligation, to be paid, year six</link:label>
    <link:label id="lab_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix_label_en-US" xlink:label="lab_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Six</link:label>
    <link:label id="lab_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix_documentation_en-US" xlink:label="lab_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix" xlink:href="dna-20251231.xsd#dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix" xlink:to="lab_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c5ce9-349e-78c3-a9de-5045863d7df1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_5a3efc26-e675-4ede-8f04-963e4ee8a8b7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_26be0776-9870-4afa-84d1-5cb1809b1ead_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_SaleOfStockAuthorizedAmount_019c5ca6-87bc-7cd0-8d93-014898eca509_terseLabel_en-US" xlink:label="lab_dna_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, authorized amount</link:label>
    <link:label id="lab_dna_SaleOfStockAuthorizedAmount_label_en-US" xlink:label="lab_dna_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:label id="lab_dna_SaleOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_dna_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SaleOfStockAuthorizedAmount" xlink:href="dna-20251231.xsd#dna_SaleOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_SaleOfStockAuthorizedAmount" xlink:to="lab_dna_SaleOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_019c5c86-3427-72ff-a227-9233eea23d06_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dna_AgreementAxis_07da12cd-8001-46bf-a336-91fb01e6392b_terseLabel_en-US" xlink:label="lab_dna_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_dna_AgreementAxis_label_en-US" xlink:label="lab_dna_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_dna_AgreementAxis_documentation_en-US" xlink:label="lab_dna_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgreementAxis" xlink:href="dna-20251231.xsd#dna_AgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dna_AgreementAxis" xlink:to="lab_dna_AgreementAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>dna-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:52002c9c-7569-4bc2-a5b5-c24c0eeac02a,g:42911b52-7f60-440e-93d3-9584b5edbad8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/Cover" xlink:type="simple" xlink:href="dna-20251231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_de84f256-acd1-417a-a6f1-90f75e2483fa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_7a8684e8-3685-4d09-b453-bafff921d43c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_de84f256-acd1-417a-a6f1-90f75e2483fa" xlink:to="loc_dei_DocumentInformationTable_7a8684e8-3685-4d09-b453-bafff921d43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cef99515-8855-4fc5-a234-c2df86b73eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_7a8684e8-3685-4d09-b453-bafff921d43c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cef99515-8855-4fc5-a234-c2df86b73eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cef99515-8855-4fc5-a234-c2df86b73eb4" xlink:to="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3a4b70b2-0f59-4ebe-9c6e-1a8ca709f73a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:to="loc_us-gaap_CommonClassAMember_3a4b70b2-0f59-4ebe-9c6e-1a8ca709f73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_6f1dd95a-a2df-4b1e-944e-31d96d55e62a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:to="loc_us-gaap_CommonClassBMember_6f1dd95a-a2df-4b1e-944e-31d96d55e62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvotingCommonStockMember_2476eb81-d734-4c57-8fad-ad2a4a12c2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c810ef36-28c3-4960-b371-254f78fb4fcf" xlink:to="loc_us-gaap_NonvotingCommonStockMember_2476eb81-d734-4c57-8fad-ad2a4a12c2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_7a8684e8-3685-4d09-b453-bafff921d43c" xlink:to="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_042b89eb-9fcc-4a31-82a5-6004fab5c6cf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentType_042b89eb-9fcc-4a31-82a5-6004fab5c6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_af3d6dad-3e43-446f-ae07-be22f7cba2ae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentAnnualReport_af3d6dad-3e43-446f-ae07-be22f7cba2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_85bf9cb7-0e94-4cc9-9673-a7861906a888" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentPeriodEndDate_85bf9cb7-0e94-4cc9-9673-a7861906a888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_977ade8b-64a6-45ec-ae5e-6df1def095db" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_CurrentFiscalYearEndDate_977ade8b-64a6-45ec-ae5e-6df1def095db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_981a6a81-b05b-4d35-98dd-ec9f5d840609" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentTransitionReport_981a6a81-b05b-4d35-98dd-ec9f5d840609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0f4626d5-3d5b-4fc9-9a1f-dcd098518d6c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityFileNumber_0f4626d5-3d5b-4fc9-9a1f-dcd098518d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5158f889-1e20-4239-a1ab-f6722d242c02" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityRegistrantName_5158f889-1e20-4239-a1ab-f6722d242c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f3cafa1a-8ba4-4f56-88cb-5fe53bc992e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f3cafa1a-8ba4-4f56-88cb-5fe53bc992e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_51d7dbf3-4576-4ec6-b75a-0a563da91294" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityTaxIdentificationNumber_51d7dbf3-4576-4ec6-b75a-0a563da91294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f85eefb2-cd34-4a44-a97b-861bea1f60be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressAddressLine1_f85eefb2-cd34-4a44-a97b-861bea1f60be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_db3dc2ea-608f-463f-95fe-772e1c87c5c6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressAddressLine2_db3dc2ea-608f-463f-95fe-772e1c87c5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f728e6cf-015f-4207-8009-6bca8009914d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressCityOrTown_f728e6cf-015f-4207-8009-6bca8009914d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_03887e3a-dcba-4f45-a015-cddbeef915fd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressStateOrProvince_03887e3a-dcba-4f45-a015-cddbeef915fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bc003bdc-0c0a-4ff9-a337-e3411eb5b768" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityAddressPostalZipCode_bc003bdc-0c0a-4ff9-a337-e3411eb5b768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_56c76648-2410-4b3f-b4db-24c72e8273ad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_CityAreaCode_56c76648-2410-4b3f-b4db-24c72e8273ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4fc5bbe6-d62d-456d-af94-0e71bda28dbf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_LocalPhoneNumber_4fc5bbe6-d62d-456d-af94-0e71bda28dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a02a832-ea50-4f0d-b09d-f9d682c7bc0c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_Security12bTitle_4a02a832-ea50-4f0d-b09d-f9d682c7bc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ffdc0466-d73b-48db-8c28-6f9fb57bf4aa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_TradingSymbol_ffdc0466-d73b-48db-8c28-6f9fb57bf4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6d55b202-aba3-4c4a-ac4f-fb7985890d5f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_SecurityExchangeName_6d55b202-aba3-4c4a-ac4f-fb7985890d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7bc7e58e-9da4-48c6-8495-77b887358952" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7bc7e58e-9da4-48c6-8495-77b887358952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d854d89e-f45e-46f5-a877-49cbecec1625" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityVoluntaryFilers_d854d89e-f45e-46f5-a877-49cbecec1625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8583a3b6-f7a2-40c8-9ffb-fbd0f9a97dbd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityCurrentReportingStatus_8583a3b6-f7a2-40c8-9ffb-fbd0f9a97dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fe70b27f-cee5-4d52-8aae-86ac9d291c96" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityInteractiveDataCurrent_fe70b27f-cee5-4d52-8aae-86ac9d291c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_07daf951-0ca5-4a94-8ad6-c0aa2efa44e0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityFilerCategory_07daf951-0ca5-4a94-8ad6-c0aa2efa44e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dff4ab27-ec4f-4c05-81fc-ee1712535355" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntitySmallBusiness_dff4ab27-ec4f-4c05-81fc-ee1712535355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_332494ae-e32f-4de7-91a4-6112a49086d3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityEmergingGrowthCompany_332494ae-e32f-4de7-91a4-6112a49086d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_f11c7dae-0228-4c7e-838a-9ff2bfd795e4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_f11c7dae-0228-4c7e-838a-9ff2bfd795e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_0dca4b85-a832-4144-969c-c1651c14166e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_0dca4b85-a832-4144-969c-c1651c14166e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6ee8df24-a9fc-42c2-8b2a-d119d7614325" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityShellCompany_6ee8df24-a9fc-42c2-8b2a-d119d7614325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_88f05479-72eb-409a-a549-eb4f9ccb323c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityPublicFloat_88f05479-72eb-409a-a549-eb4f9ccb323c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d17b3948-7533-4cac-bc52-79208dc0b78a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d17b3948-7533-4cac-bc52-79208dc0b78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_87701677-fad8-43c5-b9b8-5a21ee4d90a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_87701677-fad8-43c5-b9b8-5a21ee4d90a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ba4cad89-06bf-4e6a-84bf-1531fccc1d5f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_AmendmentFlag_ba4cad89-06bf-4e6a-84bf-1531fccc1d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7dd79db6-849c-4dca-b7d0-1caf7d92a3a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentFiscalYearFocus_7dd79db6-849c-4dca-b7d0-1caf7d92a3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_dc96d48c-2766-454b-9080-29e927db378e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_dc96d48c-2766-454b-9080-29e927db378e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6dcb9f85-f23b-4170-aa5f-5376203bf1df" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_392d7161-2123-4e7f-952c-3fa9b0b1312b" xlink:to="loc_dei_EntityCentralIndexKey_6dcb9f85-f23b-4170-aa5f-5376203bf1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AuditInformation" xlink:type="simple" xlink:href="dna-20251231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_AuditInformationAbstract_5e4ef552-0988-47d4-ac16-cc4b801c019b" xlink:href="dna-20251231.xsd#dna_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_d24f464b-09e5-427b-8b19-28a1284465a6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_AuditInformationAbstract_5e4ef552-0988-47d4-ac16-cc4b801c019b" xlink:to="loc_dei_AuditorFirmId_d24f464b-09e5-427b-8b19-28a1284465a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_ff0b4fc9-48eb-48be-87ec-c79dc146e4f8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_AuditInformationAbstract_5e4ef552-0988-47d4-ac16-cc4b801c019b" xlink:to="loc_dei_AuditorName_ff0b4fc9-48eb-48be-87ec-c79dc146e4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_70bf854d-64fe-452d-bf0f-29ed2121a458" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_AuditInformationAbstract_5e4ef552-0988-47d4-ac16-cc4b801c019b" xlink:to="loc_dei_AuditorLocation_70bf854d-64fe-452d-bf0f-29ed2121a458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f110331a-494d-4623-9fc4-219fc2951228" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4b9d2e06-acb0-4c6b-b1e4-9f88293d5441" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f110331a-494d-4623-9fc4-219fc2951228" xlink:to="loc_us-gaap_AssetsAbstract_4b9d2e06-acb0-4c6b-b1e4-9f88293d5441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3ee03c1e-c3dd-4467-8ecf-89927c8bcd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b9d2e06-acb0-4c6b-b1e4-9f88293d5441" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3ee03c1e-c3dd-4467-8ecf-89927c8bcd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_62895461-0fcd-437e-82e9-0931bb56acfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3ee03c1e-c3dd-4467-8ecf-89927c8bcd2d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_62895461-0fcd-437e-82e9-0931bb56acfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_019c4ef9-0cda-745c-bc41-a7c677a9ea07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3ee03c1e-c3dd-4467-8ecf-89927c8bcd2d" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_019c4ef9-0cda-745c-bc41-a7c677a9ea07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9906b139-ba77-477b-8bdd-ae26d6d9e04b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3ee03c1e-c3dd-4467-8ecf-89927c8bcd2d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9906b139-ba77-477b-8bdd-ae26d6d9e04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_61d0a676-1384-42af-bb25-0bddf54bfc97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3ee03c1e-c3dd-4467-8ecf-89927c8bcd2d" xlink:to="loc_us-gaap_AccountsReceivableNet_61d0a676-1384-42af-bb25-0bddf54bfc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3fdb16de-07c2-40bc-888c-822ab0f974a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3ee03c1e-c3dd-4467-8ecf-89927c8bcd2d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3fdb16de-07c2-40bc-888c-822ab0f974a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fe7765b5-55a4-4f2d-9713-2db7810be5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3ee03c1e-c3dd-4467-8ecf-89927c8bcd2d" xlink:to="loc_us-gaap_AssetsCurrent_fe7765b5-55a4-4f2d-9713-2db7810be5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0257f23-d482-4074-969a-1d900dbaa226" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b9d2e06-acb0-4c6b-b1e4-9f88293d5441" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0257f23-d482-4074-969a-1d900dbaa226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3b9f3944-ce30-4644-a310-d2c818afefd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b9d2e06-acb0-4c6b-b1e4-9f88293d5441" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3b9f3944-ce30-4644-a310-d2c818afefd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_9e82ebca-6407-4db7-893a-ff15f9914e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b9d2e06-acb0-4c6b-b1e4-9f88293d5441" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_9e82ebca-6407-4db7-893a-ff15f9914e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd8aab2a-95a3-452b-a0a6-5db4908adcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b9d2e06-acb0-4c6b-b1e4-9f88293d5441" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd8aab2a-95a3-452b-a0a6-5db4908adcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1792f3a9-9f69-4800-b96e-9f4b146dc128" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b9d2e06-acb0-4c6b-b1e4-9f88293d5441" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1792f3a9-9f69-4800-b96e-9f4b146dc128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_03ba4084-cfc9-47e8-95ee-99cbea274688" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4b9d2e06-acb0-4c6b-b1e4-9f88293d5441" xlink:to="loc_us-gaap_Assets_03ba4084-cfc9-47e8-95ee-99cbea274688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4335068e-b3fd-496f-9058-30e92b8e2970" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f110331a-494d-4623-9fc4-219fc2951228" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4335068e-b3fd-496f-9058-30e92b8e2970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2818162e-fd1e-43a2-9f34-fbbf089d23a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4335068e-b3fd-496f-9058-30e92b8e2970" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2818162e-fd1e-43a2-9f34-fbbf089d23a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a186c1c9-c581-46d1-9b23-a44ccd1e859b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2818162e-fd1e-43a2-9f34-fbbf089d23a3" xlink:to="loc_us-gaap_AccountsPayableCurrent_a186c1c9-c581-46d1-9b23-a44ccd1e859b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d61cfb9a-8e78-4c89-a4bf-d808e8f5edbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2818162e-fd1e-43a2-9f34-fbbf089d23a3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d61cfb9a-8e78-4c89-a4bf-d808e8f5edbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0a74e6b4-73b9-4c77-8b78-a9d362f992ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2818162e-fd1e-43a2-9f34-fbbf089d23a3" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0a74e6b4-73b9-4c77-8b78-a9d362f992ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c2a3c215-60de-473d-ac56-dc960ca41ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2818162e-fd1e-43a2-9f34-fbbf089d23a3" xlink:to="loc_us-gaap_LiabilitiesCurrent_c2a3c215-60de-473d-ac56-dc960ca41ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_4d86e41f-91f2-4542-9972-8cde2595f244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4335068e-b3fd-496f-9058-30e92b8e2970" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_4d86e41f-91f2-4542-9972-8cde2595f244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_88356fb0-32ce-48a8-9dbf-151469c3c6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4d86e41f-91f2-4542-9972-8cde2595f244" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_88356fb0-32ce-48a8-9dbf-151469c3c6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1644b477-896a-4f6f-8caf-d16142ca9337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4d86e41f-91f2-4542-9972-8cde2595f244" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1644b477-896a-4f6f-8caf-d16142ca9337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_682c8af8-9624-4b55-ac73-3b10c26d5615" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4d86e41f-91f2-4542-9972-8cde2595f244" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_682c8af8-9624-4b55-ac73-3b10c26d5615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d3be4ac8-0b03-417d-9bc1-626ff3b3a447" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4335068e-b3fd-496f-9058-30e92b8e2970" xlink:to="loc_us-gaap_Liabilities_d3be4ac8-0b03-417d-9bc1-626ff3b3a447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d2ea97aa-3c2c-4916-a507-71343f12047f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4335068e-b3fd-496f-9058-30e92b8e2970" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d2ea97aa-3c2c-4916-a507-71343f12047f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3e054869-ccfe-4dd4-81bb-d58e3f571964" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4335068e-b3fd-496f-9058-30e92b8e2970" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3e054869-ccfe-4dd4-81bb-d58e3f571964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f11454df-9dcc-4399-a883-bd02c0ec98ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3e054869-ccfe-4dd4-81bb-d58e3f571964" xlink:to="loc_us-gaap_PreferredStockValue_f11454df-9dcc-4399-a883-bd02c0ec98ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0576cef7-c69e-44ba-8188-a320282042af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3e054869-ccfe-4dd4-81bb-d58e3f571964" xlink:to="loc_us-gaap_CommonStockValue_0576cef7-c69e-44ba-8188-a320282042af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b29e9615-5549-4cb5-8b8d-051f991b7c34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3e054869-ccfe-4dd4-81bb-d58e3f571964" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b29e9615-5549-4cb5-8b8d-051f991b7c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89cd3ccb-dd29-4bb5-936d-3ac90915bfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3e054869-ccfe-4dd4-81bb-d58e3f571964" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89cd3ccb-dd29-4bb5-936d-3ac90915bfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9b21e841-d1fe-4b7f-b24e-2609a368657b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3e054869-ccfe-4dd4-81bb-d58e3f571964" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9b21e841-d1fe-4b7f-b24e-2609a368657b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5f75290-1b74-4723-9cae-39cc0ee539f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3e054869-ccfe-4dd4-81bb-d58e3f571964" xlink:to="loc_us-gaap_StockholdersEquity_f5f75290-1b74-4723-9cae-39cc0ee539f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e2f430c-d1d3-4649-9c23-6893d7f63329" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4335068e-b3fd-496f-9058-30e92b8e2970" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e2f430c-d1d3-4649-9c23-6893d7f63329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_91723a54-5abf-4370-b127-64069b1297ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d2df620b-2f40-475e-b9d3-e73a8bf8e619" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_91723a54-5abf-4370-b127-64069b1297ba" xlink:to="loc_us-gaap_StatementTable_d2df620b-2f40-475e-b9d3-e73a8bf8e619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfc19669-15a1-4884-82e3-1af61367807c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d2df620b-2f40-475e-b9d3-e73a8bf8e619" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfc19669-15a1-4884-82e3-1af61367807c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_62b179d8-6acb-4595-a720-157f4481db6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfc19669-15a1-4884-82e3-1af61367807c" xlink:to="loc_us-gaap_RelatedPartyDomain_62b179d8-6acb-4595-a720-157f4481db6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_96929a93-8163-4b09-a39d-fe25942f0d34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_62b179d8-6acb-4595-a720-157f4481db6a" xlink:to="loc_us-gaap_RelatedPartyMember_96929a93-8163-4b09-a39d-fe25942f0d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d2df620b-2f40-475e-b9d3-e73a8bf8e619" xlink:to="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a3c23d95-af92-40f1-ac14-be8a3efb6608" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a3c23d95-af92-40f1-ac14-be8a3efb6608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7df3324f-83a3-4674-af89-8109e8f6af79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7df3324f-83a3-4674-af89-8109e8f6af79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_54f44cf5-1b0a-45fc-8b92-aefcac258e65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_54f44cf5-1b0a-45fc-8b92-aefcac258e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e5b6ba09-4424-4522-ada4-e92b56e38fec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e5b6ba09-4424-4522-ada4-e92b56e38fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_476cf4af-63bd-43a0-b81f-573d156035c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_476cf4af-63bd-43a0-b81f-573d156035c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_eb522fec-f709-4b45-b66b-71f27be9c564" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b93cb8db-39c6-48b0-b0d6-0fb5101afbe8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_eb522fec-f709-4b45-b66b-71f27be9c564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4aadd8dc-86a8-4359-95be-d47026f53187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_423753ab-013e-4f22-831f-c9b5e8e066b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4aadd8dc-86a8-4359-95be-d47026f53187" xlink:to="loc_us-gaap_StatementTable_423753ab-013e-4f22-831f-c9b5e8e066b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c3905eb5-204d-415a-a7f6-40d7df20f6b9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_423753ab-013e-4f22-831f-c9b5e8e066b2" xlink:to="loc_srt_ProductOrServiceAxis_c3905eb5-204d-415a-a7f6-40d7df20f6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c3905eb5-204d-415a-a7f6-40d7df20f6b9" xlink:to="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringRevenueMember_104a1aae-98f3-4db2-ab4a-d37c3992bbc1" xlink:href="dna-20251231.xsd#dna_CellEngineeringRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:to="loc_dna_CellEngineeringRevenueMember_104a1aae-98f3-4db2-ab4a-d37c3992bbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_8952d83a-9095-4662-abd0-56548af4d3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:to="loc_us-gaap_ServiceMember_8952d83a-9095-4662-abd0-56548af4d3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2cb6a374-c384-4eed-8f29-793127eb5a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:to="loc_us-gaap_ProductMember_2cb6a374-c384-4eed-8f29-793127eb5a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ee70d815-90b0-4e44-9d33-c1541e71b7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9fba1079-10ce-4800-bb30-ee77b9b2c978" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ee70d815-90b0-4e44-9d33-c1541e71b7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_423753ab-013e-4f22-831f-c9b5e8e066b2" xlink:to="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8668557-1ed8-419e-b871-147a79ea9451" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8668557-1ed8-419e-b871-147a79ea9451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5920d920-2a09-41dc-85b5-8c354c623c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5920d920-2a09-41dc-85b5-8c354c623c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_489d15c1-15ff-4e35-bbd4-fb60f366ec92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_489d15c1-15ff-4e35-bbd4-fb60f366ec92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c00ad635-8c3b-436a-b117-d34ae7c033eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c00ad635-8c3b-436a-b117-d34ae7c033eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_e41b74e2-3ec9-4999-ab2f-d9edf1d9f7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_e41b74e2-3ec9-4999-ab2f-d9edf1d9f7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0f50657a-d99d-4e80-b0dc-ea34feeed10d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0f50657a-d99d-4e80-b0dc-ea34feeed10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_1b556974-8f74-4df9-86cc-e099cba361ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_1b556974-8f74-4df9-86cc-e099cba361ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8b8160e0-84a1-4b49-921a-6f4d4ca974e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3a337f1d-d865-4db8-bbbb-47672a280cfd" xlink:to="loc_us-gaap_OperatingExpenses_8b8160e0-84a1-4b49-921a-6f4d4ca974e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3c5b6472-6738-48eb-b027-7ca70006abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_OperatingIncomeLoss_3c5b6472-6738-48eb-b027-7ca70006abbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_17bb52e5-0850-4333-9767-e86e137dd0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_InterestIncomeOther_17bb52e5-0850-4333-9767-e86e137dd0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_b98bf6f2-98b3-4432-a013-3db823fa3151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_InterestExpenseNonoperating_b98bf6f2-98b3-4432-a013-3db823fa3151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_937f67b7-53ce-4067-8ad6-0a6e9f8c3d07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_937f67b7-53ce-4067-8ad6-0a6e9f8c3d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_8bbc9e5f-d5ea-4ecb-9b83-eaa743a42569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_GainLossOnInvestments_8bbc9e5f-d5ea-4ecb-9b83-eaa743a42569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_141d8348-9660-438d-a2e8-9cbd44d9a566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_141d8348-9660-438d-a2e8-9cbd44d9a566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_6f49eddf-90af-40a3-9c4d-3d0a269b8358" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_6f49eddf-90af-40a3-9c4d-3d0a269b8358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_5e5f9cf1-69f4-414a-b639-a90536634c32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_5e5f9cf1-69f4-414a-b639-a90536634c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2ef9c493-b129-42ce-872e-f2a0b3ae66cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2e4d88c2-7bd0-43c3-9842-ed99f12a5462" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2ef9c493-b129-42ce-872e-f2a0b3ae66cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4338c8d6-a5f9-4972-b47b-bfe97faa6859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4338c8d6-a5f9-4972-b47b-bfe97faa6859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_61d6e4cf-1342-4fb6-9128-4242b0084e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_61d6e4cf-1342-4fb6-9128-4242b0084e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c4efa-94ed-7c4c-ac50-59af7a5aaa86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_NetIncomeLoss_019c4efa-94ed-7c4c-ac50-59af7a5aaa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a2f8f1e1-fb75-4fbe-ad85-8350b2372b89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a2f8f1e1-fb75-4fbe-ad85-8350b2372b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6e59624f-02b3-4085-9995-201a217890ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2f8f1e1-fb75-4fbe-ad85-8350b2372b89" xlink:to="loc_us-gaap_EarningsPerShareBasic_6e59624f-02b3-4085-9995-201a217890ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a7353990-0b01-4f26-9d45-9a7e32ef8071" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2f8f1e1-fb75-4fbe-ad85-8350b2372b89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a7353990-0b01-4f26-9d45-9a7e32ef8071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_efe32c16-9080-4d3a-99db-31524eb5e0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_efe32c16-9080-4d3a-99db-31524eb5e0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e8f5344b-b453-467a-bad3-9e7fbc7667cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_efe32c16-9080-4d3a-99db-31524eb5e0fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e8f5344b-b453-467a-bad3-9e7fbc7667cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c68cd-a8d3-72e5-bb83-064d6b98acfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_efe32c16-9080-4d3a-99db-31524eb5e0fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c68cd-a8d3-72e5-bb83-064d6b98acfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_952df6cb-4bfb-4804-8acc-1eadd301e336" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0754c6d4-8b84-49ad-a146-6c0b6d5afd8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_952df6cb-4bfb-4804-8acc-1eadd301e336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c4efa-1c84-795b-a7bb-8b0d63f02989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_952df6cb-4bfb-4804-8acc-1eadd301e336" xlink:to="loc_us-gaap_NetIncomeLoss_019c4efa-1c84-795b-a7bb-8b0d63f02989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_952df6cb-4bfb-4804-8acc-1eadd301e336" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-f535-7c3c-a1dd-5b83f403ee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-f535-7c3c-a1dd-5b83f403ee2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_85571dff-d458-4433-992a-dd3dd473d547" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_85571dff-d458-4433-992a-dd3dd473d547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-8084-7902-85dd-c532a4bc719e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019c4efd-8084-7902-85dd-c532a4bc719e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7b067bda-e44b-4cb2-82d4-eadc2b711579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract_4e8a3844-6384-47fa-ba9f-daa6fe81f789" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7b067bda-e44b-4cb2-82d4-eadc2b711579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e339b8d-41cd-4d56-b47c-f06e8f39174c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_952df6cb-4bfb-4804-8acc-1eadd301e336" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e339b8d-41cd-4d56-b47c-f06e8f39174c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_04ec0992-a4e3-42e5-9c8a-3d19376163c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e6170364-da8b-408a-9e3d-f4ab5b8b28e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_04ec0992-a4e3-42e5-9c8a-3d19376163c5" xlink:to="loc_us-gaap_StatementTable_e6170364-da8b-408a-9e3d-f4ab5b8b28e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b703d51-6965-4253-8d64-dcd964376401" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e6170364-da8b-408a-9e3d-f4ab5b8b28e3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b703d51-6965-4253-8d64-dcd964376401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6efa734d-ebbc-4e72-9b65-9fb774ea4a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b703d51-6965-4253-8d64-dcd964376401" xlink:to="loc_us-gaap_RelatedPartyDomain_6efa734d-ebbc-4e72-9b65-9fb774ea4a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_c054769a-3d37-43c9-88c2-12593c412074" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6efa734d-ebbc-4e72-9b65-9fb774ea4a57" xlink:to="loc_us-gaap_RelatedPartyMember_c054769a-3d37-43c9-88c2-12593c412074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_342478a4-a4c1-4405-99c0-341c1036edf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e6170364-da8b-408a-9e3d-f4ab5b8b28e3" xlink:to="loc_us-gaap_StatementLineItems_342478a4-a4c1-4405-99c0-341c1036edf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb889d43-d854-4104-874f-15076a013224" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_342478a4-a4c1-4405-99c0-341c1036edf0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb889d43-d854-4104-874f-15076a013224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e4747663-1f47-45ec-8059-a3828658b098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f4c0d99c-7fac-4a5a-9681-dbd3fc8f5950" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e4747663-1f47-45ec-8059-a3828658b098" xlink:to="loc_us-gaap_StatementTable_f4c0d99c-7fac-4a5a-9681-dbd3fc8f5950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ed08ea5-27c6-4189-ad86-99219cfe1e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f4c0d99c-7fac-4a5a-9681-dbd3fc8f5950" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ed08ea5-27c6-4189-ad86-99219cfe1e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ed08ea5-27c6-4189-ad86-99219cfe1e3f" xlink:to="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fa5a9141-9e45-4e33-a420-4e79d5cc573d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:to="loc_us-gaap_CommonStockMember_fa5a9141-9e45-4e33-a420-4e79d5cc573d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_632080cf-a46a-46a2-8f58-e9b08858e43b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_632080cf-a46a-46a2-8f58-e9b08858e43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_90f758f9-ae85-4545-9d35-1821544791e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:to="loc_us-gaap_RetainedEarningsMember_90f758f9-ae85-4545-9d35-1821544791e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d75059cf-2ef2-4501-a9bb-d0557ca913ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_67a21f01-8ef5-4987-b9d1-1b93a19d9255" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d75059cf-2ef2-4501-a9bb-d0557ca913ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_766e4fd3-86d5-400e-92fc-f61ceafd4cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f4c0d99c-7fac-4a5a-9681-dbd3fc8f5950" xlink:to="loc_us-gaap_StatementLineItems_766e4fd3-86d5-400e-92fc-f61ceafd4cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_766e4fd3-86d5-400e-92fc-f61ceafd4cfd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5fe79e9e-b066-47ae-92f2-8546208abb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5fe79e9e-b066-47ae-92f2-8546208abb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c4f00-3516-7d1e-a3d3-7da777632bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockholdersEquity_019c4f00-3516-7d1e-a3d3-7da777632bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_14b18154-c802-43b9-a943-9f93998480a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_14b18154-c802-43b9-a943-9f93998480a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_7c1946e2-86d4-4959-ad48-c3609c92e72f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_7c1946e2-86d4-4959-ad48-c3609c92e72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e128deca-1137-470e-a1e1-7bcf1f7d6b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e128deca-1137-470e-a1e1-7bcf1f7d6b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockAwardForfeitures_019c68f8-d001-762e-84b2-2f0fdf29c11a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockAwardForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_RestrictedStockAwardForfeitures_019c68f8-d001-762e-84b2-2f0fdf29c11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_97455451-80e2-4f26-a973-466ff7090959" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_97455451-80e2-4f26-a973-466ff7090959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SettlementOfContingentConsiderationSharesRestrictedStock_e44f2a3b-6e61-463e-947f-99573b64668a" xlink:href="dna-20251231.xsd#dna_SettlementOfContingentConsiderationSharesRestrictedStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_dna_SettlementOfContingentConsiderationSharesRestrictedStock_e44f2a3b-6e61-463e-947f-99573b64668a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SettlementOfContingentConsiderationValueRestrictedStock_3a632f4e-c34e-4e20-a1ae-ff3f98723f9d" xlink:href="dna-20251231.xsd#dna_SettlementOfContingentConsiderationValueRestrictedStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_dna_SettlementOfContingentConsiderationValueRestrictedStock_3a632f4e-c34e-4e20-a1ae-ff3f98723f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_036194e7-1cc5-4837-ad04-ba25740bcb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_036194e7-1cc5-4837-ad04-ba25740bcb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f0c4d094-9e7c-4e8c-8726-3aa1f2b8d9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f0c4d094-9e7c-4e8c-8726-3aa1f2b8d9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ded538f8-8d0d-4898-8d08-9459644f3b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ded538f8-8d0d-4898-8d08-9459644f3b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0ddb11d-abcc-4ee4-bbf8-026bbd0679b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e0ddb11d-abcc-4ee4-bbf8-026bbd0679b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23ea668a-7e27-427f-a6bb-fd2fb717a4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_23ea668a-7e27-427f-a6bb-fd2fb717a4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_02556bf0-3678-4b8c-9166-f88809c8233c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_02556bf0-3678-4b8c-9166-f88809c8233c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_08340fa8-676d-428d-8f26-5cae47bf05ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_08340fa8-676d-428d-8f26-5cae47bf05ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019c4f03-27a2-7ec4-bfac-b70db48c8eea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019c4f03-27a2-7ec4-bfac-b70db48c8eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c4f03-6644-7416-84b3-217c5dae7907" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_NetIncomeLoss_019c4f03-6644-7416-84b3-217c5dae7907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_addafa99-9635-4efd-ae18-38ddb9c59e48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_addafa99-9635-4efd-ae18-38ddb9c59e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c4f02-77f6-76e5-b086-4b293747e00d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019c4f02-77f6-76e5-b086-4b293747e00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f87fdce8-9cbf-4cec-bebe-48a3f8bac989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f87fdce8-9cbf-4cec-bebe-48a3f8bac989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019c4f00-afe9-75ad-aea7-57da868f1899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b882a9ff-c3f4-453c-b633-1f01a8d024ad" xlink:to="loc_us-gaap_StockholdersEquity_019c4f00-afe9-75ad-aea7-57da868f1899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c4f07-b929-7238-90bc-576a5bc61d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StockIssuanceCosts_019c4f07-cced-71cc-afa3-eb1e2b70efa9" xlink:href="dna-20251231.xsd#dna_StockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c4f07-b929-7238-90bc-576a5bc61d9e" xlink:to="loc_dna_StockIssuanceCosts_019c4f07-cced-71cc-afa3-eb1e2b70efa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SharesReleaseFromEscrowDuringPeriod_019c4f07-cced-79d0-a8f4-4e371c65e33f" xlink:href="dna-20251231.xsd#dna_SharesReleaseFromEscrowDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c4f07-b929-7238-90bc-576a5bc61d9e" xlink:to="loc_dna_SharesReleaseFromEscrowDuringPeriod_019c4f07-cced-79d0-a8f4-4e371c65e33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_019c68d2-0efe-7a8f-8879-c3cc54fd6532" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019c4f07-b929-7238-90bc-576a5bc61d9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_019c68d2-0efe-7a8f-8879-c3cc54fd6532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40ac5127-3ef9-44e8-bd70-c32ea81f0bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40ac5127-3ef9-44e8-bd70-c32ea81f0bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c07c4cae-1277-4444-9c9c-c3798b114a16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40ac5127-3ef9-44e8-bd70-c32ea81f0bd4" xlink:to="loc_us-gaap_ProfitLoss_c07c4cae-1277-4444-9c9c-c3798b114a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40ac5127-3ef9-44e8-bd70-c32ea81f0bd4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_290c6fd3-aa0f-4953-b67e-826030597280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_DepreciationAndAmortization_290c6fd3-aa0f-4953-b67e-826030597280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_58ddd0c5-073b-415a-a3a7-c6f791db4efe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_ShareBasedCompensation_58ddd0c5-073b-415a-a3a7-c6f791db4efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_fff2ec06-c178-4f9f-abb5-bab260af4e28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_fff2ec06-c178-4f9f-abb5-bab260af4e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_f85b833a-f108-499c-b7a5-53567e057ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_RestructuringCosts_f85b833a-f108-499c-b7a5-53567e057ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NoncashCustomerConsideration_6e8f2296-6519-4a72-b16a-e0bfe3289fef" xlink:href="dna-20251231.xsd#dna_NoncashCustomerConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_dna_NoncashCustomerConsideration_6e8f2296-6519-4a72-b16a-e0bfe3289fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d1ee8a6c-0e34-47ae-ab47-264f219b4565" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d1ee8a6c-0e34-47ae-ab47-264f219b4565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_7922515e-985e-4bb4-abc8-ded708604ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_GainLossOnInvestments_7922515e-985e-4bb4-abc8-ded708604ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ChangesInFairValueOfLoansReceivable_bc1fdf61-6226-4d1b-96c5-f9d0d135e4fb" xlink:href="dna-20251231.xsd#dna_ChangesInFairValueOfLoansReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_dna_ChangesInFairValueOfLoansReceivable_bc1fdf61-6226-4d1b-96c5-f9d0d135e4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a96dd872-a98d-477a-a584-032aadd5dcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a96dd872-a98d-477a-a584-032aadd5dcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_33de860e-c634-48fd-84df-34ff0bb03257" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_33de860e-c634-48fd-84df-34ff0bb03257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_f57f941b-6554-4716-8833-0b673147f0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_f57f941b-6554-4716-8833-0b673147f0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_f57155f6-5956-4f85-890e-86a644d542c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_f57155f6-5956-4f85-890e-86a644d542c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_da792fec-02b3-4739-b7e2-b6e67943bad7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_da792fec-02b3-4739-b7e2-b6e67943bad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2584aaae-a379-41df-afc8-4f2f529edd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_2584aaae-a379-41df-afc8-4f2f529edd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_82b2464f-5387-40fd-a112-1d493252b103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_82b2464f-5387-40fd-a112-1d493252b103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NoncashInProcessResearchAndDevelopment_4696f974-a726-4358-913f-e769ea63e0b0" xlink:href="dna-20251231.xsd#dna_NoncashInProcessResearchAndDevelopment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_dna_NoncashInProcessResearchAndDevelopment_4696f974-a726-4358-913f-e769ea63e0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccretionOfDiscountOnMarketableSecurities_019c5c68-aa37-775d-9bf8-8107dd55e5a2" xlink:href="dna-20251231.xsd#dna_AccretionOfDiscountOnMarketableSecurities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_dna_AccretionOfDiscountOnMarketableSecurities_019c5c68-aa37-775d-9bf8-8107dd55e5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_4ebc8586-57b8-4531-807a-237bb7321e24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5dc1f1f9-b651-4064-8511-b864b76a12b9" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_4ebc8586-57b8-4531-807a-237bb7321e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40ac5127-3ef9-44e8-bd70-c32ea81f0bd4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9f3bd006-662e-476b-853c-c4a1c0818a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9f3bd006-662e-476b-853c-c4a1c0818a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ab0f6193-8765-457b-99de-5b4af99895ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ab0f6193-8765-457b-99de-5b4af99895ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncreaseDecreaseRightOfUseAssets_cb6f0344-9821-4135-b2cf-d4212ea7bebd" xlink:href="dna-20251231.xsd#dna_IncreaseDecreaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:to="loc_dna_IncreaseDecreaseRightOfUseAssets_cb6f0344-9821-4135-b2cf-d4212ea7bebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c3dad1e4-e203-4e04-9239-f7db7a507df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c3dad1e4-e203-4e04-9239-f7db7a507df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7a806cbd-e10c-4c3d-bd8b-b9696698ad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7a806cbd-e10c-4c3d-bd8b-b9696698ad6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_fdc4e1f4-1607-4486-9f1d-83e7974fc8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_fdc4e1f4-1607-4486-9f1d-83e7974fc8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a5c08ed4-cdaf-4904-a898-3fca48d775d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a5c08ed4-cdaf-4904-a898-3fca48d775d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1b653243-6e29-44ea-b73a-ba03f5011ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1b653243-6e29-44ea-b73a-ba03f5011ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_747a3672-82c7-4c77-b1ed-06bec41961e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0bec693-f0b7-49c1-91e8-e74d9d0a8ba1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_747a3672-82c7-4c77-b1ed-06bec41961e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_614dd4ee-5698-4492-9cd2-50d37f580da8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40ac5127-3ef9-44e8-bd70-c32ea81f0bd4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_614dd4ee-5698-4492-9cd2-50d37f580da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019c5c69-8ad4-7b6d-aad0-853fcea233de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019c5c69-8ad4-7b6d-aad0-853fcea233de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019c5c69-c343-7aa7-90a3-ce017834340e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019c5c69-c343-7aa7-90a3-ce017834340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_019c5c69-f8a1-793a-9bd8-7375cd3161b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_019c5c69-f8a1-793a-9bd8-7375cd3161b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ee332fb-6bbd-43e4-8f5d-5fb5778d994b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ee332fb-6bbd-43e4-8f5d-5fb5778d994b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982e5d40-7f0d-4c7e-876b-41c7a56298a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982e5d40-7f0d-4c7e-876b-41c7a56298a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_290a5ea3-0ad1-46ea-a6a9-6b4037a9d71b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_290a5ea3-0ad1-46ea-a6a9-6b4037a9d71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_cf552f85-4ff0-4841-8c9b-af4b101608f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_cf552f85-4ff0-4841-8c9b-af4b101608f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_52659249-e27f-452b-9103-248b6a41f66f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_52659249-e27f-452b-9103-248b6a41f66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d55ac65a-2df5-40a5-8bcc-3950c943214b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d55ac65a-2df5-40a5-8bcc-3950c943214b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7dce6591-5774-425b-9498-100fe1d2e6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7dce6591-5774-425b-9498-100fe1d2e6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f50ebf7d-31fb-4f1e-8aed-c0be2559a51e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e90d731-300c-40d2-be01-2fd8a4d558c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f50ebf7d-31fb-4f1e-8aed-c0be2559a51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c5c6b-3339-764e-b47b-7dbaca9ab62c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c5c6b-3339-764e-b47b-7dbaca9ab62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_019c5c6b-4fbe-7fa6-b9f6-fb236a581e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_019c5c6b-4fbe-7fa6-b9f6-fb236a581e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_386563ae-0670-44b7-a11b-653c6a25e74e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_386563ae-0670-44b7-a11b-653c6a25e74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cc9b47f1-48d7-4899-ba87-2dd6b95d66a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cc9b47f1-48d7-4899-ba87-2dd6b95d66a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_eb98cdcd-ad19-4905-9570-06973dc98265" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_eb98cdcd-ad19-4905-9570-06973dc98265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f48e0e60-f356-4da0-9d80-601cc0d94cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f48e0e60-f356-4da0-9d80-601cc0d94cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_019c68e7-7b2a-781a-b742-23982218f586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_019c68e7-7b2a-781a-b742-23982218f586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_64614f95-f624-46de-934d-2cf11903f115" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b5b7f50-ad18-441d-a00c-0929447400e4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_64614f95-f624-46de-934d-2cf11903f115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77d3ac4e-70a4-41aa-9283-4aedea616579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77d3ac4e-70a4-41aa-9283-4aedea616579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_984df1c8-cafc-43a2-99f4-579787595049" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_984df1c8-cafc-43a2-99f4-579787595049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc37d0b5-3c56-4510-9315-5eca7ee48fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc37d0b5-3c56-4510-9315-5eca7ee48fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_899c88a2-28f6-4f75-9f3e-24774dc5a574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_RestrictedCash_899c88a2-28f6-4f75-9f3e-24774dc5a574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13de6a5b-9b96-4cad-bcca-3f0aaf0310b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13de6a5b-9b96-4cad-bcca-3f0aaf0310b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d36c3166-514f-46ab-a5cb-74bdc801079d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d36c3166-514f-46ab-a5cb-74bdc801079d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_da2e5d41-b415-4e31-bf88-2b9af1ceaaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_RestrictedCash_da2e5d41-b415-4e31-bf88-2b9af1ceaaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee5aa70f-38ca-4e24-944d-1e8f9777048f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bdea7afa-63e7-4c34-a2b7-b2148ac5ff8b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee5aa70f-38ca-4e24-944d-1e8f9777048f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="dna-20251231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_aeac2ead-ec71-4d17-b0b8-b6132fdd324c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8060487d-062a-43d2-b46b-65a7f9e141b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aeac2ead-ec71-4d17-b0b8-b6132fdd324c" xlink:to="loc_us-gaap_StatementTable_8060487d-062a-43d2-b46b-65a7f9e141b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56d0120a-b5ef-4f6e-9982-54b3645a561a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8060487d-062a-43d2-b46b-65a7f9e141b7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56d0120a-b5ef-4f6e-9982-54b3645a561a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5f47fd04-4021-4b1b-be73-5b5180b3508e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_56d0120a-b5ef-4f6e-9982-54b3645a561a" xlink:to="loc_us-gaap_RelatedPartyDomain_5f47fd04-4021-4b1b-be73-5b5180b3508e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_6176dad4-2c43-426e-9697-4b04c6b96321" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5f47fd04-4021-4b1b-be73-5b5180b3508e" xlink:to="loc_us-gaap_RelatedPartyMember_6176dad4-2c43-426e-9697-4b04c6b96321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8060487d-062a-43d2-b46b-65a7f9e141b7" xlink:to="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_814d7f6a-bb4e-47ff-8ce9-ffc6eda47a78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_814d7f6a-bb4e-47ff-8ce9-ffc6eda47a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3d3bb898-1d2c-4c3a-adc1-58531a5caaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3d3bb898-1d2c-4c3a-adc1-58531a5caaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_cc7d823c-9ac1-41f3-803b-86bd4667b062" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23196e7e-3cb8-4274-8748-7618b19e6cc4" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_cc7d823c-9ac1-41f3-803b-86bd4667b062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="dna-20251231.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c71e849e-9cea-4bdd-8878-4e69221243cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_cb933cef-7ceb-42ad-bc23-05d26de9b176" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c71e849e-9cea-4bdd-8878-4e69221243cd" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_cb933cef-7ceb-42ad-bc23-05d26de9b176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dna-20251231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7f379c00-e45e-4b5a-b81c-726606cf518b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_54f5ad4d-eaee-4a6c-bc3b-898da9ccdf06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f379c00-e45e-4b5a-b81c-726606cf518b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_54f5ad4d-eaee-4a6c-bc3b-898da9ccdf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/Restructuring" xlink:type="simple" xlink:href="dna-20251231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9d1e0432-611d-4a7c-bed7-9eb6476e08e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9b21ae74-9136-404f-bc96-63cc14400a74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9d1e0432-611d-4a7c-bed7-9eb6476e08e1" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9b21ae74-9136-404f-bc96-63cc14400a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b5756df4-8f23-41da-9269-bb08dba86a33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_b307af00-cddb-4069-83a6-c1a27b41de2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b5756df4-8f23-41da-9269-bb08dba86a33" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_b307af00-cddb-4069-83a6-c1a27b41de2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_feb0eccc-13a1-4b8a-9aad-be2c46c6f2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_823a9764-3b98-4c93-963b-d03025555067" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_feb0eccc-13a1-4b8a-9aad-be2c46c6f2ce" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_823a9764-3b98-4c93-963b-d03025555067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/MarketableSecurities" xlink:type="simple" xlink:href="dna-20251231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c5c90-8cc0-70f1-abef-db3b8e83d76c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_019c5c90-8cc0-75e1-a2ac-59b58622b0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c5c90-8cc0-70f1-abef-db3b8e83d76c" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_019c5c90-8cc0-75e1-a2ac-59b58622b0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestments" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestments"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_a082b592-9eaa-4577-ade4-629da1ba3b84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_25dcacaf-6499-47fb-bdb5-f01a6dff3793" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_a082b592-9eaa-4577-ade4-629da1ba3b84" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_25dcacaf-6499-47fb-bdb5-f01a6dff3793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="dna-20251231.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityMeasureOfActivityAbstract_7b5f7eea-a410-464c-8373-d692e44ee321" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityMeasureOfActivityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_0c0c0bf2-4464-4101-ad84-9933e79e558c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityMeasureOfActivityAbstract_7b5f7eea-a410-464c-8373-d692e44ee321" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_0c0c0bf2-4464-4101-ad84-9933e79e558c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnet" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnet"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b310153a-bd45-46ed-a08d-1a4790768967" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3bc5b413-cdc7-4764-99d6-fa698516ab9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b310153a-bd45-46ed-a08d-1a4790768967" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3bc5b413-cdc7-4764-99d6-fa698516ab9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/Leases" xlink:type="simple" xlink:href="dna-20251231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f66a4640-c77a-4ef4-8ac3-d1bb5721e7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4eae6946-0a8f-432e-a956-8b33ac6c06e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f66a4640-c77a-4ef4-8ac3-d1bb5721e7d6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_4eae6946-0a8f-432e-a956-8b33ac6c06e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_21ee1b3b-b0e3-491d-aa93-2d8f94ab25c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f66a4640-c77a-4ef4-8ac3-d1bb5721e7d6" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_21ee1b3b-b0e3-491d-aa93-2d8f94ab25c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformation" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_SupplementalBalanceSheetInformationAbstract_c99fd52d-904c-4f8f-8e2a-f3fa8d6f3931" xlink:href="dna-20251231.xsd#dna_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_35cfc200-711e-4d88-bd72-cd096d964c22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_c99fd52d-904c-4f8f-8e2a-f3fa8d6f3931" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_35cfc200-711e-4d88-bd72-cd096d964c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dna-20251231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_29783d42-e134-49a3-b56f-13d308476801" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0ea66a9f-5fb8-4d61-85b6-b137bf9c39b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_29783d42-e134-49a3-b56f-13d308476801" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0ea66a9f-5fb8-4d61-85b6-b137bf9c39b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockholdersEquity" xlink:type="simple" xlink:href="dna-20251231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_dc69f8dd-6aa5-481d-8d5e-2487e2c17bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_15fea0ad-e1cc-40db-a4ab-cc2982a666e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_dc69f8dd-6aa5-481d-8d5e-2487e2c17bcc" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_15fea0ad-e1cc-40db-a4ab-cc2982a666e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bcf2704-31fa-4252-bb88-4826c784820b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6a872a75-5805-48b8-93e6-6b66fc745c43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bcf2704-31fa-4252-bb88-4826c784820b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6a872a75-5805-48b8-93e6-6b66fc745c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RevenueRecognition" xlink:type="simple" xlink:href="dna-20251231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_32800737-da5a-462f-99ad-aa982509bdae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1f68801b-6196-4707-b13e-932902f44210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_32800737-da5a-462f-99ad-aa982509bdae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1f68801b-6196-4707-b13e-932902f44210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SegmentInformation" xlink:type="simple" xlink:href="dna-20251231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3123a007-5a5b-4c98-9c4c-f8e3bf653e51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_de3f941d-1fc9-4c9f-adb1-958bbbee32ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3123a007-5a5b-4c98-9c4c-f8e3bf653e51" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_de3f941d-1fc9-4c9f-adb1-958bbbee32ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedParties" xlink:type="simple" xlink:href="dna-20251231.xsd#SignificantCollaborationTransactionswithRelatedParties"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_577459ad-2bf7-4cdb-978c-5a78b5e32b51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7638afa3-87e2-497d-bf44-2c80c40e3a93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_577459ad-2bf7-4cdb-978c-5a78b5e32b51" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7638afa3-87e2-497d-bf44-2c80c40e3a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="dna-20251231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3015740c-d7fa-460e-8a69-bcd6e19441c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_1e509472-46f0-4393-b8dd-fc16a7385c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3015740c-d7fa-460e-8a69-bcd6e19441c6" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_1e509472-46f0-4393-b8dd-fc16a7385c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxes" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ae9496f7-6920-4514-90d6-cbc856c5e70b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4b27cf30-501b-43b8-9938-ca0d80129bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ae9496f7-6920-4514-90d6-cbc856c5e70b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4b27cf30-501b-43b8-9938-ca0d80129bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/NetLossperShare" xlink:type="simple" xlink:href="dna-20251231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_03223a71-cc74-4e8e-92a3-74dfd9dd90ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5cef5bcc-5d03-4843-bbf0-07ad41439295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_03223a71-cc74-4e8e-92a3-74dfd9dd90ad" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5cef5bcc-5d03-4843-bbf0-07ad41439295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SubsequentEvents" xlink:type="simple" xlink:href="dna-20251231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4314d517-ec9c-4d7f-bacd-ea41fef4edf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_f7a95de2-896d-4c85-9656-e41aa84a10bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4314d517-ec9c-4d7f-bacd-ea41fef4edf0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_f7a95de2-896d-4c85-9656-e41aa84a10bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dna-20251231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0b89201d-dd4c-4d6d-982e-5fbcf82181cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0b89201d-dd4c-4d6d-982e-5fbcf82181cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_aaa4c0e6-a0fe-4d86-8fa8-cc91aae48f18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_aaa4c0e6-a0fe-4d86-8fa8-cc91aae48f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_e33e18d4-1194-4c3b-bdc7-4edaa25d71a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_e33e18d4-1194-4c3b-bdc7-4edaa25d71a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_a2e0a36b-3489-4111-b1f2-b6e876256340" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_a2e0a36b-3489-4111-b1f2-b6e876256340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b18d176e-17f2-4a99-a7c9-4995ebb06ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_UseOfEstimates_b18d176e-17f2-4a99-a7c9-4995ebb06ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_d49b52ba-bcbc-44f6-8481-8219aaff3212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_d49b52ba-bcbc-44f6-8481-8219aaff3212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_96df82d8-9162-40dc-a966-38b29a16ace2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_96df82d8-9162-40dc-a966-38b29a16ace2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ce64fec8-43be-48a9-a39b-48e1d5d60a92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ce64fec8-43be-48a9-a39b-48e1d5d60a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_712eeb15-1a5b-43c7-a4b8-9b562fdd6a48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_712eeb15-1a5b-43c7-a4b8-9b562fdd6a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8d39cb97-d65a-4f0a-ab4e-6946c78aaaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8d39cb97-d65a-4f0a-ab4e-6946c78aaaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_70f4458a-8e1a-452e-aa98-38fa3df05e99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_70f4458a-8e1a-452e-aa98-38fa3df05e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_9326711c-9fc9-4bf3-98da-215b56cd71d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_9326711c-9fc9-4bf3-98da-215b56cd71d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4807dfad-b93c-4f47-b6a0-745696e9da75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4807dfad-b93c-4f47-b6a0-745696e9da75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1dce47c2-6684-4a24-a541-3a8ed7e3df8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1dce47c2-6684-4a24-a541-3a8ed7e3df8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_fffb10f8-ae6b-4ddc-bd1b-8304a7279fde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_fffb10f8-ae6b-4ddc-bd1b-8304a7279fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_4c292777-4347-4bc4-83ef-8bf8f934545f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_4c292777-4347-4bc4-83ef-8bf8f934545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fc3377c1-49c6-4fe3-99d0-6f221a06e500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fc3377c1-49c6-4fe3-99d0-6f221a06e500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_32360408-13a3-4e31-a81c-0d6e827ce40a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_32360408-13a3-4e31-a81c-0d6e827ce40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_fc312e4d-59e8-49b9-a163-cf7fa1714553" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_fc312e4d-59e8-49b9-a163-cf7fa1714553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_737c9be3-31ef-48a2-8933-7a11bb40227e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_737c9be3-31ef-48a2-8933-7a11bb40227e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5cd42943-7ebd-45c2-859e-c3408ad087fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5cd42943-7ebd-45c2-859e-c3408ad087fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PatentCostsPolicyTextBlock_6ab8358a-8c48-4ade-b84e-880a074786f0" xlink:href="dna-20251231.xsd#dna_PatentCostsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_dna_PatentCostsPolicyTextBlock_6ab8358a-8c48-4ade-b84e-880a074786f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c52019e2-eba9-4838-80b4-de2f92d08cde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c52019e2-eba9-4838-80b4-de2f92d08cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f59cbdf5-3b69-473e-a3b1-18dc949a583e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f59cbdf5-3b69-473e-a3b1-18dc949a583e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_71208d87-0a56-4070-b3ee-ea8ddabd0773" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_71208d87-0a56-4070-b3ee-ea8ddabd0773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_95c9ba4b-3899-4f4d-bea1-8bd5f05c7105" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_95c9ba4b-3899-4f4d-bea1-8bd5f05c7105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b5ea6110-5373-494a-8141-849f01e06254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_944906e8-bed0-4985-bf61-fb160a703959" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b5ea6110-5373-494a-8141-849f01e06254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dna-20251231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_88da769a-a865-4206-b4cf-25c3ad61d3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_31464628-dd0e-4dff-8685-521f4040d0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_88da769a-a865-4206-b4cf-25c3ad61d3ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_31464628-dd0e-4dff-8685-521f4040d0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RestructuringTables" xlink:type="simple" xlink:href="dna-20251231.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4ef44026-3363-46b6-9e97-454d721303fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_455f3e4a-80c5-4531-be9a-7fcdb8fc2bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4ef44026-3363-46b6-9e97-454d721303fa" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_455f3e4a-80c5-4531-be9a-7fcdb8fc2bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresTables" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestituresTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f56da4ca-f27e-4bfb-bf6c-76aef4e3ed72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock_a68be951-edfc-4118-b015-0c9e841d776d" xlink:href="dna-20251231.xsd#dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f56da4ca-f27e-4bfb-bf6c-76aef4e3ed72" xlink:to="loc_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock_a68be951-edfc-4118-b015-0c9e841d776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d3245ae7-9a03-4407-a875-b71c3dfb8ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d0545162-0b06-4bdf-a8bb-3e64c9aa590f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d3245ae7-9a03-4407-a875-b71c3dfb8ee0" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d0545162-0b06-4bdf-a8bb-3e64c9aa590f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4e9bac83-8e72-4494-845e-495a7709a6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d3245ae7-9a03-4407-a875-b71c3dfb8ee0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4e9bac83-8e72-4494-845e-495a7709a6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_96ec1243-a5e7-4162-b2f2-7cb5c05cbb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d3245ae7-9a03-4407-a875-b71c3dfb8ee0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_96ec1243-a5e7-4162-b2f2-7cb5c05cbb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="dna-20251231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c5c90-8cc0-7e4e-a387-20d7b1cc4519" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_019c5c90-8cc0-70f0-bc0a-5a729fbe50e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c5c90-8cc0-7e4e-a387-20d7b1cc4519" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_019c5c90-8cc0-70f0-bc0a-5a729fbe50e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019c5c90-8cc0-7a38-8ffe-631fa53c6c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c5c90-8cc0-7e4e-a387-20d7b1cc4519" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019c5c90-8cc0-7a38-8ffe-631fa53c6c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsTables" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1547be26-75f2-4390-8ddf-9ffed1bf3f02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_6579e64d-6d64-4738-8315-eb0fa9156e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1547be26-75f2-4390-8ddf-9ffed1bf3f02" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_6579e64d-6d64-4738-8315-eb0fa9156e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_1e3b194a-9018-4361-9de6-b07a98de99d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1547be26-75f2-4390-8ddf-9ffed1bf3f02" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_1e3b194a-9018-4361-9de6-b07a98de99d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetTables" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnetTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e49a5c28-d71b-4d43-9420-309851acc55b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_b1bbf3f8-82c6-4ca4-889d-35153692fcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e49a5c28-d71b-4d43-9420-309851acc55b" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_b1bbf3f8-82c6-4ca4-889d-35153692fcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_aaa572a5-39dd-4e0a-a1c5-d55917ff5b51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e49a5c28-d71b-4d43-9420-309851acc55b" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_aaa572a5-39dd-4e0a-a1c5-d55917ff5b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_0f1d0c8e-85aa-460b-ac69-ed199e06e4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e49a5c28-d71b-4d43-9420-309851acc55b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_0f1d0c8e-85aa-460b-ac69-ed199e06e4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/LeasesTables" xlink:type="simple" xlink:href="dna-20251231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e830ec2e-e28d-4b8e-90f1-b833f355802d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_858ae501-32a9-402b-a1d1-625d0b0e8e58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e830ec2e-e28d-4b8e-90f1-b833f355802d" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_858ae501-32a9-402b-a1d1-625d0b0e8e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_b8cdadfe-5a7c-4494-93ae-8fb440af8b16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e830ec2e-e28d-4b8e-90f1-b833f355802d" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_b8cdadfe-5a7c-4494-93ae-8fb440af8b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_56abbc52-2c41-49b0-9105-69506232152b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e830ec2e-e28d-4b8e-90f1-b833f355802d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_56abbc52-2c41-49b0-9105-69506232152b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_cbf79bbd-ec49-4217-9524-7a8f7c5b37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e830ec2e-e28d-4b8e-90f1-b833f355802d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_cbf79bbd-ec49-4217-9524-7a8f7c5b37e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_SupplementalBalanceSheetInformationAbstract_31638ed0-3e51-408d-ae11-2a175ede69de" xlink:href="dna-20251231.xsd#dna_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3fbf4e19-9d34-47b0-837a-220b2694dcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_31638ed0-3e51-408d-ae11-2a175ede69de" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3fbf4e19-9d34-47b0-837a-220b2694dcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3b159c00-829c-4764-ab86-6aefadf54160" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_31638ed0-3e51-408d-ae11-2a175ede69de" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3b159c00-829c-4764-ab86-6aefadf54160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_22e02e49-ffe2-4dc8-8e58-78c56b2c4ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_31638ed0-3e51-408d-ae11-2a175ede69de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_22e02e49-ffe2-4dc8-8e58-78c56b2c4ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_dd6ce3be-98ae-4422-92f5-8fe3923de5bc" xlink:href="dna-20251231.xsd#dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_31638ed0-3e51-408d-ae11-2a175ede69de" xlink:to="loc_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_dd6ce3be-98ae-4422-92f5-8fe3923de5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_b5ce5ca0-55c4-4132-9977-f25e14306c85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_31638ed0-3e51-408d-ae11-2a175ede69de" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_b5ce5ca0-55c4-4132-9977-f25e14306c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="dna-20251231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_285bfa52-9f21-4277-ac67-7d54a088f06d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationTextBlock_2029aa77-5206-4bd5-a685-9ef64f5658da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCapitalizationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_285bfa52-9f21-4277-ac67-7d54a088f06d" xlink:to="loc_us-gaap_ScheduleOfCapitalizationTextBlock_2029aa77-5206-4bd5-a685-9ef64f5658da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock_da9024c0-66cc-4167-93ed-f7e2dc5b7c44" xlink:href="dna-20251231.xsd#dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_285bfa52-9f21-4277-ac67-7d54a088f06d" xlink:to="loc_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock_da9024c0-66cc-4167-93ed-f7e2dc5b7c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0e5f422-f973-4a47-ad25-0b5622a4b369" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30e7b6c2-7eac-4c0d-a37c-d3c091743040" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0e5f422-f973-4a47-ad25-0b5622a4b369" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30e7b6c2-7eac-4c0d-a37c-d3c091743040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a8112031-c1ae-4090-bc17-1107bd14821a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0e5f422-f973-4a47-ad25-0b5622a4b369" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a8112031-c1ae-4090-bc17-1107bd14821a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_360921b9-8d96-4255-b521-0144a4ce23b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0e5f422-f973-4a47-ad25-0b5622a4b369" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_360921b9-8d96-4255-b521-0144a4ce23b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a51feb3c-b2a9-46f3-8a06-d0e80bbcb4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0e5f422-f973-4a47-ad25-0b5622a4b369" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a51feb3c-b2a9-46f3-8a06-d0e80bbcb4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SummaryOfActivityForEarnoutRSATableTextBlock_922caddf-359b-4384-a370-fc2b33e94ec3" xlink:href="dna-20251231.xsd#dna_SummaryOfActivityForEarnoutRSATableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0e5f422-f973-4a47-ad25-0b5622a4b369" xlink:to="loc_dna_SummaryOfActivityForEarnoutRSATableTextBlock_922caddf-359b-4384-a370-fc2b33e94ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_019c5cb1-4376-7fb6-b315-ab5724b42305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0e5f422-f973-4a47-ad25-0b5622a4b369" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_019c5cb1-4376-7fb6-b315-ab5724b42305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="dna-20251231.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_095b3e2b-eab5-462f-b1c9-ad0b4b068131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a07febc4-120e-4e7f-ae7f-40550106bc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_095b3e2b-eab5-462f-b1c9-ad0b4b068131" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a07febc4-120e-4e7f-ae7f-40550106bc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="dna-20251231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c165d6d0-ee7a-4969-90de-36ff755e346f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_41c219f8-6269-4289-ae11-c053fc5f7346" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c165d6d0-ee7a-4969-90de-36ff755e346f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_41c219f8-6269-4289-ae11-c053fc5f7346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/OrganizationConsolidationandPresentationofFinancialStatementsTables" xlink:type="simple" xlink:href="dna-20251231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/OrganizationConsolidationandPresentationofFinancialStatementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5cbd-fe37-7d01-a7f6-3aeedf7fbc91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_019c5cbd-fe37-73e3-bafd-4c68eef1b06e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5cbd-fe37-7d01-a7f6-3aeedf7fbc91" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_019c5cbd-fe37-73e3-bafd-4c68eef1b06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6a273e50-8712-495a-942a-2bae60170227" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9da103b1-6046-44b6-8fa6-343f4171df3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a273e50-8712-495a-942a-2bae60170227" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9da103b1-6046-44b6-8fa6-343f4171df3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fb5dd374-471b-454b-a284-2c699855a138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a273e50-8712-495a-942a-2bae60170227" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fb5dd374-471b-454b-a284-2c699855a138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2a45934b-6dd3-4844-a3eb-2e26813673bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a273e50-8712-495a-942a-2bae60170227" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2a45934b-6dd3-4844-a3eb-2e26813673bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f8cc4df4-ac9e-41df-8eb1-c7090d140f43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a273e50-8712-495a-942a-2bae60170227" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f8cc4df4-ac9e-41df-8eb1-c7090d140f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_8c8157f5-690a-4cc7-8513-df612f4170db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a273e50-8712-495a-942a-2bae60170227" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_8c8157f5-690a-4cc7-8513-df612f4170db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019c5ccf-69fd-794c-8697-e2945193b400" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a273e50-8712-495a-942a-2bae60170227" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019c5ccf-69fd-794c-8697-e2945193b400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="dna-20251231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e6bbc345-caa0-4a90-ad13-ab155a28dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9056b1b8-76d5-400e-bf2e-a04b97041a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e6bbc345-caa0-4a90-ad13-ab155a28dd22" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9056b1b8-76d5-400e-bf2e-a04b97041a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_80dc1cf6-9b75-46b3-b9e6-d83abcada1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e6bbc345-caa0-4a90-ad13-ab155a28dd22" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_80dc1cf6-9b75-46b3-b9e6-d83abcada1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5c6e-3d82-7c06-8f92-576b214d4f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019c5c6e-3d82-7e2d-a9c2-f451f73bcd21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5c6e-3d82-7c06-8f92-576b214d4f3e" xlink:to="loc_us-gaap_NumberOfReportableSegments_019c5c6e-3d82-7e2d-a9c2-f451f73bcd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfCoreOfferings_019c900c-bcab-7549-a804-4e935e1507ac" xlink:href="dna-20251231.xsd#dna_NumberOfCoreOfferings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5c6e-3d82-7c06-8f92-576b214d4f3e" xlink:to="loc_dna_NumberOfCoreOfferings_019c900c-bcab-7549-a804-4e935e1507ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b762171d-964e-4ead-963b-68884d5e2746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b762171d-964e-4ead-963b-68884d5e2746" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a3311607-6c3e-42b6-9ecd-8c31a5f80170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a3311607-6c3e-42b6-9ecd-8c31a5f80170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7c5d7099-26e1-4e9c-8539-60d9f2deb4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a3311607-6c3e-42b6-9ecd-8c31a5f80170" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7c5d7099-26e1-4e9c-8539-60d9f2deb4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a8fdd1d6-58f8-401a-aceb-df99a393e481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7c5d7099-26e1-4e9c-8539-60d9f2deb4d4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a8fdd1d6-58f8-401a-aceb-df99a393e481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8f0bb111-259b-4ebe-b140-2cc03deb94ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8f0bb111-259b-4ebe-b140-2cc03deb94ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_639e367e-21c9-4df2-80a3-d3c9d63391e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8f0bb111-259b-4ebe-b140-2cc03deb94ca" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_639e367e-21c9-4df2-80a3-d3c9d63391e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_94dfcc94-5590-4341-bf46-8e608b2e2a24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_639e367e-21c9-4df2-80a3-d3c9d63391e7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_94dfcc94-5590-4341-bf46-8e608b2e2a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5e7cf198-2a31-4b73-a6fe-9538540fc592" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_srt_MajorCustomersAxis_5e7cf198-2a31-4b73-a6fe-9538540fc592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_5e7cf198-2a31-4b73-a6fe-9538540fc592" xlink:to="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OneCustomerMember_13a84a86-1d49-45b4-918e-64740fc48933" xlink:href="dna-20251231.xsd#dna_OneCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:to="loc_dna_OneCustomerMember_13a84a86-1d49-45b4-918e-64740fc48933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CustomerOneMember_019c5c70-ceb7-7ebf-837b-2e1f57d14068" xlink:href="dna-20251231.xsd#dna_CustomerOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:to="loc_dna_CustomerOneMember_019c5c70-ceb7-7ebf-837b-2e1f57d14068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CustomerTwoMember_019c5c71-00fb-72e4-8852-88e7cf0cf710" xlink:href="dna-20251231.xsd#dna_CustomerTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7fd39087-7298-4b37-b971-65acb5cde6e7" xlink:to="loc_dna_CustomerTwoMember_019c5c71-00fb-72e4-8852-88e7cf0cf710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ade1b62d-959c-41f8-8ed7-be5f3ccf1074" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ade1b62d-959c-41f8-8ed7-be5f3ccf1074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3561b37a-b2c9-4a9f-b237-69969bd4bc07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ade1b62d-959c-41f8-8ed7-be5f3ccf1074" xlink:to="loc_us-gaap_SegmentDomain_3561b37a-b2c9-4a9f-b237-69969bd4bc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringSegmentMember_b0390925-dde0-466f-b276-17e145bd1bec" xlink:href="dna-20251231.xsd#dna_CellEngineeringSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3561b37a-b2c9-4a9f-b237-69969bd4bc07" xlink:to="loc_dna_CellEngineeringSegmentMember_b0390925-dde0-466f-b276-17e145bd1bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiosecuritySegmentMember_76ef96a8-9bc7-42d2-97cd-6189a099eced" xlink:href="dna-20251231.xsd#dna_BiosecuritySegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3561b37a-b2c9-4a9f-b237-69969bd4bc07" xlink:to="loc_dna_BiosecuritySegmentMember_76ef96a8-9bc7-42d2-97cd-6189a099eced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_c02717f1-b9ec-4617-b62a-497a37c424a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_OtherCommitmentsAxis_c02717f1-b9ec-4617-b62a-497a37c424a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_ae0e52c8-e2ef-4c06-9c7f-c2cc9104c41f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_c02717f1-b9ec-4617-b62a-497a37c424a7" xlink:to="loc_us-gaap_OtherCommitmentsDomain_ae0e52c8-e2ef-4c06-9c7f-c2cc9104c41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember_17a186f7-2455-4218-b4c7-2d7bc28ad6d8" xlink:href="dna-20251231.xsd#dna_EquityMethodInvestmentFundingOfAdditionalLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_ae0e52c8-e2ef-4c06-9c7f-c2cc9104c41f" xlink:to="loc_dna_EquityMethodInvestmentFundingOfAdditionalLossesMember_17a186f7-2455-4218-b4c7-2d7bc28ad6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_01fe66b5-51d4-4082-bc21-05f5cc92940f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_StatementClassOfStockAxis_01fe66b5-51d4-4082-bc21-05f5cc92940f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_01fe66b5-51d4-4082-bc21-05f5cc92940f" xlink:to="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_21f6547f-663b-4cf5-8d36-565cf195d195" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:to="loc_us-gaap_CommonClassAMember_21f6547f-663b-4cf5-8d36-565cf195d195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_d6528cc0-1ae7-43aa-80b6-a31dc7f3c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:to="loc_us-gaap_CommonClassBMember_d6528cc0-1ae7-43aa-80b6-a31dc7f3c9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_3e54c314-e540-4d3e-ba25-d8b5584a1d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f021326d-9ec4-4a5b-b8c3-8de271f4f590" xlink:to="loc_us-gaap_CommonClassCMember_3e54c314-e540-4d3e-ba25-d8b5584a1d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fff7779a-b381-4de8-bce7-02b2fe11c118" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_52f43860-7fd9-4d2e-8976-857cd206e8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_52f43860-7fd9-4d2e-8976-857cd206e8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_531391e9-b081-4fb3-80ba-7588be8a4395" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_531391e9-b081-4fb3-80ba-7588be8a4395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2321b47c-4392-4117-a238-5103d96d1b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2321b47c-4392-4117-a238-5103d96d1b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_b46da138-ee82-4c03-87b9-6576cd3dc625" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_OtherCommitment_b46da138-ee82-4c03-87b9-6576cd3dc625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_a205fa6b-d979-4aab-aaf3-88a7540b830e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_a205fa6b-d979-4aab-aaf3-88a7540b830e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cd4177b9-1f87-494f-9001-586af0d8cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cd4177b9-1f87-494f-9001-586af0d8cdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e87a2b38-eb1b-4914-b6e1-07190b198385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e87a2b38-eb1b-4914-b6e1-07190b198385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_019c900e-47fc-79d1-a095-f028cedb16ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ac8dfc4f-c09a-449d-a114-e1ba48bb1dea" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_019c900e-47fc-79d1-a095-f028cedb16ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f0875473-301d-41d0-b00c-1d3ef0ca9f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dd0dc67-0617-461f-9a82-146a8b878eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0875473-301d-41d0-b00c-1d3ef0ca9f1b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dd0dc67-0617-461f-9a82-146a8b878eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90736a23-05bc-4273-ad5c-549045ba526a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dd0dc67-0617-461f-9a82-146a8b878eb8" xlink:to="loc_srt_RangeAxis_90736a23-05bc-4273-ad5c-549045ba526a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7791d560-2271-49ca-95a0-4103a1cad3e9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_90736a23-05bc-4273-ad5c-549045ba526a" xlink:to="loc_srt_RangeMember_7791d560-2271-49ca-95a0-4103a1cad3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7767576-6493-46a2-912e-816c23233025" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7791d560-2271-49ca-95a0-4103a1cad3e9" xlink:to="loc_srt_MinimumMember_f7767576-6493-46a2-912e-816c23233025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1209569f-703b-439c-a148-89bde98463a0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7791d560-2271-49ca-95a0-4103a1cad3e9" xlink:to="loc_srt_MaximumMember_1209569f-703b-439c-a148-89bde98463a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ca4d6809-e678-4721-a6b5-ff69c7939c47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dd0dc67-0617-461f-9a82-146a8b878eb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ca4d6809-e678-4721-a6b5-ff69c7939c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ca4d6809-e678-4721-a6b5-ff69c7939c47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ComputerEquipmentAndSoftwareMember_348fe881-a07a-4714-be91-ef4fbdc6c366" xlink:href="dna-20251231.xsd#dna_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_dna_ComputerEquipmentAndSoftwareMember_348fe881-a07a-4714-be91-ef4fbdc6c366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3efbc79a-0201-47d0-a784-c543c78857d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3efbc79a-0201-47d0-a784-c543c78857d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LabEquipmentMember_964e9f70-fb53-49b3-93b4-d33f0d558966" xlink:href="dna-20251231.xsd#dna_LabEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_dna_LabEquipmentMember_964e9f70-fb53-49b3-93b4-d33f0d558966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_7504ab05-d33b-4cc6-8910-1f1903389a47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_us-gaap_ManufacturingFacilityMember_7504ab05-d33b-4cc6-8910-1f1903389a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_e594d93a-3f45-4e8a-b2cf-30bef7f094d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1aff206f-a048-4597-8698-eb8c8cd5185b" xlink:to="loc_us-gaap_VehiclesMember_e594d93a-3f45-4e8a-b2cf-30bef7f094d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2bfde11d-7b79-4e64-99d8-525c479b0a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dd0dc67-0617-461f-9a82-146a8b878eb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2bfde11d-7b79-4e64-99d8-525c479b0a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9aec20cd-adc5-4501-856d-ce7d515df03b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2bfde11d-7b79-4e64-99d8-525c479b0a9b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9aec20cd-adc5-4501-856d-ce7d515df03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6026ddec-9619-4542-a7c4-e80c5fafaf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4cd65d81-036d-4c85-96f3-273e306a6d16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6026ddec-9619-4542-a7c4-e80c5fafaf8d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4cd65d81-036d-4c85-96f3-273e306a6d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55ad3263-227d-4129-8dfe-b6e4a1b6884c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4cd65d81-036d-4c85-96f3-273e306a6d16" xlink:to="loc_srt_RangeAxis_55ad3263-227d-4129-8dfe-b6e4a1b6884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c533875a-5a9e-456e-b992-1e7ad13bd3c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_55ad3263-227d-4129-8dfe-b6e4a1b6884c" xlink:to="loc_srt_RangeMember_c533875a-5a9e-456e-b992-1e7ad13bd3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51e92514-b37c-46e3-b8a9-f54d24b555b8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c533875a-5a9e-456e-b992-1e7ad13bd3c8" xlink:to="loc_srt_MinimumMember_51e92514-b37c-46e3-b8a9-f54d24b555b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73481a27-ed94-48b1-8bdf-3b19fa501293" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c533875a-5a9e-456e-b992-1e7ad13bd3c8" xlink:to="loc_srt_MaximumMember_73481a27-ed94-48b1-8bdf-3b19fa501293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4cd65d81-036d-4c85-96f3-273e306a6d16" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent_077296b6-f3e4-4545-bae6-da2eaea619c3" xlink:href="dna-20251231.xsd#dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:to="loc_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent_077296b6-f3e4-4545-bae6-da2eaea619c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_faefbb84-71ed-4ae7-82e2-9d2a01e1cefb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_faefbb84-71ed-4ae7-82e2-9d2a01e1cefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_1b921af6-9359-4790-add4-27e877c211cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_1b921af6-9359-4790-add4-27e877c211cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_019c5c76-5a11-7234-8e78-aeb28ec29b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_aa172b0a-cb72-44ad-a25a-7e5122caad59" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_019c5c76-5a11-7234-8e78-aeb28ec29b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RestructuringSummaryofRestructuringChargesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#RestructuringSummaryofRestructuringChargesDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/RestructuringSummaryofRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2cbf8c18-b363-4c5b-94e5-94c0834f9700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_19fbd9d0-02e3-4087-8aec-75be3e681f50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2cbf8c18-b363-4c5b-94e5-94c0834f9700" xlink:to="loc_us-gaap_RestructuringCharges_19fbd9d0-02e3-4087-8aec-75be3e681f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_546ec266-ac2a-4f46-871c-9ce75605982f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2cbf8c18-b363-4c5b-94e5-94c0834f9700" xlink:to="loc_us-gaap_AssetImpairmentCharges_546ec266-ac2a-4f46-871c-9ce75605982f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_d4e650d5-e08b-4d06-a58c-fd928b9d4c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2cbf8c18-b363-4c5b-94e5-94c0834f9700" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_d4e650d5-e08b-4d06-a58c-fd928b9d4c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e0e7cedf-78fe-4326-839a-3ca805078fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2cbf8c18-b363-4c5b-94e5-94c0834f9700" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e0e7cedf-78fe-4326-839a-3ca805078fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dc5265d1-4c5c-4ae9-a30b-fb9906e75e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ce5e71f5-bc60-4911-ae41-9c6036bdd9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dc5265d1-4c5c-4ae9-a30b-fb9906e75e5b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ce5e71f5-bc60-4911-ae41-9c6036bdd9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6efec795-2385-487e-90a1-13388f57269a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ce5e71f5-bc60-4911-ae41-9c6036bdd9d5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6efec795-2385-487e-90a1-13388f57269a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b1aa0749-76b8-4245-8a13-b6bb8a5b5d96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6efec795-2385-487e-90a1-13388f57269a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b1aa0749-76b8-4245-8a13-b6bb8a5b5d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_aed4bb03-2dc9-468e-8801-845a2f98b5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_b1aa0749-76b8-4245-8a13-b6bb8a5b5d96" xlink:to="loc_us-gaap_EmployeeSeveranceMember_aed4bb03-2dc9-468e-8801-845a2f98b5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ce5e71f5-bc60-4911-ae41-9c6036bdd9d5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d5f945a1-c395-4ef7-8df6-86817aa27745" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:to="loc_us-gaap_RestructuringCharges_d5f945a1-c395-4ef7-8df6-86817aa27745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_ba15ae8a-25ac-4cb5-9748-657b316d41b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:to="loc_us-gaap_PaymentsForRestructuring_ba15ae8a-25ac-4cb5-9748-657b316d41b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_41d2c247-2b11-4a68-822a-b76a42d8952c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5519fc9f-1a09-4362-919d-7c7040545344" xlink:to="loc_us-gaap_RestructuringReserve_41d2c247-2b11-4a68-822a-b76a42d8952c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_019c5c81-2aa1-7335-896c-622d3b603eee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_019c5c81-2aa1-7335-896c-622d3b603eee" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019c5c81-2aa1-7dc2-803c-f1a877f29222" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019c5c81-2aa1-7dc2-803c-f1a877f29222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019c5c81-2aa1-7dc2-803c-f1a877f29222" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgBiomeInc.Member_019c5c81-2aa1-7727-9677-d888a7f5541a" xlink:href="dna-20251231.xsd#dna_AgBiomeInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:to="loc_dna_AgBiomeInc.Member_019c5c81-2aa1-7727-9677-d888a7f5541a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenBankruptcyMember_019c5c81-58aa-7ecc-870d-c0c644dd273b" xlink:href="dna-20251231.xsd#dna_ZymergenBankruptcyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:to="loc_dna_ZymergenBankruptcyMember_019c5c81-58aa-7ecc-870d-c0c644dd273b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_019c5c81-a248-738f-85f5-6ffd086266fa" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c81-2aa1-72db-ac8b-26bb598d24e8" xlink:to="loc_dna_ZymergenMember_019c5c81-a248-738f-85f5-6ffd086266fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c5c81-2aa1-728f-bcdb-5867d0aaff2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c5c81-2aa1-728f-bcdb-5867d0aaff2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c5c81-2aa1-79d2-b853-4cc8b0b2e014" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c5c81-2aa1-728f-bcdb-5867d0aaff2e" xlink:to="loc_us-gaap_ClassOfStockDomain_019c5c81-2aa1-79d2-b853-4cc8b0b2e014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019c5c81-2aa1-7c65-a2b2-076582e9ec80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019c5c81-2aa1-79d2-b853-4cc8b0b2e014" xlink:to="loc_us-gaap_CommonClassAMember_019c5c81-2aa1-7c65-a2b2-076582e9ec80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019c5c81-2aa1-7dd4-8b46-4463d2d5d9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019c5c81-2aa1-7dd4-8b46-4463d2d5d9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019c5c81-2aa1-7bcf-be80-c640bfe75132" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_019c5c81-2aa1-7dd4-8b46-4463d2d5d9ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019c5c81-2aa1-7bcf-be80-c640bfe75132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_019c5c81-2aa1-7fd1-b9e4-d0b243a0d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_019c5c81-2aa1-7bcf-be80-c640bfe75132" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_019c5c81-2aa1-7fd1-b9e4-d0b243a0d0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_019c5c81-2aa1-7d3a-ac63-4141b8b00407" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_AssetAcquisitionAxis_019c5c81-2aa1-7d3a-ac63-4141b8b00407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_019c5c81-2aa1-7d3a-ac63-4141b8b00407" xlink:to="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherAssetAcquisitionsMember_019c5c81-2aa1-7d37-9ffe-14bb4dcc8522" xlink:href="dna-20251231.xsd#dna_OtherAssetAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:to="loc_dna_OtherAssetAcquisitionsMember_019c5c81-2aa1-7d37-9ffe-14bb4dcc8522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StridebioMember_019c5c81-58aa-7c26-add6-53dfb222a1fc" xlink:href="dna-20251231.xsd#dna_StridebioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:to="loc_dna_StridebioMember_019c5c81-58aa-7c26-add6-53dfb222a1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_019c5c81-58aa-7d0b-9382-cffac02fb20c" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_019c5c81-2aa1-7303-821c-42fb4d1d7238" xlink:to="loc_dna_ZymergenMember_019c5c81-58aa-7d0b-9382-cffac02fb20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5c81-8264-72a3-92a2-5ad126d71128" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5c81-8264-72a3-92a2-5ad126d71128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5c81-8264-77fd-8811-aa8c2d3f1639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5c81-8264-72a3-92a2-5ad126d71128" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5c81-8264-77fd-8811-aa8c2d3f1639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019c5c81-8264-796c-9e82-a435b06df36c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019c5c81-8264-77fd-8811-aa8c2d3f1639" xlink:to="loc_us-gaap_RelatedPartyMember_019c5c81-8264-796c-9e82-a435b06df36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c5c81-a248-798a-bf08-3777d9e1714d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c5c81-a248-798a-bf08-3777d9e1714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c5c81-a248-7b2b-85be-9cfd187ad7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c5c81-a248-798a-bf08-3777d9e1714d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c5c81-a248-7b2b-85be-9cfd187ad7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019c5c81-a248-7997-9311-fb78a595542c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c5c81-a248-7b2b-85be-9cfd187ad7f3" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_019c5c81-a248-7997-9311-fb78a595542c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c81-a248-78bd-858d-1099887a3f90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c81-a248-78bd-858d-1099887a3f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c81-a248-7c74-add5-78f9e2ea349a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c81-a248-78bd-858d-1099887a3f90" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c81-a248-7c74-add5-78f9e2ea349a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AltarSasMember_019c5c81-a248-74bc-a9e7-85a30c1ca430" xlink:href="dna-20251231.xsd#dna_AltarSasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c81-a248-7c74-add5-78f9e2ea349a" xlink:to="loc_dna_AltarSasMember_019c5c81-a248-74bc-a9e7-85a30c1ca430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c81-2aa1-78c1-82ad-b5ce7f6f3e78" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_019c5c81-2aa1-7a94-a0b7-ce1fec21a2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_019c5c81-2aa1-7a94-a0b7-ce1fec21a2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_019c5c81-2aa1-7510-a52b-f05f0dd8fbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_019c5c81-2aa1-7510-a52b-f05f0dd8fbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019c5c81-2aa1-79d8-b552-967e1ed7f87c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_019c5c81-2aa1-79d8-b552-967e1ed7f87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod_019c5c81-2aa1-723c-8b08-82c4f518fdbf" xlink:href="dna-20251231.xsd#dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod_019c5c81-2aa1-723c-8b08-82c4f518fdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_019c5c81-2aa1-7d24-8733-f091fa50ac6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_019c5c81-2aa1-7d24-8733-f091fa50ac6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019c5c81-2aa1-7f03-965f-1051d37a2cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019c5c81-2aa1-7f03-965f-1051d37a2cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_019c5c81-58aa-7a83-97fc-14047755a7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_PaymentsForRoyalties_019c5c81-58aa-7a83-97fc-14047755a7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_019c5c81-58aa-743c-bd43-5f7ab8ad8961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_019c5c81-58aa-743c-bd43-5f7ab8ad8961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_019c5c81-58aa-7e86-9764-6b36c1144273" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_019c5c81-58aa-7e86-9764-6b36c1144273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_019c5c81-58aa-7312-9572-ea2cdf6877c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_019c5c81-58aa-7312-9572-ea2cdf6877c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_019c5c81-58aa-7b7d-9c8e-0a29157ba75f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_EquityMethodInvestments_019c5c81-58aa-7b7d-9c8e-0a29157ba75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EmployeeLeaseExpense_019c5c81-8264-76c1-8650-11467223cb81" xlink:href="dna-20251231.xsd#dna_EmployeeLeaseExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_dna_EmployeeLeaseExpense_019c5c81-8264-76c1-8650-11467223cb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019c5c81-a248-726a-b592-9cc4f776a824" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_019c5c81-a248-726a-b592-9cc4f776a824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfEmployeesAcquired_019c5c81-a248-7c4c-b624-1d8528d9075d" xlink:href="dna-20251231.xsd#dna_NumberOfEmployeesAcquired"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_dna_NumberOfEmployeesAcquired_019c5c81-a248-7c4c-b624-1d8528d9075d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_019c5c81-a248-7cf5-aa12-fbc89619ad27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_019c5c81-a248-7cf5-aa12-fbc89619ad27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_019c5c81-a248-7dea-98a9-52f3abc4ac1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_019c5c81-a248-7dea-98a9-52f3abc4ac1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_019c5c81-a248-71a7-8b59-d21bacd44a74" xlink:href="dna-20251231.xsd#dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_019c5c81-a248-71a7-8b59-d21bacd44a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_019c5c81-a248-7579-bbc0-0eb66c20d650" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_019c5c81-a248-7579-bbc0-0eb66c20d650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_019c5c81-a248-7ae3-89cf-9c8e55fdbe40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_019c5c81-a248-7ae3-89cf-9c8e55fdbe40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019c5c81-a248-72fc-bcdf-319699960cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019c5c81-a248-72fc-bcdf-319699960cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_019c5c81-a248-7266-a11c-9521f44e3898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_019c5c81-a248-7266-a11c-9521f44e3898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_019c5c81-a248-7e24-a5b9-612827f435b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c81-2aa1-704a-851a-8c7c19984641" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_019c5c81-a248-7e24-a5b9-612827f435b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_019c5c83-8732-7c9d-aac1-b29b69f60a14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-8732-7dbc-8228-60f894863cff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_019c5c83-8732-7c9d-aac1-b29b69f60a14" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-8732-7dbc-8228-60f894863cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-8732-7c98-abca-9d9f274ce548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-8732-7dbc-8228-60f894863cff" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-8732-7c98-abca-9d9f274ce548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-8732-78f8-a075-4c16575130f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-8732-7c98-abca-9d9f274ce548" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-8732-78f8-a075-4c16575130f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_019c5c83-8732-7c67-a0cb-b90414dad063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-8732-78f8-a075-4c16575130f2" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_019c5c83-8732-7c67-a0cb-b90414dad063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-8732-78bf-9db6-724d6c8d6995" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-8732-7dbc-8228-60f894863cff" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-8732-78bf-9db6-724d6c8d6995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-8732-7cc4-9d0d-44affa586147" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-8732-78bf-9db6-724d6c8d6995" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-8732-7cc4-9d0d-44affa586147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_019c5c83-8732-7884-9b42-249ef279aa89" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-8732-7cc4-9d0d-44affa586147" xlink:to="loc_dna_ZymergenMember_019c5c83-8732-7884-9b42-249ef279aa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-8732-7dbc-8228-60f894863cff" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_019c5c83-8732-7b2c-8e51-61eabad6e301" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_019c5c83-8732-7b2c-8e51-61eabad6e301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019c5c83-8732-7209-aadf-d8647eb62237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_019c5c83-8732-7209-aadf-d8647eb62237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_019c5c83-8732-76bc-b01e-72b3e33d83f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_019c5c83-8732-76bc-b01e-72b3e33d83f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-7c73-93dc-36e0f630e846" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-7c73-93dc-36e0f630e846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_019c5c83-8732-7a65-bd29-50ef16fa39b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_019c5c83-8732-7a65-bd29-50ef16fa39b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_019c5c83-8732-7de3-88d8-b2337d39d74b" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_019c5c83-8732-7de3-88d8-b2337d39d74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_019c5c83-8732-77b2-860e-27b422988741" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_019c5c83-8732-77b2-860e-27b422988741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_019c5c83-8732-7525-b24e-efcc3ac28f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_019c5c83-8732-7525-b24e-efcc3ac28f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_019c5c83-8732-7f96-8b93-bd9abfce58bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_019c5c83-8732-7f96-8b93-bd9abfce58bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-74f4-87f6-217b54c38692" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-74f4-87f6-217b54c38692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_019c5c83-8732-7d0f-b159-704aae04fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_019c5c83-8732-7d0f-b159-704aae04fcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019c5c83-8732-7dcf-bdc9-5eb5276da1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_019c5c83-8732-7dcf-bdc9-5eb5276da1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-79cc-9dc1-54002c98e04c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_019c5c83-8732-79cc-9dc1-54002c98e04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_019c5c83-8732-713a-9d89-39062ec1766d" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_019c5c83-8732-713a-9d89-39062ec1766d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_019c5c83-8732-7bfb-8b6d-2cd4396649f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_019c5c83-8732-7bfb-8b6d-2cd4396649f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7aba-a5fc-d2aca3bdf9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_019c5c83-8732-7aba-a5fc-d2aca3bdf9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_019c5c83-8732-7f26-b5d3-4a99b5e69a3d" xlink:href="dna-20251231.xsd#dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-8732-715e-a860-86ea550b0825" xlink:to="loc_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet_019c5c83-8732-7f26-b5d3-4a99b5e69a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_019c5c83-a645-7aef-8fb3-944ed9f33e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-a645-7fc0-9c9b-ce3544ae5937" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_019c5c83-a645-7aef-8fb3-944ed9f33e02" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-a645-7fc0-9c9b-ce3544ae5937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-a645-79a9-be83-1354dbc4a685" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-a645-7fc0-9c9b-ce3544ae5937" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-a645-79a9-be83-1354dbc4a685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-a645-7268-9dcd-720784f4a7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_019c5c83-a645-79a9-be83-1354dbc4a685" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-a645-7268-9dcd-720784f4a7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_019c5c83-a645-79c5-9cb1-67460f15c615" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_019c5c83-a645-7268-9dcd-720784f4a7ec" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_019c5c83-a645-79c5-9cb1-67460f15c615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-a645-7b9e-b537-553285448b27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-a645-7fc0-9c9b-ce3544ae5937" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-a645-7b9e-b537-553285448b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-a645-76a4-8d32-086426f49848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_019c5c83-a645-7b9e-b537-553285448b27" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-a645-76a4-8d32-086426f49848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_019c5c83-a645-7883-93cc-179a1060e01e" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_019c5c83-a645-76a4-8d32-086426f49848" xlink:to="loc_dna_ZymergenMember_019c5c83-a645-7883-93cc-179a1060e01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_019c5c83-a645-7fc0-9c9b-ce3544ae5937" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_019c5c83-a645-7ec8-84b3-40ad3c076cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_019c5c83-a645-7ec8-84b3-40ad3c076cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_019c5c83-a645-73a0-b274-af8240b89cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_019c5c83-a645-73a0-b274-af8240b89cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_019c5c83-a645-7094-99bd-3950d6fed4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_019c5c83-a645-7094-99bd-3950d6fed4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_019c5c83-a645-7933-995d-7ca9088b46f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_019c5c83-a645-7933-995d-7ca9088b46f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_019c5c83-a645-7f86-a1a4-013ab21ea6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_019c5c83-a645-7f86-a1a4-013ab21ea6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_019c5c83-a645-71a7-99a3-7febc5f4ed46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_019c5c83-a645-71a7-99a3-7febc5f4ed46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_019c5c83-a645-7d88-97d9-f99231a9c94e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_019c5c83-a645-70b9-a981-deed04a2a2d5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_019c5c83-a645-7d88-97d9-f99231a9c94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_73b0ce99-d4a4-4609-9d1b-c5468fdb5357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_73b0ce99-d4a4-4609-9d1b-c5468fdb5357" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_904e7b0c-1503-4d3e-b400-30993b38d0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_904e7b0c-1503-4d3e-b400-30993b38d0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_904e7b0c-1503-4d3e-b400-30993b38d0bb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_10bf2f7c-487e-462e-a724-a40605baf48c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_10bf2f7c-487e-462e-a724-a40605baf48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5ebbe79a-2c90-479c-aa73-48b198ad71a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5ebbe79a-2c90-479c-aa73-48b198ad71a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d1928747-edd3-4463-9d01-78eb72f2c6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e3b4b59-7b9e-4b17-bd20-a4f4d30ffb17" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d1928747-edd3-4463-9d01-78eb72f2c6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_c6082c92-ac05-4202-bcad-9cccfce67def" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_c6082c92-ac05-4202-bcad-9cccfce67def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9250dab-9c99-4e5e-a707-457729e6e871" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c6082c92-ac05-4202-bcad-9cccfce67def" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9250dab-9c99-4e5e-a707-457729e6e871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_201e1154-c214-4fd0-b7ff-6ca9b36f0128" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e9250dab-9c99-4e5e-a707-457729e6e871" xlink:to="loc_us-gaap_MoneyMarketFundsMember_201e1154-c214-4fd0-b7ff-6ca9b36f0128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_442453a9-5684-4ba0-9ce6-6f21ca90ae00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:to="loc_us-gaap_InvestmentTypeAxis_442453a9-5684-4ba0-9ce6-6f21ca90ae00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_846e0f25-7a19-4e70-b947-a9595993fd71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_442453a9-5684-4ba0-9ce6-6f21ca90ae00" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_846e0f25-7a19-4e70-b947-a9595993fd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SynlogicIncWarrantsMember_7348075f-b574-4811-a1a7-4aa8d87c5903" xlink:href="dna-20251231.xsd#dna_SynlogicIncWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_846e0f25-7a19-4e70-b947-a9595993fd71" xlink:to="loc_dna_SynlogicIncWarrantsMember_7348075f-b574-4811-a1a7-4aa8d87c5903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MarketableEquitySecuritiesMember_ef95a119-0345-4402-b15d-177b7aa0d0ec" xlink:href="dna-20251231.xsd#dna_MarketableEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_846e0f25-7a19-4e70-b947-a9595993fd71" xlink:to="loc_dna_MarketableEquitySecuritiesMember_ef95a119-0345-4402-b15d-177b7aa0d0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c5c86-3427-784a-a89a-acd22ee062c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c5c86-3427-784a-a89a-acd22ee062c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c5c86-3427-784a-a89a-acd22ee062c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019c5c86-3427-711b-b3a7-5ef7223e97cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_019c5c86-3427-711b-b3a7-5ef7223e97cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019c5c86-3427-7d96-82fa-3e155c8b625c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019c5c86-3427-7d96-82fa-3e155c8b625c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019c5c86-3427-7e52-be67-08531eae3c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019c5c86-3427-7e52-be67-08531eae3c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MarketableEquitySecuritiesMember_019c5c86-3427-7be3-8720-1bcc66577294" xlink:href="dna-20251231.xsd#dna_MarketableEquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5c86-3427-7900-a678-d3367cbeced5" xlink:to="loc_dna_MarketableEquitySecuritiesMember_019c5c86-3427-7be3-8720-1bcc66577294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0b7451a5-27c8-404e-bbff-6aa20781c1f4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f4b0cbea-3fee-4bff-8411-eb0494447e73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f4b0cbea-3fee-4bff-8411-eb0494447e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_77b0ccd7-a0dc-49b9-a2e8-10e8d177dd83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_77b0ccd7-a0dc-49b9-a2e8-10e8d177dd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure_1ced911f-c4a3-4415-94d3-f60c16ded3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosure_1ced911f-c4a3-4415-94d3-f60c16ded3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e34bd374-0b56-4850-bcbc-efdf63e2dbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e34bd374-0b56-4850-bcbc-efdf63e2dbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e2140ebd-a231-4480-8fc2-8656f786a08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e2140ebd-a231-4480-8fc2-8656f786a08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_646c9a6c-643a-45dd-a7e0-01b3444de11b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_646c9a6c-643a-45dd-a7e0-01b3444de11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_72f07125-caaa-44c6-a17b-278998c0b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_50a8f238-9a2f-4f89-b999-440436ec7274" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_72f07125-caaa-44c6-a17b-278998c0b53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_187bcb0e-3847-4fa5-9a11-b60a8f249d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_187bcb0e-3847-4fa5-9a11-b60a8f249d1b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b555e43d-dfc9-4771-9aa8-8b528eec3c15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b555e43d-dfc9-4771-9aa8-8b528eec3c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4adc5bba-f5ed-47a2-a9c3-10f3d0cb47c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b555e43d-dfc9-4771-9aa8-8b528eec3c15" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4adc5bba-f5ed-47a2-a9c3-10f3d0cb47c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_138182bf-f4e3-4cec-ad99-6fbc004d0aff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4adc5bba-f5ed-47a2-a9c3-10f3d0cb47c6" xlink:to="loc_us-gaap_NotesReceivableMember_138182bf-f4e3-4cec-ad99-6fbc004d0aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_cae2f1e2-c7fe-44ea-b7c2-893acc8017d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_cae2f1e2-c7fe-44ea-b7c2-893acc8017d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_07b45b90-00db-4e64-8332-2f5a0b592c48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cae2f1e2-c7fe-44ea-b7c2-893acc8017d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_07b45b90-00db-4e64-8332-2f5a0b592c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PrivatePlacementWarrantsMember_44cad4cb-9013-4f3b-9075-ffc4730c4e05" xlink:href="dna-20251231.xsd#dna_PrivatePlacementWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_07b45b90-00db-4e64-8332-2f5a0b592c48" xlink:to="loc_dna_PrivatePlacementWarrantsMember_44cad4cb-9013-4f3b-9075-ffc4730c4e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_eaaf0f40-2730-4e76-a472-42fd02e2fd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_eaaf0f40-2730-4e76-a472-42fd02e2fd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14905bc4-7075-4713-a033-9f886a77091c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_eaaf0f40-2730-4e76-a472-42fd02e2fd1b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14905bc4-7075-4713-a033-9f886a77091c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_WarrantLiabilityMember_019c68e2-2603-77ab-aba1-a60043f79693" xlink:href="dna-20251231.xsd#dna_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14905bc4-7075-4713-a033-9f886a77091c" xlink:to="loc_dna_WarrantLiabilityMember_019c68e2-2603-77ab-aba1-a60043f79693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContingentConsiderationMember_8a3a76a0-704b-4432-a5ae-d9a53820c152" xlink:href="dna-20251231.xsd#dna_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_14905bc4-7075-4713-a033-9f886a77091c" xlink:to="loc_dna_ContingentConsiderationMember_8a3a76a0-704b-4432-a5ae-d9a53820c152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29a85826-daf6-4eda-a31b-91787aeb0f56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9e88467f-5310-4ecd-b422-d49f9b0f2d49" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29a85826-daf6-4eda-a31b-91787aeb0f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_34d691da-5690-46a6-b823-925f8dec9756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_29a85826-daf6-4eda-a31b-91787aeb0f56" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_34d691da-5690-46a6-b823-925f8dec9756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_34d691da-5690-46a6-b823-925f8dec9756" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_785f50c4-8fdf-4969-950a-d183f42a4e50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_785f50c4-8fdf-4969-950a-d183f42a4e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_40be9958-57a1-41cf-afb0-d791d6fc12b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_40be9958-57a1-41cf-afb0-d791d6fc12b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_2b75f0c7-e97e-4883-b528-778003a545e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_2b75f0c7-e97e-4883-b528-778003a545e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c68e4-14dc-7dfa-b6d4-dce9a777ef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_019c68e4-14dc-7dfa-b6d4-dce9a777ef1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_dda35aa4-04a9-4f42-b438-a9d7e8cd5ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_dda35aa4-04a9-4f42-b438-a9d7e8cd5ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions_378359de-e330-4172-9967-c521e2dffe0d" xlink:href="dna-20251231.xsd#dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions_378359de-e330-4172-9967-c521e2dffe0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019c68e1-2220-7412-a52a-60131fcfa8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_019c68e1-2220-7412-a52a-60131fcfa8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_6b2c221e-7cee-4ef5-8808-a70dc8a2b101" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosureAbstract_b28f606d-0153-4aaa-b5e4-c93b10399369" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_6b2c221e-7cee-4ef5-8808-a70dc8a2b101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_34d691da-5690-46a6-b823-925f8dec9756" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eac483e2-5664-40e3-a9ae-5acbfa4eb5af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eac483e2-5664-40e3-a9ae-5acbfa4eb5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f253632c-d258-4e89-806a-3be9340c5cde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f253632c-d258-4e89-806a-3be9340c5cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_019c68e5-397f-70e2-8e26-d3feab93b4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_019c68e5-397f-70e2-8e26-d3feab93b4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019c68e0-ffda-7968-8365-a371d55e223e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_019c68e0-ffda-7968-8365-a371d55e223e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_03c0c9a5-f4d9-4887-b825-807de3eaf0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_03c0c9a5-f4d9-4887-b825-807de3eaf0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_7dc6cca9-ead9-4076-8fb3-1b6e33debf56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_7dc6cca9-ead9-4076-8fb3-1b6e33debf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e9be4194-4c2b-434e-8d96-06676db4c649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNetAbstract_b70b6148-bbfe-48e3-8638-c24f84148c22" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e9be4194-4c2b-434e-8d96-06676db4c649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_185acc59-4c98-4f1c-88b6-447d8339a446" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_185acc59-4c98-4f1c-88b6-447d8339a446" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b323f0f2-70a6-479c-8aed-a99f9fce5342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b323f0f2-70a6-479c-8aed-a99f9fce5342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17601b-a404-4a82-a208-0fe03a224b18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b323f0f2-70a6-479c-8aed-a99f9fce5342" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17601b-a404-4a82-a208-0fe03a224b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6437ea51-7d99-494b-9273-9b162c42f2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17601b-a404-4a82-a208-0fe03a224b18" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6437ea51-7d99-494b-9273-9b162c42f2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_148790db-8c5e-4c32-9032-a1d752bc04dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:to="loc_us-gaap_ValuationTechniqueAxis_148790db-8c5e-4c32-9032-a1d752bc04dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_2964a2b0-aa86-40dc-8bc7-370be6120a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_148790db-8c5e-4c32-9032-a1d752bc04dd" xlink:to="loc_us-gaap_ValuationTechniqueDomain_2964a2b0-aa86-40dc-8bc7-370be6120a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ProbabilityWeightedPresentValueMember_46f68266-4e5b-42b6-8a94-ec89f08c7456" xlink:href="dna-20251231.xsd#dna_ProbabilityWeightedPresentValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_2964a2b0-aa86-40dc-8bc7-370be6120a3f" xlink:to="loc_dna_ProbabilityWeightedPresentValueMember_46f68266-4e5b-42b6-8a94-ec89f08c7456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_80009179-d6a0-4595-adfc-65e6b76d27af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_2964a2b0-aa86-40dc-8bc7-370be6120a3f" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_80009179-d6a0-4595-adfc-65e6b76d27af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d2ddd93-da80-48e1-aca0-0844ad562f4d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:to="loc_srt_RangeAxis_1d2ddd93-da80-48e1-aca0-0844ad562f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_884d0b28-e88a-4e8b-bfb0-26f0863d5dc7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1d2ddd93-da80-48e1-aca0-0844ad562f4d" xlink:to="loc_srt_RangeMember_884d0b28-e88a-4e8b-bfb0-26f0863d5dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d1314107-e3a8-4321-8fe9-f63c159a65e8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_884d0b28-e88a-4e8b-bfb0-26f0863d5dc7" xlink:to="loc_srt_MinimumMember_d1314107-e3a8-4321-8fe9-f63c159a65e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d2d310c-4123-4c06-ba4f-e7ed9142532e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_884d0b28-e88a-4e8b-bfb0-26f0863d5dc7" xlink:to="loc_srt_MaximumMember_2d2d310c-4123-4c06-ba4f-e7ed9142532e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_eb253483-dcb3-413c-824d-8168ab5084d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31d1d44c-71dd-4edf-8a15-bd64837d152a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_eb253483-dcb3-413c-824d-8168ab5084d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate_ddb100c5-ede0-4a5a-a7bc-56b9fd056f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_eb253483-dcb3-413c-824d-8168ab5084d1" xlink:to="loc_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate_ddb100c5-ede0-4a5a-a7bc-56b9fd056f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019c5c8e-5780-7e35-bd13-342a3ec80b32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019c5c8e-5780-7e35-bd13-342a3ec80b32" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c5c8e-5780-715f-82d2-a65babbb8394" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c5c8e-5780-715f-82d2-a65babbb8394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-7ab6-8171-8f5ff1506207" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_019c5c8e-5780-715f-82d2-a65babbb8394" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-7ab6-8171-8f5ff1506207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SeniorSecuredNoteMember_019c5c8e-5780-78c1-98e8-1ea894503224" xlink:href="dna-20251231.xsd#dna_SeniorSecuredNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-7ab6-8171-8f5ff1506207" xlink:to="loc_dna_SeniorSecuredNoteMember_019c5c8e-5780-78c1-98e8-1ea894503224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ConvertiblePromissoryNotesMember_019c5c8e-5780-7aca-a492-74f24dc7c5b4" xlink:href="dna-20251231.xsd#dna_ConvertiblePromissoryNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_019c5c8e-5780-7ab6-8171-8f5ff1506207" xlink:to="loc_dna_ConvertiblePromissoryNotesMember_019c5c8e-5780-7aca-a492-74f24dc7c5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c5c8e-5780-7753-a7b0-fa1bfa8c0d1b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_srt_RangeAxis_019c5c8e-5780-7753-a7b0-fa1bfa8c0d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c5c8e-5780-7203-87a2-3e5239d59ae7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019c5c8e-5780-7753-a7b0-fa1bfa8c0d1b" xlink:to="loc_srt_RangeMember_019c5c8e-5780-7203-87a2-3e5239d59ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c5c8e-5780-778e-aeee-18132d5b27de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c5c8e-5780-7203-87a2-3e5239d59ae7" xlink:to="loc_srt_MinimumMember_019c5c8e-5780-778e-aeee-18132d5b27de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c5c8e-5780-78eb-8f79-0728b1f188e5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c5c8e-5780-7203-87a2-3e5239d59ae7" xlink:to="loc_srt_MaximumMember_019c5c8e-5780-78eb-8f79-0728b1f188e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_019c5c8e-5780-7fd8-a0ed-7137b62da485" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_019c5c8e-5780-7fd8-a0ed-7137b62da485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_019c5c8e-5780-7fd8-a0ed-7137b62da485" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MeasurementInputScenarioProbabilitiesMember_019c5c8e-5780-706b-ab55-28e07cbcb0ce" xlink:href="dna-20251231.xsd#dna_MeasurementInputScenarioProbabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:to="loc_dna_MeasurementInputScenarioProbabilitiesMember_019c5c8e-5780-706b-ab55-28e07cbcb0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_019c5c8e-5780-764a-b033-3565c65ba140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_019c5c8e-5780-764a-b033-3565c65ba140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_019c5c8e-5780-7358-a48a-b2fb97041d15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_019c5c8e-5780-7579-8885-a792bc66285e" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_019c5c8e-5780-7358-a48a-b2fb97041d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c5c8e-5780-70e0-87b0-d215f31af4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c5c8e-5780-70e0-87b0-d215f31af4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c5c8e-5780-7a94-8223-4f7ad01c7117" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c5c8e-5780-70e0-87b0-d215f31af4fc" xlink:to="loc_us-gaap_SegmentDomain_019c5c8e-5780-7a94-8223-4f7ad01c7117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringSegmentMember_019c5c8e-5780-7e33-a335-c3399c5f3c48" xlink:href="dna-20251231.xsd#dna_CellEngineeringSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c5c8e-5780-7a94-8223-4f7ad01c7117" xlink:to="loc_dna_CellEngineeringSegmentMember_019c5c8e-5780-7e33-a335-c3399c5f3c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c5c8e-5780-7a8d-8c2b-a9f07e7d37f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c5c8e-5780-7a8d-8c2b-a9f07e7d37f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c5c8e-5780-7b2e-9876-349dca37ceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019c5c8e-5780-7a8d-8c2b-a9f07e7d37f1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c5c8e-5780-7b2e-9876-349dca37ceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019c5c8e-5780-727f-ae76-e082f1418c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019c5c8e-5780-7b2e-9876-349dca37ceb8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019c5c8e-5780-727f-ae76-e082f1418c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019c5c8e-5780-7a26-875b-2fa682cb8a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019c5c8e-5780-7a26-875b-2fa682cb8a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-76dd-bb1c-ede813328307" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019c5c8e-5780-7a26-875b-2fa682cb8a5f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-76dd-bb1c-ede813328307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PublicWarrantsMember_019c5c8e-5780-70bc-8ded-8fdc1cf3ed3b" xlink:href="dna-20251231.xsd#dna_PublicWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-76dd-bb1c-ede813328307" xlink:to="loc_dna_PublicWarrantsMember_019c5c8e-5780-70bc-8ded-8fdc1cf3ed3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PrivatePlacementWarrantsMember_019c5c8e-5780-7d7f-bdaf-34ecd8969f2c" xlink:href="dna-20251231.xsd#dna_PrivatePlacementWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019c5c8e-5780-76dd-bb1c-ede813328307" xlink:to="loc_dna_PrivatePlacementWarrantsMember_019c5c8e-5780-7d7f-bdaf-34ecd8969f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c5c8e-5780-7b7e-8629-8b97eb65a78d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c5c8e-5780-7b7e-8629-8b97eb65a78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c5c8e-5780-7528-b0cb-fbe5df93304a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_019c5c8e-5780-7b7e-8629-8b97eb65a78d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_019c5c8e-5780-7528-b0cb-fbe5df93304a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c5c8e-828f-78c1-9812-4857d9cb97f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c5c8e-828f-78c1-9812-4857d9cb97f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c5c8e-828f-768c-91ee-4a247bd977b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c5c8e-828f-78c1-9812-4857d9cb97f4" xlink:to="loc_us-gaap_ClassOfStockDomain_019c5c8e-828f-768c-91ee-4a247bd977b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019c5c8e-828f-7902-b0b4-16959f7ceec0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019c5c8e-828f-768c-91ee-4a247bd977b8" xlink:to="loc_us-gaap_CommonClassAMember_019c5c8e-828f-7902-b0b4-16959f7ceec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c5c8e-828f-717d-9e5a-2a3ea7bdef4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_AwardTypeAxis_019c5c8e-828f-717d-9e5a-2a3ea7bdef4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c5c8e-828f-74af-b506-0fbc3de9e848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019c5c8e-828f-717d-9e5a-2a3ea7bdef4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c5c8e-828f-74af-b506-0fbc3de9e848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_019c5c8e-828f-7e6b-bb0d-78bbf0b9f9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c5c8e-828f-74af-b506-0fbc3de9e848" xlink:to="loc_us-gaap_RestrictedStockMember_019c5c8e-828f-7e6b-bb0d-78bbf0b9f9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_019c5c8e-828f-7a42-981d-ae11b06c3c37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_019c5c8e-828f-7a42-981d-ae11b06c3c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c8e-828f-77a1-bd20-3f2b522a8628" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_019c5c8e-828f-7a42-981d-ae11b06c3c37" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c8e-828f-77a1-bd20-3f2b522a8628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CircularisMember_019c5c8e-828f-78fe-8757-8d12437e0e38" xlink:href="dna-20251231.xsd#dna_CircularisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_019c5c8e-828f-77a1-bd20-3f2b522a8628" xlink:to="loc_dna_CircularisMember_019c5c8e-828f-78fe-8757-8d12437e0e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5c8e-c0e2-7c9d-b5bd-b6e23891150f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5c8e-c0e2-7c9d-b5bd-b6e23891150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5c8e-c0e2-7c9d-b5bd-b6e23891150f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaIncPreferredStockMember_019c5c8e-c0e2-7a29-bfee-ab59307a90dc" xlink:href="dna-20251231.xsd#dna_GenomaticaIncPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:to="loc_dna_GenomaticaIncPreferredStockMember_019c5c8e-c0e2-7a29-bfee-ab59307a90dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafesMember_019c5c8e-c0e2-7f0e-9efa-f8a45ba42eb4" xlink:href="dna-20251231.xsd#dna_SafesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:to="loc_dna_SafesMember_019c5c8e-c0e2-7f0e-9efa-f8a45ba42eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NonMarketableEquitySecuritiesMember_019c5c8e-c0e2-7ceb-98f9-33bc3d4c10d5" xlink:href="dna-20251231.xsd#dna_NonMarketableEquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:to="loc_dna_NonMarketableEquitySecuritiesMember_019c5c8e-c0e2-7ceb-98f9-33bc3d4c10d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OneInvestmentMember_019c94b0-503f-73be-adf0-3cb8f8f1e630" xlink:href="dna-20251231.xsd#dna_OneInvestmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5c8e-c0e2-799d-b011-31f59bcd0d7e" xlink:to="loc_dna_OneInvestmentMember_019c94b0-503f-73be-adf0-3cb8f8f1e630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_019c5c8e-c0e2-7901-a0af-2c841c109fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_InvestmentTypeAxis_019c5c8e-c0e2-7901-a0af-2c841c109fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_019c5c8e-c0e2-7a92-a01f-04398600b77d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_019c5c8e-c0e2-7901-a0af-2c841c109fa2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_019c5c8e-c0e2-7a92-a01f-04398600b77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafeMember_019c5c8e-c0e2-7189-a623-6608f538f118" xlink:href="dna-20251231.xsd#dna_SafeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_019c5c8e-c0e2-7a92-a01f-04398600b77d" xlink:to="loc_dna_SafeMember_019c5c8e-c0e2-7189-a623-6608f538f118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019c5c8e-5780-7c55-ae1a-30e91f34c9dd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableSignificantPurchases_019c5c8e-5780-7779-8961-7cae7530ca4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableSignificantPurchases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_FinancingReceivableSignificantPurchases_019c5c8e-5780-7779-8961-7cae7530ca4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinancingReceivableInterestRateStatedPercentage_019c5c8e-5780-7a83-b503-313032e04c6b" xlink:href="dna-20251231.xsd#dna_FinancingReceivableInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_FinancingReceivableInterestRateStatedPercentage_019c5c8e-5780-7a83-b503-313032e04c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinancingReceivableMeasurementInput_019c5c8e-5780-7a9c-9722-82e5fe95765b" xlink:href="dna-20251231.xsd#dna_FinancingReceivableMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_FinancingReceivableMeasurementInput_019c5c8e-5780-7a9c-9722-82e5fe95765b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinancingReceivableMeasurementInputPeriod_019c5c8e-5780-7712-9cea-402328aacdf7" xlink:href="dna-20251231.xsd#dna_FinancingReceivableMeasurementInputPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_FinancingReceivableMeasurementInputPeriod_019c5c8e-5780-7712-9cea-402328aacdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_019c5c8e-5780-74b0-aaa1-176a287faca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_019c5c8e-5780-74b0-aaa1-176a287faca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019c5c8e-5780-7713-bde5-49acb34b0720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_019c5c8e-5780-7713-bde5-49acb34b0720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_019c5c8e-5780-7592-a9a9-b13e7cd39e64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_019c5c8e-5780-7592-a9a9-b13e7cd39e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_019c5c8e-5780-7fc8-a677-ec54e27e8b90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_019c5c8e-5780-7fc8-a677-ec54e27e8b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019c5c8e-5780-7115-9007-e2bc02e50c88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019c5c8e-5780-7115-9007-e2bc02e50c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum_019c5c8e-828f-7fc8-a33f-23c09a939048" xlink:href="dna-20251231.xsd#dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum_019c5c8e-828f-7fc8-a33f-23c09a939048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019c5c8e-828f-7da1-911d-44926e1c9d07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_019c5c8e-828f-7da1-911d-44926e1c9d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_019c5c8e-828f-7e63-9e65-d714fb04bf6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_019c5c8e-828f-7e63-9e65-d714fb04bf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_019c5c8e-828f-7669-9997-d3d2cc53dcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_019c5c8e-828f-7669-9997-d3d2cc53dcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ClassOfWarrantOrRightStockSplitConversionRatio_019c9010-d36e-72a0-8af9-a6cc6856b4fd" xlink:href="dna-20251231.xsd#dna_ClassOfWarrantOrRightStockSplitConversionRatio"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_ClassOfWarrantOrRightStockSplitConversionRatio_019c9010-d36e-72a0-8af9-a6cc6856b4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BusinessCombinationContingentConsiderationVestedValue_019c5c8e-828f-7b49-8017-145382020450" xlink:href="dna-20251231.xsd#dna_BusinessCombinationContingentConsiderationVestedValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_BusinessCombinationContingentConsiderationVestedValue_019c5c8e-828f-7b49-8017-145382020450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_019c5c8e-c0e2-7cda-a9ae-32c22975f536" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_GainLossOnInvestments_019c5c8e-c0e2-7cda-a9ae-32c22975f536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_019c5c8f-4a3f-7d59-8c2b-64c1b14782fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_019c5c8f-4a3f-7d59-8c2b-64c1b14782fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_019c5c8e-c0e2-70c3-9268-4ed2e7852c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_019c5c8e-c0e2-70c3-9268-4ed2e7852c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage_019c5c8e-c0e2-7119-a616-dfc89d6245b8" xlink:href="dna-20251231.xsd#dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage_019c5c8e-c0e2-7119-a616-dfc89d6245b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c5c8e-c0e2-730e-afd2-bc50b1281904" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c5c8e-c0e2-730e-afd2-bc50b1281904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_019c5c8e-c0e2-74ab-8211-39ad6dbec90b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_019c5c8e-c0e2-74ab-8211-39ad6dbec90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_019c5c8e-c0e2-73b2-9fd9-3db1f939c414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_019c5c8e-c0e2-73b2-9fd9-3db1f939c414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquitySecuritiesFVNIMeasurementInputTerm_019c5c8e-c0e2-780c-b8fe-881fb66f2e00" xlink:href="dna-20251231.xsd#dna_EquitySecuritiesFVNIMeasurementInputTerm"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019c5c8e-5780-759c-a8eb-060a130da80b" xlink:to="loc_dna_EquitySecuritiesFVNIMeasurementInputTerm_019c5c8e-c0e2-780c-b8fe-881fb66f2e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c5c90-8cc0-77e4-bf6b-dd578ecaaa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_019c5c90-8cc0-732b-81ce-b1c92b324b49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_019c5c90-8cc0-77e4-bf6b-dd578ecaaa1d" xlink:to="loc_us-gaap_MarketableSecuritiesTable_019c5c90-8cc0-732b-81ce-b1c92b324b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019c5cea-d6e9-7511-b373-edab03fcce70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_019c5c90-8cc0-732b-81ce-b1c92b324b49" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019c5cea-d6e9-7511-b373-edab03fcce70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019c5cea-d6e9-7511-b373-edab03fcce70" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019c5c90-8cc0-7829-b961-d00b15b6d79f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019c5c90-8cc0-7829-b961-d00b15b6d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_019c5c90-8cc0-7588-a321-11c8e016df3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_019c5c90-8cc0-7588-a321-11c8e016df3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_019c5c90-8cc0-79a9-9093-e9fc33b06640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:to="loc_us-gaap_CommercialPaperMember_019c5c90-8cc0-79a9-9093-e9fc33b06640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_019c5c90-8cc0-747d-bdc5-8845ff1ae76c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019c5cea-d6e9-7334-80b2-03c01fd48075" xlink:to="loc_us-gaap_EquitySecuritiesMember_019c5c90-8cc0-747d-bdc5-8845ff1ae76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_019c5c90-8cc0-732b-81ce-b1c92b324b49" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c5c90-8cc0-7b3a-8dfd-66d3a34f2f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019c5c90-8cc0-7b3a-8dfd-66d3a34f2f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_019c5ce8-6113-70e3-96cb-0951e40c5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_019c5ce8-6113-70e3-96cb-0951e40c5ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_019c5ce8-7e33-7f90-b657-5d76ca3d31ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_019c5ce8-7e33-7f90-b657-5d76ca3d31ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c5ce9-349e-7113-a634-c289f4382f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019c5ce9-349e-7113-a634-c289f4382f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c5ceb-8090-79bf-9bb2-41b43fa31e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c5ceb-8090-79bf-9bb2-41b43fa31e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c5cea-0247-7c7b-b51a-17c676309f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c5ceb-8090-79bf-9bb2-41b43fa31e6d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_019c5cea-0247-7c7b-b51a-17c676309f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c5cea-14b8-7264-89a7-5ebf17d20d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_019c5ceb-8090-79bf-9bb2-41b43fa31e6d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_019c5cea-14b8-7264-89a7-5ebf17d20d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c5ceb-5b74-711f-bcda-75c212266034" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_019c5c90-8cc0-7f9a-b53c-f243cf0486cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c5ceb-5b74-711f-bcda-75c212266034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c5cea-6ba3-7adf-b089-e72f1ffca020" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c5ceb-5b74-711f-bcda-75c212266034" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_019c5cea-6ba3-7adf-b089-e72f1ffca020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c5cea-7d19-7875-846c-676b30cdb046" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_019c5ceb-5b74-711f-bcda-75c212266034" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_019c5cea-7d19-7875-846c-676b30cdb046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_234fbc3c-bb61-4388-853e-b235dbc9b7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5a3d26fc-fde6-4e4e-9491-fe04f56a0ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_234fbc3c-bb61-4388-853e-b235dbc9b7d3" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5a3d26fc-fde6-4e4e-9491-fe04f56a0ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_837a7420-ae12-4881-9c98-28b38f273c51" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5a3d26fc-fde6-4e4e-9491-fe04f56a0ce4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_837a7420-ae12-4881-9c98-28b38f273c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_837a7420-ae12-4881-9c98-28b38f273c51" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafesMember_7c9645ef-b95d-469f-a32f-451abed709f9" xlink:href="dna-20251231.xsd#dna_SafesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_SafesMember_7c9645ef-b95d-469f-a32f-451abed709f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NonMarketableEquitySecuritiesMember_e9ac50ed-07e9-4c3c-8a8e-3fa86243ac1b" xlink:href="dna-20251231.xsd#dna_NonMarketableEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_NonMarketableEquitySecuritiesMember_e9ac50ed-07e9-4c3c-8a8e-3fa86243ac1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MarketableEquitySecuritiesMember_0f379e71-18b9-4034-9a41-d8e92788500b" xlink:href="dna-20251231.xsd#dna_MarketableEquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_MarketableEquitySecuritiesMember_0f379e71-18b9-4034-9a41-d8e92788500b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaIncPreferredStockMember_7c920c19-df2c-41fa-bbea-996a6609dd54" xlink:href="dna-20251231.xsd#dna_GenomaticaIncPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_GenomaticaIncPreferredStockMember_7c920c19-df2c-41fa-bbea-996a6609dd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SynlogicIncWarrantMember_36980883-5ab5-4e23-a2e6-ff4001edffe2" xlink:href="dna-20251231.xsd#dna_SynlogicIncWarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_SynlogicIncWarrantMember_36980883-5ab5-4e23-a2e6-ff4001edffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditLlcMember_898e22f3-aceb-4e3b-95f9-38c6e3cc76fb" xlink:href="dna-20251231.xsd#dna_BiomeditLlcMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_BiomeditLlcMember_898e22f3-aceb-4e3b-95f9-38c6e3cc76fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherEquityInvestessMember_969cb049-c46a-49d7-8d25-0acd5b72b0da" xlink:href="dna-20251231.xsd#dna_OtherEquityInvestessMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f27cc224-28bc-4f77-9879-14b8cbb18e91" xlink:to="loc_dna_OtherEquityInvestessMember_969cb049-c46a-49d7-8d25-0acd5b72b0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_5a3d26fc-fde6-4e4e-9491-fe04f56a0ce4" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8118f3b7-1829-4606-b3f0-2dd133914260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8118f3b7-1829-4606-b3f0-2dd133914260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_817fa631-0e29-4be6-a23e-80d8075f91bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_817fa631-0e29-4be6-a23e-80d8075f91bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_d50e727b-2846-449a-833f-74a589ac431b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_Investments_d50e727b-2846-449a-833f-74a589ac431b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_50da5a01-2ab1-4d76-a566-a7a968f3a95c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_GainLossOnInvestments_50da5a01-2ab1-4d76-a566-a7a968f3a95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f90cee1c-6807-4e97-bdf6-94eb80bae9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f90cee1c-6807-4e97-bdf6-94eb80bae9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_254469df-a12e-44e7-8401-4bd0e61aab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_9b67180b-0727-41bb-8e06-435e19dd881a" xlink:to="loc_us-gaap_EquityMethodInvestments_254469df-a12e-44e7-8401-4bd0e61aab7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c25fccef-15e0-42b3-b5de-7c0c20193880" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_881223a6-9287-4ae9-a4cf-7fb293fbe2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c25fccef-15e0-42b3-b5de-7c0c20193880" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_881223a6-9287-4ae9-a4cf-7fb293fbe2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e5ce7355-510a-4e9c-8723-a91ee254a729" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c25fccef-15e0-42b3-b5de-7c0c20193880" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e5ce7355-510a-4e9c-8723-a91ee254a729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_6c30d122-c5fe-46d5-95c0-06aea6dee216" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c25fccef-15e0-42b3-b5de-7c0c20193880" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_6c30d122-c5fe-46d5-95c0-06aea6dee216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_4f8f7959-a674-4e96-a8bf-ba8d9125b521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c25fccef-15e0-42b3-b5de-7c0c20193880" xlink:to="loc_us-gaap_GainLossOnInvestments_4f8f7959-a674-4e96-a8bf-ba8d9125b521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_fd4f91c5-28ee-4a17-a7ee-4667be5a578f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_aa5994db-1d96-4db2-9edb-f02707dc000e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_fd4f91c5-28ee-4a17-a7ee-4667be5a578f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_aa5994db-1d96-4db2-9edb-f02707dc000e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_afc26f65-6852-4cc5-aae1-7b25d5bb33bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_fd4f91c5-28ee-4a17-a7ee-4667be5a578f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_afc26f65-6852-4cc5-aae1-7b25d5bb33bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_2f7f904e-bbeb-4eaa-be08-663a701c2540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_fd4f91c5-28ee-4a17-a7ee-4667be5a578f" xlink:to="loc_us-gaap_GainLossOnInvestments_2f7f904e-bbeb-4eaa-be08-663a701c2540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_8e5d1140-4b99-4ddf-8ce5-c28af2bf3d26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49927493-6a09-4eb3-bb35-f26ddaa05e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_8e5d1140-4b99-4ddf-8ce5-c28af2bf3d26" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49927493-6a09-4eb3-bb35-f26ddaa05e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f8b65fc3-9bb3-4723-8617-948ca97885c0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49927493-6a09-4eb3-bb35-f26ddaa05e5d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f8b65fc3-9bb3-4723-8617-948ca97885c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e8a83b6a-bf5f-42ac-9d83-25b12bacf406" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f8b65fc3-9bb3-4723-8617-948ca97885c0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e8a83b6a-bf5f-42ac-9d83-25b12bacf406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NonMarketableEquitySecuritiesMember_0c781b10-f4ab-4e1d-a743-3b30c014082f" xlink:href="dna-20251231.xsd#dna_NonMarketableEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e8a83b6a-bf5f-42ac-9d83-25b12bacf406" xlink:to="loc_dna_NonMarketableEquitySecuritiesMember_0c781b10-f4ab-4e1d-a743-3b30c014082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_49927493-6a09-4eb3-bb35-f26ddaa05e5d" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_117e52cb-60df-4d78-8279-6f4cc9cfeb65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_117e52cb-60df-4d78-8279-6f4cc9cfeb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_37f80c48-6c71-48c5-be1d-af296e51af72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_37f80c48-6c71-48c5-be1d-af296e51af72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_9360e803-3a87-4cb1-a88a-e38499de0fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_9360e803-3a87-4cb1-a88a-e38499de0fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_ee2c77ae-f65c-478c-9bb2-4b0f5abeb7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d7aac1d3-b4e8-4cca-9356-698bb96d4f68" xlink:to="loc_us-gaap_Investments_ee2c77ae-f65c-478c-9bb2-4b0f5abeb7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1bf43f9c-3481-4ba9-a58f-2f7dcb652a84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1bf43f9c-3481-4ba9-a58f-2f7dcb652a84" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b961f137-09a0-4ba3-aeac-da6962cbbbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b961f137-09a0-4ba3-aeac-da6962cbbbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f17c9421-51bd-433c-8885-334ae6d7bd82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b961f137-09a0-4ba3-aeac-da6962cbbbb4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f17c9421-51bd-433c-8885-334ae6d7bd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgBiomeInc.Member_5403ff2f-6a1b-45fa-a4af-072f36dd0c30" xlink:href="dna-20251231.xsd#dna_AgBiomeInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f17c9421-51bd-433c-8885-334ae6d7bd82" xlink:to="loc_dna_AgBiomeInc.Member_5403ff2f-6a1b-45fa-a4af-072f36dd0c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7ee53d9d-1118-4f43-85b0-fd50ace755f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7ee53d9d-1118-4f43-85b0-fd50ace755f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_12187ce7-fac1-48d9-a349-9af413000342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7ee53d9d-1118-4f43-85b0-fd50ace755f8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_12187ce7-fac1-48d9-a349-9af413000342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_dad7c7cb-f656-49b3-add8-dd562d8557e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_12187ce7-fac1-48d9-a349-9af413000342" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_dad7c7cb-f656-49b3-add8-dd562d8557e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a5bcabf-ed8d-4231-ab87-aaef03ba66b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a5bcabf-ed8d-4231-ab87-aaef03ba66b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_730111a7-e747-48ea-8e83-b17006578eba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a5bcabf-ed8d-4231-ab87-aaef03ba66b6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_730111a7-e747-48ea-8e83-b17006578eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AltarSasMember_cc49d179-71d7-4206-8190-40d11ceb18ed" xlink:href="dna-20251231.xsd#dna_AltarSasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_730111a7-e747-48ea-8e83-b17006578eba" xlink:to="loc_dna_AltarSasMember_cc49d179-71d7-4206-8190-40d11ceb18ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ZymergenMember_f0e15f30-3a36-4fa8-927e-74e2d8de65d0" xlink:href="dna-20251231.xsd#dna_ZymergenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_730111a7-e747-48ea-8e83-b17006578eba" xlink:to="loc_dna_ZymergenMember_f0e15f30-3a36-4fa8-927e-74e2d8de65d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0250c05e-a2f8-44ce-b897-e02181ae408e" xlink:to="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GoodwillImpairmentDCFWeight_019c9013-2acc-745d-9ad3-d84def4ebeb1" xlink:href="dna-20251231.xsd#dna_GoodwillImpairmentDCFWeight"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_dna_GoodwillImpairmentDCFWeight_019c9013-2acc-745d-9ad3-d84def4ebeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GoodwillImpairmentGPCWeight_019c9013-989e-7e63-97b4-3a301b534c5c" xlink:href="dna-20251231.xsd#dna_GoodwillImpairmentGPCWeight"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_dna_GoodwillImpairmentGPCWeight_019c9013-989e-7e63-97b4-3a301b534c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a1dbaeb4-c81e-4068-8546-c6872557337e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a1dbaeb4-c81e-4068-8546-c6872557337e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fba86350-3dcb-4253-b90b-499b1326c4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fba86350-3dcb-4253-b90b-499b1326c4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_73e90646-e16a-4e7e-a9e7-0610a2a8b6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_73e90646-e16a-4e7e-a9e7-0610a2a8b6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6ef62589-b2f5-43d4-947c-eb9b2b6f3a17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5a1fbf87-2c62-4b36-ba69-deeae18d7c69" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6ef62589-b2f5-43d4-947c-eb9b2b6f3a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6bb99de-f802-44d7-9b14-879202c2e16b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_155d3822-4f20-4138-b472-b114c467cf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6bb99de-f802-44d7-9b14-879202c2e16b" xlink:to="loc_us-gaap_GoodwillRollForward_155d3822-4f20-4138-b472-b114c467cf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_92a8026d-0895-4079-9bc8-c8c9fc29b3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_155d3822-4f20-4138-b472-b114c467cf2c" xlink:to="loc_us-gaap_Goodwill_92a8026d-0895-4079-9bc8-c8c9fc29b3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_74281dfe-810d-420d-b3dd-b522a5f14260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_155d3822-4f20-4138-b472-b114c467cf2c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_74281dfe-810d-420d-b3dd-b522a5f14260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e90b22c0-4a56-44c2-88b6-84915c540f66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_155d3822-4f20-4138-b472-b114c467cf2c" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e90b22c0-4a56-44c2-88b6-84915c540f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_45aa158f-ddd7-4de2-8d30-645c4403f6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_155d3822-4f20-4138-b472-b114c467cf2c" xlink:to="loc_us-gaap_Goodwill_45aa158f-ddd7-4de2-8d30-645c4403f6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6af6e0a1-cdc3-4131-ab95-7d0010aee61e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3867579d-39bd-4723-b0f6-86cabb3ea7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6af6e0a1-cdc3-4131-ab95-7d0010aee61e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3867579d-39bd-4723-b0f6-86cabb3ea7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ac75a7d5-0e08-4854-aca8-017fc50e959c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3867579d-39bd-4723-b0f6-86cabb3ea7d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ac75a7d5-0e08-4854-aca8-017fc50e959c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60ab09eb-cdc5-43d6-9940-4d1b32b04f26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ac75a7d5-0e08-4854-aca8-017fc50e959c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60ab09eb-cdc5-43d6-9940-4d1b32b04f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_dcb5d254-cbda-4019-a053-9f4da5b87ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60ab09eb-cdc5-43d6-9940-4d1b32b04f26" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_dcb5d254-cbda-4019-a053-9f4da5b87ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3867579d-39bd-4723-b0f6-86cabb3ea7d3" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3673a207-311e-48a9-ba08-c1c8efbad224" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3673a207-311e-48a9-ba08-c1c8efbad224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca73e384-b141-4a02-9b97-639d8750fa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca73e384-b141-4a02-9b97-639d8750fa4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_31f76285-db86-4536-8db7-23d25cf5ffb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_31f76285-db86-4536-8db7-23d25cf5ffb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1fc7a878-04c2-43fd-ba6c-61b663fa8f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e1da075d-614a-411d-80af-128c3f1de271" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1fc7a878-04c2-43fd-ba6c-61b663fa8f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07a88faa-5ee9-43a0-a2c2-6eaade442904" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_287a2dd7-c8c5-4d78-82ad-c9e467cd8ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07a88faa-5ee9-43a0-a2c2-6eaade442904" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_287a2dd7-c8c5-4d78-82ad-c9e467cd8ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5c32d37e-d481-40c1-b1ac-65d6bfe45be2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07a88faa-5ee9-43a0-a2c2-6eaade442904" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5c32d37e-d481-40c1-b1ac-65d6bfe45be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3f6177c0-dc52-465f-a3d0-9c33b8772004" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07a88faa-5ee9-43a0-a2c2-6eaade442904" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3f6177c0-dc52-465f-a3d0-9c33b8772004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4394c101-fdeb-486c-b6da-995b5f16352b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07a88faa-5ee9-43a0-a2c2-6eaade442904" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4394c101-fdeb-486c-b6da-995b5f16352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_17f3abe3-f29c-45cd-b7e2-470fc13239fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07a88faa-5ee9-43a0-a2c2-6eaade442904" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_17f3abe3-f29c-45cd-b7e2-470fc13239fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a8e8cc71-7aef-42d2-a4bb-2848b54dacc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07a88faa-5ee9-43a0-a2c2-6eaade442904" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a8e8cc71-7aef-42d2-a4bb-2848b54dacc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_54215252-02e8-4764-acbb-6dd70b1a6fac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07a88faa-5ee9-43a0-a2c2-6eaade442904" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_54215252-02e8-4764-acbb-6dd70b1a6fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4d684157-618d-4847-926e-40a1098cc1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4d684157-618d-4847-926e-40a1098cc1e4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c39b1c9-41c4-4143-9c77-6cd7e00c4eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c39b1c9-41c4-4143-9c77-6cd7e00c4eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26125a98-cf34-4ed8-be09-bf8eeb0faee0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c39b1c9-41c4-4143-9c77-6cd7e00c4eab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26125a98-cf34-4ed8-be09-bf8eeb0faee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EquipmentLeasesMember_37f58242-29ee-4c65-b8bc-144b2e15a774" xlink:href="dna-20251231.xsd#dna_EquipmentLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26125a98-cf34-4ed8-be09-bf8eeb0faee0" xlink:to="loc_dna_EquipmentLeasesMember_37f58242-29ee-4c65-b8bc-144b2e15a774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a957ab17-22f1-4086-bef2-0296f98e57a2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:to="loc_srt_RangeAxis_a957ab17-22f1-4086-bef2-0296f98e57a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4cc8f96a-7e4a-42b4-aa99-fa52f7d7c3b7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a957ab17-22f1-4086-bef2-0296f98e57a2" xlink:to="loc_srt_RangeMember_4cc8f96a-7e4a-42b4-aa99-fa52f7d7c3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_78235d61-057e-4ab2-a4c3-feebca9122c6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4cc8f96a-7e4a-42b4-aa99-fa52f7d7c3b7" xlink:to="loc_srt_MinimumMember_78235d61-057e-4ab2-a4c3-feebca9122c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b34a251-9662-4d37-a94b-c8bad6a0d6b6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4cc8f96a-7e4a-42b4-aa99-fa52f7d7c3b7" xlink:to="loc_srt_MaximumMember_7b34a251-9662-4d37-a94b-c8bad6a0d6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfb04779-0365-4adc-903a-9ef450966159" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfb04779-0365-4adc-903a-9ef450966159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_14a44f4a-7949-484f-9d9b-d0aa2d649b12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cfb04779-0365-4adc-903a-9ef450966159" xlink:to="loc_us-gaap_RelatedPartyDomain_14a44f4a-7949-484f-9d9b-d0aa2d649b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f1b93534-3f7d-49f4-a22c-604298a6cd54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_14a44f4a-7949-484f-9d9b-d0aa2d649b12" xlink:to="loc_us-gaap_RelatedPartyMember_f1b93534-3f7d-49f4-a22c-604298a6cd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_13e5e448-9eb4-43ec-a32e-c637c606e46e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_13e5e448-9eb4-43ec-a32e-c637c606e46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d3bde41-8c76-4af7-b4e7-f1f2a32f8ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_13e5e448-9eb4-43ec-a32e-c637c606e46e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d3bde41-8c76-4af7-b4e7-f1f2a32f8ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_8253b814-bfdf-45bd-9135-c733c2b6c30f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d3bde41-8c76-4af7-b4e7-f1f2a32f8ed9" xlink:to="loc_us-gaap_BuildingMember_8253b814-bfdf-45bd-9135-c733c2b6c30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c78198a7-ee34-4e33-9012-43e51e14e7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d3bde41-8c76-4af7-b4e7-f1f2a32f8ed9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c78198a7-ee34-4e33-9012-43e51e14e7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3140c3c0-7b0a-4ba8-8dee-49e4f8c151b6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dc39f553-a16b-4d12-b56c-5e300247b2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dc39f553-a16b-4d12-b56c-5e300247b2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LesseeOperatingLeaseAreaOfRealEstateProperty_a43f2c28-99ce-48bd-93de-29e05d989b53" xlink:href="dna-20251231.xsd#dna_LesseeOperatingLeaseAreaOfRealEstateProperty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_dna_LesseeOperatingLeaseAreaOfRealEstateProperty_a43f2c28-99ce-48bd-93de-29e05d989b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LesseeOperatingLeaseNumberOfExtensionOptions_019c9014-ff70-7adb-a09b-120e1ac40ccd" xlink:href="dna-20251231.xsd#dna_LesseeOperatingLeaseNumberOfExtensionOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_dna_LesseeOperatingLeaseNumberOfExtensionOptions_019c9014-ff70-7adb-a09b-120e1ac40ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_cab64411-560a-4eed-86da-1e335b402edb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_cab64411-560a-4eed-86da-1e335b402edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_c9b7d941-f3b3-4093-a8ce-2ed10ff5db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_c9b7d941-f3b3-4093-a8ce-2ed10ff5db2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_7bf4c169-b684-48d2-855f-23bfb4d12548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_7bf4c169-b684-48d2-855f-23bfb4d12548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_462fa007-d118-4ecd-b5b5-b0931f1eae46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1d4f336b-18f6-4d94-8320-c73e09e4f7f6" xlink:to="loc_us-gaap_SubleaseIncome_462fa007-d118-4ecd-b5b5-b0931f1eae46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#LeasesScheduleofComponentsofTotalLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1be06b4d-146c-4f27-a784-58ce90ae3c02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_6d66c237-6270-405a-ba32-5aeaaf18f64a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1be06b4d-146c-4f27-a784-58ce90ae3c02" xlink:to="loc_us-gaap_OperatingLeaseCost_6d66c237-6270-405a-ba32-5aeaaf18f64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_967654cf-e7e3-431e-98c2-bee148d623f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1be06b4d-146c-4f27-a784-58ce90ae3c02" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_967654cf-e7e3-431e-98c2-bee148d623f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_8551688c-2095-4f47-8c4a-a1231921ecec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1be06b4d-146c-4f27-a784-58ce90ae3c02" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_8551688c-2095-4f47-8c4a-a1231921ecec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinanceLeaseCost_234baffc-da92-4395-87e2-e89d96224e5e" xlink:href="dna-20251231.xsd#dna_FinanceLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1be06b4d-146c-4f27-a784-58ce90ae3c02" xlink:to="loc_dna_FinanceLeaseCost_234baffc-da92-4395-87e2-e89d96224e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_deebefa1-9a6c-42c2-a8dc-5b29f8ccb2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1be06b4d-146c-4f27-a784-58ce90ae3c02" xlink:to="loc_us-gaap_VariableLeaseCost_deebefa1-9a6c-42c2-a8dc-5b29f8ccb2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_390dbdc2-e39b-4e41-b6ab-969ed203ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1be06b4d-146c-4f27-a784-58ce90ae3c02" xlink:to="loc_us-gaap_SubleaseIncome_390dbdc2-e39b-4e41-b6ab-969ed203ff14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_34b5328d-7c90-4e54-867d-153f9c7e70a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1be06b4d-146c-4f27-a784-58ce90ae3c02" xlink:to="loc_us-gaap_LeaseCost_34b5328d-7c90-4e54-867d-153f9c7e70a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9bf6c48e-2242-4fc0-a921-c0fd931139e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_569a2a54-cea9-43df-8e6f-b2e12deb4461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9bf6c48e-2242-4fc0-a921-c0fd931139e3" xlink:to="loc_us-gaap_OperatingLeasePayments_569a2a54-cea9-43df-8e6f-b2e12deb4461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_1dbe5e7f-4745-4f04-9b41-47ed45269f96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9bf6c48e-2242-4fc0-a921-c0fd931139e3" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_1dbe5e7f-4745-4f04-9b41-47ed45269f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4001b5c1-005c-4493-a3f7-7fa1a351c221" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9bf6c48e-2242-4fc0-a921-c0fd931139e3" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_4001b5c1-005c-4493-a3f7-7fa1a351c221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#LeasesScheduleofSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b2a702b6-f7ae-44a3-8505-03ba5c4c4ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fabbf63f-78a8-48da-b7b1-d30d3c53e88b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2a702b6-f7ae-44a3-8505-03ba5c4c4ca9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fabbf63f-78a8-48da-b7b1-d30d3c53e88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_7c5311d7-c3e9-4cb4-9cbf-1cbd92ce4e12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2a702b6-f7ae-44a3-8505-03ba5c4c4ca9" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_7c5311d7-c3e9-4cb4-9cbf-1cbd92ce4e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_04c5bbb1-aee3-4efa-b7f3-a6bf8463c094" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2a702b6-f7ae-44a3-8505-03ba5c4c4ca9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_04c5bbb1-aee3-4efa-b7f3-a6bf8463c094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_ea873026-169e-4968-ad02-c442f24d70dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2a702b6-f7ae-44a3-8505-03ba5c4c4ca9" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_ea873026-169e-4968-ad02-c442f24d70dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_44a9ab66-9da3-4a16-bbe3-b0aa7a0e642d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_44a9ab66-9da3-4a16-bbe3-b0aa7a0e642d" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7849af7b-495e-456b-a99f-0c673c9e2a90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7849af7b-495e-456b-a99f-0c673c9e2a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dd1a9172-8795-4671-906a-d8817f93c6be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dd1a9172-8795-4671-906a-d8817f93c6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e3c8d280-e7e4-414e-a798-44f77286f4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e3c8d280-e7e4-414e-a798-44f77286f4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_65b24fbb-68de-4f18-bc4b-2ad5d4f31b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_65b24fbb-68de-4f18-bc4b-2ad5d4f31b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5a02dad3-d6a6-4b34-b1da-cb431741c0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5a02dad3-d6a6-4b34-b1da-cb431741c0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1d3354ce-95a0-45c6-a69f-0a5bb4e04d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1d3354ce-95a0-45c6-a69f-0a5bb4e04d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f72da48-741d-45b8-8e97-ef421d03f306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f72da48-741d-45b8-8e97-ef421d03f306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_85ab7079-087a-4642-8e4b-258d16abde74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_85ab7079-087a-4642-8e4b-258d16abde74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a0f979c9-f50e-4601-ac39-6c4292cc08c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_OperatingLeaseLiability_a0f979c9-f50e-4601-ac39-6c4292cc08c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bb9d8e45-ad57-48b5-878f-8a07b691c613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bb9d8e45-ad57-48b5-878f-8a07b691c613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e1a1d11f-fb7f-475a-8f6f-b77e796356f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0db5edc2-1ee4-433d-a95c-2fc7f03fdd8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e1a1d11f-fb7f-475a-8f6f-b77e796356f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_44a9ab66-9da3-4a16-bbe3-b0aa7a0e642d" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_dd039133-3187-4396-aa27-4df10ec5a9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_dd039133-3187-4396-aa27-4df10ec5a9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_25428658-9e2b-4bc9-85b8-e9e9759222c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_25428658-9e2b-4bc9-85b8-e9e9759222c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2922635a-4a47-4661-8caf-ecef0e2c890a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2922635a-4a47-4661-8caf-ecef0e2c890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9111ed8f-104e-4503-a04d-9ad74b00c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9111ed8f-104e-4503-a04d-9ad74b00c1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_97d54de9-99d1-40bb-b4db-8e557545df8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_97d54de9-99d1-40bb-b4db-8e557545df8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_32ddb3a1-eb12-42d5-86ca-015c83c55952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_32ddb3a1-eb12-42d5-86ca-015c83c55952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_4276909c-0b20-4ae4-b01b-59be69780f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_4276909c-0b20-4ae4-b01b-59be69780f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment_a05f78f8-34b4-40cc-a17b-c0a23b0d0b9c" xlink:href="dna-20251231.xsd#dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment_a05f78f8-34b4-40cc-a17b-c0a23b0d0b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f3674103-92c0-40d0-aeef-aa4faa910066" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiability_f3674103-92c0-40d0-aeef-aa4faa910066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_436f770e-af9c-4e89-8f2f-95116e0b39a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_436f770e-af9c-4e89-8f2f-95116e0b39a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f2f847aa-0edf-4df2-88d2-638458143a85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f2f847aa-0edf-4df2-88d2-638458143a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_090720b2-9319-46c2-a5f6-23130e176470" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_18f49a7f-1364-4984-867b-7cdeede51fcb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_090720b2-9319-46c2-a5f6-23130e176470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_SupplementalBalanceSheetInformationAbstract_e80978dc-ab3b-4224-b9d7-38c3a4f4d825" xlink:href="dna-20251231.xsd#dna_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83f4251a-169b-4a4a-8567-a903dec9fbea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_e80978dc-ab3b-4224-b9d7-38c3a4f4d825" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83f4251a-169b-4a4a-8567-a903dec9fbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_95cec768-66c8-432a-a3cd-81d9e4a7a8da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_e80978dc-ab3b-4224-b9d7-38c3a4f4d825" xlink:to="loc_us-gaap_RestrictedCashCurrent_95cec768-66c8-432a-a3cd-81d9e4a7a8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_1b080f2a-4298-458b-929a-7f5e937bcab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_e80978dc-ab3b-4224-b9d7-38c3a4f4d825" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_1b080f2a-4298-458b-929a-7f5e937bcab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_510c92c8-4093-483f-abe3-f9fb683a533e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_e80978dc-ab3b-4224-b9d7-38c3a4f4d825" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_510c92c8-4093-483f-abe3-f9fb683a533e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_SupplementalBalanceSheetInformationAbstract_904a838a-4712-4627-9777-16386852c47b" xlink:href="dna-20251231.xsd#dna_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3a5e3950-e3e8-458a-938c-e5d385cf4e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_904a838a-4712-4627-9777-16386852c47b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3a5e3950-e3e8-458a-938c-e5d385cf4e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23c16c9e-ee09-4736-a2a3-65c0946de749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3a5e3950-e3e8-458a-938c-e5d385cf4e78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23c16c9e-ee09-4736-a2a3-65c0946de749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23c16c9e-ee09-4736-a2a3-65c0946de749" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LabEquipmentMember_0c60213e-66f8-471a-8f51-5760a2b59762" xlink:href="dna-20251231.xsd#dna_LabEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_dna_LabEquipmentMember_0c60213e-66f8-471a-8f51-5760a2b59762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_04c491e5-880a-4923-9536-2b7c2874ec37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_04c491e5-880a-4923-9536-2b7c2874ec37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_9a53a4b8-dc7c-4043-8b91-5994b9430f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_ManufacturingFacilityMember_9a53a4b8-dc7c-4043-8b91-5994b9430f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_3620dd61-6ded-490c-979b-9f71da2661d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_ConstructionInProgressMember_3620dd61-6ded-490c-979b-9f71da2661d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ComputerEquipmentAndSoftwareMember_049e7db8-975f-4054-a3b7-b657ad6d8afd" xlink:href="dna-20251231.xsd#dna_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_dna_ComputerEquipmentAndSoftwareMember_049e7db8-975f-4054-a3b7-b657ad6d8afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_239d0331-c605-4c68-b962-9d9dac29e746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_239d0331-c605-4c68-b962-9d9dac29e746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_8296992c-8bf9-441b-a7c9-a8885c787860" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1e1e2f3-ce75-4f06-988d-5b3ba5d01a37" xlink:to="loc_us-gaap_LandMember_8296992c-8bf9-441b-a7c9-a8885c787860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3a5e3950-e3e8-458a-938c-e5d385cf4e78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6df45faa-fb68-4c40-8509-5f6c9f5eeec4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6df45faa-fb68-4c40-8509-5f6c9f5eeec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8ace023c-680c-46a9-87d3-f8c337ffeb03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8ace023c-680c-46a9-87d3-f8c337ffeb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d03a8be9-279b-4952-bb79-7c2758af9865" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cf27570d-75f4-4204-a0f0-afde87c41b07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d03a8be9-279b-4952-bb79-7c2758af9865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_SupplementalBalanceSheetInformationAbstract_551e1fb7-957f-4d30-8e41-c405e05d11de" xlink:href="dna-20251231.xsd#dna_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_10ba66a1-82ef-4fa3-ab4d-220c41669ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_551e1fb7-957f-4d30-8e41-c405e05d11de" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_10ba66a1-82ef-4fa3-ab4d-220c41669ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_88e81d69-f432-48d2-9fa3-ba14701c60c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_10ba66a1-82ef-4fa3-ab4d-220c41669ee5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_88e81d69-f432-48d2-9fa3-ba14701c60c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff0adce1-93e6-4ce5-a8d1-641333aac044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_88e81d69-f432-48d2-9fa3-ba14701c60c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff0adce1-93e6-4ce5-a8d1-641333aac044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_7c199ab6-fb0f-4ade-b589-3e6a3a64a486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff0adce1-93e6-4ce5-a8d1-641333aac044" xlink:to="loc_us-gaap_ConstructionInProgressMember_7c199ab6-fb0f-4ade-b589-3e6a3a64a486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LabEquipmentMember_d46112a2-5a98-4479-ab00-91a42469db46" xlink:href="dna-20251231.xsd#dna_LabEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ff0adce1-93e6-4ce5-a8d1-641333aac044" xlink:to="loc_dna_LabEquipmentMember_d46112a2-5a98-4479-ab00-91a42469db46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_10ba66a1-82ef-4fa3-ab4d-220c41669ee5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7698fa96-4f10-4bbe-b72f-ec4a35aa7e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:to="loc_us-gaap_Depreciation_7698fa96-4f10-4bbe-b72f-ec4a35aa7e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_16519ebb-15db-463d-a953-ddc92005d00c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_16519ebb-15db-463d-a953-ddc92005d00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment_9b489878-7848-439c-84c5-e06b64dbc701" xlink:href="dna-20251231.xsd#dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f9345b40-3a90-459b-a7e0-7ba2be415ed8" xlink:to="loc_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment_9b489878-7848-439c-84c5-e06b64dbc701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:href="dna-20251231.xsd#dna_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f58475e4-df8f-48e0-a063-69c9c3e94be8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f58475e4-df8f-48e0-a063-69c9c3e94be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContractualShortfallLiabilityCurrent_019c9017-1da2-73af-9516-c27bc251bde7" xlink:href="dna-20251231.xsd#dna_ContractualShortfallLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_dna_ContractualShortfallLiabilityCurrent_019c9017-1da2-73af-9516-c27bc251bde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_00e467dd-c5a2-44c4-872b-13092b51f9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_00e467dd-c5a2-44c4-872b-13092b51f9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_012cdc63-7a22-45df-a2aa-227adb99939f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_012cdc63-7a22-45df-a2aa-227adb99939f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent_b22de085-d9a8-422a-a1b4-dc6e61b5538d" xlink:href="dna-20251231.xsd#dna_AccruedBiosecurityServiceRevenueAccrualsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent_b22de085-d9a8-422a-a1b4-dc6e61b5538d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_692e1241-9383-4567-8ec9-d5d6504b315b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_DeferredIncome_692e1241-9383-4567-8ec9-d5d6504b315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedEmployeeTerminationCosts_d96148ca-7374-4767-b0f2-5ec766210410" xlink:href="dna-20251231.xsd#dna_AccruedEmployeeTerminationCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_dna_AccruedEmployeeTerminationCosts_d96148ca-7374-4767-b0f2-5ec766210410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_aea74425-428d-41cd-945a-6f50155dfc18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_aea74425-428d-41cd-945a-6f50155dfc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent_f726225a-dd65-419d-8d84-fcea40be4c5c" xlink:href="dna-20251231.xsd#dna_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent_f726225a-dd65-419d-8d84-fcea40be4c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_8a252863-571c-44ed-bae7-39fd8a94b4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_8a252863-571c-44ed-bae7-39fd8a94b4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AccruedPropertyAndEquipmentCurrent_e2d50013-4bab-4ed6-a300-9e57275bb84b" xlink:href="dna-20251231.xsd#dna_AccruedPropertyAndEquipmentCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_dna_AccruedPropertyAndEquipmentCurrent_e2d50013-4bab-4ed6-a300-9e57275bb84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cbf11742-acac-4cee-94d4-95ad52143f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cbf11742-acac-4cee-94d4-95ad52143f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e195d39f-f739-45c3-b4a8-3482f7e0f857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e195d39f-f739-45c3-b4a8-3482f7e0f857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_64a75229-f06a-4ea8-9d97-4c9bd505930b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_64a75229-f06a-4ea8-9d97-4c9bd505930b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_9e206477-e4f0-4939-87e5-4049e96a4bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalBalanceSheetInformationAbstract_b10badf5-c8bd-4c10-83a1-d7b5ab96667a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_9e206477-e4f0-4939-87e5-4049e96a4bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:href="dna-20251231.xsd#dna_SupplementalFinancialStatementInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_36f780b4-cc14-45f0-87ec-9c1df19cca23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_us-gaap_InterestPaidNet_36f780b4-cc14-45f0-87ec-9c1df19cca23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_60101d37-b6c4-4694-8dc6-949b28e7a10b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_us-gaap_IncomeTaxesPaid_60101d37-b6c4-4694-8dc6-949b28e7a10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_85448c39-9921-48f1-9aaf-98f68959f110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_85448c39-9921-48f1-9aaf-98f68959f110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3fe6f49a-1c34-4bc2-964e-9dcd926c2762" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3fe6f49a-1c34-4bc2-964e-9dcd926c2762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices_f90167d8-0ae4-4156-9227-69f2c3b681c2" xlink:href="dna-20251231.xsd#dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices_f90167d8-0ae4-4156-9227-69f2c3b681c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PurchaseOfNonCashMarketableEquitySecurities_0bc4ae80-f04e-4153-a92d-1006ca1f7bc3" xlink:href="dna-20251231.xsd#dna_PurchaseOfNonCashMarketableEquitySecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_dna_PurchaseOfNonCashMarketableEquitySecurities_0bc4ae80-f04e-4153-a92d-1006ca1f7bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_94cb1e2b-f976-4ef0-8232-28cab164194d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_94cb1e2b-f976-4ef0-8232-28cab164194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment_53eda13f-2b19-4dc8-8bdc-4811e9bf6ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment_53eda13f-2b19-4dc8-8bdc-4811e9bf6ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_98223e99-0a86-4776-8c10-ec621fe3e11c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_98223e99-0a86-4776-8c10-ec621fe3e11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SettlementOfContingentConsideration_d74152cb-c667-487c-b066-57788a07d4b9" xlink:href="dna-20251231.xsd#dna_SettlementOfContingentConsideration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_dna_SettlementOfContingentConsideration_d74152cb-c667-487c-b066-57788a07d4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments_a93c68d1-69a3-44fe-ac98-8a7a4e6b7ca1" xlink:href="dna-20251231.xsd#dna_IssuanceOfCommonStockForAcquisitionRetentionPayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments_a93c68d1-69a3-44fe-ac98-8a7a4e6b7ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue_f9800cd7-4d68-4e4d-939d-3a147f1e9b51" xlink:href="dna-20251231.xsd#dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue_f9800cd7-4d68-4e4d-939d-3a147f1e9b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1081bfb7-dae7-4f5e-b91a-e588492451d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1081bfb7-dae7-4f5e-b91a-e588492451d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses_01877f58-1d5e-49a1-8611-23710e6480f4" xlink:href="dna-20251231.xsd#dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_SupplementalFinancialStatementInformationAbstract_7eb895d9-5809-414b-88e5-94518b2e22ce" xlink:to="loc_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses_01877f58-1d5e-49a1-8611-23710e6480f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b87155a6-ff41-4908-a852-e3c850f53376" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b87155a6-ff41-4908-a852-e3c850f53376" xlink:to="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_d4e44a39-c163-4805-be00-1854ea37dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_AssetAcquisitionAxis_d4e44a39-c163-4805-be00-1854ea37dca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_7b6a2645-0532-4fba-a99d-fe01875699cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d4e44a39-c163-4805-be00-1854ea37dca8" xlink:to="loc_us-gaap_AssetAcquisitionDomain_7b6a2645-0532-4fba-a99d-fe01875699cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StridebioMember_8bcdcb2e-9d19-4f70-aba0-53930df0a000" xlink:href="dna-20251231.xsd#dna_StridebioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7b6a2645-0532-4fba-a99d-fe01875699cf" xlink:to="loc_dna_StridebioMember_8bcdcb2e-9d19-4f70-aba0-53930df0a000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f6713d2d-ac37-4bac-9bb4-a731789251e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f6713d2d-ac37-4bac-9bb4-a731789251e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_64d224ec-cd49-4643-ba3c-e8e846de2e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f6713d2d-ac37-4bac-9bb4-a731789251e3" xlink:to="loc_us-gaap_ClassOfStockDomain_64d224ec-cd49-4643-ba3c-e8e846de2e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_235fed98-f95d-4fc8-aada-856eb98e8935" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64d224ec-cd49-4643-ba3c-e8e846de2e2f" xlink:to="loc_us-gaap_CommonClassAMember_235fed98-f95d-4fc8-aada-856eb98e8935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_019c5ca4-7248-7b8e-94de-421e128ac012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_OtherCommitmentsAxis_019c5ca4-7248-7b8e-94de-421e128ac012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_019c5ca4-7248-762b-81e5-b86bf892d4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_019c5ca4-7248-7b8e-94de-421e128ac012" xlink:to="loc_us-gaap_OtherCommitmentsDomain_019c5ca4-7248-762b-81e5-b86bf892d4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember_019c5ca4-7248-79de-aece-af6ab6ef45fd" xlink:href="dna-20251231.xsd#dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_019c5ca4-7248-762b-81e5-b86bf892d4ad" xlink:to="loc_dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember_019c5ca4-7248-79de-aece-af6ab6ef45fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019c5ca4-7248-77d6-9afb-22cc21b34137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019c5ca4-7248-77d6-9afb-22cc21b34137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019c5ca4-7248-752e-9721-eebd35811c36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019c5ca4-7248-77d6-9afb-22cc21b34137" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019c5ca4-7248-752e-9721-eebd35811c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019c5ca4-7248-7781-9dc3-dd4d21687831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019c5ca4-7248-752e-9721-eebd35811c36" xlink:to="loc_us-gaap_SubsequentEventMember_019c5ca4-7248-7781-9dc3-dd4d21687831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_019c5ca4-7248-7cc2-8eff-4fd5ef989507" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_srt_StatementScenarioAxis_019c5ca4-7248-7cc2-8eff-4fd5ef989507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_019c5ca4-7248-79da-8b34-163f44303b6f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_019c5ca4-7248-7cc2-8eff-4fd5ef989507" xlink:to="loc_srt_ScenarioUnspecifiedDomain_019c5ca4-7248-79da-8b34-163f44303b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_019c5ca4-7248-7b3e-a15f-1e74ec1fbd34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_019c5ca4-7248-79da-8b34-163f44303b6f" xlink:to="loc_srt_ScenarioForecastMember_019c5ca4-7248-7b3e-a15f-1e74ec1fbd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9666-2021-7efd-a4d1-7e9160913f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9666-2021-7efd-a4d1-7e9160913f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_019c9666-2021-7c23-b94c-a19c00d8c682" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_019c9666-2021-7efd-a4d1-7e9160913f81" xlink:to="loc_us-gaap_LossContingencyNatureDomain_019c9666-2021-7c23-b94c-a19c00d8c682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuretyBondMember_019c9666-2021-7d3e-9ade-f83b73bf7174" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuretyBondMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_019c9666-2021-7c23-b94c-a19c00d8c682" xlink:to="loc_us-gaap_SuretyBondMember_019c9666-2021-7d3e-9ade-f83b73bf7174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_aba84f84-ba0f-4be7-9b5e-d3c0a2f23778" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm_2cede8da-7ddb-4f35-a07c-b0549c3aedbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm_2cede8da-7ddb-4f35-a07c-b0549c3aedbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_3d60a6ff-2936-4f85-8d6f-504689f49c20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_3d60a6ff-2936-4f85-8d6f-504689f49c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_e04e3983-5f0e-4f05-a7de-c15b6a9b5448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_e04e3983-5f0e-4f05-a7de-c15b6a9b5448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_05139c4a-8fc4-4f48-94a3-0951246c15aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_05139c4a-8fc4-4f48-94a3-0951246c15aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_d08526fa-df4e-47d3-85b3-bf758bea510e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_d08526fa-df4e-47d3-85b3-bf758bea510e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_e1d1499d-937c-42fe-b3b5-600aabb8282b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_e1d1499d-937c-42fe-b3b5-600aabb8282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix_019c5ca4-7248-7b49-bed1-840dd2c3cac9" xlink:href="dna-20251231.xsd#dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix_019c5ca4-7248-7b49-bed1-840dd2c3cac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases_29fce391-06ef-46ea-8a18-0c214b46ddb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases_29fce391-06ef-46ea-8a18-0c214b46ddb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContractualShortfallLiability_019c9017-ce5d-7554-8fb2-6b2e3253066a" xlink:href="dna-20251231.xsd#dna_ContractualShortfallLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_ContractualShortfallLiability_019c9017-ce5d-7554-8fb2-6b2e3253066a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ContractualShortfallLiabilityRequiredPayment_019c9018-b952-7b2f-9bac-f378f11cbe8a" xlink:href="dna-20251231.xsd#dna_ContractualShortfallLiabilityRequiredPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_ContractualShortfallLiabilityRequiredPayment_019c9018-b952-7b2f-9bac-f378f11cbe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_274a9e2e-a587-49bd-bf42-f24ce0543f18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_274a9e2e-a587-49bd-bf42-f24ce0543f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_e9fea904-437f-4c32-bd6a-a52262f4c95b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_PaymentsForRoyalties_e9fea904-437f-4c32-bd6a-a52262f4c95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RoyaltyReceivedFromLicensingRevenue_17edbb33-6721-45ab-8029-7a4d57cd712a" xlink:href="dna-20251231.xsd#dna_RoyaltyReceivedFromLicensingRevenue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_RoyaltyReceivedFromLicensingRevenue_17edbb33-6721-45ab-8029-7a4d57cd712a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct_e89eee17-88ac-4e01-ac9a-f42bb1c11538" xlink:href="dna-20251231.xsd#dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct_e89eee17-88ac-4e01-ac9a-f42bb1c11538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_019c5ca4-7248-700a-b5fc-3357ba1cff7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_OtherCommitment_019c5ca4-7248-700a-b5fc-3357ba1cff7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContracts_019c5ca4-7248-75c5-a66d-e1636f207519" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossOnContracts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_us-gaap_LossOnContracts_019c5ca4-7248-75c5-a66d-e1636f207519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LossContingencyAmountRequiredToFund_019c9666-2021-77b9-9196-15ee1ae7d43b" xlink:href="dna-20251231.xsd#dna_LossContingencyAmountRequiredToFund"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9a55ecba-738b-487e-b4ab-0a06e202c662" xlink:to="loc_dna_LossContingencyAmountRequiredToFund_019c9666-2021-77b9-9196-15ee1ae7d43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockholdersEquityScheduleofCapitalizationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a71a4481-c891-4750-b203-c8245c8eb7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_69b514a3-e679-4cf4-b92a-cdef55b376df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a71a4481-c891-4750-b203-c8245c8eb7ca" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_69b514a3-e679-4cf4-b92a-cdef55b376df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6186b902-9b6a-4cbc-a8d4-49c7c1cfa839" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_69b514a3-e679-4cf4-b92a-cdef55b376df" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6186b902-9b6a-4cbc-a8d4-49c7c1cfa839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6186b902-9b6a-4cbc-a8d4-49c7c1cfa839" xlink:to="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_be3ccf3b-8331-4570-b4c3-756716287ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:to="loc_us-gaap_CommonClassAMember_be3ccf3b-8331-4570-b4c3-756716287ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ca965ffe-6ce7-40c2-b8aa-f0ab64af348a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:to="loc_us-gaap_CommonClassBMember_ca965ffe-6ce7-40c2-b8aa-f0ab64af348a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_53f07766-df9a-4aef-93b2-37f83450c515" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bdfbec5d-41f9-4070-85e8-125d59f54eab" xlink:to="loc_us-gaap_CommonClassCMember_53f07766-df9a-4aef-93b2-37f83450c515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_69b514a3-e679-4cf4-b92a-cdef55b376df" xlink:to="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4912c138-704a-4c62-904c-0c95830fc94d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4912c138-704a-4c62-904c-0c95830fc94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f14ce1b7-2b21-4278-b3dd-b313984dae30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:to="loc_us-gaap_CommonStockSharesIssued_f14ce1b7-2b21-4278-b3dd-b313984dae30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cdade0f6-9191-4c79-92e0-9e5f0a257918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_76514d81-4800-406c-b8ef-61ae0ec81d6d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cdade0f6-9191-4c79-92e0-9e5f0a257918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6da3048e-6ee6-4e62-acf2-b835b905e0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d46cf508-aedc-4dae-a7b9-40fd71bad897" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6da3048e-6ee6-4e62-acf2-b835b905e0e5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d46cf508-aedc-4dae-a7b9-40fd71bad897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_55233545-1f60-41f0-bab6-8cbfa3ad9be4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d46cf508-aedc-4dae-a7b9-40fd71bad897" xlink:to="loc_us-gaap_StatementClassOfStockAxis_55233545-1f60-41f0-bab6-8cbfa3ad9be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_55233545-1f60-41f0-bab6-8cbfa3ad9be4" xlink:to="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NewGinkgoPreferredStockMember_ab9cae2f-a84b-4971-8b6f-6644a160bfdf" xlink:href="dna-20251231.xsd#dna_NewGinkgoPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:to="loc_dna_NewGinkgoPreferredStockMember_ab9cae2f-a84b-4971-8b6f-6644a160bfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ac3fbfc3-39c2-421b-a756-aca5f6bc8442" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:to="loc_us-gaap_CommonClassAMember_ac3fbfc3-39c2-421b-a756-aca5f6bc8442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_4923cce0-2cc5-4a7a-b386-9911497dded2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:to="loc_us-gaap_CommonClassBMember_4923cce0-2cc5-4a7a-b386-9911497dded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassCMember_4f85f550-42b1-4aea-b757-ffc606327243" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8e81c19e-63e2-4c96-ad20-3e40b8c2eb96" xlink:to="loc_us-gaap_CommonClassCMember_4f85f550-42b1-4aea-b757-ffc606327243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019c5ca7-12fd-7ee6-a206-0989fee39125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d46cf508-aedc-4dae-a7b9-40fd71bad897" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019c5ca7-12fd-7ee6-a206-0989fee39125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7493-a437-5fba24e29065" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019c5ca7-12fd-7ee6-a206-0989fee39125" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7493-a437-5fba24e29065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ATMProgramMember_019c5ca7-376d-70c0-b05d-e12fcbca9479" xlink:href="dna-20251231.xsd#dna_ATMProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7493-a437-5fba24e29065" xlink:to="loc_dna_ATMProgramMember_019c5ca7-376d-70c0-b05d-e12fcbca9479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SalesAgreementWithAllenCompanyLLCMember_019c5ca7-8f0e-7227-9df8-d44aac9cd74c" xlink:href="dna-20251231.xsd#dna_SalesAgreementWithAllenCompanyLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c5ca7-12fd-7493-a437-5fba24e29065" xlink:to="loc_dna_SalesAgreementWithAllenCompanyLLCMember_019c5ca7-8f0e-7227-9df8-d44aac9cd74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d46cf508-aedc-4dae-a7b9-40fd71bad897" xlink:to="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_44b94447-808b-40e8-ae99-50e502828d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_44b94447-808b-40e8-ae99-50e502828d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a63d47a2-abf0-4b5e-ac46-9d6e55cab976" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a63d47a2-abf0-4b5e-ac46-9d6e55cab976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3c17487b-2e9d-4d8f-a77e-215dde5d65aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3c17487b-2e9d-4d8f-a77e-215dde5d65aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0fd5e42d-1d81-4c92-b5ad-435442aaf9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0fd5e42d-1d81-4c92-b5ad-435442aaf9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f00796fc-88e5-436a-9080-145c129056b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f00796fc-88e5-436a-9080-145c129056b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2a25a142-0ac8-4a4e-a24d-dc73376e1edb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2a25a142-0ac8-4a4e-a24d-dc73376e1edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c9c75bc0-e281-4dd9-8538-334fcef394d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c9c75bc0-e281-4dd9-8538-334fcef394d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CommonStockVotingRight_11522957-d07a-4fee-93d7-ac440c28fbf4" xlink:href="dna-20251231.xsd#dna_CommonStockVotingRight"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_dna_CommonStockVotingRight_11522957-d07a-4fee-93d7-ac440c28fbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_8d54ddb0-6896-4244-94a0-05103d346944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_us-gaap_Dividends_8d54ddb0-6896-4244-94a0-05103d346944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SaleOfStockAuthorizedAmount_019c5ca6-87bc-7c2c-932b-42b8f4dc2cd3" xlink:href="dna-20251231.xsd#dna_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_dna_SaleOfStockAuthorizedAmount_019c5ca6-87bc-7c2c-932b-42b8f4dc2cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CommonStockConversionRatio_019c9121-0d47-765c-93fd-c71c72d548bf" xlink:href="dna-20251231.xsd#dna_CommonStockConversionRatio"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8eaa26f6-77d1-4442-903d-c5c9d3b49842" xlink:to="loc_dna_CommonStockConversionRatio_019c9121-0d47-765c-93fd-c71c72d548bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_b6658be9-f847-47e0-9fe5-216e1ccd6842" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b6658be9-f847-47e0-9fe5-216e1ccd6842" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5bf4d1e2-54c9-47b7-8d83-bdf323529f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:to="loc_us-gaap_AwardTypeAxis_5bf4d1e2-54c9-47b7-8d83-bdf323529f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5bf4d1e2-54c9-47b7-8d83-bdf323529f3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_70effe29-13ce-42d7-8560-c973679291cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:to="loc_us-gaap_EmployeeStockOptionMember_70effe29-13ce-42d7-8560-c973679291cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c5ca8-54a0-7344-8401-2b0b68e30dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c5ca8-54a0-7344-8401-2b0b68e30dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019c5ca8-9fb9-781d-aedd-2cc28807a525" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab15a58c-50bf-43b4-a0df-91e7c02acd08" xlink:to="loc_us-gaap_PerformanceSharesMember_019c5ca8-9fb9-781d-aedd-2cc28807a525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_38ee17b6-a3e3-42ea-b698-144f3d5d83e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:to="loc_us-gaap_PlanNameAxis_38ee17b6-a3e3-42ea-b698-144f3d5d83e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_38ee17b6-a3e3-42ea-b698-144f3d5d83e4" xlink:to="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_fddc1983-9647-478b-ab80-f862fdf9b011" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:to="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_fddc1983-9647-478b-ab80-f862fdf9b011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_2bfc517e-06ef-4fe0-97d2-dde96995e0d3" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:to="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_2bfc517e-06ef-4fe0-97d2-dde96995e0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_InducementPlanMember_e27ffa12-19d4-4c63-9cb7-2d679cb863e1" xlink:href="dna-20251231.xsd#dna_InducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_189396cd-9324-43d6-9776-673ffe756257" xlink:to="loc_dna_InducementPlanMember_e27ffa12-19d4-4c63-9cb7-2d679cb863e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6dbedfbf-fdd9-45d3-9021-e88ad2adf080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6dbedfbf-fdd9-45d3-9021-e88ad2adf080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aecf8e2d-bcd9-4712-a262-782428f0e743" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6dbedfbf-fdd9-45d3-9021-e88ad2adf080" xlink:to="loc_us-gaap_EquityComponentDomain_aecf8e2d-bcd9-4712-a262-782428f0e743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_WarrantsToPurchaseClassACommonStockMember_2fa94e4f-15cd-4e15-8564-740a58339515" xlink:href="dna-20251231.xsd#dna_WarrantsToPurchaseClassACommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aecf8e2d-bcd9-4712-a262-782428f0e743" xlink:to="loc_dna_WarrantsToPurchaseClassACommonStockMember_2fa94e4f-15cd-4e15-8564-740a58339515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6b173b27-7230-4d81-b413-64aa38dc4d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5366ee1d-48d0-47e8-8a73-b3dded1f1a26" xlink:to="loc_us-gaap_ClassOfStockLineItems_6b173b27-7230-4d81-b413-64aa38dc4d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_97664f4f-3ab5-4506-8da7-ad165c2851d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b173b27-7230-4d81-b413-64aa38dc4d8c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_97664f4f-3ab5-4506-8da7-ad165c2851d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationSummaryofStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02327711-35a9-4aff-8bbc-006b396ff346" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02327711-35a9-4aff-8bbc-006b396ff346" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a0e69cf6-31f8-4878-b6b5-4563cf14a3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a0e69cf6-31f8-4878-b6b5-4563cf14a3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a0e69cf6-31f8-4878-b6b5-4563cf14a3ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60f502af-fa96-407f-b5a2-0a255bc487de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60f502af-fa96-407f-b5a2-0a255bc487de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e6b15207-f52f-4a93-beb7-da21a42d0f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e6b15207-f52f-4a93-beb7-da21a42d0f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_019c5ca9-522b-7069-9a96-80bea606e6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aa5dead0-52c3-407c-87bf-a31c3f7f7496" xlink:to="loc_us-gaap_CostOfSalesMember_019c5ca9-522b-7069-9a96-80bea606e6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019c5ca9-7870-7e43-898d-91e8093bdc29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019c5ca9-7870-7e43-898d-91e8093bdc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019c5ca9-7870-7392-a702-df2cb3f9d24a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019c5ca9-7870-7e43-898d-91e8093bdc29" xlink:to="loc_us-gaap_SegmentDomain_019c5ca9-7870-7392-a702-df2cb3f9d24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiosecuritySegmentMember_019c5ca9-94b3-7ad4-a908-c023da44f690" xlink:href="dna-20251231.xsd#dna_BiosecuritySegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019c5ca9-7870-7392-a702-df2cb3f9d24a" xlink:to="loc_dna_BiosecuritySegmentMember_019c5ca9-94b3-7ad4-a908-c023da44f690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c5caa-1b36-74d9-a37c-315506832181" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:to="loc_srt_ProductOrServiceAxis_019c5caa-1b36-74d9-a37c-315506832181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c5caa-1b36-7151-9989-1cda26d976d6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c5caa-1b36-74d9-a37c-315506832181" xlink:to="loc_srt_ProductsAndServicesDomain_019c5caa-1b36-7151-9989-1cda26d976d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherRevenueMember_019c5ca9-ec70-7d02-8a34-c36ee7a10aea" xlink:href="dna-20251231.xsd#dna_OtherRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c5caa-1b36-7151-9989-1cda26d976d6" xlink:to="loc_dna_OtherRevenueMember_019c5ca9-ec70-7d02-8a34-c36ee7a10aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_363333cf-de50-4ffa-b350-d727334552e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a834606-d16c-42e6-903b-42d166908479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_363333cf-de50-4ffa-b350-d727334552e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_80276c9c-2517-406e-867f-b1765dea28bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_363333cf-de50-4ffa-b350-d727334552e6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_80276c9c-2517-406e-867f-b1765dea28bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7046ee89-32ff-428f-83c7-450c29e342d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7046ee89-32ff-428f-83c7-450c29e342d3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_96e9a0da-3edb-4a3c-a547-22e4f8b2db66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_PlanNameAxis_96e9a0da-3edb-4a3c-a547-22e4f8b2db66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_96e9a0da-3edb-4a3c-a547-22e4f8b2db66" xlink:to="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandTwentyTwoInducementPlanMember_de0c53fb-1ee8-4d0c-8a65-c021fbf9adcf" xlink:href="dna-20251231.xsd#dna_TwoThousandTwentyTwoInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:to="loc_dna_TwoThousandTwentyTwoInducementPlanMember_de0c53fb-1ee8-4d0c-8a65-c021fbf9adcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_0f2cfb79-f665-41c8-932c-83b31ebcaadc" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:to="loc_dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember_0f2cfb79-f665-41c8-932c-83b31ebcaadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_00d5c583-83dc-4a5d-9170-6b1b882f0c04" xlink:href="dna-20251231.xsd#dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3a3bc7cb-f5da-47e6-8848-a2dece0e436e" xlink:to="loc_dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_00d5c583-83dc-4a5d-9170-6b1b882f0c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b2a74660-7ffd-4b8f-b9f2-26a3bd6403d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b2a74660-7ffd-4b8f-b9f2-26a3bd6403d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aef04fe6-86eb-4682-9deb-fb23d7ef5b67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2a74660-7ffd-4b8f-b9f2-26a3bd6403d3" xlink:to="loc_us-gaap_EquityComponentDomain_aef04fe6-86eb-4682-9deb-fb23d7ef5b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_61f9ee09-7d41-48a1-ae4a-d79f7f84733e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aef04fe6-86eb-4682-9deb-fb23d7ef5b67" xlink:to="loc_us-gaap_CommonStockMember_61f9ee09-7d41-48a1-ae4a-d79f7f84733e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_94981200-d0c5-4589-af26-c8821d78b294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_AwardTypeAxis_94981200-d0c5-4589-af26-c8821d78b294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_94981200-d0c5-4589-af26-c8821d78b294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a1a75580-1547-49ce-8ce3-d39258eff170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a1a75580-1547-49ce-8ce3-d39258eff170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_452a14ce-fecd-4964-bc7a-65355fbcd687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_us-gaap_RestrictedStockMember_452a14ce-fecd-4964-bc7a-65355fbcd687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5815eda0-f195-4283-bcb0-c941cd50a24f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5815eda0-f195-4283-bcb0-c941cd50a24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnoutRestrictedStockUnitsMember_71faa61e-395a-49b2-b924-138eb0a91727" xlink:href="dna-20251231.xsd#dna_EarnoutRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_dna_EarnoutRestrictedStockUnitsMember_71faa61e-395a-49b2-b924-138eb0a91727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FounderOptionsMember_1cbd6fa6-8d0c-4ec7-bc1e-0e67d0ed6a2e" xlink:href="dna-20251231.xsd#dna_FounderOptionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_dna_FounderOptionsMember_1cbd6fa6-8d0c-4ec7-bc1e-0e67d0ed6a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019c5cb3-e587-7305-9286-1f3a8a1b29aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_us-gaap_PerformanceSharesMember_019c5cb3-e587-7305-9286-1f3a8a1b29aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FounderPSUAwardsMember_019c5cb4-e5da-7eae-92f4-d25f2cb090be" xlink:href="dna-20251231.xsd#dna_FounderPSUAwardsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_372fb11a-88f5-43df-bb9a-36bb8beaaf34" xlink:to="loc_dna_FounderPSUAwardsMember_019c5cb4-e5da-7eae-92f4-d25f2cb090be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b56663ee-448b-4a4d-8f38-94f2245dd2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b56663ee-448b-4a4d-8f38-94f2245dd2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cde8a729-ddde-44e0-92df-22911c45fb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b56663ee-448b-4a4d-8f38-94f2245dd2b3" xlink:to="loc_us-gaap_ClassOfStockDomain_cde8a729-ddde-44e0-92df-22911c45fb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnOutSharesMember_98126c81-0da5-41b5-acf4-874901d3cc7c" xlink:href="dna-20251231.xsd#dna_EarnOutSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cde8a729-ddde-44e0-92df-22911c45fb4f" xlink:to="loc_dna_EarnOutSharesMember_98126c81-0da5-41b5-acf4-874901d3cc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5223761f-4cf0-4137-ba0b-4e87a83c4216" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_VestingAxis_5223761f-4cf0-4137-ba0b-4e87a83c4216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_5223761f-4cf0-4137-ba0b-4e87a83c4216" xlink:to="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e0033465-845d-487c-9cf0-1454a1a9a165" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e0033465-845d-487c-9cf0-1454a1a9a165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d10edc4f-2314-46e3-b8fb-23f523a610da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d10edc4f-2314-46e3-b8fb-23f523a610da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_047f9024-a68c-403d-85d8-cd3d9f59a300" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_047f9024-a68c-403d-85d8-cd3d9f59a300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationAwardTrancheFourMember_821fc866-f995-4e7f-abd3-859511836c67" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationAwardTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5806c46c-f26a-4a3e-ae63-f7c6407efe01" xlink:to="loc_dna_ShareBasedCompensationAwardTrancheFourMember_821fc866-f995-4e7f-abd3-859511836c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_01545eae-3a4f-4292-acdd-4638f2b78776" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_srt_RangeAxis_01545eae-3a4f-4292-acdd-4638f2b78776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ed97e9e-2a01-4b6c-9b1d-6b04c67373c7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_01545eae-3a4f-4292-acdd-4638f2b78776" xlink:to="loc_srt_RangeMember_2ed97e9e-2a01-4b6c-9b1d-6b04c67373c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2d277455-c4cd-46c9-a090-892901efd496" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2ed97e9e-2a01-4b6c-9b1d-6b04c67373c7" xlink:to="loc_srt_MinimumMember_2d277455-c4cd-46c9-a090-892901efd496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3ff32171-0cc7-43e1-9945-fd5601ddd34d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2ed97e9e-2a01-4b6c-9b1d-6b04c67373c7" xlink:to="loc_srt_MaximumMember_3ff32171-0cc7-43e1-9945-fd5601ddd34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d9ff9d6-0aa0-48fd-8288-b6ee13195b34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f7514f7-d573-49a3-93ec-1ccaffb36132" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f7514f7-d573-49a3-93ec-1ccaffb36132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_06677c55-9c55-4449-9e8b-9939c6b4f5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_06677c55-9c55-4449-9e8b-9939c6b4f5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm_298a5249-10a9-4753-9426-fccf0e82c973" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm_298a5249-10a9-4753-9426-fccf0e82c973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_e1a18ee0-681d-4bbd-b19c-37e92afe5c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_e1a18ee0-681d-4bbd-b19c-37e92afe5c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b45e0254-2011-4ced-a281-eab7e1437a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b45e0254-2011-4ced-a281-eab7e1437a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate_51f1e29e-5013-4736-a2aa-660769cf4fe8" xlink:href="dna-20251231.xsd#dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate_51f1e29e-5013-4736-a2aa-660769cf4fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d8beda6e-7436-41ef-991f-9f0ec71b5278" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d8beda6e-7436-41ef-991f-9f0ec71b5278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TypesOfTimeBasedStockOptions_019c901a-b4f8-7188-8199-fb8179d47ab8" xlink:href="dna-20251231.xsd#dna_TypesOfTimeBasedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_TypesOfTimeBasedStockOptions_019c901a-b4f8-7188-8199-fb8179d47ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_c2ed765f-6033-4025-b25e-4767b0a0cf08" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_c2ed765f-6033-4025-b25e-4767b0a0cf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cb393f33-0a49-4a3b-8660-f67fa9167b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cb393f33-0a49-4a3b-8660-f67fa9167b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0812b5f9-5a0d-4e93-b0c1-2d2076a77579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0812b5f9-5a0d-4e93-b0c1-2d2076a77579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dd8918df-d126-48dc-a28b-4df4e8deeac8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dd8918df-d126-48dc-a28b-4df4e8deeac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eb8ab907-4064-4971-b010-ea030287d65a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eb8ab907-4064-4971-b010-ea030287d65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfCompanyFounders_b27216c1-35af-4dd4-9a15-93eae0e5e21a" xlink:href="dna-20251231.xsd#dna_NumberOfCompanyFounders"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_NumberOfCompanyFounders_b27216c1-35af-4dd4-9a15-93eae0e5e21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be33fb9e-8a45-4ee7-a6da-cbfa8c2067d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be33fb9e-8a45-4ee7-a6da-cbfa8c2067d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1509e0d8-1f30-4899-bae8-073c0afe9f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1509e0d8-1f30-4899-bae8-073c0afe9f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfStockPriceHurdles_019c901d-8297-75e3-bca3-609a60e2f3b8" xlink:href="dna-20251231.xsd#dna_NumberOfStockPriceHurdles"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_NumberOfStockPriceHurdles_019c901d-8297-75e3-bca3-609a60e2f3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_34223fcb-8e86-45ac-b8d9-6e28e6c5a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_34223fcb-8e86-45ac-b8d9-6e28e6c5a0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_45e9c996-b0bd-4b2c-9952-92b5a98439b7" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_45e9c996-b0bd-4b2c-9952-92b5a98439b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_600335d9-772d-4db4-9c37-88f005d71daa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_SharePrice_600335d9-772d-4db4-9c37-88f005d71daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfVestingConditions_019c901f-0aae-76db-92de-f765386b7f73" xlink:href="dna-20251231.xsd#dna_NumberOfVestingConditions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_NumberOfVestingConditions_019c901f-0aae-76db-92de-f765386b7f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_48571889-3212-493d-aa6b-a90b1af1d4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_48571889-3212-493d-aa6b-a90b1af1d4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5f4033fe-f9c1-4d1c-8980-873076fa2a83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5f4033fe-f9c1-4d1c-8980-873076fa2a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_eed8f737-f3cb-4da5-babc-765cb7597c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_eed8f737-f3cb-4da5-babc-765cb7597c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c5cb4-c588-7b21-9004-31566306b0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c5cb4-c588-7b21-9004-31566306b0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019c5cb4-e5da-74c5-beed-dddc57102aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019c5cb4-e5da-74c5-beed-dddc57102aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019c5cb4-e5da-79bb-943f-d3db77f3d176" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019c5cb4-e5da-79bb-943f-d3db77f3d176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_019c5cb4-e5da-74f5-bf11-6c9ed358682d" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_019c5cb4-e5da-74f5-bf11-6c9ed358682d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019c5cb4-e5da-71c9-b559-61701f284864" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019c5cb4-e5da-71c9-b559-61701f284864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c5cb4-e5da-7eae-8ab2-730b72e4b84b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c5cb4-e5da-7eae-8ab2-730b72e4b84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019c901c-13c4-7779-af4b-bca994b8c4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5449216-1650-4816-abd7-bb980b3eda73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019c901c-13c4-7779-af4b-bca994b8c4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_670f8dd2-530b-4002-a141-630770c9cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3c2a6f09-6ec1-44f6-8dfc-6d69aa5115d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_670f8dd2-530b-4002-a141-630770c9cd0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3c2a6f09-6ec1-44f6-8dfc-6d69aa5115d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_413c9fea-7b4b-4d66-a77d-89abb642512e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3c2a6f09-6ec1-44f6-8dfc-6d69aa5115d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_413c9fea-7b4b-4d66-a77d-89abb642512e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_71cc1c96-e25d-44c8-a9d5-b26e5bbb2e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3c2a6f09-6ec1-44f6-8dfc-6d69aa5115d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_71cc1c96-e25d-44c8-a9d5-b26e5bbb2e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a879465-1e03-4117-a355-7eb3226b40de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3c2a6f09-6ec1-44f6-8dfc-6d69aa5115d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a879465-1e03-4117-a355-7eb3226b40de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_acf016cb-47ba-4976-9c27-ee2335aad9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3c2a6f09-6ec1-44f6-8dfc-6d69aa5115d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_acf016cb-47ba-4976-9c27-ee2335aad9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbb79575-fc39-4476-8883-8df92dff30aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3c2a6f09-6ec1-44f6-8dfc-6d69aa5115d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbb79575-fc39-4476-8883-8df92dff30aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ae66d70f-1c5e-486b-bcaf-438f01f8a4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_670f8dd2-530b-4002-a141-630770c9cd0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ae66d70f-1c5e-486b-bcaf-438f01f8a4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_196e97ba-63de-469f-81fc-e137df9d91ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_670f8dd2-530b-4002-a141-630770c9cd0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_196e97ba-63de-469f-81fc-e137df9d91ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_750798ce-4751-4359-93fa-0cb80747862a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_196e97ba-63de-469f-81fc-e137df9d91ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_750798ce-4751-4359-93fa-0cb80747862a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_be827040-bdf9-40b3-bf80-d81f33b158e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_196e97ba-63de-469f-81fc-e137df9d91ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_be827040-bdf9-40b3-bf80-d81f33b158e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9891fb87-0448-4d5f-b4e5-a8c6326615a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_196e97ba-63de-469f-81fc-e137df9d91ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9891fb87-0448-4d5f-b4e5-a8c6326615a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8b1633a5-08ae-47b5-af02-bce5ade4f80e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_196e97ba-63de-469f-81fc-e137df9d91ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_8b1633a5-08ae-47b5-af02-bce5ade4f80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b7cab777-de4e-4cab-bb4e-06e2bf8b58a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_196e97ba-63de-469f-81fc-e137df9d91ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b7cab777-de4e-4cab-bb4e-06e2bf8b58a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_424344c9-e5a2-4574-99ca-ca14985c5cea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_670f8dd2-530b-4002-a141-630770c9cd0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_424344c9-e5a2-4574-99ca-ca14985c5cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_697ce3c2-5c97-40c8-b824-8fd47de45a74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_670f8dd2-530b-4002-a141-630770c9cd0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_697ce3c2-5c97-40c8-b824-8fd47de45a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4cbf86cb-1f6c-473e-b6a0-189e10e58187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_697ce3c2-5c97-40c8-b824-8fd47de45a74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4cbf86cb-1f6c-473e-b6a0-189e10e58187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1a08884f-96cc-425a-88b1-16101502c593" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_697ce3c2-5c97-40c8-b824-8fd47de45a74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1a08884f-96cc-425a-88b1-16101502c593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract_7d6e1311-4d25-4ed5-bb54-14d3da03522e" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_670f8dd2-530b-4002-a141-630770c9cd0e" xlink:to="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract_7d6e1311-4d25-4ed5-bb54-14d3da03522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_04751ffd-8ac0-424c-a454-a4e5f63a52f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract_7d6e1311-4d25-4ed5-bb54-14d3da03522e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_04751ffd-8ac0-424c-a454-a4e5f63a52f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4101e264-300f-4082-83f1-b9fbffb51403" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract_7d6e1311-4d25-4ed5-bb54-14d3da03522e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4101e264-300f-4082-83f1-b9fbffb51403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1de7bb32-ad0c-456c-a659-e042dae4b426" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddbbd4b2-45db-4886-bbc8-94319346f183" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1de7bb32-ad0c-456c-a659-e042dae4b426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddbbd4b2-45db-4886-bbc8-94319346f183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f75116aa-a402-4d58-9bd0-c7d8d6bdb2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1de7bb32-ad0c-456c-a659-e042dae4b426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f75116aa-a402-4d58-9bd0-c7d8d6bdb2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_32c0a3cb-fc08-4347-9686-3cbd8cacc096" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1de7bb32-ad0c-456c-a659-e042dae4b426" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_32c0a3cb-fc08-4347-9686-3cbd8cacc096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3cb7c541-5e0c-46ce-af56-85c31dfd3c62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1de7bb32-ad0c-456c-a659-e042dae4b426" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3cb7c541-5e0c-46ce-af56-85c31dfd3c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d94c7376-94dc-4b62-ad9a-ac09d2aed21a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22dc240b-f0af-4224-91c7-50d505ecb983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d94c7376-94dc-4b62-ad9a-ac09d2aed21a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22dc240b-f0af-4224-91c7-50d505ecb983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ed2edf2f-c1db-4bd5-83bc-4880b9cbd7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22dc240b-f0af-4224-91c7-50d505ecb983" xlink:to="loc_us-gaap_AwardTypeAxis_ed2edf2f-c1db-4bd5-83bc-4880b9cbd7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06a496ad-d58f-4adc-8713-5af27d12b89a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ed2edf2f-c1db-4bd5-83bc-4880b9cbd7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06a496ad-d58f-4adc-8713-5af27d12b89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FounderOptionsMember_3041699a-840a-49b2-b4a0-c807a62e9b52" xlink:href="dna-20251231.xsd#dna_FounderOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06a496ad-d58f-4adc-8713-5af27d12b89a" xlink:to="loc_dna_FounderOptionsMember_3041699a-840a-49b2-b4a0-c807a62e9b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22dc240b-f0af-4224-91c7-50d505ecb983" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_87195932-b0e4-4207-954a-a817a0e6280a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_87195932-b0e4-4207-954a-a817a0e6280a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e802a6c-d177-4e20-9bff-2428c63df366" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e802a6c-d177-4e20-9bff-2428c63df366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30988e1a-cc64-424b-a103-ffa60fadf650" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30988e1a-cc64-424b-a103-ffa60fadf650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_d6f4e613-ac31-4326-b06b-4464d1aa17ff" xlink:href="dna-20251231.xsd#dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple_d6f4e613-ac31-4326-b06b-4464d1aa17ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bcc3b450-5a77-450e-bf8b-1b9d87c74054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_239461af-f7ad-4050-bd35-ada004bc693a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bcc3b450-5a77-450e-bf8b-1b9d87c74054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686af4bb-9a1e-4252-b38c-9e2e403e8bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d36faa4-3715-4f8d-8270-c00cd47b85f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686af4bb-9a1e-4252-b38c-9e2e403e8bb5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d36faa4-3715-4f8d-8270-c00cd47b85f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c6bcbced-712f-4a4d-9c1c-aa3bff0e012c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d36faa4-3715-4f8d-8270-c00cd47b85f1" xlink:to="loc_us-gaap_AwardTypeAxis_c6bcbced-712f-4a4d-9c1c-aa3bff0e012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c6bcbced-712f-4a4d-9c1c-aa3bff0e012c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4d840836-dedd-400b-9dd6-73f58d674aed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4d840836-dedd-400b-9dd6-73f58d674aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_362f2f4d-c78d-4600-b91d-0df5a9efe547" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:to="loc_us-gaap_RestrictedStockMember_362f2f4d-c78d-4600-b91d-0df5a9efe547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019c5cb3-5b0a-7541-a802-04170eccbfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_027af551-6e7e-4afd-aa4b-398721c7de97" xlink:to="loc_us-gaap_PerformanceSharesMember_019c5cb3-5b0a-7541-a802-04170eccbfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6313f9ad-cdab-45b8-bfbd-96fdbf22e0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d36faa4-3715-4f8d-8270-c00cd47b85f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6313f9ad-cdab-45b8-bfbd-96fdbf22e0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6313f9ad-cdab-45b8-bfbd-96fdbf22e0c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7dd78b5c-cacb-43d0-9680-338bb88a9f37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7dd78b5c-cacb-43d0-9680-338bb88a9f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a90b57fa-a423-4dc6-a297-cfa75efee0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a90b57fa-a423-4dc6-a297-cfa75efee0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d3d4357f-e582-4bd0-ae51-3b6f274235fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d3d4357f-e582-4bd0-ae51-3b6f274235fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_323a76cf-6338-4b29-b555-3336c7c82124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_323a76cf-6338-4b29-b555-3336c7c82124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06c4ff16-415d-48de-941b-71c5375ac99c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9ed2ca98-7f46-4553-b1e5-76e63cf3443d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06c4ff16-415d-48de-941b-71c5375ac99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6313f9ad-cdab-45b8-bfbd-96fdbf22e0c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_235816be-2f9e-43bf-ae77-d89e7d7400de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_235816be-2f9e-43bf-ae77-d89e7d7400de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50031f51-37b4-4ead-b7c9-13c8d4ea22f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50031f51-37b4-4ead-b7c9-13c8d4ea22f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7447b790-0af4-49c1-8af7-ce858a753e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7447b790-0af4-49c1-8af7-ce858a753e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_68596f07-c0cd-40c9-96e9-d316837d5af5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_68596f07-c0cd-40c9-96e9-d316837d5af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_752af2e1-33b1-466d-9812-42dc33a39b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f0f763bf-e032-42cd-a0b4-4e12f96a674b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_752af2e1-33b1-466d-9812-42dc33a39b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails" xlink:type="simple" xlink:href="dna-20251231.xsd#StockBasedCompensationSummaryofActivityForEarnoutRSADetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_243c69bb-ad7e-49d4-afc5-db72bc8e24ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c35d61-7646-4ecd-9398-0914e4449716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_243c69bb-ad7e-49d4-afc5-db72bc8e24ac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c35d61-7646-4ecd-9398-0914e4449716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6eac5d8b-e078-488d-9c0f-fb684ec37360" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c35d61-7646-4ecd-9398-0914e4449716" xlink:to="loc_us-gaap_AwardTypeAxis_6eac5d8b-e078-488d-9c0f-fb684ec37360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11c3e779-f1e9-4103-a04c-a5ab61aaa1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6eac5d8b-e078-488d-9c0f-fb684ec37360" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11c3e779-f1e9-4103-a04c-a5ab61aaa1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnoutRestrictedStockUnitsMember_89a02baa-c459-4790-b59c-2a841fe60b1a" xlink:href="dna-20251231.xsd#dna_EarnoutRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11c3e779-f1e9-4103-a04c-a5ab61aaa1d3" xlink:to="loc_dna_EarnoutRestrictedStockUnitsMember_89a02baa-c459-4790-b59c-2a841fe60b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43827e4f-dcf8-44e6-821f-98c8e8586c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c35d61-7646-4ecd-9398-0914e4449716" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43827e4f-dcf8-44e6-821f-98c8e8586c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43827e4f-dcf8-44e6-821f-98c8e8586c5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a464f5e0-3630-4b0f-ac55-c560ef41a0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a464f5e0-3630-4b0f-ac55-c560ef41a0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7f1327bd-d607-4d41-b02a-263a10e69165" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7f1327bd-d607-4d41-b02a-263a10e69165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_794ed8ae-241e-4a94-bab6-4931a3dddbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_794ed8ae-241e-4a94-bab6-4931a3dddbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b699b8a2-8ba9-44bd-8f63-d20fe2417f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19f1e123-4416-4fe9-91eb-3a6afb306455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b699b8a2-8ba9-44bd-8f63-d20fe2417f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43827e4f-dcf8-44e6-821f-98c8e8586c5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48356f86-f00b-40bb-8fbd-97c421d17709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_48356f86-f00b-40bb-8fbd-97c421d17709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3324ec81-cd65-46c6-83cc-66d8c3514739" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3324ec81-cd65-46c6-83cc-66d8c3514739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_866ff2cb-1c5b-4360-9bf6-af3523096a84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_866ff2cb-1c5b-4360-9bf6-af3523096a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_89ac379d-469b-4baf-a78e-cf9a7adc4e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_862770c0-ddef-4af5-8778-5c6b5973e85c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_89ac379d-469b-4baf-a78e-cf9a7adc4e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_73817675-e997-482a-9625-321167a5449b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_73817675-e997-482a-9625-321167a5449b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d306ae4-6e19-41e2-8bc0-ba9a8b754e27" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:to="loc_srt_ProductOrServiceAxis_5d306ae4-6e19-41e2-8bc0-ba9a8b754e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5d306ae4-6e19-41e2-8bc0-ba9a8b754e27" xlink:to="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PharmaceuticalAndBiotechnologyMember_aeb16895-b3ff-447f-86b8-26841318d355" xlink:href="dna-20251231.xsd#dna_PharmaceuticalAndBiotechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_PharmaceuticalAndBiotechnologyMember_aeb16895-b3ff-447f-86b8-26841318d355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgricultureMember_06789455-a771-49eb-8552-54a47bf421ca" xlink:href="dna-20251231.xsd#dna_AgricultureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_AgricultureMember_06789455-a771-49eb-8552-54a47bf421ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GovernmentAndDefenseMember_dbed9795-013b-451e-806c-fa921071d1b0" xlink:href="dna-20251231.xsd#dna_GovernmentAndDefenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_GovernmentAndDefenseMember_dbed9795-013b-451e-806c-fa921071d1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IndustrialAndEnvironmentMember_35256bfb-6fce-4c61-948f-c34080befd02" xlink:href="dna-20251231.xsd#dna_IndustrialAndEnvironmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_IndustrialAndEnvironmentMember_35256bfb-6fce-4c61-948f-c34080befd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CustomerAndTechnologyMember_1d6217f6-0ecd-41e0-9073-d16267396343" xlink:href="dna-20251231.xsd#dna_CustomerAndTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_CustomerAndTechnologyMember_1d6217f6-0ecd-41e0-9073-d16267396343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_FoodAndNutritionMember_4920ff5b-5038-4ccc-b62c-19d135bd98db" xlink:href="dna-20251231.xsd#dna_FoodAndNutritionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_FoodAndNutritionMember_4920ff5b-5038-4ccc-b62c-19d135bd98db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringRevenueMember_306ed298-9b29-4d5f-b3e3-cd8efbb30df8" xlink:href="dna-20251231.xsd#dna_CellEngineeringRevenueMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_98bf19ae-74b3-4ae8-af19-2e03c3d49e4e" xlink:to="loc_dna_CellEngineeringRevenueMember_306ed298-9b29-4d5f-b3e3-cd8efbb30df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b4a258e4-7552-4773-9f3c-5715cd05b541" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b4a258e4-7552-4773-9f3c-5715cd05b541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b3c0ed8e-375f-4ea2-9564-131a9519b2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b4a258e4-7552-4773-9f3c-5715cd05b541" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b3c0ed8e-375f-4ea2-9564-131a9519b2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_1c746aea-0aeb-45e2-8416-a3233c91e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b3c0ed8e-375f-4ea2-9564-131a9519b2d4" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_1c746aea-0aeb-45e2-8416-a3233c91e8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d7cc5c5-26b8-49f1-a850-909f580ac84b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d7cc5c5-26b8-49f1-a850-909f580ac84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05be5fdd-28c9-40df-9e74-50f54b23563e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3d7cc5c5-26b8-49f1-a850-909f580ac84b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05be5fdd-28c9-40df-9e74-50f54b23563e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_277457fe-e4bf-4ea5-9a82-7ff21a8953fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05be5fdd-28c9-40df-9e74-50f54b23563e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_277457fe-e4bf-4ea5-9a82-7ff21a8953fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_28f3f16f-c992-439a-9601-1a47229bf414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd7e80b0-9ea7-4987-b6ae-77c6800df2c4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_28f3f16f-c992-439a-9601-1a47229bf414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d55929a0-e133-4380-a405-556f11e626eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_28f3f16f-c992-439a-9601-1a47229bf414" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d55929a0-e133-4380-a405-556f11e626eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#RevenueRecognitionAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_45372365-7185-422f-851f-dfd57417f228" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_45372365-7185-422f-851f-dfd57417f228" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_23420cd0-0c26-4dc5-9c2d-bb80a2081ee1" xlink:to="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringRevenueMember_a9aeee8f-eaa8-4ae9-8ad4-a8826d43f5f1" xlink:href="dna-20251231.xsd#dna_CellEngineeringRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:to="loc_dna_CellEngineeringRevenueMember_a9aeee8f-eaa8-4ae9-8ad4-a8826d43f5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringMember_019c5cb5-5c57-79b9-a392-25bb314c8de3" xlink:href="dna-20251231.xsd#dna_CellEngineeringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_79375250-1429-403f-83a7-0c7bbe8480d4" xlink:to="loc_dna_CellEngineeringMember_019c5cb5-5c57-79b9-a392-25bb314c8de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_df196c00-44df-468e-b212-cc2e164d5afe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1ba9b6ab-5da7-4119-bb6d-18ab9004aa26" xlink:to="loc_srt_SegmentGeographicalDomain_df196c00-44df-468e-b212-cc2e164d5afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_014f59d4-9401-4744-9f0c-65cbe0aebf8f" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_df196c00-44df-468e-b212-cc2e164d5afe" xlink:to="loc_country_US_014f59d4-9401-4744-9f0c-65cbe0aebf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c65e6271-0068-4e99-b8c4-50c82fae4e86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ac1e4ce3-83ad-48e0-b9b7-ee6f2fa0d4ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c65e6271-0068-4e99-b8c4-50c82fae4e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_06254400-998a-4ca0-9fb2-25cef5d6dfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c65e6271-0068-4e99-b8c4-50c82fae4e86" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_06254400-998a-4ca0-9fb2-25cef5d6dfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dffcb9f9-c691-4d49-bdc1-561f9dcc8051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d5cc1c78-2d6e-45b2-9018-99c381085cb1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dffcb9f9-c691-4d49-bdc1-561f9dcc8051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_be310249-bc4a-4477-ab2f-6a45df597155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dffcb9f9-c691-4d49-bdc1-561f9dcc8051" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_be310249-bc4a-4477-ab2f-6a45df597155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:href="dna-20251231.xsd#dna_RevenuePerformanceObligationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_RevenuePerformanceObligationAxis_019c5cb8-7115-74b8-87a7-997e6e913424" xlink:to="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year1Member_019c5cb8-7115-788c-be9d-c57e400809e3" xlink:href="dna-20251231.xsd#dna_Year1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year1Member_019c5cb8-7115-788c-be9d-c57e400809e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year12Member_019c5cb8-7115-7d0c-9844-f93d78044e5b" xlink:href="dna-20251231.xsd#dna_Year12Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year12Member_019c5cb8-7115-7d0c-9844-f93d78044e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year13Member_019c5cb8-7115-7361-b7b3-1e98acabc218" xlink:href="dna-20251231.xsd#dna_Year13Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year13Member_019c5cb8-7115-7361-b7b3-1e98acabc218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year14Member_019c5cb9-7139-77d4-b14b-ee4e1e45dca9" xlink:href="dna-20251231.xsd#dna_Year14Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year14Member_019c5cb9-7139-77d4-b14b-ee4e1e45dca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_Year15Member_019c5cb9-713a-710c-8f26-653f2cafd205" xlink:href="dna-20251231.xsd#dna_Year15Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_RevenuePerformanceObligationDomain_019c5cb8-7115-7344-ba71-c42d23ddc31c" xlink:to="loc_dna_Year15Member_019c5cb9-713a-710c-8f26-653f2cafd205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_019c5cb8-7115-7555-b702-4094f12ffb47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_019c5cb8-7115-7555-b702-4094f12ffb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ff9b2c88-a570-4e21-ac37-a2079e6186f9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash_0282014e-9a03-4d1d-b865-370867934464" xlink:href="dna-20251231.xsd#dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash_0282014e-9a03-4d1d-b865-370867934464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_24ff3fe4-df94-400c-a457-4b4e6862cbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_24ff3fe4-df94-400c-a457-4b4e6862cbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b3628e3f-27b5-479a-b0bc-ed9f6629fec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b3628e3f-27b5-479a-b0bc-ed9f6629fec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_dfd0afd2-3871-4a20-ab0c-0013fee6cd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_UnbilledContractsReceivable_dfd0afd2-3871-4a20-ab0c-0013fee6cd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5c18182d-4e2f-44fe-9e36-7350c487436c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5c18182d-4e2f-44fe-9e36-7350c487436c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_112e6cde-7f91-4c11-9d43-204bd77c95d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiability_112e6cde-7f91-4c11-9d43-204bd77c95d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4d37722a-d69c-419a-aada-4d0bd7033378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4d37722a-d69c-419a-aada-4d0bd7033378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_df600c6e-cdef-49e2-82be-203793c8ed65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_df600c6e-cdef-49e2-82be-203793c8ed65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d507d9f8-70a9-46e6-9979-1542bc339163" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d507d9f8-70a9-46e6-9979-1542bc339163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_019c5cba-fb84-72d4-8d09-45198ef2c5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_be905121-9d8c-4878-80e9-1237906dc5ba" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_019c5cba-fb84-72d4-8d09-45198ef2c5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b5213c4a-91cc-4611-b6d0-4eda4d2b51dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5030b8d4-8f49-40b4-b309-de3094585fed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b5213c4a-91cc-4611-b6d0-4eda4d2b51dc" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5030b8d4-8f49-40b4-b309-de3094585fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5066b602-68a8-47ca-8c2d-8b6a3203fc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b5213c4a-91cc-4611-b6d0-4eda4d2b51dc" xlink:to="loc_us-gaap_NumberOfReportableSegments_5066b602-68a8-47ca-8c2d-8b6a3203fc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOfCoreAssets_29077e1f-cecc-40b7-86d3-e0fd008edfe4" xlink:href="dna-20251231.xsd#dna_NumberOfCoreAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b5213c4a-91cc-4611-b6d0-4eda4d2b51dc" xlink:to="loc_dna_NumberOfCoreAssets_29077e1f-cecc-40b7-86d3-e0fd008edfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_946b6f07-b522-4e13-8a35-db65df08c766" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_946b6f07-b522-4e13-8a35-db65df08c766" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_95782e32-d1e2-4c49-9b0e-45e24de03ced" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_95782e32-d1e2-4c49-9b0e-45e24de03ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30a6c006-619e-48fd-91f7-b0e6d6842d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_95782e32-d1e2-4c49-9b0e-45e24de03ced" xlink:to="loc_us-gaap_SegmentDomain_30a6c006-619e-48fd-91f7-b0e6d6842d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringAndBiosecuritySegmentsMember_c88aa77b-2136-4b71-a048-468b59025632" xlink:href="dna-20251231.xsd#dna_CellEngineeringAndBiosecuritySegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30a6c006-619e-48fd-91f7-b0e6d6842d0b" xlink:to="loc_dna_CellEngineeringAndBiosecuritySegmentsMember_c88aa77b-2136-4b71-a048-468b59025632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CellEngineeringSegmentMember_4cff99fa-0df7-4aa6-bbf2-23c093723cc6" xlink:href="dna-20251231.xsd#dna_CellEngineeringSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_CellEngineeringAndBiosecuritySegmentsMember_c88aa77b-2136-4b71-a048-468b59025632" xlink:to="loc_dna_CellEngineeringSegmentMember_4cff99fa-0df7-4aa6-bbf2-23c093723cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiosecuritySegmentMember_2d69a0fb-6366-4faa-8da8-204bc41e4881" xlink:href="dna-20251231.xsd#dna_BiosecuritySegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_CellEngineeringAndBiosecuritySegmentsMember_c88aa77b-2136-4b71-a048-468b59025632" xlink:to="loc_dna_BiosecuritySegmentMember_2d69a0fb-6366-4faa-8da8-204bc41e4881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a3b031cf-b57b-419d-b42e-ba5df7ed4e5c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:to="loc_srt_ConsolidationItemsAxis_a3b031cf-b57b-419d-b42e-ba5df7ed4e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d0d2af1d-0dcf-42d2-a7e3-b82fd0981ba9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a3b031cf-b57b-419d-b42e-ba5df7ed4e5c" xlink:to="loc_srt_ConsolidationItemsDomain_d0d2af1d-0dcf-42d2-a7e3-b82fd0981ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2cbe9e3b-37c4-4671-b454-be2fe93e657f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d0d2af1d-0dcf-42d2-a7e3-b82fd0981ba9" xlink:to="loc_us-gaap_OperatingSegmentsMember_2cbe9e3b-37c4-4671-b454-be2fe93e657f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e99989ae-7c27-4eca-beae-a00dee988d09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d0d2af1d-0dcf-42d2-a7e3-b82fd0981ba9" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e99989ae-7c27-4eca-beae-a00dee988d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7c03ba33-55e9-49ab-9692-3f81ba83c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7c03ba33-55e9-49ab-9692-3f81ba83c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f99534f4-a909-49b2-a4d8-b5b413bcab5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7c03ba33-55e9-49ab-9692-3f81ba83c21c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f99534f4-a909-49b2-a4d8-b5b413bcab5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LabEquipmentMember_33040a95-dfa3-4542-b8d8-5e7be8b01d43" xlink:href="dna-20251231.xsd#dna_LabEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f99534f4-a909-49b2-a4d8-b5b413bcab5a" xlink:to="loc_dna_LabEquipmentMember_33040a95-dfa3-4542-b8d8-5e7be8b01d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_LeaseAssetsMember_183cee1d-a4bf-4c5f-b2b7-5950f725fd6b" xlink:href="dna-20251231.xsd#dna_LeaseAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f99534f4-a909-49b2-a4d8-b5b413bcab5a" xlink:to="loc_dna_LeaseAssetsMember_183cee1d-a4bf-4c5f-b2b7-5950f725fd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_30f5ed42-b918-4ca0-8188-bb8fef47d242" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:to="loc_srt_ProductOrServiceAxis_30f5ed42-b918-4ca0-8188-bb8fef47d242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4e0f62b3-c48f-42ad-827b-a0358cf30409" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_30f5ed42-b918-4ca0-8188-bb8fef47d242" xlink:to="loc_srt_ProductsAndServicesDomain_4e0f62b3-c48f-42ad-827b-a0358cf30409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_b497651a-871e-4a94-9cc1-63ffe4faf1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4e0f62b3-c48f-42ad-827b-a0358cf30409" xlink:to="loc_us-gaap_ServiceMember_b497651a-871e-4a94-9cc1-63ffe4faf1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_06c83e25-c3c3-4c99-a3cc-9377ec65ca46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4e0f62b3-c48f-42ad-827b-a0358cf30409" xlink:to="loc_us-gaap_ProductMember_06c83e25-c3c3-4c99-a3cc-9377ec65ca46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3e29fcfe-9e05-4423-82ad-3fb2a41ceff9" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_5a4a162a-70e7-4136-96b9-233b1fe90380" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_5a4a162a-70e7-4136-96b9-233b1fe90380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7090d8ed-219e-43aa-9e36-09a9246f452b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_5a4a162a-70e7-4136-96b9-233b1fe90380" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7090d8ed-219e-43aa-9e36-09a9246f452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_fe4187da-46ca-4331-b95d-e557ff652c95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_CostOfRevenueAbstract_fe4187da-46ca-4331-b95d-e557ff652c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b250c41b-588c-4617-8c7c-09a89c54011d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_fe4187da-46ca-4331-b95d-e557ff652c95" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b250c41b-588c-4617-8c7c-09a89c54011d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_537302a6-53ca-442b-b39c-1e627a545820" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_537302a6-53ca-442b-b39c-1e627a545820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_87665109-f4fe-4c87-9f6e-2e4776cdbdba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_537302a6-53ca-442b-b39c-1e627a545820" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_87665109-f4fe-4c87-9f6e-2e4776cdbdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_c89f6223-2e48-48d0-be8f-c2ec59f92fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_c89f6223-2e48-48d0-be8f-c2ec59f92fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d3555b52-af07-4a4c-977f-14f97e2c92f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_c89f6223-2e48-48d0-be8f-c2ec59f92fb6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d3555b52-af07-4a4c-977f-14f97e2c92f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_3b020912-aca8-4269-ac4b-30a568e887ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_3b020912-aca8-4269-ac4b-30a568e887ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0f3fbd1f-438f-4ce7-bcda-97f8f4be1cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_3b020912-aca8-4269-ac4b-30a568e887ea" xlink:to="loc_us-gaap_OperatingIncomeLoss_0f3fbd1f-438f-4ce7-bcda-97f8f4be1cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:href="dna-20251231.xsd#dna_OperatingExpensesNotAllocatedToSegmentsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ab5a855-85b9-4a81-9a15-1ea447c378c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_ShareBasedCompensation_7ab5a855-85b9-4a81-9a15-1ea447c378c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_eb1c5a95-f90b-4751-898c-4658c7ca1f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_AssetImpairmentCharges_eb1c5a95-f90b-4751-898c-4658c7ca1f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_fd5a7fa5-bb36-4e32-83cb-228c19349eed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_DepreciationAndAmortization_fd5a7fa5-bb36-4e32-83cb-228c19349eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_d4a68662-aab3-4d04-b825-7c7b7ead2c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_d4a68662-aab3-4d04-b825-7c7b7ead2c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_6a03a49a-b5ee-4748-ae8b-8de1a9292537" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_LeaseCost_6a03a49a-b5ee-4748-ae8b-8de1a9292537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_91a23564-8038-4776-8107-5d8cbd5b65ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_91a23564-8038-4776-8107-5d8cbd5b65ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AcquiredInProcessResearchAndDevelopment_19e43d20-0411-4081-8adb-fe4b7278e642" xlink:href="dna-20251231.xsd#dna_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_dna_AcquiredInProcessResearchAndDevelopment_19e43d20-0411-4081-8adb-fe4b7278e642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9cefd801-b8b6-4075-8740-a8ecea41d567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_OperatingExpensesNotAllocatedToSegmentsAbstract_5185628a-f391-4e57-af01-ca9efeb0333d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9cefd801-b8b6-4075-8740-a8ecea41d567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bb39e0c7-e455-491e-8047-9176f47e634b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bb39e0c7-e455-491e-8047-9176f47e634b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EmployerPayrollTaxes_1212b410-466a-48a2-a048-f1d4e2664cc3" xlink:href="dna-20251231.xsd#dna_EmployerPayrollTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_dna_EmployerPayrollTaxes_1212b410-466a-48a2-a048-f1d4e2664cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9aada09c-8095-43b8-9137-38a20639a473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_49b39793-b8bc-4faa-830e-a94918d0a000" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9aada09c-8095-43b8-9137-38a20639a473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5cbf-c095-7686-a3f0-30da06e1937c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5cbf-c095-7686-a3f0-30da06e1937c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019c5cbf-c095-72b2-9710-6445f1c2ec5b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_srt_MajorCustomersAxis_019c5cbf-c095-72b2-9710-6445f1c2ec5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c5cbf-c095-7e1f-8b3f-210905f3dfb3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_019c5cbf-c095-72b2-9710-6445f1c2ec5b" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c5cbf-c095-7e1f-8b3f-210905f3dfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MotifFoodworksIncMember_019c5cbf-c095-7676-a79b-4ac427573764" xlink:href="dna-20251231.xsd#dna_MotifFoodworksIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c5cbf-c095-7e1f-8b3f-210905f3dfb3" xlink:to="loc_dna_MotifFoodworksIncMember_019c5cbf-c095-7676-a79b-4ac427573764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c5cbf-c095-7f93-a522-ddadda9d076f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_srt_CounterpartyNameAxis_019c5cbf-c095-7f93-a522-ddadda9d076f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019c5cbf-c095-7f93-a522-ddadda9d076f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherEquityInvesteeMember_019c5cc1-e3a6-7a0f-88ea-eac28ef84da7" xlink:href="dna-20251231.xsd#dna_OtherEquityInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_OtherEquityInvesteeMember_019c5cc1-e3a6-7a0f-88ea-eac28ef84da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaMember_019c9025-d053-72ce-b17b-f5e3a47d774d" xlink:href="dna-20251231.xsd#dna_GenomaticaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_GenomaticaMember_019c9025-d053-72ce-b17b-f5e3a47d774d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditMember_019c9028-2871-7cb1-b9af-9e67aad8b363" xlink:href="dna-20251231.xsd#dna_BiomeditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_BiomeditMember_019c9028-2871-7cb1-b9af-9e67aad8b363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ArcaeaMember_019c9033-dbe3-7a0e-9a43-4437949b5d84" xlink:href="dna-20251231.xsd#dna_ArcaeaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_ArcaeaMember_019c9033-dbe3-7a0e-9a43-4437949b5d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AlloniaMember_019c9033-dbe3-7a1f-82b6-4b1e58bdef2f" xlink:href="dna-20251231.xsd#dna_AlloniaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_AlloniaMember_019c9033-dbe3-7a1f-82b6-4b1e58bdef2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MotifMember_019c9033-dbe3-7a01-8302-0242ef4fbe3b" xlink:href="dna-20251231.xsd#dna_MotifMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cbf-c095-7b6e-a52c-c744d651259d" xlink:to="loc_dna_MotifMember_019c9033-dbe3-7a01-8302-0242ef4fbe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc1-e3a6-7941-88f2-1b57caabab70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc1-e3a6-7941-88f2-1b57caabab70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5cc1-e3a6-71db-82e5-6f049be7ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc1-e3a6-7941-88f2-1b57caabab70" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5cc1-e3a6-71db-82e5-6f049be7ff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019c5cc1-e3a6-761d-9e15-701d8b0c9ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019c5cc1-e3a6-71db-82e5-6f049be7ff1e" xlink:to="loc_us-gaap_RelatedPartyMember_019c5cc1-e3a6-761d-9e15-701d8b0c9ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgreementAxis_019c5cc1-e3a6-75f3-adbc-1809fbb21e67" xlink:href="dna-20251231.xsd#dna_AgreementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_dna_AgreementAxis_019c5cc1-e3a6-75f3-adbc-1809fbb21e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AgreementDomain_019c5cc1-e3a6-7409-9503-e84ad9c840cf" xlink:href="dna-20251231.xsd#dna_AgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_AgreementAxis_019c5cc1-e3a6-75f3-adbc-1809fbb21e67" xlink:to="loc_dna_AgreementDomain_019c5cc1-e3a6-7409-9503-e84ad9c840cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember_019c5cc1-e3a6-75df-931e-3d27f9138648" xlink:href="dna-20251231.xsd#dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_AgreementDomain_019c5cc1-e3a6-7409-9503-e84ad9c840cf" xlink:to="loc_dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember_019c5cc1-e3a6-75df-931e-3d27f9138648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_019c5cc1-e3a6-75ad-80d9-dfe4fc648538" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_019c5cc1-e3a6-75ad-80d9-dfe4fc648538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_019c5cc1-e3a6-75a6-b8f3-d46534f7657c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_019c5cc1-e3a6-75ad-80d9-dfe4fc648538" xlink:to="loc_srt_ConsolidatedEntitiesDomain_019c5cc1-e3a6-75a6-b8f3-d46534f7657c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_019c5cc1-e3a6-72bf-b50b-a9db58463dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_019c5cc1-e3a6-75a6-b8f3-d46534f7657c" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_019c5cc1-e3a6-72bf-b50b-a9db58463dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5cc1-e3a6-78bb-af70-19ef463319a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5cc1-e3a6-78bb-af70-19ef463319a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_019c5cc1-e3a6-78bb-af70-19ef463319a5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaMember_019c5cc1-e3a6-71a2-9d69-eedee8456215" xlink:href="dna-20251231.xsd#dna_GenomaticaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:to="loc_dna_GenomaticaMember_019c5cc1-e3a6-71a2-9d69-eedee8456215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaIncPreferredStockMember_019c5cc1-e3a6-790d-9b9d-9ddd7217e8c1" xlink:href="dna-20251231.xsd#dna_GenomaticaIncPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:to="loc_dna_GenomaticaIncPreferredStockMember_019c5cc1-e3a6-790d-9b9d-9ddd7217e8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_SafesMember_019c5cc1-e3a6-76e5-800f-76e9bd04e29a" xlink:href="dna-20251231.xsd#dna_SafesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_019c5cc1-e3a6-7fe1-acd8-fa432191479d" xlink:to="loc_dna_SafesMember_019c5cc1-e3a6-76e5-800f-76e9bd04e29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cbf-c095-71b4-9b2f-6bccc522359e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_NumberOFEstimatedMaterialRights_019c9029-3c79-7a85-a3f4-c097b86fd64e" xlink:href="dna-20251231.xsd#dna_NumberOFEstimatedMaterialRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_dna_NumberOFEstimatedMaterialRights_019c9029-3c79-7a85-a3f4-c097b86fd64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019c5cbf-c095-7ffe-b356-750b81528f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019c5cbf-c095-7ffe-b356-750b81528f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_019c5cc1-e3a6-7f00-9ef9-c864ff5ca3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_019c5cc1-e3a6-7f00-9ef9-c864ff5ca3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_019c5cc1-e3a6-72c0-b06b-8635c24d6ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_019c5cc1-e3a6-72c0-b06b-8635c24d6ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_UpfrontAmountReceived_019c5cc1-e3a6-76fd-84bb-a2c1b7af1239" xlink:href="dna-20251231.xsd#dna_UpfrontAmountReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_dna_UpfrontAmountReceived_019c5cc1-e3a6-76fd-84bb-a2c1b7af1239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_019c5cc1-e3a6-7f77-bf93-6bcfd1ab9a82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_us-gaap_GainLossOnInvestments_019c5cc1-e3a6-7f77-bf93-6bcfd1ab9a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_PreferredStockInvestmentImpairmentLoss_019c9025-30fb-7574-9f8d-104e7f068da9" xlink:href="dna-20251231.xsd#dna_PreferredStockInvestmentImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cbf-c095-7a18-90aa-ef7e8ec778be" xlink:to="loc_dna_PreferredStockInvestmentImpairmentLoss_019c9025-30fb-7574-9f8d-104e7f068da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5cc2-719d-7dcb-bbd7-926c03503e26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-719d-7dd8-9d05-c8f0734e111e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5cc2-719d-7dcb-bbd7-926c03503e26" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-719d-7dd8-9d05-c8f0734e111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c5cc2-719d-74bc-89e6-9300520a0011" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-719d-7dd8-9d05-c8f0734e111e" xlink:to="loc_srt_CounterpartyNameAxis_019c5cc2-719d-74bc-89e6-9300520a0011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019c5cc2-719d-74bc-89e6-9300520a0011" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AlloniaMember_019c5cc2-719d-7186-bc8c-de3c74bd2d08" xlink:href="dna-20251231.xsd#dna_AlloniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:to="loc_dna_AlloniaMember_019c5cc2-719d-7186-bc8c-de3c74bd2d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ArcaeaMember_019c5cc2-719d-708f-a572-28ec099dc856" xlink:href="dna-20251231.xsd#dna_ArcaeaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:to="loc_dna_ArcaeaMember_019c5cc2-719d-708f-a572-28ec099dc856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditMember_019c5cc2-719d-7aa2-9a23-50bfece2472a" xlink:href="dna-20251231.xsd#dna_BiomeditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:to="loc_dna_BiomeditMember_019c5cc2-719d-7aa2-9a23-50bfece2472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaMember_019c5cc2-719d-78f3-9e00-e6a9b549457a" xlink:href="dna-20251231.xsd#dna_GenomaticaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-719d-7168-b1ef-d64c3c8e4be2" xlink:to="loc_dna_GenomaticaMember_019c5cc2-719d-78f3-9e00-e6a9b549457a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cf2-42f9-7da6-b67c-c75359ece604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-719d-7dd8-9d05-c8f0734e111e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cf2-42f9-7da6-b67c-c75359ece604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5cf2-42f9-7891-a1fc-5ba69a1dfcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cf2-42f9-7da6-b67c-c75359ece604" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5cf2-42f9-7891-a1fc-5ba69a1dfcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019c5cf2-42f9-7b09-a99f-7c33ef223349" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019c5cf2-42f9-7891-a1fc-5ba69a1dfcc4" xlink:to="loc_us-gaap_RelatedPartyMember_019c5cf2-42f9-7b09-a99f-7c33ef223349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-719d-70b4-86a7-6bc12f17303c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-719d-7dd8-9d05-c8f0734e111e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-719d-70b4-86a7-6bc12f17303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019c5cc2-719d-728d-b127-cb3f5789168a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-719d-70b4-86a7-6bc12f17303c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019c5cc2-719d-728d-b127-cb3f5789168a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5cc2-dfd1-7690-9a5d-f1b3d65aad81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-dfd1-7eae-859c-1373d34520cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019c5cc2-dfd1-7690-9a5d-f1b3d65aad81" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-dfd1-7eae-859c-1373d34520cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c5cc2-dfd1-7018-8edc-5977bc672552" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-dfd1-7eae-859c-1373d34520cf" xlink:to="loc_srt_CounterpartyNameAxis_019c5cc2-dfd1-7018-8edc-5977bc672552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019c5cc2-dfd1-7018-8edc-5977bc672552" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_MotifMember_019c5cc2-dfd1-706f-9f2b-81437e55d004" xlink:href="dna-20251231.xsd#dna_MotifMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_MotifMember_019c5cc2-dfd1-706f-9f2b-81437e55d004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_ArcaeaMember_019c5cc2-dfd1-775e-8bb2-a95accf2486c" xlink:href="dna-20251231.xsd#dna_ArcaeaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_ArcaeaMember_019c5cc2-dfd1-775e-8bb2-a95accf2486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_GenomaticaMember_019c5cc2-dfd1-713c-b85e-7251d1868169" xlink:href="dna-20251231.xsd#dna_GenomaticaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_GenomaticaMember_019c5cc2-dfd1-713c-b85e-7251d1868169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AyanaMember_019c5cc2-dfd1-7cfe-b896-8357c9bd2445" xlink:href="dna-20251231.xsd#dna_AyanaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_AyanaMember_019c5cc2-dfd1-7cfe-b896-8357c9bd2445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BiomeditMember_019c5cc2-dfd1-772a-84a5-48a767834a5d" xlink:href="dna-20251231.xsd#dna_BiomeditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_BiomeditMember_019c5cc2-dfd1-772a-84a5-48a767834a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_VerbBioticsMember_019c5cc2-dfd1-71d8-9782-860a8f03216c" xlink:href="dna-20251231.xsd#dna_VerbBioticsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_VerbBioticsMember_019c5cc2-dfd1-71d8-9782-860a8f03216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_AlloniaMember_019c5cc2-dfd1-7627-b314-4593b1329df7" xlink:href="dna-20251231.xsd#dna_AlloniaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_AlloniaMember_019c5cc2-dfd1-7627-b314-4593b1329df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_OtherEquityInvesteesMember_019c5cc2-dfd1-78b5-8ba4-8c2bb8af4ec3" xlink:href="dna-20251231.xsd#dna_OtherEquityInvesteesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c5cc2-dfd1-7012-9f87-710732199804" xlink:to="loc_dna_OtherEquityInvesteesMember_019c5cc2-dfd1-78b5-8ba4-8c2bb8af4ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc2-dfd1-7851-910a-f87878f6f9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-dfd1-7eae-859c-1373d34520cf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc2-dfd1-7851-910a-f87878f6f9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019c5cc2-dfd1-7daf-8a86-ba89ba75c7db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019c5cc2-dfd1-7851-910a-f87878f6f9fa" xlink:to="loc_us-gaap_RelatedPartyDomain_019c5cc2-dfd1-7daf-8a86-ba89ba75c7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019c5cc2-dfd1-72c0-84ad-d927f934583e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019c5cc2-dfd1-7daf-8a86-ba89ba75c7db" xlink:to="loc_us-gaap_RelatedPartyMember_019c5cc2-dfd1-72c0-84ad-d927f934583e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-dfd1-765b-8552-cffed0092245" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019c5cc2-dfd1-7eae-859c-1373d34520cf" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-dfd1-765b-8552-cffed0092245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c5cc2-dfd1-7e64-b745-268c89ac8c33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019c5cc2-dfd1-765b-8552-cffed0092245" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c5cc2-dfd1-7e64-b745-268c89ac8c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple" xlink:href="dna-20251231.xsd#EmployeeBenefitPlanAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_452f94ff-9008-4148-9825-d843abf66d29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_f382844c-7e47-4c4e-aa1a-e5e4ec4c6171" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_452f94ff-9008-4148-9825-d843abf66d29" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_f382844c-7e47-4c4e-aa1a-e5e4ec4c6171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DefinedContributionPlanVestingPeriod_019c902b-50c8-7ebf-a8ce-7a4b1c3b4436" xlink:href="dna-20251231.xsd#dna_DefinedContributionPlanVestingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_452f94ff-9008-4148-9825-d843abf66d29" xlink:to="loc_dna_DefinedContributionPlanVestingPeriod_019c902b-50c8-7ebf-a8ce-7a4b1c3b4436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DefinedContributionPlanEmployeeAnnualEarningAmount_71d965a6-1ab9-4417-9645-88af7a545df8" xlink:href="dna-20251231.xsd#dna_DefinedContributionPlanEmployeeAnnualEarningAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_452f94ff-9008-4148-9825-d843abf66d29" xlink:to="loc_dna_DefinedContributionPlanEmployeeAnnualEarningAmount_71d965a6-1ab9-4417-9645-88af7a545df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DefinedContributionPlanMaximumEmployerContributionsAmount_14cdc567-08fc-4fd0-a65f-9938261a6bca" xlink:href="dna-20251231.xsd#dna_DefinedContributionPlanMaximumEmployerContributionsAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_452f94ff-9008-4148-9825-d843abf66d29" xlink:to="loc_dna_DefinedContributionPlanMaximumEmployerContributionsAmount_14cdc567-08fc-4fd0-a65f-9938261a6bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_39399474-c4cf-484d-bb04-233b1f0c131a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_452f94ff-9008-4148-9825-d843abf66d29" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_39399474-c4cf-484d-bb04-233b1f0c131a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b1ca696b-5e74-459b-bd68-c3172a662a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2a9523a0-9a43-4829-9903-e3fe9ffe499c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1ca696b-5e74-459b-bd68-c3172a662a63" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2a9523a0-9a43-4829-9903-e3fe9ffe499c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_50e4eab5-8084-4747-94f3-153d2b6053b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1ca696b-5e74-459b-bd68-c3172a662a63" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_50e4eab5-8084-4747-94f3-153d2b6053b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0e16e010-5135-4d21-8cbb-d291c0f13414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1ca696b-5e74-459b-bd68-c3172a662a63" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0e16e010-5135-4d21-8cbb-d291c0f13414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_854a716c-c3cb-4f55-96bf-631337854a97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2dd90a7b-ebcb-4aac-a693-12e78468f918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_854a716c-c3cb-4f55-96bf-631337854a97" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2dd90a7b-ebcb-4aac-a693-12e78468f918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_67f932b3-65e9-429f-92be-8c7928fbf412" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2dd90a7b-ebcb-4aac-a693-12e78468f918" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_67f932b3-65e9-429f-92be-8c7928fbf412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0975ed91-c82a-4d54-9d17-d8cfc83a6e34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2dd90a7b-ebcb-4aac-a693-12e78468f918" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0975ed91-c82a-4d54-9d17-d8cfc83a6e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6c1b7113-c29b-40b1-92e0-4227e0d06148" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2dd90a7b-ebcb-4aac-a693-12e78468f918" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6c1b7113-c29b-40b1-92e0-4227e0d06148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8ceb77cc-3ff7-483a-8348-02d3d0a73c96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_854a716c-c3cb-4f55-96bf-631337854a97" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8ceb77cc-3ff7-483a-8348-02d3d0a73c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8116ca6d-91ad-4f29-ab8d-9fa9e3a36a68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8ceb77cc-3ff7-483a-8348-02d3d0a73c96" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8116ca6d-91ad-4f29-ab8d-9fa9e3a36a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98d15565-631b-42c2-9efe-100962fc02f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8ceb77cc-3ff7-483a-8348-02d3d0a73c96" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98d15565-631b-42c2-9efe-100962fc02f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0cb46b70-a2e2-4e1d-af5e-189432cb8420" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8ceb77cc-3ff7-483a-8348-02d3d0a73c96" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0cb46b70-a2e2-4e1d-af5e-189432cb8420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_e2d2ce07-589e-46a4-9f10-99f0970e377d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8ceb77cc-3ff7-483a-8348-02d3d0a73c96" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_e2d2ce07-589e-46a4-9f10-99f0970e377d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bf56d334-eb2a-4774-a72e-9532d336d9de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_854a716c-c3cb-4f55-96bf-631337854a97" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bf56d334-eb2a-4774-a72e-9532d336d9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f102a299-0833-43b0-90aa-47b73ed6a941" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f102a299-0833-43b0-90aa-47b73ed6a941" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c5cca-c999-753f-90dd-c68c0cb50772" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c5cca-c999-753f-90dd-c68c0cb50772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c5cca-e100-7e64-bf66-4543611e2d25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c5cca-e100-7e64-bf66-4543611e2d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c5cca-f392-7447-b4a8-d01b6df33a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c5cca-f392-7447-b4a8-d01b6df33a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c5ccb-0d50-7395-8d38-f0ddd9f1d9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c5ccb-0d50-7395-8d38-f0ddd9f1d9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount_019c5ccb-53f6-70b5-a084-2d39147c6492" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount_019c5ccb-53f6-70b5-a084-2d39147c6492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount_019c5ccb-92da-7790-8e88-36f16a415a80" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount_019c5ccb-92da-7790-8e88-36f16a415a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c5ccb-a918-7bfb-b1ed-ad98ed8ace30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c5ccb-a918-7bfb-b1ed-ad98ed8ace30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c5ccb-d9d5-7b54-8651-c99234c59a55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c5ccb-d9d5-7b54-8651-c99234c59a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c5ccb-f3b3-76d5-a656-b7c7f690aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c5ccb-f3b3-76d5-a656-b7c7f690aebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c5ccc-0977-710e-bd67-fc8d24b9b2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c5ccc-0977-710e-bd67-fc8d24b9b2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-2160-7e55-827e-fe3c2c9d4a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c5cca-b2d1-7359-957d-32acafc366ae" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019c5ccc-2160-7e55-827e-fe3c2c9d4a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f102a299-0833-43b0-90aa-47b73ed6a941" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b1825347-de87-404f-a52f-2c672bf052bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b1825347-de87-404f-a52f-2c672bf052bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_26a3f8e8-ea00-4554-8067-5b0ec48fb805" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_26a3f8e8-ea00-4554-8067-5b0ec48fb805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c5cc5-ca7a-7ded-88dd-830edf156c79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c5cc5-ca7a-7ded-88dd-830edf156c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c5cc6-0ccd-7b79-99cb-4daa42051ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c5cc6-0ccd-7b79-99cb-4daa42051ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent_019c5cc6-95ab-7d7d-9061-a26e613a837d" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent_019c5cc6-95ab-7d7d-9061-a26e613a837d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent_019c5cc6-ff86-7dd2-817a-f8dcd1eeb287" xlink:href="dna-20251231.xsd#dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent_019c5cc6-ff86-7dd2-817a-f8dcd1eeb287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c5cc9-24c1-797c-9229-f49eb81b3a78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c5cc9-24c1-797c-9229-f49eb81b3a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c5cc9-401c-77eb-b9fb-74e5d080f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c5cc9-401c-77eb-b9fb-74e5d080f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_019c5cce-9b47-7dcf-96bb-a157aff2ef12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_019c5cce-9b47-7dcf-96bb-a157aff2ef12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ca4f8730-5021-4bea-ba85-ec5073b4c261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ca4f8730-5021-4bea-ba85-ec5073b4c261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d768cbcc-f17c-4666-a557-c40ae3e59211" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d768cbcc-f17c-4666-a557-c40ae3e59211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a623bbd0-b133-48b3-b79c-c466ab209fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c5cc5-70a3-7963-b3a2-be4fc7b77a65" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a623bbd0-b133-48b3-b79c-c466ab209fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b53bb27-cca0-4509-86b4-6b683fa91627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b53bb27-cca0-4509-86b4-6b683fa91627" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b6bb6a9e-93fb-4542-a2c2-3b1b679da898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b6bb6a9e-93fb-4542-a2c2-3b1b679da898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_9be9f6df-871a-4039-9407-75b06b19d2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_9be9f6df-871a-4039-9407-75b06b19d2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ff0f63de-7ece-4fb8-af4a-556ec3cfc4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ff0f63de-7ece-4fb8-af4a-556ec3cfc4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_b65fcc2b-9310-4815-a887-45f766772898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_b65fcc2b-9310-4815-a887-45f766772898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsDeferredRevenue_75be7ac9-d064-4185-88bc-b899052fa88a" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_dna_DeferredTaxAssetsDeferredRevenue_75be7ac9-d064-4185-88bc-b899052fa88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_f5179737-7143-40e0-a794-c08cf5ffb219" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_f5179737-7143-40e0-a794-c08cf5ffb219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsAmortizableIntangibles_cf5c5931-521a-4166-8b54-b14beb6f6a71" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsAmortizableIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_dna_DeferredTaxAssetsAmortizableIntangibles_cf5c5931-521a-4166-8b54-b14beb6f6a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsLeaseLiabilities_52dcfa31-3773-4e22-9e4e-dbd8c39ba6e6" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_dna_DeferredTaxAssetsLeaseLiabilities_52dcfa31-3773-4e22-9e4e-dbd8c39ba6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsInvestmentsInSubsidiaries_2d624b9c-a455-49fd-9ebf-a5269422f7c7" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsInvestmentsInSubsidiaries"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_dna_DeferredTaxAssetsInvestmentsInSubsidiaries_2d624b9c-a455-49fd-9ebf-a5269422f7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_019c902c-80aa-78ac-9c3c-e919663ed2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_019c902c-80aa-78ac-9c3c-e919663ed2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_841cc32f-2368-4cfe-b4ee-acf94420e78d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_841cc32f-2368-4cfe-b4ee-acf94420e78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0b2ba091-4b4f-43f6-bf14-73e070adc755" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0b2ba091-4b4f-43f6-bf14-73e070adc755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ae8e0c8b-7209-45a2-b7a0-a02c8fa539c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ae8e0c8b-7209-45a2-b7a0-a02c8fa539c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_fad5bebd-305c-49aa-be16-72677b6cc1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1d7e6c8e-10ef-4727-a779-192454f9fbd3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_fad5bebd-305c-49aa-be16-72677b6cc1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_80c1ae5c-8b0f-43da-a08f-d05b93f15252" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b53bb27-cca0-4509-86b4-6b683fa91627" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_80c1ae5c-8b0f-43da-a08f-d05b93f15252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxLiabilitiesAmortizableIntangibles_87924d6c-54af-48bc-a783-ff38549cb4b4" xlink:href="dna-20251231.xsd#dna_DeferredTaxLiabilitiesAmortizableIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_80c1ae5c-8b0f-43da-a08f-d05b93f15252" xlink:to="loc_dna_DeferredTaxLiabilitiesAmortizableIntangibles_87924d6c-54af-48bc-a783-ff38549cb4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4e0cc9e6-0731-4e73-840a-d977c835be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_80c1ae5c-8b0f-43da-a08f-d05b93f15252" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4e0cc9e6-0731-4e73-840a-d977c835be5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_dcd41950-bac9-48d3-acef-e76ac98be2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_80c1ae5c-8b0f-43da-a08f-d05b93f15252" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_dcd41950-bac9-48d3-acef-e76ac98be2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_360d4d2f-2f33-4e35-8745-05f0c0b5833b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_80c1ae5c-8b0f-43da-a08f-d05b93f15252" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_360d4d2f-2f33-4e35-8745-05f0c0b5833b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1365f2c6-e424-40f3-96d0-5260565a1178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_80c1ae5c-8b0f-43da-a08f-d05b93f15252" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1365f2c6-e424-40f3-96d0-5260565a1178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_86e473a8-5816-4d2f-a1e3-a190fe4c1236" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_DeferredTaxAssetsValuationAllowanceRollForward_a0d31186-2287-4fdf-9538-64c3b893c468" xlink:href="dna-20251231.xsd#dna_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_86e473a8-5816-4d2f-a1e3-a190fe4c1236" xlink:to="loc_dna_DeferredTaxAssetsValuationAllowanceRollForward_a0d31186-2287-4fdf-9538-64c3b893c468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_563dc502-f93b-4552-9a67-5914710f9c81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_DeferredTaxAssetsValuationAllowanceRollForward_a0d31186-2287-4fdf-9538-64c3b893c468" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_563dc502-f93b-4552-9a67-5914710f9c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9ebb04f1-db77-4917-88c5-d4dc0110dd24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_DeferredTaxAssetsValuationAllowanceRollForward_a0d31186-2287-4fdf-9538-64c3b893c468" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9ebb04f1-db77-4917-88c5-d4dc0110dd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f4ed881c-9999-4828-b203-a69635a9d04e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_DeferredTaxAssetsValuationAllowanceRollForward_a0d31186-2287-4fdf-9538-64c3b893c468" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f4ed881c-9999-4828-b203-a69635a9d04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a63b5011-9729-4886-9bf5-8efa86ea235f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a63b5011-9729-4886-9bf5-8efa86ea235f" xlink:to="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_75272990-9371-4a65-9a77-33cd6b4bc7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_75272990-9371-4a65-9a77-33cd6b4bc7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_75272990-9371-4a65-9a77-33cd6b4bc7b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6bb71d06-7564-42b6-9672-de0ed2170b01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:to="loc_us-gaap_DomesticCountryMember_6bb71d06-7564-42b6-9672-de0ed2170b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ff835b3d-d737-440b-95d8-1efe74da4ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ff835b3d-d737-440b-95d8-1efe74da4ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_019c5cd2-1d5f-7276-a034-9d6a56c17063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1e763467-80cd-4f0f-9001-73e43f8ed434" xlink:to="loc_us-gaap_ForeignCountryMember_019c5cd2-1d5f-7276-a034-9d6a56c17063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarryForwardsExpirationPeriodAxis_0004649b-8b7a-4226-b22b-5e6b8fc18d4d" xlink:href="dna-20251231.xsd#dna_CarryForwardsExpirationPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:to="loc_dna_CarryForwardsExpirationPeriodAxis_0004649b-8b7a-4226-b22b-5e6b8fc18d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:href="dna-20251231.xsd#dna_CarryForwardsExpirationPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_CarryForwardsExpirationPeriodAxis_0004649b-8b7a-4226-b22b-5e6b8fc18d4d" xlink:to="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BeginToExpireInTwoThousandAndTwentyNineMember_6edd2a3c-eb20-4645-9b51-7199473de6d6" xlink:href="dna-20251231.xsd#dna_BeginToExpireInTwoThousandAndTwentyNineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:to="loc_dna_BeginToExpireInTwoThousandAndTwentyNineMember_6edd2a3c-eb20-4645-9b51-7199473de6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_CarriedForwardIndefinitelyMember_b2a67163-2e8e-48ea-a4cb-a243868b7be7" xlink:href="dna-20251231.xsd#dna_CarriedForwardIndefinitelyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:to="loc_dna_CarriedForwardIndefinitelyMember_b2a67163-2e8e-48ea-a4cb-a243868b7be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BeginToExpireInTwoThousandAndThirtyMember_bdce925a-3e65-49b6-a435-17735264df02" xlink:href="dna-20251231.xsd#dna_BeginToExpireInTwoThousandAndThirtyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:to="loc_dna_BeginToExpireInTwoThousandAndThirtyMember_bdce925a-3e65-49b6-a435-17735264df02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_BeginToExpireIn2034Member_019c5cd2-9d34-78e5-a50b-25a1300d03fd" xlink:href="dna-20251231.xsd#dna_BeginToExpireIn2034Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_CarryForwardsExpirationPeriodDomain_e2855c3f-0054-41f2-baa6-535d883a125b" xlink:to="loc_dna_BeginToExpireIn2034Member_019c5cd2-9d34-78e5-a50b-25a1300d03fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_853ff554-459a-414c-9b3c-9d4989247770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_853ff554-459a-414c-9b3c-9d4989247770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d02070ee-cd2c-486f-976f-b9c105de75a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_853ff554-459a-414c-9b3c-9d4989247770" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d02070ee-cd2c-486f-976f-b9c105de75a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_a35191cc-f813-40be-89f4-bcb0d8d89060" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d02070ee-cd2c-486f-976f-b9c105de75a2" xlink:to="loc_us-gaap_ResearchMember_a35191cc-f813-40be-89f4-bcb0d8d89060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureTable_7b4d8e91-62c1-41a8-9cde-4ee389de2c5d" xlink:to="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_27403c4e-7af4-4f01-8f1b-2209f6340d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_27403c4e-7af4-4f01-8f1b-2209f6340d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_27797211-5b1c-4209-acb3-fec9328d1041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_OperatingLossCarryforwards_27797211-5b1c-4209-acb3-fec9328d1041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_7e23414f-ebb5-45d9-a10d-533995fe124f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_7e23414f-ebb5-45d9-a10d-533995fe124f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2b71f4b2-beb3-4226-9f40-e61f13e28a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2b71f4b2-beb3-4226-9f40-e61f13e28a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2564cadb-d8d5-424c-9227-edd178bc6bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_85a6524a-cb02-4966-b1d8-9b5537869178" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2564cadb-d8d5-424c-9227-edd178bc6bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#IncomeTaxesTaxPaidDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019c5ccf-edbf-7c85-b47d-d1bec3f98923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureTable_019c5ccf-edbf-7b92-b159-a60abd56b594" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019c5ccf-edbf-7c85-b47d-d1bec3f98923" xlink:to="loc_dna_IncomeTaxDisclosureTable_019c5ccf-edbf-7b92-b159-a60abd56b594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c5cd0-b3ea-7d8c-99de-7886a5b108ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureTable_019c5ccf-edbf-7b92-b159-a60abd56b594" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c5cd0-b3ea-7d8c-99de-7886a5b108ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c5cd0-b3ea-7d8c-99de-7886a5b108ae" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_019c5cd0-cb6e-7009-bbb9-564e92732e09" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:to="loc_stpr_CA_019c5cd0-cb6e-7009-bbb9-564e92732e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_019c5cd0-e5c9-7dac-ac78-06f2dbd78866" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_SC"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:to="loc_stpr_SC_019c5cd0-e5c9-7dac-ac78-06f2dbd78866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019c5cd1-03bd-767d-b98e-27f45f0d9124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c5cd0-b3ea-7379-b29c-2c328d5875ba" xlink:to="loc_us-gaap_StateAndLocalTaxJurisdictionOtherMember_019c5cd1-03bd-767d-b98e-27f45f0d9124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:href="dna-20251231.xsd#dna_IncomeTaxDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureTable_019c5ccf-edbf-7b92-b159-a60abd56b594" xlink:to="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c5ccf-edbf-714c-bb80-c41915992d90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:to="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c5ccf-edbf-714c-bb80-c41915992d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c5cd0-1f0f-71f0-a733-79862d66aa44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c5cd0-1f0f-71f0-a733-79862d66aa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019c5cd0-48ce-7a79-be9a-d629f2c583a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:to="loc_us-gaap_IncomeTaxPaidForeignAfterRefundReceived_019c5cd0-48ce-7a79-be9a-d629f2c583a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c5cd0-6dfa-7647-ad35-e84b6a8f3c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dna_IncomeTaxDisclosureLineItems_019c5ccf-edbf-7f50-8505-43e473208fa1" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019c5cd0-6dfa-7647-ad35-e84b6a8f3c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_64ae9bd5-d509-473a-9c57-8610a0544362" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_032e2978-baf7-4dcc-a43c-46a05b2e3469" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_64ae9bd5-d509-473a-9c57-8610a0544362" xlink:to="loc_us-gaap_NetIncomeLossAbstract_032e2978-baf7-4dcc-a43c-46a05b2e3469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_109783b0-d96c-428e-a477-67022dd3ab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_032e2978-baf7-4dcc-a43c-46a05b2e3469" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_109783b0-d96c-428e-a477-67022dd3ab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e702c1ce-ae4d-474e-8e72-cd7483e90c75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_64ae9bd5-d509-473a-9c57-8610a0544362" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e702c1ce-ae4d-474e-8e72-cd7483e90c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_abeb5811-3ff0-4f29-b97f-86e3e31adfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e702c1ce-ae4d-474e-8e72-cd7483e90c75" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_abeb5811-3ff0-4f29-b97f-86e3e31adfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_14924112-f8be-4d0b-88e0-22fc1ac75d58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e702c1ce-ae4d-474e-8e72-cd7483e90c75" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_14924112-f8be-4d0b-88e0-22fc1ac75d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_96dafc7c-1529-4949-958c-34f3a3a86fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e702c1ce-ae4d-474e-8e72-cd7483e90c75" xlink:to="loc_us-gaap_EarningsPerShareBasic_96dafc7c-1529-4949-958c-34f3a3a86fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#NetLossperShareSummaryofAntiDilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_956d6e9f-b1a7-4867-b6a0-67cbfdae6d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69949e01-48c9-4037-b40b-5c23eaa4cd91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_956d6e9f-b1a7-4867-b6a0-67cbfdae6d7f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69949e01-48c9-4037-b40b-5c23eaa4cd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ad0924-bce7-4174-8710-676156ce37dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69949e01-48c9-4037-b40b-5c23eaa4cd91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ad0924-bce7-4174-8710-676156ce37dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ad0924-bce7-4174-8710-676156ce37dc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_7e4a9098-dbe9-42b9-b4ff-f5e5fe326d60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_us-gaap_WarrantMember_7e4a9098-dbe9-42b9-b4ff-f5e5fe326d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cb998be0-1db3-420e-9022-5fa1eed435d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cb998be0-1db3-420e-9022-5fa1eed435d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EarnOutSharesMember_e9103bfc-f1d3-4651-ac35-4a459040120e" xlink:href="dna-20251231.xsd#dna_EarnOutSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_dna_EarnOutSharesMember_e9103bfc-f1d3-4651-ac35-4a459040120e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_54a8fb47-4ded-4e9e-a8f7-b9423e0edb86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_us-gaap_EmployeeStockOptionMember_54a8fb47-4ded-4e9e-a8f7-b9423e0edb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_EscrowSharesMember_1c52694a-97f4-4efc-891e-7fbf334fdf90" xlink:href="dna-20251231.xsd#dna_EscrowSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_dna_EscrowSharesMember_1c52694a-97f4-4efc-891e-7fbf334fdf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_019c5cd4-2bb9-794c-89b2-987eaf9e7b81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea6d2e48-ec58-4157-b491-caa22c5d8e85" xlink:to="loc_us-gaap_PerformanceSharesMember_019c5cd4-2bb9-794c-89b2-987eaf9e7b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d5715358-24f9-43fd-9516-ab9afbf9d737" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69949e01-48c9-4037-b40b-5c23eaa4cd91" xlink:to="loc_us-gaap_ClassOfStockLineItems_d5715358-24f9-43fd-9516-ab9afbf9d737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b7398f5a-d6c5-4e05-9385-022a6fb46c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d5715358-24f9-43fd-9516-ab9afbf9d737" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b7398f5a-d6c5-4e05-9385-022a6fb46c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="dna-20251231.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_89e98faf-09c7-4156-81a8-6333efd263e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c692615d-c8a6-4c58-a20a-ee1f0824cf35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_89e98faf-09c7-4156-81a8-6333efd263e5" xlink:to="loc_us-gaap_SubsequentEventTable_c692615d-c8a6-4c58-a20a-ee1f0824cf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cc30e656-3119-407f-b793-e07053615d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c692615d-c8a6-4c58-a20a-ee1f0824cf35" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cc30e656-3119-407f-b793-e07053615d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_eefb48ac-612b-46a0-bded-c7ba179b3f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cc30e656-3119-407f-b793-e07053615d0e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_eefb48ac-612b-46a0-bded-c7ba179b3f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4a98d0c2-66d5-468a-a913-d340edf4cc70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_eefb48ac-612b-46a0-bded-c7ba179b3f0d" xlink:to="loc_us-gaap_SubsequentEventMember_4a98d0c2-66d5-468a-a913-d340edf4cc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_67096e91-c916-4d92-9d93-e34f03daff1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c692615d-c8a6-4c58-a20a-ee1f0824cf35" xlink:to="loc_us-gaap_SubsequentEventLineItems_67096e91-c916-4d92-9d93-e34f03daff1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived_019c9665-29ce-76eb-8ce8-b5755e6f6a47" xlink:href="dna-20251231.xsd#dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_67096e91-c916-4d92-9d93-e34f03daff1f" xlink:to="loc_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived_019c9665-29ce-76eb-8ce8-b5755e6f6a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>dna-20251231_g1.jpg
<TEXT>
begin 644 dna-20251231_g1.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0!,17AI9@  34T *@    @  8=I  0
M   !    &@       Z !  ,    !  $  * "  0    !   '$J #  0    !
M   #/@    #_[0 X4&AO=&]S:&]P(#,N,  X0DE-! 0        X0DE-!"4
M     !#4'8S9CP"R!.F "9CL^$)^_\  $0@#/@<2 P$1  (1 0,1 ?_$ !\
M  $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$
M   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87
M&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$!
M 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_; $,  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_=  0 X__:  P# 0 "$0,1 #\
M_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__0_OXH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__1_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__2_OXH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /__3_OXH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /__4_OXH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /__5_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /__6_OXH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /__7_OXH * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * /__0_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /__1_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
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MM6.MT[W5M+GFO[ _QO\ VT?C39_&J7]L/]GK2/@)<^$_'T6C?#.+2X-7M/\
MA)M <:F=3$J:OK.LG6HM">WTI+7QGI3V.A^*%U25M-T^ :=,\^> KXVNJ_US
M#K#N%3EI6NN>.M]Y2YN72TURJ5](JQR<-9AG^81S!Y[E=/+71Q*IX1051>VI
M>_SW]I5J>T5-J"CB(<E.MS^Y!<C<OT'KT#Z<* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MQG![2A)2BUY2C=/[_ON:%,H* "@ H * /__2_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /QA_X+W^)/%/A_\ X)T^.;;PV;J.S\3_
M !"^&GAOQ?<VD\ENUMX6FUQ]6D$S1E6DM;[7M'T'2KF LL<\-^T4P>)GBE\7
M/Y3CEM11O:=2E&;7\G-?NMY**>^CU6I\#XE5JU+A7$JES*-;%82C7<7:U%U.
M=WZM2J4Z<&M+J33T;4O;_P#@D%\//AWX!_X)[?LY3_#VQTZ,^./!<7CGQGJ]
MG$@O-=\=ZY=7)\32ZM= O+>76BW\#^&+?S7/V*PT2UL(4AAMDB7?)Z=.GEV&
M]FE^\A[2<EO*I+X[O>\7[GDHV6QZ/ V%PN&X7RIX6,5]8H?6,1.*]ZIB:DI>
MV<WO*5.2=%7?NQIJ*44ES?;5K\$?@SI?Q/UGXXVOPP\!6?Q=UO2K+2=:^)Z^
M&-'7QI=Z5IEL]I;6TWB0VO\ :4<*6.RSN&CN8WNK&UL+2\>:VTVQB@[E0H*K
M*O[*FJLDE*KR+G:6BO+=:.W6Z6OPQ4?H(Y=@(8RIF,<'AHXZI",*F,]C3^L2
MA"/*DZO+S)<MHNTE>,8J5U"*C_'Z/VV_#G[?'QQ^,GB_]JG_ (*#_$_]C+X'
M>&=6CT_X#?";X30^/(Y=9TM[_4WT_6-:E\%Z/>:;=:CHUG9:;>ZQK'B6TO=9
MU75M=EM- ET#1=)BLT^/6-CF%>O/%9C5P5"+Y:%&BYKFC>5I2Y4XMI)7<DVW
M+1I*Q^&_ZPTN)<QQ]?.>)\9D&749\N6X'!?64ZD'*?)4J>PIN$ITXQC*I.K&
M52<ZCC2]E3ARGWM_P2U_;:\8>,OB!^U?^Q=XF_: O_VJ_ 7@7X6>,?B#\!OC
M[X@M]=LO$VO^$],&G:;K&@ZT?%D"^*]0G*^,-*N;:#7;F]NM!NM"\1:?8:EJ
M7A]M%-IWY5CISJ8O!3Q#Q<*=*=2AB)<W-*"LFI.7O-^_&UV[<LDFX\I]'P?Q
M#7Q&)SO(*V9RSK#8;!8C%9;F=55(UJM&'+"I3J>V7MIO_:(-*H[TW2JQBYTG
M3<?EC_@FW_RA&_X*6?\ 82^+/_JD_ %<F6?\B/,_6M_Z8IGC\*?\F\XL_P"O
MF-_]0,(?L;_P0I_Y1G? W_L/_&#_ -6[XTKV<A_Y%E#_ !5O_3TS[SPY_P"2
M1RW_ *^8_P#]3\2?)O\ P<H?\FD_ _\ [.+T_P#]5I\1*Y.)?]SH?]A*_P#3
M54\3Q9_Y$F7?]C6'_J)BCR7X0_MI?\%OM%^$WPOT;P/^P'\,_$'@K2?AWX*T
MSP?KUUX?\627.M^%[#PUIEKX?U>XDB^-UC$\^I:3%:7DKQ65G&TDS%+6W4K$
MN-''9Y&E2C3R^G*"IP4).,[R@HI1;]]:M6>WW'%@,_\ $*G@<'3PW#.$JX>G
MA</"A5=.O>I1C1A&E4=LQBKS@HR=HQ6NB6PW_@L7^T#^UAH'['/[#WCG7M9\
M7?LY?''QQXH\0'XI>%OA?XL\6>!K;3]8&@6[C0KHZ1XGOK^ZTVT?RIX[34-9
MU98WED=9"S8HSG$8N.#P-24IX:O4E+VT*4YP2?+\+M)-KR;?Y,7'>9YU2R+A
MW$5*E?*LQQ-:K]<H8.O6PZC/V2_=ODJRE*,79J,JDMVU+5GCO_!2O]F7]N;]
MCSX9^$_VSM<_X**?%_XB_$YOB+X?T7Q1X>T:7Q'X(\'>&=4\3VNK:P!\/]/L
M_&-QH*^$],U+1H](D\,3>"]'TS6["Y^WW.G:?&+C1)<LSPN.P=*.->8UJE;V
MD8SC'FA3BYW?[M*:CR)JW*XV:Z*UC@XMRCB+(L)1S^IQ3CL7B_K=*G6I4W5P
M]"C.LI5/]FA&O*DJ$)TE!T?80A4B^9PAK3/HW_@IG^VK^TKXI^'O_!/']GCX
M#^,KGX8_$_\ ;@\(?"_Q)XS\8>&M1NO#FJP77Q&B\$Z%X>\.:5KNG(VI^&M#
MU'Q7XHU.\UV_T6YM]6^P:/9:=%<_V==:I:7_ $9GC<3.GEV'P\W2JX^%*4YQ
M;C)>TY(QBFM8Q<IMR:M*T4EIS*7J\7<09M6PO"V5Y;7E@\9Q#0P=6O7I3=&:
MEBUAZ=*C"I"+G2IRK5IRJ2IN,^6$8I\LIQE\P?\ !0S]E;]LW_@G7^ROH_BW
MPK_P43^-_P 1/!OB;XD>$M \7^&[W5/&'A/6M)\63Z/XKU&PUSP/XG@\<^(=
M7T[0[W[/JMKXA\.QWVE6VJ.=*U+56UJ[T_3UTOFS'"XW+<(IPS*O4A*K",XM
MSA*,K2:E3FJDI).S4H\R4M&^9QBH>1Q1DV?<*Y-3KT>*<PQ5"MBZ-.O2E.O0
MJ4Z[IUI1J8:LL16G&G*TU5I<T%/W)3]K*,7#W+_@J3\:OC)X)^ /_!)35?!G
MQ:^)OA'5/'>A>')/'&I>&/'GBG0+_P 923>"_@C<S2>*[S2M5M;CQ"\MQJ6H
MSR-J\EZSS7][*Y9[J=GZ,UKUZ>'REPK5:;J<GM'"I.+G>%%OG:E>6K?Q<V_F
M^;T>,<PQ^'RO@F>'QV,H3Q-.B\1.CB:U*5=O#Y>VZTH33JMN<F^?FNYR=U>7
M-U'_  5@\??M,P_\%-?V*OA!^SW\=_%_P?U#XC^"_".FVGV;Q!KW_"!P>(-8
M^)_C;21XD\3>!;6Y?P_XMDL+*.%_L.LZ7>0:B+&SL+LBS&4K-JF*69X&CA\1
M.BZL(K24O9\SJ37-.FGRSLEM*,KV2>QMQKB<W7%O#^!RO,J^ EBZ%"$>6K4^
MK*K4QF(A[6MAES4J[C%+W:D&I<JC*\;\OS%^U;\-OVN?^"7_ .U7^Q]\18/V
MY/C-^T#;?&[Q^=*\4VGCG5/$]G::C!X6\0> K/Q1X=U_0-3\<^+]'UCPWXDT
MSQPR:/%M@N?#3V[FRE2]M=-U)>3%T\9E>+P=18^MB/K%3EFJCFD^25/GC*+E
M.+C)5/=6\>CT3/'SK"9WP?G.1XM<18_,UF&)Y*T<3.M%35&KAE6I5:4L16IU
M*-6.(?LU[KI6]VTHPD?0_P#P5B_;I\7W/[9G@?\ 8?T_]I'6OV0?@?HND:'K
M_P >OC7X2B\0R>+Y+K7]$F\5V6C6<W@ZW?Q;#8KH2Z+IFGZ;HMS:VNJZUXHE
MF\5>?H6FQB#IS;'S>-IX!8EX.@HJ6(KQYN?WH\RBN3WDN6R23UE/WKQ1ZO&G
M$=>6?X?AV.;5,BRZG"G5S+,**JNNY5*;KQIQ=!.LH^S]G"$*;C&=2M>NW3A&
M)\T?!S]L_P -?L;_ +7O[//AC]G7]OGXB?MH?LT_&GQ1IW@/XM>!?BO!XW_M
M/X9W6LZUI>@V/BG2;[QOH]A9VK"X\1#Q#;2^$HM.DU&+PYJVA^*+>:&XT?4J
MYJ.,C@L9AH8;,*F-PM>:IUJ=;G<J3E)14TY**7Q<WN.-^5J5]''R<!GU+(<\
MRNCE7$V*S_*<PKQPV.PV-6(Y\)*I4ITHUX2Q$%&.M554Z/+S^RG3K)IPF=G^
MVM^W'<?M!_M^?$C]F7XE_MB^,?V*?V2?@5)K?AG5]:^&\?BT^*?B5XY\/O9:
M5KNFW]SX'T^ZU:XEOM;OM2@L;/6S=>#](T/PL]ZVFS>(]03[1>-QSQ.85<+4
MQL\#A,/>,I4^;GK3C923<%>_,VDG>"C"[2D_>WS_ (B>:<38O*,7GU?A_),M
M=2C.IA%7]OB\32<:=6$I8>+FW*I*:C&I^XITJ/-RRK3YI=C_ ,$__P!M1O@]
M^WWX/_9*\ _MB>+/VUOV5OC?H-S'X2\6_$6#Q9#XL^%GQ ATK6[_ $_05N_'
M.GVNL21R2>&5TNXTW1GA\)WMMXNTK6+2RT_6['5+.>\OQOL<PA@Z>-EC<)7B
M^2=3FYZ511DU&\U%Z\EK1?(^=-133YM^&<_^H<2T,DPV?5N(,FS"E+V%;%*L
MJ^"Q2A4G&GS8B*J--T>1PIM4)*O"I%1J1G$\O^!_A;]N']LW]NW_ (*)? ?X
M>_MN_$_X'_#/PI\;/BE_PDFHGQ%XT\6ZUH_AC3?C5XTTKPQX0^&.E?\ "3:(
MOA+3I%@:UU4Z!XD\+*NCZ=8:2R:CI3W&E/E0CCL;C\RP]/'5:%*%>JI/FG.4
M8JO44(45SKV:TM+E<?=2CJKHX\NH\19_Q'Q3EN%XAQF782AF&,]K/VM>O4IT
M89AB(4J&#A[2G["%ERS]E5I>Y&$/?AS0/K7QWXS^+GPX_P""W/[%'[/L/QE^
M)6I_#[3OV?\ PII'B3PY_P )?XFL/"/C75M#^%_QAM+CQ-K_ (-36[K1+S5-
M6OM#L-6N9;]-1N5O+>UDDO;B:TAGKKJ5*U//,%A_;U736'BI0YYJ$Y*E6O*5
M/F<6VXIZ\VMM7:\?;Q&(QV%\0\@RM8_%SPL,LHPJTO;U8T,1.G@L<G6J8?GE
M3E.<J<:C<N9\RBVVXJ1X7K\?[7_[1?\ P6/_ &M?V9_A-^V%\3_@-X+7PK<7
MVKW=EKOB;Q':^%_!EGX>^$T^HVOPT\)/KVFZ3X:\6ZGKVIZ?#!XBTB]\/:AI
M.FW_ (BN[7499KF73=4PE]<Q.<XO"TL95H4^2[M*<E""C1;]E#F48S<FES+E
M<4Y-7?NR\VHL]S7CO.\HP6>XS+<.J,I3E&K6JJCAXT\%S+"4/:0A1KSJ3@E5
MA.E*$)59*6KA+3_91A_:3_8@_P""QOA/]C3Q-^TU\1?C[\,?BUX.\1:WJDWC
MO5M?NTO8+CX8^-/'^CZK)H6N^(_%%OI'BS2/$GA!],NM:TS4!)K.DS7,DXMT
MU!M.M'A%B<#G,,%/%5<12K0G)NI*3O\ NJE2+<9.24U*FXW3U6NE[1TR6.;<
M/<>4,AJYOBLSP>.H5:DWB:E62DG@\1B83]G4JUU"O"KA^1U(RO4@Y-N/-R&'
M9_\ #57_  5O_P""@'[37@#0_P!J/X@_LZ?L^?LP^)-8\/:)IOPYU37+5I8]
M#\6:EX0\-WT.C:+KGA.+4_$GBZ^\,ZWXNO\ Q'XBU#4;CPU'MT/287LQ9QP2
MOK6;YABJ4<54PV'PLI0BJ4I:\LY0B[*4%*4W&4W*7-RKW5T1E'^V>-^)LWPU
M/.,5E65Y/5J4J<,)4J1O[.M.A1DJ=.=%3JUY4:E>=6K*3I+]W#W>11U/@7/^
MUM\#?^"VGP(_9>^,G[6GQ+^//A32/ OBG[+<ZAX@\3Z+HOBWPPG[/GQ/UKPS
M-XY\$-K=_HFI^+=)OK2!KS6]0GU[4=3O-+TW7;S6+G5=SV]4/K=#.Z&%K8NK
M7A&G*UY2C&<?857%SI\SBYIK633;LI:._+>7//,N\0<MR?'YUB\RH0P];EE.
MK5ITZU'^S,94I/$8;VLJ<J\)Q7-4G*M.3A"HYRF^>/\ 5>0""#T((/;@\'D<
MC\*^J/V<_D3LOV,/^"J'_!*?XM_%;Q?^Q)X9T;XZ?!/QYJ%K=W6GV&BZ3XOU
M'5= T"[U>\\)Z1XK\!SZGI?Q&AU_0H->U>P-Y\/-3N[;5$FDN+B]2:>VL+7Y
M%8+-LJJUIX&,:]"I)-I)3;BFW!3IWC4YHJ35Z=T_*]C\/CD'&7!>-QN(X?HP
MS'+\3.,I1A3AB)5*=*525"%;"N4,6JM-5:D>;"RE&=[N=Y0C#]!O^"=G_!6W
M3_VE/C]JO[/_ .T+^S]8_ #]J35-$NK,ZQ8:9?Z;%XP7P'INK^);KP?XATSQ
M/8P^-O".H>'=&EU_7=%TC7=8\0:<UM_;C1W>E7LT%MJOH9=FZQ6(>'Q&&^KX
MIQ>J37.J:<N22E[\'&/-*,9-JU]4W:7T_"W&\<VS.>69IED<LSF=.4?:1A*"
MK_5H5*SH585E]8H3HT_:U*=.I.K"WM&G"32E\,? RV_:U_X+9?&+X_?$(_M8
M?$;]F?\ 9O\ A9XBM/#_ ,//!'PWNM8B6Y&J7&IWGAJWO=*T3Q'X0L]7U>PT
MC3H-;\3>+/$<VH:B^HZI;:5X>M+'2F$6A\%!8S.ZV(J?6ZN%PM*7+3A2;5[W
MY4U&<5)J*4I2GK=VCH[Q^=RY9WX@X_,\5_;6+RC*<'5C2PN'PDJBYN=S=%2A
M3JT(SJ1IP52M6J\TN>2ITHP@[P^F_P#@G)^T'^T[^S]^WQ\6/^"8W[3GQ8U;
MX]6&B:'>>(OA9\2?$U[>ZGXEB:V\.Z5X]L(&U76+K4]>NM(\1> ]::\NM$UC
M7-;_ .$0UO0O['T6]DTY[F1NK+<1BL/F%;*\55E748N5*K)N4M(J:]YWDU*F
M_AD_=DK+3XO7X5S/.,LXEQO"&;XVIF4:=.57!XNM)SK*U*&)BO:5)3JRIU<-
M4O*G4J3]A4I^SIR<'(^7?^"4NJ:GHGPZ_P""X>M:+J-]I&L:1H6LZII.K:7=
MW%AJ>EZG8:%^U)=V&HZ=?6LD-U97UE=0Q7-I=VTL5Q;7$4<T,B2(CURY0W&G
MG<HMII-IIV::CBFFFK--/5-/[K'C\%SG3POB'4ISE3J0IU)PG"3C.$XT\X<9
MPE%J491:3C)---)IJUS]-/\ @@[\1/B!\3_V&9O$WQ*\=>,?B'XD'QJ^(&G#
MQ!XY\3ZWXMUL:?::9X2>UL!JNOWM_?BSMGN)WM[7[1Y$+3RM&BF1]WIY#5J5
M<!SU:DZLO;5%S5)RG*R4+*\FW9=K^EM3ZWPWQ6*QG#KK8O$U\55_M#%0]KB*
MU2O4Y8PH6CSU'*7*FW97LKNU_L_ES_P3LT7X_P#[;/[$'[;7A'7_ -K'XW>$
M_$/A?XH^&/$.E^/;GQCXT\9>(+70/#_A+Q/J6J^"K&:]\;:-?6&A>* J6^J0
M6^JK9.L:/<Z=>[52O+RY8C'8''0EB\1&4*L9*I[2<Y*,83;IIN<6HSV>MN\5
M]KX_A:GF?$/#_$-"IG>84*M'&4:L,2Z^(Q%2-*E1K2GAXWKTI1IUM%-*?+UE
M%V1K?\&[W[.7C;Q';ZM^TQ9?'[QSX?\  OP_^*/C;P/K/[/%BNK?\(%XYU;4
M_A5X>6W\9:TT/BVTT<:MII\4V#6XNO!^J7.?#>G[-2AS ;(X<PTY<V)6(J1I
MTZLX2PRO[.HW25IR]Y+F7,K7C+X5MN7X6Y5B*JJ9M',\32PV%QF(P]3*X\_U
M;$SG@Z5J]2U:-/GA[:-N:A.7[J%IK3E[O_@E;^V/\2OA_P#LP?\ !2SX\_%;
MQSX\^+TGP.U73];\):3\0?''B3Q-%'>1Z7XV32/#NGW6N:AJ4NB:9K6N+H]E
M??V<$"0[)A#+)!$E;95C:M/"YGB*U2I6^KRYH*I.<]E4Y8KFD^5.5D[/Y.WO
M=/!N?8O#91Q=F6-Q.)QSRZ<:E"&*Q%6LN90Q/LZ474E)TX5*BIQERO1:ZM+E
MY']EG]C[]N__ (*5_!J[_;-\?_\ !0;XM_"OQ+XYUSQ?)\'/"?A"^\56'A+2
MO^$5UC4/"\MX-/\ "_C+PMI_@K29O$.C:IHD%EX7T*?4(K.R/B"^N]7O[V2T
M?/"X/'YG0>-J9C6HRJ2G[&$'-07)+DO:,XJ"<HM6C&]ES-MMN6&39%Q)Q;@'
MG^*XGQV#JXBI7^H4:$JT*$/8U)T7+EHUZ,</!U:<Z:C1I\RC'VLG.<N0[K]F
M']N[]HCXL?\ !.__ (*/_"KXS>,=<;]H/]D+X=>)M-T_XIZ9J\NE^,KVQN=-
M\7:/:/<:[HWV*]N/%'@WQ!X)U."7Q?%<1ZGJ]IJFCW%Y+/JMO?ZIJ6F%Q^)J
MY=F5*M.7UG!TYI5HMQFTU-)W3OSPE!^^FW+FBVTTW+HRCB3-<;PMQ7@\?7J?
MVGD>%J0AC(3<,1*,HUZ:O4I\LG6H5</-.NG&<XSIN?--2G/Q7]F;]E']M[]M
M+_@GY;?'CQ%_P42^,?AC2O#6D?%:_P#AI\.+/4O&.I?VY+X)\2>)+R]NOB?X
MV3QOH>LZSJ6J>(-.U'2]"N+ZU\2GP=X>CTB;3IYXEE\/6^&%PF.QV7JO+,:\
M5%572IJ4WS<DI-^UJ<_-)N2<8WYN2/+:]Y0CP91DG$/$'#"S*KQ3CZ,*5/&R
MPF$C.O/VKP]:JY2QF(^L4IU)SJPE"DY1K>PI*#@VKTX_1O[#/[7?[7WCK_@C
M'^TO\1/"VO>)?B9^T#\%/%OBWP#\.O$FIQW7B_QK_P (I!HGPO\ $-]J\LEY
M'J5_XF\0^"/#_C;Q=J>AR:G'JDDB:'HUI=17EM;- _3@,9C*F2XFK"4JN(HS
MG3IR=YSY5&E)OJY2A&I)QNOLJ]]3U>',\SW$< YMBJ-2MC,SR^O7PN$JSYJ^
M(]BJ>#JRJ-R5256KAZ6(KSIN?M-*=---+E/SJ_99^(OPK^*OAWPIXEU/_@KQ
M^U3^SM^V;JNJK<:]'\6]1\8:A\'+[58]<ED@TZ76AJ<_AVXT*>Q"J[^.?%4%
MA<SW1BNO"BVJ3:<_G86I2JQA-YQB\-C9/WU5<W1;OM?2'+_CDT]N16/ELFQ>
M"QM*C6GQQG.59_.=ZJQLZ\\!*:J-J+J<[I.DX[_6:\8MRLZ#BG$_MMTN*2'3
M-.AEU.;6I8K"SBDUBX6Q2XU:2.WC5]3G33+:STU)K]@;J1=/L[2Q5Y6%I;00
M".)/MEHDK\S27O.VOGI9:[Z*W:VA_0<$U""<W4:C%.HU%.;27OM02@G+XFHI
M1U]U)*Q?IE!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % 'Y"_M=_MC_ !M^#OQPU_P)X)U+0+;P_I^E>';NVBU#P]9ZA<K-J6CV
MUY=%KJ9Q(ZM/*Q12,(N%&0!713IQE&[O>[_K^OU/X^\7_&;CC@WCG,,AR/%9
M?2R[#87+:M*&(R^CB*JGB<'2KU6ZL_>:=2;Y5T6BV/IC]AGX[_$'X\^"O&NN
M?$*[TR[O]#\46VE6#Z9ID&EQK9RZ3;W;K)% S+*_G2,1(W(4[>0/EBK!1:MU
M1^F^!/'O$7'V2YWCN(JV&K8C YI2PF'>&PM/"Q5&>$IUFI1IZ2ESR;YFKI::
MGW%61^Z!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?Q[?"B#2-=_P"#
MCCQM_P +F6":_L_BC\19_!$.OK"UK)J^A?"FZ/PG8"_V1B>S\-6>D7_A1D#S
M+K%IH3:=NN?LKU\=22EQ)4]ONJM1TU*S5XTKT=[6M%)PMK=1WTYOPK!*G4\5
M<1]?LY1QN*>'52W*ZE/!/ZE\76-*-.5&UW[2-+DUY''^P=T21&CD571U9'1U
M#(Z,,,K*V596!(92,$<'.:^Q/W4_,'_@J]^TGXB_8S_85\8^+O@['9>%_%FK
MWWAGX3_#V_TJRAMK/P6_B<723ZSH]E:PK96EUHGAG2]8?P[\D5G8ZP-,N#%.
MD LKCR\VQ,L%@)SH^[-N-*FTM*;G?WDMDXQ4N79*5O27Q_&F;5<@X<KU\ HT
M:]2='!864(I1P[K<UZD(I<L73HPJ>RT48U.1V=N4_E1\":3_ ,$HO%/P&DU[
MXZ_M&?M-7/[97B[2K[Q9X@\?VWA[Q#K&A>'/B1J"SZA96,\=SHU]>^*[*POW
MM8?$FMW.O/J^NW::AJ&CZII*3VB6ORE-93.AS8C$XGZ[-.<JBC)J-5ZI;>]9
MVYGS7D[M2C]K\8PT."ZV6NIF.:YP\^KPE6JXI4JE2E1Q<KS2:E"4J\8RLJM2
M51SJ2YYTYPYH\OZ/_"/]K3XA?M/?\$*OVQ]&^+'B"^\7>._@BNF>!3XLUB\G
MU'Q!XB\'ZCX@\#:[X5O?$=_<EI]0U>Q>XUGP^=0F>2YOM.T73KF_FN=2>]NI
M_2HXRIBLAQJK2<ZE"U/G=W*4'*G*#DVW>2NXW[13;;<CZS YWBLX\.<^IXVK
M*OB<O4,-[>I)RJU:$ZN'J4959.[E.+<Z7,VY2C3@Y.4FV<+XP_Y5J/A5_P!E
M1U'_ -:A^)%1/_DF:/\ U\?_ *F53FQ'_)I<#_V&3_\ 5QC#^B7_ ()G?\H_
MOV0?^R#^ ?\ TSQ5]%EG_(OP?_8/3_\ 24?J7"7_ "3.1_\ 8MPW_IM'Y1?\
M'*W_ ";)^S__ -EWN/\ U7_BBO)XF_W7#_\ 81_[CF?%^+/_ ")\L_[&3_\
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M<\+.-3)<;-T^:7-%_6%9J&(]E#FBJ?/B)4W*51RBE!G](=?2'ZL% !0 4 %
M'__3_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M/&QDL;EN-5%\LY*#JSIJO*C!J4J<*L)PJNO"K*5/V<Z,FI?77[$'A_\ ;/\
M%_Q>UGQS^TS^Q;^RO^S1\*].\+QKX%T?PA8>$+_XLP>-QJ,4]MXA@U;PU<^*
M$6Q.F/J.G:K;ZG=^#KRUE&DW&EZ==8U-[CKP,<=.K*>*P>%PU)1_=QARNMSW
MNI7BYZ6NGS.+6EKV9[G#U+/Z^.J8G-L@R;*,%"C;#4Z$:$L<L1SW555*/MO=
MY.:$U-X>2_=N$':<I>:?\$Y/V/OVB_@-^W;_ ,%#_C+\5_AW_P (I\-OCI\1
M_&NO?"SQ)_PEO@77/^$HTG5_C%XT\5:?=?V/X;\3ZQKVB?:-!U?3[_R/$>EZ
M/<Q?:/LL\,=[%/;Q99;@\3A\?F5:M3Y*6(JSE1ESTY<\76J33M&<I1]V2?O*
M+Z-734>3A7(LURWB/BC'XW"^PPF8XO$5,%5]OAJGMH3Q^(K1ER4JU2K3O2G&
M5JL*;5[-*2Y0^,O['W[1?BO_ (+1_L[?M9Z!\._M_P"S]X%^',.@^*O'_P#P
MEO@6U_LO5D\(?%S2VM/^$5O?$]MXUO<7WB?0X//T[PW>6Q^W>:)_)MKQ[<K8
M/$SSK#8R-.^'IT^6=3GIJSY*JMR.?M'K..T&M?*3B8[(LUK<?Y9G=/"\V68?
M"^SK8KV^&7)/ZOCJ?+[&598B7O5J:O"C)>]>Z2DXG[/_ .Q]^T7X)_X+*?M/
M_M6^)_AW_9GP"^(GPYU70?!WCW_A+? M[_;&K7-G\'HH;3_A%]/\3W?C33]\
MGA77E\_5/#EC;+]@R\X6ZLFN##X/$T\ZQ6+E3MAZM-QA4YZ;NVJ.G(INHO@E
MO!+3I>/,97D6:X;CS.,YK87DRS%X6I3P^)]OAI>TG+ZC:/L8UI8B-_8U=9T8
M)<FZYH\Y\1OV/OVB]>_X+:?!']KK2?AW]K_9Y\(?#F[T'Q%\0?\ A+? L']G
MZM+\)_BMX9CM?^$3N?$\/CB[W:WXET6R\^Q\,W-L/MOVDS"TM[NXMRI@\3+/
M*&,5.^&A2<95.>GI)T:T;<G.JC]Z<5I!K6]TDPQ61YK4\0<NSR&%YLKH825*
MKBO;X9<E1X+'4E'V+K+$2_>5J<;QHRC[UVU&,G'Y:\??L5_MU?LQ_MY?'GX]
M_P#!-GQ=\(?B'9?%K5YM<^+?P@\7>+/"T>J>"+[XAZ@/&EQ8>.O"^LZOH<D&
MBS:[=:AXH\ :SH>KZ;XBAT*>ZT6*TGL!=2:]RU,#C\+CZ^(RR=&HJTN:M1G.
M-X.H^>U2+E&R;;G3:DI<MTDU<\;$\/\ $>3\29EF7"=? XJ.-FZF.P-:O1Y\
M/+%S^L..)HU*E*U-U'*OA:E.I"JJ3E347"_M_G#]FO2OV@-5_P""]WPSN/V@
M_B%X-^*?QD\*>!/%^J?%B[^'-G;VG@OX>27G[/?C72[+X?Z2;>.%+I/"+^)_
M#FCZE>26\5S)KE_?1W;75U%-?W?-A5B'G]/ZQ5A5K1IS=7V>D*5Z$TJ2_P '
M-%/9W>NK:EY64PS.?B5A'F>*H8S'T<-7GC986*6'PKEE>(A'"PM9/V#K4H3E
MRQ;J2DI7DI3E_79?QWLUC>PZ==0V.H2VES'87MS:-?VUG>O"ZVMU<6*W5DU[
M#;SF.66T6\M&N41H1=0%Q*GUSO9V=G;1M7L^CMI>W:_W7/V^2DXR4)*,W%J,
MG'F496]V3C>/,D[-QYHWVNKW/YG8?"__  7Z_8\\8^-M&\!/X0_;0^'OB/Q5
MKGB;3/$7B^^\/ZK;PWGB#4)=3O);+0=7\>> /'W@Q+B>Z>2;PCIVI:KX&T*X
M%Q%H$KVS-=W'S/+Q!@YSC3Y,;3E.4U*;B[.3N[1<H5(:OX%*5.+NH[MGY(J/
MB9D5?$4\,Z&?X6K7J585:\J51*56;DW&E4Q.&Q.'NY7="$I8>D[JG>+YI=Y^
MPQ_P3[_;0\;_ +==Y_P43_;ZA\*^"?'&FV^HMX5^&_AO4O#^J7=UJ]SX(;X=
MZ--=6WA;4?$?A[0O"?AOPC=W']F6K>)]2\4WVOV]G>:P(FAO+C4M,!EV-GCW
MF.8<D*B3Y*<7%MMP]FO@E*,81@W;64G+5I:RET\.<,9_B.(Y<4\2JCA\1!3]
MCA*4Z<Y.I+#_ %6FVJ,JM*G0HT)/D7MI5I54I5.6TN?SO1?V/_\ @I=_P3'^
M.7QHUW]@7X>?#W]HC]GKXU:JFLP^"?%VKZ9;7O@V2"_U.7P[9ZCI6H>./AUK
M"ZQX:CUB\T=-:\-:KJVCZ_X>^SW7B"QT_48+--&SC@\SRNO7EE].GB</7ES<
MDY13IZOE33J0=XW<4XN<91UE9JYRT\CXMX0S''U.&L+A<TRO,)^T6'KU(*6'
M:E)THSA+$86I[2BIRI^TI2G3J4K2JQA-14/IW_@G+^P3^TWH_P"T_P#%7_@H
M)^W9=^'[+X__ !&TZ\T3PW\//#>I:9J]OX0LK^VTS1KF]U*]T*]U70K9=,\+
M:%I7A'PAHVDZ_P"(?LOA][N;7-2EU5HA%U9;E^*CBJV88]Q6(J)QC3BU)03L
MFVU>*M&*C!1E*T?BE=V/7X5X:S>&<8SB?B.5*.9XJ$J='"TI0FJ$91A3<IRI
MRJ4UR4:<*%"$*M6U+F=27.TCD/\ @FS^P'^T5\*]+_X*:^#_ (\>"1\,M)_:
MG?\ L+X<ZX?%/@;Q:-2TG5[?XZZ7J.L&R\&>*->NM-&F6WCK0;PVFN)I-U<_
M:_*MXFDMKT6\99E^)HK,X8BG[)8IVI2YZ<[Q?MTW:$YM64XOWN5Z[:,QX3X9
MS7!0XNH9EA_J<,Y?L\+4]MAJ_/":S&$JG+AZU:4>18FE+EJ*$G>R3M)1^6_V
M(?@?_P %N?V0O#/BW]E+X9?!OX):)X!UOQMJNMVWQQ^(NO>'_$&E^![G7K;3
MM%O_ !9X430O'D.IZ]ISVFCVVM:?H6L?#G7M1M;]LZMHT,-Q-IC<F!H9Y@XS
MPE.C0C3<W)5ZLHR4.:R<X<M1N2LN91=*33WBDW$\;A[+_$+(Z-?)<)@,OIX:
MIB)U%F.*J4JL,,ZBC3E6HJGBN:K!Q@JD:53#59J7QP2?)'[%_P""-'[$/[1O
M[,OP7_:C\ ?M(^!C\.M5^*_B2P/AZ5/%/@3Q:=1TR7PIK&BZAJJGP/XG\26U
MD8+F^1EM-1FLKB3=^[A:-6=>S)<#B<+0Q5/$P]DZTEROFISNG"46_P!W.:5F
M]GROR/=X"X>S7*,!G.&S;#_59XVK#V35;#5^>'L:E.=3_9ZU91LY+2;BWV/'
M/^"1?P#_ ."D7[$7Q1US]F[XB? 'P@W[,?B;QYXH\:>,?C%%XI\.7VH6.I1>
M!WT/0=3\&M9^-X;[4M(\2ZGX<\(03Z1J'@R76]+L[B^N;N'2Y/.2#+)\/F6!
MJRPU7#P^K2J3J3K<\&T^3EBX)3;:DXQT:YHJ[:3T.'@?+.*^'L95RK%990>4
M5L36Q%?'JM1E*,EAW3I3H6Q/-.%6=*@G3EAY5(1<G+V=WR]E_P $RO\ @G%\
M9? WP,_;R^!_[6?P]NOAWX?_ &EM2@TG0I['Q=X"\47]UH5YH_C+3[G7M/?P
M=XF\30:;J&BW6KZ9J%C#K:VCO=I"3:SQ17"+>69;6IT,PH8NFZ<<5)J-ITYM
MQ<9KF7).5FKIKFL[VT=K&_"/"F/P^7\2Y?G>%EA:6;S4*;C7PU:4J<H8B+J1
M]A5K*$J;J0E%5.5N5O=LGS>"?!GX4_\ !<+_ ()_^"?$/[+/P$^$GPA^.OPN
M?7/$$_PP^*EYK7AC/A+_ (2*66_OK[2-/\1?$SP1/HL1O;FZUR;1_'/AK6=)
MM?%%S>BROM=TN5X+_GHTL\R^G+"8>C1KTKR]E5<H^XY:MI2J4[:MOEG%KFO;
MF6DO-P&"\1.&</5R?+<#@<QP?M*KP>,E4H_N?:OFE.$:N+PTJ:YFZCIXFC4A
M&M*7+*I!N$_H/]GG_@EI\8?@!_P3V_;4\':W<V/Q(_:X_:Y\!:]_;NEZ5KVG
MIID6IIHNNKX4\(+XI\27.CZ3=:TVL>*O$>H>)?$=U?V&B7&HZI':075Q8Z3!
MK.H=&'RJMA\NQL&U5QF,IRYDI*RERRY(<TN6/,I3DY2<N5MZ62O+T\LX-Q^6
M<+\04*CCB\\SS#5/:0A5AR*:A5]C0]M5=.#J.I6JRK592C3<YJ*?+!5)_7W_
M  3G_9O^-'P'_P"":VD? #XK>#/^$5^+=KH7QQLY_"7_  D7A37-ESXP\4^-
M=2\.1_V]X;UW6/#+?VC9:OITV]-::.T^T>7?/:RQ3QIV9;AJ^'RV.'K0Y*R5
M=<G-"7QSFX^]&4H:IK[3MUML>]PKE6/RWA.EEF-P_L<=&GF,70]K1J6=>OB9
MTE[2C4J4??C4B]*CY;VERM21\D_\$XOV1_V_/V5?^"=G[0_PLT'PUX-^#W[5
M'B?XRZ[XR^%A\>^)/!WC+PY%HUYX*^%&CRZO)=>";[Q_H"ZE=+X;\3:9H=EK
MBM;6^LQV-]K=D-%8/<<F6X/,,)EN(HQC"CBY5Y3I>TE"<5%PHJ_[MU8W?).,
M5+:5G)<MN;P^%<DXFR;A7-,'2HT,!G-;'U<1@_K-7#XBDJ<L/@:?M&\//$TN
M>7L:T*<:FBJ*,JL53UE\<?M,_LT?\%+_ -MWP]I_PJ^)?_!-G]F'X8_$ZZ\0
M:/?>(?VKM!\0?#S2-1BLK:;S+NZ?5-#\;>(]>N+/5V$CZ[IT#>+;AX9V^R>&
M;&_6WN+?CQ6&S/'15*KEF%I57*+EBXSIIZ;NZG*;3^TO?>ND6US1\'-\HXNX
MAI1P>,X3R?!XR56G*KG5*KA(344_>;G3Q-6HU-W=6"=:5I65)22D?T]? OX<
MW/P?^"?P?^$M[KLWBB\^&'PO\ _#V[\2SQ-!-X@N?!GA72O#L^LR0O),\+:G
M)IS7GDR3321";9)-*ZF1OIZ%-T:%&BY<SI4J=-RVYG""CS6UM>U]^O4_7LNP
MKP.7X# RJ.M+!X/#8655JSJO#T84G4LVVN=QYK-NU[7>YZI6IVA0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\[O\ P4._Y.A\
M6_\ 8!\'?^H[8UUT?@^;/\Z/I$_\G2S?_L R;_U6T#[<_P""6?\ R3/XF_\
M8]67_I@M*SK[Q]#]P^BK_P DSQ1_V/</_P"J^D?J-6!_4X4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M(>29IGF6X&AE6%^M5:..=:I#VV'H<M/V%6'-S8FM1B_>DE:,I2UO:R;C\(^
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MZ<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * /YW?^"AW_ "=#XM_[ /@[_P!1
MVQKKH_!\V?YT?2)_Y.EF_P#V 9-_ZK:!]N?\$L_^29_$W_L>K+_TP6E9U]X^
MA^X?15_Y)GBC_L>X?_U7TC]1JP/ZG"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /YW?^"AW_ "=#XM_[ /@[_P!1VQKKH_!\V?YT?2)_Y.EF_P#V
M 9-_ZK:!]N?\$L_^29_$W_L>K+_TP6E9U]X^A^X?15_Y)GBC_L>X?_U7TC]1
MJP/ZG"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MK5+*L!_SX^7M:VOH_::?=+TW)>-Q/\Z7K&%_QCV[)WZ?W9A^T;\8>_BI#_W
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MMC_^?R7K3I?_ ""]=^_1IQG7XT?$@C_D/K_X*=%]O^H6/\^M7'A;(WK]3?\
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M\H,V7]O']J=1E?B3 /\ N2O 9].Q\+=OKUZXP!77#P#\*G:_#537?_A;S_\
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M_P#/9>GE?K;WE_K5GO\ T&K_ ,)L)_\ *#,E_P""CO[8BGCXK6X_[D#X<?\
MS('/Z>_K77#Z-G@U*U^$ZCO_ -5#Q+IZ?\*Z^>C^1G_K9GW_ $&Q_P#";!__
M "OY:>O8S)O^"DO[929V_%BV'_=/_AJ?3_J3_7Z=<Y-=</HS>"\K7X1JZ]/]
M8>)O_GQ?\_-K47^MF??]!R?KA<&ORI2_X'G=N.7+_P %+OVT%^[\6K?_ ,-Y
M\,__ )CS_,<_C77#Z,7@F[7X0J[V_P"2CXH5_NSC3Y<WGM87^MF?_P#0:O\
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MA2_WY;V_W7!^?14'?:WV?GM'*F_X*M?MW)G;\:+48_ZIE\*#Z?\ 4C?R;Z]
M6ZX?1*\ Y63X(K:_]51Q=^F>_J_E:2)_URXB_P"@^/\ X283_P"9_P!?N,V7
M_@K#^WFIX^-5J/;_ (5C\)O;U\"G^0]SR*ZX?1%^C_+?@>KO_P!%3Q?I]V?Q
M_+[OM0^,^(U_S,(_/"8)_P#NO']?D[*67-_P5J_;Z7.WXVVH_P"Z7_"3V]?
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MKR/]=^)?^AA&^G_,'@?_ )E_6S[JQ,O_  5Y_P""@I_YKE:=?^B5_!_V[_\
M"!<>O*^^/X*B7T.?H[+_ )H.M?\ [*SC+_Z('?Y6[>8O]>.)?^AA'_PDP7_S
M(3+_ ,%=?^"@9Z_'&T[?\TM^$/MW'@$]?]WWX *5F_H=?1W_ .B$K?\ B5\9
M?_1 _P"MKNRD?Z\<2_\ 0PC_ .$F"_\ F0E'_!73_@H#W^.%KV_YI;\(?_F
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M2#_W0O7Z?ERV;^B)]'WIP/5_\2GB]_\ OQ7V\OGI8G_7?B:__(Q7_A'@;?\
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MNGKH)\=<4?\ 0R7_ (1X#7RUPW7Y>JT1,O\ P5(_;C/7XQVW;/\ Q;;X6_\
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MI*'_ .OTR"N;^C5X,?\ 1)5%_P!W#Q-_\^?Z^3&N/.*?^AE'_P (<!_\SO\
M+[R9?^"G'[;)_P":O6W_ (;GX8<=/^I,_E].U9/Z-O@STX2J?^)!Q+_\^%_6
MNE[17^OO%/\ T,H_^$. _P#F?_/](S+_ ,%-OVUSU^+MM_X;KX8^W_4F =_?
M!/X5+^C;X-?]$E4^7$'$O_SY_P OO:4C_7WBG_H91_\ "' ?_*!X_P""FO[:
MI_YJY;_C\._AC[>G@T]LGH./6LW]&_P;Z<)U?_$AXE_^>[_K36UY'^OG%/\
MT,H_^$. _P#F=?UWW)5_X*8_MJ'K\7;;_P -W\,O;N/!OOZ =^.5K.7T</!Q
M;<*5/3_6#B3_ .>NOW_?]D_U]XI_Z&4?_"' ?_,Z_+[[$R_\%+_VTCU^+=M_
MX;SX9^W_ %)F._Y<^M0_HY>#J_YI2I_X?^)7_P"]>/Y^6GVC_7WBG_H91_\
M"' ?_*"=?^"EG[:!Z_%NW_\ #>?#,>G.?^$.(/KT'Y "LG]'7P>Z<*U+?]C_
M (C_ /GJO/\ X.XGQ[Q3K_PI1_\ "' ?_,SM\T_DG[KQ_P %*_VS_P#HK=N?
M^Z>_#/\ ^8W\._\ 5<I?1V\(+Z<+5/\ P_\ $7Y_VM^GWZB_U]XJ_P"AE&W_
M &!9?;_U'T5N_36][(E7_@I3^V<?^:LV_;_FGOPT]O\ J3E]?3V!.:A_1X\(
M8_\ -+5/_#]Q'_\ /5_UWVD+C[BI_P#,RA\L'E[]/^89/;^[ZI7:)A_P4F_;
M,/7XLV__ (;[X:^W&/\ A#Q^AXZ<X+5D_H]>$?\ T2U1+_L?<1?_ #S_ %7X
M-R?^OO%27_(RC?\ [ <O6OE_L]K^3O\ <[1E'_!23]LH_P#-6+?_ ,-]\-A_
M[J)[_P"2.6A_1\\(^G"]3_P^\1/Y_P#(XC^7K:SYI?'O%2O_ ,*:OYX'+UO_
M -R]M]/37W59R>O_  4A_;*/_-6+?M_S3[X:^W?_ (0_T^G'/H&C_B7SPD_Z
M)>I_X?>(?_GL3_K]Q6O^9G'_ ,(<N_\ F65_+7SUVC.O_!1_]LCO\5[?M_S3
M_P"&WMZ>#_3/IQS[-F_H_P#A+TX8J?\ A\XA_7-?UW[)(2X^XL?_ #,X_P#A
M#E_Z85?G]Q,O_!1W]L8]?BM;_P#A ?#<>G?_ (0\_P#ZN>.M9R\ ?"=;<,SW
M_P"AYQ __>J_ZTTW*_U^XK_Z&<;_ /8%E]_N^JK\]]--4/'_  4<_;$)Q_PM
M6W[?\R!\.!_[J!S]/Y<BLWX!>%"U_P!6:G_A\X@_^>7]?<)\?\5[?VFO_"'+
M_NM]4>M_[WW[DJ_\%&?VPS_S52W_ /"!^'(]/^I//?\ /H,8W5D_ 3PIZ<,U
M%_W6\_\ _GL+_7_BS_H:1_\ "'+O_F0F7_@HM^V"?^:J0?\ A _#CV_ZE%3^
MOMQGYLY> WA4MN&Y_P#A[S_],TE^?R5V'^O_ !9_T-(_^$.7?_,A,/\ @HG^
MU^?^:J6_;_F0OAS[=O\ A$?ZGT[$K#\!_"S_ *)NI_X>L_T_\R7Y^8?Z_P#%
MG_0TC_X0Y=_\R$G_  \2_:^_Z*G!G_L0OAU[9_YE'W]./Q&[)^!/A;_T3<__
M  ]9_P#_ #U7]:Z72B?Z_P#%G_0TC_X0Y=_\R$B_\%#_ -KT]?BG >?^A"^'
M7Y?\BDOZC\N-TOP*\+5_S3D__#WGW2_3^TG_ .E+MWF'^O\ Q9_T-(_^$.7?
M_,A,/^"AO[7>?^2I0'U_XH/X=^WIX2;^7Y_PY_\ $#/"_P#Z)R?_ (><^_\
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MKCBH?A)X?],CFO\ NJ9Q_P#-S\O\Y:\Q_KIQ+_T,%_X1X#_Y0OS^XG3]M?\
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M_P";'_PW?1RM<7<0?]!T?_"7"6^_V"UM^&MG:Q.O[7G[0A_YGJ+_ ,)7P?\
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MP#8O]Q?R6B\N[^\ V+_<7\EHO+N_O -B_P!Q?R6B\N[^\ V+_<7\EHO+N_O
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MZ#\J+R[O[P#"^@_*B\N[^\ POH/RHO+N_O ,+Z#\J+R[O[P#"^@_*B\N[^\
MPOH/RHO+N_O ,+Z#\J+R[O[P#"^@_*B\N[^\ POH/RHO+N_O ,+Z#\J+R[O[
MP#"^@_*B\N[^\ POH/RHO+N_O 6D 4 % !0 4 ?_T/[^* "@#SN+XG>')OB7
M<_"E8M3_ .$GM?#Z^)9)3;0C2CI[201A5NOM1G-SNN$_=FT"8#'S3@4 )JWQ
M/\.:-\1O"_PONXM4;Q)XNTV_U32I8;:%]+2VTZVU.ZN!>7372312F+2;H1I'
M:RJSM$"ZAV9 "AX1^,?@KQCHOB[Q%:7-WI.C^"-7U'1]?OM>BM[&&WGTN&*>
M[N(WCNKE7M!'*OER,8Y7;Y!#N*A@#R@?MB_"$WD:&'QFNARW9LU\7OX8E7PS
MY@D,>XW!NAJ>WC=M&E^<J'+Q A@@!Z]J7Q:\(Z;XP\#^"S)>7VH_$*QN-2\-
MZAIL=M=Z+/96]M+=_:)KY;M"(IX(C);26\%PDJO&0P5BU %CQO\ $_PYX U?
MP/HNN1:I)>>/_$$/AO0VT^VAG@CU">ZL+1&U"26Z@:WMO-U&W+211W+A!(1$
M2JJX!YAXD_:E\ >&O%.O>$)]"\>ZIJWAN[%EJ9T/P[!J5JDI175DE35(Y/+<
M-A&EAB+,K@#Y30!?U3]I7P+HW@C2?'NHZ-XVM=*UGQ#/X9LK";0H(=;.HP6T
MMT7DL)M311:RQPNL,J3N\DF%$0Y:@!?!G[3/PU\:>);+PA&OB7PYK^I@C2[+
MQ9H;Z1_:4@5F$%K,EQ=0B:0)((%N'A%Q(A@@+W#1QN ?0E '\W__  =A?\H3
M/VBO^RA?L\?^KM\%4 ?KY_P3O_Y1_P#[#'_9G?[,O_JE?!- 'V)0!%//!:P3
M75U-%;6UM%)/<7$\B0P000H9)9III"L<444:L\DDC*B(I9B%!- 'Y6_'/]L7
MQ1K^HWGASX77=QX8\.6DK6TWB&!X#K^NLJ*LTEK=1>>FBV"7'F+:2:;</?7<
M445XVH6\5T^FQ 'Q7J.NZWJ^XZMK&JZH7F^T.=1U"[O=T^''G-]IFE+38DD'
MF'Y\.XR-[!@#I_ WQ-\=_#B^COO!WB74]' N%N9["*X>32+]U\L,-0TJ5FL+
MP2)$D3-- TJQJ!'(A560 _5W]G3]I&P^,=O+H.MP6FC>.-,L8[BXM89'6TUV
M)9)4NK_2(9=[0K;*+5[NS>YGGC>YD>)3:PM+0!]3T % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!X%X[^'/AOQ]\8O 4G
MC&+P'XBT3P]X$\;ZGIO@_P 11V%]XJA\4KXI^'3:9XW\,V%U8S7=IIV@VD>H
M:7K6L6%_9^1J6N^&H;B"ZE>RGLN>I2C4KTW/V<HQIS:A*SFI\]*U2*<9-**3
M4I+K*-[^[R^9B<+2Q./PSK_5JM.EAJ\X8>JH2K*M[;"\F)HQE%RC"G%2A4J1
ME&TZE).,KP<.S;X.?"IM4\7:XWP^\)MK'C[3;[1?&^IMHUFU]XKTC4O)^WZ9
MK]R8?-U2PNUMX(Y[2[:6!X8DA*&(;%OV-&\Y>SAS5$XS?*KSB]U)\NJ=E=-O
MMK8Z/J&"YZ]3ZK0Y\3&5/$3]G'FK0G;FA5EO.,K*\9:-*STL49/@1\&9=,\(
MZ*_PP\$?V5X N[^_\#V"^'M.2V\)7VJ:C%J^HWGAV-+=1I%W>:K##J,]Q8^1
M,][%'<E_-17H]A0M!>RIVIMNFN56@V[MQ]W1MZNW+JK^9+R[ .%"F\'A^3#2
ME+#Q]E"U"4YJ<Y4DOX<I32FW'5RL]T6W^"_PGDO_ !?JK?#WPF=3^(%G=:=X
MXO\ ^Q[07?BW3[V:*>[L?$-PL0EU:SN9(8_/MKQIH9(U\EXS"S1L>PHWF_9P
MO4351\JO-/5J3MJGV?-^%BOJ&"<J\WA:'/B8N&(E[./-7C)WE&J]YQ;2O&6C
MV>A5/P*^#1L/!VE_\*Q\$KI_P\O+_4/ =I'X>TZ.'P??ZGJ<.M:A>^&UCMU_
ML:[O-7MK?4Y[BQ-O-)?0171?SHT=3V%&T%[*G:FVZ:Y5[C;NW'W?=;DD[KEU
M5^ER?[.P'+0A]4P_+A92EAHJE!*A*<U4E*EM[.4II3;@[N23T:18;X*_"5[O
MQA?M\._"/VWXA07%MXZNAHUFL_BZVNKI;RYM_$4BPAM7@GN5$DL5Z9D?<\;
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MPU%5X05.%;DC[2$%!P4(S^)14&XV5E9OO:6 /V?/@:OA-O B_"7X?CP6^O\
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MS?"CP)+X4TG5;G7-,\-R>'-.;0]/UF\BCAN=4L],-N;.WOYHHQ&]U%"LVUI
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M'XC2O-X^VZ%8HOC*:347U=Y?$J+ %UF5M3EFO?,OA.PGN+AP?](FWGL*/O\
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M,-3C2H5%3BIT:<$U"G3DM80BI22C'2TFMF>-_&3X3_!/P1\%?BI<K\,M+M]
MNX;+Q;XITWP?%;>&]6UW5/#^I1ZGIVIIJ5O:R,-?L;UVO=-U22-[VVOQ'=6U
MU;7B07EOSUZ5"G0K/V2Y7:<U3M"4G&5T[V7O)ZQ=[WV:>L?/S#!9?A\OQC^I
MP5*2A7K0H*-*=2=*?-":FK_O8R]Z$VN92LURR2E'ZKKL/:"@ H * "@#_]'^
M_B@ H ^ /&VG>/\ 5/VN=5MOAOXBTKPSXA'PTLI9-1UG3TU*T;34ELA<VPMW
MM;M1-+*]LZ2>5E5B<!UW$, 4[72OB7I/[6GP:A^)WBC1O%.K2>'/%4NGWFB:
M9'I<%OI__".^,E^S30QV=F))OM*S2^84<['5=PV@4 >/3VFLW?[.WQU_LE9I
M(;;XZRW>MQP+([-HT/V/S6=8^?)@OVT^YG9@T<<4+ROM5"Z 'TQ\1_B/J.D_
M#31]:^$R?!;5OA-9>#[1KS1O&,DMU>M<VC@V^B6>CV^H6=K->1)':Q-IUY#]
MM&JI*KA95H \H\8ZYXW^(7CW]EO7_#U]HGAGQOXC\%ZM?6=X-/>;0M-NGAOF
MG$>GW/\ :+FV-G'-!#'(;@H[HV1M!4 M?%'1/C%I/Q*_9V;XH^-/#WBNWG^*
MNA+H\>B:/%I;V4R:_P"&C>/<-'I]EYRS1M;K&"S[#&Q 7<2P [1(_B-)^T#\
M?O\ A7OC?PCX+F&L:3_:DGBRUBNH]0C*77V1+(2P3['MV^T-.5"Y6:+.<+0!
MJ_M%CQS%\,OA3_PDGB'PUXO\7I\7+-K;4]%B6VT*>46FHMIEK*D"6Y41OY<=
MVR;'*DD.#M- $5D?B+\5OVB_!_AGXO2>$_!^J_";R_&>D:7X<M+\GQ1NN-)U
M+;IVHWM[>_:H-]E:-> 7$7E6]K?QQV,DT5Y+;@'Z'T ?S?\ _!V%_P H3/VB
MO^RA?L\?^KM\%4 ?KY_P3O\ ^4?_ .PQ_P!F=_LR_P#JE?!- 'V)0!\=_MK^
M.I_"_P *[?P[872V]_XYU8:5.BRHEP^@6$)O=8:%=WFM&\YTJPNRBF/[/J+Q
M2NOG(DH!^0= !0 4 ==X!\3ZAX,\:>&/%&EW'V6\T76;&[64L$C:#SEBO+>=
MF*K]FN[.2XM;H,RJUM/*K,H.Z@#^@FSNX+^SM+ZV;?;7MM!=V[]-\%S$DT38
MYQNC=3U[]Z +- &3KVM6'AO1-7\0:K+Y&FZ)IE]JU_+QE+33[:2ZG*@D!G\N
M)@B9R[E5&2: /RK\*?M _&33O$_A#XF^+O$&I-\,O$_CS6=)N-*D>)M,MK&(
MV1U&.*(6Z,MOI-KKBRZ4WG!I[C1[F,D?9I2X!^K>HZKIFD:==:OJNH6>G:59
M6[7=YJ-[<Q6UE;6R#<T\US*R11Q 8.]F53D =<, >2Z%^T3\%/$FJQZ)I'Q"
MT:74IYA;V\-U'J.EQ7,[\1PVUYJME965S)*V$A2"Y=II"L<0=V". =%XY^+O
MPW^&KVT/C;Q9IVAW5Y%Y]M8NEW?:C+;[VC%S_9VF6M]?+;-(CQI<O;+ \D<L
M:.7B<* :_@[X@>"_B!8RZAX,\2:9XAM;=UCN38S'[1:.X)C6\LIEBO+-I &,
M0N8(O-"L8]P5J .*UG]H7X+Z!K4GA[5?B#HEOJL$S6UQ#&+V\M[6X0@20W>H
M65G<:;:RQ,=DL=Q>1-%(KQR!'1U4 S_C?\9M*^&?P]F\1Z5J^B3:]J]GY_@F
M&[6XU'3=>DCGT]KDPOITL:30I87HN$D%]!&X:-HY) "E #O@-\8]-^+?A"PN
MIM2TJ;QE9V,=QXKTG2K:]MH-*FNKR^ALU5+QI_EG@M0X"7ER0P<LRY55 .0_
M:Y\8^)_ _P *[;6?"6M7F@ZH_BW2+%KVQ9$G-I/8ZO)+ 2Z2#9(\$+-\N<QK
MC&6- 'M7PQU&^UCX;?#W5M3N9+S4M4\#^$]1U"\F(,UU?7N@V%S=W,I4!3)/
M/+)*Y  W,< 9Q0!Y!XLM;-OVC? 5S)\8+[1+R/P_(L/PL2'43!K\<BZY_I2R
M12KI AO#%+)=F^M9[P-HD(AF4M9/IX!ZKXX^*WP[^&XM_P#A-O%>F:%+=HTM
MM:3&XN]0GA4[6GBTW3[>\U!X P*><ML(C)F,/OR* -#P7\0O!7Q$TV;5O!?B
M+3]?LK>00W3VK2Q3V<K+O1+VRNHK:]LVD0%XOM-O#YJJS1[@KLH!Q%W^T5\$
MK'6F\/W/Q&T!-22=K:3:UY-I\4ZR>4\<VLPVDFC0E)#M<R:@JH5;<P".4 .[
M\5^/?!_@?1;?Q%XJUZSTC1+NYM[.UU*43W%M/<7<$US;)$UG%<,XGM[>:6.0
M*8V1,[_F2@#AM1_:(^"FDZI!HU_\1-"AOYS"H1#>7%M TZ1NBWVH6UI/I^G,
MJRKYRZA=6IMSO6X$3)(B '>>*_'/A#P/HZZ_XL\0:;HFD2/'%!>7<^1=RRH9
M(X;&&$27%],\2O,L-G#/*84>;8(T=U .<\$_&?X7_$6Z:P\'>,M*UC4$C:7^
MSB+O3M2DB0$R2PZ?JMK87L\<2J6FD@@=(EVM(5#*: /,?@ZFG:=X\^-5Z/C'
M>^/@-;EN=0\.74.I)'X)%O?ZL)H)&O))K9YK?R9=)0:/#:VGV72HB8&1K6WL
M #LIOVB_@G!HPU^3XAZ+_9CWMQI\<B)J$MW+=VD%K<7,<&F163:I.L,-]:-)
M-#:/ #.B>87RB@'H7A?QKX4\:Z$OB7PMKMAK&ALTZ-J%O(4BMY+90]Q%=QW"
MPSV4T$;)++#>102QQ/'*R".1'< \_M/VB/@I?:K<Z+:_$30I=0M4N7D7-XEI
M*+2.6686>I26<>FZA)L@D,45A=W$EQ\JVZ2L\8< ] \(>-?"_CW23KOA#6+?
M7-)%U-9&]MDN(XQ=6ZQ--#MN88)-T:S1$G9M^<8)^;: =10!Y'?R:-_POCPI
M%+X>O[CQ ?A'\0)++Q6E[<+I>DZ,OC+X:+JGAZXTY(A:R7_B"];1]2L[V>=K
MB"W\,WT%I$L=Q>N^+Y?K$/=?-[&I:=]%'GI7BUM>3LT_[K2W9PR=/^TZ*=*3
MJ_4<2XU^9\D*?UC"\])PMRN527).,F[I4I)+63/7*V.X* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M W@OQ%';B5=#\2W>GW$X7,EM!KNG[\D_P02W&CVT<C$8,WV5>"RT ?EA0 4
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M/!^OZ7H^F6>L:_I4@UO5;2VACO=4>RUC5881?W,:B2X:U^>-!*S&+YE 7!%
M''?MR?\ )&+3_L=]#_\ 3=KE 'N'PCUC2(_A1\,8Y-5TV.2/X>>"TDC>^M5=
M'3PWIBLCJTP965@596 ((P0",4 ?,OQ&(;]MSX/LI!!\'0D$'((*>/R"",@@
MCD$'\\T <G\,] \,_$3]J7XS)\4;.RUW5=(O]6@\+:#KPCN[":PT_5FL+:2.
MPN1Y%\+#0X;!K:WD@EA\B\GOFM_-C6>( ]B^,/A3P?\ #7X+?&;4/A+I&D:)
MK-^FG67B5] E0W-E%=7VCVFI6)CCEE.DQ0Z%J%S=+ID LX;=+Z6_BB5YM\H!
M\U_#OP1XX\3?!:VTKP]\#?ACX@T?6],U)!XWO-?T>/Q2;^2:ZC?4WNYY5O-/
MU#2;G*6]JS1QVL=M' \3PO*)0"[\6_#GC;PC^R-X1\->.TB34](^(UE;Z<8=
M2L]5C;09-*\0W6F;+RRFN(FBA6XEMK>/S6,5M!"B8A6)5 .T^/GPC^''AG]F
MO3-<T'PCH^F:W8P>#;A-:MK8+JUQ+JC6,%^;[423=WR7"W,KF*ZEEBCDVO#'
M"444 :7C[X5>)/B?\*/V;=6\,:KH$WB;PSX,T"^M/"_B>XMUMO% E\/>&+VX
M^SP78EMKZ:U;3(EO[2[B%K=6-W+]INH1$L=T 6?A?XYDT7XT:#X1^*7P1\)^
M /B)J^CWUKH7BCPG:VEI;7-K+'-*RW%I9W5_:7$5_P#V1<6EOJD&HW5Q:3*]
M@L,-I>WCH 9/[/G_ "4K]KC_ +"^O?\ I_\ &M %#]C7X4_#OQG\-?$^M>+/
M".C>(=3E\7ZAH(NM6M1>O;:9;:'X?O(HK$2L5L)A<:G=R->68@O'WQJ9RL,*
MH >3_#6YU72_V8_VCK?19KA#;Z]H=H?*D<2)IM]?Z?INM$;,9$^CB:&[R55K
M;S=W"[6 /9_ ?@#X#W?[+LVO7^F^$KK6#X4UJZU7Q!J$EG'KUEXLB@OFALEU
M!I8]0L98;Q+>'3]-A>&*\@%N_P!GN1=L\X!Z/^P__P D5D_['+7O_272: /L
M*@#SB\.L#XN^'1%XMT>W\/O\./&9O? LNHQKK^KZQ'XF\!_V7XML=):!I9='
M\.V4NL:/JNHQ7,4=O>^*-&MKB"=KFVDM\GS>WC[\>7V4[T[^\Y<].TU'^6*Y
MHMWT<DG>Z.27M/KU*U>"I?5*_-AG/][.HJV'Y*\:=KN%*+G3G--6E6IIIWBX
M^CUJ=84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M4^BE96/O*LC]\"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H \=_:"FT6W^"_Q&G\1Z+?>(]"C\.7+:KH.FW[Z7?ZQ9>;
M#YVGVE_';W,EM/=*?*22*%I<MMB:*1EE7#%.*P]7GBYQY?>C%V<E?9/O]WJK
MW.#-'367XIU:<JU-4GSTH2<)5(W5XQDE)IO;17Z*U[Q]BK<[PH * "@ H __
MT_[^* "@ H * "@ H * "@ H * "@ H _F__ .#L+_E"9^T5_P!E"_9X_P#5
MV^"J /U\_P""=_\ RC__ &&/^S._V9?_ %2O@F@#[$H Y'QYX+T?XA^$=<\'
M:[&7T[7+)[9Y$"F:TN$99K+4+;<"HN;"\B@O+?<-AEA59 T;.K 'X=?%+X2^
M+_A+XAN=#\2V$OV82G^R]=@AE_LC6K5C(8+BSN2#&LKQQLT]C(XNK1U=)8]H
M5W /,J "@#] /V0_V>;[4M4T_P"*GC72I+;1M.>VU#P997N^*35;Y"TMMKIM
M,)(+"R<076ESRNL=Y.$N889[98YJ /U H * /$O&?P%\(>/?B%X;^(WB+4O$
ML^I>%O[+_LO18KS2T\.8TJ_EU*$7-E)H\U[.)[R4RWF-3B\]4CA.(4$= 'M$
MT,5S#+;W$:303Q20S0R*'CEBE0I)'(C95D=&964C#*2#G- 'S/H?[)GPQT3P
MWXK\)"_\8ZEX?\6W&G7EWI^HZU9A-.O]):[;3[_2Y--TG394G@%XZ,FH/J-K
M<+%;&Z@G:"-J ,K2OV/?AY9ZGIEWK7B7Q]XOTO1+A+G2O#?B77+:[T2%HV5E
MCGMK?3K5Y8=RC?!"]K!.G[FYBGA9T< ZGX@_LT^"O'OBB?QLFM^,O"7BN[BA
MBO-6\+:Z;1KP6\,5M"T\5Y;WQB\JV@A@5-/EL(BD2-)$[AG8 ZCX7? [P3\*
M+368]%34M8U#Q&?^)_K?B6YBU/5-5C!F;[-<.EO;6HM2UQ.TD4=HK7+/NO);
MEU1U /*M0_8W^&\NHW]UH7B+Q_X/TW59"VH^'_#FOV\&DS(1_J8DO--O;A(=
MQ9O*NKB]C0-Y<"PQA$4 ]PM_A7X/M?AN_P *4M;V3P@^DW&CM!<:C=75\(+F
M22>29+ZX>22.X2ZD:ZMQ&%MK658X[:VBMHX[= #CO@Y\ ?#?P5N-;G\/:_XH
MU5=;BMK>6UUN[L);.WBLYIYH'@@LM/LL7(:YF#S,2K+(VV)"S,P!UGQ5^%GA
M[XO^&(_"GB6\UFQTZ+5;35UFT.XLK6]-S9PW4$2&2_T[5(/(9+R4R*+;S"RQ
ME94 8, ?.7_#!WPA_P"AC^)'_@X\,?\ S&4 >ZWWP0\*7_Q'\(?$^;4/$*Z_
MX+T2VT#2[.*[TU='N+.UAU6".34+=M'>]EN2FL7)=[?4;6(M' 5A0+(K@'/_
M !4_9J^'GQ6U>/Q)J+:SX>\3I'%')KOAN[@M+F]6WC6*U_M"&ZM;RWG>UC58
MXKF%+6]\I8X7NGAAAC0 U_AA\ _ ?PLT77]&TJ/4=;7Q5&8/$=WXCN8[Z35;
M4Q3P_8IK6&"UT]+7R[JZ5E2U\^87$@N9Y@(U0 \ON?V,?AP;J]72O%'Q%\/Z
M#J4TDU[X8TCQ%;+I$F_ $"_:]+NKF2W"#RB+Z:^N&C^47 P"H!ZKXT^!/@OQ
MM\/-!^&-[<>(-+\,^'+G3KC3#I6IQ2:FG]EV=Y8VMO+?:W9:T9;<0WTN4,(9
M-D,<#PP1+%0!N>.?A7X>^('@!?ASK-YK-MHBQ:/"+K3+BR@U7;HCV\EH3/=:
M=?6FZ0VT8N/]!PX9O+$)*E0#CO%W[./@#QGX9\%>&]3N?$UJ_P /]'L=#\-:
M_INKI::W;65C9VMF#-_H<FD2W%RMC:RW5PND12F6(?9FM8\QT 5/AW^S7X+\
M >)X_&DVL>*_&?BJVMY+73]6\7ZK%J+Z7%)%+;N;&.*UML2FVFFMQ)<R7'E1
MRR?9E@+N6 .D\'?!#PIX(USXBZ_I6H>(;B\^)MS=W6O1ZA=Z;-;6DEY>:I>R
MC2$MM'LY;=%EU>Y6,7D^H,(T@#%V5W< TOA+\)?#GP:\.7OA?PQ>ZW?6%]K=
MSKTLVO7-A=7BWEU8Z;I\D<<FGZ;I4(MA#I=NR(ULTHE>8M*R,B* <CX;^$/A
M'X+^"?B+'H>G^)_&]GX@M=0U35/#FHG3]6O-:=+"ZA.BZ?;Z?H^G*R:BDS6Q
MBEANG_>9WD JP!^>5Y>?LUPVFJS>'OAW\39?B)?V-[8:/X%UEDOM#T37[ZVG
MMH9EV.-5U&VTNYF$UK!>+<W-V]M!'-90,\DB 'Z"?LM^ ]:^'OP@T;2O$5I+
MI^LZG?:CK][IT_%Q8#49(TM+:Y3 ,-R+"VM9;FV<"6VGEDMYE2:-T4 ^B* /
M)K^72?\ A>GA2%_"UY<Z[_PJ;X@2VOC5+^^6PT?2?^$P^&BW_A:XTQ(O[-EO
M/$EY_9VK6=_<SB^MX?"E];V,307.H.N+<?K$%R-R]C4:J7=HQYZ5X.-N6\G:
M2;=_<:2U;.&3A_:5%>QDZGU'$M8CGERTX?6,+S47"W(Y59<M2,V^9*C)15G-
MGK-;'<% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_.[_P4._Y.A\6_]@'P=_ZC
MMC771^#YL_SH^D3_ ,G2S?\ [ ,F_P#5;0/MS_@EG_R3/XF_]CU9?^F"TK.O
MO'T/W#Z*O_),\4?]CW#_ /JOI'ZC5@?U.% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YO\ %]M:3X9>-7\.>*]%\"Z[
M'H=S)I7B_P 1:DFD:%X>O8V1X=2U;4I;:\BM+&%E_?R2VES$4)26&1'9&RK\
MWL:G)4C2ER^[4F[1B^\GK9?+[SDQ_M/J>(=*O3PU14VX5ZLU"G2ETG.;C)1B
MNMXR71K^;TBM3K"@ H * "@#_]3^_B@ H * "@ H * "@ H * "@ H * /YO
M_P#@["_Y0F?M%?\ 90OV>/\ U=O@J@#]?/\ @G?_ ,H__P!AC_LSO]F7_P!4
MKX)H ^Q* "@##\0^&O#_ (MTN;1?$VC:;KVE3D-)8:I:0WEOYB B.9$F5O)N
M(MQ,-Q$4GA8[XG5A0!\TZM^Q=\$=1N?M-GINMZ*#/'*]I8:Y>36;1B9'GA5+
M\W=S'YL0DCB:.[58'=9 CHGD, ?*O[:G["OCK4O@0GB3]AWQ!-X(_:K^"_C+
MPW\9OA/;^*-<ENO /QFU7P/<R7VH_ 3XOZ?J$]OH]S\/?BOI#7WAN:_#:/=^
M%_$,^@>)X=:LK32;V&Z /T_\+WNO:EX9\.ZCXJT.W\,>)[_0M(O?$?ANTU=/
M$%IX>UZZT^WGUC0[77HK33XM;M])U"2XL(-7CL+)-2CMUO$M+99A"@!NT %
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ML+R6YAM+ZTNIK*7R;R&VN89Y;2;<Z^5<QQ.[02[HY%\N4(^Y'&,JU %N@ H
M* "@ H * "@"H^H6$=Y%ITE]:)J$\9F@L'N85O)H5\S=+%:EQ/)&/*ES(B,@
M\J3)&QZ += !0 4 % !0 4 -9E16=V5$12SNQ"JJJ,LS,<!54 DDG ')QS0!
MQ'C;XE^ OAS\.O&WQ:\:^*M(T+X;?#GPEXG\>>-_&$]Q]IT?P[X1\&:/>Z_X
MIUV^FL5NY#::+H^G7U_>"WBGG$5M((X7D 1@#S3]EG]JGX!_MJ? [P;^T?\
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MWA^"ZN=:FT&".UEMYDTZ"RNI;CSKF A8)-H; % 'T'0 4 % !0 4 % !0 4
M5++4+#4HC<:=?6E_ LC1--97,-U$LJA6:,R0/(@D571F0D, RD@9% %N@ H
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MT:ZN Z:?J=AI^KZ9K>E6@!Q7[+G_  62_;I^)O[//BW]OO\ :&_X)]Q_ O\
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M.\9>#]3T)T\1>$?$VIWMT^DZUH&MV=RUI?** /Z8_P!O3]IW_@K%X4^-NB_
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MG_!87_@NA_P3W\/^$/VH?V^O^";G[+VE?L77_BSPGX=^(UM\#?B]?>(OC?\
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M%KZ:MJ _L;P=J/C.2VBU#4@#[Q_;?_X*Q_'[]E7Q1_P1O\.2_LVZ#X'\0_\
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MWS?$D.G@'] /_!&__@I=\3?^"D_AS]L?6OB7\/O GP_G_9L_:Z\>_L[>&H?
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M1])TW6O$%[8VWA[PMI>M:/HVKG0O$\E_IKV5T >#?\%D?BO\4/@E_P '(O\
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M2N@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MX0\2KI?A;3H+BX\0WN@-XUTWQ+?VD437$?A+2/%3VT<\K+;3@'W#_P %*?\
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M:?K_ (BU7P-I^EZ;J'C2ZDTFPL]*_P"$H\.VT3WDMX[P '3?\%)+[]F75?\
M@OU\4/#W_!<WQQ\9?"'[ ^G? GX?:K^P%IT.O?&OPQ^SYK'BR+0?AR_C2[OM
M9^"?V;Q)8^)H?&DGQ..MZQ'=Z3/%J-EI&G^)==C\.VO@.TO0#;_X(M3?!.X_
MX.4_VOI/V;?$_P ?/&'[/_\ P[2@7X.>(/VC)?B7=^-KSP OCO\ 8Z&@Q^'-
M3^,MC8_%/6?A3:0!K3X3:OXV2ZU._P# ,&A36>I:IHATJ_G .Y_X),?MC_!G
M]B/_ (+=_P#!9K]DK]I6;QA\//C)^VY_P4 TC5?V;])N?!/B._TSQS:^(OB)
M\>=?T*>?5K&QFM- L=;\._$KP;KNB:QK+6NCZKI^I2-9W[S0>3* ?E#^SY\
MOV+/^"87QP_:F_8^_P""Q7Q:_P""A?[)=S;_ !I\6?$/]FWX\? ;XG?M":%^
MS_\ '_X5:O!IVGV.KV^D_"#PYXDU#5O&TL>DV%]J'BB/1K\LVHS^#O%]SX;U
MSP3'9:@ ?T,_\$IOAY_P38\/_!7]OW_@H)^QM\'?^"B7[1/A[Q#\/_%GPI\:
M:;^TOHGC3XG:Y^VSX)\$^$++6+!/@OX?\::;=7OQ/TWQ(\=Y\*]-BUN9=3T\
M6M_H/B;P[HNF7-HDH!_-7^T7XV_X(O>"/ .L?'C_ ((S_M$_\%#_ -BK_@I+
M>^(O"]OX$_8=^'^A_'5IM8\=ZAXDTJWUOX?^)].NO#VN:84TNUN];C_LK3/C
M?XCT:7[//H5GX&\1V]Y;:&P!_I$_LLZM\9M>_9D_9UUS]HS28=!_:#UGX&?"
M;5?CGHEM#9V\&D?&#4/ 6@7?Q)TV.VT]4T^U6R\8S:S;_9+ -8VIC^SV<DMM
M''*X![Q0 4 % !0!^)G[:_[-WQP^(_[0'B3Q7X(^'6M>(O#UYH_ABWMM4LI=
M-2WFFLM$M+:ZC5;F_MY<PSQO&VZ( LIVEA@UTTIQC!)M)W?]?U^I_$'C=X;<
M<\2>(69YMD?#F.S'+JV#RNG2Q5"6&5.<Z&!HTJL4JF(ISO"I%Q=X[K2^Y]7_
M /!/?X4_$/X3^ _'NE_$3PM?^%=0U3Q=:7^GVNH/:/)=6<>C6UN\\9M+FY4(
MLR-&=[*V1PN!FHK24FK.^A^M?1XX3XBX2R'B#"\1Y5B,JQ&*S>CB,/2Q#HN5
M6C'!TZ<JD?95:JLIIQU<7?O=<OZ"5B?T*% !0!_F&_\ !!C_ (+ ?\$Q?^">
M'[/W[07PJ_;>^$?BCX@_$;QE^TWXG^(/A;5=#^!?@/XI6UGX*N?!7@;PY!I\
MNM>*M=TN^L)UUWP]K=P=+MX'M4CN([L2F:ZE10#^J/X*?\%2O^">_P#P4?\
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M] ^-WC32/$M]H]Y:V4MI;^)KWXQZAI^E:A=VEKJ'B73/"UKXH,#Z1K.BWEV
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M%XVHZO/I/A?X)?M::'ITVJ:@R1M?:C)9V,+WUXT<;75RTLY12Y50#^NN@ H
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M_P#!4O5_AY\0OC[^R+^SE^QOX<_8:_:0\1^ =&O?%GBSX4Q>&?#?Q \':?\
M%2^L;IP-*T77X?B=:ZE:7-Q>6UCJ&J^&?$?AW4]4TS6O&.@MJ@!XU_P4&_;8
M^'?_  <6?'K]@C]B?_@FSX2^*7Q)^'WPE_:9\&_M*_M,?M,ZS\.O%7@#P5\'
M/"/AFPOM&.G+JFO6-GK%MJSZ)KGBJZV7]MHMMK?BJS\%:'X3N_$-WJ%[<:&
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M%?\ 90OV>/\ U=O@J@#]?/\ @G?_ ,H__P!AC_LSO]F7_P!4KX)H ^Q* "@
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M4N7^T:/[B3G]2Q-L5S3Y:<77PMZ#A;V;E6:52,FU-*A)13C*;CZK6QVA0 4
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MK"U$]S*TUQ,+>UCBB$MQ,[RS2;-\LKM)(69BU &A0 4 % !0 4 % !0 4 %
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MZP^.%A%XTT_P=XRM]>>,^/M$TOPC>Z$C^)K36( #[CH * "@ H * "@ H *
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MXJT7P7X.T>?6]4L]$T>'4_$7B"\L-*LI=4UC4+'2[!+BY1KN_O+:TA#S3(E
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M<N@C@;*T >QT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!\2?L1?\% _P!G3_@H-X<^+WBK]G/4_%FIZ3\$/C'XC^!7CM_%GA:Z
M\+3V_C[PM8:7J.K6^F075Q<-J.EI;:Q9&#4HBD<SM(@0>6=H!]MT % !0!^?
MOP/_ ."D'P-^/O[<'[5/[ O@WPK\8--^,/[(>@^#O$'Q'\2>*O \.C_#+6[3
MQG:Z3=647@SQ(FM7FIWMQ;IK>G[!K_A_PW%K\"W^I^$9?$6BZ;>:G$ ?H%0
M4 % !0 4 % 'R1^V_P#ML? O_@GQ^SSXG_:?_:-U#Q)IGPJ\(ZQX6T/6+OPG
MX=N?%6MI?^,=>LO#FBK;Z-:S6\T\4FIW]NMQ(LJBWA+S-D*58 ^D_!GBO2/'
MG@_PIXX\/O/)H/C/PWH7BO1)+J!K6YDTCQ%I=KJ^FO<VS$M;SM97D+30,2T4
MA:,DE2: . \1_M#_  &\'_&#P'^SYXK^,GPS\-_'7XI:5JFN_#;X/:WXU\/Z
M9\2O'NC:):ZO?:QJOA'P7=W\6O\ B#3]+LO#^N7=_=Z787,%I;Z/J4TSHEG<
M,@!['0 4 % 'Q)^Q_P#\% _V=/VX_$/[27A?X#:GXLU#5?V4_C'K/P*^+B>)
MO"UUX;@L_'^A7VKZ??V^A37,\RZWI:W.AWXBU* 11RHL3B,>8 H!]MT % 'Y
M^_LH?\%(/@;^V'^T9^VK^S'\,O"OQ@T/Q[^PI\1=&^&GQ9U?Q_X'A\.>#?$>
MM:U<^*;&"]^'NLV^M:I<ZKI:7W@[6A%)X@TSPQ=ZMI;:7XA\/V6K:!J*:C$
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M*;[)['K%;G:% !0 4 % '__1_OXH * "@ H * "@ H * "@ H * "@#^;_\
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M4 ^K: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MMX?'CXA_LMK>Z'^TW\#]3\2_L]?!#P-;>+O"_P ,_P!FGQG+XA\/>)_ FO\
MCOQIX1M=<U'QD?'VK_"_PO)XLTG7]=LE?5-8N=(UA(4LGO0#L?\ @O1_P6I_
M:'_9&TO]C'3?^"=IT+QOXI^+?PT\8_MF?%&:]\+:1XJMH_V0O OAO1]<M=3O
M(]6CN8] T7QM!J7B&];Q-IX75+!/!DUM87(GODAN #W/_@I3_P %2_C9'X]_
MX(W? W_@GEXVT'2O&?\ P4V^)7A#Q]>^+]3\(^'O'4^@_LK7F@^$=7UG7WT7
M7K;4M/LFN-#\>7'BV/4H+>6\CB^'&N6=O*D;727  G_!2'XW?\%1;;]JCQ#\
M(_@U_P %#/\ @F1_P30^"5OX;\,W7P4U_P#: \7_  Y\5?M$_M!:_J^BQW7B
M"7_A7_Q2L]4TKPYX=\/>)[34/#,3Z;X<ENY+,#6+.Y\3RW$EEH( [_@CG_P4
MH_;*^/&M?\%&?V./VZV^%FN_M7_\$\M8TRQE^,/PCT];#P7\7/#OBC2_'#:5
MX@&B16&FZ0L^GW_@ZWU>UU.PT3PG;:YX<\8:%:7/@K1-7T/6IM0 /C[_ ((D
M_MO?\%U_^"H?@+X(?';Q3XO_ &7/ O[+7@+XZ:UI'QT^(&L^'+*'XS?M%Z#I
M&I:7=:SX"^&W@KPQX1U+PE\/M$\,:/.-&NO$6KOX?\2:SK5[/=Z9KDMI"%TL
M G\#?MV_\%G/^"N/[77[6&F_\$Q?BQ^SW^R)^QC^QS\4=1^#-O\ $+XO_#6P
M^)&N?'KQ[H%SJ=M=QSIJ7AGQE=VFFZN+%==GC\.1^"Y_"GA#6/"@GO->\0ZC
M>1( ><?\$;=4_:2U?_@Y#_X*PW'[7WA;X<^$/VC[7]E'X*:)\3]-^$6N7_B'
MX8ZIJ?ASPU^S%X?T?QKX&OM7@MM9M/#GQ&\,:9HGQ!T[P_KD":[X4A\3#POK
M>[5='O'8 _J2_;S^*_C/X#?L-?MG?'+X<7MKIGQ#^#/[*'[17Q7\!ZC?:?:Z
MM8Z?XS^'?P@\8>+_  O>WFE7T<MCJ=K::YH]C/<:?>126M["CVUQ&\,CJP!_
M+Y^T=_P60_;K^%W_  ;<_L>?\%&/!OCOP9IO[4?Q9^+&E^#/&7B=_AEX-N?#
M%SX?D\;_ !YT V>G^!YM./AK2F72_ /AJ".6QL8GC-K-(NU[J<L )_P4H_:K
M_P"#D+]@[X(6'_!2'Q[\5?V)?#7P/\.>,/!!^(7[$?@CP2_C>X\&>&OB!XBT
M?1/#'AWQ;\6=?\&VGB3QIK5GJ6J6'A?QUKWP\^('A#3H-9OY=6\(0:GHK1'3
M0#Y?_P"#DZ[_ &W?C!XX_P""5/QO\&_%?X3>'OV<_C=\>/V:=?\ V6/AQJOA
MF6]\<_"[]H;QAX:T+7_^$Q^(FO+X4\OQ%X)@N-4TX?V5%?:H[);3_P#$BB\S
MRV /U_\ V\_^"C7[>_\ P36_9$_8F_9T\2K\(OVK_P#@KK^VO\4?%'P3^'&M
M>&-!O/#7P/GU5O'4=M;>/'\/)8^"Y&C\)Z%\0_A#X331[Z'PWI5WK^H:KXIU
MC4+C1- U*UUD ^1?VC_VM_\ @OU_P1OT'X=?M>?MW?%K]F#]NO\ 9!U7Q_X6
M\'?M#>!OA%\-[+X<^._@C:^,[J*RL]5\":_IW@?X?G7+"UOD_LO1]7\5#78]
M1UZ^L-!UC2-*AUJR\1:4 ?UV^$?%>@^._"?ACQQX5U"/5O#'C+P]HOBOPWJD
M221Q:EH/B'3;75]'U"-)DCE2.\T^\M[A$E1)%60!T5@5H _F _; _P""@O\
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M?'WA;0O!]EKNK:3#>6VMQ>(O$FI+IN@:KINH &%^S+\-?^#D'X1_M ? ^_\
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M]_XL^*OBO7/$WQ U3PWX6\+ZO]J\-Z8WB0:EK$4>F:'#)  ==^QU_P %!?\
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MUO1M7\7^%?A1JFN3:EXIM+5-;UV.XO/%>LO#!J5U+%;+/%'"H2WB" 'YD_\
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M0U;PB? ?_"F&C\(^(H;_ ,4VEKX8NU\773ZE;:1/>7]SHL=_;O+: #?V8/\
M@I%\</$O_!8G_@KS^S1\9?%OA_\ X9=_8J^#GP\^)/@:PL/!>@:?K_AVPD\$
M>"_%?BZ]U;Q/86L.O>)(HHM8\07-K:ZI=SI;"816^Q43: ?G_P#L5_M<?\'"
M?_!6_3_''[<G[)?Q7_9#_91_9(L_B-XH\+_ 3]G[XU_#:7QA+\7M+\&W\5E=
MMX[\::-X5\3>.]*M/.CET/7?%7A7Q7X=$WBJ#Q#:Z#X3LM)TZROI0#VS_@F1
M_P %4/V]_P!I'X+?\%S_ !7^TRW@KPA\6?V$/$?QDT?X5^!/#>A^$]4TCX/^
M(O!'A3XZ:E+X)O/$FD6%O:?%.T\'^)? >DZ/'XFU=+@>)+;2'OW_ '>J3!P#
MY?\ V1/VF/\ @Y6_X*0_\$X/!?[77P-^//[&WP)L].T7XKWNB:[K_P .](\1
M?%?]IK5/AY\2_&^GZK-+H$_P[\7_  M^$/ANQM]"?X6>&=-71O\ A(]>UWPC
MJ?BS7-2TG2/%&DZG8 'UK^S?_P '!&NP?\$"]1_X*D?M&^"-!\1_&[P)XC\1
M_!%_!WA%)_#'AOXL?&>U\46WAWP)=Q0L=1/A32]9TO6-(\2>//L+W5OIT.D^
M++GPU8QJVD>'H@#YV\4_M2_\%]?@]^SE>?\ !0;Q;^V__P $XOB$GAGP(/CI
M\0?^"<.F>%/!VERZ1\-;.P_X3#Q)X'\,?%33KI_B%J?Q/T#PB]U!<:')XLU2
M :OI,NGZ+K7C/41:P:\ ?7G_  4$_P""[_B;P7_P3T_8.^-W["?PXLO&?[3_
M /P5'U_PG\//V9/ _CB(:EIW@CQ7KG]EZ'XU76[6*[T>U\3>)/!'C[Q!H7P[
MT>QDNK/P]J?B35H=?OY+WP_IL^D:J ?C=_P73\"_\%TOA'_P2B^*6G_\%!/C
M7^R?^U?\%_B#XP^"S^+M=^%OAH?##XF_L^>-;7XDZ/KF@0:5;:9X"\#>%OBG
M\/-4O;>+P3J$LFFQ>,K+4]1T778LZ-IVNS7H!_<)^R[_ ,FS?LZ_]D*^$?\
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M5T/P_/X4T#2/!6L>(O&FFKX> /)=,_;U_P""M?\ P2L_;0_9)^ ?_!5_XB?
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M^$VAZSXOU6UU'4OAG;S67Q>U6/Q3J&A2KJEG%<S(DC7NG690 ^</VA?VSO\
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M7X[?#?5]8ETOPEX1TS6-?U"/2=)L;[5-3>TT^9;#3K.ZO;LQ6UO+*@!^<O\
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M_22WD\2:EH.LV6BZO#IB:;XA\>:_J.M'0[?P_+?^--$\,>$]7\6Q^&_$&O*
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MNJ:IIG]L_98IM] ']*G[)/[0ES^U5^SW\._CY=_!CXR?L]S?$*VUZ\'PA_:
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M'CGQ#HNDZ7\5O .CZKX@AM=&\=>%9M2T;6](NM'UB"Z-OJUH\H!_5-0 4 %
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M":SJTJ:;IC78O;YUM892H!_GO?MX>$OV?_VP_AE\1O#GBG_@VZ_X*#?LZ?\
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M#^BVD=AH^A:98:/I-C$TC166F:9:Q65A:1M*\DK1VUK!%"C2222%4!=V8EF
M-.@ H * "@ H * "@ H ^=?VO?@%:_M5?LI_M)?LSWFJQZ#%\?O@7\5?@^GB
M"6W>\3P[=_$/P1K?A:P\0FTCDB>Z.@WVIV^KK;+(GGM9+$6 <T ?R<_\$O\
M]O/_ (*2?\$VOV=O"?\ P2V^,W_!'7]LGXT_'WX%ZOXM\$?!#XC?"?047]GG
MXB^&O$'C/5/$.AZIXT^.>I6)\ ^$O"&@ZEXIDTNX^(FE:AXCT*#P]#IA\06N
MAZY:ZG!* <G_ ,$K?^"8G[3G[1__  1W_P""P?[&_P"TE\)/'/[,7Q=_:>_:
MW^(WC+P-;_%?X?\ CGP3H-[XKTC2/A%X]\$>)O#_ /PEVBZ1JOB/X77/Q/\
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M_@D?_P $U?V__P#@FO\ "GX=^)?$>H_MZ>*/VHO#'C/X1_![Q;X!N$TC[?\
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M/C%JGBTZ!<:?XLUC3_ ^@2WUSX3^''B[7X/%GB%$OM"UBQL-9LM)MP#])O\
M@U5L[NT_X(??LGR7-O- E]XE_:,O+-IHVC%S:']H[XIVPN(2P'F0F>VGB61<
MJ7AD /RF@#^B.@ H * "@ H * "@ H * "@ H * "@ H * /PP_X.,_V9OVH
M?VM/^"5/QM^$7[)>GZ[XF^(TOB/X>^*_$'PY\+W4EOXC^*7P[\*>(XM5\4^"
M=$@2>W&L:@9(],\40^'3(\_B,>&7T33K74-6O[#3[L _E\_;]^#G[/O[5?\
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M&_\ 0336Z]4)[/T9\Q4C\H"@!ADC$BQ%T$KH\B1E@)&CC,:R.J?>9(VEB5V
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M</HJ_P#),\4?]CW#_P#JOI'ZC5@?U.% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!^5_P;_X)BZ7\(O^"KO[7'_!4:'XR7^O:K^U9\&_ 'PB
MN_@O+X&M].T_P1#X$\-_!CP['KUOX[7Q5>7&ORZFOP?ANWTZ7PGI"VK:]+"M
MY.--26] /U0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ /((R1GN,9'N,Y&1[C'KF@#^;?Q%_P15_X*+>%]5\?^&OV9?\ @O;^
MU?\ "3X$?$3Q3XN\2W?@#XE_!KP?\>?B+X6?QSJMYX@\26_@_P"-FH^/_!/B
M/P\UUKFIZG=V%SX9TCPQ/I3WOVR.2ZU)+J]OP#]0?^":?_!-SX$_\$O/V=$_
M9^^"%[XK\4R:WXLUCXC?%#XH>/[ZWU+QW\4_B1X@AL;35?%7B*>SMK.PM$BT
M[3-,T;1M(TZUCM]/TG3;9KR?5==NM:U[5P#]!Z "@ H * "@ H * "@ H *
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M6U&8+-J>NZ[JES?ZYKVIRJCZCK6I7U\T:&<HH![C0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 >5?'![I/A+X\-EXO3P#='0ID@\:27.HV:>&7DEAC_M=[K28Y-0@2
MT#&1I+=5VC)EEAA$DR8XBZHU+5/9/E_B:^YK\6EWI_P]E=G%F+DL#B>6O]5E
M[-VQ#<U[&[7OWA>2MY?.RNSU6MCM"@ H * "@#__U/[^* "@ H * "@ H *
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MK8"G0A@,#'G4*JJU<4[-U9PA."2EO.*YY-22C35OW::DY2_J0^'_ /R Y/\
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M*[S3Y-6TM+RWT6UNY;9]0LUE53<Q!@#V.@ H * "@ H * "@ H * "@ H *
M/C3]NO\ ;Z_9C_X)Q? N[_:%_:J\<S>#/ @U_3O".@V>DZ/?>(_%GC/QCJ]O
M?7NF^%/"'AW3D:YU36+BPTK5-1E:62STW3M,TV^U+5=1L+&UEN% .B_8Q_:_
M^&7[='P#\-?M&?"'0/B;X;\"^*M0US3--TSXN>!-0^'?C%+KP[J$FE:FUQX?
MU":Y+6:W\,]O;:C9W5UI]ZT$K6ES*B,] 'U30 4 4-5U33=#TO4M;UF_M-*T
M?1["\U35=4U"XBM+#3=-T^WDN[Z_OKJ=DAMK2SM89;BYN)G2*&&-Y)&5%8T
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MU**7Q;I_@22_7Q)=^'(Y-'U:-]8@TY[!7TV^4S VTVT ]CH * "@ H * "@
MH * .:\9^+-'\!>#_%GCGQ"\\>@>"_#6N^+-<DM8&NKJ/1_#FEW6L:F]M;*5
M:XG2RLYVA@5E:60+&""P- 'S=^Q#^VO\#/\ @H-^SQX7_:?_ &<[_P 2:G\*
MO%^K^*M$T:[\6>';GPMK;WW@[7[[PUK2W&C74UQ-!''JFGW"6\C2L+B$),N
MP50#T3]IG]H#P7^RG^SY\9/VD_B+IOBS6/ GP/\ AYXG^)7BS2O NA_\)'XO
MO]#\*Z9/JE_:^']'>[T^VNM1EA@98GU#4M+TFT4M>ZQJNEZ7;7E_;@&#^R#^
MU!X!_;3_ &:/@Y^U1\+='\::!\/_ (V^#[;QGX7T;XB:%%X;\9Z=I\]W=V)M
M]<TBVO\ 5K&*=;FQN#;7>EZKJNCZK8M:ZKH^IZAI=[9WDX!](4 ?$G[3W_!0
M/]G3]D7XW?LA_L^_&34_%EE\1OVW_B#K/PR^!%MH'A:ZUW2=0\4Z#JG@#2-0
MB\3:I!/#%X<LEO?B5X76*\N4F26.6\D"8LW# 'VW0 4 % !0!^?O[ ?_  4@
M^!O_  49TCX]ZU\$?"OQ@\+6O[.WQT\4_ 'QI'\7/ T/@NXU/Q9X5C@FN]2\
M-):ZUKBW.D3Q7"%K'6'T3Q?HTA2'Q)X7T5KJP-V ?H%0 4 % 'Q)\/O^"@?[
M.GQ-_;D^/'_!/+PMJ?BR;]I#]G'X?>%OB;\3-,O?"UU9^$K7PMXQT?X=ZYHL
MNC^*GG:TU:]DL/BAX4:XLXK='@EFO8V<FR?> ?;= 'Y2_P#!1G_@L[^PM_P2
MT\2?##P?^U=XR\9:9XI^+6B>(O$OA?0? 7@F_P#&^I6^@>'+_3M+GU?78+&Y
MMO[(LM3U&_FL]$EF9O[3GT?7$B4?V;*6 /TU\%^,?#/Q$\'>$_B!X+UBT\0^
M#O'/AK0O&/A/7]/<R6&N>&?$VEVNM:#K%E(0IDM-3TN]M;VV<JI:&=&(&<4
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M<N- T'7-(NH_%.=,\4Z5KMAXSM;_ $/7- O0#YR^+[_MR77_  =0_MM^&/\
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M>U?7M*@LO!]Q9:KI4S6FK00SKX;N=/U34_&'A0 _.?\ 9<_X*1_\%+?V8?\
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M1/"6H76K>%/#.JWKK)>ZGX>T74+MT18U>ZO=-MKFX=8U 5%:65B$4!5!P
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M]!@/]CZ/X"T6._%WX@\1Z1J-UI>HZ/I.I:?< 'HO[=W_  46_P""BO[+:_\
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MI?$2VBU*+QD]J?$$%D(O#NE@Z7%=BR)BD)B)FDH /VLOV^/VD_A-_P %X_\
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M9K>NS;=&U'09[  _57]EK_@M+^TU\>_^"2W_  4_^(WQ/\)^&/A'_P %$_\
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M *K/]BB@#^K^@#^%;X(?LU>%_P#@X5_X*7_\%COVDO'K6VL?LZ?"'X(>)O\
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MX7\.ZJ_A[PYK>MZ5?:59VL45Y)H6G0WWB4^*_L_@P ^+?^"0OQFOOV<OC?\
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M (4\$P2Z1=V&@^-=#UG1_$.A:IK6GZ[HFCW>F^,M2TV6Z.J@']5% !0 4 %
M'E/QR:9/A)X]-OXP;X?RG0)T7QLD^J6S^%Q)+%&^LI/HH.J1M9HS2*UF8WR
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M\#Z%KVBW\^K@']@/_!'KX"_"[X4?LPOX_P# _P#P3J;_ ()E^*?C5XAOM?\
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MCU[3K2_U'2WH _0[_@M5^SM^T#\5+C_@@&WPO^!?QC^(Z_!K]LKX >*/B^?
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MQCI=UJO[*\L>K^#_ (:ZCX7@\:^(M'G'A[Q"]KJ.DZ+>VLT6A:O(DSC3;TP
M']3W[*/P]\?>'/\ @B?^SK\*O$'@?QAH7Q1T3_@F!\+/ &M?#;6?#.M:7X^T
MCQYI_P"RQHGAZ_\ !.J>#[ZQA\16'BZQU^*70[SPW=Z;%K-MK$4FF36*7JM;
MJ ?RQ6?[''[7:_\ !H'JW[-#?LK?M(+^T=)\<(]6C_9_;X'_ !.'QMDTH?MA
MZ9XG.II\*CX6'CMM/'AN-_$)O5T VW]AH^K>:+!6N* /Z /^"GWP>^+GC_\
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M:5;>(?$GCCRM2T!+OPI%HW]JRZCJJVNEPZA"MO=78!TW[)/_  3+^,W[4_\
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MVF\*>"->TO2=>UZX;33K.B:?IWB;Q'97FOV%U= &_P#MQ:+\??VQ_P#@I/\
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MK&D2WU[X8O\ 5;:TCU739+B6);ZU,H!^/G_! +_@I]^T=^P3_P $OM*T<_\
M!,O]J?\ :V^#WB3XO_%S4OA-\6OV3M*_X6.#XYDOM!L==^'7QC\*V%C?:[\-
M1!JWV"X\/^-%M-7L/$MAK<>GZ/H=[JVAZJC@'Z/_ /!+[_@G!^VM\0_V0_\
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M/_B;K#:9\;;;X@6&G6/@SQEIFAZ^^H^)]"T.<>%;5K!7U^ZNK&#3/M#WD&X
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M5MM%\8,WB>ZTJ^CLO"&KN@!T7_!5C_@FI=_!+_@K=XS_ ."D7Q$_X)O^*O\
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MF^*^A^ M TSXAZ^FI3?O=2&K^+;;5]0.I2+&U^;@W9AA\XPH >\4 % !0 4
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MQ_P4T_X-[_'OPM^#'Q8^)7@;X+_M;_$CQ)\8_&G@#X=>,/&7A/X3>';[QO\
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M5_[0I?[/=?4\1_M5I?NW[?#?[/?X/WR?M+:2_<75TGR^H5L=@4 % !0 4 %
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M % !0 4 % !0!\?_ +=/[)UW^VI^SIXG^ ^F_'WXU_LSZSJNL^%O%7AWXN_
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?A?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H ^1/%W[=7[,?@7]LGX6?L">)_']YI_[
M5'QH^&VK?%SX<_#M/!OC2\L]<\!:''X[EU/69?&MEH%QX'TF6W3X:^,2-,U?
MQ#9:I-_9<8ALW-_IPNP#S3QQ^V-\;?"O_!1KX,?L5Z1^Q1\8_%GP,^)OP5\3
M_$_Q3^W!IEQ<CX._#/Q1H?\ PEQL_AWKT$?A:[TAM3OY/#6C:<XO?'.C>(QJ
M7CWPL]AX0U'11=ZS0!^@U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MC%_PD.C:'XJL\VVM:5;Z@)C87<3SXMGBA>ZNWB>ZG /6J "@ H * "@ H *
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M[N]6O9+/7;^:VGU6^UG5] UCP+XLT_\ X27Q'X;U7PP^C 'YK?\ !(_X??\
M!6C_ (*\?LZ?M3:EXD_X*_\ QV_9U^%/PU_:_P#C%\,_#&H> -$N?%/Q\USQ
M7:^"_ASJ8T_5_BG=^*O"NL>$O@_X&TK6?#UQX1\%^"-3L=0UWQ#XC\?W6MZI
MI:VOANXH _5+_@VO_:I_:P^,?PZ_;J_9I_:^^,6K_M!_$+]A?]KKQ3\!M'^,
M/B=GNO%?B;0-.FUG1;BTUK6;B2;5/$$5GXC\':YJFDZIXANM3\0)I^OQ:5>Z
MQ?6>EZ=': ']+U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M3[6R8 ^K?V>/^"4'_!5+]F[XU_ CXK6O_!;;XV?M!>'K?QGIM]^U/\)_VC/
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M0(K65I] B\;?#CQ]X>NO$&BH(K:RU35M<T[3X(M(2R50#Q#_ (*,:1_P6/\
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MM/S6YZG6QVA0 4 % !0!_]+^_B@ H * "@ H * "@ H * "@!DG^KD_W&_\
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M9R:DTM.MHR?R]3]2OA__ ,@.3_L(7'_HFVH/KN'/]PG_ -A-3_TBD=Q0>^%
M!0 4 % !0 4 % !0 4 % !0 4 ?G=^WW\$/VI?%=M\+/VB_V*/B-J6C?M(?L
MT:EXBUO1O@;XF\8ZGHGP%_:L^'OBF'28_B%\"/BKI9NO^$?TC7_$5GH&FW7P
MH^+-]I\]Y\-/&UE:W$D]IH6L:U>V@!]_Z/<ZC>:1I5YK&F+HNK7>FV-SJFCI
M?1:FNDZC/;12WNF+J4$<,&H+87+RVHOH8HHKL1>?'&B2!* -*@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H \JO_ +"/C?X5W>,KRUU)_A5X_P#+^'J6
M.IMI^N6,?B[X:^?XRN-2CG71H;SPK/+;Z)96-W;2:G<0>,K^?3YX;6UU..XQ
M=OK$/WC3]C4_=6=I+GI?O&[\MX.T4FKOG;3LI(XI<O\ :-']_)3^I8FV%Y9\
MM2*KX6]=SO[-2HMJG&+3FU7DXM1C-2]5K8[0H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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ML)K33X #SO\ X-ZOV<9/VN_A9_P<(_"3XY^/+/XG>&/VH?VJ/B;\'?&WQW\
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M7AOPMH6OV.JZ'\0=3\(^!K/Q3XKL-12UTOQQX@\-W>B0&-M7@L+0)<. <_\
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M"W7CO]G+68-<_L?QEXL\/:]XL\S3? ?BRY_LWP-IGB76%_LGR7T];B^TV*]
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M-"^/>A>)KG4/$LU]IRZ[KFL^%?!^G:3HEUJ5S'IWC;4;*RTF'30#Q+_@F_\
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M \_]BSVMPFZV\2S+J/E[M)-\CH[ !_P< _L%_M8?MM_\$F?AC^S-^S#\*?\
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M>VLT_9\M/WWS=HWOU32:/5JV.T* "@ H * /_]/^_B@ H * "@ H * "@ H
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M6)I4E#Y^OC\7BH*GB*\ZL%)349**2DDXIZ1B[VDUOU>UUS?JS\/_ /D!R?\
M80N/_1-M0?7<.?[A/_L)J?\ I%([B@]\* "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M:#I%OIOA_1](TJR /JF@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * /QG_8=_X(;?LD_L/_ +0VN?M;6'CS]H[]I;]IC5=!UGPKI7QC_:I^)^G_
M !*\2^"/#>O2S#4])\#VVB^$?!NCZ(MSITTNB_;9-.O=0LM%NM4TC1[K3-)U
MK5["[ /V8H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@#RSXW/:1_"7Q_)?>-;_P"'-HGAR]:X\=:79ZIJ&H>%HP$)
MU>SLM$GMM6N9[4X9(M/N(KDD_NW!%8XBRH5;U'17*[U8J3</[R4;2;7D[^AQ
M9CRK XERQ$L)'V4KXF$9SE17\\8TW&HVNT6GV/4ZV.T* "@ H * /__4_OXH
M * "@ H * "@ H * "@ H 9)_JY/]QO_ $$T">S]&?E7^W?\![C]IK]DCXU_
M!*W^.NN_LS'QCX=TV>Y^._AN=[35_AKIOA/Q/H7C35M=BNX_$?A$V=I)I?AR
M[TW5;N3Q)I,%KI-]?7%S<-;Q2PRA^8X2M[#$TJKHK$<LG^YEM4<HN*7PRN[R
M32Y7=JVFY_))\$O^#=KP-^W?X%\!?M(?"+_@MU\>OCYX2\+^+/&-A\-OB5=?
M#GQ3JFH>$O%7A7Q,?#_B:Y\*7'BKXZ6_B'PI>R:QX8L+VWU&QATR36],M?#O
MB+3Y[S2;K1;V4/HJN=2PDYT*F54J,I1CSPYXI2C*-X\W+2Y9*TK6?-9WB]5)
M'Z=_\$4/V)/ OP2_:*_:*^)_P^_X*S?%3]OR3X6Z;X]_93^*GPA\<6_BFSLO
MA=\3+7X@^#M9N?$<]MXC^*/C)9[FW/PYUKP_X=U_3-&?0O$%EJGB+^P_$\YT
MO5;)PX,TQ4JM"A3GEU/!^T<,33JP<7[2FX22BG&G'^=2E%OFC:-XJZ9_5_\
M#_\ Y <G_80N/_1-M0>[PY_N$_\ L)J?^D4CN*#WPH * "@ H * "@ H * "
M@ H * "@ H * /S6^-/[*/Q\\._MA_#O]LS]D/XEZ=HVJ>,-0^'_ ,+OVS_@
M+\5/$'B>?X1?&GX%:-J$EE9_$'P3;V5OK;?#W]H3X.:9J>IWW@W4='T^R\/^
M/-+FO?#'BXPB<WE^ ?I#!>6ES+>0VUU;W$VGW*V=_%!/%++8W;VEK?I:WD<;
M,UM<O8WUE>K!,$E:TO+6Y"F&XB=P"Q0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % 'E%_'IH^.7A25O%]U:ZNWPH^($</@)+#4FLM;TU/%_PT:Y\7W&J1S#2(
M;KPM=/:Z-9V%U;R:E<P^,+ZXT^:&VM=22?%V^L0]]J7L:G[NSM)<]+WW+X;P
M?NI-7]]M7LSBDH?VE1?MY*I]2Q*6&Y9\M2"KX6]=SO[-2HMJG&+3FU7DXM1C
M-2]7K8[0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /YW?^"AW_ "=#XM_[ /@[
M_P!1VQKKH_!\V?YT?2)_Y.EF_P#V 9-_ZK:!]N?\$L_^29_$W_L>K+_TP6E9
MU]X^A^X?15_Y)GBC_L>X?_U7TC]1JP/ZG"@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * .+^)'C2U^&_P[\>_$2^LKC4K+P%X+\4^-+O3K62.*ZO[7PMH=]KEQ96T
MLV8H[BZBL7@ADE'EI)(K/E0: /C3_@F1^W]X/_X*;?LA>!_VO/ OP_\ $OPQ
M\.>./$'CKP_:>#_%NIZ7J^MV,W@7Q9J?A2[N+B^T<+8R17]QICW=NL8WQPRJ
MDF'5MP!]_P! !0 4 % !0 4 ?GS8_MC?&R[_ ."D&M_L33?L4?&.T^!.E_ >
MT^+-K^W)+<7/_"G-3\6SW=G"_P -((#X671?[33[5/9*J>/9/%_]J:;>2OX!
M7PN4\4J ?H-0 4 % !0 4 % !0!Y-\>_B)XF^$7P0^+_ ,5?!?PO\4?&SQ?\
M-_AIXW\<^%_@]X)=8_%_Q0U_PMX<U+6](\!>&G-K?N-;\5WUE!HNG?9M-U:]
M-S>1BPT?5[TV^FW !Y9^P_\ M!?$;]JG]E7X.?M ?%O]G?QW^RA\1/B5H&HZ
MMXF^ 'Q+ENYO&?P^N;'Q'K6AVD&J2:CH'A35#;Z_INEV?BO1AJWACP_JRZ'K
MNFKJ>D6-Z)X% /JR@ H * /D3XA?MU?LQ_"S]K7X&_L.>-_']WI/[2_[1WAC
MQ+XQ^$'@*/P;XTU*T\3>'O"&E^+-9U^]G\8:;H5UX,T%K+3_  1XEG6T\0:[
MIMW=&P6*U@FFO+*.X /-/BO^V-\;/A[_ ,% _P!FO]CSPW^Q1\8_B3\%?C?\
M-O&OC;QW^V;X=N+E/A-\$-<\,VWBN?3_  ?XKA7PM>Z2VH:C)X=TB"Y.M>-?
M"EX[>._"Z>%M-\67XO\ 3(@#]!J /'_C_P#'CX7_ +,'P7^)'[07QJ\03>%/
MA1\)?"]]XR\>>([?1=;\13:/X>TWR_ME]'H?ANPU37=3:+S$Q::7IUY=R9_=
MPMAJ )?@-\<OAG^TQ\&OAK\?O@UK\WBGX5_%SPEI/CCP%XBGT?6?#\VL^&M;
M@^T:;?R:)XBL=+US2WGA.XV>J:?9WD7W9H$88H ];H * "@ H * "@ H * "
M@ H * "@ H * "@ H \X^,/Q8\#? ;X3?$WXW?$_6!X?^''P@\ ^+OB9X\UP
MP373:5X1\#Z#?^)/$-]':6Z27-[/;:5IMU)!96L<ES>3+';6T;S3(E 'Y>?\
M$M/^"L'B7_@J"WB[QKX=_8<_:(^ '[.J:1J&M_!_]H3XN7&@)X5^-%MI_BD^
M%I[#0--TN,FUUBWN+?5)KU=*U;Q5H-J^CZA8CQ%->0^50!^Q5 !0 4 ?F+\%
M?V^OC'X_^)7_  47\+_%?]AOXU_ 'X<?L/:K?K\,_C#XWO)?^$6_:R\-:3H_
MC/5]0\2?#8ZAX6T#3X+9[+PGI^KV3Z%K?CO3X-&\8Z /$>I>'-;WZ-< 'S+X
M/_X+/^)_CA_P2<?_ (*<_LM?L*_&_P"/^O7OC"_\):!^ROX4UA=1^)&H)HWQ
M/;X<Z]XBEU#P7X2\=:E-I&CPP77B2YC\/>"_$>H1V4:"\MK#34U+6]* /NGX
MU?\ !0_]GC]EKP/^RUXG_:MU+Q)\!?$/[67B7P#\.OA]X!UCPAXL\9>(-.^+
MGCO2-,U"/X:^))? >AZ]9:+JFAWVI?V+JNLZH]AX?CO;6=OMZ0@-0!B?MV?M
MC?&S]DS6/V6]-^#O[%'QC_;!M?CW\>-"^$WQ!U+X3W%S!!\!_"6JM:+<_$OQ
M=]D\+>*%;3+5;F>YB;79/!_A!(-'U/\ X2#Q]X:9M-%^ ?H-0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 >5_&]+Q_A/XZ6P\(Q>/KT:',]MX+GM=0O8?$LL<T
M,@TB:TTN6*^N(KO;LDBA?#)D31RP&6)\<1=T*EJ?M7RZ4W=\^OPZ6>O_  ]U
M='%F*D\#B>6@L3+V>F':G)56FO<:A:33ZI?.ZNCU2MCM"@ H * "@#__U?[^
M* "@ H * "@ H * "@ H * &2?ZN3_<;_P!!- GL_1G\\'_!?B/XA2?\$>_V
MZE^&,FH1>)/^%6:,VI-IGVG[2WP^C^(W@F3XM1/]DS+]@G^%2^,X=5#_ .C'
M2GO1>8M#,:#\ZR?D_M+">TMR^T=K_P _)/V7S]IR6\[&A_P0LA_9EMO^"6?[
M(J_LNR^%)/#<OPG\)7?Q2?P\;$:NW[0,WAW21\:V\?BVQ=CQM'XXBU*UO?[3
MS(NCVVB1Z2\GAF+0G8%FWM_[0Q/M^;F]I+V?->WL;_NN3IR\EMNM[^\V?C]_
MP32MOA3#_P '*7_!2T_L;7&B_P##-!_9PLYOBS!X"\L_"K_A?4_B3X+'68O#
MO]D@Z,=87QH?B?.7C8VT6JR?$ZWT;;8%(U#TL=[3^P\#]:O[?V[]GSW]I['E
MJVYKZVY?9]M/97UNY?VM_#__ ) <G_80N/\ T3;4'K<.?[A/_L)J?^D4CN*#
MWPH * "@ H * "@ H * "@ H * "@ H * "@#\[_ !7^Q!K_ (9_;1\-_MG?
MLP?$Z#X-:Y\0[_1O#O[;?PLU71K[Q'\+?VH_A[H6@S:1X8\57'AVTU72AX0_
M:*^'L=MI&E>"_BWILV^Z\)B[\+>,]+\3:)#9Z>H!]N^%?B-\/O'.I^-=%\%>
M.?"'B_6/AMXF/@OXAZ5X9\1Z/KNH^!?& TK3==;PMXOLM,O+JX\.>(ET76=)
MU5M&U>.SU!=/U*RNVMQ#<PNX!V= !0 4 % !0 4 % !0 4 % !0 4 % !0!Y
MI>+J?_"X?#K1^$=/N=&'PT\9K=^/)+-VU71M3/BCP$=/\(VFH&4)#I_B6U&I
MZSJ-G' SW%SX3TN>:5!:P(^3O[>/N)Q]E.]2VJ?/"T$^TE>35MX*]M#DES_7
MZ5J$73^J5^;$N/OTY^VP_+0C.]E&K'GJ2BHZNC!MJT4>EUJ=84 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % '\[O_!0[_DZ'Q;_V ?!W_J.V-=='X/FS_.CZ1/\
MR=+-_P#L R;_ -5M ^W/^"6?_),_B;_V/5E_Z8+2LZ^\?0_</HJ_\DSQ1_V/
M</\ ^J^D?J-6!_4X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P#A=\,9K[3?#^H_&'4+F73-!T?4M;U+3+72]*UKQ!J]KJ-CKEEI%R@!B?\
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MXQ\-6OAKQM]M^(LVG:-KO_"3W0T+Q3;:/9:9X8T8 _0K_@J!^SI^T[\2/^"
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M H * "@ H * "@ H ^%?&_["7@S4?VOOA]^VM\(_'/BGX!?%^T\GPU^T1!X
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MPPE.BW*5/2,N>+7*]6M>Q]Q5D?N@4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M">+?$]UX<^TVNL:;+_8_BV#0=>A^T;+C2XI(;A$ /(?V(O\ @EO\=X/VO?\
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MGPE_:/\ ^"&7[''_  5/^ VK>./&/_#-_P 0?#OQL^$G@L^$OA]KU]+=>"]
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MK_[/GC6RU34]$\7:EX.U6[U#0?%/@>]N=(\=Z?)I5SJ2>';BP@U1]* /O:@
MH * "@ H * "@ H * "@ H * /.+S^V#\7?#IB\):1<: GPX\9_;?'<NG(VO
MZ1K$GB?P%_9?A*QU9IUEBTCQ'91:OK&JZ=%;2I<7OA;1KF>>!K:W2XR?-[:/
MN1Y?93O4M[RDYPM!/^623DTEO%-VT.27M/K]*U"FZ2PE?FQ+A^]A4=;#<E"-
M2]U3JQ4ZDX*+O*E3DW'EBI>CUJ=84 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M4_5+X?\ _(#D_P"PA<?^B;:@^NX<_P!PG_V$U/\ TBD=Q0>^% !0 4 % !0
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MLE5^HXE1H<KY)T_K&%YZKG?E4J<N2$8M7:JR:>DD>N5L=P4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 >9?&;^UO^%6^.!H7A+3?'>L-H=PNG>#M9
MTV36-*\17;/&L6F:CID4]LUY:3L<3QFXAC$8+S2+$CFL<1S>QJ<M-59<NE.2
MYE-Z:-=5_3ZG'F'/]2Q'LZ$,34]F^2A4@YPJROI"4$X\T7UU2ZO2YZ;6QV!0
M 4 % !0!_]'^_B@ H * "@ H * "@ H * "@!DG^KD_W&_\ 030)[/T9^$W_
M  68_9U^,/[6?_!,_P#:G_9Z^ 7A-/''Q=^)/A[P)8>#/"LFO^&O"Z:O=:+\
M6O 'B?4HCKWB_6-!\.:?]GT31-3O ^IZO91S&V^S0/)=36\$H?F^65Z6'QV'
MK5I<E.$IN4K2E9.G.*TBI2>K6R?X'R)^RI_P0 _X)P:9^R]^S=IO[1/[#'PN
MG_:!T_X"?!ZQ^.D][K_B/5;R;XQVGP\\.P?$V6[U/PSXVN?#>HW,GC6/6WGO
M_#]S<:)>2L]QI4\MA);NP=.(SC'/$5W0Q=3V+K571M&*_=<\O9Z2IJ2]RWQ*
M_>S/T*_9@_X)D?L'?L7^/M7^*/[+W[-G@?X.>/\ 7O"%_P" =8\3>&;KQ//?
MWW@_5-:T#Q%J&A3)K6NZI:BTNM:\+>']0D:.W2X$VEP!)EC,J.'%7Q^+Q4%3
MQ%>=6"DIJ,E%)22<4](Q=[2:WZO:ZYOU5^'_ /R Y/\ L(7'_HFVH/KN'/\
M<)_]A-3_ -(I'<4'OA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 ?FY^UI\(OV\=$^+?AW]J#]B'XU:1XIO=%\,Z/X+^)G[#7Q^U!=*_9Z^,
M?A32M:U75?\ A(?AW\0=!\/ZCXN^ _QY@AU[5K6'QM+9^,O!WC&&U\*Z-XV\
M-II/ABRGH ^_'\9^%+;Q1I7@._\ %'ABS\?:SH&H^*--\$/X@TT>*-2\/:+=
MZ;I^N:_I6@S36^M:CH&CZEK&E:?J.LV^F_8;.[U/3;>\DMKB^MH90#IZ "@
MH * "@ H * "@ H \XO$UMOB[X=DB\*:)<>'(OAQXS2_\<3:=$WB/2=;G\3>
M SI'A33M6:Z2:+1/$%C;ZWJ^LZ=#93Q3WWAG0KFYNK1[:TBO<GS>WC[D>7V4
M[U+>\I.=.T$_Y9)2DU;>,6[:')+VGUZE:A3=)82OS8EP7M85'6P_)0C.]U3J
M152I4@HM.5*FVXVBI>CUJ=84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\->.=;MBFJ^*_"'P_F\$^'O$FK*FIV?A+PZ]O<0 'U]X(\<^"_B9X1\/>/\
MX<^+O#7CWP+XNTNUUSPKXR\&ZYIGB7PMXDT:]3S+/5="U_1KJ]TO5=.N4^:"
M\L;N>WD .R0X(4 ZF@ H * "@ H * "@#R&_CT0_'OPG+-K>HP^)%^$/Q!CT
M_P -I9N=)U+1'\9_#)M8UNYOUE,4>HZ)?IH=A96<L"O-;>(-0F@E=8+A$Q?+
M]9C[SYO8U+0M[KCST[R;[Q?*DK;2=KZG!)4_[3HMU)JK]0Q*C2Y?<E3^L83G
MJ.5[*=.2IQC%I75233=I*/KU;'>% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M'#XB?'SX7/XL^+7[-OQ0_94^)6A>)M7\%>-?A+\4+[POX@>T\0:!#8/J&M>
M/'?@S4]2\-_$OX8ZG-?&/PA\0=-324\1Q6=Y)+H6DSP26B 'TG0 4 % !0 4
M % 'GEY%KK?%CP]/#X5T*?PS'\//&46H>-IK.W/B;2M=G\2>!'T?PKI^H->I
M=QZ%K^GV^NZOK-G#IUQ;S:AX:T*:YO;.6"T@O<GS>VC[D>7V4[U+>^I<].T$
M[WY9)2DU9ZQBVU9*7+)5/KU)JC3=%86NI8AQ7MH5'6P_)1C/FYE3JQ52I4BH
M-.=*FW*-HJ7H=:G4% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MK_'"7LHQCRZQG-W=K'L%;G>% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_.[_P
M4._Y.A\6_P#8!\'?^H[8UUT?@^;/\Z/I$_\ )TLW_P"P#)O_ %6T#[<_X)9_
M\DS^)O\ V/5E_P"F"TK.OO'T/W#Z*O\ R3/%'_8]P_\ ZKZ1^HU8']3A0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % '\[O_!0[_DZ'Q;_V ?!W_J.V-=='X/FS_.CZ1/\ R=+-
M_P#L R;_ -5M ^W/^"6?_),_B;_V/5E_Z8+2LZ^\?0_</HJ_\DSQ1_V/</\
M^J^D?J-6!_4X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M[?ZABE""2]FZ3Q&$]K*4KWYXS5%05DN64VV]%'V&MSO"@ H * "@ H * "@
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MGZAH^JV;LEYI6KZ??Z5J,%MJ%E<V\0!Z70 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^4/[5O[$/Q>^-WQ
MGUWXA>$=5\!VNAZEIGA^SMX=>UG6K/4EETO2;:QN3+!9>'=0MU1IHF,16Z<M
M'M9@C$HN].K&,;-.]WLD_P Y1_7UV1_)GBQX'<8<<<:X_B')\7D%+ XG"Y?1
MIPQ^-QM'$J>%P=*A4<Z='+<1347.#<&JLFXZM1;L?1O[%7[/7CC]GCP?XQT#
MQS>^&[V]U_Q+;:Q9/X;OM0O[=+6'2X+)EN)-0TO2Y$F,L3$)'%*FS!,@8E:B
MI-3:M?1=;?HW^?R6K/TCP2\.\]\.LGSG 9[7RVO7S#,Z6,H/+*^(Q%.-*&%A
M1:J2Q&$PDHS<XMI1C)<MFY7TC]HUF?M84 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M3=#\2^)?$/B/Q%IFFZ%X;OK>+6M0T8 \A_8*_P""Q7QC_:D_:5L?V3?VE_\
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M_M]*GMKG3YK*V5 #])_V$_\ @HY_P3J_8B_X(,_ 3]M30/A?XF_9;_9*M_\
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MK6F6FD?9[FYMM.:.$S2WT B /S=\0_\ !VI\/_AU\=_A?X4^-_\ P3A_:]^
M/[,_Q?UV"R\#?M)_&6RNO NIZWX5NM4ATU/B+I'PIUKP1::?XC\(:?%>Z?J^
MO3>%_BKK>I:=I4TYLM/U748K;3K\ _2W_@IS_P %M?"'[ /QW^#7['OPF_9C
M^+W[;/[:/QS\-R^-O!G[/_PCNHM#>V\&K/XDMK;5M=\3?V%XOOX;S4I/"'BR
M]M-*T3P;KSV&@>%]>\1>)[GP]I4>D3:R >C_ /!-C_@JAXW_ &ZOB%\7?@E\
M9/V!?VI_V'/C9\%?#'ACQGXL\.?&S0I+GP1>^'O&.I7VD>&Y/#GCN[T7P;?Z
MMJ&L7VB^(I=+A;P7:Z9JFE^']6O]+UF^?3]0M;( _7Z@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M<M[);W*0-;SH_-,OQ*PF,H8B2;C3G[]M7R3C*$VEI=J,FTKZVMI<_FM_8_\
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MV\5^//!WQU^#Z>#O#W[/FMZ'X@T^P\!V/C+QEX/\?ZEI5S\1M!G\-ZQJ.O:
MOB/P]H<>I1:5J>CWL>CR:B+67[6]O+$ ?K/_ ,&JFE? W1?#_P#P4:_82\2?
M"30_@7_P5,\.>&/BQX$O?B?K<^H3?$+6OAX1-X'UOPA81ZOJ&J:?X7NO@O\
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M6[RH"%=H(68$QH5 -K_@O=X"_P""2OQE_;N^!>@?'K]O/XN_\$X/^"@OP[^
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'GOQ8M?$
M-[\-_&-KX4\-:%XR\23Z)<IHWA;Q/;V%WX?UV^^4PZ=J]MJEYI^GS64Y!$J7
M5[:Q8&3,A :LJRDZ510A&I/E?+"=G&3[2NXJWJU^9RXV-66$KQHT:6(JNF_9
MT:RC*E4ETC-3E"+B^MY17X*7H5:G4% !0 4 % '_T?[^* "@ H * "@ H *
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MD_["%Q_Z)MJ#Z3AS_<)_]A-3_P!(I'<4'OA0 4 % !0 4 % !0 4 % !0 4
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M ?,'@/\ X)E?\$Z/A;\2++XO_#;]A3]DCP%\3M+O8M2T;QOX1_9\^%GA_7]
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M\#^&M+TSPQ8VNO:QK.L:MK5O:Z9#%JFIZMJ=_?)-=7UU+* ?/'PV_P""<?\
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M;WP;^S5\!OA#\!?"^IW<6H:OHGPC^'GA7P!8ZUJ,$1@AU+7(_#.EZ:VMZG'
MS0IJ.JM>7JQ'RA.$X8 ]UH * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MX.+/CQ\%?V2_V7?@WI'_  1]_:K^)6E?"7]G;X)_#+3/B+X>UOQC%H'C[3_
M?PU\,^%K+QKH<5M^SYK%M'I'BJVTJ+7=-CM]7U6!+*_A6+4KY MS*'K8G)*-
M7$XBJ\SP]-U*]6HX24;P<ZDI.#_?+6+=GHM5LMC]H?\ @F/_ ,%B_BK_ ,%"
M?CUXN^#'CG_@G;\>?V1])\,_"+7OB?;_ !(^*.I^([WP_K>HZ+XS\ ^%(?!%
MG%J_PB\ VRZQJ5MXUN]>MY$UBYG%EX:U!5TR:-I+JR#R\?EE/!48U88VCB7*
MHJ?)3232<9RYW:K/1.-MMY;J[4OZ.OA__P @.3_L(7'_ *)MJ#Z/AS_<)_\
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M]H* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?#?$TL5B<1B90SRA&,L16J5I1B\!2=HNI*3BF];+2^NOV?TWK _I\* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M/_L)J?\ I%([B@]\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * //KJ+Q1_PM70Y[>PTI_!7_"OO%46KZI)
M'IW]N6WB@^(_!K^'+"TE,@U8:5>Z2/%-QJ$<<4FG&\L-,::2&Y6!)\GS^VCH
MO9^RE=Z<RGSPY4OM6:YF]+72V9RM5OKM.2C#ZO\ 5:RG-J'M%6]M0=*,7_$Y
M)0]LY*W)S1A>TK'H-:G4% !0 4 % 'X4?\%"O%\GC']I+3?"<XBETGX-^"-,
M;2H'4N]MXP^(OVO4/$>IKE?*64^%++PGIMG*NZYMX+K6XED2WU*>.7]G\&\H
MI5\;F^>58<U3 PI99@V[-4ZF)A]8QM2/:I[)86E&2U5.I6BFE4FI?%YQ5=?-
MG!O]W@<-3A"/15\5S5*TVMN9488>,'9N*E52DE-QE\;5_0)QA0 4 =Y\(/'5
M[\+OC5\(OB#87!MUTWQYX?\ #/B >:\<=YX+^(&K6'@_Q1:3HN8[A+2WU.U\
M16MO,A1M6\/Z8Z/#*B3Q?F/BQE-+'<+U,QY/]JR2O1Q=&HHIS^KUZU+#8ZE?
M=4Y4:D:\TG'W\+2DV^3EE,:KPN*P>,CHZ.)I4Y_WL/BJD,/7B^C2C-5DGHZE
M&GM;FC_3)7\RGZ$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % '\[O_  4._P"3H?%O_8!\'?\ J.V-=='X/FS_
M #H^D3_R=+-_^P#)O_5;0/MS_@EG_P DS^)O_8]67_I@M*SK[Q]#]P^BK_R3
M/%'_ &/</_ZKZ1^HU8']3A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M3WKZ+KNC:;^WK\.IYOCE;6=]J%C=:?HFNP-XZUCQW\*/"6N7)N(9$'A;Q?\
M!'7([:*42>#S=RW2('U%9_VHU+!9JXJZ;PD_W-[.[3Y(QJ3C_BC55_MZ7C^U
MG_!IM^TU\!O$?[ ]C^RIHWQ,\/W?[1'P]\9?%OXD^+?A.WV^U\4Z;X!UKQAH
MUM8>+X(;RRM[35]!-WKVB6-YJ&BWFHP:7J&K:?8:F;.\NX('#S.(:%:.,>(=
M.2HSC3A&IHXN:B[QW;4K)M)I72;5[,_L=^'_ /R Y/\ L(7'_HFVH/8X<_W"
M?_834_\ 2*1W%![X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _G
M=_X*'?\ )T/BW_L ^#O_ %';&NNC\'S9_G1](G_DZ6;_ /8!DW_JMH'VY_P2
MS_Y)G\3?^QZLO_3!:5G7WCZ'[A]%7_DF>*/^Q[A__5?2/U&K _J<* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#SGXN6
MGBF^^&OC&U\$Z/IGB#Q;)H\K>']$UFWTFZTK5-3BEBFM[+4(-=E@TF2UG:,I
M+]LN+=%4[TN()E25,JZFZ53V<8SGR^[&5G&3Z)\S2MZM>JT9R8Z-:6$KK#TX
M5:[A^ZIU%!PG-.ZC)5&H6=OM->J:3/1JU.L* "@ H * /__5_OXH * "@ H
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M_P#2*1W%![X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@[_U';&NNC\'S9_G1](G_DZ6;_\ 8!DW_JMH'VY_P2S_ .29_$W_ +'JR_\
M3!:5G7WCZ'[A]%7_ ))GBC_L>X?_ -5](_4:L#^IPH * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MNOV=OVW?@G^QY^S=\/+7XW>%;+3I/&GA+QK\/_@WX-T"_P#!/Q+L]+OHM/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YO\7H
M/$]Q\-/&,7@NQTO4_%C:2[>'M/UJ/1YM*O-5CGADM(+Z/7GCTAH'D0!OMLD:
M*<-'+',(W7*OSNE/V:C*=O=4N7E;NK)\UE;U?I9G)CU6>#KK#QA.OR?NH5%3
M<)3332DJMJ=F_P"9KR<79GI%:G6% !0 4 % '__7_OXH * "@ H * "@ H *
M "@ H 9)_JY/]QO_ $$TUNO5">S]&?CQ_P %+_!7@_XB?L._'SP9X^_:=F_8
MT\(ZYHWA2'6?VE[?43I,WPMBM?B%X1O[;4$U!?$GA$VW]NWUK:^$B1XCTSS%
MU\Q>9-YAM9T?F>!G*&+HSAA_K4HN5J%K^T]R2M;EG>R;E\,OA\KQ_C:_X85_
M8J_Z6M-9_P##E3__ $3]!]+]<Q/_ $3W_E/_ .]#]AO^")G[-O[/7P=_:J\?
M^)OA-_P6QU#_ (*1>([[]GWQ5H5[\#KKQ=+K\?A71+KXC?"C4+GXKBS?XR?$
M,1OH=]IFF^$!<_V+:E%\=-$-4A\YK2]#S<TQ%:KAX1J95]12K1E[7EY>9J%1
M>SO["ENFY?$_@VZG]>/P_P#^0')_V$+C_P!$VU![?#G^X3_[":G_ *12.XH/
M?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#SRY/B;_A;&B"VDT@>#3\//%!UF%SIO]O/XF'B3P?\ \(S)
M; J=8.D1:4?%BWQ1ETT7DVG^:K71A*9/G]LK->S]E+F6G-S\\.5K[5N7GOTO
M;J<K]M]>IV</J_U6K[1>Y[3VWMJ/LFO^7G(H>VYOL<SC?WK'H=:G4% !0 4
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MM/U&SF S%=6=S/!(!E)&QE@#<H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /'OV@?^$5_X4K\2O\ A./^$A_X1'_A%=0_
MX2#_ (13^S?^$C_LW">?_8W]K_\ $L^W8QY/VW]QUWUABN3ZO6]IS^SY'S<E
MN>W]WFTOZ_Y'!FGL/[/Q?UGVOL/8R]K[#D]KR:7]G[3W.;MS:'L-;G>% !0
M4 % '__0_OXH * "@ H * "@ H * "@ H 9)_JY/]QO_ $$TUNO5">S]&?E/
M^WG^R+X>_;P_9'^-/[)?BGQAK/@#1/C)H6C:3<>,?#^GV.JZKH-SX?\ %OA_
MQEIEY#IFHO#::A =5\.64%_927%F]SI\UU#;WUC<O%>6Z/S'!XEX/$TL3&*F
MZ3;Y6VD^:,HM75VM).SMO;>S/X*?V@/^")7Q%_X)#66O_&7]H7]G']CW_@I'
M^R3IU\9]6\2^)/CQ\5?V4_C)H>F1KE+/2]+L/C!X.TE-<U!HR+31=!TWX_ZE
M<-+MM+&'!$0?74<UIYDXTJ-;%8'$-:1C1IXBE)]VW3G*R6[:H+S5O>_=K_@W
MS^+/_!%/XS?%GQ[XE_X)^?LD_$C]EG]JK2O@IJ=A\3]"\9>)/B]X^T8_"W4O
M&_@"XUNST#QQKOQ%\=?#W4+2;QGI_@B6T&IZ=X+\?WZ6%Y/I6A-H=EXAE0/(
MSBGFE*G".,Q$,1AW53IN,:4'[10G9N"A":?*Y;<\%?6:DTI?V/\ P_\ ^0')
M_P!A"X_]$VU![/#G^X3_ .PFI_Z12.XH/?"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#Q_43X4_X7]X-%
MP-?_ .$X/P?^)1TAH?[/_P"$6'A0>-/A/_PD0U#>?[5_M]M7/A<Z/]G4Z?\
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M(VNHI88I)'B<* ?8U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MG[+!YC@\%#K[*-"4WYWE+ENUUM*?53WB?V _\$</VKOVNOB!\1]=_9S^)O\
MP1[_ .':G[/?A#X1:]XX\*^(M!\$>)_ W@W5_'FG>+_A]X=L/!4&F7W@'PAH
M,NLZWX?\0^(_$<UV+BXUF[3PK<S2)<)]JN(@^:S/#X:$%6IYE]>K2J*$HN<9
MR4'&<G._/*5E**CV][IHC^H+X?\ _(#D_P"PA<?^B;:@^@X<_P!PG_V$U/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MV,O:^PY/:\FE_9^T]SF[<VA[#6YWA0 4 % !0!__TO[^* "@ H * "@ H *
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MQZLO_3!:5G7WCZ'[A]%7_DF>*/\ L>X?_P!5](_4:L#^IPH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-_B_+XFA^&G
MC"3P7<Z79^+!I++X>NM;?1X]*@U9[B%+*2^?7U;2! )F7(O4=6;:L2-.8E;*
MNYJE-TW%3M[KER\J=U:_-=6]5Z79R8]UE@Z[P[A&OR?NG4]FH*=URN7M;T[7
M?VEZ7;/2*U.L* "@ H * /_3_OXH * "@ H * "@ H * "@ H 9)_JY/]QO_
M $$TUNO5">S]&?C'_P %3?V2=;_;H_X)^_M/?LL^%;O3[+QA\3_ 5J_@B759
M3;Z7+XZ\#>*?#_Q'\$V.I78=/L%AJGBKPAI&F7NHD2II]M=RWLEO<I UO.C\
MTR_$K"8RAB))N-.?OVU?).,H3:6EVHR;2OK:VES^:W]C_P#X.7OAG^PS^SQX
M#_8V_P""B'[+'[47PT_:9_96\ ^&/@SJ.E>$?!?A*[M?%^C?#S0M/\,^#M6U
M&Q\=>._ 6K>&]?U3PW8:7+J4B6NM^%];:*;Q3H.O?V?K-EHUH'N8G(YXNM/%
M8+$8>I0Q$Y54Y3DN5S;E))PA--*3=MI+X6G9R/J+_@BQX7_:&_;D_P""B'[5
MW_!:WXU?![5O@+\+?B[\)-%^ ?[+O@#Q-#?#6->\!PW7@2Y?QQ9W-[:Z=+JF
MEV^D?#K38Y?$T-BN@^)O$/C7Q''X9*Z;X>7<'/FDJ&$P6'RNE45:I3J.MB*D
M=E.TUR.VB;<W[OQ1C"/-K(_L7^'_ /R Y/\ L(7'_HFVH/9X<_W"?_834_\
M2*1W%![X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 >?75QXI_X6KH-K;ZQI47@K_A7WBRXU;P_)-IW]MW
MWBG_ (2/P5'X>UBSMV@;5SI6E:3_ ,)-9:E-%<P:<MWK.E)/!=7+6\EIDW/V
MT5S+V?LIMQTYG/GARR2MS62YD]4KR6CWCRMUOKM.*J06'^JUG.DW#VDJWMJ"
MI5(JSGR0A[:,VG&'-.":DVG#T&M3J"@ H * "@ H * "@ H * "@ H * "@
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M,5Y/HFOZ+IFMZ>/-AU'3[6X@FC0 [J@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _G
M=_X*'?\ )T/BW_L ^#O_ %';&NNC\'S9_G1](G_DZ6;_ /8!DW_JMH'VY_P2
MS_Y)G\3?^QZLO_3!:5G7WCZ'[A]%7_DF>*/^Q[A__5?2/U&K _J<* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#Q[]H'
M_A%?^%*_$K_A./\ A(?^$1_X174/^$@_X13^S?\ A(_[-PGG_P!C?VO_ ,2S
M[=C'D_;?W'7?6&*Y/J];VG/[/D?-R6Y[?W>;2_K_ )'!FGL/[/Q?UGVOL/8R
M]K[#D]KR:7]G[3W.;MS:'L-;G>% !0 4 % '_]3^_B@ H * "@ H * "@ H
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MK+_TP6E9U]X^A^X?15_Y)GBC_L>X?_U7TC]1JP/ZG"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M3PIX;T#Q7I-GJ=QH^DZTN@^((+2WU&72M/U*.UN&L;>X@#GQ?U^#5+&RQ/\
M/&%>=246U=<T>:3BVKN-UM=K2[/UR^'_ /R Y/\ L(7'_HFVH/K.'/\ <)_]
MA-3_ -(I'<4'OA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!_.[_P4._Y.A\6_]@'P=_ZCMC771^#YL_SH^D3_ ,G2S?\
M[ ,F_P#5;0/MS_@EG_R3/XF_]CU9?^F"TK.OO'T/W#Z*O_),\4?]CW#_ /JO
MI'ZC5@?U.% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M>\E"3O>\O[:/A_\ \@.3_L(7'_HFVH/5X<_W"?\ V$U/_2*1W%![X4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M/&QJT<)/"*DH8>-#V;C/$8AR;<>;F4H[VL[-GU?69^LA0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M5.$FTE*;J)P25_M)^2>QZ+6IU!0 4 % !0!__]?^_B@ H * "@ H * "@ H
M* "@!DG^KD_W&_\ 0336Z]4)[/T9^4G[?'Q[LOV8_P!D'XY?&W5/@CJ_[2&D
M^$?#-A9ZQ\#=$M(K^_\ B3HWC+Q+H7@76/#QL+C0_$MMJ%@^F^)KJ\UBPNM"
MU*UO=(M;ZUNK?R)7=4?F.#HNOB:5)550<I-JLW94W"+FI7NK.\;)WT=K7/XQ
M?V6_^"H_[%?[%'Q+\2?&7]FO_@WI_:&^$_Q$\36>H6&K>,K3Q5\2/$E_I6C:
MG+;SZOIWA2'QMX"U_3O ^E7@M(?M>F>#H?#NGS01_998Q:%HZ#Z;$8#$XJG&
ME7SJC4A&UH6A%-K9RY)7F_.:;ZZNY^]O_!#_ /:@_P""87[5WBG]KKXP?L7?
M!75?V>?VE/B3XTT?QO\ M7_#;QS$L/C*;4KNYUJ'3O$7AUH=9UC19/!6H^(I
MO$>I:Q:>&%T1=.\:ZS?W'B;P[I=UK.ARWX>1FN'Q^'CAJ6*JJM0IP<,-.'PI
M*UXOW5+FY>5+G;O&/NMVER_TY_#_ /Y <G_80N/_ $3;4'T/#G^X3_[":G_I
M%([B@]\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * //[NX\1#XJ>'[6'Q+H4'A-OA_XPN-2\'RSV0\2ZGX
MBC\1^!X]$\2V%LUD^HOH6A:;)X@TO5YXM1M[*._\1:)'<65Y/+;3V&3<O;17
M-'D]E-N&G,Y<\+22MS<L5S)ZVO):=3EDZOUVE%5J:H?5:[GAVX^VG557#JG6
MBN5S=.G!U83:E&*G5IIQDW%P] K4Z@H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M:G_I%([B@]\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!XS^T/-X?MO@E\29_%ECJ6I^&8?#-U)KNGZ/>PZ?JEWI:R0F\@L+RXM
M[F&"Y>'>(VDBPQ^02VY87"<^*Y5AZKFFX<GO*+M)QOK9N^MOZ5[GGYJZ2R[%
MNO&<Z*I-U(TY*$Y0NN91DU))VVNONWC[-70>@% !0 4 % '_TO[^* "@ H *
M "@ H * "@ H * &2?ZN3_<;_P!!--;KU0GL_1GX7?\ !9']F7Q[^V'_ ,$R
M_P!KG]GSX6V<VI_$7QA\/])USP7HEM<FTNO$GB'X9^.O"GQ4T[PK9RX,9O?%
M4W@H>';*&X:&TN+O4X(+NYM;:26XB1^;Y97AAL?AJU1VA&;4WORQJ0E3<GUM
M'GYG:[LM$[6/QO\ ^"9/_!Q5_P $X/AS^Q#\#_@G^U)X\UO]E_XW_LR_"CP=
M\#O&_P -M>^$WQ0UJ+5KWX1^']/\"QZ[X3E\ ^"?$5K$VNPZ-;7>I>%M;CT'
MQ#X=UZ?5M)FTRZTO3(?$-^'I8_)<=/%5:N'@L12KU)58S52FK>U;G:2G.+TO
M925XRC9\R;L8/_!'3Q=K/_!1C_@L?^W7_P %;O WPY\2?#W]EJ?X-:-^S%\*
MM6\3V2:-K7Q+\16,GPIMY=:OH[,W%EJMUI_A_P"%LVI>(+%+Z\'A9?%'@709
M+V_N]+FEB!YG%8++,)ELYQGB%5=>HHNZIQ?M;+757=2T?YN6;ZH_M*^'_P#R
M Y/^PA<?^B;:@]?AS_<)_P#834_](I'<4'OA0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y#?R:&/CUX4B
MFT349O$C?"'X@R:?XD2[<:3INAIXS^&2ZQHES8+$(I-1UN_?0[^QNY9F>&V\
M/ZA#!$BSW#O@^7ZS#W7S>PJ6E?11]I2YHM=Y/E:>ND7:VO-P2=/^TZ*=.;J_
M4,2XU>;W(T_K&$YZ;C:SG4DZ<HR;=E3DDE>3EZ]6YWA0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % 'D?QJ^ /P,_:1\%R_#G]H3X.?##XX> I;
MM-1_X0_XL>!/#/Q \.1:I%;75G;ZO:Z1XITS5+*SUBUMKV\ALM7M(H-2LEN9
MOLEU"9':@#R3X/\ [%OP5_9;^ ?Q#^ '['>AC]F'P[XU;QUK>A7W@J2\\4I\
M//B%XU\.6^@IXZ\)>'_B'?\ BG0;5] GT[1M7TOPA]CC\$&\TL1R: (;[4EN
MP#SC]E7X4_\ !17X4?$'6=&_:A_:X^"/[67P/;PC?MX;\56W[-LGP&_:)M/'
MO]L:%_9,/B1O WC_ %?X,ZWX07P]_P ),-5N='\#^%]:N-=_L*6QM;'3EU&U
M< Y+Q/\ \%(#\,_C_=? WXP_L4?MT^!=#O\ XC:?X \!_M$>'?@7_P +J_9V
M\;)K^L6>A^%_$-SXT^"/B+Q_XB^'NGZWJ%[ '3XE>#?"G]D0RI)JUQ:LMW':
M 'Z"W_C3P=I7B31?!NJ>+/#.F^+_ !):7]_X=\*W^O:79^)-?L=*>!-4O=%T
M.XNXM4U6TTY[NU2_N;&UGALWN8%N'C,T8< Z:@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M6>*-+D12F$MY;F@#1H * "@ H * "@ H * "@ H * /YW?\ @H=_R=#XM_[
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MU/\ MGQ?K6FZ2OAWPWH<UCJ=A. ?WTT % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MMM.M+'X:Z7!JNKOX0U/XD>*[/PSJ%EXX6R\76;Z;_P )QH%K>:?;ZB@!W_\
MP34_X(_?M??\$\_BS_P5_P#VEOVH/C'\!OC'#^V/X5^)GBG0/$7PFB\6^'O$
MFJZQ>^)/BWX]UKQ)XT^'.J> = \(_#J;7U\86]\/"/@OQIX[TCP]?RWNAV.L
M7^FZ?9ZK>@'\\W_!OO\ LV?\%HO'G_!//XO_ !/_ ."4_P"VQ\+_ (-Z+K7[
M4WQ!^%_Q-^!?QL\,:1>>'8M9T;X0_ O6=.^,OPS\5:E\,OBPVC>.K_3?&W_"
M.>); :1X;L[K2/!WAF^FU#Q#?V&E:=I8!_3O_P $E_\ @W^\-_L:_LF_M?\
MPJ_;&\?:=^T9\:_^"@^FZGH/[4OBCPS?>(SX?C\)7NF^*;&#PWX1\3^)[73_
M !3K.N_VKXX\7>,M4^(^I:%X<U?4O$>K:6?[#A/A>RU'4 #\T? G_!$;_@X5
M_8H^'_Q _8Q_8$_X*2?L^6G[$WCC6/%LGAO4OB/9ZMX:^*_P]T;QBKOXF.DB
M'X(?$S5O >KZR+FYWS?#3Q_):/XADO?%^EP>"-<U>\OD /O&P_X-Y;GX'?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MP&)6$Q=#$--QIS]Y+?DG&4)VO9-J,FTF]6K:7/YB?V7?^#D*[_X)W? CX?\
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M &$U/_2*1W%![X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 ><7G]L#XN^'1%XMTBWT!_AQXS^V^!)=11=
M?U?6(_$_@+^R_%MCI+0-++I'ARREU?1]5U&*YB2WO?%.C6T\$[7-N]OD^;VT
M??CR^RG>G?WG)3A::7\L4W%M/>23OH<DO:?7Z5J]-4GA*_-AG/\ >SJ*MAN2
MO&G:[ITHN=.<U)6E5IQ:ES1<?1ZU.L* "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >;_& ZTOP
MR\:OX<\6:-X%UV/0[F32O%_B+4DT?0O#U[&T;PZEJNI26UY%:6,++_I$DMI<
MQ,C&.6&2-V1LJ_-[&IR5(TI<ONU)NT8OO)ZV7R^\Y,?[3ZGB'2KT\-45-N%>
MK-0ITI=)SFXR48KK>,ET:_F](K4ZPH * "@ H __U_[^* "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 >>V_PC^%-I\19OB_:?#'X>VOQ:N="O/"UQ\4;?P7X;@^(L_AC4;K3+Z_\
M.3>-H]-7Q++H5]?:+HUY>:0^IMI]S=:3IEQ/;O-8VCQ 'PU\1_\ @FGX9\6_
M'35/VA/AW^UU^WM^S[XQ\1>*](\7^+O"'PF_:?\ $U[\$_&%_I9TV.XL=8^"
M/Q6T[XE_#K3=)UFRTV/3]2M/!NB^$Y8[:XNCI-WIDTQE4 ]8_:W?_@H-8R^
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MX2C.$XJ49Q:E&49*\91DKIQ:=TT[-:J]T6Z904 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M'7JX:BME?]Q2I/2Z6U]&?I=7JGUH4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M$-^SW%!]10S+ 8>,XT<MQD(5-)P5*\):6UA*LXNZT;ZK1IG[Z?\ !)?X/_\
M!2_X>_M$>,=5_;*_X*B? #]MGX73?!+Q#I6@?"OX6>.++Q1XET#QW)XX^'%S
MI7Q!O[6'X=^$[@:1I7AVR\4>'+J^EU6ZQ?\ BO3HY+.9YUN;4/'S&K@)T8K"
MX"MA:GM8N52I!QBX<E2\$_:35W)QE;E6D>EK']/WP_\ ^0')_P!A"X_]$VU!
M]!PY_N$_^PFI_P"D4CN*#WPH * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H \RO'OO^%R^'$3Q?:VVF#X9>-'
MN/ 3W,ZWVM7Q\5> A9^+[>S,?V:6U\,6XOM&O+E93/!-XML8I(UCN8W;%W]O
M'WTE[&=Z=W>3YZ=II;-15XM[KG7<XY<W]H4OW\5#ZG7OAN9\U27ML-RUU&W*
MXTES4Y2O=.M%-6DF>FUL=@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M:\@+*)K;4;:WGB+ /&N10!V] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M4XNOA;X=PM[-RK-*I&4I*:5"2BI1E-Q]5K8[0H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /YW?^"AW_)T/BW_L ^#O_4=L:ZZ/P?-G^='TB?\ DZ6;_P#8!DW_
M *K:!]N?\$L_^29_$W_L>K+_ -,%I6=?>/H?N'T5?^29XH_['N'_ /5?2/U&
MK _J<* "@ H * /YE_\ @JE_P1%U3XP^*O&O[37[(ZVG_"P_$UW=^)_B+\%+
MRXM["'QUXHU/4OM.N^+?!&O:I?6NF:5XAU5[JZUC7O#^KS6VGZS?)>7VE:C:
MZI=KI6H?*9QD#KSJ8O!6]K-N=6@]/:3;O*=.3T4I7<I1D[2=W%QD^4_(N,_#
MV>.K8C-\C4?K5:3K8K+Y24%B:TYWJU\/5J-0A5FVZE6E4:A4ES2ISC.7LY_R
MC?$WX/?%CX*Z^/"OQ?\ AIX\^%_B-XFN(=%\?>%-<\)ZC=6BRM#]NL;;7+&R
MDO\ 3Y)$80ZA9_:+*X&'@G=&5F^/JT*U"7)7I5*,M^6I"4&UW7-:Z\UIVOHS
M\7QF!QN7U?8X["8G!U;75/$T*E"<HWMS1C4C%RBWM*/-%]),E^%OP8^+?QO\
M16WA/X/_  V\;?$KQ%<W=I9#3/!?AO5?$$UO-?+=26[ZC)I]M-;Z5:&"PU"[
MFO\ 4YK6QM;'3M0O[JYAL[&[G@*-"MB)*%"E4JR;2M3A*5K[7MHE9-W=DDFV
MTDV&#P&.S&JJ&!PF(Q=5RC'DP]*=5IRNUSN*:A&T92<IN,5&$I-J,9L_JT_X
M);?\$/=>^"OCK0OVAOVQ[7PIJ/C#PU]DU?X;_!G3;^S\6:?X5\2 2;/$?Q#U
M&&VG\-:GXA\/3B*[\,Z7X9U+Q%HEAJ2VGB!M>FU&QM+2R^PRC()4*D<3CE!S
MA:5*@FIJ$_YZKMR.4=X1A*44[2<VTHG[3P;X=U<OQ-/-,^5&5>CRU,)@(2C7
MC1K:VJXJ27L9U:3M*C"C.K3A/EJNK*<8QC_317U9^N!0 4 ?"/Q'_P""8'_!
M/+XL_%C3?CQXZ_8W_9_U+XV:7XVTKXCQ?%O3/AWHGA7XCW_CK1-6MM;T[Q/K
M_C/PG;Z'X@\3ZK'J=I;W$\WB2_U47RQ_9KX7-JSP, ;'[6?[*_Q?^/\ J7@C
MQ5\%OVX_VD/V._&7@*SURTL1\(].^#OC+X;^+GUN;39Q>?$SX8?%[X:^-]+\
M8W6CMI:1:$T.J:&EC;7VK0R)<_;B\0!TFH^'OVR?AY^RG'X>\"_$#X/_ +2/
M[8/AW2M*@L_B!\<- U7X#_"GXD:B/&-G-KEYXIT+X/Z;X]OO TW_  @4NIV.
MD#PQI6L6,OBJSTN[O;.UTJ\OX[4 S/V2_BO^V/\ $B/Q[IG[7_[(_A+]F36?
M"+^&(?">O_#_ /:,\._M >!_BV-437QXBU#0/LO@SP!XR\%1^&GTS16FT[QI
MX9@DOU\36Z:5?ZB=*U*1 #Q_X2_\%9/V+_BY\:]"_9NM?$?QB^&_Q\\4:YK/
MA[PU\+/CA^S)^T9\&=:\0ZEH-CJFJ:@FAZU\0?A?HO@K5D72M%U35(SI_BJX
M=M/LWNGB2)X6E /T1CUS19=8N?#L6L:7+X@L["WU2[T*/4+1]8M=,NYI;>TU
M&YTQ93>P6%U<6\\%O>2PK;S302Q1R,\;JH!J4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!
MY#^T!\;/!'[-GP,^+_[07Q)O?[/\!?!7X;>,_B?XMN%:-9VT/P5H%_K]]:V*
MR,HGU._BL38:59KNFO=2N;6S@CEFGCC8 _RHOAY^T_\ \%'_ (0ZU\"O^"_W
MCSXH?%36?@K\1/\ @I-\0/#?BGX8+XV\8R>$]1LDBT_X@^*/#.C:%=ZP?#2^
M!/&GAK6/B]\+/"]DNGV4/AN^^'5U':H-MD+( _T*_P#@M5\4HM6_X(J?MF?&
M+X1>-+V*P\1?LSV7COX?>//"&K7NE7=QHGB2\\+:OH/B#0=8T^:UOK9-1TC4
M+>ZM;FWFAE:WN1R S!0#P#_@UT\8^+O'G_!&#]FSQ/XY\4^(_&?B2^\8_M!1
M7OB'Q9KFI^(M<O([/X[_ ! M+2.ZU;5[J\O[A+6TAAMK9);AU@MXHX8@L:(B
M@']!] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MU+^DGX?_ /(#D_["%Q_Z)MJ#Z+AS_<)_]A-3_P!(I'<4'OA0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MG2-*@16&O:=IGBW2(X+P"ZCB /P8^*/QV_X*.^-?^".WAO\ X)*3_P#!OO\
MMD>%_ '@+P/X.BT?XVK\)?VDY==T?XD>$O%\7Q'\2?%\>&IOV<K33K6\\9>*
MKCQ=>Z_I)UY(H-%\8:WI*ZPRD7K 'W5^QK^W!_PU5_P:5?MS_!OQ+J_V_P")
MO[%?PIU7X'ZM#<3^;J-Q\+;[7-#\2?!36)(P2(-,M/#LNK_#71TQ&QB^&%PS
M(<B:< _<O_@U(_Y0B?LQ?]CI^T7_ .K_ /B+0!_1E0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ,EECACDFFD2*
M*)'EEEE=8XXHXU+/)([$*B(H+.[$*J@DD $T ><>"/C-\'_B9>WFF?#?XK_#
M7X@ZEIUJ+[4-/\$>.O"_BN]L;)IDMUO+RTT+5=0GMK5IY(X1<3)'"9G2,.78
M+0!Z50 4 % !0 4 % !0 4 % !0 4 >"_#?]J7]G#XQ?$WXL_!?X5?''X7_$
M+XL_ C4K?1_C'\._"'C/0]=\7?#?4[B6:W6R\5Z)87<U[I<T-];76EWHFBQI
M^LVEYHU^;;5;2YLH@#WJ@ H * "@#RCXZ/IT?PA^(+:MX0NO'^G?\(Y>+=>"
M['4-2TJ\\31N8T&D6NH:/#<:I:SW;LL<4MA!+<[\+$C,2*PQ-O85>:FZJY7>
MFFXN?]U.-VF_+\-6<69."P.*]I0EBH>R?-AXRG"59:?NU.FG.+D]$XIOLGL>
MKUN=H4 % !0 4 ?_U/[^* "@ H * "@ H * "@ H * &2?ZN3_<;_P!!--;K
MU0GL_1GY8_MS?LQ?"C]LG]D_XS_LW_'/Q=XD\!?"3XB^']-?QWXR\):WX;\-
MZ[X;T3P;XFT/Q])JMMKWC#0O$GAG2;6VN/"T#:K?:SHMY:0:1]O8FU<)>VZ/
MS#"5ZF&Q%*O1C&=2$GR1DI24G.+A;EBXR;][1)J[MV/XHOCQ_P $>?\ @W=_
M9^_9>^&/[9/B/]M/]O#QC^SQ\8?B'JOPO\ >//AEK/P>\90ZSXMT3_A,EU2U
M;3H/V9[/4;.VLYO 7B6WDN[RV@5I;6 QJ\-Y;RN'U%',LZK5ZF%CAL'"M2@J
MDX5(U(VB^6SO[=IW4T]&M]KIGZN_\&\'['G_  2.\-?$'XO_ +6__!-G]HO]
MIKXN>*-,\#ZE^SS\1_!?[0-YX!TZ[\+:)XR\1> _B+8Z^?"&@_"/P!XBB&LW
MOPYM+/PYXD;6+[P]?)9>+M,%I-JNFS-I8>?G.)S)PIX;'4:%.+FJT)T5/WG"
M,H-<SJU(NRJ>]&T9*\6]&N;^QGX?_P#(#D_["%Q_Z)MJ#V>'/]PG_P!A-3_T
MBD=Q0>^% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % 'E]\EO_PNGPLY\$WUU=CX7^/4C^(Z7&IC3="MV\5_
M#<S>"9[1+9M'DOO%<BP:[:7%S=Q:G%!X-O8[&VN+6;49;7)_QX_NVW[*I^]N
M[1]^G^[M\-Y_$FW?W':]V<<DO[0HOZO)R^IXE+%WGR4TZ^%OAW&WLW*LTJL6
MY<Z5"2BG%S9ZA6IV!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?SN_\%#O^3H?
M%O\ V ?!W_J.V-=='X/FS_.CZ1/_ "=+-_\ L R;_P!5M ^W/^"6?_),_B;_
M -CU9?\ I@M*SK[Q]#]P^BK_ ,DSQ1_V/</_ .J^D?J-6!_4X4 % !0 4 %
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M!?P?X_\ !FK1:C'/)J^I_%;X2Z'X+?QS'-IRRZ>UEKW@Y+D33?;AJS"*.S0
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M\!^+_"_C;0+@X@USPCK^E>)-'G. P$.IZ-=WEE*2I#?NYFX(/((:@#J* "@
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M&H^*?$$W_"0_$/Q)XL\57G]H:[JVH7WEW^N745K]H^S6*6UG%#;Q 'T90 4
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M-%W7ON4+R275KYV5V>I5L=H4 % !0 4 ?__5_OXH * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@GXU?LM>%?%%V\\0-K>1W^KZ9?3-+$#!<++O0&-P* />?^"]]I:R?\'!O_!
M.62VMWDG^*OPDAGD>&-GFAM?VI/"TUM%*[*6DCMY;BXE@1RR123RO&%:1RP
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M"-WX#OM,G\+7/AB.QBBLDT";27TI;2..W6T$*JE &1X1^ GP+^'_ ,(S\ /
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M_HFVH/N>'/\ <)_]A-3_ -(I'<4'OA0 4 % !0 4 % !0 4 % !0 4 % !0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MU/J@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MVJT[4[5\+_L[?\.]:ZJ)-J?[AVYH\W+ZE6QVA0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M&96!H L4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M[$H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#RZ^9?^%U>%T/C6YM7_P"%7>.V3X=*NIFSUU?^$L^'
M(E\:S,DJZ.MSX4(AT.V6>"?4WB\9W1M);6U2]2[Q?^\1_>-?N:G[KWK2]^G^
M\_EO#X5?WO?=M+G'+_D84O\ :))_4\1_LGO\M3]_A;XAZ^SYJ.E-73G:N[-1
M4E+U&MCL"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJ]K_ &9/KEE9PZJ\5]'I[7+Z?>K  ;WPS_;%_9L^+G[/&I_M7^#_ (GV%O\
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M=K7%_-$Q60C!Q9QVJK]TF7!=OU3+N#<JPD(RQ4'C\1O*55RC13ZJ%",K./\
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M_P!AC_LSO]F7_P!4KX)H ^Q* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H \OO5G_X73X:8>#1=6Y^%
M_CA6^(/E7Q.ASKXK^'I3P:)QNTU1XJC9];,3F*^?_A#@\?GVZ2_9\7?V\?<N
MO8S_ 'FONOGI^YV]_P"+>_N=;''*_P#:%+_9[KZGB/\ :K2_=OV^&_V>_P '
M[Y/VEM)?N+JZ3Y?4*V.P* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^=W_ (*'
M?\G0^+?^P#X._P#4=L:ZZ/P?-G^='TB?^3I9O_V 9-_ZK:!]N?\ !+/_ ))G
M\3?^QZLO_3!:5G7WCZ'[A]%7_DF>*/\ L>X?_P!5](_4:L#^IPH * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M7[GDGTA>+L!"G1S;!Y;GE.G!1=:<9X#&U+*I:4ZV&4L,YN4J?,U@ES0IM/\
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M2:E5G>4ZU::5E*M5G*4YM7ERQNH0YI*G"$6XR]5KYL]0* "@ H * "@ H *
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M2BD?3\/8F7-5PDG>/+[:FG]EIJ-1+7KS1E;RD[:MGUK7YJ?4A0 4 % !0 4
M% !0 4 % !0 4 % 'E?QPD,7PE\>N/&5Q\/,>'[H'QQ:_P!J_:?"ZL\:OK$/
M]B,FJF2T5BZBRDBF)X\V)"\B8XG^!5_>.E[O\1<UX?WO=M+3R?W'%F+M@<2_
MK#PO[I_[1'GO1U7[Q>S]^\?[MGYK<]4K8[0H * "@ H _]/^_B@ H * "@ H
M * "@ H * "@ H * /YO_P#@["_Y0F?M%?\ 90OV>/\ U=O@J@#]?/\ @G?_
M ,H__P!AC_LSO]F7_P!4KX)H ^Q* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \OOFMO\ A=/A9#XV
MOK6\/PO\>M'\.$MM3.FZ[;+XK^&XF\;3WB7*Z/'?>%)6@T*TMKFTEU.:W\97
MLMC<V]K!J,5UD_X\?WC3]E4_=6=I>_3_ 'E_AO#X4FK^^[6LSCDU_:%%?6)*
M7U/$M82T^2HE7PM\0Y7]FI46U2BG'G:KR<6HJ:/4*U.P* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@#^=W_ (*'?\G0^+?^P#X._P#4=L:ZZ/P?-G^='TB?^3I9
MO_V 9-_ZK:!]N?\ !+/_ ))G\3?^QZLO_3!:5G7WCZ'[A]%7_DF>*/\ L>X?
M_P!5](_4:L#^IPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * .6\9^!O!7Q'\.:AX.^(?@_PMX\\(ZM]G_M7PMXS\
M/Z3XH\.:G]DN8KVU_M#0]<M+[3+S[->6]O=V_P!HM9?)N8(IX]LL:.H!P'PC
M_9O_ &=_V?YO%%Q\!_@+\%_@E/XXETJ?QK/\(_A;X'^&\WC"?0EU%=#F\42^
M#="T5_$$NC+J^K+I4FK->/IRZIJ(M&A%[<"4 ^2O '_!(G_@FO\ "CXT>'_V
MA_A?^R!\*/AU\9?"_B*X\6:+XX\#VVN^%;VW\0W:WBW.I7.G:)K=EH>IO-]O
MNWD@U32KRU:6=I?(67;(H!K?M5_\$UO@7^U[\3=#^,'CWXB_M5?#WQWX>\$:
M;\/]-U']GW]JGXV? C3O[ TG7O$GB.SDN_#_ ,./%NBZ!>ZT-2\5ZJ)]?NM-
MEU>YLET[3[BZEL]+T^&U /8?BA^RY_PL;]GCPI^SSH_[17[4WPC3PAI7@71[
M#XV_"_XM^1^T/JD'@/3;72[>[\5_%#QUX?\ '=QXOU7Q1':I=^.M7\2Z7JFH
M^+-2ENM1U.Y>[N9Y7 (/V5OV:_&O[->C>+]"\6_M;?M*_M86_B'5--O]"U;]
MIG4OA9K?B?P5:V-K<6]SI6CZS\,?A;\+8M0L]4DFBN[V37-.U&Z6XMHOLDUM
M"TL3@'R_J_AGQCX/U"?P]\0/&TGQ'\8V!']O>.9O#VE>$Y_%%W<#[2NKS>&]
M" T;1Y+JWFA<V6E@6:##0I&K>6G[MP[5C6R3+IP245AXT[1ORITVZ<DKRG)\
MLHR@W)W;BV]T?GV:0<,?B5)MMU'+7>TE=7LHK5--66UM]Y9E>T< 4 % 'JOP
M13Q8?BEX3?P]IFG7VC)-K0\=WE]JTNFW&B^%W\+Z[]AU#1K1-(U)-?U2?QJO
MA'29-'FO?#Z1:-J6L:^NK3RZ$FA:S\?QO5C3R7D:BY5\70A"[DI1<>>K*<4M
M)/EI\CY[Q2FW\:@X^WD$'+'\R;2IT:DG9)IWY8)-O;67,K:WC;9R'_M&_'?_
M (*+> /B9=^'?V:_^"?/PH_:+^%\6D:1=6?Q+\7_ +<^E? 36;S6+J!GUC27
M^'MW^SG\2YK6WTF<)!!JA\42C5%8S+96878WX^?:GLO[07Q5_::^&_PC\(^+
MO@7^R?!^TA\6=6UGP]8>+O@]:?'KP/\ ":U\(:7J'AS6-2\0Z[;_ !'\>:+_
M &+XEM_#OB*RTKPU#8VND6&HZW'K:ZW!;VEKI]W;J 0_L]?%K]IWXC_"OQIX
MM^/?[(__  S?\3M$U?6[/P?\(_\ A??P^^,'_"<:58^'-+U/1M9_X3WP9IMC
MX>\,_P!N^(+O4O#/]GZI;S7.F?V3_;-VSV-];H@!XM^SQ^T]^W5\2?BCI'@O
MX]?\$Q_&/[-?@&^L-9N-2^,4W[6/[-/Q?\.Z)>V&FSW>F:=<>$_ WB*'Q_>M
MKM]%#I5M=:?X<N+>QFN4NM2-K9Q33* 1?M _M6?MO?"_XJ:_X+^#'_!+3XN_
MM,_#S3+?19=&^,GA3]J']C[X::'XEGU#1;'4-5M;3P?\6?BOX7\=::^@:I<W
M>@W,NK:+:PW]SITM]IK7&FW%I<2@'N'[2'QG_:%^$WP[\(>*O@9^QSXW_:K\
M;:[K-A8>)OA?X/\ C#\#/A9JW@?2[G0[_4;S7=0\3_&3QIX2\(ZW;Z=JUM:>
M'I;'P_JM_J-S<ZC%J%K;RZ9;75Q  'P,^,_[0OQ'^"_C+X@?%S]CGQQ^SO\
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M%?\ 90OV>/\ U=O@J@#]?/\ @G?_ ,H__P!AC_LSO]F7_P!4KX)H ^Q* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H \PO5N_\ A<_AMU\'PW-B?AAXV67Q^T%T;C1+L>*O !M_!\5U
MN-C'#XHA:YUJ>#:EU*_A"WDW20PXBQ=_;Q]RZ]C/]YK[KYZ?N=O>UEW]SR..
M7-_:%+]PG'ZG7OBK2O3E[?#6H*7PI5E>HU;F?L$]4CT^MCL"@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H _G=_X*'?\G0^+?^P#X._]1VQKKH_!\V?YT?2)_P"3
MI9O_ -@&3?\ JMH'VY_P2S_Y)G\3?^QZLO\ TP6E9U]X^A^X?15_Y)GBC_L>
MX?\ ]5](_4:L#^IPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /FKX\_#2[UU(_%^@V[7&H6-M
MY&L6,2%I[NRART%W;HI)EGLPTB31*IDFMC&8\&UV3_>\'9]2PCEE>,FH4:U3
MGPM632A2JRTG2G)_#"JTG"3:4:G,G?VJE#YW.\NG72Q="/-4A'EK02]Z<%JI
MQ764-4TM7&UOAY9?&SH\;O'(C1R(S(Z.I5T=20R.K ,K*00RD @@@@8Q7ZDF
MI)2BTTTFFG=-/5--7336J:?WW/DFFFTTTT[-/=/L]M5Z?<-IB)8()KF:&VMH
M9;BXN)8X((((WEFGFE<)%##$@9Y)9'94CC16=W8*H)(%3.<:<93G*,(0BYSG
M-J,81BKRE*3LHQBDVVW9)7=M1QBY-1BG*4FHQC%-N3;LDDM6V]$EJWHC[Y^#
M?P\?P/H4MSJ,977];\B:_1Q$6L8(E;[/IZM&\JL8VDEEG=),2.Z*R#R4K\:X
MISM9OC(TZ#O@\)SPHR3E:M.3]^NU)0LFHQC!..BBY)KGY3[G*,!]3H.516KU
MK.:=O<BOAIJUUHVW)IJ[:37NH]BKY8]8* "@ H * "@ H * "@ H * "@ H
M\L^-TL4/PF\?2S^-;WX<PIX=O#+XZTZ#5;F^\+)\@;6+6#0YK?5Y9K4'<B6$
M\-P2?ED09:L<1;V%2]1T5RO][%-N']Y*-F[>3^Z[.+,6E@L2WB)81>R=\3!3
ME*C_ 'XJFU-M?W7?U/4ZV.T* "@ H * /__5_OXH * "@ H * "@ H * "@
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MGR5(JOA;XASO[-2HMJG&,HN;5>3BXQC-2]5K8[0H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * /YW?\ @H=_R=#XM_[ /@[_ -1VQKKH_!\V?YT?2)_Y.EF__8!D
MW_JMH'VY_P $L_\ DF?Q-_['JR_],%I6=?>/H?N'T5?^29XH_P"Q[A__ %7T
MC]1JP/ZG"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^M/V;:P]IR]M9I\EH>\[]E?S35T>JUL=H4 % !0 4 ?_UO[^* "@ H * "@
MH * "@ H * "@ H _F__ .#L+_E"9^T5_P!E"_9X_P#5V^"J /U\_P""=_\
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M6A5A"%)<OU>AA(5(NC#EDI1C[TG-<ME&7M4'A+XIQCP;Y_Q=AN#HUU)+XO\
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M:\M^?W_:<U_L\MM33?PO\2CXIDU5?BG&GA=K!K>+PH/ FBF2.^.@?V>-0/B
MWYO) NNY\1?9#:K$1C2"YLP96KDJ\]_;>Y:W)[.._+:_-?\ F]ZU_*]DV7['
M%^V<_KJ]CRV]A]6IW4O9<O/[;GN_WO[WEY$O^7?PZRS/^$-^+O\ PBO]D_\
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M (7/!_PE/_"0_P!H_P#"6_\ "M=!V?V!_9OV;_A'?^$?_M;[%O\ [1_XF?\
M;/VG[5C_ $'R/)_>5/)6Y+>W7/S7Y_9+X;6Y>7;?7F^1'U?'>PY/[07MO:\_
MM_J=.WLN2WLO9>UY;\_O^TYK_9Y;:FF_A?XDMXIEU5/BG''X7:P:WB\*#P+H
MK217QT#^SUU ^(&OC>2A==SXA^Q_9$B/&D%_L8,C5R5>>_MO<M;D]G'?EM?F
MO_-[UK^5[)LOV.+]LY_75['ELJ'U:G=2]ER\_MN>[_>?O>7D2_Y=_#=RS/\
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MOY-MQ&B*<E:\_P!]H[\B]G'W+RNM=Y65X^=[O9![#&\U=_7ERU.;V$?JE/\
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M ,H__P!AC_LSO]F7_P!4KX)H ^Q* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2X])UC2)I;NQL(KXPVUK9XMEN=1MY!)+'>0W-O#J$7^B31134 ?:U '\W_\
MP=A?\H3/VBO^RA?L\?\ J[?!5 'Z^?\ !.__ )1__L,?]F=_LR_^J5\$T ?8
ME !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MVB2PJST&6(PN(PL^3$4ITI/5<RTDN\9)N,ET;B]-G:Q].T& 4 % 'MG@+_D
MC_K\N?\ VG0?=\._\B[_ +CU?R@=I0>Z% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MO^AR_:!_\,3K7_RYH /^(O/_ ((W?]#E^T#_ .&)UK_Y<T '_$7G_P $;O\
MH<OV@?\ PQ.M?_+F@ _XB\_^"-W_ $.7[0/_ (8G6O\ Y<T '_$7G_P1N_Z'
M+]H'_P ,3K7_ ,N: #_B+S_X(W?]#E^T#_X8G6O_ )<T '_$7G_P1N_Z'+]H
M'_PQ.M?_ "YH /\ B+S_ ."-W_0Y?M _^&)UK_Y<T '_ !%Y_P#!&[_H<OV@
M?_#$ZU_\N: #_B+S_P""-W_0Y?M _P#AB=:_^7- !_Q%Y_\ !&[_ *'+]H'_
M ,,3K7_RYH /^(O/_@C=_P!#E^T#_P"&)UK_ .7- !_Q%Y_\$;O^AR_:!_\
M#$ZU_P#+F@ _XB\_^"-W_0Y?M _^&)UK_P"7- !_Q%Y_\$;O^AR_:!_\,3K7
M_P N: #_ (B\_P#@C=_T.7[0/_AB=:_^7- !_P 1>?\ P1N_Z'+]H'_PQ.M?
M_+F@ _XB\_\ @C=_T.7[0/\ X8G6O_ES0 ?\1>?_  1N_P"AR_:!_P##$ZU_
M\N: #_B+S_X(W?\ 0Y?M _\ AB=:_P#ES0 ?\1>?_!&[_H<OV@?_  Q.M?\
MRYH /^(O/_@C=_T.7[0/_AB=:_\ ES0 ?\1>?_!&[_H<OV@?_#$ZU_\ +F@
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MT '_ !%Y_P#!&[_H<OV@?_#$ZU_\N: #_B+S_P""-W_0Y?M _P#AB=:_^7-
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MO^AR_:!_\,3K7_RYH /^(O/_ ((W?]#E^T#_ .&)UK_Y<T '_$7G_P $;O\
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MF^'>@^!I?CO%K/BK7WN+:*71_@9\&GU*/X:OI%M+-'._B)+9O'<#(FE&9FU
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MT&W+5R_+L8LRQ<<2Z].4,/#VDZK<G"2M"51*3O*<6[+EIJ//=:\OZ2?LF?\
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MT '_ !%Y_P#!&[_H<OV@?_#$ZU_\N: #_B+S_P""-W_0Y?M _P#AB=:_^7-
M!_Q%Y_\ !&[_ *'+]H'_ ,,3K7_RYH /^(O/_@C=_P!#E^T#_P"&)UK_ .7-
M !_Q%Y_\$;O^AR_:!_\ #$ZU_P#+F@ _XB\_^"-W_0Y?M _^&)UK_P"7- !_
MQ%Y_\$;O^AR_:!_\,3K7_P N: #_ (B\_P#@C=_T.7[0/_AB=:_^7- !_P 1
M>?\ P1N_Z'+]H'_PQ.M?_+F@ _XB\_\ @C=_T.7[0/\ X8G6O_ES0 ?\1>?_
M  1N_P"AR_:!_P##$ZU_\N: #_B+S_X(W?\ 0Y?M _\ AB=:_P#ES0 ?\1>?
M_!&[_H<OV@?_  Q.M?\ RYH /^(O/_@C=_T.7[0/_AB=:_\ ES0 ?\1>?_!&
M[_H<OV@?_#$ZU_\ +F@ _P"(O/\ X(W?]#E^T#_X8G6O_ES0 ?\ $7G_ ,$;
MO^AR_:!_\,3K7_RYH /^(O/_ ((W?]#E^T#_ .&)UK_Y<T '_$7G_P $;O\
MH<OV@?\ PQ.M?_+F@ _XB\_^"-W_ $.7[0/_ (8G6O\ Y<T '_$7G_P1N_Z'
M+]H'_P ,3K7_ ,N: #_B+S_X(W?]#E^T#_X8G6O_ )<T '_$7G_P1N_Z'+]H
M'_PQ.M?_ "YH /\ B+S_ ."-W_0Y?M _^&)UK_Y<T '_ !%Y_P#!&[_H<OV@
M?_#$ZU_\N: #_B+S_P""-W_0Y?M _P#AB=:_^7- !_Q%Y_\ !&[_ *'+]H'_
M ,,3K7_RYH /^(O/_@C=_P!#E^T#_P"&)UK_ .7- !_Q%Y_\$;O^AR_:!_\
M#$ZU_P#+F@ _XB\_^"-W_0Y?M _^&)UK_P"7- !_Q%Y_\$;O^AR_:!_\,3K7
M_P N: #_ (B\_P#@C=_T.7[0/_AB=:_^7- !_P 1>?\ P1N_Z'+]H'_PQ.M?
M_+F@ _XB\_\ @C=_T.7[0/\ X8G6O_ES0 ?\1>?_  1N_P"AR_:!_P##$ZU_
M\N: #_B+S_X(W?\ 0Y?M _\ AB=:_P#ES0 ?\1>?_!&[_H<OV@?_  Q.M?\
MRYH /^(O/_@C=_T.7[0/_AB=:_\ ES0 ?\1>?_!&[_H<OV@?_#$ZU_\ +F@
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MT '_ !%Y_P#!&[_H<OV@?_#$ZU_\N: #_B+S_P""-W_0Y?M _P#AB=:_^7-
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M;_\ S+T '_#)/[*?_1L?[/?_ (9CX;__ #+T '_#)/[*?_1L?[/?_AF/AO\
M_,O0 ?\ #)/[*?\ T;'^SW_X9CX;_P#S+T '_#)/[*?_ $;'^SW_ .&8^&__
M ,R] !_PR3^RG_T;'^SW_P"&8^&__P R] !_PR3^RG_T;'^SW_X9CX;_ /S+
MT '_  R3^RG_ -&Q_L]_^&8^&_\ \R] !_PR3^RG_P!&Q_L]_P#AF/AO_P#,
MO0 ?\,D_LI_]&Q_L]_\ AF/AO_\ ,O0 ?\,D_LI_]&Q_L]_^&8^&_P#\R] !
M_P ,D_LI_P#1L?[/?_AF/AO_ /,O0 ?\,D_LI_\ 1L?[/?\ X9CX;_\ S+T
M'_#)/[*?_1L?[/?_ (9CX;__ #+T '_#)/[*?_1L?[/?_AF/AO\ _,O0 ?\
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M_1L?[/?_ (9CX;__ #+T '_#)/[*?_1L?[/?_AF/AO\ _,O0 ?\ #)/[*?\
MT;'^SW_X9CX;_P#S+T '_#)/[*?_ $;'^SW_ .&8^&__ ,R] !_PR3^RG_T;
M'^SW_P"&8^&__P R] !_PR3^RG_T;'^SW_X9CX;_ /S+T '_  R3^RG_ -&Q
M_L]_^&8^&_\ \R] !_PR3^RG_P!&Q_L]_P#AF/AO_P#,O0 ?\,D_LI_]&Q_L
M]_\ AF/AO_\ ,O0 ?\,D_LI_]&Q_L]_^&8^&_P#\R] !_P ,D_LI_P#1L?[/
M?_AF/AO_ /,O0 ?\,D_LI_\ 1L?[/?\ X9CX;_\ S+T '_#)/[*?_1L?[/?_
M (9CX;__ #+T '_#)/[*?_1L?[/?_AF/AO\ _,O0 ?\ #)/[*?\ T;'^SW_X
M9CX;_P#S+T '_#)/[*?_ $;'^SW_ .&8^&__ ,R] !_PR3^RG_T;'^SW_P"&
M8^&__P R] !_PR3^RG_T;'^SW_X9CX;_ /S+T '_  R3^RG_ -&Q_L]_^&8^
M&_\ \R] !_PR3^RG_P!&Q_L]_P#AF/AO_P#,O0 ?\,D_LI_]&Q_L]_\ AF/A
MO_\ ,O0 ?\,D_LI_]&Q_L]_^&8^&_P#\R] !_P ,D_LI_P#1L?[/?_AF/AO_
M /,O0 ?\,D_LI_\ 1L?[/?\ X9CX;_\ S+T '_#)/[*?_1L?[/?_ (9CX;__
M #+T '_#)/[*?_1L?[/?_AF/AO\ _,O0 ?\ #)/[*?\ T;'^SW_X9CX;_P#S
M+T '_#)/[*?_ $;'^SW_ .&8^&__ ,R] !_PR3^RG_T;'^SW_P"&8^&__P R
M] !_PR3^RG_T;'^SW_X9CX;_ /S+T '_  R3^RG_ -&Q_L]_^&8^&_\ \R]
M!_PR3^RG_P!&Q_L]_P#AF/AO_P#,O0 ?\,D_LI_]&Q_L]_\ AF/AO_\ ,O0
M?\,D_LI_]&Q_L]_^&8^&_P#\R] !_P ,D_LI_P#1L?[/?_AF/AO_ /,O0 ?\
M,D_LI_\ 1L?[/?\ X9CX;_\ S+T '_#)/[*?_1L?[/?_ (9CX;__ #+T '_#
M)/[*?_1L?[/?_AF/AO\ _,O0 ?\ #)/[*?\ T;'^SW_X9CX;_P#S+T '_#)/
M[*?_ $;'^SW_ .&8^&__ ,R] !_PR3^RG_T;'^SW_P"&8^&__P R] !_PR3^
MRG_T;'^SW_X9CX;_ /S+T '_  R3^RG_ -&Q_L]_^&8^&_\ \R] !_PR3^RG
M_P!&Q_L]_P#AF/AO_P#,O0 ?\,D_LI_]&Q_L]_\ AF/AO_\ ,O0 ?\,D_LI_
M]&Q_L]_^&8^&_P#\R] !_P ,D_LI_P#1L?[/?_AF/AO_ /,O0 ?\,D_LI_\
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MI1J>QJ*G"I3DHJ<J:ITX3]U2<>92ASP7/9N,>9QNU']</V$O@K^TQX*_8D\
M_L[?M^:Q\)OBW\4?#'@O4OA)XQ\4?#GQ#XO\8>%?BA\-X+!_#^@7GBJY\<^!
MO .N/XIU#PA,F@>-%ETO4(M;O;*;Q&=6DN=>NM/TT/.Q=6A/%3K8-5*5.4U4
MC&:C"5.=[RY>251**E[T+/W4[6]U'\XO_!.;_@VB^/G[)_\ P4+^'?QX^-GQ
MD^#WQ)_9/_9R\=_%7Q]^SS\/M%\5_$;6_'\.O:O<36OPOU;Q-X8\0_#/P[X-
M\-:GIL:Z'XW\42^&O&>M*GC?PIHUO9G6+"6?44#V\=GM'$X*=&E2JT\17C3A
M6FXP4.5:U%&4:DI23UA'FC'W)-NS5C]7/^"QG_!,CX\_\%"?BA_P3P\;?!CQ
M;\(O#.E?LD_'S4/BG\1[?XGZ]XRT74-:\/W7B'X3ZM'9^"8O"G@'QK;:EK(M
MO FKH]OKUWX;L1/<::HU!DFN9;0//RS'T<%3QL*L:DGB:*IP=.,6HR4:JO/F
MG!I>^MF]GM9'"_\ !2[_ ((U_%;X]?M1>"/^"BG_  3V_:'TW]DW]N_P5I6G
M:!K&O^(=.N;KX<?%C2=+TYO#^GR^-9-.T;Q-=6NIVOA1T\)ZF-1\'>.?#_BO
MPGINB>'M5\/6RZ7#J5!6!S.G1H3P6-HO$8.;NE%VJ4VWS/D]Z-TY+F5I1<97
M:EK8\;^ _P#P3>_X+6?&O]JSX*_M ?\ !2?_ (*'>&M"^'7[/>N-KWA3X-_L
M:ZMXA\$I\0;K?:#5-%\=WFB^ ?A1I@\*>+/[-LXO$DFL_P#"?:QJ/ANXUGPM
MH]MX)BU:2]MPUK8[*Z>'JT<#@I.=>/+*KB4I^S[.%ZE5\T;OELH)2Y9/GMRG
MAWC;_@D?_P %I/A)_P %&_VSOVV_V"/VDOV)/A=IG[4_B6]86WQ4NO'_ (C\
M3IX+DO=)U6TT[6=$N_V;/'7AS2=5CU/2TFEDT76=0!B C%\R.Z,&T<QRNI@L
M+A<70Q51X>*_AJ"CS6:;3]O3;5GUC]^Y^T?_  3=^'G_  5=\!0_&,?\%/\
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MU2I5I+EC7HM*4^[E[]-INVJO*#D^91C=<OU)_P $TO\ @D7^U)\)/VQ/'O\
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M^&8^&_\ \R] !_PR3^RG_P!&Q_L]_P#AF/AO_P#,O0 ?\,D_LI_]&Q_L]_\
MAF/AO_\ ,O0 ?\,D_LI_]&Q_L]_^&8^&_P#\R] !_P ,D_LI_P#1L?[/?_AF
M/AO_ /,O0 ?\,D_LI_\ 1L?[/?\ X9CX;_\ S+T '_#)/[*?_1L?[/?_ (9C
MX;__ #+T '_#)/[*?_1L?[/?_AF/AO\ _,O0 ?\ #)/[*?\ T;'^SW_X9CX;
M_P#S+T '_#)/[*?_ $;'^SW_ .&8^&__ ,R] !_PR3^RG_T;'^SW_P"&8^&_
M_P R] !_PR3^RG_T;'^SW_X9CX;_ /S+T '_  R3^RG_ -&Q_L]_^&8^&_\
M\R] !_PR3^RG_P!&Q_L]_P#AF/AO_P#,O0 ?\,D_LI_]&Q_L]_\ AF/AO_\
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M;_\ S+T '_#)/[*?_1L?[/?_ (9CX;__ #+T '_#)/[*?_1L?[/?_AF/AO\
M_,O0 ?\ #)/[*?\ T;'^SW_X9CX;_P#S+T '_#)/[*?_ $;'^SW_ .&8^&__
M ,R] !_PR3^RG_T;'^SW_P"&8^&__P R] !_PR3^RG_T;'^SW_X9CX;_ /S+
MT '_  R3^RG_ -&Q_L]_^&8^&_\ \R] !_PR3^RG_P!&Q_L]_P#AF/AO_P#,
MO0 ?\,D_LI_]&Q_L]_\ AF/AO_\ ,O0 ?\,D_LI_]&Q_L]_^&8^&_P#\R] !
M_P ,D_LI_P#1L?[/?_AF/AO_ /,O0 ?\,D_LI_\ 1L?[/?\ X9CX;_\ S+T
M'_#)/[*?_1L?[/?_ (9CX;__ #+T '_#)/[*?_1L?[/?_AF/AO\ _,O0 ?\
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M % !0!__T_[^* "@ H * "@ H * "@ H * "@ H * /)/%OQW^$?@763X?\
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MBFAD1@\<D;LCJ0RD@T 6* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M8'_"$^'?^?*3_P "[G_XY0']@Y9_T#R_\'5O_E@?\(3X=_Y\I/\ P+N?_CE
M?V#EG_0/+_P=6_\ E@?\(3X=_P"?*3_P+N?_ (Y0']@Y9_T#R_\ !U;_ .6!
M_P (3X=_Y\I/_ NY_P#CE ?V#EG_ $#R_P#!U;_Y8'_"$^'?^?*3_P "[G_X
MY0']@Y9_T#R_\'5O_E@?\(3X=_Y\I/\ P+N?_CE ?V#EG_0/+_P=6_\ E@?\
M(3X=_P"?*3_P+N?_ (Y0']@Y9_T#R_\ !U;_ .6!_P (3X=_Y\I/_ NY_P#C
ME ?V#EG_ $#R_P#!U;_Y8'_"$^'?^?*3_P "[G_XY0']@Y9_T#R_\'5O_E@?
M\(3X=_Y\I/\ P+N?_CE ?V#EG_0/+_P=6_\ E@?\(3X=_P"?*3_P+N?_ (Y0
M']@Y9_T#R_\ !U;_ .6!_P (3X=_Y\I/_ NY_P#CE ?V#EG_ $#R_P#!U;_Y
M8'_"$^'?^?*3_P "[G_XY0']@Y9_T#R_\'5O_EAO:=IMII5O]ELHVB@\QI-C
M2/(=SXW'<Y+<[>F>.<8H/0PV%HX2G[&A%PI\SE9RE+5[N\FWT[_=<O4'0% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MV1TW0M3T6RETS33%%!_9MM'$+==.\J#,""Q:%K0"$^3B$&+*%* .SH * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@#^=W_ (*'?\G0^+?^P#X._P#4=L:ZZ/P?-G^='TB?^3I9
MO_V 9-_ZK:!]N?\ !+/_ ))G\3?^QZLO_3!:5G7WCZ'[A]%7_DF>*/\ L>X?
M_P!5](_4:L#^IPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M%H+>:](2X7R[0S?;8[G3S=^4MA#:7]PR@'W+0 4 % !0 4 ?_]7^_B@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 ?SN_P#!0[_DZ'Q;_P!@'P=_ZCMC771^#YL_SH^D3_R=+-_^P#)O_5;0
M/MS_ ()9_P#),_B;_P!CU9?^F"TK.OO'T/W#Z*O_ "3/%'_8]P__ *KZ1^HU
M8']3A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 9++%!%)--(D,,*/+
M++*ZQQ111J7DDDD8A41%!9W8A54$D@ F@#YNU'XI2>)O'GAK0M"E>'P]#X@T
M\3SC=')K,L=RA#N#\Z6$;J&@@8(TS!;BX 80Q0 'TI0 4 % !0 4 % !0 4
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M%XCZ[B5B9^UA25&/))4:*C'DBM+2N];[*/M=2?;A0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <CX]=XO!?B>2-
MVCDCT6^>.1&*.CI"S*Z,N&5E8!E93D$9&"* /.?A9\4T\0)#X?\ $$RQZY&H
M2SO'(1-711PCD\+J*J/F48%V!YD>)0Z, >Z4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_]?^_B@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MO^TQH&[7D_X63\+I'T?2XYO#_EZ-9:J#IU[XETJ30?%OA*]A\12:C?:KH^C
M'W30 4 % '\_O[=7_!P[^SA^PE^U]XA_8J\1_LP?MD?'7XO>'/!OA7QU=C]G
MOX>>!/'6FW&A^*M'@UJWEM+.^^)>@>)W.FVUS#%JLTOAZ*SMIW4)=3(R.P!]
M,?\ !-W_ (*X>!?^"DWBOXG^$_"/[*7[8_[.D_PO\/:!XAO=4_:?^%6C_#O1
M_$T7B#4K[38M/\*76F>,/$SZEJ5@]BUQJ-O+#:K!:SP2++(7** ?K50 4 %
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M* ?%?_!*3_@L#^S-_P %>OAW\5?'O[/7A_XE^![KX-^,](\(^-? _P 6]/\
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MA\(_VW_V8?CK^T-^T'^RK\+/B4_B?X\_LL2>'(OCMX&/@SQ_HB^"'\60R3Z
M%\3^(?"VD^#_ !-]NBB=B?"&OZ\+7&V\,#$"@#ZOH * "@ H * "@ H * "@
M H * "@ H * /ES]LK]LCX _L$_L]^-_VF_VE?%[>#OA=X&33X+J>SL9M8\0
M:_KNM7D>G:!X4\)Z#:D76N>)-=OY4@L;*)HK>W@2[U;5KS3=#TW4]2L@#\*_
M@_\ \'5'[$_C_P")/PP\"_$O]F+]O3]G/P]\<?$6B^'?@]\5/BO\!+&Y\">,
MKCQ)-%9^'6@7P)XR\7>*;]]<U&>WL=-3P3X<\<6[O<1SSWEO:B::  _IWH *
M "@ H ^%OV&_VO?B9^UQIOQ\OOB5^Q_\</V19?@Y\?/&?P=\+V7QKM'M)_B]
MX9\+BU-A\4_!_G:-H9F\/:R;AXA)I:>(?#(GB\O0?&WB=4O7L@#[IH * "@#
M^;_]IO\ X.7/V9_V:OVM?CC^QN/V0OVZOC?\4/@#J]EI/C6^^ _PN^'_ ([T
M!UOM&T36(=4L4_X6GIWB&+2MFO65DUWJV@Z6/M^^!%<&*24 _1/_ ()N?\%,
MO!__  4G\,_%+Q-X0_9O_:E_9TA^%>N^&]"O=-_:?^'.E_#O5?%$OB6PU/4(
M;[PE;:7XG\3KJ>GZ<NEO!JD\TMHUM<W-K&D<HE9T /TMH * "@ H \)_:6_:
M8^!O['WP4\<?M#_M'?$+1_AA\(?AY8P7WB?Q9K"7MRD+7MY;Z;I>F:9I>EVM
M]K.NZ[K6J7=II>BZ%HNGW^K:KJ%S!:65I+*X% '\YFE_\'<7[!LVH:1XC\3?
MLP?M_>!?V>/$&MVWA_1_VG/$OP)\-O\ "V2\DOOL=UJ-S)HGQ'U?4YM%M%'V
MK9X=@\1^+9HLPIX06\'V9P#^FGX4_%7X<_'+X;>"/C!\(O&.B?$#X9?$?PWI
M?B[P1XS\.78O=%\1>'M8MDNK#4+*;:DB;XV\NXM+F*"]L+J.>QO[>WO;:>"(
M ] H _/+]D?_ (*1?![]L?\ :7_;J_9;^'O@SXE>'/&_[ ?Q \&_#KXJ:YXS
ML/"]KX5\6:OXVO/B-9:;>?#ZYT3Q5KFKWNFVTGPSUEKY_$>C^&KE$O=,^SVM
MRTEV+0 _0V@ H * /A?5?B-XX@U34H8O$VI)%#?WD4:+(F$CCN)%11^[Z*H
M'L* *'_"RO'G_0T:G_W\C_\ C= !_P +*\>?]#1J?_?R/_XW0 ?\+*\>?]#1
MJ?\ W\C_ /C= %>[\?\ C._M;BRO/$-_<VEW#);W$$K1M'+#*I22-AY?1E)'
M&".H((!H Y!'>)TDC=HY(V5XY$8HZ.AW*Z,N&5E8!E93D$9&"* /KKX6?%-/
M$"0^'_$$RQZY&H2SO'(1-711PCD\+J*J/F48%V!YD>)0Z, >Z4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__]#^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#S+XK>'=?\ $?AF2UT&\D1X)#<7>EIA/[8@0!EMQ*,-YD++YL5N2(;F
M3 D!D2!D /AYT>)WCD1HY(V9)(W4HZ.AVLCJV&5E8%65AD$8."* &T % !0
M4 % 'N7P _Y'+4_^Q9O/_3KHU 'U]0 4 ?FM_P %>/V5/@C^VE_P3Y^/O[/G
M[07QGT3]G7X>>+;+P=>K\<O$NI:%I?A[X:>,?#WCWPSK7@'7-=F\3:KH>AW>
MBWOC&TT;P]JVDWNM:/+K6FZU=:5IFL:1K%YIVJ6@!_*Y\6_B]_P7G_X(*_ 7
MX8W_ .U+)^QO_P %%O\ @G!\)];^$WPZ\/&ZMM&L_%WA/PIH%WIEO\)--TB\
MO/#G@/Q=8^*='/A[2)O"GB/4M!^.MIX8U"QT^]FU2X@L;6]M0"]_P4L_X*!_
M%?\ ;6_X*@_"7]DBPL_^"DTG[%EC^QQ\,_VF(O@=_P $VDT?P[^TI\;_ !!\
M8_ WASX@:;KGCG4=6\4>%I6^'/A+1?&VEZ)KNCI<ZU%I6M>&;X6FB17^LW'B
M7P\ 7_AK\9/^"D'P@_X)Q_\ !;'X5_$WP[_P4=^'?[/'PP^ D_Q._8)^.?[<
M.FZKX-_:G\(6.H3BQ\8?#C7/BIX<UK44UO4O#U[<:7=^$KK1_%!GL-)L]2O+
M*UT.QU2/P[H(!M^%?^"='[9/Q9_X(1:G^VSHO_!2+]NSXI_M=^,OV/\ X3_'
MKX5^'H_C+XK\*>$/ &@_"JR7QM<_#KP3H_A;5H?$NN>*O%/PQ'B/PMKGB#5_
M$MQ<?$;QU-H_BW7=*?6T1Z +6L_\%'?B=_P6K^,O_!"W]DO]GSXN>/?A_P#\
M)AX%C_;#_P""CVK?!_QOXB\"ZAIMK\([G5/A_P",_AKK>L>"M3TC5='TGQ1X
MJ\!_%#2K'1=1=[>Z3XH?"'Q))IHMWTRXG .=^'W_  4/_:E_9A^&_P#P=@?'
MSPS\1O'GQ \9?LV_MF6G@K]G[3O'?B/7/'WA_P"#</Q"_:*^+_PDL]4\%^%_
M$]_J>AZ)HO@.TU_3O%$'AZSL(_#DR^$=,M=5TF]TFU:R8 _0K_@F)_P2.^*^
ML>"/V&?^"B6M_P#!7C_@H-XS^,WQ3\._"_\ :+^.7AN?XS6?C#X"?%[P[X^\
M'#QR_P &+;P/XBT_4$MO#NG76NVFC:CJNMZAXMC?3=,UQ_"_A;P+K5YH6J>"
M@#\.O^&FOV@?^"F7[6/_  4'\8?&FQ_X+B^+(O@9\=O%GP9_9G^'W_!*N;PY
MHWPO_9CTWPGJWBO1/#^M?%+2;WX@>%KW6OBEJCZ3;7E[<R6EG<:N;+Q,A\22
M6TNC:7X. /ZZO^"&_P 5/VY/BG_P3^\"'_@HC\/?B9X$_:9^'OB[Q=\-=<O_
M (N^$+SP3XZ^(_A+0&TS4?!'Q#UK2;RWM_M5[?Z#K=OX=U/7(4<:[K?AC5-3
MNYY]4N=0F< _FH_;3T?]O+7/^#J?XE6/_!.3Q5\"O!O[1Y_8S\&RP:S^T3;Z
MU=?#H>"(_ 7A7_A*;5XM \->*]0_MN<MIO\ 9;#2C"-ESYES#E0P!^@O[5_[
M3O\ P7H_X)V_\$T/V_/VEOVUOB+^QYXP\=Z'X3^#'A#]F;7_ -F70?$-S+\-
M?%?Q,^*NG_#7QOX^\:V?C+X?^%M,NSX?T?Q=HNH^!H9[?7M,E\86=E!KFF2Z
M7-<6]V ?B[\*?$__  4+^%'@_P#9(_:\_8@^&/\ P<(_&W]I[4M3^%?Q%_:.
MU+]IK2K#XF_L6?M6?##Q5H$>N_$"R\*Z!HWCOQ9K%KH.NO>V:_";7I;74;W3
MO"%Y_:=MJNE>*8M(UVR /I/]N#]K#XU_MJ?\%C_VP/V5_B=I7_!6;Q3^S1^Q
M]X8\+Z%\,OV>/^"54^A^&?'-UXFU33/"6I:E\:?CE=ZQXK\-W>J:5-J>L3OX
M1>2QU9-/2]\*VELV@+%K*>, #V#X=7G_  7Q^*W_  2"_;C_ &<?A_X<_;/\
M)?'+X3_'KP;8?LM_$[]I:RA^$/[87Q<_8S\3ZKJKZGX03X@ZAKT>GWOQG\)6
M>@V4GB#Q'I/C6_UU]+\1W?A+0/$-]<R^&$E /4_^"&_QE^"7@+]O(_LU^*?%
MO_!8?]F/]I;Q+\"O$]Y??L2?\%%OB'=_$OX0?$K6M,O+#6]0^+7PH\2:GH6@
M:U-XATG2/#7CJ[-_<>%/"^A^*]*GU34-!OITT*?2)0#^G;]KFV_;MN?"GA5?
MV#=:_9*T7QPOB&=O&\W[7/ACXQ>*/"DWA3^S9Q;1>%;;X-^+O"&KVWB$:O\
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M7B#2OB=^QM^TQIOQ*\7V'QSN+KP;X@\8ZAJ'P'\8_$/P]JMCXA\3ZAXO\/\
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M8_BG/JNO^#KFQ\47WBG6=?\  $>O:NWA_P -Q^"-,U2YTC36?QC<:^ ?'O\
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MGB_Q'KNI&( YWX]_\%#_ -MS]LG_ ()3?\$,OBH_[0?Q+^!O[07Q>_X*$O\
MLZ^._C3\-;^[\-2>.O\ A&O%MWX"T+X@^(/"6B7NB^&_&<7E1Z9JGB;PGK%M
M_P (CX@\6Z5KL4FEV>F7OV*  ^Y="^"/QT_X)>?\'#G_  3O^"7@W]O#]LO]
MI3X2?MM_"GXR7_QM\._M3_%^[^)D^O>(_"O@'XH7AOC#;:?H/AZ&RM-=T#PC
MK_A+RM!&O^&IM.U31_\ A(+[0M5GL7 /R\\'?M,?M*?\%0/BG^W%\</BU9_\
M%U?%/CCP%\;_ !Q\,_V7O#'_  3!E\/Z7\ _V5;+PU#>?\(9:^/]!E^(GA/4
M]9^(JS7%E'XJ,=CI.HZ]H]C?7DOBV]U76+<>$0#]#_VB+[_@O'^U%_P2>_8!
MOO&'PD_:ZL_B!\-_C9XX\.?\%%?A'\&O$!_9N_:Y^/?P?\&:GHJ_#/Q3X5OY
M=,76W@\0>#FUK3_&%KX9T#Q%'XA\>WFC>)+CPGJ%AI]PFD 'Z)_\&]'QX_9X
M\5^(?VM/@?\ #/XN_P#!2NR^)'P]G^'6J>,OV-O^"F.N2>(OB%^S; +?6K&^
MN_AGJ]S"-3E\)>*[V^TJ/5])UP:3K6B7&GZ'<7GA^U37X=2U< _IOH * "@
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M:-?Z!X7@LX4T_0->\1V.K6%DE[:V[T ?TA_L#?\ !&'QE^RA\5?@;^TK8?\
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M?AO#X:5KQ];;P]'X40ZJ=+50#_/<^$WQ%_:[^&W_  ;Q_P#!/.+P%\;/BK\
M[SX@_P#!9S4? _PB\;>!_$'B;0;I/A'K_@7Q/#=136-IJFE6?BWPC;?&RV^(
M&L7/A:\EE\+ZQJFG2PW]N]RMU(H!^VWC'X#?'W_@EA_P7=_X)9^%O!O_  4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]'^
M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H \+^*?PL3Q DWB#P_"L>N1J7O+- $35T4<N@'"ZBJCY6.!=@>
M7)B4([ 'RWHNCS:QKEAH>_['<7U]'8;YXW_T>:23ROWT7RR#8_$B_?7!X+#:
MP![;_P ,]:Q_T,6F?^ MW0 ?\,]:Q_T,6F?^ MW0 ?\ #/6L?]#%IG_@+=T
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MZEHFE^'GU/PWK?BCPI?^!_#M[;Z/HVF:=%<I\/[VXO[+3],M_$,VN#2-*:R
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M$'4=8\.> +7PIX*\%:[X?\.22?$G78[1M8\0>)O$NG?8]%N]/\26VJ6#W]P
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MH6K6ECK&C7]CJEC9W< !^+G[._\ P;X? K]G#XB_"3Q%X;_;@_X*:>+/@_\
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MC^'M/M;SQGIWAB;P_JWVU=#M-5NV/A&SDTG5[G6KOP5+X1_M_6$NP#9^!?\
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MO7_'M]\1M<L=>T>ZLK'4=$76=5;P1X6TBPU;3=$UF*R^&M[?-IIT77=)O;L
M_K=H * /E^_^ >KWE]>W:^(--1;J[N+A4:VNB4$\SR!21P2H;!(X)'% %3_A
MGK6/^ABTS_P%NZ #_AGK6/\ H8M,_P# 6[H /^&>M8_Z&+3/_ 6[H RM=^!^
MJZ'H^I:Q)KFGW$>FV<UY)"EO<H\J0(79$9@5#%0=N[C. 2,DJ >4:#H&J>)=
M4M](TBW-Q=W!SDY6&WA4CS;FYEP1#;P@@R2$,22L<:O,\<;@'W#X'\#Z7X(T
ML6EH!<7]P$?4]3= LUY,H.%4<F&TA+,+>W!P@)=VEFDED8 [:@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_TO[^* "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H \Q\0?#FRO\ Q3H?B[3/*L]1L=5LKG5(L;(=2MXID,D_RJ=E]$@S
MOQMN47;(5D"/0!Z=0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % '__3_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#^=W_@H=_P G0^+?^P#X._\ 4=L:ZZ/P?-G^='TB?^3I9O\ ]@&3?^JV
M@?;G_!+/_DF?Q-_['JR_],%I6=?>/H?N'T5?^29XH_['N'_]5](_4:L#^IPH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * /_]3^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MI>H/TT* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#_U?[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#__UO[^* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
-H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>dna-20251231_g2.jpg
<TEXT>
begin 644 dna-20251231_g2.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0!,17AI9@  34T *@    @  8=I  0
M   !    &@       Z !  ,    !  $  * "  0    !   ( * #  0    !
M   #C0    #_[0 X4&AO=&]S:&]P(#,N,  X0DE-! 0        X0DE-!"4
M     !#4'8S9CP"R!.F "9CL^$)^_\  $0@#C0@  P$B  (1 0,1 ?_$ !\
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M"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+"__=  0 @/_:  P# 0 "$0,1 #\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^6#SBI$C]J!RE<54 '4U85 1FF*.<5.!CB@@9Y:_Y_\ UT_MMHINX,P6/DT
M)Y:_Y_\ UT>6O^?_ -=2$,IPW6DII 0L #@4AX.*F*@]:38*?*P(XHWFD\M>
M.,YHCD<8S]*>Z+Y?'!]13$0YHY0+S-']F!5OWA;&/:J^<\T[:>.*!&1VHY6
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M[?6O#UQ:2WHTG5;N"X_LZQL95_LJU:XE@E6S@@CGL;J)6MGAG1PK2)@\X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M42.2XD 4".(;4154!551T %<-X*U :1KPU8PBX%K%,YC;H049?TSF@#^K/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]3^#^BB
MBO0.,***4<G% "4HZU)Y:_Y__70$ YI70"A<=Z=1147 :%P<Y-.HHHN HY.*
MD" <U%4J,3UI@/HHI1R<4U%L!**) 0?DHK2*LA-V"BBBJ);N21]ZL^6O^?\
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MERJU*$&!D5"H:,G8:LC..:I(;"IQT%1A">:LB-<#_/\ 6F(AV"G5+Y:_Y_\
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MT:[\1V-A<3:=8-&ES=)$S0PM+D('<#:I<@[02,X..E &/1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%AJRU6B.OB^+&FZ9IABCMVAER2T9X;=UQSS6AX1\3>+_ !'?J8;-X;2X7[[
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MB%IJ.O6;136FGK>^<J!W0YP/3]:\B^*/Q>^(O@FVFF\3Z2MQH_F;"F0FZ-N
M.E>GE.8XB-10I'EYMEF'J4W.J?FY9:@DUH,$$-SD]Q7QG_P4',$G[''Q':$
M!=$N>GTKZW\8>(]&UGQ)-<>'X!8VD[<(6XC)Z\U\2_\ !1#3?%WA/]COQS-J
MUL7TW4-&N%@N4&5)QZU^A8M_[)4<G9\DOR9^<X:G;%P45=*<?S1_#57K/PH9
M[35X+V*5[:1]1T^&.:-BKQN9@X96'0J$)![&O)J]#\(W5RNEM;6:,\J7]O<
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MVD#C=Y\JXY9<CY$)&[/!/'/. "S;11^#M+35KR/.J7BAK1''$,1Y\XC/WC_
M"/?KBH_"6E:/<3/XF\;)/)I,#%9?)D$<TTK X2-F5QNR0S?*<+UQD5G6=G?^
M*M0N-9U6?;&G[VYN)6X /0#U9L851Z>@)$7B/7VUF>.VMU,5C9KY5K#VC3J?
MJS'YF/<F@#G6V[B4SCMGTI*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'(]*+$W H ,U'N.<TN\TVD,E5BW!H\M:C!(Y%3T %%%% !14A0 9I?+7_/\
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MC<$)'.9&VQCW8?6NM\=WUN-,CBMD96U2YDNR2X8&VAS#;C:!\K B8MD_,"O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYA4;1DGI5)&1851D"0@9Z5(D:MSFE@D>-DF4\KG'XU(&)<D]ZH")8EW$<U8
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M(JI*I1]R]YV5:FW:*O)Z)[(]'*\+5G4YU%VM+7I\+Z['Y@:9X-OWE%R[>=
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MFTL[ZVE66!DV#(R0?4U-X8U#2;=+NYUJ0SQ+]W'?-?"U.%LMJ2E+$4Y5+?\
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MRBJIW^5L#<[3MR!7\QW@SP!X=UR?PW=ZSXKT_28]7U7[!=B02&73X08_]*E
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M4G;_ ,!;<?P#F?4]6U7_ ()\_L2_'JVOM7^ '[3?AVSO9[UW%CXRB_L6?>W
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MI-?8'[4NB_L^>!='TO0?@3)K FM-)M=.UB+6!Y4L6KR$37@2/.5VX5#QM(R
M3C-?)/PTU;5=%\>Z?XNTZX-M=:/.-22;!<H]L?,4D=3\P _&NM^.WQ'\:_$W
MQ=_PDWQ"OGU'7-0_XF&HW$@4,]Q= -U &0(_+ R!CD5ZXCH?V:_BQ\2_V?O$
M&J?'/X1>);3P[KVB6IMH$E >XNTO_P!S(L*%64E$)<DX"A>#G K.^&MGX?U;
M4H+WXDW4\&F:U?\ G:O<P;6N!I]NPDN2BL0I=R=L88A7DP,UY]\-/!E]X^\;
MZ?X:L[&^U".656N8].A,UPMLI!E=5Z?*F3D\#OQ7T5/\0/A?\,_BU#XO\/:(
MWB/PCI6KQV]CI.JR*&O=-L)=[I.T8X,['<^%(!; W!: /)OBYIW@;6O'-O>?
M#77)M9BUDM*R7$#0R6.^5UCMVSD.4B"%C&-@S@=*^^O ?AS]CBU_8P\5^(OC
M =;LOB--/Y?A6!8;@65UH]DT)?#A#%MDE:7>2P^=@0.M?'?BT7'COXGZM\1O
M"GA9?"T/BFZQH6CVZN\<7VTD#R3@%UC0-AE'WRO&#@>W_M!?%#X[:[8^&O@S
M\?XYH++X>V9BT_2KJV$,EOI\83R8W"E')N75-Q;#A &&00* /FYGNXL:E=_/
M?%Q/MP03?WH_=*>,A8H\OW&[ _B-;7AKPJWBO7])\#::7C.J3II-JUO&DDOD
M;\W,P7*>8\DC;(\O\V-@8;16<)=0CO6:XDS?P,\:9P#_ &A=<S.<,,""+/S?
MPR!.",D?1_['/P]^%WQA^.^D?#[XEZW=^'K/7<6>F7MJRC[)Y;@6[2LSIM26
M;DA6#G!QC<&H \#\;?"SQ'\"O$NJ?"[XEVKZ=?Z)/]HU>VE*&56CR+:W;8[
M/)NR0K$A&+<@5X^GA+QYXKLAXY^P3R:?>ZA]@%Z4(@^U,OF>5O\ N@A/FQGA
M>>E?K]^VO^P9<?L^?M,3?"?5-1U'XLWGB"RGU1I-.'D:@^H7"OM:1!]HRELJ
MF9@2-Z_+E,[J\<_:G\/_ +#.A>%_"D'['6K>))-4F%Y:W\.N(B16RH5$MTC*
MBDL=KIP6##@,ICVD ^.EO-3U?2++PEI,\LFEZ>9XM-1RS11 H&OK[9A@N57[
MP7(0+_$H-<1XBUJ+3=/-UIZF&74(OL]J 0K16"94DA>=\QR#G^'/4.*Z.Y>S
M:!E<BSLY80[X^_%IT)S''T.)9W&?<D$X7IXUJFHWWB75C<!,O,P2*->BKT55
M'H!P* +OAK2[6]N)=3U?=]AL$\Z?;PS]EC4Y'+GC/) R<'&*U[0OXHU2Z\7:
MZ@^RVVUFC0 *[GY8H(QD=<8 '1 3CC%3:S&R&U^'OAT>=(K@W#*PQ/=MP<'
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M+ +@MU$0VY5.Q)/4UQ-%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF:*>'[//YNH#R# R3*,,P+,5QG"$C[N1]F_#G]G?]G']J[Q-\.OA;X-U2_\
M"<OAZ)H?'VN:]<0PV5O%)<;(FM [J29I'^4$<-)\W )'ZB?&/_@HE\*X=1\)
M>%?B_P##>_\ B_X0U/2-.U.SU_6[9;'Q(;B8O$%M)$0><(V61DWC)(< X&ZN
MW^&7['_[('_!1'X@>(OC;^R?XOA\5^--5MKL:QI'C]9(KC3!);B&UDA2VCQ(
M\$J*-[;E(SG)ZG]O3PSY<THNFOYU[U/YR23C_P!OQ2\V'+?8^7K/_@G%\%?
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M]WJDVJ16VH6]RNFQP,LHN)(I$FEU&[1E3!CB\OR6)+$K(1CGC^@_]F[]FO\
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M"NF7T4J:_-'Y^I7^\V8E/" 9,ES(6!RJ#.,]\MGY<$ ^LOVF?C)%\0/$=]X
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M81:IKWB1FM]/S\H4@2SD=5C!_(L00ON< TM;\17.L*EK'&MK:1#$=O%G8N.
M3GEFP!ECR: +7BR[\)7-S;1>$+26VB@MUBF>:3>T\RD[I<8&P,,?)SC'6N5H
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M29B#Q42C8N+;W(Z***E*Y:5PHHIX0GFGRL?*Q40-UJW'&!Q5=%8<5>5<<T)
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M?@M)8K:%;FY8AALR%PQSD%L8X]17I0Q:A%0/*JX%RDYG0>%O']K!Y=G?*?(
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M8HA<%L$] 2//]$\-)=6#^(-=D:UTV+<-X&7FD'2.,9&6YRQZ(O)R< _U$?\
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M2[N[G 55')))X ZFO3_#VB2Z8]PNE^3-?6R[KF\<A[:QC.!NSRID.=J]>3A
M7P1U'P_\%7.OZQ;^$_ IDFGU.:/3DNHX\S7EU<X06UJI(X=FV[B5RO+;<[:_
M:O\ :0_X("_M8_#+]F]OBKH.L:/J4NB0F^OO#-F9!-%$!EW6X<!+F9!]_(08
M!"9X! /P-UGQ7;_87T+PZK+',Y-Q=.<SW;=MW]U!R0HZDY8MQA\>C:;X5C2^
M\4QF:\=1)%8DE2 PRKS>BD'.S@L.X!!JPUUI7@7;'I$BWNL*,R7&T>5:R9/R
MQ<G>P&/WG #9"@@!SY]---<2M/<,7D<DLS'))/<F@"]J^KW^N7K7^HOO=N
M,*H&<!0. !G@"LVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_G_]=4!%''C=SUJP..*0*%Z58;[.T:B(DN/O_P#UJ6B%>Q!6M8W-A'97$=W
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M]J\^MF9D+=ZZ?3;AP !WKTJ-:^C1Y]:GUN=;;^#%&9+.7)*XQ]:I2>$IK<'
MW;:Z'2]1DAXC)%=.EVAC+2<DUZ"HTY1TW.!UZD966Q\_W]N\+,C#D5B.P9@
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M^-=;+^TYKMOX+T.RTO5Y+^UM(C'+'-'EXV'0 GL 17S)KGCVYU"X:.5LY+$
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MVA7?B'3K;5K>.955CITA9;<*5)R"$+,3@EN",KSE7H4Z].5*M%2B]TU=/U3
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M%&2?:M$B968Z&,-MS5Y(\-QFHHHRI ;J*T8E!JDA-CDWYR>:T88MQYJL@.X
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M:E>:[XH1Y[Z]D:Y:1^K2.VYC^).:[/PY"NM>);=4=09'"D/QVY_"MLFP*R[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '_U?X3 @'-/HHKL.,****T@TEJ HY.*D" <U&.HJ>K
M3OL%Q1R<5)Y:_P"?_P!=1CJ*GID-C @'-/HHZ<F@044A.#U']:4YQQ0 45)!
M$\[^6G7O2M%L0,6!))&!32 BHJ0IBCR_\_Y-/E86(ZG(R,4V2(Q8+'@T[!]?
M\_E32L-,C,=*0<'FGX]Z6J!NX@MW%OYY(/L.M"C;R*$4("!WI:1*$8%SEC2T
M44# \\48S@>E.4 G!I_ECUH M6EBUY-Y*,$(&26Z5$P\LL'YQZ4F6XR<XHSU
MQQFFE<ENP\*ACW;OF]/:D90!D4Q2P.<YXQ4[#(Q5Q1+%HHHK0 I:2B@ J2-X
M=CF4$$\"H6=4&6IZ9*@,>E2R6/C[T_ ZXY]:15VTZJ&PJPOR]*C*8&:DH(FR
MQ3G,6_\ =9*>_6FTJQLW" 8H,Q*DCE5L[Q^51X[5=FMDCCA='5_-7/'8^]7$
M+$*(N>*6I(TZ&D"<[2>>AXZ&F0R2/H*N1&01_9]YV?W>U5UCVCKTJW&GS'-!
M+9>@^5<BMB# (XS61'PN*TX')-=$-T8R3-^T(7YL\UUMM>PR0NTCX91P!7$P
M,<?6M>'<-K _A7H1EIH<LHKJ=!%/YHW%OP[U/Y@VG!W$8Z>E4C<126J0!?G4
MY+CJ?8U)%//$YDC.,C&*T=]SFD[%O[1&!@9K U:WCD3<!S6LR*B*[MRQYJ*Y
MCC<;5.142:8T[.YYV]J0>]0&/:Q#'C^M=1/"%Z5FWGV98479ER>O:N:<4=]*
MI=&?'@KS4M)M )Q2UE)=BV[D)C9GX&<?RK4MXX2A,C@'THGDBN"K)&$(4*<=
M\=ZK8;H#TH2L(?SN('(J6-03FDCW=ZE5&6J2N Y4 DV^]6U9<C/W>]0HO[P.
M_"]ZNA5W;H^1G/-7%$R'NBB)'_B/44R-6N;A;9/E+'&X]*MWL+!Q< K^^!8@
M=%]JH$$$C/?-626+NTELKAH)"&V\97OBHT48#4FUB=X8YQ4ZQ\=: $4 G!JP
MD28SBF)&,_Y_QJY'$2.*U1FV(@P0*E53DU(+?!SS5U4C$*LF2V<$>U:1BR):
MC?+V*DA(.X]*W-/U>ZL+:>W@QMN5"MD9( ]*R4@PW3H<U,%);!XJN5B)H>2
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ML&CB^LU!6/"R$MRWM]*\MUB>!I5:>8,SY.U.0H["N^C36[.2O4Y5;J7[J_\
M-BY'%<V\X W9I#?6#V;A=RR+V[5SLMVVW KOYK1T/,MS2N=%'=SP0M/;SF$J
M.@[^XK#&HS7,OF,V[)SDUKZ):W.I03S[5988R%W<\GL*YV2W:SDVSGY@ 3CM
MGM7+&&YK)N^A]D?L2?!:?]HW]I[PA\+,8M;J]6XOWQD1V=M^]F8^P13^)Q6E
M^WY\;C\??VKO%OCJSD/]F6]R--TN,'Y8K&Q AA5?087=[DD]Z^KOV$'A_9X_
M8^^,7[9UTOEZG=6R>#/#CL.3=7_S3NG^Y& 3]"*_(6=F=FD=BS-R2>I)KY?+
M9/%YYB<4_@H15*/^*5IU'_Z1'U31U32C1C%[O7]%^I[]^S_\9_$GP=^+/A_X
MFZ)<&.YT&\@ND)[B-PQ'T9<J?4&OKS_@IM\,;#X>_M0W?CKPFI7PW\0[.W\3
MZ5(OW#'>C,B@],I*&4^V#WK\R+/;TD/6OV7U[6+3]JO_ ()<6&HR#SO%7P'U
M(VLS=9'T34<&-_7"N-A]-@/>ML[YL'F.#S)+W9/V,_2;3@WZ5$H_]OL**YJ<
MJ?S7RW_#\C\E[N:-6W*QVD9P?6LJZOO.42)WXQ]*J&X$C%9/KFLZ:;8Y-?5Z
M]3FNNIO07TB;06X'3VJ[<7\H=)4;Y5Z5QTEQF/ X-,CN)0I+'Y:O=61BUW/2
M(O$4=PREGVLO?Z5T6IQP_P!FVMW%O,TX);)&"!Z5X[;M92QN+N0QHJL5XW9/
MX=*WX?&C7-A;Z=. %MTVJ>_UHE=+0S<+O0]F\(3Z>^M6]I/(ZQ@AL'GYO0#'
M>OVN_;(O$^!'[/7@']C^RW0:I<*OB+Q%'$ &%U<C]U$^<_ZM>H]?I7P+_P $
MR_AGX3\=?':3XM?$?Y?!OPRM&\2:P[C*$6OS11G/!9Y  %[XQ7@/QQ_:<\:?
M';XU>(?C-KLQAFUR^DN$AW9$,1.(XA[(@"Y[XS7QN*J2Q^=TL-:]+#+VDO.I
M)-4X_P#;L>:;[-P9W0BJ=%OK+3Y+?_+[S7\33?9]4^SQG$>W:OKN[U@65YJ4
M.HPR1')\P>W)K1NM4L/$6F1WEJJQ2JOS+NR2>Y_&N=BU:..- 1\T!YSU)/2O
MLE43.3DU/:-'U+5K?1;G6(Y4@C@F5"A;EGSQCO@?6N+O]<?7=4_M2_"(D7RD
M+P6//(K@M$FEN=2>Q$A )+G<>X_2I6U-([Y;*= JB7<2!SCI64I'3".AZ-).
MMZ<A3E%48[U7@EU2+4TCMG96R""O8#M]:R]=.H>&]=>WNE8 %6R!RR,..*CF
MO5M;MIE9PSX=<\$5A*=C3V3W/66\8:SIJ2W*0F-&(P92=Y]?2M;PSXHL-1@F
MT_6;QXHI&R$7^N:\=.N/K-PYOW,I'3)[UI06"ETV2 &7KZ\5S2J:FBCI9GTI
M;^([QK%-&T5XC]G?8AVX)![FO?O#/C+5M*>ZFGE$,\MN868X92A'/7OQ7R+X
M2AU"&U^U2Q;H-X1I,9"D^]>E:_-#'-:P6,FQFB!EW'^(\8_6MU-VT&HH^_/V
M2?VE/!7@J#4OA)\3(9;KP5XCP)L_.T$QX\^/T*G&0.PKV'QUXA\6_LF_&31?
M 5Q<MK/@OQ!;11)<,-T=W:2,3\I'&5RN0.A-?"?P^^&5YX@EMKOPY,(S;!4?
M:-VV0-G./IS7WUH?C/PGJ?B$_LB_'5A)ID\Z7OAO7"/WFFWTAW*K'J(I3D$=
M!TQZ?%YK0J9;B9YGA8-PE_&@NJ7_ "]BOYXKXDOCBOYHJ_73O*/*_D_T]#YX
M_:T^!&F_#'XDP1:+JL4>EZ\!=6L;?\NR.,[7]L]*^6_#NK:5HUY;:C+*+A4F
MQ-"A_P!9&>,@]O6OVH_:2_9$\0_&K1IFC6.T\86-O'"D6_$4XC7C:>F&Z@U^
M-7@_X7^(-:^(C?"WQNDFE7%H)#(RIO?"$?= ^\.#TK[#*LUI8C#1E"2DFKIK
M5-/9IG#C,$U-3BC[>^$WQ<\(:5\-EM]5\ZTU2"YENM,NGD+)) C\J5S_  X-
M>$>.?COJ6G?%S4_%L"NTFHN'9#QC!# CZ@5#KOPGT;X?II<UMJ\OB"PU,R>2
M;>-@\4\;_P"K93PI;T[UQ^L6B/=W5]KFE30ZA'.5 E!7R"<@ [O7/%=F'G!-
MV,YMVLT=[\4O&TNK337Y,B6VL*EU$9AB57P <$8&,CTKS/1?A3K.J.=4L[RW
MN7VF5B3@MW(&>IKJ)_A+\1M>GTG2S;3 2Q&.SF+"2,\Y;G/ &X?K7UEX+_8-
M\;Q1P6NI:U$D  D+P$.$8CD$BM98Y4E9DNDZCLC\YM3U2*Q9HVX9&((]"*\K
MU#4$O[QLD ]J^POCM\!] \'?$]?"&EW\FH(55Y'3&/F'8],Y!KX=U/3)--U"
M11RJN5S]#BO4PN*4K26QQ5:%HVEN7X[Q8)3$>1ZUXY\?;M6^$7B&.,Y!LI*]
M(N!*J[D&17C'QQ+?\*DU\D8S9R5MB\0G0J+R?Y&.'I+VL/5?F?DS\5KHWGQ)
MUN=CD_;)%ZYX4X'Z"L?1VE3PYK++@(8X5)/<^8" /RS^%>J?M,?"WQ#\(_B[
M?>'/$CQ237L-MJD;0MN4PZA$MQ'GT8*X##L17G_AFT;6=)7PW H$U[JMDB,W
M3++*F"?JPS7Y,?H)](_ GP&OCW]HG1?APT<MS_:>K:%X?=(_ED5GGA$A&<YV
M^2X'U%?JQ\=?#FI>-[3]H+Q-8RJJ_$7XFZ!\/=*<#+*MD[RS*0.J[1%@#^Z?
M:OG#_@D%X1TSX@_M^>'O$>IQ&YBTN_U;7;@=0O\ 9]G/);OWY6XD0^^*_2/X
M*>$YS-^SG#XML9%.L>)?&7Q7UVVGC*DQ6"*8)&5P/O1YV>I''6@#\-_^"FGB
M>P\2_MP^.[/1GW6'A^ZA\/VH'W5BT>".S 7VS"2/K7I/[/6AGP-^SI\6_CM?
MN63P]X6M/"^G@+L(U#Q-<9<JP/+1VZ39]G&<<9^#_%&H:I\5OB_J&J0AY[WQ
M'K$LB@#+/+=S$@ >I+<5^CW[1$\/@3]@?X9_"C3G,,WQ-\4:CXNNHW(#):6"
MK86)8\'84>4YQR5)ZB@#\Q]?(T_0-)T175F:-[R50FUD><X52?XOW:*X]-^/
M6OMO]J701X#\(?![]FYP8)=,T4:[JBRL%07>ML)SG R-MNL2G.2,5Y]^RI\%
MO^&KOVS?"7P=.3I>JZM#'>.K8\O2[0 S$,<X"V\9"GMQ7O2C4/VXO^"A.MZK
MX=5EA\8^)!I6G[5)$%@259B!QLCLHG#_ -T,#[T >YR?":WN?A[\&OV9]9/V
M)O'=Y=?$'Q8^7'D:+;[EC9N"%/D13\ 8.V,GD\?#T-QKO[57[2FL^+M)LPMU
MXMU7^S]*M50M' ER?+5< 'Y+>T4CY1E?E-??/[0OQ LO[!^.G[4VEL8;/5[Z
MW^&'A'8^W99V42?:C'CE1]GC0,!P?.:O&/V1=,T_X"? _P <?M:ZW'&EUX4T
MQ=)T'<OS2>(=<7$; ,2A:VMP9<@#[I!!.#0!X;\;M+A_:!_;,T;X#>!90NF6
ME]8>#=+*_,B1I*(GD'LTKR2G_>-?>_\ P59^,UIHO[9>D? #P3IEI>^%_AA:
M0^'-)TNY#_9HH[:#RVG?8R983%I<YQF(%\C(/YE?L)^(8M"_;3^&?BC5Y%6*
MV\36$UQ+(P553SEW.S-P, Y)/\Z^E/\ @JGX2\1^ /V^/BZ=81DO-8UV:.P;
M!0M:W"J^Y<8!#(ZQ]3D,<]:^;KVGGM&,]HTIRCZN44WZI67I)]ROLGZ _P#!
M$O\ X)G>%?VWOB+KG[1OQCBDE\ >%9AIMA9GY&U"]" G<5/$<:$,W<NX'8FO
MZ^X?V"?V,+;PC_P@UO\ #+PZFF[2OEBQBW<J5)WXW[L$\YR.O6OQS_X-N/C7
M\.-4_9H\2?LVZ9=11^(_"&KRW5Q;;@7FM[L+^_7'WE$JNAQG;A>Q%?TB5_-_
MB/G^:2SVO1G5E"--VA%-I)65GIU>]_T.FE%<I_ ]_P %G/\ @DQX;_8X^)VB
M?%7X,1RQ_#GQ3))'/ S%VT^[B!D,()Y*2K_JLG.X%?3,7_!('Q#I]]^T!J?P
M-\;N%\'_ !+L9O"^IPDATN;V6,M#Y:D#'V91L3D_,'8'#87]Q?\ @X.^(>A:
MQ\(_ O[,V@$7WB_Q-KR7UM9QC>\5O:Q2*T[@ X5"X89&#M],FOYY/^"?%H/'
M_P#P5 ^$GPH^%V^30O ^IO-+-"S'[1+;H3<7!Y("L0$4# *KN(W.Y/Z]P]C\
M5F'!E2OF+?,H3M)[ODNXR]4UOW5S&22G9'Y6>,?!NO?"'QGXDTCQ>GG:_IFJ
M7>CQJ.@N;:5HIY<8).TJ50<?.P;/R8.KX4\-?V=8?9H2C3!O,N991\@N$!8*
M<;LQP)^\<X&7(3!PN[V7]I'Q?I?Q?_:W^(?Q;TN2-M-O_$FK2:0$7?$8O/ED
M\]AAOD2,^:_!W.<=,X\+\37,\DT7@O2I,2W" W#.V1;P E]K')Y8YEF/7/RX
MX(/Z=A)SG0ISJ*TFDWZVU,V=Q\*WM_$?Q,B\8VFLC0['PH9;[2'N@[RW6H6^
M9;:(! ?WUQ,JF1SA$&3GA0?U1O/^"P/Q_P#$'QF\->*/B\^C785;;3K6:/3P
MTE@ADQ-J4(.668[BL04[6"Y(QC?^2T3:3X9T)[Q6:*TAC\M0IVSO#*<A>"VR
M6Y4?/D82 $'.[YOH7]C&;]F2W\=ZW\0OVU["^O-'N=%OCI26&Y/LUV@412$J
MRX SLB0D_,02,8ST"/OK]OKXQC1?B_=?#71?'/BKX@?#+7EC\674,4L1N[^_
M^RD",,L0"P1+$C3DH=D? 7(!/I'@?PS^QW\$?^"<,_[8?Q7\(>(M?\?ZV4T?
M3;C5[J.&>"ZEA+P3V 24-':QD#:X4R<8VXYK\$_!'Q?A\&_&'1O'ALY+C1=+
MNXQ)I@E9!=:<'Q-;2..2+B+<DN>&W,",<5]:?&_XB_LX?M<?%[QK\2="M+GX
M8>'=.TVWFT/0K& 7$$EU&4BV,$9(X2X)(VCD_C0!S'P0^!_B/]H3X[Z'H6FI
M9?#34+"Q1VO-:OKBS%YJ%LGVAIFG=3(DLH97P@PJ;<'G-?J]X"^,?P;_ ."D
M/A%/V>/VNM2M-'^+UDAA\,>.%4"UU-K;)%M?;?O0J^ DC85SR.5Y_);QK\7?
M%?COPJOA+Q\%U"Y6^>5[B5$?4F=H4BCM/MCDR;0$#39(6/D 9X'*7_@SQKX9
ML=-\1ZWI%U:V^OK)<V-T\$EO:W\=K]Z2*4JJFRM^IV'#MR>,$>5FF50QD8R4
MG"K'6$UO%_JG]J+T:W&G8_3/Q)^P3^U]\=OB=+\*]9T7PUX/U3P!;Z;HLTEU
M)'I\=RLS2+%J,QY-R\K!A'L#'&,C.-WYV_MDZ%IWP8U3_AC_ /L2Q?Q#X)U:
MZ_M'Q%8WCW7]K/<+&5RI50NT9XY;)VGH<_K)I?[>?[/_ /P4H\/67[''[15H
MO@*_M+>UM/!WC%+J61X[^%=@2]=SN,,S\KDG9GL>:_/OQ%_P3R^-'P/^*.O?
M#OXL:GINB^,;.ZM+>T>_D98[O^T9C%'-:2LOER.RAGW,1Y8!/##*\^69K.=1
MX+&Q4,1%7LOAG'^>'EW6\7H]+-MKJCX7T3PQ#HL869\WY(%RX3?]C5CA44<;
M[E^<*.% '.2VSZ+^%WB'X3>!=/U3QM>7VI:%XLT*YL;KP^]M%%<V=E+#,KR-
M<%R#+<M&IV*J@"0C)5-VWT[XCZE\&?#'[+/A[P+H;6R>-]&\0:E+K=[%"YEL
MH)$6**!9\B.>6;RVDXR5R>0JX'/_ +$7[#WQ9_X*/?$J[^'OPVN;7P_HOAVU
M\^XN;G<\<*RDA=VWYI9I6!+-QP.R@*/=)/G_ /:D_:U^-'[7WQ!_X6#\8]4?
M4+F*);:W0*J)'$F< (@"Y)))( Y-<+H/ABX\,O\ :[X1KJ*JLA\\!H;&(@_O
M)AS^\(^Y'][OC.!7ZB?ML?\ !-32_P#@G1H.C_\ "8^(YM>\1^()':TO(;(Q
M:9;6T2XD =SNDNR[+Y<8!PI+GID?F_,+2T!M;?9"]MF65;IC)';N?^6UR>1)
M.QSMA (7[I!.Z@"'7M$\*2Z]%J6CVEVTUQ"C+;:A,KM(X7,EU.P5!'$Y(9(C
MN;'5B,%F2"V\O[0?-N);Q=K2CB:^D08V0@#,5LBX7<>2%SQG:MI(DG;^SX8I
M+V653>- S?O)71<M<7CC.R)%RPC)Z<G&<DBL[I(8KW4!<3'6F*P-&"ESJ,8<
MIMMEP=D =64N 06!49VL  =YX7M/#6DZ$?B1J^KV*ZEH>H6\<.G36SSVRQ_-
M(R0J,([@JJD;CG?DX"EJS?B#XMN?B!XLU3Q/J6E6NGG4KF2]71K4"WMH'?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEI,>]+5 V(V6(W'(%.')Q0%;RUE(PK4E(0]PHZ4T#)Q3&7-2QNT;B1>JG(H
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MF[0I/".OZQ+X_O=3N/[=TF1 NF1V<8_T>1".6D)ZY)ZD8&WY@!/ALO@;Q_\
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MM]>)M!DT233] -U%$8UO?LS))),0=I(W% %Y=R0 $5N1P:\8\8ZK_P $I_\
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M(O\ P4.T+[=\!OA"+SPZD][;QQ0V=_+)#'$9[+_7-;AU2/E"!(4=ONY'YP_
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M*UPY^::7<O[N,^G(^7!\.TP:A9ZE'J,-I)=7$3)=2"8YDN%0_NY+ICE8+<8
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MD,;)_K*C&X-NS3F9I#R:&K 1&-33ZDDB:, OT-=9X0^'WCKXA7\FE^ M%O\
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MJG@#@5*K**N,;;B;+\_D2R[[5=G][T-0&,5&"68<\>E3FK)N2W(M@L0M"Q;
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MIVIZIJL.@Z5:M<7M[(D<$$:%I'D=@J*JCDEB0 !U-?M7^V;>W?[+/[+6@?\
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MH;YI70D#!Z[>?*OV<O@'XF_; ^+S:-9F/1?#FC6[7VLZBW%KI.E6XRSNQ(Y
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M0J(,XRS' 'X]3Q6PO_"-:$@:0#4[U6&%Y%LN,'KPSGKP-H[Y(XH J:?I.O\
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M$(/&/_!7+X<>,?B)X9^(EGX+3PCJ-OI[PW5@]V9C/&9-P*2Q[0,8P0:^9/\
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M]"O4.IZ=#,81J&G.<7%NQP1\Z$[2P(5PK8.*3PJMH]257UU6A_3/_P '(_\
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M^T/\"_!5_IGBKPU8P3V%S+K-]<I&[W$49)CEF9&^5B.0:_A#_9G_ &;/B_\
MM=?&[0/V>_@5I3ZOXE\1W*V]M"#M1!_%)(_1(XURSL> !6U.K&:YD9SIN+LS
MP@]*NPK;S66T,?-]*_TM_P!BG_@U1_8 _9U^'-KXG_;(E?XE>*XH!/J4]Q<O
M9:+:L!EUBB5D+1IR/,G8EL;MJ9P/K!/^"*7_  03_:5TZ\\(_#/P?X3O[FW3
M$S^%M7'VN#MN9K:=F4Y_O#![UA+%POH7]7DS_*0\L?Y__72*@(R:_IJ_X+@?
M\&]'C+_@FKI;_M%?L_ZE>>+OA+-.D-RUXH;4-&DF;:BW#1JJ20LQ"K,%7#$*
MPR03_,PO"UTTYJ2YDSGJ1E%V8* OW>*]+^#_ ,)/'OQX^)V@_!WX7:=+JWB'
MQ'>Q:?86L0RTDTS!5'L!G)/8#->:G@9K^O\ _P"#/O\ 9,T?XI_M@>.?VI?%
M%LMS;_#'2(+73@XX34]:9U64>ICMX)E]C(#U HJ3Y(N1-.'-)1/ZB_\ @D?_
M ,$'/V7O^";?@S2O'7BG3+3QC\7&A62]\17L0D%E(Z_-%8HV1"J\CS!^\;G+
M '%>\?M%_P#!=7_@E+^RKX]G^%WQ>^+VGQZ]:/Y5S9Z5:7FKFV<'#+,]C!/'
M&Z_Q(SAQZ5\J_P#!RS^W5XN_8N_X)X7>C_#"^GTOQ7\2+U?#]E>6[&.6WMRI
MDNG1QRK&(; 1R-Q(((%?Y7(>2>1IKABSN<L3R23U))KAH8=UKSJ,[*U94O<@
MC_:;^"?[2O[$W_!1KX0WUY\'?$/A_P"*'A*^1K;4;)D6X4*W!CNK.X421[AS
MLFB4D<XP0:_A#_X.,O\ @A9X*_8?LX?VROV1]/>S^'.IWJ6>LZ.C-)'HUU<'
M]T\98LPMY6^0 DB-RJYPRBOPT_X):_\ !0+QC_P3<_:^\.?M#Z(UY=:)!(;?
M7M+M) AU#3Y 0\>&(4LIPZ;N RCD5_4=^V__ ,'2O[$_[8O[(OQ$_9AU/X3^
M+(1XUT.ZTV">X>R>.WNG7-O,0)B?W,P208&<J,5I&A4HU%R:Q,W6A5A[^C/X
M8HQG [>E/ &W-?<W_!.K]@7XO?\ !1_]IG2?V;OA"\=I-=(UUJ&I3J6@T^QB
M(\R=U!RV,@*H(W,0,C.1_?EX&_X-V_\ @B]^PK\)SXW_ &J)?^$ACMMBW>N^
M,-2%K;&4_P ,<,1BB4$YVIAWQU9L9KKJXB%-V>YS4Z$JBNMC_,O\FX^SB<(=
MN<9J[;*K,?-!7Y>/]ZO]0?X;?\$S/^#=K]M_3=1\&_L_:%X2UZ:UBW7">'-1
MDANX4R!Y@$<@< $@;L$9(!ZU_++_ ,%U_P#@@_I/_!,Z"S_:$^!.J7>M?"[6
MKE-/-KJ#![[2[Z12RHTJJJRQ2;6V,0K+C:V[[Q*6*A*7)JGYA4PTHQYMT?S,
M!"N.>0,4\<#%?UM?\&V__!*3]B7_ (*+?"KXF>*/VK?#=UKEYX;U6QM;![?4
M;FR$<4\+.X(MY$#9(')!(K]<?'__  :L_L9ZQ^V;9^*=*6\\(_ W0_#5K-?:
M>FHRS7.IZT]S=>:K7-P[O! EN("Y4@DD!<'<:J6,IPDX2W1G'"5)Q4X[,_SM
MQ&,ALU>MQNQD]J_U<_"O_!#;_@B[XR\'-HO@SX8^'M8M(1Y#WEG>/<3J0,<S
MI*6W?5LYK^/3_@O[_P $1/!G_!-K4-!^//[-ES>W/PX\3W+V$UA>L9Y=)O@-
MZ*)NLD,J@[-XWJRD%FW#%4,=3G+DM9CJX.=./,]4?S2HI*C%=7H6EZC?RRM:
ME69%R<G&/I7T7^Q3^QO\;_V\OC[I'[._P%T\7>KZF6>:>4E;:RM8\>9<3N =
ML: ^A))"@$D"O]!#]F+_ (-J/^":?[+?PZCUW]HX/X\UJ"#?J>K:U=FRTU"1
M\PC@1TC2,'H9&=O5NU=-7&4Z&DMWT.6CA9UKN.W<_P UY$*,VX\]_K6Y%$_D
MB;'RG@5_IVZA_P $3?\ @B+^U'X<N].^&'A;09?)&Q[SPCJO[VW;H"6@E=<^
MSJ0>X-?QT?\ !8?_ ((D?$W_ ()C:S;_ ! \'WT_BWX5ZO<>19ZK(@6YL9VY
M6"\"?*&89V2J KXZ*?EIX?,*=67(M'YF>)R^I3CSO5>1^%Y@2[C\H\5&=!EM
M8_,&60_Q$<5_03_P;S?L&?LS_M]_M%^-/A]^T[HL^M:7H^@K?VL<%Y/9E)S.
MJ9+0.C$;2>"<5_2?\<?^#9?]D#QG\6_ EC\)X+KP=\/=+BOKKQ1MOIKN\OI%
M,/V6"%KAY!$"/-:20 X Q@D@KTU<?AX3]E5NG^'YF=' UJD/:0M;\3_.@_LY
M,;BM1(EQ93">T.Q@,9Z\'K7^HWX _P""1G_!$#Q%%)\+_!'A'PGX@U&T4K-'
M#J@O-07;P2Y69I0?4GO7X$_\%D/^#<KPG^S_ /#;4_VI/V(3>S>'M$B:XUOP
MU<.;F:VMUY:XM96^=T0<R1ON95^8,0"!C1S'#SFJ=FF^YM4RZM"#FFGZ'\;+
M6QG7=WK NK=X,[N![5_71_P;V?L!?\$V_P#@H5\._&W@/]I/PM<ZE\0/"EY%
M>I-#JEW9B;2KM0B 1PRJI,,R.'8#I(@/K7@/_!Q1_P $I/@G_P $^_&O@+QA
M^S)I%QI7@[Q1:W%K<0SW4UYLU"V8-D/,SM\\;CC./EX'6G5Q,'6^KV:E^!$<
M-4]E[=M<O]>1_,?&,D \"M.X73TMT$19I#]X=A7WK_P3 _9$M/VV_P!N[X?_
M +.>LPR3:-J]_P";JPB9D8:?;*99R&4@K\BD9!!YXYK^N'_@KA_P1K_X)$?L
M"?L%^.?V@?#?@6]A\3);+IOA_P W6[^1?[4O3Y<+[&G*N(LM,5((8)@]:RJ8
MF%.HJ<KW9O2P\JD'-;(_@:"*1D9Q3MBT%_FZ8S3J[3G%!V]*F0ENM0@9.*G5
M2O2@3+"(,XJRA13D\ =34,?6KT#E#D=R.OM51,Y(F7)..P%0<LP]#5V\E^UW
M!GQLSV7I4:*,X]*H@F@C#';Z5KVUA+-&TL0)5>I[5#YJR,K!0NU0O'>NAT[4
M]2CTZ31;7;Y4YY!'/YUK"+$W8HVEM(TQA0X?&>>PK5C+1CYAQ586IMW8-\K*
M<$5;;&P9.36O*S%ZL+B:WD9(X=V,?,3ZU- 6P%)''I51!D\<#TK5L[=)EED:
M0(4 P#W-"T'%=RU;D[N.QQ5W6-4BT#1I=1F(!4';]34=HFX@ =>>:\=^,&OJ
M7BT*W;)4;F'O6.*J\E-LWPM%SJ'G4174+V2\NVRSDL"?>KTMY%9V1FCRNW@D
M=VKE[29(BKW!^4\4NIZ@SQQVB !!S[U\TVV[O<]^R6BV)+Z99KAKJ%OFXZ5F
M-<21,K.QR.?KFH0\<<;*#BL\RF5@,9)IQTW%(O&2>X8J[';Z=JU;=FMF\U<@
MD=15.T@?A3]ZM$R;(FMG4$GOZ4W)&;1H/JUS-9K9.R[4)P3UP>U6K33)Y8'N
M8SN6+K]*R8H8&MM^26WX('85O0W<MK QMN4="KTX:[$O0S2^URW;MFE20%LY
MZU1EE9D&>":;&X7C-;]#!HN2;2WRU*GF1G"9#'G-4I;A5QBNZ\ 6UOJVK&"\
M=4C"'!?H3Z"M8M#2.)>[8R_-R>YJ]%+G@UI>*[6PL-3EAT[]Y"K8$G0$]P*Y
MI)B"&/%*4D.Q[I\!?AQJ'QB^-OA3X5Z7&9)M>U2UL@!R<2R ,<>RY-?;7_!6
MGXNVWQ._;;\1Z+H,@;0_ \%KX5TM5/R+!I<8C?;[-,9&'L:ZS_@CEX<T^#]H
M_6_C]KZ Z9\+?#6I>(9';[HN$C,< SV)=LCW6OS \6^)[[Q=XLU+Q9J;>9<Z
MI=374K'J7F<N3^9KY2+6)SZ<NE"FDO\ %5=W\U&$?E(V:M2MW?Y?\.9 9C^[
MJY\R,.]4%/SU<63>P!XKZ-R3T1BDNI8DQYOF$Y([4AN\$CN1BG3(AY!.:A@@
M4OEZW@P:1JZ<Q,9W\@=Z_:W]B"]F_:V_9!\=?L$ZU-%-J^G"3Q/X+$A_>)>0
M+NN+92>TJY90/XBWKQ^(S,JOY2G:#7KGP$^-?BW]GSXQZ!\8?!,Y34- O([E
M!G D53\\;?[+KE3[&O'X@RZ>-P<H4':K%J=-OI..L?D]G_=;15*7++7;9^A=
MG^&\VF>";[7-91X)[618S&W!W X88ZC!KU7]GG]F'X@?'CX\>'_@AX.*I/KR
MI--< YCM;3&Z660]@B9)]^*^\?\ @IKX2\/W6M:-\9OA-;++X%^+UHNN:7+%
MQ]FU!N;NU;'&5DR<=LD=JZ[QSJ&A_P#!-?\ 9$7P9IBM'\:OB_8(=0<M^]T3
M0F'$0/5))SU'7&<_=&?)K<2SKY?0G@8_[17]V$7]B2TFY+M2L^;NTH[M L/R
MS?/\*_I?>?.'_!13]HKPCXWUS1OV2_V>W\KX;?"Z-M.L0G"W]ZG_ !\7C8^\
M7?=M/ISWK\Q-.TU[W+L<%!SGN:N>'51=:0RM@%@,=<YX->E77@'Q4GA^X\0V
M=E,]E&[#S%'R@J>0?3CI7OY5EU+ 86&$HZ\N[>\F]92;ZN3NWYLSDW.3DSS.
M-QO(8'IC\:T(HI)F0;=X],\Y[5J7.CRW]W9V.FLLDURNXK]W!Z[<GC..:BAM
M-4T+61!=$*ZC*M]Y3CWZ5W.3V%R"N]Q:.%NL[L9X_K76:#JPM)8[FS;;*>-S
M=@:@\'OIVL^)6_X22!KN.2.3;'&=IWX.TXXZ&HK[PAXAT(VTFJV[0K=9:')R
M2!_A4.5G8V4-#9UK56N[E0S!0IVEEXS5,V[$BVL\%&P7/>K,?A[6[O1/^$HD
MA+V1F$ F ^02'H/6K^E:7+/?F"S1V('*CK6+D[F\8:'KW@EHM#N!JCVT<P5?
MNOQG-:4U_P"#+^QN[/4[1X;Z6<2QW"M\L<8'*[>^37CD=Q<AS!O;<&X!['TK
MJ([20W$<=\-I<9W#OFHE/H:0BKGH5IIOA^+PQI^JRRB:6.7+P$89>>!GH<BL
M#QQI>C:A?!]&D,:QQ>9L?MD_='K7MVAZ!::7X*LO$=ZD<Z_: 'M'0GS8U!)<
M-V '6NC\-_";X=>,-6U-9=2,$XVM96RKSASDY+>E8NI8ZHPT/CS3]"O8;"+6
M%F5U+$/&/OK@]:]T\%_89KU8I9&(8A97 X4''6IT\)Z=X9\4W6D7RAQ!<20R
M =7P2,CM7>6/AV*QU.UM]/*-%=9E(Z; I&0WTXH=32[$TCN1X(>:VEET -=6
MT3[!(1@')Q7=>!-"\4:3J%Q;6T!>6.$M, "Q1 1GI7>>'_A+X\U#2-/NO"]X
MLR7LCNJID(-C$D<\9VU]Z_LN?"FYE\#Z_P"-H;F$7UW:26P5U#,H;[Q/OG%<
ME:LHJYO3IN6B.G_8W^--EX.N/$GA?39)=1O[BV$]H&.5*",;E^N1BO+-;\ >
M*_%EAJ'BN[MEL;/49F9&#C,;*>%(/J1P:]C_ &;?V1Y_#^LW'CO4M6/V:)3\
MT'^R?WD;>F:]6?X4Z+!KFL>$KY)[B:T@,^FHKDB48)!(Z$@GI7GQG&$N>.YI
M*#Y1?V??$6I:+I>E?##Q?9R7,7E2@2!@Q ^\I0CKP1^-?J9X+\0RZ-%;:7?2
MYFCM0P*MN$GIU[^HK\UO@PC7&C^%-?EL)5?34N['4!"27BOE;,;'V92,BNO_
M &@-2^(?PKT?^UO#$LC*SI>Q-(,M&K'YU;V&<_2N;%X:%9.,U=-6:>S79FE&
M2/H?X\_L\WOQ \767QG^'%_-I6MV$!AO+>$X%Q#DL#CN02:Z3PCX\\,-:I87
M,A>ZLX(UO(YAGD\9)/H>M<O^S)\=-8^+W@2W\6@K!+!,;>Y7JI8=U/H?>O2_
MB9\*++Q?8:CK'@X+'?W<!2\ACX\T$?>7T.:^4AB:N3-8;$.^&;M&3U=/M&3_
M )?Y9/;X9=&=,(P;YC'^,/P1^&7Q9T:*POHXHV1&DA*]!O'."/4U^>?B_P#X
M)T> +KP[#J&DW$L%[:,SWD9.?.11T7WQS7J'PHU7XX_#2Z'@KXG6<E_I<,;&
MROX_F:W)8@)*.I '0UTWBGQ!XP^%M_:>+=1FDU#PUJ,PDO%'SO:8Z$?[#=_2
MOJX8JK&UMBZE"DT?C+\</V3QX.M&OO!]VVIVLZ&40OQ-$HZ[AWP:_*CX_>#[
MS2OA=X@OY!L3[(_!XSQVK^IOXM0^#_C1X6N/B+\)#;3ZM&CPI!"^UV'LF>37
M\[_[6GA'7]/^"OB;3];L;F.]TVTE:8E#A0QYW_W>O?BO?H8QRI-2['B5\+R2
M4D?S^XL1XI LI'N+5;D"-Y 0SH&X)'J1VKZX^,TNOZ%^S/X.L]*^)MOK6B>(
MM5U+5)/!UM.6DT:YB;RA+/'N.UID.5R%R,XSR:^6O"$L'_"=VEYJ<2B%;CS9
MHP. J$LP_(&O8OVA]3\$S6'@O1/#G@&Z\$ZI8:)$-6ENY'9M5GD8L+M$=5VH
MZ_=QD'\.?/.DZ7]B'PS\5=4^/-MXM^$O@>R^(=YX4LKS6+G1=1CCFM)+2&(I
M(\B2,JML\Q60#+;PNT$\5X7IVK0:W\1KGQ9-"-,3[1/J!BL4VBW(+2*(U!&%
M5L <\ 5Z?\$K7X?V/P^\=>,=7\>7WA'Q-8:?'%H]C91.?[5^T2!9X))$9=B;
M.3G(/4YQBN=^#GPT\=^/(+W_ (0BP>\N;R[LM#MV4@+]MU-F:*-BW \R.";G
M/:@"]\14^$ME\(?"?_"OO%&I:EK^J">Y\3:5<1-%:VETCE83&WW9=T9SN!8C
MOCI5S]E+PAKWB?XSZ=JFD^"Y/'UCX<_XG&K:0L;21OIULR^<TH7D1C< QZ9(
M'>M3]L'QKXY\7?&V\TOXD>%])\(:WX9@BT*[T_1H/L\ EL!Y;,P#.&D8@[F!
MP>,5U'P7M]!\ ?L\^,?CMX=^(4NA^,%F3PVGAZWB='OK#44S)(TZNOR+Y;$I
MM(W(N3R!0!\[_%CQ7IGCKXF:[XNT33X])L;^\EEM;&'/E6MOG$4*9Z)&@55'
M8#%?6OAK7?C_ /LW_L:ZE=01Z+=>"/C;)]C9)F2ZNX9M)8D2+'G,+CS2%<@G
MOP<9^&]'TG5->U2'2=&M9KZZG;:D%NADE?N0JJ"2<>U>R?M$:A\!KSXB,O[-
MT&JVOA=+: )#K+J]P+C8/./R'&"XR/\ ]5 '+?"?0+O6_%]H+$JMP)HH;5I)
M/*07=PXC@+/D;55R&)Z #GC-?4?[27COXU?!75O#?[*_Q!@\-W=Q\);N66VN
M;"WBO([F2\V3MY\C*1<+T^5U^HKS?X1:[\ ? ]Q=Z!\?=&U#6[:;2+N6)-/<
M0/#JTT9%H7.\;HXAAFZ$,[ HP S\X:#ILOB#6H[:>39&?GFE?)"1(,LQ(!/
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M+H\;F.0%64X(/4&@!M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYW_!7OQ-H.F>-?#'PT+VFH6\-]:3+J-JI,<JB2-A^]!!P0?45]Z2_P#!,_\
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MS4%U6TN[RW;S8A'<"WMGM[I2H:(A#EA@-D@']SO^"M?_ "C.^.'_ &*&I?\
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M;<)W9=9+FB?WR_\ !S-_RA$^-OT\.?\ I^TZOY[O^#)]0OC;]HK'_/CX8_\
M1FHU_0C_ ,',O_*$3XV_3PY_Z?M.K^?#_@RA_P"1V_:)_P"O'PQ_Z,U&IA_
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M+B=5!.C:9("DE[% !B0V^5^7[L:DR,"J$5\X?\'$W_!4+XR?\$R/V2]#\1?
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MH'4]Z_JK_P""?W[(O@/_ ()A_L:R_"RXO(AI^B7&K:WJ%Z.GER2O*&8G!)2
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MQQX*\2_;_#MC'J<ZK"M\4&9MH;>C1#.'( &2001D?*GP\\+/XAUQ+_4=-O\
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MM$E\10VUS/!]BT>))'M+0ML,JKPTTK\!4XPTAZXVIG!VX?\ PD_AG4]$FO\
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MAQMB\N,_=>; S!#G'7]X_11R66+Q99W-@L=_\2E-I)"I^PZ%;_NS$&/60?\
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M6+<!Y?&XKG%?VU_!KQY?_%/X1^%_B;JFF/HMQXBTJSU-["5@\EJ;N)9?*9@
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M%NJ'\!*WYU\$_P#!F#_R>9\6_P#L2X__ $N@K[;_ .#UC_DEO[/W_85\0_\
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M+#>+?!MLL/BJ&W3Y[[28_NW# <M):]"W7R>#P@P 6_\ @S*N-!?]C'XIVUF
M-03Q?&;DX&XJ;2/9[XZ_C7XZ?\'D?_"5_P##R/P)_:?F?V1_PKNR^P]?*\S^
MT=0\[';?G9NQSMV9[5S7_!JE_P %*OAQ^Q]^T[XB_9M^.>HQZ/X9^*D=NMAJ
M,[!8+76;4D1+*QP$2XC9DWDX$BH.C$C^T[_@KE_P1\^!G_!77X4:+X>\::Q+
MX7\3^&FEET+Q%:0+=F!;G;YL<D)>,30R;%)7S%((!##G(!_E)_L4W'BBT_;%
M^%-UX(W_ -LQ^+]$:Q\LD/\ :!>1>7@CD'=CI7^N[_P5K_Y1G?'#_L4-2_\
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MOX]_]BX?_2B&@#^ _P#XBFO^"S/_ $4#2O\ P0:?_P#&*_5+_@BG_P %]_\
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MV8_^"@,%]XD\-Z0J6FD^*+51-J%G:H J0W,>09TC& D@/F!>&W8!K^,3R_\
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M_G[)&$Z<U8VY SS5SPD:E2-1O5$0QDHTW32T9]P?\$]/V\?C-_P3J_:.TO\
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M'WIQBCY?^(VO+JWB>0ELK$2B_05PEU>F1=J<"LV662>9KF7EF))_&FQNS-M
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M\-? W1? W@S4OA9K]]J^NW]E+)XCM;JV$,-C=!@(XX7R?,#+N)R.,#UP.?\
M#]E\3OCY\7K+3K,S>(O%GBC48XT-S*&EN[NX< !Y)"!EV."68#U(%=O^U5XH
M\3>*OC?K#>,/#6F^$-5T_P O3KO2]*B6&VAFLT$+$*A92S%<L02"3FM0/2/A
M+!\3?A%^S/XR^+[^!]+U[PGXV5O"D>K:DJRO87JXEWVZ[MZR!>C$8R!SQBO%
MOV>_ WAOXB?%C2O"OB[Q;:^![*4R2'6;P,8;9X49TSMR0690JGU(KK/C6?@W
MHO@CP9X?^"/BS6-;2\TR.^\1Z??1-!;6.L-\KI"#A9 %&-X!XQ\V<@<_\/OB
MIX)\(?";QG\/]?\ !UCKFJ^)!:#3]8N'99]*^SLS2&( 8/F@@')'0=>E &3\
M1_B1XF^+?Q8D\8_&;7[OQ%-+/#!=ZGP]Q+:V^(P8PV 2(U^0' ]>]=M^T!;?
ML\R6'AS7O@EJ^IWU]?6\IU:SU"%8ELFC?9!'&RDA_P!V!N.3SSWJ7]F#X;>/
M/%?BN_\ B5X N](MKGX<VH\3O'J\R1I.NGN)1'&C@B9R5XCX#=":\X^*GQ+\
M1_'CXL:M\3O&'V6WU/Q'>&XN#!&(+=7E(!(4#"@=3^= 'GMG>ZI902_8I98(
MIQY<FPE5<#YMIQP>1G'J*M^(O$_B+Q9J1U?Q3?W&HW914,US(TLFQ!A1N8DX
M4<#G@5]:_'_5/B5\!O!DG[%%QXDT7Q)X9MK^'Q(+G1\3Q-=7EM'P)F57^50J
MLO8CTKFO@'X"\9>'/#5[^U[HJZ#J.G?#G4["2YTG5I5:2\:>0*JK;,/WL>3\
M_(P.><&@#:U+Q':_L_\ P?T:[_9_^)<E[J'Q&TFXM/&&CVUN\/V)(Y$*0.[C
M$@<$G*'(VGLPSYU\)_A;\9?VQ?C39_#WPG(=:\4ZRCE'O9PF]+.$L=TCG^&*
M/ ]ABO._$FK:Q\6/B+=:KIVFPQ7WB"_9X;#3XMD2S7+_ "QPQCH,D*H'TKZ/
MU'7;?]F'PXO@6X\*:GX5^-?A[5Y7N-4NG79#93VY00_9W4XD*R;@_8$$'.*
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MH'WW>HR1YV2WTR@&9P>57[B$_*.] "^+O'/@[X7W]R_@G4#XM\9W#,;SQ+<
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M2:I;63,=/TBT06NEV(;KY-NG&3T+N7D(ZL:\-_9*_:<^('[&?[1OA/\ :?\
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MDXJ>H!U%3U<3.04H.!24H&3BF268)&#JZ\$>E69)I+J8W-P2SGO5-?D&:L
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M0?0^U.,4W:0I3LKH^B5FT&_AA!4S21D?-".XZ9]JW?B'X:UGP9X+\,W:O:W
M<2MLCSN);L^1VK@_#MQ<:9<1RJ-@A))QP6'6O7(FU/7K3^P?$-W&K6K(\&0"
M@:3GD_0>M*KA^75:B52^Z/%/AKXL\2VWB;^P;V.!KBY22*W9^(XPX).<_7BJ
MG@76(A9^)=0U81Q2*@,49)4E]P'R#N>IKHO$OA34;K4+S6;=+:&2TD$B&+A&
M*C'<]P*\<N[FZL[9=2U#RUV2!8V;@ KR>*YW?9HT4K'K/@SQ.;^QU/0I//:Y
MNXE\@QG&XH>58=QVK/NO$=G/IX20&SN8'82NP.#DXQCL?2LSQ!=>(/!OB6P\
M8^'%CD?4H8[F%(F#8\P[" O;E>GO7*>--<NM4;4)X;[=%),CL@0+(I/4'Z&A
M1+]IW1VUYXIT_1M6;3B\\%O<A#B4[3R!GCT)KJIM05]7AEMY4EL82.0/G4$=
MCWKRW3]1T'Q7X8CTS5;J*:]BSMGD/[P(">&^G:HO!&GS^+=6NM&TW5Q8O##*
M824+>:ZCY5 _VL5TQA=6.>I9>\CZQ^&?BKX8^&=7TG6=8=KZ,WCI>#^ZAP48
M>A!)YKZZ\.6WPQ\::!KFFRRRR#2M1;5'VO@3P<@%?1AFOR1T.!(=:N_#?BIF
MT^YA=%(=>"WK[@]37MK> /B4_@C5-?\ A_>2ZA8Z=&5O)+(Y_=@C)QZ5$J#W
MN'ME;4^W/&'_  SC=R'68;D[-756*##/%+'T/OG&#7P[^VW\1?AUXZ^&>OZW
M8V/V+6DLQ;%4&U2(@ )..Y JY\!O#O@/XE6%QINI7WV/78)E-H&?8KAN_/4@
MCIZUR/[0_@0K\//&VHZI<0[[739D:-QM>69%SN4>WM6L:?+N93JWV1Y+^S3^
MW/\ "'X]_"NT_8L_X*00RZMX:CQ%X;\8I\VJ>'ICPFY_O2VP/#*V<+V( Q\=
M_MH_L(?%K]C7Q-;2:]Y>N^#M;'GZ%XEL/WEAJ%NW*E7&0KX^\A.1]*^'J_3W
M]C+_ (*(77P8\%7G[,W[26DGXA?!K76/VO0[IM\M@[]9[!VYAD4_-M4A2W/!
M))^7KY=B,OJ2Q661O!N\Z6R?>5/I&7=?#+R>IFFGHS\SM/U&_P!)OX=4TJ9[
M:YMW$D4L3%'1U.0RL,$$'H16[H7B[5=%\9V7CF8)J%Y9WD=Z1> RI-)&X?$@
M)RP8CYLGD5^EW[9O_!.NQ^'/@RV_:D_9"UK_ (6+\'-9^>/4+92UYI+MSY%]
M%C=&R]-Q &1@X/7\J*]G+\QH8VE[;#RNMFGHTUNI)ZIKJF)IK<]5^-WQ9U3X
MY_%76OBQK6FZ?I%SK4_GO9Z7#]GM(B%"XCCRV!@9.223DUY5117<(]SU7Q+\
M"Y?V?=*\,Z)H-]!\0X=4GFO]8>XW6DU@R 11+%G 96R2<9_VN@'H_P "?#MQ
M\)?#R_M-?%[X:-XS^'EZ;K0;>6YE-O;?VI+"S1E77+%HPK, 5VG!YR*^1:ZF
M3QQXRF\'1_#R;5KQM!BNC>IIQF?[*MR5*&419V!]I*[L9P<4 ;_PU^%/Q&^.
M/C5/ GPFT6YUS5[E)98K*U&^0QQ LV,D<*O^<UV/QW\9_!_Q;>Z$OP?\)3>$
M4T_2;>SU2*6Y:X^UW\(Q+/S]W>><?H*W?!/BKX??#?X11_$;P!XIUS0_BU;Z
MM);QQ6(,-NNE/$O[P7"$,)"[.I4=L>M<E\ ? 'P]^*?Q2MO"7Q5\7P>"=(N8
MKF635KF%YT22*)G1"J<YD8!0?4T =!\.?#OPR\->%_$>M_&.?7?#_B:/3;;4
M/!HM8/+BNKDRG]Y([KN\H!3L9" 6!P>,5Y%XF\5^+_B9XNG\4>.-3GU76-3E
M4W%[>2&221SA0SNQSP !D] *[CXR?&KXB?&&[T:U\?:M_:\7A73TT33)?+6/
M;8V[LT8P "?O$Y;)YQ7T+;>#&_9#\-21_M%?#_3/$Y^)?AR&]T"9[X-)I\<K
M9$Z^0S;)2I'RN!CC.?F% 'H>H>&-;_9T\*^(_P!DCQ5X=\+>)-9\17^F7FGZ
MY;W"3W"R!%D$,4^X1B'Y@)"Q !++R6^7X8\8:[<03W.B6\XN)'<?;;E>LKK@
M; >GEH1A0.#C/3 &5K>I6WB_Q4;FV0:;8M*$AC):1+6 MA02 20H/)QDGGJ:
M^L?BAXID_9<TGQE^RU\*_%>@^/\ PSXN@TRZO=9LK;<1)$!,(XI&)*,C':^T
MD'H<'( !\/8QQ77Z3H]A9V@U_P 4*XMV5C;0#Y6N&&0#[1@@[F[X*@YR1:^'
M%MI#^,M,E\36Z3Z3]JBCNS,S1PJDAQF1TY51U/J!7>?M+>$-&\!?&O6O"'AW
MQ58>-+"Q:%(-6TSBTF0Q(0L0R<+%GR\ X&WCC% 'C>JZG<ZO=F[NSR1@(!A4
M4=%4=@*^W/V"?VP_B;^RG\4GB\.:=_PE'ACQ'&;+Q!X9G&^UU*S8'>&0Y4,J
MY*N1\N#GC-?('@?P-XC^(>OKX;\+1+-=>5-<$.ZH!% ADD;+$9VJI.!EFZ*"
M2 ?L+X<7_P #? GPX\8>#=5TJYU+QE<P6QTS58Y56RT]E8F8W>X_,",%8E#$
M$ '<YVKS8S!T<51EA\1'FA+=?UL^SW3U0T['[/?&?_@E-^SC\,/ ?BS]K3P+
M=:[IGA:ZTT7ND:1+:-)>Z7?7'W+*[5@94@+%0)E^=DR!(HRQ_$K]H[]K3Q_\
M6KW3H?$]W!J%YHFFP:/;7$<$42Q6ML79%/EJJNX+D!ONH.FYCN'L_P %/^"I
MG[1/P.^+\GCVXUFZ\<6.J6Z:;X@MO$$C7,>KV" J(I$<L$"J3L(RP).202#]
M!_'G_@GE\-_VF?A-?_MK?\$WKB&\\,VT+W7B/P;/*!J>@RJ"SJBL?WL/7;@Y
MQC&X9V^!A\=6RVI'"9A+FIMVA5?7M"IVET4MI^4M&[7U1['^R/\ \$CO!/B#
M]F+0OV[OBA<ZE\28;^-KN+P5X>BS/=S><8TBGN"^0NX$S84$+D!LU=_:B^*G
MPY^!VHV>N_M916'B3Q=HZX\,_"C0Y-GAWPXN/D?463_6SIP3&#ECRQQP/'/V
M</\ @K5X0_88\"P_#W]D7P;=77]MZ=;MKH\0S;]NMQJ4>2U$))\HYR%?!SC@
M=3^5=QX=NM9UF_\ B+\5)PD]_<274R;L'S)RS_O",D,Q^[$N789)V*-Q^H)-
MGXD?$SXY_M>>//\ A,/B)J$M](62V@55V6ULC'"6]K @P .BQ1J21V[U<\/:
M!I>@(EMH:!Y9&$;3GYGF8C<4^0D_+P?+AY.3YCCA:DTGQ3X8ET2^N=:LYK6Q
M6(0Z=(-L89N/,01*-S*0<D(RY)'F2'//':WK%_J]H;V_?^Q='E3RT! -U<0J
MV0D: #"#&<+MC!')+8! -W4O%(MKTZ7H<;:EJ+ QJ(1R5'($A4E5C4#_ %<6
M 0?G=L5PDT<0U2&/6V_MO52XBCL+?F!&SC:3'C/3 2/@_P![UTM,TJ_O[)[?
M3(#HVFW"E?E7?>78';J"5W<L?EC7N2<5W%O;>'?"6G22!H[*RD5HY&,F]YE.
M?DW)AICRI*Q;8,CYI.1@ XR+0)=6D.H^*KA;G[,P1;6%@EO"W&%9QP"0#^[B
MRY"]NM>H1:#=20W,D=N['1U%Q<QVZHGV--XC'RME+8>8P0R2EILGA0W7Q?6_
MB=-*8XO#$9LUAC,23[OWH5BQ(CQ\L*G=R$ )YRQR:SO ^IZ]9VFI0:)I]K/)
M=)&IOKL#%H%<997=A&I8D+EP>2-N&P: /3]5N+'3[(OJLHM89L2)%RRNHP=^
MQOWDYQC#R%(_0$=.D^#%GK_Q=^)>D>$O#N@3ZO!<L\'EK>+9W5Q(8R4 N75H
MXE5P'V1QCY 0Q/WQYY:>$+:6Z&IZK(^H7-PV_P ^9783%C@>5#_KICD-\S!4
M]2.I]U6_\6>*M&T[4?#VBQM'X,A6%[ZS@B46[2L94:[NE MX29"=F"7"_+N#
M Y /J7X9Z?\ M\_M2^!_&?@7X=PZGXGT2RL=.@UBW\M)1%:6#,;***%R97*E
M28R[G< >"!FOG3Q1^SS\8O 7B6Z\)_$71+GPUJ5AIK:C(=7<6DSVXSS]HGQ&
MH9Q($BMU9V(VY8Y:OKSQI_P4/_:%'QIM_CA\-XX_ +R6UE%=6.C0RVMCJ::?
MEHR]N%$]R!\^&D"1A<KD9Y\S_;=_;<^(O[</Q%TCQY\1](L])FT&S^PPVMJ@
MFF1<AYG?>3%;G<&.9260 ?*<9H ^:O!OQ5^(/P_\;^'?BBFJ26]]H$T%UI;2
MR310_N6#+L7)N;@,5(SE5)Z' Q7Z?_\ !2+X:^&_C#X.\+?\%$_@I;F#2_'8
M%MXELQ"9Y-(U^W4"=4M\[(6E ,A:4\'D%0U?)G[)'P/\*_';XW^!/ ?A/58M
M2\1^([^Z36%O3+#9Q)"IDVR:B/WDQGB25=EOC+8^<J:_<7_@GS^SO\#KCP-\
M=?\ @G#\6;Q[SQ'J6J2H;.QM7;2K:"W6,07T4IRS-'.VV61W#XVKC%?.9]2G
M0<,UH*\J5^9+[5-_$O-Q^./FK=65'L?RRPJOVB86K/)<QHHG>*19YU!*H1)=
M-^XMXR25!3."0N7S4(DDGCFOK4^39?<D-H_E1LR@EEFO9 7D?')5 3U "C%?
M:O[</['VC_L7/H/@[Q7X[T;6M<FCDDU'1H4;S-*D1ON_94)4LR 8:4@,5SN(
M(-?G!J_CBTNY%FM[<WDT:A%GOL2;5 P D7^K0 ]!@X''O7T%*K"I"-2F[Q:N
MFNJ>S)/2+'4)K"TDN]+"16+JT9\IWL;"1?E#JTF?/N,@[2H;N#G;Q7#ZGXMT
MF)/(8G4L#"P1C[-8K@@CY$P\@QGJ4.<$EN<^=ZKK&K:[=M?ZU<R74S8&^1BQ
MP!@#GL!P!Z5G58'>^(/B?X[\3>&['P;JNH/_ &1ICR/:V40$<$1E.YB$4 9)
MZDYK@CR<GFBB@ KKO".I^#-,_M)O&.D2ZL9[*2*Q$5T;86]VQ79,^$?S%0!O
MW?R[B1\W'/(T9QUH ZR[\<>);_P78_#^[F0Z5IUS-=P1+$BL)K@*KLT@4.V0
MB@!F(&.*Y.BB@ K:T/Q)XA\,73WOAN^N-/FD1HVDMY&B8HW525(.#W%8M%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG^!^(*<@"G9-?N)<_P#!:M;5PC_LZ?"1LC/RZ$A_K2)_P6L5_P#FW+X3<_\
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M>U^ 7P^^.GAWP=JFI6OCR4PVT4 CGD=Y2?L_EPQLTNV1%9LLH H ^X_V&/\
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M%1_^B4ZA_P!_8?\ XY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S_H<-;_\
M!A/_ /%T ?HG_P .-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^B4ZA_P!_8?\
MXY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S_H<-;_\ !A/_ /%T ?HG_P .
M-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^B4ZA_P!_8?\ XY7YV?\ "]/C9_T.
M&M_^#"?_ .+H_P"%Z?&S_H<-;_\ !A/_ /%T ?HG_P .-O\ @J/_ -$IU#_O
M[#_\<H_X<;?\%1_^B4ZA_P!_8?\ XY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%
MZ?&S_H<-;_\ !A/_ /%T ?HG_P .-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^
MB4ZA_P!_8?\ XY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S_H<-;_\ !A/_
M /%T ?HG_P .-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^B4ZA_P!_8?\ XY7Y
MV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S_H<-;_\ !A/_ /%T ?HG_P .-O\
M@J/_ -$IU#_O[#_\<H_X<;?\%1_^B4ZA_P!_8?\ XY7YV?\ "]/C9_T.&M_^
M#"?_ .+H_P"%Z?&S_H<-;_\ !A/_ /%T ?HG_P .-O\ @J/_ -$IU#_O[#_\
M<H_X<;?\%1_^B4ZA_P!_8?\ XY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S
M_H<-;_\ !A/_ /%T ?HG_P .-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^B4ZA
M_P!_8?\ XY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S_H<-;_\ !A/_ /%T
M ?HG_P .-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^B4ZA_P!_8?\ XY7YV?\
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M%1_^B4ZA_P!_8?\ XY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S_H<-;_\
M!A/_ /%T ?HG_P .-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^B4ZA_P!_8?\
MXY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S_H<-;_\ !A/_ /%T ?HG_P .
M-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^B4ZA_P!_8?\ XY7YV?\ "]/C9_T.
M&M_^#"?_ .+H_P"%Z?&S_H<-;_\ !A/_ /%T ?HG_P .-O\ @J/_ -$IU#_O
M[#_\<H_X<;?\%1_^B4ZA_P!_8?\ XY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%
MZ?&S_H<-;_\ !A/_ /%T ?HG_P .-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^
MB4ZA_P!_8?\ XY7YV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S_H<-;_\ !A/_
M /%T ?HG_P .-O\ @J/_ -$IU#_O[#_\<H_X<;?\%1_^B4ZA_P!_8?\ XY7Y
MV?\ "]/C9_T.&M_^#"?_ .+H_P"%Z?&S_H<-;_\ !A/_ /%T ?HG_P .-O\
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M-$RCGK64HZZ&J=UKN.&TPY[XJKNP0*2-R@(8TQFRV?2H942]&TP5HX/F# Y
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MV:^ZSZ"::*^D_$+XBKX8O/ 'PV6^L/#^HR*;JT6>62"X=2"AE!(B+#']T>H
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M%.;X>^#_ (H_'A=/T[2X_"5KXCU-8H=/N;@6=K8"\DQ",R[YVB0,I)* E>A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /_7_A4"8.:?117J'#(1C@9I\:LY 7DTQAD8
MIZ,T?*]:"2;#;MO<=:D*8&:C#$G>>IZU*'R<4 -5B.*EHHJDP)K5XHI=TXW+
MWIMPT+3;H%.T]NF*B;[II46)EWL3GMBJN2PHHHH*%'45.>!FH!U%3'D8H 4<
MTHZBD'%*.HJUL2T3T445K<D*?O-,IP4MTH C"JH '3.3[U:J+RS_ )__ %U+
M18+"$9&*LS3++&D80#8,9'>J]*"0<C@T6"P2*T;%&&&49((QP: 2.12R2SS.
M9)G+,W!)]!3:2\Q>H4444QEI4D"EB.!QFI@H5.M9_P P4IDX/;-62Q\K-2M#
M*29*03C)Z4H4 Y'&1@X[TSS/\_Y%2 Y7=3T)L0EF(Q4@.X5%@!=S&IX8WD.R
M,$D]/>BZ$.65B,XIM,7@[:?3 >B[C5AG)Z<9JNC;34P&3BK1,@3A]_I6E'(X
M.5&*H!2N2:TXV!&<5<21ZM@YIM.49.*;5$R) 7QTJY4(*X'%3540B%2JN.:C
M )X%3U108SQ5I5W56'6KJKMH,ZG0E$? _P _UIP&TXR,TBNNW)]<#WJXJ6?V
M=E;/F#IQUJHF974,>N,CK]:G'2BX>"3RC;Q^647#\YW'UZ<5&)"1DU1,CO/
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M:_/=:=X@.E:3=">.WE#+)C P1W'M7F_Q(U:35O#.HW4BQ^:(Y$W+P6 Z\?\
MUZZ[>ZR%N?#=%%%<1L%%%% !1110 445/;6MS>S+;6<;2R-T5 68_0#F@""B
MOJ[X7?L+?MC?&EXQ\,?AKX@U6.7&R9+*2.$YZ?O) J?^/5]M:)_P1"_;%BLU
MU/XLWGACX?VI^^^OZS;P,GKN568C%>1BL_RW#/EK8F"EVYE?[EK^ U%OH?E5
M\/\ XB>._A3XLL_'?PVU:ZT/6=/<26]Y9RF*6-AZ,N/Q'0]Z_:'2/VVOV4/^
M"@FEV7PZ_P""CVEKX7\9A%M[/XE:);@2[@,+_:,"#]XF<;G4''7@9->>W/\
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M  2;^*VOZJ^I_!WQ3X/\50$@I%::Q#O_ !5]N#^->[_K/ET'^]J.'^.,H?\
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MZ>3;@M[;MFT'O7P=\9OV_?VQ_C_(_P#PM'X@ZO?0/Q]FCG-O;J/18HMB #L
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M*]7L)/%=Q;W-U:><MO)>.&>,2D<(TAXW$=B<XK]X_@!_P5:_9X^,FL:9I/\
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M_@HC\8(OA#I?Q$B-WX8T>UTV;5=8O; ' O'@C'[J!N&1G^^I!7J!7W2GP?\
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ML?LF^._V'/VE?$W[,OQ#N(+[4/#TL6V[MC^YN;:XC6:"9,\@21NK8[9Q7R_
M0,&OV\_X.(B%_P""D]\^,[O"7A@GW/\ 9T-?ARK8YKNP\W*G&3W:.'$049N*
MVN:]S&6C#KS@5G-]X5KV$J2Q&,C)K.GB9)L&MVC%/N6(EW$U:4;:AB&UOK4Y
MX&:F)35]A&*M4:INJ,[B<\5.G !J@CIN1$8)'I5B)>,U&4R2?6IX^!BK2!Z[
M$X^4CWJS$VUN:K#YB/:IUSN&!5)"2+:ME]WI6S:)NY]JQXT^<+ZUT%G&5^4F
MM';E=S-2M)#]:=[/P_=S*>D#_H*_-F59)8YMYR22WYU^A_CZ=K?P3J,BM@B%
M@/Q&*_-V>\,8:,'#$<UX6;S]Z,3U<JC>,FB&:)HK++#&3Q6;6DTSW5@=W5>E
M9:EC]X8KQ[GK-#JE67:FS%, !HV]?:@1:1P0*:Y*TRV@GN;A+:U1I))&"JJC
M+,3T  ZFOV/^$G_!)/4=)^'5C\=/V\_'FG?!#P=J$8ELXM10W.MWL9&08;%2
M'P1TW8/MZ^=F.:X7 Q4L3.U]$DFY2?:,5>3?HF5&+>Q^.T4LB1DKT)YKV'PY
MJEQ>Z8-QR8_E8U^JBZ/_ ,$"?"&[07U?XJ>*V)VOJ216=H@(_BCC."1Z!N:[
M3PC^PM_P3U_:3W:=^PI\<Y[3Q+<C_1_#'C^V33YIW[+%=1?NF8] NT^YKQ:_
M$N'4>:O0JPA_-*G+E]7:[BO.21M23C*Z:/R@EMK66T5YR-X/&*U;3Q-9Z?)]
MFE0%3TKM_C!^SG\<_P!GOXIW'P:^+7AV\TSQ)$P2.U9"_P!HW'"M"RY616_A
M920:_3CX3_L3_ _]B/P=8_M/?\%-K@OJ5Y']H\-_#BU8?VAJ#XRDE[U\B$<9
M4\GOS\ISQN=X7#TX3C+G<_@C#5S_ ,-NG=WLEJW8]"7O:GFO[)'[ NK?'GPY
M??M&_'G5XOA]\(- .;W7[X;6NBO6"RC.#-*WW1M!^8@#)XK=_:Y_;]TW6OAS
M'^R?^Q+I;^ /A1:-B=(ODU'6Y%X\Z]F'SD-U\O./7. !X'^UO^W'\8/VN[Z#
M4?&C0Z3X<TL"/1O#NFKY.G:= O")&@^\P7J[<GVKS7X,?L\?M ?M!7,>F_"7
MP9JNO3R'"M:6SL@^KXVC\37G0P,JDEC\YE%<NL87]R'FV[<T_P"\]%]E+=UR
MW6AX?;27=C8X?G8.>:XCQ-K4>IVJ06[9;N*_;S3_ /@D-\1O!VEC7OVK?'WA
M/X4:>5!D34]02YO0#Z00D\XZ#=UXKCH?"?\ P1-_9TOLZYK'C/XZ:RI_U5E"
MNC:47'H6;SB,^I((K:7$^#EIA%*L_P#IW%R7_@>D/_)C/D/Q9T_3K=U&R)I)
ME )"@GDFOT _8N_8S_:7^-GQV\&:OX%\":[J.D6^LV4MW?QV,HM((8Y59V>=
ME$2X )Y;GMFOJ;4_^"KOA?P!&-!_8]^!?@OP&Y;;#?7EO_;%^,=&+S@(#]4;
MGO78?LZ?\%!?VV?CI^VK\(?!'Q#^(.I2Z;JWB[2+2:PMB+:T,<ERBLACA"J4
MP>F,8KDQ^/S:>%JSAAXTTHR=YSN]$_LP37_DXU!'TO\ M^?\$IOB_P#%+]KK
MXB?'7XI>//!?PY\+:SK4]U:76NZQ##(8. O[LD8.!PN<^U?"-W^S9_P2B^&$
MA3XH_M :GXPO(6"RP>$-'D,;'T%Q<!8R,?Q)N%?#W[>/BR_\1_MI?$W5=2FD
MG+>(]01?-8L0J3, !DG &.E>#V^G0'2S+*ORMR& SCZU64Y/CW@:$:^-DHJ$
M;*$8QLK+1N2FWZIHYI37-:Q^L-K^TU_P1]^$F(_A]\$/$/C^\@^Y<^*M9:.-
MF'<PVVR,@^C*:NS?\%H=;\)(;#]FWX'?#?P(!PDJZ2M[<+CH0\FT9[Y*FOQ?
M&D3J'N1@KDG-9UN29"#P_/3O7<N%L!-WQ'/5_P <YR7_ ("WR_@',^A^GOCC
M_@L%_P %*?B 7L]2^)E]I%NPP(=%AM]+0+_='V6.,D=N237ROJ?[0'[0_P 0
MKPW/CSQKKNK&1^1=ZA/*K?@SD5X?INFW=S^]EC9HUZ$=179:;:7D$2M*P(+?
M+ZXKU,-E&!PW^[X>$/\ #%+\D3=]3J+O[3-F%I#(2<DL<_SJQ:VR0[3> !>W
M'>M>ULEC+&08+@'Z47<7[D[^E>@]%H%CG+BYEN5^QLI>)#O^3KQ4\5CIFIS1
M3VY\N:-3GS.,U0ENX[.39 N=_'OS3E\C3G5IE+[QQGH,T^?34=F>AV1+^39,
MH8>M:HMF2=MP"@$8Q6=HD47V9)?XA6Q).N_YN_2LFKC6AR'BQ;MP"%^3'4\U
MY?J<R68 ;YCC@UZAX@E$D>R67:F>:\@\;06D#Q)I4GF1LN2<\@]ZNCHK,&S'
MAUF3)8]C@58FU47H_>C,G3)KB1-(JD@=#S^-:5I*TC>6!^-:-Z$FPS31MN('
MT%2R 31[^A_6I+6RFNF(C(*(,L3QBMBRLK*XN1#,_EC'&>AJ+H"?1O$6HZ7(
MERK;G1<*6Y*YKT?PS\2-:?4%:^E:1^%#'L!7E>LVZVUZUM%@A3C(Y!I+;>)@
M(WV@]_>GH)NQ]X'XEPV-F$U )<2R1,8@WKCI7NW["7[=VD^!;K7OV7_VIH'U
MGX1>+7VWUORTVDW#<+>6IY*E>K*H.['0GK^5GB*XO[+[/,\AX[^E7[ R>(?$
MELUFI:29<%4Y+8]:NKE.'QV%E1KK>UFM'%K52B^DD]4SDQ%9J=EL?;?[<W[+
MOC/]C+Q];Z=#J,6O^$/$D0U'PUXDL\/:ZC:-@JRNI*[@"-R@\9ST-?$T/Q3\
M23!R]TT$A'!B)7+>O!%?JS^R1^U#\.E\ S_L)_MN6_\ :OPO\13%--U-N;OP
MQJ$F0EQ 3_RR+']XH(QUY&0?A3]LK]BWXF_L6?%W_A O&FS4=)O4^UZ+K-K\
MUIJ5D_W)8W'&<8W+G*GVP3CE>95Z=;^R\TM[9*\96256*^TNTE]N/1ZKW6CF
MDHM<]/1?D==\'?CU^U)X$\+3:YX=\:>(=(CB(>.2#4)D  [ ;\?I7V3\./\
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M?&__  2H^*FF3^'_ !#HVO?"#4KQA%)/HKKJ-DK#INCD 8)_NJ#0\[S"@_\
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M;$@'8*H KYNHKP\%D.!PL_;0IWJ/><FY3_\  I7?R3L>^Y-A1117L""BBB@
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M(OXH>5KQ7\A5T]SY*\%?"GXR?&'QFG@'P'H.J^(M>:)YEL;6"2XN?*B&68(
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MBI$T[P1!:YO]5N'G]+6U$D6/]Z22)OPV&@#TOPCXLM?&GC_2M$U@O;V%Q.(
M;JZ++"LO'5I;>)5!P<ED4=2<5T'B&"V\-ZL;%KZV@NK=E1S:FWE$H!ZQW%BD
MZD@8R?,+>N:\DTS2]%U&R:RTO1M3U.^5M_F1N%C\L=084BD8'W\W\*[G1?$_
MQ"3PQ;_#K1-/F2W-T]Q!&T\H DF55?Y-ZI\XC0'*Y^44 ?8OPD^)/@N_@\.^
M#?B-I(L_"6G>(#J=_P");?2Y+W4=WE,J127<LENLD.\*?*<(.,\D5Z3^T?\
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M![X"_P#!Q+\;/$6D:-:G0]?^$-SXLUG1%7$"SWUC'+>0,F, 3%6D91QB7\*
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M1E:XN$@NM9L': S2$NRJPW*"3M!P.*Z#XH?#+PE\9OV&O^"7OPJ\>;3HNO\
MB'7K.]5SA7@DO-/#H3_MCY?QH _"OX+_ /!)3_@I+^T/\(5^/'P9^#OB+7O"
M<RL]O?PP*@ND0D%K:.1EEN%!!&84<9!'45Y%8?LW_'?X%_$/X8^(_C#\.K\V
M?B^_@NM'TS48/+&M16]TL4L"H_.&D_<L&48)P17ZN_\ !<W]N?\ :UTO_@J7
M\0/ /A+Q?K7@S0?AAJ<6A>&=(TB\FL+6QL["*-8GCBA95S*!YF<<AL?=P*^_
M/^"L?Q4\<_&_Q=_P3A^+?Q,C$?B#7]'LKN_.P1^9.^HVFZ4J,#,O^L..I;-
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MX(]? GX,_%S]D[]M/Q5\4O"VF>(-3\&?"VYU30KJ_MDGETV]6.Y(GMV<$QR
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MSP9\&[CP'JB>*/B'8VNI^&]-,8\_4K2]4O!+",X99%!*YQQ7KGPQ_P""5?\
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MXN>+_@=XCMM#LK=KNY=$BFN88%7<SR6L4CW**JY+%HAM ).,&OB;X8?LQ?M
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M S_@J=\4?A?\&] L/"_AS2[JU6TTW3($MK6!6MXV(2- %7+$DX'4U@_L=?\
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MQXB\->*-8BU[4+*XL[-0U]!''%&T;I LD$:)$@6&%DA&,[,DD[?[)W_!5O\
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M_&#]IWXE:A\5?C7KESKFL:A(S-).^4C4GB.)/NQQJ.%50 !7Z=_\%<YS\.O
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M>EQ4ZUXZGU3!^V5_P30_94T5;/\ 9K^#4GQ!UJ#[FN>/+CS@7[,+6(+&!GH
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M(=*._))>TI_<VIKY3MY$SK<[O45_/9G=>.?AE\6?@?XNG\'_ !=\/ZEX<UB
M[9+34+9[>08Z$!P,@]B,@CH:X37=:N-;\R]N\+(RX95&!A> :_57X7_\%A?C
MM'H,/P__ &I-&TGXS>%5&PVOB. /=QH>/W5TH\Q6'8G->G/\#_\ @EQ^VO\
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MQ?MP?M,Z3=>(]9^*WAG6="-OICK&EFVH0"WMU3S2<06T:HBKDMM4=37X<44
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MQK\A/C-\:_BQ^T/\2-3^+WQNU^\\3>)=8D\V[U"^D,LLAZ 9/ 51PJ@!5'
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ML-C>NCSQ"*%(R&:,E3DKGBOS_HH **** "BBB@ HHHH **** "BBB@ HHHH
M_]/^%U_NFEB.%YH(R,4FWY=M>J>>)N4$@]32Q*%SYGS9Z5.L@\A8-HSGK32F
M!FBX$."F3GBGH#)_JQD#K2'I3XY)8@53&#UJHE*X%"!FFTXN2,4VJ*+%(3@9
MI:*0#5;<,]*=3-I!^7I3Z!7/Z7/^"(?[%/P&^+O[+'QO_:\\0?"\?M _$?X;
MS6%MH7PZ>[>WADAN^9+V6./YY\8943YE_=L-I9E*^4?MQ?$3]@#XP_LQZV?%
MGP D_9B_:&\+ZC:_V?HVG07D.GZWI\K[9UE@N$00/$#N#;<G'WB#M',?\$F_
MV4KC]H#X4^,_&?[(?QGNOAK^U%X5O8I- T@ZLNAP:QHTJIYJPW19-TH=7#QE
M]F-F\ '(_:W]HWQ?^V#X3_X))?&/P-_P7:UGPSKOB66WMX_A?;37VFZCXE75
M]X'FI)IK2J(D7!=V;<4#*Q.X9P;]XO=&=^U9^VW^QG)_P0H^$_Q%C_9@T%/#
M_B?Q1K^EZ/X>&LW/D:%?+#(&OXI?*W2R,>=C +[UX!X>^ /_  2E_91_X)3?
MLT_\%#/VH_AP?&?B'6[36+9O#MI</;#Q#J7VV58IKV0L0(+6"(C:JX8L,AAQ
M7F'AW]GWQ-^W=_P;U_#;P!\ -:T"X\1?"?QEX@UKQ#I>H:I!97<-D\,K*Z)*
M1O)&"JCEL\9YQX;_ ,%(/$6CWO\ P1"_8<T.SO89Y[2'Q,US;1R*SQDWTF-Z
M@Y4D'C(I)=%W_P PN]WV.:_9]^.__!*+PMX>\=_M7^+?@I;_ !'^)GC#Q;);
M>$/A*MQ<1Z3H6DR*[^<S0P@7&"!&$,;'IA5Y8?8?[8_[,'P*_:#_ ."26J_\
M%#)OV9O^&;O'/@CQ79::-/M!<VEAKVEW.S=(+>X1"H#.5#A,Y7AV!*CU3_@G
M5X>_:!U?_@CCIP_X(Y:OX>T3X[7/BFZC^($TE[8:?XA;2]I^S)!<7[(B0 [6
M(#J>I4[LU[5XR^$?[2?C+_@CA^T;^S]^T-\;;#XO?'C3M1TGQ7K^C2>(UU-M
M"T>T5G6!;J>3[.\VV&>1X+9V"DJ,%G7<-ZZ=Q6TU['-_M0_MP?L7O_P0Y^%7
MQ%'[+N@+H'B3Q+XATO1_#XUFY\C1+Y8MK7T4OE;I9&)#%& 48ZU\7_L[_L3?
M"/\ 8F_84^''[7GQ'_9YUC]IOXE_&1+B_P!(T18+R70-!TBV90DMRMG$YDN+
M@MD+(2"H(4+M9F?X3_9U\3?MV?\ ! 'X>_#_ /9\UG0)]>^%/B_Q%K&OZ7J.
MJ065U%9R0AU=$E8%\@< <L>F>:^Q_@/^TO\ MF_MU?\ !,WX/> ?^"8WQKC\
M#?%OX.65QH'BGP3-JT&D3ZQ9[D^R7MO)=;(GVJI4Y< ;B"00 Q:RLN^I+U=W
MV/@3_@H-^Q5\)_CE^P@G_!1GX(_!'5OV>/$7AC7+;P]XP\&7<%S%ITR7O%M?
MV7VJ.)@I<B-U50 2,C/S-Z+^T3%_P3N_X(L:?X7_ &2OB'\ -*^//Q:U#1;+
M6?&NK^)KZ6""PEU!!(ME91Q*P4HA_P!8,$'!)<G"G_!2?Q'^VQ^S]^PS%\/O
M^"@_[26H>+OBIXNUJTEB^'NGZM;:I96NE6C+/]HOY(5(67SD7RU1RI(R&."!
MZ=_P4$_8RO\ _@M_XX\-?\%%?V'O&GA*ZN/$V@Z?:>,] UK6(=*O=#U.QB6*
M5G2?;NA(&[<O) RH8$8N#VYGH*VKLM3YN_X*D?LV?\$^]%_X)2?!+]M#]B?P
ME+X>/Q/\6:J]RM[.UQ>6"1I(LFFF4G$D5M<1.(7*[S'MW%CR?3_VMO\ @DW\
M$?BS_P %VO"_["/P/TZ+P'X%O_#FF:UK!L2Q^RV<-DUU>S)YA?\ >.J$+G(W
ML.,5UW_!7OX2?"/]GG_@AM^S=\ _A+XLLO&\7A?QKKEIJ6MZ:V^RO-59)9;T
MVS\>9##-(8%D'!\NOIG]J?\ ;3^#_P"RA_P<D^'OBW\2=3A_X076O ^F^&=;
MU"W<2I:VVJ:>8#,2F[B&0H[@9.T'O3C*5M/,IQ5]?(^!%_;N_P""(VE_'L?L
MMW_[)VD1?"*+43HMUXRN-5NW\1B%6\HZAO3YEP09#$KG(Y&/NU\@? 7X;?\
M!(KX1_MK_%;7/C;XKN_B9\(_ UE<W_@;2X?/M)O%=TZ[K6TN)8T1X_+R4D8"
M,/( ?N90_5S_ /!NM\;+K]IEO%'B+QMX+7]GV34CJ=SX\3Q'8I;_ -B-)YK$
M1&7SUG,)*C,?EA^=^.:^N/\ @E9H7[&*_'O]K#3?^":EWI%O\2=,TZ.V^"^H
M>-YH7F=(<I<W5K)=(J+-*REHV959$9 X"EQ5.44GRMDI-O5&O^SS\'_V;O\
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M!50Y/W8I\[21@ D@\-D?G%^U1^R1\<_V.?BE>_"KXWZ+-IMW;L6MKG:6M;V
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M)LMG\*!-GI$EY8W&G[K<A6C.?KBK.EWJ:@[?:/F.W(_"L71;.TNXF23)((
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M8R1SAP/;-? M>Y@\=A\725;#5%.#ZIW_ .&?=;H35MPHHHKJ$%%%% !1110
M4444 %%%% 'MVI?M%_&#5OAYX4^%M]JH_L;P5=2WNCQ)!$CV\\S!F;S H=^0
M,;R0.U:U]^UI^T1J/Q*\0?%F?Q=>KXD\46;Z?JMY$PCDN;5T"-$X0 ;2@ P
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M>X@9_,:,L=A<?Q$=,^_6JS2N7^9B6&!R>17U%9?M#>#;/X5^(OA<?AWH<O\
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M  &D_P#B:KW/@#QQ9)YE]I%W IZ&6)D!_%@*G_X2#PM_T!C_ .!4G^%(=?\
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MT33?$&G2ZLQ;4;>VU!"R6]SGGS(PO< [2.* /R:HHHH **** "BBB@ HHHH
M**** "BBB@#_U/X841I'"+U-(X\M]C=:3GL<4P)\VXG->J>>2#@YJ1B=N5&:
MA/ S4ELX#$L,T)#L,%)D<>]2E0&+$\4AEA8-M4C)P*I:#6@RBE')Q3_+_P _
MY--,JXY6R,U+M!";#EF[5#MPN!04Y)7O02V=7KO@WQ!X<\HZK"%$T8E3:P;Y
M3ZXZ5S3QR1D+(-I/0'TJ26YN9V#32,Q"A02>0!4IN3-<"6?YL#:,]J9+;&Q3
M20RB6%BCH<A@<$'VJU?:CJ&J3_:=2GDN),8WRL7;'U))KO/A+\&_BM\??'=C
M\-/@KX=U#Q3XBU)_+M=-TRW>YN92.3A$!. .2>@')-?7'[2/_!*[_@H9^R+X
M(3XE?M$?"?7/#GAYM@?4F2.YM86D^ZLTEN\JPL>FV4J<\8S4MI.UP6JN?G^>
M!FA>1FOZ/O\ @F-_P15\=_M;?L(?'?\ :"\9_#G6]2UF+P_97/PMN+:7RHM1
MOR]RERJ(&Q+M*1 A\ 9]ZQOV-/V&IK__ ()R?ME>$OB/\-5U+XP^!M7\*:-I
M,$FGB[UG3KZXNYXI[>VV*\BR2%0C+'RV .:GG6I7*S^>2TO[_3W:;3II('92
MI,;%20>V01P:E%U)% RVLC(\@VR!21N7N#ZBOT&_: _X)*?\%'OV6?A>/C5\
M>?A'KF@>%EV&?4"L=Q':B3[OVD6\DC6V3@?OE3YB%ZD _-/[/?[,?[0O[6/C
MM?AC^SAX/U/QEKC1F5K73(#*T<8ZO(W"1H.[.P4>M:+:YE-.YX)&Q(PPJS!<
M7%I,MS:NT<B'*LIP01W!'2OL#]JW]@#]L;]AN_T_3OVJO &I>#QJRL;*XN!'
M-:7!3[RQW$#RPLR]64.6 ZBM7X>_\$W_ -NGXK^(/!OA?X<_##7-8O?B!IC:
MUH"6\(9;S3D8(UR'SLCA5B 7D9%!(&:J#5KW)47M8^+'N9[BX:ZO',LC'<68
MY)/J2>M?O:GQA_X(@_M2?#;P?J_[17A_QK\&_'OAK2K?2]9'@2VL[C2M=^SK
MC[2(YE+0W,N,NQ^7)Z-U'X8^-/!WB3X>>,=6\ >,K4V.L:%>SZ??6S,KF&YM
M7,<J%D)4E74C*D@XX)%?MK^US\$?@]X3_P""(7[,GQI\,^&-,L/%WB7Q)XDM
MM6UB"V2.]O8;8CRDFF WNJ?PAB0.U$[:&D5N>.?\%,?^"@OP:_:5\$?#7]E#
M]C[PE?>#?@O\'[2X@T6WU:9)]2U"\O',EQ>W1C&U7D8G"*S<EFR-P1?R/K]!
M/V<O^"4__!0_]K#P WQ2_9_^$NN^(/#IWB+41&EM;W!CX80/</$)R#P1%O.<
MCJ*^/OBI\)/BA\#?'5_\,?C)X?U#POXATM_+NM.U.W>VN(F_VD< X(Y!Z$<C
MBJARKW4R7=ZLX87UZ+3^SQ,_V<MO\O<=F[UQTS[U##--;RK/;N4=#E64X(([
M@U^C'P%_X)$_\%*?VG/AW%\6?@E\'M>UCPY<H9+:_=([2*Z4$@FW^TO$9QD$
M?N@_(KXG\6?"'XK> _B//\'?&WAK5-)\6VUR+.71;NTEAOTN&("QF!E$F]B1
MA=N3D8JE)/1,&F<<VH7YNSJ+3R&XSN\W<=^?7=US4'G%RS$'/7GOFOU6U'_@
MAS_P5FTGX=2?%._^!OB%-*BMS=.@$#7RQ ;BQL1*;L8')!AR/2OJG_@A'_P2
MKN/^"A?[0MYJ/QS\%ZKJ?PLTG3-2MKK4;.4VL<6KQ1*UO"[J=^XD_=Q@]ZS]
MI%)N^QG[.3:5C\3/@_!\*;KXHZ#;?'.;4;;P?)>1+J\ND[#?):$_O&@\Q63S
M .1N4CVK]3?^"B/[:/[+GBS]G?X>_L)_\$^]-US3OA)X'N[O5[R_\1M%_:FM
MZU>G#7$ZPA4"QIA$^5>, * HS6_97_9F^/W[*W[5OBWX2_'G]G2;X@^(XO!6
MJW1\,:M#$\EA;RQ@IJ@5]ZC[.!O4CYAGBOSB^!7[-?QZ_:C^(*_#/]G;P?JG
MB_7I TGV/2[=IWC1>K.5&V-!W9R%'K3T;NWL+5*W<\0HK[9_:B_X)P_MR_L7
M:9::]^TY\,]9\*:9?/Y4.H31K/8M*1N\O[3 TL(DQSL+AN#QP:X?X7_L4_M8
M_&KP;I/Q"^$7P_UGQ+H^NZP^@:?<:=;FX%QJ448F>!%3+;EC8.W& O).*OF3
M5[Z$<KO:Q\T7-_>WHC2\FDE$2[4WL6"J.PST'L*C0LH\V/(*D$$<'-?;'[47
M_!.#]N3]BO0=-\7_ +3WPUU;PGI&JN(K6^G$<]JTI&X1M- \D:2$ GRW8/P>
M.#CHOV8_^"7W[??[:/A>;X@?LU_#+5O$FAQ2-$VHA8K.R:1?O)'/=20Q2NO\
M2QLS#(R!D4<\;7OH/DE>UCX,EN[J^N6NKV5YI7.6=V+,3[D\TX]*]G^.O[-'
MQ_\ V7OB1/\ "/\ :!\(:IX3\208;[!J,!BD>,])(R?EDC;!VNA9#C@UV'[)
M/[+GQ;_; ^.NC_!/X.Z!>>(=0NY4DNH+$ RQV2.HGE^8@8C0Y-6I*UR&G>W4
M^8]C5-7]4_\ P</? 6U_9+DTW]F[X/\ [.7AWP'\+=&ETR/2/']MI\8U?6;S
M[$LEQ%+?$F>55DD965R<M'G-?D!\.O\ @CO_ ,%//BU\,8OC#\/O@KXCU#P_
M<0BXMYO)2&6XB;D/!;RND\RD=#'&P-3&JG%2>@YTFI<JU/S?1^<UIV5]>:?*
M9K*5X6*E2T;%20>HR.QKUSX7_LU_''XP?%Y/V??A]X:OM0\=W$\UM#H(B,=Z
M\]NK/)&8Y-I5D5&+!L$8->RP_P#!/+]M>;X0/\?'^'&KP>$$U>+0EU.=%ABE
MU">;[.D,(D97F)F^3=&K*&X)&#6BDENR%%O9'QRC!GW-G/7(-:;ZA-$LEK82
M216LK!GBWG#$=,CH:_0?X>?\$AO^"EWQ2U[Q'X<\"_!OQ#>W?A.ZDL=4#1)"
MD-W$H=X!)*Z))*JLI,<;,_(XYK'^#'_!*W_@HE^T#XDU[PE\*_A%X@O;_P ,
M74ECJJ7, L%M;J(9:!WNVA02@<^6&WG(P.13]I'N@=.78^#%7'-+\WM7W5^S
MM\'?BQ\"_P!O?PG\)?B[\(KKQ7XGTG68HKOP%JUN(Y-1<J2+=XY5*E7&&4D%
M6&""1BL[XG?L\?''XT?'3XU>*/A=\,;K1++P7K6J7^NZ#81*8_#5N]Y*BVK*
MN %MV!@4(/X, 5<9JYG*F['QNNHWWV3^SO.D^S[MWE[CLW>NWIFD5MU?H%X_
M_P""37_!1_X5?!Z3X^_$'X/^(=+\*6\0GN+N2%3);Q''[R>W5C<0ISDM)&H
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MM3X)?"?6];\/.K/#?;([:.Y5.#]G^T/&9^>/W0?FL8\D(WOI_F7)3G*UM?\
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M(1>//''P*\9IX8\?V'Q6TBXLD@GC%V]N;=DES Q)EA8':X9"A!P:^ ?V@_\
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M5X8_MB76UDU*TAGU".ZF=I'"7C(9DC+NQ\M6"CH.  $^)/\ P5/_ &VOB_\
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M]A_XA_LT? 7X0_M ^+M3L;W3/C'I=UJVEP6V_P ZWBM)?)99MP W$\C:2,4
M9/P(_;Q_:H_9Q_:2N?VNOAEXID7XAW@NQ<:OJ$,6H22F]&V8NMRDB,6'<C([
M8KY4T/6]8\,ZS:>(O#MU+8W]A,EQ;7$#F.6*6,AD=&&"K*0"".0:RZ* /VRT
M[_@X5_X*E:=H$.FCQIID^JV]N+6'Q!/H6GRZY'"J[-HOF@,V<?QEB_HU?CKX
MU\:^+OB1XMU'QYX^U*YUC6M6G>ZO;V[D:6>>:0Y9W=B223ZUR]?7OQ=^"O[/
M_@O]EWX7_%OP!\0X?$/C?Q;_ &C_ ,))X91 LFA_9;AX[?>W5O/C59!GINH
MW?V@O^"B7[7G[4GP&\!_LT?&_P 6/K'@SX;)LT&Q^SPPF']V(E,DD:+),R1C
M:C2LQ4$@8R:\W\*_M:_'7P5^S1XG_9$\.ZM'#X"\8:E:ZMJM@;:%WFN[($0N
M)F0RH%S]U7 /<&OFVB@#]+/V3_\ @KA^W/\ L:?#J;X._"+Q/:W?@Z68W/\
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MG>6'AF'6_B2Z:5!/(ED'M[V98V\D-Y>Y% "MC( XK\]_A+_P4@_X),_L5?M
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M;K?@?5[W1KN76K"!Y[&=[>1HI)XPZ%HV4E6'##.".M?=/[?_ /P4+^$OQ]^
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MI.W_ ."FW[&G[(?P=\:^ O\ @F!\-=>\-^+OB#I\FD:EXO\ %FHQWU_9Z?<
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M+F7:VNOL6>Z;:&ZKV8#TKI[:)]-DR5"QLI));OZ5D/\ :+:,ZA%+O ;(4<C
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M^.?@QX?T7P+IYC@%MI<;S3^3-$!F3SW@B&YF&[H *M77[#/Q3UCXT>'O@/\
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M'_@5JR^&_#?AJX=HK;5=<N+@P0M<[>L2ED+#G:NYMK$ 5[W^PO\ M-_LR_\
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ML/&/AOQ9I%MX@\-^(=,S]EU+3;L;HY5!R0<$$C)&"""0:]Z_X(.W48_X*R?
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M*0\(88S_ *XCY1SG JQ9_$3X)'X*:YIUWX:NX_B1?:REY8:S:730V5K9$'?
M+<'J6.0W) X!&.?M;X6?L.>._P!J/XL:'\-?V0-9OO&>AW^EBYO]:UG1I(]/
ML+T1^9);M(5E0-E0BL"I)..F:RK5Z=&#J59*,5U;LOO86/#;S]ISXO>)OB?X
M-^+WQ6\-:+XSMO!NGQ:)9V$ELAL9[>#?L258"-[ N3GKTKZV\'?\%P_VP?A5
M\#Y_@#X8T[2]/CMTEMM.O&AD^TZ=;L25BB!;;B%3LC+ E5 !SBNVTS_@B?\
MM4:=IUSXX^/UEX>^%>@V7[MM7U#6%L85D!.V0JYER7.,(I3/& *OZ1^QA^P1
MX$DM5^)?[33^*O/ WZ;X4TD:D\DBCY@&F+C"YX;R6'<=*\1\49=+2A4=1_\
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MG@?XL?#[Q3\.Y/!%OYFH0WNIWDD,UP#\D$C"%8D+-C:9&P<\<5]#?MA? /\
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M\4/@GX_T/PEX@B\00)?!=-U"]=  T$DY@8^7CHI=@#@XXKN/^"HW[(/[8?\
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MJ?[$W[/NG:#\$9O!FI74FL1-XT\M0/%[O) $5" "QM2=O)/^LKEO W_!*/\
MX*/?$KQ_KGPO\$_!OQ-?:[X9$!U6V%H4^R&ZA6XA621RL:M)"ZR(N[<5((%
M'Y\45]B> ?V#_P!JSQG^U%#^R(W@'78O'4<H^VZ(;5DOH+=<&67RV ^58SOW
M<@CD9%?O;_P<"?L^^%OV,_"NF?LO?!G]F32/!G@+15T=;?XH&U=M5U?4)+-9
M[B$W;$EE#NR.K$G=&<8&!0!_*=17Z%> ?^"3O_!23XH_"5?CIX ^#'BC4_"L
MMM]LAOHK(@3VY&X20QL1+*A R&C1@1TS7P5;:%K=[K<?AJSLYYM2EG%LEJD;
M-.TQ;:(P@!8N6X"XSGCK0!E45^C?C7_@D-_P4X^'7PSG^,'C3X'^++#P]:Q&
MXGN'L&9X8EY9Y(5S,BJ.69D 49)P :^UO^".W_!(CQ/^W;X:^)GQ,^)/@?Q!
MJ'A/3?!&LW7A34M/8PP7?B:SDA6"V#@'S#AI,Q\9QUXH _ ZBOUY_9N^"'Q!
M_9XC_:*^$/[0W[.NH>,O%6D^ KII?MD"K/X->>V::+5I%8$J(XW64$8. #7Y
M_P#[/?[+O[1/[6'C*3X??LV^#-6\:ZQ#%Y\UMI5LTYABR%WRL!MC3) W.0,G
M% '@U%?4W[2_[$7[6_['&H6>G?M0?#[6O!3:@66TDU&W*03LF-PCF7,;D9&0
MK$BO,O&'P)^,/@#X;^&/C!XT\.WNF^%_&?VD:'J<\>VWO_L959_);^+RRZAO
M3(H \FHKUK3O@/\ &/5_@QJ/[1.F>'+V?P/I.HQZ1>:VD>;2&^E572!G[.RL
MI ]#7U/\ O\ @E7_ ,%$_P!J/X>K\5_@+\(?$/B+PW+N,.HPVXB@G"':QA:5
MD\T @@F/=R".HH _/ZBNX^)'PS^(?P=\;:A\-OBMHE]X<\0:3*8;S3M1@>VN
M8''.'C<!AD<CCD<CBN*1'E<1Q@LS'  Y))H 917Z(:M_P26_X*5Z%\()?CSK
M/P4\56WA6"#[5)>/8L&2#;N\UH?]<(POS%C'M YSBOVG_P""A/[/?P"_9O\
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M,?@7\8/C.-?/PJ\.WNO?\(MIEQK.K_9(R_V/3[12TT\O]U(U!+'M0!Y/17Z
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M444 %%%% !1110 4444 %%%% !1110!__]?^%^BFEL'%.KU#SPI1U%)2CJ*
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MFM@#4=*N[>#4-,N\8P9;2Z26$M@8W;=P'&:Z;]K[_@J'^VW^W)X>L/ _Q_\
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M5;3;+6+&>[+]/(CG1GS[;0:_<S_@Y<^'/Q2?_@IUK?QHNK6YOO!/CS1= O\
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MZ\_:S^'GBR[T/Q_?ZA<:I<:I8[8#+<74ADEW1HHB*.Q.Z/9L(XQBON;XM?\
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M 88X(KH/V6/VS_VE_P!B[Q3>>+OV<_$\N@7&HQ""]A,<=S:7<0SA9[>=)(9
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MI"]LA&_(&<5PKSAMR!BC=*LG2DBM&F,@9B,Y[YJ^:VH<I?\ %1L_LJ36S_>
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MBO;?1HH[^*,+%/)#.[2;2<F3"9Z?*><\1H'[('_!+?\ 9I\/67C/XE?'2_\
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M<UU-M^SG\6I?^$*U6Y@LKA/&=M/?:>]T(E26&V)5G>6UE$D:@@Y:0Q],9Z@
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M>,O^"@GPW\<^%_BAX;TBVTG4=4^'%S86]AK:V8VI+-!=1.(Y7&2^P#DGY\8
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M_"%])=7-IIP0W,JO#)& GF,B9RP/+#BOJ;]@#_@I9\'_ -E?]KSXL_%3XO\
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M'^RW^S;^SI9?%7]K_P#X*4?M;>&T\:^%/@KX@NX-(\-3.8[?5=<U&\F\I9V
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M79/<.7L?DA14]S;7-E<R6=Y&T4T3%'1P5964X((/((/45!7T1(4444 %%%%
M!115JQL+W5+V+3=-A>XN)W$<442EW=V. JJ.22> !0V!5H-?K;\!_P#@CO\
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MG 5T??;-WW-(L8 [UXE_:'PY\6R,+N/[)-(6VH["&5>/E(F5?*DYR6#Q1$X
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M6/VS5+BW5Y5A2"V0A?,D$,A9B2J;?NL2!67\6?\ @G]_P3)^+O[,_CGX\?\
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M  1)6[_X+(?\.M/BIXREBTR:%KZS\1Z9;J6NK"6T%W;3+%(Q52Z, Z[CM8$
MG%8OQ5_X)*?!7P1I_@G]E#X?_$R3QK^UMXH\0V.EZGX*TVWSI.B13QRM<Q7%
MV%??<6C*GGD.JH-_RD+NH _!ZBOZ2+'_ ()H_P#!&O2?B0W['?C?]IS75^,)
MG&E-JUIHJGPE!JY.S[.TC?O702G891(@[X!XKXO^$W_!&K]I3QK^W3XU_8G^
M(][I_@P_#"WN-4\8>)+TM)IFF:-;()C>AE ,BRPD/"OR[\_,4 8@ _(>BOZ.
M/"G_  3!_P""6G[7T&J_!/\ X)V?'GQ%KWQETVUGN=.TWQ5I*6&F>(3:J6DB
MLY% :*1E!,8D:0MCI@Y'\Z^K:7?Z'JESHNJQ-!=6<KP31L,,DD9*LI'J",4
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M).*_;<?\$]?V'_V7?V__  1X8^+?QREUKX2^+-)L?$_A#Q1X<T];J\N;B>>
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M_':Z\%?#[QYX)T;7K*V@LDN-9U#5]2M$N9K:UC7>%M[8.NZ9XW+$A=HZCO\
M]JOP7\&?''_!*;]@#X>_$77;O1O NK>*/$^GW.L1(C7%M93W_EK<%7 7Y00[
M@@< T ?RF:;JFI:-=KJ&D7$MK.H91)"Y1P'4JP!4@X920?4$BJ-?H+_P4B_8
M.\2?L#?MR^*OV0%NIM:ATZ[@.C7TD8C>_LKU5>WD*KD;B&V-MXWJV*Z#_@J#
M^Q+X _X)_?'/0_V=O#GB2Z\1^(H/#6FZEXH^T1)%'8:M?(97LX@A)811E,LQ
MR68C QR ?FU1110 4444 %%%% !1110 4444 %%%% '_T?X5QUJW"464/."X
MQ@BJBD]<=*E#Y.*]1'GV !LD],GH/2I&5E&6&*:0",&E;++MSTZ4P$5L\^E2
M[\\4$IM C&">M 0@YH  A!S4E%%(!0Q4[EZBD9F/S'\:*0]* +UO9FXMY;A7
M4"+L3R?I5*CH,#'/6B@#]EO^"<G[._[%/[3OP1\7^ _%7Q4B^#7[0EAJ,%YX
M1UK7M3_LWP_>6&U?,MWGP!#<*X8JS2+D,NT$@U^R?Q.^,?B3]D#_ ()4_&K]
MES_@H3^T;X4^/^O^-K*"S\"^'=)US_A*[W2KQ7!^UO>-NDMXHP R(Q RN$ZF
MOXU3TIP#%=V/UI<E]V:1FDC^T;]I/]DK]G;]LG_@DY^QA\-?$WQ3T#X6?$^R
M\*:C=>'Y/%<_V'1M5LGN@MQ;O>-\D,\;B-H@V-X9@ 3T^./%/_#-_P#P2+_X
M)P_%_P#9NTKXK^&/BM\:_CNMII%U#X,O5U+3=#TBTDWR^;=1G89I22-APV,<
M8!-?E!^V3^W?HW[4W[+_ .S[^SWIOAR;1Y_@GH-]HUQ>R7*S)J#7<ZS"1$"*
M8PH7&"6SZU^<8?)Q1&#MJ^H2FKZ'[L_\%=?B]\*?B5^RY^QUX=^'7BC2=?OO
M#'PQBL-8M=-O8;J73KL3$F&Y2)V:&7'.R0*V.U?<_P '?V@M _X*/?\ !.CX
M0_LP>!_VA+;]G_XR_ Z.\TB*WUO7)M TCQ%I%RT?D%;M'1//A$:H$;+#+%00
MW'\H5&<<^E4Z>EB>8_HJ_;4\.?"3]EK]ERW^$WQE_:0O_CQ\7/$.NV4U[IWA
MKQ1<:QX9TO1;9UDE2Z)9XKBX=U&Q204^\5&!G]//^"EG@^+]NGQ7H?QH_9I_
M;&\!?#[]G&#P_IUK9^%9O$[:7-HPMX%6>%M'MR&GN68,<%?-;A!E0M?Q.A]X
M- D).,4>SV=R'-[6/[,/V]OVOOV>?@QXK_8;_;Z_9'^(.C>//#?P8T?3_"UQ
MH[WT<?B.2'2U6VF:YL@S20>=;H_S/C#.IP017RW^U=_P36_9!_;%^/WB+]M#
M]G#]J#X:>'_AEXWOY->U*U\2ZNEAKVCRWI,L\#V#'S9)-Y?8HP7/"[NM?R\*
MV.U3TE3MLQ2J7W1_2I_P<'?%K]DCXA?#K]E/P;^QYXSTWQ=X;\&_#[^R0MK=
MPSWEFD0MTB2^AC=WMYV5,M'*%<'.1D&ORB_X)@_M>6O[!W[>/PZ_:GU6U>^T
M_P ,7\@U""(9D>QO8)+6Y"#/+>3,Y4'@G%?!(&:]:^!/Q>U;X"?&;PU\:-!L
M++5;KPUJ$&H1V6I0K<V=QY+ F*:)@5>-QE6!'0UI"*47%D\]Y<Q_0#\4O^":
M_P#P3@\6_'?4_P!J>S_:N\"I\$M6U.36YM)6[)\7);SMY[V*Z:/W_GG+1JQ
M /)K].OVY/C!\+/!G_!T)\!?BMXXU2Q\'>&=.\/Z!<7ESJ]S%96VG126EV56
M>:5ECCV[U4EF R0*_'N?]OS_ ((P:G\2Q^T_JW[+>O?\)VUR-2D\.P^(T3PJ
MU^#OW!/(\P0E\'R?+VXXK\H/VV/VP_BI^WC^TOXF_:@^,9A36O$DZO\ 9K4$
M6]I!&H2*"(,2VR-0 ,DDG)/)K-1<GKV-'.*6G<_<']DC]K3]ECQ5XX_:S_X)
M_?M*^,+;PUX"^/&NSWV@^+U87&GZ?JMG=3-!-*Z$J;:=77,H.T!!R <CT?\
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MI]K/J][#8QSW<\:B."-IG0-*Y&%126;L*_"Q6"KGWQ4US.U[<-=.JJS$9"C
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M3TPK8VXX_B.:Z!M>L-8C!O+RPU!FR";ZU,$K%F.&$L/S,V2<EVQZYK4_9O\
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ME^R3\,S\'?V?/BKK7AWPTI=H;")UDBMVD)9C")%;R\L22%P,DG&2: /Z!_\
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M)XCNO$$7@W2+?0=%6Y*XLM-M%"0V\>T#Y$4 #.3QUKZO_9U_X*W?\%'/V4/
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MT3_@NE^UG\;O^">&I:<WBWP'-J.IZCX?OHC=/KNEYC6:VBM0C&X;.#L5E?\
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MC5@W;-? NN^$?%?A?Q1<^"/$VF7>G:U97#6EQ87,+PW45PIVF)XF =7#<%2
M<\8K]FO^"GW_  4Q_;?U[_@I!\0=>T/X@^(/"UOX&\47NE^']*TV^FL[33+7
M2YVAAC2"-ECSM0>864[R2&R.*_5'_@E;\2]1_P""F7_!9W4?VLOVN?"^D>"/
M$OA/X<WOBFU;[#+%:76HZ=]GMK?4)().96C2=I\J<$Q CI5<[2NS/DBWRH_
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M??"/3&TPVEQ#<Q>'M:;=N6]:>VDC59'^\SRN&5V<A6'-6JCMI_7R#V:OJ?S
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M#@8JH5.9Z;$2ARK4X3X2_!GXL_'GQ[8?"WX*^'-1\5>(]4++:Z;IEN]S<R[
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M9W5HMM</;R[K>V%Z3,T2)*0&)VDL< #BE[5J5NE[?T]@]DG&_6US^=CX??\
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MWN=+LI&6*)!U>61FP!RS'UK[X_;7_P"2%_\ !-O_ + P_P#3E:5^L'ACX;^
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MSP%XBNO"/CC3;G1]4L7,5Q:7D30SQ..H9' 8'ZBN=K^AGQ3_ ,%2/V??BS\
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MT!%M+@2CY=TEM\D,O.=P1HB3_$.: /-M(N+M(1;>&-1CO[=@&;3M0 7?MSP
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M!_P6%^,_P _88UW]A_0_#VFWECJ<=Y;VNJRDB:V@U#/GJ8\%9"2S;&)!7/?
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MWAFT\8^(M7\8PM>V&F6E_G[/:VUJ2J[R Q<M]W /S%OE\9_:\^$?[*7[;_\
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M-\1OV5OVMO L_P 1?@C\3[U=3OM+M+G[)J6FZE#D17ME+D(LP7:K@D!@JY)
MP?R"0$@^],(P<53BGN)-H_H \9_\%!?^":7[,7[.7COX-_\ !,OX7^)5\6?$
M[3CHVK>+OB!=6U[=6&FRMNDAL8;=%C5V'RB3:K+PV6(&/P&J =17<Z[\/_'?
MA+2M*\0^*M'O=+L=;A-SIMQ=P/#%>1+C+PLP D49&2I(Y%-12!NY^A/[;W[=
M/@+]J']EK]G3X"^%=&U#3=1^#/AB;0M2N+LQ^3=S2R^8'@V,S;0./G"G-;6N
M?M]_#_4_^"/VA_\ !.>WT748_$^E?$"7Q>^JDQ_86MGMY(A$N'\WS 7!^[MP
M.M?E2VYFWGK2CGBCE0<S/Z+-3_X*5?\ !.']NWX>>#/^'K'PY\77/Q*\#Z7;
MZ(/&'@6_@MY=:L+%0(5OXKI77S2,AW09))92@.T?,O[6O_!3KP]XY^+OPFN_
MV%_!2?"[P3\!_P![X2LY)!<ZA+<M*DLMU?3CF620QJ"NXA5! /)-?CD%(4@U
M9LP%F9WD\G@\^M)02,YS9_2K\4/V_O\ @B!^UY\4D_:W_:P^!_CG3_B5>&*[
M\0Z/X7U6WB\/:W?H/GED$@%Q&)2 9/*>(G))+-EC\H>*O^"U_P >-6_X*:V7
M_!1;PWHECID>DP)HUEX4#%M/7PZL1MSISE0NY'B)W-M&'PP V@#\5FW*<$U+
M25-(7/)G])'A7]MW_@@M\,?BL/VN_AY\!/'5UX]M+K^U-/\ ">I:O;-X7M=2
M5O,5P54W#1+)RJN7 P/D%>!_LU?\%5_A!J]W\9_A[_P44^&L?CGP-\<-5&NZ
M@WATQZ=J6BZBC[XWT]FR$BC 55B+ ;4 ;>"RM^&@;;SUIWF'_/\ ^JFJ28.<
MC^A6[_X*(?\ !.3]CK]FSXG_  7_ ."9O@KQO-XD^+NE+H6L>(O'>H6TOV33
M=VYXK:"RCB1F;)&YTR/[Q'%8WAG]N[_@F)^U/^S5\._@U_P4=^'/BNP\6_"_
M2H]"TWQ5\/;FTM9M0TVW 6&.\BNHY$:1555,FUF8C=N&2*_ 0OD8J:-2.?2K
MC27S#VC1_0E\7?\ @M'\.O"GBW]GGP!^Q+X#O- ^%O[.FLOKNFV?B*\^UZGJ
MU[,P\V2YD3]W&-F\(L8P"['IA1V7QM_;O_X(I>(?CIK?[</@GX+>-_$'Q/UW
M49?$!\.>(M6M_P#A$XM9F?SGFF2%?M<T7GDR&'SMC_<PB' _G!4*K;JG/0U2
MI(AU6?U'^,_^"W?[(FK_ /!3K1_^"D6B>"O%,6HZKX(U#0O%.G-+:M%_:5U9
MFUB>R!8$0KDE_,<L>P'2OY?-=O%U?6KS4H%*K<3R2A3U =B>?IFLRO6O@1\;
M?B!^S?\ %_0/CE\*KF.T\0^&;I;RQEFB6:-95!'S(X*L""00:J,%'8F4W+<_
MIV^/'[8'C?X,_P#!NI\-/AYXWTZ.Q^(WQ8CE\)6&HOD7S^ ]*NFNADGD1R2L
ML"C&'B9L< 5_)CM(&:^M?VPOVW?VF/V\?B@GQ=_:?\22>(=7M[=;.U&Q8;>U
MMU)(CAB0!47)).!DGDDU\FG[E%*'*GW'4GS,_7C_ ()M_P#!1OP5^R9X#\??
MLS_M->"_^%D_!7XIP11Z_HD4_P!FO+>XMSNAN[23@+,C!3R1RJD,I7GZ>/\
MP41_X)P?L:_!;Q[X3_X)@_#WQA;^//B5I4VA7WBKQQ?VUQ+I>EW6//@LXK5%
M0E\;2SKNZ$NV,5_/5N^79SBK&]:?LXMW8O:R22/Z _A-_P %"O\ @GU\:?V
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MWW*/6JUJ_P#KW%[_ ..2Y>J4BK);GWO\8?\ @IAX"^"7@>[_ &<_^"8WA]_
M'AJ13!J/BJ;#>(=8XPSM-U@1N<*A! Z;>E?C/J&H7^JWLNI:I-)<W$S%Y)96
M+N['J23R2:IU/;- MS&UT"T08;PIP2O?'X5Z^795AL%%JC'WGK*3=Y2?>4GJ
M_P ELDD)R;W(E5G8(@R3V%>F?%SX,?$_X#>+SX"^+FD2Z)JX@AN?LTVTMY4Z
M[D;*DCYAS76_'V#X5ZGXI7Q?\ /#^KZ+X.GA@@A.J-YSM>1QCSP)%&PY;D+D
MD#\AI^--9^%_C/X)6?C3Q#XGUW5_BFVJ+:W-K?+YMHNDQPL$=9V8N7#!%"]
M,\8 KTA'S@>E?;7P9T76_P!J+P1X?_8\^%7@O2%\51:A?:P?$$DPAN[FWC@+
M-;NS#:$0*6')R<  <D^'_ "S^!&H?$FVM?VC[W4]/\+&&<S3Z3&LUR)0A\L!
M7(&"^,\_IR/*KZSU#1;[>8Y[4/\ /"9%,;M&WW2.F01Z<4 5;ZRN-.O9K"Z
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M9/$_AX0J/$'A^ZDC_LVZE!86[S1,&>$@\2<8YXX9:^P/AS_P5Q^*?CK6-/\
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MS\.^)(4$8TS464HBO$W^JCE/[IT3,1SM*!>5566.RZG]:A6>(H+62:CSJ/\
M-&44E*V[BU=K:5]&:/39GX9^'_BQX]\*>&/["EEMO&7A%2?,TW4@9XHB1U4
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M 3@;> 0<^-_M7^*_V>_^">?_  2JN?\ @FM\./B%HWQ.^)GQ)\36WB3QA?\
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M) S+_P "7*_C7A-% '];W_!:;XP?LA_!O]F3Q7X3_8P\9Z-XDG_:F\;1>/\
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M%F8CKM8 X^>O^"*W[$OP._:>C^-7QH^.&@:EX\M/A!X2EU^T\&:1/);W.MW
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M\&O^%^>-/BM>WP9]3ENY-"T%+:5XXX6MK1E$DLFPY\XD%@P &!G[!_;8U/\
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M,\(;/A\/B'!833+9RK&[1@-$I4C/F<[E##."1@G [UY'%X:>*W:]56,8(3J
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M/(KR\;A\92QF!CC:ZJ4O:;N'++F]G/ENT^5Z[6C'WK#5K.QY5_P3B_8VT_\
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MV6!)_G,L+"^U6^ATS3(9+FYN'6.**)2[N[' 55&223P .37]T'[1]K-\+?\
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MSAN?C9JWC>WO-&NS?1AV\+365NXY\T1 &4R'##?SZ8J]^Q/_ ,DH_P""K/\
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M*OM>?PS%XH%[G48X1<-#]DM9;CB,LH.[R]OWAC.:EV6HU=Z(WOCW_P %;?\
M@I!^TY\-G^$/QQ^+NOZ]X<F4)<6,DXCCN%':;RPAD'J&)![BO(OV5_V\OVOO
MV)M1O-1_9;\?:KX._M(JUW#92X@G*\ O$P*,0. <9QQFOGOXE>$E\ ?$;7_
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MB!\/?@Y\4/B!'#!I$,7A_0K[7[@P6&D69.51I$1F2%6ZG:Q&:_5?_@H?\5_
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MVZMV/EVL:*(YS<'ABV-NT?= ]!0!Z #XT_;"^'EQ>:OJ?A?PS!\'?"ZBWAE
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M_#[Q*E[JGC+0+N*WU'Q9H4</V.Z@);=+;6<S,$N5"<*Z%2V,94G*_9G[:'[
MW@?P1J'C7]I7X->*="\/^'=+\92Z%!H-M>D7D*Y!Q&)=A5\!F$;\;!N#%:^/
M?A7%\"G^*4>G?'ZXU&'P(;BYBO9]/MU6ZC8(RPLUOUMIA(%)="4/(P<%3H!L
M^.OA-X?\1^ /&O[6'P8N;6Q^&^B:^FF:=H>KWRQ^)H(I\;#&J>8"D>X Y=AC
ML0":^:=-U6*]M)IK.5;JWD)+ND(9E^4#_2+7H<<GS8B2,D_-C:/HSQ9^R/\
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M67_A!/[-_P"&9-+TS3<?VIYW]M_V=/!-O_X]4^R[_(V[?W^W=G)Q@^_>#/\
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M5ESVKT#]I7]OS]L_]L.VM=._:8^)&M^+[&R<R6]E>7&+.)SU9+>,)"K>X3-
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M!!KT[_@W2GM1_P %>?A#$\9,K7EZ0^>G^AS=JW5_8N^]F8NWM5IU/H/XG_\
M!3W]B;]G+X_ZY\!?@U^RWX$\3_"CP[J]QIL]QKD,DVO:M#!,RRW'VS/^CM(0
MQB5(RL:E00V*R/VR?V(?V"?V6/\ @I;\,M:\57.J1_LY?$[2=.\;VEO;127%
M^NF7T32K:*JY<[Y0L8P255N3QFND^-/_  1X^"OQM_:*\2?%OX%?M&_#;2OA
M5JVMW-S/-X@UF'3]7T5)IF,EO<6,K+(\L)+(NW EV@CK7V7X4_X* ?L#?$C_
M (+8_">%]0MF^#_P:\$CP/X6\0ZS&#9"]LK5XK6^G208$0E/RNP&&VN<8S47
M2UA?;7^NY7*WI.V^G]=CU;]B_P 0>+?VP?VFM&^";_L(^%-(^ 6L7DEA+JDN
M@3VM[:::=PCN7U&8J_FX"DC(W$X S3/^"*^O>!?V4_\ @J]\>?V$/"'@?0=1
MT_PG)XU;3_$=[#))K2V6FR>7%9F;>%,+( )!MRQYR*\]^&'@OXI?!C]O[PE^
MT]_P45_;$\+ZYX1T[Q1!>V-EI'BH:S+>B67;;_Z)"YCM;52P:1Y (XXU..@K
M,^ WQ&^!?[,'_!QU\6?&7Q1^(OA=/"GQ,M/%,NF^(;34X;G2X3K^Z:V2XN8V
M:.)\+M<,V%)&3@UFU=22VMYEIV:;[^1PW_!%3X]_#/\ :9_;S^.7Q-\;^"-&
M^'_A2X^#VNVVK:1X2A:VMELH5C6XDB61W(E>/<22V-V*Q/\ @G-^U_\ LC_M
M\?M?:!_P3Y\<_LR> M ^'/CB/4-,TRZTVWD_MW3V@M9IX)FOV;S)I"8@'8[1
MD[@ !M/E?_!.3P-\,OV#/VH_VAOAG\2_BGX(U>WU#X,>)+?3]9TG6[:?3+VZ
MOH08K:"?>$DN#C'DJ2^>,5\%_P#!"_QYX$^%O_!5_P"#OC[XFZU8>'-"TW4;
MU[O4M3N8[.T@5K"Y0&2:5E1 68*"S#)('4UHX)\S7;0S4VN1/OK]Y]C?L$_L
M._LW?"7P]^TI^W)^UKHY\;^#?V>]6D\.:+X>DD,46L:RUP\,7VAUZ1(!'E1]
MXR9X"\^\?L.?M _L@?\ !7+XV+^P9^T7\#/!WP\O/&=I=P^$_$W@JT:PO-,O
M[:%YHTE!8K.A5&^_RQ 4YW<<M^RG^TW^S-\2A^UM_P $X/VA/&%EX2\+_&CQ
M7>ZWX7\722"33;;5;6]D:(SNN5\B=1$PE!VX3K\P([']@[]DOX ?\$EOCW;_
M +?/[7OQJ\"^(H/ MK=W?AGP]X-UF#6=1UF]N()((2(X2?+BP['<V &P2>*;
M?Q7^+I]W^>XE;W>6UNO]>AXY^Q#^QW\#_P!DO]GCX]_M^_ME>%[?Q_/\&_$O
M_"#^'O#%RS)I]]KPE\F2:X  9X8RRLJ\9"OD9VU]V_\ !)GXW_L:_P#!4']H
M;6?AY^T7^S]X)\/^(]%T#4M4T6Y\.61M+.X2*/;)#=6Q9HW,8*O%(,,"#G.<
MCXK_ &+OVP/@1^V1^S)^T'^P;^UKXIL_AQJ'Q>\5-X]\->([]F_LVUUAIA-)
M;7$G_+.-M@5788P[YP0M?H__ ,$//V+_ (%_L7?M.^(]:\;_ !B\(^/O'.H^
M%=8CTK2_!M^NJP6EE'#YES=W5Q$3'&-@543.[+'/2BH[1GS?%T%37O1Y;<O4
M_.3_ ()C?L-:;HO["OB7_@H?/\'+KX^^,)]?7PQX/\)I!+<:?;R(C/<7]]'%
MAGCC VJN<;R@XW$CZP\:_LB>/OV\_P!CSXK:U^T)^R[%\ _B/\+=#E\3Z#X@
MT729-'TW5;2T^:ZLKF%\H95CR\;*<L >FWYOF/\ X)O_ +0^C_''_@GEXB_X
M)R6?Q=/P/\?:)XB'C'PIKUQ?/IVG7Z/$\5S8W5RA41*VXNI8@%U0]B#J_%/P
M!XF_97_9H\>^(?VUOVKI_''BO6-,;3_"GA'P1XQ;5?.N;@[7FU!D,B"U$1/[
ML[3)DC/&*N7-SN[UOIOM^1,>7D5EI;7;_ASJOB)K7['/[$W_  2^_9>_:3_X
M4[X?\<_%#QII.IPYUJ-FTX1P7DF^ZN88RIN)\;8HM[;%4$D'@5Y)^VOX?_9\
M_;#_ ."2?AK_ (*/^#_AOHGPR\=Z+XXD\':U#X:A^S:??V[0><DOV?.U'4LG
M0_WAT(QX;_P4*^)_PT\8_P#!,7]CSP-X1\1:9JFM^'=#UJ+5M/M+N*>ZL));
MUV1;B)&+PLR\J' )'(XKJ="^*_PFM_\ @WBNO@_J'B'3'\4'XOKJ+:"+V%=3
M>Q%I$IF6W+&41D@KYFPKFJ46DI=>;\+LER3;CTM^-D?KW^T+\']2_8Z^&WP[
MU+_@G/\ LM>#?CG\(=1\-V%_J7BV[TXZ_J-_?2 FX6<HYDMN-I 50 6(SD$#
M^9;_ (*.:S^RKXE_:4N/$G[)GA/5O >AW]C:RZCX<U: P-IFJE?])AA#.S&$
M/RA;:<'[HZ5^S/AO]D74-&U;0_C7_P $8_VJ]+\(^"[ZPM+F\TKQ/XPBT;5]
M*O-H-Q'<P,(4D3?G_EGM/(RPY/F__!6GQU^SS^W/^W1\$OA)8?$/PW-KL.@Z
M?X>\??$2S$4&C3ZHTA\RY,F8XG2)3\TNX*<X& HI47:7?>^_XH=97CVV[?@?
MS:QD*Y%6B, $]Z^@_P!K7X(^$?V<?VC_ !1\%/ 7C+3?B#I&@7$4-MXATB1)
M;*^5X8Y"\3QO(A"LY0X8\J:^?&.5 ]*[4[JZ.)JSLQXE4]C2^8O^?_U4Y553
M00M.PB6-AQ4X8*W/>H%4C!IYY8'TJT@-"-QD>U3AP3BJ,;KNQ5I/O4P+0X3F
MG*01CTIA8%<5+Y4L8#.I ;D9JX/4F1,K \4ZHXQD;NQJ2M$TR&B6-@#BKR[2
M,L:S5.#FIO-JXF<DS55T!"K5Q9550#6&LAR&K020,!6D638OB52,T]7#=*J)
MSD5/$,<50B<#)Q5B)@HP:KJ<'-/5AG'K0!>7[U2D@#)JB&.XX%66<;>:.P/9
MG!?$WP_#XJ\'7=CC,D8\Q/7<OI7YUPK);WAAD^7:<$GUK]44C#\X!&#Q]:^!
M/C!X2_X1GQ9-Y*X@N/WB_4]J\'-Z&U2)Z^5U]/9LY_2K1+B-H)6^_P +7*7V
MGRV4K03#!#?F*Z#3Y]R[Q\K+C%>A)H,?BK3F=F"RH/E/<5X<>Y[331X^)#*G
MEKC"\571%8[>F>>:L7=A>V%VUI<+M93W[U-';QW,14'#J,U:$55VA>![5K6-
MNUK+'J"91D8%1C[Q[Y]JH16\TAPHP5Y.>U=EIIN=4:.*0KA4VJH'XU=T!Z/?
M6/@SQ9I2W?A^&6'5R5#(6'E@#[WRXYSV^:N1TF[_ ++M[FR:S2:9RI65MV^!
MHV!W+@@$D @@CH:J&QNM-N?M,+'@Y&TX_6KUYJ\$T"LT6R=#DR XWC]*J+L!
M]4_"/6=+\1Z_IOA&"\73I]?N/(OKVX&4C5\ < 9'?-5?BX?$/@'Q[JOPUUV^
MMKI])G,+36YWQG8V2J_B,5YS\.=#FU<Q:[HLZ+)YB1A2<E).?FVGJ.E<'XFE
MN5U%GN@8YG^]G.[(]<\DGN>YJDM;W ]#;3X#\2++Q5X@MA=:>K)<7JQC 6 8
M#!A5[7K?2_B)\3]4@\-R[=(LY)6\Y#Y>^%3@2%<X!?\ B SUXKS^74]0NK)Q
M]J>&::(QLP/WP1C:?;&*KP^ =7TW3[3[.97:[B\R18\G]WNY)(ZCCH:8'NOP
MFUO0WUK4[?PEX#AU>5[%RD;*;@#R>7E4E?EPH)S_ /7KXX.H+<ZU+?7K.8I9
M-QC7Y>_RK]!7W9X&O;WX3:+9^&O$46HV7V_9/]HMY?*+6DQ(,6",X;:3\I&>
M^:\N^,^C^%M.M[:#3M--K>RQ1BX,J.AB,?7:"Q5@ZX.[ Y/:HDM@/TK_ ."+
MOB_1[W]H35_V?_%$?D:)\7?#U_X:F65LKYSQF2U..Y\P$#_>KX!^-_P_\<VF
MN:CI>N2/<2^';I]+)9L86S8QD '!R"N.0*H_"3XSW/PS\<^%_&NDVWV?5O#=
M];7D<L/RLYMW1E&U<=0""1UK]7?^"O/A73?!O[0D?Q5\)1C_ (1WXHZ;9^*]
M.:,#:7OH]T\?'<2J[8Q@*PKYR-L+G;B]L13O_P!OTGK\W"2^4"]X^A^%>D:7
MJHM+W7+O3Y[RSMXBCS1G:L$I9<%C@@CGH:RD>QDL6CG@;SV?<&8C85(X&W'?
MKU[UTNM/!J.HF32K@K#<$;T4D(<'N%QGUY]*[;5]5\/VFEIX<MM.2WRNZ:\G
MRTCM_#L/(5<8&,5]+?6S(//?&4OA)=.TU?#:7<4RP;+Y;A@Z&7/'EXQA<5Y'
MJ-C)%<%_X7.1GT->OZ\MM=Z0\\UXDLT91(T48+A\GL!TVC\Z\P-S;W5D8)#E
MD''K30&IX&\-7OB+57@L4\YX8_,\OGY@& /3)_B'(KZN\.^.M1^'_AG3].US
MP?82VR:RDDDTT1-Q,D#*S0"89 !'7 #8-?//P.\76W@;XIZ)XHU*+[196ETC
M7$)'WX@?F'KSWYK]//V^O@OX9\)Z/I'QCT:YFM]*\560U71-.L558K;>Q3,A
M);)^0YQ@D]3Q636MRHG>?M,?'.]_;B_M'5OC-86WA670[*.71TM;:28W$!(S
M;^=QS&&#;L8K\?K;2YO#GB&._A):T$X59=I*9[ D@#I7]!?P$^$5A^U;X9\
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MV/G*[),C\@_,#N!ZYK(262,[HF*GU!P:[*'Q;_:-N-/\70B_08VW&=MU'C/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __7
M_A2"$\TX1@G IZ\#%&6'*]:]"QQG17VCV-IIL%Y!=+*9>J#[R_I6"4"GY>E,
M!()';.:E+KBKB2T()%)Q3Z9&B %WD*GL,=:4,,9]:9(Z@ D9 HP#P>E6;;[,
M'=IRV-IV@>OO3 2BF!P>*?2 *.G-!I5!;.!TYH ."<M]:3><^;M)4=312*[(
MI&[:">?I30%^_BLHI(UL]VQERVX=ZI#KGTK0MK34]4M9;BW7=%;@$G@<5G@X
MS3M<"0N,4GEC<". .M1\]JF?CY7!&::12%!W' HW#./2FH^PXZU-!#]HF$:L
M%+ ]3Z4QW&+\W2GA#F@(8G*-V[]JV]7T:\T-+1[_ &C[;%YT>#G*^^.AH'<R
M:LCK50L ,U/Y@_S_ /JH,ZA?NAIL=I;FS+M-M;S=X  )/&WDYJ"&.*2VDN&8
MHZ\*,<'ZU19G)R*G.X_*>G>F9CJ***J(&A9W+V;^;& 21@@].:A*L>::?EX-
M6*I(B;L5LC.*LM&V,+5?RV#;JM^:IX[FFD2_(_1W]I_]N;PY\?OV%?@!^R-I
M?A^YTZ_^#4>MI=ZA+,KPWW]JSI,OEH &38%P=Q.:_-[+L27))XP3S@#M]*?L
M:HO,7_/_ .JA02V&Y-O4D*-BA9!M"@$XJ[!;S7+%(!N(7=CVJN%"]!5"0(X;
MD=J^_/\ @F9^V!H'[!O[:_@G]JOQ-HMQX@L?"LT\LEA:RK#+,)H'B 5W!48+
MYY':O@<* P#<9Z5-Z'L:=DTTQ2;331VOC_Q/#XU\?:YXQMXC!'JU_<7BQL<E
M!/(SA21U(SBN0#RQ/N5B!R#CC(/8^U-C[TK]*LSN/C<=:L5412.M7 ">E F/
M#@#%3K+*K[CBJVQJL%650Q'6@B1<#%AD=*T=)ALIKM8[UFP>F!5&)H_*QCFI
MTFFC9)U_E51)/TD_85_;$^ W[/?AWQK\%?VHOA99_$CP)X\C@BN)(S%:ZWID
MT#%DFL+QD=HR<_.G"OM&2.<_8ND_\%$OV(/V4/A)XY\(?\$YOAKXCTCQA\0=
M)FT*]\5>+M1AN;FQTZY!$T=I#;KM5W4[3(6SCG&:_#&]O_[0>.22)(MJ+&0@
MQG;_ !?6DMW Z^F*ETE)W*]LTK(T!,\:D!B"1CY>/\CVK-;Y>M/<LWW:6Y@G
MA=HYD*L "0?2NGH8BR6L]G)Y-RNQQ@X//!^F:82O7FHU\S.[>3ZECDFIVB9N
MG>D BJK]#3'#("V"5!P2.E1N'487K4L4LAA,;$X)Z9H 2.,CFK !/ I*%=5;
M!H L444540+"@MPO)'I14,<LB/\ +QFK&UCR>M4 L?WL^E7E(!S5%3M.#5P=
M!0!.7 JX\]S/L\TY"#@>U9Y CP0<D\TOF-_G_P#53)D75+8]*D#@#%0*XVBG
MU<-R;%@<\T#GBHPX Q3U<$UH3(L#@8J>-B*A!S[5*JD5I AJYIQ,, ^U6TP.
M<UD1L0:M+*0,5I=$M-&CE:FBC,H++_#68'-7H'*I]:+H$KEQ60<FG$A\A:HG
M).13D8@XJ6/E9;1F!QZ5Y)\:/"9\0>%'U*W7-Q9G</=:];C4L2:L/%#/;- _
MS!U((/3FLJM)5(23+I5'3FF?E[#,\;;1G/>O0O#'B2'1Y_.N%)4KM8>WK]:C
M^(WA:;PIXHFMHUS&[%T/J#7*(B!@L@^5^?PKX^<'"3C(^JA/F@F>N:_;Z3J5
MF+JYQ-#-S'(.JGTKR";29&DV6Q)93QCTJ :EJ%BKV$+'RF_A/.#ZBNIT'48]
M.N$F8!PXY!Y(J;H=C.,5HEBKS%FG(*E2,;6'2M+0+UK&?^T(P,Q#=ZY)XK:\
M2:(\:+KEE\UO*/F8<@-Z5REI=1V:RQ;2XDP,Y]*!V.J@U22\1S<C[Y)/'J:H
MO;QP7"S<L@(. <$COSSBJ5B62<2'."> ?>MM@&'R#@UO!JPCMK34M&TWQ-_;
M?@\3062-&PCG.YR0!NSC_:SCVKU[XOZ)9>(88O%FC;2LT2RLJ]F/#?K7S;8Z
M@=/G*J,JPQR*^A_"^JI?: _AR8X5D+H^.Y&"OTP<_450'C^GPB\C@54+,\FT
M^W %>NZCJVO^#!_9-A++#D+;S@@!Q&>H&>QSFO'IS/H^I&('Y4D!0J<$,,5]
MB:O<Z%JWP\C^+UN$NM5@N!9WD<V".A*,![@#\J=@,OX<S6WQ&U"[\.>)]>F)
ML+%19/?HSK'% _F2(&7<4/7! QR:X[XK_M):EJ^N>(M!\&0Q:7I6HRI"/(&7
M>W@7RPN_ XD'S,<<FN)T_P <76CZ+JEAI42B]UM?)ENG_@B+9*QX^[D]3W'%
M=K\6_P!G/3_@[X=\/:KJOB.SU;4=:M5NFL+4!C!&^=O[U6P>!D@C@\5+"QP_
MP1\ W'C[Q'%H$.IV6CS2Y$-S?/Y40?!.#)AMO3T-?NU\;O"=C\2O^"0>B:Y\
M2%36O$WP1UN\\,M<:?<K,OV2[E#6SLRDAH@76-<@9  X.:_!G1],MY] GVC+
MAU*H!R1SGG\J_8;_ ((_>-?"GC[XD^-_V)OB+#&FB_&;0[W3( Y^1-1BC+V[
MX)^^'3<A!^^![5\UQ7%T\/#'P5WAY*II_*KJ?_DCE\[&D-[=S\5K;3K1]+N+
MJ1B90<0@^A_E6#%!=Z@T&G7KNRJ<="<+DCMGIBN^\9:%K7@;Q9J'PRUZ+R+_
M $J^EL9T((*RPL4*\\]1WK%N=+6S$Z73O;7$0^0+GD^YSQ]:^G4HR2E'KU,K
M:E#QSX!U#P1J-O8WMY!<Q7MHEU$UM()!LDP<$CE67H0:\9OHDM;C_1VRX)#>
ME>^ZAK,>L:%I^D&SBC.G!P)8UQ(ZL<_O#_%@]#7*1^%=.U%V:1-I/W^<8;T^
MM SR"PNI['4XK@Y!1]WUK]??A[^T%9^%?V6-:\!:Q$^HF$":PE\KSA&&*R '
M.=JI(&Z>IK\L8_"SO/*V"?).>.?EZ9/I7L&EW7B)?"9T;2I'MH[G=$WE.02I
MZ@CD$'..G&*F6Q43]C_^"7GQH\5_LS_LZ_%WXRPZ*VL:E##:WVGV[Q,\3QR/
MB1MX!4+\PX)!XZ5^&GQGUJU^(7Q UKX@6$KO_:5Y)<O%-D2*TIW'@]0"<#!Z
M"OU1_85_:LB_9#O-:\,_&+2X-7\-^*=-.EB*60D!7(W8&=BD [MQ4D8XKX9C
M^'O@K3OCH==U*YCOO!_]IK).T#K(WV.5R?NJ<Y4<<>E8**;U*/FOPEH6L:I.
M%LIQ"J.LA8YPA'0D $\GC&.OI1XJBN(]3>&9C+.6)E;;M#'U&:^@OB1;_#?1
M/B_K.K_!JYN)?!\LY,&X?-L/0-W&#TY_&NR\)^&-"_:;US1_A_X6N(-/UB5;
MB."";"9:)2T:>8>I?GK36]@/ADN"2J=#TJS#))&<H<'U!K0\0Z)J7AO6;G0M
M7C,=U:NT<B]0&7@\]ZQ8_,;G%6*1>DN9TY)^G-9D\LC,=YR35AVW)CO5*4Y;
M-%-61!'EAPI(%;%AKE_ID3+9D!RRLKD992OH>U8]%6U<#NM:^(>NZ_=V=UJ[
MK*;(GR\J.^,YXYSBNF\:^*_!VH7E@/#%BUO:BW0749;AIQG<PZX!&*\? &[)
MYIQ/.8_D-2J:?4#Z@L/&'PV&L);QSRVMG=V44;DIN^SW*(!N'J P^M=;X'U_
MP+#\1[$Z5#:32V\;R&^56C_>+CG;D D^O%?&))88< YX/:B.22(YC9EQTP<?
MA42H7ZC3L?=OCGQOK6M:1+XY<R6>HL_D3>0 T<R$[<D9..*XCP[X;O\ 4_$,
MUMX=NP\\,(< _(KY[?Y%?,-OKVJ09@BN'2-NJY)7\LUKZ;XRUG191/92%7'.
MX$YS]?Z5C]7:CHRN:Y[)X^T#1YI5FN8);>ZX$[*VX;QP< CIBN%E\"Z?J$9F
MTV[2(Q@$&X!CS[#KFH-3^*.O:]/%<ZJ(G:(;<A<$CWP>327/Q%^W64=E?VR;
MHF)4CH0?7O\ K5<DDA-HV)/ .B66F176IS>=<RL,"W.<*?8@=ZT+3X=^'M0=
M;>YOA&TK;8R5P>F<5E6?CVT@AC:*"))(FR& /*^F"3WK+NO']Y<W7VN\$9PH
M 51@ CH12][JB="QKGPN30[I?+O(VC/J<'/TYK]$?V"O^">FD?&^RUG]I#]H
M_65\&?!GP6//U36+C*O?R*?^/2S4\O(W0L,XR  2>-#]A;]B'1_C?I^H?M=_
MM<ZM)X4^"GA5_,O[Z0^7-JTT?(L[('EW;&UF7IGUZ>._\%!O^"@VN_M?^*+/
MPA\/]+C\&_"SPJOV7PWX9M/DAAA3@2S!<!YG RS'IT'J?F<;CJ^,KRR_+I<O
M+_$J;J']V/1U&OE!:O6R=I):LZ3]OC_@HE??M-6.F? OX+:6/ _P:\)'9H?A
MRUP@D*\?:;HKCS)GZG.=I)ZDDG\N7#R$R ?AWI/,4Y;O3XW<?.O:O=P&7T,%
M16'P\;17S;;W;>[;>K;U;);;=V52VUMC @U86+*[B14Y$4QWR\-46("#@\BN
MP17)7. :UM(CS?Q'(^\*RO)WG<36QHZ[;^+!XW"AC1Z,1D8]:Z(^$O%1\*?\
M)Q]@N#H@NOL7VW8Q@%SMW^5OZ;]OS;>N*[+XT6FJ6GQ$O!J_AW_A%99(K:0:
M: 0(T>%"KC(&?-4B3.,'=Q7U'\()OC]XS_85^*'@+P6NFR>"- U;2M>UK[0(
MDNXW<20H87;]XP9E7*KD#';<<\Y9YA\!O&U_X)_:!\ >,_#'A>R\<ZDWD6D>
MAZK )K2]NI0]HD1C. W5"I_YZ8/:K7COPQXW\!?$/6?"?Q.T&T\-:WHOB*2*
M^L"J&.U_M-2KHQ0NODP^6NS;N"[B>XKPH:K+%X?T2^L$:RGTV[E'VR)CYA8E
M9%8=,&/J,'/TKWCX[:;\-]*^).LVGP^\=W/CNSU31X+RXUF[@:&9KTK'-+$P
M=F)*NNS=F@#TFQC^&_BK]EE-/\7^/]1D\::1>W&A:7X7-O+-:I8_/=>='(W[
MM&>X"QE00Q#9P:^=O!_Q(\3_  A^*?ACXT^#XH6U*P>"^M1=Q++"T\!V'<A.
M&4,IZXKW+X;?'IOA#X<\>PV/AG2M;D\7:99W5M<ZA$6ETV5W7S;FT8$%9$E)
M5?FX(SS@BOFWQ=IMF^FWR:>N%TV]\V,DYD:UO &7<.@$;*HRHP6DY/2@#T[]
MK_X4_%;X7?&>XNOC(VEMK7BNWC\1-_8\T<MJ%U$M)M C^6,J<@ICC'&1@UW7
M[-_A[QK?^%]3^#WAWX7V'CK7OBQ:&W\.7,KJ]Y9&P9WGDMPK_(V%);S-N0G=
M<Y\N\9-\ =0_9_\ "MQX*@UV3XA07-R/$=Q=LK:9]G+$6P@P-RD+@'<>N[M@
M#D?AKX@UW2K>2Y\+W]SIFJZ-+_:-K<V99+A(B/+N=A3#9"%7/. B/TS0!@>)
M])U*'3FBU>V:VU+19FT^\C888!"=F[DG<I#(>   HY.:^B(-!\5_'O\ 9SAM
M?A5\-;6&+X56TU[XE\1638N;BWNY,1O<*[#<(\$#RU)"Y)P!7-?%_0_@OH7Q
M=G\+_!CQ5=^*/#^KV5N9-2O[<0RB]F0/(K!F (6;C>2, GKCGPW0=:\>Z*M_
MX1\-7=[;#6=MG=V=JSC[2%;B-T7[_P W12.M 'KG@>QU3QO+9:EHEN^H7>#9
MZG;K&9,1Q+YL5RP"G*A4;> "0(LGE@*^AOB/\1KS]I_X@ZEXW^) TSPYXALM
M/FLM7C@B>*#45@1?LL<,<$95)F"'RW9BK2!,D J#\G:?I7C3X,?$)O#/Q#TR
M]T&\9!%<VM["UO-&LH#([1R)G .&P5.Y>!US7;>)L^%]8@\2103".)A:7D1(
MS]G8@!02APT+#:CG<>(VP.!0!]3_ +-G_!,WQ1^TA\"/B1\:M(\7:;ITG@!'
MDCTR16DGOD2+SBX((\M"A&T[6);((7%?KG^S7^WMX<_;)_8)?_@G;\-?#]MX
M;^*'ACP_;3^'S<)%)9:I>Z)+'<;84<8%Q.L1)5U979FS\I-?B_\ !SXW>*_V
M:OBKHOQO\'M]I;37)O+7!$&HZ=-@7%NZC:"-CEU!)^23MLQ5O]L7X:M^R[\?
M?#W[1O[,NI20^$/%^SQ1X1U&W.'MFW[I+9CVDM9<QLIZJ!GJ10!\S7=U<:3K
M/FW(;38KNZ>5"=T3:9JD1PW0$J P&5 !*[>A4&OV6\ _M-77Q2\)7/[4<.D1
M:EXX\*6(T+XJ>&B=L?BCP\X$2WX7 _?0C"R$9*D*^<5\E_M;V7A3X]^"]._;
MC^'MFEOH_C"5-,\;V%NN5TGQ$J[EG5<_*EP 9(VX&=Z'KS\Z?#;Q/\8?V>-8
MT/X\>&S;C5M/>XMS')(DT6HZ?$$66*XA7Y]C1OC+G]Y$<ICR\T ?I/KWAWX<
M^(/#EA^REXCU3^TOA]XR@DU3X3^*;K_ESFE.7TJ[;DQX?,>?^6<NT_<9J_%O
MQ9X3\1?!;QY?>!/&EI(H1S#<P-\C.@;'&<[74C\&&#7ZA:KJ?P@?0_\ A$"[
MP?!/XJSM?:!=$^9/X,\2H,F,MG_5*3Y<J\>9 RN/F2O-OB?X?O\ X[>'=3^'
M7Q/@%I\6/ 49CNY.JZQI\*@QW:E02TT<>!(0")8-C]4)(!^9&LZ<-$OTGTZ<
MS6SD2VUPHV%AU&1_"Z]&7)P>A(P:]P\)>)U\6V=P;J7%^JN)4V_>1Q\[C&=T
M;8_?H<?WU_BQGPW&BZIH:>#-:TN.PN]*A>&<0^9YDC9+B[ +/EU5L2*H"-%@
M@;ANK@_"W]D^#/'=L_C>*[:TA)9C8RB&4AE.R2-V1U*Y(."IW+QD9R #H+^P
M3PRDD-] TNB7<A6:'>#+:S@<,I'M\R-]V1./I%.+2^6#P?XGNH=@ _L[5@#M
M5#T20@9,>3@YRT1_V017I-Q=VES;F<_9BJ( R%2]O)&^  >=PAD;H00T$AP-
MHQB/5;:T\06*>'[;3Q;6]NB0FW@B(D:6)?\ 6@LS?Z1C)D48291E0". #BM2
M\2:IK-VNF^,9FL_$VE[(K342=K2"+A4F<=>,".4YP,!CMY%KQQ\./&GAF\@F
MUS1KKPWKTELMZ;*XB:V:XMY 2+BW5@,@C.Y1VY7(W;?1O$_P)\=>'OA'X7\<
M?$:2SC\/>)I[B#0-6$Z2.#;</'*JDND1[;AE&[ $U^DGQ'^#'A3Q_P# WQ=^
MU=\5=1\5^-]'T30K72O"UVES!)=:#>P%4\O45CX$;.Z&%E!5HV)/.#0!YG\%
MI_@I^U5XQT?P/\+-5M?@A8Z#X62+Q3K6L:F63494;:VZ,O%YH;<NU=X9!TX
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ME>:9<M9ZA$T,J$JR.,$$=N:]!U3PK8WMW'#:J=+O9>EM,<P2<XW0S$D;200
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M SQY#!'?G<HSQG'-???[!O[8OP5^!LP7QGX+76I% A&]8]J(1AGRX.X\\+D
M>M?*_C;X*^)_"$VGW>H0&TTW75$UK=%E:%]H)893CY<\AN0.M>)>#- LM8^(
MUIX2NM5CTFTU"Y6VGNY>88U<X,A QQCWK2R:\RC[8\=:'HZ_%OQ-X]^'GAN^
MMO &J#[3J!NX L-E',V R.#M8;CQM.<=J^&M6\,Q>%OB7<Z=I6I((H9BT5Y
M65/+;G()56'!QT^E?LC^T#X#\'K\#-9^#/P+\7G5](\#Q6\^IP!S*;MI2%$T
M; @&/<>$QA3ZU^5?C+QII7@_X>ZA\,(+&&?4]2N89I]4F!>?9&,A%R?EZX/T
MJ4K;A=%SXL_#-[I[:_TS5+:]D-HLL3JX7SU'#<'HWL:^33))"[(> I(]>E=5
M;Z[?BR6#RU9$8D$_3I^%<^1'<'"(-['[Q/>KB2S.:8L*B()&XT2*R.4?D@XI
MH;/TJR1<$C(IK'8,M5N%/-?:O2GWD&P# _*@#/#J:?41&TCC%2,0HSU^E "F
M@4Y1GD@XJW$+67@'F@+HSV!)R*0R$'$E:4ENF_:N/SJ&:WVIVS2>P7(T"%<L
M:5HXF7<#2_8Y."<8Q5H6B$;J@1C2Y!PO-?K!_P $]_V /#GQH\-ZQ^UA^U7J
M@\(_!/P01)J-[*=D^JSKRMG9J>7=S@,PZ9 &2>,O_@GU^P+IW[15QJ?QX_:"
MU(>$O@OX(Q<Z_K$OR-<[.?LEK_>FD^[QRN?7%<K_ ,%"OV]KG]K/Q)IWP^^%
MFD+X.^$_@Y?LGAKPY;G;''$G'GS <-/(.6/.,XR>2?E\QQU;&5Y9;E\K-?Q*
MB^PG]F/>I)?^ +WGK9.TK:LS_P#@H%^WWK_[8_BS2_"/@W3E\)?"_P &PBQ\
M+^&;7Y+>VMTX\V11@--(/O,>G0=R?SK?I4?F@2 M2O(O2O9P.!H8.A'#X>-H
M1_IMOJV]6WJWJQ-MN[(@0,Y]:E1FP< U!MW985*LK(,,!76(4#YMS]*G\E/O
M+WI@G5D*'K35=D& : $DW1N O2MG22/ML/\ O"LCS Q^?K6MIJ?\3&$CLPH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ3XWX-\=^+OAOK,FH>&;@VTS(8IX98UDAE0]4EBD#(Z^S*<'D<@&O]#/Q/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH _]+^$^E'448[T#J*[4CC)ZA)*X1F+<]ZFQNXJW:6/GP23RS+'Y8R
M%;JWL*L"F3@9ZU*B.W*C..3CM4?/;K4L;SQL=IVJ1@^] #3("N1ZXIT?F AD
MZFD?8S83I_6GIN49'!%-, ;>CB)A]/QJS''"4WL?F';O43-YTH:7D5>L[N6P
MNDO(=I9""%89!Q0R2HK*PRIXIU1ONDG,V I))XZ<U(>.:I"8T,"<4\ G@5$H
MRVZID.#5")%4KUJ15S@]J2,&5MB<FK4$8%P(;C*#(R?:JCL#;MH>K>#M \/:
MEIADNN9<]STKAO$=G;6&JO;VI#*,XKJ/$$NDZ-:01:%/N9U^8K_6O-993+)Y
MSDLQZU:,XIO<"#D'TKMKO6M)O-%CT\1;91U.*XH$'D4!@6VCK57'9FS/%#!N
MMX)6,;'?SZ_2L[/M4F5)RYZ"K5KI\UZC- 5RI P3@G/I2>HBAO6D\Q:Z&_\
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M",D ^]578K(5[#BJ MQ1O--L!"\$C<<9 I"PSBF1NJIEQN8C ]@:41DD8YH
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MJ8=2Y9-7B_Y9+6,OE))A"Z=R#QSX0\2?"CQWJWPU\80M:ZIHM[-9741&#'-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2J7"A9(=O*O@''4?7WC'6?\ @F_J7P(\ >)W\7Z_JGQ/\0:Q92^,S=FXDD@
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MB'Q/XC\=>*=1\5^+KE];OM?\ZYFFOR%DU#)8R*[#A;N%CNCR1G&U<[E1@#]
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ME?\ !27_ (*/V/[<WQFTSQYX<\,?V+HVF6"V+6=VPD>ZPYD+2F/ &#\JE3N
MYR#7Y9LK*Q5A@CJ#VI* /19O!EIK>C:AXJ\'7$0M=-B2>ZM+J5$N(ED<1C8#
MCSAN(^X-P') &37G5%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK6]:I#K5DH0H?L:069921<8IRELY'2JL?7-6E8 8IA9C]TA;<3T_E7C7Q?\
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MV06_4"0"*3 R>J'WK+F7RKA[<$/L.W(Z&NGELWD1HW/4\BLG4-,^SCS[?[A
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MIYT#Q-ME%E#*KW<:72XE!7;AO,"B5 &;RV[ [C0!\5/++<O+<2 Q/$DGVFU
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO (+4BTOUN J@#:MMJ'0@\D>5<J.I^4-\I 7#5Y)XPTBW@F76M,B,-O<L5>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M92"*C6-L"E5@O6JB22DXYJ \G-2GYEXJ G:<&J :9&!Q4Z.-HS51OO&I4Y%
M$I<YJ5'..M5Z<C@9JX.P%U6<]*LHK%<U61P"!4HDQFM4T)DE2AUQ5<2#'/\
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M(X-GQW$;B\MO$J+Y8U"/,P52H6ZB^28$GC)8>9@< .  .E 'W%_P4/\ A/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$R.P'\1251G&/D)'):O#+^TLYKM].TN(&WOC-:1A) KLETHN;4-N.%VOM!Z
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M'<->2QNMJR#JP64H=O4CL>AW[R&634Y?^$ALY%\K4(+F:  K-LOHS'<$[@,
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MZK+-X<MGM+0D>7'(YD8 >YK#C/EOYG6FY6C<*K4=F*>#R#CL>Q^A[U8K2O\
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M:M<K>WJC;.NA:: &C##D*Q=1C(R)&/K7\_DB-"N&&#7[F?\ !4,7&I?\$_\
M]C[Q-ISB72_^$8U*Q^0\+=P2Q&4'L#AE]SCVKY7B&"K8G+\+4^"=6[7?DA.<
M5_X%%/Y%1V;/RG_93_9I^(?[7_QY\/?L_P#POC4ZKK]P(A+(#Y<$0YDE?'.U
M%!)]>E?WI? 3_@W&_P"">/PP\#VVC_$_2+OQSKAC7[7J-Y=2P*TF.?*BB951
M<],Y..IK^9__ (-N/%?A3PS_ ,%(]/MO%$D<,VJ:-?6EB7Q\UPP5@ 3W*@XK
M_18K\>\7>*\UPF8T\OPE65*FHJ5XMIR;;ZK6RMM]YM1C%JY_$E_P6 _X-_\
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M%L/VB?\ @H;I"?#0V<'@SP+%+YQTJRD:26[=?NFYF(&\+U"*JJ#UR>:^??\
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M7ZURWPKU_P !^&+#3]6\:WNK)8SMJMG>0:-,(KC8\$7V?.XJ#&\I;>I/*J:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHV ^:)V#[]L@0E5R 00:\E\,>,O$/AKPH=6\.7*Q7-B;NQ8/%'(!;:I \,H
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M+%TC7)0J^T%PS ,"P&W(SD?6W[>OP$3]D?XQ0:Q\),Z9_9TJ:YIJR)GR(V9
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M85=@73[[9"L-W&<X%6O%5A$)8-?L /LFI*9%"]8Y5.)(V]"K<@?W&4]ZY.@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#_]3^% A@ 2" >1QUI*GFGN9DCCF.
M5B&$']T>AJ"NUJQQA111G'-(!N]<XR*> 3TJ>Q6RD<_;BT8"'&T9RW8&HHMD
M<C CS%/W2>"*JR  AS5A8P!TIHZU+O6JL!/.T,LF84\M !QG.345!..:;O%
M#J4=:4J1S3: )MZU(RE5#MT/2JIZ4T#D9R: +5%#$(,L0*3(QN'.: %E?)!"
MT4AZ4;A51)D!Z5&'.:DR#2;!5#0\=:5CDYIIJ/Y^] R2G2-D EF+'K]*9D,,
M"I4DV#;C/O0!'0PVG:W!ZTAY&*GN;F6Y*-+]Z-0%( IHF17=9 <YI\;J36AH
M^B:AXBU&'2]+7S)YL[%R!G'7DD ?B:KWEE+I]Z]C<#;+&Q1AG."/<<4Q68S>
MM.J'8:DWK4BL.HHII(.1[&JB5$L!U;H:> 3TJK%\O)J=9/7BK3L#%+ =:G#
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M'+4-!T+X1>$KX7NL"'3HRUZ4BMWGU2"6>*.8^7([V\%A;QR,T)BGFF*Q,X1
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MVF7"7D*MQB.8"*;'J2P@XYX!(Q@U3MW-]X1G@=B397"R("> LPPV![E5S]*
M)_'?C/4/'_BJ[\5:C&D#7+ )#%GRX8D 5(TSD[54 #)R>IYKD*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _];^$QF!
M&!0@('-19 Y-3*ZMT[UV]#C'4444@"E'44E%- 3,<@BH:O0:?<7EY%IFF(T\
MLIPH49);TI-1TZ_TB^?3-3A:">(E71Q@@BJ: J $')J3>*1F!&*B''-&P$[
ME213XSC&:L/IS1:=#JDCI^\)7:K9;\15/>*8%EN :NP003QR1IN\T8VJ!G-9
M(E;/_P!?_P"M5ZPU&YL;CS[;Y7Z9- #&!0E6X(ZU&7X^7K3IYGGD=V!.[EB>
MYJ$=: +;>0%!MPRDCYL^M1TW>M&]: '4;@.:;O6G+*JY)4-D8YH :\I/2G5
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MZO-14[@C?T]J0]:; MV]R8)"8CU]15B4M.?,?CV%9B<'FK7F$G JD)LM!U
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M?FK L,D:H'SR>U1@C&<8J*1T?"$9Q5A(HO):0-\PZ+ZT *K%3BIS(2!BJBC
MP3FEW$4 7MX/6GH1G-5$.10SLAV_UI2 N9^;-2[SVS51'!49H+G/%0!<SGFI
M58 8JHA<KD5(&QPW6F@+&]:<#GFJP(/(HWX.VK E9&8Y I0=HVGK3%F"J22>
M*UKO0=:M-+@UZ[M9(K.[+"&9UPCE>#@GKBG9@9XE &*>'+#(%5,YJ0.56FM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M76AE@5#,I7S!N7(ZBFCYAD<U)-)<2VL32RLWEKA<G/%5H;A[:,O'W&*0#VW
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M,KC'3GV%<G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>dna-20251231_g3.jpg
<TEXT>
begin 644 dna-20251231_g3.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M8X.3E)>VU>$F1&25H\/2\/$G982&Q46%Q.(I1L;_Q  ; 0$  P$! 0$
M         @,$!0$&!__$ $(1 0$  0,# 0,)!@4$ P  !P " P$$$A$B,@43
M0E(&(2,Q,U%QD? 406%B@:$T<K'!T15#X?$D4X(68S62@Z*R_]H # ,!  (1
M Q$ /P#?@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                  M3/.X5%IRF
MOE3332T]1#3[F/8[:YJZIX*:ME,ZYYFE67Q7/2NW4T:KZVU#+JM=@
M
M
M
M
M
M
M                      LWB#_M,7_]2_TH;/3_ /$RKS>*[J+^MH_S$_B,
MM+'81
M
M
M
M
M
M                                  LWB#_M,7_]2_TH;/3_ /$RKS>*
M[J+^MH_S$_B,M+'81
M
M
M
M
M
M                                   %O_U0J;^J<W"_)E\\=;G7'F].
M7L;(V/3XZZN+_85[+V_\>B'/NXK@*$P      '365T5"S=*YK2<15^*-5T6'
MFY=GXHP3<+=#3U$T=4S8YL+F<UW77INZ'3V>W]G4U2K)KUE5L*XXJ)J"%:VE
M=3[D]1SD=)%^2NG3]PKS;/X7L6NBEK(JQN^-S7(<^HK3R7.PB
M
M
M                //77*&WLW2.V_43C'5^*-5T4"LQG-),U86\MC?==[QOC
M9S[RNK5*TXHAK]K9/1R_P3-DVU1XIS?556NW=4,R8
M
M
M
M                         !B>E<KN,^1%]W"\G_2(CIU_@?\ ]_[:J/\
MN_T98.8O    !QDD;"W<YVUK24SU%%NN,&1[F4S=R_,[U37CVG7R55:WZJJD
MK'[Y'.<XW3$SXH.LM'.&G?43-9&W<]WNM*ZKB/:M#7V';+M='N*>6+)VI=^B
MK6G%S*CN5'HW_-[IER[3IXIZ6K+9&R1ZM=N0QIOH
M
M
M  !PFF93LW/=M:A*9ZBA7;%_N4W^6XVXMK\2JK4*:H?4/WO<]RN^8VS/%!P+
M  J-KQ)46WNJ[F1_*XR9-O-I:7Q7';;Y3W)G<=M?\KO6,&3#4+)KJ]A2D
M
M
M
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M7?T&')MZA9I?54"A(
M
M                                    !2KIBJ&CW-B]-)_!->+:5KY(
M:VMRNNLUR?K*[=\K?=:;HQS'BJUUY/.7@    /K7.C?JG=5I6*U:<7/AVLJ/
M2)\WO&3+M>OBGI:X*2NBKH=\3MS3#<5'DG-=7:02
M
M
M
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M>DK2
M
M                   'CN-\@M;.\[<_Y6EV/#5HU71;=TQ%47+HCN7'\K3H
M8L$PKUODIYJ1         ';2UDE&_=%(]JE5Q.OF]ZZJ_:<8,DVLJ.ZOS-]4
MPY-IT\5FEJW'(V1FYKMS?F:8M=.*;Z
M
M
M
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MOMU543:FGM(9LL7,S,_43IQ9)T5OB4)@
M
M                                          ZJJOCH6;I7,:TG$5?B
M\UU6]=,72U&YE/Z-GS>\;\6UF?)75J,^19)-SG;E-?35!\/!]<U6KHOB!\+
M          /7;[Q46U^K'=/E<9\N&:-->*X[7B:&X=UWHY?E<8,FVJ%LWU5(
MS)@
M
M
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MH]LE1Z23Y?=.?EW=:^*W2%<8UL3-$31$,B;D!QDB21.H'3) K5Z>J!U@
M
M
M  ?'R)&S<YVU!IIR%%NV,&0[F4WI%^;W39BVG+R0UM;]56RU<V^1SG.-\1.G
M@KZZNHM>/;:[#4W9^D;>Y[SW>J9\N:(--.2Z+1A*"V]Y_II/B[P,&7<U:V8Z
M.=XPK377O*G+D^9".+<5!4=5JW;#]3:G]]NYGS-]4Z.+-%JM=.+PF@
M     !4[7BB:W[6O])%^5ZQDR;:;2FU?M.)*.]2.C@FBDFC]>)KN]%]ISLF&
ML?DLFNKW%:0
M
M
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M%'OK;'4/2*Y6_P#)EAU56+]17EVV6-.5>/WFESJR:5INM\".\.B@=,D:QKU
MX@
M
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M.H
M
M
M                                  .BZ2)#;9GN=M:UBN<YQ[C\S5 :
MJOU/=[E45MNK(JB"2>39/3R(YKM'N1=%3ZVZ'Z'/BX^K(.7O$A78=VTUV:ZN
MI6MVM?\ WQO^E$,>XV$WW2LC-T9IPGCBUXVH^?;JIDS?>;ZLC?M3Q0Y&7#6/
MR:IOJXXMP738NACYKI89Z=VZ*>)VV2)3W%EX%1U==DS6Q!EBQL%_A=>;8WNL
MK(&KSHF_&1.NNB?859=CBS]V+MK[GFF2H\V4<)8TM>-K<E5;:N*JB5.]M=WF
MZ_%/8<?-@O%7&VF;ZJN5)/#=+%375B\QO>3WD\2S%FJ$:GJM6[X4J;8FY/31
M_%#H8MS-J]8Z*6;$0   JUGPC47)&O?Z&/YG>L8\NZF$M(ZJ[52VS =BJKA5
M214M)1Q.FGGE<B;&HFJJJF"\EY*^=9TZ(IX%NN+.TNOCL0I<+EA3(3O045%$
MU8*[&+/;+*KO4I7)MT9M1WK=\V7PVNG'Z\G^BN?I/\J3>663>%\G<.4MIPS8
MZ"TT-&SEQ-B9WFM\?675R_>I@O+5]U+-)Z,%\<W:Q93<"%JECQ%>(KMB332"
MR6Z1):ES]-423;NY**G75R:>'Q-6T].RY_'ZE>3-,-5LW;&<5G'AQ+6V')ZB
MK+304=4[D6BWT[Y('0N=W//I.J=$Z*[N(?0_],VN#']+^OP8_;Y;KM;N.'>N
MQO<LF,/SYC4=JM^-I*-CKM3VYVZFBGT[R,75W37ZU/ELW#E]%XM\<N/<\F<O
M#%@O/NRK28ALE+-(URRP5<*<JII9?9(Q[??:NBIKJFJ>![CSWC\7NL3JPY8,
MUL5<%.8=FPAF%=Y<38#Q%4>8V'$U3TJ:&945R4]:_P!5=='(R31C?49U=XZ:
MQ1GCGB^:OWZ?\*^O#R2F,*X ZI*?=U:!TN:K.B@?
M
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MM,6">.)@O+5^2US6K3<[(#\;BK\UO\;3XGY7_P#;=7T[ZJ3@/B73
M
M
M
M                        %+QM_8?=/U+)_$>X_-&GY=L&\:6.^&C.S$4E
MDNDM1;?I>KYMNJG;X)4YK^GQ9^U5#]#CQEQM:3\X6^TRP3Q#PPT-PF9AF_\
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MK!F]IW)%G+:
M
M     !PJ*AE+'ND<QJ$IGJ*!=<8*[<RF[OY9MQ;7XE56H<TSZA^Y[GN=^4;9
MGB@XE@ 4+'6(+]A>&EKK%"RJ?3RJZH@=IME9I^[X_ ECQ8\G9E1NJT\5PY8\
M1UGQXC:6K5;1=&M3?!/W6N7VZ*O]/4YV[]+RXNZ>Z4\>>:9':Y')JASE[Z
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M^<1PY/:3R>U/1L1[(#\;BK\UO\;3Y'Y7_P#;=/T[ZJ3@/B73
M
M
M
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M ^'8J"V4=!:+5;X]L5/3Q,@@IF)UZ,;HC4]IP]=:U;/J1;XK<:5/&IB2')C
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M "AQ3>Y[G3V-=)3)M.*(:[:R3T<G\$^5R;:H\6_2U48YLC-6NW-,R;Z
M
M                                             'QSD9U4"DW;%D='
MN9#Z1_\ !->+:5KY(:VMVNN4UP?NE=N_)]TW1CF/%5KKR=!>     MG&V5-J
MQLS?+'YO5M]2>+NN:OQ73Q^\MP[F\:N\<:J18\P\6Y'538+@V:_6'?\ C?7E
MB1?K7JKOJUT)9=G@W/=/;2.F6X\F7\O<W+'F91M?;JQO/V(Y]._NRQ:^Q?\
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M_P B(ZVR^R4Y/-M2[(#\;BK\UO\ &T^6^5__ &W1].^JDX#XETP
M
M
M
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MF
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M/C/E?_VW5].^JDX#XETP
M
M
M                                                   !3<91NFPK
M<F,:YSW4\C6M;]A[C\T:?DESLME=AO.G%%/50U%#60W:JU8]JL>W65RIT7JG
M1=3]$Q>,N-3.7"OVH&-,AYJ6VWJ1V)L-QN1KH)W>G@8B:;8W^")]J*3.38;D
M+Q;X&XGK(UUCN4#JJ1B\VW5&C9V:>/<7JJ)\=- FQEQ2=F;@S/1E1<;/&S#>
M(9G*]U1 WT$[U\72,\5^Y4"/%KJS^X4<9\.-X=!B"URMI7.]%6Q-YE-*FNB=
M].B+]6NI+BBH>4^>6*<D;VVOPW=JJWR>J]C7=R5-==JI\"/43MX:>U*L>87F
M]JQI'%8[O(Y&-JF=VEE5?M_%I]JD]*$JK+B!M3#3W"VUC)(I&H^">"3<US?8
MJ*GB>].HS?E'QH5V'>718EC?74K6HUM0S\:WZW^.OW:'.W'ILZ]V)?&XZ>21
MN"\?6C,&U-J[36154?O(UW>B^I4]BG%RX:QUQIKFNK#V;V2-WI[K672D;Y]3
MU$KI7-8WTC=5UTT]IU]MO)J>-,MXZ8CN$;HWN:YNUS?6:XWRK>W N;%^RON7
MG-GKI:?PWQ>LR5$77:J? IW&TQ9YXY92BZCQ27RCXZ;%BM(:+$#?HFXN7;S?
M[Q(OS:^XGVJ?-;OT3+C[L7SRVQN9U\F<;/>*2^V]M315-/5P/3NRQ2(]KOO0
MX=14Z\:7Z5U>P)     Q=G;Q<X%R%MTTEZO5*^KA7;YE3/26HU]B*Q-7(GUZ
M&[:>F;C<:]8G^JG)GF/) 3BF[3C%V<;JBVX<=+AFP/=II$[6IG9IHK7O\-%\
M=-$/LO3O0,&#NR]U.7GWE5XHGW.9]1,Y\CG2/<[O.<[<X^CG3HQTN7)WAMQ;
MQ 7AM)AVURS1==]4]NRFBT^,B]-?JU,^XWF+!/+*E&*K\4X<C>SUP#PVV1N(
ML;UE%=+C2[7NJ:QR14=,]%U1S$7VZ_7U/G=SZKGW%<<3H1MICNI8O$QVL5#A
M^FFLN6]&V:6/=$ZXSQJV)OL]&SI]J+KH7[/T2M>[.KR;SX4$<R,S+YFA?IKM
MB&Z55RKI/7EG=NZ)_H/IL>&<<\9[6*KK7R81S,XD+5A7F4MO<VX5VWNN8[T3
M7?;[?L*<V\F/%[,=7Z1^&6Y/O'#]A&JEV-?-;87NV^KX'Y-N?M:?0QXKY*$P
M
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MLO/NDK3HV(]D&W_:K%2^]S6_Q,/C/E=Y8W4].^JDU3XQTP
M
M
M
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MNYQ1,]4WZTN%VCEH.'C!L,S=LL=KA:YOW'YYN?M:=F/%?I0F
M
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M*<GFVN]D%_N/BC_&M_B8?)_*WRQNCZ=]5)JGQCI@
M
M
M
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M"A,
M                                                  4?,/\ L"O?
MZWS_ ,VXNVWVL_CH\R>"#9^A.0  +FP+FQ=<"S:12><4VW;R)7=W[OA]QDS;
M:<B<7T9IP+G%:L;,Y:2>:U71O*E[N[I[/J.3FVE8VF,D:KM*%@         H
MN-\Q+)ES9W5U[N5+;Z9OORN_H3J2P[?+FKCBGDC=SIY(AY]=HY6XDIIK;@ZE
M?;Z29FQ]=.U.?[R+L3JB)IX+XGTVS]#B.[/W.=EWG7Q1BNUXJK]7R5=;45%5
M4S.W/EED5[W?:JGT,Q.G;+'6O53;I>*2QT;JBLJ(J>%O><][MK15<7B-F>G:
M!4MGYUOP:UM9.YBM\_D;Z.)?8K$7Q^]#%FWG3Q7:8T6,;8^O&8E[FK[Q73UE
M1,[?WW+RVZ_(G@B?8<Z[J_)9,]'9@/+6]YE7B.BLUOGK)I';=S6]UOY2KX=!
M$5?B571+#([@!M6&64]PQ5-]*5[6[O-6.5L$2Z]%UZ*O3Q14T.EAV<Z>2FLB
M1-#;X+31M@IH8J6"-NUK(FI&QJ?4B=#9QXJV+\\.+C#.3M-) V9MTN^Q=E+
M[=L7V;U^&OPZF?-N9A*8ZH@9S<3^)\Z*QS:RJ?1VW=N91T[ML;4T]55317_'
MJ<[)N*R+YCHQ[1T,UPJ6PP1OFFD=M;&QNYSC.FD!D?P$7K&C(;AB23Z'MTC5
M=R/6J7?#IX:+]NIMP[.J\E594O,O<O;5E?AB&T6:G\UHX7;MNY7.<J^*JJ]5
M7NG2B)F>,J:UZM@79!?[CXH_QK?XF'Q?RM\L;J>G?52:I\8Z8
M
M
M
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MM:5UO)T\6 \U>T*S'S"AD@AN7T'2;][&T'HI6I\%D315.I@]*P8_YE%[FM6
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M8_!?!2]
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M/:C554^*=XC%S?B]K3HV"]D%_N/BC_&M_B8?%_*WRQNIZ=]5)JGQCI@
M
M
M
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MN_,/S+<_:T[T>*ZRA,
M
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ML[O[03_UUG_D1'1V7V2G)YMKO9!?[CXH_P :W^)A\G\K?+&Z/IWU4FJ?&.F
M
M
M
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MG3<C_577V)KJ630]W$-P8X*XA*"1U=0LM]T=ILN-&U&RM1/9IZJZ_6FHZ:B
M'$5P+XQR#J73^:RWJSN<NRLHXU?M1.O?8G5-$\55-"O708FPOBZYX)NL=;::
MZJM]5"[<U\3MO[OL7[SP2\X>>T\5K*>U8[I]W5K&W2!O>^MTC$\?VJ%VF42F
M<[#6=6$G*GT=?+56,5CO"1NBIU3IU1?W%+?K$5N(#LTVU5957/!-4R%LG?\
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M3Z./%=I0F
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MO5L6[(.!GX)8HDV]_P Z1NOU;&'Q7RMKZ674]/\ &DS#XYTP
M
M
M
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MM<-;%CR!P>CF[7?1</\ (/SO/]K3MX_!?!2]
M
M                       %'S#_ + KW^M\_P#-N+MM]K/XZ/,G@@V?H3D
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MKXO>+8-V07]AN)OU8G\AA\-\K?M9_!U/3_&DR3X]TP
M
M
M
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MJGM1.NAU<.VF%%7U?I1RIA\WRTL+/EHHOY#3\BS_ &M?B^CCQ7 4I@
M
M                                        "CYA_P!@5[_6^?\ FW%V
MV^UG\='F3P0;/T)R         !9N>G]K>O\ S4-&U^U59?%#/BB_N?L6?K=+
M_$=3<?94SQY-<]#0S7.LC@IXWS32.1K&,;N<Y5.'IIR:4A,B^ >ZXNY=?BES
M[30.;O;3M_'R]?!?#9]O4VX=G5>2JLJ6>7N5]CRMM/F=DM]/1QN:F]S6IOET
M33<]?:ITHB8\5-:]77F-FQ8<K+4ZLO5PBI6;5<QF[ORZ>QB>U3V\LQY$Z=42
M\]./*]8PFJ*##'-M-MW;6U#7;:F5/FZ>I]RJ<S-O*KQ7:8D?JJJDN-3)--(Z
M::9VY[W=YSE4Q+60LFN&#$^<U3')14KZ6V_WRLGU;'T716I\5^HT8]O61"KZ
M)AY+\(^%\G61U#:=ETNL;D=YY41IN:J>UB==GW*=+'MIA15]63+A<H+31R5%
M3-%3P0M5[Y'NVM:B>)?RXHH[9Z<?EMPOS*#";6W2L:[:ZJ=^(B^MGCO_ 'C#
MFWDZ>*R<:*&/,RKWF9=?/;U<)ZZ;<NQKW+MB15UT8GL3ZCGW=7Y+IGHZ<&X#
MNV85X;06>AJ*ZID[VR-N[I\PB*OQ*KHE9D?V?M!960W#%TWGU6US9&T47XIJ
MIUZK[Z+[4T.CAV?3R5ZY$D+3:*7#]MCI**GBI:6G;M9%$W:QJ?4AMF>*ECW.
MKBFPQDS3215%4VLNK?4HX-'.U5-4W_!/K*<FXF$ICJA[G1Q88ISD?)!-4?1]
ML=N;YG3NVM<Q?=>O3?\ >AS,NYNU\QT27[.[^T$_]=9_Y$1OV7V2K)YMM/9!
M?V&XF_5B?R&'R'RM^UG\'1]/\:3)/CW3
M
M
M
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M745O0
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M8
M
M
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MN6&W0MW-^IC3\VW'VM.]C\%RE3T
M
M              4?,/\ L"O?ZWS_ ,VXNVWVL_CH\R>"#9^A.0         +
M-ST_M;U_YJ&C:_:JLOBC@YS8V;G.VM;[SCN,C">>'&YAW*]\U#;-EZNK=S=L
M3O11+IT<K_!4U^"F/-NYA9,=40\UL^,29Q75T]VKI?-_<I8W;8HD^5$]OWZG
M+R9JOR73/1:]GL=9B.OCI:&EJ*JHD=M:R*-9'?O$9GJDDKDCV?-9734]PQA-
MYK"URN\PB<CGNT\-535-%^KJ;L.R^)3KD2GPC@FU8%M4=%::&"AIH6HQJ,;[
M/K7Q4Z&D3IXJN2AYK9[8;R=MO.O%PB;,[793L[\KU1-4;HFJIK\5Z$<N:8\B
M=.J(>>G&W?\ -'F45IW6.T2-VN8QWI94_+7[?AH<W-NZOQ7:1T83FF?43.>]
MSY'R+N<YW><Y3&M97R3X/<4YN/CJ)(7V>U;E:ZHJ&[7=$UZ,7KU]BZ:&G#MJ
MM"KZ)@Y.\->&,FZ"-**C945^Q&RUD[=TDO77[$^Y#J8]O,**OJO6^8@H<,T$
ME7<*JGHZ>-J[GRR)&W]_VEE5Q11FSP[0:FCIIK?@V-TSY&;?I&5JM:W7Y&+H
MNJ?6FA@S;SW87:8T6\58RN>-KK)6W6NJ*ZIF<KW.E=[5^">"?<<^KK7R6<50
MRYRGOV:UXCHK+;YZI\CE:Y^W;$S1-5U>O1.GUGL8ZOQ*KHEKD7P&6?!+(:_$
MKF7BX[4=R/5@@7Q^U53P\=#I8=G.GDIK(S_2TL-OAY<,<4,3?=8U&M;^X:U;
MKM5XH[Y3.EHJJGK(VN5CGP2)(W5/%NJ>T]FN0GYV0/\ 89B;]6)_(8?#?*W[
M6?P=7T_QI,D^/=,
M
M
M                                              ^.=M\0+*XAJC_\
MQN+D;_P15?S;B[;Z?2S^*%Z]K\LN$^(#%N0&;5TNF%KQ56V:.OJ'.BW;X)=7
MN1=\:ZM7I\4/T'3Q<9/7A3[7##^97F]HQY'%AVZ[&L;6MU=35+^ZGLU5'KX^
M&T]>\DBLU,G<&<1V$G4M[M]NO5',U6LJ&:.>W\R1O5/N4)M?7%)V3>(\LV5%
MVP5,[$5JC:CG4;N[61>MJOL:K$3Z]0AQ1(K*.NPS=>7-'44-=2O]5VL<D3T7
M]U%0/$E>&'M-L4Y.,I[5B3FXDL37*W<]VZJ@:O7H]?7Z_,I+D)Y91\0V#.(K
M##9[-<*.LYS&^<44^G-B5R>HYB^.GMTU0D]EAGB6[-'"^;4U1<\.N;AN]R.D
M>YK/ZVG>OAJSKL1%^5#WIJ\0)SDX>\59%WN2BO\ :ZBG8WO,J&MW12IKIN14
M\.OQT4KUT'7E#GQB?(^]MK+!<JBG3<CGP.=NBE^UBZI]^FI[-=!-WAY[1O#V
M:3X;=B.-N'[O)JUK]VZFE7V-1>JZ_:B(6Z7U&5,U,E<)9[8>=%=[?15S)FHY
ME5%HV7IX:2-ZZ?5KH6<>0A7G]V=N(\O9I*W#6_$%LW.=L;HV>!B)KN5%T33[
M%52FL0CS<K/5V6IY-73U%+(WW98U:[]\J'.SX@K\/S.DH*ZMH97=USJ>9\3O
MW45!U%VX.XD\;8%J72T.(*]SW=W]$2><M_<?J3G+>B/%<CN.3,IWC?(O_8XO
M_P $L]M9Q<'<;^8SO_XU%_['%_\ @#VUG!1,7<3V-\;4S8ZZ^5#6M_P#4@=^
MZW0C6:]3BL^[8HN5^8UM=<*^L:WU6SU#Y-O[JJ0JNJ3QT]/+53-CBC=(]WJM
M8W<XB,GY5<*.(LPGQSU4+K3;G-W<V?UI$U]Q.O7[31BVUVA5]$E,N<C</Y4T
M&E%2Q25/1SZJ=NZ35$\4U]3[CH8L,RHJNJW,WN)JQ9=LDIZ>1ERN6U=L43N[
M$OLWK\/L/,NYF$ICJC3F5G/>\SJQSJVH='2;NY3Q.VL:G]/WG.R9JM=,]%&P
MK@JY8TKVTUNI9:A[G;=S6]UOVJ0C'5^)5=&=LM^%.CL+XZN^2-KJEO\ >(_Q
M35]GP5?XCI8=G.GDIK(R#B#$EHP+;6NJIJ6AIX]&M8WN_N(AJJXB4./)^B/*
M6Y)69:6&:/O,DH(7-_R&GY!N/M:_%]'/BN>.9LGVF=8Y@
M
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M7)W;MQ%(
M
M
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MR63/1^L_(G^TSA?]:X/YMI^>9OM:=F?!=A6]=D=4YOB1XK'>V1'^!$?0
M
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M["(
M
M
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M0
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M7]O/X.MZ?X)<GRC<  .<<SH_L*UCOCF23P Y
M
M
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M3]$/U:QOQT3HNICR[[IXK=,;].F7LRU& +&]WBZW0.=]\;3\IR^=._*LD7@
M  ?6R*SP"QWQU"/Z+W5(\4>3L(I
M
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M3Y1N    !VQU7L<1XI<G<UR/ZH12?0
M
M
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MH-C=?Q$?(=U^MFAYPG5'DM";@>RU;X6%_P#[9+_^$>>Q@Y//)P3Y;M\+"_\
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M:?G5^;MRK)%X     !RCF=&OY)6L=\<R2 <P
M
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M=\=4UW12/%'D[2*0
M
M
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MFRX,L[D]5U%#_-M/QW+YT^DE52+P        [(ZA6IHI'BER=[9$DZH12?0
M
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MD^TEQ.KL(@
M
M
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M.[UNJ(12
M                                ?'.1G50.F2J]C27%'DZB2(
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MCOCE21.A$<@
M
M
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MJQT$#6_=&T_*\OE3ORJQX\           !]CD6/P4+'?'4-D_)(\1V$0
M
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M7L<1XI<G<UVJ:H12?0
M
M
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MK'?',DG@1'(
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M_1U,>"<?BR$85H               ;(L7@%COCJFNZ*1XH\G:12
M
M
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M                G=\ .V.JV]'$>*7)W-<CO BD^@
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M;I:B-'11+X]QBZIT7P7Q/AO4?7\^X[8[9=3#LYAGTX34
M   !RCE=&5K'?',V3[0.8
M
M
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MI':^/W'3P[><:BKZOTA8(_L,M/ZBA_FVGY#E\Z?13XJH1
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MW.<K=J1N1K3W<8?9D5U5$H3
M
M
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M%=&V%FUK6M1ONM-RMYYO!H'Z%\$?V&6G]10_S;3\9R^5?B^EE5"+P
M      !XZ^]0V[HKMS_E:6X\-6]UI0KA>)J]^BNVL^5IOQ89E55/(:!7,#_U
M[-^8G\HY^\\4X7(<]:                                   ^22-B9N
M<YK6_E#33D*)>,90T<;DA[VUJ[GN[K6Z&S%M*U\D-;81S>XK+;A::2FI)/I:
MY=-NQVZ)NOAU3HOV(I]#L_2JK^66#-NYT8SH\%XYXBJSSNY3/M]MW.V;VJR.
M+7V(SQ5%^/4Z6N;;;3MGNIFF,F7R7;B#@YMSK(UMJKIZ>XQZ.;++WFN^/@B+
M]ADCU>N7=/:NK9]O:MVRYL8MR#N3;;B.EEKK<U^ULKN\[33HUC_#Z].JFB]K
M@W,\L7DJTS9<7;3/N5>>EMQO;8Y:"J9,US=SX'NVRQ?'HO7Q]I\_O/3:BNYT
M,.XFV1+;>(;HS6-W7Y7>L<?)AJ/)HFNKU%:0
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MLS=JN=.]O+@;IX]]>FOU:DL>&K\4:KHEYD;P-X?RYY=;>VMOEU:YKV[_ ,1
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MAWONIPKIA6@
M
M
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M^TPLF('PT^);;+::ASN_4Q>DIF_OJ[]XNG,ATU9JPOGIA#'5'YQ;,06Z:/\
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M-!&ZCHVW"Z[-LM?5-WR.777HG@GW(A\-O_6,^[KN[9^YU<.VG&RR<M>
M                 ?'.1O5>Z@%,N.)&4_=B](_YO=-./;5KY/*I1*FLEK'[
MI';C=$1'B@ZBT=E-2RU3]L;7N4A5=/(75AJTOM-,[F.ZR:.V_*<G<YN=+8GH
MJ10F
M
M                                                         !3K
MIANGN'>1O+E^9IHQ;FX1UCDMRY6.>VO[[=S/F:=#%FFE.NG%XS0/K7*U=4\2
ML5.WXD?3[6R^D9\WO&;)MIU\4M-5:I:R*L9NC=N,5Q4>2?)W$7@
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MB/(F5PVK",=/M?/Z1_R^Z8,N[K7Q6Z0K#6MC;HG=:8TWT
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M9<F[F?%/2%PT=OAM[-L3=I@NZOR6::.X@]
M
M
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MC!N![1E[88;79;?2VV@I]=D$$:-:W7JO3ZU/C\V;+EKEEKE3IQ$QVRJQ
M                   .BLKHJ%FLCMOY)*,=7XO>2B7#$4E1W8O1L_A&W'MI
MT\D-=5--*(6#WVO#L]RVNV\N+YG&7+GF$IGJN2UV&GM;-6MW2_,XY^7/5K)G
MH]I2D
M
M
M     !U55'%6,V2M8Y#V+K3Q.B@73![XMSZ;O-^5WK'0Q[KKY*JA1)(UC?M<
MU[5^5QKTUZH/A8.^CN4E"_5CNGRE%XYOR>]=5<M^((ZSNO\ 1O\ RC!DVU0E
M-*B4O0            +&SXX;\$\3&":JP8UP_07RWU3%9MGC])']:/3JFB]2
M>'<5BKE!K$Z^33]Q]>3>XBR]^D,29-W!^(+/#H]UDK',;71)HY7N9)W4>B+X
M-1NX^DVOK47VY>UAR[3IXM?N0N$+K@/BQP?:KW;:^TW*COU*R>EK(7P2Q+S6
M^+'(BH=V*G7NEE6)CS^S6[_JV;^<<!2@,J<//%)B[)6_4\%LN#ZBWU#VL?1U
M&LD3M5\?8O3[2>E#: V3GTS7KZSFHXTZ#S5'] 0U^MXZC^@L>/)/[ /'/["Q
M6\<_L \L_M^\#QS^W[P/'/[?O+!Y*C^@#QU']!8/)/[ K>.?V$]/J'D?XGH\
MM1_0!PM=EK,176&AH*6HKJRJ?LB@@C61\J_!$3JI[=S$\J>SIU30X3>QMO>9
M5-1WO,*JJ+#::B+>R@@T;6.U\'*JZ[/K16ZGR_J'RFG'V[;NK[_W-N'8UKW6
MV@6NWLM-MIZ6/<Z.EB;$W=ZVC4T0^#UUZUR=9Z#P      \M==H;>SO.W+\K
M2S%AJWNM*'<KY)7=$]&SY3=BP3"JJ>$U !4[3AF:X=Y_HX_RO6,F3<S"4PN.
MWV>GMK-(V]?><[UCGY<U6LF>CU%20
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MG_P3#EW=:^*W2%6:W;T0R)@
M
M
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M?BIDZ9<K+>6?#W8\N86R)#Y]6^]/.W=^XGA^\<O<[_+F:\6WF%^>KT13(T
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MU[E_)*ZKB*[:L'^J^I_R#%EW7PIZ0KL-.RG9M8UC4_),55U6N9$
M
M
M
M4RZ87AN&YS/1R_D^J:<>YJ$*CJMRX6:>VOTD;T^+?5.C&:;\56NG%Y2X?6.=
M&_5KMKBL52WXF?"NV;O)\WO&7+MNOBE-JU3U3*IFZ-VY##<5IY).T
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M\3ZC\H<^?MQ=L_W=3#LYCS2IIZ=E)#'%$UD<<;4:QK6[6M1/!J'S[6Y@
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MVWO&"\M7Y+)GH]!6D
M
M
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ML$+=K(&MT;]QQYWU77TK9[+IXJ-44KZ29T<C7M>WW7&R:Y(N!8
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MP6W:[;S)?F<<[)N*M=I'%4"A(
M
M
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MV_$S)MK9O1O^;W3%DVW3Q3TM4VN:YFJ=Y#*]<@
M        #C)(V-FYSMK3R9Y"E7#$S8^[!WE^;W39BVOQ/*M1:BI?5OW/=N<;
M)B9\4' M'=1T,M;-LB:]SBJ[B/(F5P6O",=.F^H](_Y?=,&7=UKXK=(5EK6Q
MIHG=0QIOH
M
M
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MQ6G"L-#WY?3/_@F#+N:KQ6Z0JS6[>B&5,
M      "V79E45TYS;;-%5.A>L3W-=ZJHNBMT^TWQLJT^U5^UG7Q8ASRXCOZG
MM3YI'2SUUPD9N:YS5;$U?9\-?N.YL?3?:=WC+%N-SP8PM.7>->("O\\O-1/0
MVQSO5?W6Z?!&_P!*H=2]Q@VT\<?DRSBRY?)DFJR3M&7N5&(([;2\ZX.M=0UL
M[F[I7/Y3]-/@NOP.;^V5ERSR\>NC7["8E%?AU[0+&/#W5MM%[947NSP]QU+4
MZ\^FZZ]Q5T77\Y=#N>H^@X-WW8^VF+#O*Q]MIR9;<96!<S\#R7NCNK(O-VM\
MXI96NYT#W)KLTTZ^'BFJ'Q6X]&W6++[*I=6-SCN>3&N:/%W<\3LDI+'&ZVTC
MN[S7=Z5WQ^*'7VGHN+'W9>Y1DW-:^"SL(Y2WO,2L\YJ'2PPR.[\]1KN?^[U-
M^7<XL7;*G2*U9DP'E;;< P[J=O,JW-VOG?ZSOZ#E9MS>1IB.BY2I8
M  .,DS(6;GN:U/F=W0+3Q-FI!;U=%1-\XD^?W6EL;?KYJ=<C']^Q--7O=-6U
M&Y/RO5_<-D8_A457)9]XS B2I\UIG,YSFJYNYW>VI[43X&R-O\2/)&WB@J)J
MK&T,DLCI-T2>L[N_N'?V$\<3)G\F,SH*0"5'#A_7</Z@;_U3YWU'P_JNP>2'
M><'9]X PCQ 8ZS-S:Q-1?0MPN]1<J>VMD6-LL+GN>K7HGI%5.[^+*\7BTZZ)
M^=FSB+#^*JS"MPPK&R/#E5;974#&M5K6QZ.1.B]3E^L_X:OZ+]MYIN'QKI
M                                =590Q5S-LK6N:3BZCQ>:Z+>N>$7T
M^Y\'I&?+[QOQ[OKY*ZA1G1NCDT<W:IKZZH/A,>JANTU$_NNW,^5QGRX9HFE<
MM]\AK^B^C?\ !Q@R;>H3FGN*GH                           #P7"_0T
M*[6^D?\ DEV+!5O*I0J^YS5S]7N[ORM.A&*80JGG+ARCC=,_:UNYWY)76O05
MJUX/?(K7U+MJ?*9,NZZ>*>D+@I:.*B9MC:UK3!5UKY+781
M
M
M
M          !ZW15 I-TPK#6(Y\7HY?X)KQ;NM/)#6%NW"US6U^V1O[;W3=&2
M;\56NG%YR\<HY%A?N:[:XKK3J*M;\3.;W9^\WYFF7)M?A2FU8@J&5#-S';D,
M-3T\DG8                       ^.=HFJ@4RX8D93]V+TC_X)IQ[:M?)Y
M5*)55TE8_=([<;HB(\4>NKJ+7CG#3OJ'[6->Y?R2NJXBNVG"'OU/^0TQ9=U\
M*>D*[#3LIV;&-8U&_*8:KJM<SP
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M;A?ESUC6UU9M[V]NZ-OW>TX6??5?BVQAZ+\:UL;-K6[6M]UIE6OH
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M;/#;&:1MZ_,[UCGY<U6LF>CU%20
M
M
M                                                       '":%E
M0S9(UCD^5Q[I704.[80;Z]+_ )#C=BW7Q*JA0:BG?2OV2-<US?=<;9KD@X%@
M[::LEHW[HW;2JXB_(5NVXD94=V;T;_F]TPY-M6GBG-*FUV_JG@9GKZ
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MK'6.UR4KJC;R^:NBKX:K\QSO6?GVU?T:=MYIT'QCI
M                   !2KIA6&LW/C]#)^3ZIIQ[FM/)"H6[<+3-;7Z2M_;>
MZ=",DWXJM=.+S%XY1R.A=N8[:K?>*ZTZBKV_$VU-M1_E-,F3:?"E-JQ#,RH9
MN8[<GY)CUTXI.9X                   ZZBI92LW/=M0:16OB*-<L3.D7;
M!W4^8W8]K\2-6I,DCI'[G.W*XU::=$7PL'JMMGFNC](V]WWG>Z49<TQY&FG)
M<=KPO!0]Y[>=+\SCGY-S5K=(5,S)@
M               .=MZJ!PAF94,W,<US?F:>ZST',\              'S<C
MN@'T
M
M                               #HK[;#<&;96[ORB<9*CQ1J>JW;IA.
M:CW/A](S^$='%NIU\E=0I+F[.B^)H1?"P>JAO$U#ZKMS/E<9\N&:)I7:"]0U
MW3U7_*XP9-O4)S3VE3T               Z:RNBH&;I';?R2415^+WDHEPQ)
M+4=V+T;/X1MQ[:=/)#753-5=XFE$+![;;8:BZ=YK=K/BXSY-Q,)3/5<EKP_3
MVUFNWF2?,ISLFXJUDST>\H2
M    UA=IE'R>+&[?J.E=_P#<S]-^3?\ @9_'5P]]]HP%2YF5F5;*7S*.)U/<
M+E$VIB?[W,71[D^M39O)G',\?>O3^[-/<S3@_,6EO;XWTLSZ>K;WMF[:YJ_5
M\1EP]/)'DSYE7Q95V'61T=^:ZX4C6[6SM_&M^WXIH<7<^F1?=B[6S%NJGR2
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M\1#+'BV.E^CXJZJ= R#=S'1)W>ZJ^U>\9O4HZX*68:[FQ0^&=0
M                             '&:!E0QS7MW(X]FN@H5VP?KN?3?Y#C;
MBW7Q*JA0:BG?2/VR->U?RC=-<D' L'=1UTM _=&[;^257$7Y/>NJMV_$D50C
M6R^C?_!,&3;5IXI32I-=JFJ&=Z^@              ?'.1K-5\ *7<L1LI^[
M#Z1_S>Z:L>VZ^3RK46IK):Q^Z1VXVQ$1XH]=746O'92TLE8_9&USG%57,^0K
M]IP>V/OU/>7Y#%EW7PIZ0K<<:0LVM;M:8ZKJM<B(
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MLV]]64#DKP
M
M                                      !X+IA^GN3-=O+?\S2_'N*A
M'6.2W+E8:BVR:JW<SYFF_%GFU=3T>$U(C7;>J%8J5OQ%+2]V3TC/X11EVTZ^
M*6FJMT==%7,UC=N_),%XZCR3Y.\B\          #A+(V)FYSMK3R9Y"DW#$V
MWN0?Y1LQ;7XD:M1YIGU#]SW;G*;=-.B+@6#NH[?-6OVQ1O<XJNXCR--.2XK3
MA&.E[\_I'_+[I@R[NM?%;I"KM:V./1&[6F--]
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MWUHXPX/%=:;'8-7*:;(VPZR?B<2K$W[/0]"&\TZX*_!=@\FXP^ =8
M                                  !T5EOAN#-LL;'$XR5'B\UT6[=L
M)R4>Y\/I&?PCHXMU.ODJJ%)>US7Z+W7&A%\+![+=>IJ'HCMS/E<9\N&:)I7*
M"]0W'HCMK_E<8,F&H3FGL*GH           /%<;U#0]-VY_RM+<>WJWE4H5=
M>)JY_5VUGRM-^+#,H53RF@?6-=(_1K=SBL5BU81DJ-KY_1L^7WC+EW4SXIZ0
MN&CH8:%FV*-K6F"[J_)9IH[B#T
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M[UW[6?P=/:^+-APFH
M
M                                               /CFH[HO>0"D73
M",55N?#Z-_R^Z:\6[K3R0UA;U9;YK>_;*W:="+B_%5KIQ=!:.4$[Z=^YCG-<
M5UIU%8MN)O=J/\IIDR;3X4IM5XYF3,W,=N:8]=.*3F>      'SU4Z@4^X8B
MBI>ZSTC_ .":,>VK7R>52AUEPDKGZR._:^Z;8QS'BCUU=!>\<HXUF?M:W<XK
MK7H*W:<'K(C7U/=;\ADR;OX4](5^EI8J2%K(VL:UI@JZU\EKL(@
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M$=U_AZ_#5/'Y-F9\ ZP
M   \-TP_3W+JK>6_YFEV+/4(U/5;=TP_/;.JMW,^9IT,6>;5U/1X34B^M=LZ
MIXE8J5OQ)+3JULOI&?PC-DVTZ^*6FJMTM9%6,W1NW&*XJ/)/D[B+P      !
MT5MPBH6:R._:DHQU?B]Y*)<L1257=C]&S^$;\6VG3R0UU4WUNJH7HA8*A:\.
MSW+KMY<?S.,N7/,):1R7':[#3VMG=;N?\SCGY,U6LF>CVE*0
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MM9A3+'?71NA?<).:UCO6:GAU^T^']8S1DS]ONNKMHZ2RJ<EH
M
M
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M^A_9>[^*G/-Y]A7X:F'S;GS\_=D
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M*M6Z<,Z+T,BT     #KJ*EE)M5_O.1C?SE)3/4=A$
M
M
M         /-<+3#<F:2-[WS>\61EJ/%&IZK<NF%YJ'O1^FB_)]8WX]S-^2NH
M4LTHA8/9;[W-0KIZS/E<9<N";)I7;?>(;AT:[:_Y7&'+AJ$YIW557'1LW2.V
MM(1%7XO5%N&)GS+M@]&GS>\;<6VZ>2-6I;G.D=JO><:D7PL'KMMEGNC_ $;>
MY\SO5,^7-,&FG)<=KPS#;]KG>DD^9Q@R;FK6S'14C,F
M                                U\=KA:_-<V\/U.W;YU12=[Y]NQ#[
M_P"2=]<%1_%Q_4)[D)LVH]V7ET<G][@<_P#<0[?JL_\ QJ_!BCR5RTKNM-*O
M_FF_Q&W%X2C3T%KP   /K9'1R:M=M4#._#+BJON&'KI!-4/D9'+&C?LT<<??
MXYY2TX%.XCN-# G#';9'X@NT4ER:WN6ZG<CZESE\-6)JJ(OQ5-#&MY,7\"?'
MI=.,C-?&E(ZVT]KP_9Z.&>@B]:IU>]R+O?X+ZOP0'UI3Y*]+]<$_(_ZY#?>$
MJ\/FP5QO4N3^%\56_&6:#J>HJ;'%/%;J*5R2.EW2-57LB]9ZHK6IJGAN$>*R
MD4[EVL%[S6SXPO8,(T,6&<*272!DNUNZIG9OZIJFB(QR>S37ZR;SDC;VA4DL
MW&9CQ\F_TE>CF[O@L; 4RYV/\+[EC/,RWPMW55RPE-3PM^9[GMT0$K^X8>QW
M\SA;B#-:X14='&Q9?HVGD1NSKT=)+U333Q31%^L'%GS-[BKP9PP\*ETNV5]'
M:[A0V>M;:Z>*C<CJ6*9^Y$?JBKO1-O71>OQ";6)GQQ18TXCK])78GO%15,W*
MZ*E8Y6P0-7V-9\/M50K9[[6BK967+*.2-VYCL&P-W?8]R![2E]FWPDX\Q9GK
MAG&4%GEH\/V6L2HEJJIJQ-E8K')NCUTW^M[ :2V5\2\.[!,+_EG:W]TV['[5
M7F\&!SKLP!G3AFDY,%G<ONU$G\;CC[[QI9C\T)>V0R9O^:G')2TF'+757:MK
MK33MV4\*R;4:GK/5/!.]XG,V_@UW]:8G9)<.-^X7\O[#8L1NI_I.LQ VO>R)
MR/; C^4FS5/%>X>;S["OPU3Q^3:\?G[K
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M;'Q[H@
M                           ZI*K;ZI+BCR?(ZKV.4<3D[M4=X$4@
M
M!3KIANGN'>1O+E^9IHQ;FX1UCDMRY6.HM<G?;N9\S3H8LTTIUTXO&:!]:Y6K
MJGB5CE-4/J.KW/<--.@X%@[*6CEK';(VN<I55S/D+@M>#V0[7U'I'?+[IAR[
MKKXK=(5J.-(6;6MVM,E5U3<B(
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ML_:>+?.7IY+SHZIM=1PS,]29B/;]BIJ<K73IVKW8>
M                             'GN%KAN3-LC>OS>\61EJ/%&IZK<NF%9
MJ'<^/TD7\(WX]S-^2NH4IS=O132B%@[DN$SH>7S';/E*O93YCI+0:W=T0K%6
MM.%9J[OR^A9_",V3<S'BE,+BH;;#;V;8F[?K.?>2K\EDST>@@D
M                                    #KJJJ.C9OD<UK24Q6OB=6(\^
M>+S#62UJD=6UT7G/JLIXG;IY5]G1-=-4]JG:V'HV7/3)FW,P@GGYQPXLSJK)
M*.WR2V>T2*K6P0.]+.B^&Y>JZ_FZ'VVR](P;?NKYZ<S+N:MZL@^!#$^;[XZ^
M[<VRVR31_,E;Z>=%7KHG547\Y#S>>L8L';/=1BVM6G9D7PE8<R>M,<=OM\4,
MB=Y]0_O3SK\55?#[M#XK>^L9,U.KCVTPRW14$-OAV0QM8TXMW5^31IH[R+T
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M#:^A98RS655EW,W/&4*<+-VU\B?EJ?77];GZ?4S[PT?VV,-_J^'^6AR_4?\
M"U^&J_'Y)^'P#K
M                  %.Q9B)F%,-UERDAEJ(J-BRNCBTYCD3QTUT+,6/VE<$
M:KHHN5&=F&\Y\/0W'#]T@K(I-=S&NVOB5/%%1>O3]PNW>RS[>N.64,>6;\5U
MF5:           #KDJ&Q="7%'DZ9)ED\2*3B6*P#['(L?@H6.^.H23HO=4CQ
M'81
M       #XZ)LC-'MW-_*'446Z8/9-N?3NY;_ )?=-F+=]/)#6%OU5'+0OV2M
M>U3?%Q?BKZ:NMC72/T:W<X]>*S:<(R5";ZCT;/E]XRY=WT\4](7#14,5# UD
M36-:TP7=7Y)S/1VD$@
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M;T=N:ZCB=N_:-/D,WVE?BZF/P5$K>@
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M9^]25&',OZ2Q4T;.7$UD+4;'%$W;'%]B(?*YMY=NC,=%PM8D;=&IHGU&--R
M  /%>[Y28=MDM975$5-2P-5\DLCMK6(A[$5=<9>:UT11X@NTUH+9736++RA=
MB*Z.>D7GO+W4W5/<3Q547IU33Q/JO3_DW>OTNZ[9^[][!FWONXF3LJZZ]73
M%KJ<0MY=YFIVOK&[49MD5.O1O1.OP*,\S.6HQ>*S%RX]ST8NP';<:4;HJVG8
MYSO5E;W9&_?XGF+-6/Q2J.K#6/,@KEAE[IZ']'4FY?5]>)$37<J?Z#K8=]-^
M7:RWAZ,7YQ8PN/X 0T=7-+)34=;!.UC_ %FJDC?:O7P-F+#/+E*N]>U,7+7B
M MN,(6M23;+ZO*?HV5O]!\IN_2ZAT(S=61*2NBKF;HI&.0Y%Q4>31U=I
M#2[QX?W9E^_QB'ZMZ3_@Y?/[K[5>&37]8?\ HU_B*LR<.>$;/5W"YS<BEGFV
MRKNV1J[V_4>7<Z>1I]24/"/DK>[UC.UW>:AGI;;0SI*Z=[=K7/9M79HO7K]A
MPO5=]BC'6+WJ:]OCK6N29Q\8Z0
M                             !XL24+KGAZNID[SJBGD8W=\58Y"6/7I
M4T\II^;=,1\.^9UP@MMRJK;=K3/)1RRT\BL<[1=%;T]B[3]>X8MW@GG/*:^=
M\YUK':=G GQTU6?UVDPSB2&EAO<,'-IZB-VWS[3=O[FG31$U\5/AO7?0IVT^
MWQ>/^CJ[3=^T[:2B/F&\        XR2I&G4#HDJ7.3IW27$<"2L     #G'4
M+&OS-(\5COCE21.A$<@
M                       '554<5<S9*UCD)1=1XG1TV^RT]MZQQ]?F=ZQ.
M\U7Y(S/1ZRI(
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MOY1JF>+Q.+ ']@EE_4%/_-H? ;G[6OQU=?'X*L4O0
M                               !\DC;*QS7-W([W1IKQ'@_!FC\YYG+
M_:^Z7_M-<>+SAJ][6HUFB>!0]?0
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MR8
M        :I./+ \F!>*+%$<KMWTI4+<F;?<9*KE1I^I>A9O:;&?Y?F_)P-U'
M3+3'.7./J_+'&UOOEMDY=7;YVRM^5VBZJU?J7VG1W.WG/BK%?O*(OA7)MXR7
MS/H<XLM+3B&ADW17"!'.[NW:].CVZ?:UQ^3;S;5M\]8J]U]'COG/)=)E3
M !\<Y&=5 Z9*KV-)<4>3J)(@         !VQU6WHXCQ2Y.YKD?U0BD^@
M
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M^RK_ /84+?\ [FT_/MS]M7XZNK'BK10F
M
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MIY,]T-N5VV&GA[K>ZUK&G&J^G=;5I+VW##M7;6;Y(^[\S>]L*HSQ;VI>$T
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MO\^7MR4V1AF/%?!D6@
M                         U[=K3@%MES=L^(4FW.OE&L&SY.3M3]_>??_
M "3S\\%8OAU_U<?U&.E<D3#ZUSTMNRZXBDP;C*HP7<ZC;07IRRT;I)-K8ID3
MPU7HB*C>B?$^2^4_IWM,7MY\I^O\'0V&;I7%L&/@'8   #JDJ$;T0EQ1Y.AS
ME=U4DD!6             :Y6]4"QWQU37+HXCQ1Y.TBD
M
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M@C;*U5<]4Z)ZOM#S3ZF\<+4V<I)O.,MK.[_[%C;^XC3X#>?;U^+JXO%<9F3
M
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M9'!4R>;U'^"E=M;T]J+X?NJ<'=^E5IW2V8]PIG!;5,FK,?*CF>DQ ]S6[O\
MS413ZU/3V?X/=M7DSJ<1J
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M#L
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M8?%>)A6
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M&M5RZ)XF98J=+A*LJ:-TJ-V_*UWK.*:W437%+@ITT#Z=^U[7M7\HNFN2+@6
M   4'&F7-KQQ3.95PL;-[L[.[(S_ $EF'/6/Q1J.K#&/LC;G@][IZ;]'4>Y=
MKV?C&HGQ3_0=?;[R<GDS7CZ+9X?LXJW+7$.(HVQ\ZFFN*.>UW=<U>6Q%5%^.
MA9O-K.691Q9>"5>7.>UMQI1M5DW?]5S%T;(W[?\ Z#Y;=^FU#;&;JORFJHJI
MFZ-S'(<NHK3R:'81
M                       Q!QX8/I,8<+6*DJV[OHNE=7P?XR-':?RCK>A9
MJQ[['Q][YF;=Z=<5-41^K.  2![/7B0_J'YM-M]PJ&1V&_>BJ'/DVQP/]DJ_
M%>[I^V/GO7_3?VG!RGREKV>;V=)3<1_:086RG946^PN9B"^POV.8QVV"/XZO
MZKJGPT/F/3ODYGS]V7MG^[?FWLQXH'YS<0V*L^+KYSB"Y2U$37*Z*E:Y6P0:
M_!G@A]SL_3\&VGCBER<N:LGDL@WJUT9)T=UN.;6'X;(Z=MT=6Q\CD.VR=%U7
M33ZMQCWE3I@KVOCT68N7+M;B#\C?0                 !XZR]0T,S6.=WO
MR?=+8P7;WD]E+<$FCW,=S&%.L<?)[R>J.5)$Z$$G(
M
M                                  !@#CQO59AFPX?KJ&HEI:B.MVM>
MQVWW'GT?R>B;JIK[F#?UTF6,,/<05ES,L[;%CVVTM93.=N;.Z-'-W^".5%\-
M$=XG9R;"L5>UVU,L;F;[<K%F?G ?':[))B+ UPBN%IV.G?3RR=YK$ZIL?UWZ
M_7H;MKZU_P!K<]M(Y=M[V)$?+.EDH\#4+)8W1O;S.ZYNW^^..AZ577;3^OWL
MM^2NG20    !D7AH_L_G_4;OXVF#??9+L'D@;GMP;X\XDN-C,2+#%G=)2.O<
M[GUM1K'2Q*K_ &OT7^(Y2_BEEP;\$^77"3FA:XZS$T5VS)K*>9]/%S-FV-8W
M)(UD:*NNB;NO3[ ]E*K"G]M*F^U?Y!+-]@I_[B565G]AL/\ C'?QGS.X\W3Q
M^"XRM:  .$U0REA<^1S&L;ZSG$>(M#$V:T-'NBM_II>K=[O5;]GQ-,;?XE.N
M185\Q%-<'NGK:C=^<[NM^PUQ'PJ*KDM2]8X:W<VF[J>](XU1@^)'DB]Q5=I-
M@7AW954LUP^GL31M[E!2N1VQ_L21^O<33VZ*:YGHCKJUL\3W:%8_XG*JHIZR
MN?9[#(LC66NCD5L>QWN2*FG,T^*H>J^NC!<,+ZI^R-KY'N]UK=S@]2NX4>RA
MQKG;4T]RQ/'+A7#SG([=/'NJ9V*FJ*QG1-%\-=?N#WBGC@_*G)WL]\$^?K]&
MV56M6)]QK'))65*KWU8CUZZ*K>B:Z!-$?BN[8Z[XN\ZL^7%.^TVV1BL=<JCN
MU4J+\C$]14]BHX(:TC%P_P"*KEC3BUP3=+O755RN-9B.B?/45$BR/E7GL[RJ
MO4/&\\+$NN%VJ\ZR9MKORY6_N/<?$^KSTW-.E@\60CFK@
M
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MW3YS<;&\;9&3JN1KD<FJ>!A6OH
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MJA%)]
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M]$1 ]XIX!-+7A1_M)V[_ !LW\XI\7ZO_ (JOZ.AM_!D<Y;0
M
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M[_0<?=^E=>Z6K'N&:[+BJDOD+71R,](W<WO=UWV'S^7;7#5-]52,Z8
M                                                        ")7'
M+<J?!>83;I<9HJ>CJ*5K8G.<FZ56>OHGCTW'V/H/?@XS][F[KYJY(QTW$Y1O
MQ#RWTKX[=T;S??U]KOL/I/V"N+#[9?MPLMIQY:FNFAIZRGF;N:__ .E#+-UC
MI;TG5C+&G#--'NGLLW.;U=R)7(UWW+T0VXM]\2G7#\+&LV&Y[7>(Z2Y-EM^Y
M^QSY8UVM^OZ_N-_/K/*5/%<N,,@<0X5A\X92_25"YWHIZ7O\U/FV)JJ%&+>8
M[3K'6BRI(U@<YKFO:YO=<UQL5MEO9NY5KEWP]T]9/#+3U]^E6JG:_P""*Y(W
M)]K-JGYK\H]U[7=\?=EVMGCX8D@C@M0             #BYR1LW.=M:WWG 4
M*Z8F;5[HZ?P]5SS=AVW3NI&K4HW(@ #E&U9'M:WQ=ZI76O07=3L='#&CO6:U
M#D5YK'8DBQ]4/%COBJD=T7ND>*/)VD4@
M             'FK[U1VJ:%E554M.^H=MB261&.E7X)KX@>D !Y[A>:6SLC6
MKJH*5LSMC.;(D>Y?E37Q4#T>MU1                    \U9>*.W5$,-15
M4M/)4.VQ,?(C72K]2+X@>D
M   $2.U\=_\ F9PRG_Z;_P#O$I]9\DO\37X?[N?ZCXRTP\96<^(<D<U,/UMG
MK-L%1 Y\]*YNZ*?:K4T7V^][%0^PW66L=]KEQ/5>V1?&]8<UF6VBNLS;3<Z.
MHCK&T\[ML#I(EU1R/7HB:^S74KUUQ;CC%?B:Z<4L<J<\+=F50<^/] U#7[6M
M?(G>T]Y%3]XJPU[2.3RNUGO+'B0NN!F-HZ]OTM:G=UT4O><U/J7[?CJ8=SZ?
M.3NGMI?CW-0J>/.&7 ?$];9+GA:HBL-^V*]\#>ZV5[NO>8O7IX=W1"G#O]SM
M*XY>Z5U8\67Q13S9R)Q-DQ=74U[ML\+&M1R5#&\R!R+X=]-4U^K74^AVV\Q9
MYYXJ8[Q5'DL\V*P"^>'N98<PHT3WHE;^^TQ;W[)=@\FO3M1+/)1\9^(F-:YS
MZK;*UK6]YVY7?NG(7TR/V<? /C^YYEV?'%PHV6&SVUZ3L\]:K9:GXHD?1Z=/
M:J: TELXP^[S?,NE=^5_U"67[!5_W$I<IZKF8;Y:=[EO7=]Y\UN)[G2Q^*IX
M@QE18=9Z:3F3==K(^\[5/XOO*XQU:RKZ,?XFS"K,0/<QKO-Z?Y&_TFR,,Z,^
MM\EG7C%$%MZ;N=)\K35&&M57)B[.WB-L&4N'JBZXIO5'::.G8LO*=(G-E1.G
M<C]9_P!R*;8QSH\JFO'BN[9&Z8D\ZLV6M.^UTK7N9]+RM]/*B>#XV+T1%^#F
MZEB')![$F*KEC*ZR5UUKJJX5DSMSI9Y%<X/%[</_  KXUXE+\VBPS:9ZB'<C
M9:Q[=D$2:]5WKHBJGCHBZ@;%.%_LF<&9&PQWK&M13XFN].U7.YO<H:;KJCT3
MHNJ)XZJJ!+B]'%!VJ6!N'ZFJ+'@^&EQ%>X6.8QM+HVAIGIX:JW1'I^:H.377
MQ!<7F.>)*_35.(;Q4.HW/5T%! [ETU,B^ZB)U5/SE4(L>V'#]?BBZPT-MHZJ
MX5E0[:R"GA661WV(FJ@36X5>QROF.&4MYS!JGV.VR-9+'00.8ZIE1>J:KU1.
MGBBZ.0/>*>N'<$Y=\). '+1TMFPO:*75SI7N1KG*OBW>Y=55=OAJ$T4,\.V6
MH?PSH[)@"WMJJ-U4D55=*QKVM<Q5:FL3.BHJ=[Q10CR3EPS<'7;#=OJG.W.J
MJ>*5SOSF-4))?<*51R\F+>G_ )V;^<<?&>L3_P#)K^CH;?P9+CF23P.4T.0
M                                 //67>DMKX65%5! ^H=RXFRR(UTB
M_!-?%0/0  \U1>J.CKX:6:JI8ZFH_%1/D1KY?L1>J@>D
M             !YI+Q1PW)M&^JI6U<C=S8'2)S')\43Q ](
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M?,^M[2-ON?98ONT;-KDJ\7*F7#DM(
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MK4^OP:?+[KT_)RK+'S\FW'EGQ9 HZZ&NA;)#(V1CN]N:XY>L5IY+7<
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M\=#3/>Z:CJVO1.8Q%Y.S759'+&H&X
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M3MG;$_UF;O8?-;G#[++6+X6R*ZSR5DI3
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MGA[Q1DOA/(F5TPQI"QK6^#3DU7)8YGH    #LCJ%;T7P(\4N3O;(C_ BD^@
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M4USMB/W(R16M>^.2)RH[;)&YR>QVUW= E&
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M64LWJ\]OXMWV_ YN?87/=B:(S?$R;2U45="V6&1DD4C4<US?@ISJGHO=A(
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MSE>1C6
M =,E5[&J2XH\G2YRNZJ22 K6#FYPRX+SLB=]/66":IV;&U4;4;/$FNO1^BF[
M:>I;K;?95_17EP3?DQ=#V6N5\$S7?_5&[;[KJYFW^;.E_P#Q/O/X?DH_8,2]
ML/\  _E=A^C;"F$;;6.;_?:J-))/W>ACR^M[Z_\ N:K--KBT]U?F%LL\/X+A
MY5JL]!0Q_+%&C3!DW.7)Y5R7Z1.GBJM1:J:JII(9*>)T4C5:]NU-KT4JTNM.
MY[Q1WSRX;)L-S37.Q0OFH'=Y\#>\Z#XZ?5_$?3^G^J^T^BR^3'DP=/%A\[K,
M^-=L^T#VT5=MZ*5U(KEON&TSU*>E*_;;EZNI3KH]5^VW+:I34IS2Y[#B*:AD
M:^&1T;OR3-EQS?DG-=%\V',!)F-95-[WSM.;FV/PKIRKEI:J*K9OC<QR?DG.
MUBM/);R=H>     H&/LQ;?E[:G5-;)WW?BHF^M*OU&C;;2L]<9>7?!'_ !)F
M!7Y@7AU35R=S<O*B;ZL2? ^EP[:<4\98M;Y/;9?<%_4]T^I=EH]TSV]75;OQ
M)EU^I;+T'J85BY;#;?,:;5WKR>L<[/EYTG,O>4/0      !KMO5 .Z.J]CE(
M\4N3M:[5-4(I/H                              !IT\M4_2X<M?^4FF
M_P UW$"<W8B?I1G#O^P:W?S30-.7;,_[[+X??V2X"_SK$!F#RVW(BYW[*7(S
M,FDI726O#ERNF'[G.UJNY;ZR.FFIM?@W]"5*:K[7-3V@;7NS2XG[!QB<">5^
M/<.W*EN$-VP]1QUK8IFR/H:Z.!C*FFDT\)(YD<U47[?!4 T7=LKB:A[2KRF7
M*;+K TT5_AP?/8L)W&:ED2>!KZ>MFK[@_5NOXB*9[9/E=32-7J@&\7CD[3S)
M7LY?P3;FSC"EP[48TN,=!;Z=L:SS[5>U)*J2-NJLIX]S5DE5-$\$U<J(!FRP
M7ZRYF8/I;E;*RUX@P_>J=):>JI9HZNCKH'IT>U[55LC'([Q35%0#\U?:\9<X
M&RU\I@RCM/#]1V:R7Z2^88DO-'8VM@IJ._R7-W,:L<6C8U6G\U=*B(G5\CG=
M5<!-KRU3]+KRQ_Y1H/\ -EP D1V/G9V\/V8O9>9"X@Q!D7DW?K]=L&6ZJK;E
M<<%VZJK*R9T2*LDDLD*O>]5\55550)TY?98X;RDP\VU85P_9,,VIKM[:*U4,
M5'3,71$UY<:-;KHC?8!70/SF>5T_IN'#]^QFW?YZJP/T9@ /SF^4]?[X+X=/
MV/X7_P#B&X@?HR T=^6I<43[+DIE#DM;IG+58JN\^*+E#%Z_(I&>;TS%3VM?
M)42JB?-3?4@%FY/>33<;^ \KK#:K%Q@W/!-JIZ.-T-AH,37RDIK5O3F/A;'"
M](TVO<[78FBKJH$<^S$PQC#L7?*2K-EGF'?HKQ58HG_!6[W>*21T5Y2[T\51
M2S(^3O/UK'4NY7==S7^T#9?Y8E^E'4O[.K7_ #%6!G?R<#])/R%_6NM_SE5@
M3< CKQ9]JWD/P/9TX'R_S,QW:\-XDQ[-LI(I7;H[="J.1E36/\*6!TC>4V23
M1%=JOJ,D<P,]5M%:\=8;=#4PT%XM-RA3<R5K*FFJXW)JG1=6O8J?:B@?FLL^
M"<'8 \KVP_9.'N&UVW#E!C"G944ME5&V^F5+9NO$,36=&1I^C&NC3NM=O8B(
MU$0#],8                                  .N2H;'X>L2XCHDD63Q4
MD/@5@ #!G:)4_.X7KX[_  ?+=_\ =&G:^3U?_.EEWGV30-VFG]DF%/U/4?RV
M'W._]URL2+Y@7@  !=&6.<.(,H[KYW9*Y].KG)S(G:NBET\$>GM0MQY:CQ1J
M>J9W#;VB5NOTT-'<YF6.Z.[KN:[]#3KIZVO337V(;XSXLG;2FHZ)?8/S6H,1
M0Q[Y&T\SFHYKG.[KM?@OUGEX:T5LXY,YX8@PS>*6VLJO.*&9^W9/WN5]GP.3
MO-GBN>35AS5IVLD7[$U3>'NFK*CNM_:M:<N(Z>+35<EJ7C&S8]S*5NYWSN]4
MUQ@^)'DC5Q2=HI@/AU940W.Z,O%_C78VVT<B/E:_35&R::\M-/:J&K2.*.NK
M6GQ2=HWC[B4J:BC=7.L>'9-S&VZE<K6RL5=425??5/CHA)'DP!WIG_,K@\2B
MX6^RMQYGN^GN%ZC?A7#[G=Z6LA7GRHB:]R-=%T7P1P>\4^< 9$Y/]G[@SZ4F
M=06N;E*Q]RKY&><UBHF]6,5=-?J0)HN<57;,55Z;-:<LJ5U#3N[KKM5-7FN1
M4Z\MG16*B^W50AK2#6,L<7?,*_5%UO=PJKI<:IZOEJ*B3=)*J^+E#Q=&1?#3
MC+B,OWF&%;/45VUVV6H<U6P0?GO\$ V+<*O9#X2RM93W3&[FXHO<;DE9 YNV
MC@Z>"L77>J+X+JGV![Q9IS^XOLO.$FR-IKO700U4+$9!:Z/1T^FSN=Q.J,T]
MN@>\FN;BF[5#'.?KZBW65S\*X=F9L=3P2;IY47Q1\B:(J+\-H><D7YIGU$SG
MR.?(]W><YWK!XSYPN]G/C_B6FIZR.C=8\/2=77*LC5K7,^:-%TYG7IT4/>*>
MF"^'G)/LY\)1WR^34;KU'$C_ #ZM<R2KG>B:/;3LZ+HJ]=.H31FXK.V&Q#CJ
M:HM.7<;\.VCO,=7N_KN=/<>SPY?V+J$.2&%\OU9B2Y35M?52UE74.WOEE=N<
MY5#QOPRG=NRKPVO_ .BZ7^::%B5W!O-S,&7)G^#J$_?1Q\KZ[/TLMFW\&8SB
MM    <HYEC\"M8[XZALOYPZ#F                           #2'Y:[PX
M7;&/#QDYFE;Z7FVO MWN%DNSV-W.C2X,IW0R+\&(^B<W7YIV)[0-G797\5F'
M>,[@ RNQSAZXTU?YUA^CH[I$R9'R6^XPP,CJ::73P>V1'=%TU:YCM-'(!AO$
MO;X93V/M3*/A6HK+BK$V*:Z>GMOTS8V05EOH[C(CI)::9.8US&P1HUTLC=^Q
M>8US6JQP&LSRR#+>\96<:F0&=M/1/EMK;2EG;.S7:RJM]>^M9&]^FC5<E6Y6
M_'9)IZJ@;Z\B<\<-<2.36&\?80NE-=L,8JM\5RH*N"1'M=&]-=JJBJB/:NYK
MV^+7-5J]44#\]$^)J/M,?*]K3>,"S17["N#,1T59])4\B3TJ4]DHXEEJ$D;J
MBQNJX7-C<BZ.66/1>\!E7RC;_?!_!A_C<-__ !)*!MLX@>SGP9Q#\<F2^>=X
MC;^$.3,5RBHXN6CFW#SF-K8>8O\ ]CO=++'\'OU U)=J=_ONKAM_Q6&_^E58
M#MTO]]0<&G^*P;_\47 #;;G!V=.#,X^T'RIXAKE&W\)\K+)<[/31)&CFUBU.
MU*=[U7_P=):[:FGK56[IM U)<:/^_+LH?\5:?\W5 %#\MSR_K:7'W#]BZ.FE
M=03T%WM,E0C>Y'-')32L8OP54>]4^.U_P4#?-D]FY8<\<H\.XVP]<*6X8>Q-
M;8;M1544R/BDAEC;(CMR*J=$=UZ]%U _/OV3ETH^*/RL_-''F%G-O6&[+<\4
MW5EQIW(^!U+L?01U#7(NBQO?.S:J>*2(H&1/*9/T\3@Q_5%G_P _- S!Y8!P
MGW&\<-^7?$5A+FT>*LE;Y%!55U/W98**IE8L,VO_ )FL9!L^'G+U B'V&?%)
M3\:_E+=XS5IZ=]&N-L,UEQJ:=S=OFU0MNIF5$:?%C9FR(U?:C47V@?I' _.9
MQX?[\JP'^R;"7^;Z0#]&8 #\YV>'^_8:']DUD_\ ABD _1B  _.=GA_OV&A_
M9-9/_ABD _1B!^<WRS_^[CR%_8Q)_G!P'Z,@ $<,Q.UHR!RGXTK3D%B#,*S6
MW,>[4OG"4\\C6TM)*[9RJ2>H5>7%4RL=NCB<NKD:G@KXD>&<LR,!X;S)P976
M?%UGL=^P]51.;6T5WI8JFCECTZ\R.1%:K=-VNJ ?G+\GWM%FLWE*69M%DU4-
M=E10_A3' M+,KZ:2RMJ=E+L=JN^+G>:\M7*NK=B^('Z40
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MD\+JG_!T7\1^2>H_XFOQ?18?"5\1U37+HXQ<5G)VD4@
M                                 !URU#8_#O*2XG5T22+)XJ2'P*P
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MCAPOF7:9_/+6LDMDOUND2"YV.9Z:.=%(J*BL=M;OBD1S';456[FM<T-6]O\
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M"=P                                XR3)'X@=$E0LGAZI+B.!)6
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MTCU<UDCO1Q(O@B(FB=/ /%*P#ES?,T<0PVJP6NMNE=-[E/"K]J?,NG@GUKT
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MIEQ<K9@9MQO6),1-B^G<2W5S'5EQ6/79$UK41L,#5<Y6QM^;ON>J(H$L0
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MG.3Q2C)T9HP?F):L;4V^BJ&\S=HZ)_=DUTU\%ZK]IQ\V"L?DT1?57""8
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M_P"TCA?];XOXC\D]1_Q5?B^@P^,KQ,BQRCE=&5K'?',V3[1T',
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M1K^25K'HCE;(!R
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M4@
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MDY)Y2O4\2              =D55MZ.(\4N3O;(C_  (I/H
M
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M]IR-QZEU[,33&W^)D>CH8;?3-B@C9#$WU6L;M:<S76M?)HF>+N/'@
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MSPRCPKC6RMJFV?&%HI+W0-J(T9.V"I@9-'S$151K]CVZHBKHOM4"Y
M              <))FQ_:!T22ND XEBL     #%W$-DK69E0PU=OF;YU2MV\
MA_=:]/M^)UO2]_.#MI5FQ\T;<089K\*U\E+<*66EFC=M<U[3ZC%FG)'.&#73
MB\1<.+6M;X>\!JH[13@'QYAW-C$F.*"A^FK!=JJ2J<^EU=+1HB-UYC-.B?8J
MA#66SG*MJQY78;1>ZYMKIMW_ *I@35._6VAO%GJ*6Y0TM10U#=DL50U'1N3Y
M51>@&&\L^ W!F3_$([,'"[9;3-44M13ST$3=U,[FJQ=S.NC$;MZ(B:=X(\6#
M>VKQA>,!X>RWNMDKJRVUU+7UFVHI9%8]NL<7M3XAY3)'9;\36)N)S):[5V*)
M(*BNLMQ2W,G9&D?-8D3'[ET]O>#V4FPD   &"NT"X3ZSBZR6CLENN#*&Y6NL
M2OI6RM[D[T8YFQZ^Q-'N75$4(TP_V2W#[BSAWO>85HQ5:Y;?.Z>EY#W?BJE&
MI*F^-?:@)7IQ'=H];^%_BBI\'8BM;W8?J+7#6>?T[MTL4CWO338NB:=SQU!R
M2$RYS(LF;&$J.^X?N$%RME<S?%/$[NN__($G/,1KI, 7QK>\YUNG:W_U;@-0
M' KQ)8YR7SMP_8;?=*J&U7"L2GJ+=4:NBT>O5R,7HB_7IJ%6GU-P][Q5087M
MM/4W.L@H8:B6.!CY7;6ND>NC&_:JA:R#@[.JNM-$VFK.5=K;)IN9*[?T^I>O
M[ACR[.=>Z>VDYR=%:K,N;)F)3.J\-53*>KZN?1SNV^W[_N*9W&7#VY?S2X3K
MXK4I:Z^Y6WC1.?0S-<CG,=^+=]J>"FNIQ995]T*1GMQ[7W!MMAMMKM]+#<YD
MW/K']YK6_4Q4TZD]GZ+BNN5^+S+NJE'K">7..>)S%4DT$=;=*ESO2U52Y=D"
M*OM5==$^P[.7/@VD_"RS%9*2LRBX*\&Y$VEM]Q=54MPK*=J2R.J-/-H/CHB^
MOU\%T/G-SZKGW%>RP=K;&VF.ZEJY]]HQ#:]UJP)3Q2-CUC=7RM38W3HG+9U1
M47X]#3L_0NO=G_)#)O/A0VSDSP91LFO^,+X[O=SGU4BN=]3$U_B/HM-,6*>W
MMEAJKMC#(WB@HL]L<WJW6RC?'06N!LK*B5VU\JJ_3U/!$^\KPY_:5VE1T94-
M:+#UAX.<,T>85RQ+=_\ ;2IK*QU4R"5J-@BW*Y>J=4?]YETVT\N5)\]62L37
M;\$\&5E;14\4WF-.Z6*!O=:_:FJ)T+JUZ2@@[<N(S%&<F<%AAN%4Z&A;=J5K
M:.#NLT2=J]43Q5/BIRJW%731TZ)\G99W91?US'^>G\9&AM[X>_[2.%_UOB_B
M/R3U'_%5^+Z##XRO$R+    -=MZH!W1U7L<I'BER=K7:IJA%)]
M                             '5)5-;X$N*/)TND5_B22? K
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MQ\,$S22Y!J               #7*WJ@6.Z.JW='$>*/)W-=NZH12
M
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M?E9Q-X?X@GYD9;8 S ?9:FP-H%Q)AZCNKJ%)&W'F<KSB-_+W;&;MNFNQ-?!
M-UG^M4<+W_%OR%_]W]H_[ #-N'<.V[!N'J&T6BAH[7:K73QT=%14<+8*:C@C
M:C8XHXVHC6,:Q&HUJ(B(C=$ ]P                  XR2I&G4#IEJ'.\.Z
M2XCK)*P        !1L88#M6.J#S>YTL50SW7>\U?F12W#N<N&N6(N)U\F \S
M.%2Y8=YE597/N%&W5W*_OK4^7ZSZ3:>L3?;E[6.\%:>+$U13OI)G12M?'+&[
M:YKO68IVIKJSNMS4D9HYNYIZ'J]$ PEVC55+0\&&.IH9'1RQT37,>WUF*DK
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M65#4B[*+^N8_ST_C(T-O?#W_ &D<+_K?%_$?DGJ/^*K\7T&'QE>)D6
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M6.^.H;)T7UB7%'D["*0
M                                   #C)*D:=0.B6H63HGJDN(X$E8
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MZPQQMVLCHXVM;]Q^1;S7EGK\7T6/Q7*9T@       #E'*Z,K6.^.9) .8
M                           !QDE2-.H'3)4.=T3NDN*/)UDD0
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M  &]U[53UFE8J]OQ,Z+:V=NY/F,N7:=?%*;5FGJ&53=T;MS3#K%:>23L
M                   <XZAT?3V$>*QWQS))X$1R
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M]2WV+',_$NPX:U;*,%Y2VO![&OY?G53_ (67^A/ ^8W&]RY&V,4Z+J,BP
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MGX<K8V-YE'(B:>KN:K':(CXW,<B)KH@2   <9H&5$+HY&LD9(U6N:[U7(OL
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MTU5?%1,W2.VDHBK\7O)2)\2/J*EK(O1LW>M[QLG;3I'<AR71%ZK3FKGT
M
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M.VM/)GD*1<<3-;W:?O.^8V8MK\2-6JF%YGU%J:][M[G.4S[G3I24*B4+
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MVU6M+<.G6T:4.WXF]VH_RFFS)M/A5S:KPS,J&;F.W(XQZZ<4G,\
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MKEB9L:;8.\OS&K'M.OD\JW?@^J?5/JG2.W.Z'F[CCQXD*X8UH
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M939BVOQ(U:CU%2^K?N>[<XVS/%%]I?ZXC_.%^(ON/U&?FG#:'T
M
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MN)IC!\3)5OME/:Z9L%-"R&./NM:UNUK3E7=7W4TS/%WAX
M         %.N&(H:7NL](_\ @FC%MKU>52AUUREKGZR.Z?*;8QS'BCUU=!>\
M7;A'_<)OYRG(W7VJR%3,RP
M                              #QXA_W'J?S"[!]K*-++.TI=U'72T$F
ML;MOY)5>*;\WO756[?B**J[LOHW_ ,$P9-M6GBE-*F9WH
M    %!QMEK9\PJ/DW.E;)M]65O=>W[%+]ON\N"N6)Y<3?DC_ )F<+UWPGS*J
MV;[E0M:KG(UOI8ONZZZ)[3Z3:>KXLG;D[:9+P5IXL6R1NC>YKNZYO=<T[+.
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MKAZ[N[\IT(PS"%4\Q<+@P/\ W_[CG[[W4\:X#GK0
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M"X4[J:&!:
M                     *=?K"EYVN1VU\;=K?E+\.?V:%3R6Q76N:VOVRMV
M_E>Z=*,DWXJM=.+SEXY1S/A?N8[:I76G45BWXI]5L[?VS3)DVGPI3:KPS,J&
M;F.W-4QZZ<4G,\             +"SJX;<)Y]6=U+?;;$Z9K7<JJB:C9X%=X
MJB_'N^U%-VQ]2S[:N6*OZ*\F&<GDUY<;G9XXMR>RQQ176B.7$5F^BZC1U+&K
MIXM8WHC5C35R_6J)H?;;+U_!N)XWVTY>79U#2!44[Z.IDBEC?')&Y6/8YNUS
M53Q14 ].'YGT]]HWL=M>V=NUWWDI&TVG_K6/\U#Z)C<P 'UKMKM0)199U#JK
M+^TR.\9*5KOWCY[-/3+3;'BUJ=MY;]O$58:GO]ZR1L_)Z2RJ0*8;X7^ ''O%
M#6QR6ZA?:;)N]+<JV-8XFIIZS$719.O3NA'IHV0<+/9IX!X;H8:Z:E_"+$;6
MQO=6UC4<V"1$T?RF:)HQ5ZZ.U7ZPGQ2/M]KEJWMBIX^[ZK6M;W6D*KBDN6TX
M+C@5KZGTB_+[IEO<=?%[Q7!1T+IGMAIX7N>[NM8QNYW[QGUKXDV0\$Y#5=TY
M=1='>:P.T<V)OXQR+_$<O<>I3IVXE\;?KY,JV'#-#ANF;#14\4+/R?6.1DS5
MD\FC33BJ!6]                        #RUUTAM[.^[O?*TLQ8:M[K2AW
M"_35W1/1L^5INQ8)A55/":@];HB@52UX7FK4:]_HXORO6,F3<S"4PN:AH66Z
MF;%'ZK3FW?.N5+)GH[B"0                   &EKC)\J0QYBGBMN63G![
ME!3YO7JSU4U)+=ZJGJ[G!<WQ=R5]-2TCHW\AC_[^Z7:Y.J-1NCE#'.)O*,N.
MS@8N%OO'$APN6JDP155#8I*NGL]PLZ[G+ZC*QTU13H_;NVL<S<NGCX@;E>"7
MC"PKQZ\,&$\U\%PWFEP]BRG=/!!=*-::J@>QZQR1O1=47;(QS=T:N8[;JURI
MU TH6ORJ/BXS8SWQ=@?*_AVPKF)<,+U=6CZ6PV.\W6LBI8:CD<^2.GF<J-W.
MC17:(W=(B>U +N_U_?M)/^(Q>_\ W=XG_P#PP)SXP[0#B4LO8T6?.V@R)K:S
M/VL?$VJR];AVZ.E@1US?3/\ T$B^=II3M;-U7WMWJ@:_\P?*.^T$REP;<,28
MJX-'89P]:8N?7W2Z8'Q'1T=''KIOEEDD1K$U=XJJ 4K)?RG?CFXD<*37[+OA
M/MV/+'3U3J*6XX>PG?[G2Q3M8QSX5E@E<U)$8]BJW75$>B^U )5Y2]KEQJXP
M[/[-K,6^\*UTM&9^#[S:*+#6%G8-OD4E^IZF7;53)3N7GR\IG76+HWW@(TY@
M^4=]H)E+@VX8DQ5P:.PSAZTQ<^ONETP/B.CHZ./73?++)(C6)J[Q54 I62_E
M._'-Q(X4FOV7?"?;L>6.GJG44MQP]A._W.EBG:QCGPK+!*YJ2(Q[%5NNJ(]%
M]J ;'NR/X]N)#C'R<S-O.=^1M7E-B'"\D4>';?4X>N=J^F=T$KUT;6+NDTD8
MQO<\-W7J!!;.;M\^T1X>LM+IC+&_"%AK"^%;&QCZ^Z5]JN<5/2(^1L;5<[SK
MIJ][4^UP%,X>?*)^/SBTR]_"O+;A2PGC3#?G4E%](VNV7.>#GL1JOCU\Z]9-
MS=?S@-NF%^(#'-#V=<>:&,L+TN'<Q:+ <F);M8)8Y(X+?<8Z)U1)3*Q7K(C&
MR-VJF[=I[=0-5G9'>588XXWN._!^5.9V"\ X7LF-N?045QM'G3)8J_ENDIV/
MYTST5DBLY2(B:[Y(^NFH&P_MKN/_ !+V9G 5?,V,)66Q7Z\VNZ4-$RCN[974
MKF5$[8W*O*<QVJ([IU R#V:W%'>.-/@1RRS6Q!;[=:;QC>S-N592T&]M+ ]7
MO3;'O5SM.[[54#5YQ?>5%9F9G<5-RRDX,<HZ7-6MM$LL$E[JK?677Z3Y2[)9
MJ:EIGQJRG:[HD\KU:[QVM1450\&2_E0N=G"YQ&6;+_C5R.ARYH;URVMO5MME
M9;I:&-S]GGCH)Y)FU4"+ZZP/16[7;6O7N ;LW8PM3<)?3ZW*@^@_,_I'Z1YS
M/-O-MG,YW,UV\O9WMVNFG4#23G!Y4MG3Q/<1%VP'P8Y#19C4EG65OTO=+?6W
M&6NA:_8E6E/320I2P+[JS/57;F;D8[N 4&;RF+B^X%<=V>+BNX8Z6TX5NDR0
MLK;;:ZVSU,GS\F6>:>EGD:WKRD5B_%S474#=IP^YY6'B8R1PKF#A=U>[#V,K
M;!=K>ZMHY*6?DRL:]F^-Z(J+HOV+XM56JBJ%X@                    ZZ
MJG;64SHG^K(W:XE%<:Y"VKIA.:CW/A](SY?>.EBW4Z^2FH4AS=O130B%@]EN
MO4U#T1VYGRN,N3#-DTKMOO$-P]5VU_RN,63#4+=*>LJ>
M   ^.;JFB@6-F5D#8LQ&22K"RCKW:.\XB[KG:)HC53X&_:^I9<'\TH7AFT=\
MR,D[WEO-K4POJ*7JYM1$W='HGO+IKI]Y]-M=_BS^+#>*H6B;T ".?:8<,>(.
M*+(>GMF&W0.N5GKTN+8)7(WSE$C>Q6(JJB(O?UZ_*$:8C[%W %[RU9F9:;];
MZRVUU/543715,:Q^R;JFOBB_% \EG'.#C^P?D3Q#TN <3QU5O\\HH:R*Y>M!
MK(][$8J(FJ>IU<JZ!-F;"]VME_L%/6V>HHJJW53=\4M*YCHI6K[R*WIX@>;,
M1SH\ 7QS7;7-MT^UW_HW :LNSIXX,>8-S=PW@F2X?2E@O5>VE=!6:R.ID=XN
MC75%U^W4(:4VHXPPY:<88;J+9>Z>EK+;<&\B6"HTV2[NFGVK]74)L-90=G_A
M+(7/6HQGA1T]OCK&.CEMSG(Z"!%9II%TU3KU755"/%GL) %A<1W]K2;]41?Q
MFG9?:J,W@CX=MF8XXNIGT_#EBI\;GQO;3MVN1VUWXUAFW/V5)QY(X\$N1>)*
MK,6AQ//0RTMJI>]S9_1NEU\-$7JJ+\? Q;7#7+DLO5,6_26NWLCKKG)14\5+
MZD]0Y&MB<OUKT0Z=<?>4+1ROXBK#G!C"Y6FQNEJ&6N!LLM0YJMC<JO<S1$5/
MOU\"O%FFJXRE4=%_%Z+ L/!';L29JW+$F(ZCSJ"HK'3P44?=:Y-7=V3XZ_5H
M8?V6=:Y4LYLU4M#28-PVV"CIV0T=OBVQ1,]5K$]U#7,\5:'.,.,'$.:6;UGM
M=,[Z+LK;S3,Y$7XR5$E8GI%]O7X:'+O<U=<5^D=$UCKJ'?;/]TJ;_&L_C(7X
MC</E-_:TL7ZDC_B/R'=?;5^+Z+'XKB*$@     //67*&A9K([K\OO$HQU?B]
MUI0KAB"2L[K?1L^4WX]O,*JIX"\"P5*U88GN";E]''\SC)DW,PEI')<MMM$-
MKAVQ-];UG..?DRU?DLF>CTE20                            !3[IAV"
MY==O+D^9I?CW%0CK');=RL4]M?WF[F>ZYIT<6::4ZZ<7C- ^M<K>J=U2L5.W
MXD?3]V;TC/F]XSY=MU\4M-5:I:R*L9NC=N,%Q4>23N/       !QDUV.V^L>
M2*!=KE6->YC_ $+?R?\ 2=##BQ>ZCKJIKG*[JO>4THOA8     ZZB-TC-&MW
M?F@>&3#M9<%]%3N=_!_C/:SXH\D:GJIN)L 7BAPW55M/0NKJF&-7,HXG(V6=
M?@BJJ)^ZHC?8M:X_W1K'2'F:'&)BK"-[JK;4X79:YHW*S]%;VR-^OHNB_<?5
M;;TS!DGE%<G/O<7HQ-B#B6QCB*&2*:[.CAD]QD;&[?O1-3J1L,$>ZSUFK59]
M=B*ON3-*BNJID^5\RN;^^IIF)T0Y,+9G=L!=.!W&#K?@>JEN%]AU;/ Z3=1Q
M?%CT7WU^I/B?/>L[G;:_15/*E-;ZL5=K99V,O; 1]J%A7$5'=,/Q8?Q;A-L,
MM;%2N5U++#*KDC5FY5=KJQ^NOU'P6?#[-VMAO_VB?YI3A*6\ ^.;JFB@6=CC
M)6UXNW2Q1MH:S;W7Q=UKOM3P-VV]1RX_YI5WBG5BG$N [K@>I<VHA?)3[N[.
MSO-=_H^\[>'<XLOBHJ*T<+;<O5)U+Q7(Y(;I1R4U1&V:GF8K'L?WFN1?%I3K
MH*9PY\/N">&?#=5:<$V6"QT%=5.K)V,D>_=([;JNKE5?=\/ KS55^2<?,R<U
MW,35"E:  *#C[-##N5MDFN.(KU;;/1T[%E<^JJ&1]$ZKHB]5^Q#S2*U\'E:]
M&H?M7NW 9FM;;IEYE/42QV*36GK[XUNUU<Q?79$B]48J=%U1%\3K[78].ZF7
M)FZ]LJ+Y,]BZYVOBNQA2025$E'58?WSLYB\MK_.(O2JGAK[-1ZI$ZXD=MKW-
M[5MN3+E#N3NO]YI\CDQ\'2FN3U%;P          /+772&WLU<[K\&DXPU;W6
ME#N%^FKNB>C9\K3?BP3"JJ>$U!ZW1%*Q5+1A>:X=Y_HX_P KUBC)N9A+2.2X
M[?:(;8S2-O7YCG7EJ_)9,]'I*T@
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M^XW\X_'N3C#6K+F$\O;;@^F:VFA8Z;WI7]YSO]'W'%S;FLGDUQBG172E(
M                     .JHJHJ5FZ1VUHTBM?$4:X8F?-W8>ZGS&[%MNGDC
MKJI3W.D?JYVYQJ1?"P>NVV6>Y/[C=J?,[U3/ES3)IIR7':\-PVWO+Z1_S..?
MEW-VNTCBJ1G2                     4_%UNK+MA6Z4EOJO,Z^JHY8J>H;
M_>)',<C'_<O4#\Q'DU_'7ESV2'&CF_A'B!;/@6[7J&.P+=JJCDG2QUE%4RI4
M4D_*1SV,D>K=7(BMW4S-RHG4#]#6#N(OA[[0W -VPI8\;96YN6*]4BPW2R4M
MTH[JDL#O%)J9'N<GQ[S45%Z^(&7\-X:MV#,/4-HM%#1VNU6JGCI*.CI(6P04
MD,:(R.*.-J(C&-1&HB(FB)T0#\UWDU'$#@'AS[8K/Z\9@XXP?@2T5EAO-'3U
MN(KQ3VRGGG6]TCTB9).]C5>K&/7:BZZ-5?!% WT?ZZ;PP_\ &.R'_P"?UJ_[
M<#,>"L<67,K"=NO^'+Q:\06.[0-JJ&XVVJCJJ6LB=X212L56O8OL5%5% BEV
M_OZ3;Q!?L9=_/Q 10\C#_2JL8?\ *;<O\V6L#;@!#[M_?TFWB"_8R[^?B BA
MY&'^E58P_P"4VY?YLM8&W "#OE(_Z25GQ^M]O_SK1 81\CV_2B)/V<73^;I0
M-@'&]_<79O?L*O/_ $&8#\C&3G"_=;/V8S>*+!KZBCQ7D_FU!05E9!KK34\E
M+1S452OL3DUC&M33JJUG771- W==OWQ.VKC/\FQM>:EEY+:''$N'KDZ"-V[S
M.=U0Q)X%7XQ3-DB7ZV*!7<M<\*[AS\D6I,66RH=37&ERLEH*.H9^,@EK)WT;
M)&_!S75#53ZV@8]\BKR,M-CX+<T<Q_-(OPAQ'C+\'W52M1STHZ.CI9HV(OBB
M+)62ZI[=K-?! -C/:(]EQE)VHF#\*V/-BU7&NI<'W9;M12VZJ\SJ>]&Z.2!9
M417)!(FQ7M:K55T4:[DV@>_B=X9WVWLR\Q,H,K:.>WOBRVN>%,*4?G4D[X%^
MC)::EA269[GKIW&HYSE5/B!HK\E9[4K)3L^(\T\O\X[HS+^\XJNE)54=ZKJ.
M7D2\ADD3Z.H>UJK L;W.<WF(C?22(KFJB(X-\]MS"R [1_+>LL5%?LJLZL+.
M?%45ENIZZBOE,Q['M?&Z2)JOV*U[6JFY$5% S+#"RDA;'&UL<4;4:B-;M:U$
M\&H@'(                      !X+IAVGN/7;RW_%I?CW%0C4]5N72PSVU
M_5NYGS--^+/-J==.+PFH?6N5O5.ZI6*G;L2/I^[+Z1GS>\9LFVG7Q2TU5JEK
M(JQFZ-VXQ7%1Y).XB                   ZZNECK(7131LFB=W7->W<UWW
M'DUQ&)<T.%2@Q)))5V:1EOJG=YT3OQ3OC\50[.U]8K'VY.Y1>WZ^+ 6+,"W7
M!->ZGN5'+3JUW=<[U7?8J=#Z7#N,66><TQZQ6BE%[QTQT,,-3),R&)LTVF][
M6HUTNGAJOMT]@&OKM<.#/&F969,>8&'Z/Z6MM/:XZ.HIH/Q\'*5[U>J+XHN_
MHB:KW? (:RD5V9%+4T/!SA6"KCJ(9X62-<R5JM<WTK^[HO@'LL^S1L? YLC6
MNB<U6O:[U=/;J$D>\4=G3@:\9V8?S P^WZ#N5KK$K7Q4NGFU=[>J=43ZMN@1
MXJ5VMUYKL/\ !M755!555'5PW2BVRP2+&]OI/BG4%,5]ECQV8QSJQ;-@O%$D
M5T;3P<V"O<W;.U$338NFB*G=\?$/-*3Q"8!87$=_:TF_5$7\9IV7VJC-X(^'
M;9GGNE#35]!)#61Q34SF]]LK4='HG7KKT(T+);Q!87@Q_0X3MU1%65LW<V4N
MG*@1/#KX?N%/MIY<4N+%?:->=5&%</TU)SY/.)Y6NBBU=S?4TZ)XE&^\4\3A
MP!Y)X@R[FNUYO%&^AANE/'%!$_\ &.T77=HG@GV]3S9X:COLRZ]4E3H*D3^)
MSC8O%BQ)78<P]#]'K1RK%+6/T=*Y4Z+HG5-%_=.9GW5:=LK8AG?)62?$&0-A
M=+(^:IJK:W<][MSG*J>U39A^?$JKS6%D[P-V; M[^F+U-]+7+F\^)K=6Q0/1
M^]%3P55^TIQ[2=.ZEFML[&U6J&%[+67Z_4M/14L]54.>WN11K([Q^"%.2XB>
MY[.G5N$RWM\UIP':::HCY<T-*UCV.]U40_(MS77+52^BB>,JX5/0   ZYZAE
M.S<]VU!,]?$4>X8F<Y7,@;M;\SC;CVGQ(U:DR2+,_<YVYQKTTZ(N)8/5;[3-
M<GZ1MZ?-[I3ERS'D::<EQ6O"\-O[S_22_E>J<[)N:M;I"J>KT13,F
M                         #X]K9&:.;N:!1[MA&*HW/@]&_Y?=-F+=UIY
M(:PMZLH9:%^V5NU3?%Q?BJJ726CG3U+Z1^YCMKBNIY"LV_$S9%VS]U?F,67:
M_"GI:K1R),S<UVYICJ>+UR/0     #KJ*9E4S:]NY!I=:>(HMPPR^/O0=Y/E
M]XW8]WU\D:A3I*&:%^CHWM<:9N=7G34AH)INC(W.&N6=#IJ]<.'JF;Q:R/\
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MW:V8Z*D9TP
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M[:\)[97-\\J?GE;W?N0XFXWV7)_*UQAG1=QD3
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M76G45FWXF;(NV?NK\QBR[7X4]+5:.1)F;FNW-,=3Q>N1Z
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ML<=FM\4E=M3FUL[>9.Y?;HJZJB*OL1=#X7>^IY]W7TM=OW.KCP3C\61S M
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M<;86-:UNU&^JTQZZ\DWT
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M^2J>TXN?U&K[<7:U1@Z>2_H864L+8XVL:R-NUK6^ZB'-JN2US/0
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MN![3';FUD[4CDK)-7/EF5$Z(KY7O=I[-VFJ@94
M    #A44K*IFR1K7-^5Q*:X^(H%VP@K>_3=Y/D<;<6Z^)54*'-"^G>YCV[7-
M]UQMFN2#B6#OH[E-0O\ 1N[OR^Z47CF_(FE<M^((JSNO]&\P9-M6B<TJ)2]
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M*87#1T,5O9MB;M0P7=7Y+)GH[B"0
M        'EN%F@N3-)&]?BWUBW%FJ$:GJMRZ87FM_>9Z2+\GUCH8]S-JZA3#
M6B >ZWWZ2A[J^D9\IERX)LFE=H;I#<&=QW>^5Q@O#4+=*>D@\
M                  /#=L.T=\AVU$+'.Z[7>\TLQYJQ^+S73DM:X9;U% _=
M1R<Z+Y7>M^Z=#'OYU\E=8GCIY)J%^R>-T;OK::>W7Q0>]KN8FJ'BP   *EA=
MKO/]4]7:8MUX)0N(P)   !X;A?(:#HGI'_!I;CV]6\JE"KKM-7/[SN[\K3?&
M&80JGF- ^QQ.D?M:W<YWNM*^705JUX1?-M?4.Y;/E]XRY-WT\4](7!2T<5"S
M9&UK4,%W5^2WH[2
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M)F.UVFFLM&V"EA9#'&W:UK6G$NZONIKF>+TAX
M 'GK+E#0LUD=U^7WB48ZOQ>ZTH=PQ!+6=UGHV&_'MIA#753R]$+!4;7ANHN?
M>7T;/F<9,FYF$M(Y+DMMEI[:SN-W/^9WK'/RYJM9,]'K*D@
M
M           #S7"TPW)FDC>]\WO%D9:CQ1J>JW+IA>:A[T?I(_R?6-^/<S?D
MKJ%+-*(6#W6^^S4/=7TC/E<9<N";)I7*&Z0W!G<=WOE<8<N&H6Z4]16\
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ML'OM>'Y[EU1O+9\SC+ESS"6D<ER6VPT]NZM;N?\ ,XY^7/5K)GH]I2D
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MI
M                                .NII8JIFV1K'(2FZT\10;I@]S=SZ
M9VYO^#-^/=_$JJ%#DC6)^U[=KORC7IKU0<2P=]'<IJ%^K'=WY2B\<WY$TKMM
MQ#%6=U_HWF#)MJA.:>_HY"EZ^@
M   '":H93LW/=M:>Z:<A1KEB9SNY!W?RC9CVGQ(U:DR2+,_<YVYQKTTZ(N)8
M/3;[1-<WZ1MZ?,47DF/(TTY+CM>%H:'O2>FD_@G/R[FK\5ND*HUNWHAF3
M
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MVQQ[ORBB\DQY&FG)<=KPG%1[7R^D?_!,.7=UKXK=(55K4:FB>!D3?0
M                                          ?)(VRLVN:US?RAIKQ%
M$NV$62[GT_=7Y7>J;<>[Z>2JH4"JI)*-^V5KVN-TW->*/35U%KQV4U5+1R;H
MW;7%5Q.OF*U;<3,G[LWHW?-[IBR;;IXIS2J-<DC-4[R&5ZY
M                      X35#*=FY[MK3W33D*/<,3+IM@;^V<;,>T^)&K4
MB219G[G.W.->FG1%Q+!Z*&US7)^V-O[;W2B\DQY&FG)<=KPO#0[7R>DE_*]4
MY^7<U?BMTA5?5Z(IF3
M                                                     !Y;A:8;
MDS21O7YO>+8S5'BC4]5NW?"\U"CG1^DC_A'0Q;F;5U'%2R]$+![K??9J'NKZ
M1GRN,N7!-DTKE#=(:YG<=U^5Q@O#4+=*>H@\
M          ^.=HFJ@4ROQ+%3]V+TC_X)IQ[:M?)Y5*)55TE8_=([<;HB(\4>
MNKJ+7CG3T[ZI^R-KW.<0JNGD*_:<'M;M?4^M\C3!EW7PIZ0KD,+*=FUC6-;^
M28JKJM<CP
M                                         /DL;9&:.;N3\H::\11;
MMA%DVY]/W7_*[U39BW?3R0UA;]50R4+]DK7M4WQ<7XJ^FKJ+7CLIZI]&_=&[
M:I5<3KYBM6[$S)N[/W7?-[IBR;;IXIZ6JC9$D9JWO(97KD
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M^4KJN(KEIP?KM?4_Y#3%EW7PIZ0KT-.RG9M8UC4_),55U6N9$
M                                         #JJZ&*NAV2MW-)Q=1XH
MU/5;UVPB^)-]/Z1GR^\;\6ZFO)"H4946-^UW=5IJ0?"P>FANTUNZ,=W/E<9[
MPS9-*[;[Y#7]%]&_X.,&3;U"<T]Q4]
M'SU>J@4RY8DCI^[#Z1_S>Z:,>VK7R>52BUE=+7R:R.W?DF^(B/%'KJZ2UXYT
M].^J?LC:YSOE:0JNGD*_:\'[=KZEV[\AI@R[KX4](5R&%E.QK&-VM;ZK6F.J
MZK7(B
M                                            %-NF&:>X;G-;RY/F
M::,6YN$*CJMRY66>UO\ 2-[GS-]4Z&/--^*K73B\AH'U'+&_5/6*Q5;;B9\>
MUL_>;\WO&7+MNOBEIJK-)5,K&;HW;D,-Q6GDD[0
M         #QU]ZAMW17;G_*TMQX:MY5*%<+U-<.BNVL^5IOQ89E"J>0T#ZUN
M_HGB5BK6O"4U5M?-Z-GR^\9<FZF?%*87%0V^&WLVQ-V_-^48+R5?DLF>CO()
M
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M!>6K\EDST>@K2
M          /'<K'3W)G?;M?\S?6+L>:H1J>JW+IANHMO>1O,C^9IT,6>+5ZQ
MQ4XU(A6*A;<0RT?=?Z1A1DVTVEIJKE'<H:YFL;N]\I@O'4>2?)Z"+P
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MVIFS4TT51&[WV.1S?WBC6*T[:6::]7>1
M                    /DC&R,T<W<@%$NV#V3=^F]&[Y?=-N+==/)#6% JJ
M26A?ME:]JFZ+G7P5]-746O'93U4E*_=&[:I5437D*U;\3,F[LW=7YO=,.3:=
M/%/2U4;(V1FK7;FF6IXO7(]                          =-971T+-TCM
MI*(J_%[R42X8DEJ.[%Z-G\(VX]M.GDAKJIKG:KJII1?"P>ZUX?J+EU1O+9\S
MC+ESS"4SU7):\/P6SJC=S_F<<_+GJUDST>XI2
M
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MMO>V\R7YG'.R;BK7:1Q5 H2
M                        <W=T4"EW;"\-=WH_1R_P33CW-1Y(:PMRX6N:
MVOTD;T^;W3H1DF_%5KIQ>8O'*.187[FNVN*ZTZBK6_$RM5K)^]^49,FT^%*;
M5F&H94,W,=N:8]=.*3F>                      !TU5?%1,W2.VDHBK\7
MNM*)<,22U'=B]&S^$;<>VG3R0JU-<Y7]5-*+X6#W6NPSW)_1NUGS.,N7/,&F
MG)<ELP_3VWJC>8_YG'/RYZM=I'%[BE(
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MKJ6N@D1%WPR(_P ?CIX'S>3%>.N-ST;YKEXJ@5I
M                           =5501US-LK6.:3BZCQ.BW[IA%\.Y]/Z1/
ME]XW8]UU\E50HLL;HWZ.;M7\HUH/A8/30W2:WOU:[<WY7%-X9M[UU5RWWZ&N
M31?1O^5QS\N"H2FGO*7H                     !QDD2%FYSMK3R9Y"D7#
M$S?5@_RC9BVOQ(U:CS5#ZA^Y[MSC;IIT1<"P=]!;9K@_;$W=^457EF/,TTY+
MBM.$XZ--\WI'_P $Y^7=UKXK=(59C6M9HG=:9$WT
M
M                        !>]X@4NZ87AN'>9Z.7\GU33CW-0A4=5NW"TS
M6U^DC>GS>Z='%FFU6NG%Y2X<HY%A?N:[:XKK3J*M;<3*U&LG[WY1DR;3X4IM
M6*>I95,W,=N0Q5/3R2=@                     '%TC8V:N=M:>3/(4JX8
MF2/<R#O+\QLQ;7KY/*M1JBJ?5/W2.<Y39,3/B@ZRT=U+0RUSML4;G*57<1Y/
M>FJX;3A&*D[\_I'_ "^Z8,N[Y>*S2%8;&V./1K=J&/JF^@
M                                                  .,D+)F;7M8
MYOY1[I704*Z8/:[<^F=M_(<;<6Z^)54*#44KZ5^R1KVJTWS77Q0<"8[:6NDH
MW[HW;2JXB_)[UU5NVXD94=V7T;_X)AR;:M/%*:5-KD?U0S/7T
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MH\1T$=50U4%9!(U'-?$Y'-ZGREQ45QIT)KJ]9%Z
M                          !X[E98+HSOMVO^9I=CS5"-3U6Y=,-S6]^Y
MOI(OF:;\>XFU>L<5.-:(!4+;B"6C[K_2,_*]8R9-O-I::JY17*&N9JQW7Y?>
M,5XZA/2GH*W@                 ?.C4 I]RQ!%1]UGI'_P31CVU:^3RJ4.
MLN4E<_5[NGRFV,<QXH53H+QRAA?4/VL;N5Q76O05RT8/5RM?4]W\AIBR[KX4
M](5^GIV4C-L;6-3\DQ57+R6N9$
M
M              #C)$V9FU[6.3Y7'NE=!0[I@]KE<^F=M7Y7&W%NOB55"@U%
M+)1O<R1KVN:;9N:\4'66CMI:Z2C?NC=M*KB+\A6[;B1E1W9?1O\ X)BR;;IX
MIZ6J;7(Y-4\#*]?0                 !X+E?HZ'NM](_Y6EV+!5O*I0JZZ
M37!_?=T^5IT(Q3"%4\Y<.4<;IG[6MW.<5UKT%:M>#WR;7U/=;\GO&3+NNGBG
MI"X*6FBHX=D;6M0P5=:^2WH["(
M                                  !T5UMAN#-LK=WY7O$XR5'BC4]5
MO73"<M+N?#Z1GP]XWX]U->2NH4AS=%T4U(OA8/7;[Q-;DT1VYGRN,^7#-$TK
MMNO4-=T1VU_RN,&3;U"W2GL*G@              !3KAB&&F[K/2/-&/;5KY
M/*I0ZRX35S]9'=WY?=-L8YCQ0JG07CE#"^9[6L;N<[W6E=5Q%<M.#U=WZEVU
MOR-,67=?"GI"O4](RCAV1MVHWY3%5<O):["(
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MAC_A&;)N9CQ2F%Q6^TPVMFD3>][SO>,%Y:OR63/1Z2M(
M
M                                     Z:RWPW!FV5NY"<74>*-3U6]
M=<(R4^Y\'I&?+[QOQ;J:\E=0HZM6-^B^L:D7PL'KH;Q-0]&NW,^5QGRX9HFE
M<M]ZAKNB.VO^5Q@R;>H3FGM*GH             #SUMRAH6>D=WOE]XE&.K\
M7NM*%<,035J;6>C9^2;\>WF$-=7@-:(!4K7AF:X;7.]'$[WC)EW,PEI')<=M
MLM/:H_1M[WS.]8YV3-5^2R9Z/65I
M                                         !X;EA^GN3'*K=LGS-+L
M6>H1J>JV[IA^HMO56\QGS-.ABSS:NIZ/":D1KMO5"L5*W8BEI>[+Z1G\(S9-
MM.OBEIJK='71US-8W;C%>.H\D^3O(O           \M==H:!G?=U^4LQ8:M[
MK2AW"_35W=3T;/E-V+!,*JIX34!6*I:<+S5R-?)Z./\ *]8HR[F82F%QV^TP
M6UFD;>]\WO'.O+5^2R9Z/25I
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M'S/RDV'M\'M9\I;=EFXUQ;+#\Y=L
M                  XS0LG9M>W<A*:Z"AW;![9._3=W\AQLQ;KXE50H-12O
MI7[)&N:OY1MTUZ^*#K+1VTU9+1OW1NVE5Q%^3WKJK5OQ(RHVMF]&_P";W3%D
MVW3Q2FE4:Y',U3P,KU]          .JHJHJ)FZ1VUHB*U\11;EB9\R[8.ZGS
M>\;L6VZ>2.NJEN<Z1VJ]YQJ1?"P>RVV6>Z/[C=K/F=ZIGRYI@TTY+CM>&Z>W
M]Y6\R7YG'/R[F[6S'143.F
M
M                   !XKE8:>X]7-VO^9I=BSU"-3U6W=,.5%MZJWF,^+3H
M8L\VKJ>CP&I$:[;U0K%2MN(I*7NR>D9_"*,NVG7Q2TU5NCN$=<S6-V[\GWC!
M>.H\D^3O(O         !USU#*=FY[MJ'NFG(4:X8F=(NV#NI\QMQ[7XD:M2I
M)%F?N<[<XU::=$7$L'JM]FGN3](V]/B[U2C+FF/(TTY+CM.&8;>K7/\ 22_,
M<_)N:M;,=%3,R8
M                              #XYJ.31? "DW;"<=9N?#Z-_P#!->+=
MUIY(:PMVNMLUO?MEC<W\KW3=&2;\56NG%T%XY0S/IW[F.VJ5UIU%8M^)O59.
MW]L9,FT^%*;5>.=)F;FNW(8]=.*3F>      '5453*5FZ1VU!I%:^(HUPQ,^
M;NP]U/F-V+;=/)&K4I[G2/U<[<XU(OA8/7;;+/<GZ,;M3YG>J9\N:8--.2Y+
M7AN"WLU5O,E^9QS\NYNULQT5$SI@
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MC[*OPU3CR;F\,U;[AANAJ'NW/FIXWN=]:H?C>3S?2O<>
M                                    Z*RWPW!FV6-CB<9*CQ1J>JWK
MIA&6DW/@](SY?>-^/=37DKJ%(<U6]%[JFI%\+!ZJ*\34+^CMS/E<9\N&:)I7
M;=>H:[INVO\ E<8,FWJ$YI[2IZ     !Q<Y(V:N=M:><>0I5PQ,R-'-A[SOF
M-F+:]?)Y5J-453ZI^Z1VYQLF)GQ0=9:.VEH):Y^V-KW.*KN(\GO35<%IPBR'
MOU'I'?+[I@R[OKXK-(5J-C8V:-;M0QZZ\DWT
M
M                                    !\<U']% I5VPK#6)OB]'+_!<
M:\6[K3R0UA;M=;9K>_;+'M_*-T9)OQ5:Z<7G+QRAF? _<QVU2NM.HK%OQ/ZK
M)_\ +,F3:?"E-JO#,R9FYCMR&/73BDYG@    #XYR-35? "EW+$C*?NQ>D?\
MWNFK'MNOD\JE%J:R6L?ND=N-L1$>*/75U%KQV4]++6.VQM<YQ55S/D]Z:J_:
M<(I'M?4]Y?D,.7=]?%+2%;CC2%FUK=K3)5=5KD1
M
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MYW61I@]1SS@VU9:^Y=ACG7%N;L%N^B[)1TW_ (/ UG[B:'Y%KKR?1/6
M                                                 'ANM@I[EU<W
M:_YFEV+/4(U/5;ETP_/;7ZJWF1_,TZ&+/-JZGH\!J1/5ZHA6*E;<124O=D](
MS^$49=M.OBEIJK='<(JYFL;MWU&"\=1Y)\G>1>  #PW*^0T/=3TC_E:78L%6
M\JE"KKK-<']YVU/E:=",,PA5/,7#ZR-9)-K6[E*ZUZ"M6G"+YN_4^C;\OO&3
M+NNGBGI"X*6CCH8=D36M:8;NK\EO1VD
M
M                                    #A- RH9M>UCD_*)3704*Z8/V
M]^F_R'&W%NOB55"A34[X'N;(US7--LUR0<"P=U'<):%^L;OVI1>.;\GO757+
M;B*.J[LGHW_P3%DVU:>*4TJ+7:IJAG>OH #Q7&]0T/3=N?\ *TMQ[>K>52AW
M"\37#UG;6?*TWXL,RA5/(:!]:UTCM$[SBL5BTX1DJMKY_1L^7WC+EW4SXI3"
MX:.WPT$6V)NTP7=7Y+IEW$
M                                                \UPM<-R9I*W]
MM[Q9&6H\4:GJMVZ85FH^]%Z1G\(WX]S-^2NH4HTHA8/;;[Y-0]/QC/E<9<N"
M;)I7*&[0UW1KMK_E<8<N&H6Z4Z[C?H:'<U/22?*TEBP5:-4H===)K@_O.[GR
MF[%AF4*IYC0/J1K(_1O>5Q6*U:<(/FVOJ?1L^7WC)EW73Q3TA<%'1QT,.R)N
MUIANZOR6]':0
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M\0+$XR,#SW[*R2^6VGBFO6%]U;3]WORQHFLL+%]F]&M0OVF6HRS4H7IUE'7
M^8EOS,P]'7V^3=[D\3OQD$B>+'I\3Z_;YIR3SES;CH]E7XN-,H*36%\BEUGB
M25J-7>).4:4JK]=2S3ZD5+K2W1&E)K/$MT^M%2:TND4VL\2<JU'K"R13*SP)
M#Q>KU5#VJXB3?95Y/PYF9P5F*9^]1X3[L&UWKU#DTT5/AL>Y?M/@OE'ZI[?C
MBQ>/W_>Z^QV_#NILA/DW1
M                  *1=,)PU6YT/HW_ "^Z:\6[K3R0UA;U=;9K>_;*W;^5
M[INC)-^*K73B\Y>.4,SZ=^YCMJ_DE=:=16+?B;W9V_>TR9-I\*4VJ%1>(*>'
M>LFYKO5VF:<-:I\E%N&()JSNL]&S\DVX]M,H:ZJ>:T0"I6O#<UR[SO1Q?,XR
M9-S,):1R7';;+3VK\6WO_,XP9,U6LF>CUE*0
M
M                                             >>NML-R9ME;N_*]
MXG&2H\4:GJMVZ83FH^]%Z9G\(Z.+=3KY*ZA2?5Z*IH1"P>RWWN:A33=N9\KC
M+EP39-*S#B*FEAWJ[:OR^\9*VU<D^NBF7#$4M5W8_1L_A&C'MIT\GFNJFFE$
M+![[7AV>Y;7;>7%\SC+ESS"4SU7);;#3VWJQNY_S..?ESU:R9Z/:4I
M
M                        4^Z8=@N6YVWER_,TOQ[BH1UCDMNY6.>VO[[=
MS/F:='%FFE.NG%XS0"=WP*P+  J-KPU47'O+Z./YG&3)N9A+2.2Y+99:>VL[
MC>_\SCGY<U6LF>CUE20
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M#Y)T0
M  !PFIV5#-LC6.;^42FN@H-TP?KWZ9W[1QMQ;KXE50H<U.^G?L>U[5_*-LUR
M0<"P"L"P>FWVF:Y/TC;W?F]THO),>1IIR7':\+PT*;I/22_-[IS\FYJULQT5
M1.[X&9,
M           ZI*K;T:2XH\G3S';]=W>)).V.J]CE(\4>3N:N[P(I
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MR?\ 2:=/3=M<]LH>VK1(G+',*FS$P]#60^+F]YO\9\QO=I["N#=BOFN4QK
M                                       /!=,/4]RW+MY<OS-+\>XJ
M$:GJMNY6&HM?><W<SXM.CBS32G73B\1H  !Z*&VS7)^V)N[\KW2B\DQY&FG)
M<5HPK#1[7R^DD_@F#+N:U\5ND*LUNWHAE3
M
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M40N]5['(YKOO0^>;':
M                  //76N&X,VR-_;>\61EN/%&IZK<NV%9J'OQ>FC_ (1O
MQ[F;\E=0IU/2RU4VQC7.4T5<Z(J]:<'I'M?4][\@Q9=U\">D*Y'"R%FUC=J&
M*JZK7(\
M          '7)4)'^4X=!TR3.D7J!Q+%8  ^QR+'X*%COBJ&R>/=4CQ'81
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ML5R SCI\\LMJ.]1-;#.[T=3$G]ZD3QT]NFO@5)+W
M                     !\<ULD>BMW- H]VPG'5+O@]&_Y?=-F+=UIY(:PH
M,UIJ8:GE+&[?ZIMTRSK/-7TU5>UX/V[7U+OVC3+EW7PI:0KL-.RG9M8UC4_)
M,55U6N9$
M                                             ZZBECJF;9&M<GY1
M*;K3Q.CE#"R%FUC5:C?E%5U'(B
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M>QJ_,!]
M        #A'3LC?JV-K5=\K3W77J.9X
M                                  .,DJ1IU Z)*ASNB=UI+B.!)6
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M9P.,T@
M
M
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M\2GV(!R
M
M           #XYR,ZJ!TR56J=TEQ1Y.ISMW5220%8!TU5=%0LW2.VDHBK\7O
M)1:[$TLS](?1L:;HVLZ>:%6[8<5*V'1\>YY#7:G-U5&,%V:-:R-WY3CV=G)S
M4*]9N4%K?RZNZ4M._P"5SMIIC8=?"4*RK8O7$;8:*;ENK*JJ3YHF\QO\9LCT
MZOA0K-*V+QQ04]/4N2AM[JB/W72R<MW[G4TQZ;\=*ZW"W;IQ)WNJFW4L=+2L
M^5S=_P"_T-$^G8M/)76:EIXRS^NE!"ZMN5\?;8?5W-DY3"S]GP8Y[GG.M5C8
MXS]LEIO%I@NUZ;-<L0.VVZ!TG,EK/S$7Q]8GKFQ8^,_%]2/&M5NQ\3&&ZS._
M^I]2.JJK$+8%GEV1IR($;N5[7OUZ/1&^&A#]KQ>W]A[R7L[X<EHY8\8CLSL6
MXZIJ6QNCLF$8)'P5_,5SJZ1J=6;-.BZ_6I1AW_M*KM[93UP]%"RYS<S6QUP]
MXTO]19W?3$TNW#E'%2[)>2JZ=?BJ)UU*L.XW-X*KCW?N>ZQ.E<7EN61>:>)N
M#RCPTZ^/FQ9<*Q)Z^>MK'M<VG=NWP[]%7IW>AYKMMS>U]ER[GO.=,O)7,R."
M'\/LM\%X<I<45ECI\'MW,?!#S))W]WJJ[DT5%;T4LS>F\\4XN7'BCIFZ5R9U
MLUO?;[;2TRR/J%IXFQ.>[UI=$TU7[3I3/%2I.:V3]3G1EU=K!#2SS35E.NS9
M'N>UR=4T^W;H9-[I%X*FD\7S4I? 'DWF5B[ =#AV\X7N-I2QSNHWUM?#R(&T
M[%V,:Q>N^1J-ZIT^TXVV]8G%@XUY2TWMNM,MVWLH*FR\3-5B^WXPEM]GN447
MTE2LI4=)<7HKMZ:[DV='='==-W@<ZO4:TRUEQ=O)=['MXTSCC#@/RQS H+#3
M7S#M/=HL/ROE@;5:2\]7)IZ75/2(GL1? RYMSER_:TG,3IXLLVFTTUAM5/0T
M5/%2T='$R""&)NUD3&IHC41/!$3P*4WI QQQA?W*V87['ZW^9<!^=ZM_KN;\
M]?XP,EY,YB7NPX O%BHKI64MHND[7UE+%(K65*HG3>GM]4ESKCQ&Q?L,_P"M
ML=?XVG_D/(C8,!1\78\M6!J#SBY545.SKM3WG*GL1/B78<&7+7&$:N=/)'#.
MCC2J*ADU):G>8TSF[=S?QKO;KK[#Z;9^BSIW9.YBR;GKXHP8\SBFN$TCI)G^
MD<KG=[UM?B?08]OT8];89S$SOIK.R1'S;I?=8UW>-''HKZZKG[-/-3$.(N-C
M#,E!1^=0[*AKXMRM;RW1.1ZZZ+KHG4YOK4<MG7/M7;2OI6X4_/79
M
M
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M73HFI4];EH?Q*?8@'(
M
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MA\!N=O6#+6*OW.K%\YY*^4I@
M
M
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M:RZI)O?YPK$T1&)LT9JU%5'^TS)MRM+5-="U%[O=0EQ1Y.\BD
M
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MDCCGG\'3V-=93:/FVT
M
M
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M1T',"FVG%UNOUTKJ.DJHJB>WN1M0UG]Z5=W=7_)++Q5$<J_>\FNJI%;T
M
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MI\EDS5DKG5<G0F9T\57()
M
M
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MF3<EZL?M]U4]U2FXJ/)[-=7M()
M
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MS7++3J8\,X_%D(QK
M
M
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MN^'4^;SXO9W[/]=6R*ZSR5^AKH;E3-GIY&30R=YKVNW-<5:ST3=QX
M
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M *1JFH[E/TT]$SW$T^M3X_?^MY]UV^,_<Z>':SC2(8UK6:)W6G&:7T
M
M
M !^3'CH[8'BDSPXF,]<Q,L,W,S+)E)AK%?F%+'9K]/34%LHI99H+>Y(VN1&\
MYE,YRZ)Z[E^('Z9.SCXGHN,[@2RIS/;,V:IQAAJDJJ_9ZK:YK.76,3\VH9*W
M]J!A[M?."?B&XR;-@.#(+/*JR5J</S5K[W+%75E-],,E2G2!J^;^.Q62^M\_
M3V@:-.-'$7'!P4]HA@CAUO/%OCZ\8AQU):8J>ZT6([@VCI?I"K=31[T<J/[K
MDU=HGAX ;9^S6[+WC)X8>+.RXOSCXJJW-3 =#2U<59AZ6Z7&=M3)) YD3]DZ
M<ON/<UW7Y>@&#O*_N,S-CA$M'#^_*[,3&& 7X@FOZ7)UCN<M'Y\D*6SE<S8J
M;]O-?IKX;U^(&,\ =DMVI..LN[)BNU<8= Z&]6ZGNU+35&.[YOV2QI*QCT6B
M6/71VBIJK=?;H!>78J=LUQ X-[1JY<('%=4,O6*.?56^V7>6&)M=1U\,7G#(
M)98=L<]/- USHY=N_58^\YKNX%:\K^XS,V.$2T</[\KLQ,88!?B":_I<G6.Y
MRT?GR0I;.5S-BIOV\U^FOAO7X@8QRY[)GM2<>Y:6'%UJXPZ%\%\MM/=J.EJ,
M=7SF[)HVRL8]%HUCW:.T5-5;K[=.H%Y=B?VSO$#A/M&+EP@\5M0V]8H\XJZ"
MVW>6&)M=1U\,7G"02RP[8YZ>:!CW1R[5?JZ/O.:]-@2&\I%[:N]]EWE%AW!^
M6OF;LW,QF32T=9-"D[,/4,:HQU5RG(K9)7O=RXD<BMU9(YR+M1K@AGA3L4>T
MUS4RRAS,N7%/B.P8[N%,ER@PO58ZO$%3!N3F>;2+$GFT$B]U.4U%B17:.<U$
M4"1'DYW;79C<4>:>+N&[B%5SLW,#,J745RGA9!5W!*67DU5'5,8B-6I@?UWM
M3OL:_<FYBN>&/_*^>-G-[A%Q=D+%E=F1C+ ,=^I+Z^XML5TEHTKEB?;TC638
MJ;]N]^FOAN4"V+-V0':H5^&:&^6[C#M=4M13,K8*>7'5[W.1S4>C%1U$L>O>
M\%7;]>@%[=A+VT6>E?Q\7OA$XI)&W3'-))7TMIN\M/$RNBKJ2-\TM),^'2*:
M)T$<LD4R)JNU$W/1[=H5WC%[)CM(,VN*G,'$V7'%7:<*X"OU^JZW#]F?C:]T
MCK;1/D<L4*Q0T;XV;6;4T:YR)[%4#7'BG%?'W@_M1(N$JIXI\529BS5]+;FW
M*+&=T=9>944,5<QW-6))MJ1RM1?0:[M41%3O ;!^''LA>TOR^X@L!WW&?%I:
M+]A"QXBM]??+8S'-\G=<*"*IBDJ*=(WT36/5\37MVN<C5W:*J)U OORESMI\
MP^ 2OP/DWDJUM!F=F%2_2,UW6ECJI;?1OF?30Q4T3T<U9YIF2(CG-5&)%W45
MSD<P,!6;L$>T=QU@^GQ1>>,N^V7&DT//9:'XZOKF4;W)KR73P^C8J>#N4QS-
M==%<G50DGV$.=7'70\0F/<GN)O"U9>L*X%I_18UNFR*?SARMY,-/4,;LN44C
M-S]WKQ^_)JK8P-J0                                  ,6<7G]JYOZ
MH;_$XZ_HOV[/N/!$^NH8;E3205,,51#(W;(Q[4<UR?6BGV+GH^YB<%+\.8M=
MBG*R_5&!;_O1\M.S62VUG7O\R-=5U<G3NJ@%"FXS,ULEZ9J9D98RW""HJDIZ
M>MPU)SV\ONZR21HKW?,O@@Z(4O[+WC>RSS86L;0XFHZ&HH7HRH@NFMO?$_X:
M3;573VZ!XO*TXPM.+H72VJZ6ZZ1M[KGT=4R=K?O:JENGUCC6>);*M2*SP):"
MDUOK(6Z?6A2W,38JM>&6;KE<J"WL=ZKJBH9%N_RE0LTIXQGF/Q68&P#-3Q5%
M\@KJBLU;!%0:UCG*GN^BW:'OMIT.C%-TXLL99@0M7">#WV^%LZQ3SW=VWI\[
M&:M7ZSS3+5^,G2=%J-RMJ+Q>'7?%EREQ!<W.5S4?W8(.O38Q-/!.G74MC![U
M=R-6K,="^:>.GIH7N>YVUD43=SOL1$-%5,1RIY.G5TXPP/>L*U[4N%MK:>.2
MGCJ&SNA>V/1ZN1&J_33?W>J>)^7^O[C%EWE5B[G>V<5IB[TM>"O/REQ=@FGP
MU73,CNMK:K(M[EW5,?CKJOBOK?<=+TC?3>+V5>4J<^+I7)F6L.]+,I5=XD]/
MK5J16>)[*Q1J[Q+)5J/6^N2T5J-<"<BCW G*M1[@62]I2*[Q):/%(K"Q6HMQ
M]<L%[Y!\&;,15,UUO-=3NH)*CG^:TLS)>:_1OKJW5$3U>GB?D?[56.JG^.OY
M_>^D]G&J0]=DKABX88^B)+/1^9-:K6MV]YOW^/[YFS76:O:Y?)9'9VRQI>,C
M699XMPW#8[U6T>&([A#6UMHE=N@?4,W,9-'TU151[]W715=X&K;;*LF*LOPJ
M[R3I7%L;S.Q]^!-MO%GKI-L%91NEHYWNV[6:>D8GQV]W1/%=WM-.UV_M>.6/
M=U^=7=].U'7@]XB(,F:/&#YW13.F>UL#)7;=TTC]D;=/:BOVZZ>"=5/HO5=E
M[>L;%@R<.2Q>)FEJ;;M61W.BK'K61/=KN@5_5\>SV(CW.TU3JG7P4W;"NO\
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M8E:M'#)ABTT]751HU6K,^FEHH8GMDB1Z2+'51[7L8Y&N:B*]@;P@
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MR6.1JJU['(NJ*BZ*@%2
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MV2*FJ,FIY4;+'KWMJJW:[:NUSD0#-
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M86U#$E:UW=VH[JFNOM^)RJGI7%=+V'CT
M        _-UVZF9]AR2\J'R@QEBFX,M.&L)UV#KQ=JU\;Y$HZ6"M26616,1S
MEVL8Y=&HJKIT15 V#<<'E,G"(WA2Q];,'YB.Q]BJ^6&MM=JLEOP_<8W5E1/
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M(Z5E.Q[&/DZM1-$?*Q/VR 9[
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MX-.'_#&66 ;<^UX4PG2>:T4#Y%EE=J]SY))'+U?(^1SY'+[7.71$3H!D$
M
M      &D#RU'BC6P9"Y2Y,V^9RU>+KS-B2Y11>OR*./D0,>GM:^6ID5/RJ;Z
M@,<\/'!-VP'#EDCAO!&!,5X8PSA##]$VGMMKYN'GNHXU57[%=+3.D5^KG*Y7
M.557750,*>3N7[&/9G]O/>LD\RX*>RWK&=%687N]+%+&M)'7)&RXTLK%9HU4
M=RMD>U--*KH@'Z< /SF]O=_OH/AY_56"?\\O _1D!H3\N,_W!X:/U1B7^1:0
M/1VKWD]65+.R!LN:N2& XL.YAX/L%!BB]MI:RKJ77ZA6D8ZM162RO1'L1W/3
M:B=(I&HB[DT"5WDJ_%K@+B+[."CP[A_#>%\)XVRWECM&*Z6T6^&A==5V+YK<
MY4C1-[YXV.1\CM7.E@E]F@$2?+C/]P>&C]48E_D6D"8W#/Y-[P6XSX?\O\07
M7)2FK+O=</6ZX5D[\37K;//)3122/5B5FWJYSETTT^K0";O#+P@Y8<&F!I<-
MY68'PY@>S3R\Z>"UTJ1.JI/#?+)UDD>B=$5ZJJ)T\ -"'E'D;>%#RAW(C-Z[
M1OI\-[L+XCEJ]FYK_HVZ*E0WZW,CAB54^#V@?HSHJV&XT<-13S15%/4,1\4K
M'(YDK%35%14Z*BIX*!^<CA^JJ?C2\LCO.([!MNECPSB:X55551)NBCCM5H=0
MI+JGBQ:F&)K53HN]J^T"\/+AO[,^&_\ 46(?YRW 7/VY7D]656!>S,H<V,A<
M!Q88Q5@*C@O6(J>DK*NI^E[8^%OG+]LTKT1\"[9M6Z)RVS^*[= F=Y,1Q:X"
MXG^S/L=!A?#F%\(XJP"]MCQ;;;);X*%M35-C:D5Q?'$C=[JJ)K7.D5.LK)VI
MZH&Q<#\YV>'^_8:']DUD_P#ABD _1B!8>*>)_+S!>>F'LL;MC+#U!F#BRDFK
M[/89ZQD==<((?QCXX_'YM$\7;)%:BHQ^T+-X@.S7R XIJ6N;C_)O+G$U3<M>
M?7U%C@CN&J^+DJF-;.Q?K:]%^L#0YV*6$&<&WE0F,<ILKKG5UN7<=;B3#]:B
MU'-3S"FIYJB)DJ^^^&JA@BW^.J.^9=0_2B
M        #%G%Y_:N;^J&_P 3CK^B_;L^X\$5C[%SWEKO4<!0[CX$I%#N7M)Z
M?6*'<? EI]2%*%7>H6H4H5S]A*5=*)<?6<62BH582>THM=ZCBQXH5Q\"Z5:V
M\5?[E5/^+4Q>I_X/)^"_!]K*P\N[E>\L7T=ZP[63PK(U/.(&2*W=KXK_ /0?
M)?L$XMM.?RQUI\^GW?QT=#VW/+4^\E'D?Q>7[-*_38/IK+07K&U^Y5NLWGFD
M=LI5D5S))JA-%1Z)N:J(K5]5?B?,9>/+Z+Q=#3^9<G$]V7CZKBKP#EE:\65K
M<6XLP_57FOO=0WFMJ:^*.9[&;%7N0JD3(NG@WKI["IZBYGMDMC[A'Q7]"9GX
M=J+'+)_6]RB:LMOKD3WV2:(OC]0%1RVS^Q!@.F;]#W3F4CF]V)_I8FZ^\B+T
M0V;;?Y\'C2J\,WY,N81XVV5&V*^VUT;6L[T].[>YZ_F=$3]T[NV^4'_WS^3-
M>T^%>-'Q%82O4._Z4BI?R9^Z[^DZF/U;;7[W'\6:MOET>NEQI:K]WJ.X4M0W
M\EQOQ;G%D\:5:XJT\GGKJR'_  D7^4AJFY4\5$NUR@I&.?)-$UC?>W'FN6=)
M[Z>Z2M2Z9AV6'<BW"GU;[K7&;7U?9Q_W-%G[-EU]U:U\S<HHV.2ECEJ)/RNZ
MW]TY^X^4N")^B[J7QL*U\EL7C&%SN5 ZH;LAI-VUVS^]+\%7ZS@[OY0;S+/;
MVS_#_EJQ;/'"H4>5]=?,M&W.W4=5>+M75#8J6EI6\R6=5]U$^*E>FPJ]G6YK
MR3]MTR^R7=EODNW-+$-#B:FAK*>OM\[F7*E=Z*/GQ,:JS=%ZHJ;6Z*G16:FK
MT[!.6ISS_57FOCVKLM>0]+G?GPV@GMLM5434:MHJQM0^)M#.U^]'JB)UZ-]I
MUO4=E-Y?;U[OZ_\ +-ARUI/&5\8JCNM':FV>\S><5EI>ZG<]CE<V71=.9UT]
M;;KH=/97UGN\E&9FJUUE=<^'*SU=DHZ6GM&'8D@?54\:;IYGIU>JHB:3)M[Z
M>[N3JISYXZ;RIR^5?K\EW_:[&%K#73MS=L+HW122NKX7MWR*V.)Z2-T>O1?5
M7J=;)I]!7X,T^;-?&-BZ'."@H\0PPRT[6R_1L3W0HUM<C$]),KT777F-<U$^
M7KK[#E^E8ZP?1?U_#^#1GOGW+*X3:6V4>84U5=XWU%-8Z>2HI8F2<MK:A5:B
M32Z>+$W.3V]7)T-/J6M>RXQ[W^BO"I&=D=5#B2X.K*/S>XM>Y]4S_P Y[?\
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M<[UNJ:^'Q,>YVE1GK!*V,G6>2^8:AE131R-]21J.;N^LQ]%CF
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M[=75/G5/'R%DY+/T.E'U1B.[GCU4#9B
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M1?@BZ'Q>_P#5L^[^UKM^YU,.",?BS <Y>
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M1<,.7F%<;8@?BK&6&\-6^VWR\R54M2ZZUT-.R.HJ5EFTEDWR-<[<_O+NU=U
MU1]H%Y(CAW.3.N[YC9"9CORJN]TK'7%UCJJ.26W053W.=(^FJ(GMEI6*JZI'
MMD1JN5&[&;6H$3^(.U]IAV MGM^.[UFQ4YD9:TU=#2U$TUZFQ-:(MR^C@J(J
MYC:FE9)ZN^'8B.[J2(YS=0WI=F7QT6KM'N"; ^;MKH5M+\34KX[C;N9O^CZZ
M"1T%3"CE1-[$D8Y6.T3<QS%5$5= ,]
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M[SC/$&(F8_S=Q12I25EW;3K%26J!7<R6"EW*LC][VMWS2:.?RV:,8FY'!L0
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ML.Y,TV7^3/-CABM]RO#YKENJ&\JIV/73255\=R-[O1-5=H9]I.+'?LL7C/\
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M[48FJ^U5<U$^LYVN&_:^SE?S[>2N)WDU*D@
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MG.VF/)7S<*C'#,-P^<7"LBIZ7>UCGSNVM:KE:Q.J_%7-0:[6;\3GT7:<Q8
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M#'?)L-6O&6+*2=MII65-5OGFGCCT8Y[$TU=U[P&S[_9BW"5_P?F[_P WJ?\
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MQ+$Q^G3>Q^BJG4"8P
M
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M>D5JNY/6UVYNI%)]
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M$7%6'JN1TE#A.\I%1-<WU4G1\K]%^T^5]<CIEFOB=#:UVMEYQ6@
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MR9*R5RIT9GBJ1%X   '*.9T:_DE:QWQS)(!S
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M
M
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MV%Y-M6?X?UJNO+TJ89.DJ60R-:Z1C7R=UC7.[SOL.:N<P
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M[<UQEN*FN-)S7)ZCQX    #LCJG-Z.(\4N3O;(C_  (I/H
M
M
M                                                 #A),V/[0.B2
M5T@'$L5@ #HN5PAM-!454[N7!2Q.EE5WNL:FJN_<&FG6N,I4UI5.;-9G-Q17
MR\550RHBW204KH_Q?)8_;'HGUL:T_2\6TG;[.<4?K5P_:<\O)D0H7/+7>HX"
MAW'P)2*'<O:3T^L4.X^!+3ZD*4*N]0M0I0KG["4JZ42X^LXLE%0JPD]I1:[U
M'%CQ0KCX%TJUNXD=RZ"9?E8IB]3_ ,'D_!?@^UE(?@Q_ JJRVI:FSS4%1>>4
MGGK^G-BD5.K$5>J)K[#\KZY=)X>Z^A=/"C<76G.?,2I;-YN^&LC<U[7;7-5%
M?U12KH+BX.6X7I^UKPG5X><S=)!</I%L7XKSA:2771/9TVZC0;=&2)(S<WO(
M6#D%:V,Y,?)E?EC>KZC8G26VEDGB8]VULKT35&:_67[3![7+.+XC)?2>3RW;
M,9]AH++=JC8ZU71D;)W-TVTTCT;L77VZO<UI9&VY\HGRE'6^G<B;C3.:GI>T
M+I:QUV?^#[G^9U#FN7E\OS=VK%3X<P^DQ;6_^F<>/=_Y8:R_3L7<2&8WX95E
MVMUNN$\F'+37RMM[61^BJ4WNWJJZ_P![7:UOU.]ATMAAX<:J>ZM/G_7\5.:^
MKT\/..*RNPW=+Q734[8L.TM/;J"E?W6=_>BRJGOZ[6[D7U]J(I#=X9Y3,^]U
MUU>X]?>8JQQB-EEQRVXT$;-\<Z/B8YO=UU]7ZOZ#HQ'7%QI15,Z\2F$:&'*+
M"N(*6NJ*ZLN5/^C&S]Z35=R[O%>XWU4./Z=GK7/6"O=^IIS1V\F$L@;W<\-Y
MD.?8J66LO]R8M#;8F.V^D<K>\J>U$1KNAT]_BF\7TOC/SZJ,-=*[5X<36%ZF
MSXSIZ69KY/HVC;1/?RT:ULC-VK=4\=-WK+U4JV%3[+M][YT\T]R[>#&CJ\U,
M)7S!=NJ'4,=.V2XU+=V[SN1&>C1GU[V-1?@G4Q^J7.#+.>OP6[?OGBP9FE;Y
MJ6]S4KN[5PSK$YORJBZ+^^=G#76>3-<L_28VDQUD#56JGC\\LN&;='%S97+%
MS:UZ-6141-456*U[4^*.UZ'%C#[/=<O>K7^W_EIY]9XL+99U5OP?FC9:V[N9
M'14-5'4/;*W=$Y[5U1LGY'Q7K]AU=S-9,53+/'S4RCQ66N]T]UCN-WI8J5;Y
M$E9$QC=K6L7HB=/S==#%Z;>+6>,^[\RS-->\H?!#F@W*G&&(KQ4;)*>.EY'*
MW>DK'R/:QD3$\%3>YKE1?9JIYZMM_:Q,F"^"A\2%AAI<R*IT<<L+I&-JIXI8
MT9RIGIO>Q$35-B*YR)]7L->QOKB1S:=R_LK8:.CX=:SS>CBKKS?)99Z^H@=W
M8J5J?BO#HK=SM?A[-3%FY:[GN\9^K\5D^+"&-+LM'B&.?;RV\U-W(;M<U-?<
M^"I[%^)U(CM9M:26XEJZTXZRKL[*-L5+>\+VN)]>WU-K7JW9'HG19%1[9%^K
MVG!]-FL>6N7C6OS-6;YY8/R!PR_$684=IDFGHZ*Y/1]VK(I%]%2)U5'LZ:HK
M]AU][?#%S^'ZOQ48M.M+JXFJRDNF-KE4QPN:LCD8U^[NN1N[OHGAWOA["G93
M6F*4LRX."6X63&5GQ%;<2U36T=MH)GT[I7;O,5V.UEZ^Q?=;\6_69?5?:XZF
ML7W_ )K-OQU\F'LTL-OM.+9+?6-EC@AG:]\G+3F<E=%1=/K8YJHAUL-\YY2H
MN>YG&UW*LO'#Q<+W7S<NFO3$M-KY4:-=%3P+R^4^/HC$D1C9'*BKJYOM\3D\
M)TW/&/=^?7\=?^%_3K')A[".(GX#S:HZBU;*J;>L%*U[49S55>G7KRU_*3JA
MT<T>TP=RG37I3*W&!E?%@EEKN=+6?25'>*5L[Y7?C.9J[77QZ>Q%,/I6Y]IR
MFNVI7;B.BR>%'$]TP_<JZW6::J=<\23K2Q04\RND@A1FLTW*Z-7T;7M1==47
M["_U#'-]V7QG]:?W5X=>GBKG%104,E2U]LDBY4+&4LK&?%C-&.5?;(J-UDU\
M'Z]5\2&PUKWOU^OW)9M&7^!G$UUNF4KJ/#K8J=F&6+6.8QVYU94.ZZ(_3547
M:[>WP3IXG*]5B-,_TOO?-_3]?4OP5V]ONK1XF,W%Q=Q+8/Q+3T[:B6EDI'14
M[7=YVR=RHU?@JK[#7L-K[/9UB_'_ $0S9.N6;2>X:<TKCQ'8SNV(*B/EV'#K
M_,+<UT:-=/.K&ODJ/JTWNBT37U-?:?-;_;3M8G%[U?/K_P ?[MN&_:=S.9R6
MD                      C;VQ=9-0=E1Q$SP32PSPY?7E[)&.5KFJE'+HJ
M*G5% T%=AEV'$G:\<-N*\=WC.W&V"JC#N))+"RDI(//&3M;2T\_,5SIFJBZS
M:::>Z!<O$^_B$\EJXV\NG6O.?$&:>6.+8//9;5<72PTUSI8)6LJJ62FDDFCB
MF:Q[%CGB=N3F)T1-S%#>MVG_ !QMX%NSFS$SJM$-'=JK#]HAGLT50Y>14U57
M+%34KG(G56))4,<Y$T56M5-4\4#1IV:G8M9G^4%8 NV?V?6>^*X[=7W2>VVV
M)T/TA5U:P[>8^-'R-AI8&O<Z-D<;%35K^C$1-P9?K/)Y.+OLL^(#!N(>$7..
MJQ+9KQ=8J>ZT]>Y+9!;6.5-9;A2K(^&KI-$=N5C>:WIMCW:. W;9_/KZ7A6Q
MMY_+ ZYQX4K_ #F6E:Z*)TR4;]SHT57*Q-?!%<JHGM7Q TL^1&8IN>)O]4W]
M(W*ON')3"W+\XJ'R\O7Z9UTW*NFNUH&^@     -9_E*?:>7/@_X;;;D]EM-5
M56=F>:_0MHIZ#5U9;Z&5_(EJ(T;WDFE>[D0Z:+O>]S5UBT U>>3[Y6XVX9/*
M&J/*W&-]JKC>,(4%YH+E&RNDGIO.&V]RO1NJZ/1KUT1WMVZ@?IS   ,%]J)4
MRT79H<1$T,CX9H<L<2O8]CMKFJEJJ51R*G@J :Q_(K,27#$G#%G9)<:^LKY(
M\4436.J9G2N8GFCO#<J@;K  'YA?*!L?X^[0_MF,QL$9<W*ODH,D<&5<<K*:
MJDBBY=KH9KE7NVL\95F?)3MZ:N>V-OAX!LX\DKXMI^(OLNH\+76X25U]RIOU
M799732+)-+23KYY3RN5>NGII8FZ^R#0"]_*EKM56/L5LS:FBJIZ.ICN-DVRP
MR+&]NMUID714T4#6+V2?DY7^N5<!V$\X*[B QWA&X8DFN$'T=34'G<5+YM63
M4R+O6=BKKRMR^'K: 5'AWS\SZ[ GMIL'<.^,\UKOFGE5CFX6ND?'<IY70>:7
M&3S:&MBCF?*M)+!-NWLC>K7MB5%5=6JT-J'E#':+XA[-/LZ+IBW!DD%/C;%5
MT@PK8ZR5$?\ 1D\\4TKZI(U14<^.*GE5B+W=^Q7(Y$VN#5KV?ODT>+.U<X=[
M+G]GKGSBUMXS&B=<J"GY*W6N\W5[F1S5%342^+]NYL;6Z-9L[VJ[6AF3A.[$
M_C1[*+C^P';LE,UX<6Y&7JKYN()[LYT%LHJ1B[YX:NVK*[T[F=(9:9VY7^LZ
M)NX#>4                     !U2536]$)<4>3I=(K_$DD^!6    "AXWQ
ME380@ITJ)FT[JQ_*8]_JZFC:X/:47?12?P@=)WDK.G^,.A[&?A0ZZN.%\W+7
M<L<_@RVNBJ+IYJZKV1NW;6-5J=?\IIFW.UX8O:D7W<5Z&!, X23)"S<]VUIY
M,\AY_IND\.<PO]A3WD]#)DF9N8[<TJUTXO%'S R[LN:6%JBRW^VTMTMM1HYT
M-1&CV[VKJUZ:^#VKU1?%%ZH>X\E8ZY2]J>3MP3@>TY<X8I;-9*&EMMKH6JV*
MGIXTC8W5=571/:JN<J_%>HR9*R5RHF>*K$7B,''AGAARHH(<&15T4E^<]:CD
M-]UL?K_N;CZ/T3:Y=*]K7BR[F_=0:S"\''V&)S;7GV;/$=A;A]XA+A'BBL?;
MXL44:6VCG<U.6V;F-?WUUZ:[=$\>IR_E!L\F?!/L_P!VO5;M<LQ7<VFT]0RL
MI8Y8W;HI&HYKF^\B^!^?U/%UW8>@   8[XAN%7 O%)A62TXTL-'=(7,<QD^U
M&U,".\>7)IN9K]1?M]SEQ>*-XYOR1XRC["_(S*G&#KLMGJ+PQKT=%1UCMU,W
MZI&*JI(GVH:M?5,O'ABZ3^"K3;3Y5W)?V.PT.&;/3V^W4M/0T-*Q(X*:"-&1
M1,3V(B=$0YM5R7O8>@              !;N.,T;/E_3<RX536O\ =B9WI'?<
M:-OM,N7P1O+.B-6=/&%67IDE-22>8TW5NR)W>=]J_9[#Z79^D3C[J[F/+N.J
M-^-LVI:I[E?-W3NX\+)5LM]G;QB00XYKL%7*J9Y@ZGDK8IWN7;3*U6HK/VV_
M7]J<+UW8<_I<7DU;7-[M)DX7S8L&,*QU+07*":I;_>MW>/FLVSRX^^Y;=,LZ
MKC,Z0    #7*WJ@6.Z.J]CE(\4>3N(I
M
M
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M2=/6VZ=-5^4]:Q],OM*\J_7]&_::]O!(R.JW=''$XM7)VD4@
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MSGDODSI      ?8Y%C\%"QWQU#7>/K$>(["(
M
M
M                               ^.=M\0.J2J]C5)<4>3I<[=U4DB
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M;\L5KK+:.T%R2J\"S04^:U+9N;72VIR)<HGMK&.MKGJSO)*C^;R]>]ILTZ:
M;N>-;M(<J^S:RHP[B/.G%%+87WZJ@MU-2TL+ZFIK)U5B32Q0M](L4*/YDCM.
MZW1.KW,:X,PY?9A8<SFP);\189O%IQ-AN^4Z3T5PMU0RKI*Z%WO,D:JM>B__
M $ ?FP\ISRQP'EOVP.5U)D7;K+8<RJVFMU3=Z6P1L@;%>'5Z^92O9#HC*IR<
MMSM$1RMY3EZNU4/TV                 '&25(TZ@=,E0YW1.Z2XCK)*P
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M>+L;:>DLXG-6@       '..H6/Q]4CQ6.Z&H9-NVN[S?6/-=!S/
M
M
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MK^:WN[3%ZM_@\OX+\'VLKGX<^,+$>!66^SXWC=54=P9&^W5[].\S3\7JGO\
M>;ZQ^<X?3^?&:[:KZONU_P#+LWFZ)(39O6O"^&[M=[C614]+;W\US'NW2SH[
MU(8F)JJR.VN1O3:B^LJ(7^H[6MM6.JG]WY_>\PWSY,=UU->VXSNT]XN55613
M4\;Z"*6/E<JG=WTWHB(F_5SD^S0[GHNTG%EJI][1DW=]92PDS0NN<.&+78I9
MO,;1ANW0R5[J78_SF;EM2*%B]=.XYLCO!45JE,;:<&6LOO5K\W^Z575SQ1YO
M%.RES4IXKMYYYI).C*WD2;7SLUU7JY4147;KU713O\NN#M_HQ^^S#Q(8KN51
M#'>8J6GI[7?J)WF<[8?15,;DT5[$<FJ*J?%$5/9H<_TZ)\?>G5=FI8G!;FA_
M4OS1O%VJH:=U!1T+GOGD:KG1/T=HR-/#?(NV/K\Q=ZQ@]KBF9\NOZ_+ZT=M?
M2N2D\06&IY;\VX54=/2RWIKKBZEBU_0S'KJQJZ^U4<U5+]C?;Q^'YNJ&65VY
M2T--B+):X5]5,RX7MU1"UFR/;);X(&/C8U4T35'(K5U373;WE15,^:N&YXSV
MS_KKJG'SRQCG%B3F7B.NAI:>GGC8USG>LV5Z>^K%U3K[4TT^HZ&".WBIRTOK
M,*WVW#_T#':H:B.COUK2LEIYW(^6A<JO8F_15\7MZ?G&/;75\N7NZ_FMOYEK
M87J*R'&$UFH^5SKU$E*Z?F;)(&(K9'N8O3JK&.;^V+\FD\>5>ZA/EQ?,087M
M5EO#D5U1]#-E5K-C4Y^QJZ;.O3>GM]A+2ZUG^8UT9&RKMM3F5E1CB'SJGIZ;
M"^RY4M+M8QK4?OYVB^*]&,^I#!N+G%GQ_P WS?\ "V-.LU_*PGAN]4K,>6^Y
M5/=MU'.D\NW5KI8VKJK/M=MTZ]/CT.IETKV53#//DSAG=<*_'&6-ON=='*VI
MO5;YU%!4:.D@IV1NCC2-6ZM2/8UNJ:^M[#E[.(QY>$^[I_=?D^>5K\)>+'X/
MSF;#0^;MNMVB6@I?.-/-N\K5VRJO@SN^*==="[U/'SP<J\9^=##72GFXGL$U
M67>.;I:JS:V6G>NU[&[6RI[')[=%+-CFG+BFI>YIZ5Q7KPKX^DM^6\.'(:[;
M<+].YE1!R=VVA8C7K[%:CY._&CE[WUHB(8M_M^N7VGP_Z_\ A9AOMXL,8VM+
M*7$E8L?-I875$D3/FBCWZ>/U(=?%766:O)G?,SEW;).PU%HM+8[#:X(J5UQI
MW;8*ZHY?K;-=>8W:Y'*J::ZZ''VGS9ZFJ[J_=]VC3?CVL/Y'S2_ZH3#[&210
MR>=-6"=_JTS]6Z2]>G3\KN_$Z&^_PU*<?DR3Q@7*DS(FI\44S:6G^E)W4\3(
MM7.J8V(W]$/7PU<NY-$7W? Q^ES6*?95[OZZ+-Q\_<H_";#1T]?=+C=I*WS6
MQTZMH&4KMKFU#ETWJQ/7UW;?!?W"?J.M=LS[WU_@CA67FY(V.Y54J0NCF<]T
MLNYNUV]RZJW1.B(G@;MO/:KMF_)V.W8OX2&VZ2E?47B\5K8K;*YS/.7R-\6*
M]R_B&;FZ==>\<7<5>/?<O=G3Y_U][3'SXD=Z&JK,+XYAKJ6'F7&CEVT>WW9T
M7N.^O1=OU'=N9O%QKQ9?J9TSVM=+;<#8?L]3>/I"JHX%K:I\;=LG,EW/5BIH
MB;T5_BON^"G)V-5K55,_P7Y5A\,=5]*9KQX>EDYELNCD\]I6Z-?6,3W(W]%8
M]%ZZZIT:O4T>H:=,7M?>GZD</EQ>OB^P71X)S(NU%:Y&55M;4210/8U^UJHO
M6+5?%6^W34EZ;FK)BFJ\GNXTZ4NOA"KJ[$EA^@X6P.L6$V.N]:Z=O=EJ'II'
MT\'I&L37?'[3)ZEI,5R]ZOFT_7\4\/S]OPK O&$:&/$DEQN-93NIHY5K*IL3
M>]%K+HQJHJ=4UVJJ-U[OUF[VE\>,JJEF;,+"]XQMP_.Q2UWZ&IYVQ/MT6KH*
M.!J.9'-$]W79(B-=MUZ;M%:FFAR=IEG'NO8?W_V_HT5/*>2VNSYR7J,SN(1M
MZD\X^B<.Q(Z?=HYLLB^I&J+XL7:XO]=W?LMMQ]ZD-K'6DGN*C(&R9I9QY?I5
MTKV^=3S-K'Q-_'QPHQ[6+\$7<[KXGS_IN]RXL&3C^NK9FQ1=2SW04<5MHX:>
M%O+AIV)$QORHB:(AQ*UZ]S0[CT=5151TK-TCFM0:16OB*-<,3OF[D/=;\WO&
M['M.GDC5KGI^]31JORH<[7R7.9X                 !C3C,X=_]5QPG9C9
M7?3'X/\ ]4##U;8?I+S7SOS'SB!T7.Y6]G,V[M=N]NOAN0#4!@'R.O'.55KE
MH<+\:>+,-T4\O/EI[5@^HHXI9-$3>YL=W:CG:-:FOCHB 9/X6/)$<N,N\[+?
MCC.C-;%6?%9;965#:"OH?HVCK)&*BQ^<[IZB6:-/\'S&M=X.U;JU0V:<57"7
ME]QJY'7;+C,G#='B/"5Y8G-I9=8Y()&_BYH9&Z.BD8OJN:J*GAX*J*&GS%'D
M?V+LG\<7"XY"<4F*\"VRN=M2EJJ6>"L8Q%Z-DJJ.>))M$=T]$T#+' SY)K@7
M)#/NCS-SMS-OF>N)[;50W&EHZRA6CH'5,:M5KZKF33RU>U6MT1SF,731S'MZ
M ;5LT,%_U2,M,18=\Z\S^GK;4V[SCE\SD<Z)T>_9JFNF[735-?B@&C6P^1/W
M7"Z3);.+*X6WSC;S?-< /BYFFNFNVZIKIJ[0"H?[#'Q5_P <;$/_ #)F_P#F
MP&Z[)++M^463.$<)RW!]UEPO9*.T/KW1\IU<M/ R)9E9N=MW;-=-SM-WBOB!
M=     UZ9#]@W_41[9'$_%K_ %5?I3\)*RY57X*?@SR/-O/('1;?/?.W;]F[
M77DIN\.@&PL   L/BFR3_P!4MPQYC9<?2GT+_5 PO<\-?2/F_G/F/GE)+3<[
ME;F<S9S=VW<W=MTW)X@:5['Y%)>,,PR,MO%K<;>R1VY[:7 +XD<OQ7;=4U ]
MW^PQ\5?\<;$/_,F;_P"; 3+[:#L++KVOC,LJ*3.9^7]ERWI:J-M$W"OTJMPJ
M)^2CYU?YY#MT9"U&IM=IN>N[KH!/'+?+^UY3Y=6'"UEI_-;+AFW4]IH(/\%!
M!$V*-GW,8U (8]MWV)5L[97!F :*7'/]3R]X!K:N>GNGT']+\^GJ8V)+ L?/
M@TU?# Y';ETV*FWO:H%=XI>RANO%5V15IX7KUF?R;E;K59K7+C'\'>:ZL2VR
MT[V2+1>=)WWLIVH[TZ]7*[KX 0(PAY()F+E]AV&SV'C<QG9+33[N514&$ZFF
MIX]SE5^D;+NC4U57*O3JH&?.SG\EHRMX*\_K?FICC'&(,Z,=66H97VN>Z4:4
M-#25K5U2K6'FRR2S-7:K%DE5K5[VU7(US0FCV@79SY6=ICDA)@7-*R.N%'"]
M:BVW&CDY%QLU0K=.=32Z+M=IXM<CF/Z(YKD1 -4#?)#\U,G;Y74N4O%SB/"N
M&*^7<^E\PK*&?8O1>9YM5MCF?I[=K-?@@$G.RW\F-RU[/S.BDS3QCC*[YQ9F
M6VH?5VZOKZ-*&WVZ=Z.19TIUDE?)4)N=I+)([1='-8UZ(X#9P
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MN62&H57;G;D*MY[J4*X8E@
M
M
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M[YC5CVG7R>52C5%4^L?ND=N4W3$SXH.LM%_4W]:Q_8AP-?)H<CP
M
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MUEHN/ _];U'YR',WOE*<*Z8EH
M
M
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MT%:M>$7S;7U'HV?+[QDR[KIXIZ0N1J<MC6IX-[ISEKZ
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MH8=D36M:8;NK\EO1VD
M
M
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M>]\SO6.?ES5:R9Z/65)
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MCUE20
M
M
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M\FYJULQT53U>B*9DP
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MR;FK6S'15/5Z(IF3
M
M
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MK7(\
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MORF*JZK7(\
M
M
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M3/1W$$@
M                                !X[E8Z>YL[[>_P#,WUB['FJ$:GJM
MRZ8;J+?N<GI(OF:;\>XFU>L<5.-:(!4+?B":C[K_ $C/X1DR;:;2TU5RAN4-
MP9K&[K\OO&"\=1Y)Z4]!%X       MJ;%4M9(Y8)&<K<K6N;]70Z,;:=/)'F
MX.Q@MIAYM5-$V"/3>Y_=_?&NTG7P1YJ=F]PYX/SXY,>+K/2WZAAB?$ZBJFI)
M33M?MUWL7Q]7H9<.[RXHXXJXI:XIU\F#[7V3N77X>3272UV2Z8(:YWF>%9;:
MSS&F14[C=-51=J]Y.GB=&_6<NN#V7O?>IG;1RY,X9)\.N$N'FBN5+A*ULM-'
M<ITJ'T\6C8HE1C6(UB(G1-&^!S]SO,N?C[6N7%=&.8\5\F=)';C"X.9LV:QV
M+L-S7&HQA2Q)!3T$]T6FML[/;O;M71?5ZG7]-]2]AVY?%1FP\^Y$;-S@MS7P
M3<J6US1T&(*_$#-U!+3Q\J*FG7HM/)ZVK&=U5E^#O5Z'T6S]8Q9(JJ[>+'EV
MUZ*YEKV,=_OV9%#%F5517+#U*B3^>VBX>8S\Y6:JSEZ.Z(KMOCUVZ]-=#%G^
M4?7%]%VTG&Q[N_Q;%L)X;IL&X8MMGHM_F=II8J.#>[<[EQL:QFJ^U=&GRF2J
MJN5>\Z.D]%0/'@!\<[9U7P M&X9B6S$5?46NBJFU4L+5Y[6=YOP5IT=OM*CZ
M6I0J^7:PYG9@-V7O)QI8(=K[&Y)ZRB8[EQU,+?'3Z_XSM;;-[3Z#+[S/<=.Z
M5]Y6YK6;.'"<=XL=9%54SG+$]J.[T$B(W5CT]BIN\#%FPUBKC2R+ZL;X!X.<
MN'8SOF+H*&BNU3?*I9X*AS4D\ST1L;VQK[.K7:_>:+W>>>WX5<XYU[F%N,;
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M *Q@O)5^2W31WD'H
M
M
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MW%*0
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MYQS\N>K63/1[BE(
M
M
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M ."8<N[K7Q6Z0JS&M:S1.ZTR)OH
M
M!QGA9-'M>W<GY1*:Z"AW3!Z.W/IG;7?(XUXMU\2JH4&II9:5^V1KVJ;M->OB
M@ZRT=M-62T;]T;MI5<1?D*W;\2,J$VR^C7YO=,63;=/%.:5-KD=U3O(97KZ
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MG'1[7S>D?_!,.7=UKXK=(59K4:FB>!D3?0
M
M
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MXKJN(KEIP?KM?4_Y#3%EW7PIZ0KU/3LI&;8VL:GY)BJNJUS(@
M
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MZ?/VRG7PA]C'1V^FI;UF7,^:H=J]MJIY%;M^',DZ*BI[435#YG>_*'IV[/\
M-MQ;/KWY4]<(X-M. ;)#;;-;Z*UT-.U&LBIX4B9T^I$3K]9\IER7DKE7<Z$Z
M=/%RN&(HJ7NQ^D?_  2_'MJU\GE4HE9<)*Y^LCOVONFV,<QXH]=707O'*&%\
M[]K&[E*ZUZ"NVG!^NU]3_D-,67=?"GI"O4].RECV1M:UOY)BJNJUS(@
M
M
M
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MN_+Z&/\ A&;)N9CQ2F%QV^UPVUFD3=OY7O&"\M7Y+)GH]!6D
M
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M2)NUWO.]XP7EJ_)9,]'I*T@
M                      Z+G<Z>ST$U55314]-3L=++*]VUK&-3557[$/=-
M*UKC)KKQ13SC[36VV[%E/9,#T?TX]ST;/7._%-T7JC4Z[TT]NJ:'U.S^3-ZX
MO:;KM_@Y^3?=W'$S/E)Q0V',YD-/)(VVW21VUM.]W=D7V;%Z:_N''W?I>7!W
M?7+1BW,6R8<UH
M
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M8/9;;)471_<;M9\SO5,^7-,&FG)<EKPW3VWO*WF2?,XYV3<5:[2.*H%"0
M
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M#=/;4W*WF2?,[^@YV3<5:[2.*HE"0
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ML%TIZB3;WJ=SD;.SI[6>)\9O-AGVU<<LNMCS3D\5[&-8
M
M
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M<R^"JA6:E90WIL27*!K=/2JY-55=?#F;MRITT7P1/ ^7TW_LM]_+]7Z_!O\
M8]<3L[-/AUFP+ANLQE<XXO.L0-8VB:[1SHH$W=]%3PW;O#\DCZ_OO:5["?=^
MLV>'IW,\XFRSEOF;N&\2LJ(HX[&RICEB=KNEYD;F)I]BN./BW/3!6+XNC3K'
M6N2\3,DXND;&S5SMK3R9Y"E7+$S&;F0]YWQ-F+:]?)Y5J-453ZI^Z1VYQLF)
MGQ0=9:.ZCH9:Y^V*-SE*KN(\GO35<%IPBRG[]1Z1_P ONF#+N^OBLTA66QMC
MCT:W:ACUUY)OH
M
M   <)J=E0S:]K7-)3704&[8/7O/IO\@VXMU\2JH4.:G?3OVO:]J_E&V:Y(.!
M8.ZCN$M"_6-W[4HO'-^3WKJKEMQ%'6=V3T;_ ."8LFVK3Q2FE1:[5-4,[U]
M               >:JM5-7?C8VN):9:T>\7VAH::RT;8::&"EIX_59$U(V-^
MY".NM6?4\%PQ,V--L'>7YC7BVO7R1JU&J*I]4_=([<XV3$SXH.LM';34$E<_
M;$U[G%5W$>3WIJN&TX193]^H]([Y?=,&7=]?%9I"LQL;&S1K=J&/77DF^@
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MGM%Q]!4MD;T>V-5T2=$5.KHE<GUGP;L5'1E4(
M
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MZZ>*>D*_2T<='#LC;M:8+NK\ELR[2(
M
M                        //<+7#<V;96_MO>+(RU'BC4]5NW;"LU#N?%Z
M1G\(WX]S-^2NH4ES=O132B%@]MOODU FF[F,^5QERX)LFE<H;M#7,[KMK_E<
M8<N&H6Z4]96\              >"YWZ*A[K?2/\ E+L6"K>52AUUUFN$G?=T
M^4Z$8IA"J>8N'*.-TC]K6[G%=:]!6K3@]\VU]3W6_)[QDR[KIXIZ0K]+1QT<
M.R-NUI@JZU\EKM(@
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M 4@
M
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M9JOR63/1ZBM(
M
M          !3[IANGN&YVWER?,TOQ[BH1UCDMRZ6.HM;W*YNZ+YFG1Q9IM3K
MIQ>(T#ZUVSJGB5BIV_$CX>[-Z1GS>\9LFVG7Q2TU5JEK(JQFZ-VXQ7%1Y)\G
M<1>         #SUURAM[-9'=?E]XE&.K\7NM*'<,035G=9Z-GY)OQ[:80UU4
M\UH@%2M&&9KAM<[T<?S.,F7<S"6D<EQVVS4]K9Z-O?\ ><[UCGY<U6LF>CUE
M20
M     !^?[RAJ^8BRWX]KI+2.EM]-=F4MQI:R)JLEU92-IWHDB>S1SD5"_;>R
MY_2M.DUKB[&N9LCO;WCZC:;RHGC7=/S?5_%S-QMIU[O>^=/7LQ>TFPWD/@R/
M >)XY;7235#MET:[=$_F[6/25.FQB;>JZKZW@=.?99I^)BOG'DFO?,L\,9I\
M.M^M66WT11TN,JAUT9/3S(VA?.K&Q[F(B:1L78W7QZZJ8LNQZ8JG$G.53LL;
MQC^RYP8HP1BV'_:6SX/I:RVU#H]W/DCCIX9',E]^-%<]/ J].RY=,GLJ2S3V
M\D8<^K/FCF?C"LP3@FC;:<.4[;6^Y7%VL4;(9XG2RMJ:A$_$N5FNU4T[J%V^
MW&?<9ZQ?Q^I#%$Q/)F+B>S:P!4UCKQ?K;:ZCZ'KZN6@K[C(DD#4J61,72)4T
MYB<KNNUZ'8T]+Q=N7/[NFGS,WMZ\9:^N-CBYBXD+E3T\$,\T5OJ%E;6SR;I*
MGN-8FJ>S1&].IEWOJ6"/HL7NK]OM*ONI@3=NZ>LORGSF??\ 7[7\M/OZNOAV
MGP_G_1MY\F[X&\T\N,^*S-/$-AGL>"[AAZ6EHWUFL4MP6=\4D<L3-._'L8[O
M:^\GQ.-N<]9:77$Q/&6Z(SJ0
M
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M-.2Y+3AF&WJUS_22_,<_)N:M;,=%33N^!F3
M                                               '&:9E.S<]S&M;
M\Q[I/44J3&%,VIV(U[F?.:9VE<5?-4Z>JCK&;XW,<TSU%:>2QV$0
M                                     /CFHY-%\ */=,(Q5'>I_1O^
M7W39BW=:>2&L+>K+?);YMDK=KC?%Q?BJUTXNDM'.&H?3OW,=M<5UIU%9M^)D
M=W9V[5^9IBR[7X4IM5HY$F9N:[<TQU/%)R/0    '745+*5FY[MJ"9Z^(HUR
MQ,Z1=L'=3YC;CVGQ(U:DOD623<YVY37IIT1?"P>FWVF:Y/TC;W?F]TIRY9CR
M--.2X[7A>&A1KG^DD_*]4YV3<U:V8Z*H9DP
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MU#_$Y?QU;\/V<KW,BP
M
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MXX60LVL;M0QU75:Y'@
M                             %[OB!2[IBB&A[L?II?X)IQ;:K\D-;8O
MS@X@K)EK0<^]7!C9G=V"CB])+*OL1&)JO53L[/TZLGV4_P!6;)FG3R8)QEQ;
MYBX9?1XD?@&JI\'5&K&\V-_G.U%ZO>B+W/5Z:HB'8P^G;:_HO:?2,U;C+IW<
M>UE_(GBHPYG%1QRVBX,IZ[:G-HIW;96JOLZ]'_=J<W?>EY<7VD_U7X=Q-^+,
M=KQ=%5;63>C?\WNG#R[2M/%KTM5VN;)'JCMS3&F^@
M                          #KJ*6*L;LD:QS7$INI\10+I@]\>Y].[<WY
M7&_'NNODJJ%$DC="_:YNUWY1KTUZH.)8/10W*:A?JQW=^4IO%-O>NJN6_$$5
M9W7>C><_+@J$II4"EZ ?'.1O5>Z@%+N&)&4Z[8O2.^;W35CVW7R>52BU-9+6
M/W2.W&V(B/%!U%H[*:EEJG[8VO<I55S/D]Z:J_:<(-CVOJ7;G?(8<NZ^%+2%
M;CA9"S:QNU/R3)5=5KD1
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M3$L
M                           <&U#5=H2XG5S(@
M                                           #C)&V9FUS=S?E4::\
M11;I@]DVY].[:ORN]4VX]WT\E50H%51R4;]LL;VJ;IN:\4>FKJ+7CLI:R2C=
MNC=M4JN)U\Q6[;B1DW=F]&OS>Z8LFVZ>*>EO377J&A9ZVY_RM*L>WJRJ4*X7
MB:X>+MK/E:;\6&90JGD- ^M:KNB=Y2L5>TX3DJN_/Z-GR^\9<FZF?%*87%1V
M^&WLVQ-VF"[J_)9,]'<02
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MO^UX@I[ETW<N7Y7'*R;>H7S75[RA(
M               'EN5GANC-)&]?F;ZQ;BS5"-3U6Y=L,S6_O,])'_".ACW,
MVKJ%,+T0L'NM]]FH>ZOI&?*XRY<$V32J28D@;3;V]Y[O=,NFVKDGUT4BX7B:
MXIHKMK/E:;,6&90JGD- ^M:KNB=Y2L5BUX1EJ.]/Z-GR^\9<FZF?%*87#1V^
M&WP[8F[?Y1@NZOR63/1W$$@
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MG%]2_P 3D_'5KP_9RO4Q+
M                                           =<E0UOAZQ+BCR=$DB
MR>*DDGP*W*.9T:_DE:QZ(YDD\ .0
M                               '364,==#LE;N:3BZCQ.B@73"+X>_3
M^D;\OO&_'N^ODJJ%%<US'Z.[KC4@^%@Y2^#/S4(:?6]U^MQ)O'OM>'JBY=4;
MRXOF<9<N>82F>JY+;8:>W=6MW/\ F<<_+GJUDST>TI2
M                                                '3)5;>C27%'D
MZ7.5W5223LBJ'-\>\1XH\G<R1'^!%)R  =597143-\KMK2<15^)5+;OV..3#
M(YCFT\,;=SI7=WHAOP[/XE-6C'GYV@V'L \ZBP]MQ!=VNVN>UWH(NG5V_KJJ
M+[-#Z79>B9<G=E[98<VZG3Q1PH\,YG\:>(6U4O-JJ:-SG-EEUBHZ9?:C/%$5
M3O:Y-GL)X_\ MDTTRY3&O:0XH[.'BAPGE/)%^$N';E'2435D=L=32/E<BJU.
MOCNT/F][AP;NN=3QJFW%58^Q/OADXYLO.*JW3.PQ?J*HKJ.H=1U5+O3F13-]
M9GW'S>Y]/R8>[ZY^]NG+-,P5%3'2PNED>UD;4U<Y5Z(ABTTZK$4.*+M9LOLD
MZRXV'#]=2XFQ;0TCJU]'%,C8VPM]=V_KU3ITT^\[NS]$R7WY^V?[L>3=SIX]
MR'_!/G]B'M;J^_5>.*ZJH8J.HF904]/,KH*-49ZR1]$^74[^VSQM,'/!/'_?
M^K+<7DKA5*SBS)?,K@_OTEVMTE5'0]-U;1N5T4K$?T9*G3Q7V'8Q[O;;V>-?
MEJRZXLN)G+('M%+7B;DV_&+66FO<Y&-K&?B'?6_PV?OG)WWH51W8.Z6G#O.O
MDE7A7,)ERM\-1#4,KJ.H:CV2L=NWHOO:GRVXV7_YIT8RKJH+E#<&;HG;OR?>
M:<V\=1Y+9KJ]!!Z
M "FW3#,%Q[S6\N7YFFG'N:A"HZK;N5GGMK_2-Z?,WU3?CS3?BJUTXO*:   >
M^UX?GN6U=O+B^9QERYYA*9ZKCMEAI[7U:W=+\SCGY<]6LF>CW%*0
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M][>?&C+GYXN+<WPW?W/V"?UDI?YEI\)ZE_B<GXZNOA^SE>IB6
M
M        #C),D?B!T25#I?S0.!8K    !V1U&WHXCQ2Y.]KD?U0BD^@
M                                                          >.
MY66"YL[[=K_8YOK%V/-4(U/5;ETPW46WO(WF1_,TZ&+/%J]8XNBEMTUPF:V)
MN[NIWO=+*RS'D=.2OVK"L5'WYO2/_@F#+NZU\4](59K49T0R)OH
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M3C#<C6U/^6T^=R[7X6O2U=AJ&5#-S',<GY)BJ>BUS(@
M                            ?'QI(S:YNY!IKQ%$NV#V3+OINZ[Y?=-N
M+==/)54*-'8ZJ2IY21NW?P376:=)Y(]-5>M.$XZ--\WI'_P3%EW=:^*S2%7:
MW;T0R)@
M           #JDJFM\"7%'DZ72*_Q))/@5@  !VQU3FIHXCQ2Y.YKD?U0BD\
M>)/[':_]3R?R'$\7E+S7Q:4.+*WOLN#Z%L%XI;2^EQTV=]910^BHUFYSV++
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MV_4Y5_,W5<-W]S]@G]9*7^9:?F/J7^)R?CJ[^'[.5ZF)8
M
M  ^.<C?$#IDJMW1I+BCR=1)$  ?'?5X@67D3FQ#G1@RHO-+MY$=QK*!O=5KM
M]/4/A?X_6QP%Z@  !'*WP"QW1U7L<I'BCR=Q%(
M                                         <W=T4#C'&V/U6L;^:>Z
MUU'(\
M         #C)*D:=0.B2H=)X=UI+B.!)6     !PJ/Q#OS5/)$/<08NN&$\R
M+I-0U$L+FU4G=]UW7X'V^''-X)Y?<YU:\:9!PKGI:,:4WT??J6"-9-&NWMWQ
M2JOVZZ?>8\FSK'W8EVF6=?)>6!<O</8%H'-L-MHJ.&9RO<Z#O;M5U7KU7Q,N
M;<9<GVM+8B=/%7BM( P7Q-<!."N)"^4=\K[? V_VVHBJJ>J=KW9(W[T=^ZTU
M[?>\.VNZ5%X>K59Q;]FGC/ACRNS(CCIZJ]4^(*]*RG=!"KY-%D9(_71/9M<=
M")Q:X*]E7E_RSUSY3R1]Q1@F[XBX,\K;=16VMJ*YMTKM\385W1?HMZ=_X?>>
MZZ=<''^*7O)I\)O9@XKS.S.AQ-50MIZ3\'XK'4,G[L$2*FCWZ_WQ.[T6-5&Y
MW.#;5-9:_=]7[T8QU7@V2<*W!;A/A7PW'2V>G8ZLV;'5&W;M3Y4TTZ?6O7ZS
MYC=>JY<O;/;/W.ACV\PRO-3\GK[HP[CF]J>CJ-:*DXPP+:<?6>:@O%O@N%+,
MU6.9*WW5^"^*?<2QYJQUSE"HG7R1.SR[.6LM=5-=<#53I&M<CVT#Y$9(U=?[
MV_HFB?6NI]+L_79U[<_YL&79].Z5GY0\9V,^'^Y?0F)Z6JN5!3N5CH*IJLG@
M1/D5=->OM74T[GTK!N)]KB[5>/<UC[:3)R3XE,/9M6V.IL5RBYVU.;2RNVRM
M54ZIHNFNGQ0^4WWIM8^W++I8MQ-^++%KQ5#7=R7T,O\ !.)EVE1XM.EJJUVJ
M:H94WT
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MF+E7E39]PW?W/V"?UDI?YEI\9ZE_B<GXZNKA^SE>IB6
M                                                !ZO54 ^1R)(Q
MKFNW([U7- ^^KU5 /C'-D9JUVYH'T     .J6J1OJDN*/)T.<KNJDD@*P
M 1@X/<Y,+9%<(MVO^+KY06&T4.*+^^6HJI-NU/I6H3HB:JOW(H6::<F-,!]K
M%C/BTSVI;%D-EC+BC!%#<74%[Q;>)%I*&!-^C)H=JJY[%1KE]7<G3H0Y+:P\
M)[DZ&;MC=^S?M[VWU=Q-F<@  #['(L?@H6.^.H23HO=4CQ'81
M
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MV[HOAT\4^\^5W.RZ5PN>-.G&7KXKXMM\I[DSNNVO]YKCE9,-0MFNKVE*0
M
M                                 'EO%Y@L-MDJJF3EPPMW.<3B*NN,
MHU718Z<3F$Z>;EU=8^C7=M]*U?Z-3;KZ7G^%5^TXWI_U3&!O_&*B_P F3_00
M_P"F[GX3]IQ?$^?ZI? O_C#1?Y,G^@?]-W/PG[3B^(_U2^!?_&*B_P F3_\
M!'_3MS\)^TXOB<F\2N!G]$Q%1?Y,G^@?]-W/PG[3B^)=]KO%+?*..HI*B*HA
MD:CD<QV[HO5#'<5';2Z:ZO2>/0 !\=(C/$#HDJ%?T3NH2XH\G621
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MR?CJUX?LY7J8E@
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MR^U[]/%Z^*K[5+&2JZKL"(     '-E0YOY32/%8[XY4D3H1'(
M
M                                                    =4E0C>B>
M)+BCR=+I%?XDDGP*P        !PJ/Q#OS5/)$+,QO[/;M^JI/XS[S:_93^#F
M9/-132\ $<CHW-<UVU6]YK@,A8!X@+CA]\<%R<^NI-W>>YVZ5OW^TY^;93?@
MLC-T9DPKCBVXRHVRT-0R1VW<YG]\;]J'*RX:Q^35-]56() 'W=TT(=-1\)@
M     ##>>W!3A/.;F5<4+++>)'.?YU3QIZ57>+GLZ;UU]JG2V?JN7#V^4L^7
M;3:)]XR]S,X,\1.N%-SZ>E<YNZJIG+)23Z+T:_PU^S\H^DC<;;>QQ_\ ;!K&
M7$D-D#VAEDQLD-#BC;8[INVLGW>@EZ>*KTV*J]--%.'O?1*Q]V+NEJP[N=?)
M*+#^.FU%-&_F-JH)&HYLK7;NBGS.;9_"WS:YJ.X0W"'?$[<ASKBH\ENFKN(/
M0
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MW@<-W]S]@G]9*7^9:?G'J7^)R?CJ[F'[.5ZF)8
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M?+Q7VWU.OB8$P       #MCJMO1Q'BER=S7:IJA%)]
M
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ML<JO3[UFJQ>ZN]M.GDO(YRX
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M_'5]!A^SE>IB6
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MZK6M31#YFZY4UJH>          )(L?5 L=\=5NZ*1XH\G:12
M
M                                    #Q7S$5!AFCY]PK*6CAW;6OGD
M2-KE^5-2S'CK)VPC5='J@JHZR%LD4C9(G>JYKMS2&NG1)S/   ?'2(SQ Z)*
MA7)HA+B.LDK              <*C\0[\U3R1"S,;^SV[?JJ3^,^\VOV4_@YF
M3S44TO      *MA/'5RP;6MEHJA[6^\QWJN*<N&<GDEI?%F; &?UNQ-RZ>OV
M4-8[1O>]1R_4OL^\Y.;8U'=+3&;JO^.1)&-<US'-=ZKFF-:^@         %"
MQW;\/26WSO$$-N\VI>_S:K1K6Z?6O\19AK+RXXE=Z3[R-6>':,4%CAFM6!Z-
MLTC6HQM:^-61-3V[&=%U3]P[VS]#K7NS_DQY=Y[D,"Y*X\O&8'%%@VOO-PJ+
MA4S7RE<KI7>U96^">"?<=;>X8Q[/)$?=JS8ZZY9Y?>VV'Y.^A
M
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M&[^Y^P3^LE+_ #+3X?U+_$Y/QU=;#]G*]3$L
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MT/'@          <HY71E:QWQS-D^T#F
M
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M,
M                              "T,ULSH<#6WDQ^DKZANUC/E_*4W['9
MUEO^53FR\& JRLDN%3)-,YTDDCMSG.^L^GF>G;+!5<G620       =<U.RK8
MYDC6R,=[' 6IB#+&.;=)0NY:_([U2R<B&L+-KK;-;9G1SQOC>WYBZ:ZJG02
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M[!:>]]"4G\TTXGJ7^)R?CJUX/LI7N85P
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M
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MZX9/[HO!/Z]TG\ZTP>I?X/)^&JW!]K+<$?D3Z,
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M3/:OS55APY])X-S#M].M5487O3V+//"W3?-2RL79.QNO>]5[?%6(WJ!.
M                                   H>.\;TN!K*ZIJ'(Z1R*D,2>M*
M_P#T?$OVVVO+?&4+OBCOB"_5&)+K-5U+MTLSMWYOY)]9CQSCGC+FU7)XRU
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MZZ-9M5O1R*J]SV%6'U79[ROI^VI^K5.\&7'XHQV/,#%UXRNR]RYN5=:;YA3
M]YDO-HNWG"MK'1N@FA6-8MBIT69W7=[NFAT\.PC'N?;S7DHK)UQ<6[KAS_M!
M8*_66D_FFGY]ZC_B<GXZ_P"KKX?LI7Q'4*WHO@8N*[D[F2(_P(I.0
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M55             UVWJ@';'5>QQ'BER=S7;O BD^@
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M455';>9YK Z.KF@1L>]SG:*D35ZN7KJ!(0
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MQUKU>8F\   "^N&3^Z+P3^O=)_.M,'J7^#R?AJMP?:RW!'Y$^C
M                      !^>GRVVAOZYP9 553#.[",5INL5.]C51K:M9Z=
M:AN[JB*L20:?FKX@;I. [B5R+SSX?\*PY&8DP?682H;7!%;K1:*J)LMG@:QJ
M)!+3(O,@>WP<US477Q^('S+#LU<CLE^*[$>=F%\N[#9<Q\54J4M?=*:':WJK
MEEEBB_%Q2S:MYLD;6NDV]Y557;@SF!^<WM;?]]SY'_LGP-_TR$#]&0 #\YG'
MA_ORK ?[)L)?YOI /T9@?G^\N+_W9X9O\1B?^5:0-Z/#U_: P/\ L?M__1V
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M?\3D_'7_ %=K#]E*]#(L&NV]4 [HZKV.4CQ2Y.UKM4U0BD^@
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M;)))V=QNKGJU611M5BHG4(M^6%?I1#?V;VK^;J0,X^3?_I*&0OZUUO\ G.K
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MN-=3Q3/J*EGXB!8]O1-?7UW=%1=#?D]+S8\'M\O;]7]U$YXUKA+)QA6
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MO\WT@'Z,P/S_ 'EQ?^[/#-_B,3_RK2!4,N?(N;-CO+VPWIW$7?:5;Q;J>M=
MW",;FQ<V-LFS=YXFNF[370":G8X>3U6[LBN('$F/*3->YX^?B+#TEA6BJK&R
MWM@1U33U'-1Z3R:KZ#331/6UUZ 2IX^>SERG[2O)UN"\UL.K=J.EE6HMU?2R
M>;7*SS+T62FF1%5BJC6HYJHK'HU-S7:(!J6SI\BHIK-63W;)[/V\6BY4KEEM
MM+B.THYS7IZNM;2R1JQ4^=M.OYH'5Y/%VEV?&3W:,XAX,\_\073%U52/N5%:
MZJZ5RW"MM5QH(WSR1LJI%62:EDIXI7,1RKMVQ[=K5<@&^(
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M/Z+W5(\4>3L(I
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M     "^N&3^Z+P3^O=)_.M,'J7^#R?AJMP?:RW!'Y$^C
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M(FME6*-(]VGFJZ:[== );]DEY2A8^U:XKGY6V_*6[8+J&V2JO/TA47V.N9I
M^)O*Y;8&+UYOCK[O@!8O;D<77'%P!<8N%\V<MK+!C+AWLMO2GJ[+;[?)4Q/?
M(UOG/THC-9F/W,:L-0S2*--&KWG2-D#&+_+;LNW9>NGCR+QM^%KH-6T#KU3+
M;^;IT;YSMYFS7V^;ZZ>P"V_)W>!+.3B>[2C%W&YG'ANJPA17:2ON-AIZRC?3
M276JN#'Q*^FC?Z1*2"E>^-LCO7WQ[5=H]4#?*
M            !2\;8HI\%X5K+E4R<N.ECW;MJR=5Z)T:BJO5WL0&C#>=F&9L
M'\//*N+J?Z9NER;7W'D5$DL#JE_63E<SO)'KX)HB)\$.QZ)/_P G^C/NZ[4>
MS[!SW%\;9&;7-W-=[J@=5M=68;J>;;*CEL<[<^G?WHI?R?J^XR7M_A3F_B75
MA7,ZFO#VTU<WZ/K6MW.:_P!1WQ5%^'V]3-UZ=MO:E=#7:IJA8K?0
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MO$'Q?X#P9F7PB7G >!,07%:>\X@EP3B"A9:H>6]_,6:H7E,ZM:FK^G> V]
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M\U3R1"S,;^SV[?JJ3^,^\VOV4_@YF3S44TO'S ??XC<#HO\ X1/_ #$I'/\
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M5>J)]I/;75SRI&YXLA<,G]T7@G]>Z3^=:4^I?X/)^&J>#[66X(_(GT8
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M%@      #LBJU;T4CQ2Y.]LB2=4(I/H
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MY@G%%AHZRMJI,,UFQKI?4:S1O1$^W<<KUZ,5U[?!X_5K^*W9U6G;2<!\^U@
M               UVWJ@6.Z.J]CE(\4>3M:[5-4(I/H
M
M        #C)*D:=0.B2H=)X=UI+B+;S$RSMF9=J\VN$;_1]Z)[.ZYBFK;;K+
M@KE*FXY([9C<--]P;,Z2CC?=*/IM?$WOM^U.O[I]/M?5<67MKMICO;UHQYF!
M"S*^LM=/?JBEML]Z=MHXIY$:Z=_R(B^WO-Z&N=UCUKCR5^RI'WB/_L\C_P 0
MW^-Q]#LOLF//Y,8XBQ);\(V>:ON=53T=)3MW/EE<C6M^]355<5*'/%YQ*8;S
M@6&V6>W\Z6AEW-N;NZ[3WV(GP5=O77W3X_Y3UBR8.7'NG7ZW4]/Y:96 KA=*
MBNK&K432S-AT8W<[=L1/=*L$5DV,S\6CW)7#/R_BZ:R9)GM5ORCTK9UM\7'+
M][S=YIR5SETG49P   N[)/,[&&5N/[?7X(N5QM]^Y[64OF3EWRO5>C$1/'5>
MFAY<SQ[GLMU/#/Q:8_O^ \/Q\0%.S">):.L7E7*@=R+Q! F[>V6-=71:KL75
M==VW4X6;T*=SW;;_ ,?T;(WG#MRICY-\3DN8F$ZJMK:>GQ7A6JNSK?17*V-Y
MKY8G;4B<^!-5T];=)KI]1\WEPY-O?=VMVE3?BC'Q^=BKA7C6PQ^%V5&(HK5<
MY&2.91N<D]KK%3=HQB(K>6_?N17:NT^'0ZF'UB[X^W_/][/>VZ>+2[Q-<%./
M>%7&%1:,88=K['41^H^>-6P5B>&L4BHB2)K\#N8=_%3/+WF2\'PL130OIYG,
MD:]KV]US7'1FNO=+/6G1P/1\D8V1FCF[D J^5^:U[R#QC#>[#5/C1KD;44^[
MN3LUZM7^CZR,76*N4O>/-^F'L_\ .*LSXX/\#XKK8XH9[A1(QK&?WID:-8QJ
MK[5T\5]IP=_BF,]3/X_G\[=MZZPR=C;B$L64=-&Z_P!PBA6;\5%N]/+I\B>*
MF*/3:S_92LK-,>3(=+4-K::.9GJ3-1[?L7J<>IXK78>CA4?B'?FJ>2(69C?V
M>W;]52?QGWFU^RG\',R>:BFEX^9?_P!T;@;]43?S$I'/_A<GZ_>C'VLM6/'M
MV?N9O#OQ;W#%MZL<LV&,28KEN5/<J/66")DU9S&,D>B:,?H[P4RX-Q-XN/\
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M_G6E?J7^#R?AJ]P?:RW!'Y$^C
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MJNT]                  ^QR+'X*%COCJ$DZ+W5(\4>3L(I
M                   !YJ&[T=RFFBIJJEJ)*9VV5L4B.=$OP5$\ /2
M       'FMUYH[MS%I*J"JY;MC^5(DFU4]BZ>"@>D
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MNW23BVH:.AS,_".H2CBIW6QT?T7YO3<I?]KW.AUYWG'BN_X]-H$J@
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MQ+J@                                 =<E0V/I[1T'3),LGB!Q+%8
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M[F:;W\MBHO1=53J<_+LZS^H?2^,_.NG),8.U)*.-(V-:UNU&]UK6GTS$V<<
MN?$6:62%MI+A7127JTM\U>USF,<YC>D>B)\&;4/S+U[8>PW-5$]M.WM<W.6>
M3B-(                   '..H=%^:5K'?',DG@!R
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M:-G@IUZP1UCF>CDJFLZ2.C1&ZZ)WG(Y[PD8
M       .J2H1O1"7%'DZ72*_Q))/@5O+772&WLU>[<ORM)QAJWNM*'<+[-7=
MU/1L^5IOQ8)A55+&S4SJPWDW9Y*N^W*GI7>JR#=NEE7371$3735/:NB&_;[7
M+GKCBE7>68\FNSCD[9JGL]!-;[=-]&T[N8QM'3[)*RI37HKW=4C5OU.3UCZ+
M;^FX-OWY>ZF"]Q5^#$G#/Y0A4U%UCP[FSAFGN6&*K?3MN5%(L=PH62]R14E1
M6N35-NJM77NG,W_I&#/W8NUHP[FH\FS[)KC0L^85BLM1A"Z19I8:Q$WE-IXN
M6VY6UB-T>DK';&K"UB:JKM7NZ^/0^3W.TS[>N]T8N<C$?%SV.N2_'W05>)<"
MUU)A'%LLDG-J:&/;3U+X]8E9+3N31B(Y.KFL155OCU-&W]1J>R^Z?[HWA::^
M,_LS\R^"K$TU'BFPSMH&M<ZFNU&U9:&L1JZ;D7JYFN[^^(T^FVV^Y^'=_KHP
M7AZ([U5')0S.9+&]KFNVF^,D5'*6?73IY.HF\ ,@Y&\,.,^(:\-IL.6>HFIF
ML66>METBIH(VJU'NYCM$73=ZJ:N^HCK?%[I*9>"^'')[@?IH[Q?KE18RQ10R
MQRLN-4U?HRCF9U1]/#HCID5?%)F*G=3IU4MC9U?=G[9^[]_]?_"-9>GBP?Q$
M=HW>\PGR4.'>;;Z%K71-G<U-S6*KM4C8G=C9WM4T1--QHUSQ$\<7:CPZ^2-5
MRNE3>*R2IJZB6JJ)/6?*Y9'.^]3-5=4W01 #ZURQ/:YKMJM[S7- E+P=]JUC
MOAANUEI[NUF.,,V6?GT]MNTBRMIGJCF*]BKU5=CG(B*NTQ[O88MQYKL6>H;?
MN #M%\&\1.'6OP-BZ.VWR2JJY9L*7^3N.?42\U',EZN[B;FL8UVW1WAT0^6W
MGI.7#W3W2Z&/<S;+/$9PBY4=HQ8:FQXUPS+8L81TJ2MGY:1W"@1Z+L?S8UY<
MVBM=W=SD3VHFO7)M]W>&O]M4[Q]6M/.?L"9>&W,*2^7JY4N,,'QU7-@@I9.1
M.Z%NU595:[-$=X>AU4^I])W'MZG'X_K]S!N8X=R]<O\  ]]S$\SPO@^Q\FW-
M>K(*"W0I% WVIS']$>J)TW2*KM/:?4]-MM)Y5^;G]V3M3)X=>R_M>'X:>YXY
MF^E*QS$=]'1.5L4:KM7JJ:*JIX+UT/E?4/E/5]NV[?XMV'8]/)+.TV6CL-&V
MFH:6GHZ=OJQ01HQC?N3H?)W=7W4Z,SQ>H/  !CKB)X4< <5F#Y+'CO#=!?*.
M3U7O;LGB_,E;I(S[E+<.XRXJY2:Q.ODT_<;7D^N8/#/65&,\DKU7XBM]&WFN
MH&3<BYTR:N5^BIM:L:,]FY7+UZ*?2;3UJ;[<O:PY=MT\6,>%WM@+[D3F+98\
MU;'=+M485G<QSJ>-D59UC='MD8Y6IT1WCXJ=B^_!43[S-.O2N3<5PP\:F7'%
MWA*&YX+Q)17"5T3'5%$YW+J:9[DU5BL=HJJU>BJW5NOM/G,N&L?DZ&ESJM3B
M0_MF2?J>+_K'8V'V3-F\EB&Y6  -97;A?VU,*?J.7_J%U?93_577DQGQA?W(
MF1/ZS._C<>U]E_5'WW+B._N \E_S:C^?J!_VOZGOO!C']+CP?^O-1_.3"?LD
MF8^PZ_L[Q9_B(O\ K%#V6RL)L&\4O]EEO_4G_7<=38>+-F8LKOZSF_,7^(Z"
MAK5QO_;JN7ZZ._G#Y[+Y-4LP]J5_=2S_ *UT_P#UR>?W?P)>SM0O[;>&?V.4
MG\AHR>,_A_N>^[NTR_W2RS_8C1?S$0OPD]]*W ?]IS '[%[=_,-.GL_LU.3S
M9(X9_P"Z'P3^O=+_ #S2OU+_  >3\-4L/VLMNY^3.\[(ZAS>B]XCQ2Y.YDB/
M\"*3D                    ##G:)9E5&37 )G=BRCJ'T==AO =\N-+.QVU
M\<\5!,^)R+\=[6Z?6!J)\B*RWH*?++/S%ZT\+KK572U6=LZIK)%#'#42JQ/@
MCGRM5?CRTU\$ G7Y2QEQ09C]BSG0VMIXIIK'2T-WHGO;UIIH*^G7>SX*L;I&
M_8]4 P]Y'QF948Z[(QUJGJ'S,P;C>Z6B!CG?B(WQTU;M3ZE?5O7[7*!J_P"P
M2X],I>ST[6;/7%N<.+&8.P]=;7>+125;K;65W-JG7FEF2/9312N3N0R+JJ(W
MNZ:ZJ@&YK_9// U_Y=(O^:=]_P"Y 34RES4L.>65V&L:X5N'TGAC%UKI[S:J
MWDR0>>4E1$V6&7ER(V1FYCVKHYJ.3P5$4"X0 %G<0W]H''7['[A_T9X'YN/)
M4^TUR/[..XYY29T8X;@MN,(K$VSN=::^X>>+3+<>=_6L,NS;SXO6VZ[NFNBZ
M!(+RDWMH^&?CU[.F' N4V9<>+<5-Q707)U$EANE%^AXHZA)'\RIIHX^BO;TW
M:][H@&QGR;[]).R%_6NO_P YU8&M+ML)_P#7,_*3,C>'BGUKL.8$DMU'=Z9O
M?;Z7_;6YN3V?U@R!B_!8NOP HW&[,G96>5EX)S$9_M;A/-2NH+G6.]6!M/=(
MWVRN>]?;MJ&RU"I[.XOP _07F'_8!?/UOG_FU _,[Y*;VCF2O9[8MSMJ<X\<
MTN"H<54=FCM3IJ&KJ_.W0/K5E1/-XI--O-C];3UNFO4#-W;[<?&#>W0_J59
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MT@]GL#]$@&M_RL+])5Q]^O-E_P X0@>_R5O])#RK_5M\_P [U8&Q$
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MWW8/R=''N^GDG!@W'%HQ_9(;C9ZZ"X4=0W<Q\3MW0^6S8*Q5QRMVESKXJL0
M                   .V.JV]'$>*QW-<C^J$1]
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MYYI7ZE_@\GX:I8?M9;=S\F=X -7;X =T=5['*1XI<G:UVJ:H12?0
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MN8OUM4"$OE87Z2KC[]>;+_G"$#W^2M_I(>5?ZMOG^=ZL#8B
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M^9_Y)7=SIY/9GJE?@U^W#%!$KN_3T\<3_M1$13XS<3]+3J1XJH5)@
M                     'E=<V2321L=WXW;7$^%:/.3BYV[JIZ@
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MGR)N=TUU9X:II[=#X_U#TK+MJY>4_>Z.'/.1F4Y:X
M#XLG+Z[MH'*WW:*X321L=N6/UG"\51Y)375ZRM(
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M3F /V+V[^8:=/9_9J<GFR1PS_P!T/@G]>Z7^>:5^I?X/)^&J6'[66W<_)G>
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MJUZG8PZ<L4J-?K>NVXFV]VH_RBC)M/A>S:LPSLJ&;F.8Y/R3'KIQ2<SP
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MH5=>)JY_>=M9\K3?BPS*%4JF!_ZXJ/S4*-]XRG"XCG+0
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MX&U%=AB\5"15=&QD?+6&EW;51-W?5ST>B]43Q0^6WGI>7;_S2Z./<3;U<0?
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ML7^4A9[.WO(\\A_PL7^4@]G9R//(?\+%_E(0XT<G*.9DGJN:[\T\J>+QS/0
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M/)GD*1<,3;>[!_E.-F+:_$C5O-A^H?47Z%SW;G;OZ"[//3$0NXY2X
M
M  !2<9?[EM_QB&S9^:NU#M]^FH>Z[TC/E<:LN";5S2NT-TAN#-6.[WRF'+BJ
M%NE/25O         !0,Q+M/0V!M+1N8VONCTI:5TL+Y(MZ]5W[=-$V-=UU3J
M$I$RPL3L)4MDDM\4UOHV-BBB?J[:C4T3KX_OD\>:L=<I>:Z=?)A7-#A/J;2R
M2LP_(^J@:U7O@>Y-[-.JZ>&OU)XGT.S]:F^W.QY,'3Q8<KJ":VU+H*B&6&:/
MNN8]JM<S[E.[IK.O=+,ZR8  .BXUS+;035#]SF0L5[FM;N<[1->B)XJ>5701
MFX\N&O&'$IPJ1T6&*>@KL256((KY4,YBT;GTL=/,R+\:_P#&-8]C5:G55]AD
MC3I7M:3OY^V4>^RWS^S@M>>M/E==FU4EHA@EK:R@OE/)'4V^%%;S'Q[MKD>N
MYOK:I]1;7'3OE#1LD+QQ<W=T4#SP4LUGK/.;=,^EF]YG]ZE_.3_1H9KV\Z^#
MV;7-A_-2*2:.EN\?F=3M3T_]XE7VNU]S[U,U<H\D^G7Q7<UR2,W-=N:[WFDE
M:Q,^LY*;*G"[MLC772L:K:>)OK?G_8AJV>VK-7\J&6^B&]RN4]XKYJJID?-4
M5#U>][O6<JGT\SQ8G73_ (Z+\YIX)GX3QA+:[;3Q2-YD+6)M:WNN;T/F<N+J
MZ$TO"VW>GNL.Z&3=^3[QFK3H+8SFS<H,IL,25$\FZLF:K:6!OK.7YOJ1/B:-
MKMJRT\N^B"N<&=EOP_YY?<3W2*%\C73N:^3TDJ)XM8SQ7[$/H^W#+%]:(&>G
M'W=<4/FH,)[K71;D_1COQ\NGPUZ(B_!4U,&;>57BMTQ,Y=G[<JB[<+59/4S2
MU$TF)97.>]VYW6GB);+7K5&7Q9?IZ=]5,V.*-\DLCMK6M;N<Y?J0Z55Q4)6\
M%_ MC"JQG9<8W1SL/T=MJFU$44K=M3.B>.B+U9^V0^7]9]=P:8JP3W<OR;]M
MM*UKDG^U$;T/@G5?0+!STS>_J9VV&*%K//*[5K'N]6+ZU0Z/INQ]O?=XRJS9
M.",&+,07+$UU=67*9\TLWJN=ZOW?8?6X<4Q/&6&JZJ8V3:QS>XYCO6:YJ.:[
M[47H6U/5XBOQ?=E1@_B*?47?"O(P?BJHEWOVM_0-3T\%9XHJK[=41!R^)#64
M&<Z.%W&?!EE+>+=B2W^8W?$5:E&Y\4S)63T#>_JNW7361C50HW6;V>#VLK,&
M+GEXN>3O#W9[-:J&Z5O^V%=-%S6[_P 4W=U31/'5#N[/;3K,Y:]Y@S76E<4A
M+A:\/8+P'^&5UI>=] VY*C<FOH&1(Y^K$3VENYUQ8YK/7NO<7+7M1:R7RIN'
M$E4UV/:B.VXBGNETJJ2JIZR;8VWTL<#9%F75R:*K'.2-/>>W:B*JZ'YE66=S
M63/GK\'=X^SF9AN#[-'@UCRAR9M,5!;7R7VZ1.?55KG/]+"Y[I(D?JNU-(]B
M>SU3+EW.7)'&J\5FD3IXISY7Y5QX%8ZHFDYU?(W:YS?5:GRH4"\7N:UFJ]UH
M%'O6,(+8QRHYC6M]9\CMK35AVM6\UOHQ3CC/9KGNBM_Z(EZM=*[U6?8=G!L.
MGDRWF8TNEZJ[U4NEJIGS/=[SCI3$Z>+/5=7E)O'@Q53MK,,W*)>\V2EE9^ZQ
MQ+'\U&K[AES'X>H6Q]YK8&,;]R:'F3S-%[82RIN.)6-E?^A:;YWM[SON\3+D
MW,PLG%U90PS@>@PK#MIX=S_>E?WG..=ES5;5,='7<L:-=6>9VR%URKG>[%WF
M1:]$5ZIT0\X=)Y9>TY_"]E#ENM1,VLQ+5></:NYE%$[T3.FFB^U?W3/KNJKM
MP3_5[[/XE<FNC8Z9L%+&REIVM1K6M^"$8V_O7W)==7IP?WKQ^T4ANOLGL+K.
M6N                            67?FJV\5"JWUGJ=C;_ &4J-?K>,T/'
M;2ULM&_6-VTJN(OR>]=5;M^)(JKNR^C?_!,&3;5IXI32IM=JFJ&=Z^@
M                   #KJZ2*NIG131MFBD;M<Q[=S7?:BGDUQ$>L_NSWP_F
M4^:X8>D98;K)N>YC=?-IWNZ]4ZZ?M=#N;+US+B[<O=+/DVTZ^*%.;&2&),G;
MW)1WNVSTZ-[S9]NZ*5%\'(J=.OP\3ZW;;S%GCEBIS;QU'DLJ;Q-NGUHO/-XG
M@N#!>;ETP2]K&R>=4O\ @I>]^XOB0O#.KW2^C);;QA7/*U-@K-\,[7(YKFNV
MSP:^.FO=77[RC2LN*NU/I-L#<45KN'#79&W=+3<L36EVNZ6VM1[H-/=>Q=%\
M.JJB:?6;)]1GWE6N&D2L6=I4^.ITLF'>Y[WG[MKM?VJGFN_^%Y[-CO%7'ACV
M_5[I:*L@M,3O[Q!"R1K?O<BJ45O,NKWV4L<W[-S$^)*^2HJ[Y='2S.W.V5#X
MV_N(J(45EO5/BI>&\.U^-,24=KMU/+77*Y3-IX(F^M+(]=$;U^*N]I75=.ZG
MLRVH\ /DY=?B:FM^)LZZR6TPN=O;ARG<CIW?!*B1-4V.3JG*=KX:^T^<WOKO
M3MP?FW8MK\39?6=GWDQ69-)@1^7^'VX<DI_->5YNG/V*G72H3TR/3N]5=]YP
M?VW/R]KR[FSV<<.+3/VLG9&X>X(;4[$^%L;4%9;:B=K/H&LD3Z2@WKXL1J:+
M&GUKJ?4^F^J5N.VI_JYVXV_! @[+.OK(W/R]Y&XGAK;=42^;->CI8-W=<GU?
M!?L+8R=$:GJWL]EGVJEISVPW;<-XBN#/.G,2*BK97=YRITY,OY:>Q?!=J]3Y
M_P!8]'Z_3X/ZZ-FVW/NTGPUV_JG@?+-SZ             #HK;A%0LUD=^U)
M1CJ_%[R42Y8BDJN['Z-G\(VX]M.GDAKJIKG;NJFE$+!<."H'QOF>YKVL<U&M
M.=O-4X5\P+0
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MY9CS)E<5IPG'1[7S>D?\ONG/R[NM?%;I"K-;LZ)X&1-]
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M>-GXFK[O<*&7Z,O24L'+@FV1Z,Y;NNGCU W69E8NPMV9G9]7*Y4T-5-A+(_
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MZF-^(&YORS7]*GPK_P I5M_S?<P)V]D[^E:\-?\ R689_P T4P&?P
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M/ OAK ]RQ='#<+C<K/2OH98(*AO*=OFI(IEUT5?55[FJAR=MZKGVD5@Q??\
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MTC/X1FR;:=?%+356Z.NCKF;HW;C%<5'DGR=Q%X
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M?R3%6O+R6N9$
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ML=M7IZR=#Y7=;'VG+%7VD_W=''FZ=WNIC4->RX4S9&>JX^3R1PKBWZ4[R+P
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M W?\+G$Q@_C&X?\ "^9> KE]+84Q=1I5T4[F['M[SF21R-]R1DC7L>WV.8J
M?E-[#SM9W=DQGUF5B),M+MF7^%M!';O-:"X>9NH^74+)O5>3+JB^&FB?:!*+
MCT[=?-_M]\GZGAPR2X>+W1NQ!54M;?/-;D^\U4M/3U$4D:/VT\,5)"E0V!7S
M2N5O=:W5NO4-MG KP$5G9L]B;<,KKO54M=B6CPE>KG?IZ=VZ#SZI@FED9&NB
M:LC1S8D=IWDBW=-= ->'D.7]8\3GY^%OXKP!*[ROK])\K/V8VC_[\!D/R=7]
M(*RA_6B^?YVN(&@[L(NV6H>Q\QMF+=:W+VXY@)CBBHJ1L=)=&T+J/S>29^JJ
ML4F[=S?JTV@25[1_MJ<X^WVREM.0^3G#OB6VT%XO-/55\L%5)=YZY\.JQ1*]
M((H:6)K_ $CWR.5.XBJYC4=J&\KLA^"6K[.[L[,L\I[G/3UE]P_12U%YGA[T
M;JZJJ):JH8Q??9&^9T37>\V)%T34#&'E(_Z25GQ^M]O_ ,ZT0&$?(]OTHB3]
MG%T_FZ4#:@!K^\J/_2-,ZOS[#_GZW 6AY)-^DTX6_9'>/^D@9/\ *1;U66/L
M2L^)Z)KI)I+;;Z=S6_X.6Z44<B_=&]R@8"\CAH8J7LF;Q)&W:^JS!N<LKOF5
M*2A;K^XUH%X>5IT4-5V,V*I)$W/I<0V:6)WRO6J1FO\ DN<!@[LX;Q57/R.S
M'D=4QS8J' N.:>E5?[['S[B_7[GO>G[4"!^3/!)_JJ/)5<4XNMM'YQB7)G,R
MY8HIW,;K(Z@6DH8J^/7W6)$K9W?J5 ,U]K-QM_ZOCR6_(G&M96>>8FMN/;;A
MS$;E=ND^D**VW&*223\N9B13_9.@&Z7LG?TK7AK_ .2S#/\ FBF S^
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M#DW4SXI3"XJ&VPV]FV)NW\KWC!>2K\EDST=Y!(
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M]XP7EJ_)9,]'I*T@
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MX<^S5PWENRGN6*7-Q!>&M7=$[NTD2JK5143QWIX:ZZ?4?(>H_*3+E[<';/\
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M3Y]NGA7B)P/;YVY89GU<URK;=2MVQ3LE>U+Q;?8W55>VHA1>ZUTD>B>B4#]
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MQEH7ZL=T^4IO%-O>NJN6_$457W7^C?\ P3#DVU:>*4TJ'K=4,[U]
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MQ/;;S2TSHN?1OK*65C=Z*U-$W(B(FS=T0Y7KN.<N#VOO3_HT;2NE<6VT^0=
M  =53614;-TCMI[$5?B]Y*)<,2/F[L/HT^;WC?BVW3R0UU4QSE=U7O*:$7PL
M'LMMEGN3^XW:SYG&?+FF333DN.UX;I[;U5O,D^9QSLFXJULQT5$H3
M
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M\DK%:M.$7S;7U'HT^7WC)EW73Q3TA<%+1QT,.R)K6M,-W5^2WH[2
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M#ENGKY&25<]/1T[*>)\JL:QJR*R)JN5K6HJZZ-1.@%X
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M\WI'_+[IS\N[K7Q6Z0J[6HWHG=0R)OH
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MTA6FQ-C9HQNUOY)CUUY)OH
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MST>LJ2
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MR'DUQ%,PK@6SX)AF9:;;16]M0]99>1"D?-5?>71.I9EW&7)]K7(TB=/%5B
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MUZ"N6O!ZR=^I[J?(TQ9=U\*>D*]3TK*5FV-K6H8JKEY+781
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M.AAV1-VM,-W5^2WH[2
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MOX-8KM-;AU]EC;+<7W&G6DH[91,?RUJ$1=42/3HWYET^)]!^W8L>+^7[_O\
MQ^YC]C5TSMG1F9AJTPX!RLR\=$W ^"YZ=KI8&I'%=ZW>WFU6Q.FKG[UUU77?
MJ=?8;;IBK/7E6G]F;-?6N,^ZW7GYD[0         X35#*=F][MK?RA,]?$4:
MYXF<[NP=UOS&W'M/B1JU)DD69^YSMSC7IIT1<2P>FWVFHN3](F]/F]THO),>
M1IIR7':\*PT/>D],_P#*.?EW-7XK=(50S)@
M
M     .BNM\-P9ME;N)QDJ/%&IZK=NF$IJ7<^'TC/E]XWX]U->2NH4ES=G1?$
MU(OA8/7;[U-;^B.W,^5QGRX9HFE<M]ZAN'1.Z_Y3!DV]0G-/:5/0       "
MCXZQ%^"N&*BK3?S.D46UN_TCUV,U3X:N;K]02E]P/AMF%<-4]*D<4<SM9ZC9
MZKIWKOD5/M>YR@I[+Q8Z7$% ZEKJ>*JII/68]NYKB49*BN4O*GDI^"<N[+ES
M024MFM]/0QS/667E-1KI7K[R_%2>?<Y<M<LM<D8B8\5;*GH           .,
MDB1L<YW=:T"DWC%U/;X9'-<S;'ZSW>JPU8=I5^3S6^B.V;V=UTLN8MKFLETE
MFH[I.L%9%4-WL;I&Y4=%U[GJM/H]GL<7LJYSX_KYV++FKEVJ)=+M4WJL=/53
M.FE=[7&B8G3Q5575YR;P  7#9\H;CC"@=O;YK32-[KW^]KU31#->YF%NF*M5
M[Y/R6Z%E10/HV6^_V]J>>T[G;I&HO@]%T36-VUVU=.NU3)N=:\_=_<NQ*W48
MS^D*EU)9J=UTK&Z;N5ZD6JZ;GK[-"GAP[LO:]Y]?![:'+ACWMJL2U'GU0UV]
ME&S\5%[/#VF;7<U?;@[?XO?9?$K=1=G.A;#"UD-/&U&M8WW6H0C#.G<LZZO(
M:G@!5+5A>HKMKI/1Q?E>L9,FYF$IA<=OM-/;6:1-Z_-[QSKRU?DLF>CTE:0
M                                                !\D8V1FCF[D'
M+H*+=L(LF[]-Z-WR^Z;,6[Z>2&L+?JJ*6AFV2MVN-\7%^*OIJZBUX[*>J?2O
MW1NVN*M=.OD*Q;\3-D[L_==\S3'EVOPIZ6JT<C9&:M=N;^28ZGB]<CT
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M*D@
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MDKJN(K]IP>V/:^I[SOD:8<NZ^%/2%;@A93L:UC=K6F*JZK7,\
M
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M\+!Z[;9:BZ/[C=K/F=ZIGRYI@TTY+CM.&X;;M<[TDOS..?EW-VMTA4C.F
M                                                   !U55''6,V
MRQL<A.+K3Q.BWKKA%]/N?3NYB?+[QNQ[KKY*JA1GQK')M<W:IKTUZH/A8/30
MW2:WOU8[N_*XIO%-DTK=MOT5=W7>C?\ E'/RX*A.:5 I>@
M              '745+*5FY[MJ#2*U\11KAB99-S(.ZGS&['M?B1JU)D>Z1^
MKG;E-6FG1%\+!Z;?:9KD_2-O=^;W2B\DQY&FG)<=IPO#;^])Z:7\KU3GY-S5
MK=(50S)@
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M;V;8F[?RC!>2K\DYGH[R"0
M                                                           #
MX]K7,T7O- I-UPG%6;GP^C?_  37BW=:>2&L+=K+?-;W[98WM.A&6;\%6NG%
MT%HYPS/IW[F.VN0KK3J*O08F]5E1_EF++M?A2FU7CG29FYKMR&773BDYG@
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M\Q<%KP>R':^H](OR^Z8,N[Z^*W2%:CC;&S1K=J?DF/77DF^@
M                                              'DN5EI[HSOMVO^
M9OK%V/-4(U/5;ETPW46_O-;S(_F:;\>YFU>L<5--:(![[?B":D[KO2,_*,F3
M;S:6FJN4-TAKF:L=WOE<8KQU">E/25O                         ^.<C
M4U7P I=RQ(RG[L/I'?-[IJQ[;KY/*I1:JMDK7[I';E-L1.G@@ZBT=E/32U3]
MD;7N<5:Z]/(5ZTX/:U&OJ>\[Y6F++NOA3TA7(X60LVL:QK?R3%K75:Y'@
M
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M]UKP_/<^J-VL^9QERYYA*9ZKDM=AI[6S5&[G_,XY^7/5K)GH]Q2D
M
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M=U?DMZ.T@
M            *7=<*P5VYS/0R_D^J:<>YJ$-86Y<+3-;7Z2M[ONN]TZ$9)OQ
M5:Z<7F+Q]CD=&_<UVU6E=:=15K;B9T:[9^\WYO>,N7:=?%*;5FGJ&53-T;F.
M3\DQ:Z5IY).P\                     'BN%\AH>F[<_Y6EN/;U;RJ4*X7
M::X)HYVUGRM-^+#,H53RF@?6MU71"L5BTX3DJ-KY_1L^7WC+EW4SXIZ0N"AM
M\-O9MB;M,%Y*OR3F>CO()
M
M        "FW3#-/<-SF^CE^9IIQ[FH0UA;ERL\UK?Z1O<]UWNF_%FFE6NG%Y
M#0/J*L;]S>ZK2L52VXF?"NV?O)\WO&7+MNOBE-JU3U45:S=&[<TPW%:>23M
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MKM;MZ(9$P
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MOF=_09,FXB$M(Y+CMME@M;.XW<_YG>L8,F:K63/1["E(
M                                                  .,D+)F;7MW
M(XE-=!0[M@]LG?INZOR.-F+=?$JJ%!J*62E?MD:YJ_E&W37KXH.LM';35DM&
M_=&[:57$7Y"M6_$C)MK9O1O^;W3%DVW3Q3FE3:YKF:IWD,KUR
M      .BMN$5"S61W[4E&.K\7O)0[AB*6J[L?HV?PC?BVTZ>2&NJG+WO$O1"
MP>^UX?GN75&\MGS.,N7/,)3/5<EML,%M9JUNY_S..?ESU:R9Z/:4I
M
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M[KX4](5ZGIF4K-D;6-1ORF*JY>2US(@
M
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MYO=*+R3'D::<EQ6K"\-#M=)Z:7^"<_+N:OQ6Z0JJ=WP,R8
M                                                        !TUE
MOAKF;98VN)Q=1XG1;MUPG+2[GP^D9_"-^+=37DJJ%(<UT<FBMVN-2#X6#U4-
MVFHG]UVYGRN,^7#-$TKEOOD-?T7T;_@XP9-O4)S3W%3T            #A-,
MRG9N>[:U#W33D*1<\3>LR#_*-F/:?$C5J/-,^=^Y[MRFO33HBXE@[Z"VS7!^
MV)N[\HHO),>1IIR7%:\)Q4??F](_^"8<N[K7Q6Z0JS6HU-$\#(F^@
M
M                                               '554<=8S;+&QR
M$XNM/$Z+?NF$7T^Y].[F)\OO&_'N^ODJJ%%DC6-^US=J_E&K37J@^%@]-#=)
MJ%^K'=WY7%-XILFE<M]^BKNZOHW_ "N.?EP5"<T]Y2]              >2N
MNT-O9WG;E^5I9BPU;W6E#N%\FKNB.Y;/E:;L6"8553Q&H/6Z(I6*I:\+S5VU
M\GHXOX1GR[F82TCDN.W6F&VLVQM[WS>\<^\M7Y+)GH])6D
M
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MA3TA78864[-K&[4_),=5U6N1$
M                                       !X;I8:>Z=7-VO^9I=BSU"
M-3U6Y=,/SVWJK>8SYFG0Q9YM74]'@-2(UVWJA6*C;\12TO=D](S^$49-M-):
M:JY17"*N9K&[]J8+QU'DGR=Y%X        ?'.T350*=<L11TO=C](_\ @FC'
MMJU\GE4H=972US]TCON]TWQBF/!'KJZ2UXY0POJ'[6-W*5UKT%=M>#]R-?4N
M_:-,67=?"GI"O4].RD9MC:QJ?DF*JZK7,B
M                 'QKD=X ?0
M                                       !X[E98+HSOMVO^9I=CS5"
M-3U6Y=,-U%M[R>DC^9IOQ[B;5ZQQ4XUH@%0M^(9:/NO](SZS)DV\V32N4=RA
MKF:L=WOE,%XKA;I3T$7@         ZJBMBI6;I';6GL15^(HMPQ(^;<V'NL^
M;WC;BVTZ>2.NJEN<Z2357;G&I%\+![+;99[H_N-VL^9WJF?+FF#33DN.UX;I
M[9WE](_YG'.R;BK6S'142A,
M
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M_A&?+NIT\4IA<5#;8;>S;$W;^5[QSKR5?DLF>CO()
M                                                           '
MQS=_1? "E73"<-;N?%Z%_P#!->+=UIY(:PMRNMLUO?ME;M^5WSFZ,DWXJM=.
M+H+QRAF="_<QVUWS%=:=15[;B;5-M1_E-,F3:?"E-JQ#4,J&;F.8Y/R3%4]/
M))S     #R5]XAH>CG;G_*TLQ8:M[K2A7"^35RZ>JSY6F[%@F%54\9J "JVG
M"TU=WI?0Q?E>L8LFYF/%*87';[7#;6:1-VN^;WC!>6K\EDST>@K2
M                                   .FLN$-NAW2NVM)Q%7XO-=5O7;
M%DM5N93^C9\WO&_'M.GDKJV+\VN+##G#W#ON=PYE9-JYE'%WY9?K5-?#ZSI[
M?TFMUX3_ %47N)QLKY68T_JD9;V._K3^:NO%%%6<K=NY6]C5VZ]-=#@[O#['
M+6+X=>C3COG/)<!0F
M                               "EW3"L%=WH_0R_D^J:<>YK3R0J%N7
M"TS6U^DK>[[KO=.A&2;\56NG%YB\?8Y%A>US7;7-]XKK3J*M;<3.C[L_>;\S
M3+DVOPI3:LT]2RJ9N8[<AAJ>GDD[      XR2-B9N<[:UIY,\A2KAB9L?=@[
MR_-[ILQ;7KY/*M1:BH?5OW2.W*;--.GB@X%H[:6@EKYMD37N4JNXCR)E<-IP
MBR#:^H](_P"7W3!EW?+Q6Z0K,<;8V;6MVM;[ICUUY)OH
M
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M6LF>CW%*0
M                               '":G94,<R1K7-=\Q[-=!0KM@_UGTS
MOVCC=BW7Q*JA0IJ=]._:]KVK^4;9KD@X%@[J.NDH9-T;BJXB_)[UU5NWXBCJ
M-K9?1O\ F]TP9-M6GBE-*DUVJ:H9WKZ!TU59%1LW2.VDHBK\7O)1;AB1\W=A
M]&GS>\;<>VG3R0UU4QSE?U4THOA8/9;;'4723N-VL^9QGRYIDTTY+DM>':>V
M[7*WF2_,XYV3<5:[2.*H%"0
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M39R\YO9:\8,J-K*AO+5WO>Z4Y=IT\4M+5J.5LC-S7;FN]YIC3?0
M                                                  !QDA;,S:]N
MYKB4UT%#NV$$=WZ;NK\CC9BW7Q*JA0:BE?2OV2-<U?RC;IKU\4'66CMIJR6C
M?NC=M*KB+\GO756K?B1E1M9-Z-_S>Z8LFVZ>*6EJHUV_JG@97KZ  \%POT-&
MNUOI'_DEV+!5O*I0J^YS5S]7N[ORM.A&*80JGG+A]CC61^UK=R_DE=:]!6K7
M@]\Z-?4=UGR^\9,NZZ>*>D+@I*..CAV1-8UIS[NM?);T=IX
M
M                                                      %,NF&8
M+AN<ST<OS--./<U"%1U6Y<+/46V321O=^;W3H8LTWXJM=.+REX^QO=&_5KMJ
ME=:=11,S,K<-YV6%UOQ/;8JQ'-VLJ&]V>#\I%^(PY<NWKE@KBC<3?DB-FYV?
M^)<F<21XFP7MQ):Z&H2H92N;NGB1JZHQZ(NLGUZ(A]1M/7L6>?8;KMK[_P!S
MGY-I4=T]R0V1_$A8,RL&<_<VUW*WMY5;;I>[+ ]/'1.BJG_Y#D;K8Y<=?%-?
M5JUXLTZRO&GI[SCB'=3-^A[:YO>J)V^D<GY"=--4,5Y,>/\ FI/NU5NR6.VX
M/C<E!#SJESN_43]Y[S/7M<WVGY+--)T\79-,^H?N>[<Y2S33H.!8.^AMLUP?
MMB;N_*]THO),>1,KAM6$XJ7OS^D?\ONF'+NZU\5ND*NUJ,Z(9$WT
M
M                   \]=:X;BS;(W]L3C)4>+S71;ETPK-1HY\7I&-_RCH8
M]S.ODJJ%+<U6KHOB:47PL'LM]ZFH7Z;MS/E<9\N&:)I[:K%6Z'2*/:_\HSQM
M?B2YJ3-4/J'[I';E-FFG1%P+!W4=#+6S;(FO<XJNXCR>]-5P6O"$=/WZCTCO
ME]TP9=W6OBLTA66QMCCT:W:ACZIOH
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MUXDAK^Z[T<GRN.=DV]0NTODJ)0D
M                           #IK+?#<&;98VN)QDJ/%&IZK=NF$Y:7<^'
MTC/A[QOQ[J:\E=0I#FNC=HO=<:D7PL'JHKQ-0OZ.W,^5QGRX9HFE8CQ- Z'<
M[<U_RF.MM7)/FIEPQ#)6+M;Z-AIQ[>8>:ZO 7HA8*E:\,U%P[SO1Q_,XR9-S
M,):1R7';;+3VUG<;N?[SG>L<_+FJUDST>LJ2
M                                       <9)4C3J!UMJ>_U\"7%'D[
M6NW>!%)]
M            XR1I,S:YNYI*:Z"B7;![9-SZ;NK\GNFS%NOC55"@5%++1NVR
M-<UQMFYKQ0=9:.RGJI:5^Z-VTJN)U\QX(<%X9AQ(Z]I8:-MX=%RG3L;M:Y-=
M>J(NB]?;H>:^WX>RY=KSC/DJ-57RUGK.[K?5:WU6B,4PEUU=)<\<H87U#]K&
MO<[\DKJN(KEIP>YVU]2[;^0TQ9=U\*>D*_3T[*6/;&UC4,-56ODM<SP
M
M                          4^Z8=@N7>V\M_S-+\>XJ$=8Y+<N5AGMK^\
MW<SYFG1Q9II3KIQ>(T !];&Z231K=RE8K=IP>^;OU/=;\GO&/+N^GBGI"OTM
M'%1LV1M:U##5UKY+>CM(@
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M\UWK-,%XJCR6375ZBM(
M                   'ANEAI[IU<W:_YFEV+/4(U/5;ETP_46U^JMYC/F:=
M#%GFU=3T> U(@ #TV^TS7)^D;>[\WNE%Y)CR--.2X[7A>&A1KG^DD_*]4Y^3
M<U:V8Z*H9DP
M             %!Q3F1:<'UD,%=4,C?-JYWO<M$3UE-.':9<D\I0O+.CLLN/
MK5B:F;+;ZZGJ&2.5K>]M<[3ZET4A>#+'E)IEG7Q>YR[O$BF!6^MD6/J@6.Z.
MH1W12/%'D[2*0
M                !TUE#%6P[)6L<TG%U'B5*W[MA&2G5SZ?TC/E]XWXMU->
M2JH49S71R:*W:XU(/A8'K=$4K%4M>%YJ[O2>AB_A.,^7<S"4PN.WVF&VLTC;
MWOF]XY]Y:OR63/1Z2M(
M                                                     /BHDC-K
MN\C@*/=<(QU&Y\'HW_+[ILQ;NM/)#6%,H<)U-3-I(WEL:[O.=_0:+W4Z>"$P
MN&VV6GMK/1M[_P SO6,&7-5K)GH]94D
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MT56C(N&<SJ2[5+:.M;]'W+U70/\ >7QZ+[>AS[VUZ=T]TKM+7,G>\"I8
M#E'(Z!^YCMJM]YI76G45RUXP5NUE2W<WYVF++M?A3TM7J>JCK(=\;MS7&*IZ
M+781
M    ^.;OZ+X 4F[83AK-SX?1O^7W37BW=:>2&L*#-9:F&IY2PO<_W=OOFW3-
M.L\E?355[7@Y&]^I[R_*TRY=U\*6D*Y#"RG8UC&[6M]UIBJNJUR/
M                                                       !9N9V
M;5-@NC=#3N;-<7-[C/=B^M3?L]C66N5>*G+FX,#W2Y5%XKY*JID?--,[<YSC
MZ:(F)X0P57)2:ZPLJ*QM73R2T=?'WF5$3MKVK]Q/Z^VD.COM^>V-\M]K):KZ
M4HFOW.?4-YCW)\-Z^!FR^FX,G\J<YLL+^P?QL6FXHYMYH9[>_HUG(]*W[]=-
M#G9O1<D_95R71O)]YE+"N95AQMN2UW2EK'M:CG,9)WF_:<K+MLN/SEIC)-^*
MNE23E',Z-?R2M8[XYFR?:!S
M                            >.Y6."Z,U>W:_P"9I=CS5"-3U4*3!]2V
MIV-VN9\QMG=SQ5\%8M>&8+?WE]))\SC)EW-VG,=%1,Z8
M
M
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M^C?\WNF'+M*T\5NEJPUS9&ZIWFF1-]
M
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MQ6.Z.5)$Z$1R
M
M
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MZ;N6_P"#CGY<%0LFNKWE*0
M
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MUV[P(I/H
M
M
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M:/:R;TD?\(RY=K->*4VN*AND-R9K%)N^9I@O'4>2R:ZO002
M
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M[HZAKNB]TCQ':1
M
M
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M
M                                                     #KDJ&Q^
M'K$N*/)T22+)XJ22? K ,'\8-W2LDL=E:WTLTO/W?4NYAW_1(Z<LK+N:]U!N
MJ[0;+%W$#B; %1455EGPV]M.ZXS]ZCE5O<F65^OH]LW=1$1VOU';C)7E3-7%
MG2QXLGH::&6.1E12S,22+O;FN9[-%+.$V\^I=EIQ%379G<=M?\CO6,]Q<BH$
M0  4+,;&$6!<&7"YR2-C6GB7E;_5=)IW$^]2S;XO:5Q+KI*"]TKWW:Y5%5)Z
M]1(KW?>NI];.G3M<]T$Q]V[5Z@5["^7EPQ925U;$VGH;5;8'5%97UDFRFHXV
MIJKWOT\$1OP,NXW>+%Y+(QU9;[I@#,3**HOV!KU7X@?:;VMHN-3+3I%!O2!D
MNL2HYV]G?;WE1.OL,FTWEY<O&IX_,GEQ3I+8WV=N82X\X;+:R>J\XKK6^2GG
MW.W.B1'NY;?\AK3X?Y0[?V6\KX:=/9WUQ,['$:@ !RCF=&OY)'BL=\<S9/#U
MB(Y@
M
M
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M,50UFUDOHY/X)S\FVJ/%;I:K>MU1#,F
M
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MO3\^/W5\9YU7Q3U+*J%LD3F2,=WFN;ZKC%4\5KL/0 [(ZIS?$CQ2Y.]LB/\
M BD^@
M
M
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M.ZQ%<NO5Q_7_ !_P/KFLD];NQ.=RG^<.[L2^R*;33N?+,W1.[U<NJ#]?^O\
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M+EP3:6E\5R6V_07)G==M?\KCGY,-0LFNKVE*0
M
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MK(JJ)S4=W7=YNOQ3Q3[SA9<-8ZXTW1<Z^*JE8-<K>J!8[HZKV.4CQ1Y.XBD
M
M
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M DGB?$M%@[#=PN]RG;36VUT\M953*U7-BAC:KGOT35>B(Y>B 0Q_V2#P3?\
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M%TE+M9/Z1GS>\9<NTZ^*>EKAH[A#<&;HI-Q@N*CR6NX@
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M;44=1%40N]5S';CA7%1VTW37)Z@\?8Y%C\%"QWQU"2=%[JD>(["(
M
M
M       .%1)R(9'[7R;6J[:WUG:>Z@'Y@NPAX7<'=N-VH>;V.>(J:MQC5TM&
M[$OT)45TD'TC++4MB8DBQJU_F]-'LC2)JM:FZ)OJ)M4-KW&?Y+CPM\2645=:
M\%X-I<I<8MB7Z*OUDDG<R"1/!)Z9TJQ3QKIWNC7Z>J]J@2O[.'@GI>SRX-L&
MY2TF)KYBYN%J=6RW*Z3.>Z69[E?(D4:JJ00(]7)'$BZ,;IJKG:N4-'_D7O\
M=P9\?L9B_P X- V0>56_I(V:'ZXV/_.M(!Y?)1/TE++S]=KW_G&H M3M:.Q.
MX6,G>SFSSQSAG)?#%HQ78<)W&Z4%R@DJ>;3538W/21-9535%Z]4T A_Y*QV7
M^07''P2X]Q)FOEG8<:WRUXXEME+65LDS7P4Z4-'(D:;)&IIOE>OA[P&]W([(
M_"G#;E39<#X&LM+AW">'XG06ZVT[GNBIF.>Z16IN55ZO>Y>J^\!^9?R>[@&R
MD[0GM-L[\+9PX19C*PV:TW&ZT=*ZYUE#R:I+M3Q))NII8W+W)7IHJJG>\-=
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MQSLOK7/MXKM-G_,R#;YG5%!#([UI&(YWWH7Q76>2JIZ.XDB
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MO@J*!^=#RJ']/<X=/V,X>_\ B&X@?HR
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M0#]'WJ]$4
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M9L;NP^SVYVS9YK:-N[YOINWZ?O[= ,-^1Z.KG]D9,E7^(;CFZ)1?XGE4FO\
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MID,C8.=5+53R321PR2MUB@8KMSD5S7*C= WKY+<%UG[/7LD*K*"RUCKE!@_
MUTBJ*]T>SZ0JY8*BHJ9]NJ[$?/+*YK=5VM<C=5T U;^0Y?[D<37^-PS_ !78
M"7'E<;87=CC?EEV<QN*+/RMWK;^:[P^O;N^[4"M>3$89I\<]@]ES9;]1T]RL
MMV?B"BEI:AF^*II9+K6LDC<B^+';I$5 (+YO>3'<47 =GW>,<<&>;+Z>T5CU
M2FM[[X^T7J*!5W)33*K?-:N-J^V1S=>ZJQZ]0*#7]N%VA_9%X^L-)Q5Y?P8L
MPE<JI($J+C;Z.FDJF-ZO927&W?H5949UTE;(NGBB>*!OIX9.(?#7%IP_82S*
MP=5/J\-8TM<-TH'O:C7L8].L<B(JZ2,?NC>FO1S')[ +Z
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M\N#R=''FF_%DJT_[D4O^*;_$=C%XRY^3S>@F\
M        #0+6X?M^+_+:,2V2ZTL5PM5\MTM!6TLK=T=3!)@-B2,>GM1S=44"
M(O#?V:N.;[VRM'P17VNN59E/@+,2JQE<;?*GH*BW1P12)62=.CZFA92PHO@U
MU3I\0)C]GA(V3RP?/K:W:C:>]L1OU-CI$_H QUV@?^_(<N_V381_Z'3 ?HR
M_.=Y&O\ IA&?G[&5_P Y, R%Q0T4-Q\L^R\IZB&.HIZBDHXI8GM1T<K%L%0B
MHJ+T5%3Q0#T=B?73=DIV^V=_"A=)I:7!V8LDE3A;FN78Y\+'UMOT5>FKJ&:>
M)ZIZTL3&^*: =?DL_P"FX\9'ZIK/\\S ;ZP/SF]BO_OK_B"_9!CS_.KP/T9
M?G#Q+538N\M3A==8.]#B^F8QCOD@P\Q(7?N1QN0#]'@  !^<WR<[_?)'$5^I
M<7_Y]I@/T9 ?F([>WB#BX3?*7K5F;-:9;[#@*HPQ?GV^*?D25R4\$$G+214=
ML5VW371=/@!(['GEF]_S#PC<+-EGPWWAN,[A3R16V:JOZW"*CF5-$E6FAI$=
M-M7KLW,U^8#*7DFW93YB\(V'\>9SYJV2Y85OF8-)!:[):+E'RK@VA1_/EJ9X
MU[\:RR<I&QR(U_HG.<W1S0,8^6.9T7#-W-GA\X:\-R<ZZWVM_""HI=W26IJ9
MOHZW:_#KY\G[9 ,A>5+\#5@L?8XY7R85\UFCX=*JVVF%S7-5[;5+3LH']$]J
MS,H57\U=0)T=A#Q4?ZK_ +*')O%-14><7:WV5N';JYSMTGG5O5U(]\GY<C8F
M2_\ I4 U$>50_I[G#I^QG#W_ ,0W$#]&0
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M;;XY$F8U[';F.[S7'Y.[[F   =L=5MZ.(\4N3N:Y']4(I/H
M                    :%/*^ZCS3C2X0Y?\'45C_P!ROMX$6^W'R\S#[,3M
M+\\\&Y91R4N$N+RQ1N;1TT;G+4,K*V*2J@B1%1$E\[AJ8D31=(*US=.\BH%Y
M]H5PB4? ;VD_9QY14B1><81MV&$N4L7JU-QFQ+++63)]3JA\JI\&Z)[ /TN
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MSV[9::61GZ'HE]J>;Q*UJIX<UTZIT<!.T
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M8,NSGW5VEKBHZZ.NAWQ.W-,5Q4>2<UU=Q!(
M     :#K5_OY6N_Q7_\ PC -SUCX0,%8?XP[_GG3V]&X\Q%A>DPE5573;YI3
MU$L^[PUWO5\2.55]6FB3V :8NSJ_WX-GW_BK[_%2@6#V]]Q;P5^4HY)YSXFB
M?3X-J9<-W^>M8U7IR*.K\WJ^B(JJ^..)';$15T>SX@;O,W^TDR0R:X>+IF?<
M,SL#56%:&WR5\%12WJGG^D-K-[(J=&.59)']U&M8BN57)T TW>109776[Y@Y
M_P"9%12\NU24]OLL50Y.[/4ODFJ96-_,8V)7?XU@%8XE_P#?IV6_ZGHO\Q5
M%X>5GY(7OA[S5R$XPL"Q<C$67UZI[-<YV-7JL4KJVWODT]S>VJB>J^*2QM^H
M#%ODAN84.;O:-<3^+*>GDHZ?%% MVBIWN1SX&5%T?*C%5.BJB/T4#?7B+-W"
M>#[DZBN^*,/VNL:U'.IZRY002M1?!=KG(O4#\[?8VXZLEB\J<S\N];>;726B
MHOV.715T]9''3RH^Z/5BI(JHU=R=4T7K[ /T783S"P_CQ:A;'?+1>O-=O/\
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M3[:V-U8VQWJFN#J-'[MG,Y+G;-VUVFOCM73P O$
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ME$YJT   ".5O@%COCJFN71Q'BCR=I%(
M  -!WEAG]V+PD_XRN_Z;;P-MO&!V=&#.,?B$R'S#Q'&SZ3R,Q)-?J)O+1WGR
M/IUV0JOLVU<5'.B]?ZV5NG?U0-27E&7^^'."_P#QN&?_ (EE WX@?G,\KI_3
M<.'[]C-N_P ]58'Z,P-9?E</Z37B+]DUG_GP+X\EX_2+<CO_ .??_$%S GX
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ML='7.=44\;EE331^K&-:NOBC= /TB
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M;XI;]FYCC%F;=KQ+B.*D@J*>QW2WP4+&T]/%3Q[&34,LB*K(VJNKUZZZ:)T
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M'%7IB:NHZEL*4JS+'RO-Z6#37SA^[=N]5--.NH3$
M         HN/L6Q8-PE<+D]W=I8E=]Z]$_?<7[;#[3+,H7?246H\Q/PNKI)Z
MV9WGDSMSM_O*OP^H^RTV_LXX0Y=5U>YKM4U0\>/H     1]XW,=\N&VV&"1[
M5D_1$^QWL[R;%3]\['I6'RRL^>O=1U.XS@'?27*IH>D%1/#N^216_P 1"M)U
M&4,H^,;'.3E9&^BN3JBE:Q&>:SZ.C<S77;]7VG,W7H^VW'E*_%GJ/%LTRAS"
MAS4RWL]^BY6MPI8Y96Q.W-BD5&[V)]B]#\UWF#V&>L7PNWCOG/)<IG2
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M&Q@
M
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M^MD6/J@6.Z.H:[HO=(\4>3M(I
M                                                  '"29L?V@=$
MDSI%_) Q;Q88H?8<M/-61M<VZ2I3O=\J)W]W\$[7HN'GGY?"R;G7C*%^+^([
M .$^(JERKJ[M44.+ZR@IZV!M1&C:2?G1M>D3)-57F+NZ)MT[J]3Z33-7E7BQ
MZZ,D6W$U78W\J7TT;7;?6W?OH2UB;[I>+GM=^IKLW6)W>]YKO6*-8Z#VG@
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MNVFC'NZT\DB, YJV3,BCYMLK&2/VHZ2!W=DBU^*'S^XVN7%Y-\9)OQ7(4)
M#G'4.;T7O-(\5COCE21.A$<@
M
M
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MNBE>YK>ZW<FJM1/8A7ONS/6*?O68?GGDOLRK0 5BM81_OWW&3>>ZG"M&)Z
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MP\Y]4USY6-D_$)W=.FGMW'1V>VO+/)GRUQ4K".?EKI[C'445REMM3#HK7O\
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MLA>B.9+'(U51['(K514714ZH![@
M
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MC\/4':^>5FV[ USI8K[E[E%MMMPIY6\R!]/:H7U-3%(SP5K[E,Z!R>U')K\
M.7DON)J[@/[7WB!X7[[/*V*Y+64M)S?_ *YK;/4RI&]J?^<I)IY=4\48SZM
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MHU- _0!D7=KKB#(_!M??&NCO==8Z*HN+7>LVH?3L65/\MS@+J
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M^%,(T3:"W4O,=(YL::JKGO<JJ][GN<YSEZJYRJ!>P
M
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MIOS9IQ3RI1,]4PLI\H[;E388Z:EC;)4N;Z>I=Z\JGS.YW-9:[FV(Z+M*'H
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MM1VB:@9H
M
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M5%5.JA*L
M
M   MC&7]?Q_F'2V7BJMY;??IJ/NN](SY7%F7!-H32N4-TAN#.X[K\OO&"\-0
MMTIZ2#P      !"CM ?]UL4?J6'^)A]QZ!]E']7-W7O(3'V#FH?Y=_IG%/\
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MC5%2^K?N>[<XVS/%!>&&O]PZ?\U?XSDY_M:7X_![2EZ
M       %)Q9@&PX\IFPWRRVB]11^JROHXZEK?L1Z*![[;:Z:RT$=+1T]/1TT
M+=K(H(TCC:GU(G1 .\
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M@L%XLI,=82M]YH7/=1W*!M1 YWR.35#\CS8:Q9:Q5[KZ"->L\E4*WH
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MWV?V1_"==OI#+7*/+S!5TY2P.N-IL-/!7.C7Q8M0C.:J+[45V@&7P
M
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MNEZRI(
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MR3''#'9TG=%S+2YU UK7=YL<>U&:GQWRAP>SWE<?>^=TMG?7$SF<5H
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M[,/VM]IH]KW;G.[QR]QDYTMF>CWE"0
M
M
M                      /DL;9&:.;N3\H::\11;MA%DW?IW<MWRFS%N^GD
MAK"WZJCEI'[9&N:IOFYKQ5]-746O'93U4E*_=&[:I5437D*U;\3,F[LW=7YO
M=,63;=/%.:51KDD9JUVYIDXO7(]  !Y;E9Z.]0\JLI:>JC];9/&CV_N*>Q=1
MXO:GD]$<;86-8QK&L;W6M;W6M/'BU\Z_[65Y_4SOY)KV'V\_BCD\6L?BE_LL
MM_ZD_P"NX_3=AXN'G\F$\VL%WC%F5=V^B[77W+DOIW/\UIWR[?T1%\$4LWF2
M8Q=U(XYZTD;Q'?V$4?\ C4,>R\EN;P80.PS*OPG?W6^(/V)P?],><CU#R:,*
MJ9U_VR+A^T_B-FT^R5Y/-0;/BZXX-F=66ZJEIYH6J]NUW=U3ZBVXFY[D)UZ*
MYP-]K5<N+)[LNL1VU\=ZA:Z=E1$Y'0.CBZ^U=V]?;[#YOV$Z5REOY]>UZLS+
M!68FSCN5%04\M55U%0QC(HF[G.<K&G>V]S&#E;'>G6GJXCNQGQSQ'9%4_)NU
MML]]HZA:V*@J-7<W1CDV*K45-5W=.NGQ.)O/6,5UQG\VO%M*4KA'R%Q7PU\$
M-PPIC2TRV6^T=162RTKY&/<UCY-6.U:JIU3ZR[9W-U-RKRSTE:Y]"R*K@54C
MQM9W+ZK:V!W_ -T:4YO"OP)\T](9V5+-S',<COE/D70<P '%SDC8YSG;4;WG
M. BAQ^=JY4<+N$IK9ABJBJKG4.Y4;G]YNOMT]NFFY-?B;(V$Z3[7*A[:O&4)
M<PLV+)V@6!Z&*BQA=,,XXI7)3SVNOJ-L5ZCE[\NDO5-C'L:C6R.3H[JAEJ\N
M.N[NG_1;QG5AW,;*?$>3-[DP]9<*U5CFAI:BX_3-QFC\[K*%R-TU7<L**S:Y
M6\K23O?83BYONJD==.*PJC$5ARYKYEM^S$U[CEAE9=)]?-H)&*V3?$Q=%?JO
M=<DK53NEO&K_ )4/J4)L=_S8O;E3SBX3;G/]D<%-O>YZZ>$<:*KO#HFI/L@^
MM7I+7A;*][5K)OPJO<+XG^;Q:QV^)%8[FQRO[LBR-?M1%CU8NU>J]"'*K_E>
M_4M?%&.KKC#:VNK)9(8W*]D#?1P1*OBY(TT:BKM;JJ)U+=(G1"J4@]>LT<)O
M 9F%QA8PH[;AJTOIZ.J=M=<:QR14S43Q5-RHLFGPC1R_N%.;<3C\DHQUJW*<
M"O8>Y:\*/F]ZQ$UN.,6Q\N7SBL;NI*.1$[[8H^B/8J^',:JG'S[ZLGCVM<89
MT39IZ=E+"V.*-D<4;=K6M;M:U/J0RKV(^*/PMOVJ=/TWWF7.A+Q(?V;1?XH^
MLV7V3FY/-CPVJP     .REHY:ZJ;%!'+-+([:UC&JYSW?4B$*KB))\.'9NXD
MS2Y-RQ(Y^';.YV[8[^N9V:>+$ZHG7IWM%/G?4?E'@P=N+NK^S;AV=7Y)S9/Y
M!X8R/L,=%8+73TZM9M?4N;NEE7VN5ZZKU7KIX'P^\W^?<URRTZF/#,>*\S(F
M   'FKKI#0,U>[K\I9&.K>ZTH=POTE8NUOHV?DF[%@F%54\!J K%3M.&9KAW
MG^CC_*]8HR;F82TCDN.VV>&V,TC;U^9WK'/RYJM9,]'J*D@
M                                                          !3
M;IAF&X=YOHY?F::<>YJ$*CJMRY6>:VOT>WN_,WU3?BS32K73B\AH'UCG1OU:
M[:XK%5M^)GP[63:N;\WO&7+MNOBEIJK-/5153-T;MS3#K%:>23M
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MW?NIT_?.;F]-SX_YFB=S.J_*.X4]RCWT\T50SYF2(YO[QBUTK3R7<N3O/'@
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M6CBHV;(VM:AS[NM?);T=IX
M
M
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M8Z*D9DP
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M<[T<?S.,F3<3"6D<EQVVRP6UG<;WOF=ZQS\N:K63/1ZRI(
M
M
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M=? EI"M1QMB9M:W:UONF.JZK7(B
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M]@_)OQ[SXF=\.XDH,66V.LMU5%64TGJOB=N;T.%DQUCKC3;-=?%[R(
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MTDGY7NG/R;FK\5LQT50S)@
M
M
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MUI@NZOR6::.X@]
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M2RVN_7"5(8&L:KXIWKX-U]GWJ?(>I?)[+MYK+'=,NI@WDWVTDD?/-8
M   Z64,+:ETR0Q-F=W7/VIN_=/>NH[CP<7.:UFJ]U *9<L1LI^[#Z1_S>Z:L
M>VZ^3RJ46IK):Q^Z1VXVQ$1XH.HM'93TLE4_9&USG?DE57,^0KUIP>V/OU/>
M7Y&F++NOA3TA7(XTA9M:W:TQU75:Y$0
M
M
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MEQVVQT]M9W6[G^\YQS\F:K63/1[2E(
M                                                         #F[
MNB@4N[87AKE<^/T<G\$TX]S4>2&L+<KK7-;7Z2-[OS>Z=",DWXJM=.+S%XY1
MR+"_<UVUQ76G45:WXF5NUD[=WY1DR;3X4IM6(*AE0S<QVY#%4]/))V
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MJVOG]&SY?>,N7=3/BE,+BH[?#;V;8HVM,%Y*OR63/1W$$@
M
M
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M<_\ TCV<?"<C\)KC_P (5O\ ZY_^D>SCX3DX?3U;_P"&57_K'#C)R/IZM_\
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M3
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MGY<]6LF>CVE*0
M
M
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M64[-D;6-8WW6F'6NJUS/
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MMFN3]L3=WY7NE%Y)CR--.2X;7A*&EVOF](_Y?=,.7=UKXK=(5<R)@
M
M
M
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MHA6*O:<)S5FU\WHXOE]XSY=U.GBE,+AH;;#;6;8F[?RO>.=>2K\EDST>@@D
M
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MVO!^[OU+OVC3%EW7PIZ0KU/3LI8]D;6M;^28JKJM<R(
M
M
M
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M:\.T]M9KMYDOS..=DW%6NF>CWE"0
M
M           'QS4=T7O(!2;MA..L3?#Z-_\ !->+=UIY(:PMVNMLUO?MECV_
ME&Z,DWXJJET%XYPS/IW[F.VN0KK3J*O;\4>JV=O[8R9-I\*>EJO'.DS-S7;D
M,>NG%ZYG@     !0<<9<6C,"VR4]PI62.<U6ME3NR1+[%1?J+L&ZRXJYR7$V
MCOFIPUW7 O,JJ'?<K>WO;FM[\7VI[?N/I]GZKBS=M=M,.7;UHQJYKHWN:YNU
MS?6:==2[*6L6EYB;8I(IF+%+%+&DC)6+XM5CD5%12%Q-^1IKQ1SXNNS#P5Q+
M9=4-JP+#:,N[Y1W&:XN<YLCZ2N?*QC%15[SD]3HFJ-17&;C6/N\DJXZLJ<15
M*S"^5=/9XY(G,M]'243>5^+<L<;$>Y/J56N4W^EQW2JSTCY9[I+9;M3U<7XV
MGE25OW*=V].L\6.=>BJXPQC#?\47BY6VTT%A^FJR:MJF4;>]+-*NLCED75VC
ME]W7;\$,FVV.+%/Q++S5:@F]4NS*O)'$N<U[CHL/VNHK%<[:Z7;MBB^.KUT3
MP]FICW>^P;>>66ED8JOQ38X=^S'L>!^3<L8S-OUQV[O-6:MIHEUU1?8JJGAX
MZ'Q7J/RERY.W!VS]_P"]TL.QG3R2DMMJIK/1MIZ2GIZ6"/U611I&UOW(?,U=
M:]]-\SQ>@\>  #R7"\0V_P!9VY_RM+<>&K>ZTH=PODU=TW;6?*TVXL$PJJGB
M-0-;NZ(5BJVG"LU<FZ7T,7\(S9-S,>*4PN.AM<-O9MC;^V]XP7EN_)9,]'H*
MT@
M
M
M                              /-<+7#<F;9&_MO>+<>6H\4:GJMVZ85
MFH^]%Z2+^$;L>YF_)74*4YNWHII1"P>VWWR:AZ?C&?*XRY<$V32NT-VAKF=U
MVU?E<8<N&H6Z4]16\                    XR2)"S<YVUIY,\A2;AB9L:[
M8.\OS&S%M?B>52CU%0^H?N>[<ILG3H@ZRT=U';YJY^V*-SBJ[B/)[TU7#:<)
M1TNU\_I'_+[I@R[NM?%9I"L,:UK-$[K3&F^@
M
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MR6O#M/;>JMYDGS..=DW%6MF.BH%"8
M
M
M
M  4^Z8;I[AN=MY<GS-+\>XJ$=8Y+;N5CGM;]7MW,^9IT<6::4ZZ<7C- ^M=M
M?JGB5BJ6_$SX=K9O2)\WO&;)MIU\4M-5:I:V.M9NC=N0PW%1Y).T\
M         !3[AB"&C[K?2/\ R2[%@JWE4H=9<IJ[\8[I\ONF^,<QXH53SEXY
M1PNF?M8W<YWNE=:]!6[7@]TFU]2[:WY&F3)N_A3TA7Z>ECHX=D;6-3\DP57+
MR6NPB
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MT;W6M,:;Z
M
M
M                                             #XYK9&Z+WF@4:[8
M1CJ%WT_HW_+[ILQ;OIY(:PM^LH9*&;9*W:XWQ<7XJ^FKI+7CG3U#Z1^Z-VU2
MK73KY"M6_$S9%VSMVN^9OJF/+M?A3TM58Y&RLW-=N:XQU/%ZY'H
M  #S5UTAHF=]W7Y6ED8ZM[K2AW"_35VYK?1Q?*;L6"8553P&H *I:\+S5W>?
MZ.+\KUC)DW,PE,+BM]F@MK-(V]?B[UCG9,U7Y+)GH]16D
M
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M)FV*-D;?R3!5UKY+>CL(@
M
M
M
M ==12Q5C=LC6N:2FZT\1;]TP>^/<^F=N;\KC?CW77R55"BR1NA?M<W:[\HUZ
M:]4'$L'HH;I-0OU8[I\I3>*;>]=5<M]^BK.Z[T;_ ,HY^7!4)32H%+T
M   ZZBJ92LW2.VM&D5KXBBW#$SI-S8.ZWYC=CVG3R1UU4ITCI)-7.W*:M-.B
M+X6#UVVRSW)^C&]WYG>J9\N:8--.2X[7AF&W]YWI)?F<8,FYJULQT5(S)@
M
M                                                         'QT
M;9(]'-W(!1KMA%E1WZ?T;_E]TV8MWT\D-86_6T,E"_;*U[7&^+B_%54NDM'.
M&H?2NW,=M<5:Z=?(5FWXF:[:V?NK\QCR[7X4]+5:.1LC-6NW-,=3Q>N1Z
M    /-772&@9J]W7Y2R,=6]UI0[A?IJSNM]&SY6FW'MYA#75X#6B%8J5KPS-
M<.\[T<7S.*,FYF$M(Y+DM]G@MK-&-[WS.]8Y^7-5K)GH]14D
M
M
M
M                                 >6Y6>"Y,TD;WOF;ZQ;BS5"-3U6Y
M=L,S6_O,])'^2=#'N9M7K'%3#6B >^WWZ:C3:[TC/RC+EP3:6FJN4-TAKF]Q
MW7Y7>L8;QU">E/25O    XN<C>J]UH%,N6)&0]V'TB_-[IJQ[;KY/*M1:JMD
MK7[I';E-LQ,^*#J+1VTM')6OV11N<I55S/D3*OVG![(=KZAVYWRM,.7=]?%;
MI"MLC;$S:UK6M_),6NO)-]
M
M                          #KJJ.*L;LD:UR'L76GB=%OW3![X=SZ=VY/
ME]XZ&+==?)54*+)&L+]KF[7&O37J@XE@]%#<IJ%^K'=WY2B\<WY$TKEMOT59
MW7>C>8,N"H3FE0*7H   ==14LI6;GNVH-(K7Q%&N6)EDW,@[K?F-V/:=/)&K
M4F1[I'ZN=N4U]-47PF/5;[/-<WZ1M[OO.=ZI1>28\C33DN.TX7AM^US_ $DO
MY7JG/R;FK6Z0J9F3
M
M
M
M      IMTPS!7;G-;RY?F::<>YJ$*CJMNY6>HMK])&]/==[IOQYIOQ5:Z<7E
M- ^QR.C?N:[:K2NM.HJUMQ,L>UD_>;\QER[3KXI3:LT]4RJ9NC=N:8=8K3R2
M=@'AN%\AH=R;N8_Y6EN/;U;RJ4.ONTUPZ.=W/E:;\6&90JGE- ^M:Y[]&]YQ
M6*S:\(/J._4>C9\OO&7+N^GBGI"X*.ACH8=D3=K3!=U?DMF7<0
M
M                                                          !Y
M;A9Z>YL](WO?,WUBS'FJ/%&IZK;NF&9K?N<WTD3?>.CBW,VKUCBIIK1 /?;[
M]-1]UWI&?*XRY<$V32N4-TAKO4=WOE=ZQ@O#4+=*=[W-C9JOJD'BF7#$C(>[
M#Z1_S>Z:<>VK7R>5:BU5;)6OW2.W*;HB(\4'46CLIZ62LFV1M>Y?R2JKF?(5
M^UX/9'M?4]Y?E:8LNZ^%/2%;CC; S:QNU&^ZTQ:UU6N1X
M
M
M
M                                     '&2-)F;7-W-&FO$46[X/9)W
MZ;NK\AMQ;KXE50H%51R4<VR1NUQNBYU\$'46CLI:R2C=NC=M4JN)U\WO75ZJ
MK$$]5'M[K?S2N-M.CWD\)I1 *C:\-U%P[RMY<7S.,N7<1"6D<EQVVQT]M9W&
M[G_,[UCGY,U6LF>CV%*0
M
M                                "F7;#,-P5SF>CE^8TX]S4(5'5;EP
ML]1;'^D;W?F;ZIT,6:;\56NG%Y2\?8WNC?JUVU2'34>FLKYJAD;7R/<W:5QB
MG0JGE+Q]:UTCM$[SBL5BTX1EJ-KY_1L^7WC+EW4SXI3"X:.AAH6;8HVM:8+N
MK\EDST=Q!(
M
M
M
M      #JK*&*N9MEC8Y"<74>)T6]=,(RT^Y\#N8SY?>-^+=37DJJ%&=$Z-^C
MV[7?E&I!\+!Z+=:YKD_2-O=^;W2B\DQY&FG)<=IPK#0]^7TDO\$Y^3<U?BMT
MA56MV]$,R8
M
M                          <9(TF9M<W<TE-=!1+M@])%<^F[KOD->+=?
M&JJ% JJ.6C=LD:YJFZ;FO%'IJ^3^,?YI+3ZWCV6O#M1<>NWEL^+BC+GF$M(Y
M+DM=C@M;.ZW<_P"9QS\F:K63/1[2E(
M
M
M
M                               /'<K'3W2/OMVO^9I=CS5"-3U4^CP6
MR.9SII.8W=W6M+[WGPH:0K4,+*=FUC6-;^28ZKJM<CP
M
M
M   =-90Q5S-DK=S2<74>*-3U>.EPO34LS7KZ3;ZNXNO<UJCP5%K=G1/ S+'T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        -*':
MB]O?GWF-Q\5G"SP88=@N&,K/6/M=RORT<%=4RUT:?HB*%E1K2P04Z[FRS3HJ
M;V/]1K=SPQ!G1QZ]J?V05!9<P\\X[%F'EO/5QP5\4]+:YZ:&23^\RST$<<].
M]?!CUW1;]$[_ *JANPX$N,W"7:!\*N$<V<%NE;9L54JO=2SZ<^W5$;W1STTN
MGOQR,<W7P<FCF]UR*!H!X,^V+[3GM$\?XFL&3-ZP_BRX88B2LKX'V?#]!R('
M2+&QVZJ2-'=>FB*J@95SA[7'M/\ LLEL^+^(C+?#5[P%65\=+/)-2VYT,JN3
M7DI56R5R4\CD:[8LK535OJO1- -U?!-Q?X;X]^$G!^;6#'/;:L7V_P X932N
M1TMOJ&JZ.:FD]F^*9CV*O@NW<G14 T\<3&=_:_\ "1D/B7,C&F),O*/"N$:/
MSVY3T]'8ZB6*/>UNJ1MBU5=53H@%E\!7'3VK7:3Y-5^/<JL68%N>'+?=Y;'-
M+6VRR44C:J.*&5Z(Q\**J;*B/KX?N ;ON%6]9@8+X/,*W+/:LMT>8-KL?G6+
MZJEY7FL<\:.?*].2B1[$8W7NIH!I9N';E<;G:^<3>)L(\%F';;A/!>%W.<ZZ
MU%#12U;J5SW-BJ*VHKT?#$^78Y60Q,WIWTUDVJY \^<7'5VJW9$TE'CC.FDL
MF9^6L=1%!6ROH;=5T<&Y^FV2HH(XJFG5W@V25%CW.8FCE7:H;M,@,[K]Q*\(
M6'L>PX1O> <28LP^EP@L-\:UM9:JA\;EC9+[--^U45R-56N17,8[5B!IFXKN
M(/M=^"WA_P 29G8[Q)EY0X3PI%%-<9J6CL=3+$V2=D#-(VQ:KWY6^'V@6]P,
M<:?:P]HKD>[,+*_%> ;EAEMQFM?-K+;9*.7GQ(Q7IL?"BZ:/;U W<Y&XPQ9E
MAP9X;Q#G?74%/C'#N%HKCC>KIVQNIHJJ&FYE9(U(4V[$5KU]&FFG@@&D^W]M
MAQX]L=Q!XHL?!UAVW8'P+AAZM?7S4=!+/'3O<]():VIKDDB9+(C'*V&!NYO?
MZO1JO Z\V.T([4SL?JJV8LSUM5FS1RVEJHJ6HF=1V^>D:KETY:U-O9'/3R.\
M&/G:YBNT1&O75H&]7AWS6J\],BL)8RK\+W[!-9B:UP7&:Q7F-(Z^U/D8CUAE
M1%71Z;OJ7YFM75J!>8 #HNEUI[);:BMJYF4])1Q.FGED[K8V-3557ZD0#0WA
M7M4^/+MML]<>LX0JC#N5^5>!9TBCK[G2T?/KD<YZT_G$M3#.OG$K6.=RH&-9
M&W1KW+JCGA*/L5.T7XL\?\4F..'[BDRVND^(,%T_.=CB@L[*>CBFVMD9!524
MZ)1OY\3T=#)#LUV[5:[7<T-I
M
M
M
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M"C".:U[P#=\N[AB%DFZW5J[HJI&+HE72O71SZ:3Q8KVM7Q]9NU[PD0
M
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M)=43JC)8U_;(!D4
M
M
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M;4QL@>]?!$;([7P0"9]!1PT5'##31QQ4T+$9$R)J-8UB)HC41.B(B> '<
M
M
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M,9$QJ:(U$3HB(G1$0"(O;^_I-O$%^QEW\_$!%#R,/]*JQA_RFW+_ #9:P-N
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MNX",KJK!>4F%8\'X9KKE)=YZ**LJ:IKJJ2.*-\N^HDD?U9#$FFNG=\-=0,K
M
M
M
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M
M
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MNI;F]B-TK85I)I6,9)XK&Y6N8_>B(K-KG!G$
M
M
M
M                   '&9FZ%R)ZVT#4?Y*SV8F>79O6O/./.G _X%OQA+8G
M6A/IBWW+SQ*9+CSOZTGEV;>=%Z^W7=W==%T#9]Q'83K\></F/+'::?SJZWK#
MMPH*2#F,CY\TM-)'&S<Y48W5[FIJJHB>U0-778'\ '$IV:/9P\0UIQ!ERZU9
MJ7J>>XX,M#;[:ZCZ2JDMW+I]9HJET,;>>UJ+S7MZ:J!Z/)<^R"S2[.F#-S%^
M=>%688QIBZ6CM=KIWW2CN,OF,6^6:7F4LTK$YDTL:*CG;M:?731450V6\7.0
M-%Q5\+>8F6UQ6)E+CK#U;95D>W\0^>!\;)?M8]S7)];0-7ODRO9T<2O 7AO.
M?+S.O MRP1@['%-3U]HN5%B:W5,U-6HR6GJ.4M'4RRQR/A?$YLFB;5IO'70#
M L_9(=H+V-F>.)+YPJXP=FM@+$U:ZNJJ*JJJ1T]6KEUWUU%6/:Q]0G=19Z9_
M,>G5=B*K$#HSZR/[5WM?\(4^6>8F%<.95Y;W:HC^F7NDH[523I&]KVK4,;-/
M62,1[-R1QMV*[17)T:J!MQ[-SLTL-=G1P)6W):Q72XU$LT$\]]OU+(^CJKC<
M:F-K)ZN)455@5$:QL6BZL;%'U5R*Y0U*S]DAV@O8V9XXDOG"KC!V:V L35KJ
MZJHJJJI'3U:N77?7458]K'U"=U%GIG\QZ=5V(JL0.C/K(_M7>U_PA3Y9YB85
MPYE7EO=JB/Z9>Z2CM5).D;VO:M0QLT]9(Q'LW)'&W8KM%<G1JH&W[LM>SOPW
MV7O!OAW*O#]8^[5%(Y]PO=U?'RUN]RF1.=4;-5V,[C(V-U7:R-B*KG:N4)$@
M
M
M
M
M
M
M
M
M                                .,LK(8W/>YK6-;N<YW=:UH'5;;I3
M7BFY])44]5"[N[XI$D;^Z@'>              !\DD;"QSWN:UC6[G.=ZK4
MZ;;=*:\4S9Z2HIZJ%WJOBD21O[J =X'"HJ(Z.%TLLC(XXV[G/>[:UJ?6H'"W
M7"GNU&V>EJ(JBGD]5\4B/C=]BIT [@       .,TS*6%TDCFQL:W<YSG;6M0
M#A0UU/=*..>FFBJ().\Q\3DD8[[%3H!V@
M
M
M
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M)5UT[D39%D?]J(H&9P
M
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M[-VFYVF[3<OB!>(
M
M
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M6X*\#X&S4S K<R<;V6DV5]WJ._MW.W)3,D<G,F9"GHVRR]]Z-W+M31K0SP
M
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M[\44,EJ6AIKLMM=1HVL27FJ]*:?=ZNFFU/M]@&R#_9HM[_XHF(/^>DG_ ,K
MV[Y48KH>T!X#+#>+[9:C#]MSFP-#4W&T^<<^6WPW*@:LM/S%C;O5B3.;N5C=
M5;KM3P _/5DYAWC3\F!X@<=1V3+67,/+'$,L3:RXLM-376.[PPJ_S:I;44_>
MHZA&2O162_,J*QZ(QP$T>%+RSW*W,3%E'9<WLK\2Y8^<3-II+M;K@V]4-*Y5
MT62>/E0S1L3V\MDKD^"@36[;[-BBK^Q&SOQ3ARN@O%IQ!@K]!5M%(DT%92UJ
MQ1)-&].CHW1S;D5.FWJ!$OR+"SPP=F=F)7M;^B:K,VL@>[XLCM5K5B?NRN S
M?Y559H;IV(^:$\K=7V^XV2I@_)>MUI(OY$K@(U=D=BF;$'DC.<=)*CFLL."L
MP**)7>\QU)65'3ZM9G?>!Y/(E/[DS.K]EM+_ -#0"\/+4OTL_+S_ )3Z/_-5
MT E%V7_^]_,M?^2A_P#T24#1UY-AVR.4_9*.SF7-"AQE6?U0/H/Z-^@;?%5[
M?,_I'F\WF31[=?.HMNFNO>\-.H9F[;[MZ\+]L=D;AW(#(#+O,:ZW2_8AI:VI
MEN-NA;4UBQ->D5-34]/+,]ZNDD:KG.5NW9IM7=J@3SS+X:;[V:WDJ&+LN+RU
MOX367+NN@O+('(](*JZ53Y*F'<BJCTB6M?&KD714CU3H!87D55FIZ?LX\RKB
MUOZ*JLR:BGD7YF1VNW.8W]V5X&XH#&_&5_<B9K?L/N__ $*8#\MO8/\ ;6UO
M9$6K-"GH\H+CFI^'TMLD>ZEOCK;]&^:)5HB+I2S[]_G'Y.G+]NO0-@?^S1;W
M_P 43$'_ #TD_P#E8&\/!&)'8PP99[NZG=2K=**&L= KMSH.9&U^S71-=-VG
M@@%4
M
M
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MY-535O15315#)0
M
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M
M
M
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MQ_H-8:6G1S-?%CIJ>=R+[=VJ ;10
M
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MK.K%<_8K]F[3<[3=IN7Q O$
M
M
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M(U$1.B(!40
M
M
M
M
M
M
M
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M>O3=KT D2
M
M
M
M
M
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MOT=G?;*>57Q>8W*T154M,NJJKHH)Y4<U%55;YNSVM RMY<7_ +L\,W^(Q/\
MRK2!M<R+[+OAFNN2&#:NKX=<BJJJJK'12SSRX!M3Y)7NIV*KW*L&JJJ]550,
MIY/\#F2G#WB[\(, Y/Y6X'OSH'4OTEA_"M!;*KDO5JOBYL$37[%VMU371=J
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MW8U6L544)D
M
M
M
M
M
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M*UMMNTM#'1U_G5%_7-!51PHV)7MC9(]LK6IKRGHY7JYK@-S8
M
M
M
M
M
M
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MX$MU==KC2RR[^5)65T,M)%1PR:(D[XJ>6197)T16MU1%>U /T/
M
M
M
M
M
M
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M:FB,CC:B-8Q$\$1- />
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
0                  #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>dna-20251231_g4.jpg
<TEXT>
begin 644 dna-20251231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0*<17AI9@  34T *@    @ ! $[  (
M   .   !2H=I  0    !   !6)R=  $    <   ">.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M3F5I;"!*;VAN<W1O;@   >H<  <   $,   !:@     <Z@    $
M
M
M
M
M
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
MM1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#
M! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1
M Q$ /P#Z1HKS;XE>*M8LM;L= T.XM+&>:2QN%FN6?=<%K^*+RD"LIVC.9.N4
M;&.<B]XK\9^)-!\)6&I)X<2"ZD:V%^+FX1XK0R3)$4&QLR-E^,87').<*0#N
MZ*XKQ5XRGTWQ =(L-2T32?L]JEU=7VLN?*7S&98HE =/F8QN22W  X.:C_X2
MCQ+JE]8:5I-IIMAJ;:4NI7HNV-S&FYBB1H8W (9E<[\\ #Y23@ '<T5D^%M<
M'B7PIINLB$VYO+=97A)SY;$?,N>^#D9]JUJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;_&I:* (OLR?WI?^_K?XT?9D_O2_]_6_QJ6B@"+[,G]Z7_OZW^-'V9/[TO\
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MI:* (OLR?WI?^_K?XT?9D_O2_P#?UO\ &I:* (OLR?WI?^_K?XT?9D_O2_\
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M;_&I:* (OLR?WI?^_K?XT?9D_O2_]_6_QJ6B@"+[,G]Z7_OZW^-'V9/[TO\
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M._UKTZBBBI44[65K"KUHU;)1M8****Q.8**** "BBB@ HHHH **** "BBB@
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M<_\ S[2_FO\ C4M% $7G/_S[2_FO^-'G/_S[2_FO^-2T4 1><_\ S[2_FO\
MC1YS_P#/M+^:_P"-2T4 1><__/M+^:_XT><__/M+^:_XU+10!%YS_P#/M+^:
M_P"-'G/_ ,^TOYK_ (U+10!%YS_\^TOYK_C1YS_\^TOYK_C4M% $7G/_ ,^T
MOYK_ (T><_\ S[2_FO\ C4M% $7G/_S[2_FO^-'G/_S[2_FO^-2T4 1><_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 445'/<P6R;[F:.%?[TC!1^M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF?M*,?AA?U?Z*QR7]D>*]1_X_M72S0_P6XY'Y8_G4D'@+3]_F7]Q<WDG<N^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB\E_^?F7\E_PH\E_^?F7\E_PH EHJ+R7_P"?F7\E_P */)?_ )^9?R7_  H
MEHJ+R7_Y^9?R7_"CR7_Y^9?R7_"@"6BHO)?_ )^9?R7_  H\E_\ GYE_)?\
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M2_\ S\R_DO\ A0!+147DO_S\R_DO^%'DO_S\R_DO^% $M%1>2_\ S\R_DO\
MA1Y+_P#/S+^2_P"% $M%1>2__/S+^2_X4>2__/S+^2_X4 2T5%Y+_P#/S+^2
M_P"%'DO_ ,_,OY+_ (4 2T5%Y+_\_,OY+_A1Y+_\_,OY+_A0!+147DO_ ,_,
MOY+_ (4>2_\ S\R_DO\ A0!+147DO_S\R_DO^%'DO_S\R_DO^% $M%1>2_\
MS\R_DO\ A1Y+_P#/S+^2_P"% $M%1>2__/S+^2_X4>2__/S+^2_X4 2T5%Y+
M_P#/S+^2_P"%'DO_ ,_,OY+_ (4 2T5%Y+_\_,OY+_A1Y+_\_,OY+_A0!+14
M7DO_ ,_,OY+_ (4>2_\ S\R_DO\ A0!+147DO_S\R_DO^%'DO_S\R_DO^% $
MM%1>2_\ S\R_DO\ A10 L]M!=1B.ZACF1720+(@8!D8,K8/<,H(/8@'M4E%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %9VLZW::):&:[?+G_5Q+]YS[
M?XU5U_Q+!HJB&-?M%[(/W<"\]>A/^<FJ.C>&II[L:OXC;S[QCN2%ONQ>G'K[
M=!]:VC!)<T]OS.FG22C[2KM^+_KN4[?0+[Q5+_:'B&22W@(_T>WCP"H/?D''
M\S74Z7I=MI%BMK9*1&"22QR6)[FKE%*=64M.G8FI7G47+LNP4445D8!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%!.!D]* "N;U[Q,]O<C3-$C^U:B_'RC(B^OO_ "[U6U77[O5KTZ3X
M8^9^DUV#\J#O@_U_*M?0?#]MH=L1'^]N''[V=ARWM[#VK=15-<T]^W^9UQIQ
MHKGJ[]%_F5M \-+IS&]U!_M6I2_,\K'.S/8?XUOT45E*3F[LYZE2527-(***
M*D@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ J.>>*VA::XD6*-1EG<X K"U?Q=:6,OV6P0W]ZQ
MPL47(!]R/Y#]*H0>&]2UV9;KQ1<,L8.4LXC@+]?3]3[ULJ6G-/1'3&A9<U5V
M7XOT1D7OCR_77'>T>-K%),+'L'[Q0>N3R,UW&FZYIVK+FQND=L<QGAA^!YI\
M.CZ;;[/)L+93&,*WE#('UZUEZEX,TN^8RP(UE/G(D@X&?]WI^6*N4J,[*UC6
M<\-4LK.-NO\ F=!17'_\55X?_NZQ:K]?, _G_P"A5H:=XSTN]817#-93YP8Y
M^!G_ 'NGYXJ'1E:\=5Y&4L/.W-#WEY?U<Z"BD5@RAE(((R".]+6)S!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%0W=Y!86KW%W*L42#)9J-]$-)MV1)+*D$3
M2S.J1H,LS'  KRO5-9U/6]:G@LKF=X)9#'%#$Q563.!D?3DYKH?]-\<77\=I
MHL3?\"F(_P _0>YKKK.SM["U2VM(EBB08"K_ )ZUUQ<:&ZN_R.^G*.$UDKR[
M=O\ @D.E:3::/9BVLH]J]68_><^I-7:**Y6VW=G!*3D[O<****0@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M?ZA:Z9;)/?2^5$\
MT4"MM+9>618T' [NZC/09R<"K->3?&+0[FXO[#5;O2SK6D++8VSVR2#S+=S?
M1%F1#@,9%/E9!!&1V)(C\:V=KJ'P>TK4M.US5;VRM)+!8%N9 &F;[7$A:?"A
MF< E<' !R2-P! !Z[17!ZSI-CXI^*DFDZ];+=V%EHB7$$$N2@EEFD1I .FY1
M&N&ZC=QC-<SX0M8?'%WHUAXK']J6]GX9BFB$Y+!Y7FDB,WH7"PKANH+$CK0!
M[%17,_#>\N+_ .&VA3WEPUS,;15:9CEI-ORAB>Y(&2>]=-0 44UY!& 6#'/]
MU2W\J9]I3^[+_P!^F_PH EHK+US78=#\/:CJTL,TJ6%K+<M&L; N$0L0"1WQ
M7@_@;]H+Q1XX\7)X>.F:?:M>A_LTMLKEHMJECNW,0?E4\@#Z4TKNQ48\S2O8
M]\U;7+#1H=][, Q&5B7EV^@_K7.;]>\6_<SI>F-W_CD'\S^@^M6])\,6=K-]
MKU1IM0O6.XO+$Y4'V!'/U/Z5T?VE/[LO_?IO\*VYH4_@U??_ ".GVE.C_#U?
M=_HO\REI&@6&BQ;;.+]X1AIGY=OQ[?05I5%]I3^[+_WZ;_"C[2G]V7_OTW^%
M8N3D[LYI2E-WD[LEHJ+[2G]V7_OTW^%'VE/[LO\ WZ;_  I$DM4-2T33M67%
M]:I(V.)!PP_$<U:^TI_=E_[]-_A1]I3^[+_WZ;_"FFT[HJ,I1=XNQRI\,:OH
MS&3PYJ3-'G/V:<\'^G\OK4<OCB\TV,Q:QH\D=T/N[6VH_KR<_IFNN^TI_=E_
M[]-_A6;K.F6&NVZ17J7 V'*/'&P9?7M6\:L9/]XK_F=<,1"<E[>-_/J3:'K,
M.NZ:+N!&CPQ1T8YVL.V>_45HUQ&B79\*ZQ)I%Z6^Q7#;[>=D(.3@8/'T'U^M
M=E]I3^[+_P!^F_PJ*L5&6FSV,L134)^[\+V):*B^TI_=E_[]-_A1]I3^[+_W
MZ;_"LCG):*B^TI_=E_[]-_A1]I3^[+_WZ;_"@"6BHOM*?W9?^_3?X4?:4_NR
M_P#?IO\ "@"6BHOM*?W9?^_3?X4?:4_NR_\ ?IO\* ):*B^TI_=E_P"_3?X4
M?:4_NR_]^F_PH EHJ+[2G]V7_OTW^%'VE/[LO_?IO\* ):*B^TI_=E_[]-_A
M1]I3^[+_ -^F_P * ):*B^TI_=E_[]-_A1]I3^[+_P!^F_PH EHJ+[2G]V7_
M +]-_A1]I3^[+_WZ;_"@"6BHOM*?W9?^_3?X4?:4_NR_]^F_PH EHJ+[2G]V
M7_OTW^%'VE/[LO\ WZ;_  H EHJ+[2G]V7_OTW^%'VF/TE_[]-_A0!+17"^*
M/&DT%XEOH=PFU1F60)N^;/W>1_G-:.D>.M.N;2-=2E^S7.,/E#M)]01G]:W=
M"HHJ5CK>#K*FIVW^\ZFBJL&HVMU&)+:0S(?XHT9A^8%2_:4_NR_]^F_PK Y+
M-;DM%1?:4_NR_P#?IO\ "C[2G]V7_OTW^% $M%1?:4_NR_\ ?IO\*S=8\1V6
MC6V^?>TK#]W#L*E_S'3WIQBY.R*C&4Y<L5J6]4U6UTBS:YO9-JCA5'WG/H!7
M+VEA>>,;M;_5PT&F(<P6P.-_O_\ 7_*ETW2I];OAJWB9)"/^6%IY3;5'OQT]
MN_>NM%Q&  %D '0"%O\ "M[JEI'?O_D=3E'#JT-9=^WI_F/BBC@B6*%%2-!A
M548 %/J+[2G]V7_OTW^%'VE/[LO_ 'Z;_"N<XR6BHOM*?W9?^_3?X4?:4_NR
M_P#?IO\ "@"6BHOM*?W9?^_3?X4?:4_NR_\ ?IO\* ):*B^TI_=E_P"_3?X4
M?:4_NR_]^F_PH EHJ+[2G]V7_OTW^%'VE/[LO_?IO\* ):*B^TI_=E_[]-_A
M1]I3^[+_ -^F_P * ):*B^TI_=E_[]-_A1]I3^[+_P!^F_PH EHJ+[2G]V7_
M +]-_A1]I3^[+_WZ;_"@"6BHOM*?W9?^_3?X4?:4_NR_]^F_PH EHJ+[2G]V
M7_OTW^%'VE/[LO\ WZ;_  H EHJ+[2G]V7_OTW^%'VE/[LO_ 'Z;_"@"6BHO
MM*?W9?\ OTW^%'VE/[LO_?IO\* ):*B^TI_=E_[]-_A1]I3^[+_WZ;_"@"6B
MHOM*?W9?^_3?X4?:4_NR_P#?IO\ "@"6BHOM*?W9?^_3?X4?:4_NR_\ ?IO\
M* ):*B^TI_=E_P"_3?X4?:4_NR_]^F_PH EHJ+[2G]V7_OTW^%'VE/[LO_?I
MO\* ):*B^TI_=E_[]-_A1]I3^[+_ -^F_P * ):*B^TI_=E_[]-_A1]I3^[+
M_P!^F_PH EHJ+[2G]V7_ +]-_A1]I3^[+_WZ;_"@"6BHOM*?W9?^_3?X4?:4
M_NR_]^F_PH EHJ+[2G]V7_OTW^%'VE/[LO\ WZ;_  H EHJ+[2G]V7_OTW^%
M'VE/[LO_ 'Z;_"@"6BHOM*?W9?\ OTW^%% ')>-/ (\27,5_INH7.FZCYMFL
MTD,BJLT,-RDW(*-\ZX<H<#YL G;D5+JOP\L=2\*6?ARWU34].TVV*LR6S1,T
M[+(LJL[2QN<AUW<$9).<CBNMHH YK4?!B:D]I</K>JP:A;V[6KW]N\22W$3$
M%E<"/9U&054$=B,TRY\ Z:T&G1Z5=W^C-I]G]@BDT^559K?C]VV]6!'R@YQN
M!R01DUU%% %72]-M=&TFTTS3HA#:6<*PPQ@YVHHP!GOP.M6J** "BBB@!LD:
M31/%,BR1NI5D89# ]01W%?/GQ-^%Z> [^S\9?"^V;3[^P<SO;QL[K*/XP%)/
M&#RHP""17T+6;KUI]KTF0*,O'^\7\.OZ9J)W4;HRJ\R@W'=&5\/O'6G?$'PE
M;ZSIS!9"-EU;YRUO*!RI]NX/<$5T]?.6JQW?P8\90>.- B>7PMK,@AUBRC'%
MO)G[P';G++[DKP"*^A-.U&TU;3;?4--N$N;2YC$D,T9RKJ1D&J335T7&2E%2
M74LT444R@HHHH **** "BBB@#,U_18M<TQK:3"R#YHI,?<;_  ]:SO"NM2SB
M32=4^34+3Y3NZR*._N?Y]:Z2N:\5:--*8]8TKY+^T^;Y1_K%';W/\QQ6]-J2
M]G+Y'51DIQ]E/;H^S_R9TM%9NA:S#KFF)<Q860?++'G[C?X>E:58R3B[,YY1
M<).,MT%%%%(D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ*YN
M8+.!IKJ5(HUZLYP*Y6X\2ZCKDS6GA:W8(#A[R48"_3/3^?M6D*<I[;&U.C.I
MJMN_0W=7U^PT6'=>2_O",K"G+M^';ZFN>\K7?%W,Q.EZ6W\ ^_(/Z_H/K6EI
M'A&UL9OM>H.;^]8[FEEY /L#_,_I70U?-"G\&K[_ .1K[2G1_AZON_T1E67A
MK2;&U$$=E#*,Y+3('9CZDFK-YI&GWZ!;RSAE & 2@R!['J*N45ESR;O<P=2;
M?,V[G*S^!;:.0S:1>W-A+VVL6 _D?UJ/_BL-(_YX:K"/^^L?H?YUUU%:>VD_
MBU]398J;TG:7K_GN<K!XZMHY!#J]E<V$O?<I8#^1_2MZSU;3[]-UG>0RX&2
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MZGJ?QJQ142J2EH]C*I6G4T;T[= HHHK,Q"BBB@ HHHH **** "BBB@ HHHH
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MR!V/&X]CAO6O7?#'B73?%WARTUK19A+:W2;A_>1NZ,.S \$4 :.VX_YZQ?\
M?H__ !5&VX_YZQ?]^C_\54M% $6VX_YZQ?\ ?H__ !5&VX_YZQ?]^C_\54M%
M $6VX_YZQ?\ ?H__ !5&VX_YZQ?]^C_\54M% $6VX_YZQ?\ ?H__ !5&VX_Y
MZQ?]^C_\54M% $6VX_YZQ?\ ?H__ !5&VX_YZQ?]^C_\54M% $6VX_YZQ?\
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MC;<?\]8O^_1_^*J6B@"+;<?\]8O^_1_^*HJ6B@ HHHH **** "BBB@ HHHH
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MQB5DLK^Y5&1AZ,<!@>Q_04 >C454L=6T[4UW:;?VMVO7-O,L@_0U;H ****
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M%VF+J'AS4H+^W.-QB;YD/HRGE3[$ UK4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !117G7Q8^*<'@'38['3(Q?^)-0^2QLE!8@DX#L!SC/ '5CP.Y
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M#MEI%H[R16D03S)#\TC=6=L=R22?<UI4 ->6.( R.J ]-QQ3/M=O_P ]XO\
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M>)_[8TU.1I&IXX']U<G;^*E* /<?M=O_ ,]XO^^Q1]KM_P#GO%_WV*\=T?\
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M HHHH **** "BBB@ HHHH H:QH6E>(;!K+7-.MM0MF_Y9W$0< ^HST/N.:\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6+XDA9;>&^B_UEM(#GV)_QQ6U45S MS:R0O\
M=D4J:B<>:+1E5A[2#B+!,MQ;QS)]V10P_&I*QO#4[?8Y;.7B2V<J1[9_QS6S
M1"7-%,=*?M(*044459H%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_GE%_W]/_Q-&ZX_YY1?]_3_ /$T 2T5%NN/^>47_?T__$T;KC_GE%_W]/\
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M+W/W<OEYF.'O22H2Z;/NB_1116YV!1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445Y9\8-;O;*:QT^;46T?2K@12?;! KJ]PMU#A&=E*H%3<_.,
M[>N 00#U.BN.:T\7:CIVG277B2QTF".R,EY>:9&DOGRY&&7SD*K%L!8]\GK@
M9.)HGB+Q'XP&A6$.IMI$DVD/J-U>6UJC--^]\N':L@955P&<C&<8 (ZT >F4
M5A>"M9NM?\&Z?J.HHB7DB,EP(QA3(C%&*CL"5)'L:W: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YZ\MI=#O#?V*EK9S^^A';_/Z5T-(0&4J
MP!!&"#WJ)PYEYF56FJB[-;,CM;F*\MUF@;<C#\O:I:YR:.7P[??:+<,]A*WS
MI_</^?\ "M=-7T^2(R)>P,JC+8D!*_4=:F-3I+1D4ZR?NST:_JZ+E,FFCMXS
M)/(L:#J6.*Q9=>FO)##HULTI[RN,*/\ /O2PZ!)<R";6+EKA_P#GFIPH_P ^
MV*7M.;2"O^0O;N6E)7\^@3:_)<R&'1[9KA_^>C#"C_/OBDBT&:\D$VLW+2GM
M$APH_P ^U;4,,=O&(X(UC0= HQ3Z/9\VLW?\@]@Y:U7?RZ%1M)T]XU1[*W95
M^[NC!Q^-8\D=SX<N#+!NFL'/S)W3_/K71TC*'4JX#*1@@CK52IIZK1E3HQEK
M'1KJ1VUS%=VZS6[AT;H:EKGKBVGT"X:[L 9+-C^]AS]WW_\ KUM6=Y#?6XFM
MVW*>H[@^AHA.[Y9;A3JN3Y)Z27]71/1116AN%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR6__ #PB_P"^!4M%441?9+?_ )X1?]\"C[);_P#/"+_O@5+02%!). .23VH
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M $7V2W_YX1?]\"C[);_\\(O^^!4M% $7V2W_ .>$7_? HJ6B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N5\61OH\"ZKIA,4YD"/M&1R#\Q'X8_&NJILD:2Q
MM'*BNC##*PR#^%9U(<\;=3"O2]K3<4[/H^QQ_ASQC)-;R+K&YV5AMF1 ,^Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *P[?PCI5KJPOXDDWJV]8RWR
M*?4#']:W**B4(RLY+8SG2A4:<U>VP44459H%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 C*&4A@"#U!%9MUX?L+G)$7DO\ WHCC].E:=%3*,9;H
MB=.$U:2N</XFCUG1;%/LM_.]LS89UR&3T&>H%7O"OB!I-/6#6)66;=^[DE&-
MZ]LGUZ\FNJJO=V%M?1[+F(/Z'H1]#7/[&49\\)?(XOJDZ=7VM.?R>Q8!! (.
M0>A%%<^;#4]'.[393<V_4POU'T_^M5RQUZVNV\J;-M/T*2<<^QK55%>TM&=$
M:ZORS5G_ %LS4HHHK4Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **QX_%>CR^+&\.17T#ZDD'GM"LR$J,XVD9W;N^,=.:V* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "J=]I5IJ"_Z1'\_:1>&'XU<HI-)JS)E&,E
M:2N<_P"5JVB\PG[=:C^ _>4?Y^M:%AK5IJ&%1_+E[QOP?P]:T*R]7T6&_MI6
MB01W6P^7(O'S8XSZ\UERRA\'W'.Z=2DKTW==G^C-2BO.?#NF>(K75I)(HI8.
M#YIG&%?\^O/>NJ^T>(H^MI;RCU!'_P 544Z[G&[BT94,8ZD.:4&OE<W**P_[
M7U:/_6Z2S?[A/_UZ/^$CD3_7Z9<1_P"?<"M/;0ZFWUFGUT^3-RBL1?%5B3AX
MYT/NH_QJAJ'CRSL[I8H+:2X7C>V[;M^@QS^E3+$4HJ[9,L9AX+FE(ZJBLE?$
MVEO&KK.V& (_=M_A0?$NFC_EJY_X :OVM/NC3ZQ1_F7WFM16.?$^G#^*0_\
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M3^T[O_H"7_\ WW!_\=JY<VT=U$(Y<E5D208..58,/U J6@#._M.[_P"@)?\
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MHI/X5JU%-;1SRP229W6\AD3![[67^3&@"G_:=W_T!+__ +[@_P#CM']IW?\
MT!+_ /[[@_\ CM:-% &=_:=W_P! 2_\ ^^X/_CM']IW?_0$O_P#ON#_X[6C1
M0!G?VG=_] 2__P"^X/\ X[4=OK4UU:Q7%OHU^\4R!T;= ,J1D'!D]*U:BM;:
M.SLX;:'(CAC6-,G)P!@?RH I-J%PXP^A7K?5K<_^U:Q=2T2VU.\6XFT#4HW
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MS\/QI.O7FK:O>?VA+]ON[G3H=N([)9YGD8@=Y#OP7]  ,<YT](TB+56M=?\
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MEX=4U2.V2U-XZ;1'"@PL4:\[%XR>[-DGMCL:** "N;UKQSH6CZDVF7=\\-R
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ML ":\UOKWP[XH\7&YUR>Z&F:A"EKI=_YLMJVGWD;-YD##Y3#,258;A\VW'.
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MV*6]OKDLT9BLP,X;);S%V9#CRURQ[C&: .?6UT'7-732O FJ1QV&M1R7$]C
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M&EN)""=J@D#HK$DD  $DBF:]XHTCPS%"^LW1A,Y(BCCA>:23:,L51 6( Y)
MP.]<Y;RV>H>.K&6YNC?Z?? :KH-TDQVQRK"8I8E(ZJ8W#A>^9/2@"M+I-QXU
MU(>+-$U"ZTC4]/A-G:VMU#M\B99&,T=PH8B1'^0?+TVAE).*-#U>3QEXML[^
MULKG3-0T/S;35F8![>3=PULK@C>0RI(& PHX."Q%0V6@(_CBSN-"T#4](GM;
MZ>;4M2O'XNHV#CRP=[>:&9E8=D [' KT*TL[:PMQ;V-O%;0AF81Q(%4$DDG
M]22?QH ?%#%;H4@B2)2Q8JB@ DG)/'<DDT^BB@ HHHH **** "BBB@ KS?7?
M#USI5AJ%CJFHVO\ PB5_J+7=RILY)KK][+YCP80$%&<D;B,A21Z,/2** .)\
M >'3;65IJUT+V&XCBGL[=+DXD>R\\M;B93SO5,8S@@,P/)-=M110 55U._BT
MK2;O4+DXAM(7FDYQ\JJ2?Y5:IDT,=Q"\-Q&DL4BE71U#*P/4$'J* .2T"_TW
MQQ?:;XAA^TV6HZ3'-!<:=.H$D!F5"5<'_<4JPX(Z<$BN5TXGQ+=:OX6TNS>,
M6_B"XN[K4%;:NGLLV^,QD@[I6<;MO0*26X(!ZKQAX5U#5=8T[4/#5T=)U'<;
M>\U*)AO%J5)*;"")#G&W/W#\WJ#U-E9Q6%JL$ . !N=CEI#C!9C_ !,<<D\F
M@">BBB@ JGJ^F0:UHE]I=YN^SWUO);2[#AMCJ5.#V.#5RB@#S;QM8:=!>)$E
MSXE?7(]-6WTI=.69%WY.#YD:B,DLJ%A(=@"J2 *['PQH?]@Z2T+.3-<2FZN$
M4_NTF< R^6/X5+[FQSRQ^E;%% !1110 5YSXPT75+#Q%)J%M'=WGA_5Y(?[9
M@T]6-U'Y2,%*!/F9&_=JZK\P"G&<FO1J* //O!/AN%]9EU:VBU*TTRRF9-'B
MO \<GDR1J)D*R#>(2ZJRJV""N1A2 ?0:** "BBB@#"\5:'=ZS:V,VEW,5MJ&
MF7BWMJTZ%XF<(Z%7 YVE)&&1R#@]L5P3Z%_;7C8)?[KW5KR66WUY;:VEBLXK
M VY40[W #G?Y;*02VYG( &0/6J* (+*U^Q:?;VHFEG\B)8_-F8%Y-HQN8@#)
M.,GCK4]%% !7+:OXWTS3/%T?AW4HYHDGMXV>^'^IA>5G2.-V_@+[&VD\$@#J
M1GJ:JWNEV&HVMU;7UG#<0W<?E7"21@B5.?E;U')_.@#@/%,>G^ - \"0RF:X
MM])U)+:&14S,X%G<*JJJ@;F; 7'<D=ZZ7PAI=Y;?VAJVHV_]GW.L2K<S:<D@
M=+=P-H.<??9!'OQQN7CKDT_!/A?5=*MVD\2:C->LCE;&SEE$RV,*LVP;RH+R
M;6P7/.,#G!)["@ HHHH *YS7- L5&NZO+/?Q-?Z8MI<_8T\Q_+C\P@QJ%8E_
MWK#C/;C/-='10!YKX8\/VNJZVT^F2ZP/#VGO;SZ<]^\V\72[Q+Y7G?.(FC8(
MP/RG)VXQFO2J** "BBB@#&\6:$_B/PS=:;#<"VG=HY8)BNX1RQ2+)&2.XWHN
M1W&:\YCMM3O[V*2[TS6;;QL=2!DFV3-8I:^=\R>9_J6A\CC;]\MSM#=/7Z*
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M+R5HUBR#ND8\E?NA&.?O 5ZY45K:Q6< B@4*N<D]V8]6)[DGDGN:EH ****
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M6L(BMXUC3)8A1C))R2?<DDD]R: )**** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM/L]3M'M=2M(+RW?&Z&XC$B-]5(P:2PTVQTJU%KI=G;V5N"6$5O$L: GJ<*
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M030!T6:=)%D D=5VL%(;G<..#SCMM">\CB%C<:%#I-M:VT A%O.CQ9*G=$@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5DX9R&&&&"HZBK9\&1+\-[[PG#>N/MMG<P27DD89C)/O+RE00/OR,VT$>F:
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MEPS'-R !N?:0-H#[E')SM)Z8SMT %%%% !1110 4444 %%%% !1110 4444
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M]=910!S-KX&L;74(95O[^2RM[I[RWTUY$^SPS,6)880.>78A6<J"> ,##9?
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 16, 2026</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GINKGO BIOWORKS HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-2652913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">27 Drydock Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">8th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">422-5362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">The information required by Part III of this report is incorporated by reference from the registrant&#8217;s definitive proxy statement relating to its annual meeting of stockholders to be held in 2026, which definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001830214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,941,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,982,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Nonvoting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 167,202<span></span>
</td>
<td class="nump">$ 561,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">255,418<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">24,026<span></span>
</td>
<td class="nump">21,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable - related parties</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">24,963<span></span>
</td>
<td class="nump">18,729<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">471,838<span></span>
</td>
<td class="nump">602,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">167,783<span></span>
</td>
<td class="nump">203,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">360,918<span></span>
</td>
<td class="nump">394,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Investments</a></td>
<td class="nump">15,066<span></span>
</td>
<td class="nump">48,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">56,924<span></span>
</td>
<td class="nump">72,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">47,167<span></span>
</td>
<td class="nump">55,336<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,119,696<span></span>
</td>
<td class="nump">1,377,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,566<span></span>
</td>
<td class="nump">14,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue (includes $98 and $795 from related parties)</a></td>
<td class="nump">18,946<span></span>
</td>
<td class="nump">27,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">66,458<span></span>
</td>
<td class="nump">65,387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">95,970<span></span>
</td>
<td class="nump">107,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion (includes $64,787 and $72,260 from related parties)</a></td>
<td class="nump">75,182<span></span>
</td>
<td class="nump">98,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">417,078<span></span>
</td>
<td class="nump">438,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">22,876<span></span>
</td>
<td class="nump">16,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">611,106<span></span>
</td>
<td class="nump">661,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value (Note 13)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">6,657,053<span></span>
</td>
<td class="nump">6,555,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(6,150,320)<span></span>
</td>
<td class="num">(5,837,557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">1,851<span></span>
</td>
<td class="num">(1,806)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">508,590<span></span>
</td>
<td class="nump">716,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,119,696<span></span>
</td>
<td class="nump">$ 1,377,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, related party</a></td>
<td class="nump">$ 18,946<span></span>
</td>
<td class="nump">$ 27,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion, from related parties</a></td>
<td class="nump">$ 75,182<span></span>
</td>
<td class="nump">$ 98,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, related party</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion, from related parties</a></td>
<td class="nump">$ 64,787<span></span>
</td>
<td class="nump">$ 72,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 170,155,000<span></span>
</td>
<td class="nump">$ 227,043,000<span></span>
</td>
<td class="nump">$ 251,455,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243,773,000<span></span>
</td>
<td class="nump">424,061,000<span></span>
</td>
<td class="nump">580,621,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,290,000<span></span>
</td>
<td class="nump">246,161,000<span></span>
</td>
<td class="nump">385,025,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of lease assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96,210,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,858,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,398,000<span></span>
</td>
<td class="nump">24,172,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">485,433,000<span></span>
</td>
<td class="nump">786,800,000<span></span>
</td>
<td class="nump">1,115,861,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(315,278,000)<span></span>
</td>
<td class="num">(559,757,000)<span></span>
</td>
<td class="num">(864,406,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,616,000<span></span>
</td>
<td class="nump">38,612,000<span></span>
</td>
<td class="nump">57,217,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(94,000)<span></span>
</td>
<td class="num">(93,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,635,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,411,000)<span></span>
</td>
<td class="num">(28,827,000)<span></span>
</td>
<td class="num">(54,827,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Loss on deconsolidation of subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,013,000)<span></span>
</td>
<td class="num">(42,502,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,701,000<span></span>
</td>
<td class="nump">5,168,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (expense) income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,527,000)<span></span>
</td>
<td class="nump">3,870,000<span></span>
</td>
<td class="nump">9,138,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,678,000<span></span>
</td>
<td class="nump">12,249,000<span></span>
</td>
<td class="num">(28,534,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(313,600,000)<span></span>
</td>
<td class="num">(547,508,000)<span></span>
</td>
<td class="num">(892,940,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(837,000)<span></span>
</td>
<td class="num">(479,000)<span></span>
</td>
<td class="num">(71,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (312,763,000)<span></span>
</td>
<td class="num">$ (547,029,000)<span></span>
</td>
<td class="num">$ (892,869,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5.64)<span></span>
</td>
<td class="num">$ (10.54)<span></span>
</td>
<td class="num">$ (18.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5.64)<span></span>
</td>
<td class="num">$ (10.54)<span></span>
</td>
<td class="num">$ (18.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Number of Shares Outstanding, Basic [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,457,676<span></span>
</td>
<td class="nump">51,894,639<span></span>
</td>
<td class="nump">48,610,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,457,676<span></span>
</td>
<td class="nump">51,894,639<span></span>
</td>
<td class="nump">48,610,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (312,763,000)<span></span>
</td>
<td class="num">$ (547,029,000)<span></span>
</td>
<td class="num">$ (892,869,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,531,000<span></span>
</td>
<td class="num">(4,782,000)<span></span>
</td>
<td class="nump">4,116,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,492,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(126,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,657,000<span></span>
</td>
<td class="num">(3,290,000)<span></span>
</td>
<td class="nump">4,116,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(309,106,000)<span></span>
</td>
<td class="num">(550,319,000)<span></span>
</td>
<td class="num">(888,753,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dna_CellEngineeringRevenueMember', window );">Cell Engineering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">132,746,000<span></span>
</td>
<td class="nump">173,972,000<span></span>
</td>
<td class="nump">143,531,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,409,000<span></span>
</td>
<td class="nump">53,071,000<span></span>
</td>
<td class="nump">78,975,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,521,000<span></span>
</td>
<td class="nump">38,549,000<span></span>
</td>
<td class="nump">46,524,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,949,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,481,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,451,000<span></span>
</td>
<td class="nump">$ 5,999,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:7.52pt">Includes related party revenue of $8,784, $53,041, and $22,222 for the years ended December 31, 2025, 2024, and 2023, respectively.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481724/830-30-40-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_CellEngineeringRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_CellEngineeringRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 170,155<span></span>
</td>
<td class="nump">$ 227,043<span></span>
</td>
<td class="nump">$ 251,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 8,784<span></span>
</td>
<td class="nump">$ 53,041<span></span>
</td>
<td class="nump">$ 22,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,299,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,736,277,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 6,136,563,000<span></span>
</td>
<td class="num">$ (4,397,659,000)<span></span>
</td>
<td class="num">$ (2,632,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise or vesting of equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Issuance of common stock upon exercise or vesting of equity awards</a></td>
<td class="nump">555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Tax withholdings related to net share settlement of equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockAwardForfeitures', window );">Forfeiture of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholdings related to net share settlement of equity awards</a></td>
<td class="num">(23,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SettlementOfContingentConsiderationSharesRestrictedStock', window );">Settlement of contingent consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SettlementOfContingentConsiderationValueRestrictedStock', window );">Settlement of contingent consideration</a></td>
<td class="nump">8,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for business and asset acquisitions, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for asset acquisitions</a></td>
<td class="nump">6,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock pursuant to public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in exchange for services</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">230,880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">4,116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(892,869,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(892,869,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">4,116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,116,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,032,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">1,097,152,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">6,386,191,000<span></span>
</td>
<td class="num">(5,290,528,000)<span></span>
</td>
<td class="nump">1,484,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise or vesting of equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,783,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Issuance of common stock upon exercise or vesting of equity awards</a></td>
<td class="nump">543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholdings related to net share settlement of equity awards</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SettlementOfContingentConsiderationSharesRestrictedStock', window );">Settlement of contingent consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,385,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SettlementOfContingentConsiderationValueRestrictedStock', window );">Settlement of contingent consideration</a></td>
<td class="nump">14,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for business and asset acquisitions, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">802,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for asset acquisitions</a></td>
<td class="nump">36,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in exchange for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Forfeiture of restricted stock</a></td>
<td class="nump">4,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">112,344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(3,290,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(547,029,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(547,029,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</a></td>
<td class="nump">1,492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,492,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">$ (4,782,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,782,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">54,365,785<span></span>
</td>
<td class="nump">54,365,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 716,058,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">6,555,416,000<span></span>
</td>
<td class="num">(5,837,557,000)<span></span>
</td>
<td class="num">(1,806,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise or vesting of equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,798,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SettlementOfContingentConsiderationValueRestrictedStock', window );">Settlement of contingent consideration</a></td>
<td class="nump">1,237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock pursuant to public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,940,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in exchange for services</a></td>
<td class="nump">18,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in exchange for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Forfeiture of restricted stock</a></td>
<td class="nump">777,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">776,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">81,546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">3,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,657,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(312,763,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(312,763,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">58,207,298<span></span>
</td>
<td class="nump">58,207,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 508,590,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 6,657,053,000<span></span>
</td>
<td class="num">$ (6,150,320,000)<span></span>
</td>
<td class="nump">$ 1,851,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SettlementOfContingentConsiderationSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Contingent Consideration, Shares, Restricted Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SettlementOfContingentConsiderationSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SettlementOfContingentConsiderationValueRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Contingent Consideration, Value, Restricted Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SettlementOfContingentConsiderationValueRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481724/830-30-40-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total value of forfeitures related to restricted stock awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="num">$ (1,393,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SharesReleaseFromEscrowDuringPeriod', window );">Shares release from escrow during period | shares</a></td>
<td class="nump">24,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Forfeiture of restricted stock</a></td>
<td class="nump">$ 777,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SharesReleaseFromEscrowDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Release From Escrow During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SharesReleaseFromEscrowDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (312,763,000)<span></span>
</td>
<td class="num">$ (547,029,000)<span></span>
</td>
<td class="num">$ (892,869,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">58,990,000<span></span>
</td>
<td class="nump">63,020,000<span></span>
</td>
<td class="nump">70,507,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">81,546,000<span></span>
</td>
<td class="nump">112,344,000<span></span>
</td>
<td class="nump">229,884,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,858,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring related impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,823,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NoncashCustomerConsideration', window );">Non-cash customer consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,117,000)<span></span>
</td>
<td class="num">(1,373,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,635,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on investments</a></td>
<td class="nump">16,411,000<span></span>
</td>
<td class="nump">28,827,000<span></span>
</td>
<td class="nump">54,827,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ChangesInFairValueOfLoansReceivable', window );">Change in fair value of notes receivable</a></td>
<td class="nump">5,685,000<span></span>
</td>
<td class="nump">2,014,000<span></span>
</td>
<td class="nump">2,416,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,701,000)<span></span>
</td>
<td class="num">(5,168,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Change in fair value of contingent consideration liability</a></td>
<td class="num">(4,232,000)<span></span>
</td>
<td class="nump">3,214,000<span></span>
</td>
<td class="nump">9,168,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Loss on deconsolidation of subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,013,000<span></span>
</td>
<td class="nump">42,502,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,796,000<span></span>
</td>
<td class="nump">121,404,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="num">(1,364,000)<span></span>
</td>
<td class="num">(936,000)<span></span>
</td>
<td class="num">(801,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">844,000<span></span>
</td>
<td class="nump">842,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">30,082,000<span></span>
</td>
<td class="nump">28,095,000<span></span>
</td>
<td class="nump">28,313,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NoncashInProcessResearchAndDevelopment', window );">Non-cash in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,796,000<span></span>
</td>
<td class="nump">9,182,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_AccretionOfDiscountOnMarketableSecurities', window );">Accretion of discount on marketable securities</a></td>
<td class="num">(3,390,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash activity</a></td>
<td class="nump">2,064,000<span></span>
</td>
<td class="nump">1,224,000<span></span>
</td>
<td class="nump">3,194,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable ($357, $156 and $816 from related parties)</a></td>
<td class="num">(1,473,000)<span></span>
</td>
<td class="num">(4,725,000)<span></span>
</td>
<td class="nump">50,068,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(5,247,000)<span></span>
</td>
<td class="nump">10,085,000<span></span>
</td>
<td class="nump">10,473,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncreaseDecreaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,814,000<span></span>
</td>
<td class="nump">23,463,000<span></span>
</td>
<td class="nump">9,275,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">296,000<span></span>
</td>
<td class="num">(1,394,000)<span></span>
</td>
<td class="nump">2,570,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,992,000)<span></span>
</td>
<td class="nump">4,771,000<span></span>
</td>
<td class="num">(1,183,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,376,000<span></span>
</td>
<td class="num">(40,438,000)<span></span>
</td>
<td class="nump">16,899,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue, current and non-current ($(8,147), $(51,422) and $(17,018) from related parties)</a></td>
<td class="num">(32,393,000)<span></span>
</td>
<td class="num">(68,645,000)<span></span>
</td>
<td class="num">(35,917,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities, current and non-current</a></td>
<td class="num">(27,932,000)<span></span>
</td>
<td class="num">(14,881,000)<span></span>
</td>
<td class="num">(22,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">11,463,000<span></span>
</td>
<td class="nump">2,094,000<span></span>
</td>
<td class="nump">452,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(171,059,000)<span></span>
</td>
<td class="num">(319,585,000)<span></span>
</td>
<td class="num">(295,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable debt securities</a></td>
<td class="num">(418,630,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable debt securities</a></td>
<td class="nump">159,483,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of marketable debt securities</a></td>
<td class="nump">25,899,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(7,665,000)<span></span>
</td>
<td class="num">(62,541,000)<span></span>
</td>
<td class="num">(40,801,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Deconsolidation of subsidiaries - cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(42,980,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,400,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Purchases of notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(350,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales of marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,519,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">574,000<span></span>
</td>
<td class="nump">648,000<span></span>
</td>
<td class="nump">4,428,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">538,000<span></span>
</td>
<td class="num">(990,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(240,289,000)<span></span>
</td>
<td class="num">(62,236,000)<span></span>
</td>
<td class="num">(80,693,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from ATM offering</a></td>
<td class="nump">19,469,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs related to ATM offering</a></td>
<td class="num">(1,340,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance leases</a></td>
<td class="num">(354,000)<span></span>
</td>
<td class="num">(897,000)<span></span>
</td>
<td class="num">(1,295,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration payment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(922,000)<span></span>
</td>
<td class="num">(1,411,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of equity issuance costs and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(580,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">17,775,000<span></span>
</td>
<td class="num">(1,739,000)<span></span>
</td>
<td class="num">(3,216,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="nump">201,000<span></span>
</td>
<td class="num">(281,000)<span></span>
</td>
<td class="num">(588,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(393,372,000)<span></span>
</td>
<td class="num">(383,841,000)<span></span>
</td>
<td class="num">(379,997,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">561,572,000<span></span>
</td>
<td class="nump">944,073,000<span></span>
</td>
<td class="nump">1,315,792,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash, beginning of year</a></td>
<td class="nump">44,171,000<span></span>
</td>
<td class="nump">45,511,000<span></span>
</td>
<td class="nump">53,789,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">605,743,000<span></span>
</td>
<td class="nump">989,584,000<span></span>
</td>
<td class="nump">1,369,581,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">167,202,000<span></span>
</td>
<td class="nump">561,572,000<span></span>
</td>
<td class="nump">944,073,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash, end of year</a></td>
<td class="nump">45,169,000<span></span>
</td>
<td class="nump">44,171,000<span></span>
</td>
<td class="nump">45,511,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">$ 212,371,000<span></span>
</td>
<td class="nump">$ 605,743,000<span></span>
</td>
<td class="nump">$ 989,584,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_AccretionOfDiscountOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion Of Discount On Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_AccretionOfDiscountOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ChangesInFairValueOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of loans receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ChangesInFairValueOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_IncreaseDecreaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Right of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_IncreaseDecreaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_NoncashCustomerConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Customer Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_NoncashCustomerConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_NoncashInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_NoncashInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in maximum amount of estimate for undiscounted range of outcomes of liability in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, from related parties</a></td>
<td class="nump">$ 1,473<span></span>
</td>
<td class="nump">$ 4,725<span></span>
</td>
<td class="num">$ (50,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue, current and non-current, from related parties</a></td>
<td class="num">(32,393)<span></span>
</td>
<td class="num">(68,645)<span></span>
</td>
<td class="num">(35,917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Purchases of notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, from related parties</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue, current and non-current, from related parties</a></td>
<td class="num">$ (8,147)<span></span>
</td>
<td class="num">$ (51,422)<span></span>
</td>
<td class="num">$ (17,018)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo Bioworks Holdings, Inc.'s (&#8220;Ginkgo&#8221; or the &#8220;Company&#8221;) mission is to make biology easier to engineer. Ginkgo sells services to government and commercial customers in two business segments: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cell engineering</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, where we provide tools and biological R&amp;D services across a range of industries, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">biosecurity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, where we provide services to customers who are working to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Engineering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo does not make end products; instead, Ginkgo offers biological R&amp;D services on our platform to enable our customers to bring their products to market. Historically, Ginkgo&#8217;s primary service offering has been cell engineering R&amp;D services (solutions) where Ginkgo performs technical activities. In 2024, Ginkgo expanded its service offering to include services that provide our customers cell engineering tools for biological R&amp;D, where Ginkgo enables its customers to conduct certain in-house R&amp;D activities themselves. Ginkgo's services are designed to offer customers better results on the dimensions of probability of success, speed, or cost &#8211; and ideally on all three. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Autonomous Lab is a flexible wet lab built from our Reconfigurable Automation Cart (&#8220;RAC&#8221;) systems capable of large scale data generation; it powers generative AI and machine learning (&#8220;ML&#8221;) tools that enable more successful biological R&amp;D.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosecurity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ginkgo's primary biosecurity customers are governments. Ginkgo currently provides biosecurity services via two core offerings as introduced in early 2024:  </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Canopy, which helps our customers generate high value genomic data from strategically positioned nodes (like airports and border checkpoints) via end-to-end biomonitoring programs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Horizon, our digital surveillance, analytics and insights platform that detects and monitors biothreats worldwide.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, majority owned subsidiaries and variable interest entities if the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2024 (the &#8220;Effective Date&#8221;), with the approval of the Company's board of directors and shareholders, the Company effected a one-for-forty (1:40) reverse stock split (the &#8220;Reverse Stock Split&#8221;) for the Company&#8217;s common stock (inclusive of Class A common stock, Class B common stock and Class C common stock, par value $0.0001 per share). Accordingly, all common shares, common stock equity awards and common stock per share amounts presented herein have been retrospectively adjusted to reflect the Reverse Stock Split.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On the Effective Date, every forty shares of common stock issued and outstanding immediately prior to the Effective Date were automatically combined into one share of such class of common stock without any change to the par value per share. The number of shares reserved under the Company&#8217;s equity plans and the number of shares underlying awards outstanding under the Company&#8217;s equity plans was reduced proportionately. No fractional shares were issued in connection with the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reverse Stock Split. Shareholders entitled to receive a fractional share as a result of the Reverse Stock Split received a cash payment in lieu of such fractional shares. The number of authorized shares of common stock was not reduced.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its variable interests in variable interest entities (&#8220;VIE&#8221;) and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of each VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#8217;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion. As of December&#160;31, 2025 and 2024, the maximum risk of loss related to the Company&#8217;s VIEs was limited to the carrying value of its investment in such entities. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the consolidated financial statements. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Reported amounts and disclosures reflect the overall economic conditions that management believes are most likely to occur, and the anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, trade accounts receivable, marketable securities and notes receivable. The Company&#8217;s cash and cash equivalents and restricted cash are maintained in bank deposit accounts and money market funds that regularly exceed federally insured limits. The Company is exposed to credit risk on its cash, cash equivalents and restricted cash in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company believes that it is not exposed to significant credit risk as its deposits are generally held in financial institutions that management believes to be of high credit quality. To date, the Company has not experienced any material write-offs related to its trade accounts receivable. A portion of the Company&#8217;s Biosecurity revenue is derived from sales of services to foreign government agencies in certain developing countries. The Company is exposed to credit risk on its marketable securities. The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s policy is for no one issuer or group of issuers from the same holding company is to exceed 10% of the marketable securities portfolio at the time of purchase, with the exception of U.S. government securities or agencies, U.S. Treasuries, bank sweep and deposit programs and money market funds.  The Company&#8217;s maximum credit risk exposure with respect to notes receivable is equivalent to the carrying value of the notes as of the balance sheet date.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, one customer in the Cell Engineering segment accounted for 15% of the Company&#8217;s total revenue, while one customer in the Biosecurity segment accounted for 12% of the Company&#8217;s total revenue. For the year ended December&#160;31, 2024, two customers in the Cell Engineering segment accounted for 13% and 20% of the Company&#8217;s total revenue, while one customer in the Biosecurity segment accounted for 16% of the Company&#8217;s total revenue. For the year ended December&#160;31, 2023, one customer in the Cell Engineering segment and one customer in the Biosecurity segment accounted for 12% and 11%, respectively, of the Company's total revenue.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash is comprised of bank deposits, overnight sweep accounts and money market funds. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying value of the Company&#8217;s cash and cash equivalents approximate fair value due to their short-term maturities. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily includes cash balances collateralizing letters of credit associated with the Company&#8217;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreement. Restricted cash is included in prepaid expenses and other current assets and other non-current assets on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses to provide for the estimated amounts of receivables that will not be collected over the estimated life of the assets. The allowance is calculated by considering previous loss history, delinquency of receivables balances, current economic conditions and anticipated future economic conditions in the geographies and industries in which the Company&#8217;s customers operate. To the extent an individual customer&#8217;s credit quality deteriorates, the Company measures an allowance based on the risk characteristics of the individual customer. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. The allowance is calculated at each reporting period with changes recorded to general and administrative expense in the consolidated statements of operations and comprehensive loss. Accounts receivable are net of an allowance for credit losses of $2.2 million and $1.9 million at December&#160;31, 2025 and 2024, respectively. There were no material changes in the allowance for credit losses for the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, the Company began investing its excess cash in marketable debt securities. All debt securities are classified as available-for-sale at the time of purchase. Available-for-sale debt securities, including those with maturities extending beyond one year, are classified as current assets on the balance sheet due to their highly liquid nature and because they are considered available for use in current operations. Debt securities that are highly liquid and have original maturities of three months or less at the time of acquisition are classified as cash equivalents on the consolidated balance sheet. The Company considers securities to be highly liquid if they can be readily converted to cash with an insignificant risk of changes in value, typically due to active markets and high credit quality.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses on available-for-sale marketable debt securities that are not related to credit losses are included in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. Amortization of premium or accretion of discount, along with interest income earned on debt securities, is included in interest income, net. Realized gains and losses, if any, are included in other income (expense), net, and the cost of securities sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the balance sheet date, the Company evaluates its debt securities in an unrealized loss position to determine the extent of the loss, if any, that is attributable to expected credit losses. Expected credit losses on debt securities are recorded as an allowance on the balance sheet, with an offsetting amount recognized in other income (expense), net, in the consolidated statements of operations and comprehensive loss. To date, the Company has not recorded any credit losses on its marketable debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities also includes equity securities of publicly-traded companies that are considered to be available for use in current operations. Equity securities of publicly-traded companies that are not considered to be available for use in current operations are presented within investments on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, net </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost less accumulated depreciation. Land is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets or the remaining lease term for leasehold improvements. Estimated lives of property, plant and equipment are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"><tr><td style="width:1.0%"></td><td style="width:46.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Buildings and facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15 to 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vehicles</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the related cost and accumulated depreciation is removed from the balance sheet and any resulting gain or loss is recorded in </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the consolidated statements of operations and comprehensive loss. Construction in progress relates to assets which have not been placed in service as of the period end. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the equity method to account for its investments in common stock, or in-substance common stock, when it possesses the ability to exercise significant influence, but not control, over the operating and financial policies of the investee. The Company uses judgment when determining the level of influence over the operating and financial policies of the investee considering key factors including, among others, the Company&#8217;s ownership interest, representation on the board of directors, participation in policy-making decisions and material contractual arrangements and obligations. Income and losses are allocated based upon relative ownership interest unless there is a substantive profit-sharing agreement in place. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For investments with a substantive profit-sharing agreement, the Company utilizes the hypothetical liquidation at book value (&#8220;HLBV&#8221;) method to allocate income and losses from the equity method investment. Under the HLBV method, the Company utilizes the capital account at the end of the period assuming the book value of the entity was liquidated or sold minus the same calculation at the beginning of the period. The difference is the share of earnings or losses attributable to the equity method investment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity method, if there is a commitment for the Company to fund the losses of its equity method investees, the Company would continue to record its share of losses resulting in a negative equity method investment, which would be presented as a liability on the consolidated balance sheet. Commitments may be explicit and may include formal guarantees, legal obligations, or arrangements by contract. Implicit commitments may arise from reputational expectations, intercompany relationships, statements by the Company of its intention to provide support, a history of providing financial support or other facts and circumstances. When the Company has no commitment to fund the losses of its equity method investees, the carrying value of its equity method investments will not be reduced below zero. The Company had no commitment to fund additional losses of its equity method investments during the years ended December&#160;31, 2025, 2024 and 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its equity method investments for impairment whenever events or circumstances indicate that the carrying value of the investment may not be recoverable. The Company considers the investee&#8217;s financial position, forecasts and economic outlook, and the estimated duration and extent of losses to determine whether a recovery is anticipated. An impairment that is other-than-temporary is recognized in the period identified. The Company has not recognized an impairment loss related to its equity method investments for the years ended December&#160;31, 2025, 2024 and 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect the fair value option for its equity method investments on an investment-by-investment basis. For all equity method investments accounted for under the fair value option, the Company carries the equity method investment at fair value and records all subsequent changes in fair value as a component of loss on equity method investments in the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments include marketable equity securities in publicly-traded companies, non-marketable equity securities in privately-held companies, Simple Agreement for Future Equity (&#8220;SAFE&#8221;) and warrants, in each case, in which the Company does not possess the ability to exercise significant influence over the investee. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable equity securities or warrants of publicly-traded companies are measured at fair value with subsequent changes in fair value recorded in loss on investments in the consolidated statements of operations and comprehensive loss. Marketable equity securities are classified as non-current on the balance sheet if they are not currently available for sale.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in non-marketable equity securities of privately-held companies and SAFEs, which do not have readily determinable fair values, are carried at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Each period the Company assesses relevant transactions to identify observable price changes, and the Company regularly monitors these investments to evaluate whether there is an indication of impairment. An equity security without a readily determinable fair value is written down to its fair value if a qualitative assessment indicates that the investment is impaired and the fair value of the </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">investment is less than its carrying value. For periods in which there is no estimate of fair value, the Company evaluates whether an event or change in circumstances has occurred that may have a significant adverse effect on the value of the investment. See Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on Investments. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value and requires disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1- Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2- Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3- Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are either less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued its money market fund holdings, notes receivable  marketable debt securities, marketable equity securities, warrant liabilities and contingent consideration liabilities at fair value on a recurring basis. The carrying amounts of the Company&#8217;s other financial instruments, which include accounts receivable, certain prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its long-lived assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the carrying value of the long-lived assets to the future undiscounted cash flows expected to be generated by the assets. In determining the expected future cash flows, the Company uses assumptions believed to be reasonable, but which inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of long-lived asset is less than the carrying value. See Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_575" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">11</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of impairment losses recorded on long-lived assets. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognizes any excess of the total consideration paid over the fair value of the identifiable net assets as goodwill. Any purchase price that is considered contingent consideration is measured at its estimated fair value at the acquisition date and remeasured at each reporting period, with changes in estimated fair value recorded in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Acquisition transaction costs are expensed when incurred. The operating results of an acquisition are included in the Company&#8217;s consolidated financial statements as of the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, net </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consist of certain definite-lived assets including patents, processes and know-how related to technology acquired through business combinations and asset acquisitions. The Company amortizes such intangible assets on a straight-line basis over their estimated useful life. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represented the excess of the acquisition cost over the fair market value of the net assets acquired. All goodwill was allocated to the Cell Engineering reporting unit and segment identified in Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_187" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">16</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company considers various qualitative factors that could indicate impairment of goodwill such as macroeconomic conditions, industry and market environment, overall financial performance of the Company, cash flow from operating activities and market capitalization. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment to compare the fair value of the reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds the fair value, an impairment loss is recognized limited to the total amount of goodwill allocated to that reporting unit. A combination of the income approach and the market approach may be used to determine fair value of the reporting unit. The Company recorded a full goodwill impairment during the year ended December 31, 2024 (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_160" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). No impairment losses were recognized during the years ended December 31, 2025, and 2023.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determines if an arrangement is or contains a lease at contract inception based on the terms and conditions in the contract. A contract contains a lease if there is an identified asset and the Company has the right to control the asset. For leases with terms greater than 12 months, the Company recognizes a right-of-use asset (&#8220;ROU asset&#8221;) and a lease liability as of the lease commencement date on the balance sheet. ROU assets represent the Company&#8217;s right to use an underlying asset over the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are measured based on the present value of fixed lease payments that are unpaid as of the lease commencement date. The Company&#8217;s ROU assets balance is increased by any initial direct costs and reduced by lease incentives received or expected to be received. Some of the Company's leases include options to extend or terminate the lease; these options are included in the lease term for calculations of its ROU assets and liabilities when it is reasonably certain that the Company will exercise those options. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s leases are classified as either operating or finance, as determined at inception, with the classification affecting the pattern of expense recognition in the statement of operations. A lease is classified as a finance lease if risks and rewards are conveyed without the transfer of control. For operating leases, expense is generally recognized on a straight-line basis over the lease term. For finance leases, interest on the lease liability is recognized using the effective interest method, while the ROU asset is amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term. Leases with an initial term of 12 months or less which meet the definition of a short-term lease are not recorded on the balance sheet and the lease expense for these leases is recognized on a straight-line basis over the lease term. In limited instances, the Company acts as a lessor, primarily with certain real estate subleases. Finance leases, short-term leases and subleases are not a significant component of the Company's financial condition or results of operations. The current portion of the Company&#8217;s operating lease liabilities is included in accrued expenses and other current liabilities on the balance sheet. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements with both lease and non-lease components (such as real estate taxes, insurance and common area maintenance charges) and has elected the practical expedient to combine these lease and non-lease components for its real estate leases and non-lab equipment leases. The Company has not elected this practical expedient for lab equipment leases and the lease and non-lease components are accounted for separately for these leases. Non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses an incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments and uses the implicit rate when it is readily determinable. The Company&#8217;s incremental borrowing rate is based on management&#8217;s estimate of the rate of interest the Company would have to pay to borrow on a fully collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Engineering Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates Cell Engineering service revenue by providing end-to-end cell engineering solutions and tools to customers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We generate Cell Engineering revenue primarily through service and license agreements for our tools and solutions offerings. Under our automation solutions agreements we typically provide services related to the design, build, and deployment of our RAC systems as well as ongoing support services. These agreements typically include a fee for the sale and installation of RAC hardware and a fee for follow on support services and control software. Datapoints agreements typically include fixed fees for services related to producing a data package for our customers and are earned over a shorter time period than legacy cell engineering solutions projects.  Under our solutions agreements, we typically provide R&amp;D services for cell programming with the goal of producing an engineered cell that meets a mutually agreed specification. Our customers obtain license rights to the output of our services, which are primarily the optimized strains or cell lines, in order to manufacture and commercialize products derived from that licensed strain or cell line. Generally, the terms of these agreements provide that we receive some combination of: (1) service fees in the form of (i) upfront payments upon consummation of the agreement or other fixed payments, (ii) reimbursement for costs incurred for R&amp;D services and (iii) milestone payments upon the achievement of specified technical criteria, plus (2) downstream value share payments in the form of (i) milestone payments upon the achievement of specified commercial criteria, (ii) royalties on sales of products from or comprising engineered organisms arising from the collaboration or licensing agreement and/or (iii) royalties related to cost of goods sold reductions realized by our customers. Royalties did not comprise a material amount of our revenue during any of the periods presented. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cell Engineering revenue has historically included transactions with Platform Ventures and Legacy Structured Partnerships where we received non-cash consideration in the form of equity interests and financial instruments that are convertible into equity upon a triggering event.  We view the upfront non-cash consideration as prepayments for licenses which will be granted in the future as we complete mutually agreed upon technical development plans. In these instances, we also receive cash consideration for the R&amp;D services performed by us on a fixed fee or cost-plus basis. We are not compensated through additional milestone or royalty payments under these arrangements. As we perform R&amp;D services under the mutually agreed upon development plans, we recognize a reduction in the prefunded obligation on a cost-plus basis. In some cases we issued the customer a prepaid Cell Engineering services credit in exchange for the upfront non-cash consideration, which can and has been drawn down as payment for R&amp;D services performed under mutually agreed upon development plans. These arrangements are further described in Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_157" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">8</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">1</a><a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Options to acquire additional distinct goods and services are evaluated to determine if such options provide a material right to the customer that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which is accounted for as a separate contract upon the customer&#8217;s election of the option. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. Any upfront cash payment received upon consummation of the contract is fixed and generally nonrefundable. Variable consideration is subject to a constraint, and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. This is attained when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursement for costs incurred for the Company&#8217;s research and development efforts, milestone payments upon the achievement of certain technical and/or commercial criteria, and royalties on sales of products from or comprising engineered organisms arising from the contract. With respect to the research and development reimbursements and milestone payments, the Company uses the most likely amount method to estimate variable consideration. Milestone payments are generally not included in the transaction price until the milestone is achieved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain agreements include payment in the form of equity securities or other financial instruments that convert into equity upon a triggering event. Any non-cash consideration is measured at its estimated fair value at contract inception. For equity securities and financial instruments that are not actively traded, the estimated fair value is generally determined by referencing a recent financing round or utilizing a scenario-based valuation model. Significant unobservable inputs are used in these valuations, including expectations regarding future financings of the customer, scenario dates and probabilities, expected volatility, discount rates, and recovery rates. Changes in these assumptions can materially affect the fair value of the non-cash consideration and, consequently, the total revenue recognized for the contract. The Company did not have material non-cash consideration included in contracts entered into during  the years ended December&#160;31, 2025 and 2024, but does continue to recognize non-cash revenue from contracts originating in prior periods. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For agreements with promises that are combined into a single performance obligation, the entire transaction price is allocated to the single performance obligation. For agreements with multiple performance obligations, the transaction price is allocated to the performance obligations using the relative standalone selling price methodology. For agreements featuring variable consideration, the Company allocates variable consideration to one or more, but not all, performance obligations if certain conditions are met. Specifically, the Company assesses whether the variable consideration relates solely to its efforts to satisfy the performance obligation and whether allocating such variable consideration entirely to the performance obligation is consistent with the overall allocation objective. If these conditions are not met, the Company allocates the variable consideration based on the relative standalone selling price methodology. The key assumptions utilized in determining the standalone selling price for each performance obligation include development timelines, estimated research and development costs, commercial markets, likelihood of exercise (in the case of options considered to be material rights), and probabilities of success. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For agreements where licenses or assignments are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time when the license is effectively granted, as the licenses or assignments represent functional intellectual property. For agreements where licenses and research and development services are combined into a single performance obligation, the Company recognizes revenue over the performance period using the cost-to-cost method. This method measures progress based on the ratio of costs incurred to date to total estimated costs, as it best reflects the transfer of control to the customer for obligations satisfied over time. For automation sales the Company typically recognizes revenue at a point in time at which the hardware has been installed and passed acceptance testing at the customer site. The ongoing support services are recognized over time on a straight line basis over the related support period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its measure of progress to recognize revenue at each reporting period and, as necessary, adjusts the measure of progress and related revenue recognition. The Company&#8217;s measure of progress and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs to complete its performance obligations. The Company evaluates contract modifications and amendments to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis. The Company utilizes the right to invoice practical expedient when it has a right to consideration in an amount that corresponds directly with the value of the Company&#8217;s performance to date. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties are recognized as revenue when (or as) the later of the sales occurrence or the satisfaction (or partial satisfaction) of the related performance obligation. The Company has determined that applying this exception is appropriate when the license granted in the contract is the predominant item to which the royalties relate. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As the Company receives upfront payments for technical services under certain of its arrangements, the Company evaluates whether any significant financing components exist given the term over which the fees will be earned may exceed one year. Based on the nature of the Company&#8217;s agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing, but rather to secure technical services, exclusivity rights, and Foundry capacity, or the timing of transfer of those goods or services is at the discretion of the customer. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue represents consideration received by the Company in excess of revenue recognized and primarily results from transactions where the Company receives upfront cash payments or non-cash equity consideration. In instances where the Company has received consideration in advance for an undefined number of technical development plans (&#8220;TDPs&#8221;) under its customer agreements, the Company records the advance payments as deferred revenue, net of current portion on the consolidated balance sheet. Upon the execution of a specific TDP, the Company reclassifies the estimated consideration to be earned under that TDP within the next twelve months as current deferred revenue. The Company also classifies unexercised material rights related to future TDPs as deferred revenue, net of current portion on the consolidated balance </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sheet. When a TDP is executed, and the material right is exercised, the amount allocated to the material right, which will be earned within the next twelve months, is reclassified to current deferred revenue. All other deferred revenue is classified as current or non-current based on the timing of when the Company expects to earn the underlying revenue based upon the projected progress of activities under the TDP. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2025 any costs to obtain contracts with customers were immaterial.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosecurity Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates Biosecurity revenue through its biomonitoring and bioinformatics services provided to both government and non-government customers through the Company's two core offerings: Canopy and Horizon.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2024, product revenue consisted of sales of lateral flow assay (&#8220;LFA&#8221;) diagnostic test kits, polymerase chain reaction (&#8220;PCR&#8221;) sample collection kits, and pooled test kits, which the Company sold to customers on a standalone basis. Product revenue was billed and recognized when the test kits were shipped, and risk of loss was transferred to the carrier. The Company&#8217;s test kits were generally not subject to a customer right of return except for product recalls under the rules and regulations of the U.S. Food and Drug Administration (&#8220;FDA&#8221;). The Company included shipping and handling fees billed to customers as a component of Biosecurity revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Biosecurity service revenue generally consists of various biomonitoring and bioinformatics services including, but not limited to, sample collection, sample storage and transportation, outsourced laboratory analysis, access to results reported through a web-based portal, analytical reporting of results, and overall program management. The various services are generally combined into one performance obligation as they are either not distinct or have substantially the same pattern of transfer to the customer. Service revenue is generally recognized over time using the time elapsed method as the related services are performed, which best depicts the pattern of transfer to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts with customers are generally three years or less in length and contain a fixed amount of consideration. Under typical payment terms for testing services, amounts are billed monthly in arrears for services performed or in advance based on contractual billing terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Options to acquire additional services are evaluated to determine whether they provide the customer with a material right that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer, and upon the customer's election of the option, it is accounted for as a separate contract.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Biosecurity Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The cost of Biosecurity service revenue consists of costs related to the Company's biomonitoring and bioinformatics services. This includes costs incurred for sample collection equipment, services and materials, outsourced laboratory analysis, access to results reported through a proprietary web-based portal, and reporting of results to public authorities. Additionally, the cost of Biosecurity service revenue includes direct labor cost associated with bioinformatics, lab network management, delivery logistics, and customer support. Prior to 2024, cost of Biosecurity product revenue consisted of costs associated with the sale of diagnostic and sample collection test kits, which included costs incurred to purchase test kits from third parties.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Other Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of other revenue consists of costs related to the Company's Cell Engineering tools offerings, including Datapoints and lab automation solutions. Such costs primarily include hardware, software, materials and labor. Costs related to the Company&#8217;s end-to-end cell engineering solutions offering in which the Company retains rights to intellectual property are included in research and development expenses.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects and initiatives, acquired intellectual property deemed to be in-process research and development, as well as fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all costs as incurred in connection with the filing, prosecution, maintenance, defense, and enforcement of patent applications, including direct application fees and related legal and consulting expenses. Patent costs are included in general and administrative expenses within the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based awards based on estimated grant-date fair values recognized over the requisite service period. For awards that vest solely based on a service condition, the Company recognizes compensation expense on a straight-line basis over the requisite service period. For awards that vest based on multiple conditions, the Company recognizes compensation expense using the accelerated attribution method on a tranche-by-tranche basis over the requisite service period such that the amount of compensation expense recognized at each reporting period is at least equal to the vested tranches at that date. For awards with a performance-based vesting condition, the Company recognizes stock-based compensation when achievement of the performance condition is deemed probable. Upon achieving a performance condition that was not previously considered as probable, the Company records a cumulative catch-up adjustment to reflect the portion of the grantee&#8217;s requisite service that has been provided to date. For awards with market conditions, the compensation expense recognized over the requisite service period is not reversed if the market condition is not satisfied. The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model, inclusive of assumptions for expected term, expected volatility, risk-free interest rate and expected dividend yield. The expected term is determined using the &#8220;simplified&#8221; method, which estimates the expected term as the average of the vesting term plus the contractual term. The Company uses the &#8220;simplified&#8221; method as it does not have sufficient historical data regarding employee exercise behavior. Expected volatility is based on the historical volatility of the Company's Class A common stock. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the stock options. The Company has not paid, and does not expect to pay, dividends in the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For awards with market conditions, the Company recognizes stock-based compensation based on the estimated grant-date fair value of the awards, determined using a Monte Carlo simulation model. This model incorporates assumptions for expected stock price volatility, risk-free interest rates, expected term, and expected dividend yield. Volatility is estimated using either the historical volatility of the Company&#8217;s Class A common stock or a weighted average of its own historical volatility and the historical volatility of selected comparable publicly traded companies, particularly for awards granted when there was limited trading history for the Company&#8217;s Class A common stock. The risk-free interest rate is derived from the yield on U.S. Treasury zero-coupon securities with a duration similar to the expected term of the awards. The expected term equals the contractual term, and a dividend yield of zero is assumed.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an annual basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2025 and 2024, the Company did not have any uncertain tax positions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, a budget and reconciliation package known as the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law in the United States. Among other provisions, the OBBBA amends U.S. tax law including the permanent extension of certain expiring provisions of the 2017 Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The OBBBA did not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gains on available-for-sale securities.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share by dividing the net loss attributable to Ginkgo Bioworks Holdings, Inc. common stockholders by the weighted average number of common shares outstanding during the period. For the purposes of the net loss per share calculation, the Company has combined Class A common stock, Class B common stock, and Class C common stock, as all classes of common stock are legally entitled to equal per-share distributions, whether through dividends or liquidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is computed using the weighted average number of common shares outstanding during the period, increased to include the effect of dilutive potential common shares, such as outstanding stock options, unvested restricted stock awards, unvested restricted stock units, warrants, and contingently issued shares. Dilutive securities are excluded from the calculation of diluted weighted average common shares outstanding if their effect would be anti-dilutive under the treasury stock method.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which focuses on improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this ASU require that public business entities on an annual basis (1) disclose specific categories in the tabular rate reconciliation, using both percentages and reporting currency amounts, and (2) provide additional information for reconciling items that meet a quantitative threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company adopted this standard on January 1, 2025 using the prospective method. The adoption did not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This ASU requires public business entities to disaggregate, on both an interim and annual basis, each relevant expense caption presented on the face of the income statement into specific expense categories. Additionally, entities are required to provide a qualitative description of amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, as well as disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this ASU will have on its disclosures in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, in connection with the Company&#8217;s plans to reduce operational expenditures, management, with the approval of the Board of Directors, approved and commenced a restructuring plan. This plan includes a reduction in labor expenses, primarily through a workforce reduction of more than 50%, and the consolidation and subleasing of certain facilities. Initial workforce reductions commenced in June 2024 and continued throughout 2025. All reductions were substantially complete in 2025. The Company has consolidated certain facilities through various actions, including </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">combining office and laboratory operations into fewer locations, subleasing unused or underutilized facilities, and has taken or plans to take other related measures, such as the sale of its subsidiary, Altar, in the third quarter of 2024 (see Note </span><span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_148" style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). While the Company completed the majority of its facility consolidation actions in 2025 we continue to look for opportunities for subleasing unused or underutilized facilities, which will extend beyond 2026 or may not occur prior to termination of such lease, depending on market conditions. Additionally, restructuring expenses related to potential asset impairments or contract amendments or terminations for any facilities no longer in use or underutilized could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The costs for the reduction in force are expected to range from $31.0&#160;million to $32.0&#160;million primarily in the Cell Engineering segment and consist of cash severance and related costs. The employee termination costs are recognized as of the communication date to employees, given (i) the Company instituted a one-time employee termination benefit related to its restructuring, and (ii) the employees will not be retained to render service beyond a minimum retention period. The Company is currently unable to estimate the costs associated with consolidating its facilities. These costs may include, but are not limited to, losses on subleases, contract terminations, asset impairments, sale or disposal of equipment or other long-lived assets, and related costs and fees pertaining to the consolidation, closure, or disposition of facilities. Additional charges may be incurred as the Company progresses its restructuring plan and such charges could be material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents restructuring costs incurred during the years ended December&#160;31, 2025 and 2024, which are recorded as &#8220;Restructuring charges&#8221; in the consolidated statements of operations and comprehensive loss (in thousands):&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.333%"><tr><td style="width:1.0%"></td><td style="width:53.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-562">Employee termination costs and other</span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impairment of right-of-use asset (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total restructuring</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">1) Relates to the sublease of a facility in connection with the restructuring and reflects the excess of the right-of-use asset's carrying value over its fair value, which was determined based on estimates of future discounted cash flows and is classified as Level 3 in the fair value hierarchy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Company recorded a $7.0 million loss on the sale and deconsolidation of Altar as a component of other income (expense) in the consolidated statements of operations and comprehensive loss for year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the change in the accrued liability balance related to the restructuring activities, which is included in &#8220;Accounts payable&#8221; and &#8220;Accrued expenses and other current liabilities&#8221; in the accompanying consolidated balance sheet as of December&#160;31, 2025 (in thousands):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.333%"><tr><td style="width:1.0%"></td><td style="width:63.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Employee Termination Costs and Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Liability balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expenses incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Liability balance at December 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">Acquisitions and Divestitures<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024 AgBiome Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2024, the Company acquired certain platform assets, including fully sequenced and isolated strains, unique gene sequences, relevant functional data and metadata, and a development pipeline from AgBiome, Inc. (&#8220;AgBiome&#8221;), a biotechnology company in the agriculture industry. These assets expanded the Company&#8217;s proprietary unified metagenomics database. The fair value of the consideration transferred totaled $18.2&#160;million and was paid with the issuance of 407,240 shares of Ginkgo's Class A common stock. The Company accounted for the transaction as an asset </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">acquisition since substantially all of the value received was concentrated in the acquired developed technology, which is being amortized over a useful life of three years.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024 Other Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed three other asset acquisitions during the year ended December 31, 2024. The aggregate purchase price for the three acquisitions was $19.8&#160;million and was paid with the issuance of 394,799 shares of Ginkgo&#8217;s Class A common stock. Each transaction was accounted for as an asset acquisition as the acquired assets, consisting primarily of intellectual property rights, did not meet the definition of a business. The assets acquired represent in-process research and development with no alternative future use. Accordingly, the Company recorded $19.8&#160;million as acquired in-process research and development expense in the accompanying consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2023 StrideBio Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, the Company entered into an Asset Purchase Agreement (&#8220;APA&#8221;) with StrideBio, Inc. (&#8220;StrideBio&#8221;) to acquire StrideBio&#8217;s adeno-associated virus capsid discovery and engineering platform assets, with a secondary closing contingent upon the transfer of certain additional in-license agreements to Ginkgo. The secondary closing was finalized in October 2023. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identifiable asset. The fair value of the consideration transferred totaled $7.6&#160;million and consisted of 119,278 shares of Ginkgo&#8217;s Class A common stock valued at $6.8&#160;million and a $0.8&#160;million contingent holdback, all of which was expensed as in-process research and development during the year ended December 31, 2023. On May 9, 2025, we issued a total of 102,922 shares of our Class A common stock to StrideBio, Inc., in settlement of the $0.8&#160;million contingent holdback amount. The APA, as amended, also provides for royalty payments of up to $21.3&#160;million as described in Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_172" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">12</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2023 Zymergen Bankruptcy and Deconsolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2023, the Company&#8217;s former subsidiary, Zymergen, Inc. (&#8220;Zymergen&#8221;), and certain of its subsidiaries filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code (the &#8220;Zymergen Bankruptcy&#8221;) in the U.S. Bankruptcy Court for the District of Delaware (&#8220;Bankruptcy Court&#8221;). Neither the Company nor any of its other subsidiaries filed for bankruptcy protection. Zymergen had been operated as a distinct legal entity, separate and apart from the Company, since it was acquired in October 2022. Shortly after its acquisition, the Company entered into a non-exclusive license with Zymergen with respect to Zymergen&#8217;s intellectual property, including its databases, automation, and software capabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Zymergen Bankruptcy, also on October 3, 2023, the Company entered into an asset purchase agreement with Zymergen (the &#8220;Zymergen APA&#8221;) as the stalking horse bidder under Section 363 of the U.S. Bankruptcy Code to acquire exclusive rights to substantially all of Zymergen&#8217;s intellectual property assets and certain other assets. The Company&#8217;s bid included a $6.2&#160;million cash component, assumption of a facility lease (previously included in the Company's consolidated financial statements prior to Zymergen's deconsolidation discussed below), and acquiring Zymergen's workforce. On December 14, 2023, Zymergen concluded its auction. On December 21, 2023, the Bankruptcy Court approved the sale of substantially all of Zymergen&#8217;s assets to the Company through certain of the Company's affiliates as contemplated by the Zymergen APA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While as of December 31, 2023, Zymergen remained a wholly-owned subsidiary of the Company, as a result of the bankruptcy proceedings, the Company no longer had a controlling financial interest over Zymergen as defined under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and therefore deconsolidated Zymergen&#8217;s financial position as of October 2, 2023. The deconsolidation included the derecognition of the carrying amounts of Zymergen&#8217;s consolidated assets and liabilities that were previously included in the Company&#8217;s consolidated financial statements. Upon deconsolidation, the Company recorded a loss of $42.5&#160;million, representing the remaining net book value of the Company&#8217;s investment that was reduced to a fair value of zero. Subsequent to the deconsolidation, the Company accounted for its investment in Zymergen using the cost method of accounting, which was recorded at zero in the Company&#8217;s consolidated balance sheet as of December 31, 2023. Zymergen&#8217;s results of operations were removed from the Company&#8217;s consolidated statements of operations and comprehensive loss beginning October 3, 2023. The historical financial results for Zymergen have not been classified as a </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">discontinued operation because it does not represent a strategic shift with a major effect on the Company's operations and financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents Zymergen&#8217;s consolidated assets and liabilities which have been deconsolidated from the Company's consolidated balance sheet as of October 2, 2023. The amounts presented are before the elimination of intercompany balances.</span></div><div><span><br/></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.636%"><tr><td style="width:1.0%"></td><td style="width:73.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">October 2, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">34,321&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,190&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,558&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,938&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">135,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,679&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,486&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">248,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">730&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21,156&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">184,301&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">205,629&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Net assets deconsolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents Zymergen&#8217;s results of operations for the periods presented, included in the Company's consolidated statements of operations and comprehensive loss prior to the elimination of intercompany balances.</span></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:53.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Period from January 1, 2023 - October 2, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,370&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">200,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(192,605)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(168,985)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(168,999)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transactions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the deconsolidation, the Company had an existing employee leasing arrangement with Zymergen. The employee leasing charges were considered intercompany transactions and were eliminated in the Company's consolidated financial statements. As of the deconsolidation date, the employee leasing charges were considered related party transactions and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have been recognized in the Company's consolidated financial statements. Employee lease expense totaled $4.9&#160;million for the period from October 3, 2023 to December 31, 2023, and was immaterial during fiscal 2024. The Company had $1.7&#160;million due to Zymergen as of December 31, 2023, included in accrued expenses and other current liabilities on the balance sheet. This amount was subsequently paid in fiscal 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024 Zymergen Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2024, the Company, through certain of its affiliates, completed its acquisition of substantially all of Zymergen&#8217;s assets under the Zymergen APA, including offering employment to 91 of Zymergen&#8217;s employees. On February 5, 2024, Zymergen&#8217;s plan of liquidation was confirmed by the Bankruptcy Court. All of the Company&#8217;s interests in the Zymergen entities were extinguished and terminated as of February 23, 2024. The acquisition under the Zymergen APA was accounted for as a business combination in accordance with ASC 805,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and was not material to the Company's consolidated financial statements. The total cash purchase price was $6.2&#160;million, with $5.4&#160;million paid at closing and $0.8&#160;million released from escrow. The allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date primarily includes $19.9&#160;million of operating lease right-of-use assets, $6.0&#160;million of property and equipment, and $19.9&#160;million of operating lease liabilities. No goodwill or intangible assets were recognized. Transaction costs associated with the Zymergen APA were not material for the year ended December 31, 2024. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024 Altar Divestiture</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2024, the Company sold the equity interests of Altar for a nominal amount. As a result of the sale, the Company deconsolidated all of Altar's assets and liabilities from its consolidated financial statements effective September 30, 2024, and recognized a loss on deconsolidation of $7.0&#160;million in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. The loss on deconsolidation includes a $1.5&#160;million reclassification of accumulated currency translation adjustments to earnings. The sale did not meet the criteria to be reported as a discontinued operation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 46<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-46<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 45<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-45<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479326/805-40-45-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-30/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-20/tableOfContent<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"><tr><td style="width:1.0%"></td><td style="width:42.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">146,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">146,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">118,038&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">118,038&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">114,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">114,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,654&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,654&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Synlogic, Inc. warrants </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">190&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">190&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">410,432&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">284,390&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">118,916&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,126&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,690&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,690&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"><tr><td style="width:1.0%"></td><td style="width:42.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">521,457&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">521,457&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Synlogic, Inc. warrants </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">238&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">238&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">17,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">17,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">553,424&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">539,016&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12,565&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,843&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,922&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,922&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">The fair value of Synlogic, Inc. warrants is calculated as the quoted price of the underlying common stock, less the unpaid exercise price of the warrants. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. In 2025 and 2024, transfers from Level 2 to Level 1 occurred due to lapse of regulatory </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales restrictions on marketable equity securities. During 2025, transfers into Level 3 consisted of a note receivable that was transferred from Level 2 to Level 3 upon a change in valuation technique. Additionally, in 2024, a portion of the Private Placement Warrants' estimated fair value was transferred from Level 3 to Level 2 as a result of the Private Placement Warrants having substantially the same terms as the Public Warrants when transferred to anyone other than the initial purchasers or their permitted transferees, leading the Company to determine their fair value to be equivalent to that of the Public Warrants. There were no other transfers between Levels 1, 2, or 3 during 2025 or 2024. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a reconciliation of the beginning and ending balances for assets and liabilities measured at fair value using Level 3 significant unobservable inputs for the years ended December 31 (in thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"></td><td style="width:43.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.516%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.516%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Notes Receivable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Private Placement Warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Conversion to preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(17,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transfers to Level 2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Conversion to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,922&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notes Receivable</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For all of its notes receivable, the Company has elected the fair value option, for which changes in fair value are recorded in other (expense) income, net in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025 and 2024, the Company's notes receivable includes a senior secured note in the original principal amount of $11.8&#160;million, issued by Bolt Threads, Inc. (&#8220;Bolt Threads&#8221;), which bears interest at 12% per annum, is due December 31, 2027, and is included in other non-current assets at its estimated fair value. The Company used a discounted cash flow model to estimate the fair value of the senior secured note, incorporating significant unobservable inputs such as the recovery rate, a risk-adjusted discount rate, and a potential settlement scenario. These inputs reflect the Company&#8217;s own assumptions and was reclassified as a Level 3 measurement within the fair value hierarchy during the year ended December 31, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also holds a series of convertible debt instruments issued by customers as payment for Cell Engineering services. The Company used a scenario-based method to value the convertible debt instruments issued by customers and by Bolt Threads prior to conversion. Under this method, future cash flows are evaluated under various payoff scenarios, probability-weighted, and discounted to present value. The significant unobservable (Level 3) inputs used in the fair value measurement as of December&#160;31, 2025 included scenario probabilities ranging from 5% to 45%, a discount rate of 15.5% and estimated time to event date of up to 5 months. The significant unobservable (Level 3) inputs used in the fair value measurement as of December&#160;31, 2024 included scenario probabilities ranging from 5% to 45%, a discount rate of 15.5% and estimated time to event date of up to two years. Significant changes in these inputs could have resulted in a significantly lower or higher fair value measurement. As of December&#160;31, 2025, the convertible debt instruments had an unpaid principal balance of $9.7 million and a fair value of $0.5&#160;million. As of December&#160;31, 2024, the convertible debt instruments had an unpaid principal balance of $13.2 million and a fair value of $1.8 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, $1.5&#160;million in principal related to a convertible note issued by a customer was converted into 10,564 shares of the entity's preferred stock, which, as a new private company investment, has been classified as an investment on the balance sheet as of December&#160;31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company's merger with Soaring Eagle Acquisition Corp. (&#8220;SRNG&#8221;) on September 16, 2021 (&#8220;SRNG Business Combination&#8221;), the Company assumed 34.5&#160;million warrants (formerly traded on the New York Stock Exchange (the &#8220;NYSE,&#8221; and such warrants, the &#8220;Public Warrants&#8221;) and 17.3&#160;million private placement warrants (the &#8220;Private Placement Warrants&#8221;, and together with the Public Warrants, the &#8220;Warrants&#8221;), which were initially issued in connection with SRNG&#8217;s initial public offering. The number of outstanding Warrants did not change as a result of the Reverse Stock Split. However, each Warrant equals one-fortieth (1/40) of one share of Class A common stock (a minimum of 40 Warrants must be exercised for one share of Class A common stock) following the Reverse Stock Split.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Public Warrants was based on their observable quoted price on the NYSE. However, the Public Warrants were delisted by the NYSE on September 4, 2024, due to abnormally low selling price levels, and subsequently began trading on the over-the-counter markets. As of December&#160;31, 2025  and 2024, the Company determined that the Public Warrants had no value.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement Warrants are identical to the Public Warrants, except that they are exercisable on a cashless basis and are non-redeemable as long as they are held by the initial purchasers or their permitted transferees. As of December&#160;31, 2025, the Company concluded that the difference between the fair values of the Public Warrants and Private Placement Warrants was de minimis. Therefore, the Private Placement Warrants were measured by reference to the value of the Public Warrants and had no value. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various business acquisitions, the Company is required to make contingent earnout payments payable upon the achievement of certain technical, commercial and/or performance milestones. The Company also issued restricted stock in connection with acquisitions, which is subject to vesting conditions and is classified as contingent consideration liability.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company can settle a majority of its contingent consideration liabilities in cash or shares of Class A common stock at the Company&#8217;s election with the remainder payable in cash. During the year ended December&#160;31, 2025, no contingent consideration liabilities were settled. During the year ended December&#160;31, 2024, the Company settled $17.6 million in contingent consideration liabilities through payment of $2.8 million in cash and vesting of 1,413,909 shares of restricted stock valued at $14.7 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration related to earnout payments from acquisitions was estimated using unobservable (Level 3) inputs as illustrated in the table below. The fair value of contingent consideration related to restricted stock was estimated using the quoted price of Ginkgo's Class A common stock, an estimate of the number of shares expected to vest, probability of vesting, and a discount rate. Material increases or decreases in these inputs could result in a higher or lower fair value measurement. Changes in the fair value of contingent consideration are recorded in general and administrative expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides quantitative information regarding Level 3 inputs used in the fair value measurements of contingent consideration liabilities as of the periods presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2025<br/>Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024<br/>Range</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Earnout payments (FGen and Dutch DNA acquisitions)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Probability-weighted present value</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Probability of payment</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5% - 10%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5% - 50%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">9.3% </span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Earnout payments (Dutch DNA acquisition) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Projected years of payments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2028-2031</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1) During the year ended December&#160;31, 2025, all Dutch DNA milestones valued using the discounted cash flow method were reduced to zero due to the termination of a customer agreement to which those milestones were tied.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of certain assets, including investments in privately held companies without readily determinable fair values, on a nonrecurring basis when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, or when observable price changes occur for identical or similar securities from the same issuer.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of non-marketable equity securities is classified as Level 3 within the fair value hierarchy when the Company estimates fair value using unobservable inputs to measure an impairment loss. It is classified as Level 2 when fair value is estimated using the observable transaction price paid by third-party investors for an identical or similar security of the same issuer.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Impairments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company recorded a $2.7&#160;million downward adjustment from an observable price change related to one of its investments in non-marketable equity securities. Additionally, during the year ended December&#160;31, 2025, the Company recorded an impairment of $1.8&#160;million due to a significant deterioration in the liquidity of one of its investments in non-marketable equity securities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024, and 2023, the Company recorded impairment losses of $11.9&#160;million, and $33.0&#160;million, respectively, related to its investment in Genomatica preferred stock. The fair value estimates used to determine the impairment charges in 2023 were derived using the guideline public company method under the market approach. Significant unobservable (Level 3) inputs included estimated annual net cash flows (including revenue and expense growth rates and capitalization rates), the weighted-average cost of capital used to discount future cash flows, and the selection of guideline public company multiples for revenue and EBITDA. Material increases or decreases in these inputs could result in higher or lower fair value measurements. As of December 31, 2024, the Company determined that the investment had substantially no value. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024 and 2023, the Company recorded impairment losses of $1.7&#160;million and $8.3&#160;million, respectively, related to an investment in the preferred stock of a privately held company. The fair value as of December 31, 2023 was determined by deriving the investee&#8217;s equity value from a 2021 financing transaction involving its own securities and applying an 87% downward market adjustment to the implied equity value. The equity value was then allocated to the different classes of the securities of the investee using the option-pricing model (&#8220;OPM&#8221;). The OPM involves making assumptions around the investees&#8217; expected time to liquidity and volatility derived from selected guideline public companies. These assumptions are considered Level 3 inputs. As of December 31, 2024, the Company determined that the investment had substantially no value.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SAFEs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company received a total purchase amount of $11.0&#160;million in SAFEs from customers as prepayment for Cell Engineering services. The Company used a scenario-based method to value the SAFEs as of each contract inception date, which resulted in total fair value of $4.5&#160;million for SAFEs received during the year ended December 31, 2023. Under the scenario-based method, future cash flows were evaluated under qualified financing and dissolution scenarios with partial recovery and no recovery in dissolution. The cash flows under each scenario were probability-weighted and discounted to present value. The significant unobservable (Level 3) inputs used in the fair value measurement at contract inception during 2023 were scenario probabilities in the range of 20% to 60%, a discount rate of 14% and estimated time to event date of <span style="-sec-ix-hidden:f-801">one</span> to two years. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2025 and 2024, the Company recorded impairment losses of $14.5 million and $7.2 million, respectively, related to SAFEs. The fair values were generally estimated using the scenario-based method, where various payout scenarios were probability-weighted and discounted to present value.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the years ended December 31, 2024, the Company recorded an impairments of lab equipment, construction in progress assets, and assets related to an operating lease. Refer to Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">11</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional detail.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities, including those classified in cash and cash equivalents, are summarized as follows (in thousands):</span></div><div style="margin-top:6pt;padding-right:-13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">117,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">118,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">255,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable debt securities are summarized below by contractual maturity dates (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.333%"><tr><td style="width:1.0%"></td><td style="width:41.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">205,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">205,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Equity Method Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments and Equity Method Investments</a></td>
<td class="text">Investments and Equity Method Investments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has partnered with other investors to form business ventures, including Motif FoodWorks, Inc. (&#8220;Motif&#8221;), Allonnia, LLC (&#8220;Allonnia&#8221;), Arcaea, LLC (&#8220;Arcaea&#8221;), Verb Biotics, LLC (&#8220;Verb Biotics&#8221;), BiomEdit, LLC (&#8220;BiomEdit&#8221;) and Ayana Bio, LLC (&#8220;Ayana Bio&#8221;) (collectively &#8220;Platform Ventures&#8221;). The Company has also partnered with existing entities, including Genomatica, Inc. (&#8220;Genomatica&#8221;) and Synlogic, Inc. (&#8220;Synlogic&#8221;) (collectively, &#8220;Legacy Structured Partnerships&#8221;) with complementary assets for synthetic biology applications. The Company holds equity interests in these Platform Ventures and Legacy Structured Partnerships. The Company also holds equity interests in other public and private companies as a result of entering into collaboration and license revenue arrangements with these entities. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its investments in Platform Ventures under the equity method. The Company's marketable equity securities consist of Synlogic common stock, Synlogic warrants and the shares of common stock of other publicly traded companies. Marketable equity securities are measured at fair value with changes in fair value recorded in other income (expense) in the consolidated statements of operations and comprehensive loss. The Company&#8217;s non-marketable equity securities consist of preferred stock of Genomatica and preferred and common stock of other privately held companies without readily determinable fair values. Non-marketable equity securities are initially recorded using the measurement alternative at cost and subsequently adjusted for any impairment and observable price changes in orderly transactions for the identical or a similar security of the same issuer. Impairment losses and adjustments from observable price changes are recorded in loss on investments in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also holds investments in early-stage synthetic biology product companies via SAFEs. The Company entered into SAFE agreements in conjunction with a revenue contract with a customer under which the Company grants the customer a prepaid Cell Engineering services credit equal to the principal amount of the SAFE (the &#8220;Purchase Amount&#8221;), which may be used and drawn down as payment for the Company&#8217;s research and development services. The SAFEs will automatically convert into shares of preferred stock equal to the Purchase Amount divided by the discount price, which is calculated as the price per share sold in a qualified equity financing multiplied by a discount rate. The SAFEs also provide the Company with the right to future equity of the entity in a liquidation scenario or the cash-out amount in liquidation and dissolution scenarios or at the election of the SAFE issuer prior to an agreed outside date. The Company initially records SAFEs at fair value (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) and adjusts the carrying amount of the instrument at each reporting period for any impairments.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:68.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Investments:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">SAFEs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,125&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,218&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">17,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Synlogic warrants</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">191&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">238&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">48,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable equity securities of $18.7 million are not restricted for sale and are included in marketable securities in the consolidated balance sheet as of December&#160;31, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on investments and equity method investments consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.727%"><tr><td style="width:1.0%"></td><td style="width:56.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(Loss) gain on investments:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Genomatica preferred stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(33,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(4,557)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,735)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9,928)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,583)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,874)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">SAFEs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(14,501)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,208)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,742)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Synlogic warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total loss on investments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(16,411)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(28,827)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(54,827)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Loss on equity method investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BiomEdit</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,461)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total loss on equity method investments</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,635)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss on investments for each period were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,345)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(20,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(44,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized gains (losses) recognized on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Downward adjustments from observable price changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total loss on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,411)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28,827)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(54,827)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total realized and unrealized losses associated with equity investments accounted for at fair value or the fair value measurement alternative consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss recognized on equity investments sold </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses recognized on equity investments held as of the end of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(22,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(54,827)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total loss on investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,411)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28,827)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(54,827)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1) Reflects the difference between the sale proceeds and the carrying value of the equity investments at the beginning of the period or the acquisition date, if later.</span></div><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of non-marketable equity securities accounted for using the fair value measurement alternative and still held as of December&#160;31, 2025, including cumulative unrealized losses, were as follows (in thousands):</span></div><div style="margin-top:10pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"></td><td style="width:75.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total initial cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(91,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Downward adjustments from observable price changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityMeasureOfActivityAbstract', window );"><strong>Variable Interest Entity, Measure of Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text">Variable Interest Entities <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Company&#8217;s investments in Motif, Allonnia, Genomatica, Arcaea, BiomEdit, Verb Biotics, and Ayana Bio, the Company has concluded these entities represent VIEs. While the Company has board representation on certain of these entities and is involved in the ongoing development activities of these entities via its participation on such entities' JSC, the Company has concluded that it is not the primary beneficiary of these entities because: (i) the Company does not control the board of directors of any of the VIEs, and no voting or consent agreements exist between the Company and other members of each respective board of directors or other investors, (ii) the holders of preferred security interests in the VIEs hold certain rights that require their consent prior to taking certain actions, which include certain significant operating and financing decisions, and (iii) the Company&#8217;s representation on the JSC of each respective entity does not give it control over the development activities of any of the VIEs, as all JSC decisions are made by consensus and there are no agreements in place that would require any of the entities to vote in alignment with the Company. As the Company&#8217;s involvement in the VIEs does not give it the power to control the decisions with respect to their development or other activities, which are their most significant activities, the Company has concluded that it is not the primary beneficiary of the VIEs.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company holds equity interests in certain other privately-held companies that are not consolidated as the Company is not the primary beneficiary. As of December&#160;31, 2025 and 2024, the maximum risk of loss related to the Company&#8217;s unconsolidated VIEs was limited to the carrying value of its investments in such entities. </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">17</a></span> for additional details on the Company&#8217;s investments and equity method investments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityMeasureOfActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityMeasureOfActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, net</a></td>
<td class="text">Goodwill and Intangible Assets, net <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, due to a sustained decrease in the market price of the Company's Class A common stock and market capitalization, the Company identified that an indicator of impairment was present during the second quarter of 2024. As such, the Company completed a quantitative impairment test related to its Cell Engineering reporting unit. To conduct the impairment test of goodwill, the estimated fair value of the reporting unit was compared to its carrying value. The estimated fair value of the reporting unit was determined using a weighted approach that considered a discounted cash flow (&#8220;DCF&#8221;) model under the income approach and the guideline public company (&#8220;GPC&#8221;) method under the market approach. Significant inputs used in the DCF model included the projected future operating results of the reporting unit and the applicable discount rate, while inputs used in the GPC method consisted of a revenue multiple. The projected future operating results were based on historical experience and internal annual operating plans reviewed by management, extrapolated over the forecast period. The discount rate was determined using a weighted average cost of capital adjusted for risk factors specific to the reporting unit. The revenue multiple was based on the GPC method using comparable publicly traded company multiples of revenue for a group of benchmark companies. The DCF method was </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">weighted 75% and the GPC 25%. The fair value measurement of the reporting unit is classified as Level 3 in the fair value hierarchy because it involves significant unobservable inputs. The Company reconciled the resulting fair value of its reporting unit to the market capitalization of the Company to corroborate the fair value estimate used in the impairment test.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The result of the interim impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. As a result, the Company fully impaired goodwill and recorded an impairment loss of $47.9&#160;million in the second quarter of 2024 and for the year ended December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of goodwill consisted of the following year ended December 31, 2024 (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.727%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 31, 2023</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">49,238&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill impairment (accumulated impairment loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(47,858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impact of foreign currency translation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,380)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.545%"><tr><td style="width:1.0%"></td><td style="width:35.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Amortization </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(in Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">December 31, 2025:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">111,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(54,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">December 31, 2024:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">111,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(38,883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">72,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.6</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Gross carrying value and accumulated amortization include the impact of cumulative foreign currency translation adjustments. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $18.7 million, $18.0 million and $15.7 million for the years ended December&#160;31, 2025, 2024 and 2023, respectively. The estimated future amortization expense for intangible assets remaining as of December&#160;31, 2025 is as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.212%"><tr><td style="width:1.0%"></td><td style="width:77.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,700&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,987&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,987&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">17,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,924&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases real estate for office and lab space as well as equipment used in research and development activities under operating and finance leases.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s real estate leases have initial lease terms ranging from 1.4 years to 15.3 years and are all classified as operating. Real estate leases may contain periods of free rent, tenant improvement incentives, expansion options, rent escalation clauses at pre-determined rates or at the prevailing market rates at the time of the increase, and options to extend or terminate the lease without cause at the option of either party during the lease term. The Company is not reasonably certain to exercise these options at the commencement of the lease. Equipment leases have initial lease terms ranging from 2.2 years to 5 years and are classified as operating or finance if the lease contains bargain purchase options which the Company is reasonably certain to exercise. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost for real estate leases primarily consists of certain non-lease components such as real estate taxes, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">insurance and common area maintenance charges. These non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise. None of the Company's lease agreements contain material restrictive covenants or residual value guarantees. </span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's headquarters are located in the Seaport district of Boston, Massachusetts and comprise a set of non-cancellable operating leases within a facility totaling over 320,000 square feet of office and laboratory space. These leases expire on dates ranging from 2030 to 2036 and each contain one option to extend the lease for a five-year period at then-market rates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company entered into a lease, as amended, consisting of approximately 260,000 rentable square feet of new office and laboratory space being developed in Boston, Massachusetts near the Company's headquarters. The lease commenced on April 11, 2024, with rent payments beginning in June 2024, and it will expire on the fifteenth anniversary of the rent commencement date. The lease includes an option to extend for an additional ten years at then-market rates, as well as an expansion option if the owner constructs an additional building on the property. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has a substantial amount of excess space and is seeking to sublease excess space consistent with its restructuring plan. The leased facilities continue to be included in the Cell Engineering asset group as they have not been abandoned and do not have separately identifiable cash flows. If the Company enters into subleases at rates that are below the existing lease minimum payments, terminates or amends existing leases, or abandons the leased facilities, the right-of-use lease assets and any associated leasehold improvements would be evaluated for potential impairment and impairment charges could be material.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company&#8217;s former subsidiary, Zymergen, ceased the use of and exited a leased facility consisting of approximately 300,000 square feet of office and laboratory space in Emeryville, California. The facility was used pursuant to an operating lease with a minimum term expiring in August 2033. Zymergen&#8217;s exit resulted in an impairment loss of $96.2&#160;million, including $36.6&#160;million for the right-of-use asset and $59.6&#160;million for the related leasehold improvements. The impairment loss represents the amount by which the carrying value of the assets exceed their estimated fair values, as determined using a discounted cash flow model under the income approach. The fair value measurements are based on significant inputs not observable in the market and therefore represent Level 3 fair value measurements. The key inputs used in the valuation were estimated sublease rental income and a discount rate of 8.5%. The impairments are presented as impairment of lease assets in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of total lease cost (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.545%"><tr><td style="width:1.0%"></td><td style="width:46.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">63,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">57,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">59,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">76,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">72,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">65,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases were as follows (in thousands):  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"></td><td style="width:59.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">45,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:71.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate - finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of the Company&#8217;s lease liabilities (in thousands): </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.848%"><tr><td style="width:1.0%"></td><td style="width:59.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Finance Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,302&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58,498&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">60,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">59,301&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">371,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total undiscounted payments</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">662,799&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(222,934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">439,865&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">L<span style="-sec-ix-hidden:f-1005"><span style="-sec-ix-hidden:f-1006">ess: current portion of lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(22,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities, non-current</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">417,078&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously subleased a portion of its office and lab space to certain of its equity method investees, which are considered related parties. These lease agreements ended in 2025. Related party sublease income for the years ended December&#160;31, 2025, 2024 and 2023 was $2.1 million, $2.0 million and $2.1 million, respectively, included within </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operating expenses in 2025 and within other income, net in the consolidated statements of operations and comprehensive loss in prior years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases real estate for office and lab space as well as equipment used in research and development activities under operating and finance leases.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s real estate leases have initial lease terms ranging from 1.4 years to 15.3 years and are all classified as operating. Real estate leases may contain periods of free rent, tenant improvement incentives, expansion options, rent escalation clauses at pre-determined rates or at the prevailing market rates at the time of the increase, and options to extend or terminate the lease without cause at the option of either party during the lease term. The Company is not reasonably certain to exercise these options at the commencement of the lease. Equipment leases have initial lease terms ranging from 2.2 years to 5 years and are classified as operating or finance if the lease contains bargain purchase options which the Company is reasonably certain to exercise. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost for real estate leases primarily consists of certain non-lease components such as real estate taxes, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">insurance and common area maintenance charges. These non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise. None of the Company's lease agreements contain material restrictive covenants or residual value guarantees. </span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's headquarters are located in the Seaport district of Boston, Massachusetts and comprise a set of non-cancellable operating leases within a facility totaling over 320,000 square feet of office and laboratory space. These leases expire on dates ranging from 2030 to 2036 and each contain one option to extend the lease for a five-year period at then-market rates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company entered into a lease, as amended, consisting of approximately 260,000 rentable square feet of new office and laboratory space being developed in Boston, Massachusetts near the Company's headquarters. The lease commenced on April 11, 2024, with rent payments beginning in June 2024, and it will expire on the fifteenth anniversary of the rent commencement date. The lease includes an option to extend for an additional ten years at then-market rates, as well as an expansion option if the owner constructs an additional building on the property. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company has a substantial amount of excess space and is seeking to sublease excess space consistent with its restructuring plan. The leased facilities continue to be included in the Cell Engineering asset group as they have not been abandoned and do not have separately identifiable cash flows. If the Company enters into subleases at rates that are below the existing lease minimum payments, terminates or amends existing leases, or abandons the leased facilities, the right-of-use lease assets and any associated leasehold improvements would be evaluated for potential impairment and impairment charges could be material.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company&#8217;s former subsidiary, Zymergen, ceased the use of and exited a leased facility consisting of approximately 300,000 square feet of office and laboratory space in Emeryville, California. The facility was used pursuant to an operating lease with a minimum term expiring in August 2033. Zymergen&#8217;s exit resulted in an impairment loss of $96.2&#160;million, including $36.6&#160;million for the right-of-use asset and $59.6&#160;million for the related leasehold improvements. The impairment loss represents the amount by which the carrying value of the assets exceed their estimated fair values, as determined using a discounted cash flow model under the income approach. The fair value measurements are based on significant inputs not observable in the market and therefore represent Level 3 fair value measurements. The key inputs used in the valuation were estimated sublease rental income and a discount rate of 8.5%. The impairments are presented as impairment of lease assets in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of total lease cost (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.545%"><tr><td style="width:1.0%"></td><td style="width:46.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">63,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">57,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">59,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">76,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">72,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">65,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases were as follows (in thousands):  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"></td><td style="width:59.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">45,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:71.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate - finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of the Company&#8217;s lease liabilities (in thousands): </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.848%"><tr><td style="width:1.0%"></td><td style="width:59.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Finance Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,302&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58,498&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">60,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">59,301&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">371,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total undiscounted payments</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">662,799&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(222,934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">439,865&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">L<span style="-sec-ix-hidden:f-1005"><span style="-sec-ix-hidden:f-1006">ess: current portion of lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(22,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities, non-current</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">417,078&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously subleased a portion of its office and lab space to certain of its equity method investees, which are considered related parties. These lease agreements ended in 2025. Related party sublease income for the years ended December&#160;31, 2025, 2024 and 2023 was $2.1 million, $2.0 million and $2.1 million, respectively, included within </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">operating expenses in 2025 and within other income, net in the consolidated statements of operations and comprehensive loss in prior years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Supplemental Financial Information</a></td>
<td class="text">Supplemental Financial Information <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet to the totals shown within the consolidated statements of cash flows is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">167,202&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">561,572&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">944,073&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash included in prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Restricted cash included in other non-current assets </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,138&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,332&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,722&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">212,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">605,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">989,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes cash balances collateralizing letters of credit associated with the Company&#8217;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer agreement. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment, net </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:68.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">146,279&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">150,887&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">140,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">135,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Buildings and facilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">49,760&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">48,255&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,056&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,897&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,060&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,060&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">358,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">364,592&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(190,597)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(160,872)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">167,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">203,720&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2025, 2024 and 2023 totaled $40.3 million, $45.0 million and $54.8 million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company determined that $5.8&#160;million of construction in progress assets were impaired and this loss is included in general and administrative expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company identified excess lab equipment at two of its facilities whereby the assets were sold, classified as held for sale or otherwise impaired, resulting in aggregate impairment losses of $25.2 million, included in general and administrative expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands): </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:68.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">22,787&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,630&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contractual shortfall liabilities (Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Biosecurity costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,258&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,894&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and securities litigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">External research and development expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,072&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">713&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee termination costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">816&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,387&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">138&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1079"><span style="-sec-ix-hidden:f-1080">Accrued expenses and other current liabilities</span></span></span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">66,458&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">65,387&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental cash flow information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information for each reporting period (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for interest</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">223,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,565&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,915&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Convertible financial instruments received for Cell Engineering services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Equity securities and warrants received for Cell Engineering services</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">55&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">17,450&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">18,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued as settlement of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">14,742&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">8,896&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for retention payments related to business and asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Return of investment in equity securities for reduction in deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,760&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Conversion of notes receivable for common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance costs related to ATM offering included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">53&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Obligations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into a five-year strategic cloud and AI partnership with Google Cloud, which included minimum annual commitments to purchase cloud hosting services. The partnership previously included minimum annual commitments over the contract years ending August 27, 2027 to purchase cloud hosting services in exchange for various discounts on such services. The aggregate $289&#160;million future purchase commitment included minimum annual commitments were as follows: year 1, $8.0&#160;million; year 2, $28.0&#160;million; year 3, $54.0&#160;million; year 4, $86.0&#160;million; and year 5, $113.0&#160;million. Effective October 3, 2025, the Company entered into amendment that revised the total aggregate future purchase commitment to $110&#160;million and reset the annual commitments as follows (each annual year is defined as October 3 to October 2): year 1 (starting on October 3, 2025), $6.0&#160;million; year 2, $8.0&#160;million; year 3, $12.0&#160;million; year </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4, $18.0&#160;million; year 5, $28.0&#160;million; year 6, $38.0&#160;million. The Company recognized a contractual liability of $20.9&#160;million during year ended December 31, 2025 as a result of shortfall in purchasing relative to its commitments under the original agreement. The Company is required to make a one-time payment of $14.0&#160;million to be released from its minimum annual commitment obligations under the original agreement in January 2026. If the Company does not meet its minimum annual commitment obligations in the future, additional shortfall liabilities may be incurred and future contractual losses may be material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 1, 2025, the Company entered into an amendment to its four-year supply agreement with Twist for the purchase of diverse products including synthetic DNA. The original agreement was effective as of April 1, 2022 and obligated the Company to spend a minimum of $58.0&#160;million over the four-year term with the following minimum annual commitments (each annual year is defined as April 1 to March 31): year 1, $10.0&#160;million; year 2, $13.0&#160;million; year 3, $16.0&#160;million; and year 4, $19.0&#160;million. The amendment converts the remaining minimum annual commitments into non-refundable payments creditable against future purchases by the Company, with no expiration. The Company paid $4.0&#160;million in April 2025 and is obligated to non-refundable payments of $5.0&#160;million on April 1, 2026 and $6.0&#160;million on April 1, 2027, respectively. A contractual loss of $8.7&#160;million was recorded in the year ended December 31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Surety Bond</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2026, the Company will be required to fund a surety bond in the amount of $47.0&#160;million to fulfill its obligations under a contract with a U.S. Government National Laboratory related to the sale of RAC automation equipment. The $47.0&#160;million will be restricted until the Company completes all of its obligations under the contract. Currently the Company expects the cash to be restricted until 2029.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Related to Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the StrideBio acquisition (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_148" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">), the Company is obligated to make royalty payments of up to $21.3&#160;million payable in cash or shares of Class A common stock at the Company's election until the earlier of the tenth anniversary date of the initial closing and the date on which the aggregate amount of the royalty payments equals the amount cap. The royalties are calculated based on 10% of the net licensing revenue and 40% of all consideration received for a license or sale of a product incorporating the acquired platform assets. No amounts for the royalty payments have been recorded during the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company routinely acquires rights to intellectual property that may provide for payment of future contingent consideration, including royalties, should revenue be generated from the use of such.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may in the ordinary course of business be named as a defendant in lawsuits, indemnity claims and other legal proceedings. The Company accrues for a loss contingency when it concludes that the likelihood of a loss is probable and the amount of loss can be reasonably estimated. The Company adjusts its accruals from time to time as it receives additional information. The Company does not believe any pending litigation to be material, or that the outcome of any such pending litigation, in management&#8217;s judgment based on information currently available, would have a material adverse effect on the Company&#8217;s results of operations, cash flows or financial condition.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into standard indemnification agreements and has agreements with indemnification clauses in the ordinary course of business. Under such arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, who are generally the Company&#8217;s business partners. The terms of these indemnification arrangements are generally perpetual and effective any time after contract execution. The maximum potential liability resulting from these indemnification arrangements may be unlimited. The Company has never incurred costs to defend lawsuits or settle claims as a result of such indemnifications and the Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations as of December&#160;31, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity <span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s authorized, issued, and outstanding common stock as of the dates indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock as of December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,500,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">49,694,610</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">46,791,082</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class B</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,500,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,985,839</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,416,216</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class C</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">800,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,800,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,680,449</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58,207,298</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock as of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class A</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,500,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">45,575,423</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,696,585</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,500,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,239,682</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,669,200</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class C</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">800,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,000,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,800,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">57,815,105</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">54,365,785</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-The-Market Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2025, the Company filed a universal shelf registration statement on Form S-3, which was declared effective by the SEC on August 14, 2024, on which the Company registered for sale up to $500.0&#160;million of any combination of the Company's Class A common stock, preferred stock, warrants, and/or units from time to time and at prices and on terms that the Company may determine. On September 4, 2025, the Company entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;) with Allen &amp; Company LLC, who is acting as the sales agent (the &#8220;Agent&#8221;), pursuant to which the Company may sell shares of its Class A common stock from time to time at prices and on terms determined by market conditions at the time of offering, up to an aggregate offering price of $100.0&#160;million through or directly to the Agent in one or more at-the-market (&#8220;ATM&#8221;) offerings. Since inception of the Sales Agreement through December&#160;31, 2025, the Company has issued 1.9 million shares of Class A common stock under the Sales Agreement for net proceeds of $18.1 million.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 200&#160;million shares of preferred stock with a par value $0.0001 per share. The Company&#8217;s board of directors are authorized, without stockholder approval, to issue such shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, voting, and other rights, preferences and privileges of the shares. There were no issued and outstanding shares of preferred stock as of December&#160;31, 2025. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 15,800&#160;million shares of common stock, including 10,500&#160;million shares of Class A common stock, par value $0.0001 per share, 4,500&#160;million shares of Class B common stock, par value $0.0001 per share, and 800&#160;million shares of Class C common stock, par value $0.0001 per share. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Class A common stock are entitled to one vote per share and holders of Class B common stock are entitled to ten votes per share. Holders of Class C common stock are not entitled to vote except as otherwise expressly provided in the certificate of incorporation or required by applicable law. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to receive dividends, as may be declared by the board of directors. Different classes of common stock are legally entitled to equal per share distributions whether through dividends or liquidation. No dividends have been declared to date. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. Generally, shares of Class B common stock will convert automatically into Class A common stock upon the holder ceasing to be an Eligible Holder (i.e., director, employee, trust or legal entity of Ginkgo), unless otherwise determined by affirmative vote of a majority of independent directors of Ginkgo. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuances </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following common stock reserved for future issuance as of the date indicated:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.272%"><tr><td style="width:1.0%"></td><td style="width:77.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for grant under the 2021 Plan</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,336,606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restricted stock units outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,262,853</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Performance stock units outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,407,287</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Warrants to purchase Class A common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295,622</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for grant under the ESPP</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,500,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for grant under the 2022 Inducement Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">292,172</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">366,567</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Total common stock reserved for future issuances </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13,461,107</span></td></tr></table></div><div style="margin-top:10pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Excludes unvested earnout shares, which are restricted shares issued to equity holders of legacy Ginkgo prior to the closing of the SRNG Business Combination and to SRNG. These earnout shares are recorded in equity as shares outstanding upon satisfying the vesting conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation <span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense by financial statement line item in the Company&#8217;s consolidated statements of operations and comprehensive loss for the periods presented (in thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.121%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">34,210&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,020&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">145,879&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">84,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of Biosecurity revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,624&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">81,546&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">112,344&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">229,884&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Inducement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2022, the Company's Board of Directors adopted the Ginkgo Bioworks Holdings, Inc. 2022 Inducement Plan (the &#8220;2022 Inducement Plan&#8221;), which is a non-shareholder approved equity incentive plan adopted pursuant to the &#8220;inducement exception&#8221; provided under NYSE Listed Company Manual Section 303A.08. Pursuant to the terms of the 2022 Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock and other stock-based awards as an inducement material to individuals being hired or rehired following a bona fide period of interruption of employment, as an employee of the Company or any of its subsidiaries, including in connection with a merger or acquisition. The terms of the 2022 Inducement Plan are substantially similar to the terms of the Company&#8217;s 2021 Incentive Award Plan. The Company has reserved 625,000 shares of the Company&#8217;s common stock (which may be shares of Class A common stock or Class B common stock) for issuance under the 2022 Inducement Plan. As of December&#160;31, 2025, 292,172 shares are available for future issuance under the 2022 Inducement Plan.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Inc</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">entive Award Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;16, 2021, the 2021 Incentive Award Plan (the &#8220;2021 Plan&#8221;) became effective. The 2021 Plan provides for the grant of stock options, including incentive stock options (&#8220;ISOs&#8221;) and nonqualified stock options, stock appreciation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rights, restricted stock, dividend equivalents, RSUs and other stock or cash-based awards to employees, consultants and directors of Ginkgo and its subsidiaries. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate number of shares of common stock available for issuance under the 2021 Plan, which may be issued as Class A common stock and/or Class B common stock, was initially 5,011,024 shares. As of December&#160;31, 2025, 3,336,606 shares are available for future issuance under the 2021 Plan. The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase for ten years on January 1 of each year in an amount equal to the lesser of (a) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by the Board. The maximum number of shares of common stock that may be issued pursuant to the exercise of incentive stock options granted under the 2021 Plan is 5,000,000 shares. Shares issued under the 2021 Plan may consist of authorized but unissued shares, shares purchased on the open market or treasury shares.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2021, the 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) became effective. The ESPP authorizes (i) the grant of options that are intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code of 1986 (the &#8220;Section 423 Component&#8221;) and (ii) the grant of options that are not intended to be tax-qualified (the &#8220;Non-Section 423 Component&#8221;). All of the Company&#8217;s employees are expected to be eligible to participate in the ESPP. However, with respect to the Section 423 Component, an employee may not be granted rights to purchase stock under the ESPP if the employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of the Company&#8217;s common stock. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP initially permits the Company to deliver up to 500,000 shares of common stock pursuant to awards issued under the ESPP, which may be Class A common stock and/or Class B common stock. The number of shares of common stock reserved for issuance under the ESPP will automatically increase each January 1 by an amount equal to the lesser of (a) 1% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by the Board, provided that no more than 2,500,000 shares may be issued under the Section 423 Component. Prior to or in connection with issuing any shares of common stock under the ESPP, the ESPP administrator may convert awards covering shares of Class B common stock to Class A common stock. As of December&#160;31, 2025, no awards have been granted under the ESPP, and 2,500,000 shares remain available for future issuance. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 2014 Stock Incentive Plan (the &#8220;2014 Plan&#8221;) provided for the Company to grant options, stock appreciation rights, restricted stock, restricted stock units (&#8220;RSUs&#8221;) and other stock-based awards. From and after the effective date of the 2021 Incentive Award Plan, the Company ceased granting awards under the 2014 Plan. However, the 2014 Plan continues to govern the terms and conditions of the outstanding awards previously granted thereunder. Shares of common stock underlying any awards that are forfeited, cancelled, repurchased, or otherwise terminated by the Company under the 2014 Plan will be added back to the shares available for issuance under the 2021 Incentive Award Plan.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-based Stock Options </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All time-based options outstanding consist of awards granted to non-employee directors and are of two types: (i) initial awards granted to newly elected or appointed directors, which vest in three equal annual installments, and (ii) subsequent awards, which vest on the earlier of the first anniversary of the grant date or the day prior to the next annual shareholder meeting. These options expire no later than ten years from the grant date. The exercise price of each option is equal to the closing price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of time-based stock options activity for the year ended December&#160;31, 2025 is presented below: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.757%"><tr><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Exercise Price per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Remaining Contractual Term (in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:115%">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of  December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">267,520</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25.17&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">171,875</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(72,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">36.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">366,567</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15.38&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.9</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">136,014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:6.7pt">The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the year and the exercise prices, multiplied by the number of in-the-money stock options.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was $0.9 million and $9.1 million, respectively. There were no stock option exercises during the year ended December 31, 2025. The weighted-average fair value of options granted during the years ended December&#160;31, 2025, 2024, and 2023 was $7.48, $11.35 and $57.20 per share, respectively, and was calculated using the following key assumptions in the Black-Scholes option-pricing model:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.030%"><tr><td style="width:1.0%"></td><td style="width:50.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.06</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.27</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.94</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">97</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">93</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">6.0</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5.7</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $1.5 million of unrecognized compensation expense related to options recognizable over a weighted-average period of 2.3 years.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company granted to each of the Company's four founders an option to purchase in aggregate 125,000 shares of Ginkgo's Class A common stock with an exercise price of $100 per share, subject both to time-based and market-based vesting criteria (the &#8220;Founder Options&#8221;). The market-based vesting is tied to the achievement of four specified stock price hurdles within a five-year period, with 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $200, 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $300, 20% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $400 and the remaining 60% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $500. If the market-based criteria are achieved during the five-year period, the awards will vest on the five-year anniversary of the grant date. The weighted-average grant-date fair value of the options granted was $7.80 per share and was calculated using a Monte Carlo simulation model using a risk-free interest rate of 4.65%, expected volatility of 72%, suboptimal exercise multiple of 2.8, and a dividend yield of zero percent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, the compensation committee of the Company&#8217;s Board of Directors canceled the Founder Options and granted replacement performance-based restricted stock unit (&#8220;PSU&#8221;) awards (the &#8220;Founder PSU Awards&#8221;). The cancellation and concurrent grant of replacement awards were accounted for as a modification, resulting in $10.5&#160;million of incremental compensation expense. The performance period for these awards was through December&#160;31, 2025 and the aggregate compensation expense for the cancelled award and the new award will be recognized over the remaining requisite service period of the PSUs, which is the grant date through March 31, 2026. The PSU awards are subject to substantially similar performance metrics, vesting terms and employment terms as described in the section &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted under the 2014 Plan are subject to two vesting conditions: (i) a service-based vesting condition, generally satisfied over four years with 25% of the shares vesting on the first anniversary of the grant date and monthly vesting thereafter, and (ii) a performance-based vesting condition, which was met in 2021 in connection with the Company's merger with SRNG. RSUs granted under the 2021 Plan are subject only to the service-based vesting condition. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the year ended December&#160;31, 2025 is presented below: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.212%"><tr><td style="width:1.0%"></td><td style="width:50.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of  December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,327,398</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">69.00&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,176,419</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,797,720)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">48.74&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,443,244)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of  December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,262,853</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">55.07&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of RSUs granted during the years ended December&#160;31, 2025, 2024 and 2023 was $8.02, $43.81 and $55.60, respectively. The total fair value of the RSUs that vested during the years ended December&#160;31, 2025, 2024 and 2023 was $87.6 million, $232.9 million and $365.3 million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $58.3 million of unrecognized compensation expense related to RSUs recognizable over a weighted-average period of 1.8 years.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the compensation committee of the Company's Board of Directors approved a grant of PSU awards under the 2021 Plan to substantially all employees. The PSUs are eligible to vest based on the achievement of specific performance metrics tied to the Company&#8217;s 2025 cash flow and bookings targets. Recipients must remain employed through the date the applicable vested shares are distributed, which is expected to occur in March 2026. PSU achievement percentages may range from zero to 100% of the award. The grant-date fair value of the PSUs was determined based on the closing price of the Company&#8217;s Class A common stock on the grant date. Additionally, as summarized above, the Founder PSU Awards were granted in June 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of PSU activity for the year ended December&#160;31, 2025 is presented below:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"><tr><td style="width:1.0%"></td><td style="width:60.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Performance Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,599,647</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,192,360)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,407,287</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $7.3&#160;million of unrecognized compensation expense related to unvested PSUs outstanding, which is expected to be recognized over a service period of approximately 0.3 years. Actual expense recognized may vary based on the final achievement rate.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnouts</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Earnout shares represent equity awards, primarily in the form of restricted stock, granted to existing employees of the Company as of the closing date of the Company's merger with SRNG on September 16, 2021 (the &#8220;Closing Date&#8221;). These earnout shares are subject to the same time-based vesting and performance conditions (change in control or an initial public offering) as the underlying awards, including provisions related to vesting and termination. Additionally, the earnout shares are subject to a market condition, which is satisfied when the trading price of the Company's common stock is greater than </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">or equal to $500, $600, $700 and $800 per share for any 20 trading days within a 30 consecutive trading day period, on or before the fifth anniversary of the Closing Date (collectively, the &#8220;Earnout Targets&#8221;). The first Earnout Target of $500 per share was achieved on November&#160;15, 2021. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity during the year ended December&#160;31, 2025 for the earnout shares is presented below: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:61.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">552,457</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">510.80&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(321)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">533.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(859)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">512.62&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">551,277</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">510.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of the earnout shares that vested during the years ended December&#160;31, 2025, 2024 and 2023 was $0.2 million, $4.5&#160;million and $7.6&#160;million, respectively.</span></div>As of December&#160;31, 2025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the percentage of Cell Engineering revenues by industry based on total Cell Engineering revenue: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"><tr><td style="width:1.0%"></td><td style="width:56.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pharmaceutical and biotechnology</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">35&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">30&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Agriculture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Government and defense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Industrial and environment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Consumer and technology</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Food and nutrition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total Cell Engineering revenue</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cell Engineering revenue includes both cash and non-cash consideration. The non-cash consideration primarily consists of equity received from customers as partial or full payment in certain contracts, which is recognized as revenue as services are provided or upon contract termination. The Company did not receive equity as consideration for any customer contracts entered into during the years ended December&#160;31, 2025 or 2024, but continues to recognize revenue from prior contracts. Cell Engineering revenue recognized relating to non-cash consideration was $11.6&#160;million, $61.4&#160;million, and $48.5&#160;million for the years ended December&#160;31, 2025, 2024, and 2023, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s total revenue is derived from customers located primarily in the United States. For the years ended December&#160;31, 2025, 2024, and 2023, the Company&#8217;s revenue from customers within the United States comprised 76%, 81% and 82%, respectively, of total revenue.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as accounts receivable. The Company had no contract asset balances as of December&#160;31, 2025 and 2024. The Company&#8217;s accounts receivable consists of both billed and unbilled amounts. Unbilled receivables arise when revenue is recognized in excess of invoiced amounts and represent the Company&#8217;s unconditional right to consideration for goods or services already transferred to the customer. The balance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of unbilled accounts receivable, included in accounts receivable, net in the accompanying consolidated balance sheets, was $14.5 million and $11.3 million as of December&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities, or deferred revenue, primarily consist of payments received in advance of performance under the contract or when the Company has an unconditional right to consideration under the terms of the contract before it transfers goods or services to the customer. The Company&#8217;s collaborative arrangements with its investees and related parties typically include upfront payments consisting of cash or non-cash consideration for future research and development services and non-cash consideration in the form of convertible financial instruments and equity securities for licenses that will be transferred in the future. The Company records the upfront cash payments and fair value of the convertible financial instruments and equity securities as deferred revenue. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invoices customers based on contractual billing schedules, which results in the recording of deferred revenue to the extent payment is received prior to the Company&#8217;s performance of the related services. Contract liabilities are recognized as revenue as (or when) the Company performs under the contract. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company recognized $48.7 million of revenue that was included in the contract liabilities balance of $126.5 million as of December&#160;31, 2024. During the year ended December&#160;31, 2024, the Company recognized $88.1 million of revenue that was included in the contract liabilities balance of $202.5 million as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price that was allocated to performance obligations that have not yet been satisfied or are partially satisfied as of December&#160;31, 2025 and 2024 was $158.6 million and $85.8 million, respectively. The Company has elected the practical expedient not to provide the remaining performance obligation disclosures related to contracts for which the Company recognizes revenue on a cost-plus basis in the amount to which it has the right to invoice.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, approximately $23.0&#160;million of the unsatisfied or partially satisfied performance obligations is expected to be recognized as revenue in 2026, based on the projected customer program end date; $40.9&#160;million between 2026 and 2027; $86.9&#160;million between 2026 and 2028; $3.4&#160;million between 2026 and 2029; and $4.4&#160;million between 2026 and 2030.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When a milestone subject to the variable consideration constraint is achieved, the Company updates its estimate of the transaction price to include the milestone payment and records a cumulative catch-up in revenue. For the years ended December&#160;31, 2025, 2024 and 2023, the Company recorded $2.9 million, $7.2 million and $2.3 million, respectively, as cumulative catch-up in revenue, primarily due to the recognition of previously constrained variable consideration related to milestones or a contract modification.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in two operating and reportable segments: Cell Engineering and Biosecurity. This structure reflects the Company's internal management framework and the approach its CODM uses to evaluate operating results and allocate resources. The Company&#8217;s reportable segments are described as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cell Engineering consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological R&amp;D. The Company&#8217;s cell engineering platform includes R&amp;D services (solutions) where Ginkgo performs technical activities.  Our Autonomous Lab is a flexible wet lab built from our Reconfigurable Automation Cart (&#8220;RAC&#8221;) systems capable of large scale data generation; it powers generative AI and machine learning (&#8220;ML&#8221;) tools that enable more successful biological R&amp;D. We now offer services providing such data generation, AI and automation tools directly to Ginkgo customers. Cell Engineering revenue is generated primarily through R&amp;D service fees for our solutions and Datapoints services; and design, build, installation and ongoing support fees for our automation solutions (RAC) systems. Historically our solutions deals also included downstream value share in the form of milestone payments, royalties or equity interests. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biosecurity consists of the Company&#8217;s biomonitoring and bioinformatics support services, offered to both government and non-government customers through the Company's two core offerings: Canopy and Horizon. Biosecurity revenue is generated from fees for data, analytics, and services. Prior to 2024, Biosecurity revenue also included sales of COVID-19 diagnostic and sample collection test kits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reportable segments are those for which discrete financial information is available and whose results are regularly provided to the Company&#8217;s CODM, consisting of the Chief Executive Officer and the Chief Operating Officer, for the purpose of allocating resources and assessing financial performance. The CODM evaluates the financial performance of the Company&#8217;s segments based on segment operating income (loss). The CODM is primarily provided with the segment operating income (loss) on a quarterly basis, as well as during the annual budgeting and forecasting process, and uses this information to monitor the Company&#8217;s performance, including budget-to-actual results, and to make decisions about the allocation of operating and capital resources to each segment. For management reporting purposes, the Company&#8217;s measure of segment operating income (loss) excludes the impact of stock-based compensation expense, depreciation and amortization, asset impairment charges, restructuring charges, costs associated with excess space, transaction and integration costs associated with planned, completed or terminated mergers and acquisitions, and acquired in-process research and development expenses. The Company has determined its significant segment expenses are cost of revenue for Biosecurity, research and development expenses for Cell Engineering, and general and administrative expenses for both segments, which are regularly provided to the CODM. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The CODM is not provided with asset information by segment; therefore, such information is not presented. The accounting policies used to prepare the reportable segments financial information are the same as those used to prepare the Company&#8217;s consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary results of the Company&#8217;s reportable segments and a reconciliation of total segment operating loss to consolidated loss before income taxes (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cell Engineering</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">132,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">173,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">143,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">158,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">271,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">335,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">115,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">171,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cell Engineering operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(95,530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(218,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(363,622)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Biosecurity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">37,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">78,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Costs and operating expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Cost of Biosecurity service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">46,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Cost of Biosecurity product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">27,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">55,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Biosecurity operating (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(18,931)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(30,619)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,194)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(114,461)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(249,186)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(366,816)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Reconciling items to reconcile total segment operating loss to loss before income taxes:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">82,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">115,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">234,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impairment expense </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">121,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">63,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">70,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restructuring charges </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Carrying cost of excess space (net of sublease income) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Merger and acquisition related expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(8,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(313,600)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(547,508)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(892,940)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes $1.2 million, $3.0 million, and $5.0 million in related employer payroll taxes for the years ended December&#160;31, 2025, 2024, and 2023, respectively. </span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">For 2024, includes $47.9&#160;million related to goodwill impairment and $5.8&#160;million related to lab equipment. For 2023, includes a $25.2&#160;million impairment loss on lab equipment and a $96.2&#160;million impairment loss on lease assets associated with an exited Zymergen leased facility.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">See Note </span><span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_575" style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">, Restructuring, for composition of costs. </span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">Includes interest income, interest expense, loss on investments, losses/gains on deconsolidation of subsidiaries, changes in fair value of certain assets and liabilities, and other gains or losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Collaboration Transactions with Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Significant Collaboration Transactions with Related Parties</a></td>
<td class="text">Significant Collaboration Agreements and Transactions with Related Parties<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant transactions with its related parties are primarily comprised of revenue generating activities under collaboration and license agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Platform Ventures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has partnered with other investors, including investors who were also Company investors at the time, to form business ventures, including Motif FoodWorks, Inc. in 2018 (&#8220;Motif&#8221;), Allonnia, LLC in 2019 (&#8220;Allonnia&#8221;), Arcaea, LLC in 2021 (&#8220;Arcaea&#8221;), Verb Biotics, LLC in 2021 (&#8220;Verb&#8221;), Ayana Bio, LLC in 2021 (&#8220;Ayana&#8221;) and BiomEdit, LLC in 2022 (&#8220;BiomEdit&#8221;) (collectively &#8220;Platform Ventures&#8221;). Each of these entities is privately held with the Company holding common equity interests in each.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially consolidated Ayana and Verb at formation as variable interests where the Company was initially the primary beneficiary, subsequently deconsolidating both in 2022 when it was concluded that was no longer the case. With respect to the investments in Motif, Allonnia, Arcaea, and BiomEdit, the Company concluded these entities represent variable interest entities, however the Company has never been the primary beneficiary of these entities. The Company accounts for its investments in Platform Ventures under the equity method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the launch of each of the Platform Ventures, the Company received common equity and, with respect to Arcaea, subsequently received additional common equity. The Company generally granted each Platform Venture licenses to certain of the Company&#8217;s intellectual property and executed Technical Development Agreements (&#8220;TDAs&#8221;) that established terms under which the Company would provide technical research and development services to those entities, generally in return for fees on a fixed fee or cost-plus basis for services provided.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The common equity investments in each of the Platform Ventures were initially recorded at the then fair values determined at inception of the investments. The Company is recognizing earnings and losses on these equity method investments using the HLBV method. Accordingly, the carrying values of each of the Platform Ventures investments were reduced to zero immediately following the Company&#8217;s investments. There is no commitment for the Company to provide further financial support to these Platform Ventures, and therefore the carrying value of the equity method investments will not be reduced below zero.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The relationship with the Platform Ventures is as vendor-customer relationships and is within the scope of ASC 606, as the provision of services and corresponding license rights are considered a part of the Company&#8217;s ordinary activities. The common equity issued to the Company represent non-cash consideration under revenue contracts. While TDAs executed by the parties provides payment terms for future services, the TDAs do not provide for any transfer of goods or services between the parties as the Company contemplated provided licenses and services upon execution of future contemplated TDPs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of Ayana and Verb, the Company&#8217;s performance obligations under the initial arrangements consisted of a number of estimated materials rights provided to the Platform Ventures (BiomEdit having four and Arcaea, Allonia and Motif having ten) to future technical research and development services and commercial licenses under individual TDPs that the Company expected to execute. These material rights equated in aggregate to the fair values of the common equity issued by each of the Platform Ventures to the Company and represented advanced payment for the license rights, which would be granted upon the execution of future applicable TDPs. As there would be no additional payment for these license </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rights when future TDPs are executed, the Company determined that there are material rights associated with each of the contemplated TDPs under each of the TDAs. The value of the material rights are included in deferred revenue until recognized as revenue. The material rights are recorded as non-current deferred revenue until such time as the parties execute an applicable TDP inclusive of the material rights. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For each TDP underlying a material right, the transaction price consists of (i) either a fixed fee or, if a cost-plus arrangement, variable consideration for the most likely amount of estimated consideration to be received and (ii) non-cash consideration allocated to the material right. As the services performed by the Company under a TDP inclusive of a material right, the Company creates or enhances an asset that the Platform Ventures controls, the Company satisfies the performance obligation and recognizes revenue over time using an input method that compares total costs incurred relative to total estimated cost to complete to estimate progress under the contract. Any revisions to the estimated total budgeted costs to complete, and the resulting impact on revenue recognition, are reflected in the period of the change through a cumulative catch-up adjustment.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company and Motif mutually terminated its services agreements with no adjustment to the original consideration. As a result, the Company has no further obligation to perform services for Motif and, accordingly, the then remaining $45.4 million in material rights deferred revenue has been recognized in full as revenue during the year ended December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company and BiomEdit mutually terminated its services agreements with no adjustment to the original consideration. As a result, the Company has no further obligation to perform services for BiomEdit, and accordingly, the then remaining $7.5&#160;million in material rights deferred revenue has been recognized in full as revenue during the year ended December 31, 2025. BiomEdit is no longer considered a significant related party due to a reduction of the Company&#8217;s equity ownership interest that occurred during the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genomatica, Inc. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also partnered with Genomatica, Inc. (&#8220;Genomatica&#8221;), a previously established business that is privately held. Genomatica is deemed a variable interest entity, however the Company has never been the primary beneficiary of this entity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company purchased Series A preferred stock of Genomatica, Inc. for $15.0&#160;million and entered into a collaboration agreement, which was subsequently terminated in September 2018, whereby the Company received $40.0&#160;million of Series B preferred stock in Genomatica in exchange for providing Genomatica with up to $40.0&#160;million in services at no charge to Genomatica. The agreements between the Company and Genomatica were determined to be within the scope of ASC 606 directly or by analogy. The Company recognized the revenue for the combined performance obligations using an over-time input method. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded the preferred stock investments were not in-substance common stock and therefore did not qualify for accounting as an equity method investment and should be accounted for as equity security under the measurement alternative for equity investments that do not have a readily determinable fair value. As of December 31, 2024, the Company determined that the investment had substantially no value. During the years ended December 31, 2024, and 2023, the Company recorded impairment losses of $11.9 million, and $33.0 million, respectively, related to its investment in Genomatica preferred stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant related party transactions included in the consolidated balance sheet, excluding the Company&#8217;s investments and equity method investments, are summarized below (in thousands):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"><tr><td style="width:1.0%"></td><td style="width:63.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Deferred revenue, current and non-current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Allonnia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">36,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">36,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Arcaea</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BiomEdit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Genomatica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">64,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">73,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant related party transactions included in the consolidated statements of operations and comprehensive loss, excluding the losses on the Company&#8217;s investments and equity method investments, are summarized below (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"><tr><td style="width:1.0%"></td><td style="width:56.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cell Engineering revenue:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Motif FoodWorks</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">45,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Arcaea</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,653&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,024&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Genomatica</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Ayana Bio</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">637&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,028&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,323&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BiomEdit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Verb Biotics</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">584&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Allonnia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other equity investees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">139&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">705&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,041&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">22,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details on the Company&#8217;s investments and equity method investments held in its related parties.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan The Company maintains a 401(k) retirement savings plan for its employees who satisfy certain eligibility requirements. Under this plan, the Company makes a 5% non-elective contribution to all eligible employees equal to up to 5% of eligible compensation, which fully vests once such eligible participant has completed two years of continuous service. Effective January 1, 2024, the 5% non-elective contribution is capped for employees earning $100,000 or more in annual salary, resulting in a maximum employer contribution of $5,000. For the years ended December&#160;31, 2025, 2024 and 2023, the Company contributed $3.3 million, $5.8 million and $8.2 million, respectively, to the plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-70/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the loss before income taxes consisted of the following (in thousands):  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.090%"><tr><td style="width:1.0%"></td><td style="width:54.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Domestic</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(308,990)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(514,354)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(890,986)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(4,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(33,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(313,600)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(547,508)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(892,940)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the Company recorded the following income tax expense (benefit) (in thousands):  </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.515%"><tr><td style="width:1.0%"></td><td style="width:49.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(346)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(109)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">123&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">457&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">813&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,364)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(936)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(884)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(837)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(479)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(71)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of income tax benefit computed by applying the 21% statutory U.S. Federal income tax rate to income before income taxes after the adoption of ASU 2023-09 for year ended December&#160;31, 2025 is as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.272%"><tr><td style="width:1.0%"></td><td style="width:50.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Tax at U.S. Statutory Rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(65,856)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">State and Local Income Taxes (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Foreign Tax Effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Nontaxable or Nondeductible Items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">14,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Limitation on executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Gain/Loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Tax Credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Research &amp; Development Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(1,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Changes in Valuation Allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">45,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other Items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The states and local jurisdictions that contribute to the majority (greater than 50%) of the tax effect in this category include Massachusetts and New York state and city. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax benefit computed at the statutory corporate income tax rate to the effective income tax rate for the years ended December 31, 2024 and 2023 is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.212%"><tr><td style="width:1.0%"></td><td style="width:52.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal income tax at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Investments in subsidiaries and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(29.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended December&#160;31, 2025, the amount of cash income taxes paid by the Company was as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.545%"><tr><td style="width:1.0%"></td><td style="width:68.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State and local:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">California</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">South Carolina</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">All other state and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash income taxes, net of refunds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s deferred tax assets and liabilities consist of the following (in thousands):  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.303%"><tr><td style="width:1.0%"></td><td style="width:65.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">459,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">332,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">63,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">155,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">214,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">48,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">52,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortizable intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">112,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">116,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Investments in subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">59,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">57,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">936,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">875,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(840,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(771,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">96,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">103,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortizable intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(10,119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(92,052)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(98,184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(102,171)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(110,389)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred taxes</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,094)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,552)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Activity in the deferred tax assets valuation allowance is summarized as follows (in thousands):  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:60.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Beginning of Period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Additions<br/>(Subtractions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets valuation allowance:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Year ended December 31, 2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">771,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">68,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">840,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Year ended December 31, 2024</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">711,778&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">60,074&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">771,852&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. The Company considered its history of cumulative net losses incurred since inception and has concluded that it is more-likely-than-not that it will not realize the benefits of the deferred tax assets. Accordingly, a valuation allowance has been established against the deferred tax assets as of December&#160;31, 2025 and 2024 that are not expected to be realized. The Company reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased on a net basis by $68.2 million during the year ended December&#160;31, 2025 primarily due to increases in the deferred tax assets related to net operating loss carryforwards partially offset by the continued amortization of capitalized research and development costs as allowed by certain provisions of the One Big Beautiful Bill Act of 2025.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2025, the Company had federal net operating loss carryforwards of approximately $1.8 billion, of which $139.2 million will begin to expire in 2029 and $1.6 billion can be carried forward indefinitely. As of December&#160;31, 2025, the Company had state net operating loss carryforwards of approximately $1.5 billion, of which $1.2 billion will begin to expire in 2030 and $257.5 million can be carried forward indefinitely. The Company also had $3.9&#160;million of foreign net operating losses as of December&#160;31, 2025, of which $1.5&#160;million will begin to expire in 2034 and $2.4&#160;million can be carried forward indefinitely.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had federal research and development tax credit carryforwards of approximately $38.8 million, which will begin to expire in 2029. As of December&#160;31, 2025, the Company also had state research and development and investment tax credit carryforwards of approximately $31.4 million, which will begin to expire in 2030. </span></div><div style="margin-bottom:9pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the U.S. Internal Revenue Code, if a corporation undergoes an ownership change, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income and taxes may be limited. The Company may have experienced an ownership change in the past and may experience ownership changes in the future as a result of future transactions in its share capital, some of which may be outside of the Company&#8217;s control. As a result, if the Company earns net taxable income, the Company's ability to use its pre-change net operating loss carryforwards, or other pre-change tax attributes, to offset U.S. federal and state taxable income and taxes may be subject to significant limitations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it operates to assess their potential effect on its business and assumptions regarding future taxable income. The Company cannot predict whether specific proposals will be enacted, the terms of such proposals, or their potential impact on its business if enacted. In 2025, no major tax legislation was enacted in the jurisdictions where the Company operates that materially impacted its consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which the Company operates. In the normal course of business, the Company is subject to examination by U.S. federal, state, local, and foreign taxing authorities, where applicable. There are currently no tax examinations in progress. As of December&#160;31, 2025, with few exceptions, the Company is no longer subject to U.S. federal, state, local, or foreign examinations by tax authorities for tax years before 2016. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state taxing authorities to the extent utilized in a future period.</span></div>The Company accounts for uncertain tax positions using a more likely than not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an annual basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2025 and 2024, the Company had no recorded liabilities for uncertain tax positions and had no accrued interest or penalties related to uncertain tax positions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of earnings per common share is as follows (in thousands, except share data): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(312,763)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(547,029)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(892,869)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">55,457,676</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">51,894,639</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">48,610,507</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(5.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(10.54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(18.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:60.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested PSUs</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,407,287</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Warrants to purchase Class A common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295,622</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295,622</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295,622</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested RSUs</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,262,853</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,327,398</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,804,189</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Earnout shares </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,793,063</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,794,243</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,803,049</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">366,567</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">767,520</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">192,208</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Escrow shares </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,125,392</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,205,115</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,095,068</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Represents employee and non-employee earnout shares for which the service-based and/or market-based vesting conditions have not been satisfied. </span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Represents restricted common stock issued in connection with asset acquisitions, held in escrow for indemnification purposes, and subject to forfeiture.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2026, the Company entered into a definitive Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) to sell substantially all of the operations comprising its Biosecurity segment (the &#8220;Biosecurity Business&#8221;) to a newly formed entity (&#8220;Tower Biosecurity Holdings, Inc.&#8221;). Under the terms of the agreement, the Company will contribute the Biosecurity Business to Tower Biosecurity Holdings, Inc. in exchange for approximately 20% equity interest of the total issued and outstanding equity of Tower Biosecurity Holdings, Inc. as of closing. The transaction is expected to close in the first half of 2026, subject to customary closing conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Upon closing, the Company expects to present the Biosecurity Business as discontinued operations in its consolidated financial statements and to recast prior period amounts to conform to this presentation. The transaction was approved by the Company's Board of Directors in February 2026, and, accordingly, the assets and liabilities of the Biosecurity Business are not reflected as held for sale as of December 31, 2025 and the accompanying consolidated financial statements do not reflect the effects of this transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo integrates risk management into its overall cybersecurity strategy, and has implemented processes designed to identify, assess, prioritize and manage risks to protect Ginkgo&#8217;s data, intellectual property and information assets. As part of our risk governance and management, Ginkgo has developed processes designed to: identify and assess risks, evaluate those risks against pre-defined criteria, develop and implement strategies to address identified risks, monitor and review those risks and communicate risks to relevant stakeholders. Identifying Ginkgo&#8217;s cybersecurity risks involves a multifaceted approach that encompasses both internal assessments and external information sources. For example, we use security audits conducted by internal and external auditors to assess compliance with security policies and industry frameworks; vulnerability assessments to discover vulnerabilities in networks, systems and applications; and risk assessment processes to evaluate IT infrastructure, including using a risk register to identify risks, likelihood of their occurrence, potential impact, and remediation. We also oversee third-party service providers by conducting vendor diligence upon onboarding and additional monitoring. Vendors are assessed for risk based on the nature of their services, access to data and systems and supply chain risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Cybersecurity risk management is overseen by Ginkgo&#8217;s Chief Information Security Officer (&#8220;CISO&#8221;), who is supported by full-time information security staff. The CISO advises the executive team on the development and implementation of the information security program.</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo incorporates learning from its cybersecurity risk management process into its overall cybersecurity program. To date, Ginkgo has not experienced a cybersecurity incident that resulted in a material effect on our business strategy, results of operations, or financial condition. Despite our efforts, we cannot provide assurance that we will not be materially affected in the future by cybersecurity risks or any future material incidents. For more information, see Item 1A. Risk Factors, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%">&#8220;Significant disruptions to our and our service providers&#8217; information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.&#8221;</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Ginkgo integrates risk management into its overall cybersecurity strategy, and has implemented processes designed to identify, assess, prioritize and manage risks to protect Ginkgo&#8217;s data, intellectual property and information assets. As part of our risk governance and management, Ginkgo has developed processes designed to: identify and assess risks, evaluate those risks against pre-defined criteria, develop and implement strategies to address identified risks, monitor and review those risks and communicate risks to relevant stakeholders.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">The Board provides regular oversight of the Company&#8217;s cybersecurity risk management program. The CISO presents to the Board and the audit committee of our Board (the &#8220;Audit Committee&#8221;) at least annually and quarterly updates via business review dashboards. The Board provides guidance to the CISO, including with respect to any changes to business priorities, risk tolerance, or security initiatives. These briefings are also augmented by ongoing and continuous interactions between the Board and the CISO, as needed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">The Board provides regular oversight of the Company&#8217;s cybersecurity risk management program. The CISO presents to the Board and the audit committee of our Board (the &#8220;Audit Committee&#8221;) at least annually and quarterly updates via business review dashboards. The Board provides guidance to the CISO, including with respect to any changes to business priorities, risk tolerance, or security initiatives. These briefings are also augmented by ongoing and continuous interactions between the Board and the CISO, as needed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo's CISO has primary responsibility for assessing and managing Ginkgo&#8217;s risks from cybersecurity threats. The CISO has public and private-sector experience in information technology and has served as Ginkgo&#8217;s CISO since 2025. Executive leadership provides oversight and governance through monthly business reviews of the cybersecurity program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo also has a Disclosure Committee, which is composed of representatives from executive leadership from various departments across Ginkgo (e.g., legal, finance, accounting). Their role is to determine materiality of a cyber incident and provide guidance with respect to any disclosure obligations resulting from a cyber incident.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The CISO presents to the Board and the audit committee of our Board (the &#8220;Audit Committee&#8221;) at least annually and quarterly updates via business review dashboards. The Board provides guidance to the CISO, including with respect to any changes to business priorities, risk tolerance, or security initiatives. These briefings are also augmented by ongoing and continuous interactions between the Board and the CISO, as needed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo's CISO has primary responsibility for assessing and managing Ginkgo&#8217;s risks from cybersecurity threats. The CISO has public and private-sector experience in information technology and has served as Ginkgo&#8217;s CISO since 2025. Executive leadership provides oversight and governance through monthly business reviews of the cybersecurity program.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo's CISO has primary responsibility for assessing and managing Ginkgo&#8217;s risks from cybersecurity threats. The CISO has public and private-sector experience in information technology and has served as Ginkgo&#8217;s CISO since 2025. Executive leadership provides oversight and governance through monthly business reviews of the cybersecurity program.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo's CISO has primary responsibility for assessing and managing Ginkgo&#8217;s risks from cybersecurity threats. The CISO has public and private-sector experience in information technology and has served as Ginkgo&#8217;s CISO since 2025. Executive leadership provides oversight and governance through monthly business reviews of the cybersecurity program.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%">Ginkgo also has a Disclosure Committee, which is composed of representatives from executive leadership from various departments across Ginkgo (e.g., legal, finance, accounting). Their role is to determine materiality of a cyber incident and provide guidance with respect to any disclosure obligations resulting from a cyber incident.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div>The accompanying consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, majority owned subsidiaries and variable interest entities if the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2024 (the &#8220;Effective Date&#8221;), with the approval of the Company's board of directors and shareholders, the Company effected a one-for-forty (1:40) reverse stock split (the &#8220;Reverse Stock Split&#8221;) for the Company&#8217;s common stock (inclusive of Class A common stock, Class B common stock and Class C common stock, par value $0.0001 per share). Accordingly, all common shares, common stock equity awards and common stock per share amounts presented herein have been retrospectively adjusted to reflect the Reverse Stock Split.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On the Effective Date, every forty shares of common stock issued and outstanding immediately prior to the Effective Date were automatically combined into one share of such class of common stock without any change to the par value per share. The number of shares reserved under the Company&#8217;s equity plans and the number of shares underlying awards outstanding under the Company&#8217;s equity plans was reduced proportionately. No fractional shares were issued in connection with the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reverse Stock Split. Shareholders entitled to receive a fractional share as a result of the Reverse Stock Split received a cash payment in lieu of such fractional shares. The number of authorized shares of common stock was not reduced.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities </span></div>The Company evaluates its variable interests in variable interest entities (&#8220;VIE&#8221;) and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of each VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#8217;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion. As of December&#160;31, 2025 and 2024, the maximum risk of loss related to the Company&#8217;s VIEs was limited to the carrying value of its investment in such entities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the consolidated financial statements. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Reported amounts and disclosures reflect the overall economic conditions that management believes are most likely to occur, and the anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, trade accounts receivable, marketable securities and notes receivable. The Company&#8217;s cash and cash equivalents and restricted cash are maintained in bank deposit accounts and money market funds that regularly exceed federally insured limits. The Company is exposed to credit risk on its cash, cash equivalents and restricted cash in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company believes that it is not exposed to significant credit risk as its deposits are generally held in financial institutions that management believes to be of high credit quality. To date, the Company has not experienced any material write-offs related to its trade accounts receivable. A portion of the Company&#8217;s Biosecurity revenue is derived from sales of services to foreign government agencies in certain developing countries. The Company is exposed to credit risk on its marketable securities. The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s policy is for no one issuer or group of issuers from the same holding company is to exceed 10% of the marketable securities portfolio at the time of purchase, with the exception of U.S. government securities or agencies, U.S. Treasuries, bank sweep and deposit programs and money market funds.  The Company&#8217;s maximum credit risk exposure with respect to notes receivable is equivalent to the carrying value of the notes as of the balance sheet date.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, one customer in the Cell Engineering segment accounted for 15% of the Company&#8217;s total revenue, while one customer in the Biosecurity segment accounted for 12% of the Company&#8217;s total revenue. For the year ended December&#160;31, 2024, two customers in the Cell Engineering segment accounted for 13% and 20% of the Company&#8217;s total revenue, while one customer in the Biosecurity segment accounted for 16% of the Company&#8217;s total revenue. For the year ended December&#160;31, 2023, one customer in the Cell Engineering segment and one customer in the Biosecurity segment accounted for 12% and 11%, respectively, of the Company's total revenue.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div>The Company&#8217;s cash is comprised of bank deposits, overnight sweep accounts and money market funds. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying value of the Company&#8217;s cash and cash equivalents approximate fair value due to their short-term maturities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily includes cash balances collateralizing letters of credit associated with the Company&#8217;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agreement. Restricted cash is included in prepaid expenses and other current assets and other non-current assets on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses to provide for the estimated amounts of receivables that will not be collected over the estimated life of the assets. The allowance is calculated by considering previous loss history, delinquency of receivables balances, current economic conditions and anticipated future economic conditions in the geographies and industries in which the Company&#8217;s customers operate. To the extent an individual customer&#8217;s credit quality deteriorates, the Company measures an allowance based on the risk characteristics of the individual customer. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. The allowance is calculated at each reporting period with changes recorded to general and administrative expense in the consolidated statements of operations and comprehensive loss. Accounts receivable are net of an allowance for credit losses of $2.2 million and $1.9 million at December&#160;31, 2025 and 2024, respectively. There were no material changes in the allowance for credit losses for the years ended December&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, the Company began investing its excess cash in marketable debt securities. All debt securities are classified as available-for-sale at the time of purchase. Available-for-sale debt securities, including those with maturities extending beyond one year, are classified as current assets on the balance sheet due to their highly liquid nature and because they are considered available for use in current operations. Debt securities that are highly liquid and have original maturities of three months or less at the time of acquisition are classified as cash equivalents on the consolidated balance sheet. The Company considers securities to be highly liquid if they can be readily converted to cash with an insignificant risk of changes in value, typically due to active markets and high credit quality.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses on available-for-sale marketable debt securities that are not related to credit losses are included in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. Amortization of premium or accretion of discount, along with interest income earned on debt securities, is included in interest income, net. Realized gains and losses, if any, are included in other income (expense), net, and the cost of securities sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the balance sheet date, the Company evaluates its debt securities in an unrealized loss position to determine the extent of the loss, if any, that is attributable to expected credit losses. Expected credit losses on debt securities are recorded as an allowance on the balance sheet, with an offsetting amount recognized in other income (expense), net, in the consolidated statements of operations and comprehensive loss. To date, the Company has not recorded any credit losses on its marketable debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities also includes equity securities of publicly-traded companies that are considered to be available for use in current operations. Equity securities of publicly-traded companies that are not considered to be available for use in current operations are presented within investments on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, net</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, net </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost less accumulated depreciation. Land is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets or the remaining lease term for leasehold improvements. Estimated lives of property, plant and equipment are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"><tr><td style="width:1.0%"></td><td style="width:46.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Buildings and facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15 to 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vehicles</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the related cost and accumulated depreciation is removed from the balance sheet and any resulting gain or loss is recorded in </span></div>the consolidated statements of operations and comprehensive loss. Construction in progress relates to assets which have not been placed in service as of the period end.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the equity method to account for its investments in common stock, or in-substance common stock, when it possesses the ability to exercise significant influence, but not control, over the operating and financial policies of the investee. The Company uses judgment when determining the level of influence over the operating and financial policies of the investee considering key factors including, among others, the Company&#8217;s ownership interest, representation on the board of directors, participation in policy-making decisions and material contractual arrangements and obligations. Income and losses are allocated based upon relative ownership interest unless there is a substantive profit-sharing agreement in place. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For investments with a substantive profit-sharing agreement, the Company utilizes the hypothetical liquidation at book value (&#8220;HLBV&#8221;) method to allocate income and losses from the equity method investment. Under the HLBV method, the Company utilizes the capital account at the end of the period assuming the book value of the entity was liquidated or sold minus the same calculation at the beginning of the period. The difference is the share of earnings or losses attributable to the equity method investment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity method, if there is a commitment for the Company to fund the losses of its equity method investees, the Company would continue to record its share of losses resulting in a negative equity method investment, which would be presented as a liability on the consolidated balance sheet. Commitments may be explicit and may include formal guarantees, legal obligations, or arrangements by contract. Implicit commitments may arise from reputational expectations, intercompany relationships, statements by the Company of its intention to provide support, a history of providing financial support or other facts and circumstances. When the Company has no commitment to fund the losses of its equity method investees, the carrying value of its equity method investments will not be reduced below zero. The Company had no commitment to fund additional losses of its equity method investments during the years ended December&#160;31, 2025, 2024 and 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its equity method investments for impairment whenever events or circumstances indicate that the carrying value of the investment may not be recoverable. The Company considers the investee&#8217;s financial position, forecasts and economic outlook, and the estimated duration and extent of losses to determine whether a recovery is anticipated. An impairment that is other-than-temporary is recognized in the period identified. The Company has not recognized an impairment loss related to its equity method investments for the years ended December&#160;31, 2025, 2024 and 2023.</span></div>The Company may elect the fair value option for its equity method investments on an investment-by-investment basis. For all equity method investments accounted for under the fair value option, the Company carries the equity method investment at fair value and records all subsequent changes in fair value as a component of loss on equity method investments in the consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments include marketable equity securities in publicly-traded companies, non-marketable equity securities in privately-held companies, Simple Agreement for Future Equity (&#8220;SAFE&#8221;) and warrants, in each case, in which the Company does not possess the ability to exercise significant influence over the investee. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable equity securities or warrants of publicly-traded companies are measured at fair value with subsequent changes in fair value recorded in loss on investments in the consolidated statements of operations and comprehensive loss. Marketable equity securities are classified as non-current on the balance sheet if they are not currently available for sale.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in non-marketable equity securities of privately-held companies and SAFEs, which do not have readily determinable fair values, are carried at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Each period the Company assesses relevant transactions to identify observable price changes, and the Company regularly monitors these investments to evaluate whether there is an indication of impairment. An equity security without a readily determinable fair value is written down to its fair value if a qualitative assessment indicates that the investment is impaired and the fair value of the </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">investment is less than its carrying value. For periods in which there is no estimate of fair value, the Company evaluates whether an event or change in circumstances has occurred that may have a significant adverse effect on the value of the investment. See Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span> for additional information on Investments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value and requires disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1- Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2- Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3- Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are either less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </span></div>The Company valued its money market fund holdings, notes receivable  marketable debt securities, marketable equity securities, warrant liabilities and contingent consideration liabilities at fair value on a recurring basis. The carrying amounts of the Company&#8217;s other financial instruments, which include accounts receivable, certain prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its long-lived assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the carrying value of the long-lived assets to the future undiscounted cash flows expected to be generated by the assets. In determining the expected future cash flows, the Company uses assumptions believed to be reasonable, but which inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of long-lived asset is less than the carrying value. See Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_575" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">11</a></span> for a description of impairment losses recorded on long-lived assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognizes any excess of the total consideration paid over the fair value of the identifiable net assets as goodwill. Any purchase price that is considered contingent consideration is measured at its estimated fair value at the acquisition date and remeasured at each reporting period, with changes in estimated fair value recorded in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Acquisition transaction costs are expensed when incurred. The operating results of an acquisition are included in the Company&#8217;s consolidated financial statements as of the acquisition date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets, net</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, net </span></div>Intangible assets, net consist of certain definite-lived assets including patents, processes and know-how related to technology acquired through business combinations and asset acquisitions. The Company amortizes such intangible assets on a straight-line basis over their estimated useful life.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represented the excess of the acquisition cost over the fair market value of the net assets acquired. All goodwill was allocated to the Cell Engineering reporting unit and segment identified in Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_187" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">16</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company considers various qualitative factors that could indicate impairment of goodwill such as macroeconomic conditions, industry and market environment, overall financial performance of the Company, cash flow from operating activities and market capitalization. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment to compare the fair value of the reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds the fair value, an impairment loss is recognized limited to the total amount of goodwill allocated to that reporting unit. A combination of the income approach and the market approach may be used to determine fair value of the reporting unit. The Company recorded a full goodwill impairment during the year ended December 31, 2024 (see Note </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_160" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">). No impairment losses were recognized during the years ended December 31, 2025, and 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determines if an arrangement is or contains a lease at contract inception based on the terms and conditions in the contract. A contract contains a lease if there is an identified asset and the Company has the right to control the asset. For leases with terms greater than 12 months, the Company recognizes a right-of-use asset (&#8220;ROU asset&#8221;) and a lease liability as of the lease commencement date on the balance sheet. ROU assets represent the Company&#8217;s right to use an underlying asset over the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are measured based on the present value of fixed lease payments that are unpaid as of the lease commencement date. The Company&#8217;s ROU assets balance is increased by any initial direct costs and reduced by lease incentives received or expected to be received. Some of the Company's leases include options to extend or terminate the lease; these options are included in the lease term for calculations of its ROU assets and liabilities when it is reasonably certain that the Company will exercise those options. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s leases are classified as either operating or finance, as determined at inception, with the classification affecting the pattern of expense recognition in the statement of operations. A lease is classified as a finance lease if risks and rewards are conveyed without the transfer of control. For operating leases, expense is generally recognized on a straight-line basis over the lease term. For finance leases, interest on the lease liability is recognized using the effective interest method, while the ROU asset is amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term. Leases with an initial term of 12 months or less which meet the definition of a short-term lease are not recorded on the balance sheet and the lease expense for these leases is recognized on a straight-line basis over the lease term. In limited instances, the Company acts as a lessor, primarily with certain real estate subleases. Finance leases, short-term leases and subleases are not a significant component of the Company's financial condition or results of operations. The current portion of the Company&#8217;s operating lease liabilities is included in accrued expenses and other current liabilities on the balance sheet. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements with both lease and non-lease components (such as real estate taxes, insurance and common area maintenance charges) and has elected the practical expedient to combine these lease and non-lease components for its real estate leases and non-lab equipment leases. The Company has not elected this practical expedient for lab equipment leases and the lease and non-lease components are accounted for separately for these leases. Non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses an incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments and uses the implicit rate when it is readily determinable. The Company&#8217;s incremental borrowing rate is based on management&#8217;s estimate of the rate of interest the Company would have to pay to borrow on a fully collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Engineering Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates Cell Engineering service revenue by providing end-to-end cell engineering solutions and tools to customers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We generate Cell Engineering revenue primarily through service and license agreements for our tools and solutions offerings. Under our automation solutions agreements we typically provide services related to the design, build, and deployment of our RAC systems as well as ongoing support services. These agreements typically include a fee for the sale and installation of RAC hardware and a fee for follow on support services and control software. Datapoints agreements typically include fixed fees for services related to producing a data package for our customers and are earned over a shorter time period than legacy cell engineering solutions projects.  Under our solutions agreements, we typically provide R&amp;D services for cell programming with the goal of producing an engineered cell that meets a mutually agreed specification. Our customers obtain license rights to the output of our services, which are primarily the optimized strains or cell lines, in order to manufacture and commercialize products derived from that licensed strain or cell line. Generally, the terms of these agreements provide that we receive some combination of: (1) service fees in the form of (i) upfront payments upon consummation of the agreement or other fixed payments, (ii) reimbursement for costs incurred for R&amp;D services and (iii) milestone payments upon the achievement of specified technical criteria, plus (2) downstream value share payments in the form of (i) milestone payments upon the achievement of specified commercial criteria, (ii) royalties on sales of products from or comprising engineered organisms arising from the collaboration or licensing agreement and/or (iii) royalties related to cost of goods sold reductions realized by our customers. Royalties did not comprise a material amount of our revenue during any of the periods presented. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cell Engineering revenue has historically included transactions with Platform Ventures and Legacy Structured Partnerships where we received non-cash consideration in the form of equity interests and financial instruments that are convertible into equity upon a triggering event.  We view the upfront non-cash consideration as prepayments for licenses which will be granted in the future as we complete mutually agreed upon technical development plans. In these instances, we also receive cash consideration for the R&amp;D services performed by us on a fixed fee or cost-plus basis. We are not compensated through additional milestone or royalty payments under these arrangements. As we perform R&amp;D services under the mutually agreed upon development plans, we recognize a reduction in the prefunded obligation on a cost-plus basis. In some cases we issued the customer a prepaid Cell Engineering services credit in exchange for the upfront non-cash consideration, which can and has been drawn down as payment for R&amp;D services performed under mutually agreed upon development plans. These arrangements are further described in Notes </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_157" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">8</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">1</a><a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Options to acquire additional distinct goods and services are evaluated to determine if such options provide a material right to the customer that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which is accounted for as a separate contract upon the customer&#8217;s election of the option. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. Any upfront cash payment received upon consummation of the contract is fixed and generally nonrefundable. Variable consideration is subject to a constraint, and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. This is attained when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursement for costs incurred for the Company&#8217;s research and development efforts, milestone payments upon the achievement of certain technical and/or commercial criteria, and royalties on sales of products from or comprising engineered organisms arising from the contract. With respect to the research and development reimbursements and milestone payments, the Company uses the most likely amount method to estimate variable consideration. Milestone payments are generally not included in the transaction price until the milestone is achieved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain agreements include payment in the form of equity securities or other financial instruments that convert into equity upon a triggering event. Any non-cash consideration is measured at its estimated fair value at contract inception. For equity securities and financial instruments that are not actively traded, the estimated fair value is generally determined by referencing a recent financing round or utilizing a scenario-based valuation model. Significant unobservable inputs are used in these valuations, including expectations regarding future financings of the customer, scenario dates and probabilities, expected volatility, discount rates, and recovery rates. Changes in these assumptions can materially affect the fair value of the non-cash consideration and, consequently, the total revenue recognized for the contract. The Company did not have material non-cash consideration included in contracts entered into during  the years ended December&#160;31, 2025 and 2024, but does continue to recognize non-cash revenue from contracts originating in prior periods. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For agreements with promises that are combined into a single performance obligation, the entire transaction price is allocated to the single performance obligation. For agreements with multiple performance obligations, the transaction price is allocated to the performance obligations using the relative standalone selling price methodology. For agreements featuring variable consideration, the Company allocates variable consideration to one or more, but not all, performance obligations if certain conditions are met. Specifically, the Company assesses whether the variable consideration relates solely to its efforts to satisfy the performance obligation and whether allocating such variable consideration entirely to the performance obligation is consistent with the overall allocation objective. If these conditions are not met, the Company allocates the variable consideration based on the relative standalone selling price methodology. The key assumptions utilized in determining the standalone selling price for each performance obligation include development timelines, estimated research and development costs, commercial markets, likelihood of exercise (in the case of options considered to be material rights), and probabilities of success. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For agreements where licenses or assignments are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time when the license is effectively granted, as the licenses or assignments represent functional intellectual property. For agreements where licenses and research and development services are combined into a single performance obligation, the Company recognizes revenue over the performance period using the cost-to-cost method. This method measures progress based on the ratio of costs incurred to date to total estimated costs, as it best reflects the transfer of control to the customer for obligations satisfied over time. For automation sales the Company typically recognizes revenue at a point in time at which the hardware has been installed and passed acceptance testing at the customer site. The ongoing support services are recognized over time on a straight line basis over the related support period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its measure of progress to recognize revenue at each reporting period and, as necessary, adjusts the measure of progress and related revenue recognition. The Company&#8217;s measure of progress and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs to complete its performance obligations. The Company evaluates contract modifications and amendments to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis. The Company utilizes the right to invoice practical expedient when it has a right to consideration in an amount that corresponds directly with the value of the Company&#8217;s performance to date. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Royalties are recognized as revenue when (or as) the later of the sales occurrence or the satisfaction (or partial satisfaction) of the related performance obligation. The Company has determined that applying this exception is appropriate when the license granted in the contract is the predominant item to which the royalties relate. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As the Company receives upfront payments for technical services under certain of its arrangements, the Company evaluates whether any significant financing components exist given the term over which the fees will be earned may exceed one year. Based on the nature of the Company&#8217;s agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing, but rather to secure technical services, exclusivity rights, and Foundry capacity, or the timing of transfer of those goods or services is at the discretion of the customer. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue represents consideration received by the Company in excess of revenue recognized and primarily results from transactions where the Company receives upfront cash payments or non-cash equity consideration. In instances where the Company has received consideration in advance for an undefined number of technical development plans (&#8220;TDPs&#8221;) under its customer agreements, the Company records the advance payments as deferred revenue, net of current portion on the consolidated balance sheet. Upon the execution of a specific TDP, the Company reclassifies the estimated consideration to be earned under that TDP within the next twelve months as current deferred revenue. The Company also classifies unexercised material rights related to future TDPs as deferred revenue, net of current portion on the consolidated balance </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sheet. When a TDP is executed, and the material right is exercised, the amount allocated to the material right, which will be earned within the next twelve months, is reclassified to current deferred revenue. All other deferred revenue is classified as current or non-current based on the timing of when the Company expects to earn the underlying revenue based upon the projected progress of activities under the TDP. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2025 any costs to obtain contracts with customers were immaterial.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosecurity Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates Biosecurity revenue through its biomonitoring and bioinformatics services provided to both government and non-government customers through the Company's two core offerings: Canopy and Horizon.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2024, product revenue consisted of sales of lateral flow assay (&#8220;LFA&#8221;) diagnostic test kits, polymerase chain reaction (&#8220;PCR&#8221;) sample collection kits, and pooled test kits, which the Company sold to customers on a standalone basis. Product revenue was billed and recognized when the test kits were shipped, and risk of loss was transferred to the carrier. The Company&#8217;s test kits were generally not subject to a customer right of return except for product recalls under the rules and regulations of the U.S. Food and Drug Administration (&#8220;FDA&#8221;). The Company included shipping and handling fees billed to customers as a component of Biosecurity revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Biosecurity service revenue generally consists of various biomonitoring and bioinformatics services including, but not limited to, sample collection, sample storage and transportation, outsourced laboratory analysis, access to results reported through a web-based portal, analytical reporting of results, and overall program management. The various services are generally combined into one performance obligation as they are either not distinct or have substantially the same pattern of transfer to the customer. Service revenue is generally recognized over time using the time elapsed method as the related services are performed, which best depicts the pattern of transfer to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts with customers are generally three years or less in length and contain a fixed amount of consideration. Under typical payment terms for testing services, amounts are billed monthly in arrears for services performed or in advance based on contractual billing terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Options to acquire additional services are evaluated to determine whether they provide the customer with a material right that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer, and upon the customer's election of the option, it is accounted for as a separate contract.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Biosecurity Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Biosecurity Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The cost of Biosecurity service revenue consists of costs related to the Company's biomonitoring and bioinformatics services. This includes costs incurred for sample collection equipment, services and materials, outsourced laboratory analysis, access to results reported through a proprietary web-based portal, and reporting of results to public authorities. Additionally, the cost of Biosecurity service revenue includes direct labor cost associated with bioinformatics, lab network management, delivery logistics, and customer support. Prior to 2024, cost of Biosecurity product revenue consisted of costs associated with the sale of diagnostic and sample collection test kits, which included costs incurred to purchase test kits from third parties.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Other Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of other revenue consists of costs related to the Company's Cell Engineering tools offerings, including Datapoints and lab automation solutions. Such costs primarily include hardware, software, materials and labor. Costs related to the Company&#8217;s end-to-end cell engineering solutions offering in which the Company retains rights to intellectual property are included in research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div>Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects and initiatives, acquired intellectual property deemed to be in-process research and development, as well as fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs </span></div>The Company expenses all costs as incurred in connection with the filing, prosecution, maintenance, defense, and enforcement of patent applications, including direct application fees and related legal and consulting expenses. Patent costs are included in general and administrative expenses within the consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based awards based on estimated grant-date fair values recognized over the requisite service period. For awards that vest solely based on a service condition, the Company recognizes compensation expense on a straight-line basis over the requisite service period. For awards that vest based on multiple conditions, the Company recognizes compensation expense using the accelerated attribution method on a tranche-by-tranche basis over the requisite service period such that the amount of compensation expense recognized at each reporting period is at least equal to the vested tranches at that date. For awards with a performance-based vesting condition, the Company recognizes stock-based compensation when achievement of the performance condition is deemed probable. Upon achieving a performance condition that was not previously considered as probable, the Company records a cumulative catch-up adjustment to reflect the portion of the grantee&#8217;s requisite service that has been provided to date. For awards with market conditions, the compensation expense recognized over the requisite service period is not reversed if the market condition is not satisfied. The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model, inclusive of assumptions for expected term, expected volatility, risk-free interest rate and expected dividend yield. The expected term is determined using the &#8220;simplified&#8221; method, which estimates the expected term as the average of the vesting term plus the contractual term. The Company uses the &#8220;simplified&#8221; method as it does not have sufficient historical data regarding employee exercise behavior. Expected volatility is based on the historical volatility of the Company's Class A common stock. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the stock options. The Company has not paid, and does not expect to pay, dividends in the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For awards with market conditions, the Company recognizes stock-based compensation based on the estimated grant-date fair value of the awards, determined using a Monte Carlo simulation model. This model incorporates assumptions for expected stock price volatility, risk-free interest rates, expected term, and expected dividend yield. Volatility is estimated using either the historical volatility of the Company&#8217;s Class A common stock or a weighted average of its own historical volatility and the historical volatility of selected comparable publicly traded companies, particularly for awards granted when there was limited trading history for the Company&#8217;s Class A common stock. The risk-free interest rate is derived from the yield on U.S. Treasury zero-coupon securities with a duration similar to the expected term of the awards. The expected term equals the contractual term, and a dividend yield of zero is assumed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies. </span></div>The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an annual basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gains on available-for-sale securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share by dividing the net loss attributable to Ginkgo Bioworks Holdings, Inc. common stockholders by the weighted average number of common shares outstanding during the period. For the purposes of the net loss per share calculation, the Company has combined Class A common stock, Class B common stock, and Class C common stock, as all classes of common stock are legally entitled to equal per-share distributions, whether through dividends or liquidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is computed using the weighted average number of common shares outstanding during the period, increased to include the effect of dilutive potential common shares, such as outstanding stock options, unvested restricted stock awards, unvested restricted stock units, warrants, and contingently issued shares. Dilutive securities are excluded from the calculation of diluted weighted average common shares outstanding if their effect would be anti-dilutive under the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">which focuses on improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this ASU require that public business entities on an annual basis (1) disclose specific categories in the tabular rate reconciliation, using both percentages and reporting currency amounts, and (2) provide additional information for reconciling items that meet a quantitative threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company adopted this standard on January 1, 2025 using the prospective method. The adoption did not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This ASU requires public business entities to disaggregate, on both an interim and annual basis, each relevant expense caption presented on the face of the income statement into specific expense categories. Additionally, entities are required to provide a qualitative description of amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, as well as disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this ASU will have on its disclosures in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.2.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3D<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment Net</a></td>
<td class="text">Estimated lives of property, plant and equipment are as follows: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"><tr><td style="width:1.0%"></td><td style="width:46.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Buildings and facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15 to 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vehicles</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:68.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">146,279&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">150,887&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">140,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">135,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Buildings and facilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">49,760&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">48,255&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,056&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,897&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,060&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,060&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">358,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">364,592&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(190,597)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(160,872)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">167,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">203,720&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents restructuring costs incurred during the years ended December&#160;31, 2025 and 2024, which are recorded as &#8220;Restructuring charges&#8221; in the consolidated statements of operations and comprehensive loss (in thousands):&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.333%"><tr><td style="width:1.0%"></td><td style="width:53.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-562">Employee termination costs and other</span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impairment of right-of-use asset (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total restructuring</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">1) Relates to the sublease of a facility in connection with the restructuring and reflects the excess of the right-of-use asset's carrying value over its fair value, which was determined based on estimates of future discounted cash flows and is classified as Level 3 in the fair value hierarchy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the change in the accrued liability balance related to the restructuring activities, which is included in &#8220;Accounts payable&#8221; and &#8220;Accrued expenses and other current liabilities&#8221; in the accompanying consolidated balance sheet as of December&#160;31, 2025 (in thousands):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.333%"><tr><td style="width:1.0%"></td><td style="width:63.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Employee Termination Costs and Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Liability balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expenses incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Liability balance at December 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock', window );">Schedule of Deconsolidated Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents Zymergen&#8217;s consolidated assets and liabilities which have been deconsolidated from the Company's consolidated balance sheet as of October 2, 2023. The amounts presented are before the elimination of intercompany balances.</span></div><div><span><br/></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.636%"><tr><td style="width:1.0%"></td><td style="width:73.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">October 2, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">34,321&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,190&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,558&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,938&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">135,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,679&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,486&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">248,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">730&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21,156&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">184,301&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">205,629&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Net assets deconsolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents Zymergen&#8217;s results of operations for the periods presented, included in the Company's consolidated statements of operations and comprehensive loss prior to the elimination of intercompany balances.</span></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:53.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Period from January 1, 2023 - October 2, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,370&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">200,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(192,605)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(168,985)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(168,999)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities That Are Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"><tr><td style="width:1.0%"></td><td style="width:42.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">146,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">146,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">118,038&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">118,038&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">114,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">114,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,654&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,654&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Synlogic, Inc. warrants </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">190&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">190&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">410,432&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">284,390&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">118,916&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,126&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,690&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,690&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"><tr><td style="width:1.0%"></td><td style="width:42.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">521,457&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">521,457&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Synlogic, Inc. warrants </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">238&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">238&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">17,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">17,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">553,424&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">539,016&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12,565&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,843&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,922&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,922&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span>The fair value of Synlogic, Inc. warrants is calculated as the quoted price of the underlying common stock, less the unpaid exercise price of the warrants.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a reconciliation of the beginning and ending balances for assets and liabilities measured at fair value using Level 3 significant unobservable inputs for the years ended December 31 (in thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"></td><td style="width:43.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.516%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.516%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Notes Receivable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Private Placement Warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Conversion to preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(17,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transfers to Level 2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Conversion to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,922&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Fair Value Measurements Inputs</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides quantitative information regarding Level 3 inputs used in the fair value measurements of contingent consideration liabilities as of the periods presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2025<br/>Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2024<br/>Range</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Earnout payments (FGen and Dutch DNA acquisitions)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Probability-weighted present value</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Probability of payment</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5% - 10%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">5% - 50%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">9.3% </span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Earnout payments (Dutch DNA acquisition) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Projected years of payments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2028-2031</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1) During the year ended December&#160;31, 2025, all Dutch DNA milestones valued using the discounted cash flow method were reduced to zero due to the termination of a customer agreement to which those milestones were tied.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities, including those classified in cash and cash equivalents, are summarized as follows (in thousands):</span></div><div style="margin-top:6pt;padding-right:-13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">117,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">118,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">114,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">255,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-Sale</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable debt securities are summarized below by contractual maturity dates (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.333%"><tr><td style="width:1.0%"></td><td style="width:41.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">205,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">205,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Equity Method Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Investments and Equity Method Investments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investments consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:68.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Investments:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">SAFEs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,125&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,218&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">17,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Synlogic warrants</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">191&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">238&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">48,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable equity securities of $18.7 million are not restricted for sale and are included in marketable securities in the consolidated balance sheet as of December&#160;31, 2025.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on investments and equity method investments consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.727%"><tr><td style="width:1.0%"></td><td style="width:56.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">(Loss) gain on investments:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Genomatica preferred stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(33,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Non-marketable equity securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(4,557)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,735)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9,928)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,583)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,874)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">SAFEs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(14,501)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,208)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,742)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Synlogic warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total loss on investments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(16,411)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(28,827)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(54,827)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Loss on equity method investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BiomEdit</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,461)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total loss on equity method investments</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(2,635)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of non-marketable equity securities accounted for using the fair value measurement alternative and still held as of December&#160;31, 2025, including cumulative unrealized losses, were as follows (in thousands):</span></div><div style="margin-top:10pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"></td><td style="width:75.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total initial cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(91,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Downward adjustments from observable price changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Summary of Losses and Gains on Investments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss on investments for each period were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,345)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(20,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(44,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized gains (losses) recognized on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(7,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(9,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Downward adjustments from observable price changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total loss on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,411)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28,827)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(54,827)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total realized and unrealized losses associated with equity investments accounted for at fair value or the fair value measurement alternative consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss recognized on equity investments sold </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses recognized on equity investments held as of the end of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(22,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(54,827)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total loss on investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(16,411)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28,827)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(54,827)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1) Reflects the difference between the sale proceeds and the carrying value of the equity investments at the beginning of the period or the acquisition date, if later.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of goodwill consisted of the following year ended December 31, 2024 (in thousands): </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.727%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 31, 2023</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">49,238&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill impairment (accumulated impairment loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(47,858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impact of foreign currency translation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,380)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.545%"><tr><td style="width:1.0%"></td><td style="width:35.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Amortization </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Net</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(in Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">December 31, 2025:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">111,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(54,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">December 31, 2024:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">111,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(38,883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">72,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6.6</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span>Gross carrying value and accumulated amortization include the impact of cumulative foreign currency translation adjustments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense</a></td>
<td class="text">The estimated future amortization expense for intangible assets remaining as of December&#160;31, 2025 is as follows (in thousands):<div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.212%"><tr><td style="width:1.0%"></td><td style="width:77.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">18,700&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,987&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,987&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">17,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,924&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components Lease Cost</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of total lease cost (in thousands): </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.545%"><tr><td style="width:1.0%"></td><td style="width:46.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">63,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">57,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">59,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">76,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">72,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">65,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:  </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:71.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate - finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Operating Leases Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases were as follows (in thousands):  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"></td><td style="width:59.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">45,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information for each reporting period (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for interest</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">223,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,565&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,915&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Convertible financial instruments received for Cell Engineering services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Equity securities and warrants received for Cell Engineering services</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">55&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">17,450&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">18,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued as settlement of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">14,742&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">8,896&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for retention payments related to business and asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Return of investment in equity securities for reduction in deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,760&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Conversion of notes receivable for common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance costs related to ATM offering included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">53&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended December&#160;31, 2025, the amount of cash income taxes paid by the Company was as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.545%"><tr><td style="width:1.0%"></td><td style="width:68.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State and local:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">California</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">South Carolina</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">All other state and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash income taxes, net of refunds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of the Company&#8217;s lease liabilities (in thousands): </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.848%"><tr><td style="width:1.0%"></td><td style="width:59.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Finance Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,302&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58,498&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">60,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">59,301&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">371,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total undiscounted payments</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">662,799&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(222,934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">439,865&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">L<span style="-sec-ix-hidden:f-1005"><span style="-sec-ix-hidden:f-1006">ess: current portion of lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(22,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities, non-current</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">417,078&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Capital Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of the Company&#8217;s lease liabilities (in thousands): </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.848%"><tr><td style="width:1.0%"></td><td style="width:59.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Years Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Finance Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,302&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58,498&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">60,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">59,301&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">371,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total undiscounted payments</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">662,799&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(222,934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">439,865&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">L<span style="-sec-ix-hidden:f-1005"><span style="-sec-ix-hidden:f-1006">ess: current portion of lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(22,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities, non-current</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">417,078&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet to the totals shown within the consolidated statements of cash flows is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">167,202&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">561,572&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">944,073&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash included in prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Restricted cash included in other non-current assets </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,138&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,332&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,722&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">212,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">605,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">989,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span>Includes cash balances collateralizing letters of credit associated with the Company&#8217;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer agreement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet to the totals shown within the consolidated statements of cash flows is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">167,202&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">561,572&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">944,073&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash included in prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Restricted cash included in other non-current assets </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,138&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,332&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">40,722&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">212,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">605,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">989,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span>Includes cash balances collateralizing letters of credit associated with the Company&#8217;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer agreement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment Net</a></td>
<td class="text">Estimated lives of property, plant and equipment are as follows: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"><tr><td style="width:1.0%"></td><td style="width:46.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Buildings and facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15 to 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vehicles</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:68.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">146,279&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">150,887&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">140,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">135,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Buildings and facilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">49,760&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">48,255&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,056&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14,897&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,060&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,060&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">358,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">364,592&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(190,597)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(160,872)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">167,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">203,720&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands): </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"><tr><td style="width:1.0%"></td><td style="width:68.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">22,787&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,630&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contractual shortfall liabilities (Note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,438&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Biosecurity costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,258&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,894&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and securities litigation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">External research and development expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,072&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">713&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Employee termination costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">816&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,387&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">138&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1079"><span style="-sec-ix-hidden:f-1080">Accrued expenses and other current liabilities</span></span></span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">66,458&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">65,387&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Operating Leases Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases were as follows (in thousands):  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"></td><td style="width:59.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">45,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information for each reporting period (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for interest</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">223,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,565&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,915&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Convertible financial instruments received for Cell Engineering services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Equity securities and warrants received for Cell Engineering services</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">55&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">17,450&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">18,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued as settlement of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">14,742&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">8,896&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for retention payments related to business and asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Return of investment in equity securities for reduction in deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,760&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Conversion of notes receivable for common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance costs related to ATM offering included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">53&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended December&#160;31, 2025, the amount of cash income taxes paid by the Company was as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.545%"><tr><td style="width:1.0%"></td><td style="width:68.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State and local:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">California</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">South Carolina</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">All other state and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash income taxes, net of refunds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accrued Expenses and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationTextBlock', window );">Schedule of Capitalization</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s authorized, issued, and outstanding common stock as of the dates indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock as of December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,500,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">49,694,610</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">46,791,082</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class B</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,500,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,985,839</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,416,216</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class C</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">800,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,800,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,680,449</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58,207,298</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock as of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class A</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,500,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">45,575,423</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,696,585</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,500,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,239,682</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,669,200</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Class C</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">800,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,000,000</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,000,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15,800,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">57,815,105</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">54,365,785</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock', window );">Schedule of Common Stock Reserved For Future Issuances</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following common stock reserved for future issuance as of the date indicated:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.272%"><tr><td style="width:1.0%"></td><td style="width:77.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for grant under the 2021 Plan</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,336,606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restricted stock units outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,262,853</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Performance stock units outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,407,287</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Warrants to purchase Class A common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295,622</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for grant under the ESPP</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,500,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for grant under the 2022 Inducement Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">292,172</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">366,567</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Total common stock reserved for future issuances </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13,461,107</span></td></tr></table></div><div style="margin-top:10pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Excludes unvested earnout shares, which are restricted shares issued to equity holders of legacy Ginkgo prior to the closing of the SRNG Business Combination and to SRNG. These earnout shares are recorded in equity as shares outstanding upon satisfying the vesting conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common stock reserved for future issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the capitalization of the entity comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense by financial statement line item in the Company&#8217;s consolidated statements of operations and comprehensive loss for the periods presented (in thousands): </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.121%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">34,210&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,020&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">145,879&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">42,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">84,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of Biosecurity revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,624&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">81,546&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">112,344&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">229,884&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of time-based stock options activity for the year ended December&#160;31, 2025 is presented below: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.757%"><tr><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Exercise Price per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Remaining Contractual Term (in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:115%">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of  December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">267,520</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25.17&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">171,875</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(72,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">36.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">366,567</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">15.38&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.9</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Exercisable as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">136,014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:6.7pt">The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the year and the exercise prices, multiplied by the number of in-the-money stock options.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards Granted</a></td>
<td class="text">The weighted-average fair value of options granted during the years ended December&#160;31, 2025, 2024, and 2023 was $7.48, $11.35 and $57.20 per share, respectively, and was calculated using the following key assumptions in the Black-Scholes option-pricing model:<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.030%"><tr><td style="width:1.0%"></td><td style="width:50.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.06</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4.27</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3.94</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">97</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">93</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">6.0</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5.7</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU and RSA Activity</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the year ended December&#160;31, 2025 is presented below: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.212%"><tr><td style="width:1.0%"></td><td style="width:50.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of  December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,327,398</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">69.00&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,176,419</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,797,720)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">48.74&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,443,244)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of  December 31, 2025</span></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,262,853</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">55.07&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SummaryOfActivityForEarnoutRSATableTextBlock', window );">Summary of Activity For Earnout RSA</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity during the year ended December&#160;31, 2025 for the earnout shares is presented below: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"><tr><td style="width:1.0%"></td><td style="width:61.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of December 31, 2024</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">552,457</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">510.80&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(321)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">533.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(859)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">512.62&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">551,277</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">510.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Nonvested Performance-Based Units Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of PSU activity for the year ended December&#160;31, 2025 is presented below:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"><tr><td style="width:1.0%"></td><td style="width:60.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Performance Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,599,647</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,192,360)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested as of December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,407,287</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SummaryOfActivityForEarnoutRSATableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Earnout RSUs Table Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SummaryOfActivityForEarnoutRSATableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation Of Revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the percentage of Cell Engineering revenues by industry based on total Cell Engineering revenue: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"><tr><td style="width:1.0%"></td><td style="width:56.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pharmaceutical and biotechnology</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">35&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">26&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">30&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Agriculture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Government and defense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Industrial and environment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Consumer and technology</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Food and nutrition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total Cell Engineering revenue</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents summary results of the Company&#8217;s reportable segments and a reconciliation of total segment operating loss to consolidated loss before income taxes (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cell Engineering</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">132,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">173,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">143,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">158,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">271,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">335,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">115,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">171,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cell Engineering operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(95,530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(218,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(363,622)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Biosecurity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">37,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">78,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Costs and operating expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Cost of Biosecurity service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">38,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">46,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Cost of Biosecurity product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">27,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">55,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Biosecurity operating (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(18,931)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(30,619)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,194)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Total segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(114,461)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(249,186)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(366,816)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Reconciling items to reconcile total segment operating loss to loss before income taxes:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">82,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">115,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">234,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Impairment expense </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">121,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">58,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">63,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">70,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Restructuring charges </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">24,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Carrying cost of excess space (net of sublease income) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">25,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Merger and acquisition related expenses </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">19,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(8,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(313,600)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(547,508)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(892,940)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes $1.2 million, $3.0 million, and $5.0 million in related employer payroll taxes for the years ended December&#160;31, 2025, 2024, and 2023, respectively. </span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">For 2024, includes $47.9&#160;million related to goodwill impairment and $5.8&#160;million related to lab equipment. For 2023, includes a $25.2&#160;million impairment loss on lab equipment and a $96.2&#160;million impairment loss on lease assets associated with an exited Zymergen leased facility.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">See Note </span><span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#id8596373948b4ae4958ccd7c02fd70c1_575" style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">3</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">, Restructuring, for composition of costs. </span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt">Includes interest income, interest expense, loss on investments, losses/gains on deconsolidation of subsidiaries, changes in fair value of certain assets and liabilities, and other gains or losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Consolidation and Presentation of Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Condensed Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant related party transactions included in the consolidated balance sheet, excluding the Company&#8217;s investments and equity method investments, are summarized below (in thousands):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"><tr><td style="width:1.0%"></td><td style="width:63.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Deferred revenue, current and non-current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Allonnia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">36,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">36,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Arcaea</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BiomEdit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Genomatica</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">64,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">73,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant related party transactions included in the consolidated statements of operations and comprehensive loss, excluding the losses on the Company&#8217;s investments and equity method investments, are summarized below (in thousands): </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"><tr><td style="width:1.0%"></td><td style="width:56.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Cell Engineering revenue:</span></div></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Motif FoodWorks</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">45,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Arcaea</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,653&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,024&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Genomatica</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Ayana Bio</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">637&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,028&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,323&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BiomEdit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Verb Biotics</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">584&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Allonnia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other equity investees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">139&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">705&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">53,041&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">22,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Loss Before Provision for Incomes Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the loss before income taxes consisted of the following (in thousands):  </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.090%"><tr><td style="width:1.0%"></td><td style="width:54.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Domestic</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(308,990)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(514,354)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(890,986)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(4,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(33,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(313,600)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(547,508)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(892,940)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Income Taxes Expenses (Benefit) Incurred During the Period</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the Company recorded the following income tax expense (benefit) (in thousands):  </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.515%"><tr><td style="width:1.0%"></td><td style="width:49.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(346)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(109)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">123&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">457&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">813&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1,364)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(936)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(884)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(837)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(479)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(71)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of the Statutory Corporate Income Tax Rate to the Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of income tax benefit computed by applying the 21% statutory U.S. Federal income tax rate to income before income taxes after the adoption of ASU 2023-09 for year ended December&#160;31, 2025 is as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.272%"><tr><td style="width:1.0%"></td><td style="width:50.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Tax at U.S. Statutory Rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(65,856)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">State and Local Income Taxes (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Foreign Tax Effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other foreign jurisdictions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Nontaxable or Nondeductible Items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">14,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Limitation on executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Gain/Loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Tax Credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Research &amp; Development Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(1,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Changes in Valuation Allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">45,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other Items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The states and local jurisdictions that contribute to the majority (greater than 50%) of the tax effect in this category include Massachusetts and New York state and city. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax benefit computed at the statutory corporate income tax rate to the effective income tax rate for the years ended December 31, 2024 and 2023 is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.212%"><tr><td style="width:1.0%"></td><td style="width:52.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal income tax at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Investments in subsidiaries and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(29.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Taxes Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s deferred tax assets and liabilities consist of the following (in thousands):  </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.303%"><tr><td style="width:1.0%"></td><td style="width:65.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">459,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">332,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">63,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">155,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">214,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">21,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">28,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">48,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">52,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortizable intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">112,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">116,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Investments in subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">59,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">57,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">936,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">875,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(840,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(771,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">96,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">103,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Amortizable intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(10,119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(92,052)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(98,184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(102,171)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(110,389)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred taxes</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,094)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,552)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Deferred Tax Assets Valuation Allowance</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Activity in the deferred tax assets valuation allowance is summarized as follows (in thousands):  </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:60.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Beginning of Period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Additions<br/>(Subtractions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets valuation allowance:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Year ended December 31, 2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">771,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">68,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">840,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Year ended December 31, 2024</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">711,778&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">60,074&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">771,852&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Operating Leases Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases were as follows (in thousands):  </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"></td><td style="width:59.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">61,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">45,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information for each reporting period (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for interest</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">83&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">223,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">27,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">46&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,565&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,915&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Convertible financial instruments received for Cell Engineering services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Equity securities and warrants received for Cell Engineering services</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">55&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">17,450&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">18,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued as settlement of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">14,742&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">8,896&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued for retention payments related to business and asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">5,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Return of investment in equity securities for reduction in deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,760&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Conversion of notes receivable for common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance costs related to ATM offering included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">53&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For the years ended December&#160;31, 2025, the amount of cash income taxes paid by the Company was as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.545%"><tr><td style="width:1.0%"></td><td style="width:68.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">State and local:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">California</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">South Carolina</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">All other state and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash income taxes, net of refunds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">192&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of earnings per common share is as follows (in thousands, except share data): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(312,763)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(547,029)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(892,869)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">55,457,676</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">51,894,639</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">48,610,507</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(5.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(10.54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(18.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Anti-Dilutive Shares</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:60.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested PSUs</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,407,287</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Warrants to purchase Class A common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295,622</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295,622</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,295,622</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Unvested RSUs</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,262,853</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,327,398</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,804,189</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Earnout shares </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,793,063</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,794,243</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,803,049</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">366,567</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">767,520</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">192,208</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Escrow shares </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">20,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,125,392</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,205,115</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,095,068</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Represents employee and non-employee earnout shares for which the service-based and/or market-based vesting conditions have not been satisfied. </span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Represents restricted common stock issued in connection with asset acquisitions, held in escrow for indemnification purposes, and subject to forfeiture.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>segment </div>
<div>offering</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOfCoreOfferings', window );">Number of core offerings | offering</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_NumberOfCoreOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Core Offerings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_NumberOfCoreOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 19, 2024</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,858,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dna_EquityMethodInvestmentFundingOfAdditionalLossesMember', window );">Equity Method Investment, Funding Of Additional Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment to fund additional losses on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue from Contract with Customer Benchmark | One Customer | Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue from Contract with Customer Benchmark | One Customer | Biosecurity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue from Contract with Customer Benchmark | Customer One | Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue from Contract with Customer Benchmark | Customer two | Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 101: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 102: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 103: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 104: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 105: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 106: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dna_EquityMethodInvestmentFundingOfAdditionalLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dna_EquityMethodInvestmentFundingOfAdditionalLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dna_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dna_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dna_BiosecuritySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dna_BiosecuritySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dna_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dna_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dna_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dna_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment Net (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Buildings and facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings and facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent', window );">Restructuring and related cost, expected number of positions eliminated, percent (more than)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Loss on deconsolidation of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (7,013)<span></span>
</td>
<td class="num">$ (42,502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and related cost, expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and related cost, expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Summary of Restructuring Charges (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 11,398<span></span>
</td>
<td class="nump">$ 19,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of right-of-use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Total restructuring</a></td>
<td class="nump">$ 11,398<span></span>
</td>
<td class="nump">$ 24,172<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Total restructuring<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Summary of Changes in Accrued Liability Balance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">$ 11,398<span></span>
</td>
<td class="nump">$ 19,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Costs and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">11,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(11,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liability balance at December 31, 2025</a></td>
<td class="nump">$ 2,601<span></span>
</td>
<td class="nump">$ 2,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 10, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 05, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>materialRight </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod', window );">Asset Acquisition, Number Of Additional Acquisitions during Period | materialRight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,773,000<span></span>
</td>
<td class="nump">$ 424,061,000<span></span>
</td>
<td class="nump">$ 580,621,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Loss on deconsolidation of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,013,000<span></span>
</td>
<td class="nump">42,502,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,458,000<span></span>
</td>
<td class="nump">65,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,290,000<span></span>
</td>
<td class="nump">246,161,000<span></span>
</td>
<td class="nump">385,025,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,492,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Altar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_EmployeeLeaseExpense', window );">Employee lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=dna_OtherAssetAcquisitionsMember', window );">Other Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset Acquisition, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=dna_StridebioMember', window );">StrideBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset Acquisition, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Asset acquisition, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=dna_ZymergenMember', window );">Zymergen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected', window );">Asset acquisition, price of acquisition, expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Other Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for a business and asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | StrideBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for a business and asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset Acquisition, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Asset acquisition, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dna_AgBiomeInc.Member', window );">AgBiome, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="nump">$ 18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dna_AgBiomeInc.Member', window );">AgBiome, Inc. | Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangibles estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dna_AgBiomeInc.Member', window );">AgBiome, Inc. | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for a business and asset acquisition (in shares) | shares</a></td>
<td class="nump">407,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dna_ZymergenBankruptcyMember', window );">Zymergen Bankruptcy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Loss on deconsolidation of subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business combination, equity interest in acquiree, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dna_ZymergenMember', window );">Zymergen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOfEmployeesAcquired', window );">Number of employees acquired | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Business acquire consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Number Of Additional Acquisitions during Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_EmployeeLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_EmployeeLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_NumberOfEmployeesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_NumberOfEmployeesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionPriceOfAcquisitionExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible and intangible assets other than cash transferred by acquirer as part of consideration transferred in business combination. Includes, but is not limited to, business or subsidiary, or both, of acquirer transferred to former owner of acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability assumed in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of property, plant, and equipment acquired in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition date of equity interest in acquiree held by acquirer immediately before acquisition date in business combination achieved in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481724/830-30-40-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dna_AltarSasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dna_AltarSasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=dna_OtherAssetAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=dna_OtherAssetAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=dna_StridebioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=dna_StridebioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=dna_ZymergenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=dna_ZymergenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dna_AgBiomeInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dna_AgBiomeInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dna_ZymergenBankruptcyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dna_ZymergenBankruptcyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dna_ZymergenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dna_ZymergenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Deconsolidated Assets and Liabilities (Zymergen) (Details) - Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 02, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets</a></td>
<td class="nump">$ 56,558<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets</a></td>
<td class="nump">248,121<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities</a></td>
<td class="nump">21,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember', window );">Zymergen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">34,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">11,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property, plant and equipment, net</a></td>
<td class="nump">8,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">135,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent', window );">Intangible assets, net</a></td>
<td class="nump">16,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent', window );">Goodwill</a></td>
<td class="nump">10,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">19,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">20,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">184,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities</a></td>
<td class="nump">205,629<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet', window );">Net assets deconsolidated</a></td>
<td class="nump">$ 42,492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Assets and Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dna_ZymergenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dna_ZymergenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Results of Operations Deconsolidation (Zymergen) (Details) - Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations - Zymergen<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 02, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="nump">$ 8,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">200,975<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(192,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome', window );">Total other income, net</a></td>
<td class="nump">23,620<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Loss before income taxes</a></td>
<td class="num">(168,985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax provision</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="num">$ (168,999)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dna_ZymergenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dna_ZymergenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Notes receivable</a></td>
<td class="nump">$ 7,126<span></span>
</td>
<td class="nump">$ 14,170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">410,432<span></span>
</td>
<td class="nump">553,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">5,438<span></span>
</td>
<td class="nump">5,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Other non-current liabilities:</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">5,690<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper, Not Included with Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">118,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">114,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=dna_MarketableEquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">18,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dna_SynlogicIncWarrantsMember', window );">Synlogic, Inc. warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dna_MarketableEquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">17,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">146,136<span></span>
</td>
<td class="nump">521,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">284,390<span></span>
</td>
<td class="nump">539,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Other non-current liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial Paper, Not Included with Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">118,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">18,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Synlogic, Inc. warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">17,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">146,136<span></span>
</td>
<td class="nump">521,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">118,916<span></span>
</td>
<td class="nump">12,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Other non-current liabilities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper, Not Included with Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">114,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Synlogic, Inc. warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Notes receivable</a></td>
<td class="nump">7,126<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">7,126<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">5,438<span></span>
</td>
<td class="nump">5,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Other non-current liabilities:</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">5,690<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial Paper, Not Included with Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Synlogic, Inc. warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=dna_MarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=dna_MarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dna_SynlogicIncWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dna_SynlogicIncWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dna_MarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dna_MarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=dna_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosureAbstract', window );"><strong>Notes Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions', window );">Conversion to preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNetAbstract', window );"><strong>Derivative, Fair Value, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">9,922,000<span></span>
</td>
<td class="nump">24,273,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfers into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(4,232,000)<span></span>
</td>
<td class="nump">3,214,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements and payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,565,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers to Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">5,690,000<span></span>
</td>
<td class="nump">9,922,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dna_PrivatePlacementWarrantsMember', window );">Private Placement Warrants | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosureAbstract', window );"><strong>Notes Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions', window );">Conversion to preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNetAbstract', window );"><strong>Derivative, Fair Value, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,846,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfers into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,697,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements and payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers to Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_NotesReceivableMember', window );">Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosureAbstract', window );"><strong>Notes Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">1,843,000<span></span>
</td>
<td class="nump">14,129,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Additions</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="nump">1,407,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements and payments</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers into Level 3</a></td>
<td class="nump">6,987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers to Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions', window );">Conversion to preferred stock</a></td>
<td class="num">(1,463,000)<span></span>
</td>
<td class="num">(10,476,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Change in fair value</a></td>
<td class="num">(350,000)<span></span>
</td>
<td class="num">(3,217,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">$ 7,126,000<span></span>
</td>
<td class="nump">$ 1,843,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Conversions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-102<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=dna_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=dna_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dna_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dna_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=dna_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=dna_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Quantitative Information Regarding Level 3 Inputs (Details) - Fair Value, Recurring<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Probability-weighted present value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate', window );">Unobservable Input</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Probability-weighted present value | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate', window );">Unobservable Input</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Probability-weighted present value | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate', window );">Unobservable Input</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate', window );">Unobservable Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used to obtain present value of liability for unpaid claim and claim adjustment expense for short-duration contract issued by insurance entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=dna_ProbabilityWeightedPresentValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=dna_ProbabilityWeightedPresentValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 19, 2024</div></th>
<th class="th">
<div>Feb. 26, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debt, fair value</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of notes receivable for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,476<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum', window );">Class of warrant or right, outstanding (in shares) | shares</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ClassOfWarrantOrRightStockSplitConversionRatio', window );">Warrant, stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,411)<span></span>
</td>
<td class="num">(28,827)<span></span>
</td>
<td class="num">(54,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Downward adjustments from observable price changes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,713<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,345<span></span>
</td>
<td class="nump">20,828<span></span>
</td>
<td class="nump">44,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,155<span></span>
</td>
<td class="nump">227,043<span></span>
</td>
<td class="nump">251,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dna_SafeMember', window );">SAFE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_GenomaticaIncPreferredStockMember', window );">Genomatica, Inc. Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,885)<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SafesMember', window );">SAFEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,208)<span></span>
</td>
<td class="num">(2,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,501)<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_NonMarketableEquitySecuritiesMember', window );">Non-marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,557)<span></span>
</td>
<td class="num">(1,735)<span></span>
</td>
<td class="num">(9,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage', window );">Equity securities, downward price adjustment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_OneInvestmentMember', window );">One Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Escrow Shares | Circularis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, included in other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for a business and asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_BusinessCombinationContingentConsiderationVestedValue', window );">Business combination, contingent consideration, vested value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dna_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dna_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations', window );">Obligations, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringSegmentMember', window );">Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Financing receivable, excluding accrued interest, after allowance for credit loss</a></td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,746<span></span>
</td>
<td class="nump">$ 173,972<span></span>
</td>
<td class="nump">$ 143,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FinancingReceivableMeasurementInput', window );">Financing receivable, measurement input</a></td>
<td class="nump">0.155<span></span>
</td>
<td class="nump">0.155<span></span>
</td>
<td class="nump">0.155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Scenario Probabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Scenario Probabilities | Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FinancingReceivableMeasurementInput', window );">Financing receivable, measurement input</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_EquitySecuritiesFVNIMeasurementInputTerm', window );">Equity securities, measurement input, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Scenario Probabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Scenario Probabilities | Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FinancingReceivableMeasurementInput', window );">Financing receivable, measurement input</a></td>
<td class="nump">0.45<span></span>
</td>
<td class="nump">0.45<span></span>
</td>
<td class="nump">0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_EquitySecuritiesFVNIMeasurementInputTerm', window );">Equity securities, measurement input, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Expected Term | Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FinancingReceivableMeasurementInputPeriod', window );">Financing receivable, measurement input, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=dna_SeniorSecuredNoteMember', window );">Senior Secured Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableSignificantPurchases', window );">Financing receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FinancingReceivableInterestRateStatedPercentage', window );">Financing receivable, interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=dna_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of notes receivable for common stock</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="nump">10,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_BusinessCombinationContingentConsiderationVestedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Vested Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_BusinessCombinationContingentConsiderationVestedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant of Right, Number Of Warrants To Be Exercised, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ClassOfWarrantOrRightStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Stock Split, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ClassOfWarrantOrRightStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_EquitySecuritiesFVNIMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_EquitySecuritiesFVNIMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_FinancingReceivableInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_FinancingReceivableInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_FinancingReceivableMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_FinancingReceivableMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_FinancingReceivableMeasurementInputPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Measurement Input, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_FinancingReceivableMeasurementInputPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of obligations measured on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableSignificantPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in financing receivable from purchase. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableSignificantPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dna_SafeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dna_SafeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_GenomaticaIncPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_GenomaticaIncPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SafesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SafesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_NonMarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_NonMarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_OneInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_OneInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dna_CircularisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dna_CircularisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dna_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dna_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dna_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dna_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=dna_MeasurementInputScenarioProbabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=dna_MeasurementInputScenarioProbabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=dna_SeniorSecuredNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=dna_SeniorSecuredNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=dna_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=dna_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 236,638,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">318,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(192,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">255,418,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">205,540,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">31,098,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">205,617,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">31,147,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Treasury and Government</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">117,919,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">171,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">118,038,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">114,640,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">147,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(121,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">114,666,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,079,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(19,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,060,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 18,654,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Equity Method Investments - Schedule of Investments and Equity Method Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total</a></td>
<td class="nump">$ 15,066<span></span>
</td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="num">(16,411)<span></span>
</td>
<td class="num">(28,827)<span></span>
</td>
<td class="num">$ (54,827)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,635)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SafesMember', window );">SAFEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">SAFEs</a></td>
<td class="nump">2,188<span></span>
</td>
<td class="nump">16,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,208)<span></span>
</td>
<td class="num">(2,742)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_NonMarketableEquitySecuritiesMember', window );">Non-marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">11,125<span></span>
</td>
<td class="nump">14,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total</a></td>
<td class="nump">13,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="num">(4,557)<span></span>
</td>
<td class="num">(1,735)<span></span>
</td>
<td class="num">(9,928)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_MarketableEquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">17,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="nump">2,695<span></span>
</td>
<td class="num">(7,583)<span></span>
</td>
<td class="num">(7,874)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_GenomaticaIncPreferredStockMember', window );">Genomatica, Inc. Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,885)<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SynlogicIncWarrantMember', window );">Synlogic warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(1,283)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_BiomeditLlcMember', window );">BiomEdit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,461)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_OtherEquityInvestessMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,174)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SafesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SafesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_NonMarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_NonMarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_MarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_MarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_GenomaticaIncPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_GenomaticaIncPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SynlogicIncWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SynlogicIncWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_BiomeditLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_BiomeditLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_OtherEquityInvestessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_OtherEquityInvestessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Equity Method Investments - Summary of Gains (Losses) on Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Impairment charges</a></td>
<td class="num">$ (16,345)<span></span>
</td>
<td class="num">$ (20,828)<span></span>
</td>
<td class="num">$ (44,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Realized and unrealized gains (losses) recognized on marketable equity securities</a></td>
<td class="nump">2,647<span></span>
</td>
<td class="num">(7,999)<span></span>
</td>
<td class="num">(9,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Downward adjustments from observable price changes</a></td>
<td class="num">(2,713)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,627)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Total loss on investments</a></td>
<td class="num">$ (16,411)<span></span>
</td>
<td class="num">$ (28,827)<span></span>
</td>
<td class="num">$ (54,827)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Equity Method Investments - Schedule of Realized and Unrealized Gains and Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net realized gains (losses) recognized on equity investments sold</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (5,957)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net unrealized losses recognized on equity investments held as of the end of the period</a></td>
<td class="num">(16,411)<span></span>
</td>
<td class="num">(22,870)<span></span>
</td>
<td class="num">(54,827)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Total loss on investments</a></td>
<td class="num">$ (16,411)<span></span>
</td>
<td class="num">$ (28,827)<span></span>
</td>
<td class="num">$ (54,827)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments and Equity Method Investments - Carrying Values of Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Carrying value</a></td>
<td class="nump">$ 15,066<span></span>
</td>
<td class="nump">$ 48,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_NonMarketableEquitySecuritiesMember', window );">Non-marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Total initial cost</a></td>
<td class="nump">109,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount', window );">Impairment charges</a></td>
<td class="num">(91,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount', window );">Downward adjustments from observable price changes</a></td>
<td class="num">(4,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Carrying value</a></td>
<td class="nump">$ 13,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_NonMarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_NonMarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 10, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_GoodwillImpairmentDCFWeight', window );">Goodwill impairment, DCF weight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_GoodwillImpairmentGPCWeight', window );">Goodwill impairment, GPC weight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 47,858<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations | Zymergen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dna_AgBiomeInc.Member', window );">AgBiome, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_GoodwillImpairmentDCFWeight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Impairment, DCF Weight</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_GoodwillImpairmentDCFWeight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_GoodwillImpairmentGPCWeight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Impairment, GPC Weight</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_GoodwillImpairmentGPCWeight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dna_ZymergenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dna_ZymergenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dna_AgBiomeInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dna_AgBiomeInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, net - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 49,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">$ (47,900)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(47,858)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Impact of foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 49,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 56,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">111,202<span></span>
</td>
<td class="nump">$ 111,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(54,278)<span></span>
</td>
<td class="num">(38,883)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 56,924<span></span>
</td>
<td class="nump">$ 72,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Amortization Period (in Years)</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478072/944-805-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, net - Schedule of Estimated Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 18,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">11,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">2,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">2,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">2,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">17,650<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 56,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>extensionOption</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_LesseeOperatingLeaseAreaOfRealEstateProperty', window );">Leased facility, square feet | ft&#178;</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_LesseeOperatingLeaseNumberOfExtensionOptions', window );">Number of extension options | extensionOption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, option to extend (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">$ 96,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 96,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">5,177<span></span>
</td>
<td class="nump">11,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">36,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">$ 59,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dna_EquipmentLeasesMember', window );">Equipment leases | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dna_EquipmentLeasesMember', window );">Equipment leases | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_LesseeOperatingLeaseAreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Real Estate Property</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_LesseeOperatingLeaseAreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_LesseeOperatingLeaseNumberOfExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Extension Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_LesseeOperatingLeaseNumberOfExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dna_EquipmentLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dna_EquipmentLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Total Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 63,470<span></span>
</td>
<td class="nump">$ 57,996<span></span>
</td>
<td class="nump">$ 59,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">708<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FinanceLeaseCost', window );">Finance lease cost</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">19,701<span></span>
</td>
<td class="nump">19,421<span></span>
</td>
<td class="nump">15,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(7,600)<span></span>
</td>
<td class="num">(5,177)<span></span>
</td>
<td class="num">(11,170)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 76,283<span></span>
</td>
<td class="nump">$ 72,924<span></span>
</td>
<td class="nump">$ 65,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Operating Leases Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 61,178<span></span>
</td>
<td class="nump">$ 45,019<span></span>
</td>
<td class="nump">$ 44,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 354<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 1,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Balance Sheet Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - operating leases (in years)</a></td>
<td class="text">11 years 3 months 18 days<span></span>
</td>
<td class="text">11 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - finance leases (in years)</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - finance leases</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturity of Operating and Finance Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 56,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">56,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">58,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">60,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">59,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">371,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted payments</a></td>
<td class="nump">662,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(222,934)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">439,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of lease liability</a></td>
<td class="num">(22,787)<span></span>
</td>
<td class="num">$ (28,630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">417,078<span></span>
</td>
<td class="nump">438,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total undiscounted payments</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment', window );">Less: imputed interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion of lease liability</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">$ (335)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, Undiscounted Excess Amount, Including Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 167,202<span></span>
</td>
<td class="nump">$ 561,572<span></span>
</td>
<td class="nump">$ 944,073<span></span>
</td>
<td class="nump">$ 1,315,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash included in prepaid expenses and other current assets</a></td>
<td class="nump">7,031<span></span>
</td>
<td class="nump">5,839<span></span>
</td>
<td class="nump">4,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash included in other non-current assets</a></td>
<td class="nump">38,138<span></span>
</td>
<td class="nump">38,332<span></span>
</td>
<td class="nump">40,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 212,371<span></span>
</td>
<td class="nump">$ 605,743<span></span>
</td>
<td class="nump">$ 989,584<span></span>
</td>
<td class="nump">$ 1,369,581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Information - Summary of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant, and equipment</a></td>
<td class="nump">$ 358,380<span></span>
</td>
<td class="nump">$ 364,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(190,597)<span></span>
</td>
<td class="num">(160,872)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">167,783<span></span>
</td>
<td class="nump">203,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant, and equipment</a></td>
<td class="nump">146,279<span></span>
</td>
<td class="nump">150,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant, and equipment</a></td>
<td class="nump">140,513<span></span>
</td>
<td class="nump">135,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Buildings and facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant, and equipment</a></td>
<td class="nump">49,760<span></span>
</td>
<td class="nump">48,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant, and equipment</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant, and equipment</a></td>
<td class="nump">9,056<span></span>
</td>
<td class="nump">14,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant, and equipment</a></td>
<td class="nump">6,520<span></span>
</td>
<td class="nump">6,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant, and equipment</a></td>
<td class="nump">$ 6,060<span></span>
</td>
<td class="nump">$ 6,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 40.3<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 54.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment', window );">Number of facilities | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tangible Asset Impairment, Number Of Facilities With Impaired Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 22,787<span></span>
</td>
<td class="nump">$ 28,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ContractualShortfallLiabilityCurrent', window );">Contractual shortfall liabilities (Note 12)</a></td>
<td class="nump">15,919<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">4,258<span></span>
</td>
<td class="nump">9,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration liability</a></td>
<td class="nump">5,438<span></span>
</td>
<td class="nump">5,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent', window );">Biosecurity costs</a></td>
<td class="nump">5,046<span></span>
</td>
<td class="nump">4,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Deferred other income</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">2,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_AccruedEmployeeTerminationCosts', window );">Employee termination costs</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">2,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and securities litigation costs</a></td>
<td class="nump">4,378<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent', window );">External research and development expenses</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_AccruedPropertyAndEquipmentCurrent', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">5,691<span></span>
</td>
<td class="nump">8,764<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 66,458<span></span>
</td>
<td class="nump">$ 65,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_AccruedBiosecurityServiceRevenueAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued biosecurity service revenue accruals current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_AccruedBiosecurityServiceRevenueAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_AccruedEmployeeTerminationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Employee Termination Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_AccruedEmployeeTerminationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_AccruedExternalResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued external research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_AccruedExternalResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_AccruedPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued property and equipment current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_AccruedPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ContractualShortfallLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Shortfall Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ContractualShortfallLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SupplementalFinancialStatementInformationAbstract', window );"><strong>Supplemental Financial Statement Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">894<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU Asset obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">223,853<span></span>
</td>
<td class="nump">27,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">2,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices', window );">Convertible financial instruments received for Cell Engineering services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_PurchaseOfNonCashMarketableEquitySecurities', window );">Equity securities and warrants received for Cell Engineering services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">17,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment', window );">Common stock issued for acquisitions</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">18,245<span></span>
</td>
<td class="nump">6,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SettlementOfContingentConsideration', window );">Common stock issued as settlement of contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,742<span></span>
</td>
<td class="nump">8,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments', window );">Common stock issued for retention payments related to business and asset acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,258<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue', window );">Return of investment in equity securities for reduction in deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,760<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of notes receivable for common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,476<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses', window );">Issuance costs related to ATM offering included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible financial instruments received for Foundry services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_IssuanceOfCommonStockForAcquisitionRetentionPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock For Acquisition Retention Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_IssuanceOfCommonStockForAcquisitionRetentionPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_PurchaseOfNonCashMarketableEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Non Cash Marketable Equity Securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_PurchaseOfNonCashMarketableEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return Of Investment In Equity Securities For Reduction In Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Series E convertible preferred stock issuance costs included in accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SettlementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SettlementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SupplementalFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Statement Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SupplementalFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including amortization and accretion of premiums and discounts, on U.S. Treasury securities and other U.S. government securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2027 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 29, 2023</div></th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm', window );">Unrecorded unconditional purchase obligation, term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary', window );">Unrecorded unconditional purchase obligation, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary', window );">Unrecorded unconditional purchase obligation, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="nump">28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary', window );">Unrecorded unconditional purchase obligation, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="nump">54,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary', window );">Unrecorded unconditional purchase obligation, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000.0<span></span>
</td>
<td class="nump">86,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary', window );">Unrecorded unconditional purchase obligation, year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000.0<span></span>
</td>
<td class="nump">113,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix', window );">Unrecorded unconditional purchase obligation, to be paid, year six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases', window );">Unrecorded unconditional purchase obligation, purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Unrecorded unconditional purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="nump">$ 289,000,000<span></span>
</td>
<td class="nump">$ 58,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContracts', window );">Loss on contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases', window );">Unrecorded unconditional purchase obligation, purchases</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Surety Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_LossContingencyAmountRequiredToFund', window );">Amount required to fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember', window );">Strategic Cloud and AI Partnership with Google Cloud</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ContractualShortfallLiability', window );">Contractual shortfall liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember', window );">Strategic Cloud and AI Partnership with Google Cloud | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ContractualShortfallLiabilityRequiredPayment', window );">Contractual shortfall liability, required payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=dna_StridebioMember', window );">StrideBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Asset acquisition, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_RoyaltyReceivedFromLicensingRevenue', window );">Royalty received from licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct', window );">Royalty received from license or sale of a product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=dna_StridebioMember', window );">StrideBio | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Asset acquisition, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ContractualShortfallLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Shortfall Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ContractualShortfallLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ContractualShortfallLiabilityRequiredPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Shortfall Liability, Required Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ContractualShortfallLiabilityRequiredPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_LossContingencyAmountRequiredToFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Amount Required To Fund</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_LossContingencyAmountRequiredToFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Received From License Or Sale Of a Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_RoyaltyReceivedFromLicensingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Received From Licensing Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_RoyaltyReceivedFromLicensingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecorded Unconditional Purchase Obligation, to be Paid, Year Six</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Losses recognized in the current period on contracts which are expected to generate losses, which are probable and can be reasonably estimated, in a future period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 605<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481187/605-35-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount purchased during the period under an unrecorded unconditional purchase obligation (for example, under the take-or-pay or throughput contract).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the unrecognized unconditional purchase obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_SuretyBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_SuretyBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=dna_StridebioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=dna_StridebioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Capitalization (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">15,800,000,000<span></span>
</td>
<td class="nump">15,800,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">61,680,449<span></span>
</td>
<td class="nump">57,815,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">58,207,298<span></span>
</td>
<td class="nump">54,365,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">10,500,000,000<span></span>
</td>
<td class="nump">10,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">49,694,610<span></span>
</td>
<td class="nump">45,575,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">46,791,082<span></span>
</td>
<td class="nump">42,696,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">4,500,000,000<span></span>
</td>
<td class="nump">4,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">8,985,839<span></span>
</td>
<td class="nump">9,239,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">8,416,216<span></span>
</td>
<td class="nump">8,669,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 04, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 07, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">15,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_CommonStockConversionRatio', window );">Common stock, conversion ratio (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dna_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SaleOfStockAuthorizedAmount', window );">Sale of stock, authorized amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dna_SalesAgreementWithAllenCompanyLLCMember', window );">Sales Agreement with Allen &amp; Company LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_SaleOfStockAuthorizedAmount', window );">Sale of stock, authorized amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dna_NewGinkgoPreferredStockMember', window );">New Ginkgo Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">10,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_CommonStockVotingRight', window );">Common stock, voting rights | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_CommonStockVotingRight', window );">Common stock, voting rights | vote</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Class C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_CommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_CommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_CommonStockVotingRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_CommonStockVotingRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dna_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dna_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dna_SalesAgreementWithAllenCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dna_SalesAgreementWithAllenCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dna_NewGinkgoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dna_NewGinkgoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuances (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="nump">13,461,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=dna_WarrantsToPurchaseClassACommonStockMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="nump">1,295,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember', window );">2021 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="nump">3,336,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dna_InducementPlanMember', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="nump">292,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="nump">366,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="nump">1,262,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="nump">4,407,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=dna_WarrantsToPurchaseClassACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=dna_WarrantsToPurchaseClassACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dna_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dna_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 81,546<span></span>
</td>
<td class="nump">$ 112,344<span></span>
</td>
<td class="nump">$ 229,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">34,210<span></span>
</td>
<td class="nump">56,020<span></span>
</td>
<td class="nump">145,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">42,463<span></span>
</td>
<td class="nump">56,324<span></span>
</td>
<td class="nump">84,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales | Other Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">2,249<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales | Biosecurity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 2,624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dna_BiosecuritySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dna_BiosecuritySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>founder </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>installment </div>
<div>condition </div>
<div>stockOption </div>
<div>hurdle </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 15, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,461,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm', window );">Share-based compensation arrangement, common stock reserved for issuance, automatic increase term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_TypesOfTimeBasedStockOptions', window );">Types of time-based stock options | stockOption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Stock options, number of annual installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOfVestingConditions', window );">Number of vesting conditions | condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.48<span></span>
</td>
<td class="nump">$ 11.35<span></span>
</td>
<td class="nump">$ 57.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.06%<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">3.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,546<span></span>
</td>
<td class="nump">$ 112,344<span></span>
</td>
<td class="nump">$ 229,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">500 Then 25%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dna_EarnOutSharesMember', window );">Earnout Shares | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dna_EarnOutSharesMember', window );">Earnout Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Escrow Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based compensation arrangement by share-based payment award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.81<span></span>
</td>
<td class="nump">$ 55.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,600<span></span>
</td>
<td class="nump">$ 232,900<span></span>
</td>
<td class="nump">$ 365,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dna_EarnoutRestrictedStockUnitsMember', window );">Earnout RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dna_FounderOptionsMember', window );">Founder Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOfCompanyFounders', window );">Number of company founders | founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Grants in period, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOfStockPriceHurdles', window );">Number of stock price hurdles | hurdle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple', window );">Suboptimal exercise multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dna_FounderOptionsMember', window );">Founder Options | 500 Then 25%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Share-based payment arrangement, options vested, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dna_FounderOptionsMember', window );">Founder Options | 600 Then 25%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Share-based payment arrangement, options vested, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dna_FounderOptionsMember', window );">Founder Options | 700 Then 25%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Share-based payment arrangement, options vested, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dna_FounderOptionsMember', window );">Founder Options | 800 Then 25%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Share-based payment arrangement, options vested, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,407,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based compensation arrangement by share-based payment award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based compensation arrangement by share-based payment award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dna_FounderPSUAwardsMember', window );">Founder PSU Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Earnout Shares | 500 Then 25%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Earnout Shares | 600 Then 25%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Earnout Shares | 700 Then 25%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Earnout Shares | 800 Then 25%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dna_TwoThousandTwentyTwoInducementPlanMember', window );">2022 Inducement Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dna_TwoThousandTwentyTwoInducementPlanMember', window );">2022 Inducement Plan Member | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember', window );">2021 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,336,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">5,011,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based payment award, percentage of outstanding stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares to be issued pursuant to awards granted (in shares)</a></td>
<td class="nump">5,000,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based payment award, percentage of outstanding stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares to be issued pursuant to awards granted (in shares)</a></td>
<td class="nump">2,500,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate', window );">Percentage of non-participation of combined voting power or value of all classes of stock</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">500,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_NumberOfCompanyFounders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Company Founders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_NumberOfCompanyFounders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_NumberOfStockPriceHurdles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Price Hurdles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_NumberOfStockPriceHurdles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_NumberOfVestingConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Vesting Conditions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_NumberOfVestingConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of combined voting power or value of all classes of stock not eligible to participate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Suboptimal Exercise Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Options, Vested, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement, Common Stock Reserved For Issuance, Increase, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_TypesOfTimeBasedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Types Of Time-Based Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_TypesOfTimeBasedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dna_EarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dna_EarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dna_EarnoutRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dna_EarnoutRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dna_FounderOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dna_FounderOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dna_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dna_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dna_FounderPSUAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dna_FounderPSUAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dna_TwoThousandTwentyTwoInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dna_TwoThousandTwentyTwoInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">267,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">171,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(72,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">366,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">136,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">9.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited (in shares) | $ / shares</a></td>
<td class="nump">36.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">15.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 24.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 7.48<span></span>
</td>
<td class="nump">$ 11.35<span></span>
</td>
<td class="nump">$ 57.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.06%<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">3.94%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-based Payment Award, Founder Options, Valuation Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.06%<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">3.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dna_FounderOptionsMember', window );">Founder Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Options, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple', window );">Suboptimal exercise multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Suboptimal Exercise Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dna_FounderOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dna_FounderOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning period (in shares) | shares</a></td>
<td class="nump">3,327,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,176,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,797,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(1,443,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending balance (in shares) | shares</a></td>
<td class="nump">1,262,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 69.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">8.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">48.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">56.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 55.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">5,599,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(1,192,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending balance (in shares) | shares</a></td>
<td class="nump">4,407,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">7.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity For Earnout RSA (Details) - Earnout RSUs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning period (in shares) | shares</a></td>
<td class="nump">552,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending balance (in shares) | shares</a></td>
<td class="nump">551,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 510.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">533.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">512.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 510.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dna_EarnoutRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dna_EarnoutRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - Product Concentration Risk - Revenue from Contract with Customer Benchmark<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dna_PharmaceuticalAndBiotechnologyMember', window );">Pharmaceutical and biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dna_AgricultureMember', window );">Agriculture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dna_GovernmentAndDefenseMember', window );">Government and defense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dna_IndustrialAndEnvironmentMember', window );">Industrial and environment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dna_CustomerAndTechnologyMember', window );">Consumer and technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dna_FoodAndNutritionMember', window );">Food and nutrition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dna_CellEngineeringRevenueMember', window );">Total Cell Engineering revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_PharmaceuticalAndBiotechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_PharmaceuticalAndBiotechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_AgricultureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_AgricultureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_GovernmentAndDefenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_GovernmentAndDefenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_IndustrialAndEnvironmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_IndustrialAndEnvironmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_CustomerAndTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_CustomerAndTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_FoodAndNutritionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_FoodAndNutritionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_CellEngineeringRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_CellEngineeringRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled contracts receivable</a></td>
<td class="nump">14,500,000<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, revenue recognized</a></td>
<td class="nump">48,700,000<span></span>
</td>
<td class="nump">88,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,500,000<span></span>
</td>
<td class="nump">$ 202,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue remaining performance obligation amount</a></td>
<td class="nump">158,600,000<span></span>
</td>
<td class="nump">85,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Cumulative catch-up adjustment to revenue</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_RevenuePerformanceObligationAxis=dna_Year1Member', window );">Year 1 | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Performance obligation satisfied, revenue recognized</a></td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_RevenuePerformanceObligationAxis=dna_Year12Member', window );">Year 1 - 2 | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Performance obligation satisfied, revenue recognized</a></td>
<td class="nump">$ 40,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_RevenuePerformanceObligationAxis=dna_Year13Member', window );">Year 1 - 3 | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Performance obligation satisfied, revenue recognized</a></td>
<td class="nump">$ 86,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_RevenuePerformanceObligationAxis=dna_Year14Member', window );">Year 1 - 4 | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Performance obligation satisfied, revenue recognized</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_RevenuePerformanceObligationAxis=dna_Year15Member', window );">Year 1 - 5 | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Performance obligation satisfied, revenue recognized</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Customer Concentration Risk | Revenue from Contract with Customer Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue from customers within the United States</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dna_CellEngineeringMember', window );">Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash', window );">Revenue recognized as non cash consideration</a></td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="nump">$ 61,400,000<span></span>
</td>
<td class="nump">$ 48,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customer, Excluding Assessed Tax, Noncash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_RevenuePerformanceObligationAxis=dna_Year1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_RevenuePerformanceObligationAxis=dna_Year1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_RevenuePerformanceObligationAxis=dna_Year12Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_RevenuePerformanceObligationAxis=dna_Year12Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_RevenuePerformanceObligationAxis=dna_Year13Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_RevenuePerformanceObligationAxis=dna_Year13Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_RevenuePerformanceObligationAxis=dna_Year14Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_RevenuePerformanceObligationAxis=dna_Year14Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_RevenuePerformanceObligationAxis=dna_Year15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_RevenuePerformanceObligationAxis=dna_Year15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dna_CellEngineeringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dna_CellEngineeringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>segment </div>
<div>asset</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOfCoreAssets', window );">Number of core assets | asset</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_NumberOfCoreAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Core Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_NumberOfCoreAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,155<span></span>
</td>
<td class="nump">$ 227,043<span></span>
</td>
<td class="nump">$ 251,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Segment research and development expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,773<span></span>
</td>
<td class="nump">424,061<span></span>
</td>
<td class="nump">580,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>Segment general and administrative expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,290<span></span>
</td>
<td class="nump">246,161<span></span>
</td>
<td class="nump">385,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment operating (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total segment operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(315,278)<span></span>
</td>
<td class="num">(559,757)<span></span>
</td>
<td class="num">(864,406)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_OperatingExpensesNotAllocatedToSegmentsAbstract', window );"><strong>Reconciling items to reconcile total segment operating loss to loss before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,546<span></span>
</td>
<td class="nump">112,344<span></span>
</td>
<td class="nump">229,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,990<span></span>
</td>
<td class="nump">63,020<span></span>
</td>
<td class="nump">70,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,398<span></span>
</td>
<td class="nump">24,172<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Carrying cost of excess space (net of sublease income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,283<span></span>
</td>
<td class="nump">72,924<span></span>
</td>
<td class="nump">65,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,678)<span></span>
</td>
<td class="num">(12,249)<span></span>
</td>
<td class="nump">28,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(313,600)<span></span>
</td>
<td class="num">(547,508)<span></span>
</td>
<td class="num">(892,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_EmployerPayrollTaxes', window );">Employer payroll taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 47,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,858<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,409<span></span>
</td>
<td class="nump">53,071<span></span>
</td>
<td class="nump">78,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Segment cost of revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total segment cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,521<span></span>
</td>
<td class="nump">38,549<span></span>
</td>
<td class="nump">46,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Segment cost of revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total segment cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_OperatingExpensesNotAllocatedToSegmentsAbstract', window );"><strong>Reconciling items to reconcile total segment operating loss to loss before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LeaseAssetsMember', window );">Lease Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_OperatingExpensesNotAllocatedToSegmentsAbstract', window );"><strong>Reconciling items to reconcile total segment operating loss to loss before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_OperatingExpensesNotAllocatedToSegmentsAbstract', window );"><strong>Reconciling items to reconcile total segment operating loss to loss before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,704<span></span>
</td>
<td class="nump">115,299<span></span>
</td>
<td class="nump">234,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,654<span></span>
</td>
<td class="nump">121,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,990<span></span>
</td>
<td class="nump">63,020<span></span>
</td>
<td class="nump">70,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,398<span></span>
</td>
<td class="nump">24,172<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Carrying cost of excess space (net of sublease income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,723<span></span>
</td>
<td class="nump">25,986<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger and acquisition related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,998)<span></span>
</td>
<td class="nump">4,417<span></span>
</td>
<td class="nump">61,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,849<span></span>
</td>
<td class="nump">9,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,678)<span></span>
</td>
<td class="num">(8,075)<span></span>
</td>
<td class="nump">28,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringAndBiosecuritySegmentsMember', window );">Cell Engineering and Biosecurity | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment operating (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total segment operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,461)<span></span>
</td>
<td class="num">(249,186)<span></span>
</td>
<td class="num">(366,816)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringSegmentMember', window );">Cell Engineering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,746<span></span>
</td>
<td class="nump">173,972<span></span>
</td>
<td class="nump">143,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Segment cost of revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total segment cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,203<span></span>
</td>
<td class="nump">5,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Segment research and development expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,541<span></span>
</td>
<td class="nump">271,512<span></span>
</td>
<td class="nump">335,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>Segment general and administrative expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,532<span></span>
</td>
<td class="nump">115,028<span></span>
</td>
<td class="nump">171,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment operating (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total segment operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,530)<span></span>
</td>
<td class="num">(218,567)<span></span>
</td>
<td class="num">(363,622)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dna_BiosecuritySegmentMember', window );">Biosecurity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Segment research and development expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>Segment general and administrative expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,443<span></span>
</td>
<td class="nump">44,370<span></span>
</td>
<td class="nump">55,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment operating (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total segment operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,931)<span></span>
</td>
<td class="num">(30,619)<span></span>
</td>
<td class="num">(3,194)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dna_BiosecuritySegmentMember', window );">Biosecurity | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,409<span></span>
</td>
<td class="nump">53,071<span></span>
</td>
<td class="nump">78,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Segment cost of revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total segment cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,897<span></span>
</td>
<td class="nump">38,549<span></span>
</td>
<td class="nump">46,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dna_BiosecuritySegmentMember', window );">Biosecurity | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Segment cost of revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total segment cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In-Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_EmployerPayrollTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employer payroll taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_EmployerPayrollTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_OperatingExpensesNotAllocatedToSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating expenses not allocated to segments abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_OperatingExpensesNotAllocatedToSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LeaseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dna_LeaseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringAndBiosecuritySegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringAndBiosecuritySegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dna_CellEngineeringSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dna_BiosecuritySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dna_BiosecuritySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Collaboration Transactions with Related Parties - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>materialRight</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,500<span></span>
</td>
<td class="nump">$ 202,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue remaining performance obligation amount</a></td>
<td class="nump">$ 158,600<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="num">(16,411)<span></span>
</td>
<td class="num">(28,827)<span></span>
</td>
<td class="num">(54,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_GenomaticaIncPreferredStockMember', window );">Genomatica, Inc. Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,885)<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SafesMember', window );">SAFEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) gain on investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,208)<span></span>
</td>
<td class="num">$ (2,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">64,908<span></span>
</td>
<td class="nump">73,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Genomatica, Inc. Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_UpfrontAmountReceived', window );">Upfront amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_OtherEquityInvesteeMember', window );">Other Equity Investee [Member] | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_GenomaticaMember', window );">Genomatica | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_PreferredStockInvestmentImpairmentLoss', window );">Preferred stock investment, impairment loss</a></td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_GenomaticaMember', window );">Genomatica | Related Party | Two Thousand And Eighteen Technical Development Agreement | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue remaining performance obligation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment owned, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_BiomeditMember', window );">BiomEdit | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOFEstimatedMaterialRights', window );">Number of estimated material rights | materialRight</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_ArcaeaMember', window );">Arcaea | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOFEstimatedMaterialRights', window );">Number of estimated material rights | materialRight</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">$ 28,413<span></span>
</td>
<td class="nump">28,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_AlloniaMember', window );">Allonnia | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOFEstimatedMaterialRights', window );">Number of estimated material rights | materialRight</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">$ 36,495<span></span>
</td>
<td class="nump">36,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_MotifMember', window );">Motif FoodWorks | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_NumberOFEstimatedMaterialRights', window );">Number of estimated material rights | materialRight</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=dna_MotifFoodworksIncMember', window );">Motif FoodWorks, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_NumberOFEstimatedMaterialRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number OF Estimated Material Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_NumberOFEstimatedMaterialRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_PreferredStockInvestmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Investment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_PreferredStockInvestmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_UpfrontAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront amount received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_UpfrontAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_GenomaticaIncPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_GenomaticaIncPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SafesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dna_SafesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_OtherEquityInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_OtherEquityInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_GenomaticaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_GenomaticaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_AgreementAxis=dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_AgreementAxis=dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_BiomeditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_BiomeditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_ArcaeaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_ArcaeaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_AlloniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_AlloniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_MotifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_MotifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dna_MotifFoodworksIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dna_MotifFoodworksIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Collaboration Transactions with Related Parties - Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,500<span></span>
</td>
<td class="nump">$ 202,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">$ 64,908<span></span>
</td>
<td class="nump">73,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_AlloniaMember', window );">Allonnia | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">36,495<span></span>
</td>
<td class="nump">36,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_ArcaeaMember', window );">Arcaea | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">28,413<span></span>
</td>
<td class="nump">28,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_BiomeditMember', window );">BiomEdit | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_GenomaticaMember', window );">Genomatica | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred other income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_AlloniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_AlloniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_ArcaeaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_ArcaeaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_BiomeditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_BiomeditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_GenomaticaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_GenomaticaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Collaboration Transactions with Related Parties - statement of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 170,155<span></span>
</td>
<td class="nump">$ 227,043<span></span>
</td>
<td class="nump">$ 251,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8,784<span></span>
</td>
<td class="nump">53,041<span></span>
</td>
<td class="nump">22,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_MotifMember', window );">Motif FoodWorks | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,445<span></span>
</td>
<td class="nump">6,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_ArcaeaMember', window );">Arcaea | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,653<span></span>
</td>
<td class="nump">6,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_GenomaticaMember', window );">Genomatica | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
<td class="nump">4,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_AyanaMember', window );">Ayana Bio | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_BiomeditMember', window );">BiomEdit | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">7,583<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_VerbBioticsMember', window );">Verb Biotics | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_AlloniaMember', window );">Allonnia | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dna_OtherEquityInvesteesMember', window );">Other equity investees | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_MotifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_MotifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_ArcaeaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_ArcaeaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_GenomaticaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_GenomaticaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_AyanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_AyanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_BiomeditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_BiomeditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_VerbBioticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_VerbBioticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_AlloniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_AlloniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dna_OtherEquityInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dna_OtherEquityInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Contribution by company, percent</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DefinedContributionPlanVestingPeriod', window );">Defined contribution plan, vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DefinedContributionPlanEmployeeAnnualEarningAmount', window );">Employee annual earning</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DefinedContributionPlanMaximumEmployerContributionsAmount', window );">Maximum employer contributions</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution by company, amount</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DefinedContributionPlanEmployeeAnnualEarningAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employee Annual Earning, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DefinedContributionPlanEmployeeAnnualEarningAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DefinedContributionPlanMaximumEmployerContributionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Maximum Employer Contributions, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DefinedContributionPlanMaximumEmployerContributionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DefinedContributionPlanVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DefinedContributionPlanVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Loss Before Provision for Incomes Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (308,990)<span></span>
</td>
<td class="num">$ (514,354)<span></span>
</td>
<td class="num">$ (890,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(4,610)<span></span>
</td>
<td class="num">(33,154)<span></span>
</td>
<td class="num">(1,954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total</a></td>
<td class="num">$ (313,600)<span></span>
</td>
<td class="num">$ (547,508)<span></span>
</td>
<td class="num">$ (892,940)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Income Taxes Expenses (Benefit) Incurred During the Period (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(346)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(1,364)<span></span>
</td>
<td class="num">(936)<span></span>
</td>
<td class="num">(884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Total deferred</a></td>
<td class="num">(1,364)<span></span>
</td>
<td class="num">(936)<span></span>
</td>
<td class="num">(884)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (837)<span></span>
</td>
<td class="num">$ (479)<span></span>
</td>
<td class="num">$ (71)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of the Statutory Corporate Income Tax Rate to the Effective Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at U.S. Statutory Rate</a></td>
<td class="num">$ (65,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and Local Income Taxes</a></td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Other foreign jurisdictions</a></td>
<td class="num">(743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">14,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount', window );">Limitation on executive compensation</a></td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount', window );">Gain/Loss on investments</a></td>
<td class="nump">3,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research &amp; Development Credits</a></td>
<td class="num">(1,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in Valuation Allowance</a></td>
<td class="nump">45,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (837)<span></span>
</td>
<td class="num">$ (479)<span></span>
</td>
<td class="num">$ (71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at U.S. Statutory Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and Local Income Taxes</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Other foreign jurisdictions</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
<td class="num">(14.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent', window );">Limitation on executive compensation</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent', window );">Gain/Loss on investments</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research &amp; Development Credits</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Investments in subsidiaries and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(29.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in Valuation Allowance</a></td>
<td class="num">(14.40%)<span></span>
</td>
<td class="num">(10.40%)<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Taxes Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 459,420<span></span>
</td>
<td class="nump">$ 332,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">63,612<span></span>
</td>
<td class="nump">61,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">155,755<span></span>
</td>
<td class="nump">214,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrued expenses</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DeferredTaxAssetsDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">21,765<span></span>
</td>
<td class="nump">28,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Stock-based compensation</a></td>
<td class="nump">48,809<span></span>
</td>
<td class="nump">52,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DeferredTaxAssetsAmortizableIntangibles', window );">Amortizable intangibles</a></td>
<td class="nump">11,755<span></span>
</td>
<td class="nump">10,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">112,072<span></span>
</td>
<td class="nump">116,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DeferredTaxAssetsInvestmentsInSubsidiaries', window );">Investments in subsidiaries</a></td>
<td class="nump">59,027<span></span>
</td>
<td class="nump">57,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property, plant, and equipment</a></td>
<td class="nump">2,464<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">936,137<span></span>
</td>
<td class="nump">875,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(840,060)<span></span>
</td>
<td class="num">(771,852)<span></span>
</td>
<td class="num">$ (711,778)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">96,077<span></span>
</td>
<td class="nump">103,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DeferredTaxLiabilitiesAmortizableIntangibles', window );">Amortizable intangibles</a></td>
<td class="num">(10,119)<span></span>
</td>
<td class="num">(11,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease right-of-use assets</a></td>
<td class="num">(92,052)<span></span>
</td>
<td class="num">(98,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(102,171)<span></span>
</td>
<td class="num">(110,389)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred taxes</a></td>
<td class="num">$ (6,094)<span></span>
</td>
<td class="num">$ (6,552)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DeferredTaxAssetsAmortizableIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets amortizable intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DeferredTaxAssetsAmortizableIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DeferredTaxAssetsDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DeferredTaxAssetsDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DeferredTaxAssetsInvestmentsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, investments In Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DeferredTaxAssetsInvestmentsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DeferredTaxLiabilitiesAmortizableIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Amortizable Intangibles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DeferredTaxLiabilitiesAmortizableIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Tax Assets Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_DeferredTaxAssetsValuationAllowanceRollForward', window );"><strong>Deferred tax assets valuation allowance:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning of Period</a></td>
<td class="nump">$ 771,852<span></span>
</td>
<td class="nump">$ 711,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Additions (Subtractions)</a></td>
<td class="nump">68,208<span></span>
</td>
<td class="nump">60,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">End of Period</a></td>
<td class="nump">$ 840,060<span></span>
</td>
<td class="nump">$ 771,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_DeferredTaxAssetsValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_DeferredTaxAssetsValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, deferred tax asset, increase (decrease), amount</a></td>
<td class="nump">$ 68,208,000<span></span>
</td>
<td class="nump">$ 60,074,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, Income tax penalties and interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Begin To Expire In 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">139,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Carried Forward Indefinitely</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">31,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Carried Forward Indefinitely</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">257,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Begin To Expire In 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | Carried Forward Indefinitely</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | Begin To Expire In 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_CarryForwardsExpirationPeriodAxis=dna_BeginToExpireInTwoThousandAndTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_CarryForwardsExpirationPeriodAxis=dna_BeginToExpireInTwoThousandAndTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_CarryForwardsExpirationPeriodAxis=dna_CarriedForwardIndefinitelyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_CarryForwardsExpirationPeriodAxis=dna_CarriedForwardIndefinitelyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_CarryForwardsExpirationPeriodAxis=dna_BeginToExpireInTwoThousandAndThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_CarryForwardsExpirationPeriodAxis=dna_BeginToExpireInTwoThousandAndThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_CarryForwardsExpirationPeriodAxis=dna_BeginToExpireIn2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_CarryForwardsExpirationPeriodAxis=dna_BeginToExpireIn2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax Paid (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidForeignAfterRefundReceived', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash income taxes, net of refunds</a></td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">State and local:</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_SC', window );">South Carolina</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">State and local:</a></td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember', window );">All other state and local</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">State and local:</a></td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidFederalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidForeignAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to foreign tax jurisdiction for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidForeignAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Net loss</a></td>
<td class="num">$ (312,763)<span></span>
</td>
<td class="num">$ (547,029)<span></span>
</td>
<td class="num">$ (892,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">55,457,676<span></span>
</td>
<td class="nump">51,894,639<span></span>
</td>
<td class="nump">48,610,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (5.64)<span></span>
</td>
<td class="num">$ (10.54)<span></span>
</td>
<td class="num">$ (18.37)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Anti-Dilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">11,125,392<span></span>
</td>
<td class="nump">9,205,115<span></span>
</td>
<td class="nump">9,095,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">1,295,622<span></span>
</td>
<td class="nump">1,295,622<span></span>
</td>
<td class="nump">1,295,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">1,262,853<span></span>
</td>
<td class="nump">3,327,398<span></span>
</td>
<td class="nump">3,804,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dna_EarnOutSharesMember', window );">Earnout Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">3,793,063<span></span>
</td>
<td class="nump">3,794,243<span></span>
</td>
<td class="nump">3,803,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">366,567<span></span>
</td>
<td class="nump">767,520<span></span>
</td>
<td class="nump">192,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dna_EscrowSharesMember', window );">Escrow Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,332<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">4,407,287<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dna_EarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dna_EarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dna_EscrowSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dna_EscrowSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Additional Information) (Details)<br></strong></div></th>
<th class="th"><div>Feb. 26, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived', window );">Stock purchase agreement, percent of equity interest to be received</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Percent Of Equity Interest To Be Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>474</ContextCount>
  <ElementCount>625</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>158</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>18</UnitCount>
  <MyReports>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Investments and Equity Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestments</Role>
      <ShortName>Investments and Equity Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Goodwill and Intangible Assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnet</Role>
      <ShortName>Goodwill and Intangible Assets, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Supplemental Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SupplementalFinancialInformation</Role>
      <ShortName>Supplemental Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Significant Collaboration Transactions with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedParties</Role>
      <ShortName>Significant Collaboration Transactions with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9952179 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/Restructuring</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Acquisitions and Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresTables</Role>
      <ShortName>Acquisitions and Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/AcquisitionsandDivestitures</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/FairValueMeasurements</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/MarketableSecurities</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Investments and Equity Method Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsTables</Role>
      <ShortName>Investments and Equity Method Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Goodwill and Intangible Assets, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetTables</Role>
      <ShortName>Goodwill and Intangible Assets, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnet</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/Leases</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Supplemental Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables</Role>
      <ShortName>Supplemental Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/SupplementalFinancialInformation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/StockholdersEquity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/RevenueRecognition</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/SegmentInformation</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/OrganizationConsolidationandPresentationofFinancialStatementsTables</Role>
      <ShortName>Organization, Consolidation and Presentation of Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/IncomeTaxes</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/NetLossperShare</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Restructuring - Summary of Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/RestructuringSummaryofRestructuringChargesDetails</Role>
      <ShortName>Restructuring - Summary of Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Restructuring - Summary of Changes in Accrued Liability Balance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails</Role>
      <ShortName>Restructuring - Summary of Changes in Accrued Liability Balance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Acquisitions and Divestitures - Deconsolidated Assets and Liabilities (Zymergen) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails</Role>
      <ShortName>Acquisitions and Divestitures - Deconsolidated Assets and Liabilities (Zymergen) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Acquisitions and Divestitures - Results of Operations Deconsolidation (Zymergen) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails</Role>
      <ShortName>Acquisitions and Divestitures - Results of Operations Deconsolidation (Zymergen) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Fair Value Measurements - Quantitative Information Regarding Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails</Role>
      <ShortName>Fair Value Measurements - Quantitative Information Regarding Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Investments and Equity Method Investments - Schedule of Investments and Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails</Role>
      <ShortName>Investments and Equity Method Investments - Schedule of Investments and Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Investments and Equity Method Investments - Summary of Gains (Losses) on Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails</Role>
      <ShortName>Investments and Equity Method Investments - Summary of Gains (Losses) on Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Investments and Equity Method Investments - Schedule of Realized and Unrealized Gains and Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails</Role>
      <ShortName>Investments and Equity Method Investments - Schedule of Realized and Unrealized Gains and Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Investments and Equity Method Investments - Carrying Values of Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails</Role>
      <ShortName>Investments and Equity Method Investments - Carrying Values of Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Goodwill and Intangible Assets, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, net - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets, net - Schedule of Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Leases - Schedule of Components of Total Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Components of Total Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Leases - Schedule of Operating Leases Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Schedule of Operating Leases Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Leases - Schedule of Maturity of Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturity of Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Supplemental Financial Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Supplemental Financial Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Supplemental Financial Information - Summary of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail</Role>
      <ShortName>Supplemental Financial Information - Summary of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Supplemental Financial Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail</Role>
      <ShortName>Supplemental Financial Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Supplemental Financial Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Supplemental Financial Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Supplemental Financial Information - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Financial Information - Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Stockholders' Equity - Schedule of Capitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Capitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Founder Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-based Payment Award, Founder Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Stock-Based Compensation - Summary of Activity For Earnout RSA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity For Earnout RSA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Revenue Recognition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Significant Collaboration Transactions with Related Parties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails</Role>
      <ShortName>Significant Collaboration Transactions with Related Parties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedParties</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Significant Collaboration Transactions with Related Parties - Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails</Role>
      <ShortName>Significant Collaboration Transactions with Related Parties - Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Significant Collaboration Transactions with Related Parties - statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails</Role>
      <ShortName>Significant Collaboration Transactions with Related Parties - statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Income Taxes - Summary of Loss Before Provision for Incomes Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Loss Before Provision for Incomes Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Income Taxes - Summary of Income Taxes Expenses (Benefit) Incurred During the Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails</Role>
      <ShortName>Income Taxes - Summary of Income Taxes Expenses (Benefit) Incurred During the Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Income Taxes - Summary of Reconciliation of the Statutory Corporate Income Tax Rate to the Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of the Statutory Corporate Income Tax Rate to the Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Income Taxes - Summary of Deferred Taxes Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Taxes Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Income Taxes - Summary of Deferred Tax Assets Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Tax Assets Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Income Taxes - Tax Paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails</Role>
      <ShortName>Income Taxes - Tax Paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9955586 - Disclosure - Net Loss per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9955587 - Disclosure - Net Loss per Share - Summary of Anti-Dilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails</Role>
      <ShortName>Net Loss per Share - Summary of Anti-Dilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="dna-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9955588 - Disclosure - Subsequent Events (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ginkgobioworks.com/role/SubsequentEvents</ParentRole>
      <Position>112</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="dna-20251231.htm">dna-20251231.htm</File>
    <File>dna-20251231.xsd</File>
    <File>dna-20251231_cal.xml</File>
    <File>dna-20251231_def.xml</File>
    <File>dna-20251231_lab.xml</File>
    <File>dna-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dna-20251231_g1.jpg</File>
    <File>dna-20251231_g2.jpg</File>
    <File>dna-20251231_g3.jpg</File>
    <File>dna-20251231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1499">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>146
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dna-20251231.htm": {
   "nsprefix": "dna",
   "nsuri": "http://www.ginkgobioworks.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "dna-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "dna-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "dna-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dna-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dna-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dna-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 537,
   "keyCustom": 88,
   "axisStandard": 45,
   "axisCustom": 3,
   "memberStandard": 70,
   "memberCustom": 80,
   "hidden": {
    "total": 17,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 11,
    "http://www.ginkgobioworks.com/20251231": 2
   },
   "contextCount": 474,
   "entityCount": 1,
   "segmentCount": 158,
   "elementCount": 1096,
   "unitCount": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1499,
    "http://xbrl.sec.gov/dei/2025": 41,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://www.ginkgobioworks.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.ginkgobioworks.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
     "longName": "9952154 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952155 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "longName": "9952156 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dna:StockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dna:StockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952157 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "longName": "9952158 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncreaseDecreaseInAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:IncreaseDecreaseInAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentation",
     "longName": "9952159 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952160 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.ginkgobioworks.com/role/Restructuring",
     "longName": "9952161 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.ginkgobioworks.com/role/AcquisitionsandDivestitures",
     "longName": "9952162 - Disclosure - Acquisitions and Divestitures",
     "shortName": "Acquisitions and Divestitures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.ginkgobioworks.com/role/FairValueMeasurements",
     "longName": "9952163 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.ginkgobioworks.com/role/MarketableSecurities",
     "longName": "9952164 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestments",
     "longName": "9952165 - Disclosure - Investments and Equity Method Investments",
     "shortName": "Investments and Equity Method Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.ginkgobioworks.com/role/VariableInterestEntities",
     "longName": "9952166 - Disclosure - Variable Interest Entities",
     "shortName": "Variable Interest Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnet",
     "longName": "9952167 - Disclosure - Goodwill and Intangible Assets, net",
     "shortName": "Goodwill and Intangible Assets, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.ginkgobioworks.com/role/Leases",
     "longName": "9952168 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.ginkgobioworks.com/role/SupplementalFinancialInformation",
     "longName": "9952169 - Disclosure - Supplemental Financial Information",
     "shortName": "Supplemental Financial Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.ginkgobioworks.com/role/CommitmentsandContingencies",
     "longName": "9952170 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.ginkgobioworks.com/role/StockholdersEquity",
     "longName": "9952171 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.ginkgobioworks.com/role/StockBasedCompensation",
     "longName": "9952172 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.ginkgobioworks.com/role/RevenueRecognition",
     "longName": "9952173 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.ginkgobioworks.com/role/SegmentInformation",
     "longName": "9952174 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedParties",
     "longName": "9952175 - Disclosure - Significant Collaboration Transactions with Related Parties",
     "shortName": "Significant Collaboration Transactions with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.ginkgobioworks.com/role/EmployeeBenefitPlan",
     "longName": "9952176 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.ginkgobioworks.com/role/IncomeTaxes",
     "longName": "9952177 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.ginkgobioworks.com/role/NetLossperShare",
     "longName": "9952178 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.ginkgobioworks.com/role/SubsequentEvents",
     "longName": "9952179 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.ginkgobioworks.com/role/RestructuringTables",
     "longName": "9955513 - Disclosure - Restructuring (Tables)",
     "shortName": "Restructuring (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresTables",
     "longName": "9955514 - Disclosure - Acquisitions and Divestitures (Tables)",
     "shortName": "Acquisitions and Divestitures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dna:DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dna:DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.ginkgobioworks.com/role/FairValueMeasurementsTables",
     "longName": "9955515 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.ginkgobioworks.com/role/MarketableSecuritiesTables",
     "longName": "9955516 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsTables",
     "longName": "9955517 - Disclosure - Investments and Equity Method Investments (Tables)",
     "shortName": "Investments and Equity Method Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetTables",
     "longName": "9955518 - Disclosure - Goodwill and Intangible Assets, net (Tables)",
     "shortName": "Goodwill and Intangible Assets, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.ginkgobioworks.com/role/LeasesTables",
     "longName": "9955519 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables",
     "longName": "9955520 - Disclosure - Supplemental Financial Information (Tables)",
     "shortName": "Supplemental Financial Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.ginkgobioworks.com/role/StockholdersEquityTables",
     "longName": "9955521 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCapitalizationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCapitalizationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.ginkgobioworks.com/role/StockBasedCompensationTables",
     "longName": "9955522 - Disclosure - Stock Based Compensation (Tables)",
     "shortName": "Stock Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.ginkgobioworks.com/role/RevenueRecognitionTables",
     "longName": "9955523 - Disclosure - Revenue Recognition (Tables)",
     "shortName": "Revenue Recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.ginkgobioworks.com/role/SegmentInformationTables",
     "longName": "9955524 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.ginkgobioworks.com/role/OrganizationConsolidationandPresentationofFinancialStatementsTables",
     "longName": "9955525 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Tables)",
     "shortName": "Organization, Consolidation and Presentation of Financial Statements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.ginkgobioworks.com/role/IncomeTaxesTables",
     "longName": "9955526 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.ginkgobioworks.com/role/NetLossperShareTables",
     "longName": "9955527 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentationDetails",
     "longName": "9955528 - Disclosure - Organization and Basis of Presentation (Details)",
     "shortName": "Organization and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "dna:NumberOfCoreOfferings",
      "unitRef": "offering",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9955529 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails",
     "longName": "9955530 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment Net (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails",
     "longName": "9955531 - Disclosure - Restructuring - Narrative (Details)",
     "shortName": "Restructuring - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-77",
      "name": "dna:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "dna:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.ginkgobioworks.com/role/RestructuringSummaryofRestructuringChargesDetails",
     "longName": "9955532 - Disclosure - Restructuring - Summary of Restructuring Charges (Details)",
     "shortName": "Restructuring - Summary of Restructuring Charges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails",
     "longName": "9955533 - Disclosure - Restructuring - Summary of Changes in Accrued Liability Balance (Details)",
     "shortName": "Restructuring - Summary of Changes in Accrued Liability Balance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "longName": "9955534 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "dna:AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod",
      "unitRef": "materialright",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "dna:AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod",
      "unitRef": "materialright",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
     "longName": "9955535 - Disclosure - Acquisitions and Divestitures - Deconsolidated Assets and Liabilities (Zymergen) (Details)",
     "shortName": "Acquisitions and Divestitures - Deconsolidated Assets and Liabilities (Zymergen) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-97",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dna:DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dna:DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails",
     "longName": "9955536 - Disclosure - Acquisitions and Divestitures - Results of Operations Deconsolidation (Zymergen) (Details)",
     "shortName": "Acquisitions and Divestitures - Results of Operations Deconsolidation (Zymergen) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dna:DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dna:DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
     "longName": "9955537 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ReceivablesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ReceivablesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
     "longName": "9955538 - Disclosure - Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "shortName": "Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-154",
      "name": "dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-154",
      "name": "dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails",
     "longName": "9955539 - Disclosure - Fair Value Measurements - Quantitative Information Regarding Level 3 Inputs (Details)",
     "shortName": "Fair Value Measurements - Quantitative Information Regarding Level 3 Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-187",
      "name": "us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-187",
      "name": "us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9955540 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ConvertibleDebtFairValueDisclosures",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-195",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails",
     "longName": "9955541 - Disclosure - Marketable Securities (Details)",
     "shortName": "Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails",
     "longName": "9955542 - Disclosure - Investments and Equity Method Investments - Schedule of Investments and Equity Method Investments (Details)",
     "shortName": "Investments and Equity Method Investments - Schedule of Investments and Equity Method Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:Investments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-213",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails",
     "longName": "9955543 - Disclosure - Investments and Equity Method Investments - Summary of Gains (Losses) on Investments (Details)",
     "shortName": "Investments and Equity Method Investments - Summary of Gains (Losses) on Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails",
     "longName": "9955544 - Disclosure - Investments and Equity Method Investments - Schedule of Realized and Unrealized Gains and Losses (Details)",
     "shortName": "Investments and Equity Method Investments - Schedule of Realized and Unrealized Gains and Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails",
     "longName": "9955545 - Disclosure - Investments and Equity Method Investments - Carrying Values of Equity Securities (Details)",
     "shortName": "Investments and Equity Method Investments - Carrying Values of Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:Investments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails",
     "longName": "9955546 - Disclosure - Goodwill and Intangible Assets, net - Narrative (Details)",
     "shortName": "Goodwill and Intangible Assets, net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "dna:GoodwillImpairmentDCFWeight",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "dna:GoodwillImpairmentDCFWeight",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails",
     "longName": "9955547 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Goodwill (Details)",
     "shortName": "Goodwill and Intangible Assets, net - Schedule of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-20",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails",
     "longName": "9955548 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-236",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails",
     "longName": "9955549 - Disclosure - Goodwill and Intangible Assets, net - Schedule of Estimated Future Amortization Expense (Details)",
     "shortName": "Goodwill and Intangible Assets, net - Schedule of Estimated Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
     "longName": "9955550 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-244",
      "name": "dna:LesseeOperatingLeaseAreaOfRealEstateProperty",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-244",
      "name": "dna:LesseeOperatingLeaseAreaOfRealEstateProperty",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails",
     "longName": "9955551 - Disclosure - Leases - Schedule of Components of Total Lease Cost (Details)",
     "shortName": "Leases - Schedule of Components of Total Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.ginkgobioworks.com/role/LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails",
     "longName": "9955552 - Disclosure - Leases - Schedule of Operating Leases Supplemental Cash Flow Information (Details)",
     "shortName": "Leases - Schedule of Operating Leases Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.ginkgobioworks.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails",
     "longName": "9955553 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information (Details)",
     "shortName": "Leases - Schedule of Supplemental Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails",
     "longName": "9955554 - Disclosure - Leases - Schedule of Maturity of Operating and Finance Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturity of Operating and Finance Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9955555 - Disclosure - Supplemental Financial Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Supplemental Financial Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail",
     "longName": "9955556 - Disclosure - Supplemental Financial Information - Summary of Property and Equipment, Net (Detail)",
     "shortName": "Supplemental Financial Information - Summary of Property and Equipment, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail",
     "longName": "9955557 - Disclosure - Supplemental Financial Information - Additional Information (Detail)",
     "shortName": "Supplemental Financial Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail",
     "longName": "9955558 - Disclosure - Supplemental Financial Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "shortName": "Supplemental Financial Information - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "dna:ContractualShortfallLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails",
     "longName": "9955559 - Disclosure - Supplemental Financial Information - Schedule of Supplemental Cash Flow Information (Details)",
     "shortName": "Supplemental Financial Information - Schedule of Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "longName": "9955560 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-268",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-268",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails",
     "longName": "9955561 - Disclosure - Stockholders' Equity - Schedule of Capitalization (Details)",
     "shortName": "Stockholders' Equity - Schedule of Capitalization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCapitalizationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCapitalizationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
     "longName": "9955562 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Dividends",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail",
     "longName": "9955563 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuances (Detail)",
     "shortName": "Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuances (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dna:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-290",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dna:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails",
     "longName": "9955564 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-294",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
     "longName": "9955565 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dna:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "dna:ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "longName": "9955566 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
     "longName": "9955567 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails",
     "longName": "9955568 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Founder Options, Valuation Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Share-based Payment Award, Founder Options, Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R93": {
     "role": "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
     "longName": "9955569 - Disclosure - Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details)",
     "shortName": "Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-328",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-328",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails",
     "longName": "9955570 - Disclosure - Stock-Based Compensation - Summary of Activity For Earnout RSA (Details)",
     "shortName": "Stock-Based Compensation - Summary of Activity For Earnout RSA (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-342",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dna:SummaryOfActivityForEarnoutRSATableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-342",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dna:SummaryOfActivityForEarnoutRSATableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "longName": "9955571 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
     "longName": "9955572 - Disclosure - Revenue Recognition - Additional Information (Details)",
     "shortName": "Revenue Recognition - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.ginkgobioworks.com/role/SegmentInformationAdditionalInformationDetails",
     "longName": "9955573 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
     "longName": "9955574 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dna:EmployerPayrollTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
     "longName": "9955575 - Disclosure - Significant Collaboration Transactions with Related Parties - Narrative (Details)",
     "shortName": "Significant Collaboration Transactions with Related Parties - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-412",
      "name": "dna:UpfrontAmountReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
     "longName": "9955576 - Disclosure - Significant Collaboration Transactions with Related Parties - Balance Sheet (Details)",
     "shortName": "Significant Collaboration Transactions with Related Parties - Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R101": {
     "role": "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails",
     "longName": "9955577 - Disclosure - Significant Collaboration Transactions with Related Parties - statement of Operations (Details)",
     "shortName": "Significant Collaboration Transactions with Related Parties - statement of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-420",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail",
     "longName": "9955578 - Disclosure - Employee Benefit Plan - Additional Information (Detail)",
     "shortName": "Employee Benefit Plan - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails",
     "longName": "9955579 - Disclosure - Income Taxes - Summary of Loss Before Provision for Incomes Taxes (Details)",
     "shortName": "Income Taxes - Summary of Loss Before Provision for Incomes Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails",
     "longName": "9955580 - Disclosure - Income Taxes - Summary of Income Taxes Expenses (Benefit) Incurred During the Period (Details)",
     "shortName": "Income Taxes - Summary of Income Taxes Expenses (Benefit) Incurred During the Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails",
     "longName": "9955581 - Disclosure - Income Taxes - Summary of Reconciliation of the Statutory Corporate Income Tax Rate to the Effective Tax Rate (Details)",
     "shortName": "Income Taxes - Summary of Reconciliation of the Statutory Corporate Income Tax Rate to the Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails",
     "longName": "9955582 - Disclosure - Income Taxes - Summary of Deferred Taxes Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Summary of Deferred Taxes Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails",
     "longName": "9955583 - Disclosure - Income Taxes - Summary of Deferred Tax Assets Valuation Allowance (Details)",
     "shortName": "Income Taxes - Summary of Deferred Tax Assets Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R108": {
     "role": "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9955584 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails",
     "longName": "9955585 - Disclosure - Income Taxes - Tax Paid (Details)",
     "shortName": "Income Taxes - Tax Paid (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails",
     "longName": "9955586 - Disclosure - Net Loss per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "shortName": "Net Loss per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails",
     "longName": "9955587 - Disclosure - Net Loss per Share - Summary of Anti-Dilutive Shares (Details)",
     "shortName": "Net Loss per Share - Summary of Anti-Dilutive Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "9955588 - Disclosure - Subsequent Events (Additional Information) (Details)",
     "shortName": "Subsequent Events (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-474",
      "name": "dna:StockPurchaseAgreementPercentOfEquityInterestToBeReceived",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-474",
      "name": "dna:StockPurchaseAgreementPercentOfEquityInterestToBeReceived",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dna-20251231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dna_ATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ATMProgramMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Program",
        "label": "ATM Program [Member]",
        "documentation": "ATM Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r1298"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable - related parties",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1150",
      "r1327",
      "r1740",
      "r1741"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1573"
     ]
    },
    "dna_AccretionOfDiscountOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AccretionOfDiscountOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accretion of discount on marketable securities",
        "label": "Accretion Of Discount On Marketable Securities",
        "documentation": "Accretion Of Discount On Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "dna_AccruedBiosecurityServiceRevenueAccrualsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AccruedBiosecurityServiceRevenueAccrualsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biosecurity costs",
        "label": "Accrued Biosecurity Service Revenue Accruals Current",
        "documentation": "Accrued biosecurity service revenue accruals current."
       }
      }
     },
     "auth_ref": []
    },
    "dna_AccruedEmployeeTerminationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AccruedEmployeeTerminationCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee termination costs",
        "label": "Accrued Employee Termination Costs",
        "documentation": "Accrued Employee Termination Costs"
       }
      }
     },
     "auth_ref": []
    },
    "dna_AccruedExternalResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External research and development expenses",
        "label": "Accrued External Research And Development Expenses Current",
        "documentation": "Accrued external research and development expenses current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees and securities litigation costs",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "dna_AccruedPropertyAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AccruedPropertyAndEquipmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Accrued Property And Equipment Current",
        "documentation": "Accrued property and equipment current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r190",
      "r968"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r91",
      "r199",
      "r963",
      "r1015",
      "r1019",
      "r1704"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r19",
      "r29",
      "r756",
      "r759",
      "r857",
      "r1010",
      "r1011",
      "r1490",
      "r1491",
      "r1492",
      "r1554",
      "r1555",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite Lived Intangible Assets [Line Items]",
        "label": "Intangible Asset, Acquired, Finite-Lived [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r430",
      "r1022",
      "r1165"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Amortization Period (in Years)",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r1165"
     ]
    },
    "dna_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development",
        "label": "Acquired In-Process Research and Development",
        "documentation": "Acquired In-Process Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1388"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Financial Information",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r1298",
      "r1776"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r1038",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1705",
      "r1778"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax withholdings related to net share settlement of equity awards",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1666"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_AgBiomeInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AgBiomeInc.Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AgBiome, Inc.",
        "label": "AgBiome, Inc. [Member]",
        "documentation": "AgBiome, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1359",
      "r1370",
      "r1380",
      "r1413"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1362",
      "r1373",
      "r1383",
      "r1416"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1447"
     ]
    },
    "dna_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AgreementAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement",
        "label": "Agreement [Axis]",
        "documentation": "Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dna_AgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AgreementDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement",
        "label": "Agreement [Domain]",
        "documentation": "Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dna_AgricultureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AgricultureMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agriculture",
        "label": "Agriculture [Member]",
        "documentation": "Agriculture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1374",
      "r1384",
      "r1408",
      "r1417",
      "r1421",
      "r1429"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r595",
      "r604"
     ]
    },
    "dna_AlloniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AlloniaMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allonnia",
        "label": "Allonia [Member]",
        "documentation": "Allonnia [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r327",
      "r381",
      "r386",
      "r387",
      "r1741"
     ]
    },
    "dna_AltarSasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AltarSasMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Altar",
        "label": "Altar SAS [Member]",
        "documentation": "Altar SAS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r218",
      "r425",
      "r432",
      "r1169",
      "r1174",
      "r1175",
      "r1177",
      "r1179"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares excluded from the computation of diluted loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "dna_ArcaeaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ArcaeaMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arcaea",
        "label": "Arcaea [Member]",
        "documentation": "Arcaea [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r1022",
      "r1696"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition, Consideration Transferred",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1697",
      "r1698",
      "r1699"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r1022",
      "r1696"
     ]
    },
    "dna_AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition, Number Of Additional Acquisitions during Period",
        "label": "Asset Acquisition, Number Of Additional Acquisitions during Period",
        "documentation": "Asset Acquisition, Number Of Additional Acquisitions during Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionPriceOfAcquisitionExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionPriceOfAcquisitionExpected",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, price of acquisition, expected",
        "label": "Asset Acquisition, Price of Acquisition, Expected",
        "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition."
       }
      }
     },
     "auth_ref": [
      "r1696"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofRestructuringChargesDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of right-of-use asset",
        "verboseLabel": "Impairment expense",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r47",
      "r1308",
      "r1309"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r146",
      "r194",
      "r234",
      "r236",
      "r237",
      "r279",
      "r293",
      "r311",
      "r315",
      "r372",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r739",
      "r745",
      "r814",
      "r943",
      "r944",
      "r958",
      "r1082",
      "r1193",
      "r1194",
      "r1211",
      "r1298",
      "r1318",
      "r1319",
      "r1337",
      "r1630",
      "r1631",
      "r1727"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r201",
      "r234",
      "r236",
      "r237",
      "r372",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r739",
      "r745",
      "r814",
      "r1298",
      "r1630",
      "r1631",
      "r1727"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r1284"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r117",
      "r184",
      "r185"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r114",
      "r117",
      "r184",
      "r185"
     ]
    },
    "dna_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1342",
      "r1343",
      "r1366"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1342",
      "r1343",
      "r1366"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1342",
      "r1343",
      "r1366"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r399",
      "r957"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1581"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1582"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1586"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r950"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1585"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r949"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r399",
      "r780",
      "r806",
      "r807",
      "r808",
      "r809",
      "r940",
      "r1166",
      "r1284",
      "r1288",
      "r1295",
      "r1576",
      "r1709",
      "r1710",
      "r1711"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1424"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1425"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1420"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1420"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1420"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1420"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1420"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1420"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1423"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1422"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1421"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1421"
     ]
    },
    "dna_AyanaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "AyanaMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ayana Bio",
        "label": "Ayana [Member]",
        "documentation": "Ayana member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1545"
     ]
    },
    "dna_BeginToExpireIn2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "BeginToExpireIn2034Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Begin To Expire In 2034",
        "label": "Begin To Expire In 2034 [Member]",
        "documentation": "Begin To Expire In 2034"
       }
      }
     },
     "auth_ref": []
    },
    "dna_BeginToExpireInTwoThousandAndThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "BeginToExpireInTwoThousandAndThirtyMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Begin To Expire In 2030",
        "label": "Begin To Expire In Two Thousand And Thirty [Member]",
        "documentation": "Begin To Expire In Two Thousand And Thirty [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_BeginToExpireInTwoThousandAndTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "BeginToExpireInTwoThousandAndTwentyNineMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Begin To Expire In 2029",
        "label": "Begin To Expire In Two Thousand And Twenty Nine [Member]",
        "documentation": "Begin To Expire In 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_BiomeditLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "BiomeditLlcMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BiomEdit",
        "label": "BiomEdit LLC [Member]",
        "documentation": "BiomEdit LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_BiomeditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "BiomeditMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BiomEdit",
        "label": "BiomEdit [Member]",
        "documentation": "BiomEdit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_BiosecuritySegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "BiosecuritySegmentMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biosecurity",
        "label": "Biosecurity Segment [Member]",
        "documentation": "Biosecurity Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination",
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r1022",
      "r1228",
      "r1229",
      "r1685",
      "r1688",
      "r1690"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination",
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r1022",
      "r1228",
      "r1229",
      "r1685",
      "r1688",
      "r1690"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Line Items]",
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r665",
      "r666",
      "r667",
      "r668",
      "r674",
      "r675",
      "r676",
      "r677",
      "r683",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r722",
      "r723",
      "r724",
      "r728",
      "r1236",
      "r1246",
      "r1685",
      "r1688",
      "r1690"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger and acquisition related expenses",
        "label": "Business Combination, Acquisition-Related Cost, Expense",
        "documentation": "Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department."
       }
      }
     },
     "auth_ref": [
      "r1683",
      "r1687"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination and Asset Acquisition [Abstract]",
        "label": "Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Consideration Transferred",
        "verboseLabel": "Business Combination, Consideration Transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r724",
      "r1236",
      "r1241"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquire consideration",
        "label": "Business Combination, Consideration Transferred, Tangible and Intangible Assets, Excluding Cash",
        "documentation": "Amount of tangible and intangible assets other than cash transferred by acquirer as part of consideration transferred in business combination. Includes, but is not limited to, business or subsidiary, or both, of acquirer transferred to former owner of acquiree."
       }
      }
     },
     "auth_ref": [
      "r1274",
      "r1276"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of contingent consideration liability",
        "label": "Business Combination, Contingent Consideration, Change in Range of Outcomes, Liability, Maximum, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in maximum amount of estimate for undiscounted range of outcomes of liability in contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, included in other non-current liabilities",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r724",
      "r782",
      "r783",
      "r784",
      "r1236",
      "r1243"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration liability",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1693",
      "r1694"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities:",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1693",
      "r1694"
     ]
    },
    "dna_BusinessCombinationContingentConsiderationVestedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "BusinessCombinationContingentConsiderationVestedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, contingent consideration, vested value",
        "label": "Business Combination, Contingent Consideration, Vested Value",
        "documentation": "Business Combination, Contingent Consideration, Vested Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestitures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and Divestitures",
        "label": "Business Combination [Text Block]",
        "documentation": "The entire disclosure for business combination."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r665",
      "r669",
      "r678",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r696",
      "r699",
      "r700",
      "r706",
      "r710",
      "r711",
      "r719",
      "r723",
      "r724",
      "r725",
      "r727",
      "r729",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1243",
      "r1244",
      "r1245"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Business Combination, Recognized Liability Assumed, Liability",
        "documentation": "Amount of liability assumed in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r699"
     ]
    },
    "dna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment",
        "label": "Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment",
        "documentation": "Amount of property, plant, and equipment acquired in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1241",
      "r1689",
      "r1691"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, equity interest in acquiree, fair value",
        "label": "Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Fair Value",
        "documentation": "Fair value at acquisition date of equity interest in acquiree held by acquirer immediately before acquisition date in business combination achieved in stages."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r683",
      "r1236",
      "r1241"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Abstract]",
        "label": "Business Combination [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combination [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for business combination."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664",
      "r670",
      "r672",
      "r683",
      "r695",
      "r699",
      "r1236",
      "r1242",
      "r1275",
      "r1276"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "CA",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ]
    },
    "dna_CarriedForwardIndefinitelyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CarriedForwardIndefinitelyMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carried Forward Indefinitely",
        "label": "Carried Forward Indefinitely [Member]",
        "documentation": "Carried Forward Indefinitely [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_CarryForwardsExpirationPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CarryForwardsExpirationPeriodAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carry Forwards Expiration Period",
        "label": "Carry Forwards Expiration Period [Axis]",
        "documentation": "Carry Forwards Expiration Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_CarryForwardsExpirationPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CarryForwardsExpirationPeriodDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carry Forwards Expiration Period",
        "label": "Carry Forwards Expiration Period [Domain]",
        "documentation": "Carry Forwards Expiration Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r188",
      "r1170"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents:",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r809",
      "r1707",
      "r1708"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r133"
     ]
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Cash, Cash Equivalent, and Marketable Security [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r1575"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r107",
      "r231"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r107"
     ]
    },
    "dna_CellEngineeringAndBiosecuritySegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CellEngineeringAndBiosecuritySegmentsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cell Engineering and Biosecurity",
        "label": "Cell Engineering and Biosecurity Segments [Member]",
        "documentation": "Cell Engineering and Biosecurity Segments"
       }
      }
     },
     "auth_ref": []
    },
    "dna_CellEngineeringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CellEngineeringMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cell Engineering",
        "label": "Cell Engineering [Member]",
        "documentation": "Cell Engineering"
       }
      }
     },
     "auth_ref": []
    },
    "dna_CellEngineeringRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CellEngineeringRevenueMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cell Engineering",
        "verboseLabel": "Total Cell Engineering revenue",
        "label": "Cell Engineering Revenue [Member]",
        "documentation": "Cell Engineering Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "dna_CellEngineeringSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CellEngineeringSegmentMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cell Engineering",
        "label": "Cell Engineering Segment [Member]",
        "documentation": "Cell Engineering Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1399"
     ]
    },
    "dna_ChangesInFairValueOfLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ChangesInFairValueOfLoansReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of notes receivable",
        "label": "Changes in Fair Value of Loans Receivable",
        "documentation": "Changes in fair value of loans receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1396"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1394"
     ]
    },
    "dna_CircularisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CircularisMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Circularis",
        "label": "Circularis [Member]",
        "documentation": "Circularis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/Cover",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r196",
      "r197",
      "r198",
      "r234",
      "r237",
      "r268",
      "r269",
      "r271",
      "r273",
      "r281",
      "r282",
      "r372",
      "r470",
      "r473",
      "r474",
      "r475",
      "r479",
      "r480",
      "r488",
      "r489",
      "r491",
      "r492",
      "r494",
      "r497",
      "r500",
      "r501",
      "r504",
      "r507",
      "r514",
      "r814",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1069",
      "r1090",
      "r1108",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1452",
      "r1548",
      "r1549",
      "r1558"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r281",
      "r491",
      "r500",
      "r501",
      "r502",
      "r504",
      "r507",
      "r512",
      "r514",
      "r751",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1212",
      "r1452",
      "r1546",
      "r1548"
     ]
    },
    "dna_ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, outstanding (in shares)",
        "label": "Class of Warrant of Right, Number Of Warrants To Be Exercised, Minimum",
        "documentation": "Class of Warrant of Right, Number Of Warrants To Be Exercised, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1635"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, number of securities called by rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dna_ClassOfWarrantOrRightStockSplitConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ClassOfWarrantOrRightStockSplitConversionRatio",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant, stock split, conversion ratio",
        "label": "Class Of Warrant Or Right, Stock Split, Conversion Ratio",
        "documentation": "Class Of Warrant Or Right, Stock Split, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Collaboration Transactions with Related Parties",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r735",
      "r736"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r469",
      "r1328",
      "r1329",
      "r1330",
      "r1331"
     ]
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper, Not Included with Cash and Cash Equivalents",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r1638",
      "r1639"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 12)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r136",
      "r960",
      "r1068"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r459",
      "r461",
      "r1152",
      "r1621",
      "r1624"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/Cover",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class A",
        "verboseLabel": "Class A",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1778"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class B",
        "verboseLabel": "Class B",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1778"
     ]
    },
    "us-gaap_CommonClassCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassCMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class C",
        "verboseLabel": "Class C",
        "label": "Common Class C [Member]",
        "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total common stock reserved for future issuances (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "dna_CommonStockConversionRatio": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CommonStockConversionRatio",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, conversion ratio (in shares)",
        "label": "Common Stock, Conversion Ratio",
        "documentation": "Common Stock, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1324",
      "r1325",
      "r1326",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1554",
      "r1555",
      "r1557",
      "r1705",
      "r1774",
      "r1778"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1069"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r85",
      "r1069",
      "r1088",
      "r1778",
      "r1779"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value (Note 13)",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r489",
      "r496",
      "r962",
      "r1298"
     ]
    },
    "dna_CommonStockVotingRight": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CommonStockVotingRight",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting rights",
        "label": "Common Stock, Voting Right",
        "documentation": "Common Stock, Voting Right"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1405"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1404"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1406"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1403"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r205",
      "r207",
      "r212",
      "r941",
      "r977",
      "r978"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "dna_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment and Software [Member]",
        "documentation": "Computer Equipment and Software [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r322",
      "r1023",
      "r1024",
      "r1151",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r322",
      "r1023",
      "r1024",
      "r1151",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r322",
      "r1023",
      "r1024",
      "r1151",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r811"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "verboseLabel": "Revenue from customers within the United States",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r322",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r322",
      "r1023",
      "r1024",
      "r1151",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r244",
      "r739",
      "r740",
      "r744",
      "r745",
      "r746",
      "r862",
      "r947",
      "r1157",
      "r1629",
      "r1632",
      "r1633"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r244",
      "r739",
      "r740",
      "r744",
      "r745",
      "r746",
      "r862",
      "r947",
      "r1157",
      "r1629",
      "r1632",
      "r1633"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r234",
      "r235",
      "r241",
      "r244",
      "r279",
      "r295",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r947",
      "r1193",
      "r1194",
      "r1630",
      "r1631"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r234",
      "r235",
      "r241",
      "r244",
      "r279",
      "r295",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r947",
      "r1193",
      "r1194",
      "r1630",
      "r1631"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r1181"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r63"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dna_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Contingent Consideration [Member]",
        "documentation": "Contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract asset",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r520",
      "r522",
      "r533"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred other income",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r522",
      "r533"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligation satisfied, revenue recognized",
        "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied."
       }
      }
     },
     "auth_ref": [
      "r1214"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative catch-up adjustment to revenue",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets",
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue (includes $98 and $795 from related parties)",
        "verboseLabel": "Deferred revenue, related party",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r522",
      "r533"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets",
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, net of current portion (includes $64,787 and $72,260 from related parties)",
        "verboseLabel": "Deferred revenue, net of current portion, from related parties",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r522",
      "r533"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "dna_ContractualShortfallLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ContractualShortfallLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual shortfall liability",
        "label": "Contractual Shortfall Liability",
        "documentation": "Contractual Shortfall Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dna_ContractualShortfallLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ContractualShortfallLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual shortfall liabilities (Note 12)",
        "label": "Contractual Shortfall Liability, Current",
        "documentation": "Contractual Shortfall Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "dna_ContractualShortfallLiabilityRequiredPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ContractualShortfallLiabilityRequiredPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual shortfall liability, required payment",
        "label": "Contractual Shortfall Liability, Required Payment",
        "documentation": "Contractual Shortfall Liability, Required Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt, fair value",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1714",
      "r1715",
      "r1716",
      "r1717"
     ]
    },
    "dna_ConvertibleFinancialInstrumentsReceivedForFoundryServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ConvertibleFinancialInstrumentsReceivedForFoundryServices",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible financial instruments received for Cell Engineering services",
        "label": "Convertible Financial Instruments Received For Foundry Services",
        "documentation": "Convertible financial instruments received for Foundry services"
       }
      }
     },
     "auth_ref": []
    },
    "dna_ConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ConvertiblePromissoryNotesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Promissory Notes",
        "label": "Convertible Promissory Notes [Member]",
        "documentation": "Convertible Promissory Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Bond Securities",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1223",
      "r1225",
      "r1227",
      "r1284",
      "r1299",
      "r1321",
      "r1771"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate, Non-Segment",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r1569"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "verboseLabel": "Total segment cost of revenue",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r901",
      "r1175",
      "r1180",
      "r1281",
      "r1533"
     ]
    },
    "us-gaap_CostOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenueAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment cost of revenue",
        "label": "Cost of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Biosecurity Revenue",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1465"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r242",
      "r243",
      "r481",
      "r502",
      "r861",
      "r882",
      "r954",
      "r1171",
      "r1172",
      "r1173",
      "r1481",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1700",
      "r1701",
      "r1702",
      "r1703"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for Credit Losses",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1464",
      "r1546",
      "r1551"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r1546",
      "r1551"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1464",
      "r1546",
      "r1551",
      "r1678"
     ]
    },
    "dna_CustomerAndTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CustomerAndTechnologyMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumer and technology",
        "label": "Customer And Technology [Member]",
        "documentation": "Customer And Technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r1563"
     ]
    },
    "dna_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer One",
        "label": "Customer One [Member]",
        "documentation": "Customer One"
       }
      }
     },
     "auth_ref": []
    },
    "dna_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer two",
        "label": "Customer two [Member]",
        "documentation": "Customer two"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1351",
      "r1440"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1351",
      "r1440"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1442"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1442"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1355",
      "r1444"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1353",
      "r1442"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1346",
      "r1435"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1347",
      "r1436"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1347",
      "r1436"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1345",
      "r1434"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1345",
      "r1434"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1345",
      "r1434"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1348",
      "r1437"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1350",
      "r1439"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1350",
      "r1439"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1351",
      "r1440"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1354",
      "r1443"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1352",
      "r1441"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1349",
      "r1438"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of notes receivable for common stock",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r40"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r40"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589"
     ]
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeconsolidationGainOrLossAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on deconsolidation of subsidiaries",
        "negatedTerseLabel": "Loss on deconsolidation of subsidiaries",
        "verboseLabel": "Loss on deconsolidation of subsidiaries",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r215"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1546",
      "r1551",
      "r1677",
      "r1678"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1546",
      "r1551",
      "r1677"
     ]
    },
    "us-gaap_DeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred other income",
        "label": "Deferred Income",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1460",
      "r1742",
      "r1770"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r160",
      "r1546",
      "r1551"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r135",
      "r629"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deferred",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1546",
      "r1551",
      "r1677",
      "r1678"
     ]
    },
    "dna_DeferredTaxAssetsAmortizableIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DeferredTaxAssetsAmortizableIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortizable intangibles",
        "label": "Deferred Tax Assets Amortizable Intangibles",
        "documentation": "Deferred tax assets amortizable intangibles."
       }
      }
     },
     "auth_ref": []
    },
    "dna_DeferredTaxAssetsDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DeferredTaxAssetsDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets Deferred Revenue",
        "documentation": "Deferred tax assets deferred revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1675"
     ]
    },
    "dna_DeferredTaxAssetsInvestmentsInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DeferredTaxAssetsInvestmentsInSubsidiaries",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in subsidiaries",
        "label": "Deferred Tax Assets, investments In Subsidiaries",
        "documentation": "Deferred Tax Assets, investments In Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "dna_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "documentation": "Deferred Tax Assets, Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1670"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1675"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1675"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1675"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1675"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r1675"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1675"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails",
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "periodStartLabel": "Beginning of Period",
        "periodEndLabel": "End of Period",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dna_DeferredTaxAssetsValuationAllowanceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DeferredTaxAssetsValuationAllowanceRollForward",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets valuation allowance:",
        "label": "Deferred Tax Assets Valuation Allowance [Roll Forward]",
        "documentation": "Deferred Tax Assets Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred taxes",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1670"
     ]
    },
    "dna_DeferredTaxLiabilitiesAmortizableIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DeferredTaxLiabilitiesAmortizableIntangibles",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortizable intangibles",
        "label": "Deferred Tax Liabilities Amortizable Intangibles",
        "documentation": "Deferred Tax Liabilities Amortizable Intangibles"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1675"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxesAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property, plant and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1675"
     ]
    },
    "dna_DefinedContributionPlanEmployeeAnnualEarningAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DefinedContributionPlanEmployeeAnnualEarningAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee annual earning",
        "label": "Defined Contribution Plan, Employee Annual Earning, Amount",
        "documentation": "Defined Contribution Plan, Employee Annual Earning, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution by company, amount",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution by company, percent",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "dna_DefinedContributionPlanMaximumEmployerContributionsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DefinedContributionPlanMaximumEmployerContributionsAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum employer contributions",
        "label": "Defined Contribution Plan, Maximum Employer Contributions, Amount",
        "documentation": "Defined Contribution Plan, Maximum Employer Contributions, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plan",
        "label": "Defined Contribution Plan [Text Block]",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549"
     ]
    },
    "dna_DefinedContributionPlanVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DefinedContributionPlanVestingPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, vesting period",
        "label": "Defined Contribution Plan, Vesting Period",
        "documentation": "Defined Contribution Plan, Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r48",
      "r217",
      "r1174",
      "r1175",
      "r1177",
      "r1179"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r48"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFairValueOfDerivativeNetAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Fair Value, Net [Abstract]",
        "label": "Derivative, Fair Value, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed Technology Rights",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r1611",
      "r1612",
      "r1613",
      "r1614",
      "r1615",
      "r1616",
      "r1619",
      "r1620",
      "r1692"
     ]
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1636"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r556",
      "r587",
      "r588",
      "r590",
      "r1231"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67",
      "r69"
     ]
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r73",
      "r612",
      "r646",
      "r648"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is disposed of other than by sale. For example, but not limited to, abandonment, in an exchange measured based on the recorded amount of the nonmonetary asset relinquished, or in a distribution to owners in a spinoff. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r113"
     ]
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r24"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue",
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current",
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r114",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r114",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating expenses",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liabilities, Noncurrent",
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liabilities, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "dna_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset",
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r114",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total other income, net",
        "label": "Disposal Group, Including Discontinued Operation, Other Income",
        "documentation": "Amount of other income attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r5",
      "r64",
      "r72",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r5",
      "r64",
      "r72",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r114",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r114",
      "r117"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r185"
     ]
    },
    "dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets deconsolidated",
        "label": "Disposal Group, Including Discontinued Operations, Assets and Liabilities, Net",
        "documentation": "Disposal Group, Including Discontinued Operations, Assets and Liabilities, Net"
       }
      }
     },
     "auth_ref": []
    },
    "dna_DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deconsolidated Assets and Liabilities",
        "label": "Disposal Group, Not Including Discontinued Operations [Table Text Block]",
        "documentation": "Disposal Group, Not Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r1228",
      "r1229"
     ]
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r125"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1342",
      "r1343",
      "r1366"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1342",
      "r1343",
      "r1366",
      "r1409"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1387"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1340"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1398"
     ]
    },
    "dna_EarnOutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EarnOutSharesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnout Shares",
        "label": "Earn-Out Shares [Member]",
        "documentation": "Earn-Out Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r213",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r265",
      "r268",
      "r271",
      "r272",
      "r273",
      "r278",
      "r487",
      "r593",
      "r660",
      "r734",
      "r777",
      "r778",
      "r942",
      "r979",
      "r1184"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r213",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r268",
      "r271",
      "r272",
      "r273",
      "r278",
      "r487",
      "r593",
      "r660",
      "r734",
      "r777",
      "r778",
      "r942",
      "r979",
      "r1184"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r275"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r274",
      "r276",
      "r277"
     ]
    },
    "dna_EarnoutRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EarnoutRestrictedStockUnitsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnout RSUs",
        "label": "Earnout Restricted Stock Units [Member]",
        "documentation": "Earnout restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r1235"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax at U.S. Statutory Rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r239",
      "r614",
      "r644",
      "r1235"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Valuation Allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r1235",
      "r1546",
      "r1552",
      "r1667"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investments in subsidiaries and other",
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r1546",
      "r1552",
      "r1667",
      "r1668"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other foreign jurisdictions",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r618",
      "r1235",
      "r1546",
      "r1552",
      "r1667"
     ]
    },
    "dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain/Loss on investments",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain/Loss on investments",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Gain/Loss On Investments, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Limitation on executive compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dna_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Limitation on executive compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Limitation On Compensation, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1546",
      "r1552",
      "r1667",
      "r1669"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1546",
      "r1552",
      "r1667",
      "r1669"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1546",
      "r1552",
      "r1667",
      "r1668"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Income Taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1235",
      "r1546",
      "r1552",
      "r1667"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research &amp; Development Credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1546",
      "r1552",
      "r1667",
      "r1669"
     ]
    },
    "dna_EmployeeLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EmployeeLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee lease expense",
        "label": "Employee Lease Expense",
        "documentation": "Employee Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Termination Costs and Other",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Outstanding stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "dna_EmployerPayrollTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EmployerPayrollTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer payroll taxes",
        "label": "Employer Payroll Taxes",
        "documentation": "Employer payroll taxes."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1450"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1392"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "dna_EquipmentLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EquipmentLeasesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment leases",
        "label": "Equipment leases [Member]",
        "documentation": "Equipment leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r172",
      "r179",
      "r180",
      "r209",
      "r210",
      "r211",
      "r245",
      "r246",
      "r247",
      "r250",
      "r258",
      "r260",
      "r262",
      "r280",
      "r374",
      "r377",
      "r440",
      "r486",
      "r516",
      "r593",
      "r639",
      "r640",
      "r656",
      "r657",
      "r658",
      "r661",
      "r733",
      "r734",
      "r754",
      "r756",
      "r757",
      "r758",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r776",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r827",
      "r830",
      "r857",
      "r975",
      "r1010",
      "r1011",
      "r1012",
      "r1038",
      "r1108"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r371",
      "r652",
      "r814",
      "r1456",
      "r1457",
      "r1458",
      "r1679",
      "r1680",
      "r1681",
      "r1682"
     ]
    },
    "dna_EquityMethodInvestmentFundingOfAdditionalLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EquityMethodInvestmentFundingOfAdditionalLossesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Funding Of Additional Losses",
        "label": "Equity Method Investment, Funding Of Additional Losses [Member]",
        "documentation": "Equity Method Investment, Funding Of Additional Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Equity Method Investment, Other-than-Temporary Impairment",
        "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r1594"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments",
        "netLabel": "Equity method investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r303",
      "r315",
      "r366",
      "r1477",
      "r1595"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]",
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments and Equity Method Investments",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r370",
      "r373",
      "r1458"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r369",
      "r814"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments and Equity Method Investments",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "dna_EquitySecuritiesFVNIMeasurementInputTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EquitySecuritiesFVNIMeasurementInputTerm",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, measurement input, term",
        "label": "Equity Securities, FV-NI, Measurement Input, Term",
        "documentation": "Equity Securities, FV-NI, Measurement Input, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r1590"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total initial cost",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails": {
       "parentTag": "us-gaap_Investments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r780",
      "r806",
      "r807",
      "r808",
      "r809",
      "r954",
      "r955",
      "r1284",
      "r1320",
      "r1323",
      "r1709",
      "r1710",
      "r1711"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails": {
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized losses recognized on equity investments held as of the end of the period",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r1593"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, measurement input",
        "label": "Equity Securities, FV-NI, Measurement Input",
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails": {
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net realized gains (losses) recognized on equity investments sold",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1593"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails": {
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized and unrealized gains (losses) recognized on marketable equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1593"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r1299",
      "r1332",
      "r1333",
      "r1334",
      "r1780"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails": {
       "parentTag": "us-gaap_Investments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAFEs",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails": {
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Downward adjustments from observable price changes",
        "negatedTerseLabel": "Downward adjustments from observable price changes",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Downward adjustments from observable price changes",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount",
        "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "dna_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, downward price adjustment percentage",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Percentage",
        "documentation": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails": {
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "negatedLabel": "Impairment charges",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount",
        "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment charges",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount",
        "documentation": "Amount of cumulative impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1402"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1359",
      "r1370",
      "r1380",
      "r1413"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1356",
      "r1367",
      "r1377",
      "r1410"
     ]
    },
    "dna_EscrowSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "EscrowSharesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Escrow Shares",
        "label": "Escrow Shares [Member]",
        "documentation": "Escrow Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liabilities",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r796",
      "r1284"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r796",
      "r1284"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r1236",
      "r1243",
      "r1288"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r1236",
      "r1243",
      "r1288"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value Measurements Inputs",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r1288"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r797",
      "r1166",
      "r1286",
      "r1295"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r797",
      "r1286"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument asset measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r797",
      "r1286"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r797",
      "r1166",
      "r1286",
      "r1295"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r793",
      "r796",
      "r798",
      "r807",
      "r869",
      "r870",
      "r871",
      "r1166",
      "r1209",
      "r1210",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1284",
      "r1288",
      "r1295"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r797"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r784",
      "r1284",
      "r1710",
      "r1713"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r789",
      "r791",
      "r792",
      "r793",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r938",
      "r1284",
      "r1289"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r537",
      "r542",
      "r544",
      "r781",
      "r796",
      "r807",
      "r869",
      "r1166",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1284",
      "r1295"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r537",
      "r542",
      "r544",
      "r546",
      "r781",
      "r782",
      "r796",
      "r807",
      "r870",
      "r1166",
      "r1209",
      "r1210",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1284",
      "r1295"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level 3",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r781",
      "r782",
      "r783",
      "r784",
      "r796",
      "r807",
      "r871",
      "r1166",
      "r1209",
      "r1210",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1284",
      "r1288",
      "r1295"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obligations, fair value",
        "label": "Obligations, Fair Value Disclosure",
        "documentation": "Fair value of obligations measured on a recurring basis."
       }
      }
     },
     "auth_ref": [
      "r1707",
      "r1708",
      "r1712"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r797"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r790",
      "r797"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r784",
      "r1284",
      "r1710",
      "r1713"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers into Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r795",
      "r797"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers to Level 2",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r795",
      "r797"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r797",
      "r1286",
      "r1287"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r794",
      "r797",
      "r1286"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlements and payments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r797",
      "r1286"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers into Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r795",
      "r797",
      "r1286"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers to Level 2",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r795",
      "r797",
      "r1286"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r797",
      "r1286"
     ]
    },
    "dna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion to preferred stock",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Conversions",
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Conversions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r797"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r794",
      "r797"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlements and payments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r797"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r797"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r793",
      "r796",
      "r798",
      "r807",
      "r869",
      "r870",
      "r871",
      "r1166",
      "r1209",
      "r1210",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1284",
      "r1288",
      "r1295"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1284",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1713"
     ]
    },
    "dna_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance lease cost",
        "label": "Finance Lease Cost",
        "documentation": "Finance Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails": {
       "parentTag": "dna_FinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r841",
      "r1297"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r845"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liability",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r849"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: current portion of lease liability",
        "verboseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Capital Leases",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1723"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "dna_FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount, Including Adjustment",
        "documentation": "Finance Lease, Liability, Undiscounted Excess Amount, Including Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payments on finance leases",
        "terseLabel": "Financing cash flows from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r845"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails": {
       "parentTag": "dna_FinanceLeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of ROU assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r841",
      "r1297"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate - finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r1297"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term - finance leases (in years)",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r1297"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r383",
      "r385",
      "r388",
      "r389",
      "r394",
      "r403",
      "r404",
      "r405",
      "r483",
      "r512",
      "r751",
      "r766",
      "r803",
      "r813",
      "r816",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r953",
      "r976",
      "r1205",
      "r1284",
      "r1286",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1299",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1706",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715"
     ]
    },
    "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing receivable, excluding accrued interest, after allowance for credit loss",
        "label": "Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r1597"
     ]
    },
    "dna_FinancingReceivableInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "FinancingReceivableInterestRateStatedPercentage",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing receivable, interest rate",
        "label": "Financing Receivable, Interest Rate, Stated Percentage",
        "documentation": "Financing Receivable, Interest Rate, Stated Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dna_FinancingReceivableMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "FinancingReceivableMeasurementInput",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing receivable, measurement input",
        "label": "Financing Receivable, Measurement Input",
        "documentation": "Financing Receivable, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "dna_FinancingReceivableMeasurementInputPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "FinancingReceivableMeasurementInputPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing receivable, measurement input, period",
        "label": "Financing Receivable, Measurement Input, Period",
        "documentation": "Financing Receivable, Measurement Input, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Financing Receivable [Axis]",
        "label": "Class of Financing Receivable [Axis]",
        "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r166",
      "r167",
      "r168",
      "r169",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r388",
      "r389",
      "r394",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1574"
     ]
    },
    "us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Financing Receivable [Domain]",
        "label": "Class of Financing Receivable [Domain]",
        "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r166",
      "r167",
      "r168",
      "r169",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1574"
     ]
    },
    "us-gaap_FinancingReceivableSignificantPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableSignificantPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing receivable",
        "label": "Financing Receivable, Purchase",
        "documentation": "Amount of increase in financing receivable from purchase. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r384"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles estimated useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r406",
      "r431",
      "r1169"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1617",
      "r1781"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r1165",
      "r1169"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Amortization Expense",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r1165",
      "r1169"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r1165",
      "r1169"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r1165",
      "r1169"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r1165",
      "r1169"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r434",
      "r435",
      "r902",
      "r903",
      "r1022",
      "r1165",
      "r1169",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Value",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r431",
      "r903",
      "r1169"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r434",
      "r435",
      "r1022",
      "r1165",
      "r1169",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofEstimatedFutureAmortizationExpenseDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r1616"
     ]
    },
    "dna_FoodAndNutritionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "FoodAndNutritionMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Food and nutrition",
        "label": "Food And Nutrition [Member]",
        "documentation": "Food And Nutrition [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1374",
      "r1384",
      "r1417"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1374",
      "r1384",
      "r1417"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1374",
      "r1384",
      "r1417"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1374",
      "r1384",
      "r1417"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1374",
      "r1384",
      "r1417"
     ]
    },
    "dna_FounderOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "FounderOptionsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder Options",
        "label": "Founder Options [Member]",
        "documentation": "Founder Options"
       }
      }
     },
     "auth_ref": []
    },
    "dna_FounderPSUAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "FounderPSUAwardsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder PSU Awards",
        "label": "Founder PSU Awards [Member]",
        "documentation": "Founder PSU Awards"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1397"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of equipment",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1541"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      },
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofRealizedandUnrealizedGainsandLossesDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsSummaryofGainsLossesonInvestmentsDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss on investments",
        "negatedLabel": "Loss on investments",
        "terseLabel": "(Loss) gain on investments:",
        "totalLabel": "Total loss on investments",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r103",
      "r1451"
     ]
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Losses and Gains on Investments",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r1493",
      "r1494"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on sale of business",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r1541"
     ]
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment of long-lived assets",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value."
       }
      }
     },
     "auth_ref": [
      "r1541"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r1092"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment general and administrative expense",
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "dna_GenomaticaIncPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "GenomaticaIncPreferredStockMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genomatica, Inc. Preferred Stock",
        "label": "Genomatica, Inc. Preferred Stock [Member]",
        "documentation": "Genomatica, Inc. Preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "dna_GenomaticaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "GenomaticaMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genomatica",
        "label": "Genomatica [Member]",
        "documentation": "Genomatica [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at December 31, 2023",
        "periodEndLabel": "Balance at December 31, 2024",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r408",
      "r939",
      "r1194",
      "r1207",
      "r1236",
      "r1240",
      "r1241",
      "r1278",
      "r1285",
      "r1298",
      "r1600",
      "r1607",
      "r1695"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets, net",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1598",
      "r1610"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r420",
      "r1207"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, net",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r436",
      "r438"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impact of foreign currency translation",
        "label": "Goodwill, Foreign Currency Translation, Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r728"
     ]
    },
    "dna_GoodwillImpairmentDCFWeight": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "GoodwillImpairmentDCFWeight",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment, DCF weight",
        "label": "Goodwill Impairment, DCF Weight",
        "documentation": "Goodwill Impairment, DCF Weight"
       }
      }
     },
     "auth_ref": []
    },
    "dna_GoodwillImpairmentGPCWeight": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "GoodwillImpairmentGPCWeight",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment, GPC weight",
        "label": "Goodwill Impairment, GPC Weight",
        "documentation": "Goodwill Impairment, GPC Weight"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "verboseLabel": "Goodwill impairment",
        "negatedTerseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r409",
      "r415",
      "r420",
      "r422",
      "r728",
      "r1207",
      "r1285"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r1207"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dna_GovernmentAndDefenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "GovernmentAndDefenseMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government and defense",
        "label": "Government and Defense [Member]",
        "documentation": "Government and Defense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1342",
      "r1343",
      "r1366"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r118"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r238",
      "r613"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "terseLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r140",
      "r145",
      "r943",
      "r945",
      "r971",
      "r1176",
      "r1178",
      "r1180",
      "r1188",
      "r1193",
      "r1561",
      "r1568",
      "r1570",
      "r1571",
      "r1572"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r238",
      "r613"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofLossBeforeProvisionforIncomesTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r984",
      "r1188",
      "r1318",
      "r1319",
      "r1561",
      "r1568",
      "r1570",
      "r1571",
      "r1572"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r73",
      "r185",
      "r649",
      "r972"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on equity method investments",
        "negatedLabel": "Loss on equity method investments",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r93",
      "r139",
      "r279",
      "r300",
      "r315",
      "r366",
      "r970"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r1228",
      "r1229"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r445",
      "r451",
      "r747",
      "r748",
      "r749",
      "r750",
      "r786",
      "r790",
      "r797",
      "r815",
      "r816",
      "r817",
      "r1005",
      "r1007",
      "r1093",
      "r1165",
      "r1166",
      "r1236",
      "r1241",
      "r1282",
      "r1283",
      "r1287",
      "r1295",
      "r1684",
      "r1686",
      "r1743"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r451",
      "r747",
      "r748",
      "r749",
      "r750",
      "r786",
      "r790",
      "r797",
      "r815",
      "r816",
      "r817",
      "r1005",
      "r1007",
      "r1093",
      "r1165",
      "r1166",
      "r1236",
      "r1241",
      "r1282",
      "r1283",
      "r1287",
      "r1295",
      "r1684",
      "r1686",
      "r1743"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r614",
      "r615",
      "r624",
      "r635",
      "r1235",
      "r1674"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r614",
      "r615",
      "r624",
      "r635",
      "r1235",
      "r1674"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Line Items]",
        "label": "Income Tax Disclosure [Line Items]",
        "documentation": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]",
        "documentation": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r239",
      "r608",
      "r614",
      "r620",
      "r621",
      "r622",
      "r626",
      "r633",
      "r645",
      "r647",
      "r650",
      "r651",
      "r952",
      "r1021",
      "r1036",
      "r1235"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofIncomeTaxesExpensesBenefitIncurredDuringthePeriodDetails",
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit",
        "totalLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r161",
      "r234",
      "r261",
      "r262",
      "r279",
      "r301",
      "r315",
      "r612",
      "r614",
      "r646",
      "r985",
      "r1176",
      "r1178",
      "r1180",
      "r1235"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidFederalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Income Tax Paid, Federal, after Refund Received",
        "documentation": "Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r634"
     ]
    },
    "us-gaap_IncomeTaxPaidForeignAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidForeignAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income Tax Paid, Foreign, after Refund Received",
        "documentation": "Amount, after income tax refund received, of cash paid to foreign tax jurisdiction for tax on income."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r634"
     ]
    },
    "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local:",
        "label": "Income Tax Paid, State and Local, after Refund Received",
        "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r634"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r610",
      "r611",
      "r626",
      "r627",
      "r632",
      "r637",
      "r1030"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Valuation Allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r1235",
      "r1667"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other foreign jurisdictions",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r618",
      "r1235",
      "r1667"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax at U.S. Statutory Rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r1235"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1667",
      "r1669"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1667",
      "r1669"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1667",
      "r1668"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Income Taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1235",
      "r1667"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofReconciliationoftheStatutoryCorporateIncomeTaxRatetotheEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research &amp; Development Credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1667",
      "r1669"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r109",
      "r1542",
      "r1672",
      "r1673"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash income taxes, net of refunds",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r230",
      "r634",
      "r635"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable ($357, $156 and $816 from related parties)",
        "terseLabel": "Accounts receivable, from related parties",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current and non-current ($(8,147), $(51,422) and $(17,018) from related parties)",
        "verboseLabel": "Deferred revenue, current and non-current, from related parties",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r1540"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current and non-current",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1463",
      "r1540"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1540"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dna_IncreaseDecreaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "IncreaseDecreaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use assets",
        "label": "Increase (Decrease) Right of Use Assets",
        "documentation": "Increase (Decrease) Right of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1374",
      "r1384",
      "r1408",
      "r1417",
      "r1421",
      "r1429"
     ]
    },
    "dna_InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "InducementPlanMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Inducement Plan",
        "label": "2022 Inducement Plan [Member]",
        "documentation": "2022 Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_IndustrialAndEnvironmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "IndustrialAndEnvironmentMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industrial and environment",
        "label": "Industrial And Environment [Member]",
        "documentation": "Industrial And Environment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1344",
      "r1433"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1344",
      "r1433"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1344",
      "r1433"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r1616",
      "r1618"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r1176",
      "r1180",
      "r1495"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "us-gaap_InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for acquisitions",
        "label": "Interest Income, Securities, US Treasury and Other US Government",
        "documentation": "Amount of operating interest income, including amortization and accretion of premiums and discounts, on U.S. Treasury securities and other U.S. government securities."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r228",
      "r229"
     ]
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentOwnedAtCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment owned, at cost",
        "label": "Investment Owned, Cost",
        "documentation": "Cost of the investment."
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1056",
      "r1057",
      "r1118",
      "r1121",
      "r1127",
      "r1131",
      "r1326",
      "r1337",
      "r1775"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1053",
      "r1054",
      "r1056",
      "r1058",
      "r1115",
      "r1117",
      "r1123",
      "r1126",
      "r1128",
      "r1129",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1326"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1053",
      "r1054",
      "r1056",
      "r1058",
      "r1115",
      "r1117",
      "r1123",
      "r1126",
      "r1128",
      "r1129",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1326"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Investments",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "verboseLabel": "Carrying value",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r956",
      "r1318",
      "r1319",
      "r1320",
      "r1323"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments:",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1707",
      "r1708",
      "r1712",
      "r1714",
      "r1715",
      "r1716",
      "r1717"
     ]
    },
    "dna_IssuanceOfCommonStockForAcquisitionRetentionPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "IssuanceOfCommonStockForAcquisitionRetentionPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for retention payments related to business and asset acquisitions",
        "label": "Issuance Of Common Stock For Acquisition Retention Payments",
        "documentation": "Issuance Of Common Stock For Acquisition Retention Payments"
       }
      }
     },
     "auth_ref": []
    },
    "dna_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Lab Equipment [Member]",
        "documentation": "Lab equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1636",
      "r1637"
     ]
    },
    "dna_LeaseAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "LeaseAssetsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Assets",
        "label": "Lease Assets [Member]",
        "documentation": "Lease Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "terseLabel": "Carrying cost of excess space (net of sublease income)",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r1297"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components Lease Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1722"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r850"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r851"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r851"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dna_LesseeOperatingLeaseAreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "LesseeOperatingLeaseAreaOfRealEstateProperty",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased facility, square feet",
        "label": "Lessee, Operating Lease, Area Of Real Estate Property",
        "documentation": "Lessee, Operating Lease, Area Of Real Estate Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r1296"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1723"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dna_LesseeOperatingLeaseNumberOfExtensionOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "LesseeOperatingLeaseNumberOfExtensionOptions",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of extension options",
        "label": "Lessee, Operating Lease, Number Of Extension Options",
        "documentation": "Lessee, Operating Lease, Number Of Extension Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, option to extend (in years)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1720"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1720"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r83",
      "r234",
      "r236",
      "r237",
      "r372",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r740",
      "r745",
      "r746",
      "r814",
      "r1067",
      "r1187",
      "r1211",
      "r1337",
      "r1630",
      "r1727",
      "r1728"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r137",
      "r965",
      "r1298",
      "r1318",
      "r1319",
      "r1546",
      "r1550",
      "r1596",
      "r1718"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r187",
      "r234",
      "r236",
      "r237",
      "r372",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r740",
      "r745",
      "r746",
      "r814",
      "r1298",
      "r1630",
      "r1727",
      "r1728"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r1707"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "dna_DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r117",
      "r184",
      "r185"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r64",
      "r72",
      "r114",
      "r117",
      "r184",
      "r185"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Nature [Axis]",
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r463",
      "r464",
      "r465",
      "r468",
      "r605",
      "r1020",
      "r1208",
      "r1625",
      "r1626"
     ]
    },
    "dna_LossContingencyAmountRequiredToFund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "LossContingencyAmountRequiredToFund",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount required to fund",
        "label": "Loss Contingency, Amount Required To Fund",
        "documentation": "Loss Contingency, Amount Required To Fund"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Nature [Domain]",
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r463",
      "r464",
      "r465",
      "r468",
      "r605",
      "r1020",
      "r1208",
      "r1625",
      "r1626"
     ]
    },
    "us-gaap_LossOnContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossOnContracts",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on contracts",
        "label": "Loss on Contracts",
        "documentation": "Losses recognized in the current period on contracts which are expected to generate losses, which are probable and can be reasonably estimated, in a future period."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r517"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r1215",
      "r1218",
      "r1311",
      "r1316",
      "r1742",
      "r1744",
      "r1745",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761",
      "r1762",
      "r1763",
      "r1764",
      "r1765",
      "r1766",
      "r1767",
      "r1768",
      "r1769",
      "r1772",
      "r1773"
     ]
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and facilities",
        "label": "Manufacturing Facility [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "dna_MarketableEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "MarketableEquitySecuritiesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable equity securities",
        "label": "Marketable Equity Securities [Member]",
        "documentation": "Marketable Equity Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1479"
     ]
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Line Items]",
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Table]",
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r464",
      "r465",
      "r466",
      "r467",
      "r550",
      "r582",
      "r583",
      "r584",
      "r605",
      "r784",
      "r898",
      "r1004",
      "r1006",
      "r1020",
      "r1059",
      "r1060",
      "r1116",
      "r1122",
      "r1124",
      "r1125",
      "r1130",
      "r1143",
      "r1144",
      "r1146",
      "r1147",
      "r1163",
      "r1164",
      "r1198",
      "r1212",
      "r1230",
      "r1236",
      "r1243",
      "r1246",
      "r1288",
      "r1289",
      "r1293",
      "r1294",
      "r1312",
      "r1634",
      "r1729",
      "r1730",
      "r1731",
      "r1732",
      "r1733",
      "r1734"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1243",
      "r1246",
      "r1709",
      "r1710",
      "r1711"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Expected Term",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r1709",
      "r1710",
      "r1711"
     ]
    },
    "dna_MeasurementInputScenarioProbabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "MeasurementInputScenarioProbabilitiesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Scenario Probabilities",
        "label": "Measurement Input, Scenario Probabilities [Member]",
        "documentation": "Measurement Input, Scenario Probabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r782",
      "r783",
      "r784",
      "r1236",
      "r1243",
      "r1246",
      "r1288"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r1236",
      "r1243",
      "r1246",
      "r1288"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r464",
      "r465",
      "r466",
      "r467",
      "r550",
      "r582",
      "r583",
      "r584",
      "r605",
      "r784",
      "r898",
      "r1004",
      "r1006",
      "r1020",
      "r1059",
      "r1060",
      "r1116",
      "r1122",
      "r1124",
      "r1125",
      "r1130",
      "r1143",
      "r1144",
      "r1146",
      "r1147",
      "r1163",
      "r1164",
      "r1198",
      "r1212",
      "r1230",
      "r1236",
      "r1243",
      "r1246",
      "r1288",
      "r1289",
      "r1293",
      "r1312",
      "r1634",
      "r1729",
      "r1730",
      "r1731",
      "r1732",
      "r1733",
      "r1734"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1420"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1638",
      "r1639"
     ]
    },
    "dna_MotifFoodworksIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "MotifFoodworksIncMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motif FoodWorks, Inc.",
        "label": "Motif FoodWorks, Inc. [Member]",
        "documentation": "Motif FoodWorks, Inc.member"
       }
      }
     },
     "auth_ref": []
    },
    "dna_MotifMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "MotifMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motif FoodWorks",
        "label": "Motif [Member]",
        "documentation": "Motif [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r1215",
      "r1218",
      "r1311",
      "r1316",
      "r1742",
      "r1744",
      "r1745",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761",
      "r1762",
      "r1763",
      "r1764",
      "r1765",
      "r1766",
      "r1767",
      "r1768",
      "r1769",
      "r1772",
      "r1773"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r110"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r110",
      "r142",
      "r180",
      "r185",
      "r203",
      "r206",
      "r211",
      "r234",
      "r236",
      "r237",
      "r241",
      "r249",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r270",
      "r372",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r487",
      "r490",
      "r493",
      "r498",
      "r593",
      "r660",
      "r734",
      "r778",
      "r814",
      "r974",
      "r1089",
      "r1106",
      "r1107",
      "r1176",
      "r1178",
      "r1180",
      "r1335",
      "r1630"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r273"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r219",
      "r220",
      "r221",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r263",
      "r278",
      "r323",
      "r324",
      "r374",
      "r375",
      "r376",
      "r377",
      "r439",
      "r440",
      "r446",
      "r484",
      "r485",
      "r486",
      "r487",
      "r591",
      "r592",
      "r593",
      "r594",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r707",
      "r708",
      "r709",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r804",
      "r805",
      "r827",
      "r828",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1025"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r219",
      "r220",
      "r221",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r263",
      "r278",
      "r323",
      "r324",
      "r374",
      "r375",
      "r376",
      "r377",
      "r439",
      "r440",
      "r446",
      "r484",
      "r485",
      "r486",
      "r487",
      "r591",
      "r592",
      "r593",
      "r594",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r707",
      "r708",
      "r709",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r804",
      "r805",
      "r827",
      "r828",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1025"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dna_NewGinkgoPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NewGinkgoPreferredStockMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Ginkgo Preferred Stock",
        "label": "New Ginkgo Preferred Stock [Member]",
        "documentation": "New Ginkgo Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "dna_NonMarketableEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NonMarketableEquitySecuritiesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-marketable equity securities",
        "label": "Non Marketable Equity Securities [Member]",
        "documentation": "Non-marketable equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1363",
      "r1374",
      "r1384",
      "r1408",
      "r1417"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1391"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "dna_NoncashCustomerConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NoncashCustomerConsideration",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash customer consideration",
        "label": "Noncash Customer Consideration",
        "documentation": "Noncash Customer Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "dna_NoncashInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NoncashInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash in-process research and development",
        "label": "Noncash In Process Research And Development",
        "documentation": "Noncash In Process Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvotingCommonStockMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvoting Common Stock",
        "label": "Nonvoting Common Stock [Member]",
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesReceivableMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes Receivable",
        "label": "Notes Receivable [Member]",
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": []
    },
    "dna_NumberOFEstimatedMaterialRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NumberOFEstimatedMaterialRights",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of estimated material rights",
        "label": "Number OF Estimated Material Rights",
        "documentation": "Number OF Estimated Material Rights"
       }
      }
     },
     "auth_ref": []
    },
    "dna_NumberOfCompanyFounders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NumberOfCompanyFounders",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of company founders",
        "label": "Number Of Company Founders",
        "documentation": "Number Of Company Founders"
       }
      }
     },
     "auth_ref": []
    },
    "dna_NumberOfCoreAssets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NumberOfCoreAssets",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of core assets",
        "label": "Number Of Core Assets",
        "documentation": "Number Of Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dna_NumberOfCoreOfferings": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NumberOfCoreOfferings",
     "presentation": [
      "http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of core offerings",
        "label": "Number Of Core Offerings",
        "documentation": "Number Of Core Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "dna_NumberOfEmployeesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NumberOfEmployeesAcquired",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees acquired",
        "label": "Number Of Employees Acquired",
        "documentation": "Number Of Employees Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1194",
      "r1567"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1189",
      "r1197",
      "r1567"
     ]
    },
    "dna_NumberOfStockPriceHurdles": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NumberOfStockPriceHurdles",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock price hurdles",
        "label": "Number Of Stock Price Hurdles",
        "documentation": "Number Of Stock Price Hurdles"
       }
      }
     },
     "auth_ref": []
    },
    "dna_NumberOfVestingConditions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "NumberOfVestingConditions",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of vesting conditions",
        "label": "Number Of Vesting Conditions",
        "documentation": "Number Of Vesting Conditions"
       }
      }
     },
     "auth_ref": []
    },
    "dna_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Customer",
        "label": "One Customer [Member]",
        "documentation": "One Customer"
       }
      }
     },
     "auth_ref": []
    },
    "dna_OneInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "OneInvestmentMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Investment",
        "label": "One Investment [Member]",
        "documentation": "One Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and operating expenses:",
        "label": "Operating Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r1180"
     ]
    },
    "dna_OperatingExpensesNotAllocatedToSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "OperatingExpensesNotAllocatedToSegmentsAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciling items to reconcile total segment operating loss to loss before income taxes:",
        "label": "Operating expenses not allocated to segments abstract",
        "documentation": "Operating expenses not allocated to segments abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "terseLabel": "Total segment operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r1176",
      "r1180",
      "r1188",
      "r1561",
      "r1568",
      "r1570",
      "r1571",
      "r1572"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r1297"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of lease assets",
        "verboseLabel": "Operating lease, impairment loss",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1719"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: current portion of lease liability",
        "verboseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets",
      "http://www.ginkgobioworks.com/role/LeasesScheduleofMaturityofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofOperatingLeasesSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r845"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1541"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate - operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r1297"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term - operating leases (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r1297"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r1193",
      "r1194"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/OrganizationandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Basis of Presentation",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r131",
      "r1544"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "dna_OtherAssetAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "OtherAssetAcquisitionsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Acquisitions",
        "label": "Other Asset Acquisitions [Member]",
        "documentation": "Other Asset Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment to fund additional losses on equity method investments",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": [
      "r1547",
      "r1553",
      "r1737"
     ]
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Axis]",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Domain]",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on available-for-sale securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r19",
      "r132"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r19",
      "r132"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r975"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary",
        "terseLabel": "Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r9",
      "r91",
      "r202",
      "r819"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss)",
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r19",
      "r132",
      "r204",
      "r207",
      "r258"
     ]
    },
    "dna_OtherEquityInvesteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "OtherEquityInvesteeMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Equity Investee [Member]",
        "label": "Other Equity Investee [Member]",
        "documentation": "Other Equity Investee"
       }
      }
     },
     "auth_ref": []
    },
    "dna_OtherEquityInvesteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "OtherEquityInvesteesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other equity investees",
        "label": "Other Equity Investees [Member]",
        "documentation": "Other Equity Investees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_OtherEquityInvestessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "OtherEquityInvestessMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Equity Investess [Member]",
        "documentation": "Other Equity Investess [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-cash activity",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "negatedTerseLabel": "Other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r1281"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income, net",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "dna_OtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "OtherRevenueMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Revenue",
        "label": "Other Revenue [Member]",
        "documentation": "Other Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1361",
      "r1372",
      "r1382",
      "r1415"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1364",
      "r1375",
      "r1385",
      "r1418"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1364",
      "r1375",
      "r1385",
      "r1418"
     ]
    },
    "dna_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Patent Costs [Policy Text Block]",
        "documentation": "Patent costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1389"
     ]
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contingent consideration payment",
        "terseLabel": "Contingent consideration payment",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Payment for (Proceeds from) Other Investing Activity",
        "documentation": "Amount of cash (inflow) outflow from investing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1461",
      "r1538"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r1539"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, consideration transferred",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of equity issuance costs and other",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of issuance costs related to ATM offering",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable debt securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r222",
      "r332"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to Acquire Businesses, Gross",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r713",
      "r1236",
      "r1241",
      "r1276"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Business acquisitions, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deconsolidation of subsidiaries - cash",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of notes receivable",
        "terseLabel": "Purchases of notes receivable",
        "label": "Payments to Acquire Notes Receivable",
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1399"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1399"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1391"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1401"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "dna_PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of non-participation of combined voting power or value of all classes of stock",
        "label": "Percentage of Combined Voting Power or Value of All Classes of Stock Not Eligible to Participate",
        "documentation": "Percentage of combined voting power or value of all classes of stock not eligible to participate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "dna_PharmaceuticalAndBiotechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "PharmaceuticalAndBiotechnologyMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmaceutical and biotechnology",
        "label": "Pharmaceutical And Biotechnology [Member]",
        "documentation": "Pharmaceutical And Biotechnology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1392"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1448"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1391"
     ]
    },
    "dna_PreferredStockInvestmentImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "PreferredStockInvestmentImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock investment, impairment loss",
        "label": "Preferred Stock Investment, Impairment Loss",
        "documentation": "Preferred Stock Investment, Impairment Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r500"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1069"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r500"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1069",
      "r1088",
      "r1778",
      "r1779"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r489",
      "r495",
      "r961",
      "r1298"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1480"
     ]
    },
    "dna_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Warrants",
        "label": "Private Placement Warrants [Member]",
        "documentation": "Private Placement Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "dna_ProbabilityWeightedPresentValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ProbabilityWeightedPresentValueMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability-weighted present value",
        "label": "Probability-weighted present value [Member]",
        "documentation": "Probability-weighted present value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from ATM offering",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable debt securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r1577"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of marketable equity securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of marketable debt securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r222",
      "r332",
      "r363"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r23"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1636",
      "r1637"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Concentration Risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r1564"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r1175",
      "r1180",
      "r1215",
      "r1216"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r901",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1167",
      "r1175",
      "r1178",
      "r1180",
      "r1215",
      "r1216",
      "r1310",
      "r1312",
      "r1313",
      "r1317",
      "r1322",
      "r1462",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1521",
      "r1522",
      "r1523",
      "r1524",
      "r1525",
      "r1526",
      "r1527",
      "r1528",
      "r1529",
      "r1530",
      "r1531",
      "r1532",
      "r1534",
      "r1535",
      "r1536",
      "r1537",
      "r1627",
      "r1628",
      "r1742",
      "r1744",
      "r1745",
      "r1746",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761",
      "r1762",
      "r1763",
      "r1764",
      "r1765",
      "r1766",
      "r1767",
      "r1768",
      "r1769",
      "r1772",
      "r1773"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r901",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1167",
      "r1175",
      "r1178",
      "r1180",
      "r1215",
      "r1216",
      "r1310",
      "r1312",
      "r1313",
      "r1317",
      "r1322",
      "r1462",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1521",
      "r1522",
      "r1523",
      "r1524",
      "r1525",
      "r1526",
      "r1527",
      "r1528",
      "r1529",
      "r1530",
      "r1531",
      "r1532",
      "r1534",
      "r1535",
      "r1536",
      "r1537",
      "r1627",
      "r1628",
      "r1742",
      "r1744",
      "r1745",
      "r1746",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761",
      "r1762",
      "r1763",
      "r1764",
      "r1765",
      "r1766",
      "r1767",
      "r1768",
      "r1769",
      "r1772",
      "r1773"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r185",
      "r203",
      "r206",
      "r226",
      "r234",
      "r236",
      "r237",
      "r241",
      "r249",
      "r258",
      "r261",
      "r262",
      "r372",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r487",
      "r593",
      "r660",
      "r734",
      "r738",
      "r741",
      "r742",
      "r778",
      "r814",
      "r943",
      "r945",
      "r973",
      "r1037",
      "r1089",
      "r1106",
      "r1107",
      "r1279",
      "r1280",
      "r1336",
      "r1492",
      "r1630"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r850"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property, plant, and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r189",
      "r969"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r850",
      "r951",
      "r969",
      "r1298"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r156",
      "r159",
      "r967"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesTables",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r850"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "dna_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Warrants",
        "label": "Public Warrants [Member]",
        "documentation": "Public Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "dna_PurchaseOfNonCashMarketableEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "PurchaseOfNonCashMarketableEquitySecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities and warrants received for Cell Engineering services",
        "label": "Purchase Of Non Cash Marketable Equity Securities",
        "documentation": "Purchase Of Non Cash Marketable Equity Securities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1389"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1389"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r464",
      "r465",
      "r466",
      "r467",
      "r536",
      "r550",
      "r582",
      "r583",
      "r584",
      "r590",
      "r605",
      "r784",
      "r872",
      "r881",
      "r898",
      "r1004",
      "r1006",
      "r1020",
      "r1059",
      "r1060",
      "r1116",
      "r1122",
      "r1124",
      "r1125",
      "r1130",
      "r1143",
      "r1144",
      "r1146",
      "r1147",
      "r1163",
      "r1164",
      "r1198",
      "r1212",
      "r1230",
      "r1236",
      "r1243",
      "r1246",
      "r1288",
      "r1289",
      "r1293",
      "r1294",
      "r1312",
      "r1326",
      "r1622",
      "r1634",
      "r1710",
      "r1730",
      "r1731",
      "r1732",
      "r1733",
      "r1734"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r464",
      "r465",
      "r466",
      "r467",
      "r536",
      "r550",
      "r582",
      "r583",
      "r584",
      "r590",
      "r605",
      "r784",
      "r872",
      "r881",
      "r898",
      "r1004",
      "r1006",
      "r1020",
      "r1059",
      "r1060",
      "r1116",
      "r1122",
      "r1124",
      "r1125",
      "r1130",
      "r1143",
      "r1144",
      "r1146",
      "r1147",
      "r1163",
      "r1164",
      "r1198",
      "r1212",
      "r1230",
      "r1236",
      "r1243",
      "r1246",
      "r1288",
      "r1289",
      "r1293",
      "r1294",
      "r1312",
      "r1326",
      "r1622",
      "r1634",
      "r1710",
      "r1730",
      "r1731",
      "r1732",
      "r1733",
      "r1734"
     ]
    },
    "us-gaap_ReceivablesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes receivable",
        "label": "Receivables, Fair Value Disclosure",
        "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r807",
      "r808",
      "r809",
      "r812",
      "r1707",
      "r1708",
      "r1712"
     ]
    },
    "us-gaap_ReceivablesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Receivable",
        "label": "Receivables, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1356",
      "r1367",
      "r1377",
      "r1410"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r240",
      "r241",
      "r325",
      "r543",
      "r547",
      "r858",
      "r859",
      "r959",
      "r966",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1087",
      "r1114",
      "r1777"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r240",
      "r241",
      "r858",
      "r859",
      "r860",
      "r861",
      "r959",
      "r966",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1087",
      "r1114"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r240",
      "r241",
      "r325",
      "r543",
      "r547",
      "r858",
      "r859",
      "r959",
      "r966",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1087",
      "r1114",
      "r1726",
      "r1777"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r242",
      "r243",
      "r481",
      "r502",
      "r861",
      "r882",
      "r954",
      "r1171",
      "r1172",
      "r1173",
      "r1481",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1700",
      "r1701",
      "r1702",
      "r1703"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1165",
      "r1176",
      "r1177",
      "r1193",
      "r1735"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment research and development expense",
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1674"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1357",
      "r1368",
      "r1378",
      "r1411"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1358",
      "r1369",
      "r1379",
      "r1412"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1365",
      "r1376",
      "r1386",
      "r1419"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restricted cash, beginning of year",
        "periodEndLabel": "Restricted cash, end of year",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1476",
      "r1543",
      "r1736",
      "r1739"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash included in prepaid expenses and other current assets",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1476",
      "r1543"
     ]
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash included in other non-current assets",
        "label": "Restricted Cash Equivalent, Noncurrent",
        "documentation": "Amount of cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r1148",
      "r1149",
      "r1478",
      "r1543"
     ]
    },
    "us-gaap_RestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeiture of restricted stock (in shares)",
        "label": "Restricted Stock Award, Forfeitures",
        "documentation": "The total value of forfeitures related to restricted stock awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r125"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Escrow Shares",
        "netLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1560",
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Restructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r450",
      "r453",
      "r458"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, expected cost",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r452",
      "r455",
      "r457"
     ]
    },
    "dna_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, expected number of positions eliminated, percent (more than)",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent",
        "documentation": "Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails",
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Expenses incurred",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r214",
      "r216",
      "r454",
      "r455",
      "r1177",
      "r1623"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r216",
      "r449",
      "r450",
      "r455",
      "r456",
      "r1177"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails",
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring related impairment charges",
        "label": "Restructuring Costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostsAndAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofRestructuringChargesDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring charges",
        "terseLabel": "Total restructuring",
        "label": "Restructuring Costs and Asset Impairment Charges",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1453",
      "r1454"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability balance at December 31, 2025",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r456"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r125",
      "r964",
      "r1014",
      "r1019",
      "r1035",
      "r1070",
      "r1298"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r179",
      "r180",
      "r245",
      "r246",
      "r247",
      "r250",
      "r258",
      "r260",
      "r262",
      "r374",
      "r377",
      "r440",
      "r486",
      "r593",
      "r639",
      "r640",
      "r656",
      "r657",
      "r658",
      "r661",
      "r733",
      "r734",
      "r754",
      "r757",
      "r758",
      "r761",
      "r776",
      "r827",
      "r830",
      "r1010",
      "r1012",
      "r1038",
      "r1778"
     ]
    },
    "dna_ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Return of investment in equity securities for reduction in deferred revenue",
        "label": "Return Of Investment In Equity Securities For Reduction In Deferred Revenue",
        "documentation": "Return Of Investment In Equity Securities For Reduction In Deferred Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r279",
      "r294",
      "r295",
      "r309",
      "r315",
      "r318",
      "r320",
      "r322",
      "r530",
      "r531",
      "r532",
      "r901",
      "r1176",
      "r1180"
     ]
    },
    "dna_RevenueFromContractWithCustomerExcludingAssessedTaxNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxNoncash",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized as non cash consideration",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax, Noncash",
        "documentation": "Revenue from Contract with Customer, Excluding Assessed Tax, Noncash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r1563",
      "r1564"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r535"
     ]
    },
    "dna_RevenuePerformanceObligationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "RevenuePerformanceObligationAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Performance Obligation [Axis]",
        "label": "Revenue Performance Obligation [Axis]",
        "documentation": "Revenue Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "dna_RevenuePerformanceObligationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "RevenuePerformanceObligationDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Performance Obligation [Domain]",
        "label": "Revenue Performance Obligation [Domain]",
        "documentation": "Revenue Performance Obligation [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue remaining performance obligation amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU Asset obtained in exchange for new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r1297"
     ]
    },
    "dna_RoyaltyReceivedFromLicenseOrSaleOfAProduct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "RoyaltyReceivedFromLicenseOrSaleOfAProduct",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty received from license or sale of a product",
        "label": "Royalty Received From License Or Sale Of a Product",
        "documentation": "Royalty Received From License Or Sale Of a Product"
       }
      }
     },
     "auth_ref": []
    },
    "dna_RoyaltyReceivedFromLicensingRevenue": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "RoyaltyReceivedFromLicensingRevenue",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty received from licensing revenue",
        "label": "Royalty Received From Licensing Revenue",
        "documentation": "Royalty Received From Licensing Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "stpr_SC": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "SC",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "South Carolina",
        "label": "SOUTH CAROLINA"
       }
      }
     },
     "auth_ref": []
    },
    "dna_SafeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SafeMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAFE",
        "label": "SAFE [Member]",
        "documentation": "SAFE"
       }
      }
     },
     "auth_ref": []
    },
    "dna_SafesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SafesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAFEs",
        "label": "SAFEs [Member]",
        "documentation": "SAFEs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_SaleOfStockAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SaleOfStockAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, authorized amount",
        "label": "Sale Of Stock, Authorized Amount",
        "documentation": "Sale Of Stock, Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "dna_SalesAgreementWithAllenCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SalesAgreementWithAllenCompanyLLCMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement with Allen &amp; Company LLC",
        "label": "Sales Agreement with Allen &amp; Company LLC [Member]",
        "documentation": "Sales Agreement with Allen &amp; Company LLC"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r263",
      "r551",
      "r1455"
     ]
    },
    "dna_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]",
        "documentation": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Anti-Dilutive Shares",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]",
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r665",
      "r666",
      "r667",
      "r668",
      "r674",
      "r675",
      "r676",
      "r677",
      "r683",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r722",
      "r723",
      "r724",
      "r728",
      "r1236",
      "r1246",
      "r1685",
      "r1688",
      "r1690"
     ]
    },
    "us-gaap_ScheduleOfCapitalizationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCapitalizationTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Capitalization",
        "label": "Schedule of Capitalization [Table Text Block]",
        "documentation": "Tabular disclosure of the capitalization of the entity comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTables",
      "http://www.ginkgobioworks.com/role/LeasesTables",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leases Supplemental Cash Flow Information",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesBalanceSheetDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "dna_ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved For Future Issuances",
        "label": "Schedule Of Common Stock Reserved For Future Issuances [Table Text Block]",
        "documentation": "Tabular disclosure of common stock reserved for future issuances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Income Taxes Expenses (Benefit) Incurred During the Period",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1676"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Taxes Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1670"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1559"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of the Statutory Corporate Income Tax Rate to the Effective Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r1235",
      "r1667"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-based Compensation",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails",
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails",
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r371",
      "r652",
      "r814",
      "r1456",
      "r1457",
      "r1458",
      "r1679",
      "r1680",
      "r1681",
      "r1682"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r237",
      "r368",
      "r369",
      "r371",
      "r372",
      "r814"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsCarryingValuesofEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Table]",
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r234",
      "r237",
      "r368",
      "r369",
      "r371",
      "r372",
      "r814"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets and Liabilities That Are Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1707",
      "r1708"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r431",
      "r434",
      "r435",
      "r437",
      "r902",
      "r1165",
      "r1169",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r1207"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r1207",
      "r1599",
      "r1600",
      "r1601",
      "r1602",
      "r1603",
      "r1604",
      "r1605",
      "r1606",
      "r1607",
      "r1608",
      "r1609"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Loss Before Provision for Incomes Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1546",
      "r1551"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r1598",
      "r1610"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Income [Line Items]",
        "label": "Net Investment Income [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Investment Income Reported Amounts By Category [Table]",
        "label": "Investment Income [Table]",
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r102",
      "r976"
     ]
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested Performance-Based Units Activity",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationSummaryofPropertyandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r850"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/OrganizationConsolidationandPresentationofFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Condensed Consolidated Balance Sheets",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1724",
      "r1725"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restrictions on Cash and Cash Equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r133",
      "r1739"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringNarrativeDetails",
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r119"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r555",
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r590"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of RSU and RSA Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r127"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r123",
      "r124",
      "r125",
      "r196",
      "r197",
      "r198",
      "r281",
      "r500",
      "r501",
      "r502",
      "r504",
      "r507",
      "r512",
      "r514",
      "r751",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1212",
      "r1452",
      "r1546",
      "r1548"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1341"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r279",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r322",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r452",
      "r457",
      "r721",
      "r724",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1190",
      "r1193",
      "r1194",
      "r1207",
      "r1315",
      "r1742",
      "r1744",
      "r1745",
      "r1746",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761",
      "r1762",
      "r1763",
      "r1764",
      "r1765",
      "r1766",
      "r1767",
      "r1768",
      "r1769",
      "r1772",
      "r1773"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r320",
      "r321",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r943",
      "r944",
      "r945",
      "r946",
      "r1052",
      "r1055",
      "r1057",
      "r1117",
      "r1123",
      "r1128",
      "r1132",
      "r1143",
      "r1145",
      "r1146",
      "r1147",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1168",
      "r1185",
      "r1215",
      "r1217",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1314",
      "r1326",
      "r1742",
      "r1744",
      "r1745",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761",
      "r1762",
      "r1763",
      "r1764",
      "r1765",
      "r1766",
      "r1767",
      "r1768",
      "r1769",
      "r1772",
      "r1773"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r279",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r305",
      "r307",
      "r308",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r1189",
      "r1191",
      "r1192",
      "r1193",
      "r1195",
      "r1196",
      "r1197"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationOperatingIncomeLossAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment operating (loss) income:",
        "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationRevenueAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_SeniorSecuredNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SeniorSecuredNoteMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Secured Note",
        "label": "Senior Secured Note [Member]",
        "documentation": "Senior Secured Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "dna_SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs related to ATM offering included in accounts payable and accrued expenses",
        "label": "Series E convertible preferred stock issuance costs included in accrued expenses",
        "documentation": "Series E convertible preferred stock issuance costs included in accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r1175",
      "r1180",
      "r1215",
      "r1216"
     ]
    },
    "dna_SettlementOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SettlementOfContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued as settlement of contingent consideration liabilities",
        "label": "Settlement Of Contingent Consideration",
        "documentation": "Settlement Of Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "dna_SettlementOfContingentConsiderationSharesRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SettlementOfContingentConsiderationSharesRestrictedStock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of contingent consideration (in shares)",
        "label": "Settlement Of Contingent Consideration, Shares, Restricted Stock",
        "documentation": "Settlement Of Contingent Consideration, Shares, Restricted Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dna_SettlementOfContingentConsiderationValueRestrictedStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SettlementOfContingentConsiderationValueRestrictedStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of contingent consideration",
        "label": "Settlement Of Contingent Consideration, Value, Restricted Stock",
        "documentation": "Settlement Of Contingent Consideration, Value, Restricted Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested beginning period (in shares)",
        "periodEndLabel": "Nonvested ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested beginning balance (in dollars per share)",
        "periodEndLabel": "Nonvested ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suboptimal exercise multiple",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Suboptimal Exercise Multiple",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Suboptimal Exercise Multiple"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r555",
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r590"
     ]
    },
    "dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, number of annual installments",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Annual Installments",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Annual Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares to be issued pursuant to awards granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosureAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosure [Abstract]",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1646"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1646"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants in period, exercise price (in dollars per share)",
        "verboseLabel": "Options, grants in period, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, grants in period, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, options vested, percentage",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Vested, Percentage",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Vested, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award, percentage of outstanding stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r1666"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "dna_ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement, common stock reserved for issuance, automatic increase term",
        "label": "Share-Based Compensation Arrangement, Common Stock Reserved For Issuance, Increase, Term",
        "documentation": "Share-Based Compensation Arrangement, Common Stock Reserved For Issuance, Increase, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardFounderOptionsValuationAssumptionsDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSharebasedPaymentArrangementRestrictedStockUnitActivityDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofActivityForEarnoutRSADetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dna_ShareBasedCompensationAwardTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ShareBasedCompensationAwardTrancheFourMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "800 Then 25%",
        "label": "Share Based Compensation Award Tranche Four Member",
        "documentation": "Share based compensation award tranche four member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "500 Then 25%",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "700 Then 25%",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "600 Then 25%",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r560",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award vesting rights, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1640"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1232"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of vested stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax withholdings related to net share settlement of equity awards (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1666"
     ]
    },
    "dna_SharesReleaseFromEscrowDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SharesReleaseFromEscrowDuringPeriod",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares release from escrow during period",
        "label": "Shares Release From Escrow During Period",
        "documentation": "Shares Release From Escrow During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortDurationContractsDiscountedLiabilitiesDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortDurationContractsDiscountedLiabilitiesDiscountRate",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable Input",
        "label": "Short-Duration Contract, Discounted Liability, Discount Rate",
        "documentation": "Discount rate used to obtain present value of liability for unpaid claim and claim adjustment expense for short-duration contract issued by insurance entity."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_StateAndLocalTaxJurisdictionOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalTaxJurisdictionOtherMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTaxPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All other state and local",
        "label": "State and Local Tax Jurisdiction, Other [Member]",
        "documentation": "Designated state and local jurisdiction entitled to levy and collect income tax in country of domicile, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1542",
      "r1673"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockBasedCompensationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r183",
      "r279",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r322",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r442",
      "r452",
      "r457",
      "r721",
      "r724",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1190",
      "r1193",
      "r1194",
      "r1207",
      "r1315",
      "r1742",
      "r1744",
      "r1745",
      "r1746",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761",
      "r1762",
      "r1763",
      "r1764",
      "r1765",
      "r1766",
      "r1767",
      "r1768",
      "r1769",
      "r1772",
      "r1773"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/Cover",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCapitalizationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r196",
      "r197",
      "r198",
      "r234",
      "r237",
      "r268",
      "r269",
      "r271",
      "r273",
      "r281",
      "r282",
      "r372",
      "r470",
      "r473",
      "r474",
      "r475",
      "r479",
      "r480",
      "r488",
      "r489",
      "r491",
      "r492",
      "r494",
      "r497",
      "r500",
      "r501",
      "r504",
      "r507",
      "r514",
      "r814",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1069",
      "r1090",
      "r1108",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1452",
      "r1548",
      "r1549",
      "r1558"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r85",
      "r88",
      "r89",
      "r172",
      "r179",
      "r180",
      "r209",
      "r210",
      "r211",
      "r245",
      "r246",
      "r247",
      "r250",
      "r258",
      "r260",
      "r262",
      "r280",
      "r374",
      "r377",
      "r440",
      "r486",
      "r516",
      "r593",
      "r639",
      "r640",
      "r656",
      "r657",
      "r658",
      "r661",
      "r733",
      "r734",
      "r754",
      "r756",
      "r757",
      "r758",
      "r759",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r776",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r827",
      "r830",
      "r857",
      "r975",
      "r1010",
      "r1011",
      "r1012",
      "r1038",
      "r1108"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r320",
      "r321",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r943",
      "r944",
      "r945",
      "r946",
      "r1052",
      "r1055",
      "r1057",
      "r1117",
      "r1123",
      "r1128",
      "r1132",
      "r1143",
      "r1145",
      "r1146",
      "r1147",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1168",
      "r1185",
      "r1215",
      "r1217",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1314",
      "r1326",
      "r1742",
      "r1744",
      "r1745",
      "r1747",
      "r1748",
      "r1749",
      "r1750",
      "r1751",
      "r1752",
      "r1753",
      "r1754",
      "r1755",
      "r1756",
      "r1757",
      "r1758",
      "r1759",
      "r1760",
      "r1761",
      "r1762",
      "r1763",
      "r1764",
      "r1765",
      "r1766",
      "r1767",
      "r1768",
      "r1769",
      "r1772",
      "r1773"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r280",
      "r488",
      "r489",
      "r491",
      "r494",
      "r830",
      "r901",
      "r1026",
      "r1039",
      "r1050",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1069",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1091",
      "r1092",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1108",
      "r1178",
      "r1180",
      "r1327",
      "r1777"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r263",
      "r551",
      "r1455",
      "r1459"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r280",
      "r325",
      "r488",
      "r489",
      "r491",
      "r494",
      "r830",
      "r901",
      "r1026",
      "r1039",
      "r1050",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1069",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1091",
      "r1092",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1108",
      "r1178",
      "r1180",
      "r1327",
      "r1777"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1360",
      "r1371",
      "r1381",
      "r1414"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "dna_StockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "StockIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Stock Issuance Costs",
        "documentation": "Stock Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for business and asset acquisitions, net of issuance costs (in shares)",
        "terseLabel": "Issuance of common stock for a business and asset acquisition (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r125"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in exchange for services (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to public offering, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r84",
      "r85",
      "r125",
      "r1031",
      "r1108",
      "r1138"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise or vesting of equity awards (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r84",
      "r85",
      "r125"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r84",
      "r85",
      "r125",
      "r566"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for asset acquisitions",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r85",
      "r88",
      "r89",
      "r125"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeiture of restricted stock",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in exchange for services",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r84",
      "r85",
      "r125",
      "r1038",
      "r1108",
      "r1138",
      "r1336"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise or vesting of equity awards",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "dna_StockPurchaseAgreementPercentOfEquityInterestToBeReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "StockPurchaseAgreementPercentOfEquityInterestToBeReceived",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase agreement, percent of equity interest to be received",
        "label": "Stock Purchase Agreement, Percent Of Equity Interest To Be Received",
        "documentation": "Stock Purchase Agreement, Percent Of Equity Interest To Be Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets",
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r88",
      "r89",
      "r112",
      "r1071",
      "r1088",
      "r1109",
      "r1110",
      "r1298",
      "r1337",
      "r1546",
      "r1549",
      "r1550",
      "r1596",
      "r1718",
      "r1778"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r499",
      "r501",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r516",
      "r751",
      "r767",
      "r1111",
      "r1113",
      "r1142"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r1112"
     ]
    },
    "dna_StrategicCloudAndAIPartnershipWithGoogleCloudMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "StrategicCloudAndAIPartnershipWithGoogleCloudMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic Cloud and AI Partnership with Google Cloud",
        "label": "Strategic Cloud and AI Partnership with Google Cloud [Member]",
        "documentation": "Strategic Cloud and AI Partnership with Google Cloud"
       }
      }
     },
     "auth_ref": []
    },
    "dna_StridebioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "StridebioMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "StrideBio",
        "label": "StrideBio [Member]",
        "documentation": "StrideBio (Member)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "negatedTerseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r1297"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r864"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r864"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r864"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r864"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.ginkgobioworks.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r864"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r865"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dna_SummaryOfActivityForEarnoutRSATableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SummaryOfActivityForEarnoutRSATableTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity For Earnout RSA",
        "label": "Summary of Activity For Earnout RSA [Table Text Block]",
        "documentation": "Summary Of Earnout RSUs Table Text Block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Tax Assets Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1671"
     ]
    },
    "dna_SupplementalBalanceSheetInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SupplementalBalanceSheetInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Balance Sheet Information [Abstract]",
        "label": "Supplemental Balance Sheet Information [Abstract]",
        "documentation": "Supplemental Balance Sheet Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_SupplementalFinancialStatementInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SupplementalFinancialStatementInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Financial Statement Information [Abstract]",
        "documentation": "Supplemental Financial Statement Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SuretyBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SuretyBondMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surety Bond",
        "label": "Surety Bond [Member]",
        "documentation": "An obligation arising from a three-party agreement that legally binds together a principal who needs the bond, an obligee who requires the bond and a surety company that sells the bond."
       }
      }
     },
     "auth_ref": []
    },
    "dna_SynlogicIncWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SynlogicIncWarrantMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/InvestmentsandEquityMethodInvestmentsScheduleofInvestmentsandEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Synlogic warrants",
        "label": "Synlogic, Inc. Warrant [Member]",
        "documentation": "Synlogic, Inc. warrant."
       }
      }
     },
     "auth_ref": []
    },
    "dna_SynlogicIncWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "SynlogicIncWarrantsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Synlogic, Inc. warrants",
        "label": "Synlogic, Inc. Warrants [Member]",
        "documentation": "Synlogic, Inc. Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1407"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r116"
     ]
    },
    "dna_TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SupplementalFinancialInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of facilities",
        "label": "Tangible Asset Impairment, Number Of Facilities With Impaired Equipment",
        "documentation": "Tangible Asset Impairment, Number Of Facilities With Impaired Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1399"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1406"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1429"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ginkgobioworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r483",
      "r512",
      "r751",
      "r766",
      "r803",
      "r813",
      "r816",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r953",
      "r976",
      "r1284",
      "r1286",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1299",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1706",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1430"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1429"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1429"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1432"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1430"
     ]
    },
    "dna_TwoThousandAndEighteenTechnicalDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "TwoThousandAndEighteenTechnicalDevelopmentAgreementMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Thousand And Eighteen Technical Development Agreement",
        "label": "Two Thousand And Eighteen Technical Development Agreement [Member]",
        "documentation": "Two Thousand And Eighteen Technical Development Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Employee Stock Purchase Plan",
        "label": "Two Thousand and Twenty One Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand and twenty one employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "dna_TwoThousandAndTwentyOneIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "TwoThousandAndTwentyOneIncentiveAwardPlanMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Incentive Award Plan",
        "label": "Two Thousand and Twenty One Incentive Award Plan [Member]",
        "documentation": "Two thousand and twenty one incentive award plan."
       }
      }
     },
     "auth_ref": []
    },
    "dna_TwoThousandTwentyTwoInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "TwoThousandTwentyTwoInducementPlanMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Inducement Plan Member",
        "label": "Two Thousand Twenty Two Inducement Plan [Member]",
        "documentation": "Two Thousand Twenty Two Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RestructuringSummaryofChangesinAccruedLiabilityBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r216",
      "r449",
      "r450",
      "r455",
      "r456",
      "r1177"
     ]
    },
    "dna_TypesOfTimeBasedStockOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "TypesOfTimeBasedStockOptions",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of time-based stock options",
        "label": "Types Of Time-Based Stock Options",
        "documentation": "Types Of Time-Based Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Treasury and Government",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1223",
      "r1225",
      "r1299",
      "r1321",
      "r1771"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Treasury Securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1183",
      "r1223",
      "r1225",
      "r1227",
      "r1284",
      "r1738"
     ]
    },
    "us-gaap_UnbilledContractsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnbilledContractsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled contracts receivable",
        "label": "Unbilled Contracts Receivable",
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1426"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r625",
      "r1234"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, Income tax penalties and interest accrued",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r1234"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded unconditional purchase obligation, year five",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Five",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r1721"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded unconditional purchase obligation, year one",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r1721"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded unconditional purchase obligation, year four",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r1721"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded unconditional purchase obligation, year two",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r1721"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded unconditional purchase obligation, year three",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r1721"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded unconditional purchase obligation",
        "label": "Unrecorded Unconditional Purchase Obligation",
        "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r1721"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecordedUnconditionalPurchaseObligationPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded unconditional purchase obligation, purchases",
        "label": "Unrecorded Unconditional Purchase Obligation, Purchases",
        "documentation": "The amount purchased during the period under an unrecorded unconditional purchase obligation (for example, under the take-or-pay or throughput contract)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecordedUnconditionalPurchaseObligationTerm",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded unconditional purchase obligation, term (in years)",
        "label": "Unrecorded Unconditional Purchase Obligation, Term",
        "documentation": "Term of the unrecognized unconditional purchase obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "dna_UnrecordedUnconditionalPurchaseObligationToBePaidYearSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "UnrecordedUnconditionalPurchaseObligationToBePaidYearSix",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded unconditional purchase obligation, to be paid, year six",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Six",
        "documentation": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Six"
       }
      }
     },
     "auth_ref": []
    },
    "dna_UpfrontAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "UpfrontAmountReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront amount received",
        "label": "Upfront Amount Received",
        "documentation": "Upfront amount received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r283",
      "r286",
      "r287",
      "r288",
      "r943",
      "r945",
      "r1186"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ginkgobioworks.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.ginkgobioworks.com/role/IncomeTaxesSummaryofDeferredTaxAssetsValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions (Subtractions)",
        "verboseLabel": "Valuation allowance, deferred tax asset, increase (decrease), amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r1236",
      "r1246",
      "r1288",
      "r1711"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted cash flow",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1207",
      "r1288",
      "r1709",
      "r1710",
      "r1711"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsQuantitativeInformationRegardingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r783",
      "r1236",
      "r1246",
      "r1288",
      "r1711"
     ]
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://www.ginkgobioworks.com/role/VariableInterestEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_VariableInterestEntityMeasureOfActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityMeasureOfActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Measure of Activity [Abstract]",
        "label": "Variable Interest Entity, Measure of Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ginkgobioworks.com/role/LeasesScheduleofComponentsofTotalLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r1297"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vehicles",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "dna_VerbBioticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "VerbBioticsMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/SignificantCollaborationTransactionswithRelatedPartiesstatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Verb Biotics",
        "label": "Verb Biotics [Member]",
        "documentation": "Verb Biotics member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1395"
     ]
    },
    "dna_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/FairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability",
        "label": "Warrant Liability [Member]",
        "documentation": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareSummaryofAntiDilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase Class A common stock",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1324",
      "r1325",
      "r1328",
      "r1329",
      "r1330",
      "r1331"
     ]
    },
    "dna_WarrantsToPurchaseClassACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "WarrantsToPurchaseClassACommonStockMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/StockholdersEquityScheduleofCommonStockReservedforFutureIssuancesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants To Purchase Class A Common Stock [Member]",
        "documentation": "Warrants To Purchase Class A Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r273"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.ginkgobioworks.com/role/NetLossperShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r273"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.ginkgobioworks.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dna_Year12Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "Year12Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year 1 - 2",
        "label": "Year 1 - 2 [Member]",
        "documentation": "Year 1 - 2"
       }
      }
     },
     "auth_ref": []
    },
    "dna_Year13Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "Year13Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year 1 - 3",
        "label": "Year 1 - 3 [Member]",
        "documentation": "Year 1 - 3"
       }
      }
     },
     "auth_ref": []
    },
    "dna_Year14Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "Year14Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year 1 - 4",
        "label": "Year 1 - 4 [Member]",
        "documentation": "Year 1 - 4"
       }
      }
     },
     "auth_ref": []
    },
    "dna_Year15Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "Year15Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year 1 - 5",
        "label": "Year 1 - 5 [Member]",
        "documentation": "Year 1 - 5"
       }
      }
     },
     "auth_ref": []
    },
    "dna_Year1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "Year1Member",
     "presentation": [
      "http://www.ginkgobioworks.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year 1",
        "label": "Year 1 [Member]",
        "documentation": "Year 1"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1393"
     ]
    },
    "dna_ZymergenBankruptcyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ZymergenBankruptcyMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zymergen Bankruptcy",
        "label": "Zymergen Bankruptcy [Member]",
        "documentation": "Zymergen Bankruptcy"
       }
      }
     },
     "auth_ref": []
    },
    "dna_ZymergenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ginkgobioworks.com/20251231",
     "localname": "ZymergenMember",
     "presentation": [
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresDeconsolidatedAssetsandLiabilitiesZymergenDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.ginkgobioworks.com/role/AcquisitionsandDivestituresResultsofOperationsDeconsolidationZymergenDetails",
      "http://www.ginkgobioworks.com/role/GoodwillandIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zymergen",
        "label": "Zymergen [Member]",
        "documentation": "Zymergen [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-16"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481774/310-40-40-7A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "44",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-44"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.2.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "605",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481187/605-35-45-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-70/tableOfContent"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-10/tableOfContent"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-5"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-20/tableOfContent"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-30/tableOfContent"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479326/805-40-45-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481724/830-30-40-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "79",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "80",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "45",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-45"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "46",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-46"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r1684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r1688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r1720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>147
<FILENAME>0001628280-26-012346-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-012346-xbrl.zip
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MKJC*OA]:(#%G%$>[]?J*X\B";<@1>.;-OH? QW:]66]S;W9BJ\BXY0$F(MP
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MR6K-S-RSX;DOQEA]L[_]E!^02:U5CL3,I=]U)*SU C=$EI6?EX;O+P(FY?6
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M;9WG7<E<CVV=$>N<\ZI39Z-GQSJ7?#/4V86#8YW+7FG2;/346.>E;TCO3\-
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MPRU^+0O(AD2;PVH[T=N'\6Q(WSBT(?8Y&\@X;G9.5MF(F4N_;R-L")06IK[
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M:<VF-K-I64K?.K3Y>3;]53SP*,1;T>"OP0H3;6I^W27M;QW^7O-K)?BU+#/
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M=X7*[SQ-0M@FO I6PFQ8AC.*^."7O;^\3*JCO??WK!]P1PR<"V3<,)8_OV-
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M @Z.' E,@'-4;P#X#8MG3^4CD_-'DGZLW^%'T#NAY_S04>_8YQP(D?3_@#?
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MJS S@,<4)0E%V,Q+A20,,#;BD^(AL8[QP\3%^PT2U!JPF0'KJ_X@.J"6=YC
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M;)BP""Q+;">"=E:6I[/O_%,DCLJ+5D(OB5$-*/,M!;;BF2SQAI9%<@(G 2Y
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MYG*9!A:5M% 7X-U-H0]OF#.C/TGD[">P(7FO2'^*=[V@Q %3/62R(^$5(UQ
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M7KSDMCQ^=/'%HW^9ABM)>J(1>C.2ZCR>K(7XSE(8V?^&"\6^XK3W+FJ\4*_
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M%,G?E!2A7]4>-(@D9!^3 P9&IY7T+577L M#;-4B#R@NW^:RP_M-1$XRJ56
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M6/<RL$G];4!S&6--/4\H&)QD*&$$31>1^(QD(%DJ9YW;'H)()A=)E68#R$.
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M3C(,E]O@].J[[44:BLV0&<!IQ,O^O+S<N/R1S>VK>8=&/4LW:^&#?7N$=$S
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M8A0*1%0ET'$;B4NA0H^[D%E'#7-DJ(GH!@7:? 9K=P3(L_'-UH@O%1QSGC#
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M"ICWUEM+9V8J;'WNZGK3]G!UK:'1\GW<C7X1X>)AZ4YD*$X;SYOD^: 18F-
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MX&: %N#OP=""CR46/:ALG:]K@DD(3:?O6HLH?+'NC)'+9XOXE:\KBG!P)<$
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M0=+M9L:8,Z(_'D 7N4MZU&=8/O0T3Z:*/#-%E"$%!VC,+@(X8&PU!A2P:*Y
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MBU"R;L1](_$; >FCJ*MN27 O"M*_.5$V&Y4O8UU\"%>J./'0HEV$HRQ5U"0
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ML!+<!3TU=\+RF1";4]>R2L-,@'!AUI+%POIVW*DHN*8$^N247!(<6]@,!Q8
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M82/2X4/0G$TX 9J)R(BEIERSB7QW/F[(.\XR_>0\,(J2XAGC2C^.C4=. ^L
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MM-?/9Z.B=Y\6)_A*"H/"X9=KL#3> _%JX)'@9XCMI&=<N7TQ>F];G,DO)W
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MZ2/_JV,&D.,!0I;KHC4MNIOGYO]'C,N@#HRC59)?*TG-'7^5(B@FYW"<%U&
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MQ8C#5,EU<183QPTA/^](B9/"?7=7-QGA&1$JLK"/2L=$Z2$"<A=WA?=]^2U
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M:< 3\@!*';^!;MA*J*T ?3XL[H:*GA9;!9W5/S7RZ=XRS4DO-F.&NE@Y</0
MEIDY9L<SC "YMMS+NRC:5H(7PM>N6+5A=F"]"D?:.,YQ6HS+6D^VO0$M!"7T
M97@0LQW"2.RTP/-W<G6XB2DVA4\(XQ66SDN_U,O!Z-M#4N2$O5(&"Q#V3]$R
M_4RO?)T1$9^,*B?69/+HF!)N!"S5:5/[KV*>.M&Q<0Y2Q?/YCQ\Q C]&V_!#
M% I^_A->Z8?;0X<M_CQA2WV/DCQ_!8O!9O&:E1WU_>+V15*K042H)W)=PA2!
MO.Q.R#/^F/(MY#T,"5K(2IU^IF"(5:[DGHN,,XKDVT"PQ GN=,S<9\ADBE*Y
MSRV<J4Q$D<E2Y6,)J 6B2?%'CXKE9+'\[RQ+S+5(.UWF*E/+LC&KA>I_*BVB
MYQVG7^SJWM,IBC&BV>@3,A=8ASVU+>\*M6ZQEX,;0UAMQSD3;;%J0^077JFT
M*$IAT>^!/.J+M!"+_'3';EOQ)EMLJV:95PGT8M72@LW1!EJP&=3V>%YD&)N.
M?545B^V+?)<HQKH5I.SQQN(N!)68 ?!2@C(MJ0A;-9B>7X#T<A2E9]1H%:2[
M(K,M 3ZTGG(PP;D-PQ-6 0Y5]&O%]\A819;ZN%99RK[J6Z!BP3M+ZJ@VT./$
M(@\@MDBT $Q3X 1/TR-)7'<Z8>*CQLT<!O12; V/\^E'EV+KI=AZAI;7@PB7
ML:?S@YS%JI3F,*9&]D6SIR2WI;OO;YNH_N<4LRSLZ5Z75=4)3QNY#^$L6XO\
M1H+8/RBB+H;]'RSY.4"HZP1KUM2V<Q!+;,9^A&*-CQ -DB0Z@V]?]I93"Y&\
MQ1ZO"NO%3XW:W-4X RJQ?E3W5J]^SA;CZLA")_(?I@>>4"(GXN!CLN1H?F=/
M)>>\_67Q?1YF974[$.M_N/'/+V^^7#RE-VO:NLSE%]0H]3<PO%?AQ@S]7;P,
M[_@+_X;/.?'[B$Q"\LDX5HE8EQI9:8 DK\C9@'!:48=5L0TOMP[3)&[:G,N5
MC=&5+@ 6;TR8#M2E\1[JKJ U:G00HP=4QS#\^D[E=6@B#M:$+#*Q=2-YUSH<
MQ:O"\6.I>GAX/?(;1-4JHF*Q>*"H)<V#UM(DQ;_HZ&KM#ZNFK)6BL*E]*TMT
MW!;<LT?^H6Z#&@]+"4W]N'KGV;$IL@'2.)^>QVX2DWWKLFN'/;?<I$V-80/W
M9:7Y-ZV\P^>,&T4\H+-&"8^9\$B< +X5-<;/Q15P,(7IOUY\]M'_FDR2,3_E
MW4@_COU888O]^*.//W.%$2O $%IN[KYTN42'\+:H]H09K5B2C.22L(Z-K W\
MTA:#B@)8O"#E!PXEI4Z/!%G";2H:E)4$AK$KSZN#F+<<^?%@ :CN'&(9RI=Z
M(Q?\7J%,*0Z-L)O8,\1')&MF0\$V,/RI<'Y[F(J<\E^1REF.+C\C.)I >H?6
M4N%*T1:6([?3S*PVGA5R/9:_C6*'[F5,7:V0S/5<P&>6C90^FF E4E+0QZ&I
M'<%QT>)TJ<^Y>_\%,S0@5[P^8O&W;7,/!&UB[4=15,:4["V=$+4&NTH>PM$3
M_<0QTQ6BJB0,D7 1AU((&$GA0KKTQ950D+N>IP:^B%MOF:]>;YF=&LFO"4<K
M>SBCK!KOBR;A]4ED&\#B2EFYH6TU$"/N:$<531-Q6ZH\3US>3;UL<G1JCQHX
MW!E"VL30- TN4E=&OG^MEB:DW*V,8UZ#A&^! M<J!U #VA,3"F^3/RE(NO(6
MIHQJ+NK%E7<E0?80'\>L4"+0;AD+,@1;Q6&$84S30E:MM+/H,>*$E$J6:#O<
M.)R#P6I(S58MKU9IE:Z/@2+>+\:_ZRYJ69AHW#ZL":;"C6X(9.8@5$RS?%>X
M?%.T5G/#'U,[OL@5 6X//!C,O$_^XKA:EP2-IW7!#0 N_>"S<8DG,$[ 6^^/
MWLKDIMDW:E^'U4[5EW";02JK9'&EBIUW_J&1WE.! _&_Q\9>&&L*/<20VC![
M?15,&CZ=Z*"7$):X<\2=<GM%"QVRHVF8N?R+\XN82_J^(&5BXI],[;8D^8YD
MM:-,A;"R*I_+.M7@E%4#4N8.C):T@,'K<I0<:?HJ)Z:45]38,4U-7!(FQ:+<
M\82E /MQVB/R"8=+>$ N\$5Y*JY*/O *7OPF66#O ZU3XD]Z7AIW!B5.LN(
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M/#NF57&T]<\WF1$O4AN_M*]W;C8G6AO<)"2%7#T^LG_&G8A0EZ-,*LPB>QZ
MND?2H7QC0_!C >*H>OL>P4A?,9U/<'WA[F,C$340<>0K;=&&C*G!]=6U4LP
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M5YKIH8;*(.'1BIYA83[7!V8K'#(X5@LRU#ULIP-8X9B-/[*)5=GXZL"X/7V
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MB64W;T#M,=2%)ZA[F;6@^^5"F]\6UTFF*U%7$FBZPKZ(Y6,G/?W8>38EV30
M1 B>\N@(HA:GAQ."FCQ[.3D^?I(R!P**H35.,Z/Q&<,9_+L,^!_)CF($"',7
M(%J0;U5$B&!&F4Y;&UQ9AUW17_U2WD@![AI@RFB];;36)L<#8U;N4N'ME27#
MID'LV/8WSN!GI1Q>8(&(J:J;P!W/JX&Y\P-\EWC2>Z9!(<.FI](2*3!R=ZY4
M"KGV_?-^C_4W8N4[XUC0"5QG.#QVMA9W=NW8=DTXCY4#SK/IR;G)32ZRSK\S
M\HN;D*=$(>^%18T*B!CM[9HCP9GQO,_N,'A-1SU-N^%[C \2K_KMU10BD3?M
MA2.<U():\(;R!@I>%=1/W(^K ^091/QS)A'/>Z)K6WK.7IV@<XJL=UI \R#E
MACNTJQ%.12D>4AJR&1"(><7R!O3"Q!="XT2#1QA,-NC<#"X-2(GX+86B0.E[
M7A0A9H<&(1&84H6,<RK<+I?Q7"D^2B7C:(SG=7H5]AT/ ,GN=O5,G4^2.Y$U
MQ'?'X6P>'%^GYW/7I/N ZU0T>CLO@-&3.\'FU-NTL>:#/JB>B8RM=_9;-O9=
MLI$_"U?&RGD*7=B8J[1I_7ORWRRR"H)/(R&/SHDA3H6_ =F9KF2W/B;Q3$OI
MZNM?TP4>R\P$4_T+DTK1T$5+(Y1310Q + C:%=D@"MI=,ZK3@HP,IH7>36G)
M! X8><P1":T-0>V,@JJL)N?N1B-.G2QVP/V*F+OK5.R0QM-Y.'+1, E19-R?
MS68(IO<F-)K)'GAOB"8?$Y @[0Z!KC)+:0H\UL:5W"CNRVYRHW+3ZR:%S8B0
M#Z*/*03&D(Y0U]LH*!.%08]B/+>:P@:-XKE5&?E%\5&E_8K]MR#[/[:3XZTW
MSY9VL8ATD&</!-9DD5Y6M70ZIZ'J%H7P!IC6:BMX>-Z(6%%.3*OS9A%[ DF5
M:()[+=9>@X10+>0#5,2BH0WDFL(@PYTV%P%FR[HJ2A$2^><&4\A('>'&H //
MC0$U5X=]T*A0,Y,\5&[DRUSIX19&9HP8O-Q\2,<+19 ;%Y?VLP>8!K67ULIP
M[2PE06W _R?/(TT9C%">>:YR=/AD&E2[Q>+>GQ&CX;;>?S#/[O8I/%NE&723
MY^8#DAK58I-E1Y@CHFCF(W[(F/5,%E-OL)+^MXQ5X5P4VJ6=WT.E*1!#<VBL
M!,MN:+*Y[C/F6\1UB'"M;)0?$L<P.4\ IVNF?B[<P^(-FC%%X'WC]W&!=0H!
MD\WODC=LB0MEO.#78I_"OQ,?>K[?0*,_ 'N)D(XL?IL1NS0-AT&H%[D&GA0-
ML^YW=&7QI\S#\2J;<2\#Q3-%SM0Q? >1H11Z"<"S&>5K5YYY>7;GP%XY%F :
MV^:'CG'N?>1$;- 41Q'QR_>1J5NCURU@T;AQ7]LB1ZR_S4[(%:?=_)S3$5A#
M SAEGS-IT;$[2G1",V75' &,> T!'CMTX/2"PRU>5M)SL5A$7FX=N5LQ%)C$
M1] ?&MD1$/?YPE1D<C@$VVS(8A=!%1\]"%,8Z9@^5,8=2:^$6>H&9ZQ.8-S!
M1IT M(;B%Y/PFBC24V)&=3$)[:JN9ADCT8'SP8YD5JE:2NQ.W*^E[6PAR!#(
MOAQC F0?>_?=]1ZE%XT:"9-KY@\Q\\ "6F(F2IJ _=\]]SDYF")EP,:FLPU=
M(W=0KB9_.?9XD%XWM+.L2!ENDHP*-\3WT#.,OKNOHU(=]6A?1]W747?0'HW'
M5]+8)54E-<^(FOI5K'#<<H)FN<K:G('[[+_,M,?;D[\L)&OCK<I:01>^]!&N
M2H57]%9UG(MWK@-3"1BRARC]$Z1LJKY5VME3(7*"HG:MY/.:M4)0JJT4P 22
M2";(!;1<%SR\F[5P::=F'-]O%23UGHMO1[],BRZS)5KS])';T_1\G<3W.6&=
M^ (.>56QJ!5\-2IF-EJ.8?9*E))5F31BLM26L8H[ "7<%$'KT<4G-$5+Y_"0
M[]ET#84Y$@52J)B6* GXNE6OAAH[BR.ZI268ZB_)?1]QO^("T,8^Y1,M6?KQ
ML@4];CO3H;;9;7ES$RS,JY#T"#1LD2LV.O>4QTV+4"S07=HKO?'S);UID:#'
MENU'^MA([30JG84K_S$:U+1_"DU-2 $;ABU&21A41J!)'NUE,)0TFT4?AN*/
MKUZ?) RVMSF]T&PK4=/N6M=?.XCH[F6/6JW),I_5U12>-@V:A)#(U+2,Y.CJ
M1G.H8FHOLB4(Q&-+'$^&4FO,6=AM;/+&R/\./==;_-E>YAW@;X\'YWDT!?(A
M!,G]G-8*'<AK6Z03KD/:V0F*9+6F *C)K[:=JK82%A.,<"/L^'NRWKL.1XA@
M%"5@WO@L?$MXG(]>/'NHY3O.0ID^7WL6N47-^5GW@R$VV?!(S>3,32/ACR9O
MDLD;_#_]SS_(>O[#?/30?-!>P6VE>;8 @S'8$\%[$I'\T,*8X7Q2$GM:&N>:
ML51?S$JG-U4QW[ LQI]B!#.S9,UKY:&7]^<5X2_R#WRTR-+&?$(&<D$1>R.?
M=),Z17.]+TIJ/,?@'((M4>/![MJ*]];%Z=&.C"\.4<,,6P3'>I%.LX(Y']+9
MQ_0</TI-'><O? ;FA*C$4=(\J:^G_+.KVA2GFFFA20*>.?']:VY#7N0KSP%,
MUZ_<%@WE%HMDY 96S_X[$+X(?&H$:SROF:GQ(IM]1!XTAK9Y*4(9'<;Y$5Q-
ME=)]!3<PZI19@5IR8,N47/%@S*W]E<*.,,4936CO_U?>RZ"\TSR?8U-'2J?#
M&33"U)[K4^KNSL/)2^0/U7;X6IZ '[$!PRST5H$ZUZ"2#>9PTY.(]B<HENLJ
M'1>9!]?#FX466*V0E-4S:@>L+V.WI)7ADZIZ#B@CB"W1:40H  !XZ^M(G,2>
MH0(P(:X]TV*IDQ,Z863:KC_]E".6W+[8=QEJ0R<C>F+PS+W[FZI"%?,>B.P$
MA966"Q\$QB0[,-MEY^8?0C BM+]"<C+/5AD:1HJU']U-J_\#UUYQ@8-Q&\>0
MS$6;E<(:9?6'$Z]BR=VU7B6B(;(;NK'EW6DDO4RK23] ^IEZUD1SSO4&/J@W
MD&Z8!;Y!$:*77Q\N&,D;:*QAN"!;L1\^.N=C$WI4^B%R(*)][B:DT8).-%!W
M*? X#948$[GV8>I*(2*5L-&R$\> NQF-7</6J.X6.>L9J]HJ-QW>3#--M-@O
MLO0RIXB]7!2P&<C!BY=M?._ S-DGA1^D5U2#V  )N*X-Q]VRR=-<L#!73RA8
M6>'QCRJ.VX0&"TP3V"%F-A&K+!B0U@KKA*2,?,W:8B6H*NC-.9=QYKQ%,E)K
MR5#5G+E/-3;\"G2 8I$-6M-GJ/CM+3E<B$X$+1$W''OIYE .'2V"JNZSY":\
M9C RG3-X(X.'IP>,BJ-@4(<N20::*W^AP;CURGVW0,)S%S?5::_"ZU;J/.,I
M6S.]9@AY>*#< CD_1\J!;)==NPBK/,^87TSQ.#..<T!(OB7'!0I>.5P&%[<-
M.5*=]6K,[IK$*['JZME%VH3$E[<3P2#854$'DS286F$0K".#7O)LI0*!E.4K
MGE7D>,;K+LCZF2RY:,50"U%@3<]#D@X$.O*L8@0/)V'R//_3JBI96B 9F4]-
M"V*0&&W-Y0%G'I1R+1H@*>EN?/2$.7'B+['O6\C4"7(*^1=_^F"WSV@U]LXI
MDU^-X!'TF%F\D#:>=>8:M[Y=_ZUJI(_V-=)]C?1.>,<_#\#-ZK; "-K\ZE;.
M@,V4 :-YV</)SPRH 2NF-C':.+6GSKN[?L!P!%OU<;^7D3OE09N\\[*O(<G[
M#,&A\B);5N7OC2)*$BXZ=^<).EUTY!E^FBG<DQ,Y1\][O66/'AZ9BWRHG=-6
ML$H2__*OAY/OY((GVJS)/7%K;8R\Q?G79&\43S/4E!G9K1^3L-*E?W%F?:&T
M$A4'HX<*CZ'/A;L'K2^)F0D+>$Y4G5*<C 4^I<>%U&!,ZW/O3BS:ZET\W]OL
M>4P3<41&6 $'I>\!%EO2B4%6H%=S040B3\-W7^:<A=5&+T[;B8R"<H<RS(#2
MMJ0V7JP9U*O_0FT2PHE,^%JP#H0)[$#@GX..DSRC%OE2CZ"@^FE(5K(R'HJK
MS/L?-+-8+P^N YJGQ?5CXF_F])/QH-Q;)KA2(D76YNR0JYM?NIEQ ^LIP?O+
M>,OTJ?J>GSG5[M#54U:M*:.-#X3B!Z3-##*1$'P&L8V[3O/RNMWA'P&5/0:+
M>$.,+J/4;Q%?&!440+$^T##5U_6M-AGEIJ%+J VRTFV]VQ95G%Z[ T;Z%7K[
MR(-\)9& ;<^+VRYTWDLZHAS>ZG3B$J$N$./4K1 >)QE9],+]T[EPB[S(I=)'
MX.=&F),5E>+S[?<75DN0<(G8 R[H)GP10,! Z4,\$]$[X#"M)%9Z2>YA%1M=
M;^Y5O+Y%K&C"O?*A&GD#,X?3&GM%.$DWT2IOH@B0'"-U_M#Y*/_U1 ,ZL5&)
MQ.3@Q=;_[+GQ+S)*@P:8.D=D?,AN8DC-0QAKYK?_H-HYSR<0;?_LTPHY]<*H
M9886^DLI8V@O50AOW5!XG3O.[B0BW(YGH H'NU@18VIH$B1$/XV4U=^)B+]C
M?1H_H4+&L;O;.YRM]#:^\56AU%0<#(Q'TZKZ:-GWM#$RY]86%S:LB9L!]5@5
MV1#R.%_(H^E!8^J53)*O_%*_FU!V;R9P  T"X;NM-E*=7>:D7TO6HKQ@I1-!
M#<I5).^!@I,[%='*VF"JUE6WE3/X!MY!56]S#O"TPO=A*PS(#VI.$;8R8MEE
M/+3WP&2ON:V=+[FT@6TGJ1(B2]C=-4:8,7!E!!2>CR6TWH\UZ*V%&8H^%]J8
MX[#]/(]TJ6E$F[;(ID5UE<D2H?5+U>F "@O=1DB2Q<PDQ(S@O"!!IPS+/DD0
M[:5EKT<]5PQ1;XR5KU&W/Z_J<Z_T(]U! ,*X$Z(J697*0__<095^0O^90A)I
M70ZH:CA@!#%)T,$*F$0&UJ"++R<B$SRX!1WVH(9;&B<URXQ5/T$#%,!W S(,
M"V R\64/K^C=A;3<D,"^<8_0)H8+P40(Q<7D/?:1YDLA^&$F7=3&Z2<*D\54
MZHI*;0[/UHCG['GP(F=VG*@[+RA-2 I/]#90-K37(7:7QJO6^!&D99*!<XF6
M5_:5R\F?F>LXBP8JX$:E-<0G6CD=JP6RD+N-F'L#XIM/H,8COST*A;H=YZ.(
MXEY9GU>0J#U8MJ<DEJ8;KFVTSNRN&9;<B'@L;JD7A!Z3@OX$A#I;AY1!-\Z>
M.)^W$]">(;_0O+FXR7-4(%3(6VH7<Z/0Y[T\107-BJKC%FO&LL3WXA7AM97D
MH=AE7S%.TJ;*T0%(!TM%)3WRXP,36# 85UYN.0%_=Y9XG2Z$_*PGV8H>=+JD
M<DU/X#XB>;RVOX!^<EX!N@M-9<A<8E0;++*:"V8*BS^BY&*S6O( ZL%QXSY[
M9[07,I4O@F:D>&Y"6>.O++**;7:.O8,#=HS'9G08@O\-0UEU+1LVYYP5VO;=
MYS,R&D.#3VU8EO'R>!#4X"(F-",?+6BC$B3MAC3"^FXJ^7!U49E3:,;*;6R9
MRJRE5N-05=HX(][/10U=87 H;*<+9U;05<_G4,L=H7EO,;071%2'K\AM&8<7
M63;:U'28DL?AMG0D<T5ME)+!6-1\V@I%<+4B1T@Z(WPXAQGK"QFNIW0"R]TX
M8IUW7G&ZSE1<L)QX<6HS3PK%"P,>1WWT5HRF75;DV-H0"SQ]$0])3"R"EG-Z
M//6R&N9<=-=VN_:R*R@AB#6K<2'#@ 6BR)_->L=M.(A9^\MY'N0GL8(@D^<)
M+]OP< ED!%-S'WK*BXJ2;#3WN*%YI7 _;?=?]S0WC:H+4Z"Y$ZFF. +P$7^;
MZ=HZSE8L33J8K#)KS(0G&1EFM_2XA\/)V?#XE(/3 Y72@&(4)DD2I\K82@C/
M!U>]>SR31""I>2*:!I)(SP)(E$J^N3]>9Q^18PHX3\VJA5\L^OO?K'$W.MSS
M<Z! LC+^S4'3866Q:@IH-N(P-?3 VO,P*.Q:Y'[8T%FPHDG?PL:3(G%09$UP
MA['SH/-ML!(]V\"6# O18DE#-$@&^UA<_M.^/DSUX>-]?7A?']Y!?_TJ4Q?#
M>BB#@"CTI'CB@XBO55A>V4=74CWD"C*OL:V'%\Y2%Y:F,_9O&G>JNJ,&B=@V
M>.J7>=TI 8L[OLD-)TN+6I5^.[BL9+:$78VEV 7]QK6OK'2_.Z@6!_IB<H&$
M#HJF6I*.8OB=;PN@K#VYUW55HOI*&S-G%' 8JRKX&61<%ZU0"*/5*#Q@D-7R
M&9R,-6R!@"H6SFC"PW$';)2MWLB_J^-F UL<F)$\5YLN5YRG\@E!<'752NE%
MD1"U*X:8ED'"_:/.._L$8I).2TN&PMT:_0A8D<MPVO0Q$R:N\JVK]<1DV[AR
MQ?$%"R33<_8DQ[RO3#D3YYD$=E@F8O72DR:1,7+&]2A<0@H4?#X4CR%5EKD8
MII@T,Z625%:;_DKSZY+/Q)8:;9D^;@;O:8,F<RT5Y#7:?T5B,@H'9'+Z5,("
M(:78E]J;O"\7U0_OZX8R R6N&#D-/'T/9+HB@4;C/HZYYS02/>\W47H=74V^
MZ\'T!5MUU=[W)Y(&AU,\"XZM/BJ%=U)4TQ2-=90LU<?AY%76K'*)V-F]9@PL
MN_O!3*6U\R29EY*).CD>VL0D0 ]0TWLL.=V9:8,Y#<KAY.VUII0!,+)YY5N4
MO39V,5I C:D8TKNPQ'PMB\7F _ 7W:8^[HZX3GJH7JOA*4_:Z_R1A6@F-=EB
M(]@\X!-H>N:-$I\(/*%L)CQ=T6>S"O=2-5X&>ZK]6/FEE&V6V5P$3D:523EB
M&ZD^#V=.ZR.EK@5*OX,JFG&TPGK.TV:[TX)5)! \S;\+P!848FG%F TBK7NE
M:!=D09B)NI<^7D_,(:J"U[6A-QJ>Q%4]\DP^+@?;5Q2EFF2P6GJ>@P#:DI8Y
M26-SBQ\R]/R/K,B9"4$Y_;M6\FZ354$#88Q,6VGWIM#!]N(=)I(W;^I5@L=]
MCM[J,RZ(3:%Y)+ ?U9$;Z'?5)C0=P6SD'+:%& Q8O\VG7$="1]L$N7D=!]YY
M&U?9:=ST;KT3S9._V^^:@0@!+O KVE.!+B=$I$HEG_0J7/:E_82#M%Y73'24
MA-*03<+-BI3JL.#'>!!I'@PK7CT01;]>IJ3NIE'.W<,3(H=&R >)$43F$!>I
M"KRWC:DUJV'DK>*\691=496>6!">.T,J5&B<SYV@NVU9FI5@"4#TC+1-?2-,
M[_Q"QIT:>F-VD/LY53HD'GQ9;>6!6=[=>L6)TK?:$],M%V%[TRHC+P]D"YEX
MT?.R!]^%*;M+D5)G2,%GVJ607W''C.<<0GIZ\$2>@$Y!$(NJCIZ'[5@A=AU[
M6*1/]%H#C,/4LP7R^=:AWR2@Y-"1282D_ $0N][/%T0.ZO[X@,V)I(-PFZSF
MF] KN7=<A\=/&[6WXL7"#-REXN(/EB>9>T<49F)/&*F "[$#_1@^9=  [)0U
M P-B>IK/Z5748U+TL=I7O\-K7WNW)*NA .])<S9TCE@@HG;/[.SV?6O[W_HA
M0!^E[?'M'HDE<Q-00Z]ELF+IA'ZJG7;:-*],_2$T^<1T@]6@UX=O26%-US;H
MQEP,23 2YAQ7'#Z?/^R8AV^%OUM,-4<@V/ L'B[;*^H2[ U2*"CTT&O3 <I=
M!N@D9C2US!/W!<S^^N2]8MF9OC/@H\+ V1&:+#,*?GT3I3..= XIY2\(&@*(
MT5T><&OQ6'K=CA$UA>3/$^-<R5\W/LJ5QJU"#(/$G@S]8+:D\;(_7QA\<N)(
MDF=LJM@ ^OS5\._,6@QHHL1_J(6$\HNL7VWY'(4VV:5LS!++WB+*H %.0]_H
M)W$%0<JL:_X0M-D6+N<["VS'B#[06 . 09Q>W_<>L?AP)UR/)T145Q#=FQ0,
M>ET3VIZA;&(PJF'+HA(YVER+$BC>T4]HH*8+O+K.I:0$4QOP<S-@>EJL+=]2
MJRV)5%Y5NR-V-=EHB[4IV6]9VV:H,Q5M8]R@J<"T+_V>NVNVXS16.&W8\1Q-
M-08K/V+4>P<K]QJQ"2PXD!F8N"%2PQ.$"(U->#"Y?'PJ)),H(#&LLRZP)86"
M#-VO2J'%:Y(FBQ*; EF/(!?*7>&'P7H1OA+*HN&O!<%]^NITN#,_>WO)^RG@
M(LP#C9=9GSXG&3X1H""<J=P Z"8+<]W.05_'+&Y%W]TE_+:K(\1Z+4B4WGF9
MN8FMEL0V&%R]4>LXY@:8]1&U31U.SL!\K:#FT,\RTD"2A(P0QP*ZHGST%J6+
M%4F!7RZ\XHEX-_MB+A5S'^^+N?MB[@[:I-BO+P.?<,)X,+9 ,=^$I6()4!#*
M1>24&6F-9VC=2T , 9NRAZ+H] 0Z(B53$/*%2)L *:L-I G&%=+6+=/"R!FP
MT,/(_BC*==D\M&.&RIJD9\9&8'=/F!C99Y56>_GEZ^+:I.<?<7IV<#"-GDM;
M,#_P%2(!V!Q.*Z?I0R.W]RN8.=-(>\H1@Q>*"KRR"+DP0DV65OK0)N^1HFQ[
M]S-P3(Z322B54LTF[RKQ:#\(M#$@QYKQ4$ISW#_"S?I [PA4-\U8_F],=K&?
MP6:0@NF9H$S]<M@]<0T_7+C,J###**B<ZX^!27F$9$:?R41;2BPT%FMG8]%V
MLRG<YD!(7G:S;QGXB1A:D']$P7!;Z9"#TS&.Z3N4:.SS#MF FWITL&]_70J?
MM*TFI"*Y1:1U;/AVUV@.N!F<N:"H6.VC_).I7MWH98&=N#^V/9_;3(..>C)(
M<&BSG9;6<@8OU"OJ= ]\!1RA*9Y_A!C!D[;UF2;23\GO/->!P<VY0J!04)AW
MB^:.*;,/R^AH2.[\+R*91SX9(^Y7JD88/]15MZ)'^'"5$37:_1\>/13:B[?U
MN3NT_Q54HE[K:75:'?@GQI5>F8#S_MO7IZ_D$J\[ZH=(B8I#1>,G]U^?/O#.
MPV4^IS*O>RPR4?'HBW:E\AN3MT.4M V7+^CSET)=*9VG6L%./WGDD;MG%XM,
ML,^Q/IBN#^1'2X<;V/<]M7*0F$Q"/$:T5UI-IS%M(3,/8E4T9P2Y=ZW$2 88
M$Z"<>E49DWB[ T3)PGIL>H$A*B#^T!FH7(!85[BX+T(8L2WZP\R=%2I#[8:#
M@M'+N]5(YAO1L93-?O1Z\8QMI^*N>W^1?,AOTAUT$YJN32?;'2/0^[[/"> Q
M5M>/%$!DZ3*3;AL6HT\9*J:3D RG(&10&&LA!!FD@*Z01<U\,*MK]C%FT@4Y
M"JIN2T(5!9.$9F,V#N T\*L_:J]R=L7]@@&=06T[#^H@PX[:)+!Z"&#)O$2%
MA#86VR]=R;L17K)[WUH3?46>+79W%01N4B;_3HNLG] /?N'-G$VS&2)-G1B#
MRI3OA9#=#.9-E\P5G;R42:>Z#95H,-&A?_^S'ZZJQYZ-.($E7\P"L+2P/>!)
M0(^@B +)CNB;TWH*@3@Y[X0>W/0RPS94 ]L1<16,W90;?\7PT-8\ ,G'4NM#
MG1 1TJ[;W:7U'FGM0N@9E^XB"*,0D0+3U;5DP)/-DQ^AG+ZY:93@LV]%MFB_
M.:;?( V5H^WUFX.CYU]C-/[S/UX\??;BI;[#[WKW>$2.C@Y?8$$X.R4-?\)U
MN:AZ!?SA3GFYGX3;G02O%\4:E?OQO>7QM4:6V$)8YC7%^;]?S;<^VB8A!M^2
MVUH$A\LGEJ_.!ASJ?AYN>1ZX#S7&DWFYDPR!:/!] (LQ*3WPY>UGY'9G1+Q%
MWT(?R<O9;>.!QTRMXREC=M?1$]X-+C6$:H0O>8LWQ\Z%!GS(I1ER*^J)APQ.
M5R[2RZI.B?F44:^4.1$B#L)#95XD-)W-ZBZ;VVB/8L'6I.'X>YR%$H?S=N/[
M&.*O!PO*+&92_7,HP1VU5M67! />TG-3Y/_L\CGM8"W)2WN(0*.'CK.'$Q-U
MC>>74(BQ-E M.J%,;06TZ@$M(>6HJ::%6&UDN80%89/#SJ6+3>'/M"9L=^!2
MZ*2NJ23Y5-]$E*!C$C'MA;>H%>:GU2U] <]4.@+0CK"4_=:]=/2I)9$A#\-\
M\0KE) Z9=%K5K/5$X:R(C!)D+V<FTO2\SI37Q'8"#;Y+>0Z///+LM2,] 2,$
M\;\F\_1O!0]YLH>'[.$A7_70'$]BOT?;[OL 5*1=3>41YQ*<M=7L8Q(57IS=
M.(N(L;CA@8S<5_%R[GU[EXJV;PF['9,0H;,1H!6HK$+6M<U;R0)>D")F<Y'6
MW%1YBMZX[^!%5_0J;GYL6]<UGSP'4F,>=Y"B).5G?M.#1>>6IQ26^Z$R1EIJ
MEQ4=B43,C;]0,CUO&$.@)R6T&AMM=Z+'HG?<A/(1Z:G(;0*EH?-&:Z*%F+I+
MR\*U%^-DO% @1_ 2<A +:<<BIT+?,%$8/;Z"U+O@)CV10Y3M)SRO?FE>!98"
M^1*8_/G0E9&MXETTKV9= %CU[TV'KO-!SJF=E'*N54%LZG#MD!JGCQ1H1S5Y
MA6*M9)9P2J43W.>%E^DO3*H@)5B#\!0<,)90&$7_1+OK\I_Y!0^S-;;H-RW.
MA,OI:6-V3;C(R<A%*/5/%PG7X*!IY.NG(U\O*_HV&B#I#9K)?>ZJ #V"WX[9
M)Z([:-@OIA;SN0*(5!Q"/*T6!IO6&R.8,NZZUOE%:=O(2)RZIVQ9[(RZ;[C^
M,$K?Y?S-!\XSQ1N]RF89R-..CY+)HX>/GB0,Z X&"TV](*6E$0+!O_OUA5'R
MA<0".!'2 NJ\2CL 1'%%C7(R+BLPXRI%7]>"#@Q%\G1%-I9',_&-^6;S0C4T
M^]P'@CZ7BQ3+W_I,;KQF,Q0JS\F15RM$T==VDXQ%)(V5)E"SNGLW,GZH0>V"
M =P5PW<K=H_/+_<<%#8PU4BT+&[_9&/:$)GBP\E?PD(:73Z>*1*0DPSY34I\
M$)-$)IUF%_UK]&R;]L# M(&NT\4<'!'S*7_=!>9Y@QB369DL@$311U)G#0])
MG#S;KWKMV,.Q -B/_"08^8N <UKPW.B*QR?SBZJ:\R*;=%A:,_15\'KS@)XD
M^B/*K34KJ$CJZ-,:97GW(EYU@"@D907[#04;&BA :6F>>V=Y$M/+BG4.\QF_
MRSP#VE/23=$^Y]<)Y)2A4XR!9F)_*'=%BW29=TL6%:"L1<J%;RZ\JW8>KX>/
M;KI:-I">EH2I4YBB8W@,!)[IP\GW74W;8 EBVW;[1').P>@-IB9)P8!8;9ID
M^A_ZZOA"[/Q2P^SW[^3)8_%IK^3NOC*VN6(8#NMN]K-CTA0SEV[J6;9Q.>^L
M"T4]2TM*@!XP\P8/3EB>>1- !\RX@HRAR$Y(CDF.WP,*6\86>2(M=$2T&LZ3
M.K,TY"PJ(BSSX((E<ZDZS\1&0"=XZ?:9_PJVG@M@#]KT(V]UHC)HO9I$(D@*
M:E;K!"(?B W<A$%__%_\,D55GA]0_LR] <'ZW%)EK ]-QX7;7OQ'3RH$VB?6
M?!B:F/#(A-O3I*@T&2XU=:5'UK0B1EYK/!@6US8&.XH7KNQ&\9U=ZQ6[&%'3
MEF>G$&5WLA.!QH8)K;(2S&D169H^HSN*>^SX5Z2>5>39)2-0"<C"NU0WG1]!
MM\UF1@_34YGQ*YC/F5,70E-(+(L^2LP3O=6&"#BKJWN.H(]FU5 3C+?),I:,
MZ?I4XLX1IG 86=- Y'*-"S>(G%==W72H/,I?W/!2]GG@/7'"ORB8*7E;^ VP
M/:-I!X_3,X+TIMN?>'=MT?<"2O4](-<[T+S!N3$D[-<?\O+C>=6/4X+&"JV&
MNFO8=V,0H!=F<CN#R5^PYMG$4+V@K=A%0K/J]H>"0@H]388510%)/<L)X>)F
ML>A$;L[]C4)*<"_7.#GXL;U,0WC\RBZ-^Y[ 23^0^+\F_%Z]UT)M02/!UT5^
M#BPP.Y=!6U"VB&S'ZX=^QF3^RA%33GI73KCY)XCC!<@9,\7)]=VVIH8=N=0U
MRYLL/PV;6Z0'-'I3]PPL?-)7KO2<!8V010("EG(\8(B/J42L6@1FQ#=:9F)T
MHR*+[7@*C;$"+ L,-Q9G1]7(KJV(+&HFK]V@FO8ZU6S:QM'.1:=.1PL\#HSE
M9H0#>R,A$C-S"1X &JW>+88N=V8>:]N>&Y\;%:OBMQ]Q9(,$A+C-XH+UW31>
M'X,0H?<<Q)7/8H&QL[MQ"$M_3*%0UO/0MS[1=4$0=OF*.2R989"IH-@-938-
M6XDE_E5V%1CSS.?]$*O?LQ"!>9R-@AHM>KS@%_<W*CQ8*G=&CR"OZ!L U8)>
M-^R(+J(<LJS)>!:PZ,;7652K;G_;HKN2\($J@-?/4BD$5>X#T0Q3N"O+8_R1
MO\NX\CJXPVVG^O ($@[:)-V^C$IEU*?[,NJ^C+J#GNLPA9Z8 WA[ F_Z.Z2
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M=C:C0:Z50X"_;.'?;4<7^Z"1V,@G\/3O\'$7!ALTCHT<XS2T/&#Z)YO1D>R
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MT^D\RW+R%4!I4D XI58%2)0Z]-8&60P!JE? )B+W[=;O?U.X,LNL3#,P+?Q
M?,IYY2:Y7@59]J6G)I%<N&[:'NS)*%9Y3+L9L&DU7T<PV7(]?/"SUZ<);4FR
M):9-4=LV)8ESRC!K]] %4=B>AW2K'RWWC45>+\WSRN4];P81+!"+$5-/Z)/
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M,_0;8!@CW[/8 DU>1ZFOJ2R=+>(PO]^R^4.E9&Z1DBZ>,JT7!$#:IA5P98M
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MR,I)1.4BL<+201@=C]((ZT-+H7-?[35MTP3/7A"$EIBK"(B?4?^O:6UD\6O
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M!?M#G:XN=A>F3;M]415%=47[YYP>EM5F:YFK8$"8?FIBP=(LPZK$YJ-M -J
MYAL6^]?S4JYL%\X@B/IN\N3A0UH#V2=/&ZI_<<O&$!2>9807PG*!8@E_1\E'
MATT$S$,[UZ[Z&[8LH!.,G^+]3S],OM.N[--J.<U+%&D>>+SV..C]<'+B["/T
M8QM0LR^I:_E/1\1<  ;6PNK=N[-!FA>H13$;;XC T( <7(6"[>C=:-R<C2+)
M"WV@.C//(/+9;KD2;=U\BSW\MVH]/-[KK>Z["&]DR_.E\]KKV7_=FY?I =F
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M^ U&35)SBJ5/@Z'0V7%S2OW:9+BF!=6/A3HH';[]FU(.+I!(!CI09O5F*P-
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M^0K[3\'AZKDFN!/W[GB20NDI(-]B982(0BJH4:<PK$WC._J>*C@JC5\9:6T
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M2.QL;0 F&U+2DI6)9M)FX6D[DSY?6=HR=(0ZQ;VO%;C&4#6$OB2 *N[Z62O
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MRKJ8;@NU^SQ4*:S+6.:HBJA3F$-26N;2'@49ZE%5\^FZ O2LC.GRSV>,'"=
MG="\G6G,3N4_SEPOGOK.PZD7T';HH;,B"J'(H"DJ \<7'Z'O\<N"N?4ZM6ZG
MB_PMB>#_7/EAP?IJ<#SOYG\'%=1N]4HOU6M6Z>^+7F79M4:[L]&K%O_>M Y]
M4<M?]8Z R $)J()8^-<WC3>Y%"2Q=%HW+""S=\7;>G.WV=-?>.,\ELZB%<>H
M+=)M=Z5L:0+*(NN9X3P8R\FH+W$?=1!+;EOS?$L.#NOQ*W)L1^0["=,8^')\
MO,9I"29$7&N*'CS?<PU<X=F^8 J*H:UL= 7"',1)-;=/0)L2Q([LDM5'TLI2
M*+8=NYG]=GEF\XRZ2!!9P83ZSN#G*,(F6"=B?8,!8Z#?;P@,0.*=:F+U9>/M
M9E%RU5[7(\2Z\5*<>HW$=J3&M\^T;W6_9*-69<-6PS8[S38W()YG\WAIHT-8
MS.U749K*'37&'BC&=AIFKV-KC-48NR<8>]2T3-MNSVG^+X>L&VLT0_I_5==H
MZ+35+O%"F3E=QQ19M>=5ELBK>7Y+ZC A;:>B2"3F4RS$&WNS[9;RY$KQJ$;'
M;-9[CQ.J%1"=APN85L.L=RP-F,H!YLAJF>VVO;%4U[)[\9G>A@DEQ)2Z(-9"
M);'9)ZC*E4(RJU,WK59K0_+?Z!">DS&LHX*\(FC:=L>L-QL:F@<!S:-6V^QV
MN^L+@&<'Y($ZJNFT\P%Y>3I?UO3_4?;=VE;VQI;3.OK0:UG93M45)8Q5Z,N^
M\R8Y$F-7C:W;=I"KC?WG5ZZM)+$107G2J)6DL&#% ,]C.[*.2Z)C&W+__>+Q
M#<MLV9M:7^487'6QO&> Z9JMYJ;^"@V8'6A%H.+:FRM%>Z7Z5%+,%$<!OB+!
MLI?>(ZME-EO:K5<]P+3,7D_[P:L'EQ[0RR.#_GOE<:V,;&G-3C55B_Y>0KRT
MM-VROJ>QV3 [G4=Z&K5^_(R0:=I-L][6)F7U('-D=>NF_0B'KK9='BM?EDS1
M>D429B_U,:O;,.U>76O*E8.,W6R;UL821D-F!Q*F;9O=CK6O*2.5SMC+!C%Y
M\X.8#E[=IVZ?]IE6*BL'F6;'[+:Z&C"5 \P1A\R^*ON5YL6EH\A>3RZU99F-
MWJ8TK_6O76C&IO78RC$-F&=UO=AFI]/<5\6XDDR8YU+/)\OIM&K0RKHML]G0
MB;B' <U.MVUVZYNZHC0TJPG-HT8=]*=V1^=5[^2X:>H0C=O-.ZT]154_'#2T
M6J;=V<! W(<6 Z\2DJU6S^RT-F H&I+5A*3=;)K-SB.SLRHD'O;(BN#C@D2_
MY6QJD&ZHH!LJ;(9',R-17X\ST+;-MO7(_EI[)F;V"S"-+@!&.P.K!QALK-#K
M;=XNJ2)B?#_8L)#D.D2N([$O#9FCW@:.?PV0'91:-%^&2EZ#'EPR.O[UZ,)'
M5MML6KO/?]/JUC*@V%VS:V_N'=- ><X4$AL(Y86LQM>@!TLVC).2Y%1;,3D.
M1YA[KN=$WM-BY?N%<%H]KBIDL*&"U= :<I5@0B#12O*SM;2@ 2!\A*\7T61I
M&D9W[T21$R3J0._7HSP_CD-K9>WY(=,R.W5=;E4]N!P18*KF1Y:#!(,P8(M!
MN"]WO09C@<? L^"W"&'B!/I75&)VU#1;FW@)M!JZ@Q"FV>T\,NU5P^4Y::5K
M-GJ[IY5#3E,5U0REV4@Z7?7->\ML=QY9<J;3'*L&2]NT-^YMJH%936 >676S
M]8B>#SI=]=%^_3X;AA&38B)Q?NFB-U'1T##;]7J%"FMTB=0C'1O-CMFJ5VGT
MA(;DX[*#&PVS5W]D?Y *B8@]LB2N,K$ @B)@0^]Q3IS]](AV&SK1HUH0:79Z
M&B*5@DACDZY U<JYJ23#_<82PP>]_)'BC1_2:0-.U0W3OL^XB'MUP["W>2H5
M)C[L!-/>/-UE&\?R0GJOI@--!Z467MW>0#70=*#IX/#HP&XT3;N]:2+T"],"
M*7/O$@<^)?N!*UW7)TXT\@*YJC8<@_B%5F+#W^+[O"][3^*J%[@L2$Y/>EMM
MU-ZJ=5?V1;?K2_JB6^LV1M_6BGMK+5<]0KMFXYG=CIDQ#'T_O,=V: 0>8QJQ
M&&MPC 0N.G!MD.>!)^'@YPEN!5G;!$.-_)H(.YKH8/;3&)O5P^UL,O7#!Q89
M4^<A@J]POW.MV!;^46A V'9Z8O$>] H:#AA6<Q:P@R,'WYLD#X[G<.2^,XW9
MJ?S'F4SE\0(Z/GKHK+BL$MC2U_CELWO/3<:GG5ZMT6O\Z4UFP(@/\ZM6K?ZG
M(H/GO[?:@#I6Z:5ZK?SW1:^RNK5>H[O1JQ;_WFHWMK(HNU[K-I<O:H71M]3L
M[LW=5B+8!((\-R_OSE!DIY25_Y,YD7$):.H:']F 3?I *PW++##U-4_DI63X
M>AL]\@)@)V$:.X$;+TY.4+2D=25196%KU^W65C:ZJJ?*(9Q4<Q.4WVM7^Z+Q
M8<\3"S\@W7ZS?5=6>P?EO=OH'& BBT;8PT385L?LV)L6=NF$G:>,;5DX >SU
MI-8W;;/W4CTW=![W<G;0ZCS2^:13,);4=XJ1Y1^\,&:#-/*2!SFX_/7D8MAF
MV]Z4Z'7\_\#K; ]9U$NJYT4<3Z'WO10FCTGJUT*^JO2NI?QZ)5N/M*)TD'?[
MIU)9"NS:9J?^2%6HZOD.3W<B:5)X1:1@X="1WM-J__8MW^%93IE>=NJ!!/(&
MR\,R=AUU4^;[QF4 RV*,AE9>SZBG"W:%>V@_TQ:6Y#>4+%CHT\:]$QMOK89=
MZQCP1=^C7J,&!NA,2F-P(N8:20CW=)JU^LP]3=-PL"=>Q)R8LAK>-JV:+6^J
M&9A"D5W&+TTC#TX"=F:X\&UX+>911&P0C@)/)E*\;;9J3?5#01B<#)QXG*V9
MQ@_Q)WWY95S'D$6X6GE;W_&=8, ,)X[#@><D<.G>2\;T9,*BB1?0;U_#Q!L:
MG\+0_3V,?L:F<14,:L81ZGEV_8RNTK^MLV,XD2")G$&2[[]T [76KM8O/IFM
MBVYP#,JZ@?L!?,F# BR*JW%XQ/ASMJ(P,@9 KP[\-HW"4>1,8OZN01H#';*(
M;L<O>X$+/T6>XQM]+TS88!P ^HX>C(6X+Q"QB=DA\WE!(BVBCEBJ/B480#U_
MQ.D#$TJ3Q8_,!7%W2F<-S&GIU(O'H/[O.,H3$T;LI ]@^'GB#&&=IXY_[SS$
MR!Q5G@$,0[R\U82O+]KV4H[9GLL,6LI_AL.GGLM\'+OU)RX<L'DFGQAV"L*(
M13SEZR].%99AC",V_.N;__#<;JO7;G0:O6:WWW18L]?J#@9N9U"WAVZG/K#^
MMP.6"N5+ =E=P =Y2V;G?1G<*R0 !-D^$%..F<(&[EG$B%$ 20-C#H?#F"5&
M_Z&4M75VQ]K@MP]>.+ETO62&)\N?%['EEG$4,V9\ ^YDK$@G?#JBE>83[A[?
M-US&^OAN]>J@9W94%-\QZI(3,(T,)P684W:E;,$+?PP!58(!2J,X@1^H0SK/
MM,3,,>;'['[,J+H?D,N+C?,@2.'F:S8-HP1;^GX*HXEAU4_^04)PF$;D;G09
MR$(_/N:!1L1UH<4H0E,*65!CBC+3QP'F!DD@4'C@H5R(Y@J0$*?3L1--G %+
M25>FSQ7%JI2W<)1X,2.3WVHW-6,4@I8=X*:-HS%S_&0\ (5-R/DAIIT:,1LD
M810?KTPM?5;]>BF SV/#]6(X),R==?JP)SR="] ^PX#@"0APS>+4Y__\G@V>
M-(V%>BWJKGCVL0%R$=089%)X+!G'0BSR7/&FVN(7"0[X;^)>/I^-#! O?T_&
M5EW."=^VK:(NBWH85Z>M6GM6X]ZIPIS0IYZB,L\KPV52Q ]!P"Q8$G?M9]3Q
MA.SG*AB%:GA2V(.+E>*7U@=*8JG<%FQTYC!VUA1L-6K62DO0:N4F)2(V\-[E
MF,T1925S+>-]Q*21?\,. ^7"GB-46=S[AD5W'E!HY1T.)6N/Q=J+^&855<H2
M?&MTYVZ9Q[=.K;ZA?G*.1BQLT GBD[E=VNNI)B^D$FU"5P.$!!QE.B"9:7B3
MJ4]Z$IRNFY*L(YW905, A"#\U\GOQ_,&'N_=4?ML(TZGJ#CA0XXDS(5T>2#D
MQ_NY+B*X%Z.L0EQ<^/%:M1;W!<\0%''(M^U:O>QJ4Z!1IN.6HM&,$BQPX@$O
M":0P/CJ),PT]U-BD;A!+>Q.Q,!9<'9]!A7Z Z,84G4MJ J@^T"^@X2DOQ4WX
M3A\, ;B+ZUOD$>*JX/W8&Z Z-@'4&P!N"P4[QI$=KO%'"KH)O5EL^8(6-*OH
MX+)8X (>GL!_YE>8?2];HN'PWF'<X"#SH#R+71:"[;N:4\C2_ZCL[U+LK[I*
MS_<T6@T>1'VP**>DQ^8(R_7E_'9 I  6E&$JO0]O"J5Y8N(K0;@@GN)%%HQ1
MN99/$ZK]\F)BIE(TYJ\#-/.]?^,UO!%8+2P+C-+HP9C"DD#7F4B4%\@7TXV?
M,- #-^$'+T*784$B8CE+@$16T1U0:P9=V$4<!@'S.>F*\D67%KN@U!'NX8L@
M SB?&@FR>C2*V"@SGM[V.K5VD141@[*ZS5HOD_1HC^.!/L""8J3*F5*PG+-Q
MA0 @.V7(EIC_4#-^QP+-&/C6X(_40TV"0, 7A'1Z D<Z8'&\&"%R%IB,HS =
M<1GGQ7%*-I($(;P^>9C;XK]9%(I-]6K=+>V)X^_$\0)NH2Y8..>UR)>D%>PJ
MFX%U1U)IEEKVT!F( 1DYM!'%.)-5O!'BJLNF8(1Z_/*4!P[$QI57T8G#\="J
M3&3=Z(@*HP<RFM,)NE%C,[<C!1'P!^'$X2REX,!?AFP-WOEBO&51\5+.5\C1
M^M9N-A1\*%=XFR"@UK"PNO5:8TT3*P(,"M <5Q1!?$=[)E:54?V)1(U"+3.Y
MIW@7M#C?V%' B*.]M16?!C9,@[6X7G)L@@K?*[H[,@Q4T$6^#VZW;84/>,'*
MXFKC:(WB:EQ'@1A)C1'<81V&D+&SMU:[&"]54!N5(=^C772*FQ#UXO QU)#'
MS'&5(P1R\H%->T-/^HZN_^Q,IF<?$2$^TS_/:4$#H?[%CL^WU,N1 +]2($TR
MC">HL/];<.BW,[ZB!,X*E@X+ISV(3W""#*/8%#RL<&JY%LAU4"'Q@/XS%6?]
M*(.J5W([KH H"_B0*JQG]%0C'L.&A_ 9?%[N):7/HG;H)0@"8*N!R[EHYFA
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M,Q6%MRSGG;%AHZ@WP+JHD[9H_<O/1IT^Q/L^T_*17HK+Q:\?>7?'2WIHE[3
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MJSW"<PY8$!]O6[UB,K>++=>1V4FV[DQ@9]Z_Z0>LO"L2JT$MST[Z5!2&::E
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M.@G-A3&ST4;4<4%DO*-M#YCRP'^K&1>YLYNO7;5G8<L9UT4E/0_1**<N5KL
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MKJK/J.@<UBPSG/OYUM7!%]G <D*:+-7"95C?Q.?43T #+RJ8&6\+"WH'C6C
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MX_M] (<X]FAVYH6(^7Y@ <"&-VF@Z\14OA;#B==B6.]-7N( MR0)SF/2R'U
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MQ/Y(69P< BJUSO[\'U:[7O*_%P)Z@S 8>KA.#"AYP3",)AP$< %O@*,C#ER
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MA0"4.@?,0@Y-I+>7LI +)QX;G_SP7LONRA,>0+*G"6]O"*^'PYP2/G)Q9=Z
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M"D,??+# S ):_J?!*&..?V. [:6'V%XZ&W?[0.-NX5^!@?.]W/G%!-0U]PB
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M,9(-4:,7_XP7?E:>4]FB5RS)5 ]L=@EXKIRB74X&>/ZT%'1Z#L;JS=EVV"_
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M=V0="_N2,Q&._C&^5J4MNA<96L91Q(O+.1^\_<@^!B*["_T[P<5)0'ID7X&
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MQ_;@Q'IC!,X$%N,R[Y2"7&'T#7YX0[6;PQ.<NO.1^2'F.QE_=B;3,^,V3 =
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M;C%HI;:R,"'\246D_ZG+1_>R?+1*.*@K2W5EJ:XLW7UEZ8QEL4,S"-V(EU$
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M <%--ELW-IV(L>-=OWW2[M1=D>%>E6V)++5/D2@L2@./YZBEL?MF)FFM\\8
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M$=?<?D6?NNR;<][]04I6GGWA:-@N/[/7A3-:4SOG%,&3?'!>?%"RR&XW/K"
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MTOHY(0SMYXRN!*<2DK:#0S@T?1>/I013T\!4]K"N&TQ8&66H'2V?@B"MZ#V
MXFYBNT\,C&AE;#N^\FQ/%PS/[!?;]VTW5*:._>A,G7#;H_LDU=H:C^Y/0-5_
M(E%O1_]:<%7V8?P7)VX5MV6OOE9XTC!J%H)*G]L5L%1"T/9PVHNER7ZUYP:G
MLB=WO7"BX4%ZMRD=GB[!Y.:I^W'.OLB\5A677=#\E_T4\B%EE^I;HMP-5EFG
M[6N@TZJ=G3Q1TD!JF)3=5+)?+X+TUL!4>U93VH]*&!VJ$K]>&!FM05_5S:8T
M##OGNCK1BJ>PNDZVXZFW'0\2.9U3F>&3RDR";?74;D']?=/Z5LA.*<TXYNN#
M'LXC,E2C7=<(5HF]AF%O3Y7X]:*P0]D7';.&$H4&U>07ZRR-U!THEO[(8-M8
MI#N$]L_=@N<7R4';Y8/>P3T<=P$T>8A[)KVGW>"_^XY[\?%GZ-M 4\>U_=?[
MD,T"8$!\NN]-I\2"O.2C,O?A_"?=5+L%K=H:U!)#=F)I4$"_2?"U,.W*4CN:
M[%]UZ? ]1>G;:PUZ?4/MMQLM?<_9<7(?*SR@ KEL[%S0U)\]*C? -L(>>,^I
M6H3^/J#?;$#"K P&'TF'*($20\-PEI5W44B4G"Y*:I<EAJ:W!E8#:H#.V4_P
M!PN5*:A-^U%,"C%>].['@OC?]O3>Y\'395D:0+1U T]#,]!;8:A6MX;L[T:;
M>Y*G)$^5UZ9V8RJ3^U T8Q<E2S)58S FF:H6Y7,WIFISSTZOVVBF.F?/3J2N
M*G/F*\'$]G/M"BN$$TT@[LA;/$[960N$BB]^FA+A"_._(1S6JK#&2KGPT?9=
MH$ 0W>:#,UV$;!0+ 2T1 IWUZ1\U+^2]'3C#HF5TX8"_[N;CZ[4&W-<!Y4CN
M%LG?DK]7JM.U,+BU'8-ONY*5'(X#L+3KCF1QR>*7S>+UG^']+5F\YD-<UX#%
M>]<%X;)&L_@Y^\/_HG^PD6+#:NPG!B\XFP$\R-8(%&\1!J'MTFML-=]F,RD:
MQ; KN8338ZV2JRVS143;6T[:/Q:S1^8_C 6?$J<$#PF!RYGG*6[2#[/>W$(%
M>U=<K8'CTM1VQU*[5G[22L$'NZ.M\C2B\T9K5F,[.%S- RVX)KSB; Y=[?7;
M:M?,^[\D7@^ U^.*UW6.CSH77!->:3ZZVM4UM:.54+ R>#UG%^J=-YO[;,+<
MP'EFY$R5D_H:.*FOD=C9-EOD3,WRHK=K[&'3O,P/W:HQ\^,$0M&2"X[_6@W,
MU=![->9J2#:0;'":V15ZO\;LBA/)H3C6]O.V7\.,)1!U&$']3@[O/D63X%AH
M^N3Y\$]7&2Y\G[G#5R7T;3>8\N;M=MP9\'(:RFVM:>=<),2H&8N="UA!\CM!
M\>](</ZP6W?T/2%_TI<19//#^+O]\XOGTQ=AZ#N/B]!^G++OWA<;;E.UTM$
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M754,S>C0GVW^\O W4P6H!G,&MWAFT]?K6"*FV+1 Y BV:'=0WGB!@PNX(0Z
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MXS?'_?'D*>\=[\7S?P3*/[PI"NY 5>"\K\ZH!USY75K,?(N%"^[%M] ;_IC
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M>F-/7^S7 '&8>I^9XT9W[YKP^%68F=G^$_P4RWJZ(,%6OO1X7/M+&]HOG,=
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M(LX30J75C4I@*B%J>ZV!I6KZSC5L$D_-PE-9I:!N//7!$C+4CI8WA630?U_
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MI'Y9Q'!M[ ^0=X=MYP8XOOBOR0P\$SCN1Q,Y$#([@,S>+HY:"<HS &59G>1
MH.RBZR,_3:%!H#QSIPB P<>T#NR6CPJ(FE-#2#?QXTVE[Z5O9#\]]'?BKR_P
M'A[8#7Q#/XB-A7]/%TC6-"=S[JYL3> ,YKZIFE8- >7C'R/2M-V_;M-P0/<
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M6\RX_GN'GII("?MZ>Q<K6<$K<"H %C3PR,Z=@GQA7 U1P ZPE2?FBN%BP-D
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M9.L,&#DU'H18N;$NS*4Y)BFWH\CC%UB,/5:P)G2W^$"(_R",I]2((.V^M(/
M&SKDDHEMVV5\C^TA[TLP910>(:A')S]%EEXY3_)(D5 4?/:4]+F*S@SR/3G<
M.8*M%N"O-N7?D@$9KR"^N\PR+)ME:,@L0YEE*+,,#Y)E6%0BIU^UU^A35M.R
M#&V0S_3J&%E>BIW$96$40" ![R1Q^%386_3)2,?Q^1<@I*^6OO0*XO$9QV'-
MV8!TO'WV@B#>[OLX[+>J5DL__>#L[73JO1!1T=H6@=G/E'?56+4FK?Y'L4=$
M$UH J9<1&DN41.;%O:*BLJ<HP)_),4E<W"+H]>* 78'A*M3Z03_BU5AHLRS=
M9.J,8Y6?@Y@;!<FJT ZRI\,%#VD])L8++W!FSPZV.*+\+9Y! O;[B $!_KU@
M[O!U>7F1VJ;&C%64OT&)-JE$C/$B1 =_T4^%5^:)83AA/HGBQDFWOVR"1,ZN
MB=V8WIQZDU#\+QTAQ:99 "1GM$AUG$RNSP0/>1:D@Z<G6ZJ)BW-),GL>)S[R
M/,#@!^;;H5\$[A)0APRQ.05KN%8>*$-G*<(Q0IDW$B;?PA7;[U"<G=+@(HF$
M.SO!7E% ZR>$H\B8C!:W'@G8  K3-WG.$X&!YZ.0@LNS!BGX@KU9:#DB;LLW
M=P0*F$.=7C#A4<C=PH2F5/86T(+O4@P2,M'9!'N,P6T0A==1]7DF\H-Q8Y=1
MF'P#S\$OUA;XK9_%TUF6T;&L^N3Y'[S%8SA>3*,%?HW7%SO+NHF<[F.3C[P?
M3P&Y-(U,CDHK[>UII0;&':[S@PZ3E8:;DT+3#D "GB_*W5POB;%'J!(P6;>-
MXY17.%@;ZHH7L3&@U^Q3\?<DWILTM#A^+SS>,[&3%8:/8#>[PM5%!9 ASSP)
M@CBU)16^'K'',)-;@%ES2Q\2AU.QHS-V4#S!)\^V,\4;4 $R9DFLBGG#'?._
M77J *A1&WKH2T_A(T*6<<G1@T/>/[-43T0/$GUJPN&+-<2G*G':A9;V$KDT'
M(C6_8D,;W0SPLU?^('% XX.BUR)^$,Z(Z-&)*+T&ULA2DV>V^FSIL?@\*N[=
MPBD9$=T>PJVXWZ&(+LONQ<TZ]0K7:OIMZ"Q<\K...<6& $2>GCH2N6TX<41D
MN^!B:)L)K>DDI2AQ/262R.\).'^=B]I<L7\VK^#E@.;'5E'>46-55XR&H',-
M:/(DM-91?%JZ16RVFG<38/$:J3A1*BN]\0=I^TR88IG#'KX'+4AY@Y>\K4ES
MF*$J\Y\XA1Q^,',6,TIP&<(*H\\Q)1G/1:RE]X#?"2)QU8U8&#;1Y+I=7I)D
MK<^E*U745-!D74%T%;%+34N*R1011BA5;^E^28(SM5BE;+%X4X!D(ZXZBAJ>
MD8*MR9]XTI%(^+X2G9ZC3D S!F)P.;>X0;"]79.[L]2N(E-<M8Q8=-^B8A4S
M =DZD>N4RHTBLJ7M!O%L_'&R83P!$D4BF":/"\XBE+TUYR9:A@VNE8^%GQ=@
M*DX1)V7;7K(RBDX7-19LF+/(0CJ'1<IG-M=\+:IJX;NU&9?)6Z%X7Z;#4@;B
MLJK06'3^7ISQ/ WBIM%Q@X-TIAWJ+(^@#TY?KRBM="32 #.B-:4 \).OM!KP
M<<LGXCYM^U2Z0=)"!%'I1+KAK*0*4&-&P!<?EQ:^?IEBIT1WA"29KW.H&07]
M"8V"3HDG9U!$E% 5H@7OC1=1@]B_N5'$9.WS>.TL6CLACH04N3'H0.2:ZG"X
MF G_QH@!)C%J2.GLG\FG%"Q=A7IS\JLH96 19L]/8!M<V16N4IR:1:XX8!!L
MGSUUGEF0=<G%=:(,/8<\QDE1?8RGCTG-AG].Z!"?H<,PJOJJ"?D%F"_H06 8
M><Q_3#D:Q6O--^X,-27$LXOFH6S1,Y2OI&!]QLKX!/+<NZ)HCA#14>"4AAE2
MQ'D>L)OH+^] (82W>;UQ7((B7?0NR^08HEV>7X[/XU^+^&.O?=UK]S $*::G
MBP>+Z.0U0/O7_.?M[G7'ZA5^I5WKA9^ONE5'OS8,8^VM-@QW+YJ?NN9G!4-/
M.>WW/NBSMZG/+@WZ3!#\)^?/S\Z8949D5AYV/QR/M?'PN,/N2\3<:=H]%V=^
MFD.Q\YLW#E^ 59='A59Y_=*#04O/PVU,7#8](;98]G9SWM>5PI?##E&7[Y$_
M6OCH7TK$LMD:&,LB$[6Q]8OI[F<Q[=:@DUL,^6.7U+6MN&AI7'.3N>C3PG>=
MV%\W!H)A(&@KYMG\U@>2GIM?7=,V<H&U'^!U6@-K _#.77#CR)E89N\BIB]!
M&/?V \-N:Z!7%\;]_2S&DL*80^']PN&I75P8\[1/9V_B^%R8Q-+V@\M>NEBO
M-)=8Y8W72JOIMP:FMC\V.:$#Y)]LX@RG6[+%YO<\(2W%RI4]U8(U4]LLD<]=
M%G\N]%N=NV),K_X-*V)X3\G8\8>I>'ZAER^/B%_)Q[1^YE&I<O0#.&,QBH7Y
M>I3^AOY*2H!D;MQ1C[)OQ:PZ$5\:\=EM%"X872M_85O"* 670EVA@Y$&N!F%
MIUZ<@'IF\485WE@5#E/NRR4/+Z6=K7#PHNL6Z.[%/37R84.>DO@J^CSA]F!<
MEI(<,![HI'+=<!BUK.DH6=-ARIH.6=,A:SH.4M-1-*9%O^JLC8HTIV"7@JJ#
MW;,-D*BAO^ )LU3\X3WY+.X_RMOP\:-&C++$C#>>38^CQJ:V&"8:37Q.NL2(
M%&@X[6HN;N6!^=\I>'B?A,:7JE?-@K"7>0ZA:)&7P-]?21&@N1'H=%+B(G0P
M=8AWY!59'2(0G+1\C/OSIE,?J%]I>@P-_L:]POE3U#1SZ5OJWDPCGJ,&R11%
M%B.W*=&(^4/4E=*YC(X[GF*Q!E.5QT48)7.$OC=5DT"U8"Q,$G+374;GT7C'
MN% !5\^RC?I0QPV4?RU&O%T&+3/*FHKBY%-L149MKZ+E;/_P3)'*#_:*?AZ:
M6Q3G\*J8ZP1?DO:8+=6(:SMPUI<?3)QYG*&'>>KSU##%.+,J-R&)!@:) I9(
MSA"S7LWL'[@J3,4/8CF5I+@CX6W>4M3V?4PNG<4= ).&TS2,GA*R4LF8%#R?
M3KVAR)!!59CZ/$?:8\$;*0N74A_""1^'HMB* !== +)Q[ #P)S:1,JZHH_=!
M05@PB[TQ!\DG8I:E=@KEWB^;BI;AW\GK'$%#1J1()A8UX'! >-X/T?\@:KG^
MC\_O_QGW7$\QO=BG**\NM8VQ 9*5%,F;7"M_QAUT\?;B%VO6#,*?QO!&HD:D
M9.-@Y.S)18U\(XY,O8WX%770?A5-N/F;<R.,,DCAPD60-*J+BH4$;>B.#!!!
M')]Y+)<5O&<N$Z5&=)MHE)$82!]$YA;+IU"N)UAS09IL96;UJDA0CY@2Y;S#
MVYDO34"C;H\+D=R;%#%1244!/=AR8=H+;_,NU ;1AAX,6;I#O /BQHGUBVFQ
MBDO]#YY74SZ:!OX2];!/$OUH=$?4S?JU3)[_74P#S/G$*A+T%N )$ HA&C>)
MX.ZWJ?*TL$&&\I>>PF*G:1E*IVE&R/+R1A+ (&!GXM[#I>?:V!2&LRD<!PM^
M%(BVV<,PNG=FD".7P/ YR%[X+J6SBK:JT6[$W>NI6R_/+XYJ0(/%'&OMX.B*
M2BU%0A5\2PW^D];?_)>Q>X3./Z$19UMN_[4\[X&GW:;QMB6^BMORKP)*D*E9
MC29Y/;*I]Z+\A_E>5IV8V&M:6145Z9D;QN\]()42?&7<MS=CYR<;7>$J"D;P
MF<D@ZG)+:>]O*6;%I73VMY1V:^!ZN9+ S1\4 0]]NH+%-N./@VFT\*-3;',%
MH)B6*>H S6T;>Q[8J,A6+:PF!9D5,W2PQKHW3DB*1GU@Y61:)%"E,6DFE-V]
MND-J:L &"L68<X?4F'^Y57>J,"NMJ"?]=U(Z/7=@JM3#>&@'0G#%Q=_>(IR"
M9I)4M"0YM+#M23^>I! C*:=/2C6BN3)VM&3JI)LJ.L?IVVG"1;4;)%"OX%\
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M%:6".'DC5K?0W3]=$$"Y$S3I?Q3YR\A=Y#UBS)"> TO&\$V"/JJ'P9%D@._
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M(>FO0J^D!<19J91R0UE9HC,;NG>BG G.6YAL%[-6X9MXCV*&-A]$["U\D4'
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M$'Q/YT:GQG$5VG&\#*, >7%J0I3?9.?G%ZG*D/EH:I6?5*<F]YG;KWP($N^
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M&"MQ_$#;BRTAWI"WD.MP+KZW6&\4VAN*_060!]4ADFV!!8 J1";+X-PP1E&
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MA:W$/B>.B4+3"63N'"%08\;25YN&-HH/4_"7:B7!^76["[,M.9 ,[ZB/$(
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M=L]7HBSQ=25%!UB<AS42J1()2U1'=+,E+'F%VU1<4G=BVEA/DH2KH]:LR23
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M4/F*[O #/-]&2MESS^73Z@&X89+VI]+^DW*:-$?J-^:@\S3]['U%BL<'OG6
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M=>J<F&&52V.5(^%?5&NI]#D(1E7^NF$7PR[[L4O__&@5.[#+X.JFW;7;@ZI
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M&V#N@"6!A+!TW*GFY8U%-K6TFS<H[UN]_Q/% 7QT.YD$*^RRXZ[%[0S^>[N
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MMWQ**]*I&--*$=DL061R+[[[;\'E9L'$#=GT-[Z./.T)QEHW.Z\DWM('L!1
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MG$:Y*05=DW(_4OM/D%%9))OVL,Y(-HCDZ"@H!!J2DH1D30)):T&!*6Q&8N)
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M3YYJ^,HS#>^T1(.J/N&1O](U*#T0I'9K>$$U3X99+HU9NG5A%FP'[]O]X<$
MUF?#<*JCQ9-/(MMRIOMAO&??O]:ECGLPRY99JFEF^?#XR;U;!0%8EK?>%#9]
MPO]1FC<&.// ;J'W<F!U>BZ-'J\%9 ?S]8635/],)(7(W%V[74$+?S4D=<E^
MQXN'4]Z#+[8 OQV-+W!ZKMWK9W%IGJW-;BB*4]3P/!35;>(\9KO7,X;M"2(\
MZ2I/8\GF,\.6:46[,T.6WG$LZ^CP^>/&4JT7R;2;QR.9-J*L&DOT^"=.R,UE
M%<ZEH]#M%PR\6!2ZTJ)ABZFNI==*VTX([-ZSFY7->JP[5N0!H7?#I89+-W'I
M%O?G$"[M7MUTA_:@6=7XA5K 01ZKX"*_E*W&W7T;F]S\F?67,E382IF1O0UT
MJ#)*<:NWHKY^3'TX$'C8R/;Y6[ -"^I(")CE^=A+%D:!.Y&-6R'<B!>34X,8
MMM+R#JC<P1:Y/5!C9^%X$VPA9"S"+@^M"HN3O@3VJW'[TZ\Y#5\$\:EW8R:^
MO=!:RT%CT!Z4K;7L]1O-_J":LL9V8]#J5U1KV1WE/^1B%M4^'I HYOF>3P4H
M-4T@6HKUWD,)9LI 31GHL<I S4X5[U3GQ13,OD*3X;5U[Q#*JFX:F/K9^J[L
MDN.:&O1$JI?;E/M>> 5C>\O@91P5A?+JLU<8XLB95ZI%-_H7.*_4<$']N:#4
MO*;6*,,&(2P>_MJ#'W8(^?&*Q.$P6Y&X^_PFPPZ&'8[&#NV3LL/PZJ;3L>'=
MS\\.E^%XF+KU"KFAW3XM-XRN;KIVKY<-R9>8[6?*?^I%0ZU1IJWNF#34PZI)
M>] YQ+XP-%0[&LITFQV5AEI7-R-[U,X6EIV<ABXY]F*Z&\K'++:T*%=#_EA5
M:?='!S>-U<=/NUSR*6G/G5:.=JYN!G9OV#F_<V-HJ#H:RC2S'I6&NDA#PT&V
M1,PXR,=&.#'6)Z?XYJY>\!Z@!S$*-[+*K>>MG,5^0 B]'G7F]IK9%AKC^CQC
MXCNM^]Q'<=MNUL#U,314G<K.@ 4<E88&Z#\,NME6:.,^UZYE]248K)D^HW+4
MGR7P(?8MG-\@-4Y-=322Z7(YE$8PE]'*MI\9(GG&1))I?C^F&NU3)J-=A^C)
M)7N^U-F<-[RHK*WRXCHER[WW9<B DQ9+]5L$;=AM5>#1G[]%>8.?9EC+L-9U
M%B?DJ+R%2:ZA/6Q74&QB>.O\I&9X:S-NTTEYJW-UT^O6G;<N(S:4WV@E6[,+
M6['WZ[=*PBS@F:0Q%O9N2]K%_7PY2[MDATM.2#\D%GQYZNAY*)U2.J>S!?CM
M(\VG1E'U(0"2R)\X5J+AJM^MK.&J/BDLPQ67QA5;V@XKYXJ>X0K#%;5W4#J[
MUMCLP1\[>"PX1,3N]FM0.G,9;DD^27R.YBQX.6GJ<@RPI;2[<KTPN,#V=$-+
MG):V#&>JG):&AI:>$2V5U,R[UGL?1S/37(V6J?\^91:\,&RX9_368 M7ORNU
ME2X'I=./JZ<&S:I]X;KC@A^>&#2\:WAWQWS]D9FW99C7,*]AWA-7!!S%JA_P
M%O,J4#H,YK_8PD^K![C;1,IP\<^LP;5#P<=WN.#MPI_\B ^LPPG(]59L>AN)
MS_!V# YW"3>,@A6[JA= _7>"W7]8^AZAS_NSO#)?@O1GSF1N+>$IX.X\L8 A
M)#_'I@_3R/3;@.D%(;;:L,3L#IP6F;[5;#::!/-="IJ^WVIT1]UJ ->;C5&_
M,A3X9N?"%S4TT/3W!IK>0-,?=Z<,-/VIH.DGC)5/39[!?B9Y$T,Q6),Y*-LL
M"M6V%WW^?A5M1 F_JM1[U]%SHA<^K 6H1A@@@RYU#'6Z!SE690[UJ/&/I/C8
M+?YA./'%<&+9R<*G9<4>:E![>!B*I&'%NE"F8<5RX<0ZL6+_ZJ;;M9O=0UKI
MC\Z*)RK\.Q<YP5$OX.=3&A&Y\@+Y3QP&%5JO,#+'PM=6P";^O4??^(F)FB\3
M(I8'[XYGG7YX_.3^K@Y#!H-+,Q@A/O6[V7X_4_U5.VHZ3E/VD0AKB'!TH]'H
M_-5?AJ:.9RN<EJ9&B.[>.FC*Q-DJ"I]50.V=_^0].0&H_.F_5BK=%O@/EC^&
M6SZ27E\&[H1AP,W+";CMQ#$YFW)A'%.]<2V/Y@ON_JTZGD.L[&&38!];%1C9
M-?!J+Y?RSAQA*4UY&XO"AA46A1G:JY?4.T),X1ABKXT-"OW#L$ZJ(;T+CR <
MCM271.*XV.+(DO'**G?E,B3/2=&2AIT*4/XJ/,,S.<>&:0W3GB9450W7=BO
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M\-.)$P1KK*T397HB3I=3W!?1-V,&+^OA!8DXGJSO<R9P)<^@6UA>:5ONS%K
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M*[$X'UV*[2Z WF]OV,\JV];BMI&R;A*Y[EMJ^;=4^JVNN'O:J(DC&[X\(:9
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M\JDY[4NYSROTQWT2PC$B8VRLESBK3N=P"Z$G/$0!/"E@87=:5#\X\ ?<Z'=
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MP2\[31Y_/VYJ<J^KHYDT$55CP%ZX,HXZAW[J79?/%7OX<;@&]A7DP_BWW_Z
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M"LTK(IS DE#<*?Z#9PK^%#)8IK\"'7"OI2!_""(6P@/L.>'HABX'[4H0^;+
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M,BO#QZ=\<9X>RGA"4Z0??M!6O@ 8Y8D$&.(DEN_2GD-ZT#$2!::T_4P<E-F
M_)YDY768T<V4VF+.>/["\[C8Q0<*B'>USQV/YJ3C7O2OGWX3WD7P(\PEO\_
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M-=7BGQFY@6J[>*U\SEI,Y3O^UF_$7Q='"BXB/QDIF)#9I-.]A1=B^<$VZI8
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MCEVP&>107M&%=K'Q$_%1 ;/S8KT_2/FFDL;),05$<!+( !%1@;4D\\@A28@
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MQ1?+',59%P^8@S:K)HYO'%TKZ'#AI\;B,BD?C1\[-V/L!,45["OF+,=7'KH
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M2<IB/I(L^7]'@^E71#0FX"./ +R N6I.LY?7&7 I>.6_V.ZW)P_G1C][_K=
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M"NU%Y,!_ ?D\6+0[$)[$L+,<[V$/68ET=UM^.!<6!-B2Z1R^%WBFN8:3^@$
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MF(S.#9.%_8/,[_XBOE> $.!Y@REMHZ2\:6DL1&72OT3"9 _1"A ==PRB\O5
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MIRZ-D6L[Y?G2K^M(R1?(QQ'DGPB&%")V!?;GE 5L9DA>95?7@87[<"9G"VG
MD2G!>D5!!\3_PAXQI\JL(')V"L>2AI0B#34<4 C<0&"@RF@NZ"/A3 EK]FPV
MU7) ,?TR!CB8+3M18Q4'5+ID#/SE-Y'@:A0S>5VJ2SN@R-I;'ZT>!G%(C<11
M+-=P*F(:PB73(*3A,PGK-#+7VX)R$_%Q(K>=ZIK;5><YJ4G4SZJ9NBBI:SJ
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MYT0KD33CR#WC"\R%K R14P@!*G$)3N0$)C.NO#9,<=N8&D_IN\%83>T9<:(
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M\7XVR2.?L#C'#$A#FE=9&J,C#PJBL(KS8((6K4-+#Z,95%2H*2<:2:"A.[M
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M1!4XH!8L".22 '62)=*!LK\IM_" S*/QPB.@\#1438*//&O(5K/BI J"MTY
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ML<RX4\"["[FTJU>_@ZXV$Y]=+M]AR./)5UIY.+\@#XK,PVN%?=7\+!5C=!9
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M>@3ID"(J@^'=46(\(^5^_S(;>9O1RT+8"E:[.AKPN2CP(FBAR8W2LG6E^:.
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MAI_2Z(IZ*975Z'1G_$/$;,&H@%")M<$[KFBN[7SN ._2]-**F8K]-Q\98FZ
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MV@DN:^!<7L1:R_8KIZ^S:;10LT?UOD\]<0N&DW2WYH();9P )P)%9Y"4P_9
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M&+;!MMTOO=&7;N3Z?QMV-U\FVY6]W ON<2@ZS=JRI;M$)@:XUCK:1#45M0]
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MDD[KP9>Z%DSADJ1XE#'HIT#@"N^N/G^[&*PR;[^CI:YOKF= (N544*(A<6=
M<$;!Y&0AJ]($QSI<';;:9=S W(.''F_M/<CL70V;573!)D#<MWM &"J14Q)
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MNE:I/1#TSX^?QC./XCLMYI?15QP/E[JGW;E#7.U-67M69,8BU]%DZSOUKMZ
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MD]A8D=:CY<!=)&Q,*O!!<<BT8&&=TVRYU\I*=;\(73<59N.QD;_@D!8W':1
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M Y\E[B0O(.I &*4F0810?&GM23R.YODQ8FM9]Q"<6H7L;I958<QZ4Q(XAYI
MF4"K=@RXTHF3H:5-;!V4? +2<^7#ME+OH;OLNOQ;$80.G!;+0G*@@J+[3:@,
M.5E)3A-RS,V+E8X_VWD7,K22=L,FKRN@/7J-D3]D=21'&44]P'+VX+1T(*4J
M"8OT*K?.,^H ZYD1HXGT&W9UG3<0O('WKU%M#/%A</YY>L:Y%L)K"YG9 *H@
M@I?95BNX5NBX$LL2'QYIQ[CJIY^R6AO)K&$GU>LU_C3X.L@XS+2NK(E#D8%Q
MWH 22M7>^@R8YK0\J0QYNXTW\\W'3UFWNTFR<??4NT'OFZMDT5MQ$=HR0(Y'
MJE.U$C%-Q/HTZHK*].]9=MB=:SYQRFIL*;V&;5"73HXWHV%M D\R_5 S[N=]
M=[C@P+*R8(VNJ JMU/)D!?'0Q2[Y78]_X=15VDAVC_<:W7?/HMOU?, )CK]B
M+J/QVZLZ/:^ZE;6AZF1>A]&DOF2[+^^GO]&VHNBU(L5$;F441"@A&<S*GZ+B
M$HP*0;J<Z'=2:YMXWQ4I6AJ#R#,HEVF-%AVX8.6L( \S+YRVZDNI2-E$WYM4
MI&PBXV.I2'GU+8SS)_K+\QQKLEPS1P%:)4\KB!9<=K2"7*206O@B6T\ZN@?@
M&-.:-M+JJ)5T^WBHK"[HZT#4JD^H))(P%^TX#,]GI)J\_G[[=Q8MGV<KN%W&
M,+^_",/ZTGM=0]%A37TE/_6PGL.D2^U D^7CZ5AT?"K\#9'KH%T"S6(!168I
M!)8+>(XV,1%29JWKP$^'MT\D;ATY;3=1;0]T_9F,]]%WQ-F-\NY+7= B8<4R
M+ 6%!RX3DC>:25+:,$C>2F.]\#RU[D#Y*)@#9 P=7->C/A350[X(N4C3\2!-
M%P]/?Y)F)A\^_GD_[<G1?@L,K%2J#@?C("*+QJ%D.;;V6M8"^L&DA@KK(]<$
MQ[.N#[/Q+?7A:AF6+]&#=63I!LRY5MH(YY@-NGE9PR-0?C"HB9+ZR#Y9K'!V
MT4M7AS]$ T&BI%.Q%N@8[X K5636=.<W;U5P]_O/S4?<6K8]ZGG!Y"YH>G+N
MCL$MVUXSCZAX!['V<2'<1\6=E]ZD.J%6U)E.V8"WUH"QDHP@JXW0K7O6'($/
MTY>.-Y%FX]J23]]&GSZ/KB9AF.ER^O2-KJSO[X;X*]TIP^G@*\ZNK@IW<;>4
MG!/WY*EYHRP=7BY"B(Y!<4:47'QDG'=XD-KPL_N_['?1T&@_XFU<I/((U'L.
MS_6,OSN(12Q)<XN+2;&EMFFS60#=9=YXKY%U>G7>[NO/C1<MA=WXH/AUF*_2
MS,R]@P>%+25P =S7!M[)$'%3[>&8R>--T1F)74Z#53_[9%6[LZ#Z*$R^;I0S
M?V.M_LMH6#V6>4/V'#$7<C]*S3%3.A.X.N8'G0M9A%R8:]W@="V@YV:TMY-^
M#UGB2YBN)RIT -63,;\2T(&;B^VNN.4P8C.I]Q&,7@DN8"H.18:8*CA+AQEQ
M7H!U0HE:36F;]S#9(Q6Z=AK;$Q,V$7;CB_[?H4:TII-/HVL#9-Y'Z4XZSK4U
M4H)7J IP3=>D0JYKQ%N!52QH)Z5_T!%_Y>W?^8/[-PD:*&?4MV3[[82^&#(W
MCR]>IV&]74[#.O/6&%4(L Q1TPY@!EP.%D+F1B?A-,^\\>&P,<AC277<):.H
M7\T\2J6^DB ?1-,_7EU>AO'W45G]QSMVUM[V<VW3'9LLNE&.XY-O&H\]:=S2
M61I)_Y<*F5.U#Q>Y.604TZ^R%59*I;7 YLF".Z-NF#VY]:O0W+'PP4EE:%?2
M?DPUC&AJXG/-.Z??,)ZY![U<6N9:[@9^7YF9>V;IFC3./2K[6)(^?QW2\84W
M!O!O]3^HBZZ&;V!H?"H&)"^NCAQV$,WLFC$DZSKF$5NG%:R!<P1Q@WWR8]2/
MGGIP*!^!=FU.=P#74ZQA+;##Q!R:J;$;/7;0P?Z)$G3&D!EHD62=.Y9JL5:!
M('F2Q1:KFC<Z/P!!GHA$'(@?&XB^!UY4]X9^X.=7P_P3?L6+T9=9+.;O>L3B
MPF<VK&@F0@'RG4V%6&JWC5I>+[2.B:216Y<C=("U?Z>SH2(?9JPUU4(/D8M?
M<(CC<$$(7^5+$O5D.@[UG?4^2"077 MFH6A10 4O(6*TD(/@@>Y:5GSK%DF=
M@#TGLK371"]=V2=3LMIJ[\#[N7.>EBPB6&8\^,IDQR(&LLS08.MTZP<@GA,-
M=I-PGT^AKZ\FY!U.)A_G;M+D;A/9FC5I&5A4$IQWN:9C.N9ES$DT]\;7 7K9
M+DT[7?5!I#F6^WU+UX+IJ[3M+I #/Y3NKJAE"NPLY3Z*R]:!DEY L$Q +B)%
M67P6JK4UL0>5=WT0W:_&UPJW\4/HZ\%H@NEJ7)L2S#$MWV!>10DV9 6!#C)(
M3,@<E"ITK'5X]WSLYQ^@LF%[D8\:RZNA3S 93\_>CT?Y*DW?C3_B^.L@X5UV
M!N!1&K J>S)ER*B17&MFG!3<=7JLI _<V:ST;[<;];%OO\S[O(DF&N8^W<$S
M(0=E@6ARG_]K06URE7>CR4,@^[W*V^CHH<(;";CAV;X1.*XY>.\\\$0^J<G>
MFMPIR'A<6G_D-C^<TM?*M?%%_F[Z&<<?\"L.KW#Y2L)4[[A,UYL+4D&2!M$&
MS@*&#E?XPY^\O\N[H;A'S6350TCOU<7L[V!>?7,MXDEGC@EKDD] *K)U&#V"
M,S7ZR*VIX0OAFE<X=T-VA(6J_3Z7]Z"PPR<FO<IY]O/#Q:_#6=%M'^E(:S_2
M<Q)2]P4>3^I1T$IYP0UP4UGJZ%<A9@LQ>L>BQ!QLZY3DYY1Z)+(OY,X98"%4
M\94,3KCZ9HC()?<ZRN9CY%]@ZM$F+.TO]6@391]+ZM&]>EMOT >6 Y#$R-T,
M,@%)UH(0J(J+(D?3?.+-<742V"<#UO4=V$03_9>B=T'S4OH.;*29]37IVXBU
M?V7+(&.R*4+1!$U9-."<<A!$QH0,%?DD)ZCD3?H.--3Q)M+LK^_ O/J9?F-E
MY6Q&EK0L$3BB Y59(N_3Z!H\YB46'_)R_[.GZLO7?N_@9<<;Z61U17D[@>ZG
MQ<"CW1!8$:E$ZZ$8 JAX<K48F_#**#G&% CK9KH_B683#2C07+S[:3OR5/\#
MQK).VDF"6*>&!UV?%"T#$WET3A266)<!)"?:;*(Q+UH*>^\]"Z((5AG#P!:R
M8U5T!:(O H0A(66CZB".OA)UCK1GP0'=@W:ZZH%(JXMXNX!ZZ1T.-E)<I[KV
M;:2^QPX'A:E23U6#9%D;)\!G^E6)0F:+14?3NJG9J70X:,^$383=2^;O<LV]
MX<4C,@\V*T[G7^ 04 7(UA=;G+*R^3B#(^YPL(%R'B]1WT*R?3P@WNL\[I5W
M7# &Y/C4RACG(11A()%)P[,E!]JW#GH?V]2* QH*V^NBA]9'O33T[;*F'S,N
M-IIQL1%-]C$L8!L=G\J,"VE%B9P'<BU+G4^<2WVH"B!-C"YB"*7]H^#)\':C
M&1='1]M-5+O7&1>!!ZMU'8)= ]G*)P274$*67FB'I7#;N@'A<Y]QL9&N.\^X
MV$11_<^X6(!26@2N"$K!VBS+&P4QV0!&2ZU+3-FXUF[;2B _F-- 0?T4CZ\9
MM*$=UYC)D"UDN8(2=0A1BG5LB^(I:Q:$:EWP^1(FHS1DT0X*:QA-K('TG\-X
M.+J:KL)W/02(EQ ,1Y!>!Z)Z%!"]4,"EP\B"YU8LG44K'RB>_- +9DE[131T
M+2NXMZ.K(?V4^<5YC8>GF$VIXZ7K@ZO"9(FU!(^AL9EA-D$\E3/ZV,]^X5S8
M6=P/U:_Z'9\4):!V%JQD&KQP!GB1P05.'D%H72KZO,<G[7+-M%#20^[H!D?'
M^X]_SM:\A$@1HAS 8D!"5!1DH6M-)O,L;G!X+/WT%\R$1B)_2 +3[/'[;@O9
M^4N,-L9(1%#*U?0OE<$5Z<"K(H32.8O8V\/W,IB7'<MNHZ,>;I^[>*[?73L@
MZBDJ_1#-@9^Z=U/7\FM7&UGW\<+Y$%G*Z((5'G+.%5X='R/HH!3"<YX4^>+-
M?=U]:;_KZW;?RM]$Q(USZJI3].YJ>L^6J1%HDQP'ED--\8L:0J)KS%GE&<\R
M)=LE@W+%CSYL-_5MI#UJ)ZH>8IO_(E]V,#R?3\<60EK#"ZA4Z%;BDKR7P(B=
MZ&QP,BG!6Y>ZW/G\R[[5M]5#0T]@"<J"ZUW ]'2%WP-RF-M[:[6L5N\.,NWA
MJEX"Y9A)RB0HPH1:X($0T$@H-AG%+!9DK6=I[$'!3US0/>EW U'N[X%^=E#1
M64;GW;OA32=,QJ141H,CHZ/V[DW@Z_*YTBKPX ,WK2=K;P!O_[?]#HKL]I:^
MLQ9Z, *>AOKIV^BZCH<SS$F1L2.Y F500G0ETK\6+60PG.R8O1/F!M[S)LQV
M6CC("?.)='_3R479XIE0$(Q+4)-VP>GL(&5)%I/V0;+F@QXW ?C,2;.E)AH_
M8CX-].WH:KS Z00OR1D#Q=?'5K2E]BZ0!-9KSITT:3DE?J7_N,DW3Y$$O<JU
M<>.[#]6)6C3YTDK7R+8,=( I41L]IDS7GI&NB&B=M2U:G=U\\&4ZEMO+O.&[
MP@V(F^>-IV$T['%XY]/[[VJXI?"7U;>#Y!HW+[P+1V#V%CV""(R#BG1N^<@S
MF,@4G2'2RM0I^>W0"ES3H+"M_C816&.]_4Z2NKRZO :2A;5*:TBJ9L69Y"$P
MS\!YX1G'DCM.LWE"<_<^NM_NA%N+?=1"9HT["?\>_KX#1)8B!;<<6$H6E,3:
M7E%I*%D;QG/.4N46RKO[T1-4WM8RZ[?BK^/H5%&LYJI8R-I*4&24@Y>8@*<4
M2HG2<"E:/Y<=_U#; W=$ZU>-^XOI/"VO^;KJ,C#_.GR/X\$HGS%CK$UT OKZ
M#T5R!(\NTDZ2/IFH"GF1^R[/V60!+XZOAU-_X^?E)Q=R9V?>V8S7V_#781HC
M_=>?<'QY)KP+6A!XSD*=H*YI2RI!WG!*A:$3R2\W[MPDK+ -I!?#RT.JLH\N
M,=M*D394;8L4SO%=>7<UG4S#, ^&Y_.ZE;G=<H8\<(?(P#A>NQ[$#)'[!)*,
M(1$*ZM0\7Z;/];P8CA\=.0Y1O/[8VOZXJCI;Q,(FK[Z&P46-;='^_H7^V^E9
M)!>;6*F(FYR,_809@G <,$2+7$D;^)X>(G=>RP_"'X(4#3-:ZV5U=R_2JB()
M*O]K5 /V[T??"//X7^'BBO[LU<7%+$,,KW/$_AA-?[X8G ]H'9]&[\-X.DB#
M+V&*9YH7CH+<6<TX.016DH1%"& ,LW5^KBKH.E@?S8&]&+H>7JT]9&NUVGM7
MT\^C\>!_,)]E%TE\!L$J6HOB6,C.Y_0/,JR2Y5$+>S2^WF.+>#&</@X:-'PR
MFG6.I+]#^^[3X'*.]TY'@/F,(,]X '(['5CN'#CN/93HN/59V1"['*/KOO%B
MV--4V ])8'MU_)]B]*OA\*J.%2$S^N)B]LIZE@1F:W0!PV0=*2PT1*&13FUC
M(PN,?,<NW.D!VHNBW*%5^Y"IKLDU')]>4EQ>TL]_?QF,9W]Y$6M+47I9: TL
M*%\302*XV@*Q&%N"Y[0:W8OWWP+\BV'Q8=7^D+_^8&;DXJ;X^6\RK =D+E_'
MC#^-IG6'3L>#X6209E;U&7-<T#(\Z, R*/02(DL<1!9D*P=KM6T^YGP/ZWJ9
MK#\FLJQX<]CY >VF'=5\PN'J-?\Q&G[%R13G)>*3V3KN_OF;T61*GN-_X?0#
MIM'Y<&Y99^>YRP4R%V19NYQJ5"."RD6ARX@AM7:P>EO,B^/^<=!B!>';-<IK
MO;+Y'G\[&B]^J_X]?H;1A>C9; :C N4MI_W-&6!@D@EGL]&M"PGVN\(?6^-X
M"+1BO^R4S7[MB%3D8?A]T<VC-BRW)#RZI:0.A79N5N #US7S(R!#C8)W&?#[
MR(]_,8QJ)>(5:C_<"]C"^)F];-Q8/K^,1Q-:$TI9HD=P0=6\?+003 Z08@DN
M"69L;IWRU<,R7@P]CX4**^B]<Q>7UFNB?_LI3'')N.>:>639U>Y65>K>0PSH
M@%F96"CH"^N4R'I PJ]<V(\M<'"ZK-@4.S5'NWD@F<VK&I-A\_]=C?,%W@3'
M:S&.MV!U+<),08)A/AB&HLA.+Q&/?N#%D*F=F%<H?_>F:-L*9?:/197?G-_\
M3"HA9$D1'#IR\G1($%WV8% X-$D'EO94"[L5_A=#R8,K?P63#_.<MCBH_S5S
MVF[3)\Z41MJ7WI#3%6LBFDC@O1;@1=3!.R5]W*%&=VM<+X:A!U?J"H:V>4:;
MG?YGIO;$T+0[K!4$)4?R\Y*TM=$F8SI;GILWK;W]^HMAT8Z"7\&!K9^B[EH!
MBX/SS6B8!_<R$4JM@4:P)L?:<PVA6*.E,]&63KG[CW[@Q6B\G9A7Y-6W*5O:
MYD'U[GW[87#^>3JY>ZPY77-7/$C!!2@O,X1@(@3/(@^%9Y5Z.4M:+^3%D/1X
MZ+""Y/U/T-K(:?XWUO5A?O45Q[2Z&Q_Z;1C,LUG/=%%TI!?:Q3YQ.M%Y D>R
M!V<ELZ8$$5SSYLW[7>++W!A'2J$56Z9-P=4V!\$]2_=ZO3?KXF>(V=&=9J'(
M5-]:@X888J*K3Z=HM;=)IV.Y&IY8R\O<!(<FQ0JV'^Z-:3Y7MR9&CJ]F>9'O
MII]Q_.ES&&ZY[V\&$B3M'-@H.'C&%$BNC9',1(9'\S+5>O$O<S\=@^0WHMV*
M#7BX5[";);R:3*XNYXO_,)C\]7:,]5$#QW3D?*AE0TN3/E2B(X:.G=I2/)%U
MRD3H)[S1YZ)^;)B#TF3%1CA<>=FJ%?[\]Q>L8]/^-;J@'W-!1\:J-?H8P2M9
M(,L<K2TR\VX- 0^U%58OZ\=F.#!55FR'G:K2FJ[OXU4<T:\NP\5U,O3O5Q?3
MP9>+AUN^T)8OG(-)'K/4SCBQE!O1]F%E,[@OAN;'2H$5--_ZH;#7K?S3X.L@
MXS"OVL@\>8A:>S#<,EZ$4\[L?=[[KHMZ,5OA.&FR8B/L_![YZF+V=S"O7FK%
M/)P\@%E[A;H019WB&*U %9V*C=G<#=F+HV0/"EO!J]W+[6J6T[S)VD]7XYL4
MD1GHR=T*[.NK(5^_S"7@,BFPUGH(1<6:"^4] 4ZJM.;8YBA?'-]Z5N2*#DZ+
M)];__<\E$=-Z_IK]P>SWJP@_8/F/^K]_?OCU1MS?OGW[QSG]A?-1'(R^C<9_
M3?Z11I?_G$E\!O>!**_;F(_*ZECJ_4'(]52?:^#V9/\)IV%P,;F_ILG@LEJ/
MZ^W8OA']\U9@]P6Y@'6/J4<C.OQ[2O<C;;8#&7FW.T=(KPP/!8H-&12C[1/)
M/H60 V,J)N/ET02Q;E#O?':WZ^LO<A**12BLEK((H<#S9$&SK)G&1.=/\W?9
M5N ;GO3AXJ+7\WT3ECXXWP^B[%4]5/^CRB]/_U>Z&-'/_S__.1U?X>UOCH93
M.A9^OI@AH=,5S^LO=C9_;P9?US[XF 7F(@HDGB.HF#4X&1/=F'1-^D179FE=
MOG\/P#,8Y+$)!Y8MVZUUL;\!4+O-4N^RIIY&3?:QGL-,K-R!)IMZ]_O2\:GP
MEYF@O*$K)FM'NSOD!,YR"3H483,7T?F]6T-'P]LG!G$>.6TW46WC!NCWG83K
MH19,<>-] *=8 .6C@*@"@^28#4:@CUH\X5L]]K./T(7O76.CAN(^IED.&Q59
MDGB\]I*6QE"1<<(L>*T"!,=M8&B$8T?CS#W[FMR=?):CH\LQ[8G.J1<&'1/!
M),C<6E H&/A8"@@E7#(R%VF..BWAV63H'&0O]$*30UBR#;(N)//.(0^04NVT
M(U2$P)F$4H)A)>1B]-$4+3_S!)VCV0L-J+*?"</-DS.R*0H-F9(A20Y*BEHM
M:\A-449E'@*WI72PO7_DY[1E^;%2X)B&L'3.NX@IR:A([#K42TTSA%A<!!Y]
M=C994LF/])QCW0G'29-'Y[/L[R7[P2/LK2@^D#DW'M0%SO[;/PG)JS2EM4Z_
M-W^^W@U&WV_6#85T/ _51G)9/.V@E ,=TSHZ(FK,X$W)L0B!+!W-=*EC?*C.
MTI00%$C+-:CB:C,FRR QEK*RT>G"?SQ4[Y6E/3Y4;Z#LXWRH3B:F6(>%62YJ
M[%>1"!-/$((DSYPAXZ)U3>]S>ZC>A -K'ZHWT<6I//1U6=./A^J-'JHWHLD^
M7ORVT?&I\)<)&XK6' Q:I+65VO]$19#>6<&3S>CMB^7M1@_51T?;353; UU7
M> B3#Q__7#RCJNP4<]+0X9"K,\LB^)P-6%FTR\:J@*V[_JX%=(01@=YU/NI+
M83V\\2V!NWZ,-Z*(0CLM63)+E&$,HN<96"XZ>"RH5>O3:R60'^QIH* >SJ#W
M."ZC\64=&3\OPUC 6M3\2-"1!;!:<0B."6"*6X8IQ8*MWW,?@?*#.4V4U/#]
M:&<G_LD.*#=S3SZ,+B[>CL;U/SKSF$4*WH$MJC8$UA(B1PW6H)&I2*7DT;3!
MWVJ%1\CTGL,PQTN@8TK"Z;[:>:O2,YNS=5$G2*%VY)*9D3H< RE=C,X%7^3>
M7996BSNA3;('ENY_0VU!L6-*Y-FP^=99[7*J;0D0E)"@<JH#Z[V%5(+59)TA
M"[UT/-S#VG[LI(/LI!T(=E(VW/U^D6=99B5IH8#:B5JEP" @F<,RFB(LK5T7
M/)F-=']M/S;203;2#@0[IC2C)]=)6B@XN+M4*62P)A4P=-W6P1.S1B^:+E]I
MDDU.<'$T"4>;+^_'=CK(=MJ-9H\F+!WCCEHV9IE)JA1.NN ZUV'""%[Q6%LH
M:6EU2-Z?CI&WUE\Z2BT\V>'V[N8IK%@C(QWS3-(Q+U*&P*("A5P4;X*QS;M'
M'9D(3NA\/)DP46\4/"G?M[LXSLB<<MQ$!%HQDO]/T@AH+63GT6:K&,NG8\YW
M7_<)[;UC(/\1;N2-F'M2NW?C*26,25ZJAV1G^J/#.=KD:Z<UE^E?A6B?IWHL
MB_^QCX]S'_?)X1..GCTM"*N4C=8S8*&0(.K<(1>*A81.NV"U1'TZCZ,;+O['
M9C[.S=PGAT\Q@G<UQLG34C!.DU/$:-DLU30R.LV\00]9<N.DS3J4HZF^:;KR
M']OX.+=Q;^P]S9AAAW-,BU $DE$B(P=E3 ;OZNQ,D9.40?JHR\GLX$U]X_T5
MJ%Y=7H;Q]U&YKJHDGOX<QL/1U?3#QU?-ZU [?:WO<M/-EWP\5:5*.F%1%<BI
M.% *#3C!"VV-Y.H%;Y(^FHY9OQU?56FV2>IL.%A3'XV03E<OO0/FN4*EE+>\
M>8.E%UA5N@E+^ZLJW439QUE5:C DG5TD4\:ZVHJRUOJP B4:1^N15IK679">
M657I1AQ86U6ZB2Y.I2JORYI^5)5N5%6Z$4WV49ZWC8Y/A;^<)XEUFDGAY!VI
MVO4K,)4@Z! -#R'PO/<I\T?#VXVJ2H^.MINHMG'[XVMG8$6=XJ)DR/G 1 P!
MDM($KD;;HO8)1'"*%S0L\O"$@]3I0T<8S.E=EZ.^%'&:Q2AW(UO<DP!Y37!6
M-<VJD# ]QP@RF%"B9$;ITPEJ/IO:K9V<G>,ET&ENET4N8E!&%8T,I)$,5*2;
MC.XW#4D;AD7QP.()YK>]D-JMC5AZL-JM32AV4ADP2Q4!MG I;,R0#;.@LN(0
MF2!KQLC &1K/S>E<.B^LY.0X=](.!#NI[).'M0#6*\PN( C%:_L"KR"2"0S*
M2QYDSCG&H^EJ_J/DY$2VTVXT.ZD4D.4[.!KOHPL"7 SD_BDZ1%PQ$K)@!6GQ
MMI@?)2='DI;AC+"6)0:93H;:ND6#L]:!3H9<=BO)53I!73W[DI,C]VY[H^!)
MF>P;I-4H)[4ISD"IK=44.2ET9-82(IN4X'6@#&L]4?48UGU">^\8R'^$&WDC
MYI[4[MTTPU=*H3 Y#BD;#<HD.I)E2F!,=DEJKJP\G2W\(TO]6>SC/CE\BDY_
MMSQ?9TPI(D7@2=?^3V8VR,U *%(+R;P)[N1:4/S(4C_A;=P;>T\SS-!!!CXD
M:7WM.>OKV.A0(%B'D(H/-N2DT#U'K[:W+/4/^!6'M%,PC<[G/_.GP22<GX_Q
M?+;,45G\C>U3TS?^1+-\]-T6UR@)_?XGWUU_\M;C%Z[(PDV!Y+V@;>T#>,,X
M\*"L$+3#%6]]*3V%:=>CXI&?/T\13=FB8Y$.+PP6E'<6H@D(UB;C&,MTQ.UI
MO7M-\V[*@^4;JIG #YV7/1E/S]Z/1_DJ3=^-/^+XZR#-$^9TEHQ *S#(:TX3
MUB T7><Q^."BU0I%I^ZP]($[C*%_NV7+8]\^5%9V.Z6.&@JWH:M_!\_DU3 O
M$$T666Q=0&V2+-U-\P^![#?+N8V.'BJ\D8#WIGWO8N&^$EI%2?8Z.K)S":9
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M:[29_![JU>P:XWPS&B8Z_\>SX,R'P>2OU]]OJCNC"D([<MMLM=F4I3/#%YE
M6ZY39CIJU;I)Y1HXSR9^U5KT/3QT/X!6@2UV01=H/57_KX%UF"+^9BI\BAH[
MRK^'Q*:U$&5B2.<72$O'66T%"EX;!>2I!Z\YG72Y]=O(WJGQ1)W\09BQ@=C[
M&&<ZOS@?(+PV0Y-5=#0&8 &KYUB#@+4@(D@A9?(<76C==6$]HOUGDS13WO*,
MTG:2[Z%^=\56>(W#]/DRC/^:[0>9;4HZ:1 UI*=\J:-4=?52?-&.A>2:CY5X
M"M-+,#:V5T(/:3D/\5VC6^R/+OCV978L83L:VV,'C3Y)EP;JV(<5LHR3;E/4
M)6<0+I%[19N$=H]5Y$47K:*0VLC6LS(.0Y?-[9$]LF43+?3 DL4I^I:D0E )
M9YK^>S#]?!TT6UR3PEJE;4% %6<WL 8?G !;BN#!>2U+ZR:9G8 =@9VRDSY'
M?2MC'S;+>[K#Z3?".9)SI;47/C! +B4HZ1@$Q31H;0KG:(3!WNV5.WCVSX]>
MD\":B?Y16NPE ?55SK/_#1>_#LMH?#E;3LOTT[4?Z#'YM/O"]I5Z&M$SDA0'
MGUT"Y:P#Q] #"<]Z9G+2L?7!?=#4TU+(&TS.0="6T=E(*Z_IY! $LQX-=Z:T
MKN0ZB=3337BP4>KI)@(_VM13(95@*3-@29@Z[)INU"0RQ$C6G6".(W:*YC^7
MU-.-E/I4ZNDFPMU;\F$74"\H]70C'77*0MQ&P'O3OO72:D$>'%?U89') DX&
M2UAMC.B48]V"\,>E]4U33]LK?1.Y-LYI6_N0''Q 1%< 0W#U==J#"UF1%^^$
MR4H6O3Q2\&0?XC=20=>'^$WDUSC%= G7=?(D]TFG2,Y-TA:LCQZ")'=*Z!@E
M5\EE[)3UM.J'/S--;B&QQN?PQVF8S@RX7W!T/@Y?/L^2F>L)Q&/PT80(.M>H
M/>>>#A^3@;L0/6,J!-%I>,@3Y_"C )Z5\=5&S TS)F:@YA;[74C7+:P[@&IH
M@3T*9/\66"-%C?J2<NOM_RBX7+@WB1')52Z@C$.(@@M(22 WJ@YE:U$!M&?5
MKS'#]JGY383;4.-I=#6<CK^?_?F1KAQ5M"<SP2O&05E%ORHL@:%[".M[>W'K
MYLU-,/WC?/3UGXN?.-?PXE]N%7S[O?W>VXT$/]I):OO)2+A)S@F)HTHHJQV2
M03ED$'VT@&B**('LD>;!Q%-+>MSF\FXM^GVD(-S)SND"[4?2XX8JW""U;1OY
M[SGI,1F-1E@.C!GR']'3[>;2_VOO6YO;R)%LO]__@KMX/[YLA.QV3WBCVW;8
M[KEQ/RGP2%C<I4@/276WY]=O@J0DBB*I(HDJ4G3%=*C=MJ?J($\6D ED'I0S
MT6@1(DBPM2\)?$U%CVUYQCYF;\,CEL?6VVKOJ.9*2EPHG;.>R.CQ5SF4E#1"
M5DFG#-5+87=#.H-R@D/I6W>+BK8_1=UC4C&R:"SA20.1"J$YRBS"C<(R:C$8
MZJ"_XOSK'BO'&X>34+$[KG&I31-\?=WCP8SN6\EV"!VGJ'M,.<?@LB-1.U:N
MQ\!Y-45&E&;9I1@M5>W/+:^A[K%=;]F#A9/5/080C/("+4I?M#5P9@T\$^VE
M2IBF&U;]?KC76O>X%Y\'U3WN0T;E4Z@EP$\PF9=UH2D^AN%@L2+//Y7E\8HE
MAC%5FF ML<8;_%0,:'!,2+X6RVX\D'KI/1<3@U0W:N6^[EW8[@M]&Z#;''WL
M3?TI8HKZ##6D_@CS5JXIV!^ED.5B($S9HN2)BY2B8/&,R=\2(9P9]SNM6IGS
M_P]^PIZ>F=_#L#:2 "Z1J Q@[FRI:U1EL/+([M;M-BP]/MY,E=?E.0R^&4>B
MD3B+ \I.)&.IE*":2*>L/O.R^#K$4&U\7F(S#J$9"28(PL!9'WV(G#711UE]
MYF41=HBA*BN+S7'(IS@<XA#XPR0<#).! $A@@%%X]*XI8?(2"3O$4)7%PN8X
MU 8<'G_@EVXSUT0KD7GT.7':1&MS]9F71=@AAFIAJ_.AE:B,:##ZMG&\[_[^
M#G$&Z>O@%O_*Q_P%?W>:,5?&/_LR\Y/YA0*;0C.E%,X7E!-)G<R,YQQD(RGM
M_;<M*HW@8O+<,R"XHC+6RA>Y;:_FW=]Q>)<0_M5T"OA/^NK__C >13^]N:;<
M<LHD$.>I(#*Q1(+5B@A#K38.OUR]QR;) 0C.L!WTD,:L#FGHNG^8RYQ%!DE2
M=A+=&>=A+Y4A,DC05O-2 ]7VWOQY]P\?T\E7S?3M'-L\\^+BO+,/,+L.0G,+
M(A-N@B+2.$\"#9% <EEK[C+$V@O:+CR7YQ9U3-^"W-X?HS 8#LO-3 N,T\\0
M8?#G?$%..=$2FA%ABX0VKL/$!W1;2ADZ,NB85.UZQ!UP+LPI:AF^G6K$9_[Z
MV\ CWL'LQ].N_']#NE:1669Y*B%;$<C/N/*!T)@J*!K1*%)4O]-\/X07YCDM
MTM-.E<EVM->,\>+.0$PNIYJ1%8M(@8S+D(R)3K4AU[@=T,_D*GL9O^+YWUXY
MV[5,PAC./4G:X? 9KH_>)X]Q-4605 AA;&4/:03LPCRE/AGM*$9O=^>W-^4Z
MR?<CS.XA3_SMYDVM1<X_@/1\HDQ98U"N@<3Y!:>N:%7R .@?:#X1+21=NQBE
MU0%=F(>>#_G//=NTZ]EWMW=#A/XGO/6S>//']ZOTW_AW2G_4U_%R*/<&^!W\
M]&X"'_.GR1B9F)8J,VHPE[#$4.^(U*#+$3+:7$D>HA".Z=KBM^V-YJ?RZ<YH
M?^[0]N0[[HM[V=G]5JPG.5A)#$^2V$1=N?_'6<@\JE1;<:H6]@MSUI-0^MPU
MW9DHZ5VOE<^VH*5WS4ZEIK<^N%Y/K]?3VV_&ZO7T>CV]<SXY[O7TSD=9K=?3
MZ_7T>CV]7D^OU]/;B]"+9++7T^OU]'H]O5Y/K]?3Z_7T>CV]7D^OU],[M\6[
MU]-[-:)IO9[>02[2Z^GU>GJ]GEZOI]?KZ9UYO-'KZ9VU0%JOIU?%;7H]O7/P
MEEY/K]?3Z_7T>CV]7D^OU]/K]?1Z/;U#)7)Z/;U>3Z_7T^OU]"Z0L%Y/[Y41
MUNOIO3+"3JRGUPN4G45'7B]0UNIF9R]0U@N4]0)EO4!9+U#6"Y3U F6]0%DO
M4-8+E/4"9:]!?:07*.MR+NH%RLZ4_%Z@K!<HZ\*G>X&R7J#LC)SUX@7*EDU\
M*W)=7^(-I+LAC//RSS[#]_%DAB-;^4OAQ_(/E^)>3Z$WTBVK]>9J<F:MF**2
MRMF.]S\ZNG1!X'0G2+ !'3U[3ZR@0+R3CJ&W>4IK;W0WP77LM'K/PL==++RY
M9V%1D"> NQSG:3]51$HN,+3QB8@<N)<L0JXN@G8 S*ZTT:I[S_HTV39%IY9-
M>QCG???ZF[LI&FXZ78YH.B\'<\I8#H*3Q#"4EE$ZX@(M9>/ 90(J(LX#E9UN
M%Z!3E<JV[@WKWE>-E1;.H.X7A\5)?1,P+?7K/ %RFN:<BD2MN\#15FZ=>D%]
MT4301#.'4&Q.Q+%L" +325O)$PVOC_(7&FRZ8GP?X[8KNW8U2F\&N"+%NPGF
ML_?#7=;81&N]-R80SH0F,AA&/)6V2&0$Y9 ^+7B#:I4]7ME]/G8$,=LEO*I9
MM5UMMB6P)2X9<=%RV1.:<,32>TU"R)QP$:D3!O\5]?YL/WE'MZ5HK9&RG?C#
M+5KY,W\^TB4FGK3S- >BA=;+N#EY.S]1BI*!M+:)LN*VYU\>PU4L65FD[>UX
M-!T/!VD>FL[SH84LA0A4L)A)4#A.R5PB07(@P2MT0$@25*-C_A?DN3:__=+#
M]TIV;]T3[D5F&F"JJ-:W#4?W8GTU.-I)^1$&KBS4MQ5;HHG[S!(N/ BPE%43
M;Z#LE?"<J+-%O.[5D;Y#IJ\KSO>Q:PL9VD><%OWL,<RX7]I*8:H#$8@P4>*"
MADM;D$J2 #R#$Z"5V:7;=TBNM@5*MY)^=7@:US=R*S7C$US6,#W],!X]C4/
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MQ?I^^LI'4]:*>LUT]M#.]& $7 .9-:7_6$?\(03#R$HE DJ9G+7BT=7OV-T
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M:[B#P[F/*5SV-/4A*1V4:Z(0=K9]#OOPTJC/81^#G7F?PW(KGI(@P!.3+,Y
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M1.O5.MH^!+;@8/_/%Q7=^^MR#$COJ+,D8>)=E*DP Y<YDZQ 91!<I^J='4\
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MDB64DYWZ'$WQ"SYSB*G;J#5^#FL9ZC4!UM*!RU90ISEIJ4+=R^YPA-T[=0P
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MK$ 9>0D8CM^V#B5"VVR  ]52.C%XWB[MV0"O:7_BZD=2A>B=COEI_G%Q)ZW
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M/%Z7,!K(C:A!-#75/]28E R1B^\P?4 0!^8-!Z<DN.NN%JV(%!CEU6X+,UK
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M$<^IT:LY<Z8%E]=T+B\/N[(>0'A[*3Y*9FZA-TK=BA[\ZW/=__;5[O^C.''
MSW+A'#/**Y$7V,\FV+R+N18_U](X&"PR;&M:]6[[^(NHGGZ\%V,BTZ2\*%"6
M %>^C+@9'R4.L#,Q#$SSWXX@K1\>P:G;HNPGU*3SU)SV:W_3'5ZJ-)Z/ZO49
MCI95+WA;@HMM'2;:-%3M9X7*']B9Y$\>/F*(,[?I/-3!5TV^Y:@[C2-JVS_
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MVH,TNUOFV@W!> <3<^PMU+W#\I\&O-T_QPO_L<3L,]63[1@A.*D=3J<I/R!
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M/".\=U 0&9J#:9,RERYN'VMP>1(SJYKAN3,GALOT#.+UR$I'I;@)PTUP>='
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M0V*]#$2O'5ZE:4*E\2]+8X.HIK'.B9+QKU\=%9WM,S+D+Q>AH;#_\,[/<L"
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M_@55@W.I_19#@@P[#GAW94NP7J7Q(<8+GNV>(]ZVBV'EQZ-+^4C_9ZG-IEY
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M7%R: $2UYJHX8Q_B#!JHCS,[:S.P,W*OR>(ZQ5'39'E_1EB@*R?^U!1A\7,
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MB0XGRG6JQX+PIP!UU,*BOBP9C<O##*&%BGB!U7VPK(.0Y)X,W<3W[EG@_;#
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MP?3CV,2STE]._]^X)7K9_JK[LZ^7RX]C]Z+^'_UO0"B+)89<_E#&'UTZ%Q0
M!?ZJU$:R=7%F#2P+GT?'*<4'+/YQ)51VQ'RD7SSX_]:#AHI",*52G]_,SB#<
M__$+JRAQ'?PRJKE<5+]%212UI/WW2C?Q,Y@?17^OG@^5TI^W_[UC'3*$6/YM
MQ?_J0Q^W_ZP:_$;_CF]TKRBG5VBK-<^L^0]#:_[/;VY%;5UV;QPK_!JQ';6
M$O^.;8618\F]O1)4*)TZ57H1R"M B7CF%7W,HM*L(T:'P]F4UA-:_6\S'$WB
MO_][__#_?[YY\2[^UK^3M/_?,5X.2-,74O^[:OZ=B(__CB;J?Q_[/W6L9PS[
MG$!Q H'^?D=>@[[T=[G>^B=4>=*T_0?T__>+_^;%SY>L$3'DS) R_-^1K1$J
M-OT=[?_@NM68UW#&WZ'^__1!,F__XYMJ;7_K"<4C44,!D;L%\7[<]*M?P7BK
M4<P5"EZ>LBK:>=HHY-2**_93TR?\_,K8V+O>OUP^,&<M@]J=R\,R$@QJ"?(P
MICS*EK ^L-R*WJ6;>:4D?+ZHI#.W^$CVO: [S%.Z-G\5)::J6GCM+2SZO2SR
MQN^KU-8)&@:IRN-5.KQ-Z2T#L6F"G0Y?[X221"Z/!^JW!,V77DV9&3)X.CGB
MTF:Q=^GV@:<.A#_-2C,N*^Y!EV!J-@2I*A-OE&VEW6@ANB#*<<1#HW*K0Z*K
MRU13!@R\5?%)&;=YORC_)DOUQ&^NV/E.P/B(R!]TP7MBU^;XZ&'63*K>O,L,
MWL>WYW?TB]]XC90?VY&R\LG+CDO5MYYGUYO)7/VZ[%J]!+4!-AQ<@_\HU/FP
M.5-]+ 8^JA@QK]\YG9JR<D%N)D=[7;&<>MF]W.F*_A/?BYY9W&:O>'#\=%:I
M[%^!L?QTKFQ$Q7EJX+%0^8:R=[GL\GS7S&1%QGM/^TQ-<__K<7HG?\Q^UU^7
M'K'C<QYJR0J%[\)ZX'\9'UC900S)&!_0+^XH)J]M92=JR17MV=[])4VFB&;^
MXWWB>?/-!0WR.0??SLR>"E^GX/B'4C6YJ)6!5PU\V5RSCOJ(:$B=O!RMTUR7
ML&4"W6LC<V.MX^=XI;./WLK]=L]';9WO#N7?,+?:ZP?1Q\[*SD$2E.P5J&D#
MUITJVH,O;$#R6#)G9:?&X UT!$SQHM503S+RF2Y,)V[X'7WU[(KSK3(Y&YR=
MK385%Q?9X'Q]C1^M7GMTE8IZ@L=;K:WGS%4+&W<]R7B8_E?XBC;9$4(#MD^I
M3A5)"V*WAC,#U)2Y(V]SO0T>7@Y4H.<5O,GI<.PW'WL7=3E>[6KOJ7??31:^
MGS,/[ VO<,"]JUW&<TG+FPJN&L[V4LW+<"$4&7[UER_O[V0W)+$\$FPZKYZ2
M_8M$//(D^J?R<@K7H):U#3Y<]514/:#^=?Z6SN;1D)5Y:E8[Q,SFU7IK]MI[
MR5?O./[LD-7RT_D9ZSZ%V_VY?"& ?T?\]J;I@;[FUU.W'-T'#G?NNU9:6AQA
M<<GJKOISVS)ZQ_;XD&,E3=HN,RTS;BD&'YX-G?>2M_P=?;[M_]KS=@.5GB);
M!80&EG*%C,:3JUSTPR*<8N"&>F%*XJ $M<[B2NA0!M&F2E-PI]<M&CYTQ?^:
M7O^[Y->]%AD>P=WY5R"W'YZ.G(C4TK!)AX*4YI3T/5^I5JT]30<H^JE:AIES
M'<4G*2JZ;V)MGD_M&4 XF%>/:CIJA[E?Z%U9G>D1U,-7)C-.%^1.OZ_X*^'
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M)W:M("H*GN ;$HTGX_G%SX7JG!.AT?@*?K?$O&L&1X T-\\K.=^]HO73Y9M
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M*+'SWXRW4=_Q%MH4*Q2K^1J9IR6[Y(M7\M[^+J>?=MW]7ZD,"V3PC<.TWX\
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M^+BQ_Y3(7[J+[?N;R%_5O??AKC0IUI@W,C[>I?H8R&<UPZ;O$!+P)(+=RA&
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M6HT]3#P"A$3.?I?Q\4M(+M,87N&2.+CPXK9-RZ=3Y0\H5[4.;I/]J56:[VP
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M!"/LF@ZN/ZL;Q.B?(ND;#(*$?^OV]/--'[6>^-YI?.:FOG*I]AQ _L9G[E:
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M1>=PA/9SZFPGD+,;P;:"I#1"%A$V5'<C?_$B/ FK>N$;"*T,FO&-\*S8O)V
MG>2JKSI0YGQJ!5U"6ST,<UF3FN&H-)5W.\Q99F%M]SCA@ ]X_ZS/7\91E86$
M)&@V^P-(806+N\,UG.'*(E (!.8.E7#7[G*%.'@&0%S9J5N9>BNR(>]LEJ<K
MY&9]()81N3:;?E9_=>\(("1.K#H"?&JH/P*@C@ \W\X 1T?P^MA&;K+LIBIF
MII=^<?+RX/RF?T9Z!-IRT+:^XB,L@^2_)5IXO]"T^8EKWL27D?BG#.U3/!\[
ML>?3Z6+(LM5#'HUC4<3WE7W/J^ZY%#N^"NW\T!*6,P5>VG<NU_CZ3#\K+*.V
MPP3J(N_%@'FMDO:9^NV!7@=2W<7@I0;6FF%@L&P!VJR%)RC>=6785B*<82&D
MP_-LO,K=-G,7UDD^-=U@?/C6"><C@$,UYXOMUSYJJVK4-]U4_^ 29N-0J-_Q
MU*H88#L"6PB,:.!C@5=J5A(.R+<V/]83)&K>08N7]UO\A0D"1'#$"X_XWY$)
MFH2UV)JVJ/SE&]:M?/4;X3)0Z%L1:!)$<@LQ.:E*]O:+W="C;">H*.EJ[CVM
MSISXZ:8UN3B74+Z_(VX6B-S1)H\ZJ$WV9*)#YXIY7M4&BU8/) ^8QCE!4/"J
M?14GS^#_P:]Q_)_Y\)>AC E@HMI[@XX _,KWIAM/P.=EU!C-(:H\-9B!I&8*
M\] %HV4>2?3$^&&9V3?01EIW5=S<N%!7IO,X3^89RT64WLW(B0VOPP!P'AD\
M*Q]A^]O+!/X%!>$[:1)G+4*;[>,@3U)-8IY6B[QM,D!;VHYSOVXQ2U#1TC:-
M,\WR5=>X=G59?_3JK%E+<60JW69/V2:H16=&15-CTZ;H(\I:*BICD9JYTI@'
ME37PAXH<'W/NR#E\2/N:JB#$C;OTV_D2T_.25OEJQ@2ZR*JDR"WE7>Z6O>BO
M);<D<.]Y&0T>$[A #G?-%3WMF1Z>Y64\-YF=7)VO8;2(M+?;$/MR2/B_HK3]
M'W]L3N'.PSBFIAM;(&3-S"EXU-TH;()D_J(B[&#):[\U(0F8@L*!_Q=OWQW5
M1/KW&Q81 3$B0@2$J*BH&*(K905,=%$16<0* D)45BD1LHI(E)!!$$(1LJLK
MK+ 0%6E2 M*4D@ AL"XB'20H:6NAR8Q"&$DRW/'WWO?<]MYS[CWGO?>?"3DG
M/.5;/F5FDNF@16RJGC_,>'QGB^^9VM=96TTNG-EYQ!KKG6MS^=U\'BYH4\S=
MF?D;)6\D7>9VF;(<WRME'L<9LP^M=$ZF#<I--FW.'CW 3!ENC$FI<VK]M\FQ
MB_W_FR<U(K1%C&2*^/7'H&D4/2[H*>B+F,%1R1.,&A6]<5&+F+_1GCO'5N[B
MCV0N8DYRX]"N.XSYAW%=TH27X6]%=FM3*S/[:SJM:J^OW)K5)S6Y^'2 4/?=
MH_>MG[<0"?/ZB:=/_:QOYEBA+1T6$F_QB+"[S"P'VU:[2OW'8>#IW.OUF4I+
MWYK ]7&R5__$F_X-M7?MN9UN4V;NOXD=[/T+]GMTD>2]Y)_)(^^5QP=M%S$I
MN79]CVM[JS_4#CB;7(CF;;7S^X= J*T/VW%'3\]JI7](Q-^3YO](;<XE1E](
M#\6H]Z(#.+NW QJ,]7)Q4H 9G"8CN+=53008(YU(9^_YQKY^P1]]W'<##W'V
MQX._!+RR:OR]\WK:$>*>XS\<6;_/'!.]OT<8L;QVWN!QC^?J7[N6IUCL/G]/
MUVUMTHB7Z\$+%RR7/X[_LT?[Y0)^ZC[8L1\4IZ@V$E6!Q71 6&<:^6Z,4S3I
M=<YV4KVI?-23W_=/_]4<^Y.Y&O2/+XI(>=1?*OW,BJR"+4,Q?_?Q \6LC!NY
M]Z/*Z)D=8\2^6?=;S_L:'63^5T0S^Q/R+EQ(CZ;&. Z^8UU) W]45!SA/'^>
M0O?I;7;D))&K/.,:HV7)JDM9XMN-FV0-SQZF?/$"T:"8@GX"HVJ"LW?&?#MQ
MFVC9V9/][RJ2'A_JV__)Y+5F$>P/.K60=0EV?\R>'*A)<VD+0JP6Q,GAYP?F
M/+QV7*15G7'T&_5-/3YL6/V;:W#9E>[ZSWZ9)R,QG\M<% XPS28/B'Q(3^U
ML/V1/GJA)#SXGD];>O=[ Z1@8V,_+7R5N3#[[_IG36F:UW_9OO/6 <R\'I#
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M-4S/@S=D%W/PG]]HY_+',YZ.B<=>G31>*1+MV_[YWI);!]>MVKD7?P= >1V
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MI@\J(YK""[ZNW(7T,_> F_,AO 2;ANC!J2>'20:J,[U7TYS\AC[--NVQHQG
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M? 2G"@.LKNT:I13DE'7$+"TKH+,.5_<0'X(=R78Q:S1%9$D.!3Q)3!.; 2'
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M%J$BJ1^N4S_B7^";3\R4OH8]Y<06<J*%#51[[Y)=U_HI8@TE$?EAD&%5-+[
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M',H!EY)R\=+H4M]4?7'8)%Q>X]6R#.O)<SG1BQZN0NX*.G1J2KB]OK $SP'
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MZ^U_G@032/5#,X$&2V\^<X4#4L=OW^*^7JI+CCH'%SI(;HE[99I: E:B2.%
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M$+EY^C0IO8NEYFPI;+))-W!&::%JQOOJ&(R'QT"!<$?X8D7>A/G1AT% 1)J
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MCFX'+P)J0D3G6'3PS:+P4Q@5V1ZQ:C+O)-YZ3Z1)4'UN!/J=\^>]WQYN"$A
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M,")-:J: 4':D#^ FH+1;UU/;>Q&UF+F5U5,/Y#14"":5MHX5ZJ4FZ012YHP
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M*HJ0'W(<J$H,B\V\MP*,*ON@J"+*?.5Y*U\U>&,&[PSOH)@>,LV.'U  '-A
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M:5[+''5VT"*]/E\_S*!MF TH<LP=/PM2ML!Y-"6280=MO;,:GY7<NFJPROD
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M?;J.YV.N,A9JK/VE#U#\1",()4-J58&TTXB]!I3?\ TA:4*4/-OQP"C.)K@
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M-HD12CD(Y=\KK)D7?W^/*"""NYD&'5T-5G,62F$;W1&TAX#>5C&SQ=X0OBV
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M>$"P"!TF&X1%,'+=Y ]<ILJ*M)OA7W0;QHF.AA8D:1W*KY!C]V!N,,S..O<
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M>W[?NM]WSUKW_G/_T+6B:^VJ>O?>S_.\>W@?^:XQ%6D3Q9A^9.I@(^X]@J]
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MV7-D/&-GR1AWHP?"PRL_,XX^"K??CXHAZY^JTW95]SG-1+L9%BYD#I+->.$
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M>4:L]=%]8&71M4=C'O,#1QN>P5'R?P1RTC;-5% %&8\BI3;Z:B8C0=,$2*6
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M7Y^V+A.7T+!C)2>;<47:F1IB!%&$E'3N1FSBW&A:(,W2^QZBW&X*DW>$M.T
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M*S6W7R2;M+!L?!V5R=%K/DD=PVHZJ]_$-?X3^VC;YI0S<<M^=5L\5)/W;PW
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MT"BY!7QB-[XB?!":UU$>5T]%S9I[$^6-I7YDU4<^MJ-L]!S=KWU-_9&[H/9
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M"(61+4WP-LN,JS)$-N)^B*$DXQJ3SZIICZTJ_8G:Y!W?>>$G& EF@E5]V,)
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M0M*)683*YE77W-2T]'6S1??_SZ%N_WU=WK]P(2T &K>!Q[G6G"&IH0]))LT
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M,<DLOH'N7PT-7"Z"?-.? 8G6#27A97T>^J+ %8<GWQ1N:^W9>4*VZ1ZQQYN
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MZX_T1THG@^!RU23^OBN!1BKU-'4H456I>>ZHJ0%BIG+J:G'FH<^V19C.%T]
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MPIJQS8)^04K<3('^P><N%1>90&-X+F;X6:O'B"5D@QG^D8Q;Z$$D6\E<ACL
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M%VU_8MQ89.Z7N!O[#:$Q[3QV,QFDML K@N-5O%Z>Q@,.U-JA?4#Q*,\2N53
MFJ/+93NR?GH!=J77NW1[>COSDUS4!-A7A'[?6L5X"IP>Z<[X#?T>](]''(O>
M#0YX<1M:P]G.U<\S.BBQ!F_ULJO\OD:*5*T(198L V^K>-RUJ"/SE.:![BEI
M)08.RR4 +MS]8MQ#9!NT21@)L<FVK(/PE8</JMM+MUV(5A7:*&WBHQJT9S)S
MU_%S KFETGKOV+/H&UX) [$J1XWJP!?]FG5=@#P)*.8CEB6[8>!*41A@0#YK
M[Z3DC*I!D99>[U]Q9Z#\$3[%W::!@'_/;#E4V6IS\+:??Y>LMF1%:N[CJ^%%
MS/S2"6@3EC)W:Z^@(ED965^%,=L([M(2!X4EA-%^!;V_0+4I';P0"#'JR'U[
MM'4R$Q0?$;P.E(TY@3F-&8\R*(GL;P=@.]&O$174^A;#Y=-(A3J)'LD[VL:/
M(ILPN>(R8>]&66R,H]:7_1HHM1'CX6^+!%H;ID\M02HKK98A%I\4W%HMD" $
M[S!7BM[ .0I9_, "\&.Q@@OOC28O/,:<19(\&W*/YVDZL]=0\<=C>&/6%:6:
M%W4>L>QP=BL!W-$B#=3H9<9)&% DDI; [)XZ\@) _H  ^JGQK"U0RS5/"XBD
MK<]>#].>P27;7K2M@%KJJ8LB*HR@O+AHCR#&?C O?MTH7UG1C2S.'Q@T#W-'
MFA2ZB]J =IP;:J4_C#\"EZBH\013SYTSN+GJ?XZ1SA0$>30.F*9H8N$OD+>2
M48M?@FRN!OWNZ')EW&4P54Y(R"9T(=&/1MC+VA[6%(,)#RLX#>\WBBIRWS]D
M)CC]^?!E9:+!$+<_16.B>U2S"JB+(,MO$@1N=>KK1RYS1R7:5;"W4LA!US%%
M^R"JB+I@: 9GNK3'TTL91*RO".%>G:1;A0U\WWU6-I81G?6,9 06E8?G;?\S
MG7#ZFN%ZW 4A&(P%?F/-(UWN/X/-W86TECZ: G]-&!$#: SA'B6%  LUWAC
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MX%5\Q$JB6:/+Q*B*VA(Q!LM'L00Y9XLN21C65[.%_1:[JC=$%@'FR#*^E,E
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M]3KW'SGH9E@$G:J5S:JQ8/G![R'R40<"?!Z,JR6M@^^IFG^N<^T(#S8'27&
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MZ?L[XB47F@^;]^VZ]EDJ\O/S#6R/)0W!7=AB\;IL<@C? &T*=M051!,7LN9
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MS/AR%;*TZ3O9'%7+-\-3MC9)405!@*9)T.;Z9*W Z62)MW7>(VIP>$]RGD7
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M6"<(>3PP'+RX>Z+ZR+LAA_5M2SNK5N?+ H<O!Z65D'(?15R\>]]!^V_.)2F
M]6TLA[;4WR8G%XT)6F",E)HM+0.W'Z4*TDH><1>Q7*ZHK8Y'A#MJ3ONS;:O<
M+]X,/7'!7/B2TY#>8[W!N;KL?FK*@6DQP>.@QG5A7FBX3_:=CQ_8@0W2U:Y
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MPE.@RRO@PJ8)E"].4ZD]0V+AF>V<WA)M*7?Y.YVDIJ,,+(F,>HF1JEC.B#U
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M8R^BMB[" C0P\7WJ!/I*@),2]N9R)O6>=#L X5: D:S,RH)"/P%R?4,#"X;
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M#TR_KE1%#5J;++E*'$!H$9R!-'&\O/_SA A9G'2-@!JK_HU<C;M'49FB[QT
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M\+?Z+=".O5N@U#P6BG<7([<%*EI.#NH'(+>V0/J0A]#5P"HL!]1)6G?ZF1/
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M$B_AV1*(KK-$]A0%5XGDN_J?#+^-JOC(P(9U_*MAW;]+"CQ$UTX+OZ/*8\R
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MZ@.\P\7^33^,WV=Q\1W&">6_;Y+G-4!O8I.AE? $C%LI(/0+T)GG3;'H2,)
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M3H$H[.#OO20 1DO\6 G;<6 +Y -+R%5E]2Z+36O>PPNO41/D%5BP)1X#)[/
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ML_B#P>;_[BK];S)^#"SQ!-H-(L(U0QUN*[>@&3.K6:-TYE#-Z<4!Q-T.=MJ
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M7#-7'"AOT LIZA9%Z-\Z*';"Q?@5)3\^$ZQ]_6*]D*_B [7QBZ^B;]&G&K=
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M(D?^/^;>/*JI=$T?C64II:B(""@(*45%)J,"(F-*$1 0$)!!$*(B,D2("$B
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M0[3Y_@*PI@E7J)*N)E#FGLCR<>!R3'E=BXE_]>PP[PTP*AM@\^G8:8,?T:M
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M?Z$I9)NB4XM+QJ<R3_N?D?,45W,D&S?[(6Y&TM]?@H^H,I78Y_'[D=LE</S
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MOHDJQ.I=R)V>#JRNKGZ:$9N:\N'4A?A?SKS693GL]N3=/3!8:+O7_Z25+O/
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M*V1VO+A^EJH@R/2X'I;UTOW!%!K.6O[;/@V[_IH^#6_ !3KW.A2FT"YH9%^
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MQ=\+[M5A+Y?8VJYE_";OWK2-,*=BGABWGW_P2C]QY_B+5=@).H#AB+82.E#
MZ197)J%A%3:W@0]%(MA.O/2V/$[B,D'63-4\:Q5V$[\#TF%:'  "TI;,33U
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M&,.OX[:A*_=RXQJ&5MR>Q#/.-.>NPEQSASJ&.AT'$/,U%^MKFPM_2MOX/N7
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MOA0J0ND$?K6">^/0XH+"C$0?** E\^04IFNG;V0O*W3S[,5G4;J$*S3EHU7
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M]9*+@ER*\.'NE,37Q&'"ARM9065S_5-EA][:J*;@7\?J4OWRG_['H/Y1Z8A
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M?Y/F"::1]K[,KQ@.&'>^SH-JXZS/]2PHU0VR+Z6N2:ML*CZB[3U;(K(D]:_
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MEI;KV]J@?O8<OLI OFY*%A T9D71 **%4M->#F):"M9 JA/^\%;-N5N@'G]
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MU^QW5G3L"B_QU]FJ%A&Y^ZR/6M"NC4=WWD3^U<J0)VV";)G14FN TM*=B-(
MVRM*G0NG"PX"\[>1!PLAJGOO2X2)N4+:SA58FV_XH["*<>R#:75U2Y;/N0 G
MG,G7K)+.EDMU\3UR?(KN"JQ9C\'-1V\F68Z3^@+V2/X@FN!!C@>83IF0!/(S
M[H@]0"U>1\KBO 8V)OYE&?8%E"+B<>[1C.D[?Q\?&7T?C:ML?>83NK]B--2B
MWJNZ>_437:K(1]K1)?*TO/DRC!&*']40!O;3X8CD=LHSZ7N.9A%TAKX398C2
M/<C(B##Q;AG?#Y2EY]FAM.ME#.-OA+S6Y10",;1@A__A"_YD=]6;8;+<^1O=
M#-(3^N1Q\;<8.$12S%![JI*6/TN,$'G)&";F)LJ8(%5R.@-Z%5&QN1WWQ!J\
M,03/^Q;RHA3>.\\'TO(KZ11>5F.?V:A"XU390/:T\+M<IB2+MDH41Y#W!\,I
M(O]?K2"Z!6K<]KX7JN]BYEOF1SJ8&!AJ^]&7]K&6PJR.U-DYNKGX#!#W+>MJ
MZ1]K*DM3@\O&CY)TQA<%B5D&\H]LP0?2#:E/Q237=80[PAV2/&*8R&H&K:%E
MRY*:B:TDKR/CM#I02M#^N FYH, )CH88#LZ_4[(P(3.7]6\')?J#&G>0^A,L
M_(U*OX"0Y;6UD0KL@$/R)=(!=!TB!1TD(+=DJZ.K@@59(F<"KBW&9JZHG- A
M] 946KN3U0LV--70TP=M])@H+5">B9:#/CGE=5["B<X2$;SYS>T]95G;TR]X
MPJQ-;(7-D <//A**9B_QQU/!Z]SHEM$XE5-#-*>G,H)A#2JW\CFW!+5D55_"
MB0]#3,XZXL&GA+*.!M)3237Y0GC8Y84PVUE?_[Z9^LRCA<SK<1O7ZL^6B\B_
MF'_=7X1V^(CWQ KL-NH 1XQTUG35#1G7L6)F)"&U"W8\\$@]CMH-S"?55*KZ
M]Z:7F:95V%UJ2,B3<]J3'Y6:?8L)B^7$H_:+=X+?*LN_H^2A<F"B/68N]5FH
ME4M5(>31H;L55*\LGLZU8S)?5I9.QT3=?QXP[C.M&310.5!7%!RI:&GAK3ZT
M\7.']N]_/E_U?0%V>HV)DUM5[\*,Q.],0T+'J;[9E[4Z)Y:_MD4)HRQ..UR/
MCD0F)O'JZU,<@JZW%![43:A]>JQN;Y.VA>[CF0O[S;$]3T_D?LOW'2@M[RM;
M5WEN\O")_4Y1?=-VCK^7N)3XOCY=YKBYW/U:U+T=Z]ZZN,=MN9"'+[3_$086
M\4O?RCZ"4U%ZN#[GR9GEQS^P@P<^LO:D/6WY9J)E5]=Y8)=5V.W653]:C)=^
MBZWW,&][R9ERW7#EFTK\ <7ZG<TGM/\P1NH%U/SMJ7'  0<GM=3R@4]-P8:B
M3RX;OQ13=FW/^'IYTHSZ^)L/K;TQQSRFDG4G[+F9:JWF_N]95EA[)T/'OT@+
M>3G90[VZ/K]66EF,64\PU1T:D3E+@=X0=4\_TNW).(=@S=2,__C*Z2JY(N0]
M[JJ:I+F^MB;M$KW/7,=T[LR^FKQOEW)C'VU[N7L%AB*>Y85J[V[_0[QVPT.#
MH.$/9ZZ?:D@[]&E?40+3ZO>LK;&.M1=Y]FJVFQP1N?MK-J<=LCNQ29K-_3A>
M&OD[KTIM<N\?N:KE=]KZ']PK<:]4V[8W\VN\68F5IZ'S2Z]YDR#]&YTSFN+^
MY2?_VJ"J8@*-;E$5[P$7O%'K&5 &7C\1X87_;2K'JK+@*?\/J3/;IF0P<<TG
MZNHEO;L/7.NSOU[]L>-;51OY-^K<&"92*K@>0!X[1Q?2?1^?37&52W95,?:-
M*"&:[3[TH7Y);Z^CIVH</\_&\3^E"53^6XG!U>??J-FLVS[Q^4)\:1.#BNZ<
MEW^9OP*C(KKG#KM"QXC6,NNZD[G^W2LP[2>@+!5?ZUZ6SY$J5\K2GPJS&SHD
M+TR#ZD7KR,W[I =(?>1J1%(830DDM^CN@ZR+OZ/T^LUL5-HMZK)1IA"%EZ&$
MZT7=X0O0/CUSOO/V_2\%F7[Y**Q)[E&;:CNK72GR0N6S*[ C/V2!?X#Q\_RR
MD4A[_!SQG.0^.8B<(K4F"_#:1!?)8Y*\^!B87;&A])%R&9^A23P ="0C[9[9
ME4Y5L:?8Q.A<>LF-ZSII\;5-684GM]?>WJIWLE]E5KM:>NM7)[P*\H_6Z2;+
M4]5]85V5]\*VF!@Y>A;?<%DZXV5=;/SY;L#!]";R71M%T\T)RGDEB7?N:G]F
M7WLH^989_N-:S+-*Q%3<#7Q/Q#]98<[FK(5KBO>1>8J94UHRZ'$32M#KI^6O
M?\"D*'<2]G\]$[;=@?]JII*IW;VVV+OY@?EK?S^%TO^U./V9,1<LZHKCD"AO
MQ?05&+-)\JGN4,D*3$\3,RN@EE] LRNM/6J)")$UN;4)]SS9HDR4&![RU[7E
MK/^L:OS[#QO\ZR]J@WT#ID%-3K@(6L'6L,E&GT"_1T_JL0'CZX,5OKU75$'.
M*X9_W8G]:O#\XK5W</5SY&9S,I=RD(CI(8>L0U_H'GEP$N+QJ%JC8L<^DC&$
MYW;?0IJ :U#;?:?)HZ>A=A$S0*LWHC+0&]PXD"&\VU!:%?W,WS5:-/4EZ].9
MW^H%O^J'"Y"<R!]J;&5L1.W&,6KL[Q*O\UR5X>N_DW9#&B(/4@]GU>[Z7G0-
MM38B9=(6<@/U6L:W#" *^\V-WGO[#A#1L95(A-*]H1_#9\_ZCMZ,#C"3_+$8
MYR>\U$L.AB?":ZB"'4#T:: ]@Z>D=022/(&&[&1L:<&.*^K4>O@&U$\CF1,"
M^9[U]^:1#DK)++$?F>^_9P7F/GB9BE!#O)C;K;%NU3?&KS)>!CN0AV^F9HPK
M0RS1)>(12=4\[3Q7$.P"X<JA2>YD<T8"?2]@%L;#;)P:LO(X1U0'HA,B9)/]
M\TQT/?MB9UPEX>J\H(25;7"A073Y^SA'Z4((]TW&]O8+VE[P]?E??7+GKGVY
M762K<ZS2^_!AEEO*W: N???\+ XRK$M7<?#AS-<;61O.?2JYO/9 EKG:C</]
MK?UW#WL;SYMBC4P=QJ8Z33(F31DLCY^'_M?^)J]?K>TPM<&S/WF4+1CI^YBE
MMCP3A# 9RN#K!+9+UT'!T4\@NG7W9H+W<>"<QG)!90ET#XJ6;JR@5K$)T9B"
M">>,MHZS=:D.;[(GG1,,7Q0W2O<OG^ ;]O/%92I:#7^0=(OV-O@:C5[:^O.8
MX6+HOF]9.7O=4YS?.]LOX16F/AS>8U'T.NW<I\*$!D9P0NL>3E!T4'5OTXNO
MRYX3U-%$X3[('[00<:EM*S V2W@9PH)DY^J^6JUN&>+?2+<4FP/V&1.LQ<;C
M]#X$JR5 'S3->MD=_,S708=9.]!TK\=!^_[O$S%KI7%H1U1>36,MH[:.7O6V
MONEU4WW"W*<??2%S8>&"\,"SE7-A+W<$I\3>X$5D;RN,3O<9\=^6=>N)PK]T
M.MUP[=!_A-I,6&B>D(?B#'OT[<":ZZ%U\[RKNZI.+']P+C0<T(L]-%+L<<GM
M!PS[)(DVE: /J9EXC,0RVI9R])>:.+&N1C&5GXS?U]YJ8S,&,-5DP?JN6*U:
M42=K:6BOU"^F>-3&M_Y_)Z#_3D?QUT6*E[WV6<3/8\$"M158D(*0L (;&.4^
MATF(,K 6O0+[@%Z!G<\0'62,Y*S SE!OA\C-.O[3N??'S#<,Y!^@83OAE^>]
M HOWGZAS371L>%0]Y"W=W)VX$Z/Y\?W>[S/7><=V] BR"?K]XXAM8UH.86'N
MBZ8@>7Z39 +SMEQ$C>E;FI+^]1.O$H\97QJK>=N!^+G57<;[,LD>;>37L>):
M-#F>OF-F]N>S*6?_P^S&:C=W]T7-X=E_/W7[058G1D&67.=0LC*A@X^Y(S:G
M^MGA;=H?O,!Y97OWM$9OZ [;E?WC3:0#+S+[@/W'>ULO;CKSU-"HF"UE4*'
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MEE.<>O?1 >.(.-4S-5;MCTK]IKUSEBR/Z,)%"'+SH4H90$ZVH*-Z5F#A<,B
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M%OF @3XCN)H_LY!0J*+BZRH<.X2CKJ^_HF(@>40Z1&X^2HP&U6=:,+6NLUK
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M<1';6DWV"9><O] A<6&8J28VK&\*#*!A?+@]77 -:JJS69E3Y[]] ?*7?WD
M[G\],]P0(S4(:U$_#0<4;0UZ$",=-OZ(Q;T>[*]M64G'B,C"1=MAG\<ZQ>//
M@G/\PG0+B1B:6+B>^>&K"3\_Q1>X/-:_E<G%Y"+K)B@CGOS^\TD>5/*IIJ?9
M,2@O3IG%CSD&<^1#(;/0U2O?:3ZFV<C.R/C_V)-\_LLNQGZ<#>;0FN=M'O##
M!+;CHS=D%BQYZ2QH=>5CS_50_WCSC,C?ABX,JKU7JKWT%Q,28K/5*(>T:]%_
M%-95;(NV1XHY6:G8E6DH6P3"#ZO59%\@VY9\R^&7IAF'7NM!>5[T/+#A\"(<
M?%TKXJE;23LL3<=*PP,"C<L RAH8^K.^)IYY_2TIJ=!3SOQP4OD>==6]E_\\
M\&OL_DO $J6"M+QA*Z7,4"LC>RM/[9$2U-;DME(F1'O8NM=H>(5-BHAN!;W.
M.*!4ERD+]GWT^?/GC*N_QAZ@N*(RG0^>^JWM6:[YPQ"')&VGT)!#'U+VW5F0
M"4A;4&DYEI"]H)LO;:JVGE:PDB]=, $95PR%F$G7Z4BC5,V+.RY9U>FNI%@Z
M30PJED6<7T,^AXLK?-DYA3-X^PC&AW[-Y)^YY=9Q()W0CRHS72^3)IL_RAFZ
M<WLU_JMA&J;C,^J:*^&R]O=KT\QL9OZ%.;_AU*UEK**84KYT\]7O>;.9"W/&
M"RI?HJV?IYOX;9;/Y^"_8EYE8D<2<4J9#2"=U?RQLKEDEW\MROH3A]K%6Z *
MEH!$:,R9EERYQLN<9>OGCG4$9E74,VR"B[8^>C/\,58T4/$%<_)$C.NQ1V5G
M3/ O+8G!SNK\%7M_!8J%KC_%9K7A:K5DAM@)RCD7DY4<UF_V:<6[(C%J6?80
M.(Q*W#088_Q[&OS+0]C^&^1H&>N!\=4P!]Q;J 9,C^,XPU)HG:TD3MB,7O1F
MA;;: #KT#+*#-!./++ST5\0-7BSW9\P25\^RTOD=2&W=VOI,CP>,S=<Q+-2*
M7\Q2WY#'CZ:PJ6VHJ&\!B7H--&Y^QFY.,)@O&%0$E#R O)Q#*MXNY;C3SZRM
M$(MK2SHN)V0YSM)GI'LM2?\MIPC\GR!)_\>+^$46L+E_#Z<J'*KY1'%H\_0;
M$/0'Z,20>?:NR!GVVID1>_WS6NIN;ZC*4>6W'^T8-L0'1=4>+SPTV'8WZ5U^
M_-O28LV!S&R_=LUW[.QWBY*I9N_CNY^ZE.AW'\TQ:_R.E:2&2F;+KF[[[^ >
M]E^S&<]J;0D%&9J7XTN"+[5DC-CV%9^[?@[?==)T=?C-0S-WEY9;BP?-PBCA
MT;C.,<JM_#]:2C-"LTI<FPD^W23M_ MI^@^&RY1FL]-2_(Y/>UR+FP]M<YJK
MK[*-37%R;BP?#FVP27?5+E^9C>A_03C- 31#%KZ3[X'YA4=+HN8W[I*_['>9
M>UHYL?_,U9I7D[<OR]F<)4"OT \/ZWC\5<K^&%EN),U5D[)>SE2M<Z@>,1Z!
M:31"2I;N!ZXHB;MI\_GX JJAP*H@'[YJJLH.J:,ZQX?^SUXF=.X\]1G^@F H
M21#_N1E_VO=*8\PAKC%*F*H']9-<'AH QFM"K2R@M6HUD1JAE;LB&>^LQ-\?
M_DSW_^Z !?AMP^,P39C6U?'E.<Y2TL6.71';MO6!G6$VI-P(I05YC%3\N':-
M[;QAY2E?YB[W'X?V_ZM36OX;.(NX?-A)3];1PH*PN&:">B43$/^C1\[,%'K<
MAG;D2CLNA1/ID-NRLV52:V6]^@TT,NJ6D5I(]=*I>4&Q1+DDO(!6N5<]LLLN
M('[4L09=W?BL2G!^3,=@)^VC5S!55UE7_=)]#GV.8+4ZO_"Q(3<:JG<-9;TM
MM%+M._.F[UA:9LS&6W_D10\()2R(?ICR*TOSHP_KG+J&J/U Q1-#/=KP-%YM
MKE&KPA)%=I\ KY6;Q^#<ELA+QZ:6E&\WQ)+) 6$7*;!7XW)Q,MG#?N@\.M'[
M*_)".4)/CUP]TA\Y\=&N,!X&MKB*E;$OFK% D#YJ>=LV*SH282?+0*HVXY_;
MC?W="^H*>ZVFD6^A'\;&;K):I&%C.NK+68PHWF_,V4KJXN@Q-\6,O^KU29*4
M@3&K?<1=$4C2O'F%8.Q!AL[ML^J&Z=MV[$4+1EVDRE*]IE?&VNCL R9G5\1'
MNKQ=+3XPL&Q3S<KBB(FI?#^Y4-ZI8#MM J&3Z61F$T"C*G15<$H%5+JV$UF^
M[(,G2" U(/Y<NR2KQ>U';:VM&^?EYN,F=^0QC4*B%,+'#!]+'ID&BH7FV(WH
M^<V5].HQHD<E/\J;K)J3AYK(/[^^O2UKX(*R:\S04 LJ5!DLW P#W'?L4'6$
M&>7!PA\6:OFHM!N#@R)+LMM'8V,N]>2!=)VH9\YB1QB:F_HPSZ="N"NL)38.
MZ"WHK?%4W'1\;F/@_ XF>+?O6W(T>V:AH\DG[DD];-O.Y45!5B,^#68]XK0(
M-HJ@>KY+:)V9NFKR6$WGO&H=<2=="275TZ7@P["+4RPL39V?)VDZ! >&0>FR
MX!AU0C+=P?9[?>T;N#<-<H"C;A["3,(&',ES6<:49FU^9AU:W+@)NS2$^5"+
M:Y"*5?6Q]4\B]=AG0LG<"HT;A@F3J=A".-8G6GYK72>XTFOH;[ HE4'4IB_@
MOFUACR.1_88TYV<SWGW);KXZXTTVGQI+^*TW[WN(4Y/L_>J1BSXDH,>(4,NY
M<"*FP0.>O;YDC^.+*7YY$^8&MWZ;NO4HUOT5\<A8"BQAA97?@P)FJ#I;F!-
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M7]#IZ<DC;02S"7(LGMO62ZP8YO6@YW<WYSA&S:[(24Y4F)X%#BJQ/#@.O!Y
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M8.\'//A1-;L\CM>A[EC^E?1WN?=.W>I-M<-RQ/=9!<',92?8C]^)54KW.<=
M'V7Y2X$;Q"SA$FG$OM5=*^6=J@3 (A7\B^]38</P=ZH797H<!*ECOI3UB$V
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MP]FS6+L?_#S7K"JA:&*2/<1M7<-53XQCEQ=IQ9%._UT*?K!E<\!>&&,[HYH
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M)I[N4X_:Q;W)4G^!]OO U>O#%CK8@0VC],DJH9E5A9_"@'JDJU.X8T4O<OR
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MK+ D(L.7]L+PK-^";!AE>[1?>D10ZKX4?=U#8PKMQETOS&(S.#*E6$@G]W=
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MOHB^W<.U8FGV&Y&0<CW-_A-K42K4;=;3<]B]<V]7-R3KG:RZM"Z=_>GRI=M
M8L*7&-O,*IN0]!CK8.'S33T&=\/N#"'*""V'A=08.<5QR54Y3[L9N PHTX0
M2)=S#SHU0)FP*(IP?:7H/(%Y<!-NUD%^H>Y'^S#'Z+CZQ9#4(TS+"*XH'1QR
M?"=9RRA]3J(\TLM.K;]16ZY;OJJ+IJU:Q-+.S9,/>^Q84]%G;7=OT(6<5O_\
M:V%7DTE,@T5.CL4+>6-OV8M&=Q+##40^-PYP(A6'GQJT#D.CL13.6'E#1Q24
MZ>HSK_21:]:KBO2Y"PA"PW:A\%%J"%$__V+BFBU3_A?,7EX7>63/3U.+P]:
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MH.:,&*X=[R,X+A">MAX4]@$<2.WV@I"RO15(8^)H!(9@D6^[ 92R<MGVU<7
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M>E-<C*'QN9OO5C034D1W0!N>R<DIV39A;5Y.B4EAJK V_=30Q"5<R0B+['M
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MJ7$UZD/S-TP:V'.-V&I;RT]L6C4K-,6F_L_I+8?A>3PI!:7U-%,T3-(#4TM
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M*WP+J8M1YU=\A^$_9]5!TANVCH8DQ_XA.2I]TH24Z%</6FOPR!LY,Y&Z24_
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M EDMANGL[U(=Z^&-=DEO&X?U(6O&HC! VO.+313/6">A>M9SKT_@%;EWT-@
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M2_A=KJQQ]?[+?66F1*>H_"F25B\RS"LEX%Q%$127"D:<C/8F8.J.ZIV&=V-
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MV'"0[:HYE1VZH0R0/0S0?9^%T.V(N'+&?.L 93=Z&+D,$8[T4O0804]!;HI
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MRQS2E3U=A\O-03DW%>D('F&;0W)O5S3XQMB:3%=B1V3VLGBU3Q0L S;%J4_
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M3,2JC*F1D3WAD+&EA*2;WYE&>]PWWMRJW!Z,I8/H4/"=8YZ?JYG2=C)W4,U
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MR57)!JOLBDB):-W89#OB"+UP>=3,1#*ZH*.:=W;]<[<9IXD_'_4N8RA8-N-
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MT54-CI&!LB]?ELXQ1OSA 3FI[AW;3#5CB'9]".IN[;<H@X6-+ IVA<]BZT\
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M3IYB.>;&%&1&-OGZ7\^I!.+6XGUOT:85"U=+T@^73/:YX;D_<[984QM<UN"
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MS15%OP3!4. *@/27EZ9<^;?D7>;&HE]^0[NO>7UC[&_<.#QUR,0PB"_$.*E
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MJ#(]20^FJ0V*'<12&2!@X9\OYQ4V[B,Y+,^K4*C<9/PHJAMUP-(HT4&GMM;
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ME/!@C6K,RGZ<:BY;KC 3N'4@+[)"03&X>!'"V\>GO:1?\;E7WZ1X:B^[39D
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M"(>O#5!>\PI="[<<4?L=V)Y6"S.8OE!%W]X:?A+,GD$P25^*$!M6&X1\FQ(
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MM":%K(@QHO91]:#1:F)(]C8&T)K$4F)H42(YO?80IWL@F/R9Y;E@](GO:",
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MG_:?_\8 !@YF.U[G 'T50)G!G#P/_BYSGP"I.T=.2_MA=(?#^Z12ZR!,:66
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MWVD")TQJ(DCW'I?=5C>QP9'3Q5@:G3^\L0\'_>O0_WK\:-RC:(B7YHL4>9!
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M/(7NP-0LQ6\:R07!>(;)2]J+Z;<KWK8N+B6)5I/LE;M'CM@SBVUTNM?4>[,
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MWRD/"PK,";9$W?8:LAKH2>Q_1&8<MK^"PBA. [!!L3 3/</?L56_-["'/;;
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M4#LPQ82O^-S$WJ^(MW3S9;@(JBIL@483J>&=]\U'BV#R$JNDI,>N0!R'R?,
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M!;FX+EX #\S5'.ZJ)P, OV"')0'38*G&%\ 0V67+;.RS8#M,LM+R6/'K%7;
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MR++8["E=C9MJ+8&^CU)!NP50]43T,UIHQ3/VF6X!WHDY3*7P]/9 KRV?@]7
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MY%0.F"(!>\YUN_N9YZ!'.M# QR ZG]@#E_,""#Q ]T!%9^/<@4(^<46A3F"
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MA7_ICXKUKPW9G:Z*L;+U-)T@,"/R1_7EK$3 JPF!:1;%)<&IF\6OXS^;%%,
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M#5XUTZ#5L>M-3!!-)"U3^FE7F/N:VO\]#4HW^BNX"/<V:)G7\?!P;+K_74_
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MW<EUD\5Q\X>E-7T@#S=]MHWJP9QM=+[^A&8M@1Y).!_$I#^.ZB8-[$2V2SW
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M_T_.T]PCN64\G8@-VTNWCPGB!3GAI77//R[C"*\Y#],4C(B5<0I]]"OCE.-
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M#:EREDC\;G;,+K&]-GM%3?#X;J6PIHBT_GF';*$90?8WU;-WF<\BIKA],9\
MU5FHN1L<9/Q/,-U#D101K)O\N[J&^<.)"YNS",^%$"#/M8R^[DPF. L=*RKJ
MHSEF0_OW[@=&CFUI9\!7<QJ$3.[6;R^NXU+4.PX94XMVQ>16=_]GRU/FUR.Y
MUO AB^//+ _0Y._ HK0X^#6/M@9/HTS*0YVPJ@P%&(Q@ZX^NL&YJGSFS:4IT
MPR!T7DGK65E3Z;VJ7G5!,E>?WFYJO0"_F>NVD8V1^$8'BFHP8HE42_%[QGK=
M$&=&^D+N\F.M1N<\K_A$D*MC$ 5\"4U)OL68$05F%#+H9I"BM4G/6!0EK&WJ
MM,7M4Z4G#Q,@QF633G1 ^RU)B<.FGB$3COO,W\R="77J+(_KK*P6Q+QW&\)O
MX@=AQH[4Y!BE2F4(9M0/ZC2>=MBD?9^%4+RI=HZ7-%.U7SDMCJ@HGUODNS@]
M2KP*1E!'79'@'F3(L" T3NB\\VTB5,^<394I["3K^0'XC])/@,V*)T!C?F2W
M RC6H,TEE.]U1K\,17CE*;"LK>5'1+KV=/@6I3)*_!ST/2./!]'42MD54GU$
MG4'VOD>9X5(JJLC_F0HP+9 /)18T^@2@ZK9[ C"5Y&[2<P]2R<P%NA8[\?S2
MI%.U&J+^3TGS%G;ARN&M/KA+>5X_OLSO8YVL^C%C+60C<U>,7>H=)H[LX\<Y
M8=LG]D,CZ+- R'^(O.@K0W7030%Q8/2EJ0!S;66>_/R>QW3_!-B)8;UE \IY
M@/+H? :D@6H+<R@Z4?ZAE=PZ>2(T"W$^QR'([G'U"4 O T3J]F3QG6BC1,T(
MG@ D!Y</U28+6WU5Y66)WVM>7C+8AA^1.&?*YN3AP*W:AN,W9ZK.#&A]SNWQ
M1G^;J[ U-P:E]:L5._RH6&]@,/-ATKMRR*$L\)H9:=5<*6;)*\N3X>7D%,I8
M[GPP?P+\DFF&NP8Z&B7 SO9\"PV9_-\0[TDE]#]KO^M0_KP9D(U*%)W,@FFM
M_F:V&S:]_2MS?3EQF_ YAGSK@9/D>\VKZ3.!MAS,9&AM-<\U:JP5J-VG&G?F
MLX7+*'A5_:=0LIS)VJHBT%YVX)B$%+IB3\4>L>V?69R&Z)1(4L:4V<\Z=O*R
M\W*DG^!DL[L=S2#CMHU:T!K7>P)(("'*CC^N[H3++$Q:M)M.V#!9?(3&0-&/
MKQHAC?T<$4(Z(7IPTCRYZ\K& ZL4A[^HUW_-U^Q]9@Y\!#2LA6>C:96Q+-G8
MJH7+JE3R,!J<]'<-.II\'R<--&-?]F(E= 3R@W#-P28(*<1#UNQN80B]^PG-
MT%DAHJP!$N5?-+I(K1NT%:&YE5-34KK:7(OR09& <$\Z+!%?!(8@N/8>#^E^
M-*?J$\K\)G]2\WQMT%R7[8/0R=92W^V/'0NXWC;_#E1L8CX";!@"#)>9V!!Q
MH/I]-/E&'Q-%4YP\C"3&_SNT 2EI]O5K7\77 8_00>^$NZ\^U>.5CD/^Q1-H
M:,4+KK\]H2-)%*FIUQ/@#,*1+PA?] B?M\>-ZW]  _1!_#X2WO'ZHE.JF4L]
M8W8_!AH=KD(F#HG>*V7;>A6VQBQ;J2;3>J>RZ;;<WG_IFD72(^@'Z3J>,;I?
M5_)D390JX.Y(U+)5*9%HIMT];%73'AK?)Y[:/@%4+C'!&Q+;!2\-6Y#*PV,%
MCMC]IQPW7/FK@MN/1L =KF/.N;WX!)71R?W%)1"]L-/K69?HML#\5"\?]\\Q
MJGC,&&IU:7^GF$IJI,2IPUT\4=5169T;J7BM[Q;_9AL;\:</D2@R!C5>IC=6
M2Y%-.(A.89V\,;&%)']*D@ECSKK>B'CDA$\L-#;F7M?]G3%_SA]!+Q7Z5H]X
MYWY)R/:D0=F6KR%(N=%>%GL'&?8[TW-L-GV)8S]R*_/+U^^'_S7 5"3)=B[)
M<!!%VT.J#(N9G\-4+MO'C,K&?>N=A^&K*4B0#%G;/-AC2\-\]KSGR.D+">=R
MAU8("^=@3$X.N##.,+G7:UN2CTRU0L&>64NP'GL2+RDG5/R(:WQ2(&KOAX^2
M^VZ*P\>L=7(084:I?KVAEM($^])]QUU*V_)=X9$6.5H<(=N_$2,*)+FN%B!2
MXPJ/>5M*L$=^47-M<"0='U0$/7CDH]-OCKQ:*6UNJP\!W^V;S>QCI9U.@!LW
M-RC4419@P>]K?=4(T=YI0J[<ZM_0X57_,> Q<JD3;-(V+P0)3<]"IXQ1CC?5
M1I=@A<;)8S6W'#B&<4TZ6#)SB_"PP^R-A5\W=:L.H?H</W5_ZM25QO?4<2@2
MCEV 9/R1%97A01Z#ZA"%-%7/!Y(GV@2"^10B (1>P^"E?_5H$WCW@%:DB$A3
M1ESB5VUGGNT/HSF!YZ:82XU!FKZ1P[/"QT/;X((H&VE-8D%D H3.)@VA] 10
MZ(S8UTC>DC06K+EL[(+?8G=->IJ6*9AI[ZK]T6=9'#Y4BH?3#TJ4_(:FM_M_
M/:?]=O/U@)+-U-J/AG:(JT?*4TJA^"BAC".<SX<^6,YI19,$N63"=RI>M8+D
M4ZB;O?;C.W5ZS3_&,+.[_7GZ60! $3Q2Y7NS_['%;O?K3BW D_Y^^U@WPDN\
M>*+FSVCR$9"44@KS!D^HTU[8!R6A_EV'4=3JA"6U!\TE^!Y93#0W$OA'+=3*
MK!_3V^_ 78OI>B_5MUN%BH2JD!3:8HKR-_SAF&&L#!VXI]A\+\9<4/7/V%C=
M(W-2>U$2Z''$]*8U00PM[SX$!?)8D^U'4R N'E]WRBHB&O^P$'E\HP8X376"
MR7XYB+:=93!^"]\Q["OD9^&5EN9:Z%#GSK()QU1X<\=#O8?O-Z'Q58HWPZ,I
M_8VFJ,Q6I$E3;5(Z)%U^6.@J'2_3]J_G!)AQ$Q+5;%BOB%T@*&$5DCIM. ,U
M*'>MJ5=:26LG_M6"$%-64MLWH">GF_$^".#.ZBPN^U25;T%[IZ49R+4KN^+^
MN*?U#P432.>,_[7J-/6.:\'EC*U-WUYSESEYU7!"MDECCF19=/B8*[=4*5=?
MJXJ+4)FO)C] ]N\?'WU+YX-'M2 NDUAI!:4Z@U7FF0JMN?'$<>9+_WTPY6\[
MXZ!B5^$5CNKT(ZB)'17>-QZ&"T+F%.U;SKP_ )X<;,I#V0:O(A$@Z2GWSRU=
M^>D$_L3,JV-OE_FLBVH<L\K(6*$U^1XN)P^* :9O2KU1:#=05KY5P+'#(G1M
M[)^Y*F5E!;0@PG[&?4;>PV.OG52V=8?C<$[86Y*K'1@9Q(G ?WD17OF+N2Z^
M\N4*PW&^/K6#<I4'M)9[9Y9UKI):%WMD<59;: :,6C[="7#O\5SCZ1M:/N!:
M1!MN59/9@^HEY:EX#0>[N$-7-,ED+B8L&1"KI1EHULQ*DX>"YME@*<MW\)_U
M"$C$:<,Y]^IAFU#6]>@JX6 7[EZGXN<\A:':.!^>A.L=&5(\-YBC8^P(DU#X
M^-D!@4#4Q1TFO+JRZU5_"5]4$)]OZ)J'XR\%ZZW8U\2X9.H4[.L=@S:;UZC5
MI2D0GN=8YGE5HY <L[[ZQ_/'BLY^ZT++%4\\43'FL&E8L'0D#&<8&"?#BC02
M[<TG]<V[_0B'1!BL2_((J*HV1AR!LI3EB/%(]BS%-_=C=L%D"/)!";Y^/J2.
M#$/"K!W8\C?4?/UMDQ&?I2/;9WQE9O>?NS]"E@K.39\ \=MY<UL1\5*_/GO!
MXM]=ZO.WW!GC9O\-G[^6++J<?P*T?DBG_]$8"-)G7Z):9ZPSDWF#LW.YPZ3V
MIT8J:4CUXS,?W"D:' !3),KH<0Y"W>UP3G8H(X6L]'!Q%8J5_V4?ZX+?'ZNN
MVT)%L!"=RIJH.U<<% +I%>QV>@*0!O7[G-0[A#*2&W7.\IQ[WG$3C?[-(/?+
MT"E7.CKDIAJ@&2&F26G7%$,W(9RC"8/$Y\"X!Q%$+Q;9G6.>1V=^IX]-&0^Z
MQ+95M!EYI4<<;#@C2_+(#U9[R)7A]*6&V?9=-SX!ODU4L<YKLS9=J@1<^;YK
M2Q)]/#/ ]7E!PF#Q$6<I'ZZ3")6\L9UY MA/T?DFWDB:D% </@%>H"6:VDY/
MKW16A9L*A/94K1KLO1O<*=_CO/P] O /"E2%3PU.;#F):B4LFFCPHK2;X8@%
MUACY+QF\QZQ_[:/^X;?*]3"<)DJ/2"G^-]7Q24$0L4;(2.]H[@DO890?>RUW
M:CLZ6^\9]MTG4LFK"?\GP*E@M8,,!CP]!"7K*PG#0,A^@XY.F;77-,>H6#0N
M[,?=;0T$NR2[R[GUFGX)EI7K=ME8%C1^B$#C;4*688&.B@BE#-=FXY'NVGJ4
MS,]RT70;]?07+Q!_M9F;62-V+[%GY8;[7J!UYH=[#[N(UY8_564RE8H4^Y0I
M8_/MI"TH0BN&62WQ=;!,*5=5I?B'$N.N2/#1$G"<<$^7B$>1[$%+\[G3QE.#
M%1(*B: BH\V(?\Z?,S'NEEM>49 E)YMLU-OVR6*@S9##/WT58$I54N);JK9X
M'A6J7ZWCP75]1"B]T"5#HZV_?0"\(2@ +FY^,+@[NJZ_&O_2.@Y!D5!0ZHXK
M^9YJRY+!U>1E:$FFM9.7]+9"\4^4R@H'*)M,Q5+FXU<F*NAS>[-():"(-ZQ;
M >+(PPGY%O1LIMN*YD2*"V99Y"#@4(,,4[)J6^"S:(.LFJQ*[)1";9)!HUB;
MO'Z I5I?A4<\2]1[WW[EV2? ?QA#[LMXQ4=_[*/KX'9TGU=&Z*VL2H#7\H9F
M?)PUY4MRF9R5GO;WCT5))'\/Q@ELEDBW3T)>8["@9@<J'Q.IL.>RHR.SV2:2
MHO.W>E%<F[*GD.TGP/(O/B)@> ;?5J#FY/W%OM["INT/A_0,(M*6E  _O/!9
M9KQ0P!],\'(_Q]KPX[0L9A<KF@*95@:61(BD\/"AZ39L.SOG\HPJ%G<+25C_
MN7:_5G2I$XM8D*P-2>,""09- XD>7X/I.N8\@5$2+%#*C2C/8R?C=?$T_83<
M5];-^'HYH:3UY*$FH0(=N^;A$E>[:@UZOVXUS&3U>A[O>618'_LW2!]I[?)D
MD;HP25PI29A)YLFK65B.L9U$7KT'23:#J%L=3%S@6SB]7LXYH5SUOLE@=]UY
M'R@R3P1Q/G2.Y.@J#MB<".1UD:V3XBM8*7IAKBS2>X,RTO]@3:>[:T$T2F$+
M9*_NKXXPAD1=G1*=._')3#9--Y5Q=BZES!C[11/XD341IIK^/23]U%_[;C X
M3I)D35(+R>55>BK(E ^'W%S!S3.KD4Q8,5#)3AE!JL+2([)G5NW-:3_B3(8,
MQQFL-BWW!L$;"_R9H,[03F-&^^;S0<A<J_32+<L3H)^UUE#+8Q\$9=[.&$0=
M&\G:;L3=!M$B%LMA*VMO+AC]>'7\N T48C7$5,*LM%>VQUL_$%;II?&T@-=0
MRDB^ =EZT]N-NAS_ZD@I#2%#A.-4U2'SZ8M,Z-JL/4L+5EH"16 9[D<"]/#9
M5N?Q3?%#F'!B&!-.[$W40PY8[E$"*0O!RK=>O&JR;JMK;M=H)C,;>(M8-<.Y
MR(TYX4^A>;Z)EH4O;44.),;*,/\G1PH]4*+A*&%[<I[2E?A3MF4]%9XYGV?K
MR^\ZT-M!/7Y<YGN8_/W;]@%?I:J: ND</><6A!<D^84M1\\7"0*82\M$7(MK
MQ# %3(Q&II@[!Y<(M6Y5: B"@3!I!<V ]@?GH\D5]>;,0NJF&_6= G;L,97:
MG!QVORA@0.HDQGWV32["\.2XW.&1+O_&?.9:BW#-Q-@OJZ%M(&Q_X36K39<!
M\6F3 &YTPNRDY@#A6S"O-/TF;R8\=E ;;1P[(*$56QBQW &T:>KC,OE=[+9O
M:BIYF?(SN<$"CG%U2G;A75ZV>DSWK2U^?6V684N)4ED.< +8Q+^&1.2]<B$J
M3B^#+QX;SDGY$9W$,UX7C1%UB,BH$LN#UG%0@_^2?O%/^>](2<*[85HQ5V\0
MHA%"],</PKQ;-8[M 3XIS]OR'TP5YTD9$1=5[HXK02_!%(C('B>'_2W(P"EO
M()=)TP5VH9/ \W35$@(6[UI233T.(N8X=N9E'X 9TAZ^,@RB 7L5@D7A1#\7
MO'C\3ZIR"8O*CT3%+98$ZB%C+!:][MZ[*COGP@?FSY"@+0^4W#*:!8DH,SW(
MTJ\JERXI]ZV-C999^&KFS+LCG^1TNJRE(Z\OC?&E8S%CV^S94D_6QC>7!G9A
M]34=$YHY0];P<9WEE*!!*P4GD\#P]Q4>X=ISG%Q#X"]2JHY;K==CGYK_.5 #
M/[=V1\%HK:.8[\AN+[;[DI>C<')X %[=3$&L EH^<.6M_6A>KW-,.VCNVF2^
M5/E.8)WJ342+W87WF=Y':C& ?ZJY?,5_ZB$37W) %]>']P388@DOK8]9MTIW
M*N=2C"93M1NQEE0 J.RX32AL\A@/*R+>4T,C8DFBR+]&->F>_SL[TO]T9\7/
MKF(A.&\PN+O#1!&&(I#[,?%GLIIH;8"-@TZL-_0-0UZQU>=^]_*TW6#!JJK7
M\(=6^$W,BX#E**,SV!B3J]3OJ9(@!-#W:M/C6O2D%B5J! 8AXC>^V2)*HC<K
ME58TLRZ<U$VR1QJ;_\N/.PTUN3UWEI#IG"]KER4\%<F<8B+P',V?T=;J;%FC
MM VX_;Z/V<)&,,6\!K$C66$;A#3@].9'/@'J1P]$Z,SCX8]4334!GVH]/&<M
MJ+\G$+2.B>",GV@9 ^X<!_Q'9<Y)#I]G:#4GQ^R??]@.XWH"-"C+SRACSF>)
MA'U-=X1ID35GE.)P_JZ,=J;U_T/L*DDUA-,*Z_H%O^W-#S/'0HK#3@-N$KH6
MI<01Y)KI\[X^_>Y&(]0WH9(DXL7NF=%D].)?LB,)6J[N?DD&G%.;:L!X_.7M
M+7'QS0QW3#&:V#/:+7^>8&M18+Q-U4.L_ZP[(DXWMDXBN(BO,1[PPR^42@UU
M2QEWU]34L#TR+LZ([-#R<(-#'^^Y6%E?MJ0^,&T5,N.XQD?17A'Z5DT-*/<O
M/I)DS1Z><?/V#WF>2KQE_&#[6I4W_V7D2]X>C&TI +9O($Z_$X3N**OJP!/>
MJ\X^-@II)7U\(]./6?83'RH3Z5>EQ7(Y^K(Y<3]OS_14+N ^)0!C1&9-6IA'
M*)M1!KIH8E]8U_+O2[WN8T:9K)AWS]WKR6>)FDI:PA8*HMG82=R%64?<(\0Y
M;Z>A/T<$UOA?4M.RG(MIYZXHCX$*\^MV-N":GV2M-V)DV!_*^:XE$Z-?0 J1
M_A<L/V)#+>D5,W&UU21./7BG?QO2$,4 4+J]^7#5<R8P_4-B@Q:2PZLZ7J@?
M5DT,748VC2FV-F.J-4304NG)<XY<JE'PT>Q>%/)$5 <\%$(V=UR>@^4>LJ_S
M 6!^N$V![3:C<^_5;5M+BFRM26924<KPP@8M*\6?_2X)PTNSRL=%(+ 1^(T+
M)?D/6:W?!,=Z_WTZ_4C!+BCPSHJ-*.,N:FAM-00DAB&'/VX4RU2:I=9=;.^?
MU_Z[O_ @_<+<;/6M2D$X88HD4XB^N^J]H24"<TMYX#^]OO]FK#5(0GQDSMB6
M*_47-E]IU>BC]9%%GR4@!G!Y_[^VQO.0Q783+8*5PW3U<M]1@T95ZL#..E[;
M?**$;_'1O7=3;L$D8H">62$>7=/,E#ZI(C4FHT^G"4(L1./#P0)RM$<JF*G&
M3#QS8/&B8^ 7>-,O+Q-M0FYG0B7@AI"#]<>B%'T6[H+N*, _VI[$3PC6Q6+G
M-NL_!.JX*_XF[S4G_@WM/5YN$FN5TE!.3F,H4GS\__+!>9I_? ' VIR/I:L*
M/.*?U[M>\8AS%DG@N QA"+$4I]E+BD-\( LYUZ=T9=%++MQ(K&05-K2#$DFY
MNVGT8)4](_50(\<"JOWH4N+\51&ZS<&_M)XC+E;ZOQ[27R:O\ $4VSI^_Z^A
M5$")5PP+T]#@2].&#91$?&V]'*MW0B;I.86V'$&>;TGP=NIL>JD'JK,KS8V3
MA4*'SB\NP>.#4YPTI\4/\=]NY[H%O&X?TH>9?'_?6&:EZ_LF$&%6OB(DI"^6
MR.7"V:<IL2WM!/"H_]]==O/Z7X(IW-UTE8Y=7-6W0GYSB 2+P:K>>"AFL?]J
M!/R*<0.VKVW,Q@;O>]#VSX?E.6!+MLVC?I'% ?-;RCJ;*4\HWBQPXK[,:UCX
MLN8P,#>X@YL$AD7CI0_N_FU 85_NG&TT-SG4H3LY7S%#\I\ ^FKY(H(:KUEB
M*:9_$MKD*@H\*[Y8_%5.Z49N7<D[2C#SMB7S,_]@JRAAJ++#'SR:D4G!Q*_S
MG'AB;(E:$..L'T6F<2GB9=^M8.5* QB&OT(A+*9I#RNN1%AUU]4$36T$V(KZ
M+Q\<\YJJ8HX>):/357Y]B@!P=HI5M6F.[V=)\LCH'SWW0E%6NDO .FZU,I(3
M'LK;&UM ]:>NCHO%K)9CU43:JK&ENC'1HVI%*AA3QH&3AQ(81G<_W&*J KZJ
M14S4)R]RSRYJ-Y]E[>\M-YS0[L=<F4P(GM:>#6FXCU$6YXZ@OLHXG#!CUE+N
M+Y6<>_I,_TF/E/HFBMDH]:*D@%B4G&[+/^10)V;'G['LX!,6@PB@9U M,LY?
MWX*>@:XA#%.F@8S?._AH$D_';]C8($;XRY=)O+\3[ZR\7NEMVI3$NMTE"IW(
M"]G/26MH_3]W9Y%S5EJ>XJ:71,6\'=-)P2/)S2X##J9NG5*;5!(?[C1/='^;
MK(F[UQ B("0<3ZXS74644$B=QH;#Z"@IYM2I7&G:UM;6E7]*7==01TG0FBA&
M:?Y>-V;F]7O+/ YM @9\N^V8=&K^)D413$2"-(?E1P\%QG&3Q7R:6XI9JR83
MQN>B]C9[>85BE)R$-G_XK43>80MT)FI#2Z(UQ4K]K'\\..I )VT8B"FL\AUF
M7EO;2-#T.TV8J\!7;7[%"!1A'W$IL6*7O1(1%]UGRYJ)X!G.J@@^ QBLDFYC
M-QY8I;;:+');^!LZVHUPN_7]H?@Y=+97PUUYFSSH#76MK]'V^[VI"!SWV(#^
MTM$VG2K0+IV\TS* ?YX%L]JLOT4 5LFC+*5I.QV_MR(2:K<A%)575:_FMBPF
M4N-7XS#,)?_G1YY/%W-GP@J3_A]T&;6<[)3Q-/QW\C5UAXK6LH5BQO,Z=2Z,
M8<81RBV#[$HV ^5Z)88D[:.O8$W$[E!9^:J]Q-?)IIB@KSG.GX?E#V>+X4TI
MFOG"XXLG+R^"'2,F%T9H[Q%FU?T;F =Y8L@0;KK*ZI19,L%,&MQYID['6N0#
M@J2?B6;.$@X,YUFTVR(:V<8*%3P_XF+E.HAGE.2J_WO>&+G$5XD62B$(E"9S
M)3^7-0\JI9SS+1TRIYB],G$A1DK,;*7_-Z"K_J@=V_1F;*TF@A-U0YV+YZV3
ML7Y:*Y#_19<7M=5KB0.U-":<Y:$RWE^&:?ZXQ_Q+4#4^V?\UU\CHMMMM3YOU
M*J5SGC@>I(.D'Z@YI'LF$,R[OA8F/HE[A,NP';.Y(3_?(>[!>'U:H"#E4 =I
MJ/R7Z% ;(+4X;M'@]X(=+U[N@").7VDB0=104I;<T=M'0DS@K<_D=EBO\*:A
MX<Q8Y\B^M.#@UPT'^F87R>^N)-7[IL]W@EVT>Z66RM72"CV&!B8O:H^8*-K;
MZ*Q'C9UB5,U9+E5V#5/<S$XWXJJN'EX<][FXUS7]_.(B)KZ94'@)ZPC;&K_4
M*N]WF!S-K@L4NYYBY (-+F6IK9FK<VLWSJE@!:BL-#=K(H]-!9S&S.)A*0G9
M*?:/ HMHHG*HPSK>O$W-O%..&B_/:F%A];N*EM?=;MU6$&C)[4T"TF6[FR%H
M99U^1LI^RR520B[GR$>DRZ!,>#Z?I[.E]9V %3.M]1>)*TKTA=]X-V>"OW_6
M@_?#;Y[-AS39S?QN8EF; (5=WWR8;CZM[S=/-PP9LR*G57;]32#,0/IXMZ4;
M(V*P@Y=(X?;:II"VD@VWVK^HD/7/K:ZQ;(PV%P%GLD?NPWRC&?VR_5%@[59W
M5'[->CV*=SUH$4@L@[5B=D0G4I>E>)894*[.XIWG[QSCWL>WSLS NU:^=&[8
MNT$'V?SY7_*OD'Y== ]YPWWFU%^,/%U(!F\D[76!WN_P4MX%[+9>53X!D*P+
MUY'Q+C*O@H:96 *;NLD[Q%V;K*[,U'IH-ZV? '9.7V37JB><-*XU),VRWR^8
M_&V98TFA-L)6&\'M)S'=H=O_ZPO!U!(<W*K53E/[7DP[Y\4FD5XJ?-8XQ<&R
M+38I:GQ0=>9HT*FL^2(A^N D9<'?[]/5*=N R)*_>R9/ 9OS=;QN$@Z&JKCT
MH$&-6\G1]/'B+-O]%R$KIQX=W\]Q%XJNT(QX[#QZE PK?]/;_5#!]7JFQQ75
M>2>K!3?_F'5+P!. ;U)PI>"Z>D98;)4WL8Q7^!1[?>.1XR^SP&#('CN;<X#7
M4, #%[9Z0Y@YG>).F7M&#,T=#]IE.F69]KJ:N FA=QAD'?(X0B!NI^<NHQV7
MWU=^;!A/KDCAON7*P)D:E^>!7- %_][)Y<I7/I9YL?1E%M8T9Q5M""&SY1[W
M3^\= MQ4B0[XFW^O566=JVSK:;G3XAWJ6.I??_N?4+7,+6X5KG=8V'K[[RP2
M9KBU6*>_PW?'M'H"2$ %6L-*TH>*?"Y^,,UA$1/+C?14ZR/9-C5,MG$&94G
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MRE+O0+.PK;6"=UB>*@<=]Q>M/W1!2F$S#7@$M^!J6W?/[\YI_: UIJUTUD=
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M^)%0"1I8WPF.H)O?(8FB&\XCD\%<&48M+8BKXH&VHB97SCNL3@!3AN/V:#R
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M!O^+15H8T#]NK=M^ #"BWLP\ #9UUWRSC_IA1%671C4;]:V91HWW<J4V;,,
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M)F-?GNU>M0> 0T>3U;+[N4KTLAX%>%PW@(YO8#N_Z:;#J_R0;HQR'<S11T/
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MC54H,[27]P%@$^"ZI#0 H?H1^ %WLLZYA(C765K#@.1CJF#0"6\\F0#]L#\
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M[9:;7>E 4I6P6MG[]"[3I..LT@L<PVTFE$HU9A-G@1T+HZLG*DE[,*FP9;5
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MG(@QWM[EN4?W9B31XHY/?O1'(1U-:\P2_JXO(&JX8T(%-QVYL$TKWZ.=\U<
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M<^26W?-\!D3O9WMFTHSDAEW0CZ?AZI;ZCC,E$W99XLUQ]^HR]X,PGU]G;&Q
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MZCU. E+,LKKD=F=W.*?*^U:LD!4SGJTZ4]MV1RN6W[ZVA/K(Z4 \.3G6[MF
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M"Z;Z0<@A'<\_*N6A),N\Y:.W#&'>M,BL*BQNH>(N+C+/V-K-_%A*#]+@M43
MN\E@!5.YB'V(GE,EF^(*)/("="E,VLJM2"JD4.O<>'QR@"3:XA82+5-^,"=(
MN98MY$LQ<'OJ]$!OH>11PSU*:I';[>^S53QE5"R<_O6_N_R-[*7TX<^]IFV7
M9/MEF<(F.C6:L*'KJ HKNVD=S:J)[CSQ#_X!EQ>X[W0+P/JNGT))C [$%L@+
M^%P^/@[P69&=,>['!J$>CFK<ULS:P=K.V\:5A&1[1]OI7&/]+RKM"G(]<6UN
ML5A=V-+AI]\]!G;+V46SHJ"R$)$'L^ O<*P>)!EU%?X2#=RT[$&D@'D:@X[
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MG4E]9^[7ZQ'!T/Z"Z\9R&UR?32F^%Q\<#DW<=VPPT3'5];V[RA)Y4VU7A]V
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MS#VUZ'UYCL^(M,V@ZP#D5_33^4<%%?TO]8A"PM/:A:U._'Z)E8,AG?3'OY8
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MC/914DN[0(]F\2'A9MCQ8 7L<@#1Q2OQ(;>:5KK?\&@*/UN)N]@=3HII*0Z
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M?GLF+E9Z SY 97W\)EXZS_[I&=?1 V#I'%'"6"?:?PR)4>J1H8<?0!MNA!X
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M?NIL8_#M2 26U$)+6N@M=4U.4%)599\5:&G0EK@\^'1X?25$VM]2.&5K@\[
MU)ZGS,A(,=-]^$5 REYRSE8F_:59_N:O!N 7_\'28E\T>E%%?64Y&8"AG5NN
MH.7-?.([L-!L76A/LC[P9'5\D"1D"=3J8FX:/:!!<O1O U_XAO&$!&IJ]&3D
MLRMF:.@0O0.C(=+8U>N2O&HIB,;PO=POE7[YI:P+4-QPIH1(J=_/%7QCJD*1
ML5\?%GVC>:ZD;=W5A>1@562:)DJRF@ID &1Q*AZ%K4%AP?-*PJ>L!3B0SV@
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MG1T3AR8:%'4HQK29S8FH03;&E:N.K+.INMD^D?;C!2OZD0#<OFLI "C_?[2
MVP4<Y:B%;5;$O9%#]8T<&<?WRKOF>4.?>T1Q'Y0G/PG-).:1Q"J9GZ(NQ7^D
M#/V60$02,/Y687FNL>+[1;B;B&GNY)6@1K>@GB:+Q5Q(K$.@,ZTP+CL@6_O^
MZ\TLW:@Q9Q$ ;#N[J[I#@-."0#[#62Y:B2 C(T2"HS?RI9)Q\S>.)N8:Z?23
MGH\> \S_)YBX0'LD.UK1!Q%9'QC]7"W7496K0A!WU\D@7-GGHFGU[XJU^-^:
M^%YIYI4ZN/#V9IG+!7-8ZFF\G@+,.OQH]/]X;S6#J36DZ;TT:?W]53QF(8U2
MRHK$L'CK%[LJN[\^"MR?:/ N? %+9@F6<?@1OYH:J3TQ,L)^(>Q(G\AC(>JN
M,T*GV?JF9(@UF56?LF+8M1EO2C5=\2&7 ]*>4A%Y4NI2Z3^>(.X1(&RWM>.Z
M.)/QK#;G;$6SD"LK>G8G4IG=R>M9YFJ"%@N+N[H@!>T2W]'<:-KE5^<I*A(!
M=@5BO[WUK3+[5?5W98:R&J+SE=\2K!B26"M?$#1H-R59>5O;B7R6V6HL*?]&
M0OTCM!!.BJ_P2W%0<+BX-)Z1S3)C0\BEC*,_<OF3']=,U4I%>31]DT(5-7.V
MPV@_RB'RD[MJMI.6BJCR#Y852;VT-CWW(9$/LL9OA1<V>Q0GBJLK952,WPQ/
MJ%;F</UDU7K6?=>?,_%2EHDY;+" W'W==S%F%#K-LZ[Z5POJB7S>0Y62"+L,
MVR2IY1%+/Y4RP= #"28WG8=]+O<;@HA_5>A7<H7#/,H\/$7OB9$VV&KP9)AE
M(D^0)[W!9!*3#K^5ZABWR\O;5,)%;(#;W8>ZJ9]M/&IFC)1K8!D=7@(M<0X<
M+=7"08%.QKW'0&YW,ZYBM71)Y[WH4JL^9VE=18%PB0E7L]7+7$GFA@3A=_DY
M#=_SJ\)*_S@UP^O[<C!E;;]>%\2,WJ>=I:M=/BVQ>=O!\(XJ/V2;F/0UG?1C
M:]7W.]*Q0@;U,9;'BFUB^I#UX9%_)-T/:46($X[H""HUMDQC='B\]W6"?NNP
MR1$2S%1P09=.11Q>F? -=..M5.0?6G!1FA+/#6=&B&B]3<W??J??[Z=@(Q<H
M>K!0$> >4/CEBZ";S5\#Z06RJ&KU\'!7/C(P3PG6=U$><+AO;H-.V5S":*5*
MC[I=ZE-MC:EJ#L\25^N_P,2>Z*?L%DIG9= \9"5CVJMPX;"5 6PGL".W0:'0
M.*']EC-UOM"8_7UE\])$7YV^&3S]P1EG.1UBO/A7[L97ZFDV:4G_.-SOO$B5
M)Z^&[Y>7]U8TZ9B3Z^#7+>:Z7\E/1IHIUG*-O9PLC3NWK<:$M2DEB(N*,K9?
M7J[(!TB>J>OTB4I^1Z<K O,_,DU(@N[O;GSP-+![-,3V\*<(TE=4MT1U47E'
MFK7R<W3(EO5%58*S?W_UI_"$?Q2Y,R6[YDP=M;DC31_SO\CL?W'PDG/]5?_1
MZ^(P\H^&Z-R$3O*8P/Z*[VY5EXV@&J<B8XAIP0S/T>H@HR<3=]W\826"W,@P
M8$QD$V@\T%@W,$L]J.1J_&]'2\*(^:O#R2#RM(4L)<* SY=^+2&1]7XT\QGC
M[/+*0T_MY[#'-:1,T!$:0.2D]JR\"(U[\70#H7-_TP6[K4 ;Y2W Y]?Q\;N5
M\D+D0V\->)S/6,:"28HNXUNWA)SF<G*CY8? 9T\?L@M*=$^I:J6Z+=V$WD3R
MD@6!8+E=]5T##N[D\SS" :2].PM[GE8A1P])O/D/]*Z)5Z'NP1?(XD."\N+@
M3C((^)5CZ]PM@-OLU0EOY9O!2U-T/.G:*>?]+LTNR]Q@$"$%[A&P C)T7C]?
MC!H*:="DKRI\]6+9O<QH]_>/2**/T34IG_<("0!/!1>ZV&X!KM6KOOV@AK<I
MLN0HVVS@UTY&B(U"8PB\#:^6,%_C02WR>+ROG#F;X'. =)^5H'B[K1198+MW
MV8J'CX+BDYC\@$CGXBVF]49-Q425NO:;LH"[%0#C\$UX*@A(R#O; R)L9[G^
MHDY-WG0H)7ZMODRPDW[U[\)]/PF<O2Z)JCZGSC]O8\!46;;S3!+V$,B$^\"%
M/=KJ D>K].+D?!9H(CR<S??0!N_31EG!J;]V+A?7MM(D:26YR<)C?OZ?DR*>
MJ_--Y4(N5W5EZI;*+C/B<>,T]H!-/1*WHTH7FD-Y!Q<-=7=R$[#QLE)%L=F&
M%^8[Z9GQL5;GO MN&;K9HG4* W#/F8VXRE=/-V J33-3!B>#VWC%!EI-:S1%
MEM8AA(\&O)]8;!5X  7PV'Z4+;T0>K8C@:CB)?><1&JA>>=FXC,]XUP")+>A
M"SERXSX+QN/]A_ZO''IU*+]Z,#= >QTR&(\1]8<SBL]THQ\/Q;Y7A$\844@!
MWC]YTS/ ]]G;J$0O)&A2Y:S\Q'B,>C-=+B8_T%V%JJ-A,&MF<,!.<7!VS6>V
M,M\K-(A86<8'+6\/K6@KWD]:&F4DOD_(:.!:[*A9\G-PDZ-GJO2BZM6&\O47
MH&.BM18=H%C>1(JWPC!B9--*A$^YI"BG>+?X@//Z \0=1A;MVLF$M8QI (?Y
MBWUUR&'])6%MF+ME\MW<C5UBF"W+;J69;-7W7"E@F0C1G\-<TV;FVLO\[*LC
M,],"ZV5^^Z_4;3FZSX5SC.),EW^=_NWY_JZ@EGV]N7AP"SB00F=V@QNJ>SGN
M9(2K_[37]+*F<-A.M^3-T/IL ]MPO2?H9-#])&COD\2@K([PUQ.L_,2G/92G
MWL_6 6<M_NW@C<N\'4I7ZH**J>$7]<5AH"8Y>.0O+K)"DY2M]H7$0V6]3=@I
M[^RE02?V'48- ?H:0.X!"LE]>I"IL2@L%1:\)P:ST20N;OVUI;Q' KF($#YI
MXF$%MN'A,>W_?;$0\[9,SB#*0/WC[/)/8[4/C9_DRY9-5_VBQEN598U48(P[
MZ"JD9F?[KQGKV2HK&HO 'P*#ZYMZ<6&B$2C:K6<<[J$D<T$K;3$*Z]PS28.=
MAN"TH&'FAJ>5=E::UI7N9#W,DG/MC*D5_?5>O]N?LGTA1#+Z<?^1)I%-S[/O
M ]<F\#%_>M];O*WK4N%'*,.]_8\CM%A-;&73Z$$_I7^;4A%W\316!3XAB=#D
M^UN9?^BI%;WE/C03!=85OF*.0ZASFJ.J*KTJ'-6^K8C$TSAO<!.7$K0,<D]5
M=7)A3DZ4$0WXRM%?O<3QG=+0<?V0=I7R06=ZI0C\")>/T:1"NIT#%41IG+/?
MLG7CNT]7U\A\5!Q)<K4A8OT^R1<AAW"T^B6/BH!28M^:/RC4[YX#,!2.:F@X
MSWTJ?U-":':CL2YQNMTIA2J<KVS_@,#7FB*O^;/5O!L4>PLP/N5FLM/U'9/A
MZ*$F#*[?LW7NVP(), EF0!>>KEU9*74U_I:6R.83H1%DRY>*&56V^NU9E:39
M,'=4[RT2HR7WB$.M\)_FR"<\?.XF B\"SEVPB*EC:F/I3<G1!Y40Y1(3KC>R
MN>^=?/H0I_3?10-6*#KZ%US3V.0$Z8E3NH?,):=Y%%/4WJN9U"VWNQ;LXH!H
MHM4>1FU3Q]':Y>?Y9+Q&F0#RP8T\*@3X*=0#?L-MFG3P>F7L([58S_ _4,3.
M'G?DM+1>&29?-X6;[IE2JY7;>7HF"7T^\[W)>\C9#BB\ZL^^K#!:9B.,-U!(
M]6C4"]J6*L$^6[3#::O;XIQWY@3]$NS'9?)EP3)8(4AO1H%]^!%G"M,^TC72
MG"7CGV'DT>#'"A1/3/V3'\U_Q7>HD(OZ/LF%=ZSMPI*IK=7-R1NG:9QZ[6(2
MF)(Z/O$4("#!1=WZ06-\I&Y:FJY,)OL@IH:*,WPL&?S?+\)<+UES1I?,5\?-
MQ)[ R%(S^N9858ZD)P"JTZ% P?V9O(;&>29JJ3J6T*LGXAS5BE7R2V<Q-(BP
MEEL X?Q&R%'UHQKG0MZ-Y <70%68M&N MQML->JE*][ @\_>CI+_LC8OADOK
MS[--]T"6&RX:0\BLQZE#5R3?4)UY);O3WX.<3QX>R?M&\E2LL&,:(U]4"7WZ
M&?D"\%^K:NKNE$$7]P&IEB$[\*-2]WS'*VBPB5.;"K'V(++9AN46$/-95W>4
M_+NI=54:L#V'X:;\%F!]MSZ\U$BW0PV=XYJ:4)S]-C'.IQL15Q^Y:M::&;1$
MQ,/N$>!\['"7U9-3*_OG))C+:P9,$"_NV;)2"<;_8F=66KY(;$5X#&-RU/XY
M]AY;F2BMP<#\E<XU8T"/FO]+_PGZCQN/<*Q+)E EC$D9&?=[5%6S]/6GF!Y?
MVX_UK^[MGN0@Q=FVS8TBQTQ*DZ_G6J==QG#P$2S_=?7:X5B+EZ;[/^/(FS;T
M$):B"99ZZ WGO@7$@E#OF+[LU<E5NI="I>>LB2H=D*74U[$NK(R';)R-*H@N
MZH8_!*:HSAHW^"W@J='$AP#[[9>'1T^&>%S:J6PL"-E^1YY]/E@EB]'6S=2)
M&WC$_=]QN)Z]7,5I/EXZ82W%3^[F:7&Z&"64)B)\R/6I)AP82O^N=3+?R48V
MGT>0"M^Y,LS:O3DH](%O%MK\&\H=Z1K1#D3;]9E++HB8^$EJX@_.[':ZY*1^
M>G0XW=[@Z[%2=2+PV,:JF5$0]&( '-55SP6Y!1C];L@-7Z>?Q=[C2/CY)G_\
M"T<B=:=]SU--P>&QL=PT4@&)*6.X1W4PB+I=!E6N@MFJ^BOFV4FQ6&53/WNF
M0O/$5)U4OHQQ$Q8L%/V4D( %AE>+IADB$1L$DXM,T4$RE5\Z5:MXN[LY%P\W
MAIFD]]4K++\/HA_6K;<OHWL#*&6),T)-=7-GYGZCUPP,<.IP=/W*S#S_Q5ND
M0W0;T:N"2.20WZR5BR;RKLCT2DIJ8D2;NZ)\$3M]4R305VAP+S\=1%ZEJP7M
M:ZSDBC#I3U2K)/\0+]1.F.O[&?6ZYVQ-UA@)_8 V,$4_:$S('.NPW-%L,GG!
M?T9'C["'130.P_2'(P6*0R_3&./[I.SQII,0'+G%6.!O:<*,Y^%A9YIDCC-[
M"9B<>RP++EY6HS&ZY$%T#'/9@4 $0=7#)D2ZM![^T$ <^7[/&='U,FN+MZU3
MY>>M>;WHR?'[/T5A>1>D;[K9W9/*L0!,-4&WK^9*E&X0.ZJJL*PSCFFZ63^Y
M"JF^2?NOBQ;'8W5:OH'7*8X)@.&^(9G83%'Z"8A%M$;\E4W[U<^4I'?)Z8:F
M)@G3W0\\9208@^_]W2#S?XA9U4';!1VTWPDK5!F6#?U0G[J3>T%;H=%7;W2,
M/^NAF=OW9YZE[ ^Y"A*2*_=RZ[KZ- '8UQ@1V>A.?O2G!39U@D%] V>F+,^4
M$W]4!;Z_VZNX[TE8\SY9? 3_MRYRZ0_P2H:>=>Z%8P\F[KZ:=DF;POX)=M&$
MX=5T2SGEUYKLI$7-FPTM$.9M\:P!NGM9+U<>[2;-9@ NR&+_*](U"%K1Z:<W
MB)05V"O6Z9S^,BSLJ_+ @7I,S6^ @A  @FSFJ/LWWP)Z'G3!<F\!=;E82C&D
M4@R.&OLI]N3H]H[#$'/"J_;/[5E/VC>X$$;L[S]IY3R)VO 6%T>>*)U_1 %[
M7+^!* _;>='_!GEA8%*U!U-\%2F5$.VWIC^]'=]<3M$=@LN *%5-S(NAOJDE
M.X1KV"D8'V-JXG35%-%5=U9-,R15W^2#O[SD[#^Z\:(_^&5R$'%%R%SPO:M;
M %KL7&X19-'UU-&8/15,%F"32[ L=/>!9>[G(>)H'5&!W6HV#QRMWV/8',@%
M6.(R:G%,_G/F/'>JVA;%V1,7OG(+Z#\.]Q(K=Z^$#"&3L?K4%&7$+?6-J=Q/
M;P%/M@T&05X#_A$!/9KU375QFC=%[:(X M1Z#4G3N?,M(!IK]W%QD9K:HJT[
MY5/\WHRK%PNEI<IU<1/LJS_5+,C>S%B3SH&9&;UX^*:TAXVB A.K^%N:R;FN
MG"LX,T4HI&G\O1*^4QQ3*AS]O2.6X['6O[_7Q:U.^?KV#@TUYW&#P."-.CLL
M993N(E0'18;@RT<KZ:$*R$<(^EZ<V<X*FWC?AX=F33A&H(GQP;P4GH+MMETL
MLAP8,#*N6SFS[Q9 4WT*6A[3^"^%V,H^Y=@=P9 6L1N17F31#\1@6D+)MLQR
M[ZCE"4;QWD^H,6:V **F$<C-&8(C7^%FI6+YZM0\JCA4/?YO5-ZS6@<5CJ7.
MA4U%!-3Z4^)^;Q#;H#>^GA;:\[3+(XC21,@HC'>^IMN)[E+_'6)YT@]$L$6B
M95)L4@,>M2L MYRY:LRU/76:'(S!ZU;3N:F-LK339[23E2A-^!:N^IZ^%YHL
MJD OYCS'FOQ(S3Z\K#W)ZGI^FUF\?6:)!T@I;=TZ*P=?5$*=A#B3!W06F94Z
MT['E]S8!<AJN;M#[N$=M9?ZSTXY@R@"KZJA*=)SJK*#(4'@&0JC*B(TX61F/
MYY7S7WJ!LD]NN^ H ]PC-'^(B\WT#NK[BME66T?#P&!SIY%:Q(DAURC;-T.^
M5U^5^TJDHWU:_%U#!_]Q45SDHQ6*"H%HA>7JUJD?&?;5!5@Y3&0G;3N*H,^F
M\Q<*E\^:6:Z08\32[,&2]_TI*X_@S?0>H%ICT6,J"DR%M2F!OFMNO\8_G(_6
MITF V*Y:WGQG7>627/T8I*\>*)ZHP*.AFA5]!B)K]R7X*G), GT](YSIIWVL
MFL*9MG>O6O@Z<]BPE8QWHJ&UU)3[K=<OT]J$P5>=[%!K-&4G)YHOW[?I+3-[
M_$C)DC';"*.J24 *[U3J?<4JD!=#WHOF/L;[?L^8O [R4&/]G:R8B(4 LM.X
M>F,&VQ"3-E_PH3?/Z4@-TT1/C,[P5PZ8O%28QH\L]YOGN#^W ));@&W TJP*
MA@+)'[XNL-AN4P1Q,I2G"1.^,3JR3KE'02'S\[5G/[RQA*1!8 LR$2"(!-_\
MN 78'1,Y,$MGD.B\05WT=T@Z&1[G_#V8^S+_G7WO5^]HYL/?G:8E?:A!T(_J
MAU"#.XOQ&?L<,X3Z=QY]$U%AC8::XZ-.3R!#&JUM]BOB-H;3-L$,G<Q[8K:>
MRJ]CWE,C*P%0;Y3)>3\Z+JQ3$.N!3HW$T0!I[7TZ"K=+ WY"VK093BMGA.1Y
M?O'PC(\PE#T=9;?(_Q@5SSW-!X(AR9A58+QV/2B(Z,RDDS-=?1?)V(?KB(_+
MYWR[B8KI2ZP<%-911U+?;@&P1H)S\>:;2BC9]7LL!YHY!BDA_;;Q(H?]]T&U
MMJ]:N1,%\_#F]0LO_?0W2FO+O=$O6+LHMS&^L%M )(B91G.VOAG[W DAHVX9
MKMG23.W9>/_DG9P0W^4*.W%!8F#RW]?;22KE B![$"S?F+\W=R7S7!"EB:4R
MZ.U\V8 ZCC@SK*@W\U)LK-?R\"U?S>78&NC]Y<;*^O!]-Q[U;+PRP1T- ,.E
M!:LP>U<!P8VM?1@WG*^$2!>ORXH(G6?\(+2K_=&E"L"C>@\/WG2@4@J51%T,
M5&.>VWV#OBG<<#3.B2*(:G_N73#T\NV",\4$I&E-*#1#6:Z\A"7"#(Q7&2 N
M  'VM\;,B>K3*PSF>XG,.J3 $<USIALO==BUONJ&C]/= O3U,"[N/=59\)VS
M .?DD7V%ZZZS(^.^HP7@^:[V$:0Q%U9NFP@Z-%.4!J;#:^2]9:>T?D74#2DF
M*^]!*CM<7]>C]&)32];M9\9;"UZIX:V_ R3KC3XD?_OYJ\!UQ41NH=>5;0@2
M1&'?^6Q>F@'^Q]7X%ZK=W"5/4M&B<1;.7DZ';#)EX6Q)>#W$,H/5QOBAV^ZZ
M/@PKB 12[@I ?-^A&Z(<Z54:3L;4'!D^2#5)_Z"X.1^I+F#_MT]4';&EK4ZZ
M>OW2DMDBA9)Z51?F\L^$F( M>ZDJ $=^^)+.15JKHO<K=CSENJJX9Y,\^JV&
M+YUN+ Y;>9074#+\?(XST5.KGL9R":])IBP5+P-P302W&]1<KKN3C#W5=!BB
M@0!2DX%.]D5M_)F&L;8^UYNLZ10>?<(Y5'<T#K49VUS-ASX^O(<$1HA>B50L
M2.HG9C!%&T,)WM5$+J^(JW#-O*K:2<HQS1[J4$ ]QU'$4?U10'N]GF]7LA/Y
MCEHVMO]':'?M6\5B*P5^08L=?:CNYP!W#<<18.*NI3'<O3FO:E'%032J:,LE
M)UF6Q&L<UZ-*UVR]#"=6M4O]'V(3H73=W5+? -BC.1$9-?T6WS_:"+7TK*T<
M?;[^J\3/CA$PRR[Y+I>NY<QSLYO<3HD5+.@F$\<&ZI>A-Z&MXLR9%&Z!%"5$
MG*0HFXS&PU["HEUZ-@TFZ GZ*/PJ5.#>']E^S;&]HO'SO)*18=656[4.;1QF
M1&Y=M@PS:+B_9B9KQHL]J[.#W[B_)USP3&P=7M4+9BILM6!.KTQO=RB3_VP]
M#6N859)2J)?G(K,X;M6<&,%R+]W1$/!K1NJAYO5KB E,M!#!/LV*9OK;=.V,
MI(Y\JI<67Q!H5!-*QY 6M!XHK=;O3[X Y<8ON)I*+$*;);/E2%AK\C8*))!'
M*2[_9;ROQ!8Y-%/?H68VES=]:N+-=W1DJD0I^-*;:36P+)\]Z2_WV2J\^"#[
M6@PW<2?3]++YSS_>E$DK%>_G/)QQR3+;>(=3J$@4:9-^]%G>_\"[#2]X"=CO
MF03V]5]@EOXO9@PW#$1IYX;< FB[[/Z>^DX\'7V9VQ\/\==KK6FT]#09S]%)
MP\+HQG[F1!9$Y[P&Y<9%==4!#XE0I#.CMP"D9HA( /&;TH"A^HR8\N[$++O'
MAA99GOOF-.!%,)8Z#O<8?$V%^PVJQ8/28T0J5S%#YO/'E7P6*83L"K,+!.LG
MU,F4X38/9?*S)*8T A)4_U^/?/[_&P6]B*.Z;[&=JT"UQ_B*//:A [I<XIZW
M\" =;7&^,+3:^!%'G\OJFD?I8PO;?&*5=9^<AA?0K/=X>A&(PI^1!=T9\XA(
ML]F8L?7,3[_K5W_HU)_O1G[KW"U4^);J2Y&S5-;"<_>0QY0>5!(PVQ],"N^\
M:7_@,\[$_HQW4Y6,;*CAI9A6H*H<>>S_[UTQ/N],(-OC,@"34-*Q?AD_SRW@
M3MV:J2D$]Y(G1-8)C_$XT+X6);;V*CO]$?]97-B0YRFWX@#MA^_6P8(]/YY*
M4-:J24]:IX\)?5(YI5Q1&S?/4Z#4H7/0?ET8 7/+2'NANV]T"Q#03A>7J=-7
M W*+<,N_Y%!](SZRJTJ)ES"H2"HU*_U?*K4RJ8&'S*.:1[9L5"Q2H0J!-.[T
M.;3K\K4"*C(R?UN?;"5'3+ZL'X =%L_>^]L68VC'64Q7]G=5_=U##:[I5P_@
M%U?ZWS^+2VA%_J"L4JD47R+/TNM/V%N2*)K];HW(U'WW[1[T2WDR(7?0@+K>
MDPC=LN;M?$ .OJ;N>RMIO4*S>4./\K(V>Z'2W]^5_MNT6<AZ.!L=/<-=M99K
M2N;37&IW[JD_E2;IME#&8>-![(-DJUXH9GK1#&$_B6GW-U+H^Y<]M%A,11N?
MD*3[+O9?]PIGJ(?):C):?6<)J4SWDW9RATG2@'TT<L!*ZCLCWA[7(W:[>/%+
MN6@ UWOW"5.F;QSK#?E.=C+S!4U:\4_Y6J07:,?L,MK+KSM*Y&+)D,?&16D9
MO"G_*+VSN:850O'L@KD%A(0^W!F.UD"8,RA;2(+#<-+[K/1P.;EUCLH6?TPG
M(B5L_-UX/J].@)VYV:J:EQ/1&"-1JUR^E,'<//GW^Y4]I:8K2L\S1M$*HM3O
MBX]?GE6V)$>H:;>C=[<!;&:U05/0C $;MB0S_%.!@2_Z,YHB!$J#0AA]Z[+E
MG4K+:95D+166*_T"[F87SB!=)(OGKH[K<X%VTM,9AKEIO^A[T=MY[W9RC8-?
MO2?6*TG]] <SWZ_/FV\7F4X;C"\7%>OX7D#!6*[&F78S8[XQ/@U;"Z(?T6@N
M1^6_VF2TK/_[+C;L7A)8VO]W1E>2LZN%-T]A3<85]:R4HA\W$AR7$;R&J>AI
MB[!\%.=N[F^EDQ)E-AG=R#@_>P")Z=QJ=(\] X]/<<^D)?D?N_B<%8[FZ%H8
MC)_+QAP-7<8HI6W\5R97B[IGX%[M4M&S(?;M"N.U,:=/U72;3QP[Q C8IZ<C
MKGSEYAGE298!=7SJ3KS#=K8@H=-NF$$F1@.K6:34C+0;]:Y^.\O1&.GA@([V
MJ.;["3V74?61VPYMR-^$YNEZ#7$T6@49TT3JK\GX1H8?JK'T0X8<OWS4I=@3
M,GFS[&+WW#\\&Y,Q>C+IYF;]BM;=U-IX_+BD/^DE<>7E8JDZ_TI5NI54XQF3
M4V9;XRRH_EY++_FP<'8357;%EPNB)X]$NHEI\7)5&^[Y)J\2$@ON3KBWZN?A
M#R<NO/?!?CT=<%HUVQ-RC+?/X-'DW>HA[TXHM4U8@KW 8T^$4&455'IR/Y5I
MLV(,,Q<\!I=WU7D=>*/R80:]D"[G ,R+CS.[LA2DP+X<*G,1$/ED^P_RF\TF
MSF,I9_S/GQ\*_=T@[;P/_:_\NC.&4^VF(,"52!DJC\9['V@& <./4$9,+6K9
M;\F:([T?[>]!@'&W@ :Q0S5TUWD3)M,+#42:%[BZ[+ ;FPR=&"^_P0KT/(&S
M:74S^29JBIS,#.A/%/R%6</#C57+ULV0FB<>HB:*Q[HK6P:^N6T!*+U;P$KB
M/A*$I;@%G$/1?,7%)O:"F-A]P[G*^E7A$UA335"_Z'39Q2J=5I9%5LX9]FS-
M\:>S1 ,E^$_5*[<A:8,] BQ5HQ&4]TXRFV+D'H)J.ID4(.]]-L:]06".+IX?
MK;&:A)DJ?YQMS=KP<I,#)3B9]IJEB%1C#6AG]*.R%5.32KG]J3E\]]PO6COZ
M7Q4.3-WSUF6K]+(U 3)@'*5,!!+VGMA$L#&$?9;M3-ZY/X?)V%:F/A'D<3I)
MA0F<5^W SPL=\)$*[I1.SS,23\2D D\9 R2OHDPL22<71MK?_)P2F27,H%V@
MH!;\AS<R-5,FC^K3:&F,5/CN'7D==0MX]-4]KE)H<&4P6:0C=]E6H'*6D;89
M?_C8/!UFG7CQ&M<]'S$.84$^B':;<*5[E#]>+<U;-/53XYPD//%US8_3OP+<
M0Q[JU'=DT6S//S0!)#GPX]Y;ZH)3S(BXBMI9"1/JD<HJ3#6Y&_KSH322*FX!
M_4>^L_3C-.Y6CX?RNB>,$SF&1C^KOAD9%%Q<J,KD+K$RJLJWGP]3A$?OS+3&
MF#-HDDQ>F9XC+!DV,]M(YR-%]O._U*U1")C?![&0J5994[]XW=\YSVB@%M$Y
M67-!P-E@^<:-P4QZ-%.>$2G2R.)M^>^]A4XKT>,FZJ)_KL_$CW,KO7Q<\JRL
MJ"GPP375/%WA3H$/'Q4;:W[ZD90C-9-$KU2ZWIAC]7!H<PKL4RAL[I&IP;"M
M\>/*0) Q,?2?60M;'NVN>10<>'\_AZ>1GZ%"H(LA[>S&D8^$V8UR2B@[A&T]
M9>7J:G"/>U7,WO9;7W[IRNCH9T*V^#=_G1;X.AD=)5D^E  LY1O,O-?\N+,7
ML$(>=$;3JKTTST;C25^D]"K?]-5T_NZ"58+JK%0HQP@.J5"#W=3R)UV1PA E
M3M"0.^G#@(B=9A#_YF0,@HC=O=C)\Y!ICM@*\N?3Z/ GW9!AEK,J.YA2])UQ
M!6+*"[#O,. 2T=0*^Z:7[B3=PW@$[ *XYQ_Z2!%=X("/Q\'^CV\:.^G5KOW]
M1T6U5IRNO&/Y(Y@9ZGI$%]^Z^SXF?:=]9K5:NB-R0GD+@+,]^75R"_ HN1FZ
M!<ANX_IPF[D]V.H_RX.KQ7X^N1G!9J_.'PD\H ">J6<Y8T/=O00<C1T32DQ!
MX[+ZFR%&5YRK7\K[):.UF?KOQYF/(.B<&V0(GX5XO^D>8NV,U=[Z:YZYAC))
M/Q6\%XRN>R8QS*@O[R JUGA@X9>)TTMH)EAI.W25:VJ<?2_2."UP??-)W<WI
MI[HKN^B,XE%F#\FT]YZ3H6Y+IL:%%/ A1G1P=#JLHG";1U1@ZY/36KV:,]^Z
M0NRN?(D^=]-"2QS9[B^C<3:C\86ML!T\%G_F^3USXM_.[0I5/04CPI\4$J7[
MN@=],MS\SR.1CJ-;J_R$*KQ14_!].@[!9RFV>I/3BQRMO&1RZE3/T>]6V-97
MI4EH(QCA4V@R5'51)]TN.<2K7Y8-U:>V8ZSYD3=($8]#X1(L?ETLPM_75[;G
MZ=GJOY17/Y/>KYU'7,D"$DQ:9+'0%]F>P8#7Q+GK_L4Z\QMW-?J.]7PJLWF1
M3^#X[/ P)(<[;?;43%YCWJNB9^M;<(E.\!L"MES'&_WY3AI[W#-4=!,U#=!A
MGJ\X1S<,?RF08F1'8D7*@*T*0]-#+]+0F5J]ZU1BON<2/'(XN'PO^C,9V%Q=
MQ.BY;0/71"79A&^Y/0@N0%(LENKTR6W+%?F)%I0C9*@"E[%%'+G;M=,9YO5Y
MR>8:7RM>PRP6-EO13.O9-[F\F04!UCIA4'0S\Q_NDM\@.V>N%W$18%WJH@F%
MGC#D%O#=3E+&C BRAI08X^B*MR[S;1JJ'<8=0:?-# IM>1[7\$4+^[QV@356
MG6^%VX''G;)7="JW+9]4XN*TNNN08]IVVE5:J>2-E>_S@N;G;,]'6P'B(\C8
M!K7>%<_P_+^?(0BI]^@!9]9X600=A&"OJ/X\PUZ)35I-#0/,@WCU$56N389M
M@4<2IU.?A@Z!W^EU 'O]F3I^5]7_71$V9$U47O_H 88SGYTR-<5(/Z]RN/+\
M!F$5:WJ069X>-SI,,)K_&[G>SCF40Q5 ]FSVT$W:@.+14\-8*_(FTQN"+A'A
M@M4ZRI\'$)HHX<M*NW!]U($);X'".,L.CS@G\]E.CA2][CKQ_-$?;'DZ;UJ:
M'RYYT>G?'X=U%DG]I"^<L>OOQS@$!)3<#LU=T6SZ2?JHR7P/UJ'MB$WUL1X+
M2?0M8+&JS;<BM 7UAU++5+'G_Y/_12734#EQ,.9LQZ#&]D47/^T&L!W(\K.S
M"F-V3>2_M$%O+H@:@E='B!AN#8XDCBK#)7:O1^X7XV3 SO:YJ+?\J]3<(G,X
MGG6(%?RF]/JX>E\4]<KG2.]."&]:UF&;B"^=+"T*5]/!1\8X/"W7O$L]U"T
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M;53T2#74!?AU'WP$L;?163JQ7P)NM8#\\[I6*M3D7M[>7YV1$B]0M,@_>13
M=?AOG$+NF_-V5%+].G9$SIV!P\0$*.0RP?.C+"HK#B2RD/(">6OF[4&EC7%-
M7)&TB+-\J2+%='P*[WS$H#$/T-*MLA3QNO7M!O1/Z<_?6>Y\)X\+K*)6I$-[
M'QZ7V!N.?=4\XGDGVL^-?2AK*/H\>0=LH(6VS &GQ7J7I'@.44218ZY$ 5K!
MEH4O'NDH?8]<<VUYK;7D]&11@8^Z9,P:&_V%3Y-F5/IQHO+42?45YLW6UU7H
MBZF%EES1(F43M4K'-PN)%4Y(^?%V5@RX9^08>6N;/?%0]0_<Y.R3&&O-\"9
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MAN2D]W@^?WD)Z*"5Y1XK+80])YNCV3N'&V-C\@+C X_YX4K%I)]= >8N8Y>
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MQ6C+B^_.;0(_L'$]@\_L_0*A7XYH5BG?!6803C &S54C2RJ!"US4.7LL@$L
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M5^K>A6U!!T%AE?JE,0(9-<'/8&(XD57D+-7ITR#;LRX$+TEB_HG7ZOMIC4O
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M>)>RH^97[82MGLB&U]DSA OE;--;<==/Q)_JU#M(C!80)S32?0F8=?E7:Z.
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M#+E2O:WS#=@4U4%7^$M4ZX8P*\[1PT-M8L>-)M6?@>GA(+ 367B 4VSH;)/
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M7X?/(6I3BL-N3PH$!UVE!^GD&DVX5Q2$T:4IW-1LWL64;^BD>2[PQU:'_ U
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MZ>9=\:4O--3]M.D5&1=CH\\ORRZL<L:IBHI74^09[(W4$%.2!MX-3>.%4(*
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M2J\-4L-IWR7+)ZCAIR.YEH^U :9ZJ/(>ZZM!SZ"=/MGN.J-7V!.W>%*/HQ6
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MNDO:.C>PKBMBZST0;_2A33'EPA'HTU(:>H\8<1V<^$5[ZP^YYQOXQ#X2YVY
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MO7QJ&%T";]D9.P)9-!2,_93VK!%Z<@*L>NKR3^PU Z9T=1-9$YEI3-#D_)G
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M(X?U5LQ,L&<S?+S%V@?L?V>UQWK? !>BV='X0FAK)7;IE-HW:-P2NZY1M4>
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M%@^N2VQS?T7C^+!%ZJ2NZ+"2C9Q-"1T>Y*/FG2;W^W9GOGG\>E75D//5>T8
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MJS+:]:ZI\S+[:1=GVEADR"_>K$\1.&R@,B&[&6)W1\]%TO6 / +#/1/8E%0
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MZ@A?A2I:?\U0%<9%;BR3;EO-?CT&T=F1*VF<R&XCI/NN*.SFYDH?E@OENV+
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M,ESY*S(^R^N>VG?]I+BM[3U-I/C,_C"#S[,P-E _X@M"#;#U(&U1GC1 ^1R
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M)6MSPXP7ZA]VGH.>.FO=BK-VTG0\YNLKDKS_.&=1,.5OJ+-:)*4CI$G( (J
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M41D>O?OYX6(RQNH;.= V5.M4/SAAC9/2A9?A$V4",*7-S!N#PVL2.*E4^=8
M5R;W+#Q>T%6SLNBA6E<U-DF<=<X<+6 0&+5#Y!HE,S)1-%8^UF@0NJR/U\;F
MGR; F8C@EHX$@_;YMR8G\GJ_<1.%O.V&UUN=#:7HZ[X5^&?V\_[61NE"O!0I
MJ/MO,_</6&J8):F,S/&K3Q2[NW9E[K9/0- CM\VG;(]P#&.:[#S'K[(J^K2!
M]]@\3/+'=6$H\3KP:9.D/T"^/+,^WC7;JA'9UI&*0AN!-K)T?QJ)I;T+08;?
M<%JKVTP\^=E"GN*$+(\'_3X5+NX-GM4^858R"Y*9"OPAS/K@^4:\1@+T#9@*
ML9$#P5J6H4,WOT%YX PPD<76;%;'\EPT:4;#N.$Y!T,[P73(B_\B_"?D2I\4
MSFL G+9&#61#^M<%H_SNS\ < D+D?DP''D@DD13X'C>^X+]=O)23N)*7DU8E
M_N>N@)<0.O&L^U:ZQ>6.+T=JP>ME3JNA_T4/CU^GTXH^*B)9SR$VDB%8ZP"I
MS;DRKB,R+9"H_*Y^<O;U)97?0[28D:$[@2-TXGPA6K)[9<!E,)&C88O,R$O0
M6_.%"!%Y:_803,HE2I9M77/^/U0;AVN'.5I[%/8B#\5)WQZ>UI$J+0,)_(2;
MJOG90U,)6-C5+N#-ZQ58:/&]-BRL,$<!J9#W85VB'-+CK3GL?@SZ'FBI57NB
M]J\2H#=YO%2.5$(6(0\@L!:]:HZS?1Q1(H='-CTHG* !Z7W]+YMJEN!; ]P7
M1E[</K/) +V6G@RB4)HG0"+(PN?[Y %3W X^K!C#EH+!6M>&P:[7ZG-^<@F2
M>_CV'??I.X*ZX%SV"Z\T(@;@)J@08TCOR*+(0<CR2O_?ZO2376H3O);":G74
M=$QSOJ";[NJK1)&6/X$'^_*6[:%#TL@VA*\B(,5V,$[@]2DH.CVXB9VRP[Y]
M"2/?O_5TN@XO?U6P!]7R<69 ?%2#*6D#U]\ WD3L6Q%LB;[8P#P<TR;O(,EK
MJ$N[NT[[2?4WGX7M#4??>X:24>Q6\IUN#P]&+OPVESG+L^E[&M*-'IWD53MM
MKU#N*3*Y;=JJUOBP1H/YC\C &[W/FDN_&9_I"@DMKH!;>8F<"?COI+0_PFK#
MYZ"6TT$GAX$8PQJ,K,/N4"BZI3*0O>6K9D[ETPNP]H=$$77UGRA/""!Q>G!*
M\ :<@U+ S=!!>8>A(B%+9;-WB6E?/E5">W*FPL6OW_E%-!548LYXDF.D&1#[
M4]O$>4&;N>!P[^^/!J1'=%5H0:3KA$6GYFSV'3PB"]5L-'H.6H[%W#X'_4^9
M-'K?4DZ<.%_0!]]K?)514R9B4C]R5?O1/^U8U566X)\@33O#J!7JK89LK,7&
MX9-HC+#>X?W</:9+S(W+8N]*H2^>I'S]/O]>UC&IY&#N+-OM_CS)BN(A!M>I
M A#NG<KKR]T4E;3_8W.=BB@_734K-J.)"*@>48GS/-XWE1BR7.?PRK<VX;=S
M?-42/0G7@=VB0(P&Y7P+;7G8]?0MML&C^#ZQ.4U(,'U'>_$G8X^.U$XVFIZ&
MO(G*L.LC'^=&:H(M8UC#B@IEYHCK1CLJU1YQT=6?/9OR-UVK3 TI9/%N;-]O
M49N7/(D0@E^#.5LLGVZ>)B%;V82_6:BTW*)/&8TY7JG5S'GQ'?T@YUXZ;3^?
MROZ'?TM"4 '1?9<@HZ- <&W_YL5YS-="JQ(>OJHYJ>+]7>8KAC8O7O:93==*
M!S+PJ53D.C1Q.2R#A=[0QDV^.AE3>?OWZ;1<01N'"7=='3]F[=%0V-A/OS_@
MS1TBAR"9T0EGZHP#)VLR88.&U-KAG%VYH_=9./2>K0Z5KU&)-Z2*U]15C@HJ
M_5;?;B0S(_IE_T<+LJ6J'#' 9 $##-/*.8C9R<2MIFKB0G] 8 6_M_ AFHOC
MR52!8/38Q^]6^)S#)[.%;AO#CJ&FQ[$VJ]#F]O[U=/"%<U 0@H$H 71CTWX-
MPZ5FPE]4=&-YZ@/%\NZ%5*9'9CV0>3#";T)C^S#>4%8#$[F/PXUN&8U:9#I+
M T[8D5^WF[#.K3707UTL3^^X8>>[U^ZD^W[NH I8XN,2)3-3V?#7OOQ<W(CK
MVE-;=R=_.:XD:!^L.6\U1S:LO:RT7H6^=O[W3Z 9HM^(S T3R=LZ&@(G4*"9
M>#7H4BGFT/C^IR#VT2.I=FNU2]4WY<5]0=]?V8R742&\UC,I ^5H2,,B$=Q\
MFMC*Q@,DG<H+%Y0PY \HKD5JREPY!W%V/A >J[%*M[E;:!ZK' T+L8 /'D2*
MCS(CKG3S? 0/:-$8O%+]"8CD_^7>.@+$442NR$U$I@L0NY7]M.B@]'VH2^1[
MO7<Y4\P%!8PB/Q:B2C:#)&QY__OQG#T'6J;(;_ EU$Q%_K]7]C/&O6Z1FASU
MDY697#4A=4^3Z)8R'K1V]9GFQ32KO\B]^R0+8^$<6NKWTV(9@9<EU9Z#_+,O
MK4;YX1]B)6NWKNYS:7TKN$<5X"]X>+;(P95T9>E,OZN@?R38"7E@0+A 7EIO
M]"\ 8V<I1N$$PJ!;D]M6:/6T](O7O=S44.I/3.I"S]DZ6(/3T$J)9PXV2OC0
M=I46;<VEN41C?A5OFI5N[E/$$]1&(0+['R1U32U]<_%)']>O0G1=E\?;Y@^W
MWS/:0N,#WN9&>B2IO)#U7]MSH*-.,'^3\6#E@W1[DY8&OI_4VB< BR*EG8.\
M%)>/^GG0B0V]V.P[<W*M=CL&QLX.M0DR?/R.C:!P\:NT*,5#A9WNEPV!RU7Y
M7^R^';K&F6CYH1'>D.6RK=/]JJTS;5[XM#/GG*884MSO6NN<V.^)'(B)6/#S
M'#:SL8G.BUZBBS-E(,1&/@K[WQ3:ZR,$VZK- )-:.$&QW6H>C&O2\#Y\H [Q
M(NB/>.UDK])M-V:+B\7NDCT^F8>TMIZ#Q#8<_-)K31*'ZS(YWW]NXJBKGF,?
M>]O=D^6>DZXDE&MNHGWREYO 0.Y?YT?X9*_8#**:%]YL9#KC6:2&;H5I*WVP
M1:-_6<R0EX74,J_%(=F-Q]VW0DKG3[R(7!ID>A+!D"A(Z@XO>W(.:D8-:@5"
MF?U.3VLWWBT71*L(.FFOW6Q@EIOLTN=H])Q2__M@I$5,V_"DM?]><?8->W J
MR!U39_C4Y@/Q"H4558D10#VXG^VIMD#O(M%!=E)@-^)]UU9X'ZP_7D?P6F@1
ME!5&!4QAD)EO\$'8HZ2C0&($^E67^C0'Y ^J_>-^KIY5\QM9VJF[0@O$\<XR
MV?WHU8+7;3.C\LTJE<_<4UU=ZRSFA!8\)DYYVVGWM@WSOWWO+IF 5Q:=EET@
MCR-:+(:.,FP@S3N#9;1[1:<9^SL%:W&2 ]3!FI8ZQGGPB41ZW6]#B<*3,5,'
M_XH;;Y,Z(.XLC.O#T);(P0#HX"VSV3J?=\:IP5[;U\8,2U>_ISIF;WBR]&\E
MF*(-E(MM!)[6QWK#'.M+9<T4D>YM#G0O)^A7"FX,O9;J$%9RIKCKH*5_RV9R
M-IS8,%Z#YZ +>^B%9(R3'YE]56%OA%J]>UY5$^69:24''<]<PCWFRO4[H9QD
MM'\]%FN*%R,UPFX2;*(NS QB+ 9)@H.%JA TNVYH;%6)890["_,[=_:69\;=
M;6V/'BW=Y%:JYSM9)+,D"]PH//D1BN4QK4U]8VMO* MF9!"7UGJDX?FV+2J?
M_MGWQ4[8%5(!Q#LHJX\=!QY23!3A0"THLS'H*:B4F*LP>'GP7TR0F^'.- &5
M=#<_F>GAT^-:J/'%&RIH3:8H<#4L[J0MQ1)2 [9:"VR\,5^&Y/,=3S[^5()^
MI1N& )=W1M?_+6)3T03C0HT!.^2_2;7&K>P84\]G:LM_U"][I5DGPX<%'Y\]
M$5_<FMI?)5R&SY:U;J."-Y'+[?VWJM,/_>?M=^LJ2)-=C0,OWX8T&C+L]BXJ
M6PWKW0NQN,TY\$5>LET[AN-=H"!W9. )G<H?N@-!@A!\=KU)LC/H-7S&F7Y>
M4R(XAK^^]+?B-T>:7S_,$RORA/$WAZ,NQ/4[<6U7-K1=+U$3%@#1\TU";H(L
MK>;5K)\R,S)4U^0'F[;F]P9;O_EO23)O*7A5Q(2@.RB.8+.T=J3-"89>8#Y%
MHN!:286;WXM3M1UK#&#T7*6MQW83T':+L=/?R V(Y7!)K?/=R_KQO@?#B?.I
M(C$YZ/J?UAB38]'O82K+>SRY>])C#HG;'6Y,;[[F>=Y^'ZBL*\>WOM;1660"
MEHNNY564L^2CC9AW]E,]^;"1/"IKJ.N8Y*Q+)[3X"[)/.@?1^ .H#?#%9:(
MJ;+G9B71!XCT([3.:-Y);*B?Y1NNWU@5-Q)6DT6VQQ +;8^/8^9_+E](6<D?
M%5OK"#[SY!6DL> V,Y&W,2P+FR^"^[RU"O#-_K:+\LX&1'<R),]!3Q.&H%2P
M@-=K:I,2I2\;DEJE&KB:WU.W4_D*6Y 96PG*,*I9]"R980K+=@>K_4'W 4XM
M5>K6E^I+NR_N?<@9T]#03""5G@ /:\Q]K^?\7LP1X>Q7\YU];PD9O]4J 7[E
M6+?XO"%Q2B&%DMYIZ[Q]TN2O\)L]0#XNTK$+1]L)6WG;V?-L;&?)*_'>LB$(
M*5LJQ1R!I$;YSLP$5/O-I6G2A2;29:0UUS@:\+AD1GVA/^7^\ZB:7D]YM[*B
MS?1V84Z>183U]-NHP*TDQX#0N;\V!N%R$4J2_?'FN@V&7VOOULO2D \B72=5
MKG1G7\_86F@+.]OZS AKV/$KWROD5?WQ:92[URULYG5J,;_*A$_;41#G[3>Y
MZMR19DU=)N)&_M2S*CM?-)L:=PU-1K:S*8[&%7^<TQU$B]*C#-;$@FU%0$9J
MT#^K8$ULA[Q1>'+6CZ@RDR\VTCADRF5KA?^K$\AV>*B\#EP=';2[XB(:N?"P
M?[]YUR8G#Z#%]$6F<?^&!9%BWI^#*F]4'/Z!J)*E'506AR#L"DHE=X[ IR>U
M!;.M3/4:=_/,I!G'HNF*3K+3NV[M0KEA9EZ\<D7UF*S0<Y"\?4_\3U.A2M/^
M>WG.VZS=^.!V=S?+W)BFH?;3:_;*JO79RJ"/K -5+0N!#S_X78KZ)/HWM&@G
ML_]ZRV=UOD\'D^S=L*%<$'=E:PR#K/"/OFJ:X=<<G9^S;#2+ML)S5(9>3'VF
M#8F9Y^<QOK,J^\C;H5-*7>JQW^T9G>6(^:<TXC97][1\YU>_2UI3% 2M+*WU
MQ"OX_8WTJZ+X SM5L\<FZ_4F@E>_X(J"<O6^ES[_DTV'=/8-3'9]X/KD65["
MKG7]#5MFW/U*]8=:OJM-KKI3]I%ZMV*CW9LFOK;QA5UY%5398^27:[>R\&Y@
M+7AYENO"AYNBTR&YL@:/<";?<_5**[I>6+H]2@-LQX06)(N9?&-R[1,_A]C^
MM0FN^!GTWD0\]/I]2[V$=2XN@;=YXL%\6U<,PL=6_B[<%^&]L8L*]+I(G?FF
M/D+?I*O9I$*^]Q'M1O#C6!N#-[H>7MY8O8301]>/'\9\I4MPU.7B.'M4\$WV
M*TP#D^ZD/>>#3CFF;H?>G0U7I/>-##&+OJ3)$<F.[AB>78]F=IC<H18.-E>+
MO5B4M3-]RRM5>Q[!FOKCS6US8EX&ILL(IUKUVC<RU_[R8%;-K9A09P:7]Q(-
MKR1GMVZL7MD<##&:Z84,HE=^T0INOACP<%;E_Z:#M&%B-3[6FKK1<]:BD<U"
MA,X=*;HTSI7?:/((S=+1"K6&F9;O:HMV_KZ+<QC9DGD_5W1<W-W>U9)WK_E!
MT@'#DDTMU6)V54B!MG0G9W*71MJKK6\V[K[',".9S,Q,3HLY9?D(S[[,]H],
MHB[]HS%_Z38A^[VX<?Q'7*4S Z!6.5F[)V?TZC_7-;02)=LD\PY'$N:[\,CV
M?Z_2EM(0*67,*_BWI+J3%(J"DFH#_V;O$0Q2T4?+2CMLYY1=E 49.7K1-D.\
M+8"KSB4!V.U?>%=24I@D$(1=39(JDARIK4,PY!X&%PRR;=!57]Q*.W/TC+3L
M]7GX.^7]G/E,,5E8;;D59X(0#R=[<7J82413QI37!\"3;2F/S.#G)5&?M@0+
M!G B-E/4$UA\LEI%]EE4KM)</)48M?>O*1@[179WP!"=P"#"BZ#73I13I(EZ
MG:*RRGI@E'MY'__QH;XXHK_%30AL3W3\JFF@J=8]1Q/P#06W4-D5".RN6MX+
M<49?U?NL[?++RB+Q6NC3M5LG-5/1X^$KN>N#)GN=\EZU 7N0 %E"E^*O(X@+
MP@^ZE&V4/4C1L9"F@@H8Q6]'K(N._"()&/YXW:VC]#LO$4;5SG\"R8]<X^MS
M2$*]S.6+]M![%/H'Z4-Z@0H\!Z6CFNB&L@$3N."$BI:&Y9# VYQPPKC@3[8U
M$[>;0EG4;F)_D,T4VWJT;-4/;AL=[#7"5U,>,?Q']?2S;T#Q1S;)<!;U#Q)5
M+<[-.L;J]Z9<9KFYE&Z=/3!(FI2:--AEG,)F.J<Y<9'YPUO: QE]L>OM9^""
M78S2NY^\UHO^X@\%KIDK ;$VUS?7+PZPJS!=5;LS?FK$?Z7'=?1^3^$]/WD7
M9Y[,M+$7,OW=\6QZLO.:6A@_%IY/^_K*#6?W7>9#H6[\DG]NKHU6^YR:!<;3
ME[,K]^<??_';68G3QJ_;%X#T"B)&]D[2%5<OYAW<--C9WKOA)[#;(M$1YVN]
M+?:X^MG:2=6^2?WKW;6X/(T.(Z;LHA[(R$(JS>[+^Z^#YA8],(J<]F- 4T!Z
M!A9QYQB/8QGI&O<)V[SB_/1X4B;O;E&PCU(.!WW6_J$ZL;:QJZUI+@R/FDUB
M%#VF4IGZ)> ]^T-N)LE36*O&3-;*5EZJ,9QNPBI)I#7C>Z=='6]/QF?IBAZQ
M)4;IBL?::Z0"Q$8YI&5T/]?!&$#4C-9$^6[]Z,$>-H-7PFK?I9[E;+JJ)IWH
MU=U**"+1SL,Y$?U:D(VJ8(-:^.3I!R(+T!Y,1@T*M)2WR)N[H1<V$G\[9:]:
M]>^V0ZX3!:O%>@+%,_(];EY\I(MDXL^Q?&_SR];NU@-4$<2/&(SV6WPP7?&\
M2VD=X8U<CMQ"4AS%>VT16#CV9"$1WNE=]$"2Z2F9>",[UT"[QEQC\;'-+\3^
M$44FW%ELH<A,?<)-\HH]%X*7S,?^PRC@75NXEKH;U?[AU!$7TD/^SY6NL@PP
M]FX0,]$.B$80[B#Z5<+Q%)5*T/&8T]1>HLB!9&.^;Y8.P<>?03_'&![>H-KN
MW/4*?]1T7RE*6JWB'2I9 =W[</WWN/F,RWA<]DB,3&RQ7_'-M85#U33;3S9&
M-';&>_2:\3*,?RWUTJ1?7_C?@T5>(.#&BEU+YT*Y7[KTMF%'JJ"?R271IH2E
MG(]:M;]>PCP(;+[K_#TNR+4HTZ%;T/@CY4^%@UT>]?LAW]![VO8I:]'B7X">
MCQ,?.72T<&G 3 8C"+]Z&SX%Q;[>!]^-<R/SV. KXW&.HZ27I)+V[TN@XXO=
M7=]SLN_@9*[)SI,%B:Q (PYAC./IQ2[>+K9NP9:DSK7Z7)&A:7UW.;)D0FG*
M@&+N7CT4 OFNP"  5.VC7W8JK[92%IC'H$;B.5Q0%=EG:NU87-82N/(X:KE=
MZQC=ZP+Q0"7_+1Q!,,.DL8O#0:S?EJ,2[IKNGHP_4>G-*E,2TW PMS,-HHGX
MH7LQ9[;HF"66@GSEL)OENR+2<SV"-7WY2/NJP[+8@,!%Z\5+8T_Z35S6GM9\
M6.MNO[SY6#0-1YBD<YP-M)_ZKZETS5W\AJ9_'?VO9X911SI@7< /']BR2.8!
M4)BJJ<PP0;Z>J^_T/?!7?P2U0N6&"[^TZ51V7>C!JD/L]P-1KMDI="/:%[&\
MR>&33-;SVE<<!H.KC/Q@5?<M3BTCU&VA\X[QLELA==7,U^)83)F^I>;41[ZD
MHE*-V\</@^+*-\N6C;;8DN5Z8C'ST\H03I\UJLQZE7.0ZNE$VO#;4(&QM_QN
MKGN?]?+EM'21O$[ZN@$W_XN*'(2[*J[QVA2O8]4,0O]<Z,D[0$_&?[,]F]63
MTO#*#I4.87VTU<=6#S\'(?II(6[K2[/XMSC%S$I2U6;;0JN3)!^D^4]Z=U(2
M1-(2]@E?>_59_(7P 2]Q]W@0Y%(Y-JL10P^UF@TSM2W/R%QS6C+OF[GCT&KE
M($CO[B"[RE[T7_3UM8=EH]OVI"Q2/>JA!2"%SR'<B7K3#V9 >)M1#WRU^_;4
M2="RN:]$[ML[>?!*KNJ3@4;(B/%/<UUD0;@%($DJ)I_V0X2U>7QQ>8D<48G^
M[I#$SU>RAW]2?Y?GU,/6'08<PO@Q\GIFJ-\_WDD?]6-&G"$"Y1@MQ8%;CF(3
MV,64L(*@KL5(4U%(\O(5<OC)1036; K]]DRJ XA43.IQX/XPWIY,?% )5=5Z
M8SIU[4285V6[:''?C1 (P*UHC@:1W'>L\O .@NE5U',MC!ML(X^U/6_/;!6&
MG?*Z1&_<OA4'F]J%ZL%X26]@D5BF_P10 Q9@H' P[TT@DVN:F!1R N7#B.!&
M2A:!,^#<1<92Z3:S/S+R<X0],Y]GO8ZG95MH]L"=@X8D @K1^1/5Y0[Q[N"\
M[:9ZPQ+;6^&N5;S3M<C.Q*GE*19$OW./V-;/0AU2&Y&IBN@T^S*B^%>F@KRL
MK?Z>PL'.HW6L=#OXR(:"&\WM:8B-#"@[S&FS./MQ3"D*.S7JAY&5_15<;Q(=
MD97Q.=N#LU]FTWUJ;%E.Z%3(YIB+K+A0F>/QS.&Z<S#>-J+L'</4EG,*&I$E
M.:M<'[.@Q8)JO9WK,!HD\;@S^U-<64\JGQD3QXTG\Z8*_"'T*IO: H.SA=JT
ME3\AAY!("OJ-%X'#K(YE7YY WD%6WN AI(:@+1P\D\!R5GH%T-]B*)]KM94_
MN:JB\2E<'''#CG7TAN@QMX.78T(.&D73&D&J(')O=I^#ED>=X\P7F,9;YR1F
MI6:#AI>++HJ%:'ST>(!FN&P^FU'Z$AE$H=L@& >I"N%=AE8B<U'T2$#(^N9V
MLY>;ZIO@NM'0<,$*O?_\AWBIG)9+S =';EA0T^$+!\I:>(G<U1O9 T%@F!N.
MM/AOU\303<]&[>0P%8M"JP[; 0;WMI>@9[)RZ9E?[)(>:3TX[M% ET01=Z?.
M08'I"/7DKJF=.WN+&-[A(YXHT_Y3=$.9RO!\_=M\E["@R0Q&!@VQCJ+;]SDD
MC]:47CW)>,5XC+SDHTIFP'&/)I]TYR#"?1Y]!7_X]6PLX^>PL37/%S[W1[K]
MOR81KI2N.QV86H[=0@W74^,? //8= <@#JYLC1ON2^7YX#7CD4MRR_)<#23[
M7E-?X30&C42<(#^7I8.Q9A;)8%[RS5_.(J1,N-;/PGL.ODT?UWCFPXW:YNLO
MA@3DJF]U#YK^>/5XJ7\KS^CON%[N.2B@ZI9V2.;6.>C):!$X5G=\Z4_L.0BX
M:G1@@ 7C\[ J1R.*"5!/!&.4CF3J9L1\CIBI9&J"+[WU%R-F2RGFF(N6UVY*
MG2T Y?4^:_*XB/JM]*N:J2>FG4@!]<"M3MLU'Z9\L'@TM2;U%XW%/Z.X6;P4
M"H@DV-GO@04UI33+F(@2&UL^X!1!H^CZD]@?;0\K?M3;^U0@5,:.A=_H-TO%
MLR"4G37[FK!2*2K@BWLQH;M=!67!$CTX9]OEB6E-?WV%'^9#;O%^RP-N'Y;>
MQ=Y5,?ZBA9F%/B[R"VE+W@Q*C52=>K=[S),A_<W4GGI*+.F5"#F_W$^AW.N]
M/F]ZJ\,OC;B/=_$+"X7,M:5WD.A+''2B//R:[@\L:/80="?"L@Y=0/H[K;XW
M+!UQ,H(!DF(L0RN/KRJ)-W(Y=8HVF!OUQI2E(A$>O>"/I9PXHZ='_N%![$ZC
M445K.:%5:[I!GD-<B3W](; !W6/: 1T/?K[/I>5@#:<].&1.HD!8VTXA(/_+
M2%BF4Z&4CPQ#O]BK"_#65UUJ0_7.<6WH@/GQMU2_#^Z6(%:M;(^]BQRA6FWM
MGENDY7ZPXW#VW-Q!U<H*S6^8KK==DEXU&E*6]P3 /-:P^ !SFJGD<(KR=%]B
MX_1QA%]^TQ!DB4M.\W@FL5;F0RV]BZ=_=KQ_R3HQ.:$GZ-V*UG;)^^4;AC<B
M]Q:^WA3Y)#>V\Y/6C\L6&.9+1*7>"3\'I3Z%$".YJ/)4F]^?)=G55U!W_&8W
MM"#295<9\:9XW#UL;?4_!\5P;YW9!+PVP-4<WQ/PBE^_/Z? =GOVY6'J5/G3
M/C]]^X4^[2A/?3^,S\D*SY'P>AG[E+G^UME_=',(K,74XS5J$A+A+=W'3KR#
M<T['GH/N.FEC@#W>A6FU5UBN"_3$T4RU#Y1!H>3FJW81Y]Q(N 8?TV8BO4$$
MI6<OG?Z'L\X.*D<[0PV[?I14ZJP->YIK/H8&[NJ<P3VI&P11.TK %D;SCH*B
M>#2=J#)^5W1G]>LYZ"]IKP29J>GB$2=2"S)^FW)H(M:62B_5(1/_&.)2!]EX
M<0YB4X1LU.'+/JA,I8OV8K'/OEF\LQ^YTL6#TUF4][^O(=HATZW&_)B5A!J$
MFB#ZO<Y!&T7KS3;[[!L(>I@]P%LMWH8>/MY5B_&L#PX.[C)(&6L>PDUR@E2O
MY9@;;CL&"('[LQF)<*!DHXQO"::';9WL+>A^:]YN?8JSUVN_>B,,H>2YOX/4
M3-N'^$RM,.%321]Z;.C2^R! [I9#P22C_<<E4S\/_\#?%8Y7 C]^T_ETZ$W]
M60+7]D2,UH+1YWI&F$W/+V!58+P#)YFG+E/$G6%WF!F<\V?U>H-A&FA/H;67
M=6LPH-*@4I\%UV%G?2+^K"/E*JU\QC"]>-)JYL<,+^[QZ?_'1N;_>\![8?^*
M:&XC^F^3V6!\T]H7O=?$9\)+. <OR3>D2_96V/J>QO@S7FM<F8IDSJJIN?!.
M_ !$,T(3O3,$!N1X#TYP?ANQ,!!0N\5'-*U@B8&P#VM7NP6%(FCVK>H__FYP
M5A(//DNI'*E4F&X^Y&@]RS$ Q9X>Z!/,81ZD)NV;?M"6H /J]V\;,4>7Y"O6
MG4:#N&O&Y (J6I+9=5(%#I*XH/F&P7FY)LC[N$@BEQ2^#5>=T<=+U)W7M,;_
M7>ROEYDUQ.;_>'X)/>[BY3I<?G<H?9M;_$?EMPE6ABM]\A6/(>[:<A02B:'X
M!PAOF&")H"7.^67YMSU&GG/0_:]A#L**]WOZOWCTM"=ZW1R=X/X8N+'(CD$
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MNXZ_WTU*"V/CUE4;3.\(?"C@@2_VBOEJ%)DG'1^]&5W^S>1FYEQ\%)(1F")
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M#72H_DEE<(52?:.\*!ST+V&E&&C?@>X,VO/]>DO#D_GYP:RKPQ_GAQY\EF1
M7PY*',1#(Q%=>ATF,#>2YA::/&0'/"%5,,0YM^:KEER9(3?PPWM"3^S[I1]6
M#6V/R_9KM7:U/A&E+ZF==W0H6@W"^/V=SKKZ[E'#O]D_IN-'EP-  O@QV@,0
M@0Y=V#%R![J223SJ:-JS#65R9=I+W*H+GC)6.L&GO"2S5,(>'L>^L+W*N.V8
M?8LZ2V&&*O8/]#)FJ,KDIUT B%6,?@2G)D.6=FZ,QEOE ;3V,50ZC)[]6UHQ
M^S7G-SY:?T7HOI72Z5+M!^S_UH RYXO[2=6^ND1E8F!:@-]Q56SH@2(]!\9/
MO1L (5UK=>=W DKQB/D=7-!;0O(.!*_8T=32,*.[^3.MK$L(PYE'.#U  JN'
MF)+[58GHC -$5Q$"T,\9@(L!<>3(6\"2^'.&PGI7PY)Y=ZS$UK:&PI/PAD*W
MMNQ7N7R$7U]<S#M%]]^2H(P3IZBB,'/Z,Y@"50".98#(<@U^I)4;;1VDF3J\
M^F55U7+KR1:G^\X3EH/W^UT]37B\7A\$)T%P59!:O78J)\V,N0ZC@6#<<@7>
MELUCT75C6;1PP%[87[.J+WO/J/Y/@K+&D/B0T$>GR3N=W,D_BW*)%.1D /U7
M99?Y['H0FC3P=_LX=[WC[E\F$NS2/W481EG? +A(W)T>I]K'3(R#254]A>V]
M4@^(_K.1*,$VN#=1TB''^Y'\N]I3T0K5B'-O9%O3X<E'M.T0%#C*#5\L%82Q
MK4"Y?N>[B'CPDS32\6?*6K,4_3Y,LL=_L'_-'K<"^G-^.,+QV1IG8$W(9.Y;
MQ9*:@:W$?G5=R /^N3H&U_!'^+C4T\+&MRO\(LO S=O3P3+M/>NI2-WL9"7#
MB'G6TXO7H[ZM=GQBCCL?8,,Y)B$"W0-U;1>RX$+Z"?>?V$R8*'B]@ZJY\.AE
MO<D0.>=Q15K 4$/ QP"Y%K B3L27TR[2GYB"X-_EA"=VZDL%8!+M,TCO:=HO
MP5'E]PC=GS;'W8QT/.ZPEQ(D12D[&4<1"T&Z5KI@[#C9H</ ,O4TS"J4;(J9
MD-"-L^B6^NHTMXD,>BMF_<K;?GQPXQ@EZ:UI0W_E5?4+@34S&[019(!8]:S-
MSL(@-9A22W]K>AR@,DX\HH)I-O17'<JEHD"=PY3)>28R@@-B=+37!3>UG3?T
MDNJ&^<SQ#VOP+]N>^'_*OBCZIX(X3/6D61]5F\3%00G];Y'^XC'0Q[!(=@HE
M4MS>*C@X0.?&^^__I?5Y.<NKU8CP9#20$HE,6LRA-6MJP)@]!/&A?9$L45=[
MNDVE -,#$U-^TG"MLK3K!3'O$J6\ZU^M%$XN ]0WIT<6BR"D6\@%;HHEO<GT
M#)+(1E+%,U"X4JFHA(T M*C5QPW56+_P4QF*J5OCCWE<(TRWA[,ZJ_WLZE("
MK'4G+ZLXZZJ(5T]"'B;&2S.XFJGAC#E$X]Z3D^D/: KO7#9,^7+S]^QM5_P4
M\N9._;[<ZR/Y+RWEGR[3?_D32DFW,S.@I-NQI^-)ILFD'[0;)%JYI](4S=E7
MG7A#KNA7MM7@MFS^)C0-W;!&$UVSH5<PK5-LRD+/7"$U])>N\(JIGQWM[3@5
M;9?CT# V$_[5O6QM\?G=7E3(W(K$"##/G U_%,!4!>Q5)!^:,/4::9%BJCC!
MFYO13!#+.N%O9)ZO-NF,(8+/"1KW1J_L><D&Z%ZN:IA!6JQ_0#^A#H575@N/
M^[>''X(@G51Q7&)OIB1C!$RZ!$E"-%1T+7Q3ZU"@.0(9!V)H@K2] V6Y2\$9
MEOLB5&XO\NZM!!C6D\EZL.!TM A3*MMB. <@M?P#Z@Y'1+[C9)2Q4Z#K]6F?
M[.W3]^)%L_$\:?WZ0X+-#R-%+US4W1^G'MVX8VX"H6K3SI&16Y54BRACAIAM
M5VF2C6Q_Q5OZV^J:0,VWT@[;WV\\DNEEYT&D#ETW7P27$YD3] %;6[&52(KL
M[V!R^80[,-W9-GW"3I(1K-#\/9/&B/F?QT+GU_= R:>^.@GII#>?\N['7;QK
MQ5I?>=7AM6'0 A.CW9.?62YKK8ZK._Y;I!;AQ8F:*]BY/0;O='X?FE,S;[8W
M$B$2''9!VRGY4N$/6YYWSL2Y->_,H&QSB1 QLY1NYF=-US$(HC,5S)@]SY@I
M%=#8C5/UF-SEG&VSJ]1>7NSQ\POY>EYZKJXYXY3(Q6PV40F%%%IB![W%1(FY
MS+M4PQ" RJ??CGZ?USN,@L4:/WO;UNFHLX_MGS)ET ;Y8NXXEC.^HU'!/<&/
M$;46_8CY,N>Q(,U__"D.#GIY>UF6J:*M+M>_YLB7%L2SL07'(!QA=9..FMV_
M1Q?>G]Y\!RV#7(+@ZH4V.D#T;(: +^++KXD%^+=EI5IG-73=^+O"3;=49<_/
MII%6(1';5V"G>^[<"X7^^/K]>*>LZK\ARB7FZ#* HY+(*#*$(D?_T*8;N8)X
M#C=,),9XBWTMCW31^_HT.O*<3O.-"I8""_+I 9Y]6FJPZC!"P5@K8GLS8WZO
MIE#@X77>!WL[AR#.YF?19QIT]R*8_!)AB9 S-88%!0,G@[O0(F")S5),3&:O
M>]#$]@[5?&6T9-'55#[;AEK,N>>4172'$OO(*OW8VAV:X!KE%G")JK\A+B<S
MP3B[?E":W&:'^& Y\Q>*59FOE<E^RW=Y_Z>HBL1_LL=4"= $!.D&>/[Z"H-K
M+Y#*S9C!\H67"EO@A_VI4!*E\MV&M?>8^_)_7KW?.Q.OJ"A&RN5&4AX>E6NE
M\4\AO(LTY\P8)[APJE@PP-\S.P$%?&Z-[W#D-;S[9JC\7XH%3Z:@6J_JF?ZK
M+RZZMVV\S '"[(,_5&+_Z-^^RYA9U[1!:V]ESCD2]-,1 3N 8@71BA1 R9BJ
M,3$KAVF-$V&W\47$ZPY-A3TWD@:7;VDUJ[&7.-DT]RLJO$6NR1D^^=C9!V]F
MC(-)=J./"WVV<A%4[J.RQ28<")PF>U0V175'>*-E^'?[3/@'U)UQ"[4D42&!
M[Y_M;K'5\X!<(U=^!%WJB\#+3[XN_!H<G#6<XG_UC/%"98V,<$J=I.B+-*MA
MCXL6NIA']3._<-]MK_^[)_Y6U%QSTU'LTJ3LZ=AS&;__'(+2SR<"B!A;XZNO
M'3L+85=GKRJ9W$?_9WIZ0;J4=>,L9*UDYSO:H/!R-F^;X_!:Y&WYV/F;UU,]
M?&+#E7(_L?!_MS!\]_>6G4#>,6I/X2^>G;/(@A$CZK3]P#8%J8)IE<M]9:4P
MI/PGY,SX2J2N0+]!1677,'=LNG M^\];5IGZC]9$2%TM-SG!$*];=CY/W1GM
MGSZ%,"HNG+U]9RW0X('S1<\]V_6+&3.K!Y-7X^'?$_SN90:<9P@3W<YH65J?
MK_:])FB)NME_[[%LJZW;P>UT#]E3E*5U:(N#P?E_ RNWA21?UW*D6?(%O!E'
MEC>T\!"[W!S8I=.B;E@.AXF-?Y%N)'&X1"CD-T\W=LCG::I_M8C9(OZK<BV8
M4C:]_4UEIDV!J'9_D5-RW5W&Z.6+GJ1!2=IFIG# XL8[K'K&Y@TRJX$>_LMU
MB^JX!28@1[8&JC).>)$*\4J"7.'1GHJE[914OW?,OUB74&3DCU?;WEKUXVG;
M6P';MH RQZ^9]/]=]ZCY^?R)U!5994/N$/90-\5@@.B5&4/2G@O]U?0QLD+W
M$)1=Y]MNRU3Z">N(>O$,-6_[Y[(A](BU#\I!JFO#EU==DR6+5!0DD>\A@<5R
M:Y?H-7 EOY$3232K2A#7MX$2 )E_%ZOHO=VOBF+9\5RW"D]!)'!9H@(^#@6P
M=;&"I%F^:K]V:&B96[30'5Z>D\G,Y31SZ[W7<]XD=J9\-@96^# E7-GC8>=N
MS9Q2G&6.ZN+PZF6%+>.,7'M1!\]ZW$V19^X%@_\JSJ[DKMNI5#^[^X/\>!]<
MK.ADUUKY[T/>W29=^3?<];=JRR].UK$>WURN[KZT@ZD<$,F6B1"]=^/)G]W*
M+QA99<E.V:JK@Q]S-! G1@2_&)I(Y9UON;/6H"^6VYM5R?,]8_Z3N%8=?:9+
M9#,IV;C,0-29L(;4N>)O-_\[Q]V/I$89*E V&)UH$?ZX^>@71421Z!8V?!=P
MM,OWFU0")5(KQF;CE#Y'9+%/66JQ#5QHO3VG<0^#V=QRWB[R#:J:?[Q;4X)1
MF?3^=J/V:[95$"/W!3.V-:9M"%JW'1NT&^S\,!0*3M;K>L#SX+J3W/G+QS3R
M">[V8CXW6T1^/H=HZHK.Y(0XAQL_*@A*[F+\IHCR)_/(R4XX8'0=A,_Q\+^I
M<M%K]0P5GQ]/&7PB^ 33^G WMV;$Q,9\*2L)\V-9ZH:TD&5GU<_085=27I7"
M-_GEZYZ<JZ"]3U(=Z3%?OEU8=]AI;8\=V,JG*L&"Z5\9RCVD5MSSO%E45J;>
MGS]NU>]SOY@,F10+6CSX8\M:WWNWTO/W]X;HC]UGB2CO_(*$=,KB-^ 1?MB5
MX).DWL:-BY4NMG5LSO$66'B;[5?NU?U1$CDW+$Q!T/,AN (/,%@$'9A4W19*
M#B'H-HVWL02<#' ]YODR_^8+G]>X?:\WX-[K#JAD1 !T/H?!]1:WN9. K66G
MF&H![T.Y73:A MUJC901<\7,:R._^J.$$B[U1Z^ DY=U9YAD0\*_#D#U2:5A
M/KS_6%NRNK%JGNVG&)KM7*18N/^R-GIRMC!#>$TJUW'M.O\AB"V;<;MI(K&(
M)KY?LD"U@\]A90Y!#[ 2B&Y;<MGMO\^:%CPK7#5SO.Z)7Y(1R,P%2<B.<"IW
MQ!;VDS ?[>K#NDQ2[F=^J#(H--N['O"^.5NS[9SE=L#&PR87 W^[MXD):0I?
MKWZ3,$9%>,XY71(?5O#R7<VV,GOAG/9P5_&64=JO.R&NQE6)^H7Q\A(+/U60
M#V9P6?-@H7G@/M%G/#GO<E,(+2-.==R4'18,])&,^U_07 "K*MNRS3S-%M6D
M5^D])U\MAGD':56<G!W1SYO5FVQSY-$7+CF[5$V?;MFWNW8;47W/X>79[EL;
M?08-]TLJD5H-+F4'LBVD_"TF,^>()47/P"2#*V!:]+*W:?1/G5E\601'NZ'+
M47^"P#7+T2M9@S0[()Z$[4>ST()C29.$Y?30-T"JU<N!1\%A[V6\FD8Y;&_T
MG,S(_95W,) <QGL9ZS 9]+Z^)3W/Z5[R=Z.6$DFG.PG'<2GTHYN@?&B<]!8&
MV(DQ B7=O#"#^9=V=Z$'+4A\P;VIG:88"8#1B29B#UZ'/(3[[T?9]WG7 &$;
M>$B.HU$ M=B'@X9<3@&"VB>MSY:*9?Z%J)P"GO@%Q;,_^@)C:RTIWDR?";=.
M?AKO?DU%_;$!Z,!Q!MRH3Q,>75'9@B*=41EVNA">387A"=@E3^J2$8-5_UB&
M72YO?<*MU[BU]S#-N,HKF5_G9;K;N38"-LXU'4BT"/9Z?GC/]6!R\F ;96MV
MYO+(DB7.M=@<'X@WU)+C; AOE#(MC?TL+8M3]%J5*^>;[L9L""UX</=V>J\3
M"Z<R>X]Q)VW+IYO51(+=9MIF57*?OPT^E^TWI_W.] <U93"I>,,6^LN5NWKI
M5/;EYA3S(58M#M<2:6<OH86!^L"EK,VKMA9WWX*C)>OMKD1S?OK_<U9%-Z$<
M<".:"[V8%AE 5L&-M(:_"1![*EHR_7T;NMVR&WYA.E[T9[U#N-_ES[)&6=<U
MS4LJ#]Y 8#I'IZ1K@VFB9E>@//"Q\TXP&>!GIQ(RA?A2.;'Z:I1=K,! EH*<
M9)<"Y!RD$Z**\+>=HZ[,;D6NE *7.O1_(^_\9:5$9H'U1OYH3%PZM^]NN99A
M\0AZ;G9398LI#SA43:5($O1\1* Z#\P6L(BD-C2T&DZ%94<)S2V"B_7"YUOE
M7OV&^^'.1T/1^<OOY>J+9B#_-FP/098YJ#]-6^Z3B[2B=VBG0Y!_*:",IBD@
M>,KIU6BO"SX,,8NN]:6VH:I'K3?&Y^[4ZX_SW7KCF=]_[M))5B[::V2 YH\O
M ,9CEE]U?K[Z-?2VXC^;"._Z&?P5$<>HA!35>3@+39VTTV^;G =G(=NFZF Y
MG)<L5!NKJFI=G=)\G50%QVHEY'99?' 67?> 7P1WZYYT0J!T-W8>XSY302D.
MBDB0[/C!\L?K=,:U&K[;#UE ?R?R5BB10'4@R6B2DA(@4=2=CRDOU!'G>B1]
M=>]1#:'#,O@<#[C-450'6H?J71A-.!@E\I8O6(3CB/RW;>0(]/M7E D>7@N2
M\I<E[OS41'AE&I$A1R5*3U@'LO5'2#U/FQB0I8GMU5H%N1B:VWM;<.<^VG/C
M$1PK!#63I?&(7MNGIDK!QV@WQFOJU6_+9X0&1$MFV&K8-4MSUO%="<58)+=9
MX><TU=L@']V<!BK-*+'O$\S3?1(-YT_:ZVM<-# 4K5U!)I68 A4$84)F$F9X
MN[VR[5$/I6J]A. EX^6OL::(XP,A+5-76BRH)H@>4\AS'<>;GWG=-N]C&<JE
M#U5RUGR2J(3'AJV(#*BX>KTM7Y0?[%(4)O*IQC ET_^/V/.1"(0VS#>*O6DQ
MSB8V,_$0% S&:/X'E!+0:>(MN8W52&#@6M%5=,G!O!+KF6[6\1K6\B=W,-]5
M[T2-4J2!9#*CQXFL_TPWDQUFDFEN'5ND+O7;P\.J\@J?"?%O-JN5!C?_I07E
MMHB%3BA'$(-]XQ D@,9K4?53JQM>UM>2%O-J/.(NY"O_'&%)OYJ34+Z6 MH-
MYF&,%RHWD)#6@/9*N_:U">)N:E7UM4U*2R2FP77>'6[M-__^TJ_S^Y%\=M$]
M7@6FAK#;@ ]9D] #K.$&$G>AK.NK!AR-^=+#D!R=B_=M+^"2@NY+MX#.3L]N
M:9-MG8!Q_,[C0]!Q71OA@9:]I-U7_YS$S= I47<='>ZG.%N?54P2SU4QR739
M[T \18L$T@RK@.&V"Q_U4M\L(WPVC%)<6S$N2\+U5Q2_\_CWDE@>E"SYLDV$
M\XM$U?5)O=$7HX@?Y$X:#^M$>GC/\EVW/A\9/CIVXH%1^Z091T;!F^6>:DZ$
MUNK<0(@49/OS^3[IC'W31Z)_F[_C2HQGB8BN'4!>DWB;;$;Q:*17F.A6.\T-
M?_0C5L[Y;GN[5J4&OG^1#,)\N")Y(R;!</4Q1,WC$(3?7-\[#[V,Q6@UG]AS
M"/DO.0.MXZ@6NL%CXPY^PI#Y;2J?$.> O5[J6.\H]EU-XQZJ[\?CK\>B Y4X
M'U]?9+VXH3KD"B6O/0O&VA9N_!DAR(^WV6NS\IMSN*X/]KE\!3() ?*M5^H^
M/LBEZO@U45_>?D!=,]UE&;N$X]53O^:'$D<)7/,^/=;[8G ]8W%4SG9*P]^9
MIEW]>V^BY_UFSD+2@G^B<[9]W(F>U1IX1L#9(<*UQH.GD=7^8^\,[UM;%[Q3
M,7VV[ :&26$GV@++-DL4&QNG!''/"?A+?@J-N9.A=\0*_[M>/)_$5@T*^Q,U
M0'E&BCD$W9^/&K"O/<YRKGV7TF?1%O+RSCE$JULKD+C"F82)I4Q!&J1D"MY'
MR[]:Z;#^$S#V+U#A5GX?/S[5\&3+E)S/L^NYVAYMK0;?Z86K5QX^HG&GA3IW
MR*-?V<IFE!.D^VX*:[R!K2T:=%&O?-WW:M1_'3/&F;:XWJ%#%B'/IW)I!/&?
M4L?SK&5:]B.NUI%V!DQU 'TRMS60A:/HN8S$A^4[[*A=Z@WI#]%72. ?2Z&X
M:U\?KVD8UC9#/6>Y,%D>8GT\P\_L?->?[.Z'4+;7HBH8]#4&-Z.?P46R[8<2
M,Z7=NFJB[&-C6Y$\756+R[]+2=ENKI8OBJRCGF]F08KDGSG\F7M]1W 8!/>/
M:J4,T-_"3\&LR8Y]QDLV7F3]##DL<2_/89VCGQKR#E)7?T='\=F)96>. <Z3
MA(Y,@.NH4 =3V[Z$CT/8_D&22SGK>:$W2,^F)VT>278(<&\F251I=?Y1O;9Q
M23HAY_4L!LQC$DP]Q1A&\'2H1 50GI*4%J%R]4OF]TG E'+JCPGO.U+3><[+
M\BY+23F/^%<#W>0"B. Y+(.[]B.-E_ZB#( 2(!P;'6?(YDF:VM68_](K.$O,
M% ,A.:\%W'84I&LO@HO/P8?1I%L[;(Q)%',.](HK?Y?HC;?ITQL?? [_>[)N
M_.J+VK(AD])(/V[!^\'^M+?3<&6_V6U,>=9&)=):>S@R[L)/1WDK9Y38G^'Z
MP.+%[/N*A?0!$K(;R\2R^DBB&3*@!4V\(A*Y?)+DM1'3B#(M"RVK;?)6JE_3
M-^#G<0NRF3_!)RZ/YF[@9_OM O]DL]0]?+>F<R@@-D!5*^'BV6IYU 44R)>-
M"'F&)=U"+TCC\Y/$72<ZU(%<ZW[Y%]:!HAC1VY@W5]3P43>.A?!+(JOY::+8
M;CDM(-J8,8'F,U$A0]V-7I^6.P392+E/M<"RK%9110_2JLY:5OZMSVPR986U
M5I%1-X%[E>N-UC4>\QL1,>%#X*]#%W)R<UEDDCD'E\PC<F9:X]CPI5TV,6O=
M,T+ EI_M1P\=HT4415C1):XYG$L-#GTU"2O/<SLCT3D2,-#G+1DA[_;OM$71
M?O:O? :'M#7YC%7IQ.P3R-U20*F":$P5V8"@&JM(5#? &>\:D*SN':ON8+PB
MW;\I;7ERY"J7- O<4>%%4Q<RK<,$T274)DDZ!/6)E4B2P/T0[D.0GW]CUH:8
MD4^*"99_^5N@P7=1(9-QU ?"YJ@_+90\D_X9\+HUVR%,TR#O>BB1PM_3TKD'
MHBAB^?$&SHSAD/&03I_M/-'.#2F?OM*D@^\6#X/;K.*"A?Y+,'1AW$H^)FK>
MGY40/_:0(\1"'FE!GY2T5ZTO_(C^$[9V",IYL^IN=Z!-1ASE#3V(TC:;_&=[
MG&;0-J/^+IXQ&U>^(;!!V=-L3\H6/*$@_P!3+MO[XGIT)VV./-"=F8SEV<DH
M(@OWM.0E&F6W:A*]489R15,^I)K1+K T4]AAX_<(*YURIV=IFB8VV8VHFY@_
MD+:WCR&7>>,V<4A '4&DXZN4QFE>!&E^&3^<)Q%F_6%AX\3F[Q^#8+"YR$Z)
MW?K53X<@5"6:/H@6D5O?/W\%/J5)$T%13($J:B;&B^)!JI[Z@[.*P_N]'U]5
M_+<@=<\<L?QQ1P<+R'/V<9[OTNS5?.98$^W,[M+PV?D0="^Q\"%DH8P:*FA[
M[?J)<MC*T)'D_S9T"%+B\_A!<W?P-C3+?&^)$C\>J9C&7XN<$V.N[2A&/_Q"
M")8=[0\YH0TY:$4(7])(5[F@;U*0A,#>WL)R'()P+_*@W&T!^OUHS&9OBS*2
M%-H=P5^]49CY_!][1\K^W3NU+HI9<G+X)I!LWZ4N67]_\GWWZ[PC]O;KXESF
M]G$BM[);8Y46#9U)B5M55!;&S"&H(:@ DLJ0=9%5Z)[YKP@IL+$'\9P\Q3U5
M4,K2N(?AC4,\HHHQ!AFBJ53N%7%B486K_WE8MNMOC.YRPX/$UQ]?+7;S7<CK
MB">5TD2U*?\!#(81*9*8B(^MAN#I&:_533CQ<1(F$7JGXV<U7K1YUDC_I&]N
M<P]*[/S5I G.XB-IPH<@ K(?+.G,P*2"*3 ]5ALA[O7W"7/9Q%7Q;"%TV^V%
M+V*@[$?9'#8FI@')F8V]=R\DQ%X^(>2'B+EI;[/W*\6Z=5$CW[IP#-&E&=AQ
MUN(4/85A M@2XB@3W\I_))I/*Q^"0K@P5[R(J_?1&G#5*-L5G\Y,&7>: =!>
M;O-VTT$].5!3/4LB1C!W_R7ECJ7N@1GU&&,86KM'/*I7;S)C*K!A>KIMG %V
M7?*_"?C?;M9SC#P$^;SD=G*XWZ.@X_UMS)B]LT<. D4$M"+F\RE%]#<-MH#2
M:*;NJW]QD39?$FQ9HT:VPYO0=5,%$HWYL2''[IN?#%3/D^RY]]Q?=?:'5A]Q
M<XJR*]Z[?\O_$D*_U?>;1N45G0;'N9@+@K2TH159\S!5]88B8>S6>NFOVS +
M@J&)E7K]!,8%(^TKA!6K/?[D*4.9K:J$N%S/4*"9DGVZ$>  "$];I"]%:N1)
MM&[ZK[8GO#)CYQWD5A02#!2R^A[=WB6]]A$U:*WXY,TA8G>+Y8K(C?_G SW*
M9#1A.G4T(A"]X(5';=6@U'TXTQI>!6IL"]Q[5Y>F,ZM1UJHFV.PQSZ88CDQ7
MW4("*A5$.\TM:VH 38]>.3.//$4*JA-=FFZ1T6G,/O8<+W((BGZ;U;GWAA^#
MP$0R3A1158_N,H8D'15NF#\$4>X"H9]AITAQM$+> <KTRYS-F*_.J%P3(J)-
M1\M85>1LHE]7X#]*)DUTB'('B*0&PJ?17R!;:*K.D%X^KE0&X+2H&U=J^E$W
M__MZ[559:OV+^4I%X2$-+MD PM$'N<*IRO!)"-CD$M4%/HIN4.F15<#KI^[\
MG-7(\9CQJI\-BX_J]PO\.?EJ?^):^9?_0-J[H-D)*,E><V&/XD8O1@>,SD52
MGM)336P\5X*Y:'*DB)P',XV17T9C>9^R&LC-_)./#(A%-:@A99K"0R+Y>$%Q
MDF3I+G"]S]82>89*@1VE.N!*C: I'9P ?(=ZUK7:Z[_L/==9=4]CI59J](L'
MV="",DSK105#(H;Q'<MR5(N.'7D(>O+41)*J!M,DF6?%XK!IC6- D5G;+'$Y
M+K+GA57%LDYCXR3G)6E%LI5PL(6RT)OB>:\_^OV'H,<>*O1*AN$FHCY_JY8:
M&Q7;<PCB:KL9K5RGWHA><:ZO=KV<L9Z6&:S\^J_J=GJJFK]> HB[<#\8AR0&
M4B5A)YGP=  ["]3BD$D=\F3^[F!VMW3E8/&H@1N%#*M?A2.$Y8 &OULF>O>C
MNZZ<U7NC\2CG,?>!3T\QF,&MSEQ&G8>@Y['DX(0P?O:HR.X#=%*.JYQ@??9,
MG+7M^':0<K8SROI40&NVF.:Y0.G7,HZ_T0GUFAA-%V 3W*DIB^@RUJG2G/]K
M/R5N\<+U=T@Z?-(F0B 52Q16IC1=H6]ZWI*Y<X<VO=^%#TZ%<$-P+\$DEU@$
MQM\VN40<*,5I@CT"]HR*]^+#+1O,:R<:]FL45,_$%PTU/]6ZIC!R?3SC7?LV
M9)Z[=^\0)*8(U,4RN\M/(@'B%'RL[JZ'89-[F-\6P1PEY?OR!PIN=U8!XQII
MS'\5%-D]"BB"MV:I$HP9;$-P'Q93:EO$G&ENQ'WCX^$V_/^50-4V':4^@&V?
MKX^!;K,(#H)8?MX+;CE1^NHH7>\VQ+,4\_40U MF0^/>@=E-1'&VH(V6P-X8
MO7:<C9BE;B#?_B6J\3%GV;5K="(N&S$_B'2B9QV"@I!SD?T0480_9"Z6X)CV
MCRB..P0-M!X/P_)$#?7-AOCK1S@6>AZ"_BMA..X_M>]0_ 8R%[W]A<OS%U,Y
M07"OT%^06^Z? \#U*C01VQ65GLP4#\Z)>FJ!CNUQ0+/W.=6>++KP5FR%SFJY
MFG!R3HU*R7AZ\#CNJ'9W ;WI+LF")MA*R;>$BP/2CK;/C*Z_^#0;$S9B<E$#
M2>+[:/)+.YHY?Y'U%B@VPSX8%]4@R@?O2.3\7SI$ \0/*Q*E<OD+6;VD&=^:
MKCB'V<JT<IV___=NW;+[N[3'Q_3E.!6G=P %5%H'"^T*/1/A/SK70]#OM>6!
MG9TU/>L78S>F0;L):X&_<AG9'(GJ&#<.9.< '0OIE?G[Y#937!R"A&!R]%+F
MPGJ):$1M#1.@27 Q-%E]N17?&B=EK.ZP;$LLK\L+U@N\$)G8DGR)O>UJ)RO7
MYD6YT15+B,\A")!';AF3+'J32>@>J##<F!8\5D9^MOV>L'"_X\MX6-6;KZZN
M7?[.MX9_#<8/R03S3P6RY0!8'/]\!>-$''.,'\DHFH@PWJ=G6 'OT[>3$-.>
M7I&R9:*7SI=5M1X3?TK%.L3U6ZZ5>O% TJ+,<_=V1(8K!<9<6;/P/@@;S3B
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M?-,\H9,.Z5,AZA6&G?] =8WCFT==Z#>[=WE'#7['",1G.X#]DK@U3:IB\#T
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MR>99*FG5<-4-ES3,B>7N<(.MGPWI#A$-_&MJUSKC3]F4I[%!+S&F#S0[,Q?
M#"X.JFD4LK-4TD2P#"C"09^%%UT([C;JKQ8M:0TU7MS_F!=1TVTU/P5[*[)F
M(@7Z!\%H.])?HW'/#D&LI@(P.6:0SN2F60&_F"2<TJ%--D>O2#M,!3Y01Q9,
M< =8W_U>IFPHDI/&SG-)\P\ )2)(HY1@>MO168DGC!.I).U.*2C3;V690E$)
M];PMNLSWU,J$IGP'IG$OCWP^6*EM(/VJ-VE@U0!$11'!;^$C8)([Y GX>,?Y
M*&'"(>BIJ10LF,3Y3-U$DA#,%[5B;R/'_5M-SNID<UU3_J]\NO>SQXN= L>E
M+P6?H->8*C%U]!<H3>A[,*!T".K$)K7H]P7+POXCJU<DFSSZ#/@_BGPW;^;9
M4$T\V7RM?&?5_%F!%>C,")<(R\%1GKDV4'9T4I#I#([0J&-[^'RFBN %U@CH
M7G2BD>SNMVJS=.G+7P*\CI<8^Y+7/-Q'ZHR;[V$^MH>.KF8214DW\7Q,V&(?
MHS]E*/C)24T2==%2 5(; ?E9EZMT#ZY46PNI#4]W][."8D[W1:-I,BSD6+QM
M/P)3A*](,A4 RJS('J45M-.DFJ+0T++EGC@>\;QU_2*V-KZ-['Y+K.2I?)/X
MPETD1GP%VE4=P.#*I')&<9J3@U(C:P"(PZSW;/WO8%SVCK550X%2>@W>43-(
M3DOVVJ<WE8L&JX]-L<Q1?67,@;_NT(3%&2?8"#N/L5\=M_9PLLYO\I;_>G20
MS4N">X9#A?3GU?".&<8!42N=>.?Y(3T+N".EF=G8"<9"_X# 58/K@GM&'\<8
M  @<%J/='6.;]J]8HZ].KDBX3VGZ8,%;X!DN\\&=A'<W7]\AH#4AN ZL,$,*
M=E0=L8IV T@F)?:Z^*2T03[:^@:&7Y#;5MTT[/[_0D?'\9-$KP35?YF4ET<;
MSS1)>@$B,'C.D5(.1"+7X0:3'3(TS;%=M##&-W+,8\A?J3$@8"CZ/XUE]Q]V
M@S_D7U1QWI!@N0@VI$4QFU? !\'<AR#?0"C%G 3>&B4Q-G&.S\.=8<;&2\Z#
MC%-MC8TO%H9C= 7P$Z$-Y9F_3CYJ$O:P/@1Q*L/X 7X2)V65A'@"\9%EG>U9
MEFP&0M]"^SCJ \"%D]_"3.;U'DLY7G$?GB*T^ZQ :<)/&%Q$LC;EQ0PB ,'#
MF(;R$^$\44\<\WOUI=QFF\C7!-TM@Y1JW;7IL=9_=7P?913\^[P#&#UQ)(T<
M'3$2)#T!_C.).$?3(A&N\* WY=-+UE<<98N&PE0V+X*/(A+3-SV#V>%8:..O
MBAYD:IT5_V.:4AD60/6QLCKXA0V?.WE>@2=0:UC-\KJYX*N,B\@6F"'SQ1GT
M3)@->8/_R;(6/=]4!D-C;9\R?W4'51LV&UB_+OU='!&,;:ZXU9NFQV'0V;5?
MA4<#\J7$<1QD#DR9?T+@[S_^"\$*]/PW97**X!-O/7RLN'++2^LDM?_,W>3O
M>S<>C:@21_F9W9-BPC0_+RW@R0IG&L)_YUD^A.7!3M]^<^/LW7R/YMKT-NQ7
M7H/[GB'CM&</G82+VS^R[4I3C !C)A!VJ4!PA%C(W,VN$K$QFAT>*;DIABH4
M:ZA>^&:*+%^?%:L;EFAX971VL"),8PO9[FC _@)2:@NHSA(U(+X["V9]GTP$
M\:4<AZ#N,U4;+1#:S;S, /K;7QY7X9.1'5;Z(]C>'E_3W(-*O"UP)KCK$(39
M9/ YDC2)9=4;>1T"0&A%P*,YIPTC8F^$0,\')XR-2*C;-VVUA_LUUOA7'!KB
MBO\8<,2#ZLC_R!;$1V1(;XEDVQ.[R09^4?\],93#5[4Q6QZ4O9:5]-NSO[]?
M<K"_Q"G_V/3!NY33H/_+PW8XPQ!W2U@0V#ZP?Q8XSZ8S.-:_D$^JO/WS9O-U
MWAB4";GB)"[A3,^30G,_B5]%.GQ1;[C,?A)*[9Z>7"TO9Q6.+_0I8" &*\^<
M.TNX=>5=RID,_#4>JS[3\O2LT"8?':'YT[C5<OZ<%#K_41K\T;G2#GD&MO 0
ME!)NK!YZG63QF &>JZD@H,4"U!QZK!MS(O.D?8>^*0_,/<FI/W!<D#O%;&=
M$P-:2:X#4!$(KA@MMXM-.T#VN.O9>'F,\>6;YL >G&(?NO#QY9>"&V<,\$D2
M_9;'W"8B/ <QS8!V>\Q-L]DMSJUP)@260C.P=8%[1"35"F8Y8<I+._6U@S&4
MZ#9]-WMUQ0XMJ;P\@C$Q^<%::P#I7LI-FJ)7H'$Y1N $Q+W-G04HY1Q0_1X6
M" 2^]5#*:+^07M\HE9>NUGL\?;J\^9Z%"DM7%[%DP*@]^49$\W[\9Y@PT(H_
M!+'X@D4:D+P;8ATRY&M_77T/7G[16H#:L+#^]VRPYZL0&\ND;BG9%J_?>PB*
M9YS+Q^_U\[)2>UQ^"IJ9Y!D]56??%.WFDK^;QM)3=NSFHLSLSAK1NA0(@6Z9
M'8*\,I,/0;MQ[6%8DBMTOHR )<8S5]<(I [92810K7L[E,;:S@0'2!I[7=0I
MBHA6#$J6.JWV(X;%RM:=*;99VTL2_^I5*.C@IQQW+QRM,>Q6#EFZWQ%2!SWR
MR-'NCE/ U'/K !N.!QJG)I#_)!+U\@YRP.H_[W,(/,,0TX0+ 6[*?TSC0!EC
MAZ &'Z(Q(7B^DC&$6Z>QR$[/IOYS]Z-5J0M-?*/8J&T;X)MN\ ]//>22NES^
M8'OPH5_IZVOEKU/&4!,- 4-GD ^J?^4M+QSS$^16C&T).ND9^B1M=I<+?[03
M,=#)C[$U)VLFHG$ED/K[F>10 O\SG?D&*YH.QKT_5VF7*<$W>5]."GU]8<GV
M\%JVD8_N 9AIZU?T/(1W>BCC.)YZ#9UJJK5>"%M6G6PS6E;)BU->M2 ]?3$<
MI6#UL/G5< ZCPF!AV- AO>9Y9>,60N;L^PP._M4S"R\"6H B/).%&A/,V_%0
MMLU'0/Z5R>!M]0?AON]\O3I0*9=K1VJ;EA-NLW2C% S^MV'.]&^-?TC, MXB
M%>(/36483G0(,[G*M<J RJ@R9\>75M'*2XV4,8N_PZ<6#3Q^LN0X*N<A[QJZ
M1D NF$K2P,![\CO"WG^ !9[)I@66UR-"_1V_>7)?&YM?2)^XBK]T-LGPO@F+
MAZ_IHSPDT97!!::RT;@ NRJ:#_T=PCLSO<6BGY_+%:9%ULO]-"!;WN)15>&V
MZ-SZW[WZ5]GCEB+/LB1J+G$6TD#T9PA<P0RX'MLU*LR8AH#ABG[0XW"A*',*
MK\8.= J?O>U:1(U_B6IH3%W+)7_[><=[EU.2ZK2T[Q3R8>LS_'9_M;RD0E>?
M+Z^FG35+59'?E:KFM&LW]N\E*IEY25*&X6.,":8ZA#PUE:%GZI8N1%*4@$E/
M,J*K1'2*N(L6Z*(7Z^5^]/NSY/4]XKEYW'BCN?3#P1'M^GBJ[,HA:*Z'P@\F
M749S1>DPQEVTHN"3 P=Y;P,)R"WK850DT5>[(HD2_6GH<23JVS#$/[?=BF*S
MR#A/LKWZGX:!B2,1NE7 -'\+B;_7=MYEDC)-_]*AYH<XQI#9E$K#7$_6[2MO
MR2C[M.3J,_Q'_=W)K<N?N;59LGY?,LDG#C/;]9-\MJA48\"',D(O@)]V@KD"
MS@2;ZX$"&WJ4$+\]!Y<TU?:W3:@7M?;_AZ[OBFKB^\*-@B*]]Q(Z(DU >HF(
M-%$0D"Y$1:0)$1!!"(F ]!*!'R!%(M*DAH[4T!&1(B!56@"5)@EJ&$CAQO]]
MN2_W81ZR5F;F['W.V=_WK=EG;S.I[]LQDS$N$>8K0XAQA[;C"[M-&SIE=L6F
MZ0,^OU6UZ=IDL1'^V+644Q CXAQ<#8].P:X5(\6:D-$GIZ"TQ]QWIO2O7#G^
MZW]+L10G_RN#J_N:*GUP9I;XP^@S\A=_71SL0O5Z2ZJ-UV]>#-B<Z;C!KE*#
MR*(N8?$W,0G8^M T,BL/57**[+^FDI@H.AP+=ROFEHDEL^R@7CQWEE+6&K(R
MB3PB8*D78O J1"V@1BL*&\"^J'4=SUOZY]F<T(7D6VB;&0UFYW<.?N7-L=@O
M^[,/\%7FQ\'"6;;G-!SXOB'&W5 _PCL@\5 V<@@A>.@9F,U08%O+Y2!!PUD_
MW\#PD[K&P"\C/1M^F;0S:XZ+$+P-&I [!24CUPI/0?Q/470[[N)U!%0<V;G$
M-2RF'R$QK4YTL[S5(5R<933"0,^E9GI!_)7?"G8MIM4&!2C(]8Q*<?VB$>MT
MX<]4E;^V@7\J@X]TON3%?+?QVASO>.=GR#.G E?'Z3DK-K/J/E<*J"FSS3"^
MHFCSY;]#02<.HY\F3U<8@< -=**AQG2W,,!@T?Z5;%3U.9OH$EEM:IF<^)!4
M(<22[3'/1$W"^AP ,F9[1:7467<=_-R^-<D:@*W/#4!XPG)L9R0FSZ6<I#@P
MOE\>46I871ZX?EMOZ.=>Y_'][L=L?AL'=,A>0X@?9"&8RK2%/R*:P+B'U\$B
M*[LNS_$T3-N[VM%R6!OD?U!SJ"K)^9&AZ*/!Q53OYF+Y+QGAZ'1W"?QXQ]HR
M@M0GIM"88SWS9V2SN:/ES0U+%GR]HYE=]/\,\9.@B<V3?GP_E1%+NDY=/ 6U
M3@Q"HC<&6F[)Q6CX/S@:<K\R*^ R[[*T\,V\56N._DG1O/K^!E:<#FH-(*D7
MOI @B$EB^US,*>@>9M'L*E!,8#=NS/L#//(WW+B18V-Y/]?D92978]9M5P$&
M.FVZO'('A6<JGG+U *]GF:]+^BN?V<-O K='Y+)CB>_^>KQXPA 4AK$"D'A7
MW/"@/WC 4)SFK%%*T'#?,Y6*7?6%J],RJ07WLO,>%#,*,%EX]/1BMLNIK%1*
M/L2KR[(7*MI\D CFW'N*Y/U&TUI6J55ASPYN%3K_\>--]MA1$;=-D=I\/7E<
M<,_1D[;[?"AY<-;W%B1?ZABXT2NMNA/I4PN7S[PQK7]-(M.Z*<]OWNMFPSB=
M:874>F[<9<9M"QS7]X;%0=-D>+?7H4KZ1#/4&'8*4N)!#V$1G?]0()"2UVVP
M+28!!),DJ5.Z_ .0I$*Q:>40'7T]L=Q /QA<<:9SQ#-4ZL$#D+8>R,!,4.-W
MSIXH[<8DH)Z$@-,30H=@<>%_TW*U7FJ01&6)J[?%[)OX<C@[6_FGO_$Q\VA^
MD=+;#$YA,Z^);%)<>J16JCE5?\SKBY.?=>;0-EN.F4090^VHGR$MZ'UUDF#8
M]P,<P]X8K@K#Y X=DNA(6V6'!7-0&=\]L1DN,S7SI3!.8]?2N[F!7)+)SBF(
M!>(%3LEC3^X& PI7D]T(.0,,<99N_*8LOU!\&Q\^K2I[,'XNV/B5-TU D;F@
M:Q,#D&B$(E!!.D,.FNY6\^T&U6?>(3#$#^5KYKR718-D7?/OY*(6I5+.F@L\
M?C8"*G?(_W(*<B\NM_(].#D&7_P7L^VME\J)C0#"D!L.)335K%M?OB6;6M;+
MA_94?!'-DN[ZCO&RZ9,%X;:A0"C:XRWF*VI^FLJ8^0[^E(+6@"ZQ$W. _%*R
M.&!7[IM<U%L%=1V-"'[OJY@JE^[GSR>X8&^A(_5B^%V& 3LQC48<7. R>*V]
M]7+$O[K;#$,1[(E8END!/JK(G JRL6SZX$IR?@K'U))JT$A]C*=K >':&^UN
M>XJZ%E/&T=8Q&F5F\=5_3^*KLE)IVF+0]: &#E1K[:P4@RC!.M$^SN]DA]*)
M?+@ZWSU,O7"$%[:J WZ74#+[S08==<^_SS.8HG%SRR=CW!KMK!WKJG5WEE5&
M?S]\PHKP!L!41B.\V?I!#_M9>!"ELUO'B2R'3&R1L\/_0M'(9DV$3((XXP_.
M!L4;H?(BF1,W8QS->)DU24N88[8R,8L%1#Q.\:7:OKL"K'>%E0 = /,YA?'W
MG,!/6C"5-UN(V=D?'^;Y0&.OVV18[)V+_$IC;&<H+_Y.S,,&#'EGKASP;*_H
MX\U0?^JK :^!<"?/:.)D@>C'4]"5(/FA+0-V4:,R9._%%Z>@^'0X+^2OQCSR
M9TC3SF!_H6Q@V4S;0[@6CH8V86@:<TK64#D#+/9%JCA_J?5LZ&YL,Q:9/>)0
MM9!*M[[TL>=?UPM0!69'G4BA380?=;0%VHH:C PEME&*FU3BW.4(K2D:;[QN
M36;W1=I:^HE>.[3PE^G.YN):'4_,OEJNR!DEQ: !_":Y('MU$0;43Y"F[^DD
MM9U 5R#[%#3HYQ>XGD^1Z=QU>S1UW+(T%K#\=8)ADA3L/(UAK/E496H#@9QU
MB$M^YR<F/:O4:;!.<H9A#CR=E/;7C*4;/OY@JJS*L- '*1R]I=$I<8@GZFS8
M"GAAE1A-J=!775=)SCA^]OMGLH?!+/H^4F6YN6.&I]JF/8,7?\'X56#2T0$@
M-;''4$P&T0SK\OF7[.,'YET(<\6Q]X\]9\M9;_/W;!?:]GO^QK/US9E47I"S
M/5KP),FP^9R@Q5/''<[^D1&Y.:OX-? P="&"F$QY7=M4!5[D[W7!QCR:$_=[
M8Z#AY]7BEW#[Q7A4ST?Z%Y'J[@+2:TCT-K0+VCRQ]X:@1Z3MW.C,?I(!8AS+
MC]Y --8N^VJ%\COZ!</\UP^5P1.QU$EM\W2>[!1__3-C/MX0O!ER 8*+3RNC
M%"+.4K\B^ B007NUI<5M)0^#EC?(YP*0G\36O9M!>IS-ER\/__I>J_W^8FTH
MIIB[2'95>54*S_V9A-V/F/8PID4]>YKF5:&!VS!Z<77#<5!EH8&;$K.!BFTW
M&/O3?K<N5VSGU\J. K3Q[ 7&[/\T?[_B\2H-'Z9A-LJO"NZ/=]RK(:F1'?^E
M2H$33K"+2P/$=JOU,N"9G@SKE<R5S>)W0=5WV%_["THS8:NGNVIO%&EB/ @^
MC*OI#OH+[.($:*>[&,UX(\081!"F 7Z);$#M*[T-(^$&7ZI;,,2;H@VR:DME
M/LC@&KJR6FZ013M!RV8B<^ONC<6^A:)??W5":J\26UO4#;H&U%CT@P9N--3M
M&=$+M8=XZ!WF?BV_N+C9DH>H>M^K,?BFL[&T_2"K^%HO_]<$$?9@M]58! ?9
MFH")T3@%)71S3L)"E)C[1ECRNBB=BGAGZ?T&=?4T#KTG;3M^)\&T$<I0)R"-
M*@FGH/O6BY;N-'\;Z$[;$.2B"N?<F_-O%3KBOS9T]@8L]Z5?O#\^W]#/&_^/
M&5)R_X 3(0VP_3:2!IR?4)M;X_W;-0PA#.5U/U\WO?AI<;\\[]#H(BN/S4#:
M?D>!TGU%V[N?EC2 ^5EMAQFW(VM\&[E9CB[$7.<[]NG>*6@M'0FB7B&K$&I;
M29R(25W'07:!,#KSG+M?]2&4G,!R?:(#P#7B(UUR7&0!XJH: 6T\P:"0#U8!
MN14,R08 TQ2C*%42:+4"_/"-O4$F_E5AQ0YF&2K-G]6R9PFF6M8Z]%S)1\;R
M!B8PH3][R\2_:D_EGM:T'?\0-(@S0_IV@5TH/I2W_ZO:S?9'9:'5@5*-]8 E
M92,%.H77*]9:">"%O<WI9E'PA*?Y5MZLZ2-OY]>L.U;JF3W28>7[]21&7VP#
M>QR"CVPZ#3?B3^I4($#[$VM]P@LX7M^^D7)NL/&LJPH;,,KQ)#1I]DV8UL,C
M1IL\E^*UC]@:;[-H$*:%*DD=:$?UH>==>Z M7LG-\VOY..6*2+^2GP@+;HVL
M9(&5[8)"WA+;2LW#R\$Q4+;43W[AP2D8#Z$ZWY&<5_N/[U22,^TYAWS[_DS4
M^#SZFI[Q9<<3:)<(7(^8#T1_JR/O_N;;>G:W(5R(8MV=ZC5=*W'_Z!ULQG%K
MJ$(PWC9;BJQLM@LU*"R?X(O0,3[R%"LVY@"5EL4N)\%C1K7UYUY$2#G^\IJ*
M[A&QN[/Y/'(G,KW,^-#/>X3Y_N09<3WK&RD%RM.+Q0XZ??A+#M<0+T/*GWP
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M9<O*O_F%#_Z98)=AQ?KH<"+=\6O42V6=TOMY=0)]]](N%476VK#S.KOEI,T
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M&2'(_BW2M;!0W$H\@80;0OL06,D:]YY:7I][Z[JO>H]35QK:=BGVE8[G<6O
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MR9/O6!ZX/-[O?TD2_G!C?/R^)2&T3W<XKC;@D7.3V\T1KH%,"VJ;,D_)PFK
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MY\C<4.YM>BJU 4V%<$S$(%1]3Y#]%C2X..OC,'VN<?)O@W+MGD2NPZT4TM4
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ME@6'SI\#(>5G''\ZOD"N96+QMM9)$$;'C?(7ABQAQ7;XZI;5QW$G"I+TQ,T
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M81\A[S+KVMJQ>\Q5.734L:"RV_:7G<SK032DY%%%$&/H\Y#'JPNZUAS>[ES
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MH*O!W*$UC=Z,HT4#\^L>AH2_@T\.(V&@/P><X32RBD/MF*75,Y_)WE&%G1,
M)IFD0WN#]M@7YF6#ADY=FN7:?&TV0/M>@N'%)7G^9>!WGF!,EQO2GO=%94JU
MZ-RE2M;&^SO4B=BR5 4WCLMEL?_O)9Y);,U5L_UO\UP/B_TOE6[0LB9V$5]#
MH-RG98.P%2@O;:6+%,W$+JFKO#&5)D;G=5%Z8T'WU1R(*R> LU2MLLXODU?*
M,^*M@ZYEUA?-6,;,4F>G:T5]?+\>#Y&Z:1E=*K"!$P##Q4\ _3_.1YM57MMQ
M^HR<]*QQ0G1</Q_")BWR\+MI#_*_4I%RP]P[GO;?35G.,$\=(;^"OJZ1".08
MG$6R&>4L?<VN%J>2B%J[E/_!XVGE>D?!NB<J>_,E' V<%?>\7X@/)D0/@AJS
MTO0%J!JTZMH-(KP[@W_L4@*.E]- H+.]Y7487GXU-)ZK3U)-E16 W=ZJ$T=?
MK^488WJY9$=1<S(J<_' F.$-PMO;Q5PLR?B*6]4K/Q=:,$U;F!E32Z^7\J'B
MGDE;&&TM$2T)_UUS:Q)X5E\:^H!8E4"1WC7; '.2#<P"/9O-5ML?YB[UIWA>
M5,@3$S1V?WMSI?LQQ]-"RG4G:E@]<8B!'V>P$KK&\Q<3C GC*Z7P%!6ENLIE
M8#[77>BL:+:G0F^LQ:TB"G#=FWK.G]0^=QU.OM>E_LT7S=XD(A7EU;;X"]J1
M< KPL+8INA+*<W=C-_4P>*F%E]7SQ?NR;Z/':)-:\(CJ950]^3O8A,R',\;+
M;J"36T"-H'AG*R)OTJ.Y19NTFRV)U1EU[=[G:J!7)\>*'^>E_P97/7O$B)HJ
ML.$#&4P*$8@_AW.V8XD5,I[F1%*THSAH]UX="BPO,_A,,T/GD;Q#:X2W*M=Y
MES"3)JA4"]X?16?2"X7:&TT<7>55)D0U;C(IGF7NB+UJ'I6F->A^O7M=%K+U
MCE8,LVQ$K)W^J6^#\GY#U?]7;"0214HA5[^C^M$:81*^)X!35%;]YX&UTJFD
M-:-477(Y)_^!@6[3:].1//92A/RVGE$<11+>H\1P-P2O8^0DSG[(C$&<72^V
MSO%9)-PD\ P_CBH6]ZQ\TJL7V^6O5B/C=F&M<*T)]1SN_Z$#S$J]0RM35S(&
M0X!+&1:&N5N':V9ZRC=9)+VN##WY&UP:O- 51AAZ$8;FQKCN/%MXP;U7:,&L
M-*N7_<TI2JGU+]='2[.$)#5C.8 ;LS')RR/E!! ]J(7\7BD I!8]G/E;]Z#=
M6?I(<T,%_X* )-TC(V,(Y>M9>]5O=O0O$K"99B-0NY&ZM2O#:3K#]/N!@YOA
M =])V_OV7Q!\<.PG=$O6H)A4&;RW;XXJY&XS)%&5+/YT(:<.9FL-R+0Q%)?H
MF*QZ9C\,Y 7Y\*9TL<Q3C7&\R5W*N<N6Q*!"_:R:$G>!UJB +9=:8#'. BO,
M<^KJ$,!V%=P/XE*!G24KK&=V8&VFE</&'3<7H!Z/M-N*CF>V60R_QWW_8/3*
M4^P@>"K4V6J]N$7-ND1 6[DQ"++_.@^LP'I-4Y\+:DU.**.Z35.CB-Q5Y,;U
MY1A3=1=GHR*ZZ<9<XGOJN-XUX+7+PNO?4Y 2B^HD^P%0)IIP%X0!#6FV[V=T
MB3)"]>GOU(Z%W;Z091>,Y""3O[$#B]\S5'Y':3S: ([]#\@!?[S&YD(-("\2
M_ =AXHM-P[A UCZ,7!:73LP\IM/R[J4">[>+1CE%XA_E(EWOVK^DS\ ;07O[
M55_'/T!]R-8;X+BL*_+F'H8^U$?KMQ-;GP[S\&]S-F\P2Z8?ZF^ZE^6F-LB0
MU8Y(\H3J?FX-=OAC9):K(/&GKIKS#R=JQMN?T5D$8\&R,D&(G:,-W_ X=)X(
MQ [A;Q%<9YQ!J?JGY@Z7M5]S7C>9=2C(8DK5$:G=Q'H\\4C?%#W"6Y!.?R(2
M<BFD<*)]$DPJ2>%TD].%LNNK=T9ZQKZ"S\[HJM@F]B9,$5,)SI\-2!]H^7^2
M"9OZ,D36>,^;=[_^3+N1=*C'5W]T&XOXU<B\>X^7R25T?:LV!-ZD5+":(G5G
MFO_>@6F4I#;K#8V^S"$)/]*K]0_ )@R"8W4U+:%MP5S?IC5B:?61$M=T7#IU
MMQC:EWKT&4+*)<(:?171%V 7(B,&-2BYFG/<;QM:T[/O"^[?C[2/!IC\OE.B
MXW&Q$^F40'(B>O:MDG4"HWO4\L4"P_D$D4%B;91[[(&7A7^@O3U*:V^*XP_U
MY67WE2%-XY&GN!!^%VPJ<F]N?7^4>SLT[WNC!SD%5[*><:U?T/7J[*,9J/RS
M\->Z[X+*G 6>_O=?7]7<E=VY(%868*6!7%*GI5LZG9_(78""0$2RV:HYQ@2#
MZ>]CGHN? -A8*/:[%M2SJ,%OEPF+5'Z#.X2)FO*=J99*S[!"E>C7INYI8XJB
M J/ENM!6,4X!2@4'@**V1N?T60-V6E=0M6EONP0EK!T(7XOV[\PL8(P=U3=1
MN<(5[5E'Z<,UBM7N?7UG5P*%#]#D*Q:I7?I?Z>/ 4U2A#0GE/Q! 9]'VW;GK
M*7M*G7^^<EV5&-%]G]1M_OYNMGGT ]H[J"Q.)17!!\*^U4'V.(87$@K3]CY>
MMSCK&Z$0*%'3&,S)+F*@M_7]OO#?.P)P%86C#X?;."&J )#.GD^QH4_H2\W0
M-5]>G O<4QXE0YR;F2T=%]18\SH#>(M/Z\9-NKY\P[NIVP,&0J-P%H([L+-$
MU[1*9)(>J.;A[E.ZR+SRXZ8IP<<OBDSNA'0-1+7@'SAX#DOLYA/Z$8 3P/I9
M(GXM4T^HQK0F\KDA,&G_XQ:W1\7#%R+?>;_S;;TU>O">R9-S:CO!@("*KR+<
M1^)6HUU0TXA[JC'))BJA'A'O7Y043F24ZJ9!5HJOG<9\%/(["'4Q1^UM$_W
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M_C*JURY[E7J;;*OR K0NDC]E0CK_4PB5IC1:PW*J3/UOLBXSTDB;[@!W1V/
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MRP)([T4+H[$H4*/F(/"KO^GKWI8NR;:6U_UTL:MZ=D5>+?5C6VE&0:+L3"R
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M(-<+C@.=OY[Q+,8=G'Z!.V% \^SX^<$6JWO2^E8"VIYBQZ61R+;.BTL,W!(
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MR2\U[:@$3I$B !UH*XO5[OMTWPF()"H-85$!LW.''-P-ZR>C4M;](PO/]G7
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M_/H!CE+DZXFV[[!8<EJZVOS,%N9HU"Q:UOJ(Y;'=> "[A]X\_B88IL+(>&-
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MP/+F"<E78"E-ASU2B;6M)A?B^?]#T>?P.(74P,BO2"94VFBYJ9!919E!",_
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MN-W'\N6[O^?Q@E51 M])Z;OI&Z=)D(T"9#V*Q'U"\,,U'[16>C>M<0.A<NS
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M4'8&"M2 _- =#WQ!#"34X<-3NU0A+[KD@'9,[M  &S?LXZAOJD5_Y: Y_[O
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M4N[&\M$,\*HA'9E2.F3)KMQ/.#N[?H.R7&^DXGN)\CFE=S5G'T@FLDCQ;O[
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M%@A-MPXX\S.OZ.8H5,99^+=+RYVVHI8[+2#;5;X8++[Z$$2RX6.!:T!?.(L
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MD8>R"&8DT99"N$#).]1%ID'\S6TZ'K?/^#\K2BU*P%;*_LJ4558N[O'=1L4
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M.L-V"=*(?"C--#)[XC4N*,SGR.;=G>K!PSL\QS0_"V Y56/'M>^ 0K"KYTB
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M&C.T"&-%%K^0'6)>3=ZU"/$S(L[Z,##MN57GH\H&EIH8,B*:PG2?R Z;+P#
M12B#2*&$5KQ/U6,<'1/;+U7.-J>L][=YS5\TJ#_BZTNMNPC3AE$UOZ%L!+ZH
M.U2-!B\%#C0L=5["^SDNLS84ZEVZ^D_"YA-:8WX2]\2T NJ  <<C&T<&,>O
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M9%]CP8GC:N6[YM9P?4^3WXPU\;=P=HEK3'YZH"_.$I%5:?*^Y$_50>[T))F
M!^JX<I":P,!'5K\;<O=-<3UYF&0N$_K$\L\OM^U[GK')^X66=@[>-+OD9I1[
M_?6] &X8(]J5AV9R!\E\/*%D'R:PC-I^\UEC]Q7>,;$J:X&)FZW_KA\QTE1V
M!)#TQ@Y6_ 4R<W,9&%=M0YG[W$^NOHW[>H\TEBXSV2BPP7#EU/YO-!%T?@P
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M+._0M<MIXW?:IBG<!-DQX$4J#7-N7()X/TV[L/P@':EFIO@K_;M:;^VF1AR
MTMN,6G3"?\:9#(4B8\ <2'_4>2GRU/8NS:G=5A<-KR!=/PV[([H [\V;FDMI
M8JWC2YI:O;W7C^SW3(@/*6,%S&> B(A7_@FO$9S7\PZB^ )\'"62X[K\X/B\
M"M<\R]QIF;+\M!OUZC4:?VR9WWL@<V2E:4_#R/$D.':9P@2DJKX43NJMOC;4
M\D=S\@62![:EH@0,:>QU_.(36SQ4::9Z4SL+]7H4[;9J+Y2BVB/WF^.\M$!3
M[3N*J F.'Y])[F[R($B56N'CN^T-<*-M<\="TJ.2<N;70R2<L@5H'(2>:%]]
M!_[*RT-#!E&^@IM&]MJ)CE N<BD(_1'(JW_5 DWU7B*2R4.KM#C[1"6]'PMX
M2*+H[)^X<C9Y%:,<4^N4L'='!]%4LT#\7,"S$^#K!TE(K,WD%8C8FFYI1* O
MNI8><FO0#QY<[LN=2;PQV^ ]8SQU4X N98\W@BNPB9:$GC( 3B^0N$6 [\\
M364D+MIUU!Y;*$ZL'\%!"JR%#!CAV/.I[O]U"5^F=Z#O\_IH)O5!&7?E%.,
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M=7_-P?3ZJB2)Z3/ 4RN"=%FT$M3^L],.U=ZJ@;>:0W_;A%G0MVZJ-!EBRBZ
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M<E^NYCPM99<,[HX_ZTZ'5#3I(G[T.&]WU\'OB0G$A;=%0;3&/=C_V'6S/\V
M]OH^JDXJJOD@#DD'0I>"+O:(+)E50LKN-^4>CM]M%?KSO+AY]OFJE:1*5FH&
M1\>GM#M)G^WB+!4J\:3!HES+E<DA*J-![JEAP,M$?,1<#QMDP+D32Z[)QR2Z
MNCCE:4T[7+;0H%4=OH5K_MIWPV";ZO?VJ$Z:;A_+,8QZORI/KD'Z*HEH#@##
M5YF[+52W;*-^H'QT"DJD%:[D)PC>.TS1U.4R5-*UTB(KGP$BGL'=DY->4GX
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M4AH[;0[)<P)PY5A:PY9VAV#><@\A67%[DK,*G%+A=1MY73$V]\[6D:R_ZA+
M4VQK7Q:&XZGM]'CK&N4G73#4TB.KQ^__^?9?N _?[O4I2J/KW9<=3[6WP2U(
MO#7\PHZ>!/Y@[T[5KXXI(B\M&_^QGS:_=TE,&]VNF%9(N^)Z'C$_E2PF3(K
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M8'.NE%U;</9)AD[)@Y$ [XX+'^YFC8B'J->H,\A?U8;N*]MU'0N42ZHY,\4
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M#2OPV"$P 'IMV9X49Q9<-!:NB B6^\L_VAGS-&NX44;Y:T9:VZ0(TZ_GN<3
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MU)J..U#S:XP6",4WS=OL:_^Y>TOP7B*;YI_ME&XR]PE@]!J]/S4G@,6KY!.
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M*689/UE^B180QG2.[9*A\E!$7Y8U0^FA5/Y7AR.0U9$%2?Z PLL\= +@<,0
M4WLT21_ '.:<L>YF;QN[[KH]+KP]F@9K+B(!,19#!RFP,WJ7ER /2=+KPB<
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M80?3%-!'%&R8;U*/08<Q;[?^5F,@[J7 %60?<K&:=(-8L*M)-H4+-0(#!/)
MX8:^I)GOO/=4L(+Z&4^3!%;/EK;5U@P3UP_75T98&(GM]'@33,U 8"NOL>R2
M"07]QZ!Z))Z%T-Z'V^P)X0WP=8">6\68>H:70T/?QLC-9AJE-(-J=3OU57O&
M'X'Q]"5B=@(@462EP&-073*%=Q,[WM(#800F8OP[K:,TJF0:/@;*^2VO)9DE
M9RHI\@?? OUH#P9]@J30 ]!.P1 ]O"(HBBD(;T?$&A-MG+[@7M-_QC7!2R51
M) PI@F".INE9[W90,CH0B):'#\(2]E=/F@&Q=%6<B#8$6NC?TL>@I^XD).#D
M!N[Z2L<:M*5%$KC9>:GG)Q6U:SRQ3 I:UGUVT"&2I()@_/6:\Q>"QNI(%""A
M 7\R!\5Z08T^W,EWZ!BTN+INW]),#'E2JSB*6=H6<U*S;R;VUG^_GG?EW!AO
M631,M]QXEV77EWSW5PD']0DB /*LY#2U%$^/9D](4,ZF#(WO&!<7MVU]<:),
M#:/3XG\+!5<_3S/+\TF%K<%[3;76@55J"3H N:1#LB#"2W2I1;J!U8"<[4O=
MJO+I6C<&W=B'MQ[OYJE.+-BYD% &U/>(D,EE"*FON6D&[8],$<:D[=XO'@GQ
MC@Y+TRH^]&I)E[JRNJ9J +Y#1W@$&WHAY5/ZI$2"FHWP0R<[(0:A"6(R7:YW
M$>S; I;N8=Z5;Y\*V-D_RVGDL'%/SN_I")+*W<(TAE#XC;&10[M#.,YO?VFL
M?PD6&"PZ4=>/A,>E[60XF0?:SY4UA4E9J>WSN=E<P?*41=^/9+R(YKOTFO/K
MY'(4B>Z<2<. -\%R;9)RL920B>@M(>3 G/'@8+(O*7/1R1+BF\V9O2#FMJ47
M];"Z1)F*1J:>G!Q>PDY78Z12(NT+7!(WML_'R45%1Y62^N4V8G.'131\]7U+
M%FF_4!./Z#B4#4)PY%Q,)F41P$\;T<!E]"Z><Y!3$%"U3+M=1_1YA6-MU"$O
M.]]C4L9<N7[U!1*7&Z4MZRY5".R3>D]:X.%!U I]?1@C[N_CB&7+I$>:O8+W
MF@C@Y$8[W^8IB9;(+*Y=AGQ[+ZCZ:&7HZZ"SRM""$ZYX1QPG(&^_RTSL&(00
MIL!-B%W$>P"%VWE:2+:;@=_4?_D^H.6#=EO;I_/3C[\8^#+0 Z5<(05!;8+<
MYTQ%M-CCN6MH4QB!FYW"^34_#-E?Y;S WZ]1R#)F[KQB>E$K^T9Z<4E%+O3R
ME $SWYW_YP=\/$_C>29AL-)1G%Z2]Y U3Y;'1>E%6=V^E?*PX!US6='"_;9!
MBU'-X*W<; SRUB/X]\S9QU)/&0GLSJU768T7N_>4;8,_7_WJ9']=1"PIZ\!"
M5'3.^(:7XG1G(>(%>O,8-&<R<6; >*;PK?'1A^\>)<OQ$N2'534\W[Z@@X9O
M'[3DIF8,2LFH9N>F_[-BN,EWEZX(^FK:Q(U#&J"/(1ZH]&,0P4YI::&7 )"-
M >]HW[7]<S"WK24='>H#@@0FLB4_55E-Z\Y"..]7^QT(A2N7=E:(K$7[AB'<
MV3\#T\'9?T:?ANL1:U^&5*X EBX$UVI_]#6GT9PEU_^$<KP"'SZTU[HW,J*-
M&@T!I#6']A=G<)A=56(9C?4RV0)HGUQ;0?<'DB&\,.O^I=S=F9JF:F7!JRO#
ML%1M)JZUB=.:IXSY_RG0P<U]:C+$9Q^00>$/UDJ1B&9[/"MA!I]MB A:&].C
MX^F6NI?!"N_  1VM''7.AAO[-@>" E%6VA]E2;5!8OD0.;3G)#]M$,-^PK:#
MQ'#3=&&G=G!_^SLNW-V#)'>S:=@+//)>V2W(C3Y8/6*4=A=S&Y!ESY_4DCS<
M'L(:9R*"+4]:-%G6D<LB)"O"9H]9:3*-OZB_A(,HDU*F\52WP*Y49UEPS <V
MJLC&%59B*F6??M*)K'^9HD+'W\BE9>SF[E^B<1_D+/T&$$*PIEI=95RLS[\+
M6BZ_TAX(F]P_9#GRC+IS=51C]];'+DVE#EH?Y!Q%C]#1"VF4_0Q9*B)])"2G
MZRM17(#(#WY.>HTELJZ&Q@W#\N8357+45S+1H%/2'FN,J@R#SIZI5]$^X.7]
M/GV!8U!"M&X8D0?ZQ.W4[%L"- T.61N)Z"BZ7#AIGWTO"=*R6OE"H$,J6/&]
M?11AX8<LA1>#V]^M(^Q@$6G=DC!G['.H"-JO)J8_O=TR:3^BJ.@8Q/FK7;(R
M1,U88/1W8_E_9W<-;"U)#7^4=IG?4,2 ([JBXH$?)^=#SM'D *7/;KI%0X7!
M+1ZT2W-O9CXJ!=U_(M<HP).%S,EH\=?&_A%?F"ZMRUA!9J*Q&5EQHXA/B$',
M&8H$L/(6-F-=.B0@\&]6F'^PHX)5VD%LE3K:F+]JG_M7!-PAC@47_C']AXSA
M@P1/+E8[ LMTD7Y$7_P;LAEMXI_2YY 4&C-1/R^HW.RM_Y"QJ[/9K+0)>*)A
M@D_.-.]!F31L'SH<:H@L1-?+09(1; NT,V2R<=R0$P8OMP9^!A9$1;*+#!2F
M?=_9D2E1^#-2]GQY$>JBOSR2'M;\GT[!%R^#!W.4D*.$K_//27ZC'QXYT"II
MD#ZR*J*'(^X47!+P]"?D]H'YN[4HAH0Y5%JGV4=8[R+J8^.P4KRRD]-23G7>
M459'Y"5GH7LLF7$+I<P0;_1R-8W5A>Z)MI#%F<_-X+,4;RR8]_H:4@P68X2A
MYCXH<&?2?#C5)B.SHN8(;3?4DGHN]!>QY-E7RH3&MF.8:-SP(,"=:-FKSPC,
M8)%L3C## 7TA8DG5^:R6)WWZKBO%!^Y>]F-M5J96@&ZM94;<W#&(YX0&7':(
MPN-!IK&&$-*&_D$&E)ZA>77O!.&@P@$E(JW.79+F+?6_OVC4N93;^;-=/_\P
MAV7"0H79ISWJ<@T9[('HL8F3H0T@"&8H8;@T-![#H O&02\ 8VL_4SX&J,!2
M9_#7O(M9QO^#W9_]H#?P)>URH:/J[[>@:]E'8_2$_XR><#@'T W&_SOPAP&X
MC(W561O?' R2LT>Z?FT,M;8PHPK[E?F_-GR5)EZ@\^@<1X44?1P++]P1L"4B
M23F :@U<DJB?BRO2T\3N)S4NM_U)^Q;RMJ4S"0>,,&6PM9I:7<O/>.9]3N7T
MS7 ,P0J:"CT'=Z6;2A(UC28&L^PO=*M" =ZZ4"JJW,GMIOK/4E):FET:_FK9
M2XF#4W66RD98#M74,+L?'J76!W(D?L)@PGK(LB_V;X*NJ^_Y-^\#:)J$PSS\
MQYWVR_@]):RI9.0OVZ]YDJWJ5$G:"K2I8M>6S(#HN=WI2+Y"8:,64CAQ8,[E
MP'D"+'6SWZXF4G?\49W:)X>,'@6)IZ+R,5;-!(<<=H06])-/UQO FH0#U'%(
MOM7KY?Z%(9F=.I%145$7^YBX#!&,(_(YVF>?I;*I*C,82&7)X<& W$(_(AG#
MC<#6(_CT+U+T%R*H47TMJW*-)1C;F5K/]OI\Z=3O J8XGXSG7-?O]9\3KI(;
M_3*A.'546@TEW(4B(74A%!X(";L \04OAI"B"%&I043_FD#[$M6GAYH3-3RN
M"GDYYUE#0LXI/A95W9</?ZRZC> ZZ7Q;9*2CEC#+SYP@&&^/G=TQB+U;[I>=
MOFP'H7-GT_&F]&'&<J.[B.38BK"66WQ#^CF&(T:Z"EDH9D ($4$[F[<><@$N
M2SQ=A,O@V+E%^!.Z?<W\NWUSCNXUVX\/KHRS75,VOON1X<B!*YK_7QW9+FX%
MT8#JA0#R0[LI9 L'6(49D3.1(D*W^,7 EG:][TY/'/:38@*S)>)+>9P_+J^J
M'J1["E7^>&BW.EA@'[6T>3"TCF("C,9H9VT_PK7K9];2KB?C7 <+\R4,G@8)
MV/@E7G]TG_7W^C2ZAHXCK=>4^BSCT83($ZI *,L?,TL.6+@9(>2?3*FG8.HJ
M&&(XXY/KD7EZZT+QOWP9M!HEC&Y:LP +'=8N;V^21H \LA%%/7>-7DJD.P\\
M;-@JQ'?]K(OA6T $G-_R%%*1VW,7:7"W\JH31*'U16FSZ 9U-.6"'M%W?1;-
M15$.P>H9]X;U^.)8U6-LIW\6D-G,T\;,&I2R)J2,D7X/HJJ5K&YJ=]3H(++>
M?IPCE_#3A=^FUL'UUE" - KO^GZ,4-W3G@*XKBFH_,0YXKU]B8*M.<"S0Q4I
ML0#CAC.\/HQB34=XL@H Q>[C9>FC#ZEMQR!_##>,[<9TT[@V!5+I9_7-.2_Y
M/W(L.>5B_:IC&3)D)*,?SX^B7ZQ-+.T)"B2%4VL@7N 4,5W",:AO)1SW-S%B
M1^$4N;\EI6)KVM+GKYN'7O_3.Y;[7Q];F$RH)MRFYJ/TA6@3$((%<AE-ND],
M1NHJQ^!8G?O:XW))%^Q6'0[+Z] (#7.M_=/;5]'ZOQ) %;*IU4YW#Z%O!-HS
MR)#9?PT.1)9=)3(7HD<,X8-<*G,#E-:.06"**_')3OY#20<CVJ17TJ^CA8*Z
M09OOG;<D4YE\SNH.>K[JL,SW+R.=' [5$]>+$.P6_X4X"X<0RM9#/E.O07BE
M)Q-Q@>::3E.+S18YR]YY4LE"WSDXUM(?R&TCP;11!#/BI)]"8F$WC;#>#^6)
M4$H&<]44]$>Y"2-X+>0;:RQX879[BWM%&TE6MY6X'S"Z%U3Q'_@FP>4(EK0S
M0V0V2C!A/[U;%H .843T-?R(@+7EE*Y$I4S5Z;SR\YAP];E^J=>^PV>367X(
M3EA,J<_$T%[/;#>V_(J>Q$.Q5'L<F,(-)0D0.!([4)%H;J"V]WODEY9KCS,0
M=OS_C(G5I"#@A-UMB[B"W.TA@VD#YTL%_R Y%Y=EG^GZX_3.KMOENJ+SU0-S
M [")3Y@\[NH];A&:#*"44<L0?B@&6/@)'.-?!CC["^GQ,8W"B(/P!!0LV39M
MW,4XU&,^?A5YQIV>E:+Q@^W#GFCZPI8OWCB&:$8[:T^T4%KZ2^*AUOX).>7G
MIMC8W#;?*8&#"#3'1ZZ1OZW;M-D^,>4R/8UU=#VMO;-:A':M/09=G2G_%V?\
MTY@B($*Z0$#L3J'@BM2R;FZ8V5T@G*[+M"4PZ=500I-*+Y1S^VM]6L=-SH,S
M"1J>D\$P)@:Z<Q%NH)]".>.T$3W6- &X)C!0Y@1#]OVKF5M:<5@=E'YR+[^^
M/LFZIP\4]Y8.6)B]B)H]79 !MS. )J%ZG?.9OL9VG-"T,45:[.)LI+;2GQ3U
MEV$_R_.EK.R8>NZ2BQ!,PG_V <U;,2?\8-& (>_@[9KH1X:;%?]$5ZHC$1[[
M72_36IJ<(O433E:<68^:@O950O[;_ Q-@-9CXG4M"65][5V#17J#;>=R Y<:
MK]X>4QA:5J5E3G,-2IN,#KZ_SIXZ3*U'>("_R9(<Z.:83X>(G;;A'XS)VG"+
MZ8A]D27GY9O2 _^V"J;4JOT^M(5W6]6E\]@ZYPX&O@-F3O80 W+$%E(J478
M'0]M#.D+DENSJZGY_GU2\YGZBP@J]*9IN:=TUT#ZQWK=3SG#':'22V=VH-Z
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MO>[1\,8F!#W&Q;<9)=JR6T$VIWW!\"3C3RARL=0WNN[>:TIL%#^BZU[+&D+
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M!?LV[QZK!#SS;,7:YH>U%.HP+A8+]&,X^W H%M=OZRI&NOV'W[OSCA;.CH3
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M^%+!0J?T*A=D%?4X3I,"(8Z7MU5N/=I ABDE!Y>:21<).FLH9S'T#,ME&GR
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M"_6[N''1#,J_9F1?I) T6)48D(_RB&?@"KM;1RTP(?VN[]^I@#JO (UY^K;
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M?E((%Y=5#75.\?9EY77*>(BORI/1\S-S,WJI_G4JRK!')2/1$:Z]&*Y 73%
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M0D-':_J(QHQVR9?GZ:>>%.BO,,>O?7(&EX?C.USV^O9="^*H8^7E)1Q^21+
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M2);@E;-C[I:-F>9$IY^0^>$DII<V^L'-M":PP?3B CJSP7R'$8A@=ADPQ=L
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M\&:IZ@REDCX_!:V@1-!$/BGB:[:?EG)IM4K*R4N@:&7R;*.FY8/F+!N/ IH
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M\4P;WZG-=921,7)D/H\BLR:'50^QO]X8%<WN&Y>S>I1KG;0SF1HC)*,A\KX
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MBH OL_!3:Y^!_=1OQ$@!,^O*#O:(A&^"D1[^J5Q$%,'B37XO[8'#U8'+G6\
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M]@C(.0;Z Q2N<STK*OH^RG:TME6@*>.$$HG3](V@ 8J3,0;Q8)B'DR-B*+;
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M*64*<7!I<>P-T%(5\@9P '[H:#H,4%;"+)FBM.KM[/;>>+EV("R5<'*QN??
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M+F4[FFVS!WYU$.I)RX6=Z4 ROUN4CX.]01,%+I^D4D3-I2<\<5Y 3$E>,W=
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M.FVET[TS?G]"QA,OF#WJ^*>4M<W7B;]8/T<BN0-WGYU"REYB1:F\?7&>KOG
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M; ?'\3<_:-77^JE-3D/(H:O%K@WL..W35/2YA#[I]]\P=+UT7@$_1U7IIZP
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M"<JA0[&V*#VX0>U#>GEG_.AD]PIH!:6T7D4!D;F38Z"A>P>6ZP4DB];WVNG
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M",MZ$PVM+' E:G8M]HF3Z$[G^]6G2"\GLWH>KY5M]"]B6'>#U5%T+0S)JN\
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M<2I4?JZ2H0GB@]8^H,7*D,&+@]2]*T\6E"%$JH;M)!0UN-MC?\.H"+.PN@R
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MNMTC1))<N'7D&&+(7+EMTB!A:=M;#(Q%@Y PJ8']L;ZDPO%00K!]9=,82;%
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MT1];<.!DI)L?,+)#S<[7 V42V_FG2@1H8 ?K=@=/Q!97KL8!-A,]S)"Z=3&
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MB;,=B.U?0<7,+U_/CCV/C0-<DIYY YC4;!G(6+ ,453P'V"3?L=?3\?[E":
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M9^3_P=D9:9L %$FG-RH:-W,_5#(G725(EJ12PIPW'$][QZ7[D53/ ]$5RRN
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MMM<3144+#00Y(;U\ E/,%)UN4Q%=;QB5(OZ,9/3"&>T;ENPC 7[MFKC_]5H
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M]NK4=]T1U0@)_.GD/8G(;@[P9=K>,PZ)=9JP9\J]I7Q!9_RG]P'SD"M+!0I
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M#Q'C(4CG$QBF+'%/L.2WYN<YUF>O<G9%;FS?@!RU,%+]:6<K#;_GW\]&C:H
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M)1_U<C%#0U! A%DD5ARCK!*1A'L6^51I'#,9<*]:!ILE(_^?&"3?!A3]8'.
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MO^^IE].$9FH^TR9WN7^W:'STH:V&@27C9V)( V5*27E7XUO@JR<O4HV$I+/
MFGH!<16A*MU^94D*5YG0269072M-B"WL&2M^]OR;N>\"L(9I1\IW&B&ES78C
M4]@2[,9?Y$ZAHE^3 )[O^7?Y\Y<&H'DBOD\9SC]^ Y4LT8TOXR\;-/S(Z IQ
MUY1W>QOS0VDQ]!QR564:05HLBA^ES76PBCZ1KP#T06'Q_8=A2S?W(/;HE13-
M%BYK;=-P RW,:B,3$AJ0D.!UM^"<"?5S<RXLAL5\.(SLPQI1W@/!Z0^G-$%P
M;G[S%4Q3/%KN$#O[0L3\%,[%8H@<&&3% "?"PB-'74:$&FJ'!,IG=0:[8"))
M9-JYYS(JIF K4J966PZA>1KZ:CI2)V5/P^]$,&E%.3&C)O-#8:V*T\@=EMYP
M[0/1FO*PWP&V_IK-;3WU:BF@E9;$S:=S8WK+HQH]>>49":0J?XUKHC!AQ3V4
M9@[8XZV53#NC"A0!YQJ?;4LXM-FJ@O7\V1 L C6Z5(DI;LT/4;LEAC\J:5/^
M$07E369J3B@=?S#O79E6 #1.0@,18%XGSLJP4=H8[ZKZE.R,#V.J%#Q: <=)
M ESXQ!5&!;Y1N>G?5T4XF!2H4 W6@M^T-$/@02O3!S0J",[Q06X+@G>#:'&Q
M5_X[8;M8?D$"52)>#W "'$M/$WX#\=6(6\+?0!D%#F,!6;YS7'R'&=+J/X@L
M! SG8F"@:K@(N\5Z,"25L)-W94Q TB#8 >I2M6"0Z_J7N;GS_'EG\X9<RV!+
M.L71!WP+ 2KW)5"$%<Z7&4*,IH2$Z;VYU<8-&32+A-D"'697K?FL3^)P79E)
M[BSG<*WZY4E!&_8:3*SH-DE*X^(ZTHJO6 H+<TX%J*,7,A@^HMU7B9._.^V<
M&Z?YWYK/<2."6PBWAMQ$3CBI&'*;P[^P,=5HET[7:0N6%5R7-EY=ZLWJ-L5_
M5'M1'%NB9KNH7CY*.%[M>6$CD:R9] T=J;5_[NN@C%HWR#+Z(^?2H_\R^(K@
ML^#6<A<J=&Q-^)AP==;P8==R_Q;Z^0=M**K+9LIM0/N5GI7ZJB:4&._/R$?O
M\U-CM6I__FN9F!MNH60WA1M#GH\I'V:/_#E5TS3".+E],-2$L+VK\/2-#8XF
M)<M$AIA3=T6OH.[<BX>G1M%2!R[V@C!3W,4XB_&ZT?T,(&L,%1D4H)I+O3'(
M:^BVR$*5B$RMC?9:/86FAAMXF_\E$D-%^L)>@9'^E]$9)K-G%C&M=7Z_")-7
M?3[K.(9KZ)]@'>[Q$$]D&:1-@I3F<),Y&%*PP-M5B0<*1>ZGS9[9?[7?_X7\
M$>?Z]+[^JO7G.V!5UD24["JU@.6U\K?<CTM+PV)C"U?*]"WVF[GE&Q,BG87
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M:G!G[+H%6-O;VB<:O$7:4JQ8H6B+EN):P8L5"<$"Q25((02'[E)'-U L0-A
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M5X;Z?ZS\7\0OW_Z%[1K_Z3,RUI[_5O8_:N>3"P H[%_8YO?_5N:0#@#4O 8
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M &@"'@., &8 2X MP!'@!O "^ $" 6& %X W@&C [X!D !R0#?@(* :@ )6
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M;06NA/.KV05-10?B>X&/7@MXO]AP'$?W[L,]X?,OWS_]I0]7SNO]JY ;Q/Y
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M,%C+>0(1]*6P]M/(XSG5;\ ^A$Y"*XW;,$G(P.L+(S:%3<KB)&9]7-(VJ_7
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MT[)\?VG-120RT[$Q.S5(E!YKM3PY4>U2M<$_)$)2-[9.#(RQ)#_2XRS?,,D
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M:(MUSU&]LRD4WO,C[RO7(WN0R:2;F\1PHJQ5UQNW%3Y\A]-[G-J":E"DC6X
M>):^<3<:P9!^&#E"1.V" CTRD"BL<&0%T]KPKB6C RJNZ@HQV*]#E=M9]!0$
MX4I092,9/_GM]Y\*!S$.GH7.JN77=GVI$E6MZS:(('))\+?]U;/F>X=,@ZW$
M+EO>3Z@@2VN0/=:T5Z)=R2I0V?.3:!(X*IOY8*78'W\KK;+\G:=N$CH6AJW8
M-:[K71SL6]]N9"(:P,;*VVCE.?4MPQ#MCU\5=3:);_7Y/-'6A,)4,2M"9>%B
MI\OY/]OL7+*YK[ NV:>R^1]BM-QQN'0508+O2X&R"C.Y-P5:&Q!Y[T@@</M@
M&1YV>6:?(VZB:/)FDQA#_.'S-@6>S.-HSRJ3K^M-OC0A\N&(J4FEVL"@\DGC
MH$TMY?HGO8].J]3%)(YL<3[;\#U\(IKU4V9.^4@!+@C18(+,J#L6[K$N'%&5
MXRIO51A<XV9!]=L!3>7J;XSBZIOV!R[97ER8"N&:'KU'ZF/9$6VV/J"H$D[G
MO(3Z;,.^4VNVZ>+5_>,/BQNJ#HXU;'Z'A)$F_9F 'JZ":3L:+")KV$X'P] ;
MF:T+*5$^E@R/:,**QCG-36R*[@_DEK *R,]"JNG8ECX,/OEN(,'S"0/T?V+R
MK33%S.!;%*G0MFBC#*^^+!>1'$T#"S2]XM5K)>5([^[QQ=^[& LR'?B*YP]4
MG>(I5LI2]7;LU+ZILP2?L#6?8GVL<I^SR-T&YU@8:@J?M\U2\;\(#VG2/DJ'
MJ"$F^F&S87 )MT"EGK$*HK*N6R#N+$EX!)W@AW^3T7YW81A?LTR@4>2>^NE4
M:H8W%S[VE[4G (]$1HZE,4S=]6K@\0QN%A7C=5Q?UCD@9FUNRA;++691R ''
ME^S9)59@Z/-;RAQKA-,TT5.^1]1+=OGE;7L)LUA:IK_WUJ?BN7L.^"0ZM19V
M#NBMK?<ZJ#I<WA6.9,C.400 )#SI,MALZ.02=)>8QP-V! ,#-P[#V_7'W;]E
MVFFY?ZYK\VCO6?B(@  '&HI#Z[&A:GE)&>X6!$<!C_K'K/\VP>W:*2FQ=*@K
M#+:QH.=3X-,LVIRCE-A2TPVOG47H$/L0.F^SP7G)M8EPB/>5_/"F1!?/</]U
MP^<-T15*N4((NMEPN?[OL\J__F0-S HSCEH/0C:#.D'6QL9 4^D:-4LG4..4
M1_&>-%.A9\5(H]EX_FQBA]9J5->[XAF?X/Y03#70-R@V?85 I>>Z9+T%L;94
M3BO;/>)<GK5SJ&#KV%1G]5HR8B$X:L9XQ9>SOP^%-VV#59TU^J:F_';&R[\A
M+F7;]]67[%A*#XS]MC-"2@>]6RX=.5H32A@/E&T<.3,I?_N0$30+]->CCYNF
MQKVQ-'K69AI^QW9D8]=<T9I2KUP3GUMNQ&SV?<5^K _Q&,*G\7U\NGH 0^OF
MD!\IMP[A\]!J+QQ^_WVL(PHCV7]%XFZ?X9 NA8O7X&9%@,GG]7&VL<8(CI]*
MZ;O>+M?35M^Q][:>"?=%=<A5%N\%$,?3M0W7*] R^T!3S><=Q7V=M:71BTI2
MZ]ST>-J4%DH?N#LWNN+B.#2GY$Z6\)/2MB+O5JV#KMK;&AU<(/](<6!+X9OH
M@U6OEBKD#M#29%?2[P"7?.C J0G/[G6;"5BO3^[S*X]"E@-M5P;?I2/N%:!7
M1]G^*L/9_<IPA?]),EQV5%'$AQ9Y6N> *877/<2=U;=_IKC06%1OV/-$B]UK
MMD7%X'>?YG&[?02D>4G^BRA42&DIB9'-+ZCX6$B2W1?]P;U%H6#IA12#:A_.
M$NA59UP?QO2%KT-,;V; %,D4!,\4.VB<$%/S<>UQ S_+B7W7#N;U*?3.4OY!
MPH6C@%>#A5GB6>RO\-WES,\M0L_JL4#-A0MU'0(-BXI/GL)YMW7'A-4#G#6G
M))"<ZL ::!GLRIX)"EN2=@Z %K[T%VQC<*:",HENCAF]%T([T'D!45BVP'3E
M@ TCA\+AIJ^2;)M7&EP=U;C6;KTAVAQW2]N@PC'Y7<N8\KA^[JAF[JO^PT8(
M[MJ=+^FG!D8Z:/VJV<LWB'M ":V-D$.,+&GOY%JE6TAMY'0_E2\5?3++GGA.
M?3U(KBFY:,QFWX#1:0BO<2B"V)OG-6+DNN)(_QKA42X/(W3P!*.KUW^:0 H_
M&D'+1S[*OGB_U212]S1T(I .Z*S9A,TB=CY-L.2/V.,5[+AZ6M"W)S<!,ZIK
MM-Y+OK_)/W<F.UROGPN:R72&=)CK>)M'+8L6_1?JWC.JR73M^V9O1QT5; @H
M14=14*I(DSXJ1:1$A- # T@-!"&0T *CCO0B(" E(" $$I)("26AC-*[E"2T
M (::0$(-H?O@['T_]_M^V>M]UYJUGOLYOW)EL;@XCO-__(X6IDA=2@NKUP\6
M#>94.#BNF23<:QKX"BHJ*0:KJ)S&NL;>I([$3;OUEK>F=CV+)Q<J3!\.]IL8
M\:TW$Q*\5$)B@VO4IH1NADBRO: 5NSK-)OS$[0RM[GC>G'9R H(R):N+91,X
MU5OP< Y0"AFY<2UI%\4J]^(,TV5^;QQ2[L=]J2(U3,Y"#F\H%N\!ZG?Y'-15
M5C=\P[_S%-_MF4J5Z=CZSG-!"KO5R$9]O7/_M<[]D"^*+",MW/0BC880:U2+
M\ M\Z%<]Y=AP, G]7)"4H&%>=MEG[?.;3S2]+VE8_<-H>);/;O(%49NX 6E'
M0E%@/5+3^IQRZ,/*:W?S4WZ&.#X8])UL^QIRQS;O>+(24/V]EO0)G7FST"SR
M[PH"&TUFCB_0*VK=,AM=*S96Z#H+!F-#\<#C.T^.J/M3FYUW09Y87.D8=@,5
M+G5K)[4]8N6*/YL85#8DK.;"ZP-MSXB1AJ0](QLOA/:Q:];-M**=_G6O67>'
MI36ZN1I9)B+7!MACNS&A9;[M*Y))?#;8M<=A-=_Z.C.\$X/%=Q].4[BHM 8*
M?A@9H&X-&^+E(!SJV_JD)4#EO9B2>>!>U1H\C\K<%IR=,.87,UM04%S?>'\N
M0+-?X0,,.ZN[8B-$ S)*NSOK,(X* [O%WPKW\NY&+-E?Z]!1ZM^J6G%9=3PN
M_^O?[/;_,.C163[-W9W2V8#(C2/*#M4U.Z=?NR^:'OVBGV<#Y,%C+!RX1KGW
MV"_3VK_(64=D'&]&!$KV+(3H'QP.Y66[JDY7* :XV4LG8&L'DY /GG9JJBI,
MD@*W\[NZ(\MWE$TXP.B;/#_F;YF+/E4I #/QZY&"F$DN"6P;0[;7=\=T40N4
MU_XQ)N;Q>:T7\H4O=LVQQC<7LGE!OE43?H \N]4](+57N54^3]M<T^7MZL4<
M0AQHCN&U%I9&=6P7T;FYSZ36,H SPF"(M37R"2#Z; %$WI%%J8F00TL\]2(K
MFQ-DE-,^]1KZ)F=@FNUHKR3A-T !8]P]H?%IEV[2^R<NZ%_<N.>#,M2E19<(
MT/W^\.T2.KM5$,F/BB2&FD+LR:F=!>X% U6CS!7J;<_;I7/HTA)_A60%4LZ<
M8P#.'6UX+5F3A^I\PN!%V]GTJ2?SA=FZ?<OL?0ZCDMM;"T.$I5E:8#ZK1;AW
M9^N\'\5N;BH=B,ZW#/LJFRF1 ]8<RQ9UC8-*L2&E=?E(:^AM'UQ)@_V--WMP
MO6.A@_T[,2S-[BR7#J1Z@1S<;R#:CV,\#+LBYD+P96M+^N1: (Y;%6>!68^R
MLX-M?\1;QPW%%S+[8%RMOHF5+@6LJVCJ-WG^A4NKPRK(K7%=Y(HFLH$J083S
MCWFV5V,>X@M^FYTZ$V0E49CH]42%8I]=6+^>3\JE,@HPVB;A)XVN3OJ58)A-
M>*LN30V?K IB@92M+0PSE\8>HQ2$&J%K"XKFV,]MH4_ZS1S=2C;0ZB%1SS80
M5*T2,A 0"X]N[=UNP*JKG!D]?CA#3UK#'DI<$UJOZ18I94P!)4K7$O^G3TFO
M.L?.5G\C,J-4_1\=RYT_B/Z1R@3+R]:B_YS0<Y ;WA+YR&_YC&+RTZ;Y8N<8
M-C09U.V SG.(6DRFSS*_U%O#'*=[MEWUNMI%[O;=3$;/]Q]#_+0"I ;$KP'W
MOF9IVL[01?[0]&DVH3SVX\,YWIM(2&P\4?9N<.G;E&DT9G7X1DU%DI:"OC[]
M,CO(BZ75Z%:G6HYSL"_)71J:;OPJ2>5%8*Q#[WJ6^MR?5+'VU8"I$W '9S0.
M(4UQ)MI2**(7-U5G'@*8GKQQ]YV?@X>'_"5SU6S TU[1>2;R:CMJF/W'Y"^^
M_,AT[C() :2>>+PWEZN"H3UA<RQ^SN4ST;G<Y'S]ZHT[E&=DI[UW;TW$],2
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M] Q,9Z'(Y:5E76H[KDA-E?^4<>"CHX?&+RW<['O#N:8WKBJ>;?1DSO>5)_E
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MB<3RSV1] LUI!./6$0& FPM'IH>C6S,S_E#)?V?V8N/J=J)/+=V8.^]TS(!
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MR79QH3$]$A:&0?9[\KKPI<HO$82FO+\4R!EJ_<S$9%S& AGS4KG2YE)&6<2
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M=5 N .)$=C9NJ4&MT'B$)^.0F(-EZ"0'*.09Z]93C-:V;!Q+OZO7-LB_6T%
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MPY!$J)",@V(-%Z#:XGWTT$CK,9.Y-A'2:Y7>&%95[:J)X\X#K \S._#T&QF
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M6*=N-3)1L2<Z4:B9.E8=I7ME1Q&Q9)GA],?72NS+XH@1[@!@SVBCJ+:435%
MR1T?T>D$*EM_Y8RL[8=[Z,() !,[4.]&ZL182$[,>H.=D&[71\.+T>-.J.K*
M)Q3RF%>#7682P+P=&:-O\,M_ID43 )6[PW5T.\/U<!T&Q^$Q$Y^*.RJ6%OM[
M"S<BL (/-<_TJSDM)T!W]K_P,HQT@4+LWWNK'][U&"N>Q9NHE9)0,:.H?IJB
MZ#AFV.;4KU6*R4E'5N((P$2!XL3$J!$W5P(^!8,34,PT+G!M&&-NA GY-24)
M(Z0=SW2D/;#LKP8&B7(+-P+W>WU&4/P>=9U)[34<-V+8/QE\Z^-782%^FJN9
M.I#V>*EI$PC79K-J$[4DS2H&/MV+B3]F4A+)G)Q=J4?R\>*?N/NR< 48WXNV
M8* SWGX2X:)AX2-P/<*%9I!CZJ&]SS&3\)H]_0/%>GB6=\9Y.L-,+8,C<+&I
M&]-D@KOX7MXGMMNXEW.NM:@H>%-)P*>BI '>R[5P%(U1J#\P2O_<"WSP8X@0
MKKQ&)'%^13J7$1BTS5#=9[90C+9$2K?M+&Y(F/7_MB&KM)(2=V19Z9?Q?= -
MT \E,&1W< /+%I%8_NN1BVT]R778#DL<*P-47ZBUT+_TW@,&I>!'G3OP!9V6
MP5LE,DMBX&0>D4YMZTTD*SJ(6=NRU V8@<7M<[5L!>UEZ#86,I!R0Q5NBLLZ
MD8E2D]PLW&&KJ151)-9R[KH&,C9$?&^^T:-G=%^T--NEI5>3;K7KDZ)OVUD\
M(%5'% 3*>@4?/D@OF24/]PKN5#"L-!2?_Z,V\/,,-J0"Z_OND'4$V-7GB'NR
M)Q"ZDH->M:YB:L&HNO^TT;4DP-(],G(-;+ @SK.P:/WDL,N;S&Z<H>8X'IYV
MBY:):Y2*D2!/@+3!.;$5TL9XKY#;;88M2['SWS[ 3Y+#7)O!7;CD/%D0JD[S
MLAH/O].N;YE' PFQ=M&O0A9$5I?'Z',&'2LPPN1FO\Q.QB&J)*#NF.F!!250
M3,"_G&0J.IU?@DK\/\2]>3S;:;L_;J8SU=;6CJ+VF2IJ;TOLRTP5W5 E8M=:
M2T0L(7;3S2X&M6]%"4%4B)!8IK75$EM$$*%VD=KW)?S:6<[SG.4Y\YSO.;]S
MKC_\(:_7YUX^U^?:[NO]OG.?T+#$8&!S.[Q0=GPCU1 VO<G[,XNL]@\H04Z[
M>F'FAADXW+L])S?O;J'*,ZV<VD<L0H4O-[7*'>T6ZJE6P[O9<S+?J40<]V;?
MRU) UMM3Y44Q4,/E%(([TAAL$DN.70/J+C#OS7&R"]<1R@Z5IT;)^Y+*=[UF
M7OJ(= K+Q5"Y7< 7,,/W)G)#M2KM$T:B0O0/AQ17P*E6Q[_S?X2FI_[;S?WJ
MO5L&FXH6]<&NH=HYO1;NX+<JJ][5(J1I_0J#3-=>9I__'(".O&5SC[4@A@KH
M@E2IP.>"B_B2'#^0C.[%4%Y,%:X:TO..N#EM:>!IW&U@)JWQ_(?T_Z87^1^4
MKV;K+>DK]P>65X/1;IZRY#-#V]9I]Q5-H*LJ@P:;2HN.X\2R8=72HL67SVG0
M9D/=@5"Q/[/^+L$:E=-PV\^.ZI+/5(EUD98>]&_/?1]B\#FY2."FQ-I.G[!$
M/BEL5;:JU"S /\2EF%[,Q,*E<;>2R="*TDJWYNYG!."$6NTOA_J$[S8-7A!H
MW=]9E=+BK\7?0I?Z.>,!(37!LW"?VUL&TDR(>W'N)#=])Q<9J[-!XC5LO,EE
MR$:?A_D UKL%4]#@+"S1;-T]?_#!]N.\3Q'/CX+#7]W5GWIT7!6YR;T7KUM0
M>/"U !/ZQ6EH!DKN?/79:5A\\1RLJ>'0"5;$GW\L-%,^NQ!$X0$;:U+X(_/U
MOD^2R"%--/C-"I:0O0I$%NIX$4:K$75)I0BT.WQJ7&>@MZ+<'3M8W&@2MTXQ
M_M:L?WJ5"3]-Q74US9=K6'T8U>&P8?NH?0EB4DN"Q. 9C'L^Y>[:<(4VP&+?
M6($H5_-VR"%^!3U93^[ 97MT^?X&MV %ZIE*6>(-(#^],6^Z'._5VI=A,Q)<
ML1\_4DO33"Q[F+UP1P*UW NXO&>A97ZHM"M)%PP*L5W*V)C/4"(ES=1,I4.8
M"P=WM%TOW?!T'^Z!F?5T_OP/=.#4S/AP-7"EYIP>E4_WQXXKUE=\0UV#*P#3
M8^9-M\$>@*QL$ZNW07@)XE91V'+%,TFXPR&H95<]AYE71 Z7K7*A]<;=XV@6
M7A>V;W)5I[H?55ARFX32-$&[O96VZ,$P:2=ZFHS<7!Z7OV;]2\P5[5#K56,-
M>-AT0-AZ]_CJQCRX#9=NGUMYRU3LQ]_G\W5?KVQ\R_[48PC/1EI.)[G_+D7&
MZ2E0:3PS@,EDVR'T$(+FHLUM?,-NF[:R?AV0(!68,ES<'5*-12UH2QQ8<&^0
MBIM]1$%5VW&6A^#:[$]9[A$:G;)W8._K$Z$Q29C:ERXE3@\Q4J(B*TWGHO,)
M< 24+]PGVV\PR3PW%;UO6:O<#=1$'(PO9-\=?ES-<!H_U1)'CD,4;TJ*YVI[
M]EFOGK LJHWBF!K>\G$ZW-<'3=L@A0C>(%6WD3CH[&6)*!]W? WS7C"W"T0\
M#08[82E ,I8.*N##MH)!9+MZ=5F-XN_K'+J(0G0GWT:+C.,7 #?N<P 4.<5'
M5&Y%U:[8_6 ><[$D^M)(#B,$+@1]0.LU&@6_0Q0E&YG^!Y<[^9$?=E@0DP!H
M-RD\J741MS*BU;\2JHB3[%P5K/(\V)<N,7&*?QQ&40''9X+)K-^]6\S'WX.&
ME<.-7Q6O&R;?G6MB\KCZ3<2?L+SRW?A88N3V0.K/^LGK&0]<C>,2JZYW48S>
MKC/4;]D>R[9SV%!7AIUK74H8S7_/[#N-N5OFF.-3X(GVGVQOC5XWAHZ'RO>1
MUYT_H<><&GB0L7S$S]^G[Q5P87"H2SW!AE0)(.>L;3DVB>N\56TV0ZY+53ON
MQ"@&7.,?<6'I'&5[;Z?0QRB'U/9WWX/0Z. EP>Z8*WM'H*F!BW-0)NCTH$89
M8<4^%FJIR=T1&7;J+4*/9&"JI0%-:RQM0I42,LGK9HZ:2I1W0("VX) 67'L!
M$^Q,;JE)=SV-<[VUIEK!]?K?FK_UW@'  RGR7HRZ]J>PO^MO?767^@+;-VP0
M-D2]-*]IPBA[W3B3?4T[_]""4A]^!5T6A1Y[&XXZR-M@MX3;GPNZ2>#0D!K%
MQG\.R;X  >O__;GA_ZF8RJ?;"48L* YT[VN7(D7F\\\ARGRF7'+'F%>@QK&A
MIH7\Q4= ,)+O55VH8X[@-KBVKAPHMY>QAAXE=&X&M]L0/)ND#,O,MN^C7!9I
M]>PJ/,@DH[\5$:=,C+I*G&+,:V^_<:]:_YRVSMI?-/N:S7M]1"-EW'J?O,FI
MR_MMVX;[<>@W5\?NIGF0#%HS 0 [U*R>/4T]RQC4'5M+*#*RX89<\]8:I61J
M7IC7$^:\T;(MXD ?<%MY56'Y9,FDTETFG7D!9C@QI$O?H8Y;'EDH"!LD.UP+
MMVC9CSXR ++J_3^E#2%.(#954A1C\\D:N=@R?V*XSU(&6#/T8?7;H"/M5E/Y
MS2$OB&NJE74LA].:A^Y+[:XCT229>_ZM\;'<#KQ8F_D^D24+'E/#DK9%IE9,
M:>FZ=N%&I';8N&TUDW9?0RU!J12)=+YRO8W;4L@;*]".)5@-&9_.WUSV?/1Y
MVUCYU,1<RFBZO9?3O%M[(@FL@9,J>'!'+6-VHT*O!!5JNGM[N5>YY_[>:X:<
M\*NMA^8Z'I#@;"!(<7:WN.P9Y?F@5F6I_T)(Q?9]-970D(>#/"4S'K)CP\O@
M,%-Q$!!]Z\=_J TKZ3%L4,/Q3FWSM!DJN1 X$%=M&B5C?K;89UQ&2X%PCS7(
M0+@BKYB\%^91C^,6N<_MWS/NED=&Y&-(W;J>],8!->LJGA#@L7J("><6Y"V$
M@-F_9FY3'P(:MEBK!+^O1-2NK!;)C"U3;?>**T>7#_M;ZK>EF\9M,0,);NJ!
M-QJN83)Y.P0M!<4\A[$58\,%0GT5%1_^)47_4AE6U%L%_.H0TOYQX:QC#_!>
M2(1H_LJKZEJ0=DK)\#W<2+DA-W!O+X==I"Q/Z%!!RJ6Q!FR3=GSA5^4>/D-,
M3$Y%>*,,83!L-3I2/JASMLFQ,/5R^Y"J7Z:VD=,$@Y]QILT\WEY?N[7^N6V4
M!J%A0C0QCPYHYQ\PPG6ZVET':N%\K>GB^^&#'G$ %/K^\_<<F_0X5]C=B-:%
M#8%%G$H#C6=LT3<4*LINVH8$SR9*]JC\A]NLB6-3XI-P$PLZLF;P3A,?Q!L#
M<; 6 "^S%_HF=MZMOZ,^"_2@.*V ERNT^;SA'1K\C>O<GY'5&T /&;$:@KXV
MH?X2;SIH_@?,]RN'>?,?1Q4O(%(<-P56_0,$<;NF!5+-X"5+KW"E_ "7@9GK
M&/W=-("\54RX:J%O+2: 0#SL*Z9"UUW7'S< V05;\W:^%5UZ=2RN$2Q:XTS\
MV)KA^VHO4KD2@ILZM 5V%1%!D.C&X8( %&I+>04>\-98%MMV2\\^QF-M<C3!
M_=TJ$C]CF>%?US[?^,H$/#\@[;?4J,)\4IJ_GENTD8GQ7R:XKC)7BH5?]?F)
M.Z-(=QQ?(Y)B<L]9/;'&)NH)& B:+MU:#,'2@#[%^[D*=_Y&C?$O6X:E/'EB
M.>$_MV]E&<MA37.[66<O@:;OU894_)X^3P-.61,*>&(J*L\1+2I@30B=*7Z,
MIZOQQ6(^X28*!S;SUB0UN)VM&S2+<2WL_X_:'/]OQ3M)*0<!SJI'[]XQA%V\
M5\SEE'/@R6CB5':@A=Q%73R'NG-U?E3,CGQ4Z#%I?S'(G2$7\ F)2DHY+/0G
M2Y=D;O!D>4HXY8P>HO<;29R&2..+6UASM>_T <150+M5KH)-PH]_CG2Q'/P,
MHA;_$BR;QH#(C0WXN$JC$"BE)*G1-3/[BUJQI>@'.\@DP,*NJZ$</0GT,5)/
M]^'"]NL4ZJ.!,+W="]H"HGJ8[27$^ E+EHAMY?NH2X<*JY;0 +]O5R:!$!2U
MOCP7X#E+,>S<%C6-5):M[N;Q>=RHNB^'2EA4^OXO[:_YA5_30CI:7]7&"C>A
MYGS*;:M^^@8L1ENVBU[[*4W),=<RV"F#,9V5K;!SLWW1;64_Y<&N^FTRL6:0
MX$DFH]I"\EQC_9D+G4$)75 X9!\W-7+"LH/DY7BG'-?8TC]6GGI@;5N;1^#1
MTG03%-RY+"J>)NZ$M@PN'<B@3Z-^<\VGWGDUZQH,"/>$=PU^LI"> %[UHZBA
M10B$/ 4\3(S]/8_Q=:^#89DW UJN/#%$Y)FF0O"2EJ"V?4!W&IS4IO6#EPEU
M&M>"D5B&;O3P^87=Z=F"G_^'5V^*6+^<9K,)2Z&MIDW(=OS&^!$K>JWZ6>S9
M?O7@ETYFUS3,'&U6MLK6C*/)5 \U"M0GKAX?*+8C.2WXG4L1;3B$1Q=(%VC<
MRT3G=)8%TY&ER(E0=@_O1PG@NF(.WV&C\7N3TJK\H<[A@R/35>24AUI.H3+"
MA*!#H=U#OYWB2)7 C>=(%\JF;8+SJK/+BZXQ31T((K>/W>SM35KYTXJ!9N^.
MG&W;4!E7#'VZT.QA4Y*K@9@=!4?SQH"3Y+_]^6_KT%0IUS.(G)H$*@INX";@
M(\\N8_7+"MZU9A19^@07OH%GMFRJ4)@D&\B"L3@@K8QG7L+/ K-DCID"XC&N
M\$>N00;2AT!M@4,C!$?N_2997!+,^]> '1MG4[/=]A&W&0<9:P:$3@&*Y[%6
MIZ5C-G6- !KFUYIN37J.P-E5UIYS#W:]U2(>UQ2'/ULZQI>%5M!WTCIBK):R
MM-(#$[4=K;V8\Z4#ZL7[8*M(O,0NX!;\Z8=MHO93)-BVLR0D]O5__&Z^SH"U
M*.UR]$(+T^9UC;2(-WF$S>?:^TS X6^@QAE-I<TB;LT\5O2V.26NJ@^+D_7H
ML0J9"O68"ASWYX"1.;O?."-OB[2_6$Q&!44 56">XR0.8^,K.7_LFJHAFW3^
MY^P4[11O7F:[>CG7T/L26"5 ['U]-<B@9YZZ6)@C7H)$KM3";OD\R9.D#BU#
M0N':9_8R-B 2HWRR&\4MR7N>&N:B.!*5+D;R;R^F@^:##D$,-4+.A&V;3[=-
MFKX48M3&^>R_7=979*"U,+?*[>62X N@Z:LXV=O[A+<'2I^G&R:',[[B1[[G
MB],!KBM]R1Y3"<)Z P=5!,M-U;XTI<[B[#3Q2LYWD+'EALXP5Z%/63'8,0.>
M'_.__Z_:NO\%X<P<N\3(J#6O(DKRF4Q_=K"-_N]OD%9"1!+S%!J@;?C,#="#
MPD9T_($:P<9=;^UMT!//9.O)<3A\SMMP^K.C[0X]$%A9.E Y0JOM>YE)*NW^
M?1U]LF/4_A&1S;1DM19O_8+SA.7<Q"9H.L8ZTC>-Q[?-QL[&<%],!.QO0[*1
MMC5YJ6!<" 7A<ZL:B%UE Y=*<;<.C?.I(845&KY]LYW!.B]%J[F?";5W+[D:
MFCY.Q6A1K>>--M/"9@"F.-QV:*V]P-&H B1-_T8KOV]XBW>])Z]&(YOUL4CJ
M[1.6>([UNK8P0$&.0XVUXB%;T6_5BMO!LGM?,V/4J;*X>Y%+0:#NH]M%\*R+
M@<,)L!ARJ//JU_7YF>R)3ZX1@0IRP9.WCY\SB0?\<)&JZK8Y^[3>6O]1O]LV
M^9_\:$I^E\:8>+[K*B;]*H[3X93+*WK&59P2"W,Z)RRWCB'>;_>25J_NA;[G
M%W3?O ]P+L 5UL P6$*>S(#2!*J)?)"0,;[JNR*3:@6)\Q61Z>_YS>,&,N0?
M]%>#"(T;25^ 5WY%G%-15\K'AX.4!=>7Y\]3@)J-Y]^:R07X!Z<%0^7R%./J
M?7O$W_C8I%(O\@[#K>N/-[-]-US*+!4'/DG]0ZLJ# 1Z/ZB&H1T?9.O91Y,]
M',K;GY'TKE1F2JN[')"Z9J'K6;6'(LT]Q1O>!N5=TU/NR*18=E(W\.&R]0*7
M.V&7NP/9>F"+*_)>Z5J8HX7(C]=-<7TW3PM1:7#V2CUGN14NXT]'NN0H[2BN
MWHR?K'A$9?(.VSF,#AM]*I5)VW=TZI91@OD'77)+'S+LHTXFAKDJM!FGTSPW
M%M"6;H,=,8YMWAG#Y0V=?6R<EB0U&>DL ,@,HF0TSAP+D,^D[V8I9PG5'_'8
MN45(O-MG>A%M0A;%$=)6O-<#352&*=-ERZ;U83D:(?8]Q&)/V <)OU__7+8Z
M&'V>^GC>6$S,=4[#C3^W4L8N5HS;Y?T'=,PXK?289[+?/4[TN\S.M:I4[9YN
M_PN%2?AM+Z<PA;$%SY!F8>ZVL)DP(9YD'+?6I/$5.%'^FKS*BK.\*+BBAJ:E
MT2RPK"WZC?W;E>5&:4>"@J_</&.Z97"\&%VO7%!@8"B6U]CKV]1H5-['<]:P
MY6C"6S&9EA0O?$@PSMT^Z_;K(%38K%2WW<7EUN29=6%'Z]V[TZH-YJ;^S#C3
MP';@'.$8+-@<W:$P'-X"VG*C!M:>#P'_.QC#'\+*+^9!')M? 4=_CI*L:[F<
MJ'F&-/LT&F":!ML /L ME<P5A(T*S-?15 #3"8:VSI7"K[!))@28YU@1B+LR
MO8*ZKB@Q-MHH> R%M25#/GML.5-PYKQ[SNR-QG_$B\-YX_;(:'WO&*DS]V:*
M5RLQX7-"%@:%?:$+TBPS<9>V-V?V^2\(2DB$//"2$QZ"W1@F8B0:>W_O7ONV
M\DR'4=:2EMBQ/>Q=&MQJKV*0)Q5;51Q-TQ6 OOXOV[7_%6&-F7-$UBLVT"KW
M,VT3 #<!6N9S),X^" .7(=I#RH_5',/GQ@26GB\WD]M[9J7-8(J=NP&9'R0!
M?1!S'+X 1\*DU+-U&\DBK6_^UL+.<JK#ZVV_+1YH,D@.CW]YY5A)P-9M>C<F
MCVGHM7#TE>,)RXC#"<M/KKC.=?!^PXSDMF)+^%[S'__^<6=?6RY<,:ZQ=EP!
M4GW"8F6]*!7>9HK1F;X)2,5N(!L"&F=_'XJS?HG?B-CG/Z1%,KJ9X-7:"_?G
M7)T3O+ZL?<5]*.,*K(_<.SYCEPG3:WT;=!7B:V/_QF3EJ""V\_JL&U*\S>W]
MV_[=N:V^X[//Y>?+VCQ_*0,0@GY(^<=7@-3:9IB!C'PAU7IFBW956D0XJ@0O
M SLT7,=4:)/ML3DA%I&:=8AC)%;;35AVFW*6OQ[M"ZP"A.9QA,W45VU-NM%F
M9*WC^TY?JYF; $Q_W=RG .#NIPJM IG#]#7]$Y:[^4.-[1PUZQVSW:J8N0VG
MS/+D&N<5,X<SRS4-C.<5?AP>*YYTFV/3+=)'_!$G=#DE379CG5%H_S;]%6B*
M4L-V:6W7G*JWG,)'T-3J>#C$Z"MF5'J#]"B;:;KU2]K/G\-I";7I;U=E1"%(
M"6OOE*>^.J<Z@POQ& 45<,ATJCDAY]1XYB>249.(%$J4IVX+,BS;U%5$CN_5
MR+T/SM2T'5_7N/*FJIT!$2,T4.!%\([I2'NWQ;JJ7><5DV1?JSW93V*O< VM
MY9N9D??8;V@T:^D3\@X;#??AJE7^73F7L2[W65-JQT]Q+OEO2H_3*G..JYM?
MS[F,3^BG(V)?E3[Z0W'BDF_P>@9G#NWGT+XFM8Z6?MMHR\,=,FV<1W/S@!SL
MEU+$1">KE,BK,#)6,'FCT7Y<65_GI1Y(/"^@YTP2DNB6W>N;B?9<@-<BL=P?
M/>*;6Q.N0*:?%;B70]B3/M!5;N56$YKKX#O<'=P2X1**ZN=^%#?@%*5X';^&
M,DT70@U:#M#O9B,#WXWN_GPMX?PEAJ(OF-LDE,V+,&13NER1Z.CQMGXE"+N8
MFPC4:(Z5:9LFH:/W1ZNCWAY+E[_'L<L(BK6DF(_:_MB.M1KN*$Q45S!-8^A,
ME1TH4 .+I];1_S@1]3-_T&9#Q&#1;JKX!+[,11PZ0&_K,(_UC6OWJN#ZRL&^
M3(E)CF!ALH&*>^;!TO.IZTOY!,-;QPR<XIQWGCQ_@9L-;O*'RL6F^!,6UDLW
M($O<F<$QN3__1R-I\K%M*<E@FQ)/6))L8[^U[BHZU[0 \-T.)C3+&+UP2+]9
MNB O5!A/T@%;UT\F?6E_*K/C"HFA#!'<0XKO$]"Y4G2V9ZD(:0E(? 7X/H]?
M91+EO\=A^?^K!-%X?GQ#NU8.B%IH6YP[/EOYQX$HCLUFF+*<V%R[:SB0!&TS
MQWL'=G=<G;6P_QS:3^-))676ZXI9M+R&R8QBFRS[EU)8AW,19HJ^PO7L "W-
M)/]_-PX7PC\:]?1^G</O\(+CLTB1,>Q&H%D!$'3'@CFHX8V_+-8F@L?'VJFU
M&!U$+CO:S1TEX=&7"6[O19C&^QS7G6DA4O1SGY0^(5W: ?'Z1\4"Z#*;OG^\
ML*^^JDJ9/#\[X4DK>MY;L;HYZCK"#/0I3.G*1#Y;0NCH47OEVL_N-KE^O5T>
M:&F@L)?4LG=(I'O+"<MI>8258]J3]"J'RL@\82TY>23,S$HK63"C69P(FP:S
M#<SKB5S(+TE=#RM)N700='786-$!'2N;8'LI*I?& UI2$V"L8'TM [KCW+/U
MPC+?I5[RQ G8/?:UUC(=>VO]Q"^L;?X#7@>9X(?^H6\JL&_*BAR:MSU:;VH2
MI<AZWK0SNOAISS,V0QFITJM )[(Z5J :G0-(!#!;\JLGG=_9U/L<GX-"^SK=
MG:&G]YKE?,]A)@X"4!58T9A*QT;>7&(H_BA(>/RX[+F$O/UHKC*YZ(KG5Q_
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M%T_[-@>7X1=@.$YDHF+NX4O;@,QZIBTV3\9P[VU/OME&)NLP8%!''^<;T^9
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M@CC&32]+%9K8!('H[;K"U^OFH%L;E@G$S.ODW!2%@>']"IT<M>RF<#FUS!#
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M$DQ#,?;QHA#,5IQ@V-(^O:>[OBP(P_64W3AK%=&T3,10KPP<=5K3%_3L\))
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MM;KEL8\JA<%6O.-BMDP^A"LDDO#R#5!W%M^8OD?;VH1X.@Z'V8/ZN#FAH2H
M &!';?NBB=6EV5;O5]FO(7<J D3X<8TFUDD5<(X5<S+"F+<H45!3.@222#BA
MG6Y^DIB6>QFKLZ# %>'H?K(I]MGVZ#Q=[RK3H24_MB-__ETA]D_54(ZOY2V-
MRWMA"L9:[8/X5><J4MPJW911KJD5)3,+,U))@HS5[5T^)S^O53%B]J3NCYT
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MS<&DF%+]_LZ(?L?*9>.?>FPP,\W/]F2-C19EO!D5R9.LUN%;3&TGFT+;1-&
M!0O#OLHZK8%;S(7[AVIJRYHYL$-X4-UW9O5Z%AD%[P5GC6G:4LEBQ>9:0' K
M#!G5V90?:>=N\UWA<$"NPF_1;@'6W?.;HM_*0L<VMDIVHID%PE-E-H7#E-2
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M7+>Q[-PGY<-"2XI4Z%?"ML?S%N.G*R<H>RC9PQ;EP6R_IVVG[0IX>,Z_;'/
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M9GH3IAV]PP)O4N-^__1+O^^GC>H6QXEVNHZ!OY^RP$X)PM!IQ=H:=.Y0;7;
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M,ZG>_1.%_%7WU[9*PE6 J*')>YAKOD-<WM!>*GQ33EC3=KKM'M#8='ZC[SE
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M' .7M@+^VKH6< XPX59RCR7Z(F)UY-JT"H0=[.B8XM;EN$D:_=6=8T\T>NT
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M=EOJ+=W]4QD(0Q,B*V/ETJ8NBQ](@2Y(3)[M9QYL@4//;OTY8'M?@FI78\0
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MJ.AS=AC6>OL/UMH*KJ^L(B&_2":-#4/Q[LC,\"VPN%*JZQOYH>\UHRB8]IP
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M];J;%$^"E\/N#1"\W7_YA/VO"Q/@KS6R;3:/9I32YA)^@H/*Q-)N*,&7*8-
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M;;UZ!FA!GS<WY%\<!_GXKC:0ZMX>#&[Z-GV>^30\U_C9+DFN?5E*\;;1<DA
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M6IAQ2O?G'JO9UC$8I45T)E5#K")^S\>6CNJ/M@VSJG59*;>L016)DWOZCCP
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M!T&77]69.7&I/^>)=72$Z"$Q>P0LE*M7VO.B3?#*KWN)YX"6^)5S0(V6[CG
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M;;2W8B%&S](,;NMDX'C0T*ONG^VD[,!.>YO'I,VYHP)26_5':$-4]M[\LU/
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MGK5:QU8-XJI-^A.](6/:$@K0J<G_C! #+$LDJ_F*(O<YX.UK4@71'/P001&
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MG6,Q*T>DE5"\88Z4@U2P74(!)Z'NK<IMZSC61Z1BT,WQ-LDEH%DU]W_G[X&
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M4YNY<EKNOFOC"9]^'?5T-:]:[]%W!HV5U8Z5][8*=;QN-KC)7U!*)5M>IXT
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MVZ+Z?*:KH>QH4N[[M0WE@3"[:1]'$/'-Y.[:[O!, [BZ]K)+F&-%LF4ZD,#
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M9;9=?9_.4L\-"R5+0DPF?=>ZJ(EG;/:*3%].3\Y(%BPUE1<,F6,)W[*6K#Z
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MF]TQS.<>,2AA@5)!4.EA?6G#7_]5+G"QB*H02XNPXJI:NN<P(%3C^"7ME#4
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MW>'MQ.@JEPC5FYEW;AM9>1+06DE6+M.71"^AP_HQLCK2&TDFG0I6OWN"B]H
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MHIZ""#8)8<A.O\HV+H-FRV^T@84C:#8-,B[%:S2?+C4^'WOPFIRW%FHL/V4
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MBI(20J='3! 0"+WJ]>SM H^RB7JEWNAA4$!FB'AN;:KUFU%8J+#5+YW*+OF
M25P;D -M*?ZY'M6SJ?!B]!$5RXWJE-5.!.GX@O&A52L*H86Q5W??-@1 IK^>
MWPYPQWHFMW7>ZUM332C.;ZLNO:I&>]ZC7+^1N-H,HQX("-41S+Q'S7UM%0WN
MOA +^I=:W+<O/W$ZAW)TD8KW+9/ZCB8BF GAD*9L6K7K'F;X'-#L@54^9;E@
M*%K?\M[8<2+XAA^N*0K7ZPG-9YQD+?C@IS!G3B.S;<1/%C9EK8/<+BH/M#,S
M%'"==<2NF(KR&/'*AQ<,<FB]HKP(?WF=?/-N1--4[KGRWD,9\P,01#4C62Q
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M0/0EL8.5?VNJV$<I6ETPQ(;^><&P<4Z\8'AW>3_6DR; &BQK78S99":[>MK
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M5QZJXCMUQ7F#.3K)P][HI8&@"D3%OK@+!1T_*R4^_3AI="01++3-^ F=:-/
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M1<>31_,$;OH#+4M(&;/[.:KOI)[@ =ZY\%A7M\[Q4!'+&6]E\4*!KV7NT7D
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MG& ES5-I*T(K6$$/Z@]&6,H?=A^I[1(91TW7;[.(RZ/Y&Y\SDE2C$,T5EH8
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M-M14?,_ N.I-!>OW/XM^4@'?0;5IJ4KL*"1[M0D!5ENKYZCA366!LLGR<DR
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M2B1OI(]=VSZ(Q;72VV99*6A3J->OZ3;.##-N&9I30],1W)+P-<B?JBUDGPB
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MPI>UON8PF'$+=P]7:3;F8*Z5P9K"V(!HQON9*&:@E]1SH3G.A]U9S:O%V>8
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M>:-!Z\AZL4OCJMKM D<B$Q[(L!RBPE-V_PS[]I$N1GL;_C&]=867U7GH="(
M=*\P/*N@#'1_5O)<+U-SHU=">%I_@Q \3G:-DB-WO!$[+R!P_G)*8,Z)@#WA
M0E1ZOM2CN/-'C^^V#E^,DV8?P]@&40^5M'1SB46#12PF7"N"I27[4A14MW<M
M/TW]0EK3&B2$4&\&C0EX>G[&3*4K@F7W6']Z674-=!A2=_FPK_!$H/ [M0-_
MW?/*K;5I%'DY]8*]!!]*M%,5TWA281,]*2\[5[X VIO3#?-6,JUD!!"Y9-R_
MK,4)E ,WNWE:TGG'@$,Z)3%H;!OQD^&'^S]8IFC&#7@]_LF+"?^<&\C+_?#Z
M3(H+[,A:)?),$RXZ!O4IP7QCB>/E:?Y]S_!S2_<+E\R@KIKR02O@/UUG\NL3
MN5T@;R#J!9?NMPYUX (1#&750PDVJ4ZIGMJ:K212+!NWC +K4FM!"J3=[[Z_
MFY1]]C4Q+LFCX7/D9'>$N:4!'RAT1K"Z$I4)RW5_&T@NMP."Y#<Y;_R&AA)N
MERM$*@QSX\%>:2$OU<LE',$WW"'()=-7&AJY6%=;K >;<JL!$($1?@C$NFW3
M0@&#9\LG3H\/YQ97:O\J<WI001IW[6DK6(D@JJTM(@;XG6 5KD%29@3,,*1?
M'[]D$Z\(T$[%_GTXUL><#U>V78.]7,5=K\V'+<5^K$^,2QV)0@8Y?&;'(UDU
MC"__>CA$29#14HHQ5"_+T5C+4",O"/LZ@Z5 T-K:\D=B<21X>9;?H_!L4-_C
MPN*W]0]X(F: ]&CI?XV__Y^]_?2IZ_8&R,KB@0A&D%90&%<>2PON'(2'QG,.
M>X@1[>?[\$[:5WVA$()&CUV7K/1_'G/QG56SAW/0Z)KYTZIR%(*4Y&:\DBYQ
MR^E09.6VML+#F7PAXY1?!*095UU+Z!;KW4&=PJ3A#\[+8^;0*J)-=T9)=CU,
M1[6W#KW"I-F]YP0>.;RSEKKMJ+GA/PP<=\]<N;ZP:HL2M(_[@;&2+Q3JN4#Y
M_J"N.YE05#SFZDSHX>@FG C\;/7Z6WR'J2RW#AQ]M/:%BG\E"$XJPW6JZG*]
M"@3O8"!+7@L?&B+052_332+8N[$HZ02N(UQ=?:;]TH2'+(*.1\B&8^_Q?@)V
M^?JZK4\;J-B-XZZ.M$ZV,L-@KHO,9=?'!RH6'=J:U+[GFJUR_U)72+?H13>-
MV>!NYMWS]:RW?+6&GXBK8MGQ=7;C#'_,%W:>M(5L!S#L7>_9-([9#RH9;U@K
ME"CB0/K]55-H#,TZ?6MIJ05E!MFV. P5%= CI+YU@ 32OK'Q8P*LR%P<AE,!
M-U<I=0F.[3^H#)9CS3'+"P]01ML!(R MDPA?VZ\!U?&OT"F:#&L)1=U6OP=;
MX)LW8Z*;U[?C_!I8VINN"]I>PZ'-9I WV66@H Q-/BS34WM:!.]B?_EC,C?N
MEIWZ*_Y&A#_[>&GD"!$&'*0""ZZ]]@6[5T!NOLBE]IB?.>:62#.,C0^ /?D-
M7/T2XHH!TKQQ0>8_;>0['[9FU)-Z=D$?P$A>OO!H1A;>1G._/*T9U'0#AFG)
M^8E<+.[D$F+'$K4/#6#B/M^,H&^MT6+M]]-+*F8Z>_(!X,S75$">#^QM(7FO
MQU.U 5CWPD&;.$OI"&J.SBA; DHW0?UF9MRQ(./;V &]I;[X/Z9$%@-A9F'=
MA,L5&$U^T ]6#N^G$]O.H^._FA+!AW:O%\EU,CXFP>4;3O=FRBO3R<[7+$T!
M[<TQURT#7FZ<UY6K60[MTUPX3(='CHR&@1@.O[1Z<:>\0%'8"^%BMR+H^'20
M]C1QK&C)J1RKAK->M088_4KRY&26?^&L %BDJ'C1)?1-%7ZN0U3&9-RPK\Z>
MN@6<:^ Z?OBQR\PZ^)GF\B1]W^QFK%LK:,46"8@;(W! S5ZSY_>S%TZW(4AH
M1R40^N7BPI\X:S>3SXRMU1$^%+.J&HW[&/IE8>51)"RLLGN"W=M-Q$TRX AV
MR4\<[7^OLPY:OJS"=TD"7W83OW;-.5$FEM(D93K]FI4:1.T3);3_0/1.+ 4R
MBXGG"$C.8]SUO/^#4/[_3;ZG=Y?PZ^,])93R4PIM'6_VR+#)8,0^. 43W#F<
M"?%;T6*K^4R$KST*<D*A?>RT3'F#=[E"J&RK]__,_A'!#:AL=T+?P?R:4I9=
MG7JM3I]<J"#2)71MPS+ZHG=(W7AFZKVX3O5O ;TT_\H?^STDYPR1X*W!.A!N
MW_V:0_14ID-Y]$TI]R6I._?BA!,&GQL,UX:5Q[LMW&X0LL2VU3OIYAK.+OG0
MY1' U9''!W?Z4A6WB7B (M%G&+P?Z2P4J(B&Q)"/0 %'MT4:BF.O4M6^H :X
MP*\E&1OA>S[\ DR0DQ+UE@$0U/%X<" KPWKHUY[4*9(<8&ARZ*^I_[6SBH07
M<'C1N9-F'9X1/?22U5[D^E:Z;[&4LON6=:NP<GYQ0:/$ZF7KO6<,(8K*RA4J
M27GYW""62B)!EK6/47JK#G('^;QC\%S]O4"*R)K$,_]ET/;(2(]?5?*F[8:(
M5_D(<Z]5+YR)RBBVSF(N%'^#;FORR&AS59M%?FK]=OU6FB+!W*Y*7KDY?O8R
MXI/][]E[ZZT\R^M=)B;48 );5[*BL:@!X*:^P=U5]Z#84%)V!P:B_#IACT=&
M-'D2<7KFI_U*B%&C-)GY&!'T4KDX2]!5<VG[8B(4W[-^E #3J ==N$OSM,"T
M/ F\=B+ 2]/%<%W)9'E !-]D^\%+GB;*!(JI?5>; ,O4FZ?,;OGO7![6\TF$
MZ<R#GI*Z,1KU#QAF8M^R%+C5R^FZ2VURQ;<1HR)J=8!X?Y]E.KKZAG7PATV7
M_?Y,@%<4?MB:ZS^B8]J]#"5'PX>$&5+U%)[?-.,@C@>O?3*[^B[#SH;JO*'#
M/#V$CG9V-]!!5Q+&<CW=O*X:TW01>-+N8K'-M65H6RRPIZ]0JO#VFG8X)O-G
M^D. N$U]?;'VI3R-B$47;)9XE[OG3D0MY5/?N]%(I8'U5=W7KZ[+<%-P<(13
MU!U__V(2:-^,F.G M10'(^#?4("+#OR5LPN1O5'2OH49$*'FR^@-!8HX>K7B
M<S]1J12-BYBP*P_J-67:(]* ]B8,4C#3IQ!)BPKS/M3U\6'>D>[:@I:AVT&@
MC<G%<BO[QW5I7G(T1 !: 2X?@(KIL1,Q*#CZ*W+S"%P?&Z6JK-SYL]WL:_ ,
M:J[I46(P1(P,UBW?OKG):)FW_K-->K&Y&AN3WPWV.!'X(&[%O(K?4$-GR.\[
M^H"#/V^"&PIGEX0DIM:XM4!UGMK!P_DC89?-BA_/=#@ZOX0^\?B;9B1$M7Z+
M#IC;?&>K#M>N0E0>V;#L;*-VUXK:+]-VC^?\**F#KL\"E$1<\:'J P&L=I@S
MN6!=-9ZVV/Y]_"@>24W]Q9&WXQ+5@>W?W$-RQ*4=&ETR(\[!4>H1;5,'FZJT
M;GU&_6Y; J?!&AD5JPC*^5R6?YE-:]IS%IO#/V[U*6YIS$$,^Z:[I:)Y6M U
MVI?JDMOW,!6A/GP9G%!!NL>[*=PUE8RVY3X(1ZL7ER>C"WZ;8"?&7VQ;W]2>
M*A9,X?AUQ_OL84IBNCY@?2P!QUL!]=0N8$+GXZ@BRRIP*/,<=(JM C0!:U.^
MQ'!R]/'YW6Y!QS>\EM=+,?53"G?0K1(F8BS!0@+$J:JM<__0*I'I2(]Z5.@[
M\&?/-1%EB:55X\%-_"!BUEW0>3!<XX(KP%/7V#L3A(^.K"15=[,\L%H&T_L!
M^P>(.M!(B%DB,X&96 <N_+U_(51*]^A).3PU8QX$4=#W.[)7ZJ#3F8J\TKJ1
M]XV;P4R2G/?X=(S!&'PR-,)UD@B"F3H8?%7>I*A<%1[W8_<(&:K!@\ &FN5>
MH:W#)O8FEEHJ3$8GC9/%"'JTRMU$HX3I$Y FI7 V34S.7U60796B[$ED:AT#
MPE?-^)-CN_<R*[ENE'$0>?]X&+87FNN7*!H9L!HW>A#*;A+3D_3P+P],[2]>
M,8.18B1Y-=Q2JQWWBB*[E=C]$X&&24-!0?9M^XCH/,J#<8^\8N8$C\7;YY(Y
M.D]0M=F%>]FB:XE!D=P73"5OF&:#,$U_./"=5ACA!V\H<!J'D+[.".=RQ"T<
M,9+KY:P3 5,2%??/622$UL'$#6&Q8G7W34R<$#G0G[U11 ;8[TJ+S]81,R*;
MIS-7?%)F+4:ZSISR/=WT.=!V4LIQ4U\Q(SN"7""^H>M;.]4*)P?'?-TJ6K$:
MY&G[%*R[(W0BB*M)1I9IJJ O0?I&Y6]@>UM;/^.UOP%(*T8*+5^>2U( E04Q
M)D <!%U[^T0@Z_D"S^MPM9]T< GLX*$=$)4OCZX<I?81G>@K,6$)QAR$;NW[
MZ:;)P2_;QYR6K-'F)NG\*!63W$.=CA?NEY&W]?'.]N,N#4V.>?KNE2O?4 VH
MGURZ6D  YL-X":F8Z[N>,^5/S?(VHQ+^SLN_;\3&YS_(1E</![_-Y5M&UV8D
M+UM[)-3XU10BCNTCJ*..X$?W?*LS_+H9YI?(DNR=PMJ,U*VB-G.7R;ET1&WX
MCU<>-7OZ&K&>MZR\IF4&,/KF;=-M[/=[^%G,5RQ5]9GG-8WN8]/TNJ.73P'K
M_J%Z_YV(_1UT-K/':%ML&XR]KW-'_YJ67)4[1H(ZO_-(17PZ2P/+7/L!6,S8
MUWJMQL-87V/G7LU_\S_-/C4<L5%2AM8;#BY>+^Z=YJQ0*]L=4'4]^; )B%2*
M8MS+=\KJ)&7O#C.S: 0A2V1D*+ORW"M[6H8GQOG+()DD4VA_T)KHXO8Q+C^U
M(!N2#Q-@Y]TMQ?==VC&_"=2*A:8 <H@;N.0OX9L4U;D^IW#+MEX=<4;219IY
MQ/Y-O::PC?H4V=X3@;=BZA$[30IA#Q@;;;-S;3933)?V$P'U@[#@\0"7A-Q[
MPP50@<8&&C,T\;#]**6].[$XG]FOK>>TW.9G*O?Q*4E';+[_>CF4WC DA:\J
M^6'LZ/N(S[7]+KCPLJ%^O:'VV0R9I\XJ(ICTC]=7[FIGV=L;F (<3"-OXE[&
MM'2H-N'4#_[N"L<YSC&3]S"-!/409NCH9OM16F7Z?]QEH<7/5_[#W\17(NA=
M3T@$/J/ A5X6*^B6-'T\F')8T4]?,37X0,2^K-NY>ETH/Y76__5\R$7!PFM;
ME\."W&+TKF/*A/F:N^5!.6G'O(01%U=(7H+P].4!UG]T0OT^,W6-5GN*R;()
M07LK<?%M&[GZ8[]/ZL82(6DMF.(KP]K- PCTC>J@C U1/RTH^Q@PG=# MUO2
MC,]4G<XGYLLDO+BA2@^Q?!J;D>T'Q\/(4^T3\#7>OBHWT"A-/41O8? -FP9\
MR/*^ B_BQ5Z4(,ES:: /+5I3(52QD&Z 53U38CHC138Z*N'VL2ADN]J$S9U!
M_MT7MI.JZ?@M/?Y@=OJBP1@$24>IN>HOU*94W^AA]"F[/-D1]QVS#\Q^R-$D
ML&&IFQEW0CTL I!"^7W%UD&01C@<WF)MY;2+J?"3B[3KC,*J0[5$=*:#<MHX
M*9E1@!U!YLYB##Q5*C]<OUC!/NE#L_JYN2"Q G_4-P0PTZF/*"_!(>#A#,^X
M!W[D&J1Y6,&(47<!=K?O=B%J8$$PS?4*PT&PAWA Y#][3GW$YZ^$$0ZKB*O<
MK.:2EX&,AK)>CHZA?C*5_FC>ZQ?C&&#T8;R4HQ4?)2Q?TYXS:4<G.[_O<.BL
M^[HO*C.P_U=Y9<:9_A4GUQICQLI$O%_T%LYJN;7T9P&!>R33[D$7'E:O8$X.
MI&C1>_ .GL\&>$V$KT?9E]L##; '2%X_]'7!VGVZD[+>Y:-@F[U>F%:;;9%"
MY>TW_R^>^O^OO)U1U.&6,Q6AFU@H"P<(VA'7?5P]UX2NOET:/^ZT73V2FKH&
MHH)L(#T^ /O&4&@ZTP48HK.70FL75(,N'S%BIY9299BHE&BG*@9@@*9OI\#X
MY1^]/P3/4.N'Y>\UU6:OA3:0>E(+,3/M3BZO:(5'0UXC0FXO6\.6>%I!^N8&
MT]VY\QV:SPOJQJT[52XW;#S%]H\@/D?D_6BNX$?/6,#A1F5DZA53*Z=:+U=-
M'***XVE),I2O9LOA2"V+Y,0,Q4_OFSL$& Q(_[.VJ>TF>Q-JJ+X-"34)7]W'
M76C3Z(E4,$-G)@^<<CSO]KI^4'(E?,L"T@ZS<^==;[MUSW:K?K8W^-5%Q+.Y
MB2H)3IN<ED;^#9JDM3EN]$$K)XF\W=/6;_4H;D/X\6=_ELU3'*KBS[:&^1R(
M=4Q89!/XWE\?'CO**RMUYA&KEKP#;=OD_X(Y[4!'VL&\D'_KW[5CO%C;HJBJ
MA%"_NDBGJ J)QQ9P,$N+[NRPL4R0;-&&H/W\CBMCW9Z2/_;.++CU80 !ZQA\
M*Q(PT++?+9)VWRQ-,1)TZC-K.F8IJF$8GQ[[=VM4^N<NOU8&??7><07GGQ ^
M,TO)L;I(,%@P_:6W1>+5IM 5CP)Y(J@_R3HDSY%XM 62F8M/Q@CIX/63RT0U
M#VOS\;_O6J?>FE-V&+][;#NI;-N4VW@IK%&8-&3%" 0O:2 -R+DU]L%,1BFE
M)VD[>OM)NT0"TQ2-BQMKO*L__C0#9L.(P@13.^2;D'<J-W,&6>/]\:G3#-K2
M3#A<G:<Y&>OHQ:Z@==+/UW2$;^+QX=?PR1'/APIL3D7@>]%S]O;<LC)\;SO"
M;HF(NK5]T*X6D[RXMIJ9"5[5E_B6=K" 3UNM7D4T:Q=_1MFO#%0OC\I0I@XR
M]>U^\*G>]>,>Q<N<7RQ?Z'9ON#PSD6BK@Z[7<3!IJW3;,3"306\FX$6@56U4
MAV$M/==>;^2KOKTX^X.%"Z%.R]>V&BP#4AXQ*4<@X]RSY5.I*W63*,A70C#!
MKB2N<,@Q;J70>K')(-:UYG*R<FY^8%2P0_Q+Y*/%B"[*U#C(H9*%9,5J;!<'
MW0SK<G^N#YG\.]9ZZLV@A<)%$PG3B0O29A)$FB!A?[V:Z;;KE5!W@]A'P!5J
M;(L'6Z9TN$[M#!^)-D H)P(4D:<?.>#8L7*"*__:9I-H=.(DZEDI\X]JI 9,
MV@2XM$(V2J@*W79!43@V28/V,S<73@1H+V8>]8-(^%$ &5T^KA+B6@M(7<'Q
M487Z!BF1%;E/GP:EU(SMN6;*AYRJ=A4/._8>BGW)![=7:%CX$=_R&7#76 VU
M_4J]MFFI^L.$A0/9YXZS+J]C[MX]\A7JPF[T1S0Y:9GIEL&C<#31.?!AM(0+
M7$L?K1Q)59^^JUNEMG-IAEM8]98T+0SN^P(C9I%.N_].5_\J)D%8C_YUL*,0
MY_3!0'V?%A? [$OF[?@'$C\$^U2BFT0&'7M]8N]BT)Y>N:2'XOZD%6L_NZ E
MQNG0PU?K2^:9:JLMNW!!N@=G/V%[=(+=S](W4^6BXS"\@P=!Z[ 2B(&<6U&,
MFP6IV55E6ZSIRAM$6P;BJ\V"2,"3^3G-XAJ^ZM*:(Z*3X5X%O>F+4DJP[CD1
M,([=Z+J/^K#*#);B52@4FYF>"%B?\IW7 6ZK2I4MML-)KB!ZS,]+F%]F(''T
MO0X6081F#[0,>L%OI+0RRRL?7"$#W'W)+!2[(,1EB5@CN</8JZGFS>$CO7JD
M_J6-U_PUIF+?8/K[_@4=@\UZ?[Y%O+Y6.R3\L"R^/&G"<]M=A MZ#:D(=8T%
M3H!7\LE!4U^M%:!:8$!M38PWVYCGQBL4,1X1'<2Z8RO<BFL&UDIN[&4/ZL?0
MH,*0RN8_"K?:*%*CU]OF47$C?.2TM:@VP _O184NA)GBDGGRTP-#CBVM#<>D
MBJ0>0E_BAOQ7@-Y0GK9V,&JDALD*<XH$&'1@,DUC'HS7A9\Q^)K1\Z+$:B*A
M+&C4I<1^^A'%2TBB/\D-8?#P^AQUG*AG]8-G34P_90U"73L1H+J[-71)/I4@
M#*EBE4ZQ*U")/(T0:T7<!+L[$XRYWM9#%"O[]DX2 UO_=+C,CAV')7-S?\AG
M=P0FRBDU:K1Y6"TQ296WH&,.AE^V@YA;D>+?UGVT.;16!1OA8_BG'BBP@=WZ
M(;_J1& "K0.W!P+6^'_6$;H?@CJ(_.-09'2W/$,D.)_+B6K"\><+.X5%4TI^
M;HH^T\\TX:CHETVSLCXI3":C8T0<FL<;*/28%A2;=H&D+G(Y+YK,!KK5-I">
MQ-(_-PI#O%A++)/:MWER^FD+P0SR6@"%Y;*$#$F0)'$/$S(W_;M0CG,=K^ 4
MA].DCO @$WLM46TO;QM5IB9GZ+!/I<%DJ1)YR0UE.U-O+1S?8GOJI6(N<JDC
M+NGZXR <[ _V9 5JQ<ZJUA0]>%7V+WU&.,U*N2.*"GNBL)_0W=Z%D3$LFVLF
MJZQ?#' /'3B?KB"=U^ 4 W.]-&6GL=([7-W+,P3[[AFU<'N"#&E*>891)?QQ
M,&7EFL/A?;O@V+\G N4GHE%FBTQ=5+1"^.XRG"_N/QDV3I>K54H@F*(SB%%J
M#U]X+6!&!-9<5/[^M&,W:C@?$*$H%"S_2I[;R+BV0B:O-RZ:WOA+'NGY=?L>
M2WV"3@@ETP)<(9\<L)$F&T%Q9N5^E)4;:GQ2).JMLBE**1T<J46"Y?V[^\M_
M620AQ3BQ<LW^J39N:LA\U9HI"CU)\HA:A.L86HK,[?<8";.#7,V$%.DO?R1-
MQR,R(<#)[EB<VOP'34N%5UH/H)+EY!,!E18/2F(I]-664,L_.B\)"=[64WNP
MXJ")*=Z1M%@7IJX9TVH"LQX,N10O3@X_*W[(M'H93ALW3VT9JD3J5)=!Y&\'
M7IAF3>Y\,WV\ J4)J3>_/#%W]Y; J3+(7QHK$WNO:8>HJU0A\$Y._8WQQX,#
M,/&2["A<D9O>SGD)B5%$F2CB265B=4K?YVU^8%5U&3Y^3")<6,9JM>%YJ#PW
M#//.>5J<8 :%^80^F/!->)ZL89FVWW[[HECQMLN&>C[+5'4@LOZBDJ)]2&"*
MINEP;J43[J&N]6\7SO=@2^Y""SP7ODRD_.2_=+ C8\7#Y6FL&>\6NS_H2U';
MB8J?O\%NWL;O9=1I8%N,S$%^K4P/XF^<U" ?']$NR_!T,KP-:;(D+0B+1@TD
MC?-VKN-V!R.).X!R<>93G'9W_K(6\(7B#L4BGY)F\6Z*4^U^6L)KU!2E=C96
M"A_-09XFM'WH1N7E]G!'[&<KY]5DAE-JM&W\WG83SCGGW4(]]PDROCC1YY:Z
MC6O5Y* 6Q J[HL!UUC<BRB /^5[*ADK$G*?]R8;5AWF+X^?AC+VQR7;35 ;/
M4C]QY5'?,[4CE7P^$!GLR/M-,2[Y;<::F:5-0.L(U;7:H9[I;F-:-S(Y8TEJ
MNQ$KF4QLDU*3"B!,>I)G 3,++O2T(*,DU3S%=H^)&M6 E@EVFT/G@'8,&A5[
M#4 -!M]JW(C4%R6'VZ\J,:*>IUOG2QC$_;P=/C$)NM04Z^79=Z"O:8"KP'7=
M[6JJ=TKHXJ3P=#BD3>;8(1<>B5%R.#NK/*2-E27&WAC]9DL_(N=#40V?'MH!
MU0.6OD(76OD3=!0]Y@K0Q8,'$A8<G+I[9_50S6X\0IMW(L!-VF]W2^8=A.L6
M&IIA8^H;O(>I74(-NH8852'OG&&@XJ@N/89%[!GE;><(?GP2K.(@W%- O-@D
M\E#?E'X,QT%?+]:ZVJ<IY.UVZ" G7I;')?;(9(0'&8'":N#/NHL!2UNY;E"D
M3%9?[FK$V8]$:4L2S6H"@W+=VEA<<JW-2%W=3R$!:_9?Z04@4F55URTY!#JL
MU7:W\X7S6?:9>*V8TC)XD<4*<' K8=\\H1^=QS[;?P@JR4^*JE$;,Q'+JLV=
M:+H#V-8_[F#Y>I$5IFN[I-5F$UOD<C9'QEP*A3@K8KDL-NJF2A*LUGZ78Q.3
MTC;.RT68F7A=]RU'#B;+T+5(= *)_O(C\!W=PZ\+4/NZ>W"H<![2GM; ,</5
M!)VJ4PYS.QQZAD17\RUYS\Y@2+($ZZ28SI++T62?R^L->:#5YP'O#R A+ED.
M0$ O>\1X+BR(NO M#_M:ZD \FGQH$6N^O_?ZYXF@NI$137D=G0A>RATR%BRT
ME)H?&OX0.$[M\MMR*R=ZB*7#,"K"U[,KE5@+46U8/^!^[J#Q?F;.%B]MIA9B
ML+-/X,%@O+>E]Y1^$] 3$3O4""B+-CO$*G<]P\[;)KF&([[*QK$,[$JO5_Z,
MCDI-HM>-/J 36G *0F2WR['?;)-EG3^EYL,*6[-^ %KRGRU-\K:$.'F0,>O.
M(Q.__>]"J?^^7$*C[V!*QQ7@&D6N9LDCP:R[,5\G]^&P&^MDNI8G*WP=^+B,
M=#O]P(6%66^F/__ZQ^8G5F5I0CAK.K<[IN/;QMIT, >@E)'_.?.P6[Q97A 1
MD^+VKW\TGPOGGIVHTYQ^&_1*B!GG?@_E34X(O[9C&9GV:P$K;^]TT75DV=9+
MM9Y++LJYDBW\#%/H 6+.R#@8UKF&,'.QPXBS+WL<_S[3;V!RYHJO%)\W#4%G
M91S$],_L;@4-(=<!A.[N_(SWBCGOF/(8>>AU5N-FB$Z4R\1<!!T <%])^'YW
M"SO(N&&TK0=!G8HP7YW_B]>$QWXX$?CK&OQE(7M+Y%&R!-%E< D-<*ZL9M1^
M-MTYH,RS9O)>A_@3@F)UYO,OQ@:-/SW^^7UD-!5,U#DS?$HZ-BTLP](6:(8A
M$5I1"Q)Z;@R52@<GW,JNC8N7X0WO>-DZH=KOIU2N"3O>?)$/<;KO>/J'.U-F
MN"QP%>*FMLN<_2'R17QNRKH%+89TR$IP)RIUM^H]$4F*F:=<L03^:Q$J]/C#
M2WDI0.R%X/!W'5*J$<K%DD=%>(8;L@//N:)Z(M!7O;;?7GL8%]@,J86@DLT>
M,RRQE_HCER8G0!\XO,^#@L9NK5=(VG$XSHO"LZUZN6RW&_>]FOUD+VZ-U@V6
MONVX"T4EI_-!@8L[WS(F'$ND3'E^T7O2A;=3PCZFS+:+[#TYJU1+]CH(T@BW
M>=SVJ)LP=#N"?I_! "Y]B>"3/&L_Y$_YI2VB<M3NJM>Y?M0?)ME],/.H\,K9
M!.C>_EQ+T]%?R:K?M")I7YL-1(V#ZC/AW$.G4(;V7,^DUG15Z()V]0*NB>((
ME'QGH]K6*$B, A\A%4:&3*P3T8'37=X?F.XI:>&CN5;R=P<IW\\6Y@HER-^0
M";6/_A&:W$MNTD;J:\"-QW:H]4,6=K9Y03KRDXJ>J5UG+*85PUZMV;N$V,V_
M:3  !?FHR0?8J3/*;@+$NU;"=F,LIDHSPH>U(:R]K1,!O^9PWDSWC=+$\;_6
MBKWNH$ML-F.K/E=.U)&CI8&N#.ZJSKU@I/(\"&4*(3\,JOE:2;V8.H3[F>E:
M/V^_?2(0G\4O<+P9L 8WB]41K]%K#ZB%'!F.Q+?IU\@FK@RAAG1U2TS[>V5J
MF$IB3KC &B#-D8I#3D\46XQL"NVJ#[4.?.@VIA1\1B_%XP'U3[!*B:,3C-Y!
MQMD)W-3N)C4:7HBNK(+%R<?ER76Y 3<V#Q!:$D<4^'/G&.77XV/YHOU/> ["
M@V[]\,5Q>;"4E+*6JOZ6)QY'-=DR;[5VR^G7P["/7_[A/#ZN(64YB1;6]JY"
M5+@L&-*HEB+V:PRW=M"?F"#]^D13ZU[(/&+K0^6=*B)QW<49**2DJUF3L?&7
MV5NYJ[+VM)='?3R[ G):71O2P)!WP)BAQ^5\SPC^0'QA[0QK:O.= %_9&!D#
M>$VR<621#X^7XRJ5U=TLIH'J#CKO(4G^/+C+[TO>Y*D[>66SK<SB:RN3G?;4
M+C$QQ^W=R")6$S06)9+&W=!P*XI]35#DR$3X]T":7/2ZT:OC<H[V*Z I5W3J
M<JA6\!ANC$4\4 ;RJWO855[GP38,VF/+\[/-XWX;T2\1_.5'A5D&+,W%F PB
MW+H%4CZ>&&+"$/4^,CWS)CPP;]<OCQ<22 H5:P!W]S*,5]I;T6 TK[H1I2R7
M=CS5TH:5' Q'*H"?GR4Q'6_;\_)T8F*RCOJND"NMZI9J:\MX0.-M4145M[%H
M<&_4O*-CU(?M6,O'C ZSZ/+)'N@DO09"L:?I@-$]RHF6)1+R=;$*]8>/@L]$
MY6L^F=7M_B5SH#PC[R(3+5J330[%7RVX!315#R6'EE6V=@P#F0>.1>Y8PQ3=
MF*\N+'&;)ZZ2GGT <\^@<!.-<"#OS_;2EOD#0I.4A.<>"'A@WT"M76RGKBP=
M)J0.3,!5BG)K'BTGM1H(CX$\S5_54VR I^ /KYT5LUE[P!(Q#80TYAB#,;F"
M:+G,D VH7W[F04V)\-ENFDMAIPJS21GRA-TY!VGDHTS<3U,G(F[&. ;(-)#\
M8:=N8S=MF8[!1 ]=X_#+6+9T69B*J>+=8*MLJ\5)AGS90>;B4TV]N@7T?#_$
M_8B[JSF_MW!8(_2W)H&E+IPWL+L]ZBJ;OG-VAD8+J@#OFYHB]XD2G$5T6P>V
MC5&I['Z9MA/NVS7?]??NVU*\[MV6&>V24,+#:Q8ID>)%XUYF9-?CSOAB#6-+
M@S/NUNAM]XN*@ZA0_A?3D?O%3Q*/@K*G!TI1?P[X&,;5/6ZWO %LG]CBX[U,
M#K$:=_>[Z%,R[4XG J?) ?,3>,46>7=5+4'L^W LS-^?D]V$7Z:NR7$>[O"#
MK?L!WEN*-@U'E0D7A:Q$:UKL*+IW;WW&2(><D6RP[5H0REN2"_AC,JL!:'E%
M9]-H5K-@UZ^(L$,J\*I9RX4HKTY_R3B+9T:IVF'%+WK6&P+1R-NZJ0O9U<O6
M-QQ>ZD=QE>]^:G"4.'"/?.6%68OI,VKV/ O1K=D,U)IE6OR*0T?OM)B/G#_]
MB)$(5CY+C!,S\+NA!O6].JJMK!N4=QZB+Q8SK=[J59(/<.I#9CK:_O;?C.7G
M@J@7/CQ=T1KIV]#:M[Q.T/J)*YXWWT^Q@23$M1KX[J.,A /P.DM=<QJ7L;#7
M"%18#3"HN6!MY]\U$_/,?VHF'/^S9J+7@ZY@?:OXC8# ]X5I"75B*(YV^]]O
MW^T-SX!2G>&*FUV?SZ6/T5.WXB[HYC*OS\'7RDK*X@=3#N?[,%CA[L<+!O(#
M0TIJ+ )S/J[O[^EJI\Y<IA/+.[A.0W\JJ,YK?&[6D&Q_D^O2T(>G;B1Y?_^B
MX$G=:Y'O)G'KIGLWC(1W &U-"/SYIM>ME8Y)^2X^Z4]7?GYM>,WNH0:<<RXL
MG>FZD'-;O3V$DP3=CO)BV6C+@E*5(UL^/J'H53VU1-0[YW:7YI! =9C>9.G,
M>-[Q90;'5FS8BJ(;')SP/KV3ZW+CTY=&@2@HZ &V!MS>LA"-5>Q*P?) (DFK
M=25?W(]M$I;]-^S]H1>:C5I+H@J5=?YJ1 76O1V 2=*U,[80_(T'+<Z?N7)/
MIWP=I9NF QM%Y.^X9*3(]N#K E:I)K]/ZJ8U8_+D9R""M=D5U@%-SDO5 >6H
M-QFBPDL_Q#@V730PWOZ9SVB.F9C+0N"9".-;Z3)>B.VZ 7@-(_J-<_/&G:=#
M?I\]FMP#&T'GY$'E7Y+7>(&/D*(!E24>4(EN%R!%* 20S.AS0'5$<'1TG"*K
M KQ0I7QJW;O*SX;J7W>$0E$M;E]6OZ5VRC OKR(^UYE[[T((0MQ\7.THV^A"
M6K.#%ATBL<BDTJ>_M'N,3D2[N;#^*8K76$R)ZNHZW7'=GKA!T^YE1:BVT@$B
M75<N5T_L1RC:371$D=Y9:0Q:=QN T[%[1;,5UU_1:LZ[]I\(%(% -AYH;; 8
M.1"?R?\@TH->1)2%4^U8H19Z!9R^)U))A6><6PGB1C:[)C'0-L+,3==H;<&9
M9"JZ8(O4N+L&#$D$*Z9]9FC>8[(" _GXBJP7HDUB Q:;E8T;8D,+YNN KFE;
M_7"ORV]5)8/=I-^6_0_6OH.MR6QKFW.F.*.BHU*DCX+20<'0P7%H(DV$$%I
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MZ6+H/U5(!-E?\6S\LAV*0#6O95>>I> 2C:]XO!1S;(!*=N%;E9,Q:(;\7_^
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M7MRNV.$SRVER,UM"@JBZ1M]=5 Z.,=]T'G,+;JP;G8+^6@6R,DH>^MRH=&3
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M_@DQ?#\@CHH]Q)*A_/P$BR9[/ ZV3-M%MV_M4/<V$CE2>>(_0:Y7X&F6:D\
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MBC1?_ [3F5(NT%!3=.Y/[=;XX*%R]65??-Q0<%6.66BE8-:K3B=P8U(KP>C
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M*L&Q3O_XM[!!3%;VDMGQ-VG=4"F_6:T)SF*?U>,:N-J;MLS>-VB$(OTXN>)
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M?Q"W$DQA91$B/1LP!GW&&@TX%^NV@XE&^0,5FMAZZSY^TGZ(YSN;[2,6>X>
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MMS0$3UQU>2QP,)L.V(+C!_/RHSSY/0MY!..S]Y^W>K>-JO*!1>/L816T2#6
M$F+O;D5@$&*H$]X ,U.[>J2SIE?(ZU]^LA18QBI!%X+K:$VC/2L=%WL?L)O&
MP$)Z $5$ZKTEF8+W))%4WYU 9(>L9A>F?"^]H #J5$M3E,'O>3XL:I2CQVYH
M5V8?M3?0Y!QH#78%"X-/YB!H.V#WNO#!L6PH*2=/\6DEZD6>06J9XA",T>51
M7RKCNP^9+_H5LV\N"[.UG8*IAVM7ZL PL1@9H/(P\"+*3M*3X2(I@%D<U-#
MIOT:2!5#JBQPZ+X;2VXM,-/5]C4GVU]=.XA!9%+\VKNV!P^/ 6!.J[FQO5].
M" )097$+/R1S6P%1!ZVD>:NW[V!,![6.N)P>31S"Y;'%_@XRSMRSEUN3WL(
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MU>/G>]4[OU=/B=JN)1@GZ!2\^^_O9<7)N\7U\#%2+_)335:**-WA8.[>.//
MVJHO=$7&1Q(XN/P<H]7E*&6E?J]@F8B;^"*T-"BC^I'M7.>]I WVHOLQ 4_^
M_)!2<__COP;\Z5/QQJ5CJD[:!57A(]W&*$S&_D#3^,GKTTN>%@">+W]W:LJ.
M6H@ZO8=!/8K*$([KRI/8A(#I?)2)=X1]'IO73B-WP-+*[L,1;:,]DK'2</-
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M, 30!Y_/=T"AS#*<"J:__F-Y,VTNHZR0Y9#O;%?;JL-ZQR$O>9S*6;<0EVV
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MRYTRM,^' IVUHY'941:D%!+.17',(P+=-:&1OELZ9%>Y84V&X'<NK5LH8JM
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MGIMI[P(P6PZ[X5.O[>23Q0S)3)HX=72:QU=7BS V-2TK)]NH/WZU8,N;:B9
M <7IW]F\IL6.[%_<V-OR-6^WVMPV7&9FUB_<I:C!R['-GV7('C)^G@]VJRC
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M0L@39-5PS"'-F2+F742?.3\47S6F&G_]&\S&)A15E&#DB$ZC._),M@.YWJV
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MAE25?>JP)Q*9#>F8-HB[X,>AFX\70'V=[Y8/<1B]7GX0UTFST3(<X]93 N/
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M;'(08D'K]O5%/.M,"S1_8( N1#INLERIU_"JTF^_LA1]L]$>@BFOVZW=;I%
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M'C!ZY)WQ',=MC%CM*M<;Z9\(<H-KA'28!V%_L#9-'.I$366TZ\C.K93EB$4
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M:F%QXE[P:B1C0[XS0JJ%B<M4+9!-,)#_=H41.&N3<DJIF?<1![<'!T^$]Z^
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M ]H8)S>F,3$5LL ?UQ(\TALYQ':C@JS,WC!FO'EVHUL* $[ G2*' O0"[4S
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M9LI$YT-J#Y^9&SU)Z=7MIWT+Z9WZ_CN1DH9#0?(M=P$9%O<"B]/D5DBE.!K
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M"\O>,,S8G.Z)I]%QONQQMYO+_N/)ILQ?&FU9V#U"9F.@CQ\<)SL?OR;M \Z
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M)_OTQZ;M^L%/O=]?+SE7L2:AO9THC]E:U5Y<\>6(204> E5L=O6#SP"?7^
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ME.LFMJKW&T(K)CX',*L6L5:PM)&X9'9_CV@S^8"QUCP+I'_H9]M*,QO"GV<
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M:]PS,YN1"85P6L P_;K_>6X P&<O)-_,$B?!M\9"OS6C<LOBW\Z?;PO_TN<
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M-M937IZ>M$?6.4W#+1]I'U7W9LL2D[MAGR/C)B#\M?"LZ:@8_/,/PLV<'\X
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M&J3Y<0;^JB)\6]$/[[V?@R_NW!4 P@TT@MD8T?7.T$,N;.#;FAX&K^38VL_
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MTNS6P(UR+/_81 B(_ O.N4'B3IMZ[A[=4YDGNR:?#S ;O\<4#E_+OM:FJ1!
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MFCS46)N)$V(4#]VYK@2$!R_"2&;V=VBF!@K@&R2+FM6@A>T-8<6A>1!G22H
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M(.U9#G2A7)+=IU8+"S.(>96/>#^GZGO!;%94V]*A%W=>;5IX=./&QO8==@C
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M4WY5%];$$28L*0@OK:(YU'Z[P**O9?>(I]NNM%_1_E6UDI[5-PUW"UQ/1B,
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MN@^[G1 , SVU1L[Z]T890JD8DF"!ZWIBW>Y <2H/O8A (Y86WOABJR)QN?4
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M[-7IN+<PZZLZX,5/*Q:XKQ50/-2XRE.;["7:F]J]$HRI?\0%<F,O+5[V!,F
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M"=/PU7B^>0<4*[J^"*=U,O_8;(I8,VD$*T]2<>"W\^YA?P)LGA%>Q!8'8J;
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M4KJ;SLO%:O(O5@+&D4SR]?%%$#&499N=51ROK>@+ZA3T$7U4/R?1KT2TQK+
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M:9FY>1! JCP09">9\.6X7L+M?8TQZ&)]7,50<Z7KB.YF04( J@K__?JE78T
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M62[0AU;;T'H=X84P1)J$Z]@JQ0;IVG;7?^T/?,J7&5"L7DY=NY#A#!UC65P
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M^N5X/M\9VWC0P=$S]A"&*9ZD%%"[$JW(:@+?V4N<YT#<AJ[%-;,A"!WYFF&
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M]7HX.[8YRDG;Z/U8!W_8463RJ4X![/X;X$-GZ@ U:I2DOO2JW%1Y!;VCZNB
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M9X[@OV^5/$DCU:/N8?@\,,?S,O]DS.18KB*/D6L _2=:G0:>3153.7L"&J#
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M[[\D!8KOR(HUL/OE_[F8_X8T5!0[A&*\I_C!+>:85%WQZ+X_ ]N%A+PA\VX
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M28VI!<8)&6,E\P-I482XV_&,YL5P^,^9W]7),%CZ9^]DZ,!LMY^!Y]PBBP>
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M,O9+W/1S+-9K(#"L" 4@4?M0E)?$%6N@(\M^6__E%(*:4:OH[D[<;*O=HD4
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MUZ#*JUL_N:YL=(QXQH^$?W38[^VY_!#5-E\$\Q\3$/2P5UM.53/:YDS$9@>
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M3_KQ'>[*GG7;73U&H+Q0OH^'+I;]ZF[R/(I7_E,A0P6VO(U/Z@/=]LJA[F<
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MUC]F-!;UBY*'";)MF61-]&"'[8,ZD> 5@K9N^^5M$+RCG0W6"7V<SOU1R3
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M(C3'[V4OGUMRR1T<BULMK$QC/@KY[)^#!R/2D_Z<1_>+W"93[I(===]8WNV
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MRP/-=S03]@_[DXQ)7$;#IBVF;Q*,Q3X;&#5"!#9?%CWOA<G.9.FU[\P>DO3
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MIS\_8N]<S#YV0A7@6A8K^[*JXUAU7^>#A/-[4S(JPY"R-7:],$4(:3\=9;3
M?[>6*V6%XJ'[SG4"]#&M=OS#?;$#C_C!@'7895-;C(_9GPX#;AF/HA+49_NT
M!/#]JVX[;@OC*7\S:TQ,-[O(N^-3<GUC9D'Z>]K\]==+SCNA$\'06T303075
MP9IUL3/ YYDS ,;XP^GIA98):H@#]T\G[4&I-8GEI9!U3X[ OMWA@'00>)92
MK?FK:+9KK_WT:*1V3J)HG8%U/6Y(LG'MO#<IH#49G'@&>%]9S-I#UG0O.G2;
M@LZ]:E,40GM[ &]I=%I;08P('*1,]_D+GP 7+@;$GOQHZD;28X[2\/UC)R:6
M3$?[''7/=L^[H!L]@9E-Q@;\WZ=1$0XK!3GYU1#(: U-X[#82D0H.73:(C\_
MG0/KL7BA\;ST!GGPI+'[;:>?,AE8NOI^(_3!Y//7M90^;<>JTD?K5KF!'2:W
M,2WDVJ(1DA[P?/OXVG>&((O+R*O1'.,=A/ R=C.+6 JTF/K7:NGO6B7>:X)N
MS5QA?\BF9E[)C^<WQ"I5R7@%*7BQ!%*W45RP88=PL]]P>-@-1ZSPON>_WV^=
MF_"0C?G$G4XTRL2Z/U8V%UO/>R<GW,:I:SZ3P!-Q;9S,F1<;.]I>L'C@E +I
MY"LL:Q,H!L>L0BUF*(H%67K,YXLPWIQ!7@EMQ^KO2IHQBKNWF@U!1.@#WD>?
M<UXR;3A+R<IH2!"XJ,#./S%_M1IE1,MO(LNV)"0&00^^?ZH$W9B$Y^ K?Q<M
M3KA$>0\(-A6K8S%@RT)'N'B_$\D =N%\3,-E&]TGNZY023:GEZ]5?] *(:PW
MH;S;_2U3<Z)!W<:I.>:;68],8(L+^-7J[?,;4PSOS8NGEAZ< <Y)(_]J^/1/
M&2*S2E/C$!NNJ:YW2_Z.R/V\6'GC:<U:1;R.Z0Y\,3S_<A=OI1!9A4/.T?/5
MN*^JGAT9#S9G+-=&%>$=]/I%!FRE3,.RDS^YU2YE682&[QC-8R^8G $LMWX0
M3Y\EGGK_:]GOC'W4;=?EWK]9J^7>GI;7:&RTQ<\ND;U+AKI9.\T7VNAH3R=_
M@L'Y8SAH%X+.L[EJ3V^MQS6/ @N;DA*%\U>\PB?WM,&P$!Q6[$9!#!DW'?N
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M[([4QZ@/ R B+L5J"HM[TC@.T@W%PT(IJ9?Q;<^F-U]39T><3_6\"P+&$/=
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M0>,<O+?OD<;*GCE9#8LVW+^ZH'NO=?S39_Q+?*Z7Q34AW:XSO0\]/55]B9W
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M;#(\9PB]Z+<7'!#U2FK0EC\[4\7OYOW"YGZ:2+5*.E+1S'S[BP//V8Q0B,>
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M'/"B?<AVAM!#F4:3CHV%G\,2Z@:=TU4/,$+_T;FY-(-,7/SLT##<KLKC!,7
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MS&Y 7;EE=MC[XW1U<_M57#E4A_W'6A)6SS.B>:Y?E5-),SU2&OILL<=T&MG
MO[DZ<;_"S)O<.C@?J#N(S^OE%O#-'RLSPDN#@3Z;X>6+6I5ZM4BZ_QZUR6W4
MX%'8MB7#1170U%VU&0P$+\KW:"L@2?]_"N+'$^'>V:D9D1<=Q$GAUE-<*T0
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MX3S*)H[=[)07NICS:7GHM/)"M+)V%UZJ)4+,(EJ"/M!G^,9G1J#YDTGF<@G
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M9?,D ;'00-QG"&O[\>_UAP=Q/393Q'EP";.#35=U312$]^Z#*-4%DHG8D"3
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MHKRV9S$Q>PZ0HP=U#]I1'[3[ZYQ!=J?S9(-4XPRRK^HQ>>_]$%O59TF-S9$
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M?@< +B6<!":RC8N7.?E:\4L:)E$)S9>_A["/UA>!AR[(XD13;MNA&1\&0G+
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MV9T)!RE[DNH87_3JKIY:G1HYP?"]T7?EXZ,%;6I44-^F"\-=IGQ3]\TB[TL
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M@>+,N\_:#U!? O/3UK3'<DSU"/8V-.*Z+!%J'!JLO.+4IB(:+]?AAS&2FC@
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MG7OZ?7 756AC&:MNHC6,P^Z%OH$&8,8R5BC)/L2: H?L92ZF"O>(M6OU";S
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M[(L/U)J8ABD\JMLHJ:GB?U'U97-4;0%-VT%+3I85";UBG4H1ZB( ^-,OU/,
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M/ TAE_O:-O@2:]W%<A4CZ69SC'5^T8#0VWXVDR'M5Y-P2Y#FS/PC]ZKI5KS
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MBI_[FHH\TH? <D8;^^QI@*+MMW,CVU21[K)=&>@"-X.P)\,O-2JS[HAR=2L
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MMU/-K06$A17\8VJDDV@N@\'0BWG+VW.OY8-\:#]=%ZC97H[YZK<*_MLRC<U
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M>SKW0HM@4O9(#]4W7)\3HQ["D$_7[M7Q%X]/-$>+,%:/:X(]L2C3TRY\@=7
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M\40@2:&0;V%W.9>L+V<W7A.P[K7\S<6^C+']$M">WKZV7F<]5M5DDN#ST[+
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M%YK(*\8"VM85VGP&JLP\6A/11NHTS"O)A*_'##@/ \[O/$CU>IU-Y?JYG4O
MA1.&ZO6$FMQ!?,\E@$S4/.?&T"T$'P>L/9C*2_NF=,/M'-T[4)%Y#M4.V9"E
M3R*\,!$',W6I'[C$I.:*MPO_ZN3D<L-<\"C%!SXL'=I\M2RAHOU:\YW1BTV=
M/2=U1\.^*J_5<23LH=J!;-+[%^E-.I]M<]NMFID1YQ=!.B%N/\M/E9VMC:I,
M<LD85L4V[\S/%;?Y80R%B]59="WS!^L:4&;&0_"S&']U7V@21Z/E'>-5L8UC
MCQ1FLCE5*'QKWDF=4_;0L$>9ZV7\CHHR21?1[ \K)#%X6F#>ZUET3?0JB8_
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MHGLDZ&+G>M>?,+=K,/=I3N-Z3[J(1UT<YYLQH8B\1X[2N_V-_N6&8]8Y?D-
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M-*8_L[GW9JJ"; TG34H6AME5624G8XW&G?92E[*-,7'_%/^*\G\YEL\QEC>
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M^7Q694HNU#''D/%=%IOA(+I(RB;3\(<>'4M5 V8PE^=+3&ZZH+--2:T,O"\
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M'WF5<>RU8B_=OXL$! L*CM,0WEGP2;B%R*U<3 !XBS(37Y8\M^;B.)Z[/9B
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M>B<Q;;$6XG+G<IRI"<WLG!#" K'4(-KO>1@M,<D[X,2IG!\CM_6Q8%QN6_Z
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M)(+I'@W"S>);Y-4.*!WA/*F@Z6DN'*:G9!R:-.+RJ>1BW^&;V_8,+QI?0]S
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M#9-C7Z">V-U5Q[Y0E$JX<R8:+^S[Y=[OZ:R$M/$Z(WV<=:8-,ACH+(\W[_3
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MZCF2=Q!\E=;9NI<#5&JC"A\I7E^Z3>IA!-<%YJOXO8@@I(K6'<PCC3/8AW/
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MSS\WV'_+W4R->Z(S6"&>?*+&/B# G\,G[;^B/?_6?%3^'7N=_D?S(;-:2?Q
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M]&OV"MCVM9'Q/"ZSQ5[R9IV?21*1',\82PDRX>5.J\[&^]5GCJ,(PC$ <AQ
M'Z]W0IBT.J1]R!L>CSYXKR<;*USU]CO#DQ ,SG8&7P<$WB'>S:#RM3O"WT?8
M6=DV$?6OU(=>8-A[H+]*H'BR3"8VZ-&[<M$#<.W)VX?PS\(O,[R\L@Q_EHC
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M<4P"><UQR:1N&.%YV\1WBI)JS)6[2AT/>Y--;5='C5M'T-"[2;-N-4GKH"+
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MNE(7^B*([DGLGX*- X#DRXCPOT< K\**BFT2/_*E\-X7"/C#GV$T(E]0 \
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MNXR;J6?6OYQ,C256QP%Q[]4>]9$-!3)28(T[6, D%, 1V[1B+]*..3(V@I,
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M<":ZS%?X0B2B%C/\DF6R&$;T78FI6\7]3KY]R46!0HUC8(.SS':AN/UN)F>
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MZ59 KLRUP[DAX"5O 7,]))+:5U6,B'*J?V*L9=3@!2'@]2T+L5>&>2RUMJ"
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MBEUA-:Y0;(P(OKY5B3M\A;9,^93IVX!3A;D#S*7$U%&2+@2E<GS]?/"L]A[
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MBKD\F%"6U"A[&(5"*W.WT)P5NA0P1C!S2XW1#GOXC=7(_/<CN?]_!/!^[7\
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MF9JI7[9LZ1_W?,W:(USP5;-F$5MRPMX@)C<VHI;QN2V8MUTP]QR!VT,P&Z;
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M,@X12W6[]221$&$>0R+R'(:44!FGF40XL7$K30F/GG=1LU'ONAZ6A7UBJS&
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M\R^"Z"F_^NWPME2V3BS9<[W;I!+A/ LCR(ENP9WJYD@9)I!13DD:"HF$56#
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M[^X7PMK.C&Z9!#67=?>+AD_0970?PYL=%V >UE^.X!V, *,G5\(G9Y/Z'2-
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M&(?4)]@5TY#.+COQ,*0^T4YG(?5>;9\X\%$I.EG7]N*UT&-^VL')N@VU:49
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M:13)B B[FEE;%FS4SJFB]L-J"1FIOH!%/5"[[<QK9ZJL<34S4V-B96>B=IR
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MKP47_-7SK\HO?+?<%;/L"^KFF4@8BK(,AED4083S !*184BQC+.,)3BGH<W
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MIHGIUH;#2ERKGAO7I1EHLG'AI<6Z:EQGN-]&8^ I^P#Z)]U_H_@DBG;VBF'
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M*TX=$*9?H#KTF&N,01T)= /&C]\?R^*IB72TOUAI1&G(20XX32" F2XSI9D
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MWM:Q0A,DH:1J6U>G^SQ66BX12ZF /$*I49=B<Y(SJ_CQ'-?<@Z][4:_U@9%
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M7=NI]Y[\N*TJL:MTZDO[;VUOOB^B$N63J&ZW_):Q4KD^U2I->213F .<Q!+
M4.2 9"16_R-1%,)0RLS*'7%C8^YXG2:C3CRB8< R5\4163,K,C]>=H:EHUUG
MLS4<W329;=T/6JYN@HZOVJOK./-G<*8AX\D&.3*QJ%F:!M1+2S5Q-?N:=+V$
MT,>V._FN[8-RM_V=E/\M=OH =RQ][X:AY8"&+ ,H23'(!62 LQ2BC$!.,V8Q
M#,V*N,.=L\-4M ,[>OQ7UQ4F4'_]?F IJ"P;3=AA/&RU_$/FFG#7PG0G@XZ)
MX&X;'-FP[L=A!Y-YY?4L<+F547N"S:HFVEK\@0)G\[46JU:V%J]?>FS_\H1N
MRNK55<0YCQ!+0,Z8 %!B"3"*U5\QY6E")>&(6W=05@O/[+X=FPBK)QT:)6O1
M1^S:!($L_2LC6=QZ(/<8G];W6"^T?*_C'OL7^QOW?^[87ZX[=GW</NYWU6_B
M26R2-N$28A3&29("F< 00!I"@&&. %): K,X90G$=MFG ]1F3T.MB06)91>Y
M07C"4"91"E($*8 PC)7O%2&041*'>289R:WN5CV!XV!-^KV &^(W@7>XS Y_
MGD"PLT #\L^0U&L@HJ\N>P.4EFVP-R[R66\]@U<<>XB04E]W59]%65^9'?.(
M<A02FB .8,J(TFB1 )J*$ C!$I)1Y0\0NSXBURC-K,^?1%-7$SR*LKD-M^PF
M<A4A,R7V(K>="G<D=3^#1N29J@U'9?/57^0JG65[C(R)>]9G9/0%^TS)WGRU
M+X(5:OM__KCEG\AWHR$)PRO,K8J*A'FRXX"@PYKG3T8[M>O1##JB>@_EZZ<U
MUSDS@_);)3&.B^>4NSBP[&(IB^.B]3,5#9YVVQ@OG;/K#,@VS(A#?4K6K4,$
M 22'&< <IB)/(I:D5O-*KE*:61LO1G7:M%O+F>O7P3+;([U 8*>L;M);[Y"C
MDGG:(:_3672''!7WY0XY_H)C#?ZA[9YN#?YQ^Y8\KG=DL^(A"6'.$L!S&0'(
M4@IP%,> $\$$0RP-I='4BQ$Z<U]8'IM4/BJR8+T-6$/8LLS^"DIF6NM!=LNX
M_E%L35&G0KT=$=N^:'Y8*%]5\E>H+%L6/RSJ61W\R./V5WOOUM5C49'-KV6Q
M?_RX99N]WL?K6+>N/=H+WB9)%2^RI;[HI,T[^;=*U'>0*X%R&B),0$RB',!(
MQ "3F !&\YBDB6Z":716]<G4S";@93YEJ:F#0H*]^@NI;V;-+[:\?8B1,/HK
MP6L9@F\Y#&H6M0/?,AGTN0P.;-Z\S,>\";YT'T-QVV1)O,*W,+^#?(UOXG9%
MN>RWL;K)] WBP$6G-U*+W8/Z!J=_3>I];;N-K"IWJ\]EP?=L=U=^%>73FHG;
M'^MJ):C(>$0YH'F4 IAD*2 XEH"D'&41S E,<Y--Z1J!F3>8EF0S^["A:F;$
MK@(RO#GX$-/.T%^0,/A#D_1P_AN39LB/5._V?$CUMZ/_>'79131Y3*A.*T>?
M<SS3:2V]9?_:KYLYMFUC;Y2(+(T( 9#&2L\PQ("(+ $IXYB+!%*96O5)NDQF
M[A.=)AKTJ(ZW&;7!R/! -UERR_.<O=#VY[E!F7P=YRX36?8T-RCHV6%N^&G7
MWLQ/0NVW'Q1O7?W</]:[A[?[:E=\%V77QXL2'B9,#WA.]>!1ID<5\ SDN=):
M":,T0U87BT949U;?EH= ?Y9#F6SPIV(CZ/@(WH@M>]")FK8=F$U -5-P[U#9
MZ;L52C,D&UB)[ZVAL@G-A3LG6\!PWB+9YF4W._)W4JYU#+CVTM\6U6XELY10
MFE$0D9@"F'$&=,0'A%DN$IJ%81Y;V8PS"C/;AXY>&ZQABJ*=%3B'Q$SC)PEJ
MI]T'&=N#]MLA(:UU]ZH@GO3T?/U%=?*J>"_U[_J#L^S9[W^TYVGM,*C_TW4?
M*XQ#1%&:@RS#3&ECI#L7)VH;CY&DC*8XI]3C#GZ)AYGUM9F\6S9\>=VO+P(:
M)H)D4:0;O&J72)UF]%P*!H2R=C)'""4RMTLNG1E2IZ33+TO!Z<49F@J1=]=(
M]VGIHIT=3[KT;C'_: B19;REBQS\3+[3$$26GM3@4GX"*">-_>Y+LJV:.KZ5
MR#B*XQ"#).0I@+$, <Z@ )@C&C'*LL3NB&9*>.D@R\V+EI<]5J:%7:XBZQ:(
M\8'7Q-","U23@S5C<L\4OKE*]E4#.F-@C(5X1M]W[.3''@3?;\2=_+A]$M5.
M7^HUPS6^B,>BU+V5ZMG?U9OGMV0GOA7E<Y,:AF L(LPR$+(D U#@&%"D#G:,
MT#B$RO)D=D-M7!F9V>AT;.FBRB-C03L4IF.M'9!>!6^>@XX[MUP\Y^]A9IJ6
M0-G.5)V#ZCV+;ZK0OGK,N;*Q;*.XB6"==7N;NMX$9ZEZVW0B6R4\(1F!*2 T
M5R>TG&"0AR@%3&0TBEB8,4A6.WUJM/"(NM6M+-"!AN5A]M!CS2(WZ#(6%CZ,
MBX0.CDJEO).1EG%NOLA+_GTZ'(>UE_<J7HIUT74X>\@^+^*+;LA8W_VG.2$P
MRBA(4CT+EPG:#(M F60HSPG/8Z.D^9-5Y]ZY=7)2M5LSI3V_"Z*[,)E/&3@5
M?UAEG(6R4Y4K\GC->3@38T*BPW&MQ;(;SMCOIS2<_] ^Y;6'>UW+^96)+2G7
MQ>>RH(>&F.V=7DI$G,,P!%&2Y #B6/?>RO0D=QY)P?341^.L5@NZ,VM5_S>O
M9N4FZ)@)3K@Q3YFT 758$V>$RDY7C5$:OR:=!)=Y$NE,L+GEB4[_);/*_720
M?2"]TV:UQ3(X'43L)VFZO#YIE%5U7]2QCU)\*G:B/S0RE2F5*2$@C$@$8$@R
M?>V" <\C2D-"$$Q#IVE55TD:_;Y/&4CU6?W[ ZF4-2ADL-7$@_) W6DJTG7X
M&(ME)% (XH2F /($ 2(%!)'$D"$6Y2R2#@.GIH$W(<UU0>C,#DX^ ;';=#K*
M>AY+2SNHB?<FEWH?^S0JI]_)3M?)O<;PIE'AK\QG&G]OPEB6-^.=]=]<Z:S_
MH2BE6.]TO]K;K>X'N6["S=7'[6>AS#U_T6^_[<0O/I=K)E9Q*C.68 DB@A,
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M;H_.+6V=>%[L=-64>31S"(+QT*8GZ2T-Q8#@GB>K&LKH%/8<6G>Q&*B!</V
MJ,GC_@8\=AU.M'L!A<0@9)P A"(."*'*QTA0&N>I C6S:G Z0&MFG>V-.:P.
MI*</=[1K!>-)?#NEO3C@<88^,0;"S3CC\55ZR!B(;#+G<5I_F6[EN]V#J"],
M2O&@=NCUDVAB;WKF]R>QNY-J5_]<E/799Z?.+G1?LW%??":GNBX$5T>),(\!
MB0@%421S1)(\H<RJL]-$?JSL@6LOJ$+S6.?_'9@,UDWOM%\VBD_+(D(OGT"&
M.B9($H!8!M5I+DU FD">10BQ5&8VYG;)3^ PN>\J^,NB;F:[%\32SKXW,)YP
MUO7_^T4S]Y>;0/&GS\2*PYN@Y3'H,ZD/T@V;_K8#3WAYVC*F<K/HMN()NI=;
MCZ]EW;:G7N9,N]_=TJIN]KS"/ T%C') DQ #*#D%.*4Y8!)E, G##$*KM,;K
MI&:V:"VU8'-DX#_M;-D 2F9FRH_L=A:H1_/@5P9_='0]WBF/"^?)7 P06M02
MC O\4LD-WO!7?/)6_7V]>TO*\ED691UJ_2(JH=9^6+&<\RA5GB2FF5+JF*6
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M][2D&W,1H;T/:;[:O-M)?K-_!Z:41S7O8+'7]Z^!#MM#H-1W-#]J_.D.\D/
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MX%UH&1?F1<FIS'$*)2H81"0GD&+*8884S4J$&>.ETT42?UTB^^N[]8XNP?K
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M%\$@(KB"F)0<$LR0% 7/"N)$/']%3N1SBT8JV!JQ,["H1?JWKKV&E9TK"8"
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MRE:?<5S_/1#;>9<XP+DYF+.^ +.&J\Q@=O+;]T.8C6X8,&Q^I#8"/8)?M;G
M,"!#+0<L1O#<T=/'Q<Y0%#_*E5CLG@R_QZKN'"_>/.T^K7?_*7?&W\T93DJL
M.(*$( 61S!)(69I )J@H$\0K18G3!M]2<&17LT]J;\T\>=R8JD<=3)MLF-10
M/]9;W$7GB)ORNC?+%CS2Y_KXW'Q4_W)C*'G:^EW'9*WU*[#,'D0 ULT5M1J
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MZT?G<\N6[35/<[W61&EWBP?]D5OUU53B*<K-W^J6F^_H3M[\6&SG+.,YKJ2
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M'W5/ZKQ_>%RNGV43"K2#S@7A.EAG%2QI64)4(@DI3B3,2I.C5422THHS]IJ
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M-*_P3.?_K[])NW7D]>>6VS+4%M@<%09_-AJ#5F70U;G#"#D#A_=8*PZ.FL]
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M<QHN.\T0!@0W9=#(WR-J;(&6;.!XET'10@:GG"8T?23)H, GPSZ&W_ T KH
MQ\;A_X=2&IM*\/OE%QT=J2]@WY%Z7O^YW(5*WRU?=*RDEE5Q8W3)>[)@FR;
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M/,Q\V"GPR5%VT]@=>TT#^1V#-Z#'HO$,&":;QDH7?0WAU'-0^ +IXS \3:J
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M\7G=,^R>J?&43A^(!CRX\5-VK]PL?I]+77&GE%0*#G.$M3LZ09#R@D.!BJQ
M<22*R*F"^S7,C*RKC\('^C&2;9"!"5O1<;.U8ZC*59-@9W9.!:V;_NZX H,Q
MRO6)Z(V&.Z#9"YBP$ "D4&D.U[ R;7)$ -".4BI"C.G;8VJISS.-T^;+O/[7
MN]== QJ:%SSEJ3I;*U6'6*P;9PH,<5XF*<5%41*GN@H#M,9V"O8I TW:HPG-
M$%1V6BD0 (Z.O=.R!^]%8R%<L#Y2YRE-W$?JHLC'?:0NO^)^N+Q;\HV^I2>+
MVR7_N/P^KU;+7I0Y2A.LEB^!!:.E=OJ7$/.201:C.(_B,L4IM3U/#I,:_?ZN
M(V[.CF)'WOZD<P&KRT?!< BXWNAMA=?%X7N4/3(2+J!@?\0+AX;?J>X:5)R.
M<7:"#IS<+@PPV6'-3I#^^<SR#7>]]7FC![C_]+%>SY^U._P/]8>F\T5;.TUE
MIS)*2IBRHH2%D!@2A#BD11SQC&-"L%4+/ M:(VNNAKJNW"$Z^N"Y90!4A@/[
MQ7L)MLLZ+" 8;DJLQ>'^$]B2!AUM\"4P#O9:+" >?FKL&ER<U)BEI -Z[-((
MDRDR2U'ZFLSV%7=5]E4-(^J/RKY3)[2U/K@]5&T=55,TYJZN-T2)]'Y5K]OV
M7_J4=\M8M1&\33NM9UD9X3@6$8Q$D4.49!26&5$*,,\I8B1AE%NW,0K#TM@F
M7<L$8)H+4(F%^?;7*W#[^(?2E[+Q_\];]G2."V%LM=%7!B_DU7ANM2U(&JZ!
M:-FVUR*!9NZRTIU^/MQT<\,?^*BF8LLA>.E8!+4I.37?GZ^#>7G;*;#7]]-/
MA=^V,-F4..TA8=$;V&H"$9IL1PH+3'_C"CSR%%5;3"<$]6'/<$HX2Q(&,4X$
M1%DI(8V9@#'-"UHD:2*)56FSZ]@8>1]3WVXY9I66+9IVKL;Q,7+;6ZZHRJ(9
M>ZNR+(? O$DYEBT3/W$9ED.@KBN_<C2:G[XRJ4L;I@NO+I^,9IREJ;*A499!
M1N,4(LE36!*<PHCE+(Y)'I7"J5+!,8F1]<P>P:VY/']^(?/*>+W8-U(]N:8W
MG$#*3L]<)[^;#MD7W1 +IQ?."Q)HS9\@,.EZ/B_@X5H=>-)O'?YG$^/5^I99
M+D14EASR*%/F ,$$4H(1S'D41WG."F87W79R]+'C(KIH-74^?>GBB9JBO+?*
M_'Y^7BT;H]QM^>T#9+?RO,5V6W0MF8#.]$$! BVV_;$G76<GQ3I<8J<?\K;*
MM>7_NU#?8M?:X;4M>5!_V!S7]TMDC I*$4Q*G$"$40()(PQF>2J5.9Y*85=J
MV)>!\2UQ]WJ);@A:V^"CX>)L?1L'@6%EUX'F]4;K,2K  YGSD6H@>B$0SLQV
M(S^U@>T%S@G3VF\<[XBA>K68<V.O_Y-4\Z9'C%JHRFSXN%QKXDWEC"B/$RYQ
M 1-."=1!DK!46S\4><9HE.,B)DZVMC7ED15,1QITM($A[MQMQ1Y).WTS"CYN
MBF:/A1MP!JG7B0J+N.(1+C[)DN[4T4IN<)R(77(<P/$:3<QGS3#OC25M')NF
MBE-]OUG7:[+4":<SP9*\B/,8ZN!$B#)EN90HB94-0[.<<HXDS:RNR*S(C:Q+
M&@9 PT'3U>.F*0A7@QX7EE<I=@!>N*D*#HN;"KD6$?N;#"=!3^B&6K!_/*V^
M_W]JH$8MJ+_LM('E\-/<33B)NKUW<'O+TT>G+][OY9]UXPV\IVLR7VHGX<>_
MU>EZ^:0;(FVSCO=MG%E",EHD60(307-=!I[ LDP36"213&E$,'/K8G0%+V-[
M_>[_;%SE8-4RI6_W1,N629E;BA^]8@<+S1U8[#K].?H#KY@52\?A-%@[>A@U
M4W EH6*KQ?N^A_?'/MZ[J@B&N]VA*J!/\GJ,0CDOK^!D6B_G]9 =N4,##.D>
M3_38OR.YV[KWVP F^8FP=F'KSO/-[X4I;FDJ <Q2B7*41@P6%".(HHQ#'&,!
MA2CCK$QXFE.KW(WK69DLL%)N^; //+D2Y0N6U*38N6FZCJ]6R^TXNP%=**($
M.^Z 9@]T_($M@Y,A;1_:,QWB?B$]8R/O%,D3!JR!")XK"4P6N1,&B'[$3J 1
M/>\$NO+$IGES_;NN$9.TUTN9$)2;=LFE5.=G5&!(.)>PC)CZ#8IX1JVR@2QH
MC:S[#2F0>/:L/P&-I5\_C,".+OQ>!_F&[@UHY1_A;LY"Q- ]W$]0>IM6[.=%
M/MM1?> 5=Q?8AW9;^317)^[G]<>J6E7O5U6EZ]6LEI\6Y&FF2^%&15Q 0I,(
MHEA(2,L$01;%,HXCE(G"+J'/BMS(J[AC #07&3KAX:O:4YOV"(8=L./'WA%F
M >-E1UA8<-Q6O!,NX"_-3(A4-R>IO;QB%L-/YA6S%[7O%7-XZ\I"O/L5J<S\
MWR[Y[VKZ%MMG1-V5P2-0Q%$$"YRFL(QI GF!XB*)8Y&YA=@ZTA]90QBR)LO#
M$.Z5;O,NXVN)JYU!,"):CKYSZ^IV0Y#>Z"C<3<@B=YX A:X9;$G];4H)NT%S
MML*PXS 3=QYK>ZR8-BIUUV-EVU3E;KFNYLMZSII&4KC@+!(205FP%"*:2DC2
M-(9Y'C-1H"AE&9FDJY@+UR.KPH8'[8Q^:3L]B;]%Q>:U3@N:,_&VO<2<IC<5
M<9)$10$Y3S!$')>PS+BN+B^+#+&T(#B=?1<57?W;3G"?>^LIWG;U>CJ:ZQ]=
M72C2UH4RCP"N=;G4!\3OFL-_HV_ ;G_]Z>;5;5<.T =N^TWLUG_7Z:W7V&TK
MT$_3W<UG MZZ<YL3S_\>7=E\IB%8QS4OXIY%Q$VUR#_$^MN*WRV_BWIM@B!G
MM,!49,J22/*$091B#$E"(DA1%!<E3EB&G%(.SM 9.U:H*5#Z;,@J%;"EZUCO
M^PQ(.2MHA)@NME(J<RO/*<24<76D)#F66#==0K.E6(\/T;9$^OJG LANLPKP
M;3@>^AJI&XK@SD)J]R+EPS*%JD)^ALJT9<:'13VJ(W[A<3<])AA7)[EZKIY\
MK+@)IIR+^J%:L<^K]2U?O9B. 5WK(0N%Y33@R.JKY0,\5L0T#NFX,5X(S9+@
M&QWDIS@#+6MVZ]8-M>%5/!I@;FO: ROP5] @:B\@!MS!:KQ6!Z@M9;OTW:A,
MH@B\!._4@M_+?L;.NTT]7XJZ-M5CZ[FQQII"LJ)M$<@S6G"49C!.RU@G>A40
MEV4"&2=YD3&9):F3V7.1XL@:I*.O3U%TOB3V%T+VF-EM\D&1<%,-IT (V&K1
M6<) F_]E>I.: =;B'QH$]B_ZK?K3D89:R>PROK9MR% F92HH@VD>EQ!%)8<T
M0<JN3^)$$A%3R:WJ)_H0'UD7'(3?.IKX3BC:J82QL''3#K^K3T^(F\/HY+,Y
MGY_FM;[^,:F??Q"=\J^.$F/T;O.!)Y!J<2(]J9;Q >50X7B-X5M/Q50;>2"5
M/O*8B"E)$YI$*8)EJAL485)"3 F%O*1YFG):*A/$K9[*(8F1]4A+$!B*KD53
MCN"P4Q77">FF$/;D&R%2[+PLP>JF'!&8N&[*.0&/ZZ:<??+**,Y;_G\VC6?A
M7G8E2&9I4:1E46:0<Y%!Q'4>).489A*SC)&8"!)WK0_M%M\@/3?/W8ZJ]9?Z
MOLFMF2_[5UDKV74(\T]FN@ C*81,8@%SFN4042)AR3(,4YQA1B7F"#G=,E\/
MXA5]+MX&0CNM%PP8-P6X"YP%.\(:E([T"%&S0Q*&CIL]2>MM(F>'Q#X;.SOX
MDF=X"OLF^&8A[J6^JEHMM15T+[?A+VV1N7=B*>1\_:BSV'?NP2@M>9IQ!&,4
M)?H6)(?*GA$P+E"!94SR/.9.02?^O(P=5;=Y?B;5JUX*_>@OT!4+!;^T7/VJ
M?[\Q!6<_-+77UM]$>__L&%1PQ<38*9F)X'9301U3&NH=6_O =[#W4/_+\#=.
M;8P .(6ZI[^"DVEOWZ^'[.A./<"0?BKR07V@G\EST[VJE"S.\C2&B-%469(Q
M5B902F%9)#SC)(ORW*E03W_PD968)@4T+3=%M">^G6;Q%<I-56SE"=Z?ZQ3_
M@9;PWM"3KLE30ATNLI//>*Z:2E=86+_J(=>Z%TZ7KM?4O=EM5I(BJ>3)8"YR
M"5$<)Q GA:FS5\J"L01G3C<OMH3'7FTM&S? ,&)N([>LW("EL$P(=L;3<HF.
M@)+C\AT&:(JJ5ZX@A-(!MF2GU0^.8!SI#M?W_=/][I9R53VWC>?53C]+(D8(
MEP@JE5%"A-3^7)9Q!E,2841)D<6E7?.K 2(CZXMM"EN/;FO6VO:J&T)H6"N$
MDMM- WB)[)6==TZFJW+RC@:=/!/OG%BG\N_./NL>=O4@5JT/WS*L:OO"V'ON
MQWO[,*B=%,-KPUL Q^WPXWW *X>33'N%'.U&F2RDZ(CQ?LC0\2_="P;=+M:D
M^DKJ=OZQ+&DA:0YEGF80I32#E,<(%IP+4<J846;=.G%_Z)&_=T/,OJ[,@=@7
MMH2KA''[]@T=\/7VJT=WU@.A[(O?^ OG5\S&04BGNC2GY1BH,W/PPF1U8TXS
MVJ\#<^:)*V\$_Q"DWE0F[T+7C_ESN:*UJ+XW%5EU,8K]/%#UKTVE7;?O2#VO
M34F:QXHL:ZG6Y]URO3*E*U*31IYCH9W?7)<.B]2)-4<2YK@4&"5"Y$AXW86-
MPN[(BFA+$<P5R;;82NIY;S;.?-D=BW^>67#3H/V2-SW6P0]=$:O/?%L0YRC)
M?2L ,!+<M"6W=A-[9S.Q_M> H^(=^AYQ'&;?YB)R5.#/WF2.2]4S(^[Y9;%Z
M%>*KT!G#"L6N"!@7.)=)#F.><XAP@2$N$(=IBD3..4,R<W+YGZ$SLHKNJ()'
M43UWL="F8Y'QO-VOOPE+4_(27G::-@ *;BIR"\"6X@@A7A>D"I7]=8;*M-E?
MPZ(>97]=>-SC%/?XQT.U>JK(<_OA-95]2 '30BW4 N4Q)!&C4/*(Y:F43"16
M 9:G!A_[)/?X!VCI.1Q]#@&P.-%=(9;CF6XGD<^I[E TAW/=%2)ZGNPL)L_M
M2'=&A*%#W>$KTQWKSC"[=[ []\PU);]^7]7U)\7*^]5R/5]NE'70QG>OEO4[
M(5>5Z%7Q^6.^7.F _:X'Q^V2[X]R+I,YU25T<AI!JN\7D"AT7DB6P*A,TR*C
M4N(HGZU7:[*PV_TGY-U)9VTEL#_TZ5=\:HI-,W%V9LA/.AUNNK8-C?I%,_ K
MT,L3["0!.U$ -;* LVGP-P?%S3ZKY:\&4BPM]$B=Q*&KG4T*?]!*:=-P_@95
MUB:=DM,5VJ9EP6TG8KKH7_4Z^_/KC*5Q*267D/"H@(A&&)(R8S!&.,Z2""'&
M(ANK<S?DR+;FGY_O'C]^ %\?;Q\_?K73WSUQA]6JGQ!NVLZ.?VM5=,SRP#U9
M^W"C(-I_['1#;ZA)ENPQZ]U*.O$;;U.KTLER'T3SW[OE-HGN/7F9*PM@F_M)
MXBAB)8YAAC"%*"L+2+'Z6Y:E">8L(I@X!7+9DQYYP32I(J:2V*YK$#$-V8WO
MI)<J\A_.]I MNM;FS B8.9[\=JDCZ]76T2S 9]W"H3$OU,_?D_J;/C5]GW/!
M=4FW7_ZL3>N@7WL)N;>Z0JM)Q.T$ []THOVJYV/W:"O>* FY[JB&,S)L"4]M
M(S@"<F*+=QTA:'GH9DW?+3\(*72ZAGK N)5K[9YNRK4M%JL?VE'558RF4*8T
MA46.(ZA4F?J#YTE>TD3&U.FJ[WJ6IE-X6]I@2SQ(&6D7_%U.<E.AZNA[MBXV
MO4M+[!@VSS8LGYJ-R2I0>P Y;E%J%X9^ACK5'@!:EJ[V&=E/F_8H],LGG O]
MG:62$88*!@NL%*8Z$140XRR#/,,\YFF>B,PQ\=J1 ZLU?4TJ]BZ,_64;QB[<
M>G[Y@FNG%\< S"_<MZ_0>JS<@,%4@'"*S1.)0%K,E?JD*LL3FD/]Y#O,Q*7U
M=PG5=;UY;FKNZ@1"IE;_/U<+-8RN_J/WYUE,6)F5*85ICK&N"\<A3F-=79\P
MF<<,8>Q4M&4"GL<.)&B)@N];JA.52W>8-CO5^)--AILZ#5 JO5_O82?(#=A.
M\4X68ZW^!%72W9%_ZQKI#AS_>U1(=Y^"8/71/4C[EN]J.A=_)-5ROGSJHLN3
M.$HXB1!,BC*!J) "EC$J(<\3@G(J\P0Y5;PX36;L6!/&-L^;IM25VK#G;.YH
MIYX!QT[G7B^RFYKLZ(&.X"B%O89D"E;<ZR21B0M\#0EZ7.1K\.DK_7FWF_4W
M<^5G"A-(42""U4&3BR2#B#(":4H+F)$B32*$$U8ZK<S39$9>F3WGT):LI[=M
M'QU'#YJWS%YA"UK<_[VIYC6?M_T9 Y=S&)8KM)-JG\C;.)Y."GK6F73Z:4\'
MT;QFBY6.[6X*M72;>UOPSP0<F[V=]O;V>GO+I797GN.20Y841/<Q(Q"7>0PE
MCN.$%"@O(Z<JO->Q,_)R/VF9]XQWBZNL,>; TJTT&;+^QR)/4-T=2T&P".5G
MNHZ9:=U.08 [\D*%&=5/ >I[;?W_VLGUG2STR%^$&GFNSRCZ%[=+OO^#WI,S
M2CE.&6,PQQ%7!XRRA"6G$61Y*7@2\2)*Q:QI<?=U32K+!D-7\>2R5 \YL[]Q
M5#1O -,Q 6)'VCB"JRUCYO<W@(JG^5(;E+HJW*NPS8 .,T&%P(P4.(62I&:"
M(HACG$!"E+69ER5.,6XGZ./2\DICXNGI^!IE<H3ZX1M,"Y62%!'FL* DA@@5
M*:0QXC"7:<KRG,=Q3EVBM">;$M^XZQ9NFTF9<A[L;(?)T'4S'9KOW 0F[>CI
MU-@MG,T3&N.#'^Z]<"KV.IRQ$02\0+;&=;Q,:FH$@>W0T@@SZ#6.$-.UVOA'
M._.]$"(5C,?ZHCU5JC##D&0Y@9(6,F8"IX)F[IZ0(SK3N$*V9+T/0^=@<G&)
M7"6\ET_$26Y/A\A9J8)Z1(ZIO(%+Y*RHIWTBYQ_WO*@FNF[MU_6*_4M7U[R7
M)GF=&&]7VTLK+O.H1$Q 6L:IOF=.(<X)AGG"D(BQ6L^)51:!/<FQG1ND*>)L
M6'"\(+X,E^7];E 0'/T0??E':#IF+UNH"]#+!*>]O[0&X.CZT?Y-WZUYFU^T
MO;'<.25F):,XE1A#+DBAUGHB(:5Y"@5):)8R'"?2R<DY3&[TC7I+W#GY81 E
MVPTZE.RN^W0O:;(71[&C'7*[MI$QV*X]2&SBS=M&\.,]W.HMWZ6]5I_!G"Y$
M$V'[6:P__LT6&]UZ]K?5BO^8+Q:SE) <97D.TQ0+B)CZ@Q0Q@3@JDBQ/618A
MIZ Q&Z*C+_..A3;SR:.$M15VMLL^+"*NBW\+QFT+ADYN^F7+ NAX^#6D%K 7
M.9@NL" YL4:P!^%8+SB\ZUZ.QMPHJ./_0J<SF8SC6HGVHVD#TW2 ,9E$2$8%
M3#BEL"A*#&E21) 3J7[.A1!VT:26]*:XOZQ!U;#0U!T0A@G F^8W+PZ-;VPQ
M'%80(R#C<?^HZ^LUH&CRH*'?=01RZ09D"XI]>9S X/A5S+D:)*=R.@XB#U38
ML1EELJ([#B+UZ_"XO.:F >MJK3L \ U;U[=+_E54W^=,U.UQ79*4<5JD4/(L
MUHT#$:1Y1&".)(NRK! %2FWTWB"5D;5=2]=X_UO"=FMX&)IA=19,8#<E=D+6
M@"X,*Z&&3!@U0,]\4?_:F2[#8T^R/JW$ZU:EW<.>H0B;>KUZ%M5[S>]RW5Q$
M?9G7_^H*6^9EP:-2P P)#E$:"4@SDL,$T:@L)68\<;HIN$!OY/7940=[Y(&F
M[W@#>@$VNQ-*0##<UNX #B.$/EN*&>J^\0*U:6\4[40_NC.T?&W:JN?;GO?;
MNKKWF_6];(MGJ_T;LR2/U)$EDQ!E2$+"8@9IE!58(%+$&9NBV/D@ER/KEUTI
M[&TA[&2:"N?#<V.GCMX<<3<E=G4]\RW?-[T:YJN-Z6;\TU0QMP+WC8N7#_/X
M;U&SW KF4*7*[8AY]U24\[6N:#?#1!(AX@1&B<3*=F,"8JK^)E@J8D'BN,R<
M;+?=T".K4>TH72@RSMT/.\GM])V?/&Y*JE?0JBF]:<I4M1[@AU759..NU]6<
M;M9&6:F=8_22FL>2AVM;V T\=6/" X%.M!X\?,*S!8 I$OE5=QLPE0L^??\\
M[ZU_L]YGF'-41"2&>2RPSE&)(>:B@)$4A50_IR1'3OT +(B.O"C;@K#UEH<;
M\-S;=>>:!<?F #9(VBWET/BX+?(6FJ\]:#[]$WZ^V[=+[@81<F\CX"!RJ)X"
M-B2G;3#@ ,)1MP&7=]T[(.J8SC9$[,-*U)]7ZR\Z"+L2VA;X+JI>.U[+%HGV
M(XZL"GJ, *XX <O5&E0-+Z!CQK[+H@-2P]I@/)#<]$$?'\V$VM#7X,L!/N"O
MH/V*_63W:O?H0&:R?I#NHO<;1GJ\[6<\]"H>G8IG*LH(Q[E.Z$ID A%*8DAP
MDL%24I)D6<H2+EU25(;).6D)WQR47N%;-^O@ E1V=D$X -PTP%[ILI%#O^QD
M#&0"7" VZ>9O)_CAMF_YEF<4-_LF^$:'CK[;U/.EJ.M;IA1)/6\JTK_V_M7T
MW"XQSE"&U$%!E *BO,2P3 L*191&&<*HQ(5;[3!'!L8._VC9 ?<2= R!/D?@
MW6O_WV[=S+U1MU,>8V+IIDZVT+U?/=.N,5NP+NC7RALJ>-R5_+2AY)[@' 66
M^X[C'FUFLLHV;&TB-TR6V3:WO2N(]7FC[Y/NY<.J9>#C8FXZ_PG^("I]]S2C
M+%%J*4$045Q 1#("J<@C2)7BHI@EB<RL.U\'X6B"P\V6QS97MBF$Q12;-T!T
MA>^6AE-]6?#2\0K$EMD;'=BFV06_/.M^.NMO9'D^TG.DN1O6<V\R(^XGJ?W)
M:!DT;2E[50@_;R=CRR;XV)N,EM.I)\ ^YF[RB?"+RIML0IRB]X*"-Q#?%X;.
M9!& 06'IQPB&'=A]9],7)*3^=K=\J%9,;:&*'Z$&T*G4'_0EVJHI?IW+(N48
M2XAU7"&B(H$DB91Q748QHJG$*4ILMRX[DF-?C*V6T)1SF"_A2\.'KN1@&#&+
MD>]8L5=UEFA>WDS"8^1XV=;0!W=+T'( .A: X@%\&!$=>TT?'B4_51X"+2<M
M[2;X@!JV'&@R/>LF6%^1.K[IYY2XKY[(<O[?31L(I8E7BSEOJNDN^8-6'^V7
M<R\_*06]9'.RV&:W[TJ^16F6\2C3=YA40E1D#%(>I5#$)$I9S#BQ4Z9!N1I9
MW_9Y-#5;=EP:==OG4YLZ6TYWQ1EJ[ZH48:;-SM4Q^62X*?:IYL'991(4MT!^
ME# \3>I<"0KCH<<E[.".QJJ8S][KJJF5(.]77,P*5)"L0 @*D0N($ET6+D\S
M6)((Q3+-LY)8Q60=#CRR(M2D@*8%-#%+X^E0]@L&Y!42N6D32V'L;9LSG ]<
MKJI7FJ6L_K);P4<#36/!G&%_:Z><^[U[3(0IT/_X_/2_5C_^6+[,WR]KKO[M
M&@<Q/,K(*\$0!X_Z+/MT Q0+X(_/#W=F3YHK$(1ETJ8%&L/+)2P0;@OH(@8C
MQ#;8R>H5SW!AZ,EB&.Q$[,<M6+XQ;9K(%QU1I1U#[T@]K[>QSE_%>KUH-M59
MC J:\12I><@CB%(10U*4 I91G$4B$7&)R!2Y(I=9'?M^=$?)&+(O;:'A:9)&
M+&;*[OCP<^#OIL2N3A_9,@\,]WOY)#T)WCZ%Q![E-\XCL6#TWR*9Q![P4!DE
M#A3=O>VW3^_FJV=%E_VCZW%$<1(A)&$I3"EEKO2W(!)*620R20G*F97^/CGZ
MV 9<0\_D8?S#W@U\#,)E?_A5HCF:9'VI+N?P6HAG[]"^2DP_W[7=)#IYI\]*
M,>"(/GYG,I_S67;[[N7S#X5L[3L3&4M1'',HDDS'B40<4A9G4(G$&"%YEL=E
MU\'WT3YZ]30UJX]KOUOOHWOPJL[;XETSVC7YVS5Z]0Q2=N;4%8('[KK[>:!^
M6Z#>NH%MCS-$?H).N>?V_ M/^ZU4-7&ZE/A#M?JNCN3\W>N?M>!WRZ;NH;ZT
MUZWF#:'M34'&4<:8.AS'D<P@RJ(<8E&H11U1A M19C2A+H<R=Q;&=F+JVTZY
M6/VHFSID\XX30+:L.-8G]8#93@6,"YZCOU3CUG&BV\7^HIE1\/T*MOR EJ'7
M?GZK#JMN^ARHQ[=M#D:YB/''*Y#>\6!@4IWD#]"AOKIB)#]=]IM8JD]G<;OD
MM_QYOIS7IB#*=Z%#C9:UF&69+"1"%!:1KI6<IKJ4*F4PQI24<<J)X$ZUDB_0
M&UE+M=2-.XCLT7=339=0L]-# ;%P4SI]&/9)@Y9V..5A*60@37&)VJ1JP5+T
M0QU@^YK[%='#]Y<F1\/R,JA[?N15^4!>P?=:1ZW*5?5,%+8VN5SGI;M\N>,C
MF-L2&Y0I7'K)*6&\[FFV@TQV(W/(=O_NY>AW[HZU]Z2J7C^M*GV+HWN4SQL#
MJ2FRV=9^S!%#)(L93+.XA"CG!)8)RV&2E(*F64HC;!W#:D%O=!-<<0 Z%L".
M!^>*MS;87?;0!4;$U:X>!N-R.4TO5.P=>X'1\7/U78^2DQO00>8!QZ#-*).Y
M"AU$ZCL/75[S;@3]LJK)XK=JM7EI_B'XO7SWJKNO?%ZM^^?'[?&Q;1%OZJ1G
M#,>0) C#HA0%I'E,8!;+E#&$,B:MZ@6'8&9DK=FQ!@QO-Z#C3H<ZJN.X9O#&
MU)@X?>!V=5U>,RN6#LZ)L'9T@UX)\PBE4T, %:YGM#\K4W>,OAJT$_VBKQ_3
MLV:(+L2N4ZMF,E+_IW4<3:@N%I!32+.$09FDR@H411))X50>I!O927]Y5P(Q
M=?QU$JUC(9"M_ E'22X+ 0NI/=14Z7U<9 CBJ&24E)G .791^7[R>UJ]VB&J
MA=?:1/QMTFWJ%Z+.7+\LA?EAO:$-1'-3+] R6?@8)3L5["6[FSXU)&Y,8FC
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M>] >1CLK<!1PW#3O:5QNFO"P5_!7^]]1+#YG\4=,#CQ-]\W3_ ;AL$G8&Q[
MMS>+[NZXY/4,DX2C@I20%C&!*"TP+"G+8,[3"&.)D<R<*HUN1QY9&VSIN+8_
MZ02W6]]>XKBMW\N2>#06.> Z6)>0;MR)6WX<B'/<O^/P =]@GX6N_O9 JO5K
MVT\KH@(7.8IA1M720"1-U3DF(3"B:1)'@A8".ZV/8Q*C.U8,06 HNH;J',%A
MMVJN$]+5]='(I[T=GU?+JB>NB8T.UC_LLG#! FZ."$P<7G-.P.-@FK-/^BW
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M';%KI\-.4G'24%M:UBNM"0E?F+3#Q<5H)@=P[#3/U2*[Z9667'-G,$KXUJ!
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M<V";W$_Y6\9*]:B:_74]X1^VWT1YMU-^H-A>_^+%">,BP F,L: 013*#E*
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M;[I3^;OU,UD6BUP&619R#C4!'40LS"$)0@G3F'$NL5I>,2->.E.!$T_4(_%
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M.GK\+U!K8KEE:8RAF2^8!!D[KU"+!7],<Q;8UCY?NV[&<N?=,+.%XVRORWH
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MYP5CK==-ARVN[GXRR=:!/Z1\+2G'*S3O.M,;@&>+3W\C.Q9.1,>%$QAF89C
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MW^:@\*_J0DWPI5S;<LU_+?6<"&06")PCF$>Q;#+.G*IP19*8YSC&@EFU:)Q
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MZ_.$8)F[MFE <_-W'L&S\HCV&/2X28O!9O.=]@9V':K#W7X82(XBM#R F+$
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MKH'H"W,Y*HM2(,*2&%4)ISBF55)B9Z[I_HL#V_NA0AX#2_^Q<S0Q%0W,:H]
MII(98'"P,!79C60&PQ\5G,P .T<!)X_/2V: A_?[5_\?7BGW:;71I7>;3TWS
M\)W=;[;==\'!8"W#0^_4=9'A2;GJ)OK4+'1OR?:X7FU?-XX7WFU*L)NX)_S
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M>Y<G6:BB#)DGYNM%M*@/1"/W(%S@PBEE=#CNRO_&<@/UK6NEJ1N^X\%B'#J
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M,VCR/XIB$E&T;B3PK P.W$5E$ SON9&&!]2(=UMW8[VG@#Y@FH75:EJFZ9;
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M!@U::C+:3-N$[4??WJ9BV+YHHX/;D6H:^)[B=Y(?">MBF-V-+@B3.N->"&^
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M.>4J0U^?'VGPFG8D,][*G+P3S6=([21HE'?3?8&PG6I&@;0MY;1W'NOW?X]
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MP>YSG:A/D?-(D'*<*4;4(5A60#HRP J% J]4!HZN>&LM(W_SQ9VG_17GCO1
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M^I;[$ETY&5]<SF!"T* <.>8NZ]J!W%D4B=N8VO<+W$71\;US[OOT^]#.=<'
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M/YH<M\U]0^9R\0/Q%YQCF:[?S\(AWMU]G]+06CY*9+M;T<MD1-?H9CU=WL+
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M8L[3^GQ)8CS80-WW*4WG^#Q"9+-!/M?6Z1KA=AWL3])Z^FVZOHZO.G]=,6%
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M7[Y$3'8(-0=.:"CS7PBXTB62!AX3\6@3K6V!ANO+=]]_^I&D7SV0].JZ@(5
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M8P#KO4\^*AUB[?N;W=0T8KE&#10JZ:H!H_8IYJ!_XA<Q;.=I^W?7:RQ:)DE
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M7T=7#1B[K8S<IK=I)Z2S! @)+@M("3"<,V!)(G'2,E]]SN(SY(S<[J*.POO
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M"TF564H6L\WK=:3T@LH?O71DI1^BLJZ&_,96//[U@'"64<\I\2"R*YH=?*+
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M<IR0&X#)JS]Q%IZFNJZ(ISJ C3(';L@C9F'$)&H/$GA$0"]PV)][OSI<(PW
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ML^RNN+7^?VTSH\O!1;+ >3D7$9Z2('MHO\>KQJE1'A 5M<4[,EH^3./]/ON
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MU=.R>I+62-[ZZ<'S\GB-HS4Y\MZ\A:5WT_SHO*V5!G'+O-OP,<Y\T?C%$RN
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M8Q<W/&8U/6+UEK$OW>OLW\>9G\QC6 ^OV\SB7ZYFSA,P[DG>B[@E_5IS'TK
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M5 Z_E]GS!15O7HYAK=+=RBT)KYZ2\,MD[B^[^?7LO@$_=4GP9#UP84K=#UI
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M:O6VJ)HZ:!M2Z]5&LTQT)AQ2CF]!F)!=02XL6$R"<I)I$K6WJA>)&M="585
M?W@=H(_6 +;Z(H8/Z?7-'Q&G\V5;T2_?<%KFNKWO%B44Z::+R?0Z_]+W.%LR
M?GMS'#!HK[TK1R,*A'79%0C!0 A2L6"DU-5G.-6COEG('@*KYT![.ATW@.Y5
M4Y?/69&Q'-^]QDN<^OCY6XRE =ZK$);^"U[>A]CSUS>/Q#7/C[B\#I/IQ7:Y
M+"V*1.D\N@0QF.SQ9.\-T!E=2@,2X0Z5<K738D_#62O7"_7\@P81T< ZV8O!
M!XE(FI.\B6(6O18Z6Z6(8*+AX*@F1$EMHJO=;_E 4L>U[RVB[KE-8B (C!VB
M7RYP]AEO]S+OA0U46] T9,H946"H)2!(H-3'TFQ](X=_>WS^Z*D-^1%#*;&K
M(M&1L?!_;Z[B[").UY0G$JE,G !'GOV:A 8LTQ&TB-FM"5')T.>LYO%3QXVN
M3XV%(R3:P YXZV'<WQA+I,FE;#V95^5^-W.1+:B%$"-&:K(?K&HW.'I"1"O7
MZ_7\K^/D//9\JS7Q]RE7O[QY^X\XN?BVFJ!N">7 T/N,<AER;!8X!"-"3"*Z
M;/YZ6)!G7M'&!>6!BNOJ2[$Y,/SV\<TF&];8;/*BRI^T$\46$NHD%WZSG71/
M,-R]8MR]94@P'";%AK:0QPF97Y$&AS&3[0V-V15290*W4."5T4Q*S;FNG>&P
MG9)Q@_DZD*DHZP80<WN7]J:[<I/I4A5OLC,V"6NW[,L,I_,59?1K<F@4E]FA
M"MYEYUIFE\R2_,E:1SE37F#MVZ-]Z!O75:F+KL'TT@#F'H4%ST<%FXE(Z]$A
M.4*(EJB\K"(M$\5B]NK11@U$48(,C5-8N_C]>*K'[6]?%Y\GUF$#J'UUU<T6
MDW\M62I=VQ\S]57%I)@T%AQ+$@0/ JS0'J*SCCF5.%)=&9'/4S1N?_NZ:*LH
M^VI(&B$?^KZ%W^WO#948O?M-)\N0[LGL**G23CE7:C,@&9*Q+(*&O-,*,-IF
M(7N6+5KMSF@G396^?=FG[O+R;3<K92Q?J92!&Y;938R H-R $YJ!HU1XH;1/
MK/I\HJ=DM'$"41\ENZ*+0S70P(9YR\)7FS=SPE0 8FPVST3;+ =O<H3D;?+,
M.E[];OKVW6W Y6 E[@#%7A(]& G9?YMTX?,"9XLA#R>T8(:&%,%04FX,\S^.
MA_R/9 QE&F+0Z!&'$X.?9]7&RA'2;J?:\):9+)@XN9BN(@A_LPR"+Y<JNA\U
MD -?QGP6%Y;T(.$9F!Q*@!&62B\%26HH8_,R=6V<?]6&6&6M-#&"Y,[4"HE(
M2V%3".5".<1,>> $E)!>E.1PA4.9IS;.LZIO7OM(],C-Z]=I:"5B>^(O#AZY
M[7KC"!%<+^9'B>04)A4)4O#!\X+HDJ^4?2H="*$$8U1TJ*N1$Q>]OIU,)XOX
M^^1'?/+:U9TZ-TI+;0-P6XIF2N\WE^TR&.71.1Y1!UY9%/VI:\.1KX^IW:6Q
M5?750#CX##^O;_[ _^QFRZSS918A>BTS^1)(:48MC!2 '@T0JI.7)%II:Y\U
M[$%>*U6U=1'2G49=;2/QGK$'Z6B*H",VNK*>E\?+"JPM'8,#=9PYDIVAVB'%
MGB2.B\C!H-(?DD?KK0%8_A)_Q,ON>XF;_;=I=]E=W'PJ22AWA2_>R<"RP+P+
M"()0"T@D!YM$0.E*;4[M0^<72&H6=L?#8?.ZLZ)N&H#:NEPZ/"/"^XN[2 ,2
M+0,H*C)OE 8P!!-09CQ/-,=ONO: MWWH:Z6 >-#=>#"%-0#&9WCZ;58.C[C2
M'!G1P&E)J3)HP6'>/3SU)B:'@;':59TOT32NY1L.#?UWW/U5TS;47GF_ZLP7
MP\-L@Z\>-2^M^,!104$@86"=U:"X#4;__^R]Z7);QY(_^"KS CG_VI>(^4++
MUAU'^%H*2;X=_0F1M4F82P)J )2M?OK) D&*.['4P2G0MSO:;2WFR>5769F5
MFV8%5>OM<[M3.:X-[ &.+=37Q</S,SS^GE<3R8LUPFE(P1E06M+]D8(%(<G]
MB$67$EJ78#Y/T;@IC1Z@MZM:.ACOO(78K@K@Z31]RPO\G/]8YG)Y_MNTY DO
MT:*S%+/5-(Z2)=5"KDA2#<;(@JZXUK67A] [;A;E:  ]FDI?1P'=+\O5]*(:
M[;>7=1_4[3OCE[^^YMERL)FC^] P0LIF3P&-DL1A!%Y7$$'G[ F^R  % =ED
MQ)25$IZ=].32Y_R>AWKYG73PZ<]\_BW_<SY;?5E.A+,H:JXUUM'KF]T#F"#Z
M7'.VR64\8ORT!<6GE.S9!7N[^+.-]=IY\/60V__.N/CTYWRBHQ1)V@QI/6>6
M14ZN/-+5I),))2L=<NOA8GL1VD?U6&^8W4>+IPE5PEZ>R&*XM9%!BG4WL]$%
M4"8&/DH9G+5$Z[B6]H;4/BK1NH3KSIH\2<"^G5\N)DIZ%3GC4%)=_^S(Y0\F
M(7BO@R[<2"U:IY3VH[2/4K@>X;JS'D\3K?1W)]P623],0A$^@M*1HE2;Z71:
M5B*70OIRQ*J09RCMH]&S2[3NJL>30^M9H2_?L(HNNUBW7EG,=4UF$H J!!!.
MN:!5PAA;[]\[@-P^6D9[P^W^&NT;O/7=6BO!M2 /AXFZD\B:6HY#W!@**QEY
MZ*;@$4WJMND$^ZHAN*M>FN43!GF0_2WC,B]_S)?\=5;FBXNKN<)[O[!N\4,;
M/IGNRD*C-]#-9Z_1II)QBFL+AM?)FDY9\,+4$3/(F2>;Q)O/MKY+P:&FZ+=,
M\,[KG_ES7L;%].MZD,E5;0Q7+$H*MVQ@6'=X.' I$W,^J^(BU[QYB^@SY(S[
M_GB WN];F58B[_LB>U!DZJ+T@4>RR3PJ^H>2%+=;DF!,-C,65<8CAK5]E8\W
M@\0!]>*[Z*=OZ#U::"H,%QJ]@U@DL9>3@Y"9AU!<SH$5S+EUR^"KK1??"2H'
MUHOOHK>1)S_69:-?UTW=Z\MB4X4L;=%.* '"UU,;C8;@0@2N5!"9:[16O>!9
M/?G#NX7,X:J<MY3KB,!8+E:3#R2;?-5IX;7%P"T(46K*Q1D20:D1A3?%NTQ_
MNE7BC'[J+0M$O_IA?>Y\<-P$6.MK;7]9]@" #6Y5C*YX@V!SK2<2@:)(]!X*
MZKJFTT89MII)M@T$QK02!RCKOKKWD-S("O\GF<:+RXL-X=8)J9/AP+0EA&.H
MSU-10B&S%]%S(>)6@=0+*K_ST9&5OH_*YBWD-[;B\:_;A >ID"YR\*:.UTO2
M GH5(+J R2!+6RX >DGQMS\ZCLEOIOB]Y==!3/(AKVO=W^-B=35P!>-ZB\)/
MWV__R=H>QA*8LM8#D^2X*$P1/),(/A>E&;'+=>LM MM3-VX=PE#!\$#:Z0QW
MUWOA%"I5Z.A9KWQ]H"K@DP^0&*)(1E'\UKI"ZR$5XX8G0^G[&5CM(?S.X'.]
MI84'+S5%:9*,-9VN0N:;;EDP3 GOD )]W?I=^R$5_<!G'[T^ Y,]A-P!3-XO
MYE\S4?_^'&=U/=E-6/[3]T_T(]8'B<NLLU*.3@[=^$KF""A%AFBDC8:9K$SK
MR3U;D#5NH=)0]UEK??0,L<K0]1ZJ)$/*BH.+UI"M+A:"J@M0>1'$6W$YM?:<
MMB!K7%O5' K;0FU/O70 M9\N2:+3V>>-+79"R^"X@E!2 :5# L^EAFBEC"*8
M*%GKCN*[%'0*H'T5_&!SQM[2[@ K:]O]97Z>?KWXNIA_6^_JO-EM:!VGR]I"
MSNM';2G)=>2U7R]KGCD)* Q2 ? X.>.^]PZ-HE9ZZ )2CSD%O]UTG?*DBI0F
M '>%Q)2\ B<%JR<DL^H<V'*<VHO?=AKI,EC][%!.5$L]= .KS9:7V><U7Y_R
MXN)=>3.?796NI"A]T5H"<F)+)3HC09L(.DO&A+)!#&"P7J*JQ_*+/4'P*,":
M:63D%/=CW)PM,KXK'S*>_[*LFZRO;X$)*EE$%.1Q^ECGT-1;7J9<$[9,)^]\
MT/=FESZ:^=[EFSWF.P_#T:!2[Q!-OU_6Z_Q=^:76:R[K:J&U$)?76Q\5E&+)
MU&,*@,R3+ 7+'"-= 7&;M=R[?+/'=_!AT-1$ZIW>?Q_R+/^)Y]7H3B(&HQ3G
MH$UU%7).X&I/%B=_40?%1$ZMBQ!?(*G'MZGA;KY]==$!M.XR<F^#1_3!DG X
M%!DD*.;I,G=D?HD'SDK1*33OV7R.GAY]]3:@:J:%O1'U+2_"?$!SM5[7>#E;
M?:!+?6)#49$;#\$XBFI=$N"T+B!D**%ZBEJUGBSV$DWC]J,=VV#MK8T.+-;'
M2XJ.ZRF9Q?E%GB@C"C)F(7'NR-[6#D\=- 0Z)[SPC%FU?E*X2\&X;61#(N<
M2?<]N>NJXO;' *HW\XNO\UE]=IN73^M.M?H7WLR7JT/[QG;Y1O,VLKT9'*:K
MC(?,#!D4X,K$NM;' EJR.)HN,\\PR\A:%V^T[2J[:T.K]"8F&1.%M& $!1**
M:82 4H#&C%CJF5,XJ(=4J1C[F6EO+3_O!NTLX XNI[?3&<[BE3U>3VU_5_Y8
M7G4/W)D5ZXTU6L4"V6;RZ23/X%T4$'+F= ,;(<L HZ:V(6WLMZ9F8!I"%9TA
M[-<9_=R\7&VF!TS(;>/&N4C*K[LZB[+@HD+ >BMYP7/, [38/T7.V.],@R#I
M$)&/_"YYFXVU;152!2PE0D)?4XK$@*O#4;+SR1LA5-8O>3F/_=RQWWX.UOO!
MPNI@[/*_<#&M:<0?#*2<0R[(P==QNZI.CT"7(N@@?'$Q!A%:MXH^(&+L%YQF
M)N$P\79PC=R+[:1G*22B.4L?*+93'(+! -[XG 23I?#6Z=,]HN@!WU^:(>,
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M$<YS7SMBY<W63!^YW$9K"EM*L.!UG=J9)*N#KBDZ54QGIA/GZ24-]%INPUE
M8Y"#$YE8*R@!@TH@!*-S:HS/N;5I>UWE-KM@8^]RFUVTU(&?N$T:W[GL>#(>
MBI("5.UO])6O@%Q9QJ-A\6@![\F5V^R$ASW*;7913L]XN_7R5 K#%#,'+[.A
M4"MK0)<X&,6EE(B1J:/%O:=4;K,3%/8HM]E%+QU [=G4F8W<U]'.%,XS.I:8
M,@3M/!!G*-$H5*YU\N#@).:H)3L[*7^7).8NFNBOB"LIP[E  1K7NR4IPL'
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MJ%C(*M[/;3YKHW;Y]CB+@(YMN ;31@?6[-EU- Z%%HXB"VUYI&@X)PB8+5!
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M@4<3QIVU13O@B9A5ODZE-)R#D):S;)1C16WE^K6@II.:PZ&]PZ,KKN_2K.K
M3-=W1IV_=>,PQUI+W'3UR)X?:EAFU8+5 XNI?LRLOB'E[!XI/T^7\7R^K.LP
M;VH1G>5:HX%2%*^;>!V@TP*RC$ZSHJ6T[<>)[T!@DT:66U^\&M2+ 9TJ3D'
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MD=J\X]Q?M5V+!DI)X# RL@(J BH2!*JLBY&H1>EF^]%+S(SC\O6%U>$>  \
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M#C$9#<I$N@1DC&!,<E%JKJP\'2,P1/]6?S?XW\H2#(GG5^T([-3UXHPI1<0
M/.HZ ]6L%VH;P"*UD,P;="<WUJQ=_]8I/Y2] A,P&))?]?G?P85R'J.TONY4
M\22S@ 70N@RQ>+28HLKN-<;RK_YA[A6<_8%0W'__UH?\+<](0SG./\^F]6?^
M/%WBY\^+^KY/OYJ7S=_8OVEKYT\T[-0ZC+U&[5F;3[REL_EF/EOWK_S7=/7E
MS>5R-;_(BYN>%BL=M\9JR-Y;4$X@>",T2,&YL:B5\JU+:+8D[=#KYZ[0WUT+
M_:IX,B:;'0MT@68DMKVS$ QFL#8:QUBB:[:U4_@</>.^VPR!E?MFM)DV1G1L
MEHO5Y/UBGB[CZMWB8UY\F\:K9@>=)"-Z%9C,:TUYKMD7NFX">G3!:I7%5EL]
MZ .WD$2_^H&BI[X]>D-=(ZW.&XJX#X@LSV9IP\%RTWO@72C<5Q&H(,D/R8Y\
M=V)'9":C3,IGM=5XP>UP\I" <<#21J</ 7*@@$=N\GE/3N,%QGRYFD8\)U9^
MFLY7.7Z9S<_GG[]O6DHP!VZ<UQ!D(<=5V0+.! ?".,4E=TG>+R-_M,]GFV^-
MCHU#U3D?4+8C8^7L\V(:+\_K,\'UYD9CG5=:4QA@.=G6',!I+4 K5#84)7C<
MI@'LP0\>Y]EX&!0<)K615?Z/.06#LW4P.4L_T_=GRVLN4LC)6P(NX[(.*>89
M'#,1"GK!F>6)WR_O>U3W3W]AG(?#84#02(XCH^'76;JL?8=K8_;+[-MT,5_S
M=+T]6 MM0@E@2LR@HN'@E2L0I6+D@>62F-@"$<]_99PGI6%0T5">(R/C)DB;
MI4_W;SB>C*CU7L!J<R#Y5^2*,RLA<2.,E=Y();> Q3.?&&=,U#"8:"7)D0'Q
M=CY/Q,+OEP3OJHCKE?9>L%)T ,WJII48(P5C(@+WB4L=DG<I;(&%QW_Z5C P
MIP&#!O(;VR3D\_-?9I^GLYP7T]GG34Q^;=J8R4EX![XNVU%)%_)_LX287"XA
M2 K+W38VX9EO;(4&>QIH:";+O3%![DN8-\K(O9G/8JX/?.NA1]/EOW_Z?C.P
M(R@4VE$P;JM'K"Q9-U]D!&VYCHGIH%7KJ>?/D#-N^4KS9ZW6"N@@N_N E<K(
MYK0%&5FF0P#2TIFH(\;!:Z. PFKTFM-Q2:U?UY\A9]PGTF8J?PE*>\J_ RAM
MS/8#CJZ=KV@5'3 $AKG&:?69L'9@H!121L^SP];3F9ZGJ#- [:OX^6!:Z !3
MCQR[G_(L?KG Q;_79T\F&Z..&D1]]/O_VWNS)C=N95WT_?X7G(-Y>+D1+5GV
MT0U;4DBR3ZRG#HPM[LUF:9%LV;U__4VPV1.;0[&((M!>WMM+UF149GX?$@D@
MD<E-(LAJD>-ZDX3&UNOBW;H.R50W8>N<B]YP*)JDUKTVZUD(CCN*% *BVD-<
M"-8!LRD.6X<DN*-,2%:ZB]0AF1IS62<QX""]3H"C 7H=N(U?NV.J%!<J112Y
M6WEZ@8S5%*F4*+':")9*E][J)5AK1#N%"]W8P#3 MAU>_]>'EW14)Y:(3,@;
M S$J,SGI Q-$+%>4&I<X.5.FS*]'57 ;+;EQM'6R*!0-4.O%9/P4Y_DW[%4D
MET$(0XW%*!+&0!>-D>58("%D(B1**N/HX=<3>9I,HQF(_*'U<2@,Q2AUIJ32
MBQ!6_[;3][/4S:]7'RJ94KKW Z,FE/97[<SII%PP19D42!$M$*<T(2U(0B$%
MH7+Q 4KU><.2LZ23I@1;:Z\ULD)A6/0IQ*^>*60I5B9*HF4J_=+P]:>3'L.5
MH]))CT&CC5S!YWEQE'&*?< (>RH1#[ O,IX&Y!QLA2C6),9>1_%_KW32HU ]
ME$YZC(G;H,B62RUEF!(4MLF$Y_LGS& ",0@[L5?.1<TU[G?,_C=))ST*TU[I
MI,<8N.5+7VMLC%$G%*W5^?;3(&US]Q*MJ0R<);'9T7B<2]\SIX\>!5_?2]]C
M;-D6)^Z3((GQPCN(\;U02!EGD&6PJZ#".4:XUR'VR@K:-GB+Z:.%6## >I47
MCB]@^=4+Q5]B=S6WW[^MDJ&SIR3.&B>M0R+D4PI"##A)&1#1UAF,N;6T5P>I
M PO'3@$:OMT?&F64,79MQL2K3176DR@D8J3'8!$>$N)21^0HH<A[&HGDN75H
MB9<K.P6HM[P4 K8K;>6*5/'=#6SK;B]__P+ND">1&Z$9C@GBBL//$O9(@H^,
M^:8XZ7WM41?1_Z^K[L?_7H]X1XWU+QZ9\?B]BC0H UIWD@5;/-1]DLYB/8G<
M1Y;7UX"XCA@YXQ2*42::+*RSKO2=U*DI9'5NTX<L,J4!:)%+3S)9O!114D40
MQA+"[&C N6J?+^J\!E4BC[ITD\M7F4)V%.1'I) =8_\6J+0^7-R5O80E%9R#
MDS9&6\2]A9\EE\-V'Y,(,J18/"-QOTB-46HH])N4*HA#"[0ZE+@2A/?$*XUH
MD!%Q :H83#2HYYDF6,,B?H:LZ>.SR.K<CA=>]X9#T22U-E)50DK>F620EX;D
M%A<P#8,G2$B23/!>8S$^M5Y5%ME1##@VB^P8.!J@5[]D)1<9P32KXKG-;^!A
M+CJ:D+1<!-B6*%*\3=W?(8OL*"X,RB([!IC*I\QKA3[%^2H3 4SWT4TG=_Y_
M-2W71Z8:*4)$?H"ED596P;14449#&*<;L=?6 ^=#WZGS%G6T=:^X:1NFR7UR
MYG-M&,]-9" .]9P&RD+PC/@3B5)S'2N/:$^J##!O9;+\*]HY>7[C<B^VUAZY
M: +R0D7826AL>MU7/1FR3?B'H-2=;K(6D*;;Y0[8(Z/! ,FPH#3F/(H^C]2?
MCEGGJND<6 \Q6@M@L^UR,TF04XXA$HVVWCI/29^7Z$_'K'/D>PZPAQBM!;#Y
M<[D-R,W@!Q5 ><(=BI%'$B&F]=;T!9O7K$=S#K"'&*T%L,46N2W\ !Y))RJ1
M%"Q1;U.@N$_5NJ=CU@GNSP'V$*.U<[[P.68+3&976^WS[J_OT2]C^#JYAK_R
M,7V!WUTDV/'"GZT:SN0JU]O"7B$$^#5,$<>&)T)3<KQ7!=7C#R(*:5"G!,[H
MIZX586Z Y ??Y4!4C<%I$60"Q-A<*]BMX6@0^#%EL Q>%+_Q+O(XKGCUG=&)
M6!2*-HY"=AT!OOO+3V\"S*2+Q2+"/^&K_>M#-_-V\>T24TTQX1$9BQGB@03D
MM!2(*:RE,K#TR"/.T@9(T.0#@8$L>'E\,C8D#?BTO<\!*4^)I<A12(:#5X8@
MQ'*A$'<\2BUI3DD:^\[IV%>9Y\X3/8ULQ6%HI;#8RW=>,$^6'^+RTC%)=60)
M4>4$XLI8Y+#S* :3I*0F15\ZMMLG3Y-Y8<5(50:&!OS4[S,WF4YSUYT[G1:?
MHX^3'ZM (J2 \XX(,9WK.$/\@*R#28(Q@6D3I0^B=-BU1YPF$R[*$*H4" WP
M:=O<^'5B0;_)\O;Y"^O_B>%2>**)IB&'J;DZ?(+U/3()NWN!/1B1,^G/X+1V
M2]CD=>=X;JP05*T3\9(0FJ=.1"KEU )/L@4Y [9P%Y3R1HQ1.G&W0$V>:YR!
M9D<!T0"K>AW47/+ E*+4HB -F(M #&!ML+!KP: 49HRID<HS[!>LR4.+,BPK
M#TP#;-L[==Y^RZT1W\^^3JYCFMOK[6?G=X>$DQA>.O20)&QY9$1^U:[1Y%*3
MU$7@%IB;>1V#+)V5-JI"O=BM7R6[VR%"\[/BYOIF"JK^B&_MTG_[_?M%^"_X
M._E1V==NK?J]P7Z+=G$SCQ_3IWD'R"UR:BM6L$_32&%K$)=1YHP@P$APZCQC
MALC2-7#'TZ;7?#!_P_EP-@HT,!E.OCGZM&I'2^[OC"Q*3G.D:.!(!VQRPQZC
M8Z)>A-*UE4K)WN^P'+]*IE?!M^T2=.LWPD]*LA4N07?D!PJ6H#M%M4(EZ-8B
M?([?N_DR7\7<UQ%S@A*6T^0-\<!B"3LU)T.^8 R6!^H$"<5;O.^0Y52G^>$F
MYX)\3!^_QWPS,+M:?VAQ*3##3N>YD7BN8N(X<@QF28CP(Q=:I!@**[E3F+IW
M@$5XL.G-RAB^@67W7I$[\^2#VB>:2.DDIDCJ7+E(>8MTKH^EG;0,0NKD=>E3
M\]W2U+W:&Y5#)YJ^<G+"O19ONWE<W1TM+JG!2D62D(_9*-@II&5@*.(4,(9=
MV(O'TUN3#EZ.7/<JKB@)"ICNM04W7_RW&&ZFL4N;EGSRE]SM^@]+1CW#OCQJ
M.%3 &&/'28:##TI8(> W!3(3AK1E @4G14A8>R5+E]08*TZZM_;'?=9^<V_M
MN^PS%JE)?G4YA 7BG(+ZU ;$DJ.6$Q]3\1J] \1L-+8ZACN;Z^+88#40=3T4
M"7MSLX#=]6)QO_*OLEZ-4)I&1E'(+>ZYASC2.!Q7391XR!T(B\?N>P6JS+&Q
MZ;!)OV+8M$"T]?IQ]_" 89LKCTDDB0&1=0H0LB28I#C*(#6G 9=NHO!,@,I$
M*@?L)F4&6[FMBJ\7L_!FTBVBOYE/EO<S:K%^<.*UME8IAR#8E8@[19#%7.<*
M=DX8P%VR/DW#C_AD$VO;$%!W5X4M9N&VB+-6Y+[WL0?W:I)%.("%N+42.9<H
MHLQCDVOX>R^/9\JS;]1[DCT:H+M),]RZE5GRTC+W3:^"-!8GAR238)AD+=+!
MZE6RC.<D<JW[%!C?-7Z]1]SG8$<1JU:N'/RVFRVZZ22L0%E=+MU5)V0.,^(3
M;!O +IR8@!RG$3D+NP85 X^BU]'\@;+!V[]>^8CQ3&%N(>LWQY_[4DLX4)M(
M .\(BN0'M<BJR)#3- 5L="["/ J#:M>=+H'I7HH,,' #&Z 7%S3WOM*[:")S
MB"G/P>6"\W5<<.0B3=&P*(7:5XAZR%9HAR@M468(QEUY@S? F[?='-PO;!@_
M=+/GJVPTQFB3>S1Z"O%7]!9T@%]:C$.,1N=DA.*I53N$J=<_8Q3NE#%Z ^SY
M-.]@&BQO/TWM; E!X+M_WTR^KXX>'BLQ*X^9LXPA(:)!W%B'C#04%N]L(\T\
MW:Q>=C*/>HA5^8KMS&=]I7%JF7I/*C;#_E$PGCBR)B=.&0=SE <-,8+CA#EO
M7?'W<#W$JGO<4YP*?:DV$)?*6WL8X$&#M8]F#'-LC4 A689@;:?@]$%Z$96+
MVF$2>)_">R]';I080X'KBEFQ-@>B7:P3%];"$Y@#,<+B;U?-S+V ?0=U"@DC
M<%)4I"#[%.1[,7#=K?FH##C)AFVTFGS>5I'A)&!?";0U1-^5[-=$Z]Q6,<7$
M5:"<]EE<QNI&.MK+ZG.>X)QL^3:8LZ7]'H\X2>H8\ESG_0,80U/E(-)G0ON4
MO6.) YS7TJ3T*$Q[-2D]QL -Q+-KZ>_KG'.CI" 6:44BXM9P9+PG2+*4(D^P
M\4R]G,M1-]A/!*C.CE,!?7%S/=2Z#5!C;9*'5C%>@SL5R#,/@9,WN=.F]\@P
MI:*7PEM>.EWMF0 M]C(]A1K#K=L -?:LP+\^/&>"*(T99?+9E//K^S*&(X1P
M')QMP!;CTM6K^LA5MU+'V=.M2B/5-OO6S^ >$B6%Y99(:I'",3<%91(9Z0RB
MC#F2HL%,GY&#&](UD8!3D!G]J7<*3 T0<$!YPDN%#0XZ!D17&4X,++DJBX.-
M-93+Q 4MG1PX0,QF*7D28X[K^7,R?(W4 %PL']X8/Y@-XDRB5:YD(CW\P!B!
MG8\(* JA4I*">E.^EL<60=IZ;U;<]9UN_ :\W)T2OW1=>!KZ?NFFX=+17,N+
M."1R,Q,NB4+:*Y]G@S9><$Q(Z13ZW=+4[DYV,M1;R7.RW9OP0I\!#!#A&RCR
M$YAHVJT.=G,=@MGBB3-GBF%J)1(L6XM3AV#N>41RXU,KN-"T=)362["V'D06
M]U+EP6G :^U5ZE(K*07!!J5<EY![K9!),B(:N5+2!Q>*5XC?*U!=WS4" 8ZA
MV%%H-.'.?HFS.+=3T.8B7$]FD\6J8O2/N&DRKT$/"OMTT$0C#O,0N:@3\C1Z
M89*AR94^+.LI6N4[G+%=VA@ ->#4#JAU&9@0P@F*;'X4RBWWR"B5$.')J C!
M!DVEZY$=$*FN8QN%!L=1[2A,&J#8GJGYD'/Z?N9A@_QKMU@\6) Y3+$AH*7/
MI32H-/ S[A##5D@=M5:Q]((Z3-+*Q[X5#]M*P=< 2;>H<HD32RZ0!+NL? GC
MHT+.P\[+J*03=Y'X4+J?P18QFCTX*X;^KD3T@5!43JYZ$'_MKA<?NN7%=/7?
MQ/"U>WB[_! $$RTDU18EENM/1Z&R7R?(6P/"NUP2>./$8VOJU9&?K5ON>S2G
M-38 #7BJ+]_ Q&_L(C=KN,X*WA665CE130N!M' &@@)-D+%$P%[*<JX\4]J7
M/G_=+DF]%[ZC K^Y*IZ.0@-<6N4OOK_^;B?S;)JWH-157%Q&1[S(J:S)8(>X
M$@1ILSH6%/E0T!)PNH6YM%V2>N^!S\FE B@T<8;Q4X1O^\D=/K!YN<[._7_N
M)D8*PJID!7(NOYG.]3HT\PY1JCTQC)M8O#3.'G'J]8\^)Z]*X=& H_H<P1XW
M?GF3'^?G:XQ\@;%CW@1NI9828D_K<I\^S/,;-H&45P["SD ]CX6I=H1X];I9
MGY-Z8^'5A)];I?YGI2ZEQ<SRW&!-Q @NFFMDHW9(ATBLH88*5GJ'^/#Q>IVR
MSTFD8;9NP&/=UZJ"\-!-9G>X^'_?3!:3NZ23:3;6:F9<&F(I$Y(CC5DN&JLD
MT@0K)(+V+@@GRS<7[B]=G8WBN6DV$EJ5CR)6*L GW\\^S3L/ZFV_-+LD)G(6
M*$:8$[ <AEV+ML&A%+E35.DH-U_^;#V"Z/FY.CV@SL6HL>S>@$O[N/P6YQ^Z
M6??\@.[^6L+XF((&\SCM(*3$"G;!BF-D=?2P_25!R.+'I7LEJM..Z=RNJR J
MQW/,W'%LEEN/@&;%J/9X]'N?2SF9W>3.(G=*=K/%FYBZ>;S[>U_M7W'Q[B^P
M)8 *[GM^NSI!S(V[<Q9F-YVNS (S <+22]CQF(B]0I$+@;@A$5PY5\@0)1-7
M43)>.E]V1'7J=M0;_?:I%2)47LG?77^?=K=Q_LG>9BU6>EX22JCC!",NI45<
M6WI7ARZ1P".5DGO?Y]W^MK'K=K(;]7K@9%,VL!+G%,X_)]/IXV9Z=4MF<BM)
M;#S0V "AF=/ 9:80 WVP9,9R53Q98ZLD=1N_C9\+=+KY&^\!,;F:3=+$V]GR
M+<P1Z[H[9_MU;F>+NZY>BS\GRV_KC=$G"W:&(,?.[Q)53F@!4>;#)3M C&"*
M0@T@/LZO[&Q]H/NLK!=L,SX]4?MC^AG6PIF?V.E#*>W'V'/=EBTAGUFKI);(
MLH01PT!F&8EAJG0YJR*"EVLM\037'_$"@)M=K3\U"ZO08?L?/V7 W7/*#5,2
MQY%Q-"'IO/>"4B9,Z9/G\EK4S3<Y/Z=W=[&HPHO*]3U^L__5S>_?J]U5(MV0
MGCJ*C()027(N$EDE-/;:+QTH[/'RRZVTKZC#@ZX8*)4I]<%>@Q&?Z;"N<K"A
M1&Z?I1U+B!)LL$@L)-<K7CW K)T"U"L*<BJB76GS5M[?_M8M)^GG'%;GZ LV
M\_?5*S8<N0)'KHQ#W'I.E5!,R3X=Z78,7P__0J!U92U8O3;X33Z: >LM;[.!
MMDV+!#LVFUM3A6#A'Q.PDKURD0[6!7_Y[5;JRE=??TX&IC*Q/L?O-W/_+1?L
MNYK'E7$V5=H^^YR,62F/O.(\2' JPO1*4SK MMX"U:PQ?BKFW=@ U$[TSA<O
MN:3D\O;][$=<+&-\YG,]09%9B93%X,-UM"A:3W5,F@>K>JQ:.S]0CQ4C =F5
MMFIE:OP29UT^</3VB>RY,PP*6# ([GQ$CBB'D@!EN I*\3Y)_IOCUBM=-CX1
M3K)A_?Y)US%,EL\EUXAJ19#R+M=LL F9*)6U >([V>>BYOFH=7)8SX/]"?:K
MG7(S]S8^9RQC*+C(LL>*R%C.$.=,&6Z<"+K/[N7IF'721\^#^F#;U<9\.NUF
MDUV"YPT<S:D7CD2A78B)ICZ@/QVT3J[GF5 ?;+T6SBQVL97DVT2*,.4T)I[@
M=_O43W\R9)V\R_- /M1R#=R\/[GFNWVZP7YS^_1/GFR6'N)5PT$SG2@B3BAO
MK;-.E:\]U%>Z5MK%5#W;&!G4QNCZ;-(^:$"" P\;!9()P[(:54JD_/.832EJ
M5R<:!^\]M!I@_,;HLWT7+DF ,)S C,,$ G'L34I\1/JTT%CF5%SWT&2 D6L'
MO_<QPK;I(A)#-CB/B,8F.4=)W,P!WQ[\/AVTE>8@59>JTTS="D>VSQ:.#3("
M,Q0UM\%XS;'OM45Z/FR]P@,G +,-W@%6J@SPUS^[K]^ZFX6=A=QF:7+U;1GC
M[&OTWV83;Z=/WKP\*+G=TXF0D&$D(A:H2H8P+;GN087! C1 FB%P=^>V??6K
MX?M4L!C>S9:3G&.Y=;+E1ADX&!1RWQ,/"@BF^X0CO=M&/_]^*RT?&K@B+@!0
M@R3;/CD%_. T./; 9>X>IZ3HER0[@&;U+X)+('N *@/,W,#VZ \[G^19<_^B
M:*7-[8=N^6D^N;;SVS=Q%M/$3^"GVUTN=;F_.W;(FN"$YI*%4/JI]]%"MD6U
M(<SHS@E39:?UN ;<79K_%I??NG!W=;ZJB/SB=V/<R.=XT%,[4#$IC(B)";1D
MQ-A>1<,.N+539*Q<J*Z=%?9L0%<F]"X]MCN"% FR/FB4+&>4&,)5D0RM_5+4
M<Y'G8T$W"B0M)N8\/;BS%)D@#8HQ1-AY"4G)A@<LEY@S"D%*8G4H&Z>OX9H!
M_?W,?[H7X,NR\_^]71F# _AD S^$$!0E*FI/CF+!C@_5R]<:G18E3%N9)U]L
MBHL=)_!1P.8&I_PSXP+FD1K;@Q%/AJR7KS42]D/-U<#&K4 P]^O#2_*-@,X2
MC0RV%L4$Y(Y>P3I;^D*UI/R5"XBT$6!7)T9EU_?A)D_CCS^_6RQA2PS;[]_@
M!]@U3S_G\^3%?0:F0<PK ZIHD1_4\JR9<EJF(#=K:FYUAP<^4[O?6BWLNW&
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MM=XFSZ2T9W*X Z1O]T;Q&+[U]-%CH]M25/!<G1T&N5BNSRT>'-$S__.HO#<
MA!(LIYF'@+S4'@)U@94J?1-95(%&V'UF%NZ:#&>G1+OS8?NQ2%P\JA<)QNL*
M $E*Q 5GDI"\1RA=WN1($1LYZ&^2TT5@;9>UFT<GJW!P O%A1FYBIX]J)F8H
M4IPKY+C5*&#B9$B,63I:*'*<J(WL#9MD<5&8VV7SAR[O6&Y@;^.F<0W$EV^
MWQN[R(_2'M_ O>T6#X9V" <!4Y@9@71@&B58?8)))!A;NC!>$<'KGK:US?01
M*5#YU?;#KOW9+#ZL_:^3Z\FZ>]7LJ?[K)Y</%H"X2^;FA0+9_#*#!F8(5UYR
MLQ&0;WW2/8YT=1_-5F9Z(Z"_4MK_8B>S_*#BX^S)$XI-]0T-%BEE,-)1:\1D
M(M)R(JS&(W)^CVAUZL/_#0A?"N[7%=RLRFP_ZF<-T4BYY) C,2 ;C(Y!6Q]9
MZ6OI8V6L4_R^$5Z?!=AVB?MX(?H98 <)OSTJ%DP0H)C('9,%R2= E'$OC!5G
M.A-Y*5R=LORO@ZHG0GD\1\T=1V?Q*E=,_CHV5=]^R]5#W\_N;_;A+^1BGLO%
M'W9Z<V?=Z;3[T\Y\?%0\,<>0DJ"]E4(BI[Q*TF ;W3@%$TZ1NA>YS7\FN<<"
MOUW/O%IE+L)_W3R\,+Y3RR-LU*K)1\POH15*7@?*G7'4G^E$9%.T?O<N^#^3
MN2?AV!(]-S/W[M6@1.8S=B&0IBJB%)FGW@1N>4N)1^0_YM[O!)P:>,*S?8^Y
MS9A;MY^;IH2H!UM8!(QDR#%+D8L\>>64@B6A,#T+B=[(C5_A'(T:N#;@/?L<
MF1RZ@W=$4\&X0B%JA3CF"5E!$Z*YM;=+6%!7>N$O(';=9(PJ=.M%^?&P?R5T
MWWEK3Z5E24>-HL48<9%WJQ@"(^%P]%PGI_%Y7/9KR,QX+00O@O8K87;?FWR!
MO%46J1 #TCK #PS'D(B07I5N#E%"[KK9&Z^%Z471?R6,'W:C+Q'V/B"P>:Z#
MF9]D!&LYQ8)X6X/_KRG#X[7,AA&9\4HOO7==^]^W5'DP@1'6@7N ?;_!DB!+
M992$6<TVGPZ>)=GCF(XXHV5[U&1]*YB_4MIOO?Q_H7]*6H+^@2)-5&[H&GP@
M,3JJ^_1R'T.VNMD>KY7PQ=!^Q0'0L_P @RCW!"RO/#*4&I2XB4X30$&5KI-Q
MDL!ULT!><UAS/-ZOA-R[,PH,XIAXI%1TR)D$2Q>/(F"-$Q6E6[L,D[1NILAK
MH?.)"+>3,])'V;O2W>]GZ]Y@B[Q.Q<7']#O\)[-%-YV$+-.7&[>8A(F=W]Z;
M(B+CN(+URJ=<-\ A2X2R*=&8BE=F'4./NGDEKV4JC,J.US51CDFV\98GK1A&
M E."N(L6.:L%BEY@Q1SW5):N$U!8A<K9*Z]E?HQ%BE<2"[U(XPE*:N^\1XE
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M;Z_>S];R;TJZJ0\$&_^:EUC/AW^U#:<QF"TGF[LR7?X !:]^6F[E.^@!?_Q
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M]_ \&F_;S9NF,9LNC^(S72XJ]%K19&>3\M6!UNF%C_O>FS7SLNY07)R8@-B
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M:.*!;B[-)<5]QY,<:D Z9,%,J3<V_AVNX,J?>N''-NV'IY])%BK9DSKMQB<
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M?3.A<O'XL0!99A75U,@&81?;TM9EO6Z9YS'N8UI93)CF""ME:LE?N4 .73:
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MTA#)^B+$VU&%OV]X.8;+N- \97HM=LC:(:H F/;ZWWKVCBD]UG;MDAL3$53
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MM;]X<OPP/D$*XTS1B)(<B!P^&]:1#TO'-PE>W6%0S_9?8'YG%J&?CM\>@VN
M#4P91$*9SH!N&4DCO=^@C#A%]9PP6ZCBRAS8PI)]D0;W5')E;*L+D.R_];6T
MQVROP?';HYO'3I,<Z;Y2JVB3DIU#^9V ;@8/="#MX,F6<=I"O5T\1Z=F$\**
MVS I6KI24A;Y#GH4WP["*8QAWZP4/8;-F'+9EK3E%L+587.ZC6U3LA+I YV
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MD:3[R,@>=LZ9[[GS2<%"3^(K=Y")BT(:?BBJ]]LZ>5;45W7SODW^ J8JDYV
MAWZ,^LQR"R;*87<=3%N;CXA="N(K2" BNA*!(5$( K/?,%XDI!Y,<SC=\6PS
MU3;=3@(H,>@*;I&0L>KVIXCWX=;2W/FY]9WW.(%5V*R7G0T2+7ZD4(+8'!K?
MJ4W6=94FFR(WP4T#1 V1)!3#'[K+^:"<9$DAA# 98D*JHK$9"/'*T@.N\5&3
M<N/1(,(/MGM>RP-F$)K()8BA!NJ'QJ!4@I8T[[EUX"UP2,7%4+@7I'!ME78]
M89=I%6/?D/&58SPG"@!*[C_SS9JCV)R$_/)C(F"<^[,P[8@<([?O0B5M)%\@
MZLTM14"^:XPC\\E[$Q""SK$;-%3C-M4_(!<DM27= >7"W9]3*I7\J[19F&Y/
MI/J/RAO1Z2.B,[UB07-YG+_901L"\L>^4^(K;+$50E'LC50JE]C;BGTQXTL4
M/2_:^VWN,%Q.#$"D%=H23->"B='<#7(*0_#PX<(L%X^6WC/)C0ZJW2 4G]%9
M_[O06;@'X\O'/2^HZC=/SO_6%Y=@>-Y?<XGA;J2#W46#1AVP!I7PRH*@X*%[
M'<F8+"RI$KH)1*!'FS:7]V^9-A C#=*#*VYM'E^B[3QMJB.TIV@"[UF&=E)V
M;D.6H^;H/U*=D:_*CWR]'\:7Y3J7B'$<V@(A23:$/:['&=97QK[:\26QSIFC
MAVA#^@S<?=A5<:Q\4M45]1]MJ F;#HKHAD1#KDK*L'-Z'/Q/KN7$NW'FW1X+
M*_F[/91(%MX>0#3JS88+E24>(T6)JF2[!!D",Y ')MA=.GO\;1E(1SXF:RK?
MM/E]4>6*4W?A"ACM*_B0S-("ACF/3Y29HP+SFV] K!I<SITF'G G%6QR8P<Z
M&)$=J98;XZ9^L6^S^'(VNO0YBNTUX!;0XV,0P:/'=_1WHECQ^%(RWZ=%D_S(
M,=B?<9O%L.RTI +LQX0NXXR=%@@T@ OC$0LU4WFT@_AY,:$Y%$T:EU1C3&P-
M'^V05CL@8%N1QA[-E"?=QS!^65-0'(/GK6A"1S$</!A&*:QL=>6(DG>.DQAO
M5F+5I03&J<\=W!@)O4/:!9X9(DQ&@+_ D.'GN@'0O]4]P6\H;<5JF/N#3D9$
MS9X@V(4B7"YNF40,^!/7-T_DD+MNW5.:W;\QA>NY-$+>T)T/0Y*[U>S,VIGC
M*4 +:X.U+GR)@Z^'5\&]7 -6FF"""B!;F?'->>FSG,P+2THN^1"YZ>\^X5C6
MH?(;+)M8;[^:N $B8CS('[\?2^FH-"!V)1E?QO('*GUL8*W!TS]Y\$>6?K;>
M8M"7";'H6_X^D72NLYLA/@DKD1XB&8V.(2X5G<G)G>E,<!=D")Y@_-84B'2<
M,VU]SC3(LX?5%:/QFF5(RQX$0 431=4NL4M[?.G "T>$RDJ>&1YCD7,>3= G
M2H/**CN=GLY5Y/!@NTJ.:W<&TO50;X78Y2>^)-E-%:912-&HQ!7+NS!\DRJH
MX*<6H8LOOS:<P6C6WC=0QB/$$MG^*-1/.4D!.R _IM=2O'>R2AX^> C_7WKH
MIF $;V^IW3I>)6_/3\^L*+WMUQ9;!C<8X,\8=A:YC,67/WI95T<V$IQ$EIVW
MPP%'HK:>$HB:'6[LBQU?B@<7^S_HK"\<;W24Q@FC[,1 J1OZ6XP4PA;2M=-F
M5N12\2B^1%!<$L!F)K7B :=_ASQYGT1&]U%\.9_;F."C6'+*JZ32$I#_ZY,G
M*]T7@K^C(&:.1X+P[%/+,6+&(39 )"IAOD"&FC=&E:BLZ>W1.Y;DC N='9KZ
M8)HN=F_W47PICU?86!##=Y1I>E'LBW@,U;;?$S]IL4R>K."Y^#^7ETOS7_I6
MH"D@-\B-#T9'#7?=U W^K[M.%B<4"7_\8 F7P(NVUANFA.(<'6,0XF4@*D=3
M3_LM/#(Y>4K&\./E,$1,R3V1S$&8WA)N[@GU?9D696I[,6[ZKK<]1'1+VM<4
M[>;FR'1#S1#H0N'I :OP4L<M2=>'0'T/)E=)5S?V.P\>Y4-5U*GAV8;1=!G#
M?0?OB'6LU"MZ !O2#"NG""Z"ZR]^MF.[5$-[XXA"0Z2+QL7[Z^'O"D.!194A
M+XFQ@6]N XJY!&Q\PU2N)=@I:9-<FQ2QRJ CZ"G_EL(-&NO^T((_I*<8H2BM
M%*'Z] \>P?\W?Z.()%<I8*]+#A4N3I?)8Q=73+?@D6%7)I>&WJBEN*$F/21-
MM:^(X7=Y1:9FTF)CP_WA>]/T/=-=3ML]: 5L(.E&)!LOQ:IDG78282,P[F?
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M41\.R T=DLRMK5B" :.%ZZO$.\_/_^A^OWJ#\1,5; \U15U1*-':0/ P?Y;
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MAZLI? R(2[<]Y8$WD1O?U0O4(__B]G]02P,$%     @ 5X1:7&YEH$+@/P
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M.G&6[>\=[;.-:=[J]W")C?"F;> VVW)#,CL<B;-E7/8DT0IU\WL>[S/#:X:
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MMI#,",<S><*C3<-\=F(]F7CNRV02<XU#!F,K^_T9IM(?S])O%_"2,)3A'(7
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M0QO</4_'O%ID@QFH!K:^.!69.!Q*W@8=V>03M*A*4 M<VC/&9-3K+J5+/BF
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M&-LP?>G.2NIVT=04J"E>@Z5<\EQ6C)CT!EVY3A%VG&'N_28#_=@R(?S:)KQ
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M418SQ8"K"ES?0#MFIUC8=2(';4R,:9$%"=%,6&?BM"S75:_BM LK?V@05X/
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M?']GXF/1-<QY?/ DI<3DH'-[RVD$;LE.;^30I3L1/VN);.H$ZQ1$;J,?TD
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MO,*3A[;1F1,8'M+5.9DM>;U;U3B=ACUB9GD>QF3Q>9HYPSW2_(29&_'U[WO
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M#"V(&D,JT#,$W"!#0/(7T VP,X4J8#@=G/VTF/A<))?M%?0B.;G :3H]$Z*
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M:3WD>W()\U&8<(A@&9]FAQR1'OBL*U^"09ZRV"Z7H"^](=W"0.\;NC $[5"
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MT/>%.@ONE3D#='P.+_PC#R?G85U8'C^0"\O7\S+;P'^6S2K_[O\ 4$L#!!0
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ME4?]4GN3J8Q)CC2)N9/TA<= 3W 4*ILKI-('RCCLBZ(=L5N;0/709J>E;,
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M:MSH*-6Y@TH&2U0?JY6VUG/BF^MP)2?YP%O=NG?J^O+<3*"!T\4@I.77A,0
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M"^5X"E>I_I;*N\>5]H"IG$F.-(FYE?2%QT!/<!0JFRNDTA?*..R+HCVQWYA
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M<#X?M8N(;F<SA58!;Q8U;D/$-=PI<QA8'.&XB%0:+?<RK LKL*#HGX5*80^
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MVC*D)$2[( J_:>ZU+C[$K5X!&0]U^EB)V$OFUGFNLHV@JQX!N!2P2<L E<%
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M,4Q1@W&=-9HT<W*RHIC+  E5T-/;PJEES7B34=/?9V0NXI3XEE"B=7)Y*3F
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M@J/\3)2OIHCLK1UQG*XS6YGZUH+_%YC6"B&[Y67-;0V(O?)R$VCG!A/QG>_
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M]*/GV]OUS*WSRSK&2=CRP^Z!$B')!4IW!4: 6\KL#QXJ]?3CI@S,^5/.)^L
M!X7"5_3PYH:-8H%,6L2KFFG!>7*-,+Q'K&T7:[A"'HO @%9@@V7PHC#Q5 >A
MPF#QAV3A_05S!SWOO0EU;S%L#V(3O\L>[Z M>XCTVI<:*WU@T1%(]3OROUWE
MJ8:3X"])D8*EU/..LRSQF37X(@6IH+/\MSBT'X!@PRV8]Q O(&YP%6#*EBK
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M_3*4Q<736(,J8NP\=<46PN?B@L++:1N&W=UP0FTM2IBN#8-RI3'0Y?0+K9$
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MZ>KD.[O^?/KLW:<_#I-@"?^8Y-/HS_\?4$L#!!0    ( %>$6EQCDJ+RRP(
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M$/LWA,VT3%=F-^2OYV:Y%L/](/^H^ E02P,$%     @ 5X1:7%S4HC-H!
M0AH  !8   !D;F$M,C R-3$R,S%X97@R,S(N:'1MW5E;;]LV%'[?K^ <+.T
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M<,L9,2<,T,/3CT76!/\&' 4AT4-_SOY"8B\3@@>E0'"K=MI<1_!J=MR:'->
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M[FB6<^T\BT =5'/8X5F0%"%L BYS>:L :EPF$Y(CVP:H!L!),D-B"0*U-#7
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M3)_4E30F>M6- Z&G!S<GQM,4,L-'=ZDVI[QQAE1\YB=:-7.2]@]02P,$%
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MX_?QGS <S;3%<YR=>?4M831?A''.(12<TU QP>&.J26H)84AYRN2P!7-A%2
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MT[O5KIOT?JB4_N]RY-C>2X+TO1]3??V8NF0TAK.''7<2QPR;[ET;IV=]T\?
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M5P6(TO$PCG=,_4'S;AF9U;?16S<C]]9DY![4[.U#'A],?-HTYS@%JOC.6R1
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M$+2YC>W3<&RW0T] +-OVV./[J[5I "KPDFGZ3&:)I!2R@+?<MLV!KL)-&R.
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MKU<)-H2Y<$I.D9+FU&@,):%Y]].;OQ@2FE_ZIFBSPL38_1*&:^P7*0!A;I*
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M71)M%1ES>"R3IBS@$?2]<&KQD$IRORQ ZV3)MEK\>\M]])/S)7,[B[B/+D$
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M<L A[68UJTN%X[U\<Z'-T^XM0.A^R8+_G-79!OYGV:W*/_]_4$L! A0#%
M  @ 5H1:7-<;]4Q5_ , :T,G !               ( !     &1N82TR,#(U
M,3(S,2YH=&U02P$"% ,4    " !6A%I<],3; A$@  "6A $ $
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M82TR,#(U,3(S,5]G,BYJ<&=02P$"% ,4    " !7A%I<:H#^]==8!@ X*P<
M$P              @ &HKQ  9&YA+3(P,C4Q,C,Q7V<S+FIP9U!+ 0(4 Q0
M   ( %>$6ESF'> >::0  %G?   3              "  ; (%P!D;F$M,C R
M-3$R,S%?9S0N:G!G4$L! A0#%     @ 5X1:7$0IV?-QZ0$ 5!D3 !0
M         ( !2JT7 &1N82TR,#(U,3(S,5]L86(N>&UL4$L! A0#%     @
M5X1:7)Q=/$2/,@$ B^P. !0              ( ![989 &1N82TR,#(U,3(S
M,5]P<F4N>&UL4$L! A0#%     @ 5X1:7"<*>>?N5   NP$" !8
M     ( !KLD: &1N82TR,#(U,3(S,7AE>#$P,2YH=&U02P$"% ,4    " !7
MA%I<7D1_2W8'  "_'0  %P              @ '0'AL 9&YA+3(P,C4Q,C,Q
M>&5X,3 Q,"YH=&U02P$"% ,4    " !7A%I<;F6@0N _  #'IP$ %@
M        @ %[)AL 9&YA+3(P,C4Q,C,Q>&5X,3 R+FAT;5!+ 0(4 Q0    (
M %>$6EPF/2MS^3,  )2Z 0 6              "  8]F&P!D;F$M,C R-3$R
M,S%X97@Q,#0N:'1M4$L! A0#%     @ 5X1:7*GSA1N !P  C!T  !8
M         ( !O)H; &1N82TR,#(U,3(S,7AE>#$P-BYH=&U02P$"% ,4
M" !7A%I<E5K@59,'  #I'@  %@              @ %PHAL 9&YA+3(P,C4Q
M,C,Q>&5X,3 W+FAT;5!+ 0(4 Q0    ( %>$6ESC)^+7CP<  (,>   6
M          "  3>J&P!D;F$M,C R-3$R,S%X97@Q,#DN:'1M4$L! A0#%
M  @ 5X1:7$51J:/D1@  .,T! !8              ( !^K$; &1N82TR,#(U
M,3(S,7AE>#$Y,2YH=&U02P$"% ,4    " !7A%I<8Y*B\LL"  !P#@  %@
M            @ $2^1L 9&YA+3(P,C4Q,C,Q>&5X,C$Q+FAT;5!+ 0(4 Q0
M   ( %>$6ES*% ]\\P(  %L(   6              "  1'\&P!D;F$M,C R
M-3$R,S%X97@R,S$N:'1M4$L! A0#%     @ 5X1:7%S4HC-H!   0AH  !8
M             ( !./\; &1N82TR,#(U,3(S,7AE>#(S,BYH=&U02P$"% ,4
M    " !7A%I<@+<5;X,(  "Y*@  %@              @ '4 QP 9&YA+3(P
M,C4Q,C,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    ( %>$6ER2V'%<=@@  * J   6
M              "  8L,' !D;F$M,C R-3$R,S%X97@S,3(N:'1M4$L! A0#
M%     @ 5X1:7$S%HQ;#!   4!,  !8              ( !-14< &1N82TR
M,#(U,3(S,7AE>#,R,2YH=&U02P$"% ,4    " !7A%I<"*"*HZT$   )$P
M%@              @ $L&AP 9&YA+3(P,C4Q,C,Q>&5X,S(R+FAT;5!+ 0(4
M Q0    ( %>$6EQ@5-LJE$$   >- 0 5              "  0T?' !D;F$M
G,C R-3$R,S%X97@T,BYH=&U02P4&     !H &@#(!@  U& <

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>dna-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:dna="http://www.ginkgobioworks.com/20251231"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dna-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-16</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-16</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-16</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:EquityMethodInvestmentFundingOfAdditionalLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:EquityMethodInvestmentFundingOfAdditionalLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:EquityMethodInvestmentFundingOfAdditionalLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2024-08-19</startDate>
            <endDate>2024-08-19</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:AgBiomeInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:AgBiomeInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:AgBiomeInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:OtherAssetAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:OtherAssetAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-05</startDate>
            <endDate>2023-04-05</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-05</startDate>
            <endDate>2023-04-05</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:ZymergenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenBankruptcyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenBankruptcyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dna:ZymergenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-02</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-02</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dna:ZymergenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-10-02</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-18</startDate>
            <endDate>2024-01-18</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-18</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:ZymergenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dna:AltarSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SynlogicIncWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dna:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">dna:SeniorSecuredNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">dna:SeniorSecuredNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">dna:SeniorSecuredNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">dna:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dna:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:CircularisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dna:CircularisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">dna:ProbabilityWeightedPresentValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:OneInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:GenomaticaIncPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:GenomaticaIncPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dna:SafeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">dna:MeasurementInputScenarioProbabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2024-08-19</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:GenomaticaIncPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:NonMarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SafesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:SynlogicIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:BiomeditLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:BiomeditLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:BiomeditLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:OtherEquityInvestessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:OtherEquityInvestessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:OtherEquityInvestessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dna:EquipmentLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dna:EquipmentLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2023-08-29</startDate>
            <endDate>2023-08-29</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2025-10-03</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:StrategicCloudAndAIPartnershipWithGoogleCloudMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dna:StrategicCloudAndAIPartnershipWithGoogleCloudMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-04-01</startDate>
            <endDate>2027-04-01</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:SuretyBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">dna:StridebioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dna:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-07</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dna:SalesAgreementWithAllenCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-04</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:NewGinkgoPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dna:WarrantsToPurchaseClassACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:OtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:OtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:OtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-16</startDate>
            <endDate>2021-09-16</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-16</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-16</startDate>
            <endDate>2021-09-16</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-16</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dna:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dna:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:FounderPSUAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-16</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-16</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-16</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dna:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-16</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-16</startDate>
            <endDate>2021-09-16</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dna:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-16</startDate>
            <endDate>2021-09-16</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dna:EarnoutRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:PharmaceuticalAndBiotechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:PharmaceuticalAndBiotechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:PharmaceuticalAndBiotechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:AgricultureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:AgricultureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:AgricultureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:GovernmentAndDefenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:GovernmentAndDefenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:GovernmentAndDefenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:IndustrialAndEnvironmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:IndustrialAndEnvironmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:IndustrialAndEnvironmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CustomerAndTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CustomerAndTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CustomerAndTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:FoodAndNutritionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:FoodAndNutritionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:FoodAndNutritionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dna:CellEngineeringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year13Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year14Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year13Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year14Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dna:RevenuePerformanceObligationAxis">dna:Year15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:BiosecuritySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringAndBiosecuritySegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringAndBiosecuritySegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dna:CellEngineeringAndBiosecuritySegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dna:LeaseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:MotifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dna:MotifFoodworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:OtherEquityInvesteeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dna:AgreementAxis">dna:TwoThousandAndEighteenTechnicalDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dna:AgreementAxis">dna:TwoThousandAndEighteenTechnicalDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dna:GenomaticaIncPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:MotifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:MotifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:MotifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:ArcaeaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:GenomaticaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AyanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AyanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AyanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:BiomeditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:VerbBioticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:VerbBioticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:VerbBioticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:AlloniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:OtherEquityInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:OtherEquityInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dna:OtherEquityInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:SC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:BeginToExpireInTwoThousandAndTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:CarriedForwardIndefinitelyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:BeginToExpireInTwoThousandAndThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:CarriedForwardIndefinitelyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:BeginToExpireIn2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dna:CarryForwardsExpirationPeriodAxis">dna:CarriedForwardIndefinitelyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EscrowSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EscrowSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dna:EscrowSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001830214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-26</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>dna:segment</measure>
    </unit>
    <unit id="offering">
        <measure>dna:offering</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="materialright">
        <measure>dna:materialRight</measure>
    </unit>
    <unit id="employee">
        <measure>dna:employee</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="extensionoption">
        <measure>dna:extensionOption</measure>
    </unit>
    <unit id="facility">
        <measure>dna:facility</measure>
    </unit>
    <unit id="vote">
        <measure>dna:vote</measure>
    </unit>
    <unit id="stockoption">
        <measure>dna:stockOption</measure>
    </unit>
    <unit id="installment">
        <measure>dna:installment</measure>
    </unit>
    <unit id="founder">
        <measure>dna:founder</measure>
    </unit>
    <unit id="hurdle">
        <measure>dna:hurdle</measure>
    </unit>
    <unit id="condition">
        <measure>dna:condition</measure>
    </unit>
    <unit id="asset">
        <measure>dna:asset</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-35">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-36">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-37">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-38">0001830214</dei:EntityCentralIndexKey>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-76"
      decimals="INF"
      id="f-556"
      unitRef="number">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-562">http://fasb.org/us-gaap/2025#RestructuringCostsAndAssetImpairmentCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dna:EquitySecuritiesFVNIMeasurementInputTerm contextRef="c-200" id="f-801">P1Y</dna:EquitySecuritiesFVNIMeasurementInputTerm>
    <dna:ClassOfWarrantOrRightStockSplitConversionRatio
      contextRef="c-204"
      decimals="INF"
      id="f-805"
      unitRef="number">0.025</dna:ClassOfWarrantOrRightStockSplitConversionRatio>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-7" id="f-1005">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-7" id="f-1006">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-8" id="f-1079">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-8" id="f-1080">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-379" id="f-1401">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-380" id="f-1402">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-381" id="f-1403">P3Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-382" id="f-1404">P4Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-383" id="f-1405">P5Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-40097</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">GINKGO BIOWORKS HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">87-2652913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">27 Drydock Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">8th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">877</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">422-5362</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Class A common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">DNA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-6" id="f-30" unitRef="usd">553000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-31" unitRef="shares">49941878</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-4" decimals="0" id="f-32" unitRef="shares">8982474</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="0" id="f-33" unitRef="shares">3000000</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-34">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The information required by Part III of this report is incorporated by reference from the registrant&#x2019;s definitive proxy statement relating to its annual meeting of stockholders to be held in 2026, which definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-40">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Ginkgo integrates risk management into its overall cybersecurity strategy, and has implemented processes designed to identify, assess, prioritize and manage risks to protect Ginkgo&#x2019;s data, intellectual property and information assets. As part of our risk governance and management, Ginkgo has developed processes designed to: identify and assess risks, evaluate those risks against pre-defined criteria, develop and implement strategies to address identified risks, monitor and review those risks and communicate risks to relevant stakeholders. Identifying Ginkgo&#x2019;s cybersecurity risks involves a multifaceted approach that encompasses both internal assessments and external information sources. For example, we use security audits conducted by internal and external auditors to assess compliance with security policies and industry frameworks; vulnerability assessments to discover vulnerabilities in networks, systems and applications; and risk assessment processes to evaluate IT infrastructure, including using a risk register to identify risks, likelihood of their occurrence, potential impact, and remediation. We also oversee third-party service providers by conducting vendor diligence upon onboarding and additional monitoring. Vendors are assessed for risk based on the nature of their services, access to data and systems and supply chain risk.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Cybersecurity risk management is overseen by Ginkgo&#x2019;s Chief Information Security Officer (&#x201c;CISO&#x201d;), who is supported by full-time information security staff. The CISO advises the executive team on the development and implementation of the information security program.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Ginkgo incorporates learning from its cybersecurity risk management process into its overall cybersecurity program. To date, Ginkgo has not experienced a cybersecurity incident that resulted in a material effect on our business strategy, results of operations, or financial condition. Despite our efforts, we cannot provide assurance that we will not be materially affected in the future by cybersecurity risks or any future material incidents. For more information, see Item 1A. Risk Factors, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:132%"&gt;&#x201c;Significant disruptions to our and our service providers&#x2019; information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.&#x201d;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-41">Ginkgo integrates risk management into its overall cybersecurity strategy, and has implemented processes designed to identify, assess, prioritize and manage risks to protect Ginkgo&#x2019;s data, intellectual property and information assets. As part of our risk governance and management, Ginkgo has developed processes designed to: identify and assess risks, evaluate those risks against pre-defined criteria, develop and implement strategies to address identified risks, monitor and review those risks and communicate risks to relevant stakeholders.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-42">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-43">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-44">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-45">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;The Board provides regular oversight of the Company&#x2019;s cybersecurity risk management program. The CISO presents to the Board and the audit committee of our Board (the &#x201c;Audit Committee&#x201d;) at least annually and quarterly updates via business review dashboards. The Board provides guidance to the CISO, including with respect to any changes to business priorities, risk tolerance, or security initiatives. These briefings are also augmented by ongoing and continuous interactions between the Board and the CISO, as needed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Ginkgo's CISO has primary responsibility for assessing and managing Ginkgo&#x2019;s risks from cybersecurity threats. The CISO has public and private-sector experience in information technology and has served as Ginkgo&#x2019;s CISO since 2025. Executive leadership provides oversight and governance through monthly business reviews of the cybersecurity program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Ginkgo also has a Disclosure Committee, which is composed of representatives from executive leadership from various departments across Ginkgo (e.g., legal, finance, accounting). Their role is to determine materiality of a cyber incident and provide guidance with respect to any disclosure obligations resulting from a cyber incident.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-46">The Board provides regular oversight of the Company&#x2019;s cybersecurity risk management program. The CISO presents to the Board and the audit committee of our Board (the &#x201c;Audit Committee&#x201d;) at least annually and quarterly updates via business review dashboards. The Board provides guidance to the CISO, including with respect to any changes to business priorities, risk tolerance, or security initiatives. These briefings are also augmented by ongoing and continuous interactions between the Board and the CISO, as needed.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-47">The CISO presents to the Board and the audit committee of our Board (the &#x201c;Audit Committee&#x201d;) at least annually and quarterly updates via business review dashboards. The Board provides guidance to the CISO, including with respect to any changes to business priorities, risk tolerance, or security initiatives. These briefings are also augmented by ongoing and continuous interactions between the Board and the CISO, as needed.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-51">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Ginkgo's CISO has primary responsibility for assessing and managing Ginkgo&#x2019;s risks from cybersecurity threats. The CISO has public and private-sector experience in information technology and has served as Ginkgo&#x2019;s CISO since 2025. Executive leadership provides oversight and governance through monthly business reviews of the cybersecurity program.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-50">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Ginkgo's CISO has primary responsibility for assessing and managing Ginkgo&#x2019;s risks from cybersecurity threats. The CISO has public and private-sector experience in information technology and has served as Ginkgo&#x2019;s CISO since 2025. Executive leadership provides oversight and governance through monthly business reviews of the cybersecurity program.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-49">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Ginkgo's CISO has primary responsibility for assessing and managing Ginkgo&#x2019;s risks from cybersecurity threats. The CISO has public and private-sector experience in information technology and has served as Ginkgo&#x2019;s CISO since 2025. Executive leadership provides oversight and governance through monthly business reviews of the cybersecurity program.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-52">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-53">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Ginkgo also has a Disclosure Committee, which is composed of representatives from executive leadership from various departments across Ginkgo (e.g., legal, finance, accounting). Their role is to determine materiality of a cyber incident and provide guidance with respect to any disclosure obligations resulting from a cyber incident.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-6" id="f-54">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-6" id="f-55">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-6" id="f-56">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-6" id="f-57">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-58">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-59">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-60">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-61">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-62" unitRef="usd">167202000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-63" unitRef="usd">561572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-7" decimals="-3" id="f-64" unitRef="usd">255418000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-8" decimals="-3" id="f-65" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="-3" id="f-66" unitRef="usd">24026000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-8" decimals="-3" id="f-67" unitRef="usd">21857000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNet contextRef="c-7" decimals="-3" id="f-68" unitRef="usd">229000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-8" decimals="-3" id="f-69" unitRef="usd">586000</us-gaap:AccountsReceivableNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-70" unitRef="usd">24963000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-71" unitRef="usd">18729000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-72" unitRef="usd">471838000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-8" decimals="-3" id="f-73" unitRef="usd">602744000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-74" unitRef="usd">167783000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-75" unitRef="usd">203720000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-76" unitRef="usd">360918000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-8" decimals="-3" id="f-77" unitRef="usd">394435000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue contextRef="c-7" decimals="-3" id="f-78" unitRef="usd">15066000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue contextRef="c-8" decimals="-3" id="f-79" unitRef="usd">48704000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-80" unitRef="usd">56924000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-8" decimals="-3" id="f-81" unitRef="usd">72510000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-82" unitRef="usd">47167000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-8" decimals="-3" id="f-83" unitRef="usd">55336000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-84" unitRef="usd">1119696000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-8" decimals="-3" id="f-85" unitRef="usd">1377449000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-86" unitRef="usd">10566000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-87" unitRef="usd">14169000</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-9" decimals="-3" id="f-88" unitRef="usd">98000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-10" decimals="-3" id="f-89" unitRef="usd">795000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-7" decimals="-3" id="f-90" unitRef="usd">18946000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-8" decimals="-3" id="f-91" unitRef="usd">27710000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-7" decimals="-3" id="f-92" unitRef="usd">66458000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-8" decimals="-3" id="f-93" unitRef="usd">65387000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-94" unitRef="usd">95970000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-95" unitRef="usd">107266000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-9" decimals="-3" id="f-96" unitRef="usd">64787000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-10" decimals="-3" id="f-97" unitRef="usd">72260000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-98" unitRef="usd">75182000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-99" unitRef="usd">98783000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">417078000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-101" unitRef="usd">438766000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-102" unitRef="usd">22876000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-8" decimals="-3" id="f-103" unitRef="usd">16576000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-104" unitRef="usd">611106000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-8" decimals="-3" id="f-105" unitRef="usd">661391000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-106" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-8" id="f-107" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-108"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-109"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-110" unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-111" unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-8" decimals="INF" id="f-112" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-113" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-114" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-8" decimals="-3" id="f-115" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-116"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-117"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-118" unitRef="usd">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-3" id="f-119" unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-7" decimals="-3" id="f-120" unitRef="usd">6657053000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-8" decimals="-3" id="f-121" unitRef="usd">6555416000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-122" unitRef="usd">-6150320000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-3" id="f-123" unitRef="usd">-5837557000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">1851000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-8" decimals="-3" id="f-125" unitRef="usd">-1806000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-126" unitRef="usd">508590000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-127" unitRef="usd">716058000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-128" unitRef="usd">1119696000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-8" decimals="-3" id="f-129" unitRef="usd">1377449000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-130" unitRef="usd">132746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-131" unitRef="usd">173972000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-132" unitRef="usd">143531000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-133" unitRef="usd">37409000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-134" unitRef="usd">53071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-135" unitRef="usd">78975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-136" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-18" decimals="-3" id="f-137" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-19" decimals="-3" id="f-138" unitRef="usd">28949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">170155000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-20" decimals="-3" id="f-140" unitRef="usd">227043000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-21" decimals="-3" id="f-141" unitRef="usd">251455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-14" decimals="-3" id="f-142" unitRef="usd">31521000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-15" decimals="-3" id="f-143" unitRef="usd">38549000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-16" decimals="-3" id="f-144" unitRef="usd">46524000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-17" decimals="-3" id="f-145" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-18" decimals="-3" id="f-146" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-19" decimals="-3" id="f-147" unitRef="usd">7481000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-22" decimals="-3" id="f-148" unitRef="usd">15451000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-23" decimals="-3" id="f-149" unitRef="usd">5999000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-24" decimals="-3" id="f-150" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">243773000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-20" decimals="-3" id="f-152" unitRef="usd">424061000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-21" decimals="-3" id="f-153" unitRef="usd">580621000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">183290000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-20" decimals="-3" id="f-155" unitRef="usd">246161000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-21" decimals="-3" id="f-156" unitRef="usd">385025000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-20" decimals="-3" id="f-158" unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-21" decimals="-3" id="f-159" unitRef="usd">96210000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-20" decimals="-3" id="f-161" unitRef="usd">47858000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-21" decimals="-3" id="f-162" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">11398000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-20" decimals="-3" id="f-164" unitRef="usd">24172000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-21" decimals="-3" id="f-165" unitRef="usd">0</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">485433000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-20" decimals="-3" id="f-167" unitRef="usd">786800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-21" decimals="-3" id="f-168" unitRef="usd">1115861000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">-315278000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-20" decimals="-3" id="f-170" unitRef="usd">-559757000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-21" decimals="-3" id="f-171" unitRef="usd">-864406000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">22616000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-20" decimals="-3" id="f-173" unitRef="usd">38612000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-21" decimals="-3" id="f-174" unitRef="usd">57217000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-20" decimals="-3" id="f-176" unitRef="usd">94000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-21" decimals="-3" id="f-177" unitRef="usd">93000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-20" decimals="-3" id="f-179" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-21" decimals="-3" id="f-180" unitRef="usd">-2635000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">-16411000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-20" decimals="-3" id="f-182" unitRef="usd">-28827000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-21" decimals="-3" id="f-183" unitRef="usd">-54827000</us-gaap:GainLossOnInvestments>
    <us-gaap:DeconsolidationGainOrLossAmount contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount contextRef="c-20" decimals="-3" id="f-185" unitRef="usd">-7013000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount contextRef="c-21" decimals="-3" id="f-186" unitRef="usd">-42502000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-20" decimals="-3" id="f-188" unitRef="usd">-5701000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-21" decimals="-3" id="f-189" unitRef="usd">-5168000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">-4527000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-20" decimals="-3" id="f-191" unitRef="usd">3870000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-21" decimals="-3" id="f-192" unitRef="usd">9138000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">1678000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-20" decimals="-3" id="f-194" unitRef="usd">12249000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-21" decimals="-3" id="f-195" unitRef="usd">-28534000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">-313600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-197" unitRef="usd">-547508000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-198" unitRef="usd">-892940000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">-837000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-20" decimals="-3" id="f-200" unitRef="usd">-479000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-21" decimals="-3" id="f-201" unitRef="usd">-71000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">-312763000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-203" unitRef="usd">-547029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-204" unitRef="usd">-892869000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-205"
      unitRef="usdPerShare">-5.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-206"
      unitRef="usdPerShare">-5.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-20"
      decimals="2"
      id="f-207"
      unitRef="usdPerShare">-10.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-20"
      decimals="2"
      id="f-208"
      unitRef="usdPerShare">-10.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-21"
      decimals="2"
      id="f-209"
      unitRef="usdPerShare">-18.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-21"
      decimals="2"
      id="f-210"
      unitRef="usdPerShare">-18.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-211" unitRef="shares">55457676</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-212" unitRef="shares">55457676</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-20" decimals="0" id="f-213" unitRef="shares">51894639</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-20" decimals="0" id="f-214" unitRef="shares">51894639</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-21" decimals="0" id="f-215" unitRef="shares">48610507</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-21" decimals="0" id="f-216" unitRef="shares">48610507</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">-312763000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-218" unitRef="usd">-547029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-219" unitRef="usd">-892869000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="0" id="f-220" unitRef="usd">3531000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-20" decimals="0" id="f-221" unitRef="usd">-4782000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-21" decimals="0" id="f-222" unitRef="usd">4116000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-1" decimals="0" id="f-223" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-20" decimals="0" id="f-224" unitRef="usd">-1492000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-21" decimals="0" id="f-225" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-20" decimals="-3" id="f-227" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-21" decimals="-3" id="f-228" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">3657000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-20" decimals="-3" id="f-230" unitRef="usd">-3290000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-21" decimals="-3" id="f-231" unitRef="usd">4116000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">-309106000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-20" decimals="-3" id="f-233" unitRef="usd">-550319000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-21" decimals="-3" id="f-234" unitRef="usd">-888753000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-3" id="f-235" unitRef="usd">8784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-3" id="f-236" unitRef="usd">53041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-27" decimals="-3" id="f-237" unitRef="usd">22222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-28"
      decimals="INF"
      id="f-238"
      unitRef="shares">47299399</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-239" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-240" unitRef="usd">6136563000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-241" unitRef="usd">-4397659000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-242" unitRef="usd">-2632000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-243" unitRef="usd">1736277000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-33"
      decimals="INF"
      id="f-244"
      unitRef="shares">2469178</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="c-34" decimals="-3" id="f-245" unitRef="usd">555000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="c-21" decimals="-3" id="f-246" unitRef="usd">555000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-33"
      decimals="INF"
      id="f-247"
      unitRef="shares">360</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-34" decimals="-3" id="f-248" unitRef="usd">23000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-21" decimals="-3" id="f-249" unitRef="usd">23000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <dna:SettlementOfContingentConsiderationSharesRestrictedStock
      contextRef="c-33"
      decimals="INF"
      id="f-250"
      unitRef="shares">96198</dna:SettlementOfContingentConsiderationSharesRestrictedStock>
    <dna:SettlementOfContingentConsiderationValueRestrictedStock contextRef="c-34" decimals="-3" id="f-251" unitRef="usd">8896000</dna:SettlementOfContingentConsiderationValueRestrictedStock>
    <dna:SettlementOfContingentConsiderationValueRestrictedStock contextRef="c-21" decimals="-3" id="f-252" unitRef="usd">8896000</dna:SettlementOfContingentConsiderationValueRestrictedStock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-33"
      decimals="INF"
      id="f-253"
      unitRef="shares">119278</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-34" decimals="-3" id="f-254" unitRef="usd">6820000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-21" decimals="-3" id="f-255" unitRef="usd">6820000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-33"
      decimals="INF"
      id="f-256"
      unitRef="shares">50587</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-34" decimals="-3" id="f-257" unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-258" unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:RestrictedStockAwardForfeitures contextRef="c-33" decimals="0" id="f-259" unitRef="usd">1407</us-gaap:RestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-260" unitRef="usd">230880000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-21" decimals="0" id="f-261" unitRef="usd">230880000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-35" decimals="-3" id="f-262" unitRef="usd">4116000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-21" decimals="-3" id="f-263" unitRef="usd">4116000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-3" id="f-264" unitRef="usd">-892869000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-265" unitRef="usd">-892869000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-37"
      decimals="INF"
      id="f-266"
      unitRef="shares">50032873</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-267" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-268" unitRef="usd">6386191000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-269" unitRef="usd">-5290528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-270" unitRef="usd">1484000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-271" unitRef="usd">1097152000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-42"
      decimals="INF"
      id="f-272"
      unitRef="shares">1783763</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="c-43" decimals="-3" id="f-273" unitRef="usd">543000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="c-20" decimals="-3" id="f-274" unitRef="usd">543000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-43" decimals="-3" id="f-275" unitRef="usd">4000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-20" decimals="-3" id="f-276" unitRef="usd">4000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <dna:SettlementOfContingentConsiderationSharesRestrictedStock
      contextRef="c-42"
      decimals="INF"
      id="f-277"
      unitRef="shares">1385532</dna:SettlementOfContingentConsiderationSharesRestrictedStock>
    <dna:SettlementOfContingentConsiderationValueRestrictedStock contextRef="c-43" decimals="-3" id="f-278" unitRef="usd">14742000</dna:SettlementOfContingentConsiderationValueRestrictedStock>
    <dna:SettlementOfContingentConsiderationValueRestrictedStock contextRef="c-20" decimals="-3" id="f-279" unitRef="usd">14742000</dna:SettlementOfContingentConsiderationValueRestrictedStock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-42"
      decimals="INF"
      id="f-280"
      unitRef="shares">802038</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-43" decimals="-3" id="f-281" unitRef="usd">36801000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-20" decimals="-3" id="f-282" unitRef="usd">36801000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-42"
      decimals="INF"
      id="f-283"
      unitRef="shares">361579</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-43" decimals="-3" id="f-284" unitRef="usd">4799000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-20" decimals="-3" id="f-285" unitRef="usd">4799000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-44" decimals="-3" id="f-286" unitRef="usd">-1492000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-20" decimals="-3" id="f-287" unitRef="usd">-1492000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="-3" id="f-288" unitRef="usd">112344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-289" unitRef="usd">112344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-44" decimals="-3" id="f-290" unitRef="usd">-4782000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-20" decimals="-3" id="f-291" unitRef="usd">-4782000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-45" decimals="-3" id="f-292" unitRef="usd">-547029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-293" unitRef="usd">-547029000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-46"
      decimals="INF"
      id="f-294"
      unitRef="shares">54365785</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-295" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-296" unitRef="usd">6555416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-297" unitRef="usd">-5837557000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-298" unitRef="usd">-1806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-299" unitRef="usd">716058000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-50"
      decimals="INF"
      id="f-300"
      unitRef="shares">1798041</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <dna:StockIssuanceCosts contextRef="c-1" decimals="0" id="f-301" unitRef="usd">-1393000</dna:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-50"
      decimals="INF"
      id="f-302"
      unitRef="shares">1940550</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-51" decimals="-3" id="f-303" unitRef="usd">18078000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">18078000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <dna:SharesReleaseFromEscrowDuringPeriod contextRef="c-1" decimals="INF" id="f-305" unitRef="shares">24913</dna:SharesReleaseFromEscrowDuringPeriod>
    <dna:SettlementOfContingentConsiderationValueRestrictedStock contextRef="c-51" decimals="-3" id="f-306" unitRef="usd">1237000</dna:SettlementOfContingentConsiderationValueRestrictedStock>
    <dna:SettlementOfContingentConsiderationValueRestrictedStock contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">1237000</dna:SettlementOfContingentConsiderationValueRestrictedStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-50"
      decimals="INF"
      id="f-308"
      unitRef="shares">102922</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-50" decimals="-3" id="f-309" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-51" decimals="-3" id="f-310" unitRef="usd">776000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">777000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-51" decimals="-3" id="f-312" unitRef="usd">81546000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">81546000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-52" decimals="0" id="f-314" unitRef="usd">3657000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="0" id="f-315" unitRef="usd">3657000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-53" decimals="-3" id="f-316" unitRef="usd">-312763000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">-312763000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-54"
      decimals="INF"
      id="f-318"
      unitRef="shares">58207298</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-319" unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-320" unitRef="usd">6657053000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-321" unitRef="usd">-6150320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-322" unitRef="usd">1851000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-323" unitRef="usd">508590000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">-312763000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-20" decimals="-3" id="f-325" unitRef="usd">-547029000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-21" decimals="-3" id="f-326" unitRef="usd">-892869000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">58990000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-20" decimals="-3" id="f-328" unitRef="usd">63020000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-21" decimals="-3" id="f-329" unitRef="usd">70507000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">81546000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-20" decimals="-3" id="f-331" unitRef="usd">112344000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-21" decimals="-3" id="f-332" unitRef="usd">229884000</us-gaap:ShareBasedCompensation>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-20" decimals="-3" id="f-334" unitRef="usd">47858000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-21" decimals="-3" id="f-335" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RestructuringCosts contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts contextRef="c-20" decimals="-3" id="f-337" unitRef="usd">4823000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts contextRef="c-21" decimals="-3" id="f-338" unitRef="usd">0</us-gaap:RestructuringCosts>
    <dna:NoncashCustomerConsideration contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">0</dna:NoncashCustomerConsideration>
    <dna:NoncashCustomerConsideration contextRef="c-20" decimals="-3" id="f-340" unitRef="usd">-1117000</dna:NoncashCustomerConsideration>
    <dna:NoncashCustomerConsideration contextRef="c-21" decimals="-3" id="f-341" unitRef="usd">-1373000</dna:NoncashCustomerConsideration>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-20" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-21" decimals="-3" id="f-344" unitRef="usd">-2635000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">-16411000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-20" decimals="-3" id="f-346" unitRef="usd">-28827000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-21" decimals="-3" id="f-347" unitRef="usd">-54827000</us-gaap:GainLossOnInvestments>
    <dna:ChangesInFairValueOfLoansReceivable contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">5685000</dna:ChangesInFairValueOfLoansReceivable>
    <dna:ChangesInFairValueOfLoansReceivable contextRef="c-20" decimals="-3" id="f-349" unitRef="usd">2014000</dna:ChangesInFairValueOfLoansReceivable>
    <dna:ChangesInFairValueOfLoansReceivable contextRef="c-21" decimals="-3" id="f-350" unitRef="usd">2416000</dna:ChangesInFairValueOfLoansReceivable>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-20" decimals="-3" id="f-352" unitRef="usd">-5701000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-21" decimals="-3" id="f-353" unitRef="usd">-5168000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">4232000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="c-20" decimals="-3" id="f-355" unitRef="usd">-3214000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="c-21" decimals="-3" id="f-356" unitRef="usd">-9168000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <us-gaap:DeconsolidationGainOrLossAmount contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount contextRef="c-20" decimals="-3" id="f-358" unitRef="usd">-7013000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount contextRef="c-21" decimals="-3" id="f-359" unitRef="usd">-42502000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">0</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-20" decimals="-3" id="f-361" unitRef="usd">-5796000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-21" decimals="-3" id="f-362" unitRef="usd">-121404000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">-1364000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-20" decimals="-3" id="f-364" unitRef="usd">-936000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-21" decimals="-3" id="f-365" unitRef="usd">-801000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-20" decimals="-3" id="f-367" unitRef="usd">-844000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-21" decimals="-3" id="f-368" unitRef="usd">-842000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">30082000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-20" decimals="-3" id="f-370" unitRef="usd">28095000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-21" decimals="-3" id="f-371" unitRef="usd">28313000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <dna:NoncashInProcessResearchAndDevelopment contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">0</dna:NoncashInProcessResearchAndDevelopment>
    <dna:NoncashInProcessResearchAndDevelopment contextRef="c-20" decimals="-3" id="f-373" unitRef="usd">19796000</dna:NoncashInProcessResearchAndDevelopment>
    <dna:NoncashInProcessResearchAndDevelopment contextRef="c-21" decimals="-3" id="f-374" unitRef="usd">9182000</dna:NoncashInProcessResearchAndDevelopment>
    <dna:AccretionOfDiscountOnMarketableSecurities contextRef="c-1" decimals="-3" id="f-375" unitRef="usd">3390000</dna:AccretionOfDiscountOnMarketableSecurities>
    <dna:AccretionOfDiscountOnMarketableSecurities contextRef="c-20" decimals="-3" id="f-376" unitRef="usd">0</dna:AccretionOfDiscountOnMarketableSecurities>
    <dna:AccretionOfDiscountOnMarketableSecurities contextRef="c-21" decimals="-3" id="f-377" unitRef="usd">0</dna:AccretionOfDiscountOnMarketableSecurities>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">-2064000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-20" decimals="-3" id="f-379" unitRef="usd">-1224000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-21" decimals="-3" id="f-380" unitRef="usd">-3194000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-25" decimals="-3" id="f-381" unitRef="usd">357000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-26" decimals="-3" id="f-382" unitRef="usd">156000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-27" decimals="-3" id="f-383" unitRef="usd">816000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">1473000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-20" decimals="-3" id="f-385" unitRef="usd">4725000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-21" decimals="-3" id="f-386" unitRef="usd">-50068000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-387" unitRef="usd">5247000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-20" decimals="-3" id="f-388" unitRef="usd">-10085000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-21" decimals="-3" id="f-389" unitRef="usd">-10473000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <dna:IncreaseDecreaseRightOfUseAssets contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">-3814000</dna:IncreaseDecreaseRightOfUseAssets>
    <dna:IncreaseDecreaseRightOfUseAssets contextRef="c-20" decimals="-3" id="f-391" unitRef="usd">-23463000</dna:IncreaseDecreaseRightOfUseAssets>
    <dna:IncreaseDecreaseRightOfUseAssets contextRef="c-21" decimals="-3" id="f-392" unitRef="usd">-9275000</dna:IncreaseDecreaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-393" unitRef="usd">-296000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-20" decimals="-3" id="f-394" unitRef="usd">1394000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-21" decimals="-3" id="f-395" unitRef="usd">-2570000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-396" unitRef="usd">-2992000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-20" decimals="-3" id="f-397" unitRef="usd">4771000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-21" decimals="-3" id="f-398" unitRef="usd">-1183000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-399" unitRef="usd">10376000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-20" decimals="-3" id="f-400" unitRef="usd">-40438000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-21" decimals="-3" id="f-401" unitRef="usd">16899000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-25" decimals="-3" id="f-402" unitRef="usd">-8147000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-26" decimals="-3" id="f-403" unitRef="usd">-51422000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-27" decimals="-3" id="f-404" unitRef="usd">-17018000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-405" unitRef="usd">-32393000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-20" decimals="-3" id="f-406" unitRef="usd">-68645000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-21" decimals="-3" id="f-407" unitRef="usd">-35917000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">-27932000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-20" decimals="-3" id="f-409" unitRef="usd">-14881000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-21" decimals="-3" id="f-410" unitRef="usd">-22800000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-411" unitRef="usd">11463000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-20" decimals="-3" id="f-412" unitRef="usd">2094000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-21" decimals="-3" id="f-413" unitRef="usd">452000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">-171059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-20" decimals="-3" id="f-415" unitRef="usd">-319585000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-21" decimals="-3" id="f-416" unitRef="usd">-295500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="0" id="f-417" unitRef="usd">418630000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-20" decimals="0" id="f-418" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-21" decimals="0" id="f-419" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="0" id="f-420" unitRef="usd">159483000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-20" decimals="0" id="f-421" unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-21" decimals="0" id="f-422" unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="0" id="f-423" unitRef="usd">25899000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-20" decimals="0" id="f-424" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-21" decimals="0" id="f-425" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-426" unitRef="usd">7665000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-20" decimals="-3" id="f-427" unitRef="usd">62541000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-21" decimals="-3" id="f-428" unitRef="usd">40801000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="c-1" decimals="-3" id="f-429" unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="c-20" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="c-21" decimals="-3" id="f-431" unitRef="usd">42980000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-432" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-20" decimals="-3" id="f-433" unitRef="usd">5400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-21" decimals="-3" id="f-434" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-1" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-20" decimals="-3" id="f-436" unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-21" decimals="-3" id="f-437" unitRef="usd">350000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-20" decimals="-3" id="f-439" unitRef="usd">4519000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-21" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-441" unitRef="usd">574000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-20" decimals="-3" id="f-442" unitRef="usd">648000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-21" decimals="-3" id="f-443" unitRef="usd">4428000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-3" id="f-444" unitRef="usd">-50000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-20" decimals="-3" id="f-445" unitRef="usd">-538000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-21" decimals="-3" id="f-446" unitRef="usd">990000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-447" unitRef="usd">-240289000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-20" decimals="-3" id="f-448" unitRef="usd">-62236000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-21" decimals="-3" id="f-449" unitRef="usd">-80693000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="0" id="f-450" unitRef="usd">19469000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-20" decimals="0" id="f-451" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-21" decimals="0" id="f-452" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="0" id="f-453" unitRef="usd">1340000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-20" decimals="0" id="f-454" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-21" decimals="0" id="f-455" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-20" decimals="-3" id="f-457" unitRef="usd">84000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-21" decimals="-3" id="f-458" unitRef="usd">93000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-20" decimals="-3" id="f-460" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-21" decimals="-3" id="f-461" unitRef="usd">23000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-462" unitRef="usd">354000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-20" decimals="-3" id="f-463" unitRef="usd">897000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-21" decimals="-3" id="f-464" unitRef="usd">1295000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="-3" id="f-465" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-20" decimals="-3" id="f-466" unitRef="usd">922000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-21" decimals="-3" id="f-467" unitRef="usd">1411000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-1" decimals="0" id="f-468" unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-20" decimals="0" id="f-469" unitRef="usd">4000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-21" decimals="0" id="f-470" unitRef="usd">580000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-471" unitRef="usd">17775000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-20" decimals="-3" id="f-472" unitRef="usd">-1739000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-21" decimals="-3" id="f-473" unitRef="usd">-3216000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-474" unitRef="usd">201000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-20" decimals="-3" id="f-475" unitRef="usd">-281000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-21" decimals="-3" id="f-476" unitRef="usd">-588000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-477" unitRef="usd">-393372000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-20" decimals="-3" id="f-478" unitRef="usd">-383841000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-21" decimals="-3" id="f-479" unitRef="usd">-379997000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-480" unitRef="usd">561572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-41" decimals="-3" id="f-481" unitRef="usd">944073000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-32" decimals="-3" id="f-482" unitRef="usd">1315792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-8" decimals="-3" id="f-483" unitRef="usd">44171000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-41" decimals="-3" id="f-484" unitRef="usd">45511000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-32" decimals="-3" id="f-485" unitRef="usd">53789000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-486" unitRef="usd">605743000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-41" decimals="-3" id="f-487" unitRef="usd">989584000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-32" decimals="-3" id="f-488" unitRef="usd">1369581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-489" unitRef="usd">167202000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-490" unitRef="usd">561572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-41" decimals="-3" id="f-491" unitRef="usd">944073000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-7" decimals="-3" id="f-492" unitRef="usd">45169000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-8" decimals="-3" id="f-493" unitRef="usd">44171000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-41" decimals="-3" id="f-494" unitRef="usd">45511000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-495" unitRef="usd">212371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-496" unitRef="usd">605743000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-41" decimals="-3" id="f-497" unitRef="usd">989584000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c-1" id="f-498">Organization and Basis of Presentation &lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ginkgo Bioworks Holdings, Inc.'s (&#x201c;Ginkgo&#x201d; or the &#x201c;Company&#x201d;) mission is to make biology easier to engineer. Ginkgo sells services to government and commercial customers in two business segments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cell engineering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, where we provide tools and biological R&amp;amp;D services across a range of industries, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;biosecurity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, where we provide services to customers who are working to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cell Engineering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ginkgo does not make end products; instead, Ginkgo offers biological R&amp;amp;D services on our platform to enable our customers to bring their products to market. Historically, Ginkgo&#x2019;s primary service offering has been cell engineering R&amp;amp;D services (solutions) where Ginkgo performs technical activities. In 2024, Ginkgo expanded its service offering to include services that provide our customers cell engineering tools for biological R&amp;amp;D, where Ginkgo enables its customers to conduct certain in-house R&amp;amp;D activities themselves. Ginkgo's services are designed to offer customers better results on the dimensions of probability of success, speed, or cost &#x2013; and ideally on all three. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Autonomous Lab is a flexible wet lab built from our Reconfigurable Automation Cart (&#x201c;RAC&#x201d;) systems capable of large scale data generation; it powers generative AI and machine learning (&#x201c;ML&#x201d;) tools that enable more successful biological R&amp;amp;D.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Biosecurity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ginkgo's primary biosecurity customers are governments. Ginkgo currently provides biosecurity services via two core offerings as introduced in early 2024:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Canopy, which helps our customers generate high value genomic data from strategically positioned nodes (like airports and border checkpoints) via end-to-end biomonitoring programs; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Horizon, our digital surveillance, analytics and insights platform that detects and monitors biothreats worldwide.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-499"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <dna:NumberOfCoreOfferings
      contextRef="c-7"
      decimals="INF"
      id="f-500"
      unitRef="offering">2</dna:NumberOfCoreOfferings>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-501">Summary of Significant Accounting Policies &lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, majority owned subsidiaries and variable interest entities if the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2024 (the &#x201c;Effective Date&#x201d;), with the approval of the Company's board of directors and shareholders, the Company effected a one-for-forty (1:40) reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) for the Company&#x2019;s common stock (inclusive of Class A common stock, Class B common stock and Class C common stock, par value $0.0001 per share). Accordingly, all common shares, common stock equity awards and common stock per share amounts presented herein have been retrospectively adjusted to reflect the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Effective Date, every forty shares of common stock issued and outstanding immediately prior to the Effective Date were automatically combined into one share of such class of common stock without any change to the par value per share. The number of shares reserved under the Company&#x2019;s equity plans and the number of shares underlying awards outstanding under the Company&#x2019;s equity plans was reduced proportionately. No fractional shares were issued in connection with the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reverse Stock Split. Shareholders entitled to receive a fractional share as a result of the Reverse Stock Split received a cash payment in lieu of such fractional shares. The number of authorized shares of common stock was not reduced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its variable interests in variable interest entities (&#x201c;VIE&#x201d;) and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of each VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion. As of December&#160;31, 2025 and 2024, the maximum risk of loss related to the Company&#x2019;s VIEs was limited to the carrying value of its investment in such entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the consolidated financial statements. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Reported amounts and disclosures reflect the overall economic conditions that management believes are most likely to occur, and the anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, trade accounts receivable, marketable securities and notes receivable. The Company&#x2019;s cash and cash equivalents and restricted cash are maintained in bank deposit accounts and money market funds that regularly exceed federally insured limits. The Company is exposed to credit risk on its cash, cash equivalents and restricted cash in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company believes that it is not exposed to significant credit risk as its deposits are generally held in financial institutions that management believes to be of high credit quality. To date, the Company has not experienced any material write-offs related to its trade accounts receivable. A portion of the Company&#x2019;s Biosecurity revenue is derived from sales of services to foreign government agencies in certain developing countries. The Company is exposed to credit risk on its marketable securities. The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s policy is for no one issuer or group of issuers from the same holding company is to exceed 10% of the marketable securities portfolio at the time of purchase, with the exception of U.S. government securities or agencies, U.S. Treasuries, bank sweep and deposit programs and money market funds.  The Company&#x2019;s maximum credit risk exposure with respect to notes receivable is equivalent to the carrying value of the notes as of the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2025, one customer in the Cell Engineering segment accounted for 15% of the Company&#x2019;s total revenue, while one customer in the Biosecurity segment accounted for 12% of the Company&#x2019;s total revenue. For the year ended December&#160;31, 2024, two customers in the Cell Engineering segment accounted for 13% and 20% of the Company&#x2019;s total revenue, while one customer in the Biosecurity segment accounted for 16% of the Company&#x2019;s total revenue. For the year ended December&#160;31, 2023, one customer in the Cell Engineering segment and one customer in the Biosecurity segment accounted for 12% and 11%, respectively, of the Company's total revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash is comprised of bank deposits, overnight sweep accounts and money market funds. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying value of the Company&#x2019;s cash and cash equivalents approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash primarily includes cash balances collateralizing letters of credit associated with the Company&#x2019;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agreement. Restricted cash is included in prepaid expenses and other current assets and other non-current assets on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains an allowance for credit losses to provide for the estimated amounts of receivables that will not be collected over the estimated life of the assets. The allowance is calculated by considering previous loss history, delinquency of receivables balances, current economic conditions and anticipated future economic conditions in the geographies and industries in which the Company&#x2019;s customers operate. To the extent an individual customer&#x2019;s credit quality deteriorates, the Company measures an allowance based on the risk characteristics of the individual customer. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. The allowance is calculated at each reporting period with changes recorded to general and administrative expense in the consolidated statements of operations and comprehensive loss. Accounts receivable are net of an allowance for credit losses of $2.2 million and $1.9 million at December&#160;31, 2025 and 2024, respectively. There were no material changes in the allowance for credit losses for the years ended December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2025, the Company began investing its excess cash in marketable debt securities. All debt securities are classified as available-for-sale at the time of purchase. Available-for-sale debt securities, including those with maturities extending beyond one year, are classified as current assets on the balance sheet due to their highly liquid nature and because they are considered available for use in current operations. Debt securities that are highly liquid and have original maturities of three months or less at the time of acquisition are classified as cash equivalents on the consolidated balance sheet. The Company considers securities to be highly liquid if they can be readily converted to cash with an insignificant risk of changes in value, typically due to active markets and high credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses on available-for-sale marketable debt securities that are not related to credit losses are included in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. Amortization of premium or accretion of discount, along with interest income earned on debt securities, is included in interest income, net. Realized gains and losses, if any, are included in other income (expense), net, and the cost of securities sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the balance sheet date, the Company evaluates its debt securities in an unrealized loss position to determine the extent of the loss, if any, that is attributable to expected credit losses. Expected credit losses on debt securities are recorded as an allowance on the balance sheet, with an offsetting amount recognized in other income (expense), net, in the consolidated statements of operations and comprehensive loss. To date, the Company has not recorded any credit losses on its marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities also includes equity securities of publicly-traded companies that are considered to be available for use in current operations. Equity securities of publicly-traded companies that are not considered to be available for use in current operations are presented within investments on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment, net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost less accumulated depreciation. Land is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets or the remaining lease term for leasehold improvements. Estimated lives of property, plant and equipment are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Buildings and facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15 to 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the related cost and accumulated depreciation is removed from the balance sheet and any resulting gain or loss is recorded in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the consolidated statements of operations and comprehensive loss. Construction in progress relates to assets which have not been placed in service as of the period end. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the equity method to account for its investments in common stock, or in-substance common stock, when it possesses the ability to exercise significant influence, but not control, over the operating and financial policies of the investee. The Company uses judgment when determining the level of influence over the operating and financial policies of the investee considering key factors including, among others, the Company&#x2019;s ownership interest, representation on the board of directors, participation in policy-making decisions and material contractual arrangements and obligations. Income and losses are allocated based upon relative ownership interest unless there is a substantive profit-sharing agreement in place. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For investments with a substantive profit-sharing agreement, the Company utilizes the hypothetical liquidation at book value (&#x201c;HLBV&#x201d;) method to allocate income and losses from the equity method investment. Under the HLBV method, the Company utilizes the capital account at the end of the period assuming the book value of the entity was liquidated or sold minus the same calculation at the beginning of the period. The difference is the share of earnings or losses attributable to the equity method investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the equity method, if there is a commitment for the Company to fund the losses of its equity method investees, the Company would continue to record its share of losses resulting in a negative equity method investment, which would be presented as a liability on the consolidated balance sheet. Commitments may be explicit and may include formal guarantees, legal obligations, or arrangements by contract. Implicit commitments may arise from reputational expectations, intercompany relationships, statements by the Company of its intention to provide support, a history of providing financial support or other facts and circumstances. When the Company has no commitment to fund the losses of its equity method investees, the carrying value of its equity method investments will not be reduced below zero. The Company had no commitment to fund additional losses of its equity method investments during the years ended December&#160;31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its equity method investments for impairment whenever events or circumstances indicate that the carrying value of the investment may not be recoverable. The Company considers the investee&#x2019;s financial position, forecasts and economic outlook, and the estimated duration and extent of losses to determine whether a recovery is anticipated. An impairment that is other-than-temporary is recognized in the period identified. The Company has not recognized an impairment loss related to its equity method investments for the years ended December&#160;31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may elect the fair value option for its equity method investments on an investment-by-investment basis. For all equity method investments accounted for under the fair value option, the Company carries the equity method investment at fair value and records all subsequent changes in fair value as a component of loss on equity method investments in the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments include marketable equity securities in publicly-traded companies, non-marketable equity securities in privately-held companies, Simple Agreement for Future Equity (&#x201c;SAFE&#x201d;) and warrants, in each case, in which the Company does not possess the ability to exercise significant influence over the investee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable equity securities or warrants of publicly-traded companies are measured at fair value with subsequent changes in fair value recorded in loss on investments in the consolidated statements of operations and comprehensive loss. Marketable equity securities are classified as non-current on the balance sheet if they are not currently available for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in non-marketable equity securities of privately-held companies and SAFEs, which do not have readily determinable fair values, are carried at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Each period the Company assesses relevant transactions to identify observable price changes, and the Company regularly monitors these investments to evaluate whether there is an indication of impairment. An equity security without a readily determinable fair value is written down to its fair value if a qualitative assessment indicates that the investment is impaired and the fair value of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment is less than its carrying value. For periods in which there is no estimate of fair value, the Company evaluates whether an event or change in circumstances has occurred that may have a significant adverse effect on the value of the investment. See Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on Investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value and requires disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1- Quoted prices (unadjusted) in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2- Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3- Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are either less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company valued its money market fund holdings, notes receivable  marketable debt securities, marketable equity securities, warrant liabilities and contingent consideration liabilities at fair value on a recurring basis. The carrying amounts of the Company&#x2019;s other financial instruments, which include accounts receivable, certain prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its long-lived assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the carrying value of the long-lived assets to the future undiscounted cash flows expected to be generated by the assets. In determining the expected future cash flows, the Company uses assumptions believed to be reasonable, but which inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of long-lived asset is less than the carrying value. See Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_575" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of impairment losses recorded on long-lived assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognizes any excess of the total consideration paid over the fair value of the identifiable net assets as goodwill. Any purchase price that is considered contingent consideration is measured at its estimated fair value at the acquisition date and remeasured at each reporting period, with changes in estimated fair value recorded in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Acquisition transaction costs are expensed when incurred. The operating results of an acquisition are included in the Company&#x2019;s consolidated financial statements as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net consist of certain definite-lived assets including patents, processes and know-how related to technology acquired through business combinations and asset acquisitions. The Company amortizes such intangible assets on a straight-line basis over their estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represented the excess of the acquisition cost over the fair market value of the net assets acquired. All goodwill was allocated to the Cell Engineering reporting unit and segment identified in Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_187" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;16&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company considers various qualitative factors that could indicate impairment of goodwill such as macroeconomic conditions, industry and market environment, overall financial performance of the Company, cash flow from operating activities and market capitalization. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment to compare the fair value of the reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds the fair value, an impairment loss is recognized limited to the total amount of goodwill allocated to that reporting unit. A combination of the income approach and the market approach may be used to determine fair value of the reporting unit. The Company recorded a full goodwill impairment during the year ended December 31, 2024 (see Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_160" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). No impairment losses were recognized during the years ended December 31, 2025, and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determines if an arrangement is or contains a lease at contract inception based on the terms and conditions in the contract. A contract contains a lease if there is an identified asset and the Company has the right to control the asset. For leases with terms greater than 12 months, the Company recognizes a right-of-use asset (&#x201c;ROU asset&#x201d;) and a lease liability as of the lease commencement date on the balance sheet. ROU assets represent the Company&#x2019;s right to use an underlying asset over the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are measured based on the present value of fixed lease payments that are unpaid as of the lease commencement date. The Company&#x2019;s ROU assets balance is increased by any initial direct costs and reduced by lease incentives received or expected to be received. Some of the Company's leases include options to extend or terminate the lease; these options are included in the lease term for calculations of its ROU assets and liabilities when it is reasonably certain that the Company will exercise those options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s leases are classified as either operating or finance, as determined at inception, with the classification affecting the pattern of expense recognition in the statement of operations. A lease is classified as a finance lease if risks and rewards are conveyed without the transfer of control. For operating leases, expense is generally recognized on a straight-line basis over the lease term. For finance leases, interest on the lease liability is recognized using the effective interest method, while the ROU asset is amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term. Leases with an initial term of 12 months or less which meet the definition of a short-term lease are not recorded on the balance sheet and the lease expense for these leases is recognized on a straight-line basis over the lease term. In limited instances, the Company acts as a lessor, primarily with certain real estate subleases. Finance leases, short-term leases and subleases are not a significant component of the Company's financial condition or results of operations. The current portion of the Company&#x2019;s operating lease liabilities is included in accrued expenses and other current liabilities on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements with both lease and non-lease components (such as real estate taxes, insurance and common area maintenance charges) and has elected the practical expedient to combine these lease and non-lease components for its real estate leases and non-lab equipment leases. The Company has not elected this practical expedient for lab equipment leases and the lease and non-lease components are accounted for separately for these leases. Non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of the Company&#x2019;s leases do not provide an implicit interest rate, the Company uses an incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments and uses the implicit rate when it is readily determinable. The Company&#x2019;s incremental borrowing rate is based on management&#x2019;s estimate of the rate of interest the Company would have to pay to borrow on a fully collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cell Engineering Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates Cell Engineering service revenue by providing end-to-end cell engineering solutions and tools to customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate Cell Engineering revenue primarily through service and license agreements for our tools and solutions offerings. Under our automation solutions agreements we typically provide services related to the design, build, and deployment of our RAC systems as well as ongoing support services. These agreements typically include a fee for the sale and installation of RAC hardware and a fee for follow on support services and control software. Datapoints agreements typically include fixed fees for services related to producing a data package for our customers and are earned over a shorter time period than legacy cell engineering solutions projects.  Under our solutions agreements, we typically provide R&amp;amp;D services for cell programming with the goal of producing an engineered cell that meets a mutually agreed specification. Our customers obtain license rights to the output of our services, which are primarily the optimized strains or cell lines, in order to manufacture and commercialize products derived from that licensed strain or cell line. Generally, the terms of these agreements provide that we receive some combination of: (1) service fees in the form of (i) upfront payments upon consummation of the agreement or other fixed payments, (ii) reimbursement for costs incurred for R&amp;amp;D services and (iii) milestone payments upon the achievement of specified technical criteria, plus (2) downstream value share payments in the form of (i) milestone payments upon the achievement of specified commercial criteria, (ii) royalties on sales of products from or comprising engineered organisms arising from the collaboration or licensing agreement and/or (iii) royalties related to cost of goods sold reductions realized by our customers. Royalties did not comprise a material amount of our revenue during any of the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cell Engineering revenue has historically included transactions with Platform Ventures and Legacy Structured Partnerships where we received non-cash consideration in the form of equity interests and financial instruments that are convertible into equity upon a triggering event.  We view the upfront non-cash consideration as prepayments for licenses which will be granted in the future as we complete mutually agreed upon technical development plans. In these instances, we also receive cash consideration for the R&amp;amp;D services performed by us on a fixed fee or cost-plus basis. We are not compensated through additional milestone or royalty payments under these arrangements. As we perform R&amp;amp;D services under the mutually agreed upon development plans, we recognize a reduction in the prefunded obligation on a cost-plus basis. In some cases we issued the customer a prepaid Cell Engineering services credit in exchange for the upfront non-cash consideration, which can and has been drawn down as payment for R&amp;amp;D services performed under mutually agreed upon development plans. These arrangements are further described in Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_157" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;8&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to acquire additional distinct goods and services are evaluated to determine if such options provide a material right to the customer that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which is accounted for as a separate contract upon the customer&#x2019;s election of the option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. Any upfront cash payment received upon consummation of the contract is fixed and generally nonrefundable. Variable consideration is subject to a constraint, and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. This is attained when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursement for costs incurred for the Company&#x2019;s research and development efforts, milestone payments upon the achievement of certain technical and/or commercial criteria, and royalties on sales of products from or comprising engineered organisms arising from the contract. With respect to the research and development reimbursements and milestone payments, the Company uses the most likely amount method to estimate variable consideration. Milestone payments are generally not included in the transaction price until the milestone is achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain agreements include payment in the form of equity securities or other financial instruments that convert into equity upon a triggering event. Any non-cash consideration is measured at its estimated fair value at contract inception. For equity securities and financial instruments that are not actively traded, the estimated fair value is generally determined by referencing a recent financing round or utilizing a scenario-based valuation model. Significant unobservable inputs are used in these valuations, including expectations regarding future financings of the customer, scenario dates and probabilities, expected volatility, discount rates, and recovery rates. Changes in these assumptions can materially affect the fair value of the non-cash consideration and, consequently, the total revenue recognized for the contract. The Company did not have material non-cash consideration included in contracts entered into during  the years ended December&#160;31, 2025 and 2024, but does continue to recognize non-cash revenue from contracts originating in prior periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements with promises that are combined into a single performance obligation, the entire transaction price is allocated to the single performance obligation. For agreements with multiple performance obligations, the transaction price is allocated to the performance obligations using the relative standalone selling price methodology. For agreements featuring variable consideration, the Company allocates variable consideration to one or more, but not all, performance obligations if certain conditions are met. Specifically, the Company assesses whether the variable consideration relates solely to its efforts to satisfy the performance obligation and whether allocating such variable consideration entirely to the performance obligation is consistent with the overall allocation objective. If these conditions are not met, the Company allocates the variable consideration based on the relative standalone selling price methodology. The key assumptions utilized in determining the standalone selling price for each performance obligation include development timelines, estimated research and development costs, commercial markets, likelihood of exercise (in the case of options considered to be material rights), and probabilities of success. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements where licenses or assignments are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time when the license is effectively granted, as the licenses or assignments represent functional intellectual property. For agreements where licenses and research and development services are combined into a single performance obligation, the Company recognizes revenue over the performance period using the cost-to-cost method. This method measures progress based on the ratio of costs incurred to date to total estimated costs, as it best reflects the transfer of control to the customer for obligations satisfied over time. For automation sales the Company typically recognizes revenue at a point in time at which the hardware has been installed and passed acceptance testing at the customer site. The ongoing support services are recognized over time on a straight line basis over the related support period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its measure of progress to recognize revenue at each reporting period and, as necessary, adjusts the measure of progress and related revenue recognition. The Company&#x2019;s measure of progress and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs to complete its performance obligations. The Company evaluates contract modifications and amendments to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis. The Company utilizes the right to invoice practical expedient when it has a right to consideration in an amount that corresponds directly with the value of the Company&#x2019;s performance to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties are recognized as revenue when (or as) the later of the sales occurrence or the satisfaction (or partial satisfaction) of the related performance obligation. The Company has determined that applying this exception is appropriate when the license granted in the contract is the predominant item to which the royalties relate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company receives upfront payments for technical services under certain of its arrangements, the Company evaluates whether any significant financing components exist given the term over which the fees will be earned may exceed one year. Based on the nature of the Company&#x2019;s agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing, but rather to secure technical services, exclusivity rights, and Foundry capacity, or the timing of transfer of those goods or services is at the discretion of the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue represents consideration received by the Company in excess of revenue recognized and primarily results from transactions where the Company receives upfront cash payments or non-cash equity consideration. In instances where the Company has received consideration in advance for an undefined number of technical development plans (&#x201c;TDPs&#x201d;) under its customer agreements, the Company records the advance payments as deferred revenue, net of current portion on the consolidated balance sheet. Upon the execution of a specific TDP, the Company reclassifies the estimated consideration to be earned under that TDP within the next twelve months as current deferred revenue. The Company also classifies unexercised material rights related to future TDPs as deferred revenue, net of current portion on the consolidated balance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sheet. When a TDP is executed, and the material right is exercised, the amount allocated to the material right, which will be earned within the next twelve months, is reclassified to current deferred revenue. All other deferred revenue is classified as current or non-current based on the timing of when the Company expects to earn the underlying revenue based upon the projected progress of activities under the TDP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December&#160;31, 2025 any costs to obtain contracts with customers were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Biosecurity Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates Biosecurity revenue through its biomonitoring and bioinformatics services provided to both government and non-government customers through the Company's two core offerings: Canopy and Horizon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2024, product revenue consisted of sales of lateral flow assay (&#x201c;LFA&#x201d;) diagnostic test kits, polymerase chain reaction (&#x201c;PCR&#x201d;) sample collection kits, and pooled test kits, which the Company sold to customers on a standalone basis. Product revenue was billed and recognized when the test kits were shipped, and risk of loss was transferred to the carrier. The Company&#x2019;s test kits were generally not subject to a customer right of return except for product recalls under the rules and regulations of the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;). The Company included shipping and handling fees billed to customers as a component of Biosecurity revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biosecurity service revenue generally consists of various biomonitoring and bioinformatics services including, but not limited to, sample collection, sample storage and transportation, outsourced laboratory analysis, access to results reported through a web-based portal, analytical reporting of results, and overall program management. The various services are generally combined into one performance obligation as they are either not distinct or have substantially the same pattern of transfer to the customer. Service revenue is generally recognized over time using the time elapsed method as the related services are performed, which best depicts the pattern of transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts with customers are generally three years or less in length and contain a fixed amount of consideration. Under typical payment terms for testing services, amounts are billed monthly in arrears for services performed or in advance based on contractual billing terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to acquire additional services are evaluated to determine whether they provide the customer with a material right that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer, and upon the customer's election of the option, it is accounted for as a separate contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Biosecurity Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of Biosecurity service revenue consists of costs related to the Company's biomonitoring and bioinformatics services. This includes costs incurred for sample collection equipment, services and materials, outsourced laboratory analysis, access to results reported through a proprietary web-based portal, and reporting of results to public authorities. Additionally, the cost of Biosecurity service revenue includes direct labor cost associated with bioinformatics, lab network management, delivery logistics, and customer support. Prior to 2024, cost of Biosecurity product revenue consisted of costs associated with the sale of diagnostic and sample collection test kits, which included costs incurred to purchase test kits from third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of other revenue consists of costs related to the Company's Cell Engineering tools offerings, including Datapoints and lab automation solutions. Such costs primarily include hardware, software, materials and labor. Costs related to the Company&#x2019;s end-to-end cell engineering solutions offering in which the Company retains rights to intellectual property are included in research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects and initiatives, acquired intellectual property deemed to be in-process research and development, as well as fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all costs as incurred in connection with the filing, prosecution, maintenance, defense, and enforcement of patent applications, including direct application fees and related legal and consulting expenses. Patent costs are included in general and administrative expenses within the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock-based awards based on estimated grant-date fair values recognized over the requisite service period. For awards that vest solely based on a service condition, the Company recognizes compensation expense on a straight-line basis over the requisite service period. For awards that vest based on multiple conditions, the Company recognizes compensation expense using the accelerated attribution method on a tranche-by-tranche basis over the requisite service period such that the amount of compensation expense recognized at each reporting period is at least equal to the vested tranches at that date. For awards with a performance-based vesting condition, the Company recognizes stock-based compensation when achievement of the performance condition is deemed probable. Upon achieving a performance condition that was not previously considered as probable, the Company records a cumulative catch-up adjustment to reflect the portion of the grantee&#x2019;s requisite service that has been provided to date. For awards with market conditions, the compensation expense recognized over the requisite service period is not reversed if the market condition is not satisfied. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model, inclusive of assumptions for expected term, expected volatility, risk-free interest rate and expected dividend yield. The expected term is determined using the &#x201c;simplified&#x201d; method, which estimates the expected term as the average of the vesting term plus the contractual term. The Company uses the &#x201c;simplified&#x201d; method as it does not have sufficient historical data regarding employee exercise behavior. Expected volatility is based on the historical volatility of the Company's Class A common stock. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the stock options. The Company has not paid, and does not expect to pay, dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For awards with market conditions, the Company recognizes stock-based compensation based on the estimated grant-date fair value of the awards, determined using a Monte Carlo simulation model. This model incorporates assumptions for expected stock price volatility, risk-free interest rates, expected term, and expected dividend yield. Volatility is estimated using either the historical volatility of the Company&#x2019;s Class A common stock or a weighted average of its own historical volatility and the historical volatility of selected comparable publicly traded companies, particularly for awards granted when there was limited trading history for the Company&#x2019;s Class A common stock. The risk-free interest rate is derived from the yield on U.S. Treasury zero-coupon securities with a duration similar to the expected term of the awards. The expected term equals the contractual term, and a dividend yield of zero is assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an annual basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2025 and 2024, the Company did not have any uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, a budget and reconciliation package known as the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was signed into law in the United States. Among other provisions, the OBBBA amends U.S. tax law including the permanent extension of certain expiring provisions of the 2017 Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The OBBBA did not have a material impact on the Company&#x2019;s consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gains on available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic net loss per share by dividing the net loss attributable to Ginkgo Bioworks Holdings, Inc. common stockholders by the weighted average number of common shares outstanding during the period. For the purposes of the net loss per share calculation, the Company has combined Class A common stock, Class B common stock, and Class C common stock, as all classes of common stock are legally entitled to equal per-share distributions, whether through dividends or liquidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is computed using the weighted average number of common shares outstanding during the period, increased to include the effect of dilutive potential common shares, such as outstanding stock options, unvested restricted stock awards, unvested restricted stock units, warrants, and contingently issued shares. Dilutive securities are excluded from the calculation of diluted weighted average common shares outstanding if their effect would be anti-dilutive under the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which focuses on improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this ASU require that public business entities on an annual basis (1) disclose specific categories in the tabular rate reconciliation, using both percentages and reporting currency amounts, and (2) provide additional information for reconciling items that meet a quantitative threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company adopted this standard on January 1, 2025 using the prospective method. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This ASU requires public business entities to disaggregate, on both an interim and annual basis, each relevant expense caption presented on the face of the income statement into specific expense categories. Additionally, entities are required to provide a qualitative description of amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, as well as disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this ASU will have on its disclosures in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-502">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-503">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, majority owned subsidiaries and variable interest entities if the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-504">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2024 (the &#x201c;Effective Date&#x201d;), with the approval of the Company's board of directors and shareholders, the Company effected a one-for-forty (1:40) reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) for the Company&#x2019;s common stock (inclusive of Class A common stock, Class B common stock and Class C common stock, par value $0.0001 per share). Accordingly, all common shares, common stock equity awards and common stock per share amounts presented herein have been retrospectively adjusted to reflect the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Effective Date, every forty shares of common stock issued and outstanding immediately prior to the Effective Date were automatically combined into one share of such class of common stock without any change to the par value per share. The number of shares reserved under the Company&#x2019;s equity plans and the number of shares underlying awards outstanding under the Company&#x2019;s equity plans was reduced proportionately. No fractional shares were issued in connection with the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reverse Stock Split. Shareholders entitled to receive a fractional share as a result of the Reverse Stock Split received a cash payment in lieu of such fractional shares. The number of authorized shares of common stock was not reduced.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-505"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c-1" id="f-506">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities &lt;/span&gt;&lt;/div&gt;The Company evaluates its variable interests in variable interest entities (&#x201c;VIE&#x201d;) and consolidates VIEs when the Company is the primary beneficiary. The Company determines whether it is the primary beneficiary of each VIE based on its assessment of whether the Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance and (ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary conclusion. As of December&#160;31, 2025 and 2024, the maximum risk of loss related to the Company&#x2019;s VIEs was limited to the carrying value of its investment in such entities.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-507">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the consolidated financial statements. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Reported amounts and disclosures reflect the overall economic conditions that management believes are most likely to occur, and the anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-508">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, trade accounts receivable, marketable securities and notes receivable. The Company&#x2019;s cash and cash equivalents and restricted cash are maintained in bank deposit accounts and money market funds that regularly exceed federally insured limits. The Company is exposed to credit risk on its cash, cash equivalents and restricted cash in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company believes that it is not exposed to significant credit risk as its deposits are generally held in financial institutions that management believes to be of high credit quality. To date, the Company has not experienced any material write-offs related to its trade accounts receivable. A portion of the Company&#x2019;s Biosecurity revenue is derived from sales of services to foreign government agencies in certain developing countries. The Company is exposed to credit risk on its marketable securities. The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s policy is for no one issuer or group of issuers from the same holding company is to exceed 10% of the marketable securities portfolio at the time of purchase, with the exception of U.S. government securities or agencies, U.S. Treasuries, bank sweep and deposit programs and money market funds.  The Company&#x2019;s maximum credit risk exposure with respect to notes receivable is equivalent to the carrying value of the notes as of the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2025, one customer in the Cell Engineering segment accounted for 15% of the Company&#x2019;s total revenue, while one customer in the Biosecurity segment accounted for 12% of the Company&#x2019;s total revenue. For the year ended December&#160;31, 2024, two customers in the Cell Engineering segment accounted for 13% and 20% of the Company&#x2019;s total revenue, while one customer in the Biosecurity segment accounted for 16% of the Company&#x2019;s total revenue. For the year ended December&#160;31, 2023, one customer in the Cell Engineering segment and one customer in the Biosecurity segment accounted for 12% and 11%, respectively, of the Company's total revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-58" decimals="2" id="f-509" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-59" decimals="2" id="f-510" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-60" decimals="2" id="f-511" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-61" decimals="2" id="f-512" unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-62" decimals="2" id="f-513" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-63" decimals="2" id="f-514" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-64" decimals="2" id="f-515" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-516">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;The Company&#x2019;s cash is comprised of bank deposits, overnight sweep accounts and money market funds. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying value of the Company&#x2019;s cash and cash equivalents approximate fair value due to their short-term maturities.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-517">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash primarily includes cash balances collateralizing letters of credit associated with the Company&#x2019;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agreement. Restricted cash is included in prepaid expenses and other current assets and other non-current assets on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="c-1" id="f-518">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains an allowance for credit losses to provide for the estimated amounts of receivables that will not be collected over the estimated life of the assets. The allowance is calculated by considering previous loss history, delinquency of receivables balances, current economic conditions and anticipated future economic conditions in the geographies and industries in which the Company&#x2019;s customers operate. To the extent an individual customer&#x2019;s credit quality deteriorates, the Company measures an allowance based on the risk characteristics of the individual customer. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. The allowance is calculated at each reporting period with changes recorded to general and administrative expense in the consolidated statements of operations and comprehensive loss. Accounts receivable are net of an allowance for credit losses of $2.2 million and $1.9 million at December&#160;31, 2025 and 2024, respectively. There were no material changes in the allowance for credit losses for the years ended December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2025, the Company began investing its excess cash in marketable debt securities. All debt securities are classified as available-for-sale at the time of purchase. Available-for-sale debt securities, including those with maturities extending beyond one year, are classified as current assets on the balance sheet due to their highly liquid nature and because they are considered available for use in current operations. Debt securities that are highly liquid and have original maturities of three months or less at the time of acquisition are classified as cash equivalents on the consolidated balance sheet. The Company considers securities to be highly liquid if they can be readily converted to cash with an insignificant risk of changes in value, typically due to active markets and high credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses on available-for-sale marketable debt securities that are not related to credit losses are included in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. Amortization of premium or accretion of discount, along with interest income earned on debt securities, is included in interest income, net. Realized gains and losses, if any, are included in other income (expense), net, and the cost of securities sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the balance sheet date, the Company evaluates its debt securities in an unrealized loss position to determine the extent of the loss, if any, that is attributable to expected credit losses. Expected credit losses on debt securities are recorded as an allowance on the balance sheet, with an offsetting amount recognized in other income (expense), net, in the consolidated statements of operations and comprehensive loss. To date, the Company has not recorded any credit losses on its marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities also includes equity securities of publicly-traded companies that are considered to be available for use in current operations. Equity securities of publicly-traded companies that are not considered to be available for use in current operations are presented within investments on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-7" decimals="-5" id="f-519" unitRef="usd">2200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-8" decimals="-5" id="f-520" unitRef="usd">1900000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-521">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment, net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost less accumulated depreciation. Land is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets or the remaining lease term for leasehold improvements. Estimated lives of property, plant and equipment are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Buildings and facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15 to 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for maintenance and repairs are expensed as incurred. When assets are retired or otherwise disposed of, the related cost and accumulated depreciation is removed from the balance sheet and any resulting gain or loss is recorded in &lt;/span&gt;&lt;/div&gt;the consolidated statements of operations and comprehensive loss. Construction in progress relates to assets which have not been placed in service as of the period end.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-522">Estimated lives of property, plant and equipment are as follows: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Buildings and facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15 to 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.014%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.965%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;150,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;140,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Buildings and facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;358,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;364,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(190,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(160,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;167,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;203,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-65" id="f-523">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-66" id="f-524">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-67" id="f-525">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-68" id="f-526">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-69" id="f-527">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-70" id="f-528">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-71" id="f-529">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-72" id="f-530">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-531">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the equity method to account for its investments in common stock, or in-substance common stock, when it possesses the ability to exercise significant influence, but not control, over the operating and financial policies of the investee. The Company uses judgment when determining the level of influence over the operating and financial policies of the investee considering key factors including, among others, the Company&#x2019;s ownership interest, representation on the board of directors, participation in policy-making decisions and material contractual arrangements and obligations. Income and losses are allocated based upon relative ownership interest unless there is a substantive profit-sharing agreement in place. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For investments with a substantive profit-sharing agreement, the Company utilizes the hypothetical liquidation at book value (&#x201c;HLBV&#x201d;) method to allocate income and losses from the equity method investment. Under the HLBV method, the Company utilizes the capital account at the end of the period assuming the book value of the entity was liquidated or sold minus the same calculation at the beginning of the period. The difference is the share of earnings or losses attributable to the equity method investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the equity method, if there is a commitment for the Company to fund the losses of its equity method investees, the Company would continue to record its share of losses resulting in a negative equity method investment, which would be presented as a liability on the consolidated balance sheet. Commitments may be explicit and may include formal guarantees, legal obligations, or arrangements by contract. Implicit commitments may arise from reputational expectations, intercompany relationships, statements by the Company of its intention to provide support, a history of providing financial support or other facts and circumstances. When the Company has no commitment to fund the losses of its equity method investees, the carrying value of its equity method investments will not be reduced below zero. The Company had no commitment to fund additional losses of its equity method investments during the years ended December&#160;31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its equity method investments for impairment whenever events or circumstances indicate that the carrying value of the investment may not be recoverable. The Company considers the investee&#x2019;s financial position, forecasts and economic outlook, and the estimated duration and extent of losses to determine whether a recovery is anticipated. An impairment that is other-than-temporary is recognized in the period identified. The Company has not recognized an impairment loss related to its equity method investments for the years ended December&#160;31, 2025, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;The Company may elect the fair value option for its equity method investments on an investment-by-investment basis. For all equity method investments accounted for under the fair value option, the Company carries the equity method investment at fair value and records all subsequent changes in fair value as a component of loss on equity method investments in the consolidated statements of operations and comprehensive loss.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:OtherCommitment contextRef="c-73" decimals="INF" id="f-532" unitRef="usd">0</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-74" decimals="INF" id="f-533" unitRef="usd">0</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment contextRef="c-75" decimals="INF" id="f-534" unitRef="usd">0</us-gaap:OtherCommitment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-21" decimals="INF" id="f-535" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-20" decimals="INF" id="f-536" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-1" decimals="INF" id="f-537" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-538">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments include marketable equity securities in publicly-traded companies, non-marketable equity securities in privately-held companies, Simple Agreement for Future Equity (&#x201c;SAFE&#x201d;) and warrants, in each case, in which the Company does not possess the ability to exercise significant influence over the investee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable equity securities or warrants of publicly-traded companies are measured at fair value with subsequent changes in fair value recorded in loss on investments in the consolidated statements of operations and comprehensive loss. Marketable equity securities are classified as non-current on the balance sheet if they are not currently available for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in non-marketable equity securities of privately-held companies and SAFEs, which do not have readily determinable fair values, are carried at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Each period the Company assesses relevant transactions to identify observable price changes, and the Company regularly monitors these investments to evaluate whether there is an indication of impairment. An equity security without a readily determinable fair value is written down to its fair value if a qualitative assessment indicates that the investment is impaired and the fair value of the &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment is less than its carrying value. For periods in which there is no estimate of fair value, the Company evaluates whether an event or change in circumstances has occurred that may have a significant adverse effect on the value of the investment. See Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt; for additional information on Investments.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-539">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes its assets and liabilities measured at fair value in accordance with the authoritative accounting guidance that establishes a consistent framework for measuring fair value and requires disclosures for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1- Quoted prices (unadjusted) in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2- Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3- Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are either less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/span&gt;&lt;/div&gt;The Company valued its money market fund holdings, notes receivable  marketable debt securities, marketable equity securities, warrant liabilities and contingent consideration liabilities at fair value on a recurring basis. The carrying amounts of the Company&#x2019;s other financial instruments, which include accounts receivable, certain prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-540">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its long-lived assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the carrying value of the long-lived assets to the future undiscounted cash flows expected to be generated by the assets. In determining the expected future cash flows, the Company uses assumptions believed to be reasonable, but which inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of long-lived asset is less than the carrying value. See Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_575" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_163" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;11&lt;/a&gt;&lt;/span&gt; for a description of impairment losses recorded on long-lived assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-541">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognizes any excess of the total consideration paid over the fair value of the identifiable net assets as goodwill. Any purchase price that is considered contingent consideration is measured at its estimated fair value at the acquisition date and remeasured at each reporting period, with changes in estimated fair value recorded in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Acquisition transaction costs are expensed when incurred. The operating results of an acquisition are included in the Company&#x2019;s consolidated financial statements as of the acquisition date.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-542">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, net &lt;/span&gt;&lt;/div&gt;Intangible assets, net consist of certain definite-lived assets including patents, processes and know-how related to technology acquired through business combinations and asset acquisitions. The Company amortizes such intangible assets on a straight-line basis over their estimated useful life.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-543">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represented the excess of the acquisition cost over the fair market value of the net assets acquired. All goodwill was allocated to the Cell Engineering reporting unit and segment identified in Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_187" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;16&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company considers various qualitative factors that could indicate impairment of goodwill such as macroeconomic conditions, industry and market environment, overall financial performance of the Company, cash flow from operating activities and market capitalization. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment to compare the fair value of the reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds the fair value, an impairment loss is recognized limited to the total amount of goodwill allocated to that reporting unit. A combination of the income approach and the market approach may be used to determine fair value of the reporting unit. The Company recorded a full goodwill impairment during the year ended December 31, 2024 (see Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_160" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). No impairment losses were recognized during the years ended December 31, 2025, and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-544">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determines if an arrangement is or contains a lease at contract inception based on the terms and conditions in the contract. A contract contains a lease if there is an identified asset and the Company has the right to control the asset. For leases with terms greater than 12 months, the Company recognizes a right-of-use asset (&#x201c;ROU asset&#x201d;) and a lease liability as of the lease commencement date on the balance sheet. ROU assets represent the Company&#x2019;s right to use an underlying asset over the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are measured based on the present value of fixed lease payments that are unpaid as of the lease commencement date. The Company&#x2019;s ROU assets balance is increased by any initial direct costs and reduced by lease incentives received or expected to be received. Some of the Company's leases include options to extend or terminate the lease; these options are included in the lease term for calculations of its ROU assets and liabilities when it is reasonably certain that the Company will exercise those options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s leases are classified as either operating or finance, as determined at inception, with the classification affecting the pattern of expense recognition in the statement of operations. A lease is classified as a finance lease if risks and rewards are conveyed without the transfer of control. For operating leases, expense is generally recognized on a straight-line basis over the lease term. For finance leases, interest on the lease liability is recognized using the effective interest method, while the ROU asset is amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term. Leases with an initial term of 12 months or less which meet the definition of a short-term lease are not recorded on the balance sheet and the lease expense for these leases is recognized on a straight-line basis over the lease term. In limited instances, the Company acts as a lessor, primarily with certain real estate subleases. Finance leases, short-term leases and subleases are not a significant component of the Company's financial condition or results of operations. The current portion of the Company&#x2019;s operating lease liabilities is included in accrued expenses and other current liabilities on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements with both lease and non-lease components (such as real estate taxes, insurance and common area maintenance charges) and has elected the practical expedient to combine these lease and non-lease components for its real estate leases and non-lab equipment leases. The Company has not elected this practical expedient for lab equipment leases and the lease and non-lease components are accounted for separately for these leases. Non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of the Company&#x2019;s leases do not provide an implicit interest rate, the Company uses an incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments and uses the implicit rate when it is readily determinable. The Company&#x2019;s incremental borrowing rate is based on management&#x2019;s estimate of the rate of interest the Company would have to pay to borrow on a fully collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-545">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cell Engineering Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates Cell Engineering service revenue by providing end-to-end cell engineering solutions and tools to customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate Cell Engineering revenue primarily through service and license agreements for our tools and solutions offerings. Under our automation solutions agreements we typically provide services related to the design, build, and deployment of our RAC systems as well as ongoing support services. These agreements typically include a fee for the sale and installation of RAC hardware and a fee for follow on support services and control software. Datapoints agreements typically include fixed fees for services related to producing a data package for our customers and are earned over a shorter time period than legacy cell engineering solutions projects.  Under our solutions agreements, we typically provide R&amp;amp;D services for cell programming with the goal of producing an engineered cell that meets a mutually agreed specification. Our customers obtain license rights to the output of our services, which are primarily the optimized strains or cell lines, in order to manufacture and commercialize products derived from that licensed strain or cell line. Generally, the terms of these agreements provide that we receive some combination of: (1) service fees in the form of (i) upfront payments upon consummation of the agreement or other fixed payments, (ii) reimbursement for costs incurred for R&amp;amp;D services and (iii) milestone payments upon the achievement of specified technical criteria, plus (2) downstream value share payments in the form of (i) milestone payments upon the achievement of specified commercial criteria, (ii) royalties on sales of products from or comprising engineered organisms arising from the collaboration or licensing agreement and/or (iii) royalties related to cost of goods sold reductions realized by our customers. Royalties did not comprise a material amount of our revenue during any of the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cell Engineering revenue has historically included transactions with Platform Ventures and Legacy Structured Partnerships where we received non-cash consideration in the form of equity interests and financial instruments that are convertible into equity upon a triggering event.  We view the upfront non-cash consideration as prepayments for licenses which will be granted in the future as we complete mutually agreed upon technical development plans. In these instances, we also receive cash consideration for the R&amp;amp;D services performed by us on a fixed fee or cost-plus basis. We are not compensated through additional milestone or royalty payments under these arrangements. As we perform R&amp;amp;D services under the mutually agreed upon development plans, we recognize a reduction in the prefunded obligation on a cost-plus basis. In some cases we issued the customer a prepaid Cell Engineering services credit in exchange for the upfront non-cash consideration, which can and has been drawn down as payment for R&amp;amp;D services performed under mutually agreed upon development plans. These arrangements are further described in Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_157" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;8&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to acquire additional distinct goods and services are evaluated to determine if such options provide a material right to the customer that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which is accounted for as a separate contract upon the customer&#x2019;s election of the option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. Any upfront cash payment received upon consummation of the contract is fixed and generally nonrefundable. Variable consideration is subject to a constraint, and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. This is attained when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursement for costs incurred for the Company&#x2019;s research and development efforts, milestone payments upon the achievement of certain technical and/or commercial criteria, and royalties on sales of products from or comprising engineered organisms arising from the contract. With respect to the research and development reimbursements and milestone payments, the Company uses the most likely amount method to estimate variable consideration. Milestone payments are generally not included in the transaction price until the milestone is achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain agreements include payment in the form of equity securities or other financial instruments that convert into equity upon a triggering event. Any non-cash consideration is measured at its estimated fair value at contract inception. For equity securities and financial instruments that are not actively traded, the estimated fair value is generally determined by referencing a recent financing round or utilizing a scenario-based valuation model. Significant unobservable inputs are used in these valuations, including expectations regarding future financings of the customer, scenario dates and probabilities, expected volatility, discount rates, and recovery rates. Changes in these assumptions can materially affect the fair value of the non-cash consideration and, consequently, the total revenue recognized for the contract. The Company did not have material non-cash consideration included in contracts entered into during  the years ended December&#160;31, 2025 and 2024, but does continue to recognize non-cash revenue from contracts originating in prior periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements with promises that are combined into a single performance obligation, the entire transaction price is allocated to the single performance obligation. For agreements with multiple performance obligations, the transaction price is allocated to the performance obligations using the relative standalone selling price methodology. For agreements featuring variable consideration, the Company allocates variable consideration to one or more, but not all, performance obligations if certain conditions are met. Specifically, the Company assesses whether the variable consideration relates solely to its efforts to satisfy the performance obligation and whether allocating such variable consideration entirely to the performance obligation is consistent with the overall allocation objective. If these conditions are not met, the Company allocates the variable consideration based on the relative standalone selling price methodology. The key assumptions utilized in determining the standalone selling price for each performance obligation include development timelines, estimated research and development costs, commercial markets, likelihood of exercise (in the case of options considered to be material rights), and probabilities of success. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements where licenses or assignments are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time when the license is effectively granted, as the licenses or assignments represent functional intellectual property. For agreements where licenses and research and development services are combined into a single performance obligation, the Company recognizes revenue over the performance period using the cost-to-cost method. This method measures progress based on the ratio of costs incurred to date to total estimated costs, as it best reflects the transfer of control to the customer for obligations satisfied over time. For automation sales the Company typically recognizes revenue at a point in time at which the hardware has been installed and passed acceptance testing at the customer site. The ongoing support services are recognized over time on a straight line basis over the related support period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its measure of progress to recognize revenue at each reporting period and, as necessary, adjusts the measure of progress and related revenue recognition. The Company&#x2019;s measure of progress and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs to complete its performance obligations. The Company evaluates contract modifications and amendments to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis. The Company utilizes the right to invoice practical expedient when it has a right to consideration in an amount that corresponds directly with the value of the Company&#x2019;s performance to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties are recognized as revenue when (or as) the later of the sales occurrence or the satisfaction (or partial satisfaction) of the related performance obligation. The Company has determined that applying this exception is appropriate when the license granted in the contract is the predominant item to which the royalties relate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company receives upfront payments for technical services under certain of its arrangements, the Company evaluates whether any significant financing components exist given the term over which the fees will be earned may exceed one year. Based on the nature of the Company&#x2019;s agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing, but rather to secure technical services, exclusivity rights, and Foundry capacity, or the timing of transfer of those goods or services is at the discretion of the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue represents consideration received by the Company in excess of revenue recognized and primarily results from transactions where the Company receives upfront cash payments or non-cash equity consideration. In instances where the Company has received consideration in advance for an undefined number of technical development plans (&#x201c;TDPs&#x201d;) under its customer agreements, the Company records the advance payments as deferred revenue, net of current portion on the consolidated balance sheet. Upon the execution of a specific TDP, the Company reclassifies the estimated consideration to be earned under that TDP within the next twelve months as current deferred revenue. The Company also classifies unexercised material rights related to future TDPs as deferred revenue, net of current portion on the consolidated balance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sheet. When a TDP is executed, and the material right is exercised, the amount allocated to the material right, which will be earned within the next twelve months, is reclassified to current deferred revenue. All other deferred revenue is classified as current or non-current based on the timing of when the Company expects to earn the underlying revenue based upon the projected progress of activities under the TDP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December&#160;31, 2025 any costs to obtain contracts with customers were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Biosecurity Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates Biosecurity revenue through its biomonitoring and bioinformatics services provided to both government and non-government customers through the Company's two core offerings: Canopy and Horizon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2024, product revenue consisted of sales of lateral flow assay (&#x201c;LFA&#x201d;) diagnostic test kits, polymerase chain reaction (&#x201c;PCR&#x201d;) sample collection kits, and pooled test kits, which the Company sold to customers on a standalone basis. Product revenue was billed and recognized when the test kits were shipped, and risk of loss was transferred to the carrier. The Company&#x2019;s test kits were generally not subject to a customer right of return except for product recalls under the rules and regulations of the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;). The Company included shipping and handling fees billed to customers as a component of Biosecurity revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biosecurity service revenue generally consists of various biomonitoring and bioinformatics services including, but not limited to, sample collection, sample storage and transportation, outsourced laboratory analysis, access to results reported through a web-based portal, analytical reporting of results, and overall program management. The various services are generally combined into one performance obligation as they are either not distinct or have substantially the same pattern of transfer to the customer. Service revenue is generally recognized over time using the time elapsed method as the related services are performed, which best depicts the pattern of transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts with customers are generally three years or less in length and contain a fixed amount of consideration. Under typical payment terms for testing services, amounts are billed monthly in arrears for services performed or in advance based on contractual billing terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to acquire additional services are evaluated to determine whether they provide the customer with a material right that it would not have otherwise received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer, and upon the customer's election of the option, it is accounted for as a separate contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-546">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Biosecurity Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of Biosecurity service revenue consists of costs related to the Company's biomonitoring and bioinformatics services. This includes costs incurred for sample collection equipment, services and materials, outsourced laboratory analysis, access to results reported through a proprietary web-based portal, and reporting of results to public authorities. Additionally, the cost of Biosecurity service revenue includes direct labor cost associated with bioinformatics, lab network management, delivery logistics, and customer support. Prior to 2024, cost of Biosecurity product revenue consisted of costs associated with the sale of diagnostic and sample collection test kits, which included costs incurred to purchase test kits from third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of other revenue consists of costs related to the Company's Cell Engineering tools offerings, including Datapoints and lab automation solutions. Such costs primarily include hardware, software, materials and labor. Costs related to the Company&#x2019;s end-to-end cell engineering solutions offering in which the Company retains rights to intellectual property are included in research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-547">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;Research and development costs are expensed as incurred. Research and development costs consist of direct and indirect internal costs related to specific projects and initiatives, acquired intellectual property deemed to be in-process research and development, as well as fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <dna:PatentCostsPolicyTextBlock contextRef="c-1" id="f-548">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs &lt;/span&gt;&lt;/div&gt;The Company expenses all costs as incurred in connection with the filing, prosecution, maintenance, defense, and enforcement of patent applications, including direct application fees and related legal and consulting expenses. Patent costs are included in general and administrative expenses within the consolidated statements of operations and comprehensive loss.</dna:PatentCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-549">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock-based awards based on estimated grant-date fair values recognized over the requisite service period. For awards that vest solely based on a service condition, the Company recognizes compensation expense on a straight-line basis over the requisite service period. For awards that vest based on multiple conditions, the Company recognizes compensation expense using the accelerated attribution method on a tranche-by-tranche basis over the requisite service period such that the amount of compensation expense recognized at each reporting period is at least equal to the vested tranches at that date. For awards with a performance-based vesting condition, the Company recognizes stock-based compensation when achievement of the performance condition is deemed probable. Upon achieving a performance condition that was not previously considered as probable, the Company records a cumulative catch-up adjustment to reflect the portion of the grantee&#x2019;s requisite service that has been provided to date. For awards with market conditions, the compensation expense recognized over the requisite service period is not reversed if the market condition is not satisfied. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model, inclusive of assumptions for expected term, expected volatility, risk-free interest rate and expected dividend yield. The expected term is determined using the &#x201c;simplified&#x201d; method, which estimates the expected term as the average of the vesting term plus the contractual term. The Company uses the &#x201c;simplified&#x201d; method as it does not have sufficient historical data regarding employee exercise behavior. Expected volatility is based on the historical volatility of the Company's Class A common stock. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the stock options. The Company has not paid, and does not expect to pay, dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For awards with market conditions, the Company recognizes stock-based compensation based on the estimated grant-date fair value of the awards, determined using a Monte Carlo simulation model. This model incorporates assumptions for expected stock price volatility, risk-free interest rates, expected term, and expected dividend yield. Volatility is estimated using either the historical volatility of the Company&#x2019;s Class A common stock or a weighted average of its own historical volatility and the historical volatility of selected comparable publicly traded companies, particularly for awards granted when there was limited trading history for the Company&#x2019;s Class A common stock. The risk-free interest rate is derived from the yield on U.S. Treasury zero-coupon securities with a duration similar to the expected term of the awards. The expected term equals the contractual term, and a dividend yield of zero is assumed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-550">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected, estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies. &lt;/span&gt;&lt;/div&gt;The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity, and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an annual basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-8" decimals="0" id="f-551" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="0" id="f-552" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-553">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive loss consists of foreign currency translation adjustments and unrealized gains on available-for-sale securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-554">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic net loss per share by dividing the net loss attributable to Ginkgo Bioworks Holdings, Inc. common stockholders by the weighted average number of common shares outstanding during the period. For the purposes of the net loss per share calculation, the Company has combined Class A common stock, Class B common stock, and Class C common stock, as all classes of common stock are legally entitled to equal per-share distributions, whether through dividends or liquidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is computed using the weighted average number of common shares outstanding during the period, increased to include the effect of dilutive potential common shares, such as outstanding stock options, unvested restricted stock awards, unvested restricted stock units, warrants, and contingently issued shares. Dilutive securities are excluded from the calculation of diluted weighted average common shares outstanding if their effect would be anti-dilutive under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-555">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which focuses on improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this ASU require that public business entities on an annual basis (1) disclose specific categories in the tabular rate reconciliation, using both percentages and reporting currency amounts, and (2) provide additional information for reconciling items that meet a quantitative threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company adopted this standard on January 1, 2025 using the prospective method. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This ASU requires public business entities to disaggregate, on both an interim and annual basis, each relevant expense caption presented on the face of the income statement into specific expense categories. Additionally, entities are required to provide a qualitative description of amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, as well as disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this ASU will have on its disclosures in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-557">Restructuring&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2024, in connection with the Company&#x2019;s plans to reduce operational expenditures, management, with the approval of the Board of Directors, approved and commenced a restructuring plan. This plan includes a reduction in labor expenses, primarily through a workforce reduction of more than 50%, and the consolidation and subleasing of certain facilities. Initial workforce reductions commenced in June 2024 and continued throughout 2025. All reductions were substantially complete in 2025. The Company has consolidated certain facilities through various actions, including &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;combining office and laboratory operations into fewer locations, subleasing unused or underutilized facilities, and has taken or plans to take other related measures, such as the sale of its subsidiary, Altar, in the third quarter of 2024 (see Note &lt;/span&gt;&lt;span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_148" style="color:#3051f2;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). While the Company completed the majority of its facility consolidation actions in 2025 we continue to look for opportunities for subleasing unused or underutilized facilities, which will extend beyond 2026 or may not occur prior to termination of such lease, depending on market conditions. Additionally, restructuring expenses related to potential asset impairments or contract amendments or terminations for any facilities no longer in use or underutilized could be material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The costs for the reduction in force are expected to range from $31.0&#160;million to $32.0&#160;million primarily in the Cell Engineering segment and consist of cash severance and related costs. The employee termination costs are recognized as of the communication date to employees, given (i) the Company instituted a one-time employee termination benefit related to its restructuring, and (ii) the employees will not be retained to render service beyond a minimum retention period. The Company is currently unable to estimate the costs associated with consolidating its facilities. These costs may include, but are not limited to, losses on subleases, contract terminations, asset impairments, sale or disposal of equipment or other long-lived assets, and related costs and fees pertaining to the consolidation, closure, or disposition of facilities. Additional charges may be incurred as the Company progresses its restructuring plan and such charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents restructuring costs incurred during the years ended December&#160;31, 2025 and 2024, which are recorded as &#x201c;Restructuring charges&#x201d; in the consolidated statements of operations and comprehensive loss (in thousands):&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.686%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-562"&gt;Employee termination costs and other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment of right-of-use asset (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total restructuring&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1) Relates to the sublease of a facility in connection with the restructuring and reflects the excess of the right-of-use asset's carrying value over its fair value, which was determined based on estimates of future discounted cash flows and is classified as Level 3 in the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, the Company recorded a $7.0 million loss on the sale and deconsolidation of Altar as a component of other income (expense) in the consolidated statements of operations and comprehensive loss for year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the change in the accrued liability balance related to the restructuring activities, which is included in &#x201c;Accounts payable&#x201d; and &#x201c;Accrued expenses and other current liabilities&#x201d; in the accompanying consolidated balance sheet as of December&#160;31, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.068%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Termination Costs and Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Liability balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Liability balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <dna:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent contextRef="c-77" decimals="2" id="f-558" unitRef="number">0.50</dna:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-78" decimals="-5" id="f-559" unitRef="usd">31000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-79" decimals="-5" id="f-560" unitRef="usd">32000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-561">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents restructuring costs incurred during the years ended December&#160;31, 2025 and 2024, which are recorded as &#x201c;Restructuring charges&#x201d; in the consolidated statements of operations and comprehensive loss (in thousands):&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.686%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-562"&gt;Employee termination costs and other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment of right-of-use asset (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total restructuring&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1) Relates to the sublease of a facility in connection with the restructuring and reflects the excess of the right-of-use asset's carrying value over its fair value, which was determined based on estimates of future discounted cash flows and is classified as Level 3 in the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the change in the accrued liability balance related to the restructuring activities, which is included in &#x201c;Accounts payable&#x201d; and &#x201c;Accrued expenses and other current liabilities&#x201d; in the accompanying consolidated balance sheet as of December&#160;31, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.068%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Termination Costs and Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Liability balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Liability balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-563" unitRef="usd">11398000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-20" decimals="-3" id="f-564" unitRef="usd">19349000</us-gaap:RestructuringCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-20" decimals="-3" id="f-566" unitRef="usd">4823000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-567" unitRef="usd">11398000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-20" decimals="-3" id="f-568" unitRef="usd">24172000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-20" decimals="-5" id="f-569" unitRef="usd">-7000000.0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:RestructuringReserve contextRef="c-80" decimals="-3" id="f-570" unitRef="usd">2854000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-81" decimals="-3" id="f-571" unitRef="usd">11398000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-81" decimals="-3" id="f-572" unitRef="usd">11651000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-82" decimals="-3" id="f-573" unitRef="usd">2601000</us-gaap:RestructuringReserve>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-574">Acquisitions and Divestitures&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024 AgBiome Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 10, 2024, the Company acquired certain platform assets, including fully sequenced and isolated strains, unique gene sequences, relevant functional data and metadata, and a development pipeline from AgBiome, Inc. (&#x201c;AgBiome&#x201d;), a biotechnology company in the agriculture industry. These assets expanded the Company&#x2019;s proprietary unified metagenomics database. The fair value of the consideration transferred totaled $18.2&#160;million and was paid with the issuance of 407,240 shares of Ginkgo's Class A common stock. The Company accounted for the transaction as an asset &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquisition since substantially all of the value received was concentrated in the acquired developed technology, which is being amortized over a useful life of three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024 Other Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company completed three other asset acquisitions during the year ended December 31, 2024. The aggregate purchase price for the three acquisitions was $19.8&#160;million and was paid with the issuance of 394,799 shares of Ginkgo&#x2019;s Class A common stock. Each transaction was accounted for as an asset acquisition as the acquired assets, consisting primarily of intellectual property rights, did not meet the definition of a business. The assets acquired represent in-process research and development with no alternative future use. Accordingly, the Company recorded $19.8&#160;million as acquired in-process research and development expense in the accompanying consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023 StrideBio Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2023, the Company entered into an Asset Purchase Agreement (&#x201c;APA&#x201d;) with StrideBio, Inc. (&#x201c;StrideBio&#x201d;) to acquire StrideBio&#x2019;s adeno-associated virus capsid discovery and engineering platform assets, with a secondary closing contingent upon the transfer of certain additional in-license agreements to Ginkgo. The secondary closing was finalized in October 2023. The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identifiable asset. The fair value of the consideration transferred totaled $7.6&#160;million and consisted of 119,278 shares of Ginkgo&#x2019;s Class A common stock valued at $6.8&#160;million and a $0.8&#160;million contingent holdback, all of which was expensed as in-process research and development during the year ended December 31, 2023. On May 9, 2025, we issued a total of 102,922 shares of our Class A common stock to StrideBio, Inc., in settlement of the $0.8&#160;million contingent holdback amount. The APA, as amended, also provides for royalty payments of up to $21.3&#160;million as described in Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_172" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;12&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023 Zymergen Bankruptcy and Deconsolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 3, 2023, the Company&#x2019;s former subsidiary, Zymergen, Inc. (&#x201c;Zymergen&#x201d;), and certain of its subsidiaries filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code (the &#x201c;Zymergen Bankruptcy&#x201d;) in the U.S. Bankruptcy Court for the District of Delaware (&#x201c;Bankruptcy Court&#x201d;). Neither the Company nor any of its other subsidiaries filed for bankruptcy protection. Zymergen had been operated as a distinct legal entity, separate and apart from the Company, since it was acquired in October 2022. Shortly after its acquisition, the Company entered into a non-exclusive license with Zymergen with respect to Zymergen&#x2019;s intellectual property, including its databases, automation, and software capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Zymergen Bankruptcy, also on October 3, 2023, the Company entered into an asset purchase agreement with Zymergen (the &#x201c;Zymergen APA&#x201d;) as the stalking horse bidder under Section 363 of the U.S. Bankruptcy Code to acquire exclusive rights to substantially all of Zymergen&#x2019;s intellectual property assets and certain other assets. The Company&#x2019;s bid included a $6.2&#160;million cash component, assumption of a facility lease (previously included in the Company's consolidated financial statements prior to Zymergen's deconsolidation discussed below), and acquiring Zymergen's workforce. On December 14, 2023, Zymergen concluded its auction. On December 21, 2023, the Bankruptcy Court approved the sale of substantially all of Zymergen&#x2019;s assets to the Company through certain of the Company's affiliates as contemplated by the Zymergen APA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While as of December 31, 2023, Zymergen remained a wholly-owned subsidiary of the Company, as a result of the bankruptcy proceedings, the Company no longer had a controlling financial interest over Zymergen as defined under ASC 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and therefore deconsolidated Zymergen&#x2019;s financial position as of October 2, 2023. The deconsolidation included the derecognition of the carrying amounts of Zymergen&#x2019;s consolidated assets and liabilities that were previously included in the Company&#x2019;s consolidated financial statements. Upon deconsolidation, the Company recorded a loss of $42.5&#160;million, representing the remaining net book value of the Company&#x2019;s investment that was reduced to a fair value of zero. Subsequent to the deconsolidation, the Company accounted for its investment in Zymergen using the cost method of accounting, which was recorded at zero in the Company&#x2019;s consolidated balance sheet as of December 31, 2023. Zymergen&#x2019;s results of operations were removed from the Company&#x2019;s consolidated statements of operations and comprehensive loss beginning October 3, 2023. The historical financial results for Zymergen have not been classified as a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discontinued operation because it does not represent a strategic shift with a major effect on the Company's operations and financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents Zymergen&#x2019;s consolidated assets and liabilities which have been deconsolidated from the Company's consolidated balance sheet as of October 2, 2023. The amounts presented are before the elimination of intercompany balances.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;October 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;248,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;184,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net assets deconsolidated&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents Zymergen&#x2019;s results of operations for the periods presented, included in the Company's consolidated statements of operations and comprehensive loss prior to the elimination of intercompany balances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Period from January 1, 2023 - October 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;200,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(192,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(168,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(168,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the deconsolidation, the Company had an existing employee leasing arrangement with Zymergen. The employee leasing charges were considered intercompany transactions and were eliminated in the Company's consolidated financial statements. As of the deconsolidation date, the employee leasing charges were considered related party transactions and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have been recognized in the Company's consolidated financial statements. Employee lease expense totaled $4.9&#160;million for the period from October 3, 2023 to December 31, 2023, and was immaterial during fiscal 2024. The Company had $1.7&#160;million due to Zymergen as of December 31, 2023, included in accrued expenses and other current liabilities on the balance sheet. This amount was subsequently paid in fiscal 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024 Zymergen Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2024, the Company, through certain of its affiliates, completed its acquisition of substantially all of Zymergen&#x2019;s assets under the Zymergen APA, including offering employment to 91 of Zymergen&#x2019;s employees. On February 5, 2024, Zymergen&#x2019;s plan of liquidation was confirmed by the Bankruptcy Court. All of the Company&#x2019;s interests in the Zymergen entities were extinguished and terminated as of February 23, 2024. The acquisition under the Zymergen APA was accounted for as a business combination in accordance with ASC 805,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and was not material to the Company's consolidated financial statements. The total cash purchase price was $6.2&#160;million, with $5.4&#160;million paid at closing and $0.8&#160;million released from escrow. The allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date primarily includes $19.9&#160;million of operating lease right-of-use assets, $6.0&#160;million of property and equipment, and $19.9&#160;million of operating lease liabilities. No goodwill or intangible assets were recognized. Transaction costs associated with the Zymergen APA were not material for the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024 Altar Divestiture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2024, the Company sold the equity interests of Altar for a nominal amount. As a result of the sale, the Company deconsolidated all of Altar's assets and liabilities from its consolidated financial statements effective September 30, 2024, and recognized a loss on deconsolidation of $7.0&#160;million in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024. The loss on deconsolidation includes a $1.5&#160;million reclassification of accumulated currency translation adjustments to earnings. The sale did not meet the criteria to be reported as a discontinued operation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-83" decimals="-5" id="f-575" unitRef="usd">18200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-84" decimals="0" id="f-576" unitRef="shares">407240</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-85" id="f-577">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <dna:AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod
      contextRef="c-8"
      decimals="INF"
      id="f-578"
      unitRef="materialright">3</dna:AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod>
    <dna:AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod
      contextRef="c-8"
      decimals="INF"
      id="f-579"
      unitRef="materialright">3</dna:AssetAcquisitionNumberOfAdditionalAcquisitionsDuringPeriod>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-86" decimals="-5" id="f-580" unitRef="usd">19800000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-87" decimals="0" id="f-581" unitRef="shares">394799</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-86" decimals="-5" id="f-582" unitRef="usd">19800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-88" decimals="-5" id="f-583" unitRef="usd">7600000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-89" decimals="0" id="f-584" unitRef="shares">119278</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-89" decimals="-5" id="f-585" unitRef="usd">6800000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-90" decimals="-5" id="f-586" unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-91" decimals="0" id="f-587" unitRef="shares">102922</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-90" decimals="-5" id="f-588" unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsForRoyalties contextRef="c-92" decimals="-5" id="f-589" unitRef="usd">21300000</us-gaap:PaymentsForRoyalties>
    <us-gaap:AssetAcquisitionPriceOfAcquisitionExpected contextRef="c-93" decimals="-5" id="f-590" unitRef="usd">6200000</us-gaap:AssetAcquisitionPriceOfAcquisitionExpected>
    <us-gaap:DeconsolidationGainOrLossAmount contextRef="c-94" decimals="-5" id="f-591" unitRef="usd">-42500000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="c-94" decimals="INF" id="f-592" unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:EquityMethodInvestments contextRef="c-95" decimals="INF" id="f-593" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <dna:DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock contextRef="c-1" id="f-594">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents Zymergen&#x2019;s consolidated assets and liabilities which have been deconsolidated from the Company's consolidated balance sheet as of October 2, 2023. The amounts presented are before the elimination of intercompany balances.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;October 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;248,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;184,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net assets deconsolidated&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents Zymergen&#x2019;s results of operations for the periods presented, included in the Company's consolidated statements of operations and comprehensive loss prior to the elimination of intercompany balances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Period from January 1, 2023 - October 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;200,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(192,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(168,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(168,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dna:DisposalGroupNotIncludingDiscontinuedOperationsTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="c-96" decimals="-3" id="f-595" unitRef="usd">34321000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="c-96" decimals="-3" id="f-596" unitRef="usd">11047000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent contextRef="c-96" decimals="-3" id="f-597" unitRef="usd">11190000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-97" decimals="-3" id="f-598" unitRef="usd">56558000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent contextRef="c-96" decimals="-3" id="f-599" unitRef="usd">8938000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <dna:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset contextRef="c-96" decimals="-3" id="f-600" unitRef="usd">135800000</dna:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent contextRef="c-96" decimals="-3" id="f-601" unitRef="usd">16679000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent contextRef="c-96" decimals="-3" id="f-602" unitRef="usd">10660000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets contextRef="c-96" decimals="-3" id="f-603" unitRef="usd">19486000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-97" decimals="-3" id="f-604" unitRef="usd">248121000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue contextRef="c-96" decimals="-3" id="f-605" unitRef="usd">730000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities contextRef="c-96" decimals="-3" id="f-606" unitRef="usd">20426000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-97" decimals="-3" id="f-607" unitRef="usd">21156000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <dna:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent contextRef="c-96" decimals="-3" id="f-608" unitRef="usd">184301000</dna:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities contextRef="c-96" decimals="-3" id="f-609" unitRef="usd">172000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-96" decimals="-3" id="f-610" unitRef="usd">205629000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <dna:DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet contextRef="c-96" decimals="-3" id="f-611" unitRef="usd">42492000</dna:DisposalGroupIncludingDiscontinuedOperationsAssetsAndLiabilitiesNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-98" decimals="-3" id="f-612" unitRef="usd">8370000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="c-98" decimals="-3" id="f-613" unitRef="usd">200975000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c-98" decimals="-3" id="f-614" unitRef="usd">-192605000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome contextRef="c-98" decimals="-3" id="f-615" unitRef="usd">23620000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-98" decimals="-3" id="f-616" unitRef="usd">-168985000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-98" decimals="-3" id="f-617" unitRef="usd">14000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-98" decimals="-3" id="f-618" unitRef="usd">-168999000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <dna:EmployeeLeaseExpense contextRef="c-26" decimals="-5" id="f-619" unitRef="usd">4900000</dna:EmployeeLeaseExpense>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-10" decimals="-5" id="f-620" unitRef="usd">1700000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <dna:NumberOfEmployeesAcquired
      contextRef="c-99"
      decimals="INF"
      id="f-621"
      unitRef="employee">91</dna:NumberOfEmployeesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-99" decimals="-5" id="f-622" unitRef="usd">6200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-99" decimals="-5" id="f-623" unitRef="usd">5400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1 contextRef="c-99" decimals="-5" id="f-624" unitRef="usd">800000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <dna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets contextRef="c-100" decimals="-5" id="f-625" unitRef="usd">19900000</dna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-100" decimals="-5" id="f-626" unitRef="usd">6000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-100" decimals="-5" id="f-627" unitRef="usd">19900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-101" decimals="-5" id="f-628" unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-102" decimals="-5" id="f-629" unitRef="usd">-7000000.0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-102" decimals="-5" id="f-630" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-631">Fair Value Measurements &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Synlogic, Inc. warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;410,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;284,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses and other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;521,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;521,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Synlogic, Inc. warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;553,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;539,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses and other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;The fair value of Synlogic, Inc. warrants is calculated as the quoted price of the underlying common stock, less the unpaid exercise price of the warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. In 2025 and 2024, transfers from Level 2 to Level 1 occurred due to lapse of regulatory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sales restrictions on marketable equity securities. During 2025, transfers into Level 3 consisted of a note receivable that was transferred from Level 2 to Level 3 upon a change in valuation technique. Additionally, in 2024, a portion of the Private Placement Warrants' estimated fair value was transferred from Level 3 to Level 2 as a result of the Private Placement Warrants having substantially the same terms as the Public Warrants when transferred to anyone other than the initial purchasers or their permitted transferees, leading the Company to determine their fair value to be equivalent to that of the Public Warrants. There were no other transfers between Levels 1, 2, or 3 during 2025 or 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a reconciliation of the beginning and ending balances for assets and liabilities measured at fair value using Level 3 significant unobservable inputs for the years ended December 31 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.517%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notes Receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Private Placement Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements and payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion to preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements and payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers to Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Notes Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all of its notes receivable, the Company has elected the fair value option, for which changes in fair value are recorded in other (expense) income, net in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2025 and 2024, the Company's notes receivable includes a senior secured note in the original principal amount of $11.8&#160;million, issued by Bolt Threads, Inc. (&#x201c;Bolt Threads&#x201d;), which bears interest at 12% per annum, is due December 31, 2027, and is included in other non-current assets at its estimated fair value. The Company used a discounted cash flow model to estimate the fair value of the senior secured note, incorporating significant unobservable inputs such as the recovery rate, a risk-adjusted discount rate, and a potential settlement scenario. These inputs reflect the Company&#x2019;s own assumptions and was reclassified as a Level 3 measurement within the fair value hierarchy during the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also holds a series of convertible debt instruments issued by customers as payment for Cell Engineering services. The Company used a scenario-based method to value the convertible debt instruments issued by customers and by Bolt Threads prior to conversion. Under this method, future cash flows are evaluated under various payoff scenarios, probability-weighted, and discounted to present value. The significant unobservable (Level 3) inputs used in the fair value measurement as of December&#160;31, 2025 included scenario probabilities ranging from 5% to 45%, a discount rate of 15.5% and estimated time to event date of up to 5 months. The significant unobservable (Level 3) inputs used in the fair value measurement as of December&#160;31, 2024 included scenario probabilities ranging from 5% to 45%, a discount rate of 15.5% and estimated time to event date of up to two years. Significant changes in these inputs could have resulted in a significantly lower or higher fair value measurement. As of December&#160;31, 2025, the convertible debt instruments had an unpaid principal balance of $9.7 million and a fair value of $0.5&#160;million. As of December&#160;31, 2024, the convertible debt instruments had an unpaid principal balance of $13.2 million and a fair value of $1.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2025, $1.5&#160;million in principal related to a convertible note issued by a customer was converted into 10,564 shares of the entity's preferred stock, which, as a new private company investment, has been classified as an investment on the balance sheet as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company's merger with Soaring Eagle Acquisition Corp. (&#x201c;SRNG&#x201d;) on September 16, 2021 (&#x201c;SRNG Business Combination&#x201d;), the Company assumed 34.5&#160;million warrants (formerly traded on the New York Stock Exchange (the &#x201c;NYSE,&#x201d; and such warrants, the &#x201c;Public Warrants&#x201d;) and 17.3&#160;million private placement warrants (the &#x201c;Private Placement Warrants&#x201d;, and together with the Public Warrants, the &#x201c;Warrants&#x201d;), which were initially issued in connection with SRNG&#x2019;s initial public offering. The number of outstanding Warrants did not change as a result of the Reverse Stock Split. However, each Warrant equals one-fortieth (1/40) of one share of Class A common stock (a minimum of 40 Warrants must be exercised for one share of Class A common stock) following the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Public Warrants was based on their observable quoted price on the NYSE. However, the Public Warrants were delisted by the NYSE on September 4, 2024, due to abnormally low selling price levels, and subsequently began trading on the over-the-counter markets. As of December&#160;31, 2025  and 2024, the Company determined that the Public Warrants had no value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Private Placement Warrants are identical to the Public Warrants, except that they are exercisable on a cashless basis and are non-redeemable as long as they are held by the initial purchasers or their permitted transferees. As of December&#160;31, 2025, the Company concluded that the difference between the fair values of the Public Warrants and Private Placement Warrants was de minimis. Therefore, the Private Placement Warrants were measured by reference to the value of the Public Warrants and had no value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with various business acquisitions, the Company is required to make contingent earnout payments payable upon the achievement of certain technical, commercial and/or performance milestones. The Company also issued restricted stock in connection with acquisitions, which is subject to vesting conditions and is classified as contingent consideration liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company can settle a majority of its contingent consideration liabilities in cash or shares of Class A common stock at the Company&#x2019;s election with the remainder payable in cash. During the year ended December&#160;31, 2025, no contingent consideration liabilities were settled. During the year ended December&#160;31, 2024, the Company settled $17.6 million in contingent consideration liabilities through payment of $2.8 million in cash and vesting of 1,413,909 shares of restricted stock valued at $14.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of contingent consideration related to earnout payments from acquisitions was estimated using unobservable (Level 3) inputs as illustrated in the table below. The fair value of contingent consideration related to restricted stock was estimated using the quoted price of Ginkgo's Class A common stock, an estimate of the number of shares expected to vest, probability of vesting, and a discount rate. Material increases or decreases in these inputs could result in a higher or lower fair value measurement. Changes in the fair value of contingent consideration are recorded in general and administrative expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides quantitative information regarding Level 3 inputs used in the fair value measurements of contingent consideration liabilities as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2025&lt;br/&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;br/&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Earnout payments (FGen and Dutch DNA acquisitions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Probability-weighted present value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5% - 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5% - 50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Earnout payments (Dutch DNA acquisition) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028-2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) During the year ended December&#160;31, 2025, all Dutch DNA milestones valued using the discounted cash flow method were reduced to zero due to the termination of a customer agreement to which those milestones were tied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of certain assets, including investments in privately held companies without readily determinable fair values, on a nonrecurring basis when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, or when observable price changes occur for identical or similar securities from the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of non-marketable equity securities is classified as Level 3 within the fair value hierarchy when the Company estimates fair value using unobservable inputs to measure an impairment loss. It is classified as Level 2 when fair value is estimated using the observable transaction price paid by third-party investors for an identical or similar security of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2025, the Company recorded a $2.7&#160;million downward adjustment from an observable price change related to one of its investments in non-marketable equity securities. Additionally, during the year ended December&#160;31, 2025, the Company recorded an impairment of $1.8&#160;million due to a significant deterioration in the liquidity of one of its investments in non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2024, and 2023, the Company recorded impairment losses of $11.9&#160;million, and $33.0&#160;million, respectively, related to its investment in Genomatica preferred stock. The fair value estimates used to determine the impairment charges in 2023 were derived using the guideline public company method under the market approach. Significant unobservable (Level 3) inputs included estimated annual net cash flows (including revenue and expense growth rates and capitalization rates), the weighted-average cost of capital used to discount future cash flows, and the selection of guideline public company multiples for revenue and EBITDA. Material increases or decreases in these inputs could result in higher or lower fair value measurements. As of December 31, 2024, the Company determined that the investment had substantially no value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2024 and 2023, the Company recorded impairment losses of $1.7&#160;million and $8.3&#160;million, respectively, related to an investment in the preferred stock of a privately held company. The fair value as of December 31, 2023 was determined by deriving the investee&#x2019;s equity value from a 2021 financing transaction involving its own securities and applying an 87% downward market adjustment to the implied equity value. The equity value was then allocated to the different classes of the securities of the investee using the option-pricing model (&#x201c;OPM&#x201d;). The OPM involves making assumptions around the investees&#x2019; expected time to liquidity and volatility derived from selected guideline public companies. These assumptions are considered Level 3 inputs. As of December 31, 2024, the Company determined that the investment had substantially no value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;SAFEs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company received a total purchase amount of $11.0&#160;million in SAFEs from customers as prepayment for Cell Engineering services. The Company used a scenario-based method to value the SAFEs as of each contract inception date, which resulted in total fair value of $4.5&#160;million for SAFEs received during the year ended December 31, 2023. Under the scenario-based method, future cash flows were evaluated under qualified financing and dissolution scenarios with partial recovery and no recovery in dissolution. The cash flows under each scenario were probability-weighted and discounted to present value. The significant unobservable (Level 3) inputs used in the fair value measurement at contract inception during 2023 were scenario probabilities in the range of 20% to 60%, a discount rate of 14% and estimated time to event date of &lt;span style="-sec-ix-hidden:f-801"&gt;one&lt;/span&gt; to two years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2025 and 2024, the Company recorded impairment losses of $14.5 million and $7.2 million, respectively, related to SAFEs. The fair values were generally estimated using the scenario-based method, where various payout scenarios were probability-weighted and discounted to present value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, during the years ended December 31, 2024, the Company recorded an impairments of lab equipment, construction in progress assets, and assets related to an operating lease. Refer to Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_169" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional detail.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-632">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Synlogic, Inc. warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;410,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;284,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;118,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses and other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;521,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;521,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Synlogic, Inc. warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;553,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;539,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses and other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;The fair value of Synlogic, Inc. warrants is calculated as the quoted price of the underlying common stock, less the unpaid exercise price of the warrants.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-633" unitRef="usd">146136000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-104" decimals="-3" id="f-634" unitRef="usd">146136000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-635" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-636" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-637" unitRef="usd">4060000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-638" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-109" decimals="-3" id="f-639" unitRef="usd">4060000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-640" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-641" unitRef="usd">118038000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-642" unitRef="usd">118038000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-113" decimals="-3" id="f-643" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-114" decimals="-3" id="f-644" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-115" decimals="-3" id="f-645" unitRef="usd">114666000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-116" decimals="-3" id="f-646" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-117" decimals="-3" id="f-647" unitRef="usd">114666000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-118" decimals="-3" id="f-648" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-119" decimals="-3" id="f-649" unitRef="usd">18654000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-120" decimals="-3" id="f-650" unitRef="usd">18654000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-121" decimals="-3" id="f-651" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-122" decimals="-3" id="f-652" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-123" decimals="-3" id="f-653" unitRef="usd">190000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-124" decimals="-3" id="f-654" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-125" decimals="-3" id="f-655" unitRef="usd">190000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-126" decimals="-3" id="f-656" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-657" unitRef="usd">1562000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-658" unitRef="usd">1562000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-129" decimals="-3" id="f-659" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-130" decimals="-3" id="f-660" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-7" decimals="-3" id="f-661" unitRef="usd">7126000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-131" decimals="-3" id="f-662" unitRef="usd">0</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-132" decimals="-3" id="f-663" unitRef="usd">0</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-133" decimals="-3" id="f-664" unitRef="usd">7126000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-7" decimals="-3" id="f-665" unitRef="usd">410432000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-131" decimals="-3" id="f-666" unitRef="usd">284390000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-132" decimals="-3" id="f-667" unitRef="usd">118916000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-133" decimals="-3" id="f-668" unitRef="usd">7126000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-7" decimals="-3" id="f-669" unitRef="usd">5438000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-131" decimals="-3" id="f-670" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-132" decimals="-3" id="f-671" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-133" decimals="-3" id="f-672" unitRef="usd">5438000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-673" unitRef="usd">252000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-131" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-132" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-133" decimals="-3" id="f-676" unitRef="usd">252000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-7" decimals="-3" id="f-677" unitRef="usd">5690000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-131" decimals="-3" id="f-678" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-132" decimals="-3" id="f-679" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-133" decimals="-3" id="f-680" unitRef="usd">5690000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-134" decimals="-3" id="f-681" unitRef="usd">521457000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-135" decimals="-3" id="f-682" unitRef="usd">521457000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-136" decimals="-3" id="f-683" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-137" decimals="-3" id="f-684" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-138" decimals="-3" id="f-685" unitRef="usd">238000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-139" decimals="-3" id="f-686" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-140" decimals="-3" id="f-687" unitRef="usd">238000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-141" decimals="-3" id="f-688" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-142" decimals="-3" id="f-689" unitRef="usd">17559000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-143" decimals="-3" id="f-690" unitRef="usd">17559000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-144" decimals="-3" id="f-691" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-145" decimals="-3" id="f-692" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-8" decimals="-3" id="f-693" unitRef="usd">14170000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-146" decimals="-3" id="f-694" unitRef="usd">0</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-147" decimals="-3" id="f-695" unitRef="usd">12327000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-148" decimals="-3" id="f-696" unitRef="usd">1843000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-8" decimals="-3" id="f-697" unitRef="usd">553424000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-146" decimals="-3" id="f-698" unitRef="usd">539016000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-147" decimals="-3" id="f-699" unitRef="usd">12565000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-148" decimals="-3" id="f-700" unitRef="usd">1843000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-8" decimals="-3" id="f-701" unitRef="usd">5438000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-146" decimals="-3" id="f-702" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-147" decimals="-3" id="f-703" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-148" decimals="-3" id="f-704" unitRef="usd">5438000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-705" unitRef="usd">4484000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-146" decimals="-3" id="f-706" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-147" decimals="-3" id="f-707" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-148" decimals="-3" id="f-708" unitRef="usd">4484000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-8" decimals="-3" id="f-709" unitRef="usd">9922000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-146" decimals="-3" id="f-710" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-147" decimals="-3" id="f-711" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-148" decimals="-3" id="f-712" unitRef="usd">9922000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-713">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a reconciliation of the beginning and ending balances for assets and liabilities measured at fair value using Level 3 significant unobservable inputs for the years ended December 31 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.517%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notes Receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Private Placement Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements and payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion to preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements and payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers to Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-149" decimals="-3" id="f-714" unitRef="usd">1843000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-150" decimals="-3" id="f-715" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-151" decimals="-3" id="f-716" unitRef="usd">9922000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-152" decimals="-3" id="f-717" unitRef="usd">159000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-153" decimals="-3" id="f-718" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-154" decimals="-3" id="f-719" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-152" decimals="-3" id="f-720" unitRef="usd">-350000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-153" decimals="-3" id="f-721" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-154" decimals="-3" id="f-722" unitRef="usd">-4232000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-152" decimals="-3" id="f-723" unitRef="usd">-50000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-153" decimals="-3" id="f-724" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-154" decimals="-3" id="f-725" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 contextRef="c-152" decimals="0" id="f-726" unitRef="usd">6987000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 contextRef="c-153" decimals="0" id="f-727" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 contextRef="c-154" decimals="0" id="f-728" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions contextRef="c-152" decimals="-3" id="f-729" unitRef="usd">-1463000</dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions>
    <dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions contextRef="c-153" decimals="-3" id="f-730" unitRef="usd">0</dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions>
    <dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions contextRef="c-154" decimals="-3" id="f-731" unitRef="usd">0</dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-155" decimals="-3" id="f-732" unitRef="usd">7126000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-156" decimals="-3" id="f-733" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-157" decimals="-3" id="f-734" unitRef="usd">5690000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-158" decimals="-3" id="f-735" unitRef="usd">14129000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-159" decimals="-3" id="f-736" unitRef="usd">1846000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-160" decimals="-3" id="f-737" unitRef="usd">24273000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-161" decimals="-3" id="f-738" unitRef="usd">1407000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-162" decimals="-3" id="f-739" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-163" decimals="-3" id="f-740" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-161" decimals="0" id="f-741" unitRef="usd">-3217000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-162" decimals="0" id="f-742" unitRef="usd">-1697000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-163" decimals="0" id="f-743" unitRef="usd">3214000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-161" decimals="-3" id="f-744" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-162" decimals="0" id="f-745" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-163" decimals="0" id="f-746" unitRef="usd">-17565000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 contextRef="c-161" decimals="0" id="f-747" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="c-162" decimals="-3" id="f-748" unitRef="usd">-149000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="c-163" decimals="-3" id="f-749" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions contextRef="c-161" decimals="-3" id="f-750" unitRef="usd">-10476000</dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions>
    <dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions contextRef="c-162" decimals="-3" id="f-751" unitRef="usd">0</dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions>
    <dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions contextRef="c-163" decimals="-3" id="f-752" unitRef="usd">0</dna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisConversions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-149" decimals="-3" id="f-753" unitRef="usd">1843000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-150" decimals="-3" id="f-754" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-151" decimals="-3" id="f-755" unitRef="usd">9922000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FinancingReceivableSignificantPurchases contextRef="c-164" decimals="-5" id="f-756" unitRef="usd">11800000</us-gaap:FinancingReceivableSignificantPurchases>
    <us-gaap:FinancingReceivableSignificantPurchases contextRef="c-165" decimals="-5" id="f-757" unitRef="usd">11800000</us-gaap:FinancingReceivableSignificantPurchases>
    <dna:FinancingReceivableInterestRateStatedPercentage contextRef="c-166" decimals="2" id="f-758" unitRef="number">0.12</dna:FinancingReceivableInterestRateStatedPercentage>
    <dna:FinancingReceivableMeasurementInput contextRef="c-167" decimals="2" id="f-759" unitRef="number">0.05</dna:FinancingReceivableMeasurementInput>
    <dna:FinancingReceivableMeasurementInput contextRef="c-168" decimals="2" id="f-760" unitRef="number">0.45</dna:FinancingReceivableMeasurementInput>
    <dna:FinancingReceivableMeasurementInput contextRef="c-169" decimals="3" id="f-761" unitRef="number">0.155</dna:FinancingReceivableMeasurementInput>
    <dna:FinancingReceivableMeasurementInputPeriod contextRef="c-170" id="f-762">P5M</dna:FinancingReceivableMeasurementInputPeriod>
    <dna:FinancingReceivableMeasurementInput contextRef="c-171" decimals="2" id="f-763" unitRef="number">0.05</dna:FinancingReceivableMeasurementInput>
    <dna:FinancingReceivableMeasurementInput contextRef="c-172" decimals="2" id="f-764" unitRef="number">0.45</dna:FinancingReceivableMeasurementInput>
    <dna:FinancingReceivableMeasurementInput contextRef="c-173" decimals="3" id="f-765" unitRef="number">0.155</dna:FinancingReceivableMeasurementInput>
    <dna:FinancingReceivableMeasurementInputPeriod contextRef="c-174" id="f-766">P2Y</dna:FinancingReceivableMeasurementInputPeriod>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-175" decimals="-5" id="f-767" unitRef="usd">9700000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-7" decimals="-5" id="f-768" unitRef="usd">500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-176" decimals="-5" id="f-769" unitRef="usd">13200000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-149" decimals="-5" id="f-770" unitRef="usd">1800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-177" decimals="-5" id="f-771" unitRef="usd">1500000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c-177"
      decimals="INF"
      id="f-772"
      unitRef="shares">10564</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-178"
      decimals="-5"
      id="f-773"
      unitRef="shares">34500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-179"
      decimals="-5"
      id="f-774"
      unitRef="shares">17300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <dna:ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum contextRef="c-7" decimals="INF" id="f-775" unitRef="shares">40</dna:ClassOfWarrantOfRightNumberOfWarrantsToBeExercisedMinimum>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-180" decimals="0" id="f-776" unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-181" decimals="-5" id="f-777" unitRef="usd">17600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-182" decimals="-5" id="f-778" unitRef="usd">2800000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-182"
      decimals="INF"
      id="f-779"
      unitRef="shares">1413909</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <dna:BusinessCombinationContingentConsiderationVestedValue contextRef="c-181" decimals="-5" id="f-780" unitRef="usd">14700000</dna:BusinessCombinationContingentConsiderationVestedValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-781">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides quantitative information regarding Level 3 inputs used in the fair value measurements of contingent consideration liabilities as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2025&lt;br/&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2024&lt;br/&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Earnout payments (FGen and Dutch DNA acquisitions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Probability-weighted present value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5% - 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5% - 50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Earnout payments (Dutch DNA acquisition) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:400;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Projected years of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028-2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) During the year ended December&#160;31, 2025, all Dutch DNA milestones valued using the discounted cash flow method were reduced to zero due to the termination of a customer agreement to which those milestones were tied.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate contextRef="c-183" decimals="2" id="f-782" unitRef="number">0.05</us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate>
    <us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate contextRef="c-184" decimals="2" id="f-783" unitRef="number">0.10</us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate>
    <us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate contextRef="c-185" decimals="2" id="f-784" unitRef="number">0.05</us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate>
    <us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate contextRef="c-186" decimals="2" id="f-785" unitRef="number">0.50</us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate>
    <us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate contextRef="c-187" decimals="3" id="f-786" unitRef="number">0.149</us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate>
    <us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate contextRef="c-188" decimals="3" id="f-787" unitRef="number">0.093</us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate>
    <us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate contextRef="c-189" decimals="3" id="f-788" unitRef="number">0.106</us-gaap:ShortDurationContractsDiscountedLiabilitiesDiscountRate>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount contextRef="c-1" decimals="-5" id="f-789" unitRef="usd">2700000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-190" decimals="-5" id="f-790" unitRef="usd">1800000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-191" decimals="-5" id="f-791" unitRef="usd">11900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-192" decimals="-5" id="f-792" unitRef="usd">33000000.0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-193" decimals="-5" id="f-793" unitRef="usd">1700000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-194" decimals="-5" id="f-794" unitRef="usd">8300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <dna:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage contextRef="c-193" decimals="2" id="f-795" unitRef="number">0.87</dna:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-195" decimals="-5" id="f-796" unitRef="usd">11000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations contextRef="c-196" decimals="-5" id="f-797" unitRef="usd">4500000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput contextRef="c-197" decimals="2" id="f-798" unitRef="number">0.20</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput contextRef="c-198" decimals="2" id="f-799" unitRef="number">0.60</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput contextRef="c-199" decimals="2" id="f-800" unitRef="number">0.14</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <dna:EquitySecuritiesFVNIMeasurementInputTerm contextRef="c-201" id="f-802">P2Y</dna:EquitySecuritiesFVNIMeasurementInputTerm>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-202" decimals="-5" id="f-803" unitRef="usd">-14500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-203" decimals="-5" id="f-804" unitRef="usd">7200000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-806">Marketable Securities&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities, including those classified in cash and cash equivalents, are summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-right:-13.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.756%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.589%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of marketable debt securities are summarized below by contractual maturity dates (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-807">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities, including those classified in cash and cash equivalents, are summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-right:-13.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.756%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.589%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-205" decimals="-3" id="f-808" unitRef="usd">117919000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain contextRef="c-206" decimals="0" id="f-809" unitRef="usd">171000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss contextRef="c-206" decimals="0" id="f-810" unitRef="usd">52000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-205" decimals="0" id="f-811" unitRef="usd">118038000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-207" decimals="-3" id="f-812" unitRef="usd">114640000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain contextRef="c-208" decimals="0" id="f-813" unitRef="usd">147000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss contextRef="c-208" decimals="0" id="f-814" unitRef="usd">121000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-207" decimals="0" id="f-815" unitRef="usd">114666000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-209" decimals="-3" id="f-816" unitRef="usd">4079000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain contextRef="c-210" decimals="0" id="f-817" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss contextRef="c-210" decimals="0" id="f-818" unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-209" decimals="0" id="f-819" unitRef="usd">4060000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-211" decimals="-3" id="f-820" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain contextRef="c-212" decimals="0" id="f-821" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss contextRef="c-212" decimals="0" id="f-822" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-211" decimals="0" id="f-823" unitRef="usd">18654000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-7" decimals="-3" id="f-824" unitRef="usd">236638000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain contextRef="c-6" decimals="0" id="f-825" unitRef="usd">318000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss contextRef="c-6" decimals="0" id="f-826" unitRef="usd">192000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-7" decimals="0" id="f-827" unitRef="usd">255418000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-828">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of marketable debt securities are summarized below by contractual maturity dates (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-7" decimals="0" id="f-829" unitRef="usd">205540000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-7" decimals="0" id="f-830" unitRef="usd">205617000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-7" decimals="0" id="f-831" unitRef="usd">31098000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-7" decimals="0" id="f-832" unitRef="usd">31147000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c-1" id="f-833">Investments and Equity Method Investments &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has partnered with other investors to form business ventures, including Motif FoodWorks, Inc. (&#x201c;Motif&#x201d;), Allonnia, LLC (&#x201c;Allonnia&#x201d;), Arcaea, LLC (&#x201c;Arcaea&#x201d;), Verb Biotics, LLC (&#x201c;Verb Biotics&#x201d;), BiomEdit, LLC (&#x201c;BiomEdit&#x201d;) and Ayana Bio, LLC (&#x201c;Ayana Bio&#x201d;) (collectively &#x201c;Platform Ventures&#x201d;). The Company has also partnered with existing entities, including Genomatica, Inc. (&#x201c;Genomatica&#x201d;) and Synlogic, Inc. (&#x201c;Synlogic&#x201d;) (collectively, &#x201c;Legacy Structured Partnerships&#x201d;) with complementary assets for synthetic biology applications. The Company holds equity interests in these Platform Ventures and Legacy Structured Partnerships. The Company also holds equity interests in other public and private companies as a result of entering into collaboration and license revenue arrangements with these entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its investments in Platform Ventures under the equity method. The Company's marketable equity securities consist of Synlogic common stock, Synlogic warrants and the shares of common stock of other publicly traded companies. Marketable equity securities are measured at fair value with changes in fair value recorded in other income (expense) in the consolidated statements of operations and comprehensive loss. The Company&#x2019;s non-marketable equity securities consist of preferred stock of Genomatica and preferred and common stock of other privately held companies without readily determinable fair values. Non-marketable equity securities are initially recorded using the measurement alternative at cost and subsequently adjusted for any impairment and observable price changes in orderly transactions for the identical or a similar security of the same issuer. Impairment losses and adjustments from observable price changes are recorded in loss on investments in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also holds investments in early-stage synthetic biology product companies via SAFEs. The Company entered into SAFE agreements in conjunction with a revenue contract with a customer under which the Company grants the customer a prepaid Cell Engineering services credit equal to the principal amount of the SAFE (the &#x201c;Purchase Amount&#x201d;), which may be used and drawn down as payment for the Company&#x2019;s research and development services. The SAFEs will automatically convert into shares of preferred stock equal to the Purchase Amount divided by the discount price, which is calculated as the price per share sold in a qualified equity financing multiplied by a discount rate. The SAFEs also provide the Company with the right to future equity of the entity in a liquidation scenario or the cash-out amount in liquidation and dissolution scenarios or at the election of the SAFE issuer prior to an agreed outside date. The Company initially records SAFEs at fair value (see Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_151" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and adjusts the carrying amount of the instrument at each reporting period for any impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.014%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.965%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;SAFEs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Synlogic warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable equity securities of $18.7 million are not restricted for sale and are included in marketable securities in the consolidated balance sheet as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on investments and equity method investments consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(Loss) gain on investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Genomatica preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(33,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;SAFEs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Synlogic warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total loss on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(54,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Loss on equity method investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;BiomEdit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total loss on equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss on investments for each period were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized and unrealized gains (losses) recognized on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Downward adjustments from observable price changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total realized and unrealized losses associated with equity investments accounted for at fair value or the fair value measurement alternative consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized loss recognized on equity investments sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized losses recognized on equity investments held as of the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Reflects the difference between the sale proceeds and the carrying value of the equity investments at the beginning of the period or the acquisition date, if later.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of non-marketable equity securities accounted for using the fair value measurement alternative and still held as of December&#160;31, 2025, including cumulative unrealized losses, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total initial cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Downward adjustments from observable price changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c-1" id="f-834">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.014%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.965%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;SAFEs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Synlogic warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable equity securities of $18.7 million are not restricted for sale and are included in marketable securities in the consolidated balance sheet as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on investments and equity method investments consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;(Loss) gain on investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Genomatica preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(33,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;SAFEs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Synlogic warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total loss on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(54,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Loss on equity method investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;BiomEdit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total loss on equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of non-marketable equity securities accounted for using the fair value measurement alternative and still held as of December&#160;31, 2025, including cumulative unrealized losses, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total initial cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Downward adjustments from observable price changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-213" decimals="-3" id="f-835" unitRef="usd">2188000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-214" decimals="-3" id="f-836" unitRef="usd">16689000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-215" decimals="-3" id="f-837" unitRef="usd">11125000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-216" decimals="-3" id="f-838" unitRef="usd">14218000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-217" decimals="-3" id="f-839" unitRef="usd">1562000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-218" decimals="-3" id="f-840" unitRef="usd">17559000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-219" decimals="-3" id="f-841" unitRef="usd">191000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-220" decimals="-3" id="f-842" unitRef="usd">238000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:Investments contextRef="c-7" decimals="-3" id="f-843" unitRef="usd">15066000</us-gaap:Investments>
    <us-gaap:Investments contextRef="c-8" decimals="-3" id="f-844" unitRef="usd">48704000</us-gaap:Investments>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-120" decimals="-5" id="f-845" unitRef="usd">18700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:GainLossOnInvestments contextRef="c-221" decimals="-3" id="f-846" unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-191" decimals="-3" id="f-847" unitRef="usd">-11885000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-192" decimals="-3" id="f-848" unitRef="usd">-33000000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-222" decimals="-3" id="f-849" unitRef="usd">-4557000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-193" decimals="-3" id="f-850" unitRef="usd">-1735000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-194" decimals="-3" id="f-851" unitRef="usd">-9928000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-223" decimals="-3" id="f-852" unitRef="usd">2695000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-224" decimals="-3" id="f-853" unitRef="usd">-7583000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-225" decimals="-3" id="f-854" unitRef="usd">-7874000</us-gaap:GainLossOnInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-202" decimals="-3" id="f-855" unitRef="usd">-14501000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:GainLossOnInvestments contextRef="c-203" decimals="-3" id="f-856" unitRef="usd">-7208000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-226" decimals="-3" id="f-857" unitRef="usd">-2742000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-227" decimals="-3" id="f-858" unitRef="usd">-48000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-228" decimals="-3" id="f-859" unitRef="usd">-416000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-229" decimals="-3" id="f-860" unitRef="usd">-1283000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-861" unitRef="usd">-16411000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-20" decimals="-3" id="f-862" unitRef="usd">-28827000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-21" decimals="-3" id="f-863" unitRef="usd">-54827000</us-gaap:GainLossOnInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-230" decimals="-3" id="f-864" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-231" decimals="-3" id="f-865" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-232" decimals="-3" id="f-866" unitRef="usd">-1461000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-233" decimals="-3" id="f-867" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-234" decimals="-3" id="f-868" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-235" decimals="-3" id="f-869" unitRef="usd">-1174000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-870" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-20" decimals="-3" id="f-871" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-21" decimals="-3" id="f-872" unitRef="usd">-2635000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="c-1" id="f-873">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss on investments for each period were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized and unrealized gains (losses) recognized on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Downward adjustments from observable price changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total realized and unrealized losses associated with equity investments accounted for at fair value or the fair value measurement alternative consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized loss recognized on equity investments sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized losses recognized on equity investments held as of the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Reflects the difference between the sale proceeds and the carrying value of the equity investments at the beginning of the period or the acquisition date, if later.&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-1" decimals="-3" id="f-874" unitRef="usd">16345000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-20" decimals="-3" id="f-875" unitRef="usd">20828000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-21" decimals="-3" id="f-876" unitRef="usd">44043000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-877" unitRef="usd">2647000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-20" decimals="-3" id="f-878" unitRef="usd">-7999000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-21" decimals="-3" id="f-879" unitRef="usd">-9157000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount contextRef="c-1" decimals="-3" id="f-880" unitRef="usd">2713000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount contextRef="c-20" decimals="-3" id="f-881" unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount contextRef="c-21" decimals="-3" id="f-882" unitRef="usd">1627000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-883" unitRef="usd">-16411000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-20" decimals="-3" id="f-884" unitRef="usd">-28827000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-21" decimals="-3" id="f-885" unitRef="usd">-54827000</us-gaap:GainLossOnInvestments>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-1" decimals="-3" id="f-886" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-20" decimals="-3" id="f-887" unitRef="usd">-5957000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-21" decimals="-3" id="f-888" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-3" id="f-889" unitRef="usd">-16411000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-20" decimals="-3" id="f-890" unitRef="usd">-22870000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-21" decimals="-3" id="f-891" unitRef="usd">-54827000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-892" unitRef="usd">-16411000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-20" decimals="-3" id="f-893" unitRef="usd">-28827000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-21" decimals="-3" id="f-894" unitRef="usd">-54827000</us-gaap:GainLossOnInvestments>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-215" decimals="-3" id="f-895" unitRef="usd">109460000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount contextRef="c-215" decimals="-3" id="f-896" unitRef="usd">91806000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount contextRef="c-215" decimals="-3" id="f-897" unitRef="usd">4341000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:Investments contextRef="c-215" decimals="-3" id="f-898" unitRef="usd">13313000</us-gaap:Investments>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-899">Variable Interest Entities &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the Company&#x2019;s investments in Motif, Allonnia, Genomatica, Arcaea, BiomEdit, Verb Biotics, and Ayana Bio, the Company has concluded these entities represent VIEs. While the Company has board representation on certain of these entities and is involved in the ongoing development activities of these entities via its participation on such entities' JSC, the Company has concluded that it is not the primary beneficiary of these entities because: (i) the Company does not control the board of directors of any of the VIEs, and no voting or consent agreements exist between the Company and other members of each respective board of directors or other investors, (ii) the holders of preferred security interests in the VIEs hold certain rights that require their consent prior to taking certain actions, which include certain significant operating and financing decisions, and (iii) the Company&#x2019;s representation on the JSC of each respective entity does not give it control over the development activities of any of the VIEs, as all JSC decisions are made by consensus and there are no agreements in place that would require any of the entities to vote in alignment with the Company. As the Company&#x2019;s involvement in the VIEs does not give it the power to control the decisions with respect to their development or other activities, which are their most significant activities, the Company has concluded that it is not the primary beneficiary of the VIEs.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company holds equity interests in certain other privately-held companies that are not consolidated as the Company is not the primary beneficiary. As of December&#160;31, 2025 and 2024, the maximum risk of loss related to the Company&#x2019;s unconsolidated VIEs was limited to the carrying value of its investments in such entities. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_190" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;17&lt;/a&gt;&lt;/span&gt; for additional details on the Company&#x2019;s investments and equity method investments.</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-900">Goodwill and Intangible Assets, net &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, due to a sustained decrease in the market price of the Company's Class A common stock and market capitalization, the Company identified that an indicator of impairment was present during the second quarter of 2024. As such, the Company completed a quantitative impairment test related to its Cell Engineering reporting unit. To conduct the impairment test of goodwill, the estimated fair value of the reporting unit was compared to its carrying value. The estimated fair value of the reporting unit was determined using a weighted approach that considered a discounted cash flow (&#x201c;DCF&#x201d;) model under the income approach and the guideline public company (&#x201c;GPC&#x201d;) method under the market approach. Significant inputs used in the DCF model included the projected future operating results of the reporting unit and the applicable discount rate, while inputs used in the GPC method consisted of a revenue multiple. The projected future operating results were based on historical experience and internal annual operating plans reviewed by management, extrapolated over the forecast period. The discount rate was determined using a weighted average cost of capital adjusted for risk factors specific to the reporting unit. The revenue multiple was based on the GPC method using comparable publicly traded company multiples of revenue for a group of benchmark companies. The DCF method was &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;weighted 75% and the GPC 25%. The fair value measurement of the reporting unit is classified as Level 3 in the fair value hierarchy because it involves significant unobservable inputs. The Company reconciled the resulting fair value of its reporting unit to the market capitalization of the Company to corroborate the fair value estimate used in the impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The result of the interim impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. As a result, the Company fully impaired goodwill and recorded an impairment loss of $47.9&#160;million in the second quarter of 2024 and for the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the carrying amount of goodwill consisted of the following year ended December 31, 2024 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Goodwill impairment (accumulated impairment loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(47,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impact of foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.661%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortization &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortization Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;December 31, 2025:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(54,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;December 31, 2024:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Gross carrying value and accumulated amortization include the impact of cumulative foreign currency translation adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense was $18.7 million, $18.0 million and $15.7 million for the years ended December&#160;31, 2025, 2024 and 2023, respectively. The estimated future amortization expense for intangible assets remaining as of December&#160;31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.336%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <dna:GoodwillImpairmentDCFWeight contextRef="c-7" decimals="2" id="f-901" unitRef="number">0.75</dna:GoodwillImpairmentDCFWeight>
    <dna:GoodwillImpairmentGPCWeight contextRef="c-7" decimals="2" id="f-902" unitRef="number">0.25</dna:GoodwillImpairmentGPCWeight>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-77" decimals="-5" id="f-903" unitRef="usd">47900000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-904">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the carrying amount of goodwill consisted of the following year ended December 31, 2024 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Goodwill impairment (accumulated impairment loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(47,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impact of foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-41" decimals="-3" id="f-905" unitRef="usd">49238000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-20" decimals="-3" id="f-906" unitRef="usd">47858000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-20" decimals="-3" id="f-907" unitRef="usd">1380000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-8" decimals="-3" id="f-908" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-909">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.661%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortization &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortization Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;December 31, 2025:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(54,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;December 31, 2024:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;111,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(38,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Gross carrying value and accumulated amortization include the impact of cumulative foreign currency translation adjustments.</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-236" decimals="-3" id="f-910" unitRef="usd">111202000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-236" decimals="-3" id="f-911" unitRef="usd">54278000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-236" decimals="-3" id="f-912" unitRef="usd">56924000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-237" id="f-913">P6Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-238" decimals="-3" id="f-914" unitRef="usd">111393000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-238" decimals="-3" id="f-915" unitRef="usd">38883000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-238" decimals="-3" id="f-916" unitRef="usd">72510000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-239" id="f-917">P6Y7M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-918" unitRef="usd">18700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-20" decimals="-5" id="f-919" unitRef="usd">18000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-21" decimals="-5" id="f-920" unitRef="usd">15700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c-1" id="f-921">The estimated future amortization expense for intangible assets remaining as of December&#160;31, 2025 is as follows (in thousands):&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.336%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-7" decimals="-3" id="f-922" unitRef="usd">18700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-7" decimals="-3" id="f-923" unitRef="usd">11613000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-7" decimals="-3" id="f-924" unitRef="usd">2987000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-7" decimals="-3" id="f-925" unitRef="usd">2987000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-7" decimals="-3" id="f-926" unitRef="usd">2987000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-7" decimals="-3" id="f-927" unitRef="usd">17650000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-7" decimals="-3" id="f-928" unitRef="usd">56924000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-930">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases real estate for office and lab space as well as equipment used in research and development activities under operating and finance leases.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s real estate leases have initial lease terms ranging from 1.4 years to 15.3 years and are all classified as operating. Real estate leases may contain periods of free rent, tenant improvement incentives, expansion options, rent escalation clauses at pre-determined rates or at the prevailing market rates at the time of the increase, and options to extend or terminate the lease without cause at the option of either party during the lease term. The Company is not reasonably certain to exercise these options at the commencement of the lease. Equipment leases have initial lease terms ranging from 2.2 years to 5 years and are classified as operating or finance if the lease contains bargain purchase options which the Company is reasonably certain to exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost for real estate leases primarily consists of certain non-lease components such as real estate taxes, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;insurance and common area maintenance charges. These non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise. None of the Company's lease agreements contain material restrictive covenants or residual value guarantees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's headquarters are located in the Seaport district of Boston, Massachusetts and comprise a set of non-cancellable operating leases within a facility totaling over 320,000 square feet of office and laboratory space. These leases expire on dates ranging from 2030 to 2036 and each contain one option to extend the lease for a five-year period at then-market rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2021, the Company entered into a lease, as amended, consisting of approximately 260,000 rentable square feet of new office and laboratory space being developed in Boston, Massachusetts near the Company's headquarters. The lease commenced on April 11, 2024, with rent payments beginning in June 2024, and it will expire on the fifteenth anniversary of the rent commencement date. The lease includes an option to extend for an additional ten years at then-market rates, as well as an expansion option if the owner constructs an additional building on the property. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has a substantial amount of excess space and is seeking to sublease excess space consistent with its restructuring plan. The leased facilities continue to be included in the Cell Engineering asset group as they have not been abandoned and do not have separately identifiable cash flows. If the Company enters into subleases at rates that are below the existing lease minimum payments, terminates or amends existing leases, or abandons the leased facilities, the right-of-use lease assets and any associated leasehold improvements would be evaluated for potential impairment and impairment charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, the Company&#x2019;s former subsidiary, Zymergen, ceased the use of and exited a leased facility consisting of approximately 300,000 square feet of office and laboratory space in Emeryville, California. The facility was used pursuant to an operating lease with a minimum term expiring in August 2033. Zymergen&#x2019;s exit resulted in an impairment loss of $96.2&#160;million, including $36.6&#160;million for the right-of-use asset and $59.6&#160;million for the related leasehold improvements. The impairment loss represents the amount by which the carrying value of the assets exceed their estimated fair values, as determined using a discounted cash flow model under the income approach. The fair value measurements are based on significant inputs not observable in the market and therefore represent Level 3 fair value measurements. The key inputs used in the valuation were estimated sublease rental income and a discount rate of 8.5%. The impairments are presented as impairment of lease assets in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of total lease cost (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to the Company&#x2019;s operating leases were as follows (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases were as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.301%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term - operating leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term - finance leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturity of the Company&#x2019;s lease liabilities (in thousands): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;60,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;371,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total undiscounted payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;662,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(222,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;439,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;L&lt;span style="-sec-ix-hidden:f-1005"&gt;&lt;span style="-sec-ix-hidden:f-1006"&gt;ess: current portion of lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;417,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously subleased a portion of its office and lab space to certain of its equity method investees, which are considered related parties. These lease agreements ended in 2025. Related party sublease income for the years ended December&#160;31, 2025, 2024 and 2023 was $2.1 million, $2.0 million and $2.1 million, respectively, included within &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;operating expenses in 2025 and within other income, net in the consolidated statements of operations and comprehensive loss in prior years.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-929">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases real estate for office and lab space as well as equipment used in research and development activities under operating and finance leases.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s real estate leases have initial lease terms ranging from 1.4 years to 15.3 years and are all classified as operating. Real estate leases may contain periods of free rent, tenant improvement incentives, expansion options, rent escalation clauses at pre-determined rates or at the prevailing market rates at the time of the increase, and options to extend or terminate the lease without cause at the option of either party during the lease term. The Company is not reasonably certain to exercise these options at the commencement of the lease. Equipment leases have initial lease terms ranging from 2.2 years to 5 years and are classified as operating or finance if the lease contains bargain purchase options which the Company is reasonably certain to exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost for real estate leases primarily consists of certain non-lease components such as real estate taxes, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;insurance and common area maintenance charges. These non-lease components are typically variable in nature and are recognized as lease expense in the period in which they arise. None of the Company's lease agreements contain material restrictive covenants or residual value guarantees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's headquarters are located in the Seaport district of Boston, Massachusetts and comprise a set of non-cancellable operating leases within a facility totaling over 320,000 square feet of office and laboratory space. These leases expire on dates ranging from 2030 to 2036 and each contain one option to extend the lease for a five-year period at then-market rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2021, the Company entered into a lease, as amended, consisting of approximately 260,000 rentable square feet of new office and laboratory space being developed in Boston, Massachusetts near the Company's headquarters. The lease commenced on April 11, 2024, with rent payments beginning in June 2024, and it will expire on the fifteenth anniversary of the rent commencement date. The lease includes an option to extend for an additional ten years at then-market rates, as well as an expansion option if the owner constructs an additional building on the property. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has a substantial amount of excess space and is seeking to sublease excess space consistent with its restructuring plan. The leased facilities continue to be included in the Cell Engineering asset group as they have not been abandoned and do not have separately identifiable cash flows. If the Company enters into subleases at rates that are below the existing lease minimum payments, terminates or amends existing leases, or abandons the leased facilities, the right-of-use lease assets and any associated leasehold improvements would be evaluated for potential impairment and impairment charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, the Company&#x2019;s former subsidiary, Zymergen, ceased the use of and exited a leased facility consisting of approximately 300,000 square feet of office and laboratory space in Emeryville, California. The facility was used pursuant to an operating lease with a minimum term expiring in August 2033. Zymergen&#x2019;s exit resulted in an impairment loss of $96.2&#160;million, including $36.6&#160;million for the right-of-use asset and $59.6&#160;million for the related leasehold improvements. The impairment loss represents the amount by which the carrying value of the assets exceed their estimated fair values, as determined using a discounted cash flow model under the income approach. The fair value measurements are based on significant inputs not observable in the market and therefore represent Level 3 fair value measurements. The key inputs used in the valuation were estimated sublease rental income and a discount rate of 8.5%. The impairments are presented as impairment of lease assets in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of total lease cost (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to the Company&#x2019;s operating leases were as follows (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases were as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.301%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term - operating leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term - finance leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturity of the Company&#x2019;s lease liabilities (in thousands): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;60,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;371,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total undiscounted payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;662,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(222,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;439,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;L&lt;span style="-sec-ix-hidden:f-1005"&gt;&lt;span style="-sec-ix-hidden:f-1006"&gt;ess: current portion of lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;417,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously subleased a portion of its office and lab space to certain of its equity method investees, which are considered related parties. These lease agreements ended in 2025. Related party sublease income for the years ended December&#160;31, 2025, 2024 and 2023 was $2.1 million, $2.0 million and $2.1 million, respectively, included within &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;operating expenses in 2025 and within other income, net in the consolidated statements of operations and comprehensive loss in prior years.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-78" id="f-931">P1Y4M24D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-79" id="f-932">P15Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-240" id="f-933">P2Y2M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-241" id="f-934">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dna:LesseeOperatingLeaseAreaOfRealEstateProperty contextRef="c-1" decimals="0" id="f-935" unitRef="sqft">320000</dna:LesseeOperatingLeaseAreaOfRealEstateProperty>
    <dna:LesseeOperatingLeaseNumberOfExtensionOptions
      contextRef="c-7"
      decimals="INF"
      id="f-936"
      unitRef="extensionoption">1</dna:LesseeOperatingLeaseNumberOfExtensionOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-7" id="f-937">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dna:LesseeOperatingLeaseAreaOfRealEstateProperty contextRef="c-242" decimals="INF" id="f-938" unitRef="sqft">260000</dna:LesseeOperatingLeaseAreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-243" id="f-939">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dna:LesseeOperatingLeaseAreaOfRealEstateProperty contextRef="c-244" decimals="INF" id="f-940" unitRef="sqft">300000</dna:LesseeOperatingLeaseAreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-244" decimals="-5" id="f-941" unitRef="usd">96200000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-245" decimals="-5" id="f-942" unitRef="usd">36600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-246" decimals="-5" id="f-943" unitRef="usd">59600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-247" decimals="3" id="f-944" unitRef="number">0.085</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-945">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of total lease cost (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases were as follows:  &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.301%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term - operating leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term - finance leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-946" unitRef="usd">63470000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-20" decimals="-3" id="f-947" unitRef="usd">57996000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-21" decimals="-3" id="f-948" unitRef="usd">59588000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-949" unitRef="usd">708000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-20" decimals="-3" id="f-950" unitRef="usd">655000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-21" decimals="-3" id="f-951" unitRef="usd">1047000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-952" unitRef="usd">4000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-20" decimals="-3" id="f-953" unitRef="usd">29000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-21" decimals="-3" id="f-954" unitRef="usd">79000</us-gaap:FinanceLeaseInterestExpense>
    <dna:FinanceLeaseCost contextRef="c-1" decimals="-3" id="f-955" unitRef="usd">712000</dna:FinanceLeaseCost>
    <dna:FinanceLeaseCost contextRef="c-20" decimals="-3" id="f-956" unitRef="usd">684000</dna:FinanceLeaseCost>
    <dna:FinanceLeaseCost contextRef="c-21" decimals="-3" id="f-957" unitRef="usd">1126000</dna:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-958" unitRef="usd">19701000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-20" decimals="-3" id="f-959" unitRef="usd">19421000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-21" decimals="-3" id="f-960" unitRef="usd">15862000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-3" id="f-961" unitRef="usd">7600000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-20" decimals="-3" id="f-962" unitRef="usd">5177000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-21" decimals="-3" id="f-963" unitRef="usd">11170000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-964" unitRef="usd">76283000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-20" decimals="-3" id="f-965" unitRef="usd">72924000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-21" decimals="-3" id="f-966" unitRef="usd">65406000</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c-1" id="f-967">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to the Company&#x2019;s operating leases were as follows (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information for each reporting period (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.068%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.140%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash paid for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;223,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Purchases of property and equipment included in accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Convertible financial instruments received for Cell Engineering services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Equity securities and warrants received for Cell Engineering services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;17,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Common stock issued for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;18,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Common stock issued as settlement of contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;8,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Common stock issued for retention payments related to business and asset acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Return of investment in equity securities for reduction in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;6,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Conversion of notes receivable for common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;10,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Issuance costs related to ATM offering included in accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the years ended December&#160;31, 2025, the amount of cash income taxes paid by the Company was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.318%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.482%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State and local:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;California&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;South Carolina&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;All other state and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash income taxes, net of refunds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-968" unitRef="usd">61178000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-20" decimals="-3" id="f-969" unitRef="usd">45019000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-21" decimals="-3" id="f-970" unitRef="usd">44051000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-971" unitRef="usd">4000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-20" decimals="-3" id="f-972" unitRef="usd">32000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-21" decimals="-3" id="f-973" unitRef="usd">83000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-974" unitRef="usd">354000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-20" decimals="-3" id="f-975" unitRef="usd">897000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-21" decimals="-3" id="f-976" unitRef="usd">1295000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-977">P11Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-8" id="f-978">P11Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-979">P0Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-8" id="f-980">P0Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-981" unitRef="number">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-8" decimals="3" id="f-982" unitRef="number">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-983" unitRef="number">0.039</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-8" decimals="3" id="f-984" unitRef="number">0.038</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-986">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturity of the Company&#x2019;s lease liabilities (in thousands): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;60,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;371,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total undiscounted payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;662,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(222,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;439,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;L&lt;span style="-sec-ix-hidden:f-1005"&gt;&lt;span style="-sec-ix-hidden:f-1006"&gt;ess: current portion of lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;417,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-985">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the maturity of the Company&#x2019;s lease liabilities (in thousands): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;60,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;371,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total undiscounted payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;662,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(222,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;439,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;L&lt;span style="-sec-ix-hidden:f-1005"&gt;&lt;span style="-sec-ix-hidden:f-1006"&gt;ess: current portion of lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(22,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;417,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-7" decimals="-3" id="f-987" unitRef="usd">56302000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-7" decimals="-3" id="f-988" unitRef="usd">20000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-7" decimals="-3" id="f-989" unitRef="usd">56745000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-7" decimals="-3" id="f-990" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-7" decimals="-3" id="f-991" unitRef="usd">58498000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-7" decimals="-3" id="f-992" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-7" decimals="-3" id="f-993" unitRef="usd">60271000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-7" decimals="-3" id="f-994" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-7" decimals="-3" id="f-995" unitRef="usd">59301000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-7" decimals="-3" id="f-996" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-7" decimals="-3" id="f-997" unitRef="usd">371682000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-7" decimals="-3" id="f-998" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-7" decimals="-3" id="f-999" unitRef="usd">662799000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-7" decimals="-3" id="f-1000" unitRef="usd">20000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-7" decimals="-3" id="f-1001" unitRef="usd">222934000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <dna:FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment contextRef="c-7" decimals="-3" id="f-1002" unitRef="usd">0</dna:FinanceLeaseLiabilityUndiscountedExcessAmountIncludingAdjustment>
    <us-gaap:OperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-1003" unitRef="usd">439865000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-7" decimals="-3" id="f-1004" unitRef="usd">20000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-1007" unitRef="usd">22787000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-1008" unitRef="usd">20000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-1009" unitRef="usd">417078000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SubleaseIncome contextRef="c-25" decimals="-5" id="f-1010" unitRef="usd">2100000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-26" decimals="-5" id="f-1011" unitRef="usd">2000000.0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-27" decimals="-5" id="f-1012" unitRef="usd">2100000</us-gaap:SubleaseIncome>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="c-1" id="f-1013">Supplemental Financial Information &lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet to the totals shown within the consolidated statements of cash flows is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;167,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;561,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;944,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted cash included in prepaid expenses and other current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Restricted cash included in other non-current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;212,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;605,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;989,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Includes cash balances collateralizing letters of credit associated with the Company&#x2019;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment, net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.014%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.965%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;150,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;140,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Buildings and facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;358,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;364,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(190,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(160,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;167,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;203,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2025, 2024 and 2023 totaled $40.3 million, $45.0 million and $54.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, the Company determined that $5.8&#160;million of construction in progress assets were impaired and this loss is included in general and administrative expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company identified excess lab equipment at two of its facilities whereby the assets were sold, classified as held for sale or otherwise impaired, resulting in aggregate impairment losses of $25.2 million, included in general and administrative expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.014%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.965%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contractual shortfall liabilities (Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biosecurity costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees and securities litigation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;External research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1079"&gt;&lt;span style="-sec-ix-hidden:f-1080"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental cash flow information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information for each reporting period (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.068%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.140%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash paid for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;223,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;27,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Purchases of property and equipment included in accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Convertible financial instruments received for Cell Engineering services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Equity securities and warrants received for Cell Engineering services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;17,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Common stock issued for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;18,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;6,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Common stock issued as settlement of contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;8,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Common stock issued for retention payments related to business and asset acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Return of investment in equity securities for reduction in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;6,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Conversion of notes receivable for common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;10,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Issuance costs related to ATM offering included in accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-1015">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet to the totals shown within the consolidated statements of cash flows is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;167,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;561,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;944,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted cash included in prepaid expenses and other current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Restricted cash included in other non-current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;212,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;605,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;989,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Includes cash balances collateralizing letters of credit associated with the Company&#x2019;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer agreement.</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-1014">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet to the totals shown within the consolidated statements of cash flows is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;167,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;561,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;944,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted cash included in prepaid expenses and other current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Restricted cash included in other non-current assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;212,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;605,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;989,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Includes cash balances collateralizing letters of credit associated with the Company&#x2019;s facility leases and customer prepayments requiring segregation and restrictions in its use in accordance with the customer agreement.</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-1016" unitRef="usd">167202000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-1017" unitRef="usd">561572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-41" decimals="-3" id="f-1018" unitRef="usd">944073000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-7" decimals="-3" id="f-1019" unitRef="usd">7031000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-8" decimals="-3" id="f-1020" unitRef="usd">5839000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-41" decimals="-3" id="f-1021" unitRef="usd">4789000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent contextRef="c-7" decimals="-3" id="f-1022" unitRef="usd">38138000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent contextRef="c-8" decimals="-3" id="f-1023" unitRef="usd">38332000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent contextRef="c-41" decimals="-3" id="f-1024" unitRef="usd">40722000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-1025" unitRef="usd">212371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-1026" unitRef="usd">605743000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-41" decimals="-3" id="f-1027" unitRef="usd">989584000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-248" decimals="-3" id="f-1028" unitRef="usd">146279000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-249" decimals="-3" id="f-1029" unitRef="usd">150887000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-250" decimals="-3" id="f-1030" unitRef="usd">140513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-251" decimals="-3" id="f-1031" unitRef="usd">135964000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-252" decimals="-3" id="f-1032" unitRef="usd">49760000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-253" decimals="-3" id="f-1033" unitRef="usd">48255000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-254" decimals="-3" id="f-1034" unitRef="usd">192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-255" decimals="-3" id="f-1035" unitRef="usd">1984000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-256" decimals="-3" id="f-1036" unitRef="usd">9056000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-257" decimals="-3" id="f-1037" unitRef="usd">14897000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-67" decimals="-3" id="f-1038" unitRef="usd">6520000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-258" decimals="-3" id="f-1039" unitRef="usd">6545000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-259" decimals="-3" id="f-1040" unitRef="usd">6060000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-260" decimals="-3" id="f-1041" unitRef="usd">6060000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-1042" unitRef="usd">358380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-8" decimals="-3" id="f-1043" unitRef="usd">364592000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-1044" unitRef="usd">190597000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-1045" unitRef="usd">160872000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-1046" unitRef="usd">167783000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-1047" unitRef="usd">203720000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-1048" unitRef="usd">40300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-20" decimals="-5" id="f-1049" unitRef="usd">45000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-21" decimals="-5" id="f-1050" unitRef="usd">54800000</us-gaap:Depreciation>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-261" decimals="-5" id="f-1051" unitRef="usd">5800000</us-gaap:TangibleAssetImpairmentCharges>
    <dna:TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment
      contextRef="c-20"
      decimals="INF"
      id="f-1052"
      unitRef="facility">2</dna:TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-262" decimals="-5" id="f-1053" unitRef="usd">25200000</us-gaap:TangibleAssetImpairmentCharges>
    <dna:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-1054">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.014%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.965%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contractual shortfall liabilities (Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biosecurity costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees and securities litigation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;External research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee termination costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1079"&gt;&lt;span style="-sec-ix-hidden:f-1080"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</dna:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-1055" unitRef="usd">22787000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-8" decimals="-3" id="f-1056" unitRef="usd">28630000</us-gaap:OperatingLeaseLiabilityCurrent>
    <dna:ContractualShortfallLiabilityCurrent contextRef="c-7" decimals="-3" id="f-1057" unitRef="usd">15919000</dna:ContractualShortfallLiabilityCurrent>
    <dna:ContractualShortfallLiabilityCurrent contextRef="c-8" decimals="-3" id="f-1058" unitRef="usd">0</dna:ContractualShortfallLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-7" decimals="-3" id="f-1059" unitRef="usd">5438000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-8" decimals="-3" id="f-1060" unitRef="usd">5438000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <dna:AccruedBiosecurityServiceRevenueAccrualsCurrent contextRef="c-7" decimals="-3" id="f-1061" unitRef="usd">5046000</dna:AccruedBiosecurityServiceRevenueAccrualsCurrent>
    <dna:AccruedBiosecurityServiceRevenueAccrualsCurrent contextRef="c-8" decimals="-3" id="f-1062" unitRef="usd">4032000</dna:AccruedBiosecurityServiceRevenueAccrualsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-1063" unitRef="usd">4258000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-1064" unitRef="usd">9894000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-7" decimals="-3" id="f-1065" unitRef="usd">4378000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-8" decimals="-3" id="f-1066" unitRef="usd">2167000</us-gaap:AccruedProfessionalFeesCurrent>
    <dna:AccruedExternalResearchAndDevelopmentExpensesCurrent contextRef="c-7" decimals="-3" id="f-1067" unitRef="usd">1072000</dna:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <dna:AccruedExternalResearchAndDevelopmentExpensesCurrent contextRef="c-8" decimals="-3" id="f-1068" unitRef="usd">713000</dna:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <us-gaap:DeferredIncome contextRef="c-7" decimals="-3" id="f-1069" unitRef="usd">1033000</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c-8" decimals="-3" id="f-1070" unitRef="usd">2889000</us-gaap:DeferredIncome>
    <dna:AccruedEmployeeTerminationCosts contextRef="c-7" decimals="-3" id="f-1071" unitRef="usd">816000</dna:AccruedEmployeeTerminationCosts>
    <dna:AccruedEmployeeTerminationCosts contextRef="c-8" decimals="-3" id="f-1072" unitRef="usd">2387000</dna:AccruedEmployeeTerminationCosts>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-1073" unitRef="usd">20000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-8" decimals="-3" id="f-1074" unitRef="usd">335000</us-gaap:FinanceLeaseLiabilityCurrent>
    <dna:AccruedPropertyAndEquipmentCurrent contextRef="c-7" decimals="-3" id="f-1075" unitRef="usd">0</dna:AccruedPropertyAndEquipmentCurrent>
    <dna:AccruedPropertyAndEquipmentCurrent contextRef="c-8" decimals="-3" id="f-1076" unitRef="usd">138000</dna:AccruedPropertyAndEquipmentCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-1077" unitRef="usd">5691000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-1078" unitRef="usd">8764000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-7" decimals="-3" id="f-1081" unitRef="usd">66458000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-8" decimals="-3" id="f-1082" unitRef="usd">65387000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-1083" unitRef="usd">4000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-20" decimals="-3" id="f-1084" unitRef="usd">32000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-21" decimals="-3" id="f-1085" unitRef="usd">83000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-1086" unitRef="usd">192000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-20" decimals="-3" id="f-1087" unitRef="usd">894000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-21" decimals="-3" id="f-1088" unitRef="usd">670000</us-gaap:IncomeTaxesPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-1089" unitRef="usd">336000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-20" decimals="-3" id="f-1090" unitRef="usd">223853000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-21" decimals="-3" id="f-1091" unitRef="usd">27668000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-1092" unitRef="usd">46000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-20" decimals="-3" id="f-1093" unitRef="usd">2565000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-21" decimals="-3" id="f-1094" unitRef="usd">2915000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <dna:ConvertibleFinancialInstrumentsReceivedForFoundryServices contextRef="c-1" decimals="-3" id="f-1095" unitRef="usd">0</dna:ConvertibleFinancialInstrumentsReceivedForFoundryServices>
    <dna:ConvertibleFinancialInstrumentsReceivedForFoundryServices contextRef="c-20" decimals="-3" id="f-1096" unitRef="usd">0</dna:ConvertibleFinancialInstrumentsReceivedForFoundryServices>
    <dna:ConvertibleFinancialInstrumentsReceivedForFoundryServices contextRef="c-21" decimals="-3" id="f-1097" unitRef="usd">4542000</dna:ConvertibleFinancialInstrumentsReceivedForFoundryServices>
    <dna:PurchaseOfNonCashMarketableEquitySecurities contextRef="c-1" decimals="-3" id="f-1098" unitRef="usd">0</dna:PurchaseOfNonCashMarketableEquitySecurities>
    <dna:PurchaseOfNonCashMarketableEquitySecurities contextRef="c-20" decimals="-3" id="f-1099" unitRef="usd">55000</dna:PurchaseOfNonCashMarketableEquitySecurities>
    <dna:PurchaseOfNonCashMarketableEquitySecurities contextRef="c-21" decimals="-3" id="f-1100" unitRef="usd">17450000</dna:PurchaseOfNonCashMarketableEquitySecurities>
    <us-gaap:InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment contextRef="c-1" decimals="-3" id="f-1101" unitRef="usd">777000</us-gaap:InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment>
    <us-gaap:InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment contextRef="c-20" decimals="-3" id="f-1102" unitRef="usd">18245000</us-gaap:InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment>
    <us-gaap:InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment contextRef="c-21" decimals="-3" id="f-1103" unitRef="usd">6820000</us-gaap:InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment>
    <dna:SettlementOfContingentConsideration contextRef="c-1" decimals="-3" id="f-1104" unitRef="usd">0</dna:SettlementOfContingentConsideration>
    <dna:SettlementOfContingentConsideration contextRef="c-20" decimals="-3" id="f-1105" unitRef="usd">14742000</dna:SettlementOfContingentConsideration>
    <dna:SettlementOfContingentConsideration contextRef="c-21" decimals="-3" id="f-1106" unitRef="usd">8896000</dna:SettlementOfContingentConsideration>
    <dna:IssuanceOfCommonStockForAcquisitionRetentionPayments contextRef="c-1" decimals="-3" id="f-1107" unitRef="usd">0</dna:IssuanceOfCommonStockForAcquisitionRetentionPayments>
    <dna:IssuanceOfCommonStockForAcquisitionRetentionPayments contextRef="c-20" decimals="-3" id="f-1108" unitRef="usd">5258000</dna:IssuanceOfCommonStockForAcquisitionRetentionPayments>
    <dna:IssuanceOfCommonStockForAcquisitionRetentionPayments contextRef="c-21" decimals="-3" id="f-1109" unitRef="usd">0</dna:IssuanceOfCommonStockForAcquisitionRetentionPayments>
    <dna:ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue contextRef="c-1" decimals="-3" id="f-1110" unitRef="usd">0</dna:ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue>
    <dna:ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue contextRef="c-20" decimals="-3" id="f-1111" unitRef="usd">6760000</dna:ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue>
    <dna:ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue contextRef="c-21" decimals="-3" id="f-1112" unitRef="usd">0</dna:ReturnOfInvestmentInEquitySecuritiesForReductionInDeferredRevenue>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-1" decimals="-3" id="f-1113" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-20" decimals="-3" id="f-1114" unitRef="usd">10476000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-21" decimals="-3" id="f-1115" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <dna:SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses contextRef="c-1" decimals="-3" id="f-1116" unitRef="usd">53000</dna:SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses>
    <dna:SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses contextRef="c-20" decimals="-3" id="f-1117" unitRef="usd">0</dna:SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses>
    <dna:SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses contextRef="c-21" decimals="-3" id="f-1118" unitRef="usd">0</dna:SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1119">Commitments and Contingencies &lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company entered into a five-year strategic cloud and AI partnership with Google Cloud, which included minimum annual commitments to purchase cloud hosting services. The partnership previously included minimum annual commitments over the contract years ending August 27, 2027 to purchase cloud hosting services in exchange for various discounts on such services. The aggregate $289&#160;million future purchase commitment included minimum annual commitments were as follows: year 1, $8.0&#160;million; year 2, $28.0&#160;million; year 3, $54.0&#160;million; year 4, $86.0&#160;million; and year 5, $113.0&#160;million. Effective October 3, 2025, the Company entered into amendment that revised the total aggregate future purchase commitment to $110&#160;million and reset the annual commitments as follows (each annual year is defined as October 3 to October 2): year 1 (starting on October 3, 2025), $6.0&#160;million; year 2, $8.0&#160;million; year 3, $12.0&#160;million; year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4, $18.0&#160;million; year 5, $28.0&#160;million; year 6, $38.0&#160;million. The Company recognized a contractual liability of $20.9&#160;million during year ended December 31, 2025 as a result of shortfall in purchasing relative to its commitments under the original agreement. The Company is required to make a one-time payment of $14.0&#160;million to be released from its minimum annual commitment obligations under the original agreement in January 2026. If the Company does not meet its minimum annual commitment obligations in the future, additional shortfall liabilities may be incurred and future contractual losses may be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 1, 2025, the Company entered into an amendment to its four-year supply agreement with Twist for the purchase of diverse products including synthetic DNA. The original agreement was effective as of April 1, 2022 and obligated the Company to spend a minimum of $58.0&#160;million over the four-year term with the following minimum annual commitments (each annual year is defined as April 1 to March 31): year 1, $10.0&#160;million; year 2, $13.0&#160;million; year 3, $16.0&#160;million; and year 4, $19.0&#160;million. The amendment converts the remaining minimum annual commitments into non-refundable payments creditable against future purchases by the Company, with no expiration. The Company paid $4.0&#160;million in April 2025 and is obligated to non-refundable payments of $5.0&#160;million on April 1, 2026 and $6.0&#160;million on April 1, 2027, respectively. A contractual loss of $8.7&#160;million was recorded in the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Surety Bond&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2026, the Company will be required to fund a surety bond in the amount of $47.0&#160;million to fulfill its obligations under a contract with a U.S. Government National Laboratory related to the sale of RAC automation equipment. The $47.0&#160;million will be restricted until the Company completes all of its obligations under the contract. Currently the Company expects the cash to be restricted until 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Related to Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the StrideBio acquisition (see Note &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_148" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the Company is obligated to make royalty payments of up to $21.3&#160;million payable in cash or shares of Class A common stock at the Company's election until the earlier of the tenth anniversary date of the initial closing and the date on which the aggregate amount of the royalty payments equals the amount cap. The royalties are calculated based on 10% of the net licensing revenue and 40% of all consideration received for a license or sale of a product incorporating the acquired platform assets. No amounts for the royalty payments have been recorded during the years ended December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company routinely acquires rights to intellectual property that may provide for payment of future contingent consideration, including royalties, should revenue be generated from the use of such.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may in the ordinary course of business be named as a defendant in lawsuits, indemnity claims and other legal proceedings. The Company accrues for a loss contingency when it concludes that the likelihood of a loss is probable and the amount of loss can be reasonably estimated. The Company adjusts its accruals from time to time as it receives additional information. The Company does not believe any pending litigation to be material, or that the outcome of any such pending litigation, in management&#x2019;s judgment based on information currently available, would have a material adverse effect on the Company&#x2019;s results of operations, cash flows or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into standard indemnification agreements and has agreements with indemnification clauses in the ordinary course of business. Under such arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, who are generally the Company&#x2019;s business partners. The terms of these indemnification arrangements are generally perpetual and effective any time after contract execution. The maximum potential liability resulting from these indemnification arrangements may be unlimited. The Company has never incurred costs to defend lawsuits or settle claims as a result of such indemnifications and the Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationTerm contextRef="c-263" id="f-1120">P5Y</us-gaap:UnrecordedUnconditionalPurchaseObligationTerm>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-264" decimals="-5" id="f-1121" unitRef="usd">289000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary contextRef="c-264" decimals="-5" id="f-1122" unitRef="usd">8000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary contextRef="c-264" decimals="-5" id="f-1123" unitRef="usd">28000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary contextRef="c-264" decimals="-5" id="f-1124" unitRef="usd">54000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary contextRef="c-264" decimals="-5" id="f-1125" unitRef="usd">86000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary contextRef="c-264" decimals="-5" id="f-1126" unitRef="usd">113000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-265" decimals="-5" id="f-1127" unitRef="usd">110000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary contextRef="c-265" decimals="-5" id="f-1128" unitRef="usd">6000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary contextRef="c-265" decimals="-5" id="f-1129" unitRef="usd">8000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary contextRef="c-265" decimals="-5" id="f-1130" unitRef="usd">12000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary contextRef="c-265" decimals="-5" id="f-1131" unitRef="usd">18000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary contextRef="c-265" decimals="-5" id="f-1132" unitRef="usd">28000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary>
    <dna:UnrecordedUnconditionalPurchaseObligationToBePaidYearSix contextRef="c-265" decimals="-5" id="f-1133" unitRef="usd">38000000.0</dna:UnrecordedUnconditionalPurchaseObligationToBePaidYearSix>
    <dna:ContractualShortfallLiability contextRef="c-266" decimals="-3" id="f-1134" unitRef="usd">20900000</dna:ContractualShortfallLiability>
    <dna:ContractualShortfallLiabilityRequiredPayment contextRef="c-267" decimals="-5" id="f-1135" unitRef="usd">14000000.0</dna:ContractualShortfallLiabilityRequiredPayment>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationTerm contextRef="c-268" id="f-1136">P4Y</us-gaap:UnrecordedUnconditionalPurchaseObligationTerm>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-269" decimals="-5" id="f-1137" unitRef="usd">58000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationTerm contextRef="c-268" id="f-1138">P4Y</us-gaap:UnrecordedUnconditionalPurchaseObligationTerm>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary contextRef="c-270" decimals="-5" id="f-1139" unitRef="usd">10000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary contextRef="c-270" decimals="-5" id="f-1140" unitRef="usd">13000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary contextRef="c-270" decimals="-5" id="f-1141" unitRef="usd">16000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary contextRef="c-270" decimals="-5" id="f-1142" unitRef="usd">19000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases contextRef="c-271" decimals="-5" id="f-1143" unitRef="usd">4000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases contextRef="c-272" decimals="-5" id="f-1144" unitRef="usd">5000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases contextRef="c-273" decimals="-5" id="f-1145" unitRef="usd">6000000.0</us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases>
    <us-gaap:LossOnContracts contextRef="c-1" decimals="-5" id="f-1146" unitRef="usd">8700000</us-gaap:LossOnContracts>
    <dna:LossContingencyAmountRequiredToFund contextRef="c-274" decimals="-5" id="f-1147" unitRef="usd">47000000.0</dna:LossContingencyAmountRequiredToFund>
    <dna:LossContingencyAmountRequiredToFund contextRef="c-274" decimals="-5" id="f-1148" unitRef="usd">47000000.0</dna:LossContingencyAmountRequiredToFund>
    <us-gaap:PaymentsForRoyalties contextRef="c-92" decimals="-5" id="f-1149" unitRef="usd">21300000</us-gaap:PaymentsForRoyalties>
    <dna:RoyaltyReceivedFromLicensingRevenue
      contextRef="c-275"
      decimals="INF"
      id="f-1150"
      unitRef="number">0.10</dna:RoyaltyReceivedFromLicensingRevenue>
    <dna:RoyaltyReceivedFromLicenseOrSaleOfAProduct
      contextRef="c-275"
      decimals="INF"
      id="f-1151"
      unitRef="number">0.40</dna:RoyaltyReceivedFromLicenseOrSaleOfAProduct>
    <us-gaap:PaymentsForRoyalties contextRef="c-90" decimals="INF" id="f-1152" unitRef="usd">0</us-gaap:PaymentsForRoyalties>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1153">Stockholders' Equity &lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s authorized, issued, and outstanding common stock as of the dates indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Common stock as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,694,610&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,791,082&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,985,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,416,216&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;800,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,800,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,680,449&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,207,298&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Common stock as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,575,423&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,696,585&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,239,682&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,669,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;800,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,800,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,815,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54,365,785&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-The-Market Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2025, the Company filed a universal shelf registration statement on Form S-3, which was declared effective by the SEC on August 14, 2024, on which the Company registered for sale up to $500.0&#160;million of any combination of the Company's Class A common stock, preferred stock, warrants, and/or units from time to time and at prices and on terms that the Company may determine. On September 4, 2025, the Company entered into a Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Allen &amp;amp; Company LLC, who is acting as the sales agent (the &#x201c;Agent&#x201d;), pursuant to which the Company may sell shares of its Class A common stock from time to time at prices and on terms determined by market conditions at the time of offering, up to an aggregate offering price of $100.0&#160;million through or directly to the Agent in one or more at-the-market (&#x201c;ATM&#x201d;) offerings. Since inception of the Sales Agreement through December&#160;31, 2025, the Company has issued 1.9 million shares of Class A common stock under the Sales Agreement for net proceeds of $18.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 200&#160;million shares of preferred stock with a par value $0.0001 per share. The Company&#x2019;s board of directors are authorized, without stockholder approval, to issue such shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, voting, and other rights, preferences and privileges of the shares. There were no issued and outstanding shares of preferred stock as of December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 15,800&#160;million shares of common stock, including 10,500&#160;million shares of Class A common stock, par value $0.0001 per share, 4,500&#160;million shares of Class B common stock, par value $0.0001 per share, and 800&#160;million shares of Class C common stock, par value $0.0001 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Voting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Class A common stock are entitled to one vote per share and holders of Class B common stock are entitled to ten votes per share. Holders of Class C common stock are not entitled to vote except as otherwise expressly provided in the certificate of incorporation or required by applicable law. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stockholders are entitled to receive dividends, as may be declared by the board of directors. Different classes of common stock are legally entitled to equal per share distributions whether through dividends or liquidation. No dividends have been declared to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Conversion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. Generally, shares of Class B common stock will convert automatically into Class A common stock upon the holder ceasing to be an Eligible Holder (i.e., director, employee, trust or legal entity of Ginkgo), unless otherwise determined by affirmative vote of a majority of independent directors of Ginkgo. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Reserved for Future Issuances &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had the following common stock reserved for future issuance as of the date indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for grant under the 2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,336,606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,262,853&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Performance stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,407,287&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrants to purchase Class A common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295,622&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for grant under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,500,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for grant under the 2022 Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;292,172&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;366,567&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total common stock reserved for future issuances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,461,107&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Excludes unvested earnout shares, which are restricted shares issued to equity holders of legacy Ginkgo prior to the closing of the SRNG Business Combination and to SRNG. These earnout shares are recorded in equity as shares outstanding upon satisfying the vesting conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfCapitalizationTextBlock contextRef="c-1" id="f-1154">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s authorized, issued, and outstanding common stock as of the dates indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Common stock as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,694,610&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,791,082&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,985,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,416,216&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;800,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,800,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,680,449&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,207,298&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Common stock as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,575,423&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,696,585&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,500,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,239,682&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,669,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Class C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;800,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,800,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,815,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54,365,785&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCapitalizationTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-276"
      decimals="INF"
      id="f-1155"
      unitRef="shares">10500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-276"
      decimals="INF"
      id="f-1156"
      unitRef="shares">49694610</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-276"
      decimals="INF"
      id="f-1157"
      unitRef="shares">46791082</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-277"
      decimals="INF"
      id="f-1158"
      unitRef="shares">4500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-277"
      decimals="INF"
      id="f-1159"
      unitRef="shares">8985839</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-277"
      decimals="INF"
      id="f-1160"
      unitRef="shares">8416216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-278"
      decimals="INF"
      id="f-1161"
      unitRef="shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-278"
      decimals="INF"
      id="f-1162"
      unitRef="shares">3000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-278"
      decimals="INF"
      id="f-1163"
      unitRef="shares">3000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-7"
      decimals="INF"
      id="f-1164"
      unitRef="shares">15800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-7"
      decimals="INF"
      id="f-1165"
      unitRef="shares">61680449</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-7"
      decimals="INF"
      id="f-1166"
      unitRef="shares">58207298</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-279"
      decimals="INF"
      id="f-1167"
      unitRef="shares">10500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-279"
      decimals="INF"
      id="f-1168"
      unitRef="shares">45575423</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-279"
      decimals="INF"
      id="f-1169"
      unitRef="shares">42696585</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-280"
      decimals="INF"
      id="f-1170"
      unitRef="shares">4500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-280"
      decimals="INF"
      id="f-1171"
      unitRef="shares">9239682</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-280"
      decimals="INF"
      id="f-1172"
      unitRef="shares">8669200</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-281"
      decimals="INF"
      id="f-1173"
      unitRef="shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-281"
      decimals="INF"
      id="f-1174"
      unitRef="shares">3000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-281"
      decimals="INF"
      id="f-1175"
      unitRef="shares">3000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-8"
      decimals="INF"
      id="f-1176"
      unitRef="shares">15800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-8"
      decimals="INF"
      id="f-1177"
      unitRef="shares">57815105</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-8"
      decimals="INF"
      id="f-1178"
      unitRef="shares">54365785</us-gaap:CommonStockSharesOutstanding>
    <dna:SaleOfStockAuthorizedAmount contextRef="c-282" decimals="-5" id="f-1179" unitRef="usd">500000000.0</dna:SaleOfStockAuthorizedAmount>
    <dna:SaleOfStockAuthorizedAmount contextRef="c-283" decimals="-5" id="f-1180" unitRef="usd">100000000.0</dna:SaleOfStockAuthorizedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-50"
      decimals="-5"
      id="f-1181"
      unitRef="shares">1900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-5" id="f-1182" unitRef="usd">18100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-284"
      decimals="-6"
      id="f-1183"
      unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-284"
      decimals="4"
      id="f-1184"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-284"
      decimals="INF"
      id="f-1185"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-284"
      decimals="INF"
      id="f-1186"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="-6" id="f-1187" unitRef="shares">15800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-276"
      decimals="-6"
      id="f-1188"
      unitRef="shares">10500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-276"
      decimals="4"
      id="f-1189"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-277"
      decimals="-6"
      id="f-1190"
      unitRef="shares">4500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-277"
      decimals="4"
      id="f-1191"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-278"
      decimals="-6"
      id="f-1192"
      unitRef="shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-278"
      decimals="4"
      id="f-1193"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <dna:CommonStockVotingRight
      contextRef="c-285"
      decimals="INF"
      id="f-1194"
      unitRef="vote">1</dna:CommonStockVotingRight>
    <dna:CommonStockVotingRight
      contextRef="c-286"
      decimals="INF"
      id="f-1195"
      unitRef="vote">10</dna:CommonStockVotingRight>
    <us-gaap:Dividends contextRef="c-1" decimals="INF" id="f-1196" unitRef="usd">0</us-gaap:Dividends>
    <dna:CommonStockConversionRatio
      contextRef="c-7"
      decimals="INF"
      id="f-1197"
      unitRef="shares">1</dna:CommonStockConversionRatio>
    <dna:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock contextRef="c-1" id="f-1198">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had the following common stock reserved for future issuance as of the date indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for grant under the 2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,336,606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,262,853&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Performance stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,407,287&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrants to purchase Class A common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295,622&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for grant under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,500,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for grant under the 2022 Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;292,172&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;366,567&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total common stock reserved for future issuances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,461,107&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Excludes unvested earnout shares, which are restricted shares issued to equity holders of legacy Ginkgo prior to the closing of the SRNG Business Combination and to SRNG. These earnout shares are recorded in equity as shares outstanding upon satisfying the vesting conditions.&lt;/span&gt;&lt;/div&gt;</dna:ScheduleOfCommonStockReservedForFutureIssuancesTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-287"
      decimals="INF"
      id="f-1199"
      unitRef="shares">3336606</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-288"
      decimals="INF"
      id="f-1200"
      unitRef="shares">1262853</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-289"
      decimals="INF"
      id="f-1201"
      unitRef="shares">4407287</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-290"
      decimals="INF"
      id="f-1202"
      unitRef="shares">1295622</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-291"
      decimals="INF"
      id="f-1203"
      unitRef="shares">2500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-292"
      decimals="INF"
      id="f-1204"
      unitRef="shares">292172</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-293"
      decimals="INF"
      id="f-1205"
      unitRef="shares">366567</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-7"
      decimals="INF"
      id="f-1206"
      unitRef="shares">13461107</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1207">Stock-Based Compensation &lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense by financial statement line item in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the periods presented (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.121%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.457%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.457%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of Biosecurity revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;112,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;229,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16, 2022, the Company's Board of Directors adopted the Ginkgo Bioworks Holdings, Inc. 2022 Inducement Plan (the &#x201c;2022 Inducement Plan&#x201d;), which is a non-shareholder approved equity incentive plan adopted pursuant to the &#x201c;inducement exception&#x201d; provided under NYSE Listed Company Manual Section 303A.08. Pursuant to the terms of the 2022 Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock and other stock-based awards as an inducement material to individuals being hired or rehired following a bona fide period of interruption of employment, as an employee of the Company or any of its subsidiaries, including in connection with a merger or acquisition. The terms of the 2022 Inducement Plan are substantially similar to the terms of the Company&#x2019;s 2021 Incentive Award Plan. The Company has reserved 625,000 shares of the Company&#x2019;s common stock (which may be shares of Class A common stock or Class B common stock) for issuance under the 2022 Inducement Plan. As of December&#160;31, 2025, 292,172 shares are available for future issuance under the 2022 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Inc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;entive Award Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;16, 2021, the 2021 Incentive Award Plan (the &#x201c;2021 Plan&#x201d;) became effective. The 2021 Plan provides for the grant of stock options, including incentive stock options (&#x201c;ISOs&#x201d;) and nonqualified stock options, stock appreciation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rights, restricted stock, dividend equivalents, RSUs and other stock or cash-based awards to employees, consultants and directors of Ginkgo and its subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate number of shares of common stock available for issuance under the 2021 Plan, which may be issued as Class A common stock and/or Class B common stock, was initially 5,011,024 shares. As of December&#160;31, 2025, 3,336,606 shares are available for future issuance under the 2021 Plan. The number of shares of common stock reserved for issuance under the 2021 Plan will automatically increase for ten years on January 1 of each year in an amount equal to the lesser of (a) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by the Board. The maximum number of shares of common stock that may be issued pursuant to the exercise of incentive stock options granted under the 2021 Plan is 5,000,000 shares. Shares issued under the 2021 Plan may consist of authorized but unissued shares, shares purchased on the open market or treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 16, 2021, the 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) became effective. The ESPP authorizes (i) the grant of options that are intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code of 1986 (the &#x201c;Section 423 Component&#x201d;) and (ii) the grant of options that are not intended to be tax-qualified (the &#x201c;Non-Section 423 Component&#x201d;). All of the Company&#x2019;s employees are expected to be eligible to participate in the ESPP. However, with respect to the Section 423 Component, an employee may not be granted rights to purchase stock under the ESPP if the employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP initially permits the Company to deliver up to 500,000 shares of common stock pursuant to awards issued under the ESPP, which may be Class A common stock and/or Class B common stock. The number of shares of common stock reserved for issuance under the ESPP will automatically increase each January 1 by an amount equal to the lesser of (a) 1% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by the Board, provided that no more than 2,500,000 shares may be issued under the Section 423 Component. Prior to or in connection with issuing any shares of common stock under the ESPP, the ESPP administrator may convert awards covering shares of Class B common stock to Class A common stock. As of December&#160;31, 2025, no awards have been granted under the ESPP, and 2,500,000 shares remain available for future issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2014 Stock Incentive Plan (the &#x201c;2014 Plan&#x201d;) provided for the Company to grant options, stock appreciation rights, restricted stock, restricted stock units (&#x201c;RSUs&#x201d;) and other stock-based awards. From and after the effective date of the 2021 Incentive Award Plan, the Company ceased granting awards under the 2014 Plan. However, the 2014 Plan continues to govern the terms and conditions of the outstanding awards previously granted thereunder. Shares of common stock underlying any awards that are forfeited, cancelled, repurchased, or otherwise terminated by the Company under the 2014 Plan will be added back to the shares available for issuance under the 2021 Incentive Award Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Time-based Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All time-based options outstanding consist of awards granted to non-employee directors and are of two types: (i) initial awards granted to newly elected or appointed directors, which vest in three equal annual installments, and (ii) subsequent awards, which vest on the earlier of the first anniversary of the grant date or the day prior to the next annual shareholder meeting. These options expire no later than ten years from the grant date. The exercise price of each option is equal to the closing price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of time-based stock options activity for the year ended December&#160;31, 2025 is presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.757%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.260%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Exercise Price per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:115%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding as of  December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;267,520&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;171,875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(72,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;366,567&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercisable as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:6.7pt"&gt;The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the year and the exercise prices, multiplied by the number of in-the-money stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was $0.9 million and $9.1 million, respectively. There were no stock option exercises during the year ended December 31, 2025. The weighted-average fair value of options granted during the years ended December&#160;31, 2025, 2024, and 2023 was $7.48, $11.35 and $57.20 per share, respectively, and was calculated using the following key assumptions in the Black-Scholes option-pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.06&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.94&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, there was $1.5 million of unrecognized compensation expense related to options recognizable over a weighted-average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Market-based Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024, the Company granted to each of the Company's four founders an option to purchase in aggregate 125,000 shares of Ginkgo's Class A common stock with an exercise price of $100 per share, subject both to time-based and market-based vesting criteria (the &#x201c;Founder Options&#x201d;). The market-based vesting is tied to the achievement of four specified stock price hurdles within a five-year period, with 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $200, 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $300, 20% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $400 and the remaining 60% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $500. If the market-based criteria are achieved during the five-year period, the awards will vest on the five-year anniversary of the grant date. The weighted-average grant-date fair value of the options granted was $7.80 per share and was calculated using a Monte Carlo simulation model using a risk-free interest rate of 4.65%, expected volatility of 72%, suboptimal exercise multiple of 2.8, and a dividend yield of zero percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2025, the compensation committee of the Company&#x2019;s Board of Directors canceled the Founder Options and granted replacement performance-based restricted stock unit (&#x201c;PSU&#x201d;) awards (the &#x201c;Founder PSU Awards&#x201d;). The cancellation and concurrent grant of replacement awards were accounted for as a modification, resulting in $10.5&#160;million of incremental compensation expense. The performance period for these awards was through December&#160;31, 2025 and the aggregate compensation expense for the cancelled award and the new award will be recognized over the remaining requisite service period of the PSUs, which is the grant date through March 31, 2026. The PSU awards are subject to substantially similar performance metrics, vesting terms and employment terms as described in the section &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based Restricted Stock Units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted under the 2014 Plan are subject to two vesting conditions: (i) a service-based vesting condition, generally satisfied over four years with 25% of the shares vesting on the first anniversary of the grant date and monthly vesting thereafter, and (ii) a performance-based vesting condition, which was met in 2021 in connection with the Company's merger with SRNG. RSUs granted under the 2021 Plan are subject only to the service-based vesting condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the year ended December&#160;31, 2025 is presented below: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.801%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of Shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of  December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,327,398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,176,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,797,720)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,443,244)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of  December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,262,853&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of RSUs granted during the years ended December&#160;31, 2025, 2024 and 2023 was $8.02, $43.81 and $55.60, respectively. The total fair value of the RSUs that vested during the years ended December&#160;31, 2025, 2024 and 2023 was $87.6 million, $232.9 million and $365.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, there was $58.3 million of unrecognized compensation expense related to RSUs recognizable over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2025, the compensation committee of the Company's Board of Directors approved a grant of PSU awards under the 2021 Plan to substantially all employees. The PSUs are eligible to vest based on the achievement of specific performance metrics tied to the Company&#x2019;s 2025 cash flow and bookings targets. Recipients must remain employed through the date the applicable vested shares are distributed, which is expected to occur in March 2026. PSU achievement percentages may range from zero to 100% of the award. The grant-date fair value of the PSUs was determined based on the closing price of the Company&#x2019;s Class A common stock on the grant date. Additionally, as summarized above, the Founder PSU Awards were granted in June 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of PSU activity for the year ended December&#160;31, 2025 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Performance Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,599,647&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,192,360)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,407,287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, there was $7.3&#160;million of unrecognized compensation expense related to unvested PSUs outstanding, which is expected to be recognized over a service period of approximately 0.3 years. Actual expense recognized may vary based on the final achievement rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnouts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnout shares represent equity awards, primarily in the form of restricted stock, granted to existing employees of the Company as of the closing date of the Company's merger with SRNG on September 16, 2021 (the &#x201c;Closing Date&#x201d;). These earnout shares are subject to the same time-based vesting and performance conditions (change in control or an initial public offering) as the underlying awards, including provisions related to vesting and termination. Additionally, the earnout shares are subject to a market condition, which is satisfied when the trading price of the Company's common stock is greater than &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or equal to $500, $600, $700 and $800 per share for any 20 trading days within a 30 consecutive trading day period, on or before the fifth anniversary of the Closing Date (collectively, the &#x201c;Earnout Targets&#x201d;). The first Earnout Target of $500 per share was achieved on November&#160;15, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity during the year ended December&#160;31, 2025 for the earnout shares is presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of Shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;552,457&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;510.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;533.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(859)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;512.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;551,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;510.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of the earnout shares that vested during the years ended December&#160;31, 2025, 2024 and 2023 was $0.2 million, $4.5&#160;million and $7.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2025</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1208">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense by financial statement line item in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the periods presented (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.121%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.457%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.457%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of Biosecurity revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cost of other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;112,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;229,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-294" decimals="-3" id="f-1209" unitRef="usd">34210000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-295" decimals="-3" id="f-1210" unitRef="usd">56020000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-296" decimals="-3" id="f-1211" unitRef="usd">145879000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-297" decimals="-3" id="f-1212" unitRef="usd">42463000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-298" decimals="-3" id="f-1213" unitRef="usd">56324000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-299" decimals="-3" id="f-1214" unitRef="usd">84005000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-300" decimals="-3" id="f-1215" unitRef="usd">2624000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-301" decimals="-3" id="f-1216" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-302" decimals="-3" id="f-1217" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-303" decimals="-3" id="f-1218" unitRef="usd">2249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-304" decimals="-3" id="f-1219" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-305" decimals="-3" id="f-1220" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-1221" unitRef="usd">81546000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-20" decimals="-3" id="f-1222" unitRef="usd">112344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-21" decimals="-3" id="f-1223" unitRef="usd">229884000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-306"
      decimals="INF"
      id="f-1224"
      unitRef="shares">625000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-307"
      decimals="INF"
      id="f-1225"
      unitRef="shares">292172</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-308"
      decimals="INF"
      id="f-1226"
      unitRef="shares">5011024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-287"
      decimals="INF"
      id="f-1227"
      unitRef="shares">3336606</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <dna:ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm contextRef="c-7" id="f-1228">P10Y</dna:ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-308"
      decimals="2"
      id="f-1229"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-309"
      decimals="INF"
      id="f-1230"
      unitRef="shares">5000000000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <dna:PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate
      contextRef="c-310"
      decimals="2"
      id="f-1231"
      unitRef="number">0.05</dna:PercentageOfCombinedVotingPowerOrValueOfAllClassesOfStockNotEligibleToParticipate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-311"
      decimals="INF"
      id="f-1232"
      unitRef="shares">500000000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-310"
      decimals="2"
      id="f-1233"
      unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-311"
      decimals="INF"
      id="f-1234"
      unitRef="shares">2500000000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-312"
      decimals="INF"
      id="f-1235"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-291"
      decimals="INF"
      id="f-1236"
      unitRef="shares">2500000000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <dna:TypesOfTimeBasedStockOptions
      contextRef="c-7"
      decimals="INF"
      id="f-1237"
      unitRef="stockoption">2</dna:TypesOfTimeBasedStockOptions>
    <dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="c-1"
      decimals="INF"
      id="f-1238"
      unitRef="installment">3</dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-1" id="f-1239">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1240">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of time-based stock options activity for the year ended December&#160;31, 2025 is presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.757%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.260%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Exercise Price per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:700;line-height:115%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding as of  December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;267,520&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;171,875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(72,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;366,567&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercisable as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136,014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:6.7pt"&gt;The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the year and the exercise prices, multiplied by the number of in-the-money stock options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-8" decimals="0" id="f-1241" unitRef="shares">267520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-8"
      decimals="2"
      id="f-1242"
      unitRef="usdPerShare">25.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="0" id="f-1243" unitRef="shares">171875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1244"
      unitRef="usdPerShare">9.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="0" id="f-1245" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1246"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="0" id="f-1247" unitRef="shares">72828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1248"
      unitRef="usdPerShare">36.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="0" id="f-1249" unitRef="shares">366567</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-1250"
      unitRef="usdPerShare">15.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1251">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-7" decimals="-3" id="f-1252" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-7" decimals="0" id="f-1253" unitRef="shares">136014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-1254"
      unitRef="usdPerShare">24.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1255">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-7" decimals="-3" id="f-1256" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-20" decimals="-5" id="f-1257" unitRef="usd">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-21" decimals="-5" id="f-1258" unitRef="usd">9100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="0" id="f-1259" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1260">The weighted-average fair value of options granted during the years ended December&#160;31, 2025, 2024, and 2023 was $7.48, $11.35 and $57.20 per share, respectively, and was calculated using the following key assumptions in the Black-Scholes option-pricing model:&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.06&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.27&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.94&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-1261"
      unitRef="usdPerShare">7.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-20"
      decimals="2"
      id="f-1262"
      unitRef="usdPerShare">11.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-21"
      decimals="2"
      id="f-1263"
      unitRef="usdPerShare">57.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-1264" unitRef="number">0.0406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-20" decimals="4" id="f-1265" unitRef="number">0.0427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-21" decimals="4" id="f-1266" unitRef="number">0.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="3" id="f-1267" unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-20" decimals="3" id="f-1268" unitRef="number">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-21" decimals="3" id="f-1269" unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-1270">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-20" id="f-1271">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-21" id="f-1272">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="2" id="f-1273" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-20" decimals="2" id="f-1274" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-21" decimals="2" id="f-1275" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-293" decimals="-5" id="f-1276" unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-313" id="f-1277">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <dna:NumberOfCompanyFounders
      contextRef="c-314"
      decimals="0"
      id="f-1278"
      unitRef="founder">4</dna:NumberOfCompanyFounders>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-315"
      decimals="0"
      id="f-1279"
      unitRef="shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c-315"
      decimals="2"
      id="f-1280"
      unitRef="usdPerShare">100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <dna:NumberOfStockPriceHurdles
      contextRef="c-316"
      decimals="INF"
      id="f-1281"
      unitRef="hurdle">4</dna:NumberOfStockPriceHurdles>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-317" id="f-1282">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="c-318"
      decimals="2"
      id="f-1283"
      unitRef="number">0.10</dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <us-gaap:SharePrice
      contextRef="c-319"
      decimals="0"
      id="f-1284"
      unitRef="usdPerShare">200</us-gaap:SharePrice>
    <dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="c-320"
      decimals="2"
      id="f-1285"
      unitRef="number">0.10</dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <us-gaap:SharePrice
      contextRef="c-321"
      decimals="0"
      id="f-1286"
      unitRef="usdPerShare">300</us-gaap:SharePrice>
    <dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="c-322"
      decimals="2"
      id="f-1287"
      unitRef="number">0.20</dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <us-gaap:SharePrice
      contextRef="c-323"
      decimals="0"
      id="f-1288"
      unitRef="usdPerShare">400</us-gaap:SharePrice>
    <dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="c-324"
      decimals="2"
      id="f-1289"
      unitRef="number">0.60</dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <us-gaap:SharePrice
      contextRef="c-325"
      decimals="0"
      id="f-1290"
      unitRef="usdPerShare">500</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-317" id="f-1291">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-317" id="f-1292">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c-317"
      decimals="2"
      id="f-1293"
      unitRef="usdPerShare">7.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-317"
      decimals="4"
      id="f-1294"
      unitRef="number">0.0465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-317"
      decimals="3"
      id="f-1295"
      unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple
      contextRef="c-317"
      decimals="1"
      id="f-1296"
      unitRef="number">2.8</dna:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsSuboptimalExerciseMultiple>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-317"
      decimals="3"
      id="f-1297"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-326" decimals="-5" id="f-1298" unitRef="usd">10500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <dna:NumberOfVestingConditions
      contextRef="c-7"
      decimals="INF"
      id="f-1299"
      unitRef="condition">2</dna:NumberOfVestingConditions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-327" id="f-1300">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-327"
      decimals="2"
      id="f-1301"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-1302">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the year ended December&#160;31, 2025 is presented below: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.801%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of Shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of  December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,327,398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,176,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,797,720)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,443,244)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of  December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,262,853&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-328"
      decimals="0"
      id="f-1303"
      unitRef="shares">3327398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-328"
      decimals="2"
      id="f-1304"
      unitRef="usdPerShare">69.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-329"
      decimals="0"
      id="f-1305"
      unitRef="shares">1176419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-329"
      decimals="2"
      id="f-1306"
      unitRef="usdPerShare">8.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-329"
      decimals="0"
      id="f-1307"
      unitRef="shares">1797720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-329"
      decimals="2"
      id="f-1308"
      unitRef="usdPerShare">48.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-329"
      decimals="0"
      id="f-1309"
      unitRef="shares">1443244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-329"
      decimals="2"
      id="f-1310"
      unitRef="usdPerShare">56.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-288"
      decimals="0"
      id="f-1311"
      unitRef="shares">1262853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-288"
      decimals="2"
      id="f-1312"
      unitRef="usdPerShare">55.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-329"
      decimals="2"
      id="f-1313"
      unitRef="usdPerShare">8.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-330"
      decimals="2"
      id="f-1314"
      unitRef="usdPerShare">43.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-331"
      decimals="2"
      id="f-1315"
      unitRef="usdPerShare">55.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-329" decimals="-5" id="f-1316" unitRef="usd">87600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-330" decimals="-5" id="f-1317" unitRef="usd">232900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-331" decimals="-5" id="f-1318" unitRef="usd">365300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-288" decimals="-5" id="f-1319" unitRef="usd">58300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-329" id="f-1320">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-332"
      decimals="2"
      id="f-1321"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-333"
      decimals="2"
      id="f-1322"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock contextRef="c-1" id="f-1323">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of PSU activity for the year ended December&#160;31, 2025 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.609%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Performance Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,599,647&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,192,360)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,407,287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-334"
      decimals="INF"
      id="f-1324"
      unitRef="shares">5599647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-334"
      decimals="2"
      id="f-1325"
      unitRef="usdPerShare">8.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-334"
      decimals="INF"
      id="f-1326"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-334"
      id="f-1327"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-334"
      decimals="INF"
      id="f-1328"
      unitRef="shares">1192360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-334"
      decimals="2"
      id="f-1329"
      unitRef="usdPerShare">7.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-289"
      decimals="INF"
      id="f-1330"
      unitRef="shares">4407287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-289"
      decimals="2"
      id="f-1331"
      unitRef="usdPerShare">8.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-289" decimals="-5" id="f-1332" unitRef="usd">7300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-334" id="f-1333">P0Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharePrice
      contextRef="c-335"
      decimals="0"
      id="f-1334"
      unitRef="usdPerShare">500</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-336"
      decimals="0"
      id="f-1335"
      unitRef="usdPerShare">600</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-337"
      decimals="0"
      id="f-1336"
      unitRef="usdPerShare">700</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-338"
      decimals="0"
      id="f-1337"
      unitRef="usdPerShare">800</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-339" id="f-1338">P20D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-340" id="f-1339">P30D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharePrice
      contextRef="c-341"
      decimals="0"
      id="f-1340"
      unitRef="usdPerShare">500</us-gaap:SharePrice>
    <dna:SummaryOfActivityForEarnoutRSATableTextBlock contextRef="c-1" id="f-1341">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity during the year ended December&#160;31, 2025 for the earnout shares is presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of Shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;552,457&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;510.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;533.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(859)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;512.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;551,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;510.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dna:SummaryOfActivityForEarnoutRSATableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-342"
      decimals="0"
      id="f-1342"
      unitRef="shares">552457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-342"
      decimals="2"
      id="f-1343"
      unitRef="usdPerShare">510.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-343"
      decimals="0"
      id="f-1344"
      unitRef="shares">321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-343"
      decimals="2"
      id="f-1345"
      unitRef="usdPerShare">533.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-343"
      decimals="0"
      id="f-1346"
      unitRef="shares">859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-343"
      decimals="2"
      id="f-1347"
      unitRef="usdPerShare">512.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-344"
      decimals="0"
      id="f-1348"
      unitRef="shares">551277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-344"
      decimals="2"
      id="f-1349"
      unitRef="usdPerShare">510.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-343" decimals="-5" id="f-1350" unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-345" decimals="-5" id="f-1351" unitRef="usd">4500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-346" decimals="-5" id="f-1352" unitRef="usd">7600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-344" decimals="-5" id="f-1353" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-1354">Revenue Recognition &lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the percentage of Cell Engineering revenues by industry based on total Cell Engineering revenue: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.488%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.488%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Pharmaceutical and biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Agriculture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government and defense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Industrial and environment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Consumer and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Food and nutrition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Cell Engineering revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cell Engineering revenue includes both cash and non-cash consideration. The non-cash consideration primarily consists of equity received from customers as partial or full payment in certain contracts, which is recognized as revenue as services are provided or upon contract termination. The Company did not receive equity as consideration for any customer contracts entered into during the years ended December&#160;31, 2025 or 2024, but continues to recognize revenue from prior contracts. Cell Engineering revenue recognized relating to non-cash consideration was $11.6&#160;million, $61.4&#160;million, and $48.5&#160;million for the years ended December&#160;31, 2025, 2024, and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s total revenue is derived from customers located primarily in the United States. For the years ended December&#160;31, 2025, 2024, and 2023, the Company&#x2019;s revenue from customers within the United States comprised 76%, 81% and 82%, respectively, of total revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Balances &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as accounts receivable. The Company had no contract asset balances as of December&#160;31, 2025 and 2024. The Company&#x2019;s accounts receivable consists of both billed and unbilled amounts. Unbilled receivables arise when revenue is recognized in excess of invoiced amounts and represent the Company&#x2019;s unconditional right to consideration for goods or services already transferred to the customer. The balance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of unbilled accounts receivable, included in accounts receivable, net in the accompanying consolidated balance sheets, was $14.5 million and $11.3 million as of December&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities, or deferred revenue, primarily consist of payments received in advance of performance under the contract or when the Company has an unconditional right to consideration under the terms of the contract before it transfers goods or services to the customer. The Company&#x2019;s collaborative arrangements with its investees and related parties typically include upfront payments consisting of cash or non-cash consideration for future research and development services and non-cash consideration in the form of convertible financial instruments and equity securities for licenses that will be transferred in the future. The Company records the upfront cash payments and fair value of the convertible financial instruments and equity securities as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also invoices customers based on contractual billing schedules, which results in the recording of deferred revenue to the extent payment is received prior to the Company&#x2019;s performance of the related services. Contract liabilities are recognized as revenue as (or when) the Company performs under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2025, the Company recognized $48.7 million of revenue that was included in the contract liabilities balance of $126.5 million as of December&#160;31, 2024. During the year ended December&#160;31, 2024, the Company recognized $88.1 million of revenue that was included in the contract liabilities balance of $202.5 million as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price that was allocated to performance obligations that have not yet been satisfied or are partially satisfied as of December&#160;31, 2025 and 2024 was $158.6 million and $85.8 million, respectively. The Company has elected the practical expedient not to provide the remaining performance obligation disclosures related to contracts for which the Company recognizes revenue on a cost-plus basis in the amount to which it has the right to invoice.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, approximately $23.0&#160;million of the unsatisfied or partially satisfied performance obligations is expected to be recognized as revenue in 2026, based on the projected customer program end date; $40.9&#160;million between 2026 and 2027; $86.9&#160;million between 2026 and 2028; $3.4&#160;million between 2026 and 2029; and $4.4&#160;million between 2026 and 2030.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When a milestone subject to the variable consideration constraint is achieved, the Company updates its estimate of the transaction price to include the milestone payment and records a cumulative catch-up in revenue. For the years ended December&#160;31, 2025, 2024 and 2023, the Company recorded $2.9 million, $7.2 million and $2.3 million, respectively, as cumulative catch-up in revenue, primarily due to the recognition of previously constrained variable consideration related to milestones or a contract modification.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-1355">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the percentage of Cell Engineering revenues by industry based on total Cell Engineering revenue: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.488%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.488%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Pharmaceutical and biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Agriculture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government and defense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Industrial and environment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Consumer and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Food and nutrition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total Cell Engineering revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-347"
      decimals="2"
      id="f-1356"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-348"
      decimals="2"
      id="f-1357"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-349"
      decimals="2"
      id="f-1358"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-350"
      decimals="2"
      id="f-1359"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-351"
      decimals="2"
      id="f-1360"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-352"
      decimals="2"
      id="f-1361"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-353"
      decimals="2"
      id="f-1362"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-354"
      decimals="2"
      id="f-1363"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-355"
      decimals="2"
      id="f-1364"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-356"
      decimals="2"
      id="f-1365"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-357"
      decimals="2"
      id="f-1366"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-358"
      decimals="2"
      id="f-1367"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-359"
      decimals="2"
      id="f-1368"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-360"
      decimals="2"
      id="f-1369"
      unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-361"
      decimals="2"
      id="f-1370"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-362"
      decimals="2"
      id="f-1371"
      unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-363"
      decimals="2"
      id="f-1372"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-364"
      decimals="2"
      id="f-1373"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-365"
      decimals="2"
      id="f-1374"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-366"
      decimals="2"
      id="f-1375"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-367"
      decimals="2"
      id="f-1376"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <dna:RevenueFromContractWithCustomerExcludingAssessedTaxNoncash contextRef="c-368" decimals="-5" id="f-1377" unitRef="usd">11600000</dna:RevenueFromContractWithCustomerExcludingAssessedTaxNoncash>
    <dna:RevenueFromContractWithCustomerExcludingAssessedTaxNoncash contextRef="c-369" decimals="-5" id="f-1378" unitRef="usd">61400000</dna:RevenueFromContractWithCustomerExcludingAssessedTaxNoncash>
    <dna:RevenueFromContractWithCustomerExcludingAssessedTaxNoncash contextRef="c-370" decimals="-5" id="f-1379" unitRef="usd">48500000</dna:RevenueFromContractWithCustomerExcludingAssessedTaxNoncash>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-371"
      decimals="2"
      id="f-1380"
      unitRef="number">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-372"
      decimals="2"
      id="f-1381"
      unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-373"
      decimals="2"
      id="f-1382"
      unitRef="number">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-7" decimals="0" id="f-1383" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-8" decimals="0" id="f-1384" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:UnbilledContractsReceivable contextRef="c-7" decimals="-5" id="f-1385" unitRef="usd">14500000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable contextRef="c-8" decimals="-5" id="f-1386" unitRef="usd">11300000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-1387" unitRef="usd">48700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability contextRef="c-8" decimals="-5" id="f-1388" unitRef="usd">126500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-20" decimals="-5" id="f-1389" unitRef="usd">88100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability contextRef="c-41" decimals="-5" id="f-1390" unitRef="usd">202500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-7" decimals="-5" id="f-1391" unitRef="usd">158600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-8" decimals="-5" id="f-1392" unitRef="usd">85800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized contextRef="c-374" decimals="-5" id="f-1393" unitRef="usd">23000000.0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized contextRef="c-375" decimals="-5" id="f-1394" unitRef="usd">40900000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized contextRef="c-376" decimals="-5" id="f-1395" unitRef="usd">86900000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized contextRef="c-377" decimals="-5" id="f-1396" unitRef="usd">3400000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized contextRef="c-378" decimals="-5" id="f-1397" unitRef="usd">4400000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="c-1" decimals="-5" id="f-1398" unitRef="usd">2900000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="c-20" decimals="-5" id="f-1399" unitRef="usd">7200000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="c-21" decimals="-5" id="f-1400" unitRef="usd">2300000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1406">Segment Information&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in two operating and reportable segments: Cell Engineering and Biosecurity. This structure reflects the Company's internal management framework and the approach its CODM uses to evaluate operating results and allocate resources. The Company&#x2019;s reportable segments are described as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Cell Engineering consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological R&amp;amp;D. The Company&#x2019;s cell engineering platform includes R&amp;amp;D services (solutions) where Ginkgo performs technical activities.  Our Autonomous Lab is a flexible wet lab built from our Reconfigurable Automation Cart (&#x201c;RAC&#x201d;) systems capable of large scale data generation; it powers generative AI and machine learning (&#x201c;ML&#x201d;) tools that enable more successful biological R&amp;amp;D. We now offer services providing such data generation, AI and automation tools directly to Ginkgo customers. Cell Engineering revenue is generated primarily through R&amp;amp;D service fees for our solutions and Datapoints services; and design, build, installation and ongoing support fees for our automation solutions (RAC) systems. Historically our solutions deals also included downstream value share in the form of milestone payments, royalties or equity interests. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Biosecurity consists of the Company&#x2019;s biomonitoring and bioinformatics support services, offered to both government and non-government customers through the Company's two core offerings: Canopy and Horizon. Biosecurity revenue is generated from fees for data, analytics, and services. Prior to 2024, Biosecurity revenue also included sales of COVID-19 diagnostic and sample collection test kits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's reportable segments are those for which discrete financial information is available and whose results are regularly provided to the Company&#x2019;s CODM, consisting of the Chief Executive Officer and the Chief Operating Officer, for the purpose of allocating resources and assessing financial performance. The CODM evaluates the financial performance of the Company&#x2019;s segments based on segment operating income (loss). The CODM is primarily provided with the segment operating income (loss) on a quarterly basis, as well as during the annual budgeting and forecasting process, and uses this information to monitor the Company&#x2019;s performance, including budget-to-actual results, and to make decisions about the allocation of operating and capital resources to each segment. For management reporting purposes, the Company&#x2019;s measure of segment operating income (loss) excludes the impact of stock-based compensation expense, depreciation and amortization, asset impairment charges, restructuring charges, costs associated with excess space, transaction and integration costs associated with planned, completed or terminated mergers and acquisitions, and acquired in-process research and development expenses. The Company has determined its significant segment expenses are cost of revenue for Biosecurity, research and development expenses for Cell Engineering, and general and administrative expenses for both segments, which are regularly provided to the CODM. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM is not provided with asset information by segment; therefore, such information is not presented. The accounting policies used to prepare the reportable segments financial information are the same as those used to prepare the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents summary results of the Company&#x2019;s reportable segments and a reconciliation of total segment operating loss to consolidated loss before income taxes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cell Engineering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;173,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Costs and operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Cost of other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;158,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;335,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;171,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cell Engineering operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(95,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(218,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(363,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Biosecurity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Costs and operating expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Cost of Biosecurity service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Cost of Biosecurity product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biosecurity operating (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(30,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total segment operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(114,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(249,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(366,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reconciling items to reconcile total segment operating loss to loss before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock-based compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;82,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;234,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;121,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;70,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restructuring charges &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Carrying cost of excess space (net of sublease income) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Merger and acquisition related expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(313,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(547,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(892,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Includes $1.2 million, $3.0 million, and $5.0 million in related employer payroll taxes for the years ended December&#160;31, 2025, 2024, and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;For 2024, includes $47.9&#160;million related to goodwill impairment and $5.8&#160;million related to lab equipment. For 2023, includes a $25.2&#160;million impairment loss on lab equipment and a $96.2&#160;million impairment loss on lease assets associated with an exited Zymergen leased facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt"&gt;See Note &lt;/span&gt;&lt;span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_575" style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, Restructuring, for composition of costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt"&gt;The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt"&gt;Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt"&gt;Includes interest income, interest expense, loss on investments, losses/gains on deconsolidation of subsidiaries, changes in fair value of certain assets and liabilities, and other gains or losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1407"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1408"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <dna:NumberOfCoreAssets contextRef="c-1" decimals="INF" id="f-1409" unitRef="asset">2</dna:NumberOfCoreAssets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1410">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents summary results of the Company&#x2019;s reportable segments and a reconciliation of total segment operating loss to consolidated loss before income taxes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cell Engineering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;173,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Costs and operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Cost of other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;158,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;335,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;171,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cell Engineering operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(95,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(218,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(363,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Biosecurity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Costs and operating expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Cost of Biosecurity service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Cost of Biosecurity product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Biosecurity operating (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(30,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total segment operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(114,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(249,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(366,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reconciling items to reconcile total segment operating loss to loss before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock-based compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;82,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;115,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;234,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Impairment expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;121,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;70,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restructuring charges &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Carrying cost of excess space (net of sublease income) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Merger and acquisition related expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(313,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(547,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(892,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Includes $1.2 million, $3.0 million, and $5.0 million in related employer payroll taxes for the years ended December&#160;31, 2025, 2024, and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;For 2024, includes $47.9&#160;million related to goodwill impairment and $5.8&#160;million related to lab equipment. For 2023, includes a $25.2&#160;million impairment loss on lab equipment and a $96.2&#160;million impairment loss on lease assets associated with an exited Zymergen leased facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt"&gt;See Note &lt;/span&gt;&lt;span style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_575" style="color:#3051f2;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, Restructuring, for composition of costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt"&gt;The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt"&gt;Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:3.02pt"&gt;Includes interest income, interest expense, loss on investments, losses/gains on deconsolidation of subsidiaries, changes in fair value of certain assets and liabilities, and other gains or losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-384" decimals="-3" id="f-1411" unitRef="usd">132746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-385" decimals="-3" id="f-1412" unitRef="usd">173972000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-386" decimals="-3" id="f-1413" unitRef="usd">143531000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-384" decimals="-3" id="f-1414" unitRef="usd">13203000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-385" decimals="-3" id="f-1415" unitRef="usd">5999000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-386" decimals="-3" id="f-1416" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-384" decimals="-3" id="f-1417" unitRef="usd">158541000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-385" decimals="-3" id="f-1418" unitRef="usd">271512000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-386" decimals="-3" id="f-1419" unitRef="usd">335943000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-384" decimals="-3" id="f-1420" unitRef="usd">56532000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-385" decimals="-3" id="f-1421" unitRef="usd">115028000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-386" decimals="-3" id="f-1422" unitRef="usd">171210000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c-384" decimals="-3" id="f-1423" unitRef="usd">-95530000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-385" decimals="-3" id="f-1424" unitRef="usd">-218567000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-386" decimals="-3" id="f-1425" unitRef="usd">-363622000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-387" decimals="-3" id="f-1426" unitRef="usd">37409000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-388" decimals="-3" id="f-1427" unitRef="usd">53071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-389" decimals="-3" id="f-1428" unitRef="usd">78975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-390" decimals="-3" id="f-1429" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-391" decimals="-3" id="f-1430" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-392" decimals="-3" id="f-1431" unitRef="usd">28949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-387" decimals="-3" id="f-1432" unitRef="usd">28897000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-388" decimals="-3" id="f-1433" unitRef="usd">38549000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-389" decimals="-3" id="f-1434" unitRef="usd">46524000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-390" decimals="-3" id="f-1435" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-391" decimals="-3" id="f-1436" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-392" decimals="-3" id="f-1437" unitRef="usd">7481000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-393" decimals="-3" id="f-1438" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-394" decimals="-3" id="f-1439" unitRef="usd">771000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-395" decimals="-3" id="f-1440" unitRef="usd">1599000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-393" decimals="-3" id="f-1441" unitRef="usd">27443000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-394" decimals="-3" id="f-1442" unitRef="usd">44370000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-395" decimals="-3" id="f-1443" unitRef="usd">55514000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c-393" decimals="-3" id="f-1444" unitRef="usd">-18931000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-394" decimals="-3" id="f-1445" unitRef="usd">-30619000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-395" decimals="-3" id="f-1446" unitRef="usd">-3194000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-396" decimals="-3" id="f-1447" unitRef="usd">-114461000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-397" decimals="-3" id="f-1448" unitRef="usd">-249186000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-398" decimals="-3" id="f-1449" unitRef="usd">-366816000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-399" decimals="-3" id="f-1450" unitRef="usd">82704000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-400" decimals="-3" id="f-1451" unitRef="usd">115299000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-401" decimals="-3" id="f-1452" unitRef="usd">234908000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges contextRef="c-399" decimals="-3" id="f-1453" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-400" decimals="-3" id="f-1454" unitRef="usd">53654000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-401" decimals="-3" id="f-1455" unitRef="usd">121404000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DepreciationAndAmortization contextRef="c-399" decimals="-3" id="f-1456" unitRef="usd">58990000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-400" decimals="-3" id="f-1457" unitRef="usd">63020000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-401" decimals="-3" id="f-1458" unitRef="usd">70507000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-399" decimals="-3" id="f-1459" unitRef="usd">11398000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-400" decimals="-3" id="f-1460" unitRef="usd">24172000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-401" decimals="-3" id="f-1461" unitRef="usd">0</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:LeaseCost contextRef="c-399" decimals="-3" id="f-1462" unitRef="usd">53723000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-400" decimals="-3" id="f-1463" unitRef="usd">25986000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-401" decimals="-3" id="f-1464" unitRef="usd">0</us-gaap:LeaseCost>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-399" decimals="-3" id="f-1465" unitRef="usd">-5998000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-400" decimals="-3" id="f-1466" unitRef="usd">4417000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-401" decimals="-3" id="f-1467" unitRef="usd">61188000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <dna:AcquiredInProcessResearchAndDevelopment contextRef="c-399" decimals="-3" id="f-1468" unitRef="usd">0</dna:AcquiredInProcessResearchAndDevelopment>
    <dna:AcquiredInProcessResearchAndDevelopment contextRef="c-400" decimals="-3" id="f-1469" unitRef="usd">19849000</dna:AcquiredInProcessResearchAndDevelopment>
    <dna:AcquiredInProcessResearchAndDevelopment contextRef="c-401" decimals="-3" id="f-1470" unitRef="usd">9582000</dna:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-399" decimals="-3" id="f-1471" unitRef="usd">1678000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-400" decimals="-3" id="f-1472" unitRef="usd">8075000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-401" decimals="-3" id="f-1473" unitRef="usd">-28535000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-1474" unitRef="usd">-313600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-1475" unitRef="usd">-547508000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-1476" unitRef="usd">-892940000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <dna:EmployerPayrollTaxes contextRef="c-1" decimals="-5" id="f-1477" unitRef="usd">1200000</dna:EmployerPayrollTaxes>
    <dna:EmployerPayrollTaxes contextRef="c-20" decimals="-5" id="f-1478" unitRef="usd">3000000.0</dna:EmployerPayrollTaxes>
    <dna:EmployerPayrollTaxes contextRef="c-21" decimals="-5" id="f-1479" unitRef="usd">5000000.0</dna:EmployerPayrollTaxes>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-20" decimals="-5" id="f-1480" unitRef="usd">47900000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AssetImpairmentCharges contextRef="c-262" decimals="-5" id="f-1481" unitRef="usd">5800000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-402" decimals="-5" id="f-1482" unitRef="usd">25200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-403" decimals="-5" id="f-1483" unitRef="usd">96200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-1484">Significant Collaboration Agreements and Transactions with Related Parties&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant transactions with its related parties are primarily comprised of revenue generating activities under collaboration and license agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Platform Ventures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has partnered with other investors, including investors who were also Company investors at the time, to form business ventures, including Motif FoodWorks, Inc. in 2018 (&#x201c;Motif&#x201d;), Allonnia, LLC in 2019 (&#x201c;Allonnia&#x201d;), Arcaea, LLC in 2021 (&#x201c;Arcaea&#x201d;), Verb Biotics, LLC in 2021 (&#x201c;Verb&#x201d;), Ayana Bio, LLC in 2021 (&#x201c;Ayana&#x201d;) and BiomEdit, LLC in 2022 (&#x201c;BiomEdit&#x201d;) (collectively &#x201c;Platform Ventures&#x201d;). Each of these entities is privately held with the Company holding common equity interests in each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company initially consolidated Ayana and Verb at formation as variable interests where the Company was initially the primary beneficiary, subsequently deconsolidating both in 2022 when it was concluded that was no longer the case. With respect to the investments in Motif, Allonnia, Arcaea, and BiomEdit, the Company concluded these entities represent variable interest entities, however the Company has never been the primary beneficiary of these entities. The Company accounts for its investments in Platform Ventures under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the launch of each of the Platform Ventures, the Company received common equity and, with respect to Arcaea, subsequently received additional common equity. The Company generally granted each Platform Venture licenses to certain of the Company&#x2019;s intellectual property and executed Technical Development Agreements (&#x201c;TDAs&#x201d;) that established terms under which the Company would provide technical research and development services to those entities, generally in return for fees on a fixed fee or cost-plus basis for services provided.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The common equity investments in each of the Platform Ventures were initially recorded at the then fair values determined at inception of the investments. The Company is recognizing earnings and losses on these equity method investments using the HLBV method. Accordingly, the carrying values of each of the Platform Ventures investments were reduced to zero immediately following the Company&#x2019;s investments. There is no commitment for the Company to provide further financial support to these Platform Ventures, and therefore the carrying value of the equity method investments will not be reduced below zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship with the Platform Ventures is as vendor-customer relationships and is within the scope of ASC 606, as the provision of services and corresponding license rights are considered a part of the Company&#x2019;s ordinary activities. The common equity issued to the Company represent non-cash consideration under revenue contracts. While TDAs executed by the parties provides payment terms for future services, the TDAs do not provide for any transfer of goods or services between the parties as the Company contemplated provided licenses and services upon execution of future contemplated TDPs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the exception of Ayana and Verb, the Company&#x2019;s performance obligations under the initial arrangements consisted of a number of estimated materials rights provided to the Platform Ventures (BiomEdit having four and Arcaea, Allonia and Motif having ten) to future technical research and development services and commercial licenses under individual TDPs that the Company expected to execute. These material rights equated in aggregate to the fair values of the common equity issued by each of the Platform Ventures to the Company and represented advanced payment for the license rights, which would be granted upon the execution of future applicable TDPs. As there would be no additional payment for these license &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rights when future TDPs are executed, the Company determined that there are material rights associated with each of the contemplated TDPs under each of the TDAs. The value of the material rights are included in deferred revenue until recognized as revenue. The material rights are recorded as non-current deferred revenue until such time as the parties execute an applicable TDP inclusive of the material rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each TDP underlying a material right, the transaction price consists of (i) either a fixed fee or, if a cost-plus arrangement, variable consideration for the most likely amount of estimated consideration to be received and (ii) non-cash consideration allocated to the material right. As the services performed by the Company under a TDP inclusive of a material right, the Company creates or enhances an asset that the Platform Ventures controls, the Company satisfies the performance obligation and recognizes revenue over time using an input method that compares total costs incurred relative to total estimated cost to complete to estimate progress under the contract. Any revisions to the estimated total budgeted costs to complete, and the resulting impact on revenue recognition, are reflected in the period of the change through a cumulative catch-up adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2024, the Company and Motif mutually terminated its services agreements with no adjustment to the original consideration. As a result, the Company has no further obligation to perform services for Motif and, accordingly, the then remaining $45.4 million in material rights deferred revenue has been recognized in full as revenue during the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2025, the Company and BiomEdit mutually terminated its services agreements with no adjustment to the original consideration. As a result, the Company has no further obligation to perform services for BiomEdit, and accordingly, the then remaining $7.5&#160;million in material rights deferred revenue has been recognized in full as revenue during the year ended December 31, 2025. BiomEdit is no longer considered a significant related party due to a reduction of the Company&#x2019;s equity ownership interest that occurred during the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genomatica, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also partnered with Genomatica, Inc. (&#x201c;Genomatica&#x201d;), a previously established business that is privately held. Genomatica is deemed a variable interest entity, however the Company has never been the primary beneficiary of this entity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company purchased Series A preferred stock of Genomatica, Inc. for $15.0&#160;million and entered into a collaboration agreement, which was subsequently terminated in September 2018, whereby the Company received $40.0&#160;million of Series B preferred stock in Genomatica in exchange for providing Genomatica with up to $40.0&#160;million in services at no charge to Genomatica. The agreements between the Company and Genomatica were determined to be within the scope of ASC 606 directly or by analogy. The Company recognized the revenue for the combined performance obligations using an over-time input method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded the preferred stock investments were not in-substance common stock and therefore did not qualify for accounting as an equity method investment and should be accounted for as equity security under the measurement alternative for equity investments that do not have a readily determinable fair value. As of December 31, 2024, the Company determined that the investment had substantially no value. During the years ended December 31, 2024, and 2023, the Company recorded impairment losses of $11.9 million, and $33.0 million, respectively, related to its investment in Genomatica preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related Party Transactions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant related party transactions included in the consolidated balance sheet, excluding the Company&#x2019;s investments and equity method investments, are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred revenue, current and non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Allonnia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Arcaea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;BiomEdit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Genomatica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant related party transactions included in the consolidated statements of operations and comprehensive loss, excluding the losses on the Company&#x2019;s investments and equity method investments, are summarized below (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.488%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.488%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cell Engineering revenue:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Motif FoodWorks&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Arcaea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Genomatica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ayana Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;BiomEdit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Verb Biotics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Allonnia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other equity investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Notes &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#id8596373948b4ae4958ccd7c02fd70c1_154" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional details on the Company&#x2019;s investments and equity method investments held in its related parties.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <dna:NumberOFEstimatedMaterialRights
      contextRef="c-404"
      decimals="INF"
      id="f-1485"
      unitRef="materialright">4</dna:NumberOFEstimatedMaterialRights>
    <dna:NumberOFEstimatedMaterialRights
      contextRef="c-405"
      decimals="INF"
      id="f-1486"
      unitRef="materialright">10</dna:NumberOFEstimatedMaterialRights>
    <dna:NumberOFEstimatedMaterialRights
      contextRef="c-406"
      decimals="INF"
      id="f-1487"
      unitRef="materialright">10</dna:NumberOFEstimatedMaterialRights>
    <dna:NumberOFEstimatedMaterialRights
      contextRef="c-407"
      decimals="INF"
      id="f-1488"
      unitRef="materialright">10</dna:NumberOFEstimatedMaterialRights>
    <us-gaap:ContractWithCustomerLiability contextRef="c-408" decimals="-5" id="f-1489" unitRef="usd">45400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-409" decimals="-5" id="f-1490" unitRef="usd">7500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-410" decimals="-5" id="f-1491" unitRef="usd">15000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InvestmentOwnedAtCost contextRef="c-411" decimals="-5" id="f-1492" unitRef="usd">40000000.0</us-gaap:InvestmentOwnedAtCost>
    <dna:UpfrontAmountReceived contextRef="c-412" decimals="-5" id="f-1493" unitRef="usd">40000000.0</dna:UpfrontAmountReceived>
    <dna:PreferredStockInvestmentImpairmentLoss contextRef="c-413" decimals="-5" id="f-1494" unitRef="usd">11900000</dna:PreferredStockInvestmentImpairmentLoss>
    <dna:PreferredStockInvestmentImpairmentLoss contextRef="c-414" decimals="-5" id="f-1495" unitRef="usd">33000000.0</dna:PreferredStockInvestmentImpairmentLoss>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c-1" id="f-1496">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant related party transactions included in the consolidated balance sheet, excluding the Company&#x2019;s investments and equity method investments, are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred revenue, current and non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Allonnia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Arcaea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;BiomEdit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Genomatica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant related party transactions included in the consolidated statements of operations and comprehensive loss, excluding the losses on the Company&#x2019;s investments and equity method investments, are summarized below (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.488%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.488%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Cell Engineering revenue:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Motif FoodWorks&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Arcaea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Genomatica&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ayana Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;BiomEdit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Verb Biotics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Allonnia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other equity investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-406" decimals="-3" id="f-1497" unitRef="usd">36495000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-415" decimals="-3" id="f-1498" unitRef="usd">36495000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-405" decimals="-3" id="f-1499" unitRef="usd">28413000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-416" decimals="-3" id="f-1500" unitRef="usd">28413000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-404" decimals="-3" id="f-1501" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-417" decimals="-3" id="f-1502" unitRef="usd">7583000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-418" decimals="-3" id="f-1503" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-419" decimals="-3" id="f-1504" unitRef="usd">564000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-9" decimals="-3" id="f-1505" unitRef="usd">64908000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-10" decimals="-3" id="f-1506" unitRef="usd">73055000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-420" decimals="-3" id="f-1507" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-421" decimals="-3" id="f-1508" unitRef="usd">45445000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-422" decimals="-3" id="f-1509" unitRef="usd">6660000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-423" decimals="-3" id="f-1510" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-424" decimals="-3" id="f-1511" unitRef="usd">4653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-425" decimals="-3" id="f-1512" unitRef="usd">6024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-413" decimals="-3" id="f-1513" unitRef="usd">564000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-414" decimals="-3" id="f-1514" unitRef="usd">1453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-426" decimals="-3" id="f-1515" unitRef="usd">4232000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-427" decimals="-3" id="f-1516" unitRef="usd">637000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-428" decimals="-3" id="f-1517" unitRef="usd">1028000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-429" decimals="-3" id="f-1518" unitRef="usd">1323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-430" decimals="-3" id="f-1519" unitRef="usd">7583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-431" decimals="-3" id="f-1520" unitRef="usd">197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-432" decimals="-3" id="f-1521" unitRef="usd">2171000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-433" decimals="-3" id="f-1522" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-434" decimals="-3" id="f-1523" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-435" decimals="-3" id="f-1524" unitRef="usd">584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-436" decimals="-3" id="f-1525" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-437" decimals="-3" id="f-1526" unitRef="usd">126000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-438" decimals="-3" id="f-1527" unitRef="usd">523000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-439" decimals="-3" id="f-1528" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-440" decimals="-3" id="f-1529" unitRef="usd">139000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-441" decimals="-3" id="f-1530" unitRef="usd">705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-3" id="f-1531" unitRef="usd">8784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-3" id="f-1532" unitRef="usd">53041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-27" decimals="-3" id="f-1533" unitRef="usd">22222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="c-1" id="f-1534">Employee Benefit Plan The Company maintains a 401(k) retirement savings plan for its employees who satisfy certain eligibility requirements. Under this plan, the Company makes a 5% non-elective contribution to all eligible employees equal to up to 5% of eligible compensation, which fully vests once such eligible participant has completed two years of continuous service. Effective January 1, 2024, the 5% non-elective contribution is capped for employees earning $100,000 or more in annual salary, resulting in a maximum employer contribution of $5,000. For the years ended December&#160;31, 2025, 2024 and 2023, the Company contributed $3.3 million, $5.8 million and $8.2 million, respectively, to the plan.</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c-1" decimals="2" id="f-1535" unitRef="number">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c-1" decimals="2" id="f-1536" unitRef="number">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <dna:DefinedContributionPlanVestingPeriod contextRef="c-1" id="f-1537">P2Y</dna:DefinedContributionPlanVestingPeriod>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c-1" decimals="2" id="f-1538" unitRef="number">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <dna:DefinedContributionPlanEmployeeAnnualEarningAmount contextRef="c-1" decimals="INF" id="f-1539" unitRef="usd">100000</dna:DefinedContributionPlanEmployeeAnnualEarningAmount>
    <dna:DefinedContributionPlanMaximumEmployerContributionsAmount contextRef="c-1" decimals="INF" id="f-1540" unitRef="usd">5000</dna:DefinedContributionPlanMaximumEmployerContributionsAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-1" decimals="-5" id="f-1541" unitRef="usd">3300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-20" decimals="-5" id="f-1542" unitRef="usd">5800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-21" decimals="-5" id="f-1543" unitRef="usd">8200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1544">Income Taxes &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, the loss before income taxes consisted of the following (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.314%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.314%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.317%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(308,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(514,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(890,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(33,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(313,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(547,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(892,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, the Company recorded the following income tax expense (benefit) (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A reconciliation of income tax benefit computed by applying the 21% statutory U.S. Federal income tax rate to income before income taxes after the adoption of ASU 2023-09 for year ended December&#160;31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.230%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Tax at U.S. Statutory Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(65,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;State and Local Income Taxes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Foreign Tax Effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other foreign jurisdictions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Nontaxable or Nondeductible Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Limitation on executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Gain/Loss on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Tax Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Research &amp;amp; Development Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Changes in Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;45,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The states and local jurisdictions that contribute to the majority (greater than 50%) of the tax effect in this category include Massachusetts and New York state and city. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax benefit computed at the statutory corporate income tax rate to the effective income tax rate for the years ended December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal income tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Investments in subsidiaries and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(29.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the years ended December&#160;31, 2025, the amount of cash income taxes paid by the Company was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.318%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.482%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State and local:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;California&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;South Carolina&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;All other state and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash income taxes, net of refunds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s deferred tax assets and liabilities consist of the following (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.303%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.902%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;459,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;332,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;155,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;214,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;112,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;116,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Investments in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;936,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;875,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(840,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(771,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;103,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(92,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(98,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(102,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(110,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in the deferred tax assets valuation allowance is summarized as follows (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Beginning of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Additions&lt;br/&gt;(Subtractions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets valuation allowance:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;771,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;840,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;711,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;60,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;771,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. The Company considered its history of cumulative net losses incurred since inception and has concluded that it is more-likely-than-not that it will not realize the benefits of the deferred tax assets. Accordingly, a valuation allowance has been established against the deferred tax assets as of December&#160;31, 2025 and 2024 that are not expected to be realized. The Company reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased on a net basis by $68.2 million during the year ended December&#160;31, 2025 primarily due to increases in the deferred tax assets related to net operating loss carryforwards partially offset by the continued amortization of capitalized research and development costs as allowed by certain provisions of the One Big Beautiful Bill Act of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2025, the Company had federal net operating loss carryforwards of approximately $1.8 billion, of which $139.2 million will begin to expire in 2029 and $1.6 billion can be carried forward indefinitely. As of December&#160;31, 2025, the Company had state net operating loss carryforwards of approximately $1.5 billion, of which $1.2 billion will begin to expire in 2030 and $257.5 million can be carried forward indefinitely. The Company also had $3.9&#160;million of foreign net operating losses as of December&#160;31, 2025, of which $1.5&#160;million will begin to expire in 2034 and $2.4&#160;million can be carried forward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company had federal research and development tax credit carryforwards of approximately $38.8 million, which will begin to expire in 2029. As of December&#160;31, 2025, the Company also had state research and development and investment tax credit carryforwards of approximately $31.4 million, which will begin to expire in 2030. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Sections 382 and 383 of the U.S. Internal Revenue Code, if a corporation undergoes an ownership change, the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income and taxes may be limited. The Company may have experienced an ownership change in the past and may experience ownership changes in the future as a result of future transactions in its share capital, some of which may be outside of the Company&#x2019;s control. As a result, if the Company earns net taxable income, the Company's ability to use its pre-change net operating loss carryforwards, or other pre-change tax attributes, to offset U.S. federal and state taxable income and taxes may be subject to significant limitations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it operates to assess their potential effect on its business and assumptions regarding future taxable income. The Company cannot predict whether specific proposals will be enacted, the terms of such proposals, or their potential impact on its business if enacted. In 2025, no major tax legislation was enacted in the jurisdictions where the Company operates that materially impacted its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which the Company operates. In the normal course of business, the Company is subject to examination by U.S. federal, state, local, and foreign taxing authorities, where applicable. There are currently no tax examinations in progress. As of December&#160;31, 2025, with few exceptions, the Company is no longer subject to U.S. federal, state, local, or foreign examinations by tax authorities for tax years before 2016. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state taxing authorities to the extent utilized in a future period.&lt;/span&gt;&lt;/div&gt;The Company accounts for uncertain tax positions using a more likely than not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an annual basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2025 and 2024, the Company had no recorded liabilities for uncertain tax positions and had no accrued interest or penalties related to uncertain tax positions.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1545">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, the loss before income taxes consisted of the following (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.314%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.314%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.317%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(308,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(514,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(890,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(33,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(313,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(547,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(892,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-1546" unitRef="usd">-308990000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-20" decimals="-3" id="f-1547" unitRef="usd">-514354000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-21" decimals="-3" id="f-1548" unitRef="usd">-890986000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-1549" unitRef="usd">-4610000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-20" decimals="-3" id="f-1550" unitRef="usd">-33154000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-21" decimals="-3" id="f-1551" unitRef="usd">-1954000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-1552" unitRef="usd">-313600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-20" decimals="-3" id="f-1553" unitRef="usd">-547508000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-21" decimals="-3" id="f-1554" unitRef="usd">-892940000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1555">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, the Company recorded the following income tax expense (benefit) (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1556" unitRef="usd">873000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-20" decimals="-3" id="f-1557" unitRef="usd">566000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-21" decimals="-3" id="f-1558" unitRef="usd">690000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1559" unitRef="usd">-346000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-20" decimals="-3" id="f-1560" unitRef="usd">-109000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-21" decimals="-3" id="f-1561" unitRef="usd">123000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1562" unitRef="usd">527000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-20" decimals="-3" id="f-1563" unitRef="usd">457000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-21" decimals="-3" id="f-1564" unitRef="usd">813000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1565" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-20" decimals="-3" id="f-1566" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-21" decimals="-3" id="f-1567" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1568" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-20" decimals="-3" id="f-1569" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-21" decimals="-3" id="f-1570" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1571" unitRef="usd">-1364000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-20" decimals="-3" id="f-1572" unitRef="usd">-936000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-21" decimals="-3" id="f-1573" unitRef="usd">-884000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-1574" unitRef="usd">-1364000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-20" decimals="-3" id="f-1575" unitRef="usd">-936000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-21" decimals="-3" id="f-1576" unitRef="usd">-884000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1577" unitRef="usd">-837000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-20" decimals="-3" id="f-1578" unitRef="usd">-479000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-21" decimals="-3" id="f-1579" unitRef="usd">-71000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1580">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A reconciliation of income tax benefit computed by applying the 21% statutory U.S. Federal income tax rate to income before income taxes after the adoption of ASU 2023-09 for year ended December&#160;31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.238%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.230%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Tax at U.S. Statutory Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(65,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;State and Local Income Taxes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Foreign Tax Effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other foreign jurisdictions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Nontaxable or Nondeductible Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Limitation on executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Gain/Loss on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Tax Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Research &amp;amp; Development Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Changes in Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;45,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The states and local jurisdictions that contribute to the majority (greater than 50%) of the tax effect in this category include Massachusetts and New York state and city. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax benefit computed at the statutory corporate income tax rate to the effective income tax rate for the years ended December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.212%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal income tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Investments in subsidiaries and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(29.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-1581" unitRef="usd">-65856000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1582" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-1583" unitRef="usd">663000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1584" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-1585" unitRef="usd">-743000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1586" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-1587" unitRef="usd">14728000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1588" unitRef="number">-0.047</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount contextRef="c-1" decimals="-3" id="f-1589" unitRef="usd">1495000</dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationAmount>
    <dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent contextRef="c-1" decimals="3" id="f-1590" unitRef="number">-0.005</dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent>
    <dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount contextRef="c-1" decimals="-3" id="f-1591" unitRef="usd">3446000</dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsAmount>
    <dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent contextRef="c-1" decimals="3" id="f-1592" unitRef="number">-0.011</dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGainLossOnInvestmentsPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="-3" id="f-1593" unitRef="usd">461000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-1594" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-1595" unitRef="usd">1079000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-1596" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-1597" unitRef="usd">45212000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-1598" unitRef="number">-0.144</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-1599" unitRef="usd">836000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1600" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1601" unitRef="usd">-837000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1602" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-20" decimals="3" id="f-1603" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-21" decimals="3" id="f-1604" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-20" decimals="3" id="f-1605" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-21" decimals="3" id="f-1606" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-20" decimals="3" id="f-1607" unitRef="number">-0.104</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-21" decimals="3" id="f-1608" unitRef="number">0.136</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-20" decimals="3" id="f-1609" unitRef="number">-0.077</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-21" decimals="3" id="f-1610" unitRef="number">-0.142</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent contextRef="c-20" decimals="3" id="f-1611" unitRef="number">0.002</dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent>
    <dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent contextRef="c-21" decimals="3" id="f-1612" unitRef="number">0.081</dna:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLimitationOnCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-20" decimals="3" id="f-1613" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-21" decimals="3" id="f-1614" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary contextRef="c-20" decimals="3" id="f-1615" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary contextRef="c-21" decimals="3" id="f-1616" unitRef="number">0.290</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-20" decimals="3" id="f-1617" unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-21" decimals="3" id="f-1618" unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-20" decimals="3" id="f-1619" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-21" decimals="3" id="f-1620" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxPaidFederalAfterRefundReceived contextRef="c-1" decimals="-3" id="f-1621" unitRef="usd">0</us-gaap:IncomeTaxPaidFederalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-442" decimals="-3" id="f-1622" unitRef="usd">12000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-443" decimals="-3" id="f-1623" unitRef="usd">148000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-444" decimals="-3" id="f-1624" unitRef="usd">32000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidForeignAfterRefundReceived contextRef="c-1" decimals="-3" id="f-1625" unitRef="usd">0</us-gaap:IncomeTaxPaidForeignAfterRefundReceived>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-1626" unitRef="usd">192000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1627">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s deferred tax assets and liabilities consist of the following (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.303%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.902%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;459,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;332,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;155,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;214,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;28,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;52,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;112,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;116,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Investments in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;936,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;875,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(840,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(771,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;103,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(11,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(92,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(98,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(102,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(110,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-1628" unitRef="usd">459420000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-8" decimals="-3" id="f-1629" unitRef="usd">332482000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-3" id="f-1630" unitRef="usd">63612000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-8" decimals="-3" id="f-1631" unitRef="usd">61497000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-7" decimals="-3" id="f-1632" unitRef="usd">155755000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-8" decimals="-3" id="f-1633" unitRef="usd">214208000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-7" decimals="-3" id="f-1634" unitRef="usd">201000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-8" decimals="-3" id="f-1635" unitRef="usd">986000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <dna:DeferredTaxAssetsDeferredRevenue contextRef="c-7" decimals="-3" id="f-1636" unitRef="usd">21765000</dna:DeferredTaxAssetsDeferredRevenue>
    <dna:DeferredTaxAssetsDeferredRevenue contextRef="c-8" decimals="-3" id="f-1637" unitRef="usd">28549000</dna:DeferredTaxAssetsDeferredRevenue>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-7" decimals="-3" id="f-1638" unitRef="usd">48809000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-8" decimals="-3" id="f-1639" unitRef="usd">52388000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <dna:DeferredTaxAssetsAmortizableIntangibles contextRef="c-7" decimals="-3" id="f-1640" unitRef="usd">11755000</dna:DeferredTaxAssetsAmortizableIntangibles>
    <dna:DeferredTaxAssetsAmortizableIntangibles contextRef="c-8" decimals="-3" id="f-1641" unitRef="usd">10695000</dna:DeferredTaxAssetsAmortizableIntangibles>
    <dna:DeferredTaxAssetsLeaseLiabilities contextRef="c-7" decimals="-3" id="f-1642" unitRef="usd">112072000</dna:DeferredTaxAssetsLeaseLiabilities>
    <dna:DeferredTaxAssetsLeaseLiabilities contextRef="c-8" decimals="-3" id="f-1643" unitRef="usd">116118000</dna:DeferredTaxAssetsLeaseLiabilities>
    <dna:DeferredTaxAssetsInvestmentsInSubsidiaries contextRef="c-7" decimals="-3" id="f-1644" unitRef="usd">59027000</dna:DeferredTaxAssetsInvestmentsInSubsidiaries>
    <dna:DeferredTaxAssetsInvestmentsInSubsidiaries contextRef="c-8" decimals="-3" id="f-1645" unitRef="usd">57534000</dna:DeferredTaxAssetsInvestmentsInSubsidiaries>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-1646" unitRef="usd">2464000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-1647" unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-7" decimals="-3" id="f-1648" unitRef="usd">1257000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-8" decimals="-3" id="f-1649" unitRef="usd">1232000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-1650" unitRef="usd">936137000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-8" decimals="-3" id="f-1651" unitRef="usd">875689000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-1652" unitRef="usd">840060000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-1653" unitRef="usd">771852000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-7" decimals="-3" id="f-1654" unitRef="usd">96077000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-8" decimals="-3" id="f-1655" unitRef="usd">103837000</us-gaap:DeferredTaxAssetsNet>
    <dna:DeferredTaxLiabilitiesAmortizableIntangibles contextRef="c-7" decimals="-3" id="f-1656" unitRef="usd">10119000</dna:DeferredTaxLiabilitiesAmortizableIntangibles>
    <dna:DeferredTaxLiabilitiesAmortizableIntangibles contextRef="c-8" decimals="-3" id="f-1657" unitRef="usd">11660000</dna:DeferredTaxLiabilitiesAmortizableIntangibles>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-1658" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-1659" unitRef="usd">545000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-7" decimals="-3" id="f-1660" unitRef="usd">92052000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-8" decimals="-3" id="f-1661" unitRef="usd">98184000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-1662" unitRef="usd">102171000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-8" decimals="-3" id="f-1663" unitRef="usd">110389000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-1664" unitRef="usd">6094000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-8" decimals="-3" id="f-1665" unitRef="usd">6552000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-1666">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in the deferred tax assets valuation allowance is summarized as follows (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Beginning of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Additions&lt;br/&gt;(Subtractions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets valuation allowance:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;771,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;840,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;711,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;60,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;771,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-1667" unitRef="usd">771852000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-3" id="f-1668" unitRef="usd">68208000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-1669" unitRef="usd">840060000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-41" decimals="-3" id="f-1670" unitRef="usd">711778000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-20" decimals="-3" id="f-1671" unitRef="usd">60074000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-1672" unitRef="usd">771852000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-1673" unitRef="usd">68200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-445" decimals="-5" id="f-1674" unitRef="usd">1800000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-446" decimals="-5" id="f-1675" unitRef="usd">139200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-447" decimals="-5" id="f-1676" unitRef="usd">1600000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-448" decimals="-5" id="f-1677" unitRef="usd">1500000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-449" decimals="-5" id="f-1678" unitRef="usd">1200000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-450" decimals="-5" id="f-1679" unitRef="usd">257500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-451" decimals="-5" id="f-1680" unitRef="usd">3900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-452" decimals="-5" id="f-1681" unitRef="usd">1500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-453" decimals="-5" id="f-1682" unitRef="usd">2400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-454" decimals="-5" id="f-1683" unitRef="usd">38800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-455" decimals="-5" id="f-1684" unitRef="usd">31400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-6" id="f-1685" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-8" decimals="-6" id="f-1686" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1687">Net Loss per Share &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of earnings per common share is as follows (in thousands, except share data): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(312,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(547,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(892,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;55,457,676&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;51,894,639&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;48,610,507&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(10.54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(18.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,407,287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrants to purchase Class A common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295,622&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295,622&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295,622&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,262,853&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,327,398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,804,189&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Earnout shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,793,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,794,243&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,803,049&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;366,567&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;767,520&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;192,208&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Escrow shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,125,392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,205,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,095,068&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Represents employee and non-employee earnout shares for which the service-based and/or market-based vesting conditions have not been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Represents restricted common stock issued in connection with asset acquisitions, held in escrow for indemnification purposes, and subject to forfeiture.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1688">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of earnings per common share is as follows (in thousands, except share data): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(312,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(547,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(892,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;55,457,676&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;51,894,639&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;48,610,507&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(10.54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(18.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic contextRef="c-1" decimals="-3" id="f-1689" unitRef="usd">-312763000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic contextRef="c-20" decimals="-3" id="f-1690" unitRef="usd">-547029000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic contextRef="c-21" decimals="-3" id="f-1691" unitRef="usd">-892869000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-1692" unitRef="shares">55457676</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-20" decimals="0" id="f-1693" unitRef="shares">51894639</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-21" decimals="0" id="f-1694" unitRef="shares">48610507</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1695"
      unitRef="usdPerShare">-5.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-20"
      decimals="2"
      id="f-1696"
      unitRef="usdPerShare">-10.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-21"
      decimals="2"
      id="f-1697"
      unitRef="usdPerShare">-18.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1698">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,407,287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrants to purchase Class A common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295,622&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295,622&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,295,622&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,262,853&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,327,398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,804,189&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Earnout shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,793,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,794,243&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,803,049&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;366,567&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;767,520&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;192,208&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Escrow shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,125,392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,205,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,095,068&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Represents employee and non-employee earnout shares for which the service-based and/or market-based vesting conditions have not been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt"&gt;Represents restricted common stock issued in connection with asset acquisitions, held in escrow for indemnification purposes, and subject to forfeiture.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-456"
      decimals="0"
      id="f-1699"
      unitRef="shares">4407287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-457"
      decimals="0"
      id="f-1700"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-458"
      decimals="0"
      id="f-1701"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-459"
      decimals="0"
      id="f-1702"
      unitRef="shares">1295622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-460"
      decimals="0"
      id="f-1703"
      unitRef="shares">1295622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-461"
      decimals="0"
      id="f-1704"
      unitRef="shares">1295622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-462"
      decimals="0"
      id="f-1705"
      unitRef="shares">1262853</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-463"
      decimals="0"
      id="f-1706"
      unitRef="shares">3327398</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-464"
      decimals="0"
      id="f-1707"
      unitRef="shares">3804189</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-465"
      decimals="0"
      id="f-1708"
      unitRef="shares">3793063</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-466"
      decimals="0"
      id="f-1709"
      unitRef="shares">3794243</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-467"
      decimals="0"
      id="f-1710"
      unitRef="shares">3803049</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-468"
      decimals="0"
      id="f-1711"
      unitRef="shares">366567</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-469"
      decimals="0"
      id="f-1712"
      unitRef="shares">767520</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-470"
      decimals="0"
      id="f-1713"
      unitRef="shares">192208</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-471"
      decimals="0"
      id="f-1714"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-472"
      decimals="0"
      id="f-1715"
      unitRef="shares">20332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-473"
      decimals="0"
      id="f-1716"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-1717" unitRef="shares">11125392</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-20" decimals="0" id="f-1718" unitRef="shares">9205115</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-21" decimals="0" id="f-1719" unitRef="shares">9095068</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1720">Subsequent Events &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 26, 2026, the Company entered into a definitive Stock Purchase Agreement (the &#x201c;Stock Purchase Agreement&#x201d;) to sell substantially all of the operations comprising its Biosecurity segment (the &#x201c;Biosecurity Business&#x201d;) to a newly formed entity (&#x201c;Tower Biosecurity Holdings, Inc.&#x201d;). Under the terms of the agreement, the Company will contribute the Biosecurity Business to Tower Biosecurity Holdings, Inc. in exchange for approximately 20% equity interest of the total issued and outstanding equity of Tower Biosecurity Holdings, Inc. as of closing. The transaction is expected to close in the first half of 2026, subject to customary closing conditions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon closing, the Company expects to present the Biosecurity Business as discontinued operations in its consolidated financial statements and to recast prior period amounts to conform to this presentation. The transaction was approved by the Company's Board of Directors in February 2026, and, accordingly, the assets and liabilities of the Biosecurity Business are not reflected as held for sale as of December 31, 2025 and the accompanying consolidated financial statements do not reflect the effects of this transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <dna:StockPurchaseAgreementPercentOfEquityInterestToBeReceived
      contextRef="c-474"
      decimals="2"
      id="f-1721"
      unitRef="number">0.20</dna:StockPurchaseAgreementPercentOfEquityInterestToBeReceived>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-131"
          xlink:label="f-131"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-132"
          xlink:label="f-132"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-130"
          xlink:label="f-130"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:7.52pt">Includes related party revenue of $8,784, $53,041, and $22,222 for the years ended December 31, 2025, 2024, and 2023, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-131"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-132"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-130"
          xlink:to="fn-1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
